sentence	label
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$ â€¢ Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not alter the pharmacokinetics of @DRUG$ 1000 mg twice daily.	DDI-false
Ergot Derivatives : Dihydroergotamine , ergonovine , @DRUG$ , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ Toxicity characterized by peripheral vasospasm and ischemia of extremities and other tissues.	DDI-false
@DRUG$: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of amphetamines.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an @DRUG$ ( @DRUG$ , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
May interact with the following: cholestyramine, @DRUG$ (use with thiazide diuretics may prevent the @DRUG$ from working properly;	DDI-false
Nevertheless , clinical studies , as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of @DRUG$ and @DRUG$ In some patients.	DDI-false
Note: dissolution of aerosol particles of @DRUG$ in @DRUG$, a model lung surfactant.	DDI-false
Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blockers, azathioprin, @DRUG$ , gold , hydroxychloroquine , @DRUG$ , Sulfasalazine, and Anakinra.	DDI-false
Population pharmacokinetic analyses revealed that MTX , NSAIDs , @DRUG$ , and TNF blocking agents did not influence @DRUG$ clearance .	DDI-false
Further, no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and @DRUG$.	DDI-false
Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission ( e.g. , @DRUG$ ) should only be carried out with caution, since the effect of @DRUG$ It can be potentiated.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Although increased plasma concentrations (AUC 0-24 hrs) of @DRUG$ and/or descarboethoxyloratadine were observed following coadministration of @DRUG$ with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	DDI-false
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in @DRUG$ half-life.	DDI-false
For both species, (-)-NANM, but not @DRUG$ , antagonised the rate-reducing effects of @DRUG$ Replying to FI and FR.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Central nervous system depressants : Concomitant use of DURAGESIC (Fentanyl transdermal system ) with other central nervous system depressants, including but not limited to others @DRUG$ , sedatives, hypnotism, @DRUG$ ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Lithium: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-effect
the doses of @DRUG$ required to antagonize the effects of @DRUG$ were more than 100 times higher than those required to antagonize the effects of morphine.	DDI-effect
Although increased plasma concentrations ( AUC 0 - 24 hrs ) of loratadine and/or @DRUG$ When co-administered with @DRUG$ With each of these medications in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine as evaluated by electrocardiographic parameters, clinical laboratory tests, vital signs and adverse events.	DDI-false
- Lithium: Lithium should generally not be given with diuretics (such as @DRUG$) because they reduce its renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
The absorption of @DRUG$, furosemide, penicillin G, @DRUG$, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
@DRUG$/@DRUG$	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$, lidocaine, @DRUG$, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
In addition, there was no pharmacodynamic interaction as a result of coadministration of @DRUG$ and @DRUG$ ER.	DDI-false
Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or descarboethoxyloratadine were observed following coadministration of @DRUG$ with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	DDI-false
The concomitant use of other CYP3A4 inhibitors such as @DRUG$ and @DRUG$ with transdermal fentanyl may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	DDI-false
@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-false
@DRUG$: @DRUG$ had no effect on the steady-state plasma concentrations of carbamazepine or its epoxide metabolite in patients with epilepsy.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Particular caution should be observed with @DRUG$ since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and @DRUG$.	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
When @DRUG$ is added to or withdrawn from treatment , dosage adjustment of @DRUG$ may be required .	DDI-advise
Lithium : In a study conducted in healthy subjects, mean steady state @DRUG$ plasma levels increased approximately 17 % in subjects receiving lithium 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving lithium alone .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Ritonavir: concomitant use of @DRUG$ The use of VIRACEPT resulted in an increase in nelfinavir plasma AUC of 152% and very small changes in @DRUG$ plasma A.C.	DDI-false
CONCLUSIONS : Macrolide antibiotics inhibit the metabolism of @DRUG$ that are metabolized by CYP3A4 ( i.e. , atorvastatin , cerivastatin , lovastatin , @DRUG$ ) .	DDI-false
@DRUG$ may decrease the effect of phenothiazines , levodopa , and @DRUG$.	DDI-effect
For example , when @DRUG$ are administered concomitantly with @DRUG$ , prothrombin time should be carefully monitored and if necessary , the dosage of vitamin K antagonists should be reduced .	DDI-advise
This drug may interact with @DRUG$ or other CNS depressants ( may potentiate the CNS depressant effects of either these medications or antihistamines ) , anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$ ) , and monoamine oxidase ( MAO ) inhibitors ( concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ) .	DDI-false
Hydrochlorothiazide : In normal volunteers , concomitant administration of diflunisal and @DRUG$ resulted in significantly increased plasma levels of @DRUG$.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ (@DRUG$ tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	DDI-false
@DRUG$ (such as @DRUG$, lidocaine, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis , it is particularly important that physicians query patients or their guardians carefully about @DRUG$ , alcohol and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned .	DDI-false
@DRUG$ and colestipol resins: Absorption of hydrochlorothiazide is impaired in the presence of @DRUG$.	DDI-false
@DRUG$ taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl @DRUG$ by 55 % and 33 % , respectively .	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
The following examples are substances that can reduce the blood glucose lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, @DRUG$ , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral @DRUG$ ) .	DDI-false
Potassium-sparing diuretics (e.g. @DRUG$ , triamterene , or amiloride ) , potassium supplements , or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as @DRUG$ , beta-adrenergic blocking agents , @DRUG$ , and angiotensin converting enzyme inhibitors, without any change in the adverse event profile.	DDI-false
CONCLUSIONS : Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 ( i.e. , @DRUG$ , cerivastatin , @DRUG$ ==References====External links==	DDI-false
Rifabutin : Coadministration of rifabutin and VIRACEPT resulted in a 32 % decrease in @DRUG$ plasma AUC and a 207 % increase in @DRUG$ plasma A.C.	DDI-false
- Lithium: Lithium should generally not be given with @DRUG$ (such as bumetanide) because they reduce its renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , @DRUG$ ), myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g. @DRUG$ , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems .	DDI-false
@DRUG$-induced renal and mesenteric vasodilation is neither antagonistic by alpha nor by @DRUG$.	DDI-false
Acetaminophene, lidocaine, phenobarbital, quinidine, @DRUG$ , and @DRUG$ The pooled human serum was added at therapeutic concentrations.	DDI-false
Since the concomitant administration of warfarin with @DRUG$ increases the prothrombin time by 100 % after 3 to 4 days , the dose of the @DRUG$ Prothrombin times should be closely monitored.	DDI-false
Results demonstrate that @DRUG$ 10-monohydroxymetabolite ( @DRUG$ ) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated ( CYP1A2 , CYP2A6 , CYP2C9 , CYP2D6 , CYP2E1 , CYP4A9 and CYP4A11 ) with the exception of CYP2C19 and CYP3A4/5 .	DDI-false
In separate studies with patients receiving maintenance doses of warfarin, @DRUG$ , or digoxin , irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ The pharmacokinetics of digoxin (prothrombin time) or digoxin.	DDI-false
conversely, @DRUG$ may interfere with antihypertensive drugs (i.e., guanethidine, @DRUG$).	DDI-int
Medicines not to be administered with VIRACEPT @DRUG$ : amiodarone , @DRUG$ Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
The reported examples include: @DRUG$ : @DRUG$ are known to inhibit CYP3A4 to varying degrees .	DDI-false
Adrenergic blockers : @DRUG$ are inhibited by @DRUG$.	DDI-effect
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$ , azathioprin, chloroquine, gold, hydroxychloroquine, @DRUG$ , sulfasalazine , and anakinra .	DDI-false
Prednisone/@DRUG$: Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone.	DDI-false
It can interact with thyroid medications (e.g., @DRUG$ ) , iodine-containing products , antacids , H2-antagonists ( e.g. , @DRUG$ , ranitidine) and proton pump inhibitors (e. g. lansoprazole, omeprazole).	DDI-false
@DRUG$, nifedipine, @DRUG$	DDI-false
Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$, including lisinopril.	DDI-effect
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , @DRUG$ , ritonavir , indinavir , saquinavir , @DRUG$ A reduction in the dose of budesonide should be considered.	DDI-false
Experience with co-administration of @DRUG$ and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of @DRUG$ in patients receiving Fentanyl.	DDI-false
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with magnesium/@DRUG$-containing @DRUG$.	DDI-false
@DRUG$ , ampicillin , oxacillin , @DRUG$ In vitro, doxycycline, cephalothine, erythromycin and sulfamethoxazole have no influence on the protein binding of diclofenac in human serum.	DDI-false
Like @DRUG$ (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with NPH human insulin immediately before injection produced some attenuation in the peak concentration of @DRUG$, but that the time to peak and the total bioavailability of @DRUG$ were not significantly affected.	DDI-false
Curariform muscle relaxants ( eg , @DRUG$ ) and other medicines, including ether, succinylcholine, gallamine, @DRUG$ The neuromuscular blocking effect should be increased in patients treated with Coly-Mycin M Parenteral and sodium citrate should be administered with extreme caution.	DDI-false
- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered @DRUG$ in patients to whom @DRUG$ are also being given should be avoided, except in life-threatening conditions.	DDI-advise
Medicines that may alter the plasma concentration of imatinib Drugs that may increase the plasma concentration of imatinib @DRUG$ Plasma concentrations: Caution should be exercised when gleevec is administered with inhibitors of the CYP3A4 family (e.g. ketoconazole, itraconazole, erythromycin, @DRUG$ ) .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine , Innovar Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of @DRUG$ , with ketamine or innovar as with pentobarbital.	DDI-false
Before using this medicine, tell your doctor or pharmacist about all prescription and non-prescription products that you can use, especially: aminoglycosides (e.g., @DRUG$ Amikacin, amphotericin B, cyclosporin, nonsteroidal anti-inflammatory drugs (e.g. ibuprofen), tacrolimus, @DRUG$.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.	DDI-false
Specific studies have confirmed these effects with sevoflurane, isoflurane, @DRUG$, alfentanil, and @DRUG$.	DDI-false
Acetaminophene: Pharmacokinetic or pharmacodynamic drug-effect interactions between @DRUG$ and concomitantly administered @DRUG$ ( 162.5 mg orally administered 26 and 2 hours before the start of argatroban 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after the start of argatroban 1.5 g/kg/min for 18 hours).	DDI-false
Other concomitant therapies : In clinical trials, the safety profile in patients treated with acamprosate concomitantly with anxiolytics, @DRUG$ and @DRUG$ ( including benzodiazepines ) , or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
There is no pharmacokinetic interaction between @DRUG$ and @DRUG$.	DDI-false
Antacids: Absorption of @DRUG$ is moderately reduced ( approximately 25 % ) when coadministered with magnesium/aluminum-containing antacid products .	DDI-false
@DRUG$ : @DRUG$ The antihypertensive effect of antihypertensive agents may be antagonistic.	DDI-false
Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other NSAID while taking digoxin, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.	DDI-false
@DRUG$ : Macrolid antibiotics have been reported to have a significant decrease in @DRUG$ clearance .	DDI-false
Hypersensitivity Reactions : Patients with a history of severe hypersensitivity reactions to products containing Cremophor   EL ( eg , @DRUG$ for injection concentrate and @DRUG$ TAXOL should not be used to prepare an injection concentrate.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and @DRUG$.	DDI-false
Haloperidol: @DRUG$ blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$.	DDI-effect
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , @DRUG$ , warfarin, tacrolimus, cyclosporin, @DRUG$ When co-administered with saquinavir, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
Coadministration of @DRUG$ 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of @DRUG$.	DDI-false
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Since MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyltransferase, it is unlikely that it has an effect on drugs that are mainly eliminated by conjugation by UDP-glucuronyltransferase (e.g. @DRUG$ , @DRUG$ ) .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other cardiovascular agents: @DRUG$ There were concurrently with beta-adrenergic blockers, methyldopa, nitrates, @DRUG$ , hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : @DRUG$ (e.g. pentazocin, nalbuphine, @DRUG$ , Decocin and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesics such as levo-dromorane.	DDI-false
Furosemide: Clinical studies, as well as post marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-effect
The co-administration of Natrecor with IV @DRUG$ such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	DDI-false
Thus , @DRUG$ The co-administration with @DRUG$ should not be performed.	DDI-advise
â€¢ Aspirin/@DRUG$ : Pharmacokinetic or pharmacodynamic drug-effect interactions have been reported between: @DRUG$ and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1   g/kg/min . over 4 hours ) or acetaminophen ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of Argatroban 1.5   g/kg/min . over 18 hours ) .	DDI-false
@DRUG$ In vitro studies in peripheral mononuclear blood cells, U937 and Molt-4 cells showed that lamivudine significantly inhibited. @DRUG$ phosphorylation in a dose dependent manner .	DDI-false
Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	DDI-false
In EM individuals treated with @DRUG$ or fluoxetine, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-mechanism
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO @DRUG$ INTOXICATION , PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY , A BASELINE @DRUG$ ....................................................................................................................................................................................................................................................................	DDI-false
@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
In clinical trials, @DRUG$ was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
For example, inhibitors are azole antimycotics, @DRUG$ , clarithromycin , diclofenac , @DRUG$ , erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Other drug interactions Cimetidine, @DRUG$ and @DRUG$ had no effect on the pharmacokinetics of MHD.	DDI-false
@DRUG$ SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING @DRUG$ AND ITS CONGENERS .	DDI-advise
Based on the chemical similarity of itraconazole and ketoconazole, concomitant use of @DRUG$ with @DRUG$ is contraindicated .	DDI-advise
ANTACID ( Magnesium-Aluminum Hydroxide ): @DRUG$ plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
@DRUG$ (e. g., ketoconazole, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Although this effect was noted even when @DRUG$ was given 4 hours prior to @DRUG$ , this regimen did not result in diminished efficacy .	DDI-effect
@DRUG$: @DRUG$ enhances the effect of warfarin.	DDI-effect
Therefore , when @DRUG$ and @DRUG$ are used concomitantly , the patient should be observed closely to determine if the desired effect of the diuretic is obtained .	DDI-advise
@DRUG$ ( tricyclic ) , atropine or other anticholinergic agents , or digitalis glycosides : concurrent use with @DRUG$ It may cause additive inotropic and/or chronotropic effects.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , @DRUG$ , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
However , a crossover study in healthy subjects receiving either @DRUG$ 300 mg q.i.d. or 800 mg h.s. with a dose of 300 mg b.i.d. @DRUG$ ( Theo-Dur , Key Pharmaceuticals , Inc. ) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s . regimen , particularly in subjects aged 54 years and older .	DDI-mechanism
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
Magnesium/@DRUG$-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and @DRUG$.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
@DRUG$: Amiodarone, bepridil, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Cyclosporine: Administration of @DRUG$ concomitantly with cyclosporine has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
@DRUG$ is a neutralizing agent for @DRUG$ that protects against renal damage.	DDI-effect
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
@DRUG$ : Probenecid interferes with renal tubular secretion of @DRUG$ This leads to an increase in serum ciprofloxacin levels.	DDI-false
Aspirin : Concomitant use of aspirin with @DRUG$ may result in an increased risk of GI ulceration and complications compared to @DRUG$ alone .	DDI-false
While all the @DRUG$ (SSRIs), e.g., @DRUG$, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , sulfonamides , chloramphenicol , @DRUG$ , coumarins , @DRUG$ And beta-adrenergic blockers.	DDI-false
Because of the high inter-individual variability and limited sampling, the increase in SN38 levels in patients with concomitant @DRUG$ and @DRUG$ is uncertain .	DDI-false
While all the @DRUG$ ( SSRIs), e.g. fluoxetine, sertraline, @DRUG$ , and fluvoxamine, inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
Hepatic enzyme inducers, inhibitors and substrates : drugs that induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity (e.g. barbiturates, phenytoin, @DRUG$ , @DRUG$ ) can improve the metabolism of corticosteroids and require that the dosage of corticosteroids be increased.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-false
@DRUG$ ( tricyclic ) , atropine or other @DRUG$ , or digitalis glycosides : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects .	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$, @DRUG$, warfarin, cimetidine and phenobarbital.	DDI-false
"In the Steady State, @DRUG$ 50 mg once daily did not affect the platelet anti-activity of a low dose ( 81 mg once daily) @DRUG$ , as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood .	DDI-false
- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral @DRUG$ with @DRUG$ may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics	DDI-effect
Benzthiazide may interact with alcohol , blood thinners , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , @DRUG$ , norepinephrine , NSAIDs like Aleve or @DRUG$ , and high blood pressure medications.	DDI-false
Preliminary studies show that the concomitant use of @DRUG$ and @DRUG$ The result is a higher cardiac output and, usually, a lower pressure on the lungs than when each drug is used alone.	DDI-effect
However, because some @DRUG$ have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with @DRUG$ or its derivatives.	DDI-false
The compounds tested in humans include warfarin, @DRUG$ , phenytoin, diazepam, @DRUG$ and antipyrine .	DDI-false
While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , citalopram , escitalopram , @DRUG$ , sertraline , and @DRUG$ , inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of @DRUG$ , phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$ This delays elimination and increases blood levels of these drugs.	DDI-false
cimetidine ) and many that are substrates for P450 2D6 ( many other @DRUG$ , phenothiazines , and the Type 1C antiarrhythmics propafenone and @DRUG$ ) .	DDI-false
A similar association, albeit less pronounced, was proposed with barbiturates, phenylbutazone, @DRUG$ , @DRUG$ , griseofulvin, topiramat, and possibly ampicillin and tetracycline 72.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , @DRUG$ , certain @DRUG$ , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
- If Bezalip or Bezalip retard is used concomitantly with anion exchange resins (e.g. cholestryramine), a distance of at least 2 hours between the two medicinal products should be maintained as the absorption of @DRUG$ or @DRUG$ is impaired	DDI-false
Accordingly , careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking @DRUG$ and @DRUG$.	DDI-advise
These drugs include: @DRUG$ and other diuretics , corticosteroids , phenothiazines , thyroid products , @DRUG$ , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
@DRUG$ ; Simultaneous use of anticholinesterases and @DRUG$ may produce severe weakness in patients with myasthenia gravis .	DDI-false
- @DRUG$ (e.g. mesantoin) use of @DRUG$ If these medicines are used, the likelihood of side effects of these medicines may be increased.	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$ , @DRUG$ , acetaminophen , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	DDI-false
In addition , several @DRUG$ The cytochrome P450 inducers may reduce the plasma concentrations of oxcarbazepine and @DRUG$.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	DDI-effect
@DRUG$ did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan, and @DRUG$ had no clinically significant effect after oral administration.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Coadministration of single, oral doses of @DRUG$ with erythromycin (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in @DRUG$s maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.	DDI-false
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
@DRUG$: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
Multivitamins , or other products containing @DRUG$ or @DRUG$ , antacids or sucralfate should not be administered concomitantly with , or within 2 hours of , the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , @DRUG$ ( also referred to as NSAIDs ) , and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
Coadministration of @DRUG$ with doses higher than 40 mg @DRUG$ ( e.g. , 40 mg BID ) have not been studied .	DDI-false
In clinical trials, @DRUG$ In a pharmacokinetic sub-study in patients with congestive heart failure receiving furosemide or digoxin starting treatment with FLOLAN, apparent values for oral clearance of FLOLAN in combination with digoxin, diuretics, anticoagulants, oral vasodilators and additional oxygen were used. @DRUG$ On the second day of therapy, digoxin (n=30) and n=23 were reduced by 13 % and 15 % respectively.	DDI-false
Administration of @DRUG$ concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	DDI-false
Aspirin: Concomitant administration of @DRUG$ and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of @DRUG$, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
@DRUG$: @DRUG$ had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ Eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - tricyclic antidepressants : @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG$.	DDI-false
Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving @DRUG$ alone.	DDI-false
Chlorpromazine : Chlorpromazine blocks dopamine and norepinephrine receptors and thus inhibits the central stimulating effects of @DRUG$ and can be used to treat @DRUG$ poisoning .	DDI-false
Plasma exposure ( AUC ) to @DRUG$ When co-administered with fluconazole and co-administered with @DRUG$, the dose was increased by 62%.	DDI-mechanism
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , @DRUG$ , diclofenac , doxycycline , erythromycin , @DRUG$ , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
@DRUG$: In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
@DRUG$ therapy : Urinary excretion of @DRUG$ The effectiveness is reduced by acidic agents used in methenamin therapy.	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Ergot derivatives: dihydroergotamine, ergonovine, ergotamine, @DRUG$ CONTRAINDICATE because of the potential for serious and life-threatening reactions such as acute @DRUG$ Toxicity characterized by peripheral vasospasm and ischemia of extremities and other tissues.	DDI-false
Patients on @DRUG$ should receive 70 mg of @DRUG$ daily .	DDI-advise
Antiacid , clarithromycin , Didanosine , Fluconazole , @DRUG$ , indanavir, ketoconazole, phenytoin, phenobarbitol, carbamazepine, rifabutin, rifampin, ritanovir, @DRUG$.	DDI-false
@DRUG$: Coadministration of eszopiclone 3 mg and @DRUG$ 10 mg produced a decrease in DSST scores.	DDI-false
Another oral azole antifungal, ketoconazole, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of astemizole and its active metabolite @DRUG$ which may prolong QT intervals.	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , @DRUG$ , @DRUG$ ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
@DRUG$-induced renal and mesenteric vasodilation is not antagonized by either @DRUG$.	DDI-false
Specific studies have confirmed these effects with sevoflurane, isoflurane. @DRUG$ , @DRUG$ , and midazolam.	DDI-false
Other drugs : Drugs like @DRUG$ , disopyramide , @DRUG$ , phenothiazines, antihistamines and tricyclic antidepressants may be associated with QT interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Digoxin: @DRUG$ concentrations are increased by about 15% when @DRUG$ and carvedilol are administered concomitantly.	DDI-false
The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	DDI-false
Concomitant use with @DRUG$s may result in the reduced absorption of @DRUG$.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The use of @DRUG$ before succinylcholine to attenuate some of the side effects of @DRUG$ has not been studied.	DDI-false
@DRUG$: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in @DRUG$ plasma A.C.	DDI-false
Dexamethasone and @DRUG$ similarly inhibit and stimulate @DRUG$- or insulin-induced proliferation of prostatic epithelium .	DDI-effect
@DRUG$: @DRUG$ 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single 0.5 mg oral dose.	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
In addition, @DRUG$ and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral @DRUG$, resulting in a lower plasma concentration of these drugs.	DDI-false
- @DRUG$ : @DRUG$ blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity .	DDI-false
A two-way interaction between the hydantoin antiepileptic, @DRUG$ , and the @DRUG$s has been suggested .	DDI-false
@DRUG$ caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin ( 12 % and 15 % , respectively ) , and in the pharmacodynamic effects ( prothrombin time , measured as INR ) of @DRUG$.	DDI-effect
@DRUG$ DURAGESIC is not recommended for use in patients who: @DRUG$ within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics	DDI-false
@DRUG$ had a similar effect in the presence of @DRUG$.	DDI-false
The use of NUROMAX before @DRUG$ to attenuate some of the side effects of @DRUG$ has not been studied.	DDI-false
Considerable caution should be exercised if @DRUG$ The concomitant use of phenuron ( @DRUG$ ) since paranoid symptoms have been reported during therapy with this combination .	DDI-advise
Ketoconazole (200 mg once daily) produced a 10-fold increase in @DRUG$ AUC and a 4-fold increase in Cmax when co-administered with @DRUG$ (5 mg) in healthy volunteers.	DDI-false
@DRUG$ , bepridil , @DRUG$ ==References====External links==	DDI-false
When @DRUG$ was coadministered with phenytoin, rifampin, or H2antagonists, reduced plasma concentrations of @DRUG$ were reported.	DDI-false
Magnesium/Aluminum-containing @DRUG$ : Absorption of zalcitabine is moderately reduced ( approximately 25 % ) when coadministered with @DRUG$/aluminum-containing antacid products .	DDI-false
Antihypertensive Medications and @DRUG$: The following adverse events were experienced more commonly in patients receiving concomitant @DRUG$ or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Short-term pharmacokinetic studies have shown that concomitant use of @DRUG$ and Lodine   ( etodolac capsules and tablets ) results in reduced protein binding of @DRUG$ However, there was no change in the release of free warfarin.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ , @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , gentamicin , and @DRUG$ # Amphotericin B, Foscarnet, intravenous pentamidine, vancomycin and @DRUG$ ] is contraindicated.	DDI-false
Hemodynamic and electrophysiological interactions have also been observed after co-administration with propranolol, @DRUG$ , and @DRUG$.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with @DRUG$ and @DRUG$ 72.	DDI-false
In clinical studies performed with @DRUG$ , the concomitant use of oral anticoagulants ( @DRUG$ ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
Therophylline : A recent study has shown that concomitant administration of isooniazide and theophylline may lead to increased plasma levels. @DRUG$ , and in some cases a slight decrease in elimination of @DRUG$.	DDI-false
Patients with major psychotic disorders , treated with @DRUG$ , should be accompanied by @DRUG$ Only if the potential benefits outweigh the risks.	DDI-advise
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Delayed Adverse Reactions to @DRUG$: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute, atypical adverse reactions.	DDI-false
Cephalosporine-@DRUG$ containing side chains of N-methylthiotetrazole (Cefmenoxime), @DRUG$ , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
@DRUG$: @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	DDI-false
@DRUG$ Gastrointestinal acid (Guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	DDI-false
These drugs include thiazides and other diuretics, @DRUG$ , phe-nothiazines , @DRUG$ , estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, @DRUG$, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Cytochrome P-450 inducers, such as phenytoin, @DRUG$ and @DRUG$, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or @DRUG$, and high blood pressure medications.	DDI-false
Ingestion of @DRUG$ â€¢ may increase the serum concentration of digoxin and @DRUG$ Cyclosporin s Nephrotoxicity increase.	DDI-mechanism
@DRUG$: In vitro data indicate that nefazodone inhibits the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Phenytoin : @DRUG$ has no apparent pharmacokinetic interaction when administered with @DRUG$.	DDI-false
â€¢ Methenamin therapy: urinary excretion of amphetamines is increased, and efficacy is reduced by: @DRUG$ used in @DRUG$ therapy .	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or @DRUG$ (ACEI/ARB).	DDI-false
@DRUG$, @DRUG$ Amphetamines may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	DDI-false
The following examples are substances that can reduce the blood glucose lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g., @DRUG$ , salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ ( e.g. , in oral contraceptives ) .	DDI-false
These drugs include thiazides and other @DRUG$ , corticosteroids, phenothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
Medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$ , ethionamide, glutethimide, gold, @DRUG$ , iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
A study in eight healthy volunteers has shown a 50% increase in mean peak nimodipine plasma concentrations and a 90% increase in mean area under the curve, after a one week course of @DRUG$ at 1,000 mg/day and @DRUG$ at 90 mg/day.	DDI-mechanism
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an @DRUG$ with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazide, and some @DRUG$.	DDI-mechanism
Concurrent administration of HEXALEN and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.@DRUG$, an inhibitor of microsomal drug metabolism, increased @DRUG$s half-life and toxicity in a rat model.	DDI-mechanism
, Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors ( e.g. , itraconazole , ritonavir , and erythromycin ) has not been studied , increased exposures to almotriptan may be expected when @DRUG$ The drug is used at the same time as these drugs.	DDI-false
No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, @DRUG$ , and @DRUG$ It's been detected.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
Single doses of either cholestyramine or colestipol @DRUG$ bind the @DRUG$ and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	DDI-false
Haloperidol reduced or eliminated the increase in FI response caused by intermediate doses of either @DRUG$ or PCP in pigeons , but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of @DRUG$.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Patients who start taking this medicine @DRUG$ or who increase their diclofenac dose or any other NSAID while taking @DRUG$ , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs .	DDI-effect
Antihypertensive agents: amiodarone should be used with caution in patients who block -@DRUG$ (e.g. propranolol, CYP3A4 inhibitor) or @DRUG$ antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
The continued need for the other @DRUG$ agent should be reviewed after the effects of @DRUG$ have been established, and discontinuation ordinarily should be attempted.	DDI-false
Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
Other concomitant therapy Although no specific interaction studies have been performed, clinical trials with 1 mg or more of finasteride doses have been conducted at the same time. @DRUG$ , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , @DRUG$ , calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or @DRUG$ antagonists ( e.g. , verapamil , a CYP3A4 substrate , and @DRUG$ , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
@DRUG$ (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Similarly dialyzed were @DRUG$, quinidine, and theophylline, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Coadministration of valdecoxib and Ortho-Novum 1/35  increased the exposure of @DRUG$ and @DRUG$ by 20% and 34%, respectively.	DDI-false
Effect of @DRUG$ on the Pharmacokinetics of Other Drugs : Clonazepam does not appear to alter the pharmacokinetics of phenytoin , carbamazepine , or @DRUG$.	DDI-false
In the present study , the @DRUG$ @DRUG$ was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates ( DRL ) procedures .	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and Lodine  (@DRUG$ capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.	DDI-mechanism
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Based on the results of these studies , it is concluded that @DRUG$ may be safely coadministered with both @DRUG$ and dideoxyinosine .	DDI-false
Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and @DRUG$.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis , it is particularly important that physicians query patients or their guardians carefully about @DRUG$ , alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned .	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of @DRUG$ that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, @DRUG$).	DDI-false
@DRUG$ has additive effects with alcohol and other @DRUG$ (hypnotics, sedatives, tranquilizers, etc).	DDI-effect
@DRUG$ Not used as a replacement for oral or inhaled @DRUG$.	DDI-false
While all the @DRUG$ (SSRIs), e.g., citalopram, escitalopram, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
The absorption of tetracycline, furosemide, @DRUG$, @DRUG$, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
High-dose @DRUG$ with @DRUG$ protection .	DDI-effect
@DRUG$, @DRUG$, ethosuximide	DDI-false
In patients receiving @DRUG$ and a @DRUG$ concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.	DDI-advise
Potential interactions between Keppra and other AEDs ( @DRUG$ , gabapentin, lamotrigine, phenobarbital, @DRUG$ In placebo-controlled clinical trials, serum concentrations of levetiracetam and these AEDs have also been studied.	DDI-false
Warfarin @DRUG$ The pharmacokinetics of @DRUG$ were not affected (1000 mg twice daily).	DDI-false
To evaluate the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, @DRUG$ , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , @DRUG$ , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Antihypertensives : @DRUG$ should be used with caution in patients receiving   -@DRUG$ blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
The absorption of tetracycline, @DRUG$ , penicillin G , hydrochlorothiazide , and gemfibrozil was significantly decreased when given simultaneously with @DRUG$ ;	DDI-mechanism
Curariform muscle relaxants (e.g. tubocurarin) and other medicines, including ethers, succinylcholine, @DRUG$ , @DRUG$ The neuromuscular blocking effect should be increased in patients treated with Coly-Mycin M Parenteral and sodium citrate should be administered with extreme caution.	DDI-false
The AUC and Cmax of both the ( R ) and ( S ) isomers of @DRUG$ were unaffected by concurrent dosing of 0.3 mg @DRUG$.	DDI-false
Since @DRUG$ are potentiated by the @DRUG$, they should be used cautiously in the treatment of convulsions.	DDI-advise
poor metabolizers of debrisoquin : Interactions of @DRUG$ with strong inhibitors of CYP2D6 ( such as quinidine , @DRUG$ , paroxetine, and propafenone) were not studied, but these medications would be expected to increase the blood levels of the R(+) enantiomer of scientilol.	DDI-false
Since chronic dosing is required for therapeutic efficacy of @DRUG$, future studies should focus on investigation of chronic dosing effects of these drugs in combination with @DRUG$.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, warfarin, @DRUG$, Maalox, and ranitidine.	DDI-false
Clinical interaction studies with @DRUG$ and warfarin indicated that the coadministration of @DRUG$ These drugs do not lead to clinically significant drug interactions.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
Omeprazole : The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion .	DDI-false
@DRUG$, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Amiodarone may suppress certain CYP450 enzymes , including CYP1A2 , @DRUG$ , @DRUG$ , and CYP3A4 .	DDI-false
In patients who have received muscle relaxants, @DRUG$ may temporarily mask the residual effects of @DRUG$.	DDI-effect
Therefore you may need to take one @DRUG$ supplement while taking @DRUG$.	DDI-advise
hypersensitivity reactions have been reported in patients receiving combination regimens with sequentially high-dose PROLEUKIN and @DRUG$ , specifically , dacarbazine , @DRUG$ , tamoxifen and interferon alpha.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
Since higher doses of @DRUG$ (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of Vardenafil should not be exceeded in a 24-hour period when used in combination with @DRUG$ 400 mg daily.	DDI-false
Co-administration of @DRUG$ and @DRUG$ or other agents interfering with neuromuscular transmission ( e.g. , curare-like compounds ) should only be performed with caution as the effect of the toxin may be potentiated .	DDI-advise
It would be expected that @DRUG$ use during therapy with @DRUG$ would worsen the incidence or severity of diarrhea, but this has not been studied.	DDI-effect
In clinical studies, FLOLAN was used with digoxin, diuretics, @DRUG$ , oral @DRUG$ In a pharmacokinetic sub-study in patients with congestive heart failure receiving furosemide or digoxin starting treatment with FLOLAN, visible values for oral clearance of furosemide (n = 23) and digoxin (n = 30) were reduced by 13% and 15% respectively on the second day of therapy and returned to baseline by day 87.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$ , @DRUG$ , sympathomimet-ics , calcium channel blocking drugs , and isoniazid .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
In addition, the results of regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance (efavirenz, @DRUG$ , @DRUG$ , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations .	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ (such as loop or thiazide diuretics) can be acutely worsened by beta-agonists, especially when the recommended dose of the @DRUG$ is exceeded.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital , @DRUG$ , glutethimide , chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with @DRUG$ The anti-tumour effectiveness of PROLEUKIN can be reduced and should therefore be avoided. 12 beta-blockers and others @DRUG$ may potentiate the hypotension seen with PROLEUKIN .	DDI-false
@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
@DRUG$ increases @DRUG$s serum concentrations.	DDI-mechanism
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital.	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-mechanism
In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of phenytoin, @DRUG$, and methotrexate.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$ : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , @DRUG$ , gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with @DRUG$/@DRUG$-containing antacids.	DDI-false
@DRUG$, such as @DRUG$ and isoproterenol;	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
While all selective serotonin reuptake inhibitors ( @DRUG$ ) , e.g. , citalopram , escitalopram , fluoxetine , @DRUG$ , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
Combinations in these categories result in reduced efficacy of @DRUG$ * Phenothiazine, haloperidol, methoclopramide, @DRUG$.	DDI-effect
Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-false
Since there is a theoretical basis for these effects to be additive, the use of ergotamine-containing or ergot drugs (such as dihydroergotamine or @DRUG$ ) and @DRUG$ within 24 hours of each other should be avoided .	DDI-advise
Co-administration of @DRUG$ decreased the plasma concentrations of @DRUG$ by approximately 40%.	DDI-mechanism
The concomitant use of @DRUG$ tablets and other @DRUG$ is not recommended due to the increased possibility of gastrointestinal toxicity , with little or no increase in efficacy .	DDI-effect
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, @DRUG$, or @DRUG$) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Compounds that have been tested in man include antipyrine , @DRUG$ , propranolol, theophylline, and @DRUG$ No clinically significant interactions were found.	DDI-false
May interact with thyroid medication (e.g., @DRUG$), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Potassium Supplements and Potassium-Sparing Diuretics: @DRUG$ can attenuate potassium loss caused by @DRUG$.	DDI-effect
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
@DRUG$ , ampicillin , oxacillin , chlortetracycline , @DRUG$ , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum .	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
acetaminophen/@DRUG$ , lidocaine/quinidine , @DRUG$/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
@DRUG$: In healthy subjects given single 500 mg doses of cephalexin and @DRUG$, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	DDI-false
Antidepressants, @DRUG$: Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-false
- @DRUG$ Indomethacin dulls the increase in urine volume and sodium excretion observed during bumetanide treatment and inhibits the @DRUG$-induced increase in plasma renin activity.	DDI-false
Lithium carbonate : The anorectic and stimulatory effects of @DRUG$ It can be inhibited by @DRUG$.	DDI-effect
The gastrointestinal absorption of @DRUG$ and @DRUG$ is accelerated when they are coadministered with cisapride .	DDI-false
@DRUG$ It was given with tolazolin, @DRUG$ , dobutamine, steroids, surfactant, and high-frequency ventilation.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
Therapeutic concentrations of digoxin, warfarin, @DRUG$, naproxen, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
@DRUG$ (tricyclic), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, @DRUG$, phenytoin sodium, @DRUG$, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin, gentamicin and @DRUG$ ) , amphotericin B , @DRUG$ , intravenous pentamidine , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-false
@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Since @DRUG$ is a substrate for @DRUG$ , there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels .	DDI-false
The effect of TORADOL on plasma @DRUG$ has not been studied, but cases of increased lithium plasma levels during @DRUG$ therapy have been reported.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$ , @DRUG$ , calcium channel blocking drugs , and isoniazid .	DDI-false
OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of @DRUG$ and @DRUG$.	DDI-false
Another oral azole antifungal, @DRUG$, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite desmethylastermizole which may prolong QT intervals.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Diuretics: @DRUG$ and other NSAIDs can inhibit the activity of @DRUG$.	DDI-effect
@DRUG$/Hypnotics: triazolam, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
It may increase excretion of barbiturates , @DRUG$ , and @DRUG$ and may also increase the toxicity of salicylates .	DDI-false
It can interact with thyroid medications (e.g., @DRUG$ ) , iodine-containing products , antacids , H2-antagonists ( e.g. , famotidine , @DRUG$ , and proton pump inhibitors (e. g. lansoprazole, omeprazole).	DDI-false
May interact @DRUG$ (changed hypoprothrombinemic effect), @DRUG$ , rifampin and other inducers of hepatic microsomal enzyme oxidation system ( decreased effect of diethylstilbestrol ) , corticosteroids ( increased effect of corticosteroids ) .	DDI-false
@DRUG$ : @DRUG$ enhance the adrenergic effect of norepinephrine .	DDI-false
Ephedrine : Ephedrine may enhance the metabolic clearance of @DRUG$ , resulting in decreased blood levels and decreased physiological activity, so that an increase in the @DRUG$ dosage .	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, @DRUG$, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
If @DRUG$ is mixed with @DRUG$ , NovoLog should be drawn into the syringe first .	DDI-false
acetaminophen/theophylline , lidocaine/@DRUG$ , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Pregnancy: Category X: Use With @DRUG$ (see CONTRAINDICATIONS) Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to @DRUG$.	DDI-false
Clinical studies of @DRUG$ alone or in combination with @DRUG$ The number of people aged 65 and over was not sufficient to determine whether they react differently than younger people.	DDI-false
@DRUG$: Coadministration of a single dose of zaleplon and @DRUG$ (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.	DDI-false
Beta-blockers (@DRUG$, @DRUG$) serum concentrations and pharmacologic effects may be increased.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as @DRUG$ , intraconazole, ritonavir, indinavir, @DRUG$ , erythromycin , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
therefore, the use of @DRUG$ does not necessitate an adjustment in @DRUG$ dose to maintain therapeutic digoxin levels.	DDI-false
@DRUG$, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Since there is a theoretical basis for these effects to be additive, the use of ergotamine containing or @DRUG$ (such as dihydroergotamine or @DRUG$ AXERT and AXERT should be avoided within 24 hours of each other.	DDI-false
Selective serotonin reuptake inhibitors (SSRIs): SSRIs (e.g., @DRUG$ , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with @DRUG$.	DDI-effect
@DRUG$ : For normal volunteers, simultaneous use of @DRUG$ Acetaminophene and acetaminophene resulted in an approximate 50% increase in acetaminophene plasma levels.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The data from in vitro studies with benzodiazepines other than alprazolam indicate a possible interaction of the following medicinal products: @DRUG$ , cyclosporine , amiodarone , @DRUG$ And nifedipine.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of azathioprine , gold , chloroquine , D-penicillamine , prednisolone , @DRUG$ , or @DRUG$ The peak and AUC values of Diclofenac were not significantly affected.	DDI-false
In a clinical pharmacology study, indomethacin or @DRUG$ was administered to hypertensive patients receiving @DRUG$.	DDI-false
Warfarin: @DRUG$ had no clinically significant effect on prothrombin time when administered to patients receiving chronic @DRUG$ treatment.	DDI-false
In healthy volunteers, the pharmacokinetics of a 1-mg dose of @DRUG$ administered as STADOL NS were not affected by the coadministration of a single 6-mg subcutaneous dose of @DRUG$.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and @DRUG$  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral @DRUG$, digoxin, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
These drugs include the thiazides and other diuretics , @DRUG$ , phe-nothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin , nicotinic acid , sympathomimet-ics , calcium channel blocking drugs , and isoniazid .	DDI-false
Substances that are potent inhibitors of CYP3A4 activity (e.g. @DRUG$ and itraconazole ) decrease @DRUG$ metabolism and increase gefitinib plasma concentrations .	DDI-mechanism
Antiacid, clarithromycin, didanosine, fluconazole, fluoxetine, indanavir, ketoconazole, phenytoin, phenobarbitol, carbamazepine, @DRUG$ , @DRUG$ , Ritanovir , Saquinavir .	DDI-false
While all the @DRUG$ ( SSRIs), e.g., citalopram, @DRUG$ Fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, @DRUG$, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
Levosimendan has no clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$ , @DRUG$ , ethanol or itraconazole .	DDI-false
Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., @DRUG$, @DRUG$) and NovoSeven.	DDI-false
@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecolin - eproxindine - ethanol : @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Benzylpenicillin, ampicillin, oxacillin, @DRUG$, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
@DRUG$: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG$n, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	DDI-false
The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with PRINIVIL.	DDI-false
The medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$ , disulfiram, ethionamide, glutethimide, @DRUG$ , hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Cimetidine (400 mg b.i.d.) had no effect on @DRUG$ bioavailability (AUC) and maximum concentration (Cmax) of @DRUG$ when co-administered with 20 mg Vardenafil in healthy volunteers.	DDI-false
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (TMP/@DRUG$).	DDI-false
conversely , @DRUG$ may interfere with @DRUG$ ( i.e. , guanethidine , a-methyldopa ) .	DDI-int
For example, inhibitors are azole antimycotics, ciprofloxacin, @DRUG$ , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , @DRUG$ , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
@DRUG$ The AUC(s) of amprenavir decreased significantly by 82%, but amprenavir did not affect the AUC(s) of amprenavir. @DRUG$ pharmacokinetics .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ , carbamazepine , @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
@DRUG$: It has not been established if there is a pharmacokinetic interaction between @DRUG$ and combined oral contraceptives.	DDI-false
Rifampin significantly decreased the AUC(ss) of @DRUG$ by 82%, but amprenavir had no effect on @DRUG$ pharmacokinetics.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : @DRUG$ ( eg , pentazocine , @DRUG$ , butorphanol, dezocin and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesics such as levo-dromorane.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Antidepressants (tricyclic), @DRUG$ or other anticholinergic agents, or @DRUG$: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Limited comparative data in patients with high viral loads treated with @DRUG$- or @DRUG$-based regimens currently exist.	DDI-false
Although the magnitude of changes in diazepam plasma exposure when coadministered with @DRUG$ were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of @DRUG$ under this circumstance.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
In vitro studies have shown @DRUG$ can displace @DRUG$s, such as warfarin, from their protein-binding sites.	DDI-mechanism
Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of @DRUG$ This leads to an average eight-fold increase in @DRUG$ AUC.	DDI-false
Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or @DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of @DRUG$	DDI-false
Valdecoxib caused a statistically significant increase in plasma exposures of @DRUG$ and @DRUG$ ( 12 % and 15 % , respectively ) , and in the pharmacodynamic effects ( prothrombin time , measured as INR ) of warfarin .	DDI-false
Magnesium- and/or aluminum-containing antacids , products containing ferrous sulfate ( iron ) , multivitamin preparations containing @DRUG$ or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
Based on the results of these studies, it is concluded that azithromycin may be safely coadministered with both @DRUG$ and @DRUG$.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a @DRUG$ Inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a @DRUG$ inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).	DDI-false
Therefore, it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and @DRUG$ given before the evening meal would not result in a significant decrease in the clinical effect of @DRUG$.	DDI-false
Beta-blockers, @DRUG$, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
Patients who have other narcotic analgesics, general anaesthetics, phenothiazine, @DRUG$ , sedative hypnotic agents, tricyclic antidepressants or other CNS depressants (including @DRUG$ ) concomitantly with DILAUDID may exhibit an additive CNS depression .	DDI-false
Use With @DRUG$ @DRUG$ is genotoxic and mutagenic.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-false
@DRUG$ plus @DRUG$ ==References====External links==	DDI-false
- ketoconazole, miconazole, coagulation agents, @DRUG$ , etc . ): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
Methenamin therapy : Urine excretion of @DRUG$ The effectiveness is determined by: @DRUG$ ==References====External links==	DDI-mechanism
@DRUG$: When Lodine is administered with @DRUG$, its protein binding is reduced, although the clearance of free etodolac is not altered.	DDI-false
@DRUG$: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$ Imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Anticoagulants including coumarin derivatives , indandione derivatives , and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs ( @DRUG$ ) , and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin .	DDI-false
Antidepressants ( @DRUG$ ) , atropine or other @DRUG$ Co-administration with arbutamine may lead to additive inotropic and/ or chronotropic effects.	DDI-false
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , antacids , H2-antagonists ( e.g. , famotidine , @DRUG$ ) , and @DRUG$ ( e.g. , lansoprazole , omeprazole ) .	DDI-false
The compounds in these categories result in reduced efficacy of bromocliptin mesylate: phenothiazine, haloperidol, @DRUG$ , @DRUG$.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/@DRUG$ , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/@DRUG$.	DDI-false
Cimetidine : @DRUG$ The plasma concentrations and the LDL-C reduction were not altered by the concomitant use of @DRUG$.	DDI-false
@DRUG$: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that lamivudine significantly inhibited @DRUG$ phosphorylation in a dose dependent manner.	DDI-false
Antifungals: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Antidepressants ( tricyclic ) , @DRUG$ Other anticholinergics or digitalisglycosides: co-administration with @DRUG$ It may cause additive inotropic and/or chronotropic effects.	DDI-false
- In isolated cases, patients with severe but reversible renal impairment (accompanied by a corresponding increase in serum creatinine levels) have been reported in organ transplant patients with severe but reversible renal impairment. @DRUG$ therapy and concomitant @DRUG$.	DDI-effect
Anticholinesterases ( neostgmine , physostigmine ) , @DRUG$ , @DRUG$ , procainamide can enhance toxicity and cause cardio respiratory depression .	DDI-false
In pigeons, @DRUG$ did not systematically alter the effects of (-)-NANM, (+)-NANM or @DRUG$.	DDI-false
For treatment with CYP3A4 inhibitors (such as ketoconazole, intraconazole, ritonavir, @DRUG$ , @DRUG$ , erythromycin, etc.) is indicated, reduction of budesonide dose should be considered.	DDI-false
@DRUG$ ( such as @DRUG$ , lidocaine , or quinidine ): concurrent use with arbutamine may have a proarrhythmic effect .	DDI-false
An alternative non-CYP3A4 substrate @DRUG$ may be considered in patients taking CYP3A4 inducers such as rifampin , phenytoin , @DRUG$ , and phenobarbital .	DDI-false
The concentrations of SN38, the active metabolite of @DRUG$, were on average 33% higher in patients receiving bolus-IFL in combination with @DRUG$ when compared with bolus-IFL alone.	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, @DRUG$ , felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$ , ethanol or itraconazole .	DDI-false
Potassium-sparing diuretics ( e.g. , spironolactone , triamterene , or @DRUG$ ) , @DRUG$ supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with medications of @DRUG$ ( including , for example , ondansetron , granisetron , dolasetron , @DRUG$ ==References====External links==	DDI-false
Carbamazepine : @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of @DRUG$ The toxicity should be closely monitored and an appropriate dose adjustment of the anticonvulsant should be made.	DDI-false
In separate studies in patients receiving maintenance doses of warfarin, hydrochlorothiazide or @DRUG$ , @DRUG$ The 7-day administration did not affect the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.	DDI-false
The benzodiazepines are a family of benzodiazepines. @DRUG$ and @DRUG$.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Therapeutic concentrations of digoxin , @DRUG$ , ibuprofen , naproxen , piroxicam , acetaminophen , phenytoin andtolbutamide did not alter @DRUG$ protein binding .	DDI-false
Oral @DRUG$ inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, methotrexate and @DRUG$.	DDI-mechanism
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing @DRUG$ (1 microgram/ml), EGF (10 ng/ml), and @DRUG$ (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , @DRUG$ , warfarin , @DRUG$ , carvedilol , ethanol or itraconazole .	DDI-false
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, @DRUG$ for injection concentrate and teniposide for injection concentrate) should not be treated with @DRUG$.	DDI-advise
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$ : Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated .	DDI-false
Therefore , when using doses of @DRUG$ A dose reduction of more than 1200 mg/day during add-on therapy @DRUG$ may be required .	DDI-advise
cimetidine ) and many that are substrates for P450 2D6 ( many other antidepressants , @DRUG$ , and the type 1C antiarrhythmia @DRUG$ ==References====External links==	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between @DRUG$ (a benzodiazepine) and @DRUG$ under acidic conditions similar to those found in vivo , resulting in a 3-ethoxylated product .	DDI-mechanism
@DRUG$ and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and zidovudine against HIV .	DDI-false
Compounds that have been tested in man include antipyrine, digoxin, @DRUG$, @DRUG$, and warfarin and no clinically meaningful interactions were found.	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of @DRUG$, dextromethorphan, and @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$: @DRUG$ inhibit the hypotensive effect of veratrum alkaloids.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ - phenytoin, carbamazepine and @DRUG$ And the antituberculosis drug rifampin.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Naproxen : The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite .	DDI-mechanism
certain @DRUG$ (such as @DRUG$);	DDI-false
@DRUG$ containing @DRUG$, when administered concomitantly with nitrofurantoin, reduce both the rate and extent of absorption.	DDI-false
Multivitamins or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with , or within 2 hours of , the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of @DRUG$ , oral vitamin B-12, @DRUG$ and 5-fluorouracil .	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug @DRUG$.	DDI-false
In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of @DRUG$ or vinblastine and that @DRUG$ is not a substrate for P-glycoprotein-mediated transport.	DDI-false
@DRUG$: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, @DRUG$, alprazolam).	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (@DRUG$ capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free warfarin.	DDI-false
@DRUG$: In hypercholesterolemic patients, steady-state cerivastatin AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-false
A similar association, albeit less pronounced, was suggested with barbiturates, phenylbutazone, phenytoin sodium, @DRUG$ , griseofulvin, topiramate, and possibly ampicillin and @DRUG$ 72 .	DDI-false
Ritonavir: Co-administration of ritonavir and VIRACEPT resulted in an increase of 152% @DRUG$ AUC in plasma and very small change in AUC in @DRUG$ plasma A.C.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ , alfentanyl, alprazoleam, and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
acetaminophen/theophylline , lidocaine/@DRUG$ , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/@DRUG$.	DDI-false
Clidinium may have the effect of @DRUG$ , levodopa , and @DRUG$.	DDI-false
@DRUG$ plus @DRUG$ was well tolerated.	DDI-false
It is structurally distinct from the other currently available @DRUG$ (lovastatin, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
@DRUG$ : The concomitant administration of @DRUG$ with the sulfonylurea glyburide has , on rare occasions , resulted in severe hypoglycemia .	DDI-false
@DRUG$ : concurrent use may blunt the response to @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with 5HT3 antagonist class medications (including, for example, ondansetron, @DRUG$ , dolasetron, palonosetron, and @DRUG$ ) is contraindicated .	DDI-false
The successive application of @DRUG$ (5 or 10 mg/kg egg weight (e.w.) and glutamate (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of @DRUG$ alone.	DDI-false
In addition, results from regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance ( @DRUG$ , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in @DRUG$ concentrations .	DDI-false
In clinical studies, FLOLAN was used with digoxin, diuretics, @DRUG$ , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for @DRUG$ ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided . 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN .	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of fissteride doses have been co-administered in clinical trials with acetaminophen, @DRUG$ , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac @DRUG$ , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Patients who start taking Diclofenac or increase their dose of Diclofenac or any other NSAID while taking Diclofenac @DRUG$ , @DRUG$ Cyclosporin can develop toxicity properties for these drugs.	DDI-false
Although neither dexamethasone nor retinyl acetate proliferates in RPMI1640, @DRUG$ alone , they modify the mitogenic effect of @DRUG$ and insulin .	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including non-steroidal anti-inflammatory drugs and other drugs that are highly protein bound, salicylates, @DRUG$ , chloramphenicol, probenecid, coumarine, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
However, caution should be exercised when co-administering @DRUG$ With one of the @DRUG$ and also in switching from one class to the other .	DDI-advise
1 hour after the beginning of the @DRUG$ or @DRUG$ 500 mg p.o.	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/@DRUG$ and valproic acid/phenobarbital.	DDI-false
Urinary alkalinizing agents (acetazolamide, some @DRUG$) increase the concentration of the non-ionized species of the @DRUG$ molecule, thereby decreasing urinary excretion.	DDI-mechanism
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	DDI-false
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or @DRUG$ On the second day of therapy, apparent values for oral clearance of furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13 % and 15 % respectively and were returned to baseline by day 87.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
A similar association, albeit less pronounced, was proposed with barbiturates, phenyl-butazone, @DRUG$ , carbamazepine and possibly with griseofulvin , ampicillin , and @DRUG$ ( 72 )	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : @DRUG$ , @DRUG$ Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
Lack of an effect of @DRUG$ on the disposition of zidovudine and @DRUG$ in HIV-infected patients .	DDI-false
Warfarin : @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin , nor were there any changes in the pharmacodynamic profile ( prothrombin time ) following a single 25 mg oral dose of @DRUG$	DDI-false
Central nervous system depressants : Concomitant use of DURAGESIC (Fentanyl transdermal system ) with other central nervous system depressants, including but not limited to others @DRUG$ , sedatives , hypnotics , tranquilizers ( e.g. , @DRUG$ ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
@DRUG$ Simultaneous use of clonidine with @DRUG$ may potentiate blood-pressure- and heart-rate-lowering effects .	DDI-false
Prednisone/@DRUG$ : Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ can interact with @DRUG$, increasing the metabolism of chlorpromazine.	DDI-mechanism
Co-administration of cimetidine results in increased peak plasma concentrations and AUC of @DRUG$ , there is no effect on @DRUG$ Absorption when co-administered with ranitidine.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, @DRUG$ , cardiac nitrates, @DRUG$ H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$, including @DRUG$, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents.	DDI-false
@DRUG$ may interact with alcohol , blood thinners , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , norepinephrine , NSAIDs like @DRUG$ Or ibuprofen, and high blood pressure medications.	DDI-int
Dopamine antagonists : since @DRUG$ It is possible that dopamine antagonists, such as neuroleptics (phenothiazine, butyrophenone, @DRUG$ (i. e., methoclopramid, may reduce the efficacy of APOKYN.	DDI-false
Colestipol-Concomitant intake of @DRUG$ The intake of @DRUG$ can be reduced by vitamin K.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/@DRUG$ , @DRUG$/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
@DRUG$ : The effect of celecoxib on the anti-coagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of 2 - 5 mg of warfarin .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
When antizole is used concomitantly with medicinal products that increase or inhibit the cytochrome P450 system, reciprocal interactions may occur (e.g. phenytoin, @DRUG$ , @DRUG$ , ketoconazole), although this has not been studied	DDI-false
Because @DRUG$ is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard @DRUG$.	DDI-false
Rifabutin: Coadministration of rifabutin and @DRUG$ resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
In clinical studies, FLOLAN was used with digoxin, diuretics, @DRUG$ In a pharmacokinetic sub-study in patients with heart failure: @DRUG$ The apparent values for oral clearance of furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13% and 15% respectively on the second day of therapy and were returned to baseline by day 87.	DDI-false
Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism, inhibitors of this enzyme system, notably oral @DRUG$, should be used cautiously in patients receiving @DRUG$.	DDI-advise
To evaluate the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, @DRUG$ , vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipide and prednisone with @DRUG$ Bleomycin) without antiretroviral therapy.	DDI-false
While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , citalopram , @DRUG$ , @DRUG$ , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
Verapamil : Coadministration of @DRUG$ @DRUG$ plasma concentrations increased by 24%.	DDI-false
Dexamethasone and @DRUG$ similarly inhibit and stimulate @DRUG$- or insulin-induced proliferation of prostatic epithelium.	DDI-effect
Aspirin: Concomitant administration of low-dose aspirin with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Suppression by verapamil of @DRUG$-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ in wistar rats.	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, @DRUG$, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$ , and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Therefore, concurrent use of Trileptal with @DRUG$ may render these @DRUG$ less effective.	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$ and @DRUG$ In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ ARB).	DDI-false
@DRUG$ had no significant effect on @DRUG$ pharmacokinetics.	DDI-false
@DRUG$: Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of @DRUG$ after a single 0.5 mg oral dose.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetic agents, ACE inhibitors, @DRUG$ , fibrates , @DRUG$ , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Ergot Derivatives: Dihydroergotamine, ergonovine, @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
@DRUG$ Co-administration of ciprofloxacin with sulphonylurea @DRUG$ Rare cases have led to severe hypoglycaemia.	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , granisetron , dolasetron , @DRUG$ ==References====External links==	DDI-advise
@DRUG$ or @DRUG$ increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as dopamine.	DDI-false
Repeated doses of @DRUG$ Before a single dose @DRUG$ In human studies, it has been reported that propranolol absorption is reduced.	DDI-mechanism
Diphenhydramine hydrochloride has additive effects with @DRUG$ and other @DRUG$ (hypnotics, sedatives, sedatives, etc ).	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
In monkeys, @DRUG$ was about 10 times more potent than @DRUG$ in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with (+)-NANM.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , non-steroidal anti-inflammatory drugs ( e.g. , @DRUG$ ) , @DRUG$ , vancomycin .	DDI-false
When @DRUG$ was coadministered with @DRUG$ , rifampin , or H2antagonists , reduced plasma concentrations of itraconazole were reported .	DDI-mechanism
@DRUG$: The effects of warfarin and @DRUG$ on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other @DRUG$ , including, but not limited to, others @DRUG$ Anaesthetics, hypnosis, tranquilizers (e.g. benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants and alcohol may cause respiratory depression, hypotension and deep sedation, or possibly lead to coma or death.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , @DRUG$ , isosorbide mononitrate, knitztilol, @DRUG$ or itraconazole .	DDI-false
Cohort 1 then received @DRUG$ plus rifabutin for 10 days, and cohort 2 received @DRUG$ plus rifampin for 4 days.	DDI-false
In pigeons , @DRUG$ The effects of (-)-NANM, (+)-NANM or @DRUG$ have not been systematically altered.	DDI-false
Lithium generally should not be given with @DRUG$ because they reduce lithiums renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
Tetracycline, a @DRUG$, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided.	DDI-false
When a @DRUG$ For the treatment of a patient who: @DRUG$ An additional antihypertensive effect is usually observed.	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
Stavudine and @DRUG$ In vitro, ribavirin may increase the antiviral activity of @DRUG$ and zidovudine against HIV .	DDI-false
Micro-dosed @DRUG$ Preparations: Micro-dosed progesterone preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during @DRUG$ therapy.	DDI-false
unlike @DRUG$, @DRUG$ does not affect responding for a nondrug reinforcer (water).	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, @DRUG$ , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , @DRUG$ Prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Other CONCOMITANT THERAPY: Although no specific interaction studies have been conducted, cerivastatin sodium was co-administered with @DRUG$ , betablockers , @DRUG$ , diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g., @DRUG$ Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amikacin, Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika Amika, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin Amika Amika Amika Amika Amika Amika Amikacin, Amikacin, Amika Amika Amika Amikacin, Amikacin, Amikacin, Amika Amika Amika Amika Amika Amikacin, Amikacin, Amika Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin Amikacin, Amikacin Amikacin Amikacin, Amikacin, Amikacin Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin, Amikacin Amikacin Amikacin, Amikacin, Amikacin, Amikacin Amikacin @DRUG$ , intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
@DRUG$ (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
â€¢ Concomitant use of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
In patients receiving @DRUG$ , the addition of @DRUG$ to therapy could prolong the prothrombin time .	DDI-effect
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, @DRUG$ such as erythromycin) have the potential to result in increased plasma concentrations of @DRUG$.	DDI-mechanism
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ ( caution is recommended during coadministration with alprazolam ): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ The clearance decreased by 46%, the half-life decreased by 17% and the measured psychomotor performance decreased.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
It is recommended that if @DRUG$ In patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustments of the @DRUG$ dose may be necessary .	DDI-advise
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , @DRUG$ , H2-antagonists ( e.g. , famotidine , ranitidine ) , and @DRUG$ ( e.g. , lansoprazole , omeprazole ) .	DDI-false
Potential interactions between @DRUG$, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, @DRUG$, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
@DRUG$ DURAGESIC is not recommended for use in patients who received MAOI within 14 days, as severe and unpredictable potentiation by MAO inhibitors has been reported. @DRUG$	DDI-false
Antiacid , clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir , @DRUG$ , @DRUG$ , phenobarbitol, carbamazepine, rifabutin, rifampin, ritanovir, saquinavir.	DDI-false
Antiacid , clarithromycin , Didanosine , @DRUG$ , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , @DRUG$ , Ritanovir , Saquinavir .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , @DRUG$ , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral @DRUG$ ) .	DDI-false
Other Drug Interactions : No pharmacokinetic interactions were observed between @DRUG$ and the following drugs : glyburide , warfarin , @DRUG$ , Maalox , and ranitidine .	DDI-false
Concomitant administration of @DRUG$ with @DRUG$ is contraindicated.	DDI-advise
The extent to which SSRI-@DRUG$ interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved.	DDI-false
Concomitant use with @DRUG$s may result in the reduced absorption of @DRUG$.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as @DRUG$ or @DRUG$) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
@DRUG$ ( @DRUG$ It produces psychotomimetic effects in people who are similar to schizophrenia symptoms.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin , nicotinic acid , sympathomimetics , @DRUG$ , and isoniazid .	DDI-false
In patients receiving Nalfon and a @DRUG$ , at the same time, any reduction of the @DRUG$ Dosage should be done gradually to avoid possible complications of sudden steroid withdrawal.	DDI-false
Multivitamins, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
Special care should be taken when using Gleevec with CYP3A4 substrates with a narrow therapeutic window (e. g. @DRUG$ or @DRUG$ ) .	DDI-false
These drugs include the thiazides and other @DRUG$ , corticosteroids , phe-nothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimet-ics , calcium channel blocking drugs , and @DRUG$.	DDI-false
The clinical significance of this reduction is not known, hence @DRUG$ is not recommended to be ingested simultaneously with magnesium/aluminum-containing @DRUG$.	DDI-advise
Samplenecid : As with others @DRUG$ The renal excretion of Loracarbef is inhibited by probenecid and led to an increase in AUC of about 80% for @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , @DRUG$ , danazol, diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazide, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$ , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Drugs that cause significant sustained elevation in gastric pH (@DRUG$ such as ranitidine or cimetidine) may reduce plasma concentrations of @DRUG$ and therefore potentially may reduce efficacy.	DDI-mechanism
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , @DRUG$ , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , @DRUG$ , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Rifabutin: Coadministration of rifabutin and @DRUG$ resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in @DRUG$ plasma A.C.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
These results suggest that acute dosing with @DRUG$ would not affect behaviors most closely associated with @DRUG$ intoxication.	DDI-false
Nonsteroidal Anti-Inflammatory Drugs: The administration of @DRUG$ to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-mechanism
However, patients on @DRUG$ may show elevations of digoxin concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to @DRUG$ toxicity.	DDI-false
Orlistat-@DRUG$ may decrease the absorption of @DRUG$.	DDI-mechanism
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and @DRUG$.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-advise
Other concomitant therapy Although specific interaction studies have not been performed, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, @DRUG$ HMG-CoA reductase inhibitors, @DRUG$ ==See also==*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID==References==	DDI-false
@DRUG$ did not affect the conversion of @DRUG$ to the active metabolite after intravenous administration of losartan, and erythromycin had no clinically significant effect after oral administration.	DDI-false
@DRUG$: Aminoglutethimide may diminish adrenal suppression by @DRUG$.	DDI-false
poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 ( such as quinidine , @DRUG$ , paroxetine, and propafenone) have not been studied, but these medications would be expected to increase blood levels of R(+) enantiomer @DRUG$ .	DDI-effect
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as @DRUG$ , @DRUG$ , carbamazepine , and phenobarbital .	DDI-false
Ergot Derivatives: @DRUG$, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Warfarin: @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or @DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Iodine or iodine excess may decrease the effect of @DRUG$, and an iodine deficiency can increase the effect of @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
Hormonal @DRUG$ Concomitant use of Trileptal with an oral contraceptive has shown that plasma concentrations of the two hormonal components are ethinylestradiol (EE) and @DRUG$ ( LNG ) .	DDI-false
Clidinium may decrease the effect of phenothiazines, @DRUG$, and @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
ACE-inhibitors:Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Therefore, @DRUG$ serum levels should be monitored and appropriate @DRUG$ dosage adjustments made when these drugs are used concomitantly.	DDI-false
In addition, under the influence of sympatholytic medicinal products such as @DRUG$, clonidine, guanethidine, and @DRUG$, the signs of hypoglycemia may be reduced or absent.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-false
The effects of @DRUG$ (RR) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Lithium: In a study conducted in healthy subjects, mean steady-state @DRUG$ plasma levels increased approximately 17% in subjects receiving @DRUG$ 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.	DDI-false
Some drugs/substances are known to accelerate the metabolism of @DRUG$ by stimulating the synthesis of @DRUG$ (enzyme induction).	DDI-false
Agents Increasing Serum Potassium: @DRUG$ attenuates potassium loss caused by @DRUG$.	DDI-effect
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, @DRUG$, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	DDI-effect
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , @DRUG$ , dapsone , disopyramide , quinine , @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$ â€¢ may cause electrolyte loss in connection with @DRUG$ therapy .	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Central nervous system depressants : Co-administration of @DRUG$ Fentanyl transdermal system (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotic agents, sedatives (e.g. benzodiazepines), general anesthetics, @DRUG$ , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-effect
@DRUG$ - prior ingestion of diphenidol may decrease the @DRUG$ response to apomorphine in the treatment of poisoning.	DDI-false
@DRUG$: Bioavailability is mildly reduced (approximately 10%) when zalcitabine and @DRUG$ are coadministered.	DDI-false
Magnesium- and/or aluminum-containing @DRUG$, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
@DRUG$: Histamine H2-receptor antagonists appear to have no significant effect on the bioavailability of @DRUG$.	DDI-false
â™ª Drugs that can change â™ª @DRUG$ Plasma concentrations Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when gleevec is administered with CYP3A4 inhibitors (e.g. @DRUG$ , itraconazole , erythromycin , clarithromycin ) .	DDI-false
Interactions with @DRUG$: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Drugs that cause significant sustained elevation in gastric pH ( histamine H2-receptor antagonists such as ranitidine or @DRUG$ ) may reduce plasma concentrations of @DRUG$ For this reason, effectiveness can be reduced.	DDI-mechanism
@DRUG$ ( 5 mg/ kg ), moclobemid ( 30 mg/ kg ), clonazepam ( 0.25 mg/ kg ), fluoxetine ( 20 mg/ kg ) @DRUG$ ( 30 mg/kg ) or vehicle was administered .	DDI-false
Beta-blockers , clonidine , @DRUG$ salts , and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin .	DDI-false
The use of @DRUG$ Before succinylcholine to get some of the side effects of @DRUG$ has not been studied .	DDI-false
@DRUG$ or iodine excess may decrease the effect of Carbimazole, and an @DRUG$ deficiency can increase the effect of Carbimazole.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Co-administration of @DRUG$ with @DRUG$ has been shown to increase the mean half-life and the area under the concentration-time curve.	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
In these subjects, @DRUG$ did not alter the anticoagulant effect of @DRUG$ As determined by prothrombin time.	DDI-false
Special care should be taken when: @DRUG$ since there are conflicting results for the effect of @DRUG$ To the availability of digoxin and digoxin.	DDI-effect
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Antiarrhythmics : @DRUG$ , bepridil , flecainide , @DRUG$ , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/@DRUG$).	DDI-false
The coadministration of @DRUG$ decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of @DRUG$ in the urine.	DDI-false
Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
@DRUG$ : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , @DRUG$ , dolasetron , palonosetron , and alosetron ) is contraindicated .	DDI-false
Insulin or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of @DRUG$ and oral @DRUG$.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
Therapeutic concentrations of digoxin, @DRUG$ , ibuprofen, naproxen, piroxicam, acetaminophene, @DRUG$ The binding of ketorolac-tromethamine proteins was not altered by andtolbutamide.	DDI-false
It is advisable to check the coagulation time within the first days after initiation and discontinuation of treatment. @DRUG$ Treatment, with appropriate adjustment of the @DRUG$ Dose if necessary.	DDI-advise
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , @DRUG$ , nicotinic acid, @DRUG$ , calcium channel blocking drugs , and isoniazid .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , nifedipine , @DRUG$ , diazepam , certain tricyclic antidepressants , @DRUG$ , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
Sinus bradycardia has been reported with oral @DRUG$ in combination with lidocaine (CYP3A4 substrate) given for local @DRUG$.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, @DRUG$, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
Warfarin and @DRUG$ : Increased prothrombin time , with or without clinical bleeding , has been reported when @DRUG$ It is given at the same time.	DDI-effect
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
), phenobarbital/acetaminophen, phenobarbital/ valproic acid, quinidine/ lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$ , @DRUG$ , vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipide and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with @DRUG$ or @DRUG$.	DDI-false
In addition, several @DRUG$ s that are cytochrome P450 inducers can decrease plasma concentrations of oxcarbazepine and @DRUG$.	DDI-false
Antacids containing @DRUG$, when administered concomitantly with @DRUG$, reduce both the rate and extent of absorption.	DDI-mechanism
Aspirin/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1   g/kg/min . over 4 hours ) or acetaminophen ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of @DRUG$ 1.5 g/kg/min over 18 hours).	DDI-false
@DRUG$ ( @DRUG$ Sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, increasing urinary excretion.	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, carbamazepine, rifampin, @DRUG$ or St.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Hormonal @DRUG$ The concomitant use of Trileptal with oral @DRUG$ has been shown to influence the plasma concentrations of the two hormonal components , ethinylestradiol ( EE ) and levonorgestrel ( LNG ) .	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with @DRUG$ plus @DRUG$.	DDI-effect
Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Little or no change in the pharmacokinetics of either drug was observed when @DRUG$ was coadministered with lamivudine or @DRUG$.	DDI-false
@DRUG$ â€¢ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9; @DRUG$ , and CYP3A4 .	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , @DRUG$ , ritonavir and @DRUG$ In the absence of studies, increased exposure to almotriptan may be expected when Almotriptan is co-administered with these medicines.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , @DRUG$ Dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$ , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Results of studies in multiple sclerosis patients taking @DRUG$ Interferon beta-1a (AVONEX 30 mcg IM once weekly) or @DRUG$ This was not conclusive in terms of the need for dose adjustment of beta interferon or glatiramer acetate.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
In patients with mild to moderate hypertension, administration of 25 mg daily of @DRUG$ with the ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to @DRUG$ alone.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , fibrates , @DRUG$ , monoamine oxidase (MAO) inhibitors, propoxyphene, salicylate, somatostatin analogue (e.g., octreotide), @DRUG$.	DDI-false
Because prostaglandins play an important role in hemostasis , and @DRUG$ affect platelet function as well , concurrent therapy with all NSAIDs , including diclofenac , and warfarin requires close monitoring of patients to be certain that no change in their @DRUG$ Dosage is required.	DDI-false
â€¢ Drug interaction studies have shown that esomeprazole does not interact clinically significantly with @DRUG$ , warfarin, quinidine, @DRUG$ or amoxicillin .	DDI-false
@DRUG$: Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis , it is particularly important that physicians query patients or their guardians carefully about benzodiazepine , @DRUG$ and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned .	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ [e.g. intravenous aminoglycosides (e.g. @DRUG$ Amphotericin B, foscarnet, intravenous pentamidine, vancomycin and nonsteroidal anti-inflammatory agents] is contraindicated.	DDI-advise
@DRUG$: @DRUG$ causes a slight decrease (about 10%) in steady-state valproate concentrations.	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and @DRUG$ 72.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including barbiturates, tranquilizers, and @DRUG$.	DDI-effect
Serum @DRUG$ Concentrations should be monitored frequently if: @DRUG$ It is given concurrently with lithium.	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, @DRUG$, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with @DRUG$ or potent diuretics such as furosemide.	DDI-effect
Lithium: @DRUG$ 40 mg BID for 7 days produced significant decreases in @DRUG$ serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.	DDI-mechanism
The effects of oral @DRUG$ on @DRUG$ Induced hypertension has been studied in conscious sheep.	DDI-false
Interaction of @DRUG$ with Highly Protein Bound Drugs: In vitro data showed that @DRUG$ is 96% bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds.	DDI-false
Imidazoles (e.g. ketoconazole, miconazole, clots, fluconazole, etc.): in vitro and animal studies with the combination of: @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
"John s Spice") may increase the formation of @DRUG$ , a metabolite of @DRUG$ ==References====External links==	DDI-false
Digoxin, @DRUG$, Cyclosporine: @DRUG$, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Lithium : @DRUG$ decreases lithium renal clearance and increases @DRUG$ plasma levels .	DDI-mechanism
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , @DRUG$ , chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine and @DRUG$.	DDI-false
During co-administration, systemic levels of @DRUG$ and @DRUG$ were essentially unchanged.	DDI-false
In two clinical trials, @DRUG$ A dose of 4 mg/kg or 2 doses of 3 mg/kg) increased the AUC of @DRUG$ by approximately 35 % .	DDI-mechanism
@DRUG$ (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), @DRUG$ (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.	DDI-false
Bacteriostatic Antibiotics: Chloramphenicol, @DRUG$, @DRUG$, or tetracyclines may interfere with the bactericidal effect of penicillins.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Benzylpenicillin , ampicillin , oxacillin , @DRUG$ , doxycycline , @DRUG$ In vitro, erythromycin and sulfamethoxazole have no influence on the protein binding of diclofenac in human serum.	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of cisplatin.	DDI-false
Anticoagulants: Potentiation of warfarin-type (@DRUG$ and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
The cardiac effect of dopamine is due to: @DRUG$ , such as @DRUG$ and metoprolol .	DDI-false
Numerous drug interactions are possible with some @DRUG$, such as phenobarbitone and @DRUG$, which affect hepatic microsomal enzyme systems.	DDI-false
While no in vivo drug interaction studies have been conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (e.g. @DRUG$ , @DRUG$ , rifampin , and barbiturates ) would be expected to decrease estazolam concentrations .	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , @DRUG$ ), beta-blockers, calcium channel blockers, diuretics and non-steroidal anti-inflammatory drugs ( @DRUG$ ) without evidence of clinically significant adverse interactions.	DDI-false
Theophylline : As with some other @DRUG$ , concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life .	DDI-false
Beta-Blocking Agents  A pharmacokinetic study of @DRUG$ in conjunction with @DRUG$ demonstrated no significant effects on the pharmacokinetics of felodipine.	DDI-false
@DRUG$ and colestipol @DRUG$: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.	DDI-false
" Medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, @DRUG$ , cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$ , phenytoin, ribavirin and vincristine.	DDI-false
Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
Corticosteroids and Corticotropin (@DRUG$): may potentiate @DRUG$- induced hypokalemia which may predispose the patient to cardiac dysfunction.	DDI-effect
Antacids : In a clinical pharmacology study , coadministration of an antacid ( @DRUG$ , magnesium hydroxide and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat compared to fosinopril alone, suggesting that: @DRUG$ The absorption of Fosinopril may be impaired.	DDI-false
Other CONCOMITANT THERAPY: Although no specific interaction studies have been conducted, cerivastatin sodium was used in clinical trials with angiotensin converting enzyme inhibitors (ACE), @DRUG$ , calcium-channel blockers , @DRUG$ , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (@DRUG$, @DRUG$, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ And other drugs that are highly protein bound, salicylates, sulphonamides, chloramphenicol, probenecid, @DRUG$ , monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-false
- Anabolic steroids ( @DRUG$ [ e.g. Anaboline ], Oxandrolone [ e.g. Anavar ], @DRUG$ [ e.g. Anadrol ], stanozozole [ e.g. Winstrol ] or	DDI-false
Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an @DRUG$/levonorgestrol oral contraceptive product in healthy subjects.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
CANCIDAS reduced the blood AUC0 - 12 of @DRUG$ 2 doses of 0.1 mg/ kg at 12 hours intervals) was administered on the 10th day of CANCIDAS 70 mg daily compared to results from a control period during which: @DRUG$ For this reason, it was given alone.	DDI-false
@DRUG$ ( 200 mg once daily ) produced a 10-fold increase in @DRUG$ AUC and a 4-fold increase in Cmax when co-administered with vardenafil ( 5 mg ) in healthy subjects.	DDI-mechanism
@DRUG$-induced renal and mesenteric vasodilation is not antagonized by either alpha- or @DRUG$.	DDI-false
In a similar study with @DRUG$ in healthy volunteers, 1 of 24 subjects dosed with @DRUG$ 20 mg and tamsulosin 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.	DDI-false
A two-way interaction between the @DRUG$, @DRUG$, and the coumarin anticoagulants has been suggested.	DDI-int
Investigations into the effect of @DRUG$ on the protein binding of @DRUG$ (warfarin) revealed no interaction.	DDI-false
Antacids containing magnesium and/or aluminium, products containing iron sulphate ( @DRUG$ ), multivitamin preparations containing by weight: @DRUG$ The pediatric powder for oral solution must not be taken within 3 hours before or 2 hours after FACTIV.	DDI-false
Two groups ( SH/DA ; SH/FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol , @DRUG$ , higher @DRUG$ and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages ;	DDI-false
- methotrexate (e.g. mexate) use of @DRUG$ with @DRUG$ The likelihood of adverse reactions affecting the liver and/or the side effects of methotrexate may increase.	DDI-effect
Administration of @DRUG$ during therapy with a @DRUG$ has been shown to produce a  stimulating  effect in some depressed patients.	DDI-effect
With simultaneous dosing of @DRUG$ 10 mg and @DRUG$ 10 mg, 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.	DDI-effect
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
@DRUG$ : Coadministration of @DRUG$ 3 mg and 10 mg olanzapine resulted in a decrease in DSST.	DDI-false
Because a similar interaction is likely , @DRUG$ The co-administration with @DRUG$ should also not be performed.	DDI-advise
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Lithium : Diclofenac decreases @DRUG$ renal clearance and increases @DRUG$ plasma levels .	DDI-false
CONCLUSIONS: Macrolid antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors metabolised by CYP3A4 (i.e. atorvastatin, @DRUG$ , lovastatin , @DRUG$ ) .	DDI-false
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	DDI-false
There are rare reports, however, from marketing experiences, of changes in effects of @DRUG$ or oral hypoglycemic agents in the presence of @DRUG$ that necessitated changes in the doses of such agents.	DDI-effect
@DRUG$: Gastrointestinal acidifying agents (@DRUG$, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
Based on the chemical resemblance of itraconazole and @DRUG$ , coadministration of @DRUG$ with itraconazole is contraindicated .	DDI-false
â€¢ Dopamine antagonists : Since apomorphine is a dopamine agonist, it is possible that @DRUG$ , such as the neuroleptics ( @DRUG$ , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Patients who have other @DRUG$s, general anesthetics, phenothiazines, sedatives, sedative hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$ DILAUDID can be combined with an additive CNS depression.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , @DRUG$ , thyroid hormones, estrogens, progestogens (e.g., orally) @DRUG$ ) .	DDI-false
Iodine or @DRUG$ excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of @DRUG$.	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
If @DRUG$ The medicine is mixed with NPH human insulin, @DRUG$ should be drawn into the syringe first .	DDI-false
Indinavir: Coadministration of indinavir with @DRUG$ resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , @DRUG$ ( Piroxicam ) and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Norepinephrine : @DRUG$ enhance the adrenergic effect of @DRUG$.	DDI-effect
therefore, nitroglycerin or other @DRUG$ (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting @DRUG$.	DDI-advise
@DRUG$ ( such as flecainide , lidocaine , or @DRUG$ Co-administration with arbutamine may have a proarrhythmic effect.	DDI-false
Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Colestipol-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
In vitro binding studies with human serum proteins indicate that glipizide binds differently than @DRUG$ and does not interact with @DRUG$ or dicumarol.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$ Anticoagulant activity should be monitored, especially in the first few days following initiation or change of VIOXX therapy in patients who: @DRUG$ or similar agents , since these patients are at an increased risk of bleeding complications .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
A similar association , though less marked , has been suggested with @DRUG$ , phenyl-butazone , phenytoin sodium , carbamazepine and possibly with griseofulvin , @DRUG$ , and tetracyclines ( 72 )	DDI-false
Potential drug interactions between Keppra   and other @DRUG$ ( carbamazepine , @DRUG$ , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
Patients taking @DRUG$ concomitantly with @DRUG$ more commonly reported both weight gain and weight loss, compared with patients taking either medication alone.	DDI-effect
Beta-adrenergic receptor antagonists (@DRUG$) and @DRUG$ may interfere with the effect of each other when administered concurrently.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , @DRUG$ , cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$ And vincristine.	DDI-false
In EM individuals treated with paroxetine or @DRUG$ , the AUC of atomoxetine is approximately 6- to 8-fold and Css , max is about 3- to 4-fold greater than @DRUG$ alone .	DDI-false
Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of carbamazepine, @DRUG$, topiramate, or lamotrigine.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , @DRUG$ , sympathomimetics (e.g. epinephrine, @DRUG$ , terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
However, since some quinolones have been reported to improve the anticoagulant effects of warfarin or its derivatives in patients, prothrombin time or other appropriate coagulation tests should be closely monitored if a @DRUG$ It is used at the same time as @DRUG$ ==References==<br>	DDI-advise
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
These drugs include the thiazides and other @DRUG$ , corticosteroids , @DRUG$ , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
The effect of @DRUG$ * Bezalip or @DRUG$.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
Effect of @DRUG$ on the Pharmacokinetics of Other Drugs: @DRUG$ does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or phenobarbital.	DDI-false
Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	DDI-effect
An alternative non-CYP3A4 substrate @DRUG$ may be considered in patients taking CYP3A4 inducers such as @DRUG$, phenytoin, carbamazepine, and phenobarbital.	DDI-false
- anabolic steroids (Nandrolone [e.g. Anaboline ], @DRUG$ [ e.g. Anavar ], oxymetholone [ e.g. Anadrol ], @DRUG$ (e.g. Winstrol ]) or	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and Lodine   ( @DRUG$ However, there was no change in the clearance of free warfarin.	DDI-mechanism
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The effect of benzodiazepines can be enhanced by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$ , phenothiazines , @DRUG$ , or other medicines that produce CNS depression.	DDI-false
@DRUG$ Elevated serum lithium levels and symptoms of lithium toxicity have been reported in patients with concomitant lithium and @DRUG$ therapy .	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
@DRUG$ is also expected to reduce plasma concentrations of other @DRUG$ A significant CYP3A4 metabolism, such as lovastatin and atorvastatin.	DDI-mechanism
@DRUG$ : Because @DRUG$ Nephrotoxicity can be produced with a decrease in creatinine clearance and an increase in serum creatinine, and since renal excretion is the primary elimination pathway of fibrat drugs including TRICOR, there is a risk of an interaction leading to deterioration.	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors , e.g. , @DRUG$ , fluoxetine, and @DRUG$.	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ @DRUG$ and flecainide).	DDI-false
Ritonavir : Coadministration of ritonavir with @DRUG$ This resulted in a 152% increase in nelfinavir plasma AUC and a very small change in AUC in nelfinavir plasma. @DRUG$ plasma A.C.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$ : The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ The dose was given alone or when Proquin XR was administered 2 hours after omeprazole, which suppresses gastric acid secretion maximum.	DDI-false
* Drug interactions : Flupentixol may interact with some drugs, such as @DRUG$ ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and @DRUG$ Cause additive CNS depression - Tricyclic antidepressants : flupenthixol increases the effect of tricyclic antidepressants	DDI-false
A similar association , though less marked , has been suggested with @DRUG$ , phenylbutazone , phenytoin sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and @DRUG$ 72 .	DDI-false
Therophylline : A recent study has shown that @DRUG$ Treatment with theophylline may lead to increased plasma levels. @DRUG$ , and in some cases a slight decrease in the elimination of isoniazid.	DDI-false
The hypoglycaemic effect of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , @DRUG$ , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-effect
Alkalinisation agent : gastrointestinal alkalinisation agent ( @DRUG$ ==References====External links==	DDI-mechanism
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, @DRUG$, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Concomitant use of @DRUG$ supplements and @DRUG$ may increase calcium absorption	DDI-mechanism
The concomitant use of @DRUG$s, vasoconstricting agents (such as ergonovine) and some @DRUG$ may result in severe hypertension.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, methanol, higher alcohols and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
A possible interaction between glyburide and @DRUG$ , a fluoroquinolone antibiotic , has been reported , resulting in a potentiation of the hypoglycemic action of @DRUG$.	DDI-false
MAO inhibitors @DRUG$, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.	DDI-mechanism
May interact with thyroid medication ( e.g. , @DRUG$ ) , iodine-containing products , antacids , H2-antagonists ( e.g. , famotidine , ranitidine ) , and @DRUG$ ( e.g. , lansoprazole , omeprazole ) .	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenously] @DRUG$ ( e.g. , tobramycin , @DRUG$ Amphotericin B, foscarnet, intravenous pentamidine, vancomycin and nonsteroidal anti-inflammatory agents] is contraindicated.	DDI-false
When Itraconazole was coadministered with @DRUG$, @DRUG$, or H2antagonists, reduced plasma concentrations of itraconazole were reported.	DDI-false
@DRUG$ The extension of the QT interval observed with @DRUG$ could be exaggerated by tricyclic antidepressants.	DDI-effect
Other, no impact on either @DRUG$ In a study with concomitant administration of warfarin and @DRUG$, levels or prothrombin times were observed.	DDI-false
In some patients the combined use of @DRUG$ and @DRUG$ has been associated with fatal gastrointestinal hemorrhage.	DDI-effect
Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
â€¢ Use of epinephrine in patients who: @DRUG$ or @DRUG$ Like halothanes, which sensitize myocardial infarction, can cause cardiac arrhythmias.	DDI-false
Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.	DDI-false
bacteriostatic antibiotics : chloramphenicol, erythromycins, @DRUG$ , or @DRUG$ may interfere with the bactericidal effect of penicillins .	DDI-false
Dopamine antagonists : since @DRUG$ It's a dopamine agonist, it's possible that @DRUG$ The efficacy of APOKYN may be reduced by neuroleptics (phenothiazines, butyrophenone, thioxanthene) or metoclopramide.	DDI-false
Methenamine therapy: Urinary excretion of @DRUG$ is increased, and efficacy is reduced, by @DRUG$ used in methenamine therapy.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Similarly dialyzed were phenobarbital, @DRUG$, and theophylline, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
Cimetidine (400 mg b.i.d.) did not affect @DRUG$ bioavailability ( AUC ) and maximum concentration ( Cmax ) of @DRUG$ when co-administered with 20 mg Vardenafil in healthy volunteers .	DDI-false
- Poor metabolisers of schuttoquine : interactions of geschnitzilol with strong inhibitors of CYP2D6 (such as @DRUG$ , fluoxetine , @DRUG$ , and propafenone ) have not been studied , but these drugs would be expected to increase blood levels of the R(+ ) enantiomer of carvedilol .	DDI-false
It is structurally distinct from the other currently available @DRUG$ ( lovastatin , @DRUG$ , and pravastatin), resulting in unique biopharmaceutical properties compared to the other active substances of this class.	DDI-false
- @DRUG$ (e.g., Mexate) Use of methotrexate with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , @DRUG$ , isoniazid , @DRUG$ , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , gentamicin , and amikacin ) , @DRUG$ , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-advise
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
@DRUG$ and methaqualone interact pharmacologically with orally administered @DRUG$ However, the effect is not clinically significant.	DDI-int
Antifungals : In vitro and/or in vivo data indicate that @DRUG$ , itraconazole , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of @DRUG$, carbamazepine, or @DRUG$.	DDI-false
Some @DRUG$/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of @DRUG$ (enzyme induction).	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin , carbamazepine , and barbiturates , and the antituberculosis drug @DRUG$.	DDI-false
Serial plasma and urine samples for the measurement of @DRUG$ , rifabutin, and @DRUG$ and their 25-O-desacetyl metabolites , were measured by high-performance liquid chromatography .	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
@DRUG$: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma @DRUG$ mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$ , @DRUG$ , carvedilol , ethanol or itraconazole .	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and @DRUG$, and the antituberculosis drug rifampin.	DDI-false
Sulfapyridine may interact with any of the following: @DRUG$ ( e.g. , @DRUG$ (with a long-term high dose) or	DDI-false
Verapamil : Coadministration of @DRUG$ and @DRUG$ This resulted in an increase of 24% in plasma concentrations of almotriptan.	DDI-mechanism
Based on reports of narcotic withdrawal syndrome in patients with @DRUG$ and @DRUG$ concurrently , and evidence of decreased plasma concentrations of methadone .	DDI-effect
Antidiabetic drugs: (oral agents and @DRUG$) - dosage adjustment of the @DRUG$ may be required.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , @DRUG$ , quinine, amiodarone, quinidine, @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Acidifying agents: @DRUG$ (guanethidine, @DRUG$, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
MAO Inhibitors : @DRUG$ The use in patients who received MAOI within 14 days is not recommended as severe and unpredictable potentiation has been reported with MAO inhibitors. @DRUG$	DDI-false
), phenobarbital/acetaminophen, phenobarbital/ valproic acid, quinidine/ lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin , @DRUG$ , and barbiturates , and the @DRUG$ rifampin .	DDI-false
@DRUG$ NSAIDs have an increase in plasma lithium levels and a decrease in renal @DRUG$ clearance .	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, nevirapine, phenytoin, dexamethasone, or @DRUG$) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
HIV protease inhibitors : @DRUG$ Co-administration of vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil Cmax. @DRUG$ half-life .	DDI-false
Beta-blockers, @DRUG$, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
Coadministration of @DRUG$ The pharmacokinetics of @DRUG$ have not been affected.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
The similarity of the @DRUG$ Study 1 (without concomitant use of AVONEX) and Study 2 (with concomitant use of AVONEX) @DRUG$ ) indicates that this change in clearance is not required to reduce the TYSABRI dose to maintain safety.	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, @DRUG$ , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , @DRUG$ , progestogens (e.g. in oral contraceptives).	DDI-false
Patients receiving other narcotic analgesics , general anesthetics , phenothiazines , @DRUG$ , @DRUG$ , tricyclic antidepressants or other CNS depressants ( including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression .	DDI-false
Because changes in glucose concentrations with valdecoxib coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for @DRUG$ (5 mg QD and 10 mg BID) with @DRUG$ coadministration (up to 40 mg QD) is not indicated.	DDI-advise
@DRUG$-Concomitant intake of mineral oil and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
- medicines associated with peripheral neuropathy include: @DRUG$ , chloramphenicol , cisplatin , dapsone , @DRUG$ , ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Dose adjustment is not recommended . Levetiracetam had no effect on plasma concentrations of carbamazepine , @DRUG$ , @DRUG$ Or lamotrigine.	DDI-false
Acidifying agents : @DRUG$ ( guanethidine , @DRUG$ , glutamic acid HCl, ascorbic acid, fruit juices, etc. ) lower absorption of amphetamines.	DDI-false
Promethazine : Coadministration of a single dose of zaleplon and @DRUG$ ( 10 and 25 mg , respectively ) resulted in a 15 % decrease in maximal plasma concentrations of @DRUG$ , but no change in the area under the plasma concentration-time curve .	DDI-false
Pharmacokinetic or pharmacodynamic drug-effect interactions between argatroban and concomitant argatroban have not been established. @DRUG$ ( 162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1   g/kg/min . over 4 hours ) or acetaminophen ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of Argatroban 1.5   g/kg/min . over 18 hours ) .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
INOmax has been administered with @DRUG$ , dopamine , dobutamine , steroids , @DRUG$ , and high-frequency ventilation .	DDI-false
Oral @DRUG$: Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically , @DRUG$ , cis-platinum , @DRUG$ and interferon-alfa .	DDI-false
WARFARIN : Co- administration of @DRUG$ This did not result in changes in prothrombin time or coagulation factor VII compared to co-administration of cerivastatin in healthy volunteers. @DRUG$ and placebo .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , @DRUG$ Dosages of 1 mg or more have been reported simultaneously in clinical trials with acetaminophene, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also as: @DRUG$ In addition, quinolones anti-infections with no evidence of clinically significant adverse interactions.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blockers, @DRUG$ , chloroquine , gold , hydroxychloroquine , @DRUG$ , Sulfasalazine, and Anakinra.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions between VIRACEPT and Dapson, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or @DRUG$.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, @DRUG$, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Effect of @DRUG$ on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or @DRUG$.	DDI-false
â€¢ Furosemide : clinical trials, as well as post-marketing observations, have shown that: @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients .	DDI-effect
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated , apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
If it is necessary to continue the @DRUG$, initiate therapy with @DRUG$ at a dose of 5 mg daily, and provide close medical supervision after the initial dose until blood pressure has stabilized.	DDI-advise
@DRUG$ : A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide ( 1 gm/day ) 11 days after the addition of @DRUG$ ( 75 mg/day ) .	DDI-false
For example, when @DRUG$ are administered concomitantly with nilutamide, prothrombin time should be carefully monitored and if necessary, the dosage of @DRUG$ should be reduced.	DDI-false
Antihypertensives : @DRUG$ should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or @DRUG$ â€¢ antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
The effect of @DRUG$ on plasma @DRUG$ has not been studied, but cases of increased lithium plasma levels during TORADOL therapy have been reported.	DDI-false
@DRUG$: In controlled studies in healthy volunteers, @DRUG$ either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum digoxin concentrations.	DDI-false
@DRUG$ may enhance the effects of alcohol, barbiturates, and other @DRUG$.	DDI-effect
The action of the benzodiazepines may be potentiated by @DRUG$ , antihistamines , alcohol , barbiturates , monoamine oxidase inhibitors , @DRUG$ , Phenothiazine, psychotropic drugs, or other drugs that produce CNS depression.	DDI-false
Coadministration with @DRUG$ increased exposure of @DRUG$ (AUC) by 46%.	DDI-mechanism
(ii) the effects of @DRUG$ were more efficiently inhibited by added cholesterol , the major membrane sterol in human cells , whereas the effects of @DRUG$ The main membrane sterol in the yeast was more efficiently affected by ergosterol.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and @DRUG$ Cause additive CNS depression - Tricyclic antidepressants : flupenthixol increases the effect of tricyclic antidepressants	DDI-false
@DRUG$ , or other products containing @DRUG$ or zinc , antacids or sucralfate should not be administered concomitantly with , or within 2 hours of , the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin .	DDI-false
Phenytoin: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing @DRUG$.	DDI-false
@DRUG$ not only block the therapeutic effects of @DRUG$ However, severe bronchospasm can be produced in COPD patients.	DDI-effect
While no in vivo drug interaction studies have been conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (e.g. @DRUG$ , phenytoin , @DRUG$ Estazolam concentrations and barbiturates are expected to decrease.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , @DRUG$ , carvedilol , @DRUG$ or itraconazole .	DDI-false
@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
@DRUG$ (ammonium chloride, sodium phosphate, etc.) increase the concentration of the ionized species of @DRUG$ ==References====External links==* Official website	DDI-mechanism
Concurrent administration of a @DRUG$ The use of ORENCIA has been associated with an increased risk of severe infections and no significant additional efficacy when using ORENCIA. @DRUG$ alone .	DDI-false
@DRUG$ : @DRUG$ The absorption of phenytoin in the intestine may be delayed;	DDI-false
@DRUG$ containing @DRUG$ , when administered concomitantly with nitrofurantoin , reduce both the rate and extent of absorption .	DDI-false
Cardiovasculars: @DRUG$: In patients receiving digoxin therapy, administration of oral amiodarone regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
Therapeutic concentrations of @DRUG$ , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , @DRUG$ The binding of ketorolac-tromethamine proteins was not altered by andtolbutamide.	DDI-false
Higher concentrations of @DRUG$ ( 10(-8 ) - 10(-6 ) M ) or @DRUG$ ( 3 X 10(-8 ) - 10(-7 ) M ) enhance the mitogenic activity of EGF .	DDI-false
The effect of benzodiazepines may be increased by: @DRUG$ , antihistamines , alcohol , @DRUG$ , monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic drugs, or other drugs that produce CNS depression.	DDI-false
Binding to plasma protein is not significantly altered by @DRUG$, @DRUG$, or phenylbutazone.	DDI-false
Digoxin , Nimodipine and @DRUG$ : Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine , and losartan has no significant effect on plasma levels of bosentan .	DDI-false
It is recommended that concomitant use of @DRUG$ Containing aluminium hydroxide @DRUG$ At least 4 hours after administration of ethambutol.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, @DRUG$, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with @DRUG$ and tetracyclines 72.	DDI-false
In clinical trials , @DRUG$ was used with digoxin , diuretics , anticoagulants , oral @DRUG$ In a pharmacokinetic sub-study in patients with congestive heart failure receiving furosemide or digoxin starting treatment with FLOLAN, visible values for oral clearance of furosemide (n = 23) and digoxin (n = 30) were reduced by 13% and 15% respectively on the second day of therapy and returned to baseline by day 87.	DDI-false
@DRUG$: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
@DRUG$ : The concomitant administration of diflunisal and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third .	DDI-false
Patients receiving high doses of @DRUG$ concomitantly with furosemide, as in rheumatic disease, may experience @DRUG$ toxicity at lower doses because of competitive renal excretory sites.	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, CYP2D6, and @DRUG$.	DDI-false
@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	DDI-false
In vitro data suggest that @DRUG$, when compared to @DRUG$, has a less pronounced effect on the biotransformation system responsible for the metabolism of astemizole.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and @DRUG$.	DDI-effect
No data from prospective clinical trials currently exist comparing the 3 approved agents (@DRUG$, @DRUG$ or delavirdine).	DDI-false
Blood glucose concentrations should be carefully monitored when @DRUG$ and oral @DRUG$ are coadministered.	DDI-advise
Clinical interaction studies with @DRUG$ and warfarin indicated that the coadministration of @DRUG$ with these drugs does not result in clinically- significant drug interactions.	DDI-false
@DRUG$: In healthy subjects receiving @DRUG$, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, @DRUG$, anesthetics) should be considered.	DDI-false
The medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, @DRUG$ Dapsone, disulfiram, @DRUG$ , glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline ( an anticholinergic agent with multiple effects on the GI tract ) to healthy volunteers , the AUC of @DRUG$ was 10 % lower and the Cmax of clonazepam was 20 % lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone .	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, @DRUG$, diltiazem, isoniazide, and some @DRUG$.	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , granisetron , dolasetron , palonosetron , and @DRUG$ ) is contraindicated .	DDI-advise
To assess the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, @DRUG$ , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide, @DRUG$ , teniposide, and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
Because prostaglandins play an important role in hemostasis , and NSAIDs affect platelet function as well , concurrent therapy with all NSAIDs , including diclofenac , and @DRUG$ The patients must be closely monitored to be sure that their @DRUG$ dosage is required .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( phenytoin , valproate , oral contraceptive , @DRUG$ , warfarin , @DRUG$ ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients .	DDI-false
@DRUG$ : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a @DRUG$ Inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , @DRUG$ , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , @DRUG$ , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Patients treated with @DRUG$ The effect of @DRUG$ can be resistant.	DDI-effect
Interaction of GABITRIL with Other Drugs : @DRUG$ : Co-administration of cimetidine (800 mg/day) to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and sedatives (including @DRUG$), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
The effect of rifampin on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ " and extended a similar length of time after @DRUG$ withdrawal .	DDI-false
@DRUG$: Because @DRUG$ may increase blood glucose concentrations, dosage adjustments of antidiabetic agents may be required.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as @DRUG$), diphen-hydramine and @DRUG$ (such as cimetidine or ranitidine).	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$ , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide, @DRUG$ , teniposide, and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
Because prostaglandins play an important role in hemostasis , and @DRUG$ affect platelet function as well , concurrent therapy with all @DRUG$ , including Diclofenac, and warfarin requires close monitoring of patients to ensure that no change in their anticoagulant dosage is required.	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, @DRUG$, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Both ibogaine and @DRUG$ block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens ;	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The following specific interactions have been reported: Itraconazole co-administration of another prolonged formulation of felodipine with @DRUG$ The result was an approximately 8-fold increase in AUC, a more than 6-fold increase in Cmax and a 2-fold increase in the half-life of @DRUG$.	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, @DRUG$, sedatives, tranquilizers).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Antidepressants, @DRUG$ Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , @DRUG$ , tetracyclines , bacitracin , polymyxins , lincomycin , @DRUG$ , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
@DRUG$ : Administration of terfenadine with @DRUG$ resulted in the appearance of unchanged terfenadine in plasma ;	DDI-false
Urinary acidifying agents These agents ( ammonium chloride , @DRUG$ ) increase the concentration of ionized species of @DRUG$ molecule , thereby increasing urinary excretion .	DDI-mechanism
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , @DRUG$ , sulfasalazine , and @DRUG$.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , @DRUG$ , @DRUG$ , fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analogue (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , @DRUG$ , colistin , and sodium colistimethate ) , magnesium salts , @DRUG$ , local anesthetics, procainamide, and quinidine.	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$ , @DRUG$ , certain tricyclic antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
Aerosol particles of @DRUG$ were generated from an @DRUG$ solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for dissolution experiments.	DDI-false
@DRUG$: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
@DRUG$ also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by @DRUG$.	DDI-effect
@DRUG$ â€¢ Co-administration of a single dose of Sonata 20 mg and @DRUG$ 20 mg daily for 7 days produces no interaction on psychomotor performance.	DDI-false
In vitro studies have shown that precipitation occurs when eye drops, @DRUG$ are mixed with @DRUG$.	DDI-false
@DRUG$ ; Haloperidol blocks dopamine receptors and thus inhibits the central stimulating effects of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , @DRUG$ , and @DRUG$.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	DDI-effect
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Acid-catalyzed ethanolysis of @DRUG$ in anhydrous and aqueous @DRUG$ solutions .	DDI-mechanism
When CANCIDAS is co-administered with inducers of drug clearance , such as @DRUG$ , nevirapine , phenytoin , dexamethasone , or @DRUG$ , use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
Carbamazepine: @DRUG$ is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-mechanism
@DRUG$ had a similar effect in the presence of @DRUG$.	DDI-false
Antibiotics: In vitro and/or in vivo data show that @DRUG$, erythromycin, and @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Note: Dissolution of aerosol particles of budesonide in @DRUG$ A model @DRUG$.	DDI-false
The concurrent use of intravenously or orally administered @DRUG$ (e.g., aminophylline, @DRUG$) by patients receiving BROVANA has not been completely evaluated.	DDI-false
â€¢ Dopamine antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as neuroleptics (phenothiazines, @DRUG$ , thioxanthene) or methoclopramide, may reduce the effectiveness of @DRUG$.	DDI-effect
In comparison of digitalis tolerance in dogs anaesthetized with ketamine, Innovar Vet or pentobarbital, the dose of Ouabain required to cause ventricular tachycardia was significantly higher than the LD50 of @DRUG$ , with ketamine or @DRUG$ than with pentobarbital .	DDI-false
Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
@DRUG$ , @DRUG$ , verapamil	DDI-false
Saquinavir : Coadministration of saquinavir ( using an experimental soft-gelatin capsule formulation of saquinavir 1200 mg ) with @DRUG$ resulted in an 18 % increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
@DRUG$ Elevated blood and moclobemide @DRUG$ At different times after glucose overload.	DDI-false
@DRUG$ , tricyclic antidepressants , and MAOIs may increase anticholinergic effect of @DRUG$.	DDI-effect
It is desirable to monitor @DRUG$ plasma levels whenever a @DRUG$ is going to be co-administered with another drug known to be an inhibitor of P450 2D6.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -@DRUG$ blocking agents ( e.g. , @DRUG$ , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Combination of @DRUG$ with other @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone.	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including @DRUG$ With multivalent cation-containing products such as magnesium or aluminium antacids, @DRUG$ , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., tranexamic acid, @DRUG$) and @DRUG$.	DDI-false
In clinical trials , FLOLAN was used with digoxin , @DRUG$ , anticoagulants , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for @DRUG$ ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
â€¢ Saquinavir: concomitant use of @DRUG$ When using an experimental soft gelatine capsule formulation of saquinavir 1200 mg with VIRACEPT, this resulted in an increase of 18% in nelfinavir plasma AUC and a 4-fold increase in plasma plasma concentrations. @DRUG$ plasma A.C.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and @DRUG$ ) , @DRUG$ salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
The data from alprazoleam in vitro studies indicate a possible interaction with alprazoleam for the following medicinal products: @DRUG$ and @DRUG$.	DDI-false
@DRUG$ In some patients, the administration of a non-steroidal anti-inflammatory agent may reduce the diuretic, natriuretic and blood pressure lowering effect of @DRUG$.	DDI-false
The absorption of oral @DRUG$ is significantly reduced by the concomitant administration of an antacid containing @DRUG$ and magnesium.	DDI-mechanism
poor metabolizers of @DRUG$ ==References====External links==* Official website* Official website* Official website @DRUG$ , fluoxetine, paroxetine, and propafenone) were not studied, but these medications would be expected to increase the blood levels of the R(+) enantiomer of geschnitzilol.	DDI-false
Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	DDI-false
Refer to the package insert for @DRUG$ preparations before use of such preparations with @DRUG$.	DDI-advise
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because @DRUG$ increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.	DDI-false
Benzylpenicillin , @DRUG$ , oxacillin, chlortetracycline, doxycycline, cephalothine, @DRUG$ , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Similarly dialyzed were @DRUG$ , quinidine , and theophylline , both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum .	DDI-false
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of azathioprine , @DRUG$ , chloroquine, D-penicillamine, prednisolone, doxycycline or digitoxin did not significantly affect the peak and AUC values of @DRUG$.	DDI-false
@DRUG$ : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely , and appropriate dosage adjustment of the anticonvulsant should be made .	DDI-false
Use with @DRUG$: The use of @DRUG$ to control hypertension in patients on azathioprine has been reported to induce severe leukopenia.	DDI-false
@DRUG$: @DRUG$ has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG-DRUG$.	DDI-false
Since higher doses of ketoconazole (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of @DRUG$ should not be exceeded in a 24-hour period when used in combination with @DRUG$ 400 mg daily.	DDI-advise
There were no clinically relevant pharmacokinetic interactions when PRINIVIL co-administered with @DRUG$ or @DRUG$.	DDI-false
The addition of 540 mg/kg/day of @DRUG$ (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of @DRUG$ (approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) appears to have increased the incidence of both resorptions and malformations.	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and @DRUG$] is contraindicated.	DDI-false
The concomitant intake of alcohol and @DRUG$ The pharmacokinetics of alcohol or @DRUG$ are not affected.	DDI-false
The effect of benzodiazepines may be increased by: @DRUG$ , antihistamines , alcohol , barbiturates , @DRUG$ , narcotics , phenothiazines , psychotropic medications , or other drugs that produce CNS depression .	DDI-false
@DRUG$ Keppra   ( 1500 mg twice daily ) did not alter the pharmacokinetics of @DRUG$ in healthy volunteers .	DDI-false
Valproate: The addition of tiagabine to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics, but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
However, no harmful interactions were observed when ROMAZICON was administered after stunning, inhalation. @DRUG$ , @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia .	DDI-false
The concomitant use of @DRUG$ and @DRUG$ is contraindicated .	DDI-advise
Imidazoles (e. g., ketoconazole, @DRUG$, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Concurrent administration of HEXALEN and @DRUG$ may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased @DRUG$s half-life and toxicity in a rat model.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
A similar association, albeit less marked, was suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate and possibly with @DRUG$ and @DRUG$ 72 .	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , intraconazole , ritonavir , indinavir , @DRUG$ , @DRUG$ , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
Urinary acidifying agents These agents (@DRUG$, sodium acid phosphate, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	DDI-mechanism
@DRUG$ , @DRUG$ , or narcotics : potentiation of orthostatic hypotension may occur .	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and @DRUG$.	DDI-false
The effect of benzodiazepines can be enhanced by anticonvulsants, antihistamines, alcohol, barbiturates, @DRUG$ Anaesthetics, phenothiazines, @DRUG$ , or other drugs that produce CNS depression .	DDI-false
Effects of @DRUG$ on other Antiepilepsy Drugs ( AEDs ) : Phenytoin : Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ In patients with epilepsy.	DDI-false
Suppression by @DRUG$ of @DRUG$-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane in wistar rats.	DDI-effect
Hormonal Contraceptives , Including Oral , Injectable , Transdermal , and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14 % and 31 % , respectively .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ may decrease arterial responsiveness to @DRUG$.	DDI-effect
Antacids : In a clinical pharmacology study, concomitant administration of antacids (aluminium hydroxide, magnesium hydroxide and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that @DRUG$ The absorption of Fosinopril may be impaired.	DDI-false
While all selective serotonin reuptake inhibitors ( SSRIs), e.g. @DRUG$ , escitalopram , @DRUG$ , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
The steady-state plasma concentrations of @DRUG$ and @DRUG$ have been reported to be increased an average of 31 % and 20 % , respectively , by the concomitant administration of alprazolam tablets in doses up to 4 mg/day .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , @DRUG$ Doses of 1 mg or more were evaluated in clinical trials with acetaminophene, acetylsalicylic acid, A-blockers, @DRUG$ Angiotensin converting enzymes (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also called NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
As with other @DRUG$, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as anesthetics, opiates, and alcohol.	DDI-false
The interaction is a consequence of blocking hepatic metabolism of @DRUG$ by @DRUG$, a highly potent CYP3A4 inhibitor, which also inhibits CYP2C9.	DDI-mechanism
While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , @DRUG$ , @DRUG$ , fluoxetine , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, cis-platinum, tamoxifen and @DRUG$.	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between VIRACEPT and dapsone , trimethoprim/sulfamethoxazole , @DRUG$ , @DRUG$ , itraconazole or fluconazole .	DDI-false
In the @DRUG$ study , @DRUG$ had no effect on the prothrombin time or other pharmacodynamic parameters .	DDI-false
To evaluate the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, @DRUG$ , vincristine, and @DRUG$ ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Note: dissolution of aerosol particles of @DRUG$ in Survanta, a model @DRUG$.	DDI-false
No clinically important pharmacokinetic interactions occurred when @DRUG$ was used concomitantly with @DRUG$ or hydrochlorothiazide.	DDI-false
Therapeutic concentrations of digoxin , warfarin , @DRUG$ , naproxene, piroxicam, acetaminophene, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
Caution should also be taken in concurrent or serial use of other @DRUG$ and @DRUG$ because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate neomycin sulfate neuromuscular blocking effects.	DDI-false
Non-steroidal Anti-inflammatory Agents : In some patients with compromised renal function who are being treated with @DRUG$ , the concomitant use of @DRUG$ For this reason, further deterioration of renal function may result.	DDI-effect
The use of local anaesthetics containing epinephrine or norepinephrine in patients who: @DRUG$ , tricyclic antidepressants or @DRUG$ may produce severe , prolonged hypotension or hypertension .	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , sulfonamides , chloramphenicol , @DRUG$ , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-effect
No important interactions to date @DRUG$ There are no clinically important pharmacokinetic interactions with captopril, @DRUG$ , felodipine, digoxin, warfarin, isosorbide mononitrate, schnitztilol, ethanol or itraconazole.	DDI-false
The intensity , uniformity and time course of anticoagulant interference by @DRUG$ , secobarbital , glutethimide , chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
These drugs include: @DRUG$ and other diuretics , @DRUG$ , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isonazide.	DDI-false
Cytochrome P-450 inducers , such as phenytoin , @DRUG$ Inducing clonazepam metabolism, resulting in a decrease in plasma by about 30% @DRUG$ levels .	DDI-false
Antiacid, clarithromycin, @DRUG$, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , @DRUG$ , @DRUG$ Diazepam, certain tricyclic antidepressants, lidocaine, theophylline, and metronidazole, delaying the elimination and increase in blood levels of these drugs.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , @DRUG$ Phenytoin and tolbutamide did not change @DRUG$ protein binding .	DDI-false
Considerable caution should be exercised if @DRUG$ is administered concurrently with Phenurone (@DRUG$) since paranoid symptoms have been reported during therapy with this combination.	DDI-advise
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or @DRUG$ in pigeons , but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of @DRUG$.	DDI-false
Since @DRUG$ is primarily eliminated by the kidneys , coadministration of @DRUG$ with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug .	DDI-false
In a phase I study in which escalating doses of TAXOL ( 110 - 200 mg/m2) and cisplatin ( 50 or 75 mg/m2) were administered as sequential infusions, myelosuppression was lower when TAXOL was given after cisplatin than with the alternative sequence (i.e., @DRUG$ before @DRUG$ ) .	DDI-false
Potential drug interactions between: @DRUG$   and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , @DRUG$ In placebo-controlled clinical trials, serum concentrations of levetiracetam and these AEDs have also been studied.	DDI-false
In patients who have received @DRUG$, doxapram may temporarily mask the residual effects of @DRUG$.	DDI-false
In these patients whose hypertension was controlled with @DRUG$, @DRUG$ 20 mg produced mean additional supine systolic/diastolic blood pressure reductions of 6/5 mm Hg compared to placebo.	DDI-effect
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ , pimozide , carbamazepine , @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
( In some patients, the steroid may reduce the diuretic, natriuretic and blood pressure lowering effect of @DRUG-DRUG$.	DDI-false
Therefore , esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability ( eg , @DRUG$ , @DRUG$ Salts and digoxin).	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with @DRUG$.	DDI-false
- Indomethacin: Indomethacin blunts the increases in urine volume and sodium excretion seen during @DRUG$ treatment and inhibits the @DRUG$-induced increase in plasma renin activity.	DDI-false
Therapeutic concentrations of digoxin, warfarin, @DRUG$, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
Multivitamins , or other products containing @DRUG$ or zinc , @DRUG$ The use of norfloxacin or sucralfate should not occur simultaneously with or within 2 hours of administration of norfloxacin as it may impair absorption, resulting in lower serum and urine levels of norfloxacin.	DDI-false
Two percent of patients treated concurrently with @DRUG$ and @DRUG$ developed neutropenia (ANC  1 x 109/L).	DDI-effect
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	DDI-false
When Itraconazole was coadministered with @DRUG$ , @DRUG$ , or H2antagonists , reduced plasma concentrations of itraconazole were reported .	DDI-false
Estrogens, including oral @DRUG$: @DRUG$ may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.	DDI-false
@DRUG$ In normal subjects, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	DDI-false
Acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and @DRUG$ (e.g., lansoprazole, omeprazole).	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
Warfarin : @DRUG$ Increases the effect of @DRUG$.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , @DRUG$ , and @DRUG$.	DDI-false
Interaction of @DRUG$ Cimetidine: co-administration of cimetidine ( 800 mg/ day) in patients who: @DRUG$ chronically had no effect on tiagabine pharmacokinetics .	DDI-false
Erythromycin : In healthy people, plasma concentrations of @DRUG$ increased approximately 40 % with coadministration of atorvastatin and @DRUG$ , a known inhibitor of cytochrome P450 3A4 .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , @DRUG$ , @DRUG$ , HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$ , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , @DRUG$ , and verapamil .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
In contrast to the digital tolerance in dogs, Innovar Vet is anaesthetized with ketamine, or @DRUG$ , the dosage of Ouabain was needed to cause ventricular tachycardia significantly higher, such as the LD50 of @DRUG$ , with ketamine or innovar as with pentobarbital.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , @DRUG$ , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , @DRUG$ ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ ( @DRUG$ The risk of decreased saquinavir plasma concentrations is the sole protease inhibitor.	DDI-false
Micro-dosed progesterone preparations : Micro-dosed progesterone preparations @DRUG$ preparations ( minipills that do not contain an estrogen ) may be an inadequate method of contraception during @DRUG$ therapy .	DDI-effect
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, @DRUG$, or carbamazepine) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations.	DDI-mechanism
Co-administration of @DRUG$ and @DRUG$ or other agents interfering with neuromuscular transmission ( e.g. , curare-like compounds ) should only be performed with caution as the effect of the toxin may be potentiated .	DDI-advise
Digoxin, Nimodipine and @DRUG$: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, @DRUG$, @DRUG$, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
- @DRUG$ (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
@DRUG$ including coumarin derivatives , indandione derivatives , and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs ( NSAIDs ) , and @DRUG$ The risk of bleeding may be increased when co-administered with ardeparin.	DDI-false
Two groups ( SH/DA ; SH/FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol , methanol , higher @DRUG$ and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages ;	DDI-false
Warfarin: @DRUG$ enhances the effect of @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., @DRUG$, clarithromycin, nefazodone, troleandomycin, ritonavir, @DRUG$) would be expected to behave similarly.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , @DRUG$ , cyclosporine , @DRUG$ medicines (e.g. ibuprofen), tacrolimus, vancomycin.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , @DRUG$ , oral contraceptives , @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Potential interactions between Keppra and other AEDs ( @DRUG$ , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of @DRUG$ These AEDs during placebo-controlled clinical trials.	DDI-false
Other nephrotoxic medications: agents such as @DRUG$, @DRUG$, and pentamidine may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.	DDI-false
Antiarrhythmics : Amiodarone , bepridil , flecainide , @DRUG$ , @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
Use with @DRUG$: The use of angiotensin converting enzyme inhibitors to control hypertension in patients on @DRUG$ has been reported to induce severe leukopenia.	DDI-false
No significant pharmacokinetic interactions between medicinal products and medicinal products have been established in interaction studies with: @DRUG$ , digoxin , warfarin , cimetidine and @DRUG$.	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$ , isosorbide mononitrate, @DRUG$ , ethanol or itraconazole .	DDI-false
A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with @DRUG$ immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of @DRUG$ were not significantly affected.	DDI-false
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of @DRUG$, digoxin or an @DRUG$/levonorgestrol oral contraceptive product in healthy subjects.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral @DRUG$ , @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ â€¢ may cause certain CYP450 enzymes, including: @DRUG$ , CYP2C9 , CYP2D6 , and CYP3A4 .	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ : When Lodine is administered with aspirin , its protein binding is reduced , although the clearance of free @DRUG$ is not altered .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , @DRUG$ , warfarin, isosorbide mononitrate, schnitztilol, ethanol or @DRUG$.	DDI-false
Patients using CYP3A4 metabolized @DRUG$ should have cholesterol levels monitored after @DRUG$ is initiated to see whether the statin dose needs adjustment.	DDI-advise
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$ and @DRUG$ should not be administered to patients receiving coumarin drugs.	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (TMP/@DRUG$).	DDI-false
Prior administration of @DRUG$ has no clinically important effect on the neuromuscular blocking action of @DRUG$.	DDI-false
In addition, the results of regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, @DRUG$ , or @DRUG$ ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations .	DDI-false
These drugs include the thiazides and other @DRUG$ , corticosteroids, phenothiazines, @DRUG$ , estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
Effect of @DRUG$ on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, @DRUG$, or phenobarbital.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received @DRUG$ within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with @DRUG$	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants , antihistamines , alcohol , barbiturates , @DRUG$ , @DRUG$ , Phenothiazine, psychotropic drugs, or other drugs that produce CNS depression.	DDI-false
@DRUG$: Coadministration of @DRUG$ with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
While no in vivo drug-drug interaction studies have been conducted, drug-drug interaction studies have been conducted. @DRUG$ and inducers of CYP3A , compounds that are potent CYP3A inducers ( such as @DRUG$ , phenytoin , rifampin , and barbiturates ) would be expected to decrease estazolam concentrations .	DDI-mechanism
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, @DRUG$, cimetidine, @DRUG$), though this has not been studied	DDI-false
Population pharmacokinetic analyses have shown that: @DRUG$ , @DRUG$ , corticosteroids and TNF blockers did not affect abatacept clearance.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
The similarity of the @DRUG$ -associated adverse event profile between Study 1 ( without co-administered @DRUG$ ) and Study 2 ( with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI   dose to maintain safety , General ) .	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with medications of @DRUG$ ( including , for example , @DRUG$ Granisetron is contraindicated, and is contraindicated.	DDI-false
@DRUG$: Concomitant administration of diclofenac and aspirin is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) @DRUG$ @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
Interactions with @DRUG$ : Agonist/antagonist analgesics ( eg , pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-false
Oral @DRUG$ : @DRUG$ Norethindron/ ethinylestradiol ( 1 mg/35 mcg combination, ortho-novum 1/35 ) is not associated with the metabolism of the combination of norethindron/ ethinylestradiol oral contraceptives ( 40 mg twice daily).	DDI-false
however, it adversely affected response duration suggesting that pyridoxine should not be administered with @DRUG$ and/or @DRUG$.1	DDI-false
@DRUG$ : Potentiation of warfarin-type ( CYP2C9 and CYP3A4 substrate ) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .	DDI-false
@DRUG$: When multiple doses of atorvastatin and @DRUG$ were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	DDI-false
@DRUG$ should be taken as directed and @DRUG$ should be taken with a main meal of the day, preferably the evening meal..	DDI-false
@DRUG$ The area below the curve in steady state ( AUC(ss ) @DRUG$ by 2.93-fold and the AUC(ss ) of 25-O-desacetylrifabutin by 13.3-fold .	DDI-mechanism
Both @DRUG$ and 18-MC block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-effect
Multivitamins, or other products containing iron or zinc, @DRUG$ or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
These drugs include thiazides and other @DRUG$ , corticosteroids , phenothiazines , thyroid products , @DRUG$ , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ Including coumarin derivatives, indandion derivatives and platelet aggregation inhibitors such as non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin may increase the risk of bleeding when administered at the same time as @DRUG$.	DDI-effect
@DRUG$ Valdecoxib 40 mg twice daily for 7 days resulted in a significant decrease in lithium serum clearance ( 25% ) and renal clearance ( 30% ) with 34% higher serum exposure compared to @DRUG$ alone .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The effects of @DRUG$ were very strong and completely depressed the @DRUG$-induced hyperlocomotion.	DDI-effect
@DRUG$ Incorporating coumarin derivatives, indandion derivatives and platelet aggregation inhibitors such as: @DRUG$ NSAIDs and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
In clinical studies, FLOLAN was used with digoxin, diuretics, @DRUG$ , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for furosemide ( n = 23 ) and @DRUG$ ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
The effect of @DRUG$ on the pharmacokinetics of @DRUG$ administered orally has not been investigated.	DDI-false
However, it has been established that @DRUG$ interferes with the contraceptive effect of microdosed @DRUG$ minipill preparations.	DDI-effect
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION , PRIOR TO ADMINISTERING @DRUG$ TO A PATIENT @DRUG$ THERAPY , A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED .	DDI-effect
CONCLUSIONS: @DRUG$ inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., @DRUG$, cerivastatin, lovastatin, simvastatin).	DDI-mechanism
@DRUG$ Isoniazid is known to slow down your metabolism @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely , and appropriate dosage adjustment of the anticonvulsant should be made .	DDI-false
The effects of @DRUG$ and of @DRUG$ Anaesthesia on digitalis tolerance in dogs.	DDI-false
Antidepressants , @DRUG$ Amphetamines may increase the activity of tricyclic antidepressants or @DRUG$ ;	DDI-false
Potential drug interactions between Keppra   and other AEDs ( @DRUG$ , gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also evaluated by the evaluation of levetiracetam serum concentrations. @DRUG$ during placebo-controlled clinical studies .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$ (600 mg B.i.d.) with @DRUG$ 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax .	DDI-mechanism
Samplenecid : As with others @DRUG$ , renal excretion of @DRUG$ is inhibited by probenecid and resulted in an approximate 80 % increase in the AUC for loracarbef .	DDI-false
The clinical significance of this reduction is unknown and is therefore recommended not to take zalcitabine concomitantly with @DRUG$/aluminium containing @DRUG$.	DDI-false
These drugs include the @DRUG$ and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Antacids, iron products, multivitamin preparations containing zinc or other metal cations or videx ( @DRUG$ ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
, Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors ( e.g. , itraconazole , @DRUG$ Erythromycin) has not been studied, increased exposure to almotriptan can be expected when almotriptan is co-administered with these medicines.	DDI-false
In vitro studies have shown @DRUG$ @DRUG$s, such as warfarin, can be displaced from their protein-binding pages.	DDI-mechanism
Digoxin , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and @DRUG$ It has no significant influence on @DRUG$ plasma levels.	DDI-false
Thus, smaller doses of @DRUG$ may be effective in the presence of @DRUG$.	DDI-effect
This may occur because @DRUG$ competitively displaces @DRUG$ from protein binding sites .	DDI-mechanism
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
@DRUG$ : TORADOL IV/IM reduced the @DRUG$ response to furosemide in normovolemic healthy subjects by approximately 20 % ( mean sodium and urinary output decreased 17 % ) .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
This antagonistic effect of @DRUG$ on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of @DRUG$.	DDI-false
@DRUG$ If Lodine together with @DRUG$ , its protein binding is reduced , although the clearance of free etodolac is not altered .	DDI-false
Vitamin A : Because of the relationship of @DRUG$ to vitamin A , patients should be advised against taking vitamin supplements containing @DRUG$ To avoid additive toxic effects	DDI-false
Garlic capsules Garlic capsules should not be used during ingestion @DRUG$ Fortovase as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$: An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with @DRUG$.	DDI-false
Clinical interaction studies with: @DRUG$ and @DRUG$ Co-administration of femara with these medicinal products does not result in clinically significant drug interactions.	DDI-false
Although @DRUG$ have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and @DRUG$/Phenobarbital.	DDI-false
During co-administration , systemic levels of @DRUG$ and @DRUG$ were essentially unchanged .	DDI-false
Poor metabolizers have higher than expected lasma concentrations of @DRUG$ (@DRUG$) when given usual doses.	DDI-false
In addition, there have been cases reported in which concomitant use of @DRUG$ and @DRUG$ was followed by cardiac enlargement and congestive heart failure.	DDI-effect
In clinical trials, FLOLAN was used with digoxin, @DRUG$, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (@DRUG$, @DRUG$, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, @DRUG$ , bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and @DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, @DRUG$).	DDI-false
To evaluate the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, @DRUG$ , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus @DRUG$ ) without antiretroviral therapy.	DDI-false
Therophylline: A recent study has shown that concomitan administration of isoniazid and @DRUG$ may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
The concomitant use of BOTOX with aminoglycosides or other substances that impair neuromuscular transmission (e.g. @DRUG$ ) should only be performed with caution as the effect of the @DRUG$ It can be potentiated.	DDI-false
The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or @DRUG$.	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants : @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents .	DDI-advise
@DRUG$    @DRUG$ antagonism	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants , antihistamines , @DRUG$ , barbiturates , @DRUG$ , narcotics , phenothiazines , psychotropic medications , or other drugs that produce CNS depression .	DDI-false
Effects of @DRUG$ on Drug Metabolizing Enzymes and Drug Transport Systems @DRUG$ inhibits CYP3A4 and CYP2C8 in vitro at clinically relevant concentrations.	DDI-false
Lithium : NSAIDs have produced an elevation of plasma @DRUG$ Concentrations and a reduction in kidneys @DRUG$ clearance .	DDI-false
Antiacid , clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , @DRUG$ , Rifabutin , @DRUG$ , ritanovir, saquinavir.	DDI-false
Compounds that have been tested in man include antipyrine, digoxin, @DRUG$, theophylline, and @DRUG$ and no clinically meaningful interactions were found.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, @DRUG$, and nifedipine.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Use with @DRUG$ : The principal pathway for detoxification of @DRUG$ is inhibited by allopurinol .	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, fluoxetine, and @DRUG$.	DDI-false
Co-administration: Concomitant use of Argatroban with antiplatelet agents, @DRUG$, and other @DRUG$ may increase the risk of bleeding.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Administration of @DRUG$ sympathomimetics, or @DRUG$ may result in an additive pressor effect .	DDI-effect
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	DDI-false
There were no significant interactions between: @DRUG$ and warfarin or @DRUG$.	DDI-false
d-amphetamine with @DRUG$ or @DRUG$ The concentration of D-amphetamine in the brain is significantly and sustainably increased by the tricycles and possibly by other tricycles;	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-effect
Injection : Lorazepam injection , like other injectable @DRUG$ , produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$ , barbiturates , MAO inhibitors , and other antidepressants . When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-effect
Antimycobacterial agents : rifampin, which has been used since the concomitant use of this medicinal product with @DRUG$ In an antiretroviral regimen, this reduces the plasma concentrations of @DRUG$.	DDI-false
Verapamil: concomitant use of almotriptan and @DRUG$ The result was an increase in plasma concentrations of 24% of @DRUG$.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance , such as efavirenz , @DRUG$ , @DRUG$ Administration of a daily dose of 70 mg CANCIDAS should be considered	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$ , @DRUG$ , teniposide, and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
@DRUG$ : Coadministration of single doses of eszopiclone 3 mg and @DRUG$ 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug .	DDI-false
@DRUG$ is inhibited by @DRUG$.	DDI-mechanism
In a 12-month controlled trial that included a 50 mcg once daily @DRUG$ dose, 30 of the 528 BROVANA -treated subjects received concomitant @DRUG$ at study entry.	DDI-false
These drugs include the @DRUG$ and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The pharmacokinetics of a 1-mg dose of @DRUG$ Concomitant use of STADOL NS was due to the concomitant use of @DRUG$ ( 300 mg QID ).	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam ( caution is recommended during coadministration with @DRUG$ ): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .	DDI-false
Although neither @DRUG$ nor @DRUG$ Influences the proliferation of prostate epithelium in RPMI1640 with transferrin alone, altering the mitogenic effect of EGF and insulin.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or @DRUG$, use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
Cyclosporine , Digoxin , Methotrexate Lodine , like other @DRUG$ By effects on renal prostaglandins, changes in the elimination of these drugs can lead to increased serum levels of cyclosporin, @DRUG$ , methotrexate , and increased toxicity .	DDI-mechanism
@DRUG$: @DRUG$ (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
Physiological oral @DRUG$ supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with @DRUG$s, with practically only one contra-indication: overt renal failure.	DDI-false
Coadministration of @DRUG$ and @DRUG$ 1/35   increased the exposure of norethindrone and ethinyl estradiol by 20 % and 34 % , respectively .	DDI-mechanism
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO @DRUG$ INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON @DRUG$ THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.	DDI-false
In addition to the above interactions, the chronic (2 weeks) oral administration of Cordaron affects the metabolism of @DRUG$ , @DRUG$ , and methotrexate .	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat .	DDI-false
Anticoagulants : Potentiation of warfarin-type ( CYP2C9 and @DRUG$ substrate ) @DRUG$ The response is almost always observed in patients receiving amiodarone and can lead to severe or fatal bleeding.	DDI-false
Take special care with Digitalis preparations, as contradictory results for the effect of colestipol hydrochloride on the availability of @DRUG$ and @DRUG$.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/@DRUG$).	DDI-false
The compounds that have been tested in humans include: @DRUG$ , digoxin , @DRUG$ , theophylline , and warfarin and no clinically meaningful interactions were found .	DDI-false
â€¢ Anabolic steroids ( @DRUG$ [ e.g. Anaboline ], Oxandrolone [ e.g. Anavar ], Oxymetholone [ e.g. Anadrol ], Stanozolol [ e.g., @DRUG$ ] ) or	DDI-false
@DRUG$ ('Seroquel') is a newly introduced @DRUG$ with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
Valproate : @DRUG$ â€¢ causes a slight decrease ( about 10% ) in steady-state @DRUG$ concentrations .	DDI-mechanism
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , gentamicin , and amikacin ) , amphotericin B , foscarnet , intravenous @DRUG$ , vancomycin, and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-advise
Co-medicines that induce CYP3A4 (e.g. @DRUG$ , phenytoin , carbamazepine , rifampin , @DRUG$ or St.	DDI-false
Other Chemotherapy Agents In a separate study, concomitant administration of @DRUG$ with capecitabine did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of @DRUG$).	DDI-false
These drugs include the thiazides and other @DRUG$ , corticosteroids , phe-nothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimet-ics , @DRUG$ , and isoniazid .	DDI-false
@DRUG$ may block the antihypertensive action of @DRUG$ and similarly acting compounds .	DDI-effect
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, @DRUG$ , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , @DRUG$ , thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
In addition , @DRUG$ does not affect the in vitro glucuronidation of @DRUG$.	DDI-false
In separate studies with patients receiving maintenance doses of warfarin, @DRUG$ , or digoxin, @DRUG$ The 7-day administration did not affect the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.	DDI-false
Phenobarbital toxicity has been reported to have occurred in a patient on chronic @DRUG$ treatment following the initiation of @DRUG$ therapy.	DDI-effect
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , @DRUG$ , @DRUG$ , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Caution is advised in patients receiving concomitant high-dose @DRUG$ and @DRUG$, as anorexia, tachypnea, lethargy and coma have been rarely reported due to a possible drug interaction.	DDI-advise
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, @DRUG$, and alosetron) is contraindicated .	DDI-false
Magnesium/@DRUG$-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.	DDI-false
Alcohol , @DRUG$ , or @DRUG$ There may be an intensification of orthostatic hypotension.	DDI-false
May interact anticoagulants ( altered hypo-prothrombinemic effect ) , barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system ( decreased effect of diethylstilbestrol ) , @DRUG$ ( increased effect of @DRUG$ ) .	DDI-false
@DRUG$ The effects of an increased pH on the bioavailability of H2 receptor antagonists: @DRUG$ The study was conducted in 18 healthy adult volunteers.	DDI-false
@DRUG$ effects are potentiated by @DRUG$.	DDI-effect
Other cardiovascular agents: @DRUG$ It was co-administered with beta-adrenerg blockers, methyldopa, nitrates, calcium blockers, hydralazine and enalapril IV. @DRUG$ And digoxin without evidence of clinically significant adverse interactions.	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin , hydrochlorothiazide , or digoxin , @DRUG$ The 7-day administration did not affect the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of @DRUG$.	DDI-false
@DRUG$ - Taking @DRUG$ and a phenothiazine together may increase the risk of convulsions ( seizures ) .	DDI-false
1- nc denotes a mean change of less than 10 % 2- Pediatrics 3- Mean increase in adults at high @DRUG$ In vivo plasma levels of phenytoin increased by up to 40% if: @DRUG$ The dose was given at doses greater than 1200 mg/ day.	DDI-false
There are rare reports, however, from marketing experiences, from changes in the effect of insulin or oral @DRUG$ in the presence of @DRUG$ The changes required in the doses of such agents.	DDI-effect
Cyclosporine: Increased activity of both @DRUG$ and @DRUG$ may occur when the two are used concurrently.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, methyldopa, @DRUG$.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as @DRUG$, phenytoin, @DRUG$, and barbiturates) would be expected to decrease estazolam concentrations.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$ , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and @DRUG$.	DDI-false
Rifabutin : Coadministration of @DRUG$ and VIRACEPT resulted in a 32 % decrease in nelfinavir plasma AUC and a 207 % increase in @DRUG$ plasma A.C.	DDI-false
Concomitant @DRUG$, doxorubicin, vincristine, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/@DRUG$ Theophylline/acetaminophene and valproic acid/phenobarbital.	DDI-false
Warfarin: The effect of @DRUG$ on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of @DRUG$.	DDI-false
- @DRUG$: Interaction studies in humans have shown no effect on @DRUG$ blood levels.	DDI-false
A clinical study in healthy male volunteers ( n=24 ) demonstrated that mixing @DRUG$ Just before the injection, NPH caused some attenuation in the peak concentration of human insulin. @DRUG$ However, the time to peak and total bioavailability of NovoLog were not significantly affected.	DDI-false
The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
Standard therapy includes @DRUG$ , like penicillin and @DRUG$ ;	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 ( eg , phenobarbital , phenytoin , @DRUG$ , carbamazepine ) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral @DRUG$ with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral @DRUG$	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , @DRUG$ , @DRUG$ , leflunomide , sulfasalazine , and anakinra .	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -@DRUG$ blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a @DRUG$ substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Oral neomycin inhibits gastrointestinal absorption of penicillin V, oral vitamin B-12, @DRUG$ and @DRUG$.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , @DRUG$ , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
To avoid the occurrence of severe hypersensitivity reactions, all TAXOL-treated patients with corticosteroids (such as dexamethasone), diphenhydramine and H2 antagonists (such as @DRUG$ or @DRUG$ ) .	DDI-false
@DRUG$ Amiodarone should be used with caution in patients who are -@DRUG$ blockers (e.g. propranolol, a CYP3A4 inhibitor ) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus still and AV block;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Probenecid: As with other @DRUG$, renal excretion of @DRUG$ is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, @DRUG$, and @DRUG$, without any change in the adverse reaction profile.	DDI-false
â€¢ cholestyramine, colestipol (application with @DRUG$ may prevent the @DRUG$ from working properly ;	DDI-false
These drugs include: @DRUG$ And other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Antidepressants (tricyclic), atropine or other @DRUG$ , or digitalis glycosides : concurrent use with @DRUG$ It may cause additive inotropic and/or chronotropic effects.	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (@DRUG$/SMX).	DDI-false
Antiacid , @DRUG$ , Didanosine , Fluconazole , Fluoxetine , Indanavir , @DRUG$ , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , Rifampin , Ritanovir , Saquinavir .	DDI-false
@DRUG$ : Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride , there is no effect on @DRUG$ Absorption when co-administered with ranitidine.	DDI-false
In EM-persons treated with @DRUG$ The AUC of atomoxetine is about 6- to 8-fold and Css, max is about 3- to 4-fold greater than @DRUG$ alone .	DDI-false
Antiarrhythmics: Amiodarone, bepridil, @DRUG$, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , acetaminophen , @DRUG$ andtolbutamide did not alter @DRUG$ protein binding .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , @DRUG$ ==References====External links==	DDI-effect
@DRUG$ : Since @DRUG$ may bind other drugs given concurrently , patients should take TRICOR at least 1 hour before or 4 - 6 hours after a bile acid binding resin to avoid impeding its absorption .	DDI-false
@DRUG$: May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or @DRUG$ toxicity.	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance, such as efavirenz, @DRUG$, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-advise
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Hypotension    Patients on @DRUG$ Therapy : Patients on diuretics and especially those in whom diuretic therapy was recently instituted , as well as those on severe dietary salt restriction or dialysis , may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of @DRUG$.	DDI-false
Agents Causing Renin Release: The antihypertensive effect of enalapril and enalapril IV is augmented by @DRUG$ that cause renin release (e.g., @DRUG$).	DDI-false
Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
Haemodynamic effects of @DRUG$ and @DRUG$ were additive when somatostatin was co-administered but not under basal conditions .	DDI-false
@DRUG$ may increase sensitivity to the @DRUG$.	DDI-effect
Plasma exposure of @DRUG$ Following administration of valdecoxib ( 40 mg twice daily ) for 12 days, plasma exposure of 10 mg twice daily was increased by 28%. @DRUG$ After administration of diazepam ( 10 mg twice daily ) for 12 days, the dose ( 40 mg twice daily ) was not significantly increased.	DDI-false
The concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, indomethacin), myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g. methotrexate), @DRUG$ ) effects with @DRUG$ may increase toxicity in these organ systems .	DDI-effect
@DRUG$: Vardenafil 20 mg, when co-administered with slow-release @DRUG$ 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, @DRUG$, @DRUG$).	DDI-false
Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and @DRUG$ ( 12 % and 15 % , respectively ) , and in the pharmacodynamic effects ( prothrombin time , measured as INR ) of @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$ , chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Therefore, when @DRUG$ and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.	DDI-false
Central nervous system depressants: the concomitant use of DURAGESIC ( @DRUG$ The transdermal system) with other central nervous system depressants, including but not limited to others @DRUG$ Anaesthetics, hypnosis, tranquilizers (e.g. benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants and alcohol may cause respiratory depression, hypotension and deep sedation, or possibly lead to coma or death.	DDI-effect
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Quinolones , including @DRUG$ , may enhance the effects of oral anticoagulants , including @DRUG$ or its derivatives or similar agents .	DDI-effect
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$ , @DRUG$ , phenobarbital , quinidine , theophylline , and valproic acid were added to pooled human serum at therapeutic concentrations .	DDI-false
Concurrent therapy with @DRUG$ and @DRUG$ is not recommended .	DDI-advise
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$ In controlled studies of healthy volunteers, @DRUG$ They either had no effect (one study) or were associated with modest increases, approximately 30% (two studies) at steady-state serum digoxin concentrations.	DDI-false
@DRUG$ ==References====External links== @DRUG$ , miconazole , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, @DRUG$ , probenecid , coumarins , @DRUG$ And beta-adrenergic blockers.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , @DRUG$ , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
The following examples are substances that can reduce the blood glucose lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g., @DRUG$ , salbutamol , @DRUG$ ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Lithium carbonate : The stimulatory effects of @DRUG$ may be inhibited by @DRUG$.	DDI-effect
Anticoagulant inhibition was observed during the administration of @DRUG$, @DRUG$ and glutethimide;	DDI-false
Combination of amiodarone with other @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and @DRUG$ ( including @DRUG$ ) , or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-false
(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	DDI-false
Compounds tested in man include @DRUG$, @DRUG$, phenytoin, diazepam, aminopyrine and antipyrine.	DDI-false
@DRUG$ Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be used prior to concomitant administration with isoniazid, signs and symptoms of @DRUG$ The toxicity should be closely monitored and an appropriate dose adjustment of the anticonvulsant should be made.	DDI-false
The medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$ , disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$ , nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and @DRUG$.	DDI-false
Co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone or IV @DRUG$ has not been evaluated ( these drugs were not co-administered with @DRUG$ From clinical trials).	DDI-false
The medicinal products associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$ , metronidazole , nitrofurantoin , phenytoin , @DRUG$ And vincristine.	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, @DRUG$ , erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$ , quinidine, and verapamil.	DDI-false
In clinical trials, @DRUG$ was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , @DRUG$ , @DRUG$ , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$ may increase slightly the effect of @DRUG$ , e.g. , guanethidine , methyldopa , reserpine .	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
Antimycobacterial Agents : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ The regimen reduces the plasma concentrations of @DRUG$.	DDI-false
Oral @DRUG$ : Valdecoxib ( 40 mg BID ) did not induce the metabolism of the combination oral @DRUG$ norethindrone/ethinyl estradiol ( 1 mg /35 mcg combination , Ortho-Novum 1/35 ) .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Ergot Derivatives: Dihydroergotamine, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$ : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : @DRUG$	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , @DRUG$ , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as @DRUG$ ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Vitamin A: Because of the relationship of @DRUG$ to vitamin A, patients should be advised against taking @DRUG$ containing vitamin A to avoid additive toxic effects	DDI-false
@DRUG$: Coadministration of @DRUG$ and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, @DRUG$, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-advise
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Although the printer activity of @DRUG$ is very low compared to its antidiuretic activity , large doses of @DRUG$ Tablets should be used with other pressor agents only with careful patient monitoring .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ Other medicines, including ether, succinylcholine, gallamine, decamethonium and @DRUG$ Neuromuscular blocking should be intensified and administered with extreme caution to patients treated with Coly-Mycin M Parenteral.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Hypotension - Patients on Diuretic Therapy: Patients on @DRUG$, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Naproxen: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
@DRUG$ and @DRUG$ may reduce or reverse the pressor effect of epinephrine.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
It has been reported that plasma levels of several closely related tricyclic antidepressants have been associated with the concomitant use of @DRUG$ or hepatic enzyme inhibitors ( e.g. , cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , barbiturates , @DRUG$ ) , and such an effect may be anticipated with CMI as well .	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with @DRUG$ , methyldopa , nitrates , @DRUG$ , hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
" Medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, @DRUG$ , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , @DRUG$ , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
@DRUG$: In controlled studies in healthy volunteers, bepridil hydrochloride either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum @DRUG$ concentrations.	DDI-false
Erythromycin: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of @DRUG$ and erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
Co-administration of MYOBLOC and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar Vet , or @DRUG$ The dosage of ouabain needed to cause ventricular tachycardia was significantly higher, such as the LD50 of ouabain, with @DRUG$ Or Innovar as with Pentobarbital.	DDI-false
Concomitant cyclophosphamide, @DRUG$, vincristine, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
@DRUG$ : @DRUG$ caused a decrease in zalcitabine phosphorylation ( 50 % inhibition of total phosphate formation ) in U937/Molt 4 cells .	DDI-false
Vitamin A : Because of the relationship of @DRUG$ to vitamin A , patients should be advised against taking @DRUG$ containing vitamin A to avoid additive toxic effects	DDI-false
Compounds tested in man include warfarin, @DRUG$, @DRUG$, diazepam, aminopyrine and antipyrine.	DDI-false
Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Loratadine (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, @DRUG$, and @DRUG$ in controlled clinical pharmacology studies in adult volunteers.	DDI-false
Ephedrine : @DRUG$ Metabolic clearance of corticosteroids can be increased, resulting in reduced blood levels and physiological activity, which increases the @DRUG$ dosage .	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
@DRUG$ Histamine H2 receptor antagonists do not appear to have a significant influence on the bioavailability of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., @DRUG$, @DRUG$, cimetidine, ketoconazole), though this has not been studied	DDI-false
Since @DRUG$ is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of @DRUG$.	DDI-false
Other medicines that can enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX are certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), @DRUG$ salts , @DRUG$ , local anesthetics, procainamide, and quinidine.	DDI-false
While all selective serotonin reuptake inhibitors ( SSRIs), e.g., citalopram, escitalopram, fluoxetine, @DRUG$ , and @DRUG$ , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
At a median follow-up of 33 months, the combination of @DRUG$ and tamoxifen did not demonstrate any efficacy benefit when compared with @DRUG$ in all patients as well as in the hormone receptor-positive subpopulation.	DDI-false
When used in external subcutaneous infusion pumps for insulin, @DRUG$ should not be mixed with any other @DRUG$ or diluent.	DDI-false
No pharmacokinetic interactions between dexmedetomidine and @DRUG$ , propofol , @DRUG$ ==References====External links==	DDI-false
In a similar study with @DRUG$ 1 out of 24 subjects with @DRUG$ 20 mg and 0.4 mg tamsulosin separated by 6 hours had standing systolic blood pressure below 85 mm Hg.	DDI-false
@DRUG$: In a study of young healthy male subjects no evidence of a direct pharmacokinetic @DRUG$-digoxin interaction could be found.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Ethinyl Estradiol and Norethindrone: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
Specific studies have confirmed these effects with sevoflurane, isoflurane. @DRUG$ , alfentanil, and @DRUG$.	DDI-false
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including barbiturates, @DRUG$, and alcohol.	DDI-effect
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and @DRUG$.	DDI-effect
Amantadine, @DRUG$, and @DRUG$ may increase anticholinergic effect of clidinium.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, @DRUG$, anesthetics) should be considered.	DDI-advise
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
@DRUG$ and retinyl acetate similarly inhibit and stimulate EGF- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-effect
Psychoactive Drugs: Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs (fluoxetine, @DRUG$, alprazolam).	DDI-effect
The action of the benzodiazepines may be potentiated by anticonvulsants , @DRUG$ - alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$ , or other drugs that produce CNS depression .	DDI-false
In addition , Fondaparinux neither influenced the pharmacodynamics of warfarin , @DRUG$ , @DRUG$ The pharmacokinetics of digoxin in steady state.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	DDI-false
May interact with the following: @DRUG$, colestipol (use with @DRUG$ may prevent the diuretic from working properly;	DDI-effect
Based on the chemical resemblance of @DRUG$ and @DRUG$ , coadministration of astemizole with itraconazole is contraindicated .	DDI-false
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (fluoxetine, thiothixene, @DRUG$).	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other @DRUG$ (@DRUG$, sedatives, tranquilizers, etc).	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/@DRUG$ , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
Reports in the literature suggest that plasma levels of @DRUG$ (and its active metabolite doxorubicinol) may be increased when @DRUG$ and doxorubicin are used in combination.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as @DRUG$, @DRUG$, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
Benzthiazide may interact with alcohol , blood thinners , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , @DRUG$ , NSAIDs like Aleve or @DRUG$ , and high blood pressure medications .	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodon, @DRUG$ Propofol, protease inhibitors, quinidine and verapamil.	DDI-false
No clinically important pharmacokinetic interactions occurred when PRINIVIL was used concomitantly with @DRUG$ or @DRUG$.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
@DRUG$ : Increased serum @DRUG$ Concentrations and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., @DRUG$, ritonavir, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	DDI-false
@DRUG$ may interfere with the anti-glaucoma action of carbachol or @DRUG$;	DDI-effect
Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , procainamide , @DRUG$ , and @DRUG$ , have been used concurrently with amiodarone .	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$ , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and @DRUG$.	DDI-false
In addition, @DRUG$ and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of @DRUG$ and oral contraceptives, resulting in a lower plasma concentration of these drugs.	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
The medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, @DRUG$ , dapsone , @DRUG$ , ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Oral @DRUG$ inhibits the gastrointestinal absorption of @DRUG$, oral vitamin B-12, methotrexate and 5-fluorouracil.	DDI-mechanism
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , @DRUG$ , hypnotism, sedatives (e.g., @DRUG$ ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
This antagonistic effect of probenecid on @DRUG$ natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of @DRUG$.	DDI-false
Concurrent administration of @DRUG$ and @DRUG$ This may lead to increased serum levels of oxyphenbutazone.	DDI-mechanism
@DRUG$ The effect of valdecoxib on the anticoagulant effect of warfarin ( 1 - 8 mg/ day ) was evaluated in healthy subjects by concomitant administration of @DRUG$ 40 mg BID for 7 days .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ (Phenytoin): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of @DRUG$ (a CYP 3A4 inducer).	DDI-false
Urinary alkalinizing agents (@DRUG$, some @DRUG$) increase the concentration of the non-ionized species of the amphetamine molecule, thereby decreasing urinary excretion.	DDI-false
Therefore, when @DRUG$ is given to a patient receiving @DRUG$, the dosage of warfarin should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-advise
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
In comparison of the digitalis tolerance in dogs stunned with @DRUG$ , Innovar Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of @DRUG$ , with ketamine or Innovar than with pentobarbital .	DDI-false
@DRUG$-based therapies can have multiple benefits over @DRUG$-based therapy for first or longer therapy, including more convenient regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration.	DDI-false
The pharmacokinetics of @DRUG$ were not affected by coadministration of @DRUG$ or hydrochlorothiazide	DDI-false
For patients with monoamine oxidase inhibitors and tricyclic antidepressants: FORADIL should be used in patients with monoamine oxidase inhibitors or @DRUG$ because the action of @DRUG$ On the cardiovascular system can be potentiated by these active substances.	DDI-false
Central nervous system depressants : Co-administration of @DRUG$ Fentanyl transdermal system with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$ , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-effect
There was no significant difference in the pharmacodynamic effect of warfarin administered alone and @DRUG$ administered with @DRUG$ As measured by prothrombin time.	DDI-false
The peripheral vasoconstriction caused by high doses of @DRUG$ is antagonized by @DRUG$.	DDI-effect
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Concomitant administration of @DRUG$ and other related compounds (eg, quinine, quinidine and @DRUG$) may produce electrocardiographic abnormalities and increase the risk of convulsions.	DDI-effect
Antacids containing iron sulphate, @DRUG$ containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
Clinical studies with @DRUG$ Potentially significant interactions with fluconazole and @DRUG$ have been identified.	DDI-int
poor metabolizers of @DRUG$: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
@DRUG$ with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain ;	DDI-mechanism
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: @DRUG$ , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , @DRUG$ , leflunomide , sulfasalazine , and anakinra .	DDI-false
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with @DRUG$ (10 mg @DRUG$ BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents (@DRUG$, nevirapine or @DRUG$).	DDI-false
Antiarrhythmics: Amiodarone, @DRUG$, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
It may be necessary to adjust the dosage of oral anticoagulants upon beginning or stopping @DRUG$. since @DRUG$ may prolong prothrombin time.	DDI-false
@DRUG$ : In healthy subjects given single 500 mg doses of cephalexin and @DRUG$ , plasma metformin mean cmax and AUC increased by an average of 34 % and 24 % , respectively , and metformin mean renal clearance decreased by 14 % .	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
In addition, under the influence of sympatholytics such as beta-blockers, @DRUG$ , @DRUG$ Reserpine, the signs of hypoglycaemia may be reduced or absent.	DDI-false
@DRUG$ ; Reports indicate that NSAIDs can reduce the antihypertensive effect of @DRUG$.	DDI-false
Interaction with phenytoin, @DRUG$ and @DRUG$ has also been reported to produce adverse clinical effects.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$.	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ (e. g. cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline ( an @DRUG$ â€¢ with multiple effects on the GI tract) for healthy subjects, the AUC of @DRUG$ was 10 % lower and the Cmax of clonazepam was 20 % lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone .	DDI-false
Benzylpenicillin , @DRUG$ , oxacillin, chlortetracycline, doxycycline, cephalothine, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum .	DDI-false
@DRUG$ and @DRUG$ (ACTH): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.	DDI-false
In well-controlled patients undergoing concurrent therapy with @DRUG$, a decrease in the steady-state serum concentrations of @DRUG$ may occur when cime-tidine therapy is discontinued.	DDI-mechanism
@DRUG$ : Co-administration of @DRUG$ with rifampin 600 mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in rofecoxib plasma concentrations .	DDI-false
Although no clinical studies have been conducted , it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers ( such as @DRUG$ , @DRUG$ CYP3A4 inhibitors (e. g. azole antifungals, ketoconazole);	DDI-false
When LEVSIN is co-administered with others @DRUG$ , amantadine , haloperidol , @DRUG$ , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some antihistamines .	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
Acetaminophen/theophylline, lidocaine/@DRUG$, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
It is desirable to monitor @DRUG$ Plasma levels if: @DRUG$ is going to be co-administered with another drug known to be an inhibitor of P450 2D6 .	DDI-false
@DRUG$ , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
Steady-state serum concentrations of @DRUG$ are reported to fluctuate significantly when @DRUG$ is either added or deleted from the drug regimen.	DDI-mechanism
Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , itraconazole , @DRUG$ , and erythromycin ) has not been studied , increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications .	DDI-advise
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of @DRUG$ , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain @DRUG$ , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
For information on the pharmacokinetics of @DRUG$ and @DRUG$ In combination, see drug interactions under CLINICAL PHARMACOLOGY section.	DDI-false
High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.	DDI-mechanism
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when using Gleevec with CYP3A4 inhibitors (e.g. @DRUG$ , @DRUG$ , erythromycin , clarithromycin ) .	DDI-false
Uricosuric drugs , such as @DRUG$ and @DRUG$ , can inhibit renal tubular secretion of nitrofurantoin.	DDI-false
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
As with other antipsychotic agents , it should be noted that @DRUG$ may be capable of potentiating @DRUG$ such as anesthetics , opiates , and alcohol .	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , @DRUG$ , phenothiazine derivatives, @DRUG$ , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
@DRUG$ : Coadministration of a single dose of zaleplon and promethazine ( 10 and 25 mg , respectively ) resulted in a 15 % decrease in maximal plasma concentrations of @DRUG$ However, no change in the area under the plasma concentration-time curve.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
However, concomitant administration of @DRUG$ with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of CELEBREX alone.	DDI-effect
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of @DRUG$, digoxin or an ethinylestradiol/levonorgestrol oral @DRUG$ in healthy subjects.	DDI-false
Although @DRUG$ used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with BETAGAN and @DRUG$ may occur.	DDI-false
Antimycotics: In vitro and/or in vivo data show that fluconazole, itraconazole and oral ketoconazole clearly demonstrate the metabolism of @DRUG$ , which can result in an increase in plasma @DRUG$ The concentrations and prolongation of the QT interval on the ECG.	DDI-false
@DRUG$: Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs (fluoxetine, thiothixene, alprazolam).	DDI-false
Concomitant oral administration of @DRUG$ (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral @DRUG$.	DDI-mechanism
Other interactions: no pharmacokinetic interactions between: @DRUG$ and the following drugs : glyburide , @DRUG$ ==References====External links==	DDI-false
Valdecoxib caused a statistically significant increase in plasma exposures of @DRUG$ and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of @DRUG$.	DDI-false
Interactions may occur between EPA supplements and aspirin and other @DRUG$ and herbs such as garlic ( Allium sativum ) and ginkgo ( @DRUG$ ) .	DDI-false
@DRUG$ : In healthy subjects receiving ketoconazole , a CYP3A4 inhibitor , at 200 mg twice daily for 7 days , systemic exposure ( AUC ) to @DRUG$ The half-life increased to 1.7 times the control.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , @DRUG$ , chloroquine, gold, @DRUG$ , leflunomide, sulfasalazine, and anakinra.	DDI-false
When LEVSIN is co-administered with others @DRUG$ Amantadine, haloperidol, phenothiazine, @DRUG$ , tricyclic antidepressants or some antihistamines .	DDI-false
Benzthiazide may interact with alcohol , @DRUG$s , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , norepinephrine , NSAIDs like Aleve or @DRUG$ , and high blood pressure medications .	DDI-false
The effects of @DRUG$ and L-CCG-1 upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice .	DDI-false
Because of the small effect on half-life, the coadministration with @DRUG$ to extend the half-life of @DRUG$ is not recommended.	DDI-advise
Co-administration of either intravenous or oral methylxanthines (e.g. @DRUG$ , @DRUG$ Patients receiving BROVANA have not been fully studied.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Epinephrine should also be used cautiously with other medicines (e.g. @DRUG$ , @DRUG$ Myocardial infarction (also known as myocardial infarction) has been reported in patients treated with myocardial infarction.	DDI-false
- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$ , and sodium colistimethate ) , magnesium salts , lithium , local @DRUG$ , procainamide , and quinidine .	DDI-false
Central nervous system depressants: the concomitant use of DURAGESIC ( @DRUG$ Transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, sedatives (e.g., @DRUG$ ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-effect
In two combined 12-week placebo controlled trials that included @DRUG$ doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 @DRUG$ -treated subjects received concomitant theophylline at study entry.	DDI-false
In addition , @DRUG$ neither influenced the pharmacodynamics of warfarin , @DRUG$ , piroxicam , and digoxin , nor the pharmacokinetics of digoxin at steady state .	DDI-false
When CANCIDAS is co-administered with drug clearance inducers such as efavirenz, nevirapine, phenytoin, @DRUG$ , or @DRUG$ Administration of a daily dose of 70 mg CANCIDAS should be considered.	DDI-false
@DRUG$ and butyrophenones may reduce or reverse the pressor effect of @DRUG$.	DDI-effect
In a 12-week endoscopy study in OA patients, there was no difference in the cumulative incidence of endoscopic gastrointestinal ulcers in patients receiving a low dose ( 81 mg ) @DRUG$ plus @DRUG$ 25 mg daily, compared to the ibuprofen 2400 mg daily alone.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and @DRUG$ ), magnesium salts, lithium, local anaesthetics, procainamide and @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral @DRUG$, @DRUG$, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Drugs which inhibit CYP 3A4 (e.g., @DRUG$, macrolide antibiotics such as @DRUG$) have the potential to result in increased plasma concentrations of corticosteroids.	DDI-false
Antibiotics : In vitro and/or in vivo data show that @DRUG$ , erythromycin and @DRUG$ markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$ , sympathomimet-ics , @DRUG$ , and isoniazid .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
It can interact with thyroid medications (e.g. levothyroxin), @DRUG$-containing products, antacids, @DRUG$ * (e.g. famotidine, ranitidine) and proton pump inhibitors (e.g. lansoprazole, omeprazole).	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( @DRUG$ ) , @DRUG$ Acetylsalicylic acid, NSAIDs (piroxicam) and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Pharmacokinetic Interaction between amprenavir and @DRUG$ or @DRUG$ in healthy males.	DDI-false
Concurrent administration of HEXALEN and @DRUG$ may cause severe orthostatic hypotension.@DRUG$, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.	DDI-false
Sinus bradycardia has been reported with oral @DRUG$ in combination with lidocaine (@DRUG$ substrate) given for local anesthesia.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions between VIRACEPT and Dapson, @DRUG$/sulfamethoxazole, clarithromycin, are not expected. @DRUG$ Itraconazole or fluconazole.	DDI-false
Thus, @DRUG$ should not be administered concurrently with @DRUG$.	DDI-advise
The @DRUG$ are a family of anxiolytic and @DRUG$.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
@DRUG$: Vardenafil (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by @DRUG$ (two 81 mg tablets).	DDI-false
Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
Interaction on the antinociceptive effect between @DRUG$ and enkephalins or @DRUG$.	DDI-effect
Haloperidol reduced or eliminated the increase in FI response caused by intermediate doses of either @DRUG$ or @DRUG$ in pigeons , but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM .	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
The use of @DRUG$ in patients receiving @DRUG$ may be rarely associated with ventricular fibrillation.	DDI-effect
Antiarrhythmics : Other @DRUG$ Medicines such as quinidine, procainamide, disopyramide and phenytoin were used concomitantly with @DRUG$.	DDI-false
Although no clinical studies have been conducted , it is likely that the metabolism of @DRUG$ , CYP3A4 inhibitors (e. g. azole antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals, antifungals. @DRUG$ ;	DDI-mechanism
INOmax has been administered with tolazoline, @DRUG$, dobutamine, steroids, @DRUG$, and high-frequency ventilation.	DDI-false
Patients receiving both @DRUG$ and @DRUG$ should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved.	DDI-advise
The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide, and @DRUG$ was significantly decreased when given simultaneously with @DRUG$;	DDI-mechanism
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with beta-adrenergic blockers, methyldopa, @DRUG$ , @DRUG$ , hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$: Phenylbutazone causes increase (by about 80%) in the free fraction of @DRUG$.	DDI-false
These results suggest that the hepatoxicity of @DRUG$ in alcoholic beverages is enhanced by interaction with its congeners and @DRUG$;	DDI-effect
Coadministration of esomeprazole 30 mg and @DRUG$, a CYP2C19 substrate, resulted in a 45% decrease in clearance of @DRUG$.	DDI-false
Theophylline: As with some other quinolones, concomitant use of ciprofloxacin with @DRUG$ It can lead to increased serum concentrations. @DRUG$ Elongation of elimination half-life.	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: @DRUG$ does not appear to alter the pharmacokinetics of phenytoin, carbamazepine, or @DRUG$.	DDI-false
Potential drug interactions between Keppra   and other AEDs ( carbamazepine , @DRUG$ , lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$ ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	DDI-false
@DRUG$ The blood AUC0 - 12 of tacrolimus is reduced by approximately 20%, the maximum blood concentration (Cmax) by 16% and the 12-hour blood concentration (C12h) by 26% in healthy volunteers when tacrolimus (2 doses of 0.1 mg/kg at 12 hours interval) was administered on the 10th day of CANCIDAS 70 mg daily, compared with results from a control period in which: @DRUG$ was administered alone .	DDI-false
@DRUG$, including norfloxacin, may enhance the effects of oral anticoagulants, including @DRUG$ or its derivatives or similar agents.	DDI-effect
@DRUG$: Reports suggest that @DRUG$ may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.	DDI-false
Terfenadine : use of @DRUG$ with VIRACEPT resulted in the appearance of unchanged @DRUG$ in plasma ;	DDI-false
Studies in rats have shown that the administration of neomycin to certain types of @DRUG$ dependent hypertension , including @DRUG$ hypertension .	DDI-false
Discontinuing colestipol hydrochloride could pose a hazard to health if a potentially toxic drug that is significantly bound to the @DRUG$ has been titrated to a maintenance level while the patient was taking @DRUG$.	DDI-false
There were transient increases in liver ALT and AST when @DRUG$ and @DRUG$ were co-administered .	DDI-effect
- medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, @DRUG$ Antihistamines : @DRUG$ , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
Multivitamins, or other products containing @DRUG$ or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , @DRUG$ , diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$ , protease inhibitors , quinidine , and verapamil .	DDI-false
@DRUG$ Indinavir (800 mg t.i.d.) with vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life .	DDI-false
Other concomitant therapy Although no specific interaction studies have been performed, clinical trials with 1 mg or more of finasteride doses have been conducted at the same time. @DRUG$ , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , @DRUG$ , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Reports in the literature suggest that plasma levels of @DRUG$ Doxorubicinol (and its active metabolite doxorubicinol) may be increased if paclitaxel and @DRUG$ are used in combination .	DDI-false
It is recommended to avoid concurrent administration of ethambutol with @DRUG$ containing @DRUG$ for at least 4 hours following ethambutol administration.	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	DDI-effect
John s wort) may increase the formation of @DRUG$, a metabolite of @DRUG$ associated with hemolysis.	DDI-false
When @DRUG$ was coadministered with phenytoin, @DRUG$, or H2antagonists, reduced plasma concentrations of itraconazole were reported.	DDI-mechanism
@DRUG$ Incorporating tranylcypromin sulfate, phenylzinsulfate and pargylin HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension .	DDI-false
â€¢ Anabolic steroids ( @DRUG$ [ e.g. , Anabolin ] , oxandrolone [ e.g. , @DRUG$ ] , oxymetholone [ e.g. , Anadrol ] , stanozolol [ e.g. , Winstrol ] ) or	DDI-false
@DRUG$: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and live or @DRUG$ due to inhibition of antibody response.	DDI-false
The possibility of hypotensive effects with @DRUG$ or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-false
Drug interaction studies have shown that: @DRUG$ does not have any clinically significant interactions with phenytoin , @DRUG$ , quinidine , clarithromycin or amoxicillin .	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between @DRUG$ , trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$, digoxin, @DRUG$, cimetidine and phenobarbital.	DDI-false
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including @DRUG$, and warfarin requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.	DDI-false
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
@DRUG$ In a clinical pharmacology study, concomitant administration of antazide (aluminium hydroxide, magnesium hydroxide and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and salicylates is not recommended.	DDI-false
Concomitant administration of @DRUG$ (10 mg) and cimetidine (800 mg) produced an 85% increase in the mean Cmax and AUC of @DRUG$.	DDI-false
Drug-Drug Interactions Between Keppra  And Other @DRUG$ (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	DDI-false
@DRUG$: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with @DRUG$ (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).	DDI-false
While @DRUG$ and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
" Medicinal products not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, @DRUG$ Antimigraine : Ergo derivatives @DRUG$ rifampin benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
It is not known whether other @DRUG$, such as implants and injectables, are adequate methods of contraception during @DRUG$ therapy.	DDI-false
Acetaminophen , lidocaine , @DRUG$ , quinidine, theophylline, and @DRUG$ The pooled human serum was added at therapeutic concentrations.	DDI-false
In a 12-week endoscopy study in OA patients, there was no difference in the cumulative incidence of endoscopic gastrointestinal ulcers in patients with low-dose ( 81 mg) enteric-coated aspirin plus @DRUG$ 25 mg daily, compared to those who @DRUG$ 2400 mg daily alone .	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, @DRUG$, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-false
Patients receiving other narcotic analgesics , general @DRUG$ , phenothiazines , @DRUG$ , sedative-hypnotics , tricyclic antidepressants or other CNS depressants ( including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression .	DDI-false
Diphenhydramine hydrochloride has additive effects with @DRUG$ and other CNS depressants (hypnotics, sedatives, @DRUG$, etc).	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , @DRUG$ , @DRUG$ , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all @DRUG$, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	DDI-false
Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, @DRUG$, ketoconazole), though this has not been studied	DDI-mechanism
Substances that are potent inhibitors of CYP3A4 activity (eg, @DRUG$ and itraconazole) decrease gefitinib metabolism and increase @DRUG$ plasma concentrations.	DDI-mechanism
Products containing iron sulphate, multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable tablets or the oral pediatric powder should not be taken within 3 hours before or 2 hours after FACTIV.	DDI-false
Patients receiving other narcotic analgesics , general @DRUG$ , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic antidepressants or other CNS depressants ( including @DRUG$ ) concomitantly with DILAUDID may exhibit an additive CNS depression .	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients with receptor blockers (e.g. propranolol, @DRUG$ inhibitor ) or @DRUG$ â€¢ antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , @DRUG$ , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and @DRUG$ , respiratory depression, hypotension, and deep sedation, or possibly lead to coma or death.	DDI-false
@DRUG$ did not alter the pharmacokinetics of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines , @DRUG$ , estrogens, oral contraceptives, phenytoin, @DRUG$ , sympathomimet-ics , calcium channel blocking drugs , and isoniazid .	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin, Gentamicin and amikacin), amphotericin B, @DRUG$ , intravenous @DRUG$ , vancomycin, and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Population pharmacokinetic analyses revealed that MTX, NSAIDs, @DRUG$, and TNF blocking agents did not influence @DRUG$ clearance.	DDI-false
@DRUG$ should be administered with caution to patients receiving Antabuse (@DRUG$, Wyeth-Ayerst Laboratories).	DDI-advise
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), @DRUG$, prednisolone (10% decrease in binding), or warfarin.	DDI-false
The absorption of tetracycline, @DRUG$, penicillin G, @DRUG$, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral @DRUG$, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
For this reason, the dose of the @DRUG$ should be reduced by 30 - 50% at the start of treatment with Bezalip or @DRUG$ retard and then titrated according to the blood clotting parameters	DDI-advise
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine @DRUG$ Astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ Midazolam, triazolam GI Motility agent: cisapride	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, antihistamines or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
â€¢ Multiple administration of potent CYP3A4 inducer @DRUG$ However, reduced ( 600 mg every 24 hours, q24h, for 14 days), @DRUG$ Cmax and AUC by about 80%.	DDI-mechanism
Diphenhydramine hydrochloride has additive effects on alcohol and other CNS depressants ( @DRUG$ , @DRUG$ , sedatives, etc.	DDI-false
@DRUG$ ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of @DRUG$ Imidazole and imidazoles indicate that imidazoles can cause fungal resistance to amphotericin B.	DDI-false
Because there are no data on the compatibility of NovoLog and crystalline @DRUG$ preparations, @DRUG$ should not be mixed with these preparations.	DDI-false
Patients who begin taking diclofenac or who increase their @DRUG$ Dose or other @DRUG$ while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs .	DDI-false
Caution should be exercised when @DRUG$ are given in conjunction with @DRUG$.	DDI-advise
@DRUG$ should not be administered concomitantly with other @DRUG$ * (like isoproterenol) due to possible additive effects and increased toxicity.	DDI-advise
Although the magnitude of changes in @DRUG$ plasma exposure when coadministered with @DRUG$ However, in order to justify dose adjustments, patients may experience increased sedative adverse reactions caused by increased exposure to diazepam under this circumstance.	DDI-false
Lack of an effect of @DRUG$ On the disposition of @DRUG$ - and dideoxyinosin in HIV infected patients.	DDI-false
No information is available about the use of @DRUG$ concurrently with @DRUG$.	DDI-false
@DRUG$: Coadministration of a single dose of Sonata 20 mg and @DRUG$ 20 mg daily for 7 days did not produce any interaction on psychomotor performance.	DDI-false
Due to high inter-patient variability and limited sampling, the extent of the increase in @DRUG$ levels in patients receiving concurrent @DRUG$ and AVASTIN is uncertain.	DDI-false
Other oral interactions @DRUG$ Keppra ( 500 mg twice daily ) did not affect the pharmacokinetics of an oral contraceptive of 0.03 mg @DRUG$ The decisive factor for impairment of the efficacy of contraception is impairment of levonorgestrel and 0.15 mg levonorgestrel or luteinisation hormone and progesterone levels.	DDI-false
CNS-Active Drugs Ethanol: @DRUG$ 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after @DRUG$ administration.	DDI-false
Benzylpenicillin, @DRUG$, @DRUG$, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
@DRUG$ may interact with any of the following : - Acetaminophen ( e.g. , @DRUG$ (with a long-term high dose) or	DDI-int
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following : ergotamine , @DRUG$ , amiodarone, nicardipine, and nifedipine.	DDI-int
Erythromycin Co-administration of @DRUG$ (PLENDIL) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of @DRUG$.	DDI-false
- medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam , triazolam GI motility agents : cisapride	DDI-false
@DRUG$/prednisolone : Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, @DRUG$, and possibly with @DRUG$ and tetracyclines 72.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$ , ergotic derivatives, @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
@DRUG$ If multiple doses of atorvastatin and digoxin have been co-administered, steady-state plasma is @DRUG$ Concentrations increased by about 20%.	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of @DRUG$, @DRUG$, and methotrexate.	DDI-false
@DRUG$ ( @DRUG$ Cerivastatin plasma concentrations were not affected by concomitant administration of antacids.	DDI-false
Plasma concentrations ( AUC 0 - 24 hrs ) of @DRUG$ â€¢ 15% when loratadine is co-administered compared to @DRUG$ alone .	DDI-false
Benzthiazide may interact with @DRUG$ - blood thinners, decongestant medications (allergic agents, colds, and sinus drugs), diabetics, lithium, norepinephrine, @DRUG$ Such as Aleve or ibuprofen, and high blood pressure medications.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Potential drug interactions between: @DRUG$ The serum concentrations of carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate have also been studied. @DRUG$ and these AEDs during placebo-controlled clinical studies .	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Multivalent Cation-Containing products: co-administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids , @DRUG$ VIDEX chewable/buffer tablets or paediatric powders or products containing calcium, iron or zinc may significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and nifedipine.	DDI-int
Concomitant @DRUG$, doxorubicin, vincristine, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Both the toxicity of @DRUG$ and the therapeutic value of @DRUG$ can be rationalized at the cellular and molecular level by the following observations: (i) these polyene antibiotics showed differential effects on cells;	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and @DRUG$.	DDI-effect
Co-administration of @DRUG$ and cerivastatin did not alter the pharmacokinetics of @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as @DRUG$, nevirapine, phenytoin, dexamethasone, or @DRUG$, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with @DRUG$ , Innovar Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital .	DDI-false
@DRUG$: @DRUG$-induced hypokalemia may potentiate digitalis toxicity.	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , @DRUG$ , @DRUG$ , chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, which delays the elimination and increase in blood levels of these drugs.	DDI-false
@DRUG$ : Increased serum lithium levels and symptoms of @DRUG$ Toxicity has been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, @DRUG$, metoclopramide, @DRUG$.	DDI-false
Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other NSAID while taking digoxin, @DRUG$, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-false
When @DRUG$ It is co-administered with inducers of drug clearance, e.g. @DRUG$ , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-advise
These drugs include the @DRUG$ and other diuretics, @DRUG$ , phe-nothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimet-ics , calcium channel blocking drugs , and isoniazid .	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital.	DDI-false
In clinical trials , the concomitant administration of @DRUG$ and @DRUG$ did not alter the adverse reaction profile .	DDI-false
The compounds tested in humans include warfarin, theophylline, phenytoin, @DRUG$ , @DRUG$ and antipyrine .	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs ( e.g. , triazolo-benzodiazepines , @DRUG$ , certain HMG-CoA reductase inhibitors , etc . ) .	DDI-mechanism
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, fluoxetine, @DRUG$, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron , the concomitant use of apomorphine with drugs of the @DRUG$ It is contraindicated (including, for example, Ondansetron, Granisetron, Dolasetron, Palonosetron, and Alosetron).	DDI-false
Therefore , when @DRUG$ and non-steroidal anti-inflammatory agents are used concomitantly , the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained .	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ and @DRUG$ is not recommended.	DDI-advise
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or @DRUG$ than with pentobarbital.	DDI-false
@DRUG$: Co-administration of VIOXX with @DRUG$ 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.	DDI-false
@DRUG$: Coadministration of single doses of Sonata 20 mg and @DRUG$ 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, @DRUG$, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/@DRUG$ , quinidine/lidocaine , @DRUG$/acetaminophen , and valproic acid/phenobarbital .	DDI-false
@DRUG$ In vitro and/or in vivo data show that clarithromycin, @DRUG$ , and troleandomycin markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-false
Other Chemotherapy Agents In a separate study, concomitant administration of @DRUG$ with @DRUG$ did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of capecitabine).	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Rifampin decreased AUC(ss) of @DRUG$ However, amprenavir had no effect on @DRUG$ pharmacokinetics .	DDI-false
Digoxin , Nimodipine and @DRUG$ : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and @DRUG$ It has no significant influence on bosentan plasma levels.	DDI-false
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to @DRUG$ alone.	DDI-false
@DRUG$ taken concomitantly with procainamide for less than seven days increases plasma concentrations of procainamide and n-acetyl @DRUG$ by 55% and 33%, respectively.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
We report on the case of a young person with a changed consciousness caused by: @DRUG$ overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of @DRUG$ With a toxicological screen for tricyclic antidepressants.	DDI-false
Coadministration of phenytoin with 40 mg @DRUG$ tablets in epileptic patients lowered the @DRUG$ plasma concentrations to undetectable levels.	DDI-false
Phenytoin: Altered serum levels of @DRUG$ (increased and decreased) have been reported in patients receiving concomitant @DRUG$.	DDI-mechanism
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other @DRUG$ , including but not limited to other opioids, sedatives, hypnotic, sedatives (e.g., @DRUG$ Common anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may result in respiratory depression, hypotension and deep sedation, or possibly coma or death.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-effect
The oral anticoagulant ATTENTION MUST BE OUT OF @DRUG$ ARE GIVEN IN CONJUNCTION WITH @DRUG$.	DDI-advise
Agents Affecting Cytochrome P450 3A4 Isoenzyme System @DRUG$ Metabolism is mainly via the human cytochrome P450 3A4 isoenzyme system ( CYP3A4 ), therefore possible interactions may occur if: @DRUG$   is given concurrently with agents that affect CYP3A4 activity .	DDI-false
@DRUG$ : Since both acitretin and @DRUG$ can cause increased intracranial pressure , their combined use is contraindicated .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of @DRUG$ with a toxicology screen for @DRUG$.	DDI-advise
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, warfarin, cimetidine and @DRUG$.	DDI-false
In Europe, @DRUG$  was observed to occasionally intensify the effect of @DRUG$ taken concomitantly by patients suffering from hypertension;	DDI-effect
Analysis of the concentration of budesonide following ultracentrifugation indicated that there is rapid equilibration of @DRUG$ between the @DRUG$ and aqueous phase.	DDI-false
( In some patients @DRUG$ can reduce the diuretic , natriuretic , and antihypertensive effects of @DRUG$.	DDI-effect
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e.g. , cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , @DRUG$ , phenytoin, and such an effect can also be expected with CMI.	DDI-mechanism
The action of the @DRUG$ may be potentiated by anticonvulsants , antihistamines , alcohol , @DRUG$ , monoamine oxidase inhibitors , narcotics , phenothiazines , psychotropic medications , or other drugs that produce CNS depression .	DDI-effect
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, @DRUG$, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	DDI-mechanism
Because of the increased risk of adverse reactions in patients who: @DRUG$ on a regular basis , it is particularly important that physicians query patients or their guardians carefully about benzodiazepine , alcohol and @DRUG$ Use ROMAZICON as part of the story before any method in which the use of ROMAZICON is planned.	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin , @DRUG$ , milrinone or IV ACE inhibitors have not been studied (these medicinal products have not been co-administered with @DRUG$ in clinical trials ) .	DDI-false
- corticosteroids, methylxanthine and @DRUG$ ; Concomitant treatment with xanthine derivatives, steroids or @DRUG$ may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Close supervision and careful adjustment of dosage are required when Anafranil is administered with @DRUG$ or @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, @DRUG$ , @DRUG$ E. g. epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e. g. in oral contraceptives).	DDI-false
Cyclosporine, Digoxin, Methotrexate Lodine, like other @DRUG$, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, @DRUG$, and increased toxicity.	DDI-mechanism
Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the @DRUG$ effect by flumazenil.	DDI-false
Co-administration of aspirin reduces the biological half-life of @DRUG$ because of an increase in metabolic clearance that results in a greater amount of @DRUG$ In the urine.	DDI-false
Sulfapyridine may interact with any of the following: - @DRUG$ (e.g., @DRUG$) (with long-term, high-dose use) or	DDI-false
Cohort 1 then received @DRUG$ plus rifabutin for 10 days , and cohort 2 received amprenavir plus @DRUG$ for 4 days .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , @DRUG$ , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$ Ribavirin and vincristine.	DDI-false
If intravenous @DRUG$ is required to treat Pneumocystis carinii pneumonia, treatment with @DRUG$ should be interrupted.	DDI-advise
Other concomitant therapies : In clinical trials, the safety profile in patients with @DRUG$ concomitantly with @DRUG$ , hypnotics and sedatives ( including benzodiazepines ) , or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
It may increase excretion of @DRUG$, lithium, and @DRUG$ and may also increase the toxicity of salicylates.	DDI-false
@DRUG$, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
The following are known examples of drugs that inhibit the metabolism of other related benzodiazepines, probably by inhibition of CYP3A: @DRUG$ , fluvoxamine, cimetidine, diltiazem, @DRUG$ , and some macrolide antibiotics .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of carbamazepine, valproate, @DRUG$, or lamotrigine.	DDI-false
Co-administration of BOTOX and @DRUG$ The effect of neuromuscular transmission (e.g. curare-like compounds) should be done with caution. @DRUG$ It can be potentiated.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-mechanism
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , betablockers , @DRUG$ , diuretics and nonsteroidal anti-inflammatory drugs ( @DRUG$ ) without evidence of clinically significant adverse interactions .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines , presumably through inhibition of CYP3A : nefazodone , @DRUG$ , cimetidine , diltiazem , @DRUG$ And some macrolide antibiotics.	DDI-false
The effects of ruthenium red ( @DRUG$ ) on @DRUG$ The reactions induced with InsP(3) were studied in combination with Fura-2 microfluorometry on megacaryocytes of the rat's bone marrow with the patch-clamp whole cell recording technique.	DDI-false
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, salbutamol, terbutaline), @DRUG$ , phenothiazine derivatives , somatropin , @DRUG$ , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
@DRUG$-Broad-Spectrum Antibiotics can sterilize the intestine and reduce the @DRUG$ contribution to the body by the intestinal microflora .	DDI-false
@DRUG$: @DRUG$ BID did not show a significant effect on the plasma exposure or renal clearance of methotrexate.	DDI-false
Antiacid, clarithromycin, didanosine, fluconazole, fluoxetine, indanavir, @DRUG$ , phenytoin, phenobarbitol, @DRUG$ , rifabutin, rifampin, ritanovir, saquinavir.	DDI-false
Central nervous system depressants: Concomitant use of DURAGESIC (Fentanyl transdermal system) with others @DRUG$ , including but not limited to other opioids, sedatives, hypnotic agents, sedatives (e.g. benzodiazepines), generally @DRUG$ , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Other medicinal products Interactions oral contraceptives @DRUG$ The pharmacokinetics of an oral contraceptive with 0.03 mg @DRUG$ The decisive factor for impairment of the efficacy of contraception is impairment of levonorgestrel and 0.15 mg levonorgestrel or luteinisation hormone and progesterone levels.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
@DRUG$ , tricyclic antidepressants, and @DRUG$ The anticholinergic effect of clidinium can be increased.	DDI-false
Aspirin: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and @DRUG$ were administered concomitantly.	DDI-mechanism
Other medicines: medicines such as quinidine, disopyramide, @DRUG$ , phenothiazines , @DRUG$ , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
Magnesium- and/or aluminum-containing @DRUG$ , products containing ferrous sulfate ( iron ) , multivitamin preparations containing zinc or other metal cations , or @DRUG$ Do not take chewable/buffered tablets or the pediatric powder for oral solution within 3 hours before or 2 hours after FACTIVE.	DDI-false
Other substances : Grapefruit juice administered to healthy volunteers increases @DRUG$ AUC by 50 % and Cmax by 84 % , resulting in increased plasma levels of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines , thyroid products , @DRUG$ , oral contraceptives, phenytoin, @DRUG$ , sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Other Drugs : Drugs such as quinidine , disopyramide , @DRUG$ , phenothiazine, antihistamines and @DRUG$ It may be associated with QT interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Substances that are potent inhibitors of CYP3A4 activity ( eg , @DRUG$ and itraconazole ) decrease gefitinib metabolism and increase @DRUG$ plasma concentrations .	DDI-mechanism
In patients receiving @DRUG$ and a steroid concomitantly, any reduction in @DRUG$ dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetic agents, ACE inhibitors, @DRUG$ , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , @DRUG$ , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Therefore , there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 ( e.g. , amitriptyline , @DRUG$ , and @DRUG$ ) .	DDI-false
Antidepressants, @DRUG$ Amphetamines may enhance the activity of tricyclic antidepressants or @DRUG$;	DDI-false
Saquinavir: concomitant use of saquinavir (with an experimental soft gelatine capsule formulation of @DRUG$ 1200 mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically , @DRUG$ , @DRUG$ , tamoxifen and interferon-alfa .	DDI-false
@DRUG$: TORADOL IV/IM reduced the diuretic response to @DRUG$ in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of @DRUG$ when @DRUG$ is added to the drug regimen.	DDI-effect
- Lithium : Lithium should generally not be given with @DRUG$ Because they reduce renal clearance and have a high risk of @DRUG$ toxicity .	DDI-false
Coadministration of valdecoxib ( 40 mg BID ( day 1 ) and 40 mg QD ( days 2 - 7 ) ) with @DRUG$ 10 mg glyburide twice daily) resulted in an increase in AUC0-12 of 21% and an increase in AUC0-12 of 16%. @DRUG$ Cmax leading to a 16 % decrease in glucose AUC0 - 24 .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , @DRUG$ , polymyxins, lincomycin, clindamycin, colistin, and @DRUG$ ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
@DRUG$ toxicity was usually reversible upon discontinuation of lithium and the @DRUG$.	DDI-false
Digoxin, nimodipine and losartan: bosentan has no significant pharmacokinetic interactions with @DRUG$ and @DRUG$ , and losartan has no significant effect on plasma levels of bosentan .	DDI-false
Although the specific drug interaction was not studied in a clinical trial , there have been more than 50 episodes of concomitant use of antifibrinolytic therapies ( i.e. , @DRUG$ , aminokaproic acid) and @DRUG$.	DDI-false
Coadministration of @DRUG$ and drugs that inhibit CYP3A may increase @DRUG$ plasma concentrations .	DDI-false
magnesium and/or @DRUG$-containing antacids, iron sulphate-containing products; @DRUG$ containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
â€¢ Nifedipine: vardenafil 20 mg when administered concomitantly with a slow release dose @DRUG$ 30 mg or 60 mg once daily , did not affect the relative bioavailability ( AUC ) or maximum concentration ( Cmax ) of @DRUG$ , a drug that is metabolized via CYP3A4 .	DDI-false
Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the @DRUG$ effect by @DRUG$.	DDI-false
@DRUG$ ( SSRIs ): @DRUG$ Fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$ , @DRUG$ , and verapamil .	DDI-false
@DRUG$s and @DRUG$: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.	DDI-false
Accordingly, careful patient monitoring and dose adjustment of metformin is recommended in patients concomitantly taking @DRUG$ and @DRUG$.	DDI-advise
It is recommended that serum lithium levels be monitored frequently if @DRUG$ It is given at the same time as @DRUG$.	DDI-advise
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$, ampicillin, @DRUG$, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
and (ii) the effects of @DRUG$ were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of @DRUG$ were more efficiently inhibited by ergosterol, the major membrane sterol in yeast.	DDI-false
- Perhexiline hydrogen maleate or MAO-inhibitors (with hepatotoxic potential) must not be administered together with @DRUG$ or @DRUG$.	DDI-false
Accordingly, when @DRUG$ is administered with oral @DRUG$, the prothrombin time should be closely monitored during and for several days after concomitant drug administration.	DDI-advise
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Drugs That Induce CYP3A4 (Rifampicin) Racemic @DRUG$ exposure was decreased 80% by concomitant useof @DRUG$, a potent inducer of CYP3A4.	DDI-mechanism
May interact anticoagulants ( altered hypo-prothrombinemic effect ) , @DRUG$ , rifampin and other inducers of the liver microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ ( increased effect of corticosteroids ) .	DDI-false
Saturation agents : gastrointestinal saturation agents ( @DRUG$ , reserpine , @DRUG$ , ascorbic acid , fruit juices , etc . ) lower absorption of amphetamines .	DDI-false
Antiarrhythmia: amiodarone, @DRUG$ , @DRUG$ , propafenone, quinidine CONTRAINDICATES due to the potential for serious and/or life-threatening reactions.	DDI-false
Warfarin: @DRUG$ have been reported to enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	DDI-effect
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, @DRUG$, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	DDI-false
@DRUG$ Patients receiving corticosteroid therapy may experience a reduced response to toxoids and toxoids. @DRUG$ Because of the inhibition of the antibody response.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
however , no deleterious interactions were seen when ROMAZICON was administered after @DRUG$ , inhalational @DRUG$ , muscle relaxants and muscle relaxant antagonists are administered in combination with sedation or anesthesia.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$ , fibrous acid derivatives, niacin (nicotinic acid), @DRUG$ Azol Antimycotics.	DDI-false
Pyrantel ( e.g. , @DRUG$ ) - Taking piperazin and pyrantel together may reduce the impact of @DRUG$.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, @DRUG$, and verapamil.	DDI-false
@DRUG$ Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$ , and phenytoin, were used at the same time as amiodarone.	DDI-false
@DRUG$ , a bacteriostatic antibiotic , may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided .	DDI-effect
Serial plasma and urine samples for measurement of amprenavir, @DRUG$, and rifampin and their @DRUG$, were measured by high-performance liquid chromatography.	DDI-false
The concomitant use of @DRUG$ It is not recommended that @DRUG$ It can antagonistize the antibacterial effect of norfloxacin in the urinary tract.	DDI-false
Specific studies have confirmed these effects with sevoflurane , isoflurane , propofol , @DRUG$ , and @DRUG$.	DDI-false
@DRUG$ , warfarin , @DRUG$ , NSAIDs	DDI-false
Drugs that may alter @DRUG$ Medicines that may increase the plasma concentration of imatinib: Caution is recommended when administering imatinib @DRUG$ With inhibitors of the CYP3A4 family (e.g. ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat .	DDI-effect
Both the toxicity of @DRUG$ and the therapeutic value of amphotericin B can be rationalized at the cellular and molecular level by the following observations: (i) these @DRUG$ showed differential effects on cells;	DDI-false
However , because some quinolones have been reported to enhance the anticoagulant effects of @DRUG$ or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with @DRUG$ or its derivatives .	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$, @DRUG$, phenobarbital, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like @DRUG$ ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
â€¢ Amiodarone together with @DRUG$ â€¢ for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl procainamide by 55 % and 33 % , respectively .	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma ( HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide), @DRUG$ , teniposide , and prednisone with vincristine plus bleomycin ) without receiving @DRUG$ therapy .	DDI-false
Furosemide: @DRUG$ IV/IM reduced the diuretic response to @DRUG$ in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	DDI-effect
5HT3 Antagonists : Based on reports of deep hypotension and loss of consciousness when @DRUG$ was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , granisetron , dolasetron , palonosetron , and @DRUG$ ) is contraindicated.	DDI-false
The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of @DRUG$ with itraconazole resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of @DRUG$.	DDI-false
@DRUG$: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Co-administration with other drugs that are metabolized by CYP 3A4 ( e.g. , @DRUG$ , @DRUG$ ) may increase their clearance, resulting in a decreased plasma concentration.	DDI-false
@DRUG$ therapy : Urinary excretion of amphetamines is increased , and efficacy is reduced , by acidifying agents used in @DRUG$ therapy .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
medicines that inhibit CYP 3A4 (e.g. ketoconazole, @DRUG$ such as @DRUG$ ==See also==* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid* Corticosteroid==References==	DDI-false
Lithium : @DRUG$ â€¢ have caused an increase in plasma @DRUG$ levels and a reduction in renal lithium clearance .	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , @DRUG$ , dapsone , @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$ The hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$ , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-mechanism
@DRUG$: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
Antidepressants, @DRUG$: Amphetamines may enhance the activity of tricyclic or @DRUG$;	DDI-false
The incidence of akathisia in weekly dosing clinical trials was greater (8.5%, 4/47 patients). @DRUG$ It was on the same day as @DRUG$ When these drugs were administered on separate days ( 1.3%, 1/80 patients).	DDI-effect
@DRUG$ ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of @DRUG$ compared to etoposide alone.	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
However, the pharmacokinetics of butorphanol were significantly altered in another study in healthy subjects (29% decrease in AUC and 38% decrease in Cmax) when a 1 mg dose of @DRUG$ 1 minute after a 20 mg dose @DRUG$ nasal spray .	DDI-mechanism
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
The high dose of cyclosporin A, which resulted in concentrations above 2000 ng/ml administered with oral etoposide, resulted in an 80% increase in @DRUG$ exposure with a 38 % decrease in total body clearance of @DRUG$ compared to etoposide alone .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with TAXOL should be premedicated with @DRUG$ Dexamethasone, diphenhydramine and @DRUG$ ( such as cimetidine or ranitidine ) .	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with CNS depressants ( @DRUG$ , @DRUG$ , opiates, sedatives, anaesthetics) should be considered.	DDI-false
These drugs include thiazides and other @DRUG$ , @DRUG$ , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
(1968, 1970), the higher serum concentrations of @DRUG$ and cephaloridine reached after administration of @DRUG$ are due not only to slower renal elimination but also to an altered distribution in the body.	DDI-mechanism
Selective Serotonin Reuptake Inhibitors ( SSRIs ): SSRIs ( e.g. , fluoxetine , @DRUG$ , paroxetine , @DRUG$ ) have been rarely reported to cause weakness, hyperreflection, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
Cholestyramine-Concomitant intake of cholestyramine and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , @DRUG$ , @DRUG$ , calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
Patients receiving both @DRUG$ and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of @DRUG$ is achieved.	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
@DRUG$ and verapamil use may be rarely associated with ventricular fibrillation when combined with @DRUG$.	DDI-effect
@DRUG$ : @DRUG$ For this reason, myopathy can occur, which manifests as muscle pain or weakness associated with increased CPK levels.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , @DRUG$ , oral contraceptives, phenytoin, @DRUG$ , sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Samplenecid : As with others @DRUG$ , renal excretion of @DRUG$ The treatment is inhibited by probenecid.	DDI-false
MAO Inhibitors: @DRUG$  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with opioid analgesics	DDI-false
@DRUG$: Concomitant treatment with Accutane and @DRUG$ should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	DDI-false
Coingestion of acetaminophen with theophylline, @DRUG$ with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
@DRUG$ : No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of @DRUG$ The dose is given as a single dose.	DDI-false
Ergot Derivatives: Dihydroergotamine, @DRUG$, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Antidepressants ( tricyclic ) , atropine or other @DRUG$ , or @DRUG$ Co-administration with arbutamine may lead to additive inotropic and/ or chronotropic effects.	DDI-false
Patients receiving other @DRUG$s , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , @DRUG$ Additional CNS depression may occur simultaneously with DILAUDID or other CNS depressions (including alcohol).	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
ACE Inhibitors and Angiotensin II Receptor Antagonists ( Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS , 3020 ( 91 % ) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists ( ACEI/@DRUG$ ) .	DDI-false
@DRUG$: @DRUG$ and other NSAIDs can inhibit the activity of diuretics.	DDI-false
When a @DRUG$ is added to the therapy of a patient receiving @DRUG$, an additional antihypertensive effect is usually observed.	DDI-effect
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$ , beta blockers , calcium-channel blockers , cardiac nitrates , @DRUG$ , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Based on known metabolic profiles, clinically significant drug interactions between VIRACEPT and Dapson, trimethoprim/sulfamethoxazole, clarithromycin are not expected. @DRUG$ , @DRUG$ or fluconazole .	DDI-false
It has been reported that plasma levels of several closely related tricyclic antidepressants have been associated with the concomitant use of @DRUG$ or hepatic enzyme inhibitors ( e.g. , cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , @DRUG$ , phenytoin, and such an effect can also be expected with CMI.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
@DRUG$: The effect of celecoxib on the anti-coagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking @DRUG$, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.	DDI-false
No pharmacokinetic interactions between dexmedetomidine and @DRUG$, @DRUG$, alfentanil, and midazolam have been demonstrated.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Diltiazem, @DRUG$, @DRUG$	DDI-false
@DRUG$: In diabetic patients receiving diflunisal and tolbutamide, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$ , hypnotics and sedatives ( including @DRUG$ ) , or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
The concentrations of @DRUG$ , the active metabolite of @DRUG$ In patients receiving bolus-IFL in combination with AVASTIN, an average of 33% was higher than bolus-IFL alone.	DDI-false
Plasma concentrations of @DRUG$ are reduced when given concurrently with @DRUG$.	DDI-mechanism
Methotrexate: In an interaction study of rheumatoid arthritis patients taking @DRUG$, CELEBREX did not have a significant effect on the pharmacokinetics of @DRUG$.	DDI-false
@DRUG$ : @DRUG$ has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various tricyclic antidepressants .	DDI-false
@DRUG$ ( e.g. , Antiminth ) - Taking piperazine and @DRUG$ Together, the effect of piperazin can decrease.	DDI-false
Haloperidol : @DRUG$ The dopamine and norepinephrine recovery is blocked, which inhibits the central stimulant effects of @DRUG$.	DDI-effect
It has been reported that results of studies in animals indicate that @DRUG$-induced ventricular arrhythmias during anesthesia can be reversed by @DRUG$.	DDI-effect
Monitoring for @DRUG$ toxicity and serial measurement of amiodarone serum concentration during concomitant @DRUG$ therapy should be considered.	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with 5HT3 antagonist class medications (including, for example, @DRUG$ , granisetron, dolasetron, @DRUG$ , and alosetron ) is contraindicated .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating CNS depressants such as @DRUG$, opiates, and alcohol.	DDI-effect
Although no clinical studies have been conducted, it is likely that the metabolism of @DRUG$ may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., @DRUG$;	DDI-mechanism
@DRUG$ Keppra  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of @DRUG$ given as a 0.25 mg dose every day.	DDI-false
@DRUG$ : @DRUG$ This did not affect steady-state plasma concentrations of carbamazepine or its epoxy metabolites in patients with epilepsy.	DDI-false
Fluoxetine and @DRUG$ increased blood @DRUG$ at different times after the glucose overload .	DDI-false
@DRUG$ It can cause acidic drugs such as phenytoin or @DRUG$ from their binding sites .	DDI-mechanism
, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Potential drug interactions between Keppra   and other AEDs ( carbamazepine , gabapentin , @DRUG$ , @DRUG$ , phenytoin, primidone and valproate) were also evaluated by assessing levetiracetam serum concentrations and these AEDs in placebo-controlled clinical trials.	DDI-false
The absorption of oral gemifloxacin is due to the concomitant use of @DRUG$ containing @DRUG$ and magnesium .	DDI-false
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Potential drug interactions between Keppra   and other @DRUG$ ( @DRUG$ , gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also evaluated by the evaluation of levetiracetam serum concentrations and these AEDs during placebo-controlled clinical trials.	DDI-false
- Urine alkalinisation agents ( @DRUG$ , some @DRUG$ ) increase the concentration of the non-ionized species of the amphetamine molecule , thereby decreasing urinary excretion .	DDI-false
Interactions with mixed agonists/antagonists Opioid analgesics : agonists/antagonists analgesics (e.g. @DRUG$ , @DRUG$ , butorphanol, dezocin and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesics such as levo-dromorane.	DDI-false
Antidepressants (@DRUG$), atropine or other @DRUG$, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , @DRUG$ , @DRUG$ , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blockers, azathioprin, @DRUG$ , @DRUG$ , hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
These results suggest that both @DRUG$ and @DRUG$ The proliferation of prostate epithelium, and possibly other glucocorticoids and retinoids, may be controlled by dose-dependent changes in insulin and EGF activity.	DDI-false
@DRUG$ When co-administered with other sympathomimetic medicines (e. g. @DRUG$ ) due to possible additive effects and increased toxicity.	DDI-advise
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ : Elevated carbamazepine levels have been reported in postmarketing experience when @DRUG$ It is given at the same time.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Ritonavir : Coadministration of @DRUG$ with @DRUG$ resulted in a 152 % increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	DDI-mechanism
In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of @DRUG$ or @DRUG$ and that ertapenem is not a substrate for P-glycoprotein-mediated transport.	DDI-false
Catecholamine-depleting Agents : Patients taking both @DRUG$ A drug called catecholamine deplete (e.g. reserpine and @DRUG$ ) should be observed closely for signs of hypotension and/or severe bradycardia .	DDI-effect
@DRUG$: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
Concomitant cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Effects of @DRUG$ on other Antiepilepsy Drugs ( @DRUG$ ) : Phenytoin : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy .	DDI-false
Drugs With A Narrow Therapeutic Index Digoxin A single dose of @DRUG$ 3 mg had no effect on the pharmacokinetics of @DRUG$ After a dose of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days, measured at steady state.	DDI-false
@DRUG$: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of @DRUG$ and erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
- Indomethacin: @DRUG$ blunts the increases in urine volume and sodium excretion seen during @DRUG$ treatment and inhibits the bumetanide-induced increase in plasma renin activity.	DDI-mechanism
@DRUG$, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
Since indomethacin and @DRUG$, including @DRUG$, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.	DDI-false
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital , secobarbital , @DRUG$ , chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
While no in vivo drug interaction studies have been conducted between estazolam and CYP3A inducers, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, @DRUG$ , and @DRUG$ Estazolam concentrations are expected to be reduced.	DDI-false
While all selective serotonin reuptake inhibitors ( @DRUG$ ) , e.g. , citalopram , escitalopram , fluoxetine , sertraline , and @DRUG$ , inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
Anticholinesterases (neostgmine, physostigmine), lignocaine, @DRUG$, @DRUG$ can enhance toxicity and cause cardio respiratory depression.	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance, such as @DRUG$, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-advise
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazide, @DRUG$ , @DRUG$ Propofol, protease inhibitors, quinidine and verapamil.	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenylbutazone , @DRUG$ , carbamazepine, griseofulvin, @DRUG$ , and possibly with ampicillin and tetracyclines 72 .	DDI-false
Dopamine antagonists : since @DRUG$ It is possible that dopamine antagonists, such as neuroleptics (phenothiazine, @DRUG$ , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
Experience with the concomitant use of HMG-CoA reductase inhibitors and @DRUG$ Therefore, a temporary suspension of the use of: @DRUG$ In patients receiving fentanyl.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, @DRUG$, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
The concomitant use of vasopressors, vasoconstricting agents (such as @DRUG$) and some @DRUG$ may result in severe hypertension.	DDI-effect
Example inhibitors include azole antifungals , ciprofloxacin , @DRUG$ , diclofenac , @DRUG$ , erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Other cardiovascular agents : enalapril and @DRUG$ In addition to beta-adrenergic blockers, methyldopa, nitrates, calcium blockers, hydralazine, prazosin and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
In the presence of this methylxanthine, larger doses of @DRUG$ - may be required or @DRUG$ Maybe not be effective.	DDI-false
In addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , @DRUG$ , or carbamazepine ) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations .	DDI-mechanism
@DRUG$: Alcohol (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and @DRUG$ plasma levels were not altered when dosed simultaneously.	DDI-false
Multivalent Cation-Containing products: co-administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ Antacids, sucralfate, VIDEX chewable/buffer tablets or children's powder, or products containing calcium, iron, or @DRUG$ The absorption of ciprofloxacin can be significantly reduced, resulting in significantly lower serum and urine levels than desired.	DDI-false
@DRUG$/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after starting argatroban 1.5 g/kg/min for 18 hours).	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
@DRUG$ : No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or @DRUG$ Co-administration of tiagabin as a single dose.	DDI-false
Some drugs/substances are known to accelerate the metabolism of @DRUG$ by stimulating the synthesis of @DRUG$ (enzyme induction).	DDI-false
Anticoagulants: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
These drugs include: @DRUG$ and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , @DRUG$ , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
@DRUG$ : Administration of @DRUG$ with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma ;	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Other CONCOMITANT THERAPY : Although specific interaction studies have not been conducted in clinical trials, @DRUG$ was used concomitantly with @DRUG$ Beta-blockers, calcium channel blockers, diuretics and non-steroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (lovastatin, @DRUG$, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
@DRUG$ taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of procainamide and n-acetyl procainamide by 55% and 33%, respectively.	DDI-false
Drugs that cause significant sustained elevation in gastric pH ( @DRUG$ such as @DRUG$ IRESSA plasma concentrations can be reduced and may therefore reduce efficacy.	DDI-false
@DRUG$: Bioavailability is mildly reduced (approximately 10%) when @DRUG$ and metoclopramide are coadministered.	DDI-false
As with other antipsychotic agents, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as anesthetics, @DRUG$, and alcohol.	DDI-effect
The effects of @DRUG$ ( @DRUG$ InsP(3))-induced reactions were investigated in inositol 1.4.5-trisphosphate (InsP(3))-induced megacaryocytes of the rat's bone marrow with the patch clamp whole cell recording technique in combination with the Fura-2 microfluorometry.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, @DRUG$, and possibly with ampicillin and @DRUG$ 72.	DDI-false
ACE inhibitors : Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , @DRUG$ Salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-effect
Micro-dosed Progesterone Preparations: Micro-dosed @DRUG$ preparations (minipills that do not contain an @DRUG$) may be an inadequate method of contraception during Accutane therapy.	DDI-false
Protein Binding In vitro , diclofenac interferes minimally or not at all with the protein binding of @DRUG$ ( 20 % decrease in binding ) , tolbutamide , prednisolone ( 10 % decrease in binding ) , or @DRUG$.	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Patients in a clinical study who were on established therapy with @DRUG$, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or @DRUG$ alone.	DDI-false
Oral @DRUG$: Multiple dose administration of tiagabine (8 mg/day monotherapy) did not alter the pharmacokinetics of oral @DRUG$ in healthy women of childbearing age.	DDI-false
@DRUG$ containing magnesium trisilicate , when administered concomitantly with @DRUG$ , reduce both the rate and extent of absorption .	DDI-false
Before using this medication, tell your doctor or pharmacist about all prescription and non-prescription products you can use, especially from: @DRUG$ ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , non-steroidal anti-inflammatory drugs ( e.g. , ibuprofen ) , @DRUG$ , vancomycin .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, @DRUG$, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	DDI-false
@DRUG$/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	DDI-false
The results of assays with red cells from healthy subjects to determine if @DRUG$ would cause direct Coombs reactions in vitro showed no positive reaction at @DRUG$ Concentrations of up to 40 g/ml.	DDI-false
@DRUG$: Concomitant administration of @DRUG$ may reduce plasma levels of diflunisal.	DDI-false
There were no clinically relevant pharmacokinetic interactions if: @DRUG$ was used concomitantly with @DRUG$ or hydrochlorothiazide .	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , @DRUG$ , @DRUG$ , sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Preliminary animal and human studies have shown that small quantities of systemically administered @DRUG$ enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual @DRUG$ concentrations following intrathecal administration.	DDI-false
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole ( @DRUG$ , @DRUG$ , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
At higher than recommended doses, @DRUG$ 75 mg administered once daily for 10 days increased plasma concentrations by 23%, as measured by AUC0 - 24 hours in patients who: @DRUG$ 7.5 to 15 mg/week for rheumatoid arthritis .	DDI-mechanism
Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$ , signs and symptoms of carbamazepine toxicity should be monitored closely , and appropriate dosage adjustment of the @DRUG$ It should be done.	DDI-false
Co-medications that induce CYP3A4 ( e.g. , dexamethasone , phenytoin , @DRUG$ , rifampin , @DRUG$ or St.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Interactions may occur between @DRUG$ supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (@DRUG$).	DDI-int
The concomitant use of itraconazole and @DRUG$ , tacrolimus or @DRUG$ has led to increased plasma concentrations of the latter three drugs .	DDI-false
Nephrotoxic agents: Concomitant use of @DRUG$ and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , gentamicin , and @DRUG$ ) , amphotericin B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-advise
there was no significant change in prothrombin test results during the trials of @DRUG$ and @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Therefore , when @DRUG$ and @DRUG$ are used concomitantly , the patient should be observed closely to determine if the desired effect of the diuretic is obtained . )	DDI-advise
- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Oral anticoagulant agents: Pharmacokinetic drug-drug interactions between @DRUG$ and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	DDI-false
Coingestion of acetaminophen with theophylline, @DRUG$ with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
@DRUG$: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
It is recommended to avoid concurrent administration of ethambutol with aluminum hydroxide containing @DRUG$ for at least 4 hours following @DRUG$ administration.	DDI-false
Lymphocytopenia has been reported in patients receiving @DRUG$ And it is possible that the management of @DRUG$ Antiemetic prophylaxis may have increased the probability of this effect.	DDI-effect
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Probenecid : @DRUG$ Influences renal tubular secretion of @DRUG$ This leads to an increase in serum ciprofloxacin levels.	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , @DRUG$ , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , @DRUG$ , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Co-administration of single 25-mg dose @DRUG$ had no effect on the pharmacokinetics of total @DRUG$.	DDI-false
Benzthiazide may interact with alcohol , blood thinners , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , @DRUG$ , @DRUG$ , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications .	DDI-false
In a similar study with tamsulosin in healthy volunteers , 1 of 24 subjects dosed with @DRUG$ 20 mg and @DRUG$ 0.4 mg separated by 6 hours of standing systolic blood pressure below 85 mm Hg.	DDI-effect
Coingestion of acetaminophen with @DRUG$, @DRUG$ with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Data from in vitro studies @DRUG$ Other than alprazolem, a possible interaction may be proposed for the following medicinal products: ergotamine, cyclosporin, @DRUG$ , nicardipine , and nifedipine .	DDI-int
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , @DRUG$ (e.g. epinephrine, @DRUG$ , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
@DRUG$ " : Reports indicate that @DRUG$ The antihypertensive effect of angiotensin converting enzymes ( ACE) inhibitors may be reduced.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
@DRUG$ â€¢ co-administration of single doses of Eszopiclone 3 mg and @DRUG$ 20 mg daily for 7 days showed no pharmacokinetic or pharmacodynamic interactions.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
The co-administration of @DRUG$s, vasoconstriction agents (such as e.g. @DRUG$ ) and some oxytocic drugs may result in severe hypertension .	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations : Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( e.g. , @DRUG$ , itraconazole , erythromycin , @DRUG$ ) .	DDI-false
Imipramine (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), @DRUG$ (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered.	DDI-false
@DRUG$ The effect of @DRUG$ type ( CYP2C9 and CYP3A4 substrate) on anticoagulants is almost always observed in patients receiving amiodarone and can lead to severe or fatal bleeding.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	DDI-false
@DRUG$: Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic @DRUG$ treatment.	DDI-false
Patients receiving these drugs in combination with @DRUG$ should be monitored for signs of toxicity and the dose of @DRUG$ reduced if warranted.	DDI-false
@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).	DDI-false
It is not known if @DRUG$ or @DRUG$ The ingredients are excreted in breast milk.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, @DRUG$, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-mechanism
@DRUG$ and @DRUG$ : a drug interaction.	DDI-int
@DRUG$ Serum levels should be monitored and appropriate dose adjustments considered in patients receiving theophylline and @DRUG$.	DDI-false
The effects of DCG-IV and L-CCG-1 upon @DRUG$ (@DRUG$)-induced movement and behavioural changes in mice.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, @DRUG$, digoxin, Maalox, and ranitidine.	DDI-false
@DRUG$ Supplements and potassium sparing diuretics : @DRUG$ can attenuate potassium loss caused by thiazide diuretics .	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/@DRUG$ (TMP/SMX).	DDI-false
@DRUG$ , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , @DRUG$ , nifedipine , chlordiazepoxide , diazepam , certain tricyclic antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-mechanism
Concomitant @DRUG$, doxorubicin, @DRUG$, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
When used in external subcutaneous infusion pumps for @DRUG$ , NovoLog should not be mixed with any other @DRUG$ or diluent .	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing a high sequential dose. @DRUG$ and antineoplastic agents , specifically , dacarbazine , cis-platinum , tamoxifen and @DRUG$.	DDI-effect
These drugs include thiazides and other @DRUG$ , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and @DRUG$.	DDI-false
In addition, oxcarbazepine and @DRUG$ induce a subgroup of the cytochrome P450 3A family ( CYP3A4 and CYP3A5 ) responsible for the metabolism of @DRUG$ and oral contraceptives , resulting in a lower plasma concentration of these drugs .	DDI-false
Although in clinical studies with IOPIDINE 0.5 % ophthalmic solution no specific drug interactions with topical glaucoma or systemic drugs have been identified, there is a possibility of additive or potentiating effects with: @DRUG$ - alcohol, barbiturates, opiates, @DRUG$ Anaesthetics) should be considered.	DDI-false
Other concomitant therapy Although no specific interaction studies have been performed, clinical trials with 1 mg or more of finasteride doses have been conducted at the same time. @DRUG$ , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , @DRUG$ , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
It is recommended not to exceed a single dose of 2.5 mg. @DRUG$ dose in a 24-hour period when used in combination with @DRUG$.	DDI-advise
Effect of @DRUG$ Paediatric patients experienced an increase in apparent total body clearance of about 22%. @DRUG$ when it was co-administered with enzyme-inducing AEDs .	DDI-false
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin , @DRUG$ , carbamazepine, and @DRUG$.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF .	DDI-effect
ACE inhibitors: Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
- Methotrexate (e.g., @DRUG$) Use of methotrexate with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
The co-administration of Natrecor with IV vasodilators such as @DRUG$, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Amantadine, tricyclic antidepressants, and @DRUG$ may increase anticholinergic effect of @DRUG$.	DDI-effect
Therefore , interactions could occur following concomitant administration of @DRUG$ ( e.g. , @DRUG$ , analgesics, antiemetics, sedatives, sedatives.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or @DRUG$).	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
CANCIDAS reduced the blood AUC0-12 of @DRUG$ by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which @DRUG$ was administered alone.	DDI-false
It has been reported that QTc prolongation with or without TdP has been reported in patients taking amiodarone, @DRUG$ , @DRUG$ , or azoles were administered concomitantly .	DDI-false
There have been more than 2-fold increases in plasma levels of other @DRUG$ , including @DRUG$ , when fluoxetine hydrochloride has been administered in combination with these agents .	DDI-false
@DRUG$ : Inhibition of renal lithium clearance , leading to an increase in plasma @DRUG$ The concentration, has been reported with some prostaglandin synthetic-inhibiting drugs.	DDI-false
In addition, oxcarbazepine and @DRUG$ induce a subgroup of the cytochrome P450 3A family ( CYP3A4 and CYP3A5 ) responsible for the metabolism of dihydropyridine calcium antagonists and oral @DRUG$ , resulting in a lower plasma concentration of these drugs .	DDI-false
Omeprazole : The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion .	DDI-false
@DRUG$ - is a substrate for both @DRUG$ and CYP3A4 .	DDI-false
Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics , @DRUG$ ##############################################################################################################################################################################################################################################################################################################################################################################################################################################################################################################################	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and @DRUG$.	DDI-false
The increase of @DRUG$ level , however , is small ( 15 % ) when given with @DRUG$.	DDI-mechanism
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
Compounds tested in man include warfarin, @DRUG$, phenytoin, @DRUG$, aminopyrine and antipyrine.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine , Innovar Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with ketamine or @DRUG$ As with Pentobarbital.	DDI-false
The extent to which @DRUG$-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved.	DDI-false
@DRUG$ may interact with alcohol or other @DRUG$ Decisive for increased sedative effects.	DDI-effect
ACE inhibitors and angiotensin II receptor antagonists (hypertension)- In clinical trials in patients with hypertension, the addition of @DRUG$ 50 to 100 mg up to @DRUG$ Angiotensin II receptor antagonists slightly increased the mean serum potassium (approximately 0.09 - 0.13 mEq/L).	DDI-effect
In some patients , the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic , natriuretic , and antihypertensive effects of @DRUG-DRUG$.	DDI-false
@DRUG$ inhibits @DRUG$.	DDI-false
The addition of 540 mg/kg/day of @DRUG$ 340 times the recommended daily dose of inhalation in adults on mg/m2 basis) to 2.7 mg/kg/day @DRUG$ ( approximately 7 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis ) appears to have increased the incidence of both resorptions and malformations .	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
poor metabolizers of @DRUG$ â€¢ interactions of Brexit with potent CYP2D6 inhibitors (such as quinidine, @DRUG$ , paroxetine , and propafenone ) have not been studied , but these drugs would be expected to increase blood levels of the R(+ ) enantiomer of carvedilol .	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 ( eg , phenobarbital , @DRUG$ Dexamethasone, carbamazepine) may lead to decreased plasma levels of @DRUG$.	DDI-mechanism
@DRUG$: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Possible drug interactions of @DRUG$ with @DRUG$ or with other anticholinesterase agents.	DDI-int
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ : In some patients with compromised renal function who are being treated with non-steroidal anti-inflammatory drugs , the co-administration of @DRUG$ For this reason, further deterioration of renal function may result.	DDI-false
@DRUG$: Chloramphenicol, erythromycins, @DRUG$, or tetracyclines may interfere with the bactericidal effect of penicillins.	DDI-false
This medicine can be used with alcohol or other forms of interaction. @DRUG$ (may increase the CNS-depressive effect of these drugs or @DRUG$ Anticholinergic agents, anticholinergic agents or other medicines with anticholinergic activity (anticholinergic effects can be intensified if these drugs are used at the same time as antihistamines), and monoamine oxidase (MAO) inhibitors ( concomitant use with antihistamines can prolong and enhance the anticholinergic and CNS depressive effects of antihistamines.	DDI-false
Coadministration of @DRUG$ 30 mg and diazepam, a CYP2C19 substrate, resulted in a 45% decrease in clearance of @DRUG$.	DDI-false
- Antidiabetics , oral ( diabetes medicine you take by mouth ) Use of oral @DRUG$ with @DRUG$ The likelihood of side effects affecting blood and/or side effects or oral antidiabetic agents may be increased.	DDI-effect
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, @DRUG$ , amiodarone , @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, @DRUG$, dexamethasone, or carbamazepine) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations.	DDI-mechanism
Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and AXERT within 24 hours of each other should be avoided.	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when using Gleevec with CYP3A4 inhibitors (e.g. @DRUG$ , itraconazole , @DRUG$ ,,,,,,,,,,,	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between: @DRUG$ and dapsone , trimethoprim/sulfamethoxazole , clarithromycin , erythromycin , @DRUG$ or fluconazole .	DDI-false
â€¢ Dopamine antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ ( @DRUG$ , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
@DRUG$ caused a statistically significant increase in plasma exposures of @DRUG$ and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.	DDI-mechanism
@DRUG$ : Amphetamines may delay intestinal absorption of @DRUG$.	DDI-false
@DRUG$ not only block the therapeutic effects of @DRUG$, but may produce severe bronchospasm in COPD patients.	DDI-effect
- skeletal muscle relaxants, not depolarising (e.g., @DRUG$ ): possible increased responsiveness to the @DRUG$.	DDI-false
In Study 1, patients with colorectal cancer were given @DRUG$/5-FU/leucovorin (bolus-IFL) with or without @DRUG$.	DDI-false
@DRUG$ NSAIDs have caused an increase in plasma @DRUG$ The concentrations and a reduction in renal lithium clearance.	DDI-false
Non-steroidal anti-inflammatory agents : In some patients with renal impairment who have had @DRUG$ , the concomitant use of @DRUG$ For this reason, further deterioration of renal function may result.	DDI-effect
In rats, simultaneous ingestion of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that @DRUG$ may react with @DRUG$ in the rat stomach to form a nitrosamine, which is tumorigenic.	DDI-effect
No pharmacokinetic interactions between @DRUG$ and isoflurane , @DRUG$ , alfentanil, and midazolam have been detected.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , @DRUG$ , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , somatostatin analog ( e.g. , octreotide ) , @DRUG$.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, @DRUG$, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Digoxin, @DRUG$, @DRUG$: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
Drugs which inhibit CYP 3A4 (e.g., @DRUG$, macrolide antibiotics such as erythromycin) have the potential to result in increased plasma concentrations of @DRUG$.	DDI-mechanism
In patients receiving @DRUG$ and a steroid concomitantly , any reduction in @DRUG$ Dosage should be done gradually to avoid possible complications of sudden steroid withdrawal.	DDI-false
In addition , we have shown that @DRUG$ It is a useful pharmacological tool to investigate the @DRUG$-mediated reactions of megakaryocytes.	DDI-false
Human pharmacokinetics data indicate that oral ketoconazole potently inhibits the metabolism of @DRUG$ resulting in an eight-fold increase in the mean AUC of @DRUG$.	DDI-false
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$, @DRUG$, methotrexate, and increased toxicity.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , @DRUG$ , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local @DRUG$ , procainamide, and quinidine.	DDI-false
Bacteriostatic Antibiotics: Chloramphenicol, @DRUG$, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of penicillins.	DDI-false
Cyclosporin : Increased activity of both @DRUG$ and @DRUG$ It may happen that the two are used at the same time.	DDI-effect
Discontinuing @DRUG$ could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking @DRUG$.	DDI-false
Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.	DDI-false
Co-administration of BOTOX and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
Iodine or @DRUG$ The excess may reduce the effect of carbimazole, and a lack of iodine may increase the effect of @DRUG$.	DDI-false
Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with phenytoin, @DRUG$, quinidine, clarithromycin or amoxicillin.	DDI-false
However, the absolute number of @DRUG$-related deaths is far greater than the number of deaths in amphetamine or @DRUG$ users .	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Serum @DRUG$ levels should be monitored frequently if @DRUG$ is administered concomitantly with lithium.	DDI-false
@DRUG$: The administration of diflunisal to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-false
Other nephrotoxic medications: agents such as @DRUG$, cyclosporine, and @DRUG$ may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.	DDI-false
There have been case reports of increased steady-state levels of @DRUG$, procainamide, and @DRUG$ during concomitant therapy with amiodarone.	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
The pharmacokinetics of a 1-mg dose of butorphanol administered as @DRUG$ were not affected by the coadministration of @DRUG$ (300 mg QID).	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipoid, and @DRUG$ with vincristine plus bleomycin ) without receiving @DRUG$ therapy .	DDI-false
The possibility of hypotensive effects can be minimized by either discontinuing the @DRUG$ or increasing salt intake prior to initiation of treatment with @DRUG$.	DDI-effect
Drug interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupentixol and @DRUG$ Cause of additive CNS depression - @DRUG$ : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ : @DRUG$ , a renal tubular secretion blocking agent , administered at a dose of 500 mg four times a day , did not change the pharmacokinetics of levetiracetam 1000 mg twice daily .	DDI-false
Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$: The concomitant use of @DRUG$ with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g., @DRUG$ , gentamicin , and amikacin ) , @DRUG$ , Foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, CYP2D6, and @DRUG$.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral @DRUG$ , ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylate, somatostatin analogue (e.g., octreotide), @DRUG$.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a @DRUG$ Inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and @DRUG$ , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Plasma concentrations ( AUC 0 - 24 hours ) of @DRUG$ 15 % with co-administration of @DRUG$ relative to that observed with erythromycin alone .	DDI-mechanism
@DRUG$ In vitro and/or in vivo data show that clarithromycin, erythromycin and troleandomycin significantly inhibit the metabolism of clarithromycin. @DRUG$ This may lead to an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs : @DRUG$ The pharmacokinetics of phenytoin do not appear to change, @DRUG$ , or phenobarbital.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e.g. , @DRUG$ , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , @DRUG$ , phenytoin, and such an effect can also be expected with CMI.	DDI-false
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.	DDI-mechanism
In some patients, the combined use of @DRUG$ and @DRUG$ It was associated with fatal gastrointestinal bleeding.	DDI-effect
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$ Supplements and Potassium-Sparing Diuretics: Fosinopril sodium can attenuate potassium loss caused by @DRUG$.	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	DDI-false
Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Warfarin : Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG-DRUG$ , nor were there any changes in the pharmacodynamic profile ( prothrombin time ) following a single 25 mg oral dose of warfarin	DDI-false
@DRUG$: As with other b-lactams, the renal excretion of cephalexin is inhibited by @DRUG$.	DDI-false
Studies to evaluate possible interactions between @DRUG$ and drugs other than @DRUG$ have not been performed .	DDI-false
Benzthiazide can interact with alcohol, blood thinners, @DRUG$ (allergic, cold, and sinus medicines), diabetic, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen , and high blood pressure medications .	DDI-false
Antipyrine: Because atorvastatin does not affect the pharmacokinetics of @DRUG$, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	DDI-false
Antifungals: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
@DRUG$ has been administered with tolazoline , dopamine , @DRUG$ , steroids , surfactant , and high-frequency ventilation .	DDI-false
Warfarin : Quinolones have been reported to enhance the effects of the oral @DRUG$ @DRUG$ or its derivatives .	DDI-false
- @DRUG$ (Nandrolone [e.g. Anaboline], Oxandrolone [e.g. Anavar], Oxymetholone [e.g. Anadrol], Stanozolol [e.g. @DRUG$ ] ) or	DDI-false
poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 ( such as quinidine , @DRUG$ , paroxetine , and @DRUG$ ) have not been studied , but these drugs would be expected to increase blood levels of the R(+ ) enantiomer of carvedilol .	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin, @DRUG$, or @DRUG$ may develop toxicity characteristics for these drugs.	DDI-false
These effects were not observed if: @DRUG$ 20 mg was taken 24 hours before the @DRUG$.	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs (@DRUG$) : Phenytoin: @DRUG$ had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
@DRUG$ : @DRUG$ may enhance the metabolic clearance of corticosteroids , resulting in decreased blood levels and lessened physiologic activity , thus requiring an increase in corticosteroid dosage .	DDI-false
@DRUG$: Diclofenac decreases @DRUG$ renal clearance and increases lithium plasma levels.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Data from in vitro studies of @DRUG$ A possible interaction with alprazoleam is recommended for the following: sertraline and @DRUG$.	DDI-false
In a clinical pharmacology study, @DRUG$ or @DRUG$ was administered to hypertensive patients receiving VASOTEC.	DDI-false
Co-administration of @DRUG$ and @DRUG$ did not alter the pharmacokinetics of cerivastatin sodium .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
TABLE 1 Effects on Plasma Concentrations ( AUC 0 - 24 hrs ) of @DRUG$ After 10 days of co-administration of descarboethoxyloratadine ( @DRUG$ 10 mg ) in Normal Volunteers	DDI-false
A possible interaction between @DRUG$ , and ciprofloxacin, a @DRUG$ , has been reported to enhance the hypoglycaemic effect of glyburide.	DDI-false
Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with @DRUG$ (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of glyburide.	DDI-false
Antacids containing magnesium and/or aluminium, products containing iron sulphate ( @DRUG$ ) , @DRUG$ containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
Tinnitus and decreased hearing have been reported in patients with concomitant @DRUG$ and @DRUG$.	DDI-effect
@DRUG$ ( eg , @DRUG$ ) and other medicines, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, enhance neuromuscular blocking effect and should be used with extreme caution in patients treated with Coly-Mycin M Parenteral.	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with griseofulvin, ampicillin, and tetracyclines (72)	DDI-false
Cyclopentolate may interfere with the anti-glaucoma action of @DRUG$ or @DRUG$;	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis , it is particularly important that physicians query patients or their guardians carefully about benzodiazepine , @DRUG$ and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned .	DDI-false
For this reason, the dose of the anticoagulant should be reduced by 30-50% at the start of treatment. @DRUG$ or @DRUG$ retard and then titrated according to the blood clotting parameters	DDI-false
Benzylpenicillin, ampicillin, oxacillin, @DRUG$, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
- methotrexate (e.g. @DRUG$ ) Use of methotrexate with @DRUG$ The likelihood of adverse reactions affecting the liver and/or the side effects of methotrexate may increase.	DDI-false
@DRUG$ decreased the hyperuricemic effect of @DRUG$.	DDI-effect
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin , carbamazepine , and barbiturates , and the @DRUG$ rifampin .	DDI-false
@DRUG$ inhibits the ERMBT, and @DRUG$ and rifabutin are equipotent inducers of the ERMBT.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or @DRUG$.	DDI-false
Antihypertensives : @DRUG$ Propranolol, an inhibitor of CYP3A4 or calcium channel antagonists (e.g. verapamil, @DRUG$ Substrate, and diltiazem, an inhibitor of CYP3A4) due to the potential for bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ , @DRUG$ , sparfloxacin, and terodilin.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , @DRUG$ , erythromycin, imatinib, isoniazid, nefazodone, @DRUG$ , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent @DRUG$ such as @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including anti-arrhythmic agents such as @DRUG$ and procainamide , @DRUG$ and tricyclic anti-depressants .	DDI-false
It is also expected that bosentan will increase plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4 , such as @DRUG$ and atorvastatin .	DDI-false
Pharmacokinetic Interaction between @DRUG$ and @DRUG$ rifampin in healthy men.	DDI-false
In monkeys, the effects of @DRUG$, but not (+)-NANM or PCP, were antagonized by @DRUG$;	DDI-effect
Co-administration of intravenous or oral administration @DRUG$ ( e.g. , aminophylline , theophylline ) by patients receiving @DRUG$ The evaluation has not yet been completed.	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ â€¢ the effect of @DRUG$ , levodopa , and ketoconazole .	DDI-effect
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , pentazocine , nalbuphine , butorphanol , @DRUG$ Do NOT use buprenorphine in patients who have had a @DRUG$ Like Levo-Dromoran.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , @DRUG$ , @DRUG$ , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital.	DDI-false
Delayed Adverse Reactions to Iodinated Contrast Media : A review of the literature revealed that 12.6 % ( range 11 - 28 % ) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered @DRUG$ experienced acute , atypical adverse reactions .	DDI-effect
In clinical trials, @DRUG$ was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
In pigeons , naloxone did not systematically alter the effects of @DRUG$ , (+)-NANM or @DRUG$.	DDI-false
Samplenecid : As with others @DRUG$ , the renal excretion of cephalexin is inhibited by @DRUG$.	DDI-false
Possible interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$ , primidone and valproate) were also evaluated by estimating serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies .	DDI-false
Ergot Derivatives: @DRUG$, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Carbamazepine : @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$ The signs and symptoms of carbamazepine toxicity should be closely monitored and the anticonvulsant dose adjusted accordingly.	DDI-false
Cephalosporine-@DRUG$ containing side chains of N-methylthiotetrazole (Cefmenoxime, Cefoperazone), @DRUG$ , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
- @DRUG$ ( e.g. , @DRUG$ , Synkayvite ) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Higher concentrations of @DRUG$ (10(-8) - 10(-6) M) or @DRUG$ (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of EGF.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
However, patients on digoxin may show elevations of @DRUG$ concentrations after initiation of therapy with @DRUG$, which may be clinically significant in patients prone to digoxin toxicity.	DDI-false
In a similar study with @DRUG$ in healthy volunteers, 1 of 24 subjects dosed with Vardenafil 20 mg and @DRUG$ 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , @DRUG$ , and @DRUG$ â€¢ with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$, digoxin, warfarin, @DRUG$ and phenobarbital.	DDI-false
No significant drug-drug pharmacokinetic ( or pharmacodynamic ) interactions have been found in interaction studies with @DRUG$ , digoxin , @DRUG$ And nifedipine.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$ , @DRUG$ , quinidine , and verapamil .	DDI-false
These results suggest that both @DRUG$ and retinyl acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Rifampin significantly decreased amprenavir AUC(s) by 82%, but @DRUG$ No effect on @DRUG$ pharmacokinetics .	DDI-false
As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by @DRUG$ is lengthened and the duration of block is shortened in patients receiving phenytoin or @DRUG$.	DDI-effect
Lithium: Diclofenac decreases @DRUG$ renal clearance and increases @DRUG$ plasma levels.	DDI-false
Rifampin : Coadministration of rifampin and @DRUG$ resulted in an 82 % decrease in @DRUG$ plasma A.C.	DDI-false
A possible interaction between glyburide and @DRUG$, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of @DRUG$.	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
CONCLUSIONS: @DRUG$ inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, @DRUG$, lovastatin, simvastatin).	DDI-mechanism
The concomitant use of @DRUG$ or other @DRUG$ may have an additive effect.	DDI-false
Therapeutic concentrations of digoxin , warfarin , ibuprofen , @DRUG$ , piroxicam, acetaminophene, @DRUG$ The binding of ketorolac-tromethamine proteins was not altered by andtolbutamide.	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin , carbamazepine , and @DRUG$ And the antituberculosis drug rifampin.	DDI-effect
Atromid-S may displace acidic drugs such as @DRUG$ or @DRUG$ from their binding sites.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of @DRUG$ was 20% lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone.	DDI-mechanism
The @DRUG$ Study-dose patients with 1200 mg/ day @DRUG$ ( n = 7 ) ( later changed to 600 mg/day [ n = 5 ] ) for Days 8 to 21 of a 21-day course of 100 mg , five times/day of zidovudine .	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The concomitant use of other CYP3A4 inhibitors such as diltiazem and @DRUG$ with transdermal fentanyl may also result in an increase in @DRUG$ plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	DDI-false
@DRUG$: Because of the relationship of Accutane to vitamin A, patients should be advised against taking @DRUG$ containing vitamin A to avoid additive toxic effects	DDI-false
@DRUG$ Oral hypoglycaemic episodes: agents with b-blocking properties may increase the hypoglycaemic effect of insulin and oral @DRUG$.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
Exposure from the proposed topical dose is about 1% of that from the 100 mg oral dose, even when co-administered with @DRUG$/@DRUG$.	DDI-false
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , antacids , H2-antagonists ( e.g. , famotidine , @DRUG$ , and proton pump inhibitors (e.g. lansoprazole, @DRUG$ ) .	DDI-false
â€¢ Saquinavir: co-administration of saquinavir (using an experimental soft gelatine capsule formulation of saquinavir 1200 mg) with: @DRUG$ resulted in an 18 % increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, @DRUG$, cimetidine and @DRUG$.	DDI-false
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without propantheline ( an anticholinergic agent with multiple effects on the GI tract ) to healthy volunteers , the AUC of @DRUG$ was 10 % lower and the Cmax of clonazepam was 20 % lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone .	DDI-false
@DRUG$ While studies have not shown @DRUG$ to interact with anticoagulants of the warfarin type , caution should be exercised , nonetheless , since interactions have been seen with other NSAIDs .	DDI-false
As with other antipsychotic agents , it should be noted that HALDOL may be capable of potentiating CNS depressants such as @DRUG$ , @DRUG$ And alcohol.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
A similar association , though less marked , has been suggested with barbiturates , @DRUG$ , phenytoin sodium , carbamazepine , @DRUG$ , topiramate, and possibly ampicillin and tetracycline 72.	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( @DRUG$ transdermal system ) with other @DRUG$ , including but not limited to other opioids , sedatives , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-effect
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, @DRUG$, fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with TAXOL should be premedicated with @DRUG$ ( such as dexamethasone ) , diphen-hydramine and H2 antagonists ( such as @DRUG$ or ranitidine ) .	DDI-false
@DRUG$: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing VIOXX therapy in patients receiving @DRUG$ or similar agents, since these patients are at an increased risk of bleeding complications.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Ritonavir : Coadministration of @DRUG$ â€¢ with VIRACEPT to an increase of 152% @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
@DRUG$ , including norfloxacin, the effect of oral @DRUG$ , including warfarin or its derivatives or similar agents.	DDI-effect
Plasma exposure ( AUC ) to @DRUG$ was increased 62 % when coadministered with @DRUG$ and 38 % when coadministered with ketoconazole .	DDI-mechanism
The pressor effects of catecholamines such as @DRUG$ or norepinephrine are enhanced by @DRUG$.	DDI-effect
Dexamethasone: Steady-state trough concentrations of @DRUG$ were about 56% higher when 8 mg dexamethasone was coadministered with each dose of @DRUG$ (15 mg/kg/day) in eight neurocysticercosis patients.	DDI-false
Anticoagulants including coumarin derivatives , indandione derivatives , and @DRUG$ - Non-steroidal anti-inflammatory medicines ( @DRUG$ ) , and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin .	DDI-false
Potential drug interactions between Keppra   and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and @DRUG$ ) were also assessed by evaluating the serum concentrations of @DRUG$ These AEDs during placebo-controlled clinical trials.	DDI-false
Patients who have been treated with @DRUG$ Within two to three weeks prior to administration of dopamine, HCl @DRUG$ Not greater than one tenth ( 1/10 ) of the usual dose.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-effect
Antihypertensives : Amiodarone should be used with caution in patients receiving   -@DRUG$ blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and @DRUG$ , a CYP3A4 inhibitor) because of the potential for bradycardia, sinus arrest, and AV block;	DDI-false
Colestipol : Plasma concentrations of @DRUG$ 25 % if Colestipol and @DRUG$ were coadministered .	DDI-false
Valproate: The addition of @DRUG$ to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
It is recommended that serum @DRUG$ Concentrations are often monitored when: @DRUG$ It is given concurrently with lithium.	DDI-false
Other medicines that can improve neuromuscular blocking effects of non-depolarizing agents such as NUROMAX are certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local @DRUG$ , @DRUG$ , and quinidine .	DDI-false
@DRUG$ The hypotensive effect of alcohol during the 4-hour observation period in healthy volunteers was not increased when 20 mg was administered concomitantly. @DRUG$ ( 0.5 g/kg body weight ) .	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, @DRUG$, oral contraceptive, digoxin, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Since amiodarone is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced amiodarone levels.	DDI-false
Concomitant administration of Sonata ( 10 mg ) and @DRUG$ The mean Cmax and AUC of @DRUG$ increased by 85% (800 mg).	DDI-false
@DRUG$: @DRUG$ may delay intestinal absorption of ethosuximide.	DDI-false
If cholinergic blockades occur, additive undesirable effects may occur if: @DRUG$ Amantadine is co-administered with other antimuscarinics, amantadine, @DRUG$ , phenothiazine, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
therefore, @DRUG$ or other nitrates (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting @DRUG$.	DDI-advise
Aspirin: When @DRUG$ is administered with aspirin, its protein binding is reduced, although the clearance of free @DRUG$ is not altered.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4 , such as @DRUG$ and atorvastatin .	DDI-mechanism
@DRUG$: @DRUG$*, terfenadine* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
@DRUG$: Simvastatin (@DRUG$ substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of azathioprine , gold , chloroquine , @DRUG$ , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ may interact with @DRUG$ or other CNS depressants , causing increased sedative effects .	DDI-effect
Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of @DRUG$ , the concomitant use of Nalfon and salicylates is not recommended .	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (nicotinic acid), @DRUG$, azole antifungals.	DDI-false
@DRUG$: Amiodarone, @DRUG$, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
CANCIDAS reduced the blood AUC0-12 of @DRUG$ by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of @DRUG$ 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.	DDI-false
@DRUG$: @DRUG$ plasma concentrations and LDL-C reduction were not altered by coadministration of cimetidine.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , @DRUG$ , non-steroidal anti-inflammatory drugs (e.g. ibuprofen), tacrolimus, @DRUG$.	DDI-false
Concomitant administration of @DRUG$ (equivalent to 145mg TRICOR) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for @DRUG$ by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	DDI-false
These increases should be considered when selecting an oral @DRUG$ for a woman taking @DRUG$.	DDI-advise
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ @DRUG$ , carbamazepine, and barbiturates, and the antituberculosis drug rifampin.	DDI-false
- @DRUG$ , oral ( diabetes medicine you take by mouth ) Use of oral antidiabetics with @DRUG$ The likelihood of side effects affecting blood and/or side effects or oral antidiabetic agents may be increased.	DDI-false
@DRUG$ inhibits @DRUG$.	DDI-false
While all selective serotonin reuptake inhibitors ( @DRUG$ ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, @DRUG$ , fluoxetine , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Other Drugs : Drugs such as quinidine , disopyramide , procainamide , phenothiazines , @DRUG$ , and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir (FORTOVASE) as the sole @DRUG$ due to the risk of decreased @DRUG$ plasma concentrations.	DDI-false
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors , 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors , sodium channels , and the 5-HT transporter .	DDI-false
@DRUG$ , @DRUG$ Azole is known to cause QTc prolongation.	DDI-false
Ritonavir: Coadministration of @DRUG$ with @DRUG$ resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	DDI-mechanism
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	DDI-mechanism
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The effects of @DRUG$ and of Innovar anesthesia on @DRUG$ tolerance in dogs.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
@DRUG$ : Because @DRUG$ may increase blood glucose concentrations , dosage adjustments of antidiabetic agents may be required .	DDI-false
These data indicate that @DRUG$ Do not affect the plasma concentration of other @DRUG$ These AEDs do not affect the pharmacokinetics of levetiracetam.	DDI-false
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: @DRUG$ , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin @DRUG$ midazolam , triazolam GI motility agents : cisapride	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, @DRUG$ , carbamazepine, fentanyl, alfentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
- When @DRUG$ or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or Bezalip retard is impaired	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, quinidine, @DRUG$ or @DRUG$.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , @DRUG$ , quinidine , warfarin , @DRUG$ (e. g. cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Amiodarone taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl procainamide by 55% and 33%, respectively.	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ and salicylates is not recommended.	DDI-false
@DRUG$: Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	DDI-false
Dosage adjustment of @DRUG$ Paroxetine may be necessary when co-administered with CYP2D6 inhibitors, e.g. @DRUG$ , and quinidine .	DDI-advise
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ Fortovase is the only @DRUG$ Because of the risk of decreased saquinavir plasma concentration.	DDI-false
Valproate: The addition of tiagabine to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Data from in vitro studies with benzodiazepines other than: @DRUG$ * Ergotamine, cyclosporin, amiodarone, nicardipine and @DRUG$.	DDI-int
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , @DRUG$ , @DRUG$ , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , @DRUG$ , @DRUG$ , progestogens (e.g. in oral contraceptives).	DDI-false
Antiacid, @DRUG$, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ should be used cautiously in conjunction with @DRUG$ in hypoprothrombinemia .	DDI-advise
* Delayed side effects on @DRUG$ A review of the literature showed that 12.6% ( range 11 - 28% ) of 501 patients treated with different interleukin-2-containing regimens were subsequently administered @DRUG$ experienced acute , atypical adverse reactions .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
Since @DRUG$ is primarily eliminated by the kidneys , coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either @DRUG$ - or the co-administered drug.	DDI-false
The risk of a possible interaction between @DRUG$ and @DRUG$ concentrates has not been adequately evaluated in preclinical or clinical studies .	DDI-false
â€¢ Metoclopramide: Bioavailability is slightly reduced (about 10%) if: @DRUG$ and @DRUG$ are coadministered .	DDI-mechanism
@DRUG$ The addition of @DRUG$ In patients chronically taking valproate, this did not affect the pharmacokinetics of tiagabin, but valproate significantly reduced the binding of tiagabin in vitro from 96.3 to 94.8%, resulting in an increase in free tiagabin concentration of about 40%.	DDI-false
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, macrolide antibiotics such as @DRUG$) have the potential to result in increased plasma concentrations of @DRUG$.	DDI-mechanism
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$, warfarin, quinidine, @DRUG$ or amoxicillin.	DDI-false
Benzylpenicillin , @DRUG$ , oxacillin, chlortetracycline, @DRUG$ In vitro, cephalothine, erythromycin and sulfamethoxazole have no influence on the protein binding of diclofenac in human serum.	DDI-false
In separate studies of patients receiving maintenance doses of @DRUG$, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
In general, these drugs have one or more pharmacological activities, similar to @DRUG$ , including antiarrhythmic agents such as quinidine and procainamide, @DRUG$ And tricyclic antidepressants.	DDI-false
Both @DRUG$ and @DRUG$ morphin-induced and nicotine-induced dopamine release in the nucleus of accumben;	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-false
Aspirin: Concomitant administration of diclofenac and @DRUG$ is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
Valdecoxib caused a statistically significant increase in plasma exposures of R-warfarin and @DRUG$ (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of @DRUG$.	DDI-false
- The action of sulphonylureas and @DRUG$ may be enhanced by @DRUG$ or Bezalip retard.	DDI-effect
Since the concomitant administration of @DRUG$ with @DRUG$ increases the prothrombin time by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
@DRUG$: @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	DDI-false
Coadministration of @DRUG$ and the potent CYP3A4 inhibitor @DRUG$ (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of almotriptan.	DDI-mechanism
Nitrates: The concomitant use of @DRUG$ with long- and short-acting @DRUG$ has been safely tolerated in patients with stable angina pectoris.	DDI-false
Anti-arrhythmic agents, class I (such as @DRUG$ , lidocaine, or @DRUG$ ): concurrent use with arbutamine may have a proarrhythmic effect .	DDI-false
@DRUG$ : In controlled studies in healthy volunteers , bepridil hydrochloride either had no effect ( one study ) or was associated with modest increases , about 30 % ( two studies ) in steady-state serum @DRUG$ concentrations .	DDI-false
Human pharmacokinetic data suggest that oral @DRUG$ â€¢ strongly inhibits the metabolism of @DRUG$ This resulted in an eightfold increase in the mean AUC of cisaprid.	DDI-mechanism
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs ( e.g. , triazolo-@DRUG$ , dihydropyridine calcium channel blockers , certain HMG-CoA reductase inhibitors , etc . ) .	DDI-mechanism
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen and valproic acid/phenobarbital.	DDI-false
@DRUG$ : Concomitant use of @DRUG$ In patients with myasthenia gravis, corticosteroids may cause severe weakness.	DDI-false
There have been reports of @DRUG$-related side effects in patients on concomitant therapy with @DRUG$ and theophylline.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
@DRUG$: Dihydroergotamine, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Co-administration : Concomitant use of Argatroban with antiplatelet agents , @DRUG$ , and other @DRUG$ may increase the risk of bleeding .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with @DRUG$ (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in @DRUG$ Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
In a study in which the orally decaying 2 mg clonazepam tablet with and without @DRUG$ ( an anticholinergic agent with multiple effects on the GI tract ) to healthy volunteers , the AUC of clonazepam was 10 % lower and the Cmax of @DRUG$ was 20 % lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone .	DDI-false
Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG$n, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of @DRUG$	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
The concomitant use of other CYP3A4 inhibitors such as @DRUG$ and erythromycin with transdermal @DRUG$ may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	DDI-mechanism
Therapeutic concentrations of @DRUG$ , warfarin, ibuprofen, naproxen, piroxicam, acetaminophene, phenytoin andtolbutamide not altered @DRUG$ protein binding .	DDI-false
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of @DRUG$ , @DRUG$ , chloroquine , D-penicillamine , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
Ethopropazine can interact with @DRUG$, increasing the metabolism of @DRUG$.	DDI-false
While no in vivo drug interaction studies have been conducted between estazolam and CYP3A inducers, compounds that are potent CYP3A inducers (such as carbamazepine, @DRUG$ , @DRUG$ , and barbiturates ) would be expected to decrease estazolam concentrations .	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazide, @DRUG$ , nicardipine , propofol , @DRUG$ , quinidine, and verapamil.	DDI-false
Coadministration of valdecoxib and @DRUG$ 1/35  increased the exposure of norethindrone and @DRUG$ by 20% and 34%, respectively.	DDI-false
Although these results do not indicate a significant interaction between TORADOL and @DRUG$ or heparin, the administration of TORADOL to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
Therefore , the concomitant administration of @DRUG$ and @DRUG$ It is contraindicated and alternative hypoglycaemia should be considered.	DDI-advise
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, @DRUG$ , diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$ Oestrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Co-administration of MYOBLOC and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , @DRUG$ , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
@DRUG$ In a study in healthy subjects, mean steady-state lithium plasma levels increased in patients who: @DRUG$ 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone .	DDI-false
It is therefore necessary to be familiar with the clinical and paraclinical pattern @DRUG$ â€¢ Deficit and discrimination between: @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation .	DDI-false
Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , @DRUG$ , danazol, diuretics, sympathomimetics (e.g., epinephrine, @DRUG$ , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
The effects of adenosine are antagonized by @DRUG$ such as @DRUG$ and theophylline.	DDI-false
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Hemodynamic and electrophysiological interactions have also been reported after concomitant use of @DRUG$ , Diltiazem, and @DRUG$.	DDI-false
Rifampin : Coadministration of @DRUG$ and VIRACEPT resulted in an 82 % decrease in @DRUG$ plasma A.C.	DDI-false
- may affect anticoagulants (modified hypoprothrombinemic activity), @DRUG$ , rifampin and other inducers of hepatic microsomal enzyme oxidation system ( decreased effect of diethylstilbestrol ) , corticosteroids ( increased effect of @DRUG$ ) .	DDI-false
Cardiac effects of @DRUG$ are antagonized by beta-adrenergic blocking agents, such as @DRUG$ and metoprolol.	DDI-effect
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like @DRUG$ or methysergide) and AXERT within 24 hours of each other should be avoided.	DDI-false
Ingestion of @DRUG$ may increase serum concentrations of digoxin and methotrexate and increase @DRUG$ s nephrotoxicity .	DDI-effect
@DRUG$ : In healthy subjects given single 500 mg doses of @DRUG$ Metformin and metformin, mean cmax plasma and AUC increased by an average of 34% and 24%, respectively, and mean renal clearance of metformin by 14%.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
@DRUG$: In vitro and/or in vivo data show that @DRUG$, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Therefore, interactions following concomitant administration of psychotropic medicinal products (e.g. narcotics, @DRUG$ , antiemetics , @DRUG$ , sedatives).	DDI-false
Co-administration of warfarin and @DRUG$ did not alter the pharmacokinetics of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , @DRUG$ , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	DDI-false
Antiacid, @DRUG$, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
There was no apparent pharmacokinetic interaction between @DRUG$ and @DRUG$ After single dose ( 10 mg or 600 mg) of each medicinal product.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate , @DRUG$ , and pargyline HC1 : Concomitant use of L-tyrosine and non-selective @DRUG$ - May cause high blood pressure.	DDI-false
Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, the administration of @DRUG$ to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.	DDI-advise
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	DDI-false
Selective serotonin reuptake inhibitors (SSRIs): @DRUG$ ==References====External links== @DRUG$ Paoxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like @DRUG$ ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Anticoagulants : Potentiation of @DRUG$-type ( CYP2C9 and CYP3A4 substrate ) anticoagulant response is almost always seen in patients receiving @DRUG$ And can lead to severe or fatal bleeding.	DDI-false
Ritonavir and @DRUG$ When vardenafil 5 mg is co-administered with 600 mg twice daily @DRUG$ The Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
No pharmacokinetic interactions between dexmedetomidine and isoflurane, @DRUG$ , @DRUG$ , and midazolam have been demonstrated .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ Aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides, aminoglycosides @DRUG$ , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Psychoactive Drugs : Hallucinations have been reported when @DRUG$ In patients receiving psychoactive medicinal products ( @DRUG$ , thiothixene , alprazolam ) .	DDI-effect
@DRUG$ (200 mg once daily) produced a 10-fold increase in @DRUG$ AUC and a 4-fold increase in Cmax when co-administered with Vardenafil (5 mg) in healthy volunteers.	DDI-mechanism
@DRUG$ The rate and extent of absorption of ciprofloxacin were bioequivalent if Proquin XR was given alone or if Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion .	DDI-false
rifampin pre-treatment of healthy volunteers with multiple doses followed by a single dose @DRUG$ , increased @DRUG$ oral-dose clearance by 3.8-fold , which significantly ( p 0.05 ) decreased mean cmax and AUC(0 - 8) .	DDI-false
The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin , nitroprusside , @DRUG$ ACE inhibitors have not been studied (these medicinal products have not been administered with Natrecor in clinical trials).	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-effect
@DRUG$: Patients on diuretics, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$.	DDI-false
Magnesium/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Warfarin @DRUG$   ( 1000 mg twice daily ) did not influence the pharmacokinetics of R and @DRUG$.	DDI-false
Simultaneous use of a @DRUG$ with @DRUG$ It has been associated with an increased risk of severe infections and no significant additional efficacy compared to the sole use of TNF antagonists.	DDI-effect
Co-administration of valdecoxib ( 40 mg twice daily ( day 1 ) and 40 mg twice daily ( days 2 - 7 ) with glyburide ( 10 mg) @DRUG$ â€¢ BID) led to an increase of 21% @DRUG$ AUC0-12 and a 16% increase in glyburide Cmax lead to a 16% decrease in glucose AUC0-24.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , intraconazole , ritonavir , indinavir , saquinavir , @DRUG$ , etc . ) is indicated , reduction of the @DRUG$ dose should be considered .	DDI-advise
@DRUG$: When Vardenafil 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of @DRUG$, significant hypotension developed in a substantial number of subjects.	DDI-false
The @DRUG$ Study participants with 1200 mg/day azithromycin ( n = 7 ) ( subsequently changed to 600 mg/day [ n = 5 ]) for days 8 to 21 of a 21-day course of 100 mg, five times/day @DRUG$.	DDI-false
May interact with thyroid medication ( e.g. , levothyroxine ) , @DRUG$-containing products , @DRUG$ H2 antagonists (e.g. famotidine, ranitidine) and proton pump inhibitors (e.g. lansoprazole, omeprazole).	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$ and @DRUG$	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.	DDI-false
In addition, the results of regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, @DRUG$ CANCIDAS may cause clinically significant reductions in @DRUG$ concentrations .	DDI-false
Therophylline : A recent study has shown that @DRUG$ and @DRUG$ may cause elevated plasma levels of theophylline , and in some instances a slight decrease in the elimination of isoniazid .	DDI-mechanism
Vitamin A: Because of the relationship of @DRUG$ to vitamin A, patients should be advised against taking vitamin supplements containing @DRUG$ to avoid additive toxic effects	DDI-false
Plasma concentrations (AUC 0-24 hrs) of @DRUG$ decreased 15% with coadministration of loratadine relative to that observed with @DRUG$ alone.	DDI-false
Although @DRUG$ administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by @DRUG$ or on the location, histologic type, depth of involvement, labeling index, apoptotic index or tumor vascularity of intestinal cancers, it significantly decreased the incidence of cancer metastasis.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
Benzylpenicillin, ampicillin, @DRUG$, @DRUG$, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Therefore, when @DRUG$ and nonsteroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.)	DDI-false
Interactions may occur between EPA supplements and @DRUG$ and other @DRUG$ and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).	DDI-false
In two combined 12-week placebo controlled trials that included @DRUG$ doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 BROVANA -treated subjects received concomitant @DRUG$ at study entry.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , fibrates , fluoxetine , @DRUG$ , @DRUG$ , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: MTX, NSAIDs, @DRUG$ TNF blockers, @DRUG$ , chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine and anakinra.	DDI-false
Folic acid in large amounts may counteract the antiepileptic effect of @DRUG$, phenytoin and @DRUG$, and increase the frequency of seizures in susceptible pediatric patients.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , @DRUG$ Clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
@DRUG$  may interact with drugs known to interact with the conventional formulation of @DRUG$.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	DDI-false
Non-selective MAO inhibitors including @DRUG$ , @DRUG$ , and pargyline HC1 : Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension .	DDI-false
Patients receiving other @DRUG$s, general anaesthetics, @DRUG$ , tranquilizers , sedative-hypnotics , tricyclic antidepressants or other CNS depressants ( including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression .	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs , e.g. , @DRUG$ , methyldopa , reserpine .	DDI-effect
@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, @DRUG$, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Lack of an effect of azithromycin on the disposition of @DRUG$ and @DRUG$ in HIV-infected patients.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Benzylpenicillin , ampicillin , oxacillin , chlortetracycline , doxycycline , @DRUG$ In vitro, erythromycin and sulfamethoxazole have no effect on protein binding of @DRUG$ In human serum.	DDI-false
Drugs Which Require a Dose Reduction When Coadminstered With @DRUG$ @DRUG$ : rifabutin	DDI-advise
Therefore, interactions may occur after concomitant administration of psychotropic medicinal products (e. g. @DRUG$ , @DRUG$ , antiemetics , sedatives , tranquilizers ) .	DDI-false
@DRUG$ has also been shown to inhibit P450 1A2 , an isoform also involved in @DRUG$metabolism .	DDI-mechanism
@DRUG$ : In normal volunteers , concomitant administration of @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
@DRUG$ In a study in healthy male subjects, no significant pharmacokinetic interactions occurred if: @DRUG$ and allopurinol were administered concomitantly for 6 days .	DDI-false
Bacteriostatic Antibiotics : @DRUG$ , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of @DRUG$.	DDI-effect
In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$ alone (0%).	DDI-false
Antidepressants, tricyclic: amphetamines can increase the activity of @DRUG$ or @DRUG$ ;	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
In addition to the interactions noted above , chronic (   2 weeks ) oral Cordarone administration impairs metabolism of @DRUG$ , Dextromethorphan, and @DRUG$.	DDI-false
Effect of @DRUG$ on the pharmacokinetics of @DRUG$.	DDI-false
Other potent inhibitors of CYP3A4 (e.g. itraconazole, @DRUG$ , nefazodone , @DRUG$ Ritonavir, nelfinavir, is expected to behave similarly.	DDI-false
Garlic capsules Garlic capsules should not be used while taking saquinavir ( @DRUG$ ) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , @DRUG$ , @DRUG$ Methylthiadiazole (Cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Standard therapy includes @DRUG$, such as @DRUG$ and gentamicin;	DDI-false
Rhabdomyolysis has been observed in patients who: @DRUG$ â€¢ Alone (at recommended doses) or concomitantly with immunosuppressive medicinal products including @DRUG$.	DDI-effect
Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Dexamethasone: Steady-state trough concentrations of @DRUG$ were about 56% higher when 8 mg @DRUG$ was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : @DRUG$ ( eg , pentazocine , nalbuphine , butorphanol , @DRUG$ and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Patients receiving these drugs who are given @DRUG$, or any other @DRUG$, and particularly those patients with altered renal function, should be observed for the development of the specific toxicities of these drugs.	DDI-false
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all @DRUG$, including diclofenac, and @DRUG$ requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	DDI-advise
==References====External links== @DRUG$ and @DRUG$ in vitro .	DDI-effect
@DRUG$ and colestipol resins : Absorption of hydrochlorothiazide is impaired in the presence of @DRUG$.	DDI-false
Antiarrhythmic agents, class I (such as flecainide, @DRUG$ , or quinidine ): concurrent use with @DRUG$ - May have a proarrhythmic effect.	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$ , antihistamines , @DRUG$ , barbiturates , monoamine oxidase inhibitors , narcotics , phenothiazines , psychotropic medications , or other drugs that produce CNS depression .	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g. itraconazole, ritonavir and erythromycin) has not been studied, exposure to @DRUG$ It can be expected if: @DRUG$ The drug is used at the same time as these drugs.	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as @DRUG$, opiates, and alcohol.	DDI-false
MAO inhibitors: DURAGESIC is not recommended for use in patients who: @DRUG$ within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with @DRUG$	DDI-false
Digoxin , @DRUG$ Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$ , and losartan has no significant effect on plasma levels of bosentan .	DDI-false
An alternative non-CYP3A4 substrate @DRUG$ Treatment may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, carbamazepine and @DRUG$.	DDI-false
@DRUG$: The addition of tiagabine to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
The zidovudine study dosed subjects with 1200 mg/day of @DRUG$ (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of @DRUG$.	DDI-false
Oral @DRUG$ Co-administration of atorvastatin and oral @DRUG$ increased AUC values for norethindrone and ethinyl estradiol by approximately 30 % and 20 % .	DDI-false
Experience with co-administration of @DRUG$ and @DRUG$ Therefore, the use of HMG-CoA reductase inhibitors should be temporarily suspended in patients receiving fentanyl.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin, gentamicin and amikacin), @DRUG$ , Foscarnet, intravenous @DRUG$ , vancomycin, and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Cholestyramine and colestipol @DRUG$: Absorption of @DRUG$ is impaired in the presence of anionic exchange resins.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
When @DRUG$ was coadministered with phenytoin , @DRUG$ , or H2antagonists , reduced plasma concentrations of itraconazole were reported .	DDI-mechanism
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
Urinary acidifying agents These agents ( @DRUG$ , sodium acid phosphate , etc . ) increase the concentration of the ionized species of the @DRUG$ ==References====External links==* Official website	DDI-mechanism
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, @DRUG$, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in @DRUG$ concentrations.	DDI-false
The concentrations of @DRUG$, the active metabolite of @DRUG$, were on average 33% higher in patients receiving bolus-IFL in combination with AVASTIN when compared with bolus-IFL alone.	DDI-false
The foreclosure of colestipolhydrochloride could pose a health risk if a potentially toxic drug, which is significantly reduced to @DRUG$ The patient was titrated to a maintenance level while taking @DRUG$.	DDI-false
Multivalent Cation-Containing products: co-administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of @DRUG$ , which leads to serum and urine levels significantly lower than desired.	DDI-false
Since @DRUG$ and @DRUG$ , including MIDAMOR , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently .	DDI-effect
In addition, under the influence of sympatholytics such as @DRUG$ , @DRUG$ , guanethidine, and reserpine, the signs of hypoglycaemia may be reduced or absent.	DDI-false
Single doses of any of the following doses: @DRUG$ * Colestipol resins bind the @DRUG$ and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent , respectively .	DDI-mechanism
INOmax has been administered with tolazoline , @DRUG$ , dobutamine, steroids, @DRUG$ , and high-frequency ventilation .	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, @DRUG$, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
- @DRUG$ : Lithium should generally not be given with diuretics ( such as @DRUG$ ) because they reduce its renal clearance and add a high risk of lithium toxicity .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , calcium-blocking agents , hydralazine , @DRUG$ and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
Population pharmacokinetic analyses revealed that MTX , @DRUG$ , @DRUG$ , and TNF blocking agents did not influence abatacept clearance .	DDI-false
Promethazine : Coadministration of a single dose of @DRUG$ and @DRUG$ ( 10 and 25 mg , respectively ) resulted in a 15 % decrease in maximal plasma concentrations of zaleplon , but no change in the area under the plasma concentration-time curve .	DDI-mechanism
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , @DRUG$ , hypnotics , @DRUG$ â€¢ (e.g. benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants and alcohol, may cause respiratory depression, hypotension and deep sedation, or may lead to coma or death.	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including @DRUG$ Like quinidine and procainamide, @DRUG$ And tricyclic antidepressants.	DDI-false
In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated aspirin plus @DRUG$ 25 mg daily, as compared to those taking @DRUG$ 2400 mg daily alone.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : @DRUG$ Antimycobacterial agents : rifampin @DRUG$ midazolam , triazolam GI motility agents : cisapride	DDI-false
Notably, systemic exposure (AUC0-12) of @DRUG$ (@DRUG$) was more than doubled in the presence of TMP/SMX.	DDI-false
@DRUG$ (e.g., Antiminth) - Taking @DRUG$ and pyrantel together may decrease the effects of piperazine.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
To evaluate the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, @DRUG$ , @DRUG$ , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
@DRUG$ In vitro and/or in vivo data show that clarithromycin, erythromycin and troleandomycin significantly inhibit the metabolism of cisapride, which may lead to an increase in plasma. @DRUG$ The concentrations and prolongation of the QT interval on the ECG.	DDI-false
Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone ( at recommended dosages ) or concomitantly with @DRUG$ including @DRUG$.	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be able to treat CNS depressants such as: @DRUG$ ##############################################################################################################################################################################################################################################################################################################################################################################################################################################################################################################################	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
By contrast , @DRUG$ ( 1 mM ) and @DRUG$ 1 mM) had no significant effect on translocation when added alone.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Co-administration of @DRUG$ with @DRUG$ produced a 25 % increase in AUC and a 33 % increase in the Cmax of acamprosate .	DDI-mechanism
In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of @DRUG$, dextromethorphan, and methotrexate.	DDI-false
It is recommended that the concomitant use of ethambutol with aluminium hydroxide is avoided. @DRUG$ for at least 4 hours following @DRUG$ administration .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Therefore , @DRUG$ should be taken at least 1 hour before or 4 - 6 hours after a @DRUG$ To avoid hindering its absorption.	DDI-advise
Therefore, the prothrombin time should be used in patients who: @DRUG$ and @DRUG$-like drugs simultaneously .	DDI-advise
@DRUG$ : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , @DRUG$ , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
@DRUG$ The plasma concentrations of atorvastatin decreased by about 25% if: @DRUG$ and atorvastatin were coadministered .	DDI-false
Central nervous system depressants : Co-administration of @DRUG$ Fentanyl transdermal system (Fentanyl transdermal system) with other @DRUG$ , including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and deep sedation, or possibly lead to coma or death.	DDI-effect
However, because some @DRUG$ have been reported to enhance the anticoagulant effects of @DRUG$ or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives .	DDI-effect
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-advise
Patients receiving other @DRUG$s , general anesthetics , phenothiazines , tranquilizers , @DRUG$ , tricyclic antidepressants or other CNS depressants (including alcohol) together with DILAUDID may exhibit additive CNS depression.	DDI-false
Phenytoin : @DRUG$ Intestinal absorption may be delayed @DRUG$ ;	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Non-selective MAO inhibitors including @DRUG$ , phenelzine sulfate , and pargyline HC1 : Concomitant use of @DRUG$ Non-selective MAO inhibitors can lead to hypertension.	DDI-false
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including @DRUG$, tranquilizers, and @DRUG$.	DDI-false
Coadministration of @DRUG$ ( 10 mg BID for 7 days ) with glyburide ( 5 mg QD or 10 mg BID ) did not affect the pharmacokinetics ( exposure ) of @DRUG$.	DDI-false
There was no significant difference in the pharmacodynamic effect of warfarin administered alone and @DRUG$ administered with @DRUG$ as measured by prothrombin time.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
@DRUG$: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, @DRUG$, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or beta-adrenergic blocking agents , calcium channel blockers , @DRUG$ or @DRUG$ Also tricyclic antidepressants and phenothiazines could contribute to an extension of the QTc interval.	DDI-false
â€¢ Saquinavir : The combination of @DRUG$ , saquinavir, and @DRUG$ has been studied ( as triple combination ) in adults .	DDI-false
Hepatic enzyme inducers, inhibitors and substrates: drugs that induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity (e.g. barbiturates, phenytoin, carbamazepine, @DRUG$ ) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased .	DDI-false
@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;	DDI-false
â€¢ Non-selective MAO inhibitors including @DRUG$ , phenelzine sulfate , and @DRUG$ HC1 : Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension .	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenylbutazone , phenytoin sodium , carbamazepine , @DRUG$ , topiramate , and possibly with @DRUG$ and tetracyclines 72 .	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , @DRUG$ , a-blockers , analgesics , @DRUG$ , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa.	DDI-false
Phenothiazines and @DRUG$ may reduce or reverse the pressor effect of @DRUG$.	DDI-effect
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, @DRUG$, carvedilol, ethanol or itraconazole.	DDI-false
Microdosed minipill @DRUG$ preparations are not recommended for use with @DRUG$.	DDI-advise
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, @DRUG$ or itraconazole.	DDI-false
Lithium : Increased serum @DRUG$ levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy .	DDI-false
A similar association, though less marked, has been suggested with barbiturates, @DRUG$, @DRUG$, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$.	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , itraconazole , ritonavir , and @DRUG$ ) has not been studied, increased exposure to almotriptan may be expected if: @DRUG$ The drug is used at the same time as these drugs.	DDI-advise
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, @DRUG$, cimetidine and phenobarbital.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, @DRUG$, dexamethasone, or @DRUG$, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide , digoxin , @DRUG$ , cimetidine and @DRUG$.	DDI-false
While @DRUG$ Ibogain has similar affinities for kappa opioid and possibly nicotinic acid receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors , sodium channels , and the 5-HT transporter .	DDI-false
@DRUG$: @DRUG$ is a CYP 2C9 substrate.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Anti-arrhythmic agents, class I (such as @DRUG$ , @DRUG$ Co-administration with arbutamine may have a proarrhythmic effect.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Micro-dosed @DRUG$ Preparations: micro-dosed progesterone preparations (minipills which do not contain: @DRUG$ ) may be an inadequate method of contraception during Accutane therapy .	DDI-false
Patients treated with @DRUG$ and @DRUG$ concomitantly may need to be monitored for increases in INR and prothrombin time.	DDI-effect
Earlier studies showed a significant reduction in oral bioavailability of @DRUG$ and ciprofloxacin when administered concomitantly with an intravenous @DRUG$ Like morphine.	DDI-mechanism
Another oral @DRUG$ , @DRUG$ Astemizole inhibits the metabolism of astemizole, resulting in increased plasma concentrations of astemizole and its active metabolite desmethylastermizole, which may prolong QT intervals.	DDI-false
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.	DDI-false
In clinical trials, @DRUG$ was used with digoxin, @DRUG$ , anticoagulants , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Experience with co-administration of HMG-CoA reductase inhibitors and @DRUG$ in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving @DRUG$.	DDI-false
Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another @DRUG$ and @DRUG$ but may be seen after several months.	DDI-effect
In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors @DRUG$, tolbutamide and @DRUG$.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin , @DRUG$ , or @DRUG$ Administration of irbesartan for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.	DDI-false
There was no significant difference in the pharmacodynamic effect of @DRUG$ Administration alone and warfarin co-administered with @DRUG$ as measured by prothrombin time .	DDI-false
@DRUG$ may potentiate the adverse effects of other @DRUG$ administered concomitantly.	DDI-effect
Ergot Derivatives : @DRUG$ , ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute @DRUG$ Toxicity characterized by peripheral vasospasm and ischemia of extremities and other tissues.	DDI-false
Possible interactions between Keppra and other medicinal products @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ In placebo-controlled clinical trials, serum concentrations of levetiracetam and these AEDs have also been studied.	DDI-false
Concurrent administration of @DRUG$ and @DRUG$ may result in elevated serum levels of oxyphenbutazone.	DDI-mechanism
When other antiplatelet agents or @DRUG$ are used concomitantly , there is the potential for @DRUG$ To increase the risk of bleeding.	DDI-effect
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
@DRUG$ Rofecoxib 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of @DRUG$ after a single 0.5 mg oral dose .	DDI-false
@DRUG$-@DRUG$ in large doses may inhibit vitamin K epoxide reductase resulting in vitamin K deficiency.	DDI-false
Antibiotics: @DRUG$ have been reported to cause a significant decrease in @DRUG$ clearance.	DDI-mechanism
Digoxin , @DRUG$ , Cyclosporine : @DRUG$ , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs .	DDI-false
Other Drugs : Drugs such as quinidine , @DRUG$ , @DRUG$ , phenothiazines , antihistamines , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , @DRUG$ , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with @DRUG$ Bleomycin) without antiretroviral therapy.	DDI-false
@DRUG$ Not co-administered with D2 antagonists such as phenothiazines, @DRUG$ Thioxanthine or methoclopramide.	DDI-advise
@DRUG$: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving @DRUG$ alone.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , @DRUG$ , disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylate, somatostatin analogue (e.g., octreotide), @DRUG$.	DDI-false
@DRUG$ Keppra   ( 1000 mg twice daily ) did not influence the pharmacokinetics and pharmacodynamics ( ECG ) of @DRUG$ given as a 0.25 mg dose every day .	DDI-false
Therefore, when Dopamine HCl is used in patients who: @DRUG$ or @DRUG$.	DDI-false
Theophylline: As with some other quinolones, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Prednisone/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or @DRUG$.	DDI-false
Since @DRUG$ does not markedly inhibit CYP450s (CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, or CYP3A4) in vitro, @DRUG$ is not expected to significantly interact with other drugs in vivo by inhibition of metabolism mediated by these isozymes.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with @DRUG$ and tetracyclines 72.	DDI-false
Patients in a clinical study who were on established therapy with sulfasalazine , to which ENBREL was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or @DRUG$ alone .	DDI-false
It is suggested that in patients receiving dopamine HCl, alternatives to @DRUG$ should be used if @DRUG$ therapy is needed.	DDI-false
Lithium generally should not be given with diuretics because they reduce @DRUG$s renal clearance and add a high risk of @DRUG$ toxicity .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
However, high doses of @DRUG$ may reduce the efficacy of intrathecally administered @DRUG$.	DDI-effect
Because prostaglandins play an important role in hemostasis , and NSAIDs affect platelet function as well , concurrent therapy with all NSAIDs , including @DRUG$ , and warfarin requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , @DRUG$ , A-blockers, analgesics, angiotensin converting enzyme ( ACE) inhibitors, anticonvulsants, @DRUG$ Beta blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
Tetracyclines: Concomitant treatment with Accutane and tetracyclines should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$	DDI-effect
Because there is a theoretical basis that these effects may be additive , use of @DRUG$-containing or @DRUG$ AXERT (such as dihydroergotamine or methysergide) and AXERT should be avoided within 24 hours of each other.	DDI-false
@DRUG$: The anorectic and stimulatory effects of amphetamines may be inhibited by @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , @DRUG$ , A-blockers, analgesics, angiotensin converting enzyme ( ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$ Prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Imidazoles (e. g., @DRUG$, miconazole, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
No pharmacokinetic interactions between dexmedetomidine and isoflurane, propofol, @DRUG$, and @DRUG$ have been demonstrated.	DDI-false
Antihistamines : @DRUG$ may counteract the sedative effect of @DRUG$.	DDI-effect
Other concomitant therapy Although specific interaction studies have not been performed, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, @DRUG$ , @DRUG$ Prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Drug interaction studies have shown that @DRUG$ No clinically relevant interactions with phenytoin, warfarin, quinidine, @DRUG$ or amoxicillin .	DDI-false
The concomitant intake of @DRUG$ and @DRUG$ does not affect the pharmacokinetics of either alcohol or acamprosate .	DDI-false
@DRUG$ SSRIs: SSRIs (e.g. fluoxetine, fluvoxamine, paroxetine, @DRUG$ ) have been rarely reported to cause weakness, hyperreflection, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-mechanism
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , @DRUG$ - chewable/buffered tablets or paediatric powders, or products that can significantly reduce the absorption of calcium, iron or zinc @DRUG$ , resulting in serum and urine levels considerably lower than desired .	DDI-false
Imipramine ( 5 mg/kg ) , @DRUG$ ( 30 mg/ kg ), @DRUG$ ( 0.25 mg/kg ) , fluoxetine ( 20 mg/kg ) sertraline ( 30 mg/kg ) or vehicle was administered .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
" Medicinal products not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, @DRUG$ Antimigraine : Ergot derivatives Antimycobacterial agents : @DRUG$ Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
Other Drug Interactions Oral @DRUG$ Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg @DRUG$ and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
@DRUG$: Coadministration of @DRUG$ resulted in a 27% decrease in almotriptan clearance and an increase in Cmax of approximately 6%.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine) with @DRUG$ may result in clinically meaningful reductions in @DRUG$ concentrations.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (@DRUG$/SMX).	DDI-false
However, neither phenobarbital nor @DRUG$ appears to affect @DRUG$ metabolism.	DDI-false
Concomitant use of agents in the @DRUG$ (which includes Anafranil) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug.	DDI-false
- medicines associated with peripheral neuropathy include: @DRUG$ , chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$ , and vincristine .	DDI-false
Like @DRUG$ ( 40 mg/kg ) , 18-MC ( 40 mg/kg ) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats ;	DDI-false
FLEXERIL may have the effect of @DRUG$ , Barbiturates, and others @DRUG$.	DDI-false
Warfarin : No significant differences were observed in the steady-state pharmacokinetics of @DRUG$ or S-warfarin with the addition of @DRUG$ given as a single dose .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , @DRUG$ , disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$ * Salicylates, somatostatin analogue (e.g. octreotide), sulphonamide antibiotics.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
apomorphine - prior ingestion of @DRUG$ may decrease the @DRUG$ response to apomorphine in the treatment of poisoning.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, antiemetics, sedatives, @DRUG$).	DDI-false
â€¢ Drug interactions: Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and @DRUG$ Cause additive CNS depression - Tricyclic antidepressants : flupenthixol increases the effect of tricyclic antidepressants	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
Iodine or @DRUG$ excess may decrease the effect of Carbimazole, and an @DRUG$ deficiency can increase the effect of Carbimazole.	DDI-false
Other Cardiovascular Agents : @DRUG$ and enalapril IV have been used concomitantly with @DRUG$ , methyldopa, nitrates, calcium blockers, hydralacin, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Antacids : In a clinical pharmacology study, concomitant administration of antacids (aluminium hydroxide, magnesium hydroxide and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ Compared to Fosinopril alone, which suggests that antacids may affect the absorption of @DRUG$.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
Certain endocrine and liver function tests may be affected by @DRUG$-containing oral @DRUG$.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Additionally, paroxetine did not alter the pharmacokinetics of @DRUG$, reflecting the absence of a role of CYP2D6 in @DRUG$ s metabolism.	DDI-false
The dosages of naloxone required to antagonize the effects of naloxone @DRUG$ The effects of @DRUG$ were more than 100 times higher than those needed to counter them.	DDI-false
Aspirin : In normal volunteers , a small decrease in @DRUG$ The concentrations were observed when multiple doses of @DRUG$ and aspirin were administered concomitantly .	DDI-false
Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited , therefore , consideration should be given to temporarily suspending use of @DRUG$ in patients receiving @DRUG$.	DDI-advise
- Anabolic steroids ( nandrolone [ e.g. , @DRUG$ ], Oxandrolone [e.g., @DRUG$ ] , oxymetholone [ e.g. , Anadrol ] , stanozolol [ e.g. , Winstrol ] ) or	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous @DRUG$ such as @DRUG$.	DDI-false
In clinical trials, FLOLAN was treated with: @DRUG$ , diuretics , anticoagulants , oral @DRUG$ , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Concomitant use of antihistamines with other medicinal products may result in additive CNS depression. @DRUG$ including barbiturates , tranquilizers , and @DRUG$.	DDI-false
In clinical studies with fondaparinux, the concomitant use of oral anticoagulants ( @DRUG$ , platelet inhibitors (acetylsalicylic acid) and NSAIDs ( @DRUG$ Digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
The medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, @DRUG$ , dapsone, disulfiram, ethionamide, @DRUG$ , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Antidepressants, tricyclic amphetamines can increase the activity of @DRUG$ or @DRUG$ ;	DDI-false
Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an ethinylestradiol/levonorgestrol oral @DRUG$ In healthy subjects.	DDI-false
Patients receiving @DRUG$ and @DRUG$ concomitantly should have a dose reduction of azathioprine , to approximately 1/3 to 1/4 the usual dose .	DDI-advise
The safety and efficacy of concomitant use of @DRUG$ and @DRUG$ is unknown, and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks.	DDI-effect
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, @DRUG$) should be considered.	DDI-false
In separate studies in patients receiving maintenance doses of warfarin, hydrochlorothiazide or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of @DRUG$ The pharmacokinetics of digoxin (prothrombin time) or digoxin.	DDI-false
Oral Contraceptives: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral @DRUG$ norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to @DRUG$ , including antiarrhythmics such as quinidine and procainamide, cardiac glycosides and @DRUG$.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, warfarin, @DRUG$, Maalox, and ranitidine.	DDI-false
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: @DRUG$ , terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$ Triazolam GI motility agent: cisapride	DDI-false
@DRUG$: Coadministration of single doses of @DRUG$ 3 mg and lorazepam 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.	DDI-false
Concomitant administration of @DRUG$ , quinidine and other related compounds (e.g. quinine, quinidine and @DRUG$ ) may produce electrocardiographic abnormalities and increase the risk of convulsions .	DDI-effect
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, D-penicillamine, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
@DRUG$: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat amphetamine poisoning.	DDI-false
A dose increase of lopinavir/@DRUG$ to 533/133 mg twice daily with food is recommended in combination with @DRUG$.	DDI-advise
Imidazole (e.g. @DRUG$ , miconazole , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ It can lead to fungal resistance against amphotericin B.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, warfarin, digoxin, @DRUG$, and ranitidine.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
The compounds tested in humans include warfarin, theophylline, phenytoin, diazepam, @DRUG$ and @DRUG$.	DDI-false
The ECG changes and/ or hypokalaemia resulting from the administration of non-kalium-sparing diuretics (e.g. @DRUG$ ) can be acutely worsened by @DRUG$ , especially if the recommended dose of the beta agonist is exceeded.	DDI-effect
Another oral azole antifungal, @DRUG$ , inhibits the metabolism of @DRUG$ , resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals .	DDI-mechanism
As with some other @DRUG$, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving phenytoin or @DRUG$.	DDI-effect
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
In addition, the results of regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance (efavirenz, @DRUG$ , phenytoin , dexamethasone , or carbamazepine ) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations .	DDI-mechanism
Antacids containing magnesium and/or aluminium, products containing iron sulphate ( @DRUG$ () Multivitamin preparations containing zinc or other metal cations or Videx (didanosine) chewable tablets or the oral pediatric powder should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
The effects of @DRUG$ and L-CCG-1 upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice .	DDI-false
Cyclosporin, digoxin, methotrexate lodine, such as other NSAIDs, due to effects on renal prostaglandins, may cause changes in the elimination of these drugs to increase serum levels of @DRUG$ , @DRUG$ , methotrexate , and increased toxicity .	DDI-false
@DRUG$ : Caution should be used if @DRUG$ is administered concomitantly with methotrexate .	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, alcohol, @DRUG$, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
The following specific interactions have been reported : Itraconazole Co-administration of another extended release formulation of @DRUG$ with @DRUG$ The result was an approximately 8-fold increase in AUC, a more than 6-fold increase in Cmax and a 2-fold increase in the half-life of felodipine.	DDI-false
Before using this medicine, tell your doctor or pharmacist about all prescription and non-prescription products you can use, especially: aminoglycosides (e.g., gentamicin, @DRUG$ Amphotericin B, cyclosporin, nonsteroidal anti-inflammatory medicines (e.g. ibuprofen), @DRUG$ , vancomycin .	DDI-false
Since the concomitant use of @DRUG$ with amiodarone increases the prothrombin time by 100 % after 3 to 4 days , the dose of the @DRUG$ Prothrombin times should be closely monitored.	DDI-false
Rifampin: Coadministration of @DRUG$ and VIRACEPT resulted in an 82% decrease in @DRUG$ plasma A.C.	DDI-false
In EM patients treated with paroxetine or fluoxetine, the AUC of @DRUG$ This is about 6- to 8-fold and Css, max is about 3- to 4-fold larger than @DRUG$ alone .	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, @DRUG$, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/ARB).	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance , such as efavirenz , nevirapine , phenytoin , dexamethasone , or @DRUG$ , use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
Similarly, @DRUG$ decreased the rate of elimination of @DRUG$ (by approximately 50%) by the same mechanism.	DDI-mechanism
Estrogens, including oral contraceptives: @DRUG$ may decrease the hepatic metabolism of certain @DRUG$, thereby increasing their effect.	DDI-mechanism
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
When CANCIDAS is co-administered with inducers of drug clearance, e.g. @DRUG$ Nevirapine, phenytoin, dexamethasone or carbamazepine, administration of a daily dose of 70 mg @DRUG$ should be considered	DDI-false
While all the @DRUG$ (@DRUG$), e.g., citalopram, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Antipyrine : Because @DRUG$ â€¢ Does not affect the pharmacokinetics of antipyrin, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected .	DDI-false
Benzylpenicillin , ampicillin , @DRUG$ , chlortetracycline, doxycycline, cephalothine, @DRUG$ , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum .	DDI-false
acetaminophen/@DRUG$ , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , @DRUG$/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$ and valproic acid/@DRUG$.	DDI-false
@DRUG$-Concomitant intake of @DRUG$ The absorption of vitamin K can be reduced.	DDI-false
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with @DRUG$, digoxin, warfarin, and @DRUG$.	DDI-false
@DRUG$ plus @DRUG$ was poorly tolerated, and 5 of 11 subjects discontinued therapy.	DDI-effect
In addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( @DRUG$ , nevirapine, phenytoin, @DRUG$ , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$.	DDI-false
The authors investigated the possibility of a similar interaction between @DRUG$ and @DRUG$.	DDI-false
H2 Receptor Antagonists: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on cisapride absorption when it is coadministered with ranitidine.	DDI-mechanism
Phenytoin: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing @DRUG$.	DDI-false
@DRUG$, such as @DRUG$, diltiazem and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
â€¢ Saquinavir: concomitant use of @DRUG$ (with an experimental soft gelatine capsule formulation of saquinavir 1200 mg) with: @DRUG$ resulted in an 18 % increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, @DRUG$, ribavirin, and vincristine.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , @DRUG$ , @DRUG$ Dolasetron, palonosetron, and Alosetron) is contraindicated.	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
@DRUG$: Gastrointestinal acidifying agents (guanethidine, reserpine, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin , carbamazepine , and barbiturates , and the @DRUG$ rifampin .	DDI-false
However, since there is an increased risk of bleeding with @DRUG$ , caution should be employed when @DRUG$ is used with other drugs that affect hemostasis .	DDI-false
Psychoactive Drugs: Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs (@DRUG$, thiothixene, alprazolam).	DDI-effect
Lithium : Lithium should not generally be used with diuretics (such as @DRUG$ Because they reduce renal clearance and have a high risk of @DRUG$ toxicity .	DDI-false
Selective serotonin reuptake inhibitors (SSRIs): @DRUG$ It has been rarely reported that fluoxetine, fluvoxamine, paroxetine, sertraline weakness, hyperreflexia and incoordination are associated with @DRUG$.	DDI-effect
Central nervous system depressants : Concomitant use of DURAGESIC (Fentanyl transdermal system ) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, sedatives (e.g., @DRUG$ ), general anaesthetics, phenothiazines, @DRUG$ , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
However, it is unlikely that this decrease in phosphorylation will occur. @DRUG$ concentration is of clinical significance , as @DRUG$ is a more efficient substrate for deoxycytidine kinase than zalcitabine .	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Population pharmacokinetic analyses showed that MTX, NSAIDs, @DRUG$ , and @DRUG$ did not influence abatacept clearance .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$ : @DRUG$ Infects dopamine and norepinephrine receptors and thus inhibits the central stimulating effects of amphetamines and can be used to treat amphetamine poisoning.	DDI-false
The medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$ , glutethimide , gold , hydralazine , @DRUG$ , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Other CNS depressant drugs (e.g. @DRUG$, tranquilizers, @DRUG$ and general anesthetics) have additive or potentiating effects with INAPSINE.	DDI-false
Interaction of GABITRIL with Other Drugs : @DRUG$ : Co-administration of @DRUG$ (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.	DDI-false
@DRUG$ A single dose of 10 mg tiagabin did not affect the pharmacokinetics of @DRUG$ At Steady State.	DDI-false
As with other @DRUG$ , it should be pointed out that: @DRUG$ Maybe it is able to increase CNS depressants such as anesthetics, opiates and alcohol.	DDI-false
These drugs include thiazides and other diuretics, @DRUG$ , phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Tetracyclines : Concomitant treatment with Accutane and tetracyclines should be avoided because @DRUG$ The use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which are associated with concomitant use of @DRUG$	DDI-effect
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$ , chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ And metronidazole, which delays the elimination and increase in blood levels of these drugs.	DDI-false
Agents Affecting Cytochrome P450 3A4 Isoenzyme System @DRUG$ is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when @DRUG$  is given concurrently with agents that affect CYP3A4 activity.	DDI-false
As with some other nondepolarizing neuromuscular blocking agents , the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving @DRUG$ or @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
We report the case of an adolescent with altered consciousness caused by @DRUG$ overdose with a positive @DRUG$ Level to warn clinicians about the cross-reactivity of carbamazepine with a toxicological screen for tricyclic antidepressants.	DDI-effect
, Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors ( e.g. , @DRUG$ If almotriptan is co-administered with these medications, increased exposure to almotriptan may be expected.	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Concurrent administration of low-dose @DRUG$ and @DRUG$ may produce an additive or potentiating effect on urine flow.	DDI-effect
@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
Prednisone/prednisolone : @DRUG$ did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone .	DDI-false
Although these results do not indicate a significant interaction between TORADOL and @DRUG$ or heparin, the administration of @DRUG$ to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
CONCLUSIONS/INTERPRETATION : @DRUG$ and @DRUG$ Â· can perform additive vasodilator properties on renal and eye circulation.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
However, caution should be exercised when administering it. @DRUG$ with @DRUG$ since these patients are at increased risk of bleeding complications .	DDI-advise
â€¢ quinolones, including norfloxacin, may affect the effects of oral @DRUG$ , including @DRUG$ or its derivatives or similar agents .	DDI-false
@DRUG$ therapy: Urinary excretion of @DRUG$ is increased, and efficacy is reduced, by acidifying agents used in methenamine therapy.	DDI-false
There were transient increases in liver ALT and AST when @DRUG$ and @DRUG$ were co-administered.	DDI-effect
@DRUG$ and @DRUG$ similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been used in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, @DRUG$ Angiotensin converter enzyme inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium channel blockers, cardiac nitrates, diuretics, @DRUG$ , HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ may augment the activity of other @DRUG$.	DDI-effect
Injection : Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system if with @DRUG$ , @DRUG$ , barbiturates , MAO inhibitors , and other antidepressants . When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-false
@DRUG$: As with some other @DRUG$, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
Diuretics : Diclofenac and others @DRUG$ The activity of @DRUG$ can inhibit.	DDI-effect
In the presence of these @DRUG$, larger doses of adenosine may be required or @DRUG$ may not be effective.	DDI-advise
@DRUG$ The administration of tiagabin in patients who received valproate chronically did not affect the pharmacokinetics of tiagabin, but valproate decreased significantly. @DRUG$ binding in vitro from 96.3 to 94.8 % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .	DDI-false
The concomitant use of valdecoxib and @DRUG$ 1/35 increased the exposure of @DRUG$ Ethinylestradiol by 20 % and 34 % respectively.	DDI-false
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
Interaction of GABITRIL with Other Drugs : @DRUG$ : Co-administration of cimetidine ( 800 mg/day ) to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics .	DDI-false
The pharmacokinetic properties of each medicinal product have been altered only slightly or not at all if: @DRUG$ was coadministered with @DRUG$ or stavudine .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
Response to @DRUG$ It can be extended by @DRUG$.	DDI-effect
@DRUG$: Concomitant treatment with Accutane and tetracyclines should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	DDI-false
Specific studies have confirmed these effects with @DRUG$ , Isoflurane, Propofol, Alfentanil, and @DRUG$.	DDI-false
@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Physiological changes resulting from smoking cessation , with or without nicotine replacement , may alter the pharmacokinetics of certain concomitant medications , such as @DRUG$ and @DRUG$.	DDI-false
@DRUG$: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
however, it is considered to be unlikely that this decrease of phosphorylated @DRUG$ concentration is of clinical significance, as @DRUG$ is a more efficient substrate for deoxycytidine kinase than zalcitabine.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
Drugs That Induce CYP3A4 (@DRUG$) Racemic zopiclone exposure was decreased 80% by concomitant useof @DRUG$, a potent inducer of CYP3A4.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , @DRUG$ Angiotensin converter enzyme inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$ Prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ , @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$ , nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$ ==References====External links==	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
@DRUG$ Supplements and Potassium Sparing Diuretics : Fosinopril Sodium may weaken potassium loss by @DRUG$.	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$ , digoxin , warfarin , isosorbide mononitrate , carvedilol , ethanol or @DRUG$.	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the @DRUG$ Before starting treatment with Enalapril or enalaprilat, increase or increase salt intake.	DDI-effect
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , @DRUG$ , or pentobarbital , the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital .	DDI-effect
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with @DRUG$ , @DRUG$ , and verapamil .	DDI-false
Benzylpenicillin , ampicillin , @DRUG$ , chlortetracycline, doxycycline, @DRUG$ In vitro, erythromycin and sulfamethoxazole have no influence on the protein binding of diclofenac in human serum.	DDI-false
@DRUG$ and Corticotropin (ACTH): may potentiate @DRUG$- induced hypokalemia which may predispose the patient to cardiac dysfunction.	DDI-effect
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$, warfarin, @DRUG$, clarithromycin or amoxicillin.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant studies: @DRUG$ : MTX , @DRUG$ , corticosteroids, TNF blockers, azathioprin, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine and anakinra.	DDI-false
There have been case reports of increased steady-state levels of @DRUG$, @DRUG$, and phenytoin during concomitant therapy with amiodarone.	DDI-false
@DRUG$/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/@DRUG$ , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Since Nalfon has not been shown to have any additional effect over the @DRUG$ alone and because @DRUG$ increases the rate of excretion of Nalfon , the concomitant use of Nalfon and salicylates is not recommended .	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , @DRUG$/valproic acid , quinidine/lidocaine , theophylline/@DRUG$ , and valproic acid/phenobarbital .	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
Cyclosporin, digoxin, methotrexate lodine, such as other NSAIDs, due to effects on renal prostaglandins, may cause changes in the elimination of these drugs to increase serum levels of @DRUG$ , digoxin , @DRUG$ , and increased toxicity .	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-effect
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.	DDI-false
Interactions with @DRUG$ : Agonist/antagonist analgesics ( eg , pentazocine , nalbuphine , butorphanol , dezocine and @DRUG$ (i) Do not administer to a patient who has received or is receiving therapy with a pure agonist opioid analgesics such as levo-dromorane.	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, @DRUG$, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well , concurrent therapy with all NSAIDs , including diclofenac , and @DRUG$ requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.	DDI-effect
Although the occurrence has not been reported with @DRUG$ Nephrotoxicity has been reported following concomitant administration of other cephalosporins and @DRUG$.	DDI-false
In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before @DRUG$).	DDI-false
Concomitant @DRUG$ , doxorubicin , @DRUG$ , and prednisone chemotherapy plus highly active antiretroviral therapy in patients associated with human immunodeficiency virus, non-Hodgkin lymphoma.	DDI-false
Methenamine therapy Urinary excretion of @DRUG$ is increased , and efficacy is reduced by acidifying agents used in @DRUG$ therapy .	DDI-mechanism
@DRUG$ : The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion .	DDI-false
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib : Caution should be exercised when gleevec is administered with CYP3A4 inhibitors (e.g. ketoconazole, @DRUG$ , erythromycin , @DRUG$ ) .	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
In patients receiving Nalfon and a steroid concomitantly, any reduction in @DRUG$ dosage should be gradual in order to avoid the possible complications of sudden @DRUG$ withdrawal.	DDI-false
The effect of clonazepam on the pharmacokinetics of other medicinal products: @DRUG$ does not appear to alter the pharmacokinetics of @DRUG$ , carbamazepine, or phenobarbital.	DDI-false
A direct causal relationship has not been established , but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to @DRUG$ or oral @DRUG$.	DDI-false
However, because some quinolones have been reported to enhance the anticoagulant effects of @DRUG$ or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with @DRUG$ or its derivatives.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Co-administration of MYOBLOC and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
@DRUG$ should not be used concomitantly with @DRUG$ because of the possibility of ototoxicity.	DDI-advise
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following : ergotamine , cyclosporine , @DRUG$ , nicardipine , and nifedipine .	DDI-int
@DRUG$ (tricyclic), atropine or other anticholinergic agents, or @DRUG$: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
The absorption of oral @DRUG$ The concomitant use of @DRUG$ containing aluminum and magnesium .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Compounds tested in man include warfarin, theophylline, phenytoin, diazepam, @DRUG$ and @DRUG$.	DDI-false
Therefore, a starting daily dose of 25 mg of @DRUG$ should be considered for the treatment of osteoarthritis when @DRUG$ is co-administered with potent inducers of hepatic metabolism.	DDI-false
In addition, additional interaction studies with: @DRUG$ and propranolol have not demonstrated any effect on @DRUG$ Plasma levels and administration to a patient population receiving chronic digoxin did not differ in the extent of bioavailability of digoxin compared to control data.	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants, @DRUG$, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
In vitro binding studies with human serum proteins indicate that @DRUG$ binds differently than tolbutamide and does not interact with salicylate or @DRUG$.	DDI-false
Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and @DRUG$ requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	DDI-false
However, because some quinolones have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a @DRUG$ is administered concomitantly with @DRUG$ or its derivatives.	DDI-advise
Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants : @DRUG$ In patients treated with monoamine oxidase inhibitors or tricyclic antidepressants, the use should be carried out with extreme caution as the effect of @DRUG$ on the cardiovascular system may be potentiated by these agents .	DDI-false
Plasma exposure (AUC) to @DRUG$ was increased 62% when coadministered with @DRUG$ and 38% when coadministered with ketoconazole.	DDI-mechanism
Antibiotics: In vitro and/or in vivo data show that @DRUG$, @DRUG$, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Dexamethasone : steady-state trough concentrations of @DRUG$ At 8 mg the dose was about 56% higher. @DRUG$ was coadministered with each dose of albendazole ( 15 mg/kg/day ) in eight neurocysticercosis patients .	DDI-false
1- nc means a mean change of less than 10% 2- Paediatric 3 mean increase in adults with high @DRUG$ In vivo, plasma levels of @DRUG$ The dose increased by up to 40% when Trileptal was administered at doses greater than 1200 mg/ day.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-effect
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, @DRUG$ , polymyxins, lincomycin, clindamycin, colistine, and sodium colistimethate, magnesium salts, lithium, local anaesthetics, @DRUG$ , and quinidine .	DDI-false
Further, in clinical studies with @DRUG$ (@DRUG$, 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%.	DDI-false
Both @DRUG$ and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
In comparison to the digital tolerance in dogs stunned with ketamine, @DRUG$ The dose of Ouabain needed to cause ventricular tachycardia, or pentobarbital, was significantly higher, such as the LD50 of Ouabain, with ketamine or @DRUG$ than with pentobarbital .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Dextromethorphan is a substrate for both @DRUG$ and @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Although the magnitude of changes in @DRUG$ plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of @DRUG$ under this circumstance.	DDI-false
Rifabutin: Coadministration of @DRUG$ and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in @DRUG$ plasma A.C.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, @DRUG$, @DRUG$, and some macrolide antibiotics.	DDI-false
@DRUG$ and @DRUG$ should not be coadministered.	DDI-advise
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , @DRUG$ , TNF blocking agents , azathioprine , chloroquine , gold , @DRUG$ , leflunomide , sulfasalazine , and anakinra .	DDI-false
@DRUG$ does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on @DRUG$, a drug with metabolism very sensitive to C.P.A. inhibition.	DDI-false
CANCIDAS reduced the blood AUC0-12 of @DRUG$ by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when @DRUG$ (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.	DDI-false
There were no significant interactions between: @DRUG$ and @DRUG$ or digoxin .	DDI-false
These drugs include the thiazides and other @DRUG$ , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$, @DRUG$, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
@DRUG$, tricyclic: @DRUG$ may enhance the activity of tricyclic or sympathomimetic agents;	DDI-false
Before using this medicine, tell your doctor or pharmacist about all prescription and non-prescription products you can use, in particular: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$ - non-steroidal anti-inflammatory medicinal products (e.g. ibuprofen), @DRUG$ , vancomycin .	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, @DRUG$, @DRUG$, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Presumably , @DRUG$ acts as a stimulator of @DRUG$ metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations .	DDI-mechanism
@DRUG$: There is no significant pharmacokinetic interaction between ZDV and @DRUG$ which has been confirmed clinically.	DDI-false
The concomitant use of aspirin and @DRUG$ This may lead to an increased rate of GI ulceration or other complications compared to the use of @DRUG$ alone .	DDI-false
The risk of myopathy during treatment with medicines in this class is associated with the use of @DRUG$ , fibrous acid derivatives, niacin ( @DRUG$ Erythromycin, azole antifungals.	DDI-false
The medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$ , @DRUG$ , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Co-administration of @DRUG$ and cerivastatin did not alter the pharmacokinetics of @DRUG$.	DDI-false
@DRUG$ , other , especially diazoxide , or pre@DRUG$ and anesthetic agents used in surgery or skeletal-muscle relaxants , nondepolarizing , used in surgery	DDI-false
The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume @DRUG$ and @DRUG$ on a regular basis.	DDI-mechanism
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, @DRUG$, @DRUG$, tranquilizers).	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
Valproate @DRUG$   ( 1500 mg twice daily ) did not alter the pharmacokinetics of @DRUG$ in healthy volunteers .	DDI-false
Since @DRUG$ and potassium-sparing diuretics , including @DRUG$ The potential effects on potassium kinetics and renal function should be considered when co-administering these agents.	DDI-effect
Based on the chemical resemblance of itraconazole and @DRUG$, coadministration of astemizole with @DRUG$ is contraindicated.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , @DRUG$ , @DRUG$ , and isoniazid .	DDI-false
Acetaminophen : In normal volunteers, concomitant use of @DRUG$ and acetaminophen resulted in an approximate 50 % increase in plasma levels of @DRUG$.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or @DRUG$.	DDI-false
@DRUG$: The administration of diflunisal to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Although these results do not indicate a significant interaction between @DRUG$ and warfarin or heparin, the administration of @DRUG$ to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or @DRUG$.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e.g. , cimetidine , @DRUG$ ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , barbiturates , @DRUG$ This effect can also be expected with CMI.	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations : Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , erythromycin , @DRUG$ ) .	DDI-false
WARFARIN: Co- administration of @DRUG$ and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , @DRUG$ , glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$ , and vincristine .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	DDI-false
@DRUG$: Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance , such as @DRUG$ , nevirapine , phenytoin , @DRUG$ , or carbamazepine , use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, @DRUG$).	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , @DRUG$ , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral @DRUG$ ) .	DDI-false
Antihypertensives : @DRUG$ should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a @DRUG$ Inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
@DRUG$ , such as @DRUG$ , can inhibit renal tubular secretion of nitrofurantoin.	DDI-false
These results appear to be against the clinical use of @DRUG$ with @DRUG$ If plasma asparagine levels are below normal, or during the time after ELSPAR therapy.	DDI-advise
@DRUG$: Concomitant administration of clonidine with @DRUG$ may potentiate blood-pressure- and heart-rate-lowering effects.	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, @DRUG$, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., @DRUG$;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
@DRUG$ should not be administered concomitantly with other @DRUG$ (such as isoproterenol) because of possible additive effects and increased toxicity.	DDI-advise
@DRUG$ In vitro and/or in vivo data indicate that fluconazole, itraconazole and orally @DRUG$ markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs ( @DRUG$ ) : @DRUG$ : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy .	DDI-false
Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of theophylline , digoxin or an @DRUG$/levonorgestrol oral contraceptive product in healthy subjects .	DDI-false
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , @DRUG$ , glutethimide , @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
The clinical significance of this reduction is unknown, therefore @DRUG$ is not recommended to be ingested simultaneously with @DRUG$/aluminum-containing antacids .	DDI-advise
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
@DRUG$ Co-administration of cimetidine results in increased peak plasma concentrations and AUC of @DRUG$ There is no effect on cisapride absorption when co-administered with ranitidine.	DDI-false
As with other antipsychotic agents, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as anesthetics, opiates, and @DRUG$.	DDI-effect
HIV Protease Inhibitors : @DRUG$ Co-administration of vardenafil 10 mg (800 mg t.i.d.) resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil AUC. @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
@DRUG$ : The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2 - 5 mg of @DRUG$.	DDI-false
The effects of catecholamines, e.g. @DRUG$ or norepinephrine are enhanced by @DRUG$.	DDI-effect
Plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e.g. , cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , barbiturates , @DRUG$ ) , and such an effect may be anticipated with CMI as well .	DDI-mechanism
Medicines that may alter the plasma concentration of imatinib Drugs that may increase the plasma concentration of imatinib @DRUG$ Plasma concentrations: Caution should be exercised when gleevec is administered with inhibitors of the CYP3A4 family (e.g. ketoconazole, itraconazole, @DRUG$ ,,,,,,,,,,,	DDI-false
Aspirin: Concomitant administration of @DRUG$ with @DRUG$ may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , @DRUG$ , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , @DRUG$ , thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Antihypertensives : @DRUG$ Propranolol, an inhibitor of CYP3A4 or calcium channel antagonists (e.g. @DRUG$ , a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
The use of antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$ , isoniazid, metronidazole, nitrofurantoin, @DRUG$ , ribavirin , and vincristine .	DDI-false
INOmax was co-administered with tolazolin, dopamine, @DRUG$ , steroids , @DRUG$ , and high-frequency ventilation .	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines , thyroid products , estrogens , oral @DRUG$ , @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
If cholinergic blockades occur, additive undesirable effects may occur if: @DRUG$ is administered concomitantly with other antimuscarinics , amantadine , haloperidol , @DRUG$ , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some antihistamines .	DDI-effect
Binding to plasma protein is not significantly altered by diazepam, @DRUG$, or @DRUG$.	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
Furosemide: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.	DDI-false
@DRUG$, @DRUG$: Amphetamines may enhance the activity of tricyclic or sympathomimetic agents;	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, @DRUG$ , lincomycin, clindamycin, colistine, and sodium colistimethate, magnesium salts, lithium, local @DRUG$ , procainamide, and quinidine.	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
The concentrations of @DRUG$, the active metabolite of irinotecan, were on average 33% higher in patients receiving bolus-IFL in combination with @DRUG$ when compared with bolus-IFL alone.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
The following are examples of substances that can reduce the blood glucose-lowering effect: @DRUG$ , niacin, danazol, diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazide, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ ( e.g. , in oral contraceptives ) .	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, @DRUG$, @DRUG$, diltiazem, isoniazide, and some macrolide antibiotics.	DDI-false
@DRUG$ may augment the activity of other @DRUG$.	DDI-effect
Considerable caution should be exercised if PEGANONE is administered concurrently with @DRUG$ (@DRUG$) since paranoid symptoms have been reported during therapy with this combination.	DDI-false
@DRUG$ (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Drugs which inhibit CYP 3A4 (e.g., ketoconazole, @DRUG$ such as @DRUG$) have the potential to result in increased plasma concentrations of corticosteroids.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and procainamide, @DRUG$ and tricyclic anti-depressants.	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., @DRUG$, @DRUG$, lovastatin, simvastatin).	DDI-false
Oral Contraceptives: Coadministration of @DRUG$ and an oral @DRUG$ increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	DDI-mechanism
High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80 % increase in etoposide exposure with a 38 % decrease in total body clearance of @DRUG$ Compared to etoposide alone.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Aspirin: Concomitant administration of @DRUG$ and @DRUG$ is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-advise
When @DRUG$ It is co-administered with inducers of drug clearance, such as efavirenz, @DRUG$ , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-advise
In clinical trials , FLOLAN was used with digoxin , @DRUG$ , anticoagulants , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ The apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13% and 15% respectively on the second day of therapy and were returned to baseline by day 87.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Cardiovasculars : @DRUG$ The oral administration of amiodarone regularly increases serum levels in patients receiving digoxin therapy. @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity .	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
@DRUG$ , but not @DRUG$ , decreases heart rate at high doses .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl , @DRUG$ , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., @DRUG$, methyldopa, reserpine.	DDI-false
Concomitant administration of @DRUG$ (10 mg) and @DRUG$ (800 mg) produced an 85% increase in the mean Cmax and AUC of zaleplon.	DDI-mechanism
Methotrexate: In an interaction study of rheumatoid arthritis patients taking @DRUG$, @DRUG$ did not have a significant effect on the pharmacokinetics of methotrexate.	DDI-false
Drugs Interactions : Flupentixol may interact with some drugs, such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - @DRUG$ - Eproxindine - @DRUG$ Flupentixol and ethanol cause additive CNS depression - tricyclic antidepressants : flupentixol increases the effect of tricyclic antidepressants	DDI-false
In a comparison of @DRUG$ The tolerance in dogs that are stunned with ketamine, @DRUG$ To cause ventricular tachycardia, or pentobarbital, the dosage of Ouabain required to cause ventricular tachycardia was significantly higher, such as the LD50 of Ouabain, with ketamine or innovar than with pentobarbital.	DDI-false
Beta-blockers , @DRUG$ , lithium salts and alcohol can either increase or weaken the blood glucose lowering effect of @DRUG$.	DDI-effect
â€¢ Vaccines: patients receiving corticosteroid therapy may have a reduced response to toxoids and @DRUG-DRUG$ due to inhibition of antibody response .	DDI-false
@DRUG$ â€¢ the adverse effects of other @DRUG$ administered concomitantly .	DDI-effect
@DRUG$: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
â€¢ Drug-drug interactions between Keppra and others @DRUG$ Phenytoin Keppra ( 3000 mg daily ) had no effect on the pharmacokinetics of @DRUG$ in patients with refractory epilepsy .	DDI-false
With simultaneous dosing of @DRUG$ 10 mg and @DRUG$ 10 mg , 6 of 8 subjects experienced a standing systolic blood pressure of less than 85 mm Hg .	DDI-effect
This medication may interact with alcohol or other CNS depressants (may potentiate the CNS depressive effect of either these drugs or antihistamines), @DRUG$ - or other medicines with anticholinergic activity (anticholinergic effects can be intensified if these drugs are used at the same time as antihistamines), and @DRUG$ Concomitant use of antihistamines may prolong and increase the anticholinergic and CNS depressive effects of antihistamines.	DDI-false
@DRUG$: @DRUG$ (Valium) is a CYP 3A4 and CYP 2C19 substrate.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), @DRUG$, prednisolone (10% decrease in binding), or @DRUG$.	DDI-false
Although no clinical studies have been performed, it is likely that the metabolism of levobupivacaine by the known CYP3A4 inducers (such as phenytoin, @DRUG$ CYP3A4 inhibitors (e. g. azole antifungals, @DRUG$ ;	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , @DRUG$ , tetracyclines, bacitracin, polymyxins, @DRUG$ Clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
Oral contraceptives: concomitant use of @DRUG$ and an oral @DRUG$ AUC values for norethindron and ethinylestradiol were increased by approximately 30% and 20%.	DDI-mechanism
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , @DRUG$ , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , @DRUG$ , local anesthetics, procainamide, and quinidine.	DDI-false
Other medicines: In small groups of patients ( 7 - 10/interaction study ), the concomitant administration of azathioprin, gold, @DRUG$ , D-penicillamine , @DRUG$ Doxycycline or digitoxin did not significantly affect the peak and AUC values of Diclofenac.	DDI-false
Co-administration of warfarin and @DRUG$ did not alter the pharmacokinetics of @DRUG$.	DDI-false
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of @DRUG$ , gold, chloroquine, @DRUG$ Prednisolone, doxycycline or digitoxin did not significantly affect the peak and AUC values of diclofenac.	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$ , lidocaine , theophylline and @DRUG$ This delays elimination and increases blood levels of these drugs.	DDI-false
Drug/Laboratory Test Interaction After treatment with @DRUG$, a false-positive reaction for glucose in the urine may occur with @DRUG$ tests (Benedicts solution, Fehlings solution, or Clinitest tablets) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP.	DDI-false
Possible drug interactions between Keppra and other AEDs (carbamazepine, gabapentin, @DRUG$ , phenobarbital, phenytoin, @DRUG$ In placebo-controlled clinical trials, serum concentrations of levetiracetam and these AEDs have also been studied.	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-false
Co-administration of MYOBLOC and @DRUG$ The effect of neuromuscular transmission (e.g. curare-like compounds) should be done with caution. @DRUG$ may be potentiated .	DDI-false
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without @DRUG$ (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-mechanism
Benzthiazide may interact with @DRUG$ , blood thinners, decongestant medications (allergy, cold, and sinus drugs), diabetes medications, lithium, @DRUG$ , NSAIDs such as Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
@DRUG$ The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion .	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ ( also referred to as @DRUG$ ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of @DRUG$.	DDI-false
Magnesium/Aluminium-containing antacid products: Zalcitabine absorption is moderately reduced (approximately 25%) when co-administered with @DRUG$/Aluminium-containing @DRUG$.	DDI-false
@DRUG$, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
@DRUG$ : @DRUG$ ( Valium ) is a CYP 3A4 and CYP 2C19 substrate .	DDI-false
Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents , such as @DRUG$ and @DRUG$.	DDI-false
Anticoagulant inhibition was observed during the administration of phenobarbital , @DRUG$ and @DRUG$ ;	DDI-false
â€¢ Higher concentrations of dexamethasone ( 10(-8 ) - 10(-6 ) M or @DRUG$ ( 3 X 10(-8 ) - 10(-7 ) M ) increase the mitogenic activity of @DRUG$.	DDI-effect
Lack of an effect of @DRUG$ on the disposition of zidovudine and @DRUG$ in HIV-infected patients.	DDI-false
@DRUG$   has not been formally evaluated in combination with @DRUG$.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Cardiovascular diseases : Cardiovascular glycoside disorders : In patients who have @DRUG$ therapy , administration of oral amiodarone regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity .	DDI-false
@DRUG$ has a tendency to antagonize the skeletal muscle relaxing effect of @DRUG$ and may potentiate the action of succinylcholine.	DDI-effect
ACE inhibitors and angiotensin II receptor antagonists (congestive heart failure after myocardial infarction)- In EPHESUS, 3020 (91%) patients received @DRUG$ 25 to 50 mg also received ACE inhibitors or @DRUG$ ( ACEI/ARB ) .	DDI-false
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, warfarin, and @DRUG$.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$: Administration of @DRUG$ concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
Therefore, EXTREME WARNING should be used when @DRUG$ In patients receiving cyclopropane or @DRUG$.	DDI-advise
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the @DRUG$ be increased.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
However, it was found that @DRUG$ â€¢ Impairs the contraceptive effect of microdoses @DRUG$ minipill preparations .	DDI-effect
Antiacid , clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir , @DRUG$ , phenytoin, phenobarbitol, carbamazepine, @DRUG$ , Rifampin , Ritanovir , Saquinavir .	DDI-false
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , antacids , H2-antagonists ( e.g. , @DRUG$ , ranitidine ) , and @DRUG$ ( e.g. , lansoprazole , omeprazole ) .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Influence of @DRUG$ On @DRUG$ Concentration ( Mean change , 90 % Confidence Interval )	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Valproate : The addition of @DRUG$ to patients taking valproate chronically had no effect on @DRUG$ The pharmacokinetics of valproate significantly reduced tiagabin binding in vitro from 96.3 to 94.8%, resulting in an increase of approximately 40% in free tiagabin concentrations.	DDI-false
Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue @DRUG$ and @DRUG$ treatment.	DDI-false
Antidepressants ( tricyclic ) , atropine or other anticholinergic agents , or @DRUG$ â€¢ Concomitant use with @DRUG$ It may cause additive inotropic and/or chronotropic effects.	DDI-false
The continuing need for the other @DRUG$ The active substance should be reviewed after the effects of: @DRUG$ It has been noted, and usually it should be attempted to stop treatment.	DDI-false
The effects of mixing @DRUG$ with insulins of animal source or @DRUG$ preparations produced by other manufacturers have not been studied .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin, nicotinic acid, @DRUG$ , calcium channel block drugs, and isoniazid.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (nicotinic acid), erythromycin, @DRUG$.	DDI-false
@DRUG$-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
Coadministration of valdecoxib ( 40 mg BID ( day 1 ) and 40 mg QD ( days 2 - 7 ) ) with @DRUG$ ( 10 mg @DRUG$ The BID led to an increase in the AUC of glyburide by 21%-12 and an increase in Cmax of glyburide by 16%, resulting in a 16% decrease in the AUC of glucose.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , @DRUG$ , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , somatostatin analog ( e.g. , octreotide ) , @DRUG$.	DDI-false
Since @DRUG$ and @DRUG$, including MIDAMOR, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.	DDI-effect
In @DRUG$-dependent patients, @DRUG$ may precipitate withdrawal symptoms .	DDI-false
The absorption of @DRUG$ , furosemide, penicillin G, @DRUG$ Gemfibrozil was significantly reduced when co-administered with colestipol hydrochloride;	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy , with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
Drug-drug interactions have not been observed between @DRUG$ and digoxin or @DRUG$.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Oral @DRUG$ : Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30 % and 20 % .	DDI-false
Drugs with a Narrow Therapeutic Index @DRUG$: @DRUG$ (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin (0.375 mg q24h for 8 days).	DDI-false
Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of Gleevec, increased @DRUG$ oral-dose clearance by 3.8-fold , which significantly ( p 0.05 ) decreased mean cmax and AUC(0 - 8) .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , @DRUG$ , warfarin , @DRUG$ (e. g. cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
In about 30% of patients, the dose of @DRUG$ had to be reduced in order to maintain @DRUG$ concentrations within the therapeutic range, while in the remainder no adjustment was needed.	DDI-false
â€¢ Paroxetine: co-administration of single doses @DRUG$ 3 mg and @DRUG$ 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction .	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, @DRUG$, @DRUG$ and phenobarbital.	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients who are receptor blockers (e.g. propranolol, CYP3A4 inhibitor) or calcium channel antagonists (e.g. @DRUG$ , a @DRUG$ substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , @DRUG$ , chlordiazepoxide, diazepam, certain @DRUG$ , lidocaine, theophylline and metronidazole, delaying the elimination and increase in blood levels of these drugs.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Theophylline: As with some other @DRUG$, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-mechanism
The AUC of @DRUG$ was increased 2.2-fold by coadministration of @DRUG$, a potent inhibitor of CYP3A4, 400 mg daily for 5 days.	DDI-mechanism
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Erythromycin Co-administration of @DRUG$ ( PLENDIL ) with @DRUG$ The result was an approximately 2.5-fold increase in AUC and Cmax and an approximately 2-fold increase in the half-life of felodipine.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ @DRUG$, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to @DRUG$ , including @DRUG$ such as quinidine and procainamide , cardiac glycosides and tricyclic anti-depressants .	DDI-false
Standard monitoring of @DRUG$-related toxicity should be continued if VIOXX and @DRUG$ are administered concomitantly .	DDI-false
@DRUG$: In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-false
==References==<br> @DRUG$ and @DRUG$ ;	DDI-false
However, a crossover study in healthy subjects receiving either @DRUG$ 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state @DRUG$ peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	DDI-false
Similarly dialyzed were @DRUG$, quinidine, and @DRUG$, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ for the following : sertraline and @DRUG$.	DDI-int
- @DRUG$ (e.g. AquaMEPHYTON, Synkayvite ) @DRUG$ These medicines may increase the likelihood of side effects affecting the blood.	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-advise
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
DIGOXIN: Plasma digoxin levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and @DRUG$ with @DRUG$ Bleomycin) without antiretroviral therapy.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been used in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, @DRUG$ , @DRUG$ , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , @DRUG$ The dose of Ouabain needed to cause ventricular tachycardia, or pentobarbital, was significantly higher, such as the LD50 of Ouabain, with ketamine or Innovar than with @DRUG$.	DDI-false
Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
Oral contraceptives: concomitant use of atorvastatin and oral contraceptives @DRUG$ Elevated AUC values for @DRUG$ and ethinyl estradiol by approximately 30 % and 20 % .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as @DRUG$.	DDI-advise
@DRUG$: The pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of @DRUG$ (400 mg) in 6 healthy subjects.	DDI-false
- Anabolic steroids (@DRUG$ [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., guanethidine, methyldopa, @DRUG$.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$ An increased incidence of sedation, hallucinations and irrational behaviour was observed with co-administration of scopolamine with injectable lorazepam.	DDI-false
@DRUG$ â€¢ Corticotropin (ACTH): may increase @DRUG$-induced hypokalaemia, which may predispose the patient to cardiac dysfunction.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , @DRUG$ , nicotinic acid, sympathomimetics, @DRUG$ , and isoniazid .	DDI-false
All subjects received amprenavir ( 1,200 mg twice a day ) for 4 days , followed by a 7-day washout period , followed by either @DRUG$ ( 300 mg once daily [ QD ] ) ( cohort 1 ) or @DRUG$ ( 600 mg QD ) ( cohort 2 ) for 14 days.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Methotrexate: In an interaction study of rheumatoid arthritis patients taking methotrexate, @DRUG$ did not have a significant effect on the pharmacokinetics of @DRUG$.	DDI-false
Concomitant administration of fenofibrate ( equivalent to 145 mg @DRUG$ ) with pravastatin ( 40 mg ) once daily for 10 days has been shown to increase the mean Cmax and AUC values for @DRUG$ by 36 % ( range from 69 % decrease to 321 % increase ) and 28 % ( range from 54 % decrease to 128 % increase ) , respectively , and for 3 -hydroxy-iso-pravastatin by 55 % ( range from 32 % decrease to 314 % increase ) and 39 % ( range from 24 % decrease to 261 % increase ) , respectively in 23 healthy adults .	DDI-false
@DRUG$ : Coadministration of @DRUG$ The result was a 32% decrease in nelfinavir plasma AUC and an increase of 207 % in rifabutin plasma AC.	DDI-false
Nephrotoxicity following concomitant administration of @DRUG$ With aminoglycoside antibiotics or potent diuretics such as @DRUG$.	DDI-effect
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Therefore, @DRUG$ may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, iron salts and @DRUG$).	DDI-mechanism
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
In a phase I study with escalating doses of @DRUG$ Myelosuppression was lower when TAXOL was given after cisplatin than with the alternative sequence ( i. e. TAXOL prior to @DRUG$ ) .	DDI-false
Phenytoin: @DRUG$ may delay intestinal absorption of @DRUG$;	DDI-mechanism
Caution should also be taken in concurrent or serial use of other @DRUG$ and @DRUG$ Because they can increase nephrotoxicity and/or ototoxicity of neomycin and increase the effect of neomycin sulfate neuromuscular blockages.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, @DRUG$, @DRUG$) should be considered.	DDI-false
Antiarrhythmics : Amiodarone , @DRUG$ , flecainide , propafenone , @DRUG$ CONTRAINDICATE because of the potential for serious and/or life-threatening reactions.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral @DRUG$ The pharmacokinetics/pharmacodynamics of @DRUG$ were not significantly affected by warfarin, platelet inhibitors ( acetylsalicylic acid), NSAIDs (piroxicam) and digoxin.	DDI-false
@DRUG$ Administration of non-sterioal anti-inflammatory medicinal products together with @DRUG$ has been associated with an increase in cyclosporine-induced toxicity , possibly due to decreased synthesis of renal prostacyclin .	DDI-false
Injection : Lorazepam injection , like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl alcohol , phenothiazines , barbiturates , @DRUG$ If scopolamine is used simultaneously with injectable @DRUG$ An increased incidence of sedation, hallucinations, and irrational behaviour has been observed.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
It is assumed that increased interaction between 3H-spiroperidol and high affinity binding sites for @DRUG$ on dopamine2- and serotonin2-receptors underlies the antipsychotic action of @DRUG$ after their prolonged administration.	DDI-false
@DRUG$-Vitamin K can antagonize the effect of @DRUG$	DDI-false
astemizole , @DRUG$ , Sparfloxacin, and @DRUG$.	DDI-false
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of azathioprine , gold , @DRUG$ D-penicillamin, prednisolone, doxycycline or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital.	DDI-false
@DRUG$ (@DRUG$): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).	DDI-false
Zidovudine: There is no significant pharmacokinetic interaction between @DRUG$ and @DRUG$ which has been confirmed clinically.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Verapamil: Coadministration of @DRUG$ and verapamil resulted in a 24% increase in plasma concentrations of @DRUG$.	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , @DRUG$ , nitrates , calcium-blocking agents , hydralazine , prazosin and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
@DRUG$ In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ ( ACEI/ARB ) .	DDI-false
@DRUG$: The concomitant administration of @DRUG$ with the sulfonylurea glyburide has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
Sedatives/Hypnotics : @DRUG$ , @DRUG$ CONTRAINDICATE because of the potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Antidepressants, tricyclic Amphetamines may enhance the activity of @DRUG$ or @DRUG$;	DDI-false
Colestipol: Plasma concentrations of @DRUG$ decreased approximately 25% when colestipol and @DRUG$ were coadministered.	DDI-false
Hormonal @DRUG$ Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components , @DRUG$ ( EE ) and Levonorgestrel ( LNG ).	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to inhibit the hepatic metabolism of warfarin type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and @DRUG$ This delays elimination and increases blood levels of these drugs.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, @DRUG$, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in @DRUG$ concentrations.	DDI-false
In bioavailability studies with normal subjects, the concurrent administration of @DRUG$ at therapeutic levels did not significantly influence the bioavailability of @DRUG$ tablets.	DDI-false
@DRUG$ : Coadministration of almotriptan and @DRUG$ This resulted in an increase of 24% in plasma concentrations of almotriptan.	DDI-false
@DRUG$: When @DRUG$ is administered with aspirin, its protein binding is reduced, although the clearance of free etodolac is not altered.	DDI-false
Digoxin When co-administered with @DRUG$ the pharmacokinetics of @DRUG$ in patients with heart failure were not significantly altered .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, @DRUG$, oral contraceptive, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, @DRUG$, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Warfarin: No significant differences were observed in the steady-state pharmacokinetics of @DRUG$ or S-warfarin with the addition of @DRUG$ given as a single dose.	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI   and concomitant @DRUG$ ( AVONEX   30 mcg IM once weekly ) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ ==References==<br>	DDI-false
@DRUG$: Concomitant administration of @DRUG$ with valdecoxib may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.	DDI-false
In clinical studies with fondaparinux, the concomitant use of oral anticoagulants ( @DRUG$ ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the @DRUG$ propafenone and flecainide).	DDI-false
@DRUG$, warfarin, heparin, @DRUG$	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and @DRUG$ (such as cimetidine or ranitidine).	DDI-false
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (@DRUG$) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
Earlier studies showed a significant reduction in oral bioavailability of trovafloxacin and @DRUG$ when administered concomitantly with an intravenous @DRUG$ Like morphine.	DDI-mechanism
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, @DRUG$.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
d-amphetamine with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain ;	DDI-false
Dexamethasone and retinyl acetate similarly inhibit and stimulate @DRUG$- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-false
â€¢ Furosemid : Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ Some patients were diagnosed with thiazides and thiazides.	DDI-effect
Imidazole (e.g. ketoconazole, miconazole, @DRUG$ In vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Insulin or Oral @DRUG$: @DRUG$ may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.	DDI-false
@DRUG$ taken concomitantly with @DRUG$ increases quinidine serum concentration by 33% after two days.	DDI-false
These results suggest that an acute @DRUG$ would not affect behaviors most closely associated with @DRUG$ intoxication .	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, @DRUG$.	DDI-false
This drug may interact with alcohol or other @DRUG$ (may potentiate CNS depressive effects of either these drugs or antihistamines), anticholinergics or other anticholinergic drugs (anticholinergic effects may be intensified if these drugs are co-administered with antihistamines) and monoamine oxidase (MAO) inhibitors (co-administered with @DRUG$ The anticholinergic and CNS depressive effects of antihistamines may be prolonged and intensified.	DDI-false
The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either alcohol or @DRUG$.	DDI-false
In addition, oxcarbazepine and MHD induce a subset of the cytochrome P450 3A family ( CYP3A4 and CYP3A5) that is responsible for the metabolism of @DRUG$ and oral @DRUG$ , resulting in a lower plasma concentration of these drugs.	DDI-false
therefore , @DRUG$ One hour after or more than two hours before @DRUG$ should be given (with food).	DDI-advise
Rhabdomyolysis has been observed in patients receiving @DRUG$ administered alone ( at recommended dosages ) or concomitantly with @DRUG$ including cyclosporine .	DDI-effect
In vitro studies indicate that, at therapeutic concentrations of salicylate (300 m g/mL), the binding of @DRUG$ was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound @DRUG$ plasma levels.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
The effects of ruthenium red (@DRUG$) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
@DRUG$ and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for @DRUG$), that may affect strategies during conversion from one drug to the other.	DDI-false
Although no studies have been conducted, concomitant administration of Itraconazole and @DRUG$ may alter the metabolism of @DRUG$;	DDI-false
In patients receiving @DRUG$ and a steroid concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden @DRUG$ withdrawal.	DDI-false
In addition, under the influence of sympatholytic medicinal products such as @DRUG$, @DRUG$, guanethidine, and reserpine, the signs of hypoglycemia may be reduced or absent.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Co-administration of @DRUG$ - Decreased plasma concentrations of @DRUG$ by approximately 40 % .	DDI-mechanism
Curariform muscle relaxants ( eg , @DRUG$ ) and other medicines, including ether, succinylcholine, @DRUG$ , Decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients treated with Coly-Mycin M Parenteral.	DDI-false
@DRUG$ : @DRUG$ is a CYP 3A4 substrate and CYP 2C19 substrate and inhibitor .	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
@DRUG$ The effect of antihypertensive agents may increase slightly, e.g. guanethidine, @DRUG$ , reserpine .	DDI-effect
The absorption of tetracycline, furosemide, @DRUG$, hydrochlorothiazide, and @DRUG$ was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
Patients in a clinical study who were on established therapy with @DRUG$, to which @DRUG$ was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or sulfasalazine alone.	DDI-effect
Plasma levels of @DRUG$ may become subtherapeutic during @DRUG$ therapy .	DDI-mechanism
The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
No pharmacokinetic interactions between @DRUG$ and isoflurane, propofol, alfentanil, and @DRUG$ have been demonstrated.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, @DRUG$ , quinidine , @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, @DRUG$ , probenecid , coumarins , monoamine oxidase inhibitors , and @DRUG$.	DDI-false
@DRUG$ Iron or other products containing iron @DRUG$ Antacids or sucralfate should not be administered concomitantly with or within 2 hours after administration of norfloxacin as they may impair absorption, resulting in lower serum and urine levels of norfloxacin.	DDI-false
Other drugs that inhibit the neuromuscular blocking effect of non-depolarizing substances such as e.g. @DRUG$ These include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and @DRUG$.	DDI-effect
Ritonavir ( 600 mg b.i.d . ) co-administered with @DRUG$ 5 mg resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in vardenafil Cmax .	DDI-false
However, in another study in healthy volunteers, the pharmacokinetics of @DRUG$ were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of @DRUG$ was administered 1 minute after a 20-mg dose of sumatriptan nasal spray.	DDI-false
Another oral @DRUG$, ketoconazole, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.	DDI-false
1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high @DRUG$ doses In vivo, the plasma levels of phenytoin increased by up to 40%, when @DRUG$ was given at doses above 1200 mg/day.	DDI-false
In monkeys (-)-NANM was about 10 times stronger than (+)-NANM in decreasing response, while in pigeons @DRUG$ It was about the equipment with @DRUG$.	DDI-false
Can be used with thyroid medications (e.g. levothyroxin), iodine-containing products, antacids, H2 antagonists (e.g. famotidine, ranitidine) and @DRUG$ ( e.g. , lansoprazole , @DRUG$ ) .	DDI-false
Central nervous system depressants : Co-administration of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), generally @DRUG$ , phenothiazines , skeletal muscle relaxants , and @DRUG$ , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of @DRUG$ to desbutyl levobupivacaine and @DRUG$, respectively.	DDI-false
Warfarin : No significant differences were observed in steady-state pharmacokinetics of @DRUG$ or @DRUG$ with the addition of tiagabine given as a single dose .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with @DRUG$, hypnotics and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
DISCUSSION: @DRUG$ is a potent inhibitor of CYP3A4, the major enzyme responsible for @DRUG$ metabolism.	DDI-mechanism
The concomitant intake of alcohol and @DRUG$ does not affect the pharmacokinetics of either @DRUG$ or acamprosate.	DDI-false
@DRUG$ may interfere with the anti-glaucoma action of carbachol or @DRUG$ ;	DDI-effect
Pharmacokinetic Interaction between @DRUG$ and rifabutin or @DRUG$ in healthy males.	DDI-false
Acute symptoms should be treated with a short-acting, inhaled  @DRUG$ such as @DRUG$ (the physician should provide the patient with such medication and instruct the patient in how it should be used).	DDI-false
- The action of @DRUG$ and insulin may be enhanced by @DRUG$ or Bezalip retard.	DDI-effect
Cimetidine : @DRUG$ The concentrations in bile and cystic fluid were increased 2-fold ( n = 7 ) in patients with hydatiden cysts treated with cimetidine ( 10 mg/ kg/ day ) ( n = 7 ) compared to @DRUG$ Alone ( 20 mg/kg/day ) ( n=12 ).	DDI-false
@DRUG$ , such as probenecid and sulfinpyrazone, can inhibit the renal tubular secretion of @DRUG$.	DDI-mechanism
Analysis of the concentration of @DRUG$ following ultracentrifugation indicated that there is rapid equilibration of @DRUG$ between the Survanta and aqueous phase.	DDI-false
- Anabolic steroids ( nandrolone [ e.g. , @DRUG$ ], Oxandrolone [e.g., Anavar], Oxymetholone [e.g., Anadrol], Stanozolol [e.g., @DRUG$ ] ) or	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium @DRUG$ , Sucralfat, VIDEX chew/buffer tablets or paediatric powder, or products that can significantly reduce calcium, iron or zinc absorption of @DRUG$ , which leads to serum and urine levels significantly lower than desired.	DDI-false
Methotrexate : In an interaction study in patients with rheumatoid arthritis taking methotrexate, @DRUG$ The pharmacokinetics of @DRUG$ were not significantly affected.	DDI-false
Therefore , caution should be used when administering @DRUG$ â€¢ at the same time as other highly plasma protein-bound medicinal products with narrow therapeutic indices, as there may be competition for binding sites (e.g. @DRUG$ ) .	DDI-mechanism
"Ergot derivatives: dihydroergotamine, @DRUG$ , @DRUG$ , Methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischaemia of extremities and other tissues.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and @DRUG$.	DDI-false
Moreover, the mechanisms underlying the development of dependence may be similar for @DRUG$ and @DRUG$.	DDI-false
The coadministration of @DRUG$ decreases the biologic half-life of fenoprofen because of an increase in metabolic clearance that results in a greater amount of @DRUG$ In the urine.	DDI-false
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: orally @DRUG$ , ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$ , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Like @DRUG$ 40 mg/kg and 18-MC ( 40 mg/kg) reduce intravenous self-administration of morphine and cocaine and oral self-administration of @DRUG$ and nicotine in rats ;	DDI-false
Tetracyclines : Concomitant treatment with Accutane and @DRUG$ should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri ( benign intracranial hypertension ) , some of which involved concomitant use of @DRUG$	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Coingestion of acetaminophen with theophylline, @DRUG$ with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
@DRUG$: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-false
The pharmacokinetics of irbesartan were not affected by coadministration of @DRUG$ or @DRUG$	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
â€¢ Dopamine antagonists : Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as neuroleptics ( @DRUG$ However, it is not possible to use the following formula: butyrophenone, thioxanthene) or @DRUG$ , can reduce the effectiveness of APOKYN.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Acidifying agents: @DRUG$ (guanethidine, reserpine, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
The administration of other @DRUG$ with @DRUG$ The antihypertensive effect has been shown to decrease in some patients and to lead to severe hyperkalaemia in patients with renal impairment.	DDI-effect
Benzthiazide can interact with alcohol, blood thinners, decongestant medications (allergic agents, colds, and sinus drugs), diabetic drugs, @DRUG$ , norepinephrine , NSAIDs like @DRUG$ or Ibuprofen , and high blood pressure medications .	DDI-false
Hypotension    Patients on Diuretic Therapy : Patients on diuretics and especially those in whom @DRUG$ therapy was recently instituted , as well as those on severe dietary salt restriction or dialysis , may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of @DRUG$.	DDI-false
@DRUG$: @DRUG$ blocks dopamine receptors, thus inhibiting the central stimulant effects of amphetamines.	DDI-false
These drugs include: @DRUG$ And other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$ , and isoniazid .	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$, lidocaine, phenobarbital, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Cohort 1 then received @DRUG$ plus rifabutin for 10 days, and cohort 2 received amprenavir plus @DRUG$ for 4 days.	DDI-false
@DRUG$, disopyramide, @DRUG$	DDI-false
Caution should be exercised when administering @DRUG$ with drugs that are known to inhibit phosphatase activities (e.g., @DRUG$).	DDI-advise
However , @DRUG$ Speeded up, but not significantly inhibited, proliferation in the presence of @DRUG$.	DDI-effect
The extent to which @DRUG$-TCAinteractions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved .	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, dexamethasone, carbamazepine) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
As @DRUG$ The predominant plasma substrate is only a weak inducer of UDP-glucuronyl transferase, it is unlikely that it has an effect on drugs that are mainly eliminated by conjugation by UDP-glucuronyl transferase (e.g. valproic acid, @DRUG$ ) .	DDI-false
Nevirapine and @DRUG$ should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy ofthe drug.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: @DRUG$, warfarin, digoxin, Maalox, and @DRUG$.	DDI-false
@DRUG$ overdose recognized by a @DRUG$ assay .	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, @DRUG$ , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , @DRUG$ , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
No data are available for the coadministration of @DRUG$/@DRUG$ or FORTOVASE/ritonavir and garlic capsules.	DDI-false
Acidifying agents : @DRUG$ (Guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	DDI-mechanism
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , @DRUG$ ), beta blockers, @DRUG$ , diuretics , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
The effects of @DRUG$ and L-CCG-1 upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
Other medicines: In small groups of patients ( 7 - 10 / interaction study ), the concomitant use of azathioprin, @DRUG$ , chloroquine, D-penicillamine, @DRUG$ , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , @DRUG$ , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , @DRUG$ , and isoniazid .	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$ , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , @DRUG$ , local anesthetics , procainamide , and quinidine .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Concurrent administration of oxyphenbutazone and @DRUG$ may result in elevated serum levels of @DRUG$.	DDI-false
In general, these are drugs that have one or more pharmacological activities such as bepridil hydrochloride, including antiarrhythmics such as e.g. @DRUG$ and procainamide , cardiac glycosides and @DRUG$.	DDI-false
- Lithium : Lithium should generally not be given with @DRUG$ ( such as @DRUG$ Because they reduce renal clearance and increase a high risk of lithium toxicity.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine , @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Potentiation occurs with @DRUG-DRUG$.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Amiodarone, @DRUG$, @DRUG$	DDI-false
In a phase I study in which escalating doses of TAXOL ( 110 - 200 mg/ m2 ) and cisplatin ( 50 or 75 mg/ m2 ) were administered as sequential infusions, myelosuppression was lower than TAXOL after @DRUG$ (i.e., TAXOL before @DRUG$ ) .	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
Patients who begin taking @DRUG$ - if your dose of Diclofenac or any other NSAID while taking digoxin, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs .	DDI-effect
Both @DRUG$ and @DRUG$ block morphine-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-false
Based on known metabolic profiles, clinically significant drug interactions between VIRACEPT and @DRUG$ , trimethoprim/sulfamethoxazole , clarithromycin , erythromycin , @DRUG$ or fluconazole .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : @DRUG$ Antimycobacterial agents: rifampin benzodiazepine midazolam, triazolam GI motility agent: @DRUG$	DDI-false
@DRUG$ ; co-management of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo .	DDI-false
Treatment with @DRUG$ once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in @DRUG$ AUC.	DDI-mechanism
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
@DRUG$ (metoprolol, @DRUG$) serum concentrations and pharmacologic effects may be increased.	DDI-false
@DRUG$ , Nimodipine and @DRUG$ : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
@DRUG$: NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , @DRUG$ , diclofenac , doxycycline , erythromycin , imatinib , @DRUG$ , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , @DRUG$ , a CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, @DRUG$ substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, @DRUG$, @DRUG$, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
A similar association , though less marked , has been suggested with barbiturates , @DRUG$ , phenytoin sodium , carbamazepine , griseofulvin , topiramate , and possibly with @DRUG$ 72. and tetracyclines 72.	DDI-false
The concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, @DRUG$ ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , @DRUG$ Hepatotoxic (e.g. methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Caution should be exercised when administering @DRUG$ The use of medicines known to inhibit phosphatase activity (e.g. @DRUG$ ) .	DDI-advise
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive @DRUG$ level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for @DRUG$.	DDI-false
There have been case reports of increased steady-state levels of @DRUG$ , procainamide and @DRUG$ during concomitant therapy with amiodarone .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
Naproxen: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
Histamine H2 receptor antagonists : @DRUG$ The bioavailability of @DRUG$ does not appear to be significant.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, @DRUG$, @DRUG$, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	DDI-int
These data indicate that @DRUG$ does not influence the plasma concentration of other AEDs and that these AEDs do not influence the pharmacokinetics of @DRUG$.	DDI-false
Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (@DRUG$) was more than doubled in the presence of TMP/@DRUG$.	DDI-false
Anticoagulants: While studies have not shown @DRUG$ to interact with @DRUG$, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ The AUC(ss) of rifabutin significantly increased the area under the curve in steady state ( AUC(ss) ) by 2.93 times and the AUC(ss) of rifabutin by 2.93 times. @DRUG$ by 13.3-fold .	DDI-mechanism
Lithium : Increased serum @DRUG$ The concentrations and symptoms of lithium toxicity have been reported in patients who are at the same time: @DRUG$ and ACE inhibitor therapy .	DDI-false
@DRUG$ did not increase the plasma levels of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The hypoglycaemic effect of sulphonylureas may be due to certain medications, including: @DRUG$ And other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, probenecid, coumarin, @DRUG$ And beta-adrenergic blockers.	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that corticosteroid or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , @DRUG$ , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , somatostatin analog ( e.g. , @DRUG$ ) , sulfonamide antibiotics .	DDI-false
Acetaminophen/@DRUG$, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Antiacid, clarithromycin, @DRUG$ , Fluconazole , @DRUG$ , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , Rifampin , Ritanovir , Saquinavir .	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$ , doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without reception @DRUG$ therapy .	DDI-false
@DRUG$ To reduce renal clearance of lithium and a high risk for @DRUG$ toxicity .	DDI-effect
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ , cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Hormonal Contraceptives , Including Oral , Injectable , Transdermal , and Implantable @DRUG$ : An interaction study showed that the concomitant use of bosentan and oral hormonal contraceptives Ortho-Novum was an average decrease in @DRUG$ and ethinyl estradiol levels of 14 % and 31 % , respectively .	DDI-false
1 hour after starting the @DRUG$ or @DRUG$ 500 mg p.o.	DDI-false
A clinical study in healthy male volunteers (n=24) demonstrated that mixing @DRUG$ with NPH human insulin immediately before injection produced some attenuation in the peak concentration of @DRUG$, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$ , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimet-ics , calcium channel blocking drugs , and @DRUG$.	DDI-false
Ritonavir : Coadministration of ritonavir with @DRUG$ This led to an increase of 152% @DRUG$ Plasma AUC and very small change in ritonavir plasma A.C.	DDI-false
Other CNS depressant drugs ( e.g. barbiturates , tranquilizers , @DRUG$ ==References====External links==* http://www.statistics.sk/mosmis/eng/run.html* http://www.statistics.sk/mosmis/eng/run.html* http://www.statistics.sk/mosmis/eng/run.html	DDI-effect
Central Nervous System Depressants : The concomitant use of @DRUG$ Fentanyl transdermal system with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, sedatives (e.g. benzodiazepines), generally @DRUG$ , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-effect
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (FORTOVASE) as the sole @DRUG$ due to the risk of decreased saquinavir plasma concentrations.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Imidazoles ( e. g. , ketoconazole , @DRUG$ In vitro and animal studies with the combination of amphotericin B and imidazoles suggest that: @DRUG$ It can lead to fungal resistance against amphotericin B.	DDI-false
Since there is a theoretical basis for these effects to be additive, the use of ergotamine-containing or ergot-like drugs (e.g. @DRUG$ (for example, methysergide) and @DRUG$ within 24 hours of each other should be avoided .	DDI-advise
Rhabdomyolysis has been observed in patients receiving @DRUG$ administered alone (at recommended dosages) or concomitantly with @DRUG$ including cyclosporine.	DDI-effect
The effects of @DRUG$ and @DRUG$ upon phencyclidine (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
Based on the chemical resemblance of itraconazole and ketoconazole, coadministration of @DRUG$ with @DRUG$ is contraindicated.	DDI-advise
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Drug Interactions : @DRUG$ MAOI could theoretically influence flupenthixol pharmacodynamics - arecoline - eproxindine - @DRUG$ Flupentixol and ethanol cause additive CNS depression - tricyclic antidepressants : flupentixol increases the effect of tricyclic antidepressants	DDI-false
As with some other @DRUG$ The time of onset of the neuromuscular block induced by @DRUG$ The block duration is shortened in patients receiving phenytoin or carbamazepine.	DDI-false
oral contraceptives: valdecoxib ( 40 mg twice daily) did not lead to metabolism of the oral combination @DRUG$ * Norethindron/ ethinylestradiol (combination 1 mg/35 mcg, @DRUG$ 1/35 ) .	DDI-false
May interact anticoagulants ( altered hypo-prothrombinemic effect ) , barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system ( decreased effect of @DRUG$ ), corticosteroids (increased effect of @DRUG$ ) .	DDI-false
Further , in clinical studies with @DRUG$ ( @DRUG$ In older men with benign prostatic hyperplasia (BPH), PSA levels are reduced by about 50%.	DDI-false
@DRUG$ has additive effects with alcohol and other CNS depressants (hypnotics, sedatives, @DRUG$, etc).	DDI-effect
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , fibrates , fluoxetine , @DRUG$ , propoxyphene , salicylates , somatostatin analog ( e.g. , @DRUG$ ) , sulfonamide antibiotics .	DDI-false
Acetaminophen : In normal volunteers , concomitant administration of @DRUG$ and @DRUG$ resulted in an approximate 50 % increase in plasma levels of acetaminophen .	DDI-mechanism
The extent to which @DRUG$-@DRUG$interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved .	DDI-int
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, @DRUG$, niacin (nicotinic acid), erythromycin, azole antifungals.	DDI-false
@DRUG$: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with @DRUG$.	DDI-false
Patients who have other narcotic analgesics, general anesthetics, phenothiazine, sedatives, sedative hypnotics, @DRUG$ or other CNS depressants ( including alcohol ) concomitantly with @DRUG$ It may have additive CNS depression.	DDI-effect
@DRUG$ has additive effects with @DRUG$ and other CNS depressants (hypnotics, sedatives, tranquilizers, etc).	DDI-effect
@DRUG$ , other , especially @DRUG$ , or pre-anaesthetic and anaesthetic agents in surgery or skeletal muscle relaxants, not depolarizing, used in surgery	DDI-false
@DRUG$: @DRUG$ may antagonize the hypotensive effects of antihypertensives.	DDI-false
In addition, fondaparinux did not affect the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$ , and digoxin , nor the pharmacokinetics of @DRUG$ at steady state .	DDI-false
The successive application of @DRUG$ ( 5 or 10 mg/kg egg weight ( e.w . ) and glutamate ( 15 mg/kg e.w . ) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of @DRUG$ alone .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
@DRUG$ It has been reported that the @DRUG$ requirements in human subjects ingesting these agents simultaneously .	DDI-mechanism
Corticosteroids , Methylxanthines and @DRUG$ : Accompanying treatment with xanthine derivatives, @DRUG$ , or diuretics may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
@DRUG$: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
In a clinical pharmacology study , @DRUG$ or @DRUG$ It was used in hypertensive patients receiving VASOTEC.	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, @DRUG$.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or beta-adrenergic blocking agents , @DRUG$ , @DRUG$ or H1-blocking agents , tricyclic antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval .	DDI-false
@DRUG$ also should be used cautiously with other drugs (e.g., digitalis, glycosides) that sensitize the myocardium to the actions of @DRUG$.	DDI-false
Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, @DRUG$, and TNF blocking agents did not influence abatacept clearance.	DDI-false
Medicines not to be treated at the same time @DRUG$ Antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, terfenadine antimigrain: ergot derivatives antimycobacterial agents: rifampine benzodiazepine midazolam, @DRUG$ GI motility agents : cisapride	DDI-advise
Response to @DRUG$ may be enhanced by @DRUG$.	DDI-effect
Glyburide: @DRUG$ has no apparent pharmacokinetic interaction when administered with @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , @DRUG$ , salbutamol, terbutaline), isoniazid, @DRUG$ , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
@DRUG$: While studies have not shown diclofenac to interact with @DRUG$, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ [e.g. intravenous aminoglycosides (e.g. tobramycin, gentamicin and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$ , and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-advise
Hormonal contraceptives Co-administration of Trileptal with an oral @DRUG$ has been shown to influence the plasma concentrations of the two hormonal components, @DRUG$ (EE) and levonorgestrel (LNG).	DDI-false
Potential pharmacokinetic interactions have been reported in clinical pharmacokinetic studies (phenytoin, @DRUG$ , oral contraceptive , digoxin , @DRUG$ , probenecid) and by pharmacokinetic screening in placebo-controlled clinical trials in epilepsy patients.	DDI-false
Drugs that cause significant sustained elevation in gastric pH ( histamine H2-receptor antagonists such as @DRUG$ Cimetidine) may increase the plasma concentration of @DRUG$ For this reason, effectiveness can be reduced.	DDI-mechanism
Amiodarone , @DRUG$ , @DRUG$	DDI-false
Close supervision and careful adjustment of the dosage are required when @DRUG$ is used with other @DRUG$ or sympathomimetic drugs.	DDI-advise
@DRUG$: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	DDI-false
The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	DDI-false
however, no deleterious interactions were seen when @DRUG$ was administered after narcotics, inhalational @DRUG$, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	DDI-false
- single doses of cholestyramine, or @DRUG$ resins bind the @DRUG$ and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent , respectively .	DDI-mechanism
Drugs That Alter Renal Excretion @DRUG$ : @DRUG$ is known to affect renal function and , consequently , alter the renal excretion of other drugs .	DDI-false
Pharmacokinetic studies have demonstrated that omeprazole and @DRUG$ The systemic exposure of @DRUG$ Main metabolites and/or its main metabolites.	DDI-mechanism
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ * Amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Drug-Drug Interactions Between Keppra  And Other @DRUG$ (AEDs) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
As with other antipsychotics, it should be noted that: @DRUG$ It may be possible to increase CNS depressants such as anesthetics, opiates and @DRUG$.	DDI-effect
Cytochrome P-450 inducers , such as phenytoin , @DRUG$ and phenobarbital , induce @DRUG$ Metabolism, resulting in a decrease of approximately 30% in plasma clonazepam levels.	DDI-mechanism
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Benzylpenicillin, @DRUG$, oxacillin, @DRUG$, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including @DRUG$ With multivalent cation-containing products such as magnesium or aluminium antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Glyburide: The concomitant administration of ciprofloxacin with the @DRUG$ @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
Pharmacokinetic studies have demonstrated that @DRUG$ and @DRUG$ significantly increased the systemic exposure of cilostazol and/or its major metabolites .	DDI-false
Anticonvulsants ( @DRUG$ ): Steady state plasma exposure ( AUC ) of valdecoxib ( 40 mg BID for 12 days ) was decreased by 27 % when co-administered with multiple doses ( 300 mg QD for 12 days ) of @DRUG$ ( a CYP 3A4 inducer).	DDI-false
Stavudine and Zidovudine @DRUG$ can antagonize the in vitro antiviral activity of stavudine and @DRUG$ against HIV.	DDI-effect
INOmax has been administered with @DRUG$, dopamine, @DRUG$, steroids, surfactant, and high-frequency ventilation.	DDI-false
However , the absolute number of alcohol-related deaths is far greater than the number of deaths in @DRUG$ or @DRUG$ users .	DDI-false
FLEXERIL may have the effect of @DRUG$ , @DRUG$ And other CNS depressants.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Specific studies have confirmed these effects with sevoflurane , @DRUG$ , @DRUG$ , alfentanil, and midazolam.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Therefore, @DRUG$ should be discontinued at least two weeks prior to the cautious initiation of therapy with @DRUG$.	DDI-advise
aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and @DRUG$ At the same time, and evidence of decreased plasma concentrations of @DRUG$.	DDI-false
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
â€¢ Broadband spectrum antibiotics-@DRUG$ can sterilize the intestine and the @DRUG$ contribution to the body by the intestinal microflora .	DDI-false
bacteriostatic antibiotics : chloramphenicol, @DRUG$ , sulphonamides or @DRUG$ The bactericidal effect of penicillins may be impaired.	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone , they modify the mitogenic effect of EGF and @DRUG$.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-advise
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , @DRUG$ , iodoquinol , isoniazid , metronidazole , @DRUG$ , phenytoin , ribavirin , and vincristine .	DDI-false
Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, corticosteroids, and TNF blocking agents did not influence @DRUG$ clearance.	DDI-false
@DRUG$ The administration of terfenadine with VIRACEPT resulted in the occurrence of unchanged @DRUG$ in plasma ;	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , pentazocine , nalbuphine , butorphanol , @DRUG$ and @DRUG$ (i) Do not administer to a patient who has received or is receiving therapy with a pure agonist opioid analgesics such as levo-dromorane.	DDI-false
Studies in humans show that the absorption of @DRUG$ as reflected in urinary excretion is markedly decreased even when administered one hour before @DRUG$.	DDI-mechanism
@DRUG$ The amount of digoxin can be reduced ( @DRUG$ Lanoxicaps that are absorbed into your body.	DDI-mechanism
Adverse reactions related to @DRUG$s, such as CNS, cardiac, and systemic (eg, flu-like) effects may be more severe in the elderly and caution should be exercised in the use of @DRUG$ in this population.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions between VIRACEPT and Dapson, @DRUG$/sulfamethoxazole, are not expected. @DRUG$ , erythromycin , itraconazole or fluconazole .	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, @DRUG$ , lincomycin, clindamycin, colistine, and sodium colistimethate, magnesium salts, lithium, local anaesthetics, @DRUG$ ==References====External links==	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , @DRUG$ , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , @DRUG$ , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
In well-controlled patients who are also treated with @DRUG$ , a decrease in the steady-state serum concentrations of @DRUG$ If treatment with Cime-Tidine is discontinued, treatment with Cime-Tidine can be stopped.	DDI-mechanism
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Magnesium- and/or aluminum-containing @DRUG$ Products containing iron sulphate, multivitamin preparations containing zinc or other metal cations, or Videx ( @DRUG$ ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , @DRUG$ , diuretics, sympathomimetics (e.g., @DRUG$ , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
In monkeys , @DRUG$ was about 10 times more potent than @DRUG$ The pigeons (-)-NANM was about the equitotent with (+)-NANM.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ Caution is recommended when co-administered with alprazolem: @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital.	DDI-false
Catecholamine-depleting Agents: Patients taking both @DRUG$ and a drug that can deplete catecholamines (e.g., @DRUG$ and monoamine oxidase inhibitors) should be observed closely for signs of hypotension and/or severe bradycardia.	DDI-effect
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing @DRUG$ , iron or zinc can be the absorption of @DRUG$ , which leads to serum and urine levels significantly lower than desired.	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Therefore, caution should be used when administering @DRUG$ concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., @DRUG$).	DDI-mechanism
@DRUG$ generally should not be given with @DRUG$ because they reduce lithiums renal clearance and add a high risk of lithium toxicity.	DDI-advise
Iodine or @DRUG$ excess may decrease the effect of @DRUG$ , and a lack of iodine may increase the effect of carbimazole.	DDI-false
Therefore, interactions following concomitant administration of psychotropic medicinal products (e.g. narcotics, @DRUG$ , @DRUG$ , sedatives , tranquilizers ) .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , @DRUG$ , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , @DRUG$ , and anakinra .	DDI-false
@DRUG$ : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely , and appropriate dosage adjustment of the @DRUG$ should be made .	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, @DRUG$, monoamine oxidase inhibitors, narcotics, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Psychoactive Drugs: Hallucinations have been reported when @DRUG$ was used in patients taking @DRUG$ (fluoxetine, thiothixene, alprazolam).	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , @DRUG$ , sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$ , progestogens (e.g. in oral contraceptives).	DDI-false
In rats , simultaneous ingestion of @DRUG$ and @DRUG$ in the diet for 78 weeks has been reported to cause tumors , and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine , which is tumorigenic .	DDI-effect
- @DRUG$: Lithium should generally not be given with diuretics (such as @DRUG$) because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Anticoagulants: @DRUG$ type potentiation ( CYP2C9 and CYP3A4 substrate ) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , @DRUG$ , isoniazid , metronidazole , nitrofurantoin , phenytoin , @DRUG$ And vincristine.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, D-penicillamine, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Oral @DRUG$ : Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and @DRUG$ by approximately 30 % and 20 % .	DDI-false
Metformin: In healthy subjects given single 500 mg doses of @DRUG$ and metformin, plasma @DRUG$ mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-effect
Other @DRUG$ Concomitant use of other @DRUG$ Within 24 hours after treatment with AXERT is contraindicated.	DDI-false
@DRUG$ and @DRUG$ exert additive ocular and renal vasodilator effects on healthy humans .	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including non-steroidal anti-inflammatory drugs and other drugs that are highly protein bound, salicylates, @DRUG$ , @DRUG$ , probenecid, coumarine, monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-false
@DRUG$, such as @DRUG$ and sulfinpyrazone, can inhibit renal tubular secretion of nitrofurantoin.	DDI-false
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including diclofenac, and @DRUG$ requires close monitoring of patients to be certain that no change in their @DRUG$ dosage is required.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Since indomethacin and @DRUG$ , including @DRUG$ , may each be associated with increased serum potassium levels , the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently .	DDI-false
It has been reported that @DRUG$ enhances the anticoagulant effect of @DRUG$-like drugs.	DDI-effect
Although there are no study data to evaluate the possibility, @DRUG$, including @DRUG$ and nitroglycerin, may have an additive effect with INOmax on the risk of developing methemoglobinemia.	DDI-false
Hypotension : Patients on Diuretic Therapy : Patients on @DRUG$ Especially those who have recently started diuretic therapy may occasionally experience an excessive reduction in blood pressure after initiation of Enalapril or @DRUG$ therapy.	DDI-effect
Psychoactive Drugs : Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ ( fluoxetine , @DRUG$ ==References====External links==	DDI-false
No dose adjustment of @DRUG$ is necessary, but increased effects of @DRUG$ should be considered.	DDI-false
The concomitant use of @DRUG$s , vasoconstricting agents ( such as ergonovine ) and some @DRUG$ For this reason, severe hypertension may occur.	DDI-effect
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Concomitant administration of @DRUG$ with @DRUG$ is contraindicated .	DDI-advise
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, @DRUG$, carbamazepine, griseofulvin, topiramate, and possibly with @DRUG$ and tetracyclines 72.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
- When Bezalip or @DRUG$ is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or @DRUG$ is impaired	DDI-false
@DRUG$ The doses of procainamide and procainamide should be reduced by one third when co-administered with @DRUG$.	DDI-false
Based on the results of these studies, it is concluded that @DRUG$ may be safely coadministered with both zidovudine and @DRUG$.	DDI-false
@DRUG$ Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce and reduce the natriuretic effect of furosemide @DRUG$ In some patients.	DDI-false
Therefore, a starting dose of 25 mg daily should be administered. @DRUG$ should be considered for the treatment of osteoarthritis when @DRUG$ It is used concomitantly with potent inducers of hepatic metabolism.	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, @DRUG$ , thyroid products , estrogens , oral @DRUG$ , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e.g. , cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , @DRUG$ , phenytoin, and such an effect can be expected @DRUG$ as well .	DDI-mechanism
Potential drug interactions between Keppra   and other AEDs ( @DRUG$ , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and @DRUG$ ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, escitalopram, fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
* Chloramphenicol has shown itself to be antagonistic to @DRUG$ , including @DRUG$ , based on in vitro studies and time-killing curves with enteric gram-negative bacilli.	DDI-false
Patients who start taking this medicine @DRUG$ or who increase their diclofenac dose or any other NSAID while taking digoxin , @DRUG$ Cyclosporin can develop toxicity properties for these drugs.	DDI-effect
The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Additional reductions in blood pressure may occur when @DRUG$ is administered with @DRUG$ , antihypertensive agents, or other vasodilators.	DDI-effect
Bacteriostatic Antibiotics : @DRUG$ , erythromycins , @DRUG$ , or tetracyclines may interfere with the bactericidal effect of penicillins .	DDI-false
@DRUG$ significantly decreased the AUC(ss) of amprenavir by 82%, but amprenavir had no effect on @DRUG$ pharmacokinetics.	DDI-false
Imidazoles (e. g., @DRUG$, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Magnesium/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.	DDI-false
@DRUG$ : Coadministration of single doses of @DRUG$ 3 mg and lorazepam 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , @DRUG$ , fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$ , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Benzthiazide may interact with alcohol , blood thinners , @DRUG$ ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , norepinephrine , NSAIDs like Aleve or @DRUG$ , and high blood pressure medications.	DDI-false
Potassium-sparing diuretics ( e.g. , spironolactone , triamterene , or amiloride ) , @DRUG$ supplements , or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
Presumably , phenytoin acts as a stimulator of @DRUG$ Metabolism and has been reported to reduce serum levels of @DRUG$ and increased prothrombin-proconvertin concentrations .	DDI-false
The possibility of hypotensive effects with PRINIVIL can be minimized by either: @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$.	DDI-effect
Although @DRUG$ It has been shown that PROLEUKIN-induced adverse reactions such as fever, renal insufficiency, hyperbilirubinaemia, confusion and dyspnoea are reduced, the concomitant administration of these active substances with PROLEUKIN can reduce the antitumour effectiveness of PROLEUKIN and should therefore be avoided. @DRUG$ may potentiate the hypotension seen with PROLEUKIN .	DDI-false
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, DCG-IV and @DRUG$, on the above behavioral changes induced by @DRUG$ were found.	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$, @DRUG$, quinidine, clarithromycin or amoxicillin.	DDI-false
@DRUG$ and colestipol @DRUG$ The absorption of hydrochlorothiazide is impaired in the presence of anionic resins.	DDI-false
It has been reported that @DRUG$ enhances the anticoagulant effect of @DRUG$-like drugs .	DDI-effect
Epinephrine also should be used cautiously with other drugs (e.g., digitalis, @DRUG$) that sensitize the myocardium to the actions of @DRUG$.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an @DRUG$ (Aluminium hydroxide, magnesium hydroxide and simethicone) with: @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-mechanism
@DRUG$: Caution should be used if @DRUG$ is administered concomitantly with methotrexate.	DDI-false
Simultaneous use of a TNF antagonist with @DRUG$ has been associated with an increased risk of serious infections and no significant additional efficacy over use of the @DRUG$ alone .	DDI-false
However, the absolute number of @DRUG$-related deaths is far greater than the number of deaths in amphetamine or @DRUG$ users.	DDI-false
The use of antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, and other medicines associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$ , @DRUG$ , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
- methotrexate (e.g. mexate) use of methotrexate with @DRUG$ This may increase the likelihood of side effects that may affect the liver and/or the side effects of @DRUG$	DDI-false
Concurrent administration of HEXALEN and @DRUG$ For this reason, severe orthostatic hypotension may occur.@DRUG$, an inhibitor of microsomal metabolism, increased altretamine half-life and toxicity in a rat model.	DDI-false
The co-administration of medicinal products which are nephrotoxic (e. g. @DRUG$ , indomethacin), myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$ , asparaginase ) effects with PROLEUKIN may increase toxicity in these organ systems .	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
Vitamin A : Because of the relationship of Accutane to vitamin A , patients should be advised against taking @DRUG$ containing @DRUG$ To avoid additive toxic effects	DDI-false
- anabolic steroids (Nandrolone [e.g., @DRUG$ ] , @DRUG$ [ e.g. , Anavar ] , oxymetholone [ e.g. , Anadrol ] , stanozolol [ e.g. , Winstrol ] ) or	DDI-false
@DRUG$ Amiodarone should be used with caution in patients who are receptor blockers (e.g. propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate), and @DRUG$ , a CYP3A4 inhibitor) because of the potential for bradycardia, sinus arrest, and AV block;	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. @DRUG$ , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and @DRUG$ ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
* Drug interactions between argatroban and co-administered aspirin (162.5 mg orally administered 26 and 2 hours before starting argatroban 1 g/kg/min over 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after starting argatroban. @DRUG$ 1.5 g/kg/min over 18 hours).	DDI-false
The pressor effects of @DRUG$ such as dopamine or @DRUG$ are enhanced by Bretylium Tosylate.	DDI-false
In addition, oxcarbazepine and MHD induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of @DRUG$ and oral @DRUG$, resulting in a lower plasma concentration of these drugs.	DDI-false
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as @DRUG$), diphen-hydramine and H2 antagonists (such as @DRUG$ or ranitidine).	DDI-false
- @DRUG$, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with @DRUG$ may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics	DDI-false
@DRUG$:Reports suggest that @DRUG$ The antihypertensive effect of ACE inhibitors can be reduced.	DDI-false
Aminosalicylic acid may decrease the amount of @DRUG$ (Lanoxin, @DRUG$) that gets absorbed into your body.	DDI-false
It is recommended to avoid concurrent administration of @DRUG$ with aluminum hydroxide containing @DRUG$ for at least 4 hours following ethambutol administration.	DDI-false
@DRUG$ may antagonize the neuron blockade produced by @DRUG$ resulting in decreased antihypertensive effect and requiring increased dosage of the latter.	DDI-effect
Cholestyramine and @DRUG$ @DRUG$ : Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins .	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of cisplatin.	DDI-false
In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid ( 20 % decrease in binding), tolbutamide, @DRUG$ ( 10 % decrease in binding ) , or @DRUG$.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of @DRUG$ 50 to 100 mg to ACE inhibitors and @DRUG$ increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-effect
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, @DRUG$ , benzodiazepines , beta blockers , @DRUG$ , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Patients who start taking this medicine @DRUG$ or who increase their @DRUG$ Dose or other NSAIDs while taking digoxin, methotrexate or cyclosporin may develop toxicity properties for these drugs.	DDI-false
@DRUG$ : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ The regimen reduces the plasma concentrations of saquinavir.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
@DRUG$ has been administered with tolazoline, @DRUG$, dobutamine, steroids, surfactant, and high-frequency ventilation.	DDI-false
This indicates that @DRUG$ does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of @DRUG$.	DDI-false
- medicines associated with peripheral neuropathy include: @DRUG$ , chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$ , isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , @DRUG$ , thyroid products, @DRUG$ , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and @DRUG$  (etodolac capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free warfarin.	DDI-false
@DRUG$ The dose given as 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of @DRUG$ or the level of platelet aggregation in healthy adults .	DDI-false
@DRUG$: The effects of @DRUG$ and NSAIDs on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.	DDI-false
Consequently, drugs with a low therapeutic margin, such as @DRUG$, phenytoin, and @DRUG$, could have a delayed elimination and increases in their serum half-life leading to a toxic level.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Other drug interactions @DRUG$ , erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of @DRUG$.	DDI-false
Compounds tested in man include @DRUG$ , theophylline , phenytoin , diazepam , aminopyrine and @DRUG$.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with corticosteroids (such as @DRUG$), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).	DDI-false
@DRUG$ ; : Simultaneous use of @DRUG$ may increase the risk of renal impairment , particularly in volume-depleted patients .	DDI-false
CNS-Active Drugs @DRUG$ Sonata 10 mg potentiated the CNS-impairing effect of ethanol 0.75 g/kg on equilibrium testing and response time for 1 hour after ethanol administration and on the digit symbol substitution test ( DSST ), symbol copying test and the variability component of the divided attention test for 2.5 hours after @DRUG$ administration .	DDI-false
In clinical studies, FLOLAN was used with digoxin, diuretics, @DRUG$ In a pharmacokinetic sub-study in patients with heart failure receiving furosemide or digoxin in whom treatment with @DRUG$ was initiated , apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
@DRUG$ * Chloramphenicol, erythromycins, @DRUG$ , or tetracyclines may interfere with the bactericidal effect of penicillins .	DDI-false
A similar association, albeit less pronounced, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine and possibly with @DRUG$ , @DRUG$ â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€”	DDI-false
Pyrantel ( e.g. , @DRUG$ - taking piperazin and @DRUG$ together may decrease the effects of piperazine .	DDI-false
Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite @DRUG$) may be increased when @DRUG$ and doxorubicin are used in combination.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e.g. , cimetidine , @DRUG$ Hepatic enzyme inducers (e. g., liver enzyme inducers) and decreased by concomitant administration of liver enzyme inducers (e. g. @DRUG$ , phenytoin ) , and such an effect may be anticipated with CMI as well .	DDI-false
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	DDI-false
In vitro studies show that at therapeutic concentrations of salicylate (300 m g/ ml) the binding of @DRUG$ The increase in unbound imports was reduced from around 99.2% to 97.5%, which is a potential double increase in imports from third countries. @DRUG$ plasma levels .	DDI-false
Catecholamine-depleting Agents : Patients taking both @DRUG$ , and a medicine that deplete catecholamine (e.g., @DRUG$ Monoamine oxidase inhibitors) should be closely monitored for signs of hypotension and/ or severe bradycardia.	DDI-effect
@DRUG$ : In normal volunteers , a small decrease in diflunisal levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly .	DDI-false
Hypotension    Patients on @DRUG$ Therapy : Patients on diuretics and especially those in whom @DRUG$ therapy was recently instituted , as well as those on severe dietary salt restriction or dialysis , may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril .	DDI-false
These drugs include: @DRUG$ And other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$ , oral contraceptives , phenytoin , nicotinic acid , sympathomimet-ics , calcium channel blocking drugs , and isoniazid .	DDI-false
@DRUG$ â€¢ the effect of @DRUG$ , barbiturates , and other CNS depressants .	DDI-effect
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, @DRUG$, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
- Oral @DRUG$ (birth control pills) containing @DRUG$ or	DDI-false
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (nicotinic acid), @DRUG$, azole antifungals.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant studies: @DRUG$ : MTX , NSAIDs , @DRUG$ TNF blockers, azathioprin, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine and anakinra.	DDI-false
Cohort 1 then received @DRUG$ plus @DRUG$ For 10 days, and cohort 2 received amprenavir plus rifampin for 4 days.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and @DRUG$.	DDI-false
The use of local anesthetics containing epinephrine or norepinephrine in patients receiving monoamine oxidase inhibitors, @DRUG$ or @DRUG$ may produce severe , prolonged hypotension or hypertension .	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramide, @DRUG$ , @DRUG$ Monoamine oxidase (MAO) inhibitors, propoxyphene, salicylate, somatostatin analogue (e.g. octreotide), sulphonamide antibiotics.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
Consequently, estazolam should be avoided in patients receiving @DRUG$ and @DRUG$, which are very potent inhibitors of CYP3A.	DDI-false
Antidepressants (@DRUG$), atropine or other anticholinergic agents, or @DRUG$: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Antiarrhythmics : Amiodarone , @DRUG$ , flecainide , @DRUG$ , Chinidine CONTRAINDICATES due to the potential for serious and/or life-threatening reactions.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$ : MTX , NSAIDs , corticosteroids , @DRUG$ , azathioprin, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine and anakinra.	DDI-false
In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose ( 81 mg ) enteric coated @DRUG$ â€¢ plus VIOXX 25 mg daily, compared to those who @DRUG$ 2400 mg daily alone .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Patients receiving other narcotic analgesics , general anesthetics , phenothiazines , tranquilizers , @DRUG$ , tricyclic antidepressants or other CNS depressants ( including alcohol ) concomitantly with @DRUG$ It may have additive CNS depression.	DDI-effect
Although glucocorticoids have been shown to reduce PROLEUKIN-induced adverse reactions including fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, concomitant use of these active substances with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
@DRUG$ and @DRUG$: a drug interaction.	DDI-int
Because of its lack of anti-platelet effect @DRUG$ is not a substitute for @DRUG$ for cardiovascular prophylaxis.	DDI-false
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, @DRUG$ , danazol, diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g. in oral contraceptives).	DDI-false
@DRUG$: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in @DRUG$ plasma A.C.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
(In some patients, the @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium sparing, and @DRUG$.	DDI-effect
A clinical study in healthy male subjects ( n=24 ) showed that NovoLog with @DRUG$ immediately before injection produced some attenuation in the peak concentration of @DRUG$ However, the time to peak and total bioavailability of NovoLog were not significantly affected.	DDI-false
- Vitamin K (e.g., AquaMEPHYTON, @DRUG$) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the blood	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, @DRUG$, @DRUG$, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Co-administration of @DRUG$ and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-advise
When used in external subcutaneous infusion pumps for @DRUG$, @DRUG$ should not be mixed with any other insulins or diluent.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
Drugs that cause significant sustained elevation in gastric pH ( @DRUG$ B. ranitidine or @DRUG$ IRESSA may decrease plasma concentrations and may reduce efficacy.	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
An interaction study with @DRUG$ showed no clinically significant effect of anastrozole on @DRUG$ pharmacokinetics or anticoagulant activity.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, @DRUG$ , quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
There is no pharmacokinetic interaction between @DRUG$ and @DRUG$.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , @DRUG$ , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , @DRUG$ , nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
The plasma valproate concentration should be monitored if: @DRUG$ and valproate are co administered , and appropriate dosage adjustments of @DRUG$ should be made .	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$ â€¢ (such as flecainide, lidocaine or quinidine): co-administration with @DRUG$ may have a proarrhythmic effect .	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Drugs with a Narrow Therapeutic Index Digoxin: @DRUG$ (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of @DRUG$ (0.375 mg q24h for 8 days).	DDI-false
@DRUG$ : Chlorpromazine blocks dopamine and norepinephrine receptors , thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat amphetamine poisoning .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
@DRUG$ and Corticotropin ( @DRUG$ ): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction .	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9. @DRUG$ , and @DRUG$.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , @DRUG$ , and @DRUG$.	DDI-false
In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors @DRUG$ , tolbutamide and @DRUG$.	DDI-false
Reports suggest that @DRUG$ The antihypertensive effect of @DRUG$ , including Lisinopril.	DDI-effect
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , @DRUG$ drugs ( e.g. , ibuprofen ) , @DRUG$ , vancomycin .	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and @DRUG$, and the antituberculosis drug rifampin.	DDI-false
@DRUG$, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Agents increase serum potassium: @DRUG$ The potassium loss is attenuated by @DRUG$.	DDI-effect
@DRUG$: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$.	DDI-false
In monkeys (-)-NANM was about 10 times stronger than @DRUG$ The pigeons (-)-NANM was an equipotent with @DRUG$.	DDI-false
The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or acamprosate .	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Although no studies have been conducted, concomitant administration of @DRUG$ and @DRUG$ may alter the metabolism of phenytoin;	DDI-mechanism
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Benzthiazide may interact with @DRUG$ - blood thinners, inflammatory medications (allergic agents, colds and sinus drugs), diabetics, lithium, norepinephrine, NSAIDs such as aleve or @DRUG$ , and high blood pressure medications .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , @DRUG$ , cardiac nitrates, diuretics, @DRUG$ , HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
In patients with mild to moderate hypertension , administration of 25 mg daily of @DRUG$ with the ACE inhibitor @DRUG$ , 10 to 40 mg for 4 weeks , was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone .	DDI-effect
Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : @DRUG$ - Tricyclic antidepressants : @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Although no studies have been conducted , concomitant administration of Itraconazole and @DRUG$ may alter the metabolism of @DRUG$ ;	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, @DRUG$, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Lack of an effect of azithromycin on the disposition of @DRUG$ and @DRUG$ in HIV-infected patients .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
- Antidiabetics, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with @DRUG$ may increase the chance of side effects affecting the blood and/or the side effects or oral @DRUG$	DDI-false
- When Bezalip or @DRUG$ is used concurrently with anion-exchange resins (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	DDI-advise
In pigeons , @DRUG$ The effect of (-)-NANM has not changed systematically, @DRUG$ or PCP .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide, quinine, amiodarone, quinidine, @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Anticoagulants : Potentiation of @DRUG$-type ( CYP2C9 and @DRUG$ The substrate) Anticoagulant response is almost always seen in patients receiving amiodarone and can lead to severe or fatal bleeding.	DDI-false
Another oral azole antimycotics, ketoconazole, inhibits the metabolism of @DRUG$ , resulting in elevated plasma concentrations of astemizole and its active metabolite @DRUG$ , which can prolong QT intervals.	DDI-false
In patients taking @DRUG$ and lithium at the same time, @DRUG$ The toxicity may develop.	DDI-false
Coadministration of @DRUG$ decreased the maximum plasma concentration of @DRUG$ by 6 % , decreased clearance by 38 % , and increased half-life by 58 % .	DDI-mechanism
In a phase I study with escalating doses of @DRUG$ ( 110 - 200 mg/m2 ) and cisplatin ( 50 or 75 mg/m2 ) given as sequential infusions , myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence ( ie , @DRUG$ Before cisplatin).	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between VIRACEPT and @DRUG$ , trimethoprim/sulfamethoxazole , clarithromycin , @DRUG$ , itraconazole or fluconazole .	DDI-false
@DRUG$ may enhance the effects of @DRUG$, barbiturates, and other CNS depressants.	DDI-effect
Drug/Laboratory Test Interaction Because @DRUG$ may affect the APTT assay, @DRUG$ present in plasma samples may interfere with one-stage coagulation assays based on the APTT (such as factor VIII, IX, and XI assays).	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ may also potentiate the replication of some organisms contained in @DRUG$.	DDI-effect
To determine whether @DRUG$ has a direct effect on the distribution of cloxacillin , the elimination and distribution of cloxacillin was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of @DRUG$.	DDI-false
@DRUG$ ( 10 mg once daily ) has been coadministered with therapeutic doses of @DRUG$ , cimetidine , and ketoconazole in controlled clinical pharmacology studies in adult volunteers .	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, @DRUG$, Ritanovir, Saquinavir.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Acetaminophene, lidocaine, @DRUG$ , @DRUG$ Theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Patients receiving high doses of salicylates concomitantly with @DRUG$, as in rheumatic disease, may experience @DRUG$ toxicity at lower doses because of competitive renal excretory sites.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
These drugs include thiazides and other @DRUG$ , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$ ==References====External links==	DDI-false
Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
However , neither @DRUG$ nor @DRUG$ It seems to affect the Dantrium metabolism.	DDI-false
In separate studies of patients receiving maintenance doses of @DRUG$, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$ , estrogens , oral contraceptives , phenytoin , nicotinic acid , @DRUG$ , calcium channel block drugs, and isoniazid.	DDI-false
Coadministration of @DRUG$ The exposure of norethindron and ortho-novum 1/35 increased @DRUG$ , by 20 % and 34 % respectively.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ And antineoplastic agents, especially dacarbazine, @DRUG$ , tamoxifen and interferon alpha.	DDI-effect
These drugs include the thiazides and other @DRUG$ , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , @DRUG$ ==References====External links==	DDI-false
While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , @DRUG$ , sertraline , paroxetine , and @DRUG$ , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-false
H2 Receptor Antagonists: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on @DRUG$ absorption when it is coadministered with ranitidine.	DDI-false
Drugs With A Narrow Therapeutic Index Digoxin A single dose of @DRUG$ 3 mg did not affect the pharmacokinetics of @DRUG$ measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.	DDI-false
Injection : Lorazepam injection, as other injectable @DRUG$ , produces depression of the central nervous system when administered with ethyl alcohol , phenothiazines , barbiturates , MAO inhibitors , and other antidepressants . When @DRUG$ It is administered concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations and irrational behaviour has been observed.	DDI-false
@DRUG$ : Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in @DRUG$ plasma concentration .	DDI-false
Hepatic enzyme inducers, inhibitors and substrates : drugs that induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity (e.g. barbiturates, @DRUG$ , carbamazepine , rifampin ) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased .	DDI-mechanism
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	DDI-false
Population pharmacokinetic analyses revealed that MTX , @DRUG$ , corticosteroids and TNF blockers did not affect @DRUG$ clearance .	DDI-false
Standard therapy includes @DRUG$, such as penicillin and @DRUG$;	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other @DRUG$ , sedatives , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , @DRUG$ , skeletal muscle relaxants, and alcohol, may result in respiratory depression, hypotension, and deep sedation, or possibly in coma or death.	DDI-false
Concomitant administration of @DRUG$ ( equivalent to 145 mg TRICOR ) with @DRUG$ ( 40 mg ) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36 % ( range from 69 % decrease to 321 % increase ) and 28 % ( range from 54 % decrease to 128 % increase ) , respectively , and for 3 -hydroxy-iso-pravastatin by 55 % ( range from 32 % decrease to 314 % increase ) and 39 % ( range from 24 % decrease to 261 % increase ) , respectively in 23 healthy adults .	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , @DRUG$ , iodoquinol , @DRUG$ , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
@DRUG$ may accentuate the electrolyte loss associated with @DRUG$ therapy.	DDI-effect
The intensity, uniformity and time course of the anticoagulant interference by phenobarbital, @DRUG$ , glutethimide, chloral hydrate and methaqualone have been systematically studied in 16 patients who: @DRUG$ therapy .	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, CYP2D6, and CYP3A4.	DDI-false
Nifedipine: @DRUG$ 20 mg, when co-administered with slow-release @DRUG$ 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.	DDI-false
@DRUG$: When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Both efavirenz and @DRUG$ have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
@DRUG$ : @DRUG$ It is reported to be a weak inhibitor of aldehyde oxidase in the rat's liver, but its inhibitory effects in the human liver are not known.	DDI-false
Based on the chemical resemblance of itraconazole and @DRUG$, coadministration of @DRUG$ with itraconazole is contraindicated.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , @DRUG$ , @DRUG$ , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Central nervous system depressants : Co-administration of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ â€¢ (e.g. benzodiazepines), general anaesthetics, @DRUG$ , skeletal muscle relaxants, and alcohol, may result in respiratory depression, hypotension, and deep sedation, or possibly in coma or death.	DDI-false
In vitro and/or in vivo data indicate that: @DRUG$ , itraconazole and oral ketoconazole clearly inhibit the metabolism of @DRUG$ , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-mechanism
Acetaminophen, lidocaine, phenobarbital, quinidine, @DRUG$, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of @DRUG$ compared to @DRUG$ alone.	DDI-false
] METHOD : This study was a multicentre randomized double-blind study in 101 patients randomly receiving 1:1:1. @DRUG$ tablets at doses of 0.5 mg , 1 mg , or 2 mg twice daily with cyclosporine and @DRUG$.	DDI-false
For treatment with CYP3A4 inhibitors (such as ketoconazole, intraconazole, @DRUG$ , indinavir , saquinavir , @DRUG$ , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$-based regimens may have several advantages over @DRUG$-based therapy for initial or prolonged therapy, including more convenient administration regimens, lower tablet volume, fewer drug interactions, and central nervous system penetration.	DDI-false
Calcium Channel Blockers : Isolated cases of conduction disturbance ( rarely with hemodynamic compromise ) have been observed when @DRUG$ ==References====External links==	DDI-effect
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$ , presumably through inhibition of CYP3A : nefazodone , fluvoxamine , cimetidine , diltiazem , @DRUG$ And some macrolide antibiotics.	DDI-mechanism
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with beta-adrenergic blockers, methyldopa, @DRUG$ - Calcium blockers, hydralazine, prazosin and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$ : Aminoglutethimide can reduce adrenal suppression by @DRUG$.	DDI-false
@DRUG$ ('@DRUG$') is a newly introduced atypical antipsychotic with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
Tolazamide : A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on @DRUG$ ( 1 gm/day ) 11 days after the addition of @DRUG$ ( 75 mg/day ) .	DDI-effect
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , @DRUG$ ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with @DRUG$ The toxicity in these organ systems can be increased.	DDI-effect
As @DRUG$, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., @DRUG$, lamotrigine).	DDI-false
- Lithium: @DRUG$ should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
@DRUG$ (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
@DRUG$ The pharmacokinetics of theophylline ( @DRUG$ 5.8 mg/ kg over 20 minutes) were unchanged in 6 healthy subjects following a single oral dose of albendazole (400 mg).	DDI-false
@DRUG$: @DRUG$, bepridil, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Other CONCOMITANT THERAPY: Although specific interaction studies have not been performed, in clinical studies cerivastatin sodium was used together with angiotensin converting enzyme (ACE) inhibitors, beta-blockers, calcium channel blockers, diuretics, and @DRUG$ ( @DRUG$ ) without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$ : Amphetamines inhibit the hypotensive effect of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics , @DRUG$ , phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , non-steroidal anti-inflammatory drugs ( e.g. , @DRUG$ ), Tacrolimus, @DRUG$.	DDI-false
If cholinergic blockades occur, additive undesirable effects may occur if: @DRUG$ is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , @DRUG$ , tricyclic antidepressants or some antihistamines .	DDI-effect
Because there is a theoretical basis that these effects may be additive , use of ergotamine-containing or ergot-type medications ( like @DRUG$ or @DRUG$ AXERT and AXERT should be avoided within 24 hours of each other.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ It is co-administered with other antimuscarinics, @DRUG$ , haloperidol, phenothiazine, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , @DRUG$ , glutethimide , @DRUG$ , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
In interaction studies with hydrochlorothiazide, no significant pharmacokinetic interactions were found. @DRUG$ , @DRUG$ , cimetidine and phenobarbital.	DDI-false
Administration of @DRUG$ Patients who: @DRUG$ Medicines that inhibit monoamine oxidase may lead to an additive pressure agent effect.	DDI-effect
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, @DRUG$, @DRUG$, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Use in Ambulatory Patients The effects of @DRUG$ may wear off before a @DRUG$ is completely cleared from the body.	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, @DRUG$ , thyroid products , estrogens , oral contraceptives , phenytoin , @DRUG$ , sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic @DRUG$.	DDI-effect
@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-int
The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing @DRUG$ and @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral @DRUG$ , phenytoin, nicotinic acid, @DRUG$ , calcium channel block drugs, and isoniazid.	DDI-false
- anabolic steroids (Nandrolone [e.g. Anaboline], Oxandrolone [e.g., Anavar], @DRUG$ [ e.g. , Anadrol ] , stanozolol [ e.g. , @DRUG$ ] ) or	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and @DRUG$ levels of 14% and 31%, respectively.	DDI-false
The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with captopril (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	DDI-effect
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$ , and sodium colistimethate ) , magnesium salts , @DRUG$ , local anesthetics , procainamide , and quinidine .	DDI-false
These drugs include the thiazides and other @DRUG$ , corticosteroids, phenothiazines, thyroid products, @DRUG$ , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , @DRUG$ , H2 antagonists (e.g. famotidine, ranitidine) and proton pump inhibitors (e.g. lansoprazole, @DRUG$ ) .	DDI-false
The effect of @DRUG$ on @DRUG$ clearance has not been studied.	DDI-false
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: @DRUG$ , Terfenadine Antimigrain: Ergot derivatives Antimycobacterial agents: @DRUG$ benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics , hypnotics and sedatives ( including benzodiazepines ) , or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
If other potent parental antihypertensive agents, such as e.g. @DRUG$ , are used in combination with @DRUG$ , patients should be continuously observed for several hours for any excessive fall in blood pressure .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ ( Neostgmin, Physostigmin), lignocaine, @DRUG$ , procainamide can enhance toxicity and cause cardio respiratory depression .	DDI-false
Magnesium/Aluminum-containing @DRUG$ : Absorption of zalcitabine is moderately reduced ( approximately 25 % ) when coadministered with magnesium/aluminum-containing @DRUG$.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Patients who start taking Diclofenac or increase their dose of Diclofenac or any other NSAID while taking Diclofenac @DRUG$ , methotrexate , or @DRUG$ It can develop toxicity characteristics for these drugs.	DDI-false
@DRUG$ ( 400 mg b.i.d . ) had no effect on vardenafil bioavailability ( AUC ) and maximum concentration ( Cmax ) of vardenafil when co-administered with 20 mg @DRUG$ in healthy volunteers .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-false
Oral @DRUG$ : Pharmacokinetic interactions between argatroban and @DRUG$ 7.5 mg oral single dose) has not been established.	DDI-false
@DRUG$-Concomitant intake of mineral oil and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent @DRUG$ such as furosemide.	DDI-false
The concurrent use of @DRUG$ with @DRUG$ has not been formally studied.	DDI-false
A crossover study in healthy subjects that either @DRUG$ 300 mg q.i.d . or 800 mg h.s . concomitantly with a 300 mg b.i.d . dosage of theophylline ( @DRUG$ Key Pharmaceuticals, Inc.) showed a lower change in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, especially in subjects aged 54 years and older.	DDI-mechanism
Both efavirenz and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with @DRUG$.	DDI-false
@DRUG$ : @DRUG$ blocks dopamine and norepinephrine reuptake , thus inhibiting the central stimulant effects of amphetamines .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of @DRUG$	DDI-false
Before using this medication, tell your doctor or pharmacist about all prescription and non-prescription products you can use, especially from: @DRUG$ Amphotericin B, cyclosporin, nonsteroidal anti-inflammatory medicines (e.g. ibuprofen), tacrolimus, @DRUG$.	DDI-false
CNS-Active Drugs Ethanol : Sonata 10 mg potentiated the CNS-impairing effects of @DRUG$ 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test ( DSST ) , symbol copying test , and the variability component of the divided attention test for 2.5 hours after @DRUG$ administration .	DDI-false
Slow-channel calcium blockers, such as verapamil, @DRUG$ and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
The benefits and risks of using @DRUG$ with @DRUG$ The lowest effective dose to be administered should be carefully considered.	DDI-advise
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
The absorption of tetracycline , furosemide , penicillin G , @DRUG$ , and @DRUG$ was significantly decreased when given simultaneously with colestipol hydrochloride ;	DDI-false
Administration of rifampin concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Imipramine ( 5 mg/kg ) , moclobemide ( 30 mg/kg ) , @DRUG$ ( 0.25 mg/kg ) , @DRUG$ Sertraline ( 30 mg/kg) or vehicle was administered.	DDI-false
These results suggest that both dexamethasone and retinyl acetate , and possibly other @DRUG$ and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, @DRUG$ , benzodiazepines, beta blockers, calcium channel blockers, cardiac nitrates, diuretics, @DRUG$ , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Exposure from the proposed topical dose is about 1 % of that from the 100 mg oral dose , even when co-administered with @DRUG$/@DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Interactions may occur between EPA supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic ( Allium sativum ) and ginkgo ( @DRUG$ ) .	DDI-false
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of @DRUG$ and cyclosporine (INN, @DRUG$) when coadministered in de novo kidney allograft recipients during the first year after transplantation.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 ( such as quinidine , fluoxetine , @DRUG$ , and propafenone ) have not been studied , but these drugs would be expected to increase blood levels of the R(+ ) enantiomer of @DRUG$ .	DDI-effect
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , @DRUG$/valproic acid , @DRUG$/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
medicines that should not be combined with VIRACEPT antiarrhythmics: @DRUG$ , quinidine Antihistamines : astemizole, terfenadine Antimigrain : ergot derivatives Antimycobacterial agents : rifampin @DRUG$ midazolam , triazolam GI motility agents : cisapride	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Clinical studies with @DRUG$ have identified potentially significant interactions with @DRUG$ and lithium .	DDI-int
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	DDI-false
When other potent parental @DRUG$ , such as @DRUG$ Patients should be monitored continuously for several hours for an excessive decrease in blood pressure, when used in combination with hydralazine.	DDI-effect
@DRUG$: In normal volunteers, concomitant administration of @DRUG$ and acetaminophen resulted in an approximate 50% increase in plasma levels of acetaminophen.	DDI-false
Warfarin: @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG$n, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including non-steroidal anti-inflammatory drugs and other drugs that are highly protein bound, salicylates, @DRUG$ , chloramphenicol , @DRUG$ , Cumarine, monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-false
Coadministration of @DRUG$ did not affect the pharmacokinetics of @DRUG$.	DDI-false
Cimetidine: @DRUG$ has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various @DRUG$.	DDI-mechanism
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and @DRUG$.	DDI-int
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$ , sympathomimetics , @DRUG$ ==References====External links==	DDI-false
Patients receiving other @DRUG$s, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Selective serotonin reuptake inhibitors ( @DRUG$ ): SSRIs ( e.g. , fluoxetine , fluvoxamine , paroxetine , @DRUG$ ) have been rarely reported to cause weakness, hyperreflection, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
Effects of @DRUG$ About other antiepilepsia drugs ( AEDs ) : @DRUG$ : Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy .	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines , presumably through inhibition of CYP3A : nefazodone , fluvoxamine , @DRUG$ , diltiazem , isoniazide , and some @DRUG$.	DDI-false
Further , no effects on either warfarin levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and @DRUG$.	DDI-false
Seizure, associated with increased @DRUG$ concentrations, has been reported with concomitant administration of intravenous @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
DOSTINEX should not be administered concurrently with D2-antagonists , such as phenothiazines , @DRUG$ , @DRUG$ , or metoclopramide .	DDI-false
Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided.	DDI-advise
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or @DRUG$ antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80 % increase in etoposide exposure with a 38 % decrease in total body clearance of etoposide compared to @DRUG$ alone .	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and salicylates is not recommended.	DDI-false
@DRUG$ : In a study of young healthy male subjects no evidence of a direct pharmacokinetic @DRUG$-digoxin interaction could be found .	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Pyrantel (e.g., @DRUG$) - Taking @DRUG$ and pyrantel together may decrease the effects of piperazine.	DDI-false
In monkeys, the effects of (-)-NANM, but not (+)-NANM, or @DRUG$ , were antagonized by @DRUG$ ;	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic clonidine.It is not known whether the concurrent use of these agents with @DRUG$ in humans can lead to resulting interference with the IOP lowering effect.	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like @DRUG$ MAOI could theoretically influence flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of tricyclic antidepressants	DDI-int
The concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, indomethacin) is myelotoxic (e.g. @DRUG$ chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , @DRUG$ Effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Benzthiazide can be used with @DRUG$ , @DRUG$s, decongestant medications (allergy, cold, and sinus drugs), diabetes medications, lithium, norepinephrine, NSAIDs such as aleve or ibuprofen, and high blood pressure medications.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin , nitroprusside , milrinone , or IV @DRUG$ These medicines were not administered with Natrecor in clinical trials.	DDI-false
May interact with the following: @DRUG$, colestipol (use with thiazide diuretics may prevent the @DRUG$ from working properly;	DDI-false
Potential drug interactions between Keppra   and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , @DRUG$ , @DRUG$ In placebo-controlled clinical trials, serum concentrations of levetiracetam and these AEDs have also been studied.	DDI-false
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and enalapril IV is augmented by @DRUG$ that cause renin release (e.g., diuretics).	DDI-effect
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$ , salicylates , somatostatin analog ( e.g. , octreotide ) , @DRUG$.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
In addition, higher-than expected steady-state serum concentrations of @DRUG$ have been observed when therapy is initiated in patients already taking @DRUG$.	DDI-mechanism
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local @DRUG$ , procainamide, and quinidine.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
"May interact with thyroid drugs (e.g. levothyroxine), products containing iodine, @DRUG$ , H2-antagonists ( e.g. , famotidine , @DRUG$ ) , and proton pump inhibitors ( e.g. , lansoprazole , omeprazole ) .	DDI-false
The aim of this paper was to study the interaction between neurotensin and both @DRUG$ or its synthetic analogue @DRUG$, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
Fenfluramine may slightly increase the effect of antihypertensive agents, e.g. @DRUG$ , methyldopa , @DRUG$.	DDI-false
A direct causal relationship has not been established, but physicians should consider the possibility that diclofenac may alter a diabetic patient s response to @DRUG$ or oral @DRUG$.	DDI-false
ERYTHROMYCIN: In hypercholesterolemic patients, steady-state @DRUG$ AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-mechanism
- if bezalip or @DRUG$ When co-administered with anion exchange resins (e.g. cholestryramine), a distance of at least 2 hours between the two medicinal products should be maintained as the absorption of bezalip or @DRUG$ is impaired	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac @DRUG$ , @DRUG$ H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
While all the @DRUG$ ( SSRIs), e.g. citalopram, escitalopram, fluoxetine, @DRUG$ , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors ( @DRUG$ , @DRUG$ , and pravastatin ) , leading to unique biopharmaceutical properties relative to the other agents of this class .	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators and supplementary @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin who started treatment with FLOLAN, apparent oral clearance values for @DRUG$ On the second day of therapy, digoxin (n=30) and n=23 were reduced by 13 % and 15 % respectively.	DDI-false
Concomitant use of calcium supplements and @DRUG$ may increase @DRUG$ absorption	DDI-false
Warfarin Keppra   ( 1000 mg twice daily ) did not influence the pharmacokinetics of @DRUG-DRUG$.	DDI-false
Oral Contraceptives : Coadministration of atorvastatin and an oral @DRUG$ Elevated AUC values for norethindrone and @DRUG$ by approximately 30 % and 20 % .	DDI-false
Interactions with mixed agonists/antagonists Opioid analgesics : agonists/antagonists analgesics (e.g. @DRUG$ , nalbuphine , @DRUG$ , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$: Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ or its epoxide metabolite in patients with epilepsy.	DDI-false
@DRUG$ and @DRUG$ exert additive ocular and renal vasodilator effects on healthy humans.	DDI-false
â€¢ Interaction of GABITRIL with other medicinal products: cimetidine: concomitant use of @DRUG$ ( 800 mg/day ) to patients taking @DRUG$ Chronically, he had no influence on the pharmacokinetics of tiagabin.	DDI-false
Concurrent administration of @DRUG$ and of @DRUG$ may cause severe , persistent hypertension or cerebrovascular accidents .	DDI-false
Concomitant use of @DRUG$ with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug .	DDI-false
Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, @DRUG$, or tetracyclines may interfere with the bactericidal effect of @DRUG$.	DDI-effect
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Experience with the concomitant use of HMG-CoA reductase inhibitors and @DRUG$ in patients is limited , therefore , consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving @DRUG$.	DDI-false
Saquinavir : Coadministration of saquinavir ( using an experimental soft-gelatin capsule formulation of saquinavir 1200 mg ) with VIRACEPT resulted in an 18 % increase in @DRUG$ Plasma AUC and a 4-fold increase in AUC @DRUG$ plasma A.C.	DDI-false
In vitro binding studies with human serum proteins indicate that @DRUG$ binds differently than @DRUG$ and does not interact with salicylate or dicumarol .	DDI-false
Therefore, @DRUG$ and @DRUG$ should not be used concomitantly.	DDI-advise
The effect of TORADOL on plasma @DRUG$ has not been studied, but cases of increased @DRUG$ plasma levels during TORADOL therapy have been reported.	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Drug-drug interactions have not been observed between @DRUG$ and digoxin or @DRUG$.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other @DRUG$ ( @DRUG$ , sedatives , tranquilizers , etc ) .	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been used in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, @DRUG$ Angiotensin converting enzymes (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$ , calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
Imidazoles ( e. g. , ketoconazole , miconazole , @DRUG$ In vitro and animal studies with the combination of amphotericin B and imidazoles suggest that: @DRUG$ It can lead to fungal resistance against amphotericin B.	DDI-false
Digoxin: When multiple doses of @DRUG$ and digoxin were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	DDI-false
@DRUG$ should be used with caution in patients taking @DRUG$, and renal function should be carefully monitored.	DDI-advise
The effect of @DRUG$ on plasma lithium has not been studied , but cases of increased lithium plasma levels during @DRUG$ therapy have been reported .	DDI-false
hypersensitivity reactions have been reported in patients receiving combination regimens with sequentially high-dose PROLEUKIN and @DRUG$ , specifically , dacarbazine , cis-platinum , tamoxifen and @DRUG$.	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., @DRUG$, cerivastatin, @DRUG$, simvastatin).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as @DRUG$, phenytoin, rifampin, and barbiturates) would be expected to decrease @DRUG$ concentrations.	DDI-false
Co-administration: Concomitant use of Argatroban with @DRUG$, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Cimetidine: @DRUG$ plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	DDI-false
@DRUG$ ( beta-blockers ) and @DRUG$ The effect of each other may be impaired when co-administered.	DDI-effect
However, no harmful interactions were seen when: @DRUG$ was administered after narcotics , inhalational @DRUG$ , muscle relaxants and muscle relaxant antagonists are administered in combination with sedation or anesthesia.	DDI-false
- Methotrexate (e.g., @DRUG$) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
â€¢ Non-selective MAO inhibitors including @DRUG$ , phenelzine sulfate , and pargyline HC1 : Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Beta-blocking Agents : The concomitant use of @DRUG$ and @DRUG$ The treatment was well tolerated in patients with stable angina pectoris.	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$ , anticoagulants, oral vasodilators and add-on oxygen. In a pharmacokinetic sub-study in patients with congestive heart failure, furosemide or @DRUG$ On the second day of therapy, apparent values for oral clearance of furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13 % and 15 % respectively and were returned to baseline by day 87.	DDI-false
Â· High dose cyclosporin A with concentrations above 2000 ng/ml administered with oral @DRUG$ has led to an 80 % increase in etoposide exposure with a 38 % decrease in total body clearance of etoposide compared to @DRUG$ alone .	DDI-false
Central nervous system depressants : Co-administration of @DRUG$   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , @DRUG$ Anaesthetics (e.g. benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants and alcohol can cause respiratory depression, hypotension and deep sedation, or possibly lead to coma or death.	DDI-effect
Co-medicines that induce CYP3A4 (e.g. dexamethasone, @DRUG$ , carbamazepine , @DRUG$ , phenobarbital or St.	DDI-false
Corticosteroids , @DRUG$ and @DRUG$ : Concomitant treatment with xanthine derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
Another oral azole antifungal, ketoconazole, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite desmethylastermizole which may prolong QT intervals.	DDI-false
Ketoconazole had no effect on the @DRUG$ After intravenous administration of losartan with the active metabolite and @DRUG$ had no clinically significant effect after oral administration .	DDI-false
Single doses of either @DRUG$ or @DRUG$ resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent , respectively .	DDI-false
* Cytochrome P-450 inducers, such as: @DRUG$ , @DRUG$ and phenobarbital , induce clonazepam metabolism , causing an approximately 30 % decrease in plasma clonazepam levels .	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( phenytoin , valproate , oral @DRUG$ , digoxin , @DRUG$ , probenecid) and by pharmacokinetic screening in placebo-controlled clinical trials in epilepsy patients.	DDI-false
( Concomitant use with @DRUG$ â€¢ may increase the possibility of: @DRUG$ Toxicity associated with hypokalaemia. )	DDI-effect
Carbamazepine: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
The addition of tiagabin in a limited number of patients in three controlled studies did not lead to systematic changes in @DRUG$ or @DRUG$ concentrations when compared to placebo .	DDI-false
@DRUG$ Angiotensin II receptor antagonists (hypertension)- In clinical trials in patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors, and @DRUG$ increased mean serum potassium slightly ( about 0.09 - 0.13 mEq/L ) .	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Example inhibitors include azole antifungals , @DRUG$ , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and @DRUG$.	DDI-false
In addition , certain drugs that are metabolized by this isoenzyme , including many @DRUG$ (tricyclic antidepressants, @DRUG$ , and others), can inhibit the activity of this isoenzyme, and so normal metab-olisers such as poor metabolisers in relation to concomitant therapy with other drugs metabolized by this enzyme system, resulting in drug interactions.	DDI-false
Cholestyramine increases enterohepatic elimination of @DRUG$ and may reduce its serum levels and @DRUG$/2 .	DDI-false
The blood pressure effect of @DRUG$ tended to be greater in patients on atenolol than in patients on no other @DRUG$ therapy.	DDI-false
In vitro binding studies with human serum proteins indicate that glipizide binds differently than @DRUG$ and does not interact with salicylate or @DRUG$.	DDI-false
Potential interactions between TAXOL , a substrate of CYP3A4 , and @DRUG$ ( ritonavir , saquinavir , indinavir , and @DRUG$ In clinical trials, substrates and/or inhibitors of CYP3A4 have not been studied.	DDI-false
Since higher doses of ketoconazole ( 400 mg daily ) may result in higher increases in Cmax and AUC , a single 2.5 mg dose of @DRUG$ should not be exceeded in a 24-hour period when used in combination with @DRUG$ 400 mg daily.	DDI-advise
Administration of doxapram to patients who: @DRUG$ or @DRUG$ may result in an additive pressor effect .	DDI-false
Drugs With A Narrow Therapeutic Index @DRUG$ A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of @DRUG$ measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.	DDI-false
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in @DRUG$ AUC0-12 and a 16% increase in @DRUG$ Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
Adrenergic blockers @DRUG$ This is inhibited by @DRUG$.	DDI-effect
Therefore , @DRUG$ and @DRUG$ Concomitant use should not be performed.	DDI-advise
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Co-administration : Concomitant use of Argatroban with @DRUG$ , @DRUG$ And other anticoagulants can increase the risk of bleeding.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , @DRUG$ , azathioprin, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$ , and anakinra .	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Tolbutamide : In diabetic patients who @DRUG$ and @DRUG$ , no significant effects were seen on tolbutamide plasma levels or fasting blood glucose .	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, @DRUG$, rifampin, phenobarbital or St.	DDI-false
Probenecid: As with other @DRUG$, renal excretion of loracarbef is inhibited by @DRUG$ and resulted in an approximate 80% increase in the AUC for loracarbef.	DDI-mechanism
It is assumed that increased interaction between @DRUG$ and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of @DRUG$ ==References====External links==	DDI-false
@DRUG$ Retinyl acetate also inhibits and stimulates @DRUG$ or insulin-induced proliferation of prostate epithelium.	DDI-effect
@DRUG$ : amphotericin B-induced hypokalemia may potentiate @DRUG$ toxicity .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , @DRUG$ , latamoxef ) or methylthiadiazole ( @DRUG$ ) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , @DRUG$ , vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. @DRUG$ , doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
In Study 1, patients with colorectal cancer @DRUG$/@DRUG$/leucovorin (bolus-IFL) were administered with or without AVASTIN.	DDI-false
Since entecavir is primarily eliminated by the kidneys, coadministration of @DRUG$ with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either @DRUG$ or the coadministered drug.	DDI-false
A possible interaction between @DRUG$ and ciprofloxacin, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , @DRUG$ , and @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Other cardiovascular agents: @DRUG$ , methyldopa, nitrates, calcium blockers, @DRUG$ , prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Beta-blockers, clonidine, @DRUG$ salts , and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
medicines that require dose reduction if they are used with: @DRUG$ Antimycobacterial agents : @DRUG$	DDI-advise
Other medicines that can enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX are certain @DRUG$ - aminoglycosides, tetracyclines, @DRUG$ , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with CNS depressants ( alcohol , barbiturates , opiates , sedatives , @DRUG$ ) should be considered.	DDI-advise
Pediatric Use The safety and effectiveness of @DRUG$ , alone or in combination with @DRUG$ No evidence was provided in patients under 18 years of age.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$ Elevates the deerohepatic elimination of amiodarone and may lower its serum levels and @DRUG$/2.	DDI-false
If @DRUG$ is administered with drugs that inhibit Pgp, increased concentrations of @DRUG$ are likely, and caution should be exercised.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, @DRUG$, digoxin, Maalox, and ranitidine.	DDI-false
Potential drug interactions between Keppra   and other AEDs ( carbamazepine , gabapentin , lamotrigine , @DRUG$ , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Reciprocal interactions may occur with concomitant use of antizole and medicinal products that potentiate or inhibit the cytochrome P450 system (e.g. @DRUG$ , @DRUG$ , cimetidine, ketoconazole), although this has not been studied	DDI-false
Micro-dosed Progesterone Preparations : Micro-dosed @DRUG$ preparations ( minipills that do not contain an @DRUG$ ) may be an inadequate contraceptive method during Accutane therapy.	DDI-false
Nevertheless, clinical studies, as well as postmarketing observations have shown that Lodine can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.	DDI-false
The co-administration of medicinal products which are nephrotoxic (e. g. @DRUG$ , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with @DRUG$ may increase toxicity in these organ systems .	DDI-effect
Injection : @DRUG$ Injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazine, barbiturates, MAO inhibitors and other @DRUG$.If scopolamine is used together with injectable lorazepam, an increased incidence of sedation, hallucinations and irrational behaviour has been observed.	DDI-effect
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$ , colistin , and @DRUG$ ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent if @DRUG$ was given alone or when Proquin XR was given 2 hours after @DRUG$ At the dose that suppresses gastric acid secretion maximum.	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$, digoxin, warfarin, cimetidine and @DRUG$.	DDI-false
@DRUG$-Orlistat may decrease the absorption of @DRUG$.	DDI-false
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, salbutamol, terbutaline), @DRUG$ , @DRUG$ , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and @DRUG$.	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with @DRUG$, ampicillin, and tetracyclines (72)	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [ e.g. , intravenous @DRUG$ It is contraindicated (e.g., tobramycin, gentamicin and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin and nonsteroidal anti-inflammatory agents.	DDI-advise
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics ( such as @DRUG$ Beta-agonists may cause acute exacerbation, especially if the recommended dose of @DRUG$ is exceeded .	DDI-false
@DRUG$ , clonidine, lithium salts and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin .	DDI-false
The medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$ , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and @DRUG$.	DDI-false
Antidiabetics : Because @DRUG$ may increase blood glucose concentrations , dosage adjustments of @DRUG$ It may be necessary.	DDI-effect
Other medicinal products Interactions: No pharmacokinetic interactions between vardenafil and the following medicines have been observed: glyburide, warfarin, @DRUG$ ==References====External links==	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
In vitro binding studies with human serum proteins indicate that glipizide binds differently than @DRUG$ and does not interact with salicylate or @DRUG$.	DDI-false
- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	DDI-false
@DRUG$ : Co-administration with @DRUG$ Toxic epidermal necrolysis has been reported when co-administered.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines , thyroid products , @DRUG$ , oral contraceptives , phenytoin , nicotinic acid , sympathomimet-ics , @DRUG$ ==References====External links==	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , @DRUG$ , Amiodaron, Nicardipine, and @DRUG$.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with beta-adrenergic blockers, @DRUG$ , nitrates , calcium-blocking agents , hydralazine , @DRUG$ and digoxin without evidence of clinically significant adverse interactions .	DDI-false
The concurrent use of intravenously or orally administered @DRUG$ (e.g., @DRUG$, theophylline) by patients receiving BROVANA has not been completely evaluated.	DDI-false
In vitro studies indicate that, at therapeutic concentrations of @DRUG$ (300 m g/mL), the binding of ketorolac was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound @DRUG$ plasma levels.	DDI-false
Potential drug interactions between Keppra   and other @DRUG$ ( carbamazepine , gabapentin , lamotrigine , phenobarbital , @DRUG$ , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
Patients receiving other narcotic analgesics , general @DRUG$ , phenothiazine, sedatives, sedative hypnotics, @DRUG$ Additional CNS depression may occur simultaneously with DILAUDID or other CNS depressions (including alcohol).	DDI-false
@DRUG$ inhibits the ERMBT , and rifampin and @DRUG$ are equipotent inducers of the ERMBT .	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( @DRUG$ ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and @DRUG$, have been used concurrently with @DRUG$.	DDI-false
- @DRUG$ (nandrolone [e.g. anaboline], @DRUG$ [ e.g. Anavar ], oxymetholone [ e.g. Anadrol ], Stanozolol [ e.g. Winstrol ] or	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , @DRUG$ , hydralacin, iodoquinol, @DRUG$ , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without @DRUG$ (an @DRUG$ with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80 % increase in @DRUG$ exposure with a 38 % decrease in total body clearance of etoposide compared to @DRUG$ alone .	DDI-false
The management of the local @DRUG$ containing @DRUG$ Patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may experience severe, prolonged hypertension.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, simvastatin, and @DRUG$), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Hormonal Contraceptives , Including Oral , Injectable , Transdermal , and Implantable @DRUG$ : An interaction study demonstrated that co-administration of @DRUG$ The oral hormonal contraceptives Ortho-Novum and the oral hormonal contraceptives resulted in an average decrease in norethindrone and ethinylestradiol levels of 14% and 31% respectively.	DDI-false
Since @DRUG$ This is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes can decrease metabolism and increase serum concentration of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel , 5 % , in combination with double strength ( 160 mg/800 mg ) trimethoprim/@DRUG$ ( @DRUG$/SMX ) .	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
ACE inhibitors and angiotensin II receptor antagonists (congestive heart failure after myocardial infarction)- In EPHESUS, 3020 (91%) patients also received INSPRA 25-50 mg. @DRUG$ Angiotensin II receptor antagonists (ACEI/@DRUG$).	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as @DRUG$, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
@DRUG$/@DRUG$: triazolam, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
- Poor Metabolisers of Schuttoquin : Interactions of @DRUG$ with strong inhibitors of CYP2D6 ( such as @DRUG$ , fluoxetine , paroxetine , and propafenone ) have not been studied , but these drugs would be expected to increase blood levels of the R(+ ) enantiomer of carvedilol .	DDI-false
The blood pressure effect of @DRUG$ The tendency was greater in patients receiving atenolol than in any other patient. @DRUG$ therapy .	DDI-false
Interaction with @DRUG$ , lidocaine and @DRUG$ has also been reported to produce adverse clinical effects .	DDI-false
@DRUG$ - can occur with one of the following interactions : - @DRUG$ ug (e.g. tylenol) (with long-term high dose) or	DDI-int
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and barbiturates, and the antituberculosis drug rifampin.	DDI-effect
The risk of using @DRUG$ in combination with other drugs has not been systematically evaluated, but alcohol may potentiate the side effects of @DRUG$.	DDI-false
Concurrent therapy with @DRUG$ and @DRUG$ is not recommended.	DDI-advise
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
The following examples are substances that can reduce the blood glucose lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g., @DRUG$ , salbutamol, terbutaline), @DRUG$ Phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Glyburide: The concomitant administration of @DRUG$ with the sulfonylurea @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	DDI-effect
Caution should be exercised in monitoring if: @DRUG$ It is given at the same time as @DRUG$.	DDI-advise
In a study in which patients with active RA up to 24 weeks with concomitant ENBREL and @DRUG$ A 7% rate of severe infections was observed during treatment, which was higher than in @DRUG$   alone ( 0 % ) .	DDI-false
Potential drug interactions between @DRUG$   and other AEDs ( carbamazepine , gabapentin , lamotrigine , @DRUG$ , phenytoin, primidone and valproate) were also evaluated by assessing levetiracetam serum concentrations and these AEDs in placebo-controlled clinical trials.	DDI-false
Cyclosporine : Administration of @DRUG$ Co-administration of cyclosporin has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacycline.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/@DRUG$.	DDI-false
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, @DRUG$, @DRUG$, or metoclopramide.	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other @DRUG$ while taking digoxin, @DRUG$, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-effect
It is suggested that in patients receiving @DRUG$, alternatives to phenytoin should be used if @DRUG$ therapy is needed.	DDI-false
It is structurally distinct from the other currently available HMGCoA reductase inhibitors (@DRUG$, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of @DRUG$ , oral vitamin B-12 , methotrexate and @DRUG$.	DDI-false
In @DRUG$-dependent patients, @DRUG$ may precipitate withdrawal symptoms.	DDI-false
Before using this medicine, tell your doctor or pharmacist about all prescription and non-prescription products you can use, especially: aminoglycosides (e.g., gentamicin, @DRUG$ ) , amphotericin B , cyclosporine , @DRUG$ drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin .	DDI-false
Antifungals : In vitro and/or in vivo data indicate that fluconazole , @DRUG$ , and oral @DRUG$ markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-false
Therophylline: A recent study has shown that concomitan administration of isoniazid and @DRUG$ may cause elevated plasma levels of @DRUG$, and in some instances a slight decrease in the elimination of isoniazid.	DDI-false
Dopamine Antagonists: Since @DRUG$ is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
The pressor effects of catecholamines such as @DRUG$ or @DRUG$ are enhanced by Bretylium Tosylate.	DDI-false
Antidepressants (tricyclic), atropine or other @DRUG$, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, @DRUG$, carbamazepine, griseofulvin, @DRUG$, and possibly with ampicillin and tetracyclines 72.	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$ , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , granisetron , dolasetron , @DRUG$ ==References====External links==	DDI-false
Drugs Interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect @DRUG$ pharmacodynamics - arecoline - eproxindine - ethanol : flupentixol and ethanol lead to additive CNS depression - tricyclic antidepressants : flupentixol increases the effect of @DRUG$	DDI-false
CNS-Active Drugs Ethanol : @DRUG$ 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance tests and response time for 1 hour after ethanol administration and on the digit symbol substitution test ( DSST ), symbol copying test and the variability component of the divided attention test for 2.5 hours after @DRUG$ administration .	DDI-false
However , in the second study , administration of 12 g @DRUG$ One hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in cerivastatin AUC of less than 8% and a decrease in Cmax of about 30% compared to the dose. @DRUG$ alone .	DDI-false
Coadministration with @DRUG$ ( 40 mg BID for 7 days ) resulted in a significant increase in @DRUG$ The plasma levels indicate that valdecoxib is a weak inhibitor of 2D6 at these doses.	DDI-mechanism
The effect of @DRUG$ on plasma lithium has not been studied, but cases of increased @DRUG$ plasma levels during TORADOL therapy have been reported.	DDI-false
@DRUG$ @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics of R and S warfarin.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Acetaminophen, lidocaine, @DRUG$, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
BACKGROUND : The effects of the combined administration of bombsin and verapamil hydrochloride (Verapamil ), a @DRUG$ , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( @DRUG$ ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
Plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e.g. , @DRUG$ Fluoxetine) and decreased by concomitant administration of liver enzyme inducers (e.g., barbiturates, phenytoin), and such an effect can also be expected with CMI.	DDI-mechanism
Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
Probenecid : As with other b-lactam antibiotics , renal excretion of @DRUG$ is inhibited by probenecid and resulted in an approximate 80 % increase in the AUC for @DRUG$.	DDI-false
In vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
Concurrent administration of a @DRUG$ with @DRUG$ has been associated with an increased risk of serious infections and no significant additional efficacy over use of the TNF antagonists alone.	DDI-effect
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	DDI-false
@DRUG$ MAOI antidepressants, as well as a metabolite of @DRUG$, slow amphetamine metabolism.	DDI-false
@DRUG$: In healthy subjects receiving ketoconazole, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to @DRUG$ was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	DDI-false
Other Drug Interactions Oral Contraceptives @DRUG$  (500 mg twice daily) did not influence the pharmacokinetics of an oral @DRUG$ containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
@DRUG$ In some patients with renal impairment, @DRUG$ , the co-administration of enalapril may result in a further deterioration of renal function .	DDI-false
Although no clinical studies have been conducted , it is likely that the metabolism of @DRUG$ - phenytoin, phenobarbital, @DRUG$ ) , CYP3A4 inhibitors ( azole antimycotics e.g. , ketoconazole ;	DDI-mechanism
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide, quinine, amiodarone, @DRUG$ , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines , presumably through inhibition of CYP3A : nefazodone , fluvoxamine , @DRUG$ , @DRUG$ Isoniazid, and some macrolide antibiotics.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , @DRUG$ , metronidazole, nitrofurantoin, @DRUG$ , ribavirin , and vincristine .	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Cyclosporine: Administration of nonsteroial anti-inflammatory drugs concomitantly with @DRUG$ has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
In clinical trials, FLOLAN was used with @DRUG$, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$ , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , @DRUG$ , hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , @DRUG$ , hydralazine , @DRUG$ and digoxin without evidence of clinically significant adverse interactions .	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including nonsteroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, probenecid, @DRUG$ , @DRUG$ , and beta adrenergic blocking agents .	DDI-false
Plasma concentrations ( AUC 0 - 24 hrs ) of erythromycin decreased 15 % with coadministration of @DRUG$ relative to that observed with @DRUG$ alone .	DDI-false
Cholestyramine-Concomitant intake of @DRUG$ The intake of @DRUG$ can be reduced by vitamin K.	DDI-false
In Study 1, patients with colorectal cancer were given @DRUG$/5-FU/@DRUG$ (bolus-IFL) with or without AVASTIN.	DDI-false
Pharmacokinetic studies have demonstrated that omeprazole and @DRUG$ significantly increased the systemic exposure of @DRUG$ and/or its major metabolites.	DDI-mechanism
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , @DRUG$ , @DRUG$ And nifedipine.	DDI-false
Magnesium- and/or aluminum-containing antacids , products containing @DRUG$ Do not take Videx (didanosine) chewable tablets or the oral pediatric powder within 3 hours before or 2 hours after @DRUG$.	DDI-advise
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital.	DDI-false
@DRUG$ Co-administration of procainamide for less than seven days increases plasma concentrations of @DRUG$ n-acetylprocainamide by 55% and 33% respectively.	DDI-false
Psychoactive Drugs : Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (fluoxetine, thiothixes, @DRUG$ ) .	DDI-false
@DRUG$: Since bile acid sequestrants may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption.	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Drug-Drug Interactions Between @DRUG$ And other antiepileptics ( AEDs ) @DRUG$ Keppra   ( 3000 mg daily ) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy .	DDI-false
@DRUG$/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.	DDI-false
Theophylline serum levels should be monitored and appropriate dose adjustments should be considered in patients receiving both patients. @DRUG$ and @DRUG$.	DDI-advise
Aspirin/@DRUG$ : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1   g/kg/min . over 4 hours ) or acetaminophen ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of Argatroban 1.5   g/kg/min . over 18 hours ) .	DDI-false
The medicinal products associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isonazide, metronidazole, nitrofurantoin, @DRUG$ , ribavirin , and @DRUG$.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
- @DRUG$ (Nandrolone [e.g. Anaboline], Oxandrolone [e.g. Anavar], Oxymetholone [e.g., @DRUG$ ] , stanozolol [ e.g. , Winstrol ] ) or	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with 5HT3 antagonist class medications (including, for example, ondansetron, granisetron, @DRUG$ , @DRUG$ , and alosetron ) is contraindicated .	DDI-false
Cohort 1 then received amprenavir plus @DRUG$ for 10 days , and cohort 2 received @DRUG$ plus rifampin for 4 days .	DDI-false
Population pharmacokinetic analyses revealed that MTX, NSAIDs, corticosteroids, and @DRUG$ did not influence @DRUG$ clearance.	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with beta-adrenergic blockers, @DRUG$ , @DRUG$ , calcium-blocking agents , hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
Cholestyramine increases enterohepatic elimination of @DRUG$ and may reduce its serum levels and @DRUG$/2.	DDI-false
Concomitant administration of Mefloquine and other related compounds (eg, @DRUG$, @DRUG$ and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$ , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , @DRUG$ A QTc interval prolongation could also contribute to QTc interval prolongation, or beta-adrenergic blockers, calcium channel blockers, antihistamines, or H1-blockers, tricyclic antidepressants, and phenothiazines.	DDI-effect
Beta-blockers , clonidine , lithium salts , and @DRUG$ The blood glucose-lowering effect of @DRUG$ can either potentiate or weaken.	DDI-effect
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , @DRUG$ , somatostatin analog ( e.g. , octreotide ) , @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , @DRUG$ , terbutaline), isoniazid, phenothiazine derivatives, @DRUG$ , thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$ , carbamazepine, and barbiturates, and the antituberculosis drug rifampin.	DDI-effect
In addition, additional interaction studies with niacin and propranolol have not shown any effects on fluvastatin plasma levels and use in a patient population that is chronically @DRUG$ resulted in no difference in the extent of bioavailability of @DRUG$ Relative to the control data.	DDI-false
The interaction of GABITRIL with other drugs : @DRUG$ : Co-administration of @DRUG$ 800 mg/ day) did not affect the pharmacokinetics of tiagabin in patients chronically receiving tiagabin.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
@DRUG$ : isolated cases of conduction disorders (frequently with hemodynamic compromise) were observed when: @DRUG$ It is used together with diltiazem.	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , @DRUG$ and sedatives ( including @DRUG$ ) , or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
Plasma valproate concentration should be monitored when @DRUG$ and valproate are co administered, and appropriate dosage adjustments of @DRUG$ should be made.	DDI-false
Alpha-blockers: When @DRUG$ 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of @DRUG$, significant hypotension developed in a substantial number of subjects.	DDI-effect
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
The co-administration of diflunisal and diflunisal @DRUG$ In normal subjects, this did not affect plasma levels of @DRUG$ However, urinary excretion of naproxene and its glucuronide metabolite was significantly reduced.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
CONCLUSIONS : Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 ( i.e. , @DRUG$ , @DRUG$ , lovastatin , simvastatin ) .	DDI-false
In rats, simultaneous ingestion of @DRUG$ and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with @DRUG$ in the rat stomach to form a nitrosamine, which is tumorigenic.	DDI-false
@DRUG$ Elevated serum lithium levels and symptoms of lithium toxicity have been reported in patients concomitantly @DRUG$ Treatment and ACE inhibitors.	DDI-false
@DRUG$ , including @DRUG$ The effect of oral anticoagulants, including warfarin or its derivatives or similar active substances, may be enhanced.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , @DRUG$ Amphotericin B, foscarnet, intravenous pentamidine, vancomycin and nonsteroidal anti-inflammatory agents] is contraindicated.	DDI-advise
Other medicines: medicines such as quinidine, @DRUG$ , procainamide , phenothiazines , antihistamines , and @DRUG$ It may be associated with QT interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
While all the @DRUG$ (SSRIs), e.g., fluoxetine, @DRUG$, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$-@DRUG$ In large doses, vitamin K-epoxide reductase can inhibit, leading to vitamin K deficiency.	DDI-false
Aspirin: Concomitant administration of diclofenac and aspirin is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of @DRUG$, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-mechanism
Pyrantel (e.g., Antiminth) - Taking @DRUG$ and pyrantel together may decrease the effects of @DRUG$.	DDI-false
Warfarin : No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or @DRUG$ with the addition of @DRUG$ The dose is given as a single dose.	DDI-false
In the first study, concomitant administration of 0.2 mg @DRUG$ and 12 g @DRUG$ resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing cerivastatin sodium alone.	DDI-mechanism
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including @DRUG$ , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , @DRUG$ , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
Although there are no study data to evaluate the possibility , nitric oxide donor compounds , including sodium nitroprusside and @DRUG$ , can have an additive effect with @DRUG$ About the risk of developing methaemoglobinaemia.	DDI-effect
@DRUG$ and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and @DRUG$ increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
An alternative non-CYP3A4 substrate @DRUG$ may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, carbamazepine, and @DRUG$.	DDI-false
Injection : Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system if with @DRUG$ , phenothiazines , barbiturates , @DRUG$ , and other antidepressants . When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, @DRUG$ , bacitracin , @DRUG$ , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
The use of @DRUG$ in patients receiving @DRUG$ may be rarely associated with ventricular fibrillation .	DDI-effect
In EM individuals treated with paroxetine or @DRUG$, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-mechanism
High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80 % increase in etoposide exposure with a 38 % decrease in total body clearance of etoposide compared to etoposide alone .	DDI-mechanism
Other cardiovascular agents: Enalapril and Enalapril IV were used together with beta-adrenergic blockers, methyldopa, nitrates, @DRUG$ , hydralacin, prazosin and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with @DRUG$ , methyldopa, nitrates, calcium blockers, hydralacin, prazosin and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
Drugs that cause significant sustained elevation in gastric pH (@DRUG$ such as @DRUG$ or cimetidine) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.	DDI-false
Amprenavir inhibits the ERMBT, and @DRUG$ and @DRUG$ are equipotent inducers of the ERMBT.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and barbiturates, and the antituberculosis drug @DRUG$.	DDI-false
Benzylpenicillin , ampicillin , @DRUG$ , chlortetracycline , @DRUG$ In vitro, cephalothine, erythromycin and sulfamethoxazole have no influence on the protein binding of diclofenac in human serum.	DDI-false
In chronic hepatitis C patients treated with @DRUG$ In combination with COPEGUS, @DRUG$ treatment did not affect ribavirin distribution or clearance .	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and nifedipine.	DDI-int
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, @DRUG$, oral contraceptive, digoxin, @DRUG$, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and @DRUG$ Etodolac capsules and tablets lead to a reduced protein binding of @DRUG$ However, there was no change in the release of free warfarin.	DDI-false
Combinations in these categories result in reduced efficacy of @DRUG$ - Phenothiazine, haloperidol, @DRUG$ , pimozide .	DDI-effect
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
Concurrent administration of @DRUG$ Androgens and androgens may lead to increased serum levels of @DRUG$.	DDI-false
@DRUG$ toxicity may be aggravated by the initial release of norepinephrine caused by @DRUG$ Injection.	DDI-effect
@DRUG$ : An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with @DRUG$.	DDI-false
@DRUG$: Concurrent administration of @DRUG$ may lower meclofenamate sodium plasma levels, possibly by competing for protein-binding sites.	DDI-false
Magnesium/@DRUG$-containing antacid products: Zalcitabine absorption is moderately reduced (approximately 25%) when co-administered with Magnesium/@DRUG$-containing antacid products.	DDI-false
A dose increase of @DRUG$/ritonavir to 533/133 mg twice daily with food isrecommended in combination with @DRUG$.	DDI-advise
Dopamine antagonists : Da apomorphine is a @DRUG$ It is possible that dopamine antagonists, such as neuroleptics ( @DRUG$ APOKYN may decrease the efficacy of APOKYN (e. g., butyrophenone, thioxanthene) or methoclopramide.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ Ingestion that requires only oral physiological supplement and @DRUG$ The depletion associated with a dysregulation of the control mechanisms of magnesium status, which requires more or less specific regulation of its causal dysregulation.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$ , colistine, and sodium colistimethate, magnesium salts, lithium, local anaesthetics, @DRUG$ , and quinidine .	DDI-false
Based on the results of these studies, it is concluded that @DRUG$ may be safely coadministered with both @DRUG$ and dideoxyinosine.	DDI-false
Agents Having Vasodilator Activity : Data on the effect of concomitant use of other @DRUG$ in patients receiving @DRUG$ For heart failure are not available ;	DDI-false
â€¢ Hormonal contraceptives Concomitant use of @DRUG$ with an oral @DRUG$ It has been shown that plasma concentrations of the two hormone components ethinylestradiol (EE) and levonorgestrel (LNG) are affected.	DDI-mechanism
Short-term pharmacokinetic studies have shown that concomitant use of @DRUG$ The result is a reduced protein binding of warfarin, but there was no change in the clearance of free @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
In addition , @DRUG$ â™ª Alone can inhibit the adrenal glands â™ª @DRUG$ Synthesis and can cause adrenal insufficiency during corticosteroid withdrawal.	DDI-effect
Dopamine Antagonists : Since @DRUG$ is a @DRUG$ It is possible that dopamine antagonists, such as neuroleptics (phenothiazines, butyrophenone, thioxanthene) or metoclopramide, may reduce the efficacy of APOKYN.	DDI-false
The following specific interactions have been reported : Itraconazole Co-administration of another extended release formulation of @DRUG$ The use of itraconazole resulted in an approximately 8-fold increase in AUC, a more than 6-fold increase in Cmax and a 2-fold increase in the half-life of @DRUG$.	DDI-false
@DRUG$ : Simvastatin ( CYP3A4 substrate ) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis .	DDI-false
@DRUG$ has been shown to have neuromuscular blocking properties that may enhance the action of other @DRUG$.	DDI-effect
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking digoxin , @DRUG$ , or @DRUG$ It can develop toxicity characteristics for these drugs.	DDI-false
Dopamine Antagonists : Since apomorphine is a @DRUG$ It is possible that dopamine antagonists, such as neuroleptics (phenothiazine, butyrophenone, @DRUG$ ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
@DRUG$ Keppra   ( 1000 mg twice daily ) did not influence the pharmacokinetics of @DRUG$.	DDI-false
Non-steroidal anti-inflammatory drugs (but not @DRUG$): These drugs in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies.	DDI-false
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, @DRUG$, carbamazepine, and @DRUG$.	DDI-false
Ritonavir and @DRUG$ : Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir , the Cmax and AUC of @DRUG$ Production was reduced by around 20%.	DDI-false
â€¢ Anabolic steroids ( @DRUG$ [ e.g. , @DRUG$ ], Oxandrolone [e.g. Anavar], Oxymetholone [e.g. Anadrol], Stanozolol [e.g. Winstrol]) or	DDI-false
The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, @DRUG$, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Potential drug interactions between: @DRUG$ AED and other AEDs (carbamazepine, @DRUG$ , lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also evaluated by the evaluation of levetiracetam serum concentrations and these AEDs in placebo-controlled clinical trials.	DDI-false
@DRUG$: NSAIDs have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	DDI-false
Haemodynamic effects of @DRUG$ and @DRUG$ were additive when somatostatin was co-administered but not under basal conditions.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	DDI-false
@DRUG$ â€¢ 150 mg twice daily did not significantly interact with @DRUG$ The AUC was reduced by 15 - 20 %.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( @DRUG$ , @DRUG$ , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
Possible drug interactions of @DRUG$ with succinylcholine or with other @DRUG$.	DDI-int
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other @DRUG$ , including but not limited to other opioids, @DRUG$ , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Bacteriostatic Antibiotics: Chloramphenicol, @DRUG$, sulfonamides, or tetracyclines may interfere with the bactericidal effect of @DRUG$.	DDI-effect
@DRUG$ (Magnesium-Aluminum Hydroxide): @DRUG$ plasma concentrations were not affected by co-administration of antacid.	DDI-false
Both @DRUG$ and @DRUG$ â€¢ Improvement of locomotor and/or stereotypical effects of stimulants.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
Experience with co-administration of @DRUG$ Therefore, consideration should be given to temporarily suspending the use of fentanyl. @DRUG$ In patients receiving fentanyl.	DDI-false
FACTIVE had no significant effect on the anticoagulant effect of @DRUG$ in healthy subjects on stable @DRUG$ therapy.	DDI-false
Benzylpenicillin , @DRUG$ , @DRUG$ Chlortetracycline, doxycycline, cephalothine, erythromycin and sulfamethoxazole have no in vitro effect on the protein binding of diclofenac in human serum.	DDI-false
Taking a @DRUG$ while you are taking or within 2 weeks of taking @DRUG$ may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction .	DDI-effect
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
@DRUG$: Co-administration of VIOXX with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in @DRUG$ plasma concentrations.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
There were no clinically relevant pharmacokinetic interactions if: @DRUG$ was used concomitantly with propranolol or @DRUG$.	DDI-false
Combination of @DRUG$ with other @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to amiodarone .	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ Hallucinations have been reported when TORADOL has been used in patients who: @DRUG$ Fluoxetine, thiothixes, alprazoleam).	DDI-false
Central nervous system depressants : Concomitant use of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$ , skeletal muscle relaxants , and @DRUG$ , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
A similar association, albeit less pronounced, was suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, @DRUG$ , and possibly with @DRUG$ 72. and tetracyclines 72.	DDI-false
However, patients on @DRUG$ may show elevations of @DRUG$ concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to digoxin toxicity.	DDI-false
@DRUG$/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , @DRUG$/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral contraceptive, digoxin, warfarin, @DRUG$) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Therefore, it would be expected that a dosage regimen of @DRUG$ given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of @DRUG$.	DDI-false
Cephalosporine-@DRUG$ containing N-methylthiotetrazole page chains ( @DRUG$ , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , @DRUG$ , quinidine , and verapamil .	DDI-false
Hepatic enzyme inducers, inhibitors and substrates : drugs that induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity (e.g. barbiturates, @DRUG$ , @DRUG$ , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased .	DDI-false
Drug-Drug Interactions Between Keppra  And Other @DRUG$ (AEDs) @DRUG$ Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
Medicines that induce CYP3A4 @DRUG$ CYP3A4 is usually a small metabolic enzyme of @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ also significantly decreased the incidence of lymphatic invasion of adenocarcinomas , which was enhanced by @DRUG$.	DDI-effect
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Five days of @DRUG$ treatment did not significantly affect steady-state pharmacokinetic variables of @DRUG$ - Compared to placebo;	DDI-false
Digoxin, @DRUG$, Cyclosporine: Diclofenac, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
This medicine can be used with @DRUG$ or other CNS depressants ( may potentiate the CNS depressant effects of either these medications or antihistamines ) , anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ) , and monoamine oxidase ( MAO ) inhibitors ( concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ) .	DDI-false
Coingestion of acetaminophen with @DRUG$ , @DRUG$ with acetaminophen , and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-false
Thus , concomitant therapy with @DRUG$ and @DRUG$ should not require dosage adjustment of either drug .	DDI-false
A dose increase of lopinavir/@DRUG$ to 533/133 mg twice daily with food isrecommended in combination with @DRUG$.	DDI-advise
@DRUG$ and Angiotensin II Receptor Antagonists ( Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS , 3020 ( 91 % ) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists ( ACEI/@DRUG$ ) .	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-effect
Levosimendan has no clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$ , digoxin , warfarin , isosorbide mononitrate , @DRUG$ , ethanol or itraconazole .	DDI-false
In two combined 12-week placebo-controlled studies containing BROVANA doses of 15 mcg twice daily, 25 mcg twice daily and 50 mcg once daily, 54 of 873 @DRUG$ Patients treated concomitantly @DRUG$ at study entry .	DDI-false
The clinical significance of this reduction is not known , hence @DRUG$ is not recommended to be ingested simultaneously with magnesium/@DRUG$-containing antacids .	DDI-advise
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-effect
Example inhibitors include azole antifungals , ciprofloxacin , @DRUG$ , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , @DRUG$ , quinidine , and verapamil .	DDI-false
@DRUG$ In some patients, the use of a @DRUG$ The diuretic, natriuretic and blood pressure lowering effects of loop, potassium sparing and thiazide diuretics can be reduced.	DDI-false
Interactions with @DRUG$ : Agonist/antagonist analgesics ( eg , @DRUG$ , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran .	DDI-false
Medicines not to be administered with VIRACEPT @DRUG$ Amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	DDI-false
@DRUG$: @DRUG$ may cause myopathy, which is manifested as muscle pain or weakness associated with elevated levels of CPK.	DDI-false
@DRUG$ therapy Urinary excretion of amphetamines is increased, and efficacy is reduced by acidifying agents used in @DRUG$ therapy.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Data from in vitro studies of alprazolam suggest a possible drug interaction with alprazolam for the following: @DRUG$ and @DRUG$.	DDI-false
( 1968, 1970), the higher serum concentrations of @DRUG$ ed and cephaloridine after administration of @DRUG$ The cause is not only a slower renal elimination, but also a changed distribution in the body.	DDI-mechanism
No important interactions to date @DRUG$ There are no clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, scotilol, ethanol or @DRUG$.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, D-penicillamine, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
@DRUG$ : In healthy subjects given single 500 mg doses of cephalexin and metformin , plasma @DRUG$ mean cmax and AUC increased by an average of 34 % and 24 % , respectively , and metformin mean renal clearance decreased by 14 % .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
@DRUG$ also should be used cautiously with other drugs (e.g., @DRUG$, glycosides) that sensitize the myocardium to the actions of sympathomimetic drugs.	DDI-advise
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
To determine whether probenecid has a direct influence on the distribution of cloxacillin, the elimination and distribution of @DRUG$ It has been studied in six patients, five patients without renal function and one patient with partial renal impairment, in the presence or absence of @DRUG$.	DDI-false
Sedatives/@DRUG$: triazolam, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Medicines not to be treated at the same time @DRUG$ Antiarrhythmics : @DRUG$ , quinidine Antihistamines : astemizole, terfenadine Antimigrain : ergot derivatives Antimycobacterial agents : rifampine Benzodiazepines Midazolam, triazolam GI Motility agent : cisaprid	DDI-advise
Antidepressants, tricyclic: @DRUG$ may enhance the activity of tricyclic or @DRUG$ ;	DDI-effect
@DRUG$: Plasma digoxin levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	DDI-false
Digoxin, Methotrexate, Cyclosporine: @DRUG$, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.	DDI-false
Medicines not to be administered with VIRACEPT @DRUG$ : @DRUG$ , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
@DRUG$ prolong and intensify the anticholinergic (drying) effects of @DRUG$.	DDI-effect
The effect of clonazepam on the pharmacokinetics of other medicinal products: @DRUG$ does not appear to alter the pharmacokinetics of phenytoin , carbamazepine , or @DRUG$.	DDI-false
@DRUG$ Adrenergic blockers are inhibited by @DRUG$.	DDI-false
Antiacid, clarithromycin, didanosine, @DRUG$ , Fluoxetine , Indanavir , Ketoconazole , @DRUG$ , phenobarbitol, carbamazepine, rifabutin, rifampin, ritanovir, saquinavir.	DDI-false
Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite doxorubicinol) may be increased when @DRUG$ and @DRUG$ are used in combination.	DDI-mechanism
In pigeons, @DRUG$ did not systematically alter the effects of @DRUG$, (+)-NANM or PCP.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$ , @DRUG$ , and barbiturates , and the antituberculosis drug rifampin .	DDI-false
A similar association, albeit less pronounced, was proposed with barbiturates, @DRUG$ , phenytoin sodium , @DRUG$ , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72 .	DDI-false
- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	DDI-false
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, cyclosporin for injection concentrate and @DRUG$ for injection concentrate) should not be treated with @DRUG$.	DDI-advise
@DRUG$: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (@DRUG$/ARB).	DDI-false
@DRUG$ does not , however , appear to cause increased blood levels of drugs metabolized by CYP3A4 , as it had no effect on @DRUG$ A drug with metabolism very sensitive to C.P.A. inhibition.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as @DRUG$ and procainamide, cardiac glycosides and tricyclic anti-depressants.	DDI-false
@DRUG$: @DRUG$ may delay intestinal absorption of ethosuximide.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
Patients using CYP3A4 metabolized @DRUG$ The Cholesterol level should be @DRUG$ It is initiated to determine whether the statin dose needs to be adjusted.	DDI-advise
Other binding proteins may be increased in serum (i.e., corticosteroid binding globulin ( CBG), sex hormone binding globulin (SHBG), leading to increased overall circulation. @DRUG$ and @DRUG$ , respectively .	DDI-false
Saquinavir: concomitant use of saquinavir (with an experimental soft gelatine capsule formulation of @DRUG$ 1200 mg ) with VIRACEPT resulted in an 18 % increase in @DRUG$ Plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.	DDI-false
@DRUG$: @DRUG$ concentrations are increased by about 15% when digoxin and carvedilol are administered concomitantly.	DDI-false
@DRUG$ : Concomitant administration of aspirin with @DRUG$ may result in an increased risk of GI ulceration and complications compared to valdecoxib alone .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
HMG-CoA reductase inhibitors: @DRUG$ ( CYP3A4 substrate ) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis .	DDI-false
The absorption of @DRUG$, furosemide, @DRUG$, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : @DRUG$ Increases the effect of tricyclic antidepressants	DDI-false
Although @DRUG$ have been shown to reduce @DRUG$-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .	DDI-effect
Theophylline : As with some other quinolones , concurrent administration of @DRUG$ Theophylline may cause increased serum concentrations of @DRUG$ Elongation of elimination half-life.	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with @DRUG$ , @DRUG$ , warfarin , cimetidine and phenobarbital .	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, escitalopram, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Therapeutic concentrations of digoxin, warfarin, @DRUG$, naproxen, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
The effect of @DRUG$ on @DRUG$ clearance has not been studied .	DDI-false
To determine whether @DRUG$ , has a direct influence on the distribution of cloxacillin, the elimination and distribution of @DRUG$ For this reason, six patients, five patients without renal function and one patient with partial renal impairment have been studied in the presence or absence of probenecid.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Both ibogaine and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens , but only @DRUG$ Elevates extracellular serotonin levels in the nucleus accumbens.	DDI-false
These drugs include the thiazides and other @DRUG$ , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$ , calcium channel block drugs, and isoniazid.	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of @DRUG$ may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, @DRUG$), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;	DDI-mechanism
Central nervous system depressants: the concomitant use of DURAGESIC ( @DRUG$ Transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotic agents, sedatives (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$ , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-effect
This seems to be the only clinically relevant interaction of this species with mefloquines, although theoretically, the concomitant use of other drugs is known to alter heart conduction (e.g., @DRUG$ - calcium channel blockers or beta-adrenerg blockers, @DRUG$ Tricyclic antidepressants and phenothiazines can also contribute to the prolongation of the QTc interval.	DDI-false
In both species, @DRUG$, but not (+)-NANM, antagonized the rate-decreasing effects of @DRUG$ on FI and FR responding.	DDI-effect
In clinical trials, the concomitant administration of @DRUG$ and @DRUG$ did not alter the adverse reaction profile.	DDI-false
The following examples are substances that can reduce the blood glucose lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, @DRUG$ , terbutaline ) , @DRUG$ Phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Corticosteroids , @DRUG$ Abs and diuretics: Concomitant treatment with xanthine derivatives, steroids or diuretics may potentiate a possible hypocalemic effect @DRUG$	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenylbutazone , @DRUG$ , carbamazepine , @DRUG$ , topiramate, and possibly ampicillin and tetracycline 72.	DDI-false
Particular caution should be observed with @DRUG$ since there are conflicting results for the effect of colestipol hydrochloride on the availability of @DRUG$ and digitoxin.	DDI-false
Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, @DRUG$, @DRUG$, clarithromycin or amoxicillin.	DDI-false
@DRUG$: Concomitant administration of daptomycin (6 mg/kg once every 24 hours for 5 days) and @DRUG$ (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.	DDI-false
The risk of myopathy during treatment with medicines in this class is increased when cyclosporin is co-administered. @DRUG$ , @DRUG$ ( nicotinic acid ) , erythromycin , azole antifungals .	DDI-false
- @DRUG$ (e.g., @DRUG$) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
@DRUG$: The concomitant administration of ciprofloxacin with the @DRUG$ glyburide has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
The compounds tested in humans include: @DRUG$ , theophylline , phenytoin , diazepam , @DRUG$ and antipyrine .	DDI-false
@DRUG$ and related drugs may decrease arterial responsiveness to @DRUG$.	DDI-effect
Antiacid , @DRUG$ , Didanosine , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , Rifampin , Ritanovir , @DRUG$.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : @DRUG$ ( e.g. , gentamicin , amikacin ) , amphotericin B , @DRUG$ , non-steroidal anti-inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin .	DDI-false
Aspirin: @DRUG$ (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by @DRUG$ (two 81 mg tablets).	DDI-false
Coadministration with @DRUG$ ( 40 mg BID for 7 days ) resulted in a significant increase in dextromethorphan plasma levels suggesting that , at these doses , @DRUG$ ==References====External links==	DDI-false
Serial plasma and urine samples for measurement of amprenavir , @DRUG$ , and rifampin and their @DRUG$ , were measured by high-performance liquid chromatography.	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$ , geschnitztilol, ethanol or @DRUG$.	DDI-false
These drugs include the @DRUG$ and other diuretics , corticosteroids , @DRUG$ , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
@DRUG$ In an interaction study in rheumatoid arthritis patients taking methotrexate, CELEBREX had no significant effect on the pharmacokinetics of @DRUG$.	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
- medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine antimigrain: ergot derivatives antimycobacterial agents: rifampin benzodiazepine midazolam, @DRUG$ GI motility agent: cisapride	DDI-false
Hydrochlorothiazide: In normal volunteers, concomitant administration of @DRUG$ and @DRUG$ resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-mechanism
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with alprazolam for the following: @DRUG$ and paroxetine.	DDI-false
As with other antipsychotic agents, it should be noted that @DRUG$ may be capable of potentiating @DRUG$ such as anesthetics, opiates, and alcohol.	DDI-effect
There was no significant change in prothrombin test results during @DRUG$ and @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
aBased on reports of narcotic withdrawal syndrome in patients treated with @DRUG$ and @DRUG$ concurrently, and evidence of decreased plasma concentrations of methadone.	DDI-effect
Co-administration : Concomitant use of Argatroban with @DRUG$ , thrombolytics , and other @DRUG$ The risk of bleeding can be increased.	DDI-false
@DRUG$ : Patients on @DRUG$ Especially in patients with intravascular volume depletion, excessive blood pressure reduction may occur occasionally after initiation of fosinopril sodium therapy.	DDI-false
Nephrotoxicity following concomitant administration of @DRUG$ and @DRUG$.	DDI-effect
@DRUG$   may interact with drugs known to interact with the conventional formulation of @DRUG$.	DDI-false
No important interactions to date @DRUG$ There are no clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$ , warfarin , isosorbide mononitrate , carvedilol , ethanol or itraconazole .	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and @DRUG$  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free @DRUG$.	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, @DRUG$ , @DRUG$ , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin , warfarin , @DRUG$ , clarithromycin or @DRUG$.	DDI-false
â€¢ Rifampin: concomitant use of @DRUG$ and @DRUG$ This resulted in an 82% decrease in nelfinavir plasma A.C.	DDI-mechanism
The AUC and Cmax of both the (R) and (S) isomers of @DRUG$ were unaffected by concurrent dosing of 0.3 mg @DRUG$.	DDI-false
Antidepressants : In vitro data suggest that @DRUG$ inhibits the metabolism of cisapride , which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG .	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with griseofulvin, @DRUG$, and tetracyclines (72)	DDI-false
Valproate : The addition of tiagabine to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics , but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8 % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .	DDI-false
Agents Causing Renin Release : The antihypertensive effect of @DRUG$ Enalapril IV is enhanced by antihypertensive agents that cause the release of renin (e.g. @DRUG$ ) .	DDI-effect
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., @DRUG$]) or	DDI-false
Terfenadine: Administration of @DRUG$ with VIRACEPT resulted in the appearance of unchanged @DRUG$ in plasma;	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, @DRUG$, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
When the STADOL NS was administered 30 minutes after the @DRUG$ nasal spray, the AUC of @DRUG$ increased 11% and Cmax decreased 18%.	DDI-false
However, no harmful interactions were seen when: @DRUG$ was administered after @DRUG$ Inhalation anesthetics, muscle relaxants and muscle relaxant antagonists are administered in combination with sedation or anesthesia.	DDI-false
@DRUG$ : @DRUG$ Toxicity has been reported in patients receiving lithium concomitantly with medicinal products that cause the excretion of sodium, including ACE inhibitors.	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	DDI-false
Magnesium- and/or @DRUG$-containing @DRUG$, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
@DRUG$ ( @DRUG$ BROVANA and BROVANA may affect each other when administered at the same time.	DDI-false
Although these results do not indicate a significant interaction between @DRUG$ and @DRUG$ or heparin, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat may be due to discontinuation of @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
@DRUG$: Amiodarone, bepridil, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , @DRUG$ , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic antidepressants , lidocaine , theophylline and @DRUG$ This delays elimination and increases blood levels of these drugs.	DDI-false
Several drug interaction studies have been completed with both @DRUG$ and @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
However , neither @DRUG$ Also, diazepam does not seem to affect @DRUG$ metabolism .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-advise
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , @DRUG$ , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and @DRUG$.	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	DDI-false
@DRUG$ ( 400 mg b.i.d . ) had no effect on vardenafil bioavailability ( AUC ) and maximum concentration ( Cmax ) of @DRUG$ When co-administered with 20 mg vardenafil in healthy volunteers.	DDI-false
Possible drug interactions between Keppra and other AEDs (carbamazepine, @DRUG$ , lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also evaluated by estimating the serum concentrations of levetiracetam and these @DRUG$ â€¢ during placebo-controlled clinical trials.	DDI-false
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	DDI-false
Curariform muscle relaxants (e.g., @DRUG$ ) and other drugs , including ether , @DRUG$ , gallamine , decamethonium and sodium citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral .	DDI-false
The effects of the simultaneous @DRUG$ administration on the steady-state pharmacokinetics of @DRUG$.	DDI-false
Sedatives/@DRUG$: @DRUG$, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Therefore, when meclofenamate sodium is given to a patient receiving @DRUG$, the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-false
Acidifying agents : Gastrointestinal acidifying agents ( guanethidine , @DRUG$ , glutamic acid HCl , ascorbic acid , fruit juices , etc . ) lower absorption of @DRUG$.	DDI-mechanism
In chronic hepatitis C patients treated with @DRUG$ in combination with @DRUG$ Treatment with PEGASYS did not affect the distribution or clearance of ribavirin.	DDI-false
Although there is no interaction between @DRUG$ and @DRUG$ has been observed , it is not recommended for use with MAO inhibitors .	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
@DRUG$ or Oral @DRUG$: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.	DDI-false
In particular, convulsions have been reported when @DRUG$ is administered with @DRUG$ and special care should be taken when the treatment regimen includes both of these drugs.	DDI-effect
MAO Inhibitors : @DRUG$   is not recommended for use in patients who have received @DRUG$ Within 14 days severe and unforeseeable potentiation by MAO inhibitors in opioid analgesics has been reported.	DDI-advise
The possibility of hypotensive effects with @DRUG$ The treatment can be done by stopping the diuretic or increasing the intake of salt about one week before starting treatment with @DRUG$ (Captopril tablets, USP) or initiation of small doses (6.25 or 12.5 mg).	DDI-false
Administration of @DRUG$ concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone.	DDI-false
Clidinium may decrease the effect of @DRUG$ , @DRUG$ , and ketoconazole .	DDI-false
Other drugs that inhibit the neuromuscular blocking effect of non-depolarizing substances such as e.g. @DRUG$ These include certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local @DRUG$ , procainamide , and quinidine .	DDI-effect
Potassium-sparing diuretics (e.g. @DRUG$ , @DRUG$ , or amiloride ) , potassium supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ : Since both @DRUG$ and tetracyclines can cause increased intracranial pressure , their combined use is contraindicated .	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent @DRUG$ such as furosemide.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , @DRUG$ , @DRUG$ , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
@DRUG$ " should not be used at the same time as @DRUG$ because of the possibility of ototoxicity .	DDI-advise
Indinavir: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in @DRUG$ plasma A.C.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or beta-adrenergic blocking agents , calcium channel blockers , antihistamines or H1-blocking agents , @DRUG$ and @DRUG$ ) might also contribute to a prolongation of the QTc interval .	DDI-false
@DRUG$: It has not been established if there is a pharmacokinetic interaction between acitretin and @DRUG$.	DDI-false
Corticosteroids and @DRUG$ ( @DRUG$ ): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction .	DDI-false
In Study 1, patients with colorectal cancer were given irinotecan/@DRUG$/@DRUG$ (bolus-IFL) with or without AVASTIN.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.	DDI-false
Although inhibition of CYP 3A4/5 by @DRUG$ and @DRUG$ It occurred at high concentrations, it is probably not of clinical importance.	DDI-false
These increased exposures of norethindrone and @DRUG$ The choice of an oral contraceptive for women under @DRUG$ should be considered.	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including @DRUG$ , with multivalent cation-containing products such as magnesium or @DRUG$ Antacids, sucralfate, VIDEX chewable tablets or paediatric powders or products containing calcium, iron or zinc may significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-mechanism
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	DDI-false
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without @DRUG$ The AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the oral disintegrating tablet was administered with propanthelin compared to the single dose.	DDI-mechanism
Antibiotics: In vitro and/or in vivo data show that @DRUG$, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ And other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$ , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
Other medicinal products Interactions: No pharmacokinetic interactions between vardenafil and the following medicinal products have been observed: @DRUG$ , warfarin , digoxin , Maalox , and @DRUG$.	DDI-false
Co-medicines that induce CYP3A4 (e.g. @DRUG$ , phenytoin, carbamazepine, @DRUG$ , phenobarbital or St.	DDI-false
Patients receiving other @DRUG$s , general @DRUG$ , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic antidepressants or other CNS depressants ( including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression .	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, @DRUG$, @DRUG$, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Tetracyclines : Concomitant treatment with @DRUG$ Tetracyclines and tetracyclines should be avoided because: @DRUG$ use has been associated with a number of cases of pseudotumor cerebri ( benign intracranial hypertension ) , some of which involved concomitant use of tetracyclines	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with CNS depressants ( alcohol , barbiturates , opiates , @DRUG$ , anesthetics ) should be considered .	DDI-advise
May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Interaction of @DRUG$ with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, @DRUG$, @DRUG$, and increased toxicity.	DDI-false
No Important Interactions To Date @DRUG$ No clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$ , isosorbide mononitrate , carvedilol , ethanol or itraconazole .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , @DRUG$ , danazol, diuretics, @DRUG$ E. g. epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e. g. in oral contraceptives).	DDI-false
Medicines associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$ , gold , @DRUG$ , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	DDI-effect
@DRUG$ may interact with any of the following: - Acetaminophen (e.g., @DRUG$) (with long-term, high-dose use) or	DDI-int
Micro-dosed Progesterone Preparations: Micro-dosed @DRUG$ preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during @DRUG$ therapy.	DDI-effect
@DRUG$ ) and many that are substrates for P450 2D6 ( many other antidepressants , phenothiazines , and the Type 1C antiarrhythmics propafenone and @DRUG$ ) .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$ , acetylsalicylic acid , a-blockers , analgesics , @DRUG$ , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Antidepressants ( tricyclic ) , @DRUG$ or other @DRUG$ Co-administration with arbutamine may lead to additive inotropic and/ or chronotropic effects.	DDI-false
Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Cardiovasculars: Cardiac glycosides: In patients receiving @DRUG$ therapy, administration of oral @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an @DRUG$ containing @DRUG$ and magnesium.	DDI-false
Limited clinical data in angina patients @DRUG$ and @DRUG$ The therapy does not indicate any apparent changes in serum digoxin levels.	DDI-false
The co-administration of Natrecor with IV vasodilators such as @DRUG$, @DRUG$, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
@DRUG$: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI   and concomitant interferon beta-1a ( AVONEX   30 mcg IM once weekly ) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or @DRUG$.	DDI-false
@DRUG$ â€¢ Interchanges may include alcohol, blood thinners, decongestant medications (allergic, cold, and sinus drugs), diabetes medications, lithium, norepinephrine, @DRUG$ Such as Aleve or ibuprofen, and high blood pressure medications.	DDI-int
Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of Gleevec, increased @DRUG$ oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
However, it affected the duration of response, suggesting that: @DRUG$ It should not be used with HEXALEN and/or @DRUG$.1.	DDI-advise
@DRUG$ : A single 10 mg dose of @DRUG$ did not affect the pharmacokinetics of theophylline at steady state .	DDI-false
@DRUG$ Amphetamines increase the adrenergic effect of @DRUG$.	DDI-false
Other drugs : Drugs like @DRUG$ , @DRUG$ , procainamide , phenothiazines , antihistamines , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
- Poor Metabolisers of Schuttoquin : Interactions of @DRUG$ with strong inhibitors of CYP2D6 ( such as quinidine , fluoxetine , paroxetine , and @DRUG$ ) have not been studied , but these drugs would be expected to increase blood levels of the R(+ ) enantiomer of carvedilol .	DDI-false
Like @DRUG$ ( 40 mg/kg ) , @DRUG$ 40 mg/kg) decreases intravenous self-administration of morphine and cocaine and oral self-administration of ethanol and nicotine in rats;	DDI-false
Multivalent Cation-Containing products: co-administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing @DRUG$ Iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-false
A study in eight healthy volunteers has shown a 50% increase in mean peak @DRUG$ plasma concentrations and a 90% increase in mean area under the curve, after a one week course of @DRUG$ at 1,000 mg/day and nimodipine at 90 mg/day.	DDI-false
@DRUG$ may block the antihypertensive action of @DRUG$ and similarly acting compounds.	DDI-effect
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Concurrent administration of @DRUG$ and @DRUG$ may result in elevated serum levels of oxyphenbutazone .	DDI-mechanism
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Based on known metabolic profiles, clinically relevant drug interactions between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or @DRUG$ are not expected.	DDI-false
The co-administration of Natrecor with IV @DRUG$ such as nitroglycerin, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Naproxen: The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-mechanism
Drugs which inhibit CYP 3A4 ( e.g. , ketoconazole , macrolide antibiotics such as @DRUG$ ) have the potential to result in increased plasma concentrations of @DRUG$.	DDI-mechanism
Clinical trials with celecoxib may have significant interactions with @DRUG$ and @DRUG$.	DDI-false
The concomitant use of Natrecor with IV vasodilators such as @DRUG$ Nitroprusside, milrinone or IV ACE inhibitors have not been studied (these medicinal products have not been co-administered with @DRUG$ in clinical trials ) .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , @DRUG$ , lincomycin , clindamycin , colistin , and sodium colistimethate ) , @DRUG$ Salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
Coadministration of @DRUG$ and potent CYP3A4 inhibitor @DRUG$ The result (400 mg q.d. for 3 days) was an approximately 60% increase in area under the plasma concentration-time curve and the maximum plasma concentrations of almotriptan.	DDI-mechanism
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , @DRUG$ , @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Ritonavir and indinavir: Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID ritonavir, the Cmax and AUC of @DRUG$ were reduced by approximately 20%.	DDI-false
In addition, additional interaction studies with: @DRUG$ and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels , and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data .	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, @DRUG$, narcotics, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Drug interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupentixol and @DRUG$ Cause additive CNS depression - Tricyclic antidepressants : @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$ , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$ ==References====External links==	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
In a phase I study in which escalating doses of TAXOL ( 110 - 200 mg/ m2 ) and cisplatin ( 50 or 75 mg/ m2 ) were administered as sequential infusions, myelosuppression was lower than TAXOL after @DRUG$ , than with the alternative sequence (i.e., @DRUG$ Before cisplatin).	DDI-false
There is a significant increase in exposure to @DRUG$ When Gleevec is co-administered with @DRUG$ ( CYP3A4 inhibitor ) .	DDI-false
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (@DRUG$, thiothixene, alprazolam).	DDI-false
Effect of @DRUG$ on the apparent volume of distribution and elimination of @DRUG$.	DDI-false
Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$ , signs and symptoms of @DRUG$ toxicity should be monitored closely , and appropriate dosage adjustment of the anticonvulsant should be made .	DDI-false
@DRUG$: Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of @DRUG$ in serum.	DDI-false
@DRUG$: Etodolac has no apparent pharmacokinetic interaction when administered with furosemide or @DRUG$.	DDI-false
@DRUG$ and @DRUG$ interact pharmacologically with orally administered anticoagulant agents , but the effect is not clinically significant .	DDI-false
@DRUG$ and @DRUG$: Increased prothrombin time, with or without clinical bleeding, has been reported when cefixime is administered concomitantly.	DDI-false
@DRUG$: The concomitant administration of diflunisal and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	DDI-false
Although the occurrence has not been reported with @DRUG$ Nephrotoxicity following concomitant administration of @DRUG$ and aminoglycosides .	DDI-false
Although these results do not indicate a significant interaction between @DRUG$ and warfarin or heparin, the administration of TORADOL to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
In vitro and/or in vivo data indicate that: @DRUG$ , itraconazole , and oral @DRUG$ Remarkably, inhibit the metabolism of cisaprid, which may lead to an increase in plasma cisaprid levels and prolongation of the QT interval on the ECG.	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents (efavirenz, @DRUG$ or @DRUG$).	DDI-false
In addition, certain drugs that are metabolized by this isoenzyme, including many @DRUG$ (@DRUG$, selective serotonin reuptake inhibitors, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.	DDI-false
Ergot Derivatives: @DRUG$, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
CONCLUSIONS : Macrolide antibiotics inhibit the metabolism of @DRUG$ Metabolised by CYP3A4 (i.e. atorvastatin, cerivastatin, @DRUG$ ==References====External links==	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin, nicotinic acid, sympathomimetics, @DRUG$ ==References====External links==	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-effect
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ Insufficient magnesium intake, which requires only oral physiological supplement and magnesium deficiency, with a dysregulation of the control mechanisms of @DRUG$ Status that requires more or less specific regulation of its causal dysregulation.	DDI-false
There have been more than 2-fold increases in plasma levels of other antidepressants, including: @DRUG$ , when @DRUG$ has been administered in combination with these agents .	DDI-mechanism
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of Nalfon , the concomitant use of Nalfon and @DRUG$ is not recommended .	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
Imidazoles (e. g., ketoconazole, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
Antiarrhythmics : Other @DRUG$ drugs , such as quinidine , @DRUG$ ==References====External links==* Official website* Official website	DDI-false
On administration of oral @DRUG$ , the need for @DRUG$ Treatment should be reviewed and the dose reduced or discontinued by approximately 50%.	DDI-advise
@DRUG$ : @DRUG$ Plasma concentrations and LDL-C reduction were not altered by co-administration of cimetidine.	DDI-false
Administration of @DRUG$ during therapy with a @DRUG$ has been shown to produce a   stimulating   effect in some depressed patients .	DDI-effect
Cardiac effects of dopamine are antagonized by @DRUG$, such as propranolol and @DRUG$.	DDI-false
These drugs include thiazides and other @DRUG$ , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$ , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on cisapride absorption when it is coadministered with @DRUG$.	DDI-false
In clinical trials , @DRUG$ was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ On the second day of therapy, apparent values for oral clearance of furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13 % and 15 % respectively and were returned to baseline by day 87.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, @DRUG$, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Interactions with mixed agonists/antagonists opioid analgesics : agonists/antagonists analgesics (e.g. pentazocin, nalbuphine, @DRUG$ , @DRUG$ It should NOT be given to a patient who has received or received therapy with a pure agonist opioid analgesics such as levo-dromorane.	DDI-false
@DRUG$ Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ and @DRUG$ are not .	DDI-false
@DRUG$/Aluminum-containing Antacid Products : Absorption of zalcitabine is moderately reduced ( approximately 25 % ) when coadministered with magnesium/aluminum-containing @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
Antidepressants , @DRUG$ Amphetamines may enhance the activity of @DRUG$ sympathomimetics;	DDI-false
Probenecid: As with other @DRUG$, the renal excretion of cephalexin is inhibited by @DRUG$.	DDI-false
Example inhibitors include @DRUG$, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics : amiodarone , quinidine @DRUG$ Astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampine Benzodiazepines Midazolam, triazolam GI Motility agent: cisaprid	DDI-advise
In vitro data suggest that @DRUG$, when compared to ketoconazole, has a less pronounced effect on the biotransformation system responsible for the metabolism of @DRUG$.	DDI-mechanism
Nonsteroidal Anti-Inflammatory Drugs : The administration of diflunisal to normal volunteers receiving @DRUG$ Elevated renal clearance and significantly increased plasma levels of @DRUG$.	DDI-false
Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-effect
Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of @DRUG$ (40 mg BID) for 12 days, while plasma exposure of @DRUG$ (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.	DDI-false
BACKGROUND : The effects of combined administration of @DRUG$ and @DRUG$ ( verapamil ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
Although no specific drug interactions with topical glaucoma or systemic medications have been identified in clinical studies, there has been an increase in the incidence of adverse drug reactions. @DRUG$ 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with CNS depressants ( @DRUG$ , barbiturates, opiates, sedatives, anaesthetics) should be considered.	DDI-advise
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (@DRUG$), erythromycin, azole antifungals.	DDI-false
Lithium : In a study conducted in healthy subjects , mean steady-state @DRUG$ Plasma levels increased in patients who: @DRUG$ 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone .	DDI-false
Other reported interactions with amiodarone: @DRUG$ (CYP3A4 substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
In vitro studies indicate that @DRUG$ â€¢ does not inhibit P-glycoprotein-mediated transport of @DRUG$ The ertapenem is not a substrate for P-glycoprotein-mediated transport.	DDI-false
Acetaminophen, lidocaine, @DRUG$, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
This drug may interact with alcohol or other @DRUG$ (may increase the CNS depressive effects of either these drugs or antihistamines), anticholinergics or other anticholinergic drugs (anticholinergic effects may be increased if these drugs are used concomitantly with antihistamines), and @DRUG$ ( concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ) .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , @DRUG$ H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as @DRUG$ In addition, quinolones anti-infections with no evidence of clinically significant adverse interactions.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, @DRUG$, opiates, sedatives, anesthetics) should be considered.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , @DRUG$ Cisplatin, Dapson, @DRUG$ , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Theophylline: The pharmacokinetics of @DRUG$ (@DRUG$ 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.	DDI-false
@DRUG$ (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of @DRUG$ when co-administered with 20 mg Vardenafil in healthy volunteers.	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , @DRUG$ (e.g. in oral contraceptives).	DDI-false
@DRUG$: Concomitant administration of low-dose aspirin with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
Use with @DRUG$ : The use of angiotensin converting enzyme inhibitors to control hypertension in patients on @DRUG$ has been reported to induce severe leukopenia .	DDI-false
MAO inhibitors @DRUG$ , as well as a metabolite of furazolidone , slow @DRUG$ metabolism .	DDI-mechanism
The compounds tested in humans include warfarin, @DRUG$ , phenytoin , @DRUG$ , aminopyrine and antipyrine .	DDI-false
Single doses of any of the following doses: @DRUG$ or colestipol @DRUG$ Bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent respectively.	DDI-false
The steady-state plasma concentrations of @DRUG$ It has been reported that desipramine is co-administered with @DRUG$ Tablets at doses up to 4 mg/ day.	DDI-mechanism
Magnesium and/or aluminium antacids, iron sulphate products, multivitamin preparations containing zinc or other metal cations; or @DRUG$ ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
In some patients , the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic , natriuretic , and antihypertensive effects of @DRUG-DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , @DRUG$ , metronidazole , @DRUG$ , phenytoin , ribavirin , and vincristine .	DDI-false
Other medicines: medicines such as quinidine, @DRUG$ , procainamide , @DRUG$ , antihistamines and tricyclic antidepressants may be associated with QT interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$ - prior ingestion of diphenidol may decrease the @DRUG$ response to apomorphine in the treatment of poisoning .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe , prolonged hypertension .	DDI-false
Antiacid , @DRUG$ , Didanosine , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , @DRUG$ , Ritanovir , Saquinavir .	DDI-false
The availability of potent @DRUG$ NNRTI-based antiretroviral therapy regimens and concerns about protease inhibitor (@DRUG$)-related metabolic disorders have led to significant shifts in treatment practices in HIV infection.	DDI-false
Promethazine: Coadministration of a single dose of @DRUG$ and @DRUG$ (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.	DDI-mechanism
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , @DRUG$ Fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$ Somatostatin analogue (e.g. octreotide), sulphonamide antibiotics.	DDI-false
When NovoLog is mixed with @DRUG$ , @DRUG$ The syringe should be drawn into the syringe first.	DDI-false
@DRUG$: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Coadministration of @DRUG$ ( 40 mg BID ( day 1 ) and 40 mg QD ( days 2 - 7 ) ) with @DRUG$ 5 mg QD) does not affect the pharmacokinetics (exposure) or pharmacodynamics (blood glucose and insulin levels) of glyburide.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been used in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, @DRUG$ , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , @DRUG$ , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Rifampin: Coadministration of @DRUG$ and @DRUG$ resulted in an 82% decrease in nelfinavir plasma A.C.	DDI-mechanism
No pharmacokinetic interactions between dexmedetomidine and @DRUG$ , propofol , alfentanil , and @DRUG$ have been demonstrated .	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , @DRUG$ , isoniazid, nefazodon, @DRUG$ , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
@DRUG$: There is no significant pharmacokinetic interaction between @DRUG$ and zalcitabine which has been confirmed clinically.	DDI-false
Corticosteroids , @DRUG$ â€¢ diuretics: concomitant treatment with @DRUG$ , steroids , or diuretics may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
Naproxen : The concomitant administration of diflunisal and @DRUG$ This did not affect Naproxen plasma levels in normal subjects, but significantly reduced the urinary excretion of Naproxen. @DRUG$ and its glucuronide metabolite .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, @DRUG$, @DRUG$, and ranitidine.	DDI-false
In the presence of these methylxanthines, larger doses of @DRUG$ may be required or @DRUG$ may not be effective.	DDI-false
Aspirin: Concomitant administration of @DRUG$ with valdecoxib may result in an increased risk of GI ulceration and complications compared to @DRUG$ alone.	DDI-false
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of @DRUG$ and @DRUG$ (INN, ciclosporin) when coadministered in de novo kidney allograft recipients during the first year after transplantation.	DDI-false
Possible drug interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$ , phenytoin , @DRUG$ In placebo-controlled clinical trials, serum concentrations of levetiracetam and these AEDs have also been studied.	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of @DRUG$, oral vitamin B-12, @DRUG$ and 5-fluorouracil.	DDI-false
Possible interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ The serum concentrations of valproate and valproate have also been studied by @DRUG$ These AEDs during placebo-controlled clinical trials.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , @DRUG$ , thyroid hormones , estrogens , @DRUG$ ( e.g. , in oral contraceptives ) .	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants , @DRUG$ , alcohol , @DRUG$ , monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic drugs, or other drugs that produce CNS depression.	DDI-false
@DRUG$ The bioavailability is slightly reduced (about 10%) when zalcitabine and @DRUG$ are coadministered .	DDI-false
These increased exposures of @DRUG$ and ethinyl estradiol should be taken into consideration when selecting an oral contraceptive for women taking @DRUG$.	DDI-false
gastrointestinal acidifying agents ( guanethidine, reserpine, @DRUG$ , ascorbic acid , fruit juices , etc . ) lower absorption of @DRUG$.	DDI-mechanism
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$ , quinidine , and @DRUG$.	DDI-false
Adequate monitoring of @DRUG$ plasma concentrations should be considered when therapy with VIOXX is initiated or changed in patients receiving @DRUG$.	DDI-false
Concomitant administration of @DRUG$ ( equivalent to 145 mg TRICOR ) with @DRUG$ ( 20 mg ) once daily for 10 days resulted in approximately 17 % decrease ( range from 67 % decrease to 44 % increase ) in atorvastatin AUC values in 22 healthy males .	DDI-mechanism
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Patients in a clinical study who were on established therapy with sulfasalazine, to which @DRUG$ was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or sulfasalazine alone.	DDI-false
Loratadine ( 10 mg once daily ) has been coadministered with therapeutic doses of erythromycin , @DRUG$ , and @DRUG$ in controlled clinical pharmacology studies in adult volunteers .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without @DRUG$ (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of @DRUG$ was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
@DRUG$: Valdecoxib 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to @DRUG$ alone.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
Study results in patients with multiple sclerosis, TYSABRI and concomitantly @DRUG$ ( AVONEX   30 mcg IM once weekly ) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$ , @DRUG$ , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, @DRUG$, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
Interaction with @DRUG$, @DRUG$ and theophylline has also been reported to produce adverse clinical effects.	DDI-false
Methotrexate Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of @DRUG$.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of @DRUG$.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	DDI-false
However, the impact of the @DRUG$ on travelers receiving comedication , particularly diabetics or patients using @DRUG$ , should be checked before departure .	DDI-advise
Psychoactive Drugs : Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs ( fluoxetine , @DRUG$ , alprazolam ) .	DDI-effect
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	DDI-mechanism
Potential drug interactions between: @DRUG$   and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , @DRUG$ In placebo-controlled clinical trials, serum concentrations of levetiracetam and these AEDs have also been studied.	DDI-false
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine @DRUG$ : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : @DRUG$	DDI-false
@DRUG$: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving @DRUG$ 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.	DDI-false
@DRUG$: Because corticosteroids may increase blood glucose concentrations, dosage adjustments of @DRUG$ may be required.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
In a study in which patients with active RA were treated with concomitant treatment for up to 24 weeks @DRUG$ A 7% rate of serious infections was observed in etanercept treatment, which was higher than in etanercept treatment. @DRUG$ Alone ( 0% ).	DDI-false
Aminosalicylic acid may decrease the amount of digoxin (@DRUG$, @DRUG$) that gets absorbed into your body.	DDI-false
Co-medicines that induce CYP3A4 (e.g. dexamethasone, @DRUG$ , @DRUG$ , rifampin, phenobarbital or St.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Effects of @DRUG$ About other antiepilepsia drugs ( AEDs ) : phenytoin : @DRUG$ This did not affect steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
@DRUG$ ) and many that are substrates for P450 2D6 ( many other antidepressants , @DRUG$ , and the type 1C antiarrhythmics propafenone and flecainide).	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , pentazocine , @DRUG$ , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ Like Levo-Dromoran.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Other @DRUG$ (e.g. barbiturates, @DRUG$ , opioids and general anesthetics ) have additive or potentiating effects with INAPSINE .	DDI-false
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , chloral hydrate and @DRUG$ It has been systematically studied in 16 patients who: @DRUG$ therapy .	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Antihypertensives : @DRUG$ Propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and @DRUG$ , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be able to: @DRUG$ such as anesthetics , opiates , and @DRUG$.	DDI-false
Patients who begin taking @DRUG$ or who increase their diclofenac dose or any other @DRUG$ while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-false
Plasma levels of several closely related @DRUG$ It has been reported that the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g. cimetidine, fluoxetine) has been increased and decreased by the concomitant administration of hepatic enzyme inducers (e.g. barbiturates, phenytoin), and such an effect may be associated with: @DRUG$ as well .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$ , @DRUG$ And metronidazole, which delays the elimination and increase in blood levels of these drugs.	DDI-false
During transfer to oral @DRUG$, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral @DRUG$.	DDI-false
- @DRUG$ (e.g., AquaMEPHYTON, Synkayvite) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the blood	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
Co-medications that induce CYP3A4 ( e.g. , dexamethasone , phenytoin , carbamazepine , @DRUG$ , @DRUG$ or St.	DDI-false
In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to @DRUG$ and @DRUG$, respectively.	DDI-false
@DRUG$, bepridil, @DRUG$, and terodiline.	DDI-false
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
Possible interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, @DRUG$ , and @DRUG$ In clinical trials, substrates and/or inhibitors of CYP3A4 have not been studied.	DDI-false
The steady state plasma concentrations of imipramine and @DRUG$ have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of @DRUG$ tablets in doses up to 4 mg/day.	DDI-mechanism
The absorption of tetracycline, furosemide, penicillin G, @DRUG$ , and gemfibrozil has been significantly reduced if concomitantly with @DRUG$ ;	DDI-mechanism
Both @DRUG$ and its major metabolite, @DRUG$, are inhibitors of the cytochrome P450 3A4 enzyme system.	DDI-false
Antimycobacterial Agents : rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an @DRUG$ regimen reduces the plasma concentrations of saquinavir .	DDI-false
While all the @DRUG$ (@DRUG$), e.g., fluoxetine, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or Bezalip retard is impaired	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
- Decreased concentrations of anti-factor Xa and @DRUG$ , decreased @DRUG$ activity ;	DDI-false
Verapamil: Coadministration of @DRUG$ and @DRUG$ resulted in a 24% increase in plasma concentrations of almotriptan.	DDI-mechanism
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
Benzylpenicillin , ampicillin , oxacillin , chlortetracycline , doxycycline , @DRUG$ , erythromycin , and @DRUG$ In vitro does not affect the protein binding of diclofenac in human serum.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -@DRUG$ blocking agents ( e.g. , propranolol , a @DRUG$ Inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
In addition , @DRUG$ and MHD induce a subgroup of the cytochrome P450 3A family ( CYP3A4 and CYP3A5 ) responsible for the metabolism of dihydropyridine calcium antagonists and oral @DRUG$ , resulting in a lower plasma concentration of these drugs .	DDI-false
" Medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, @DRUG$ , cisplatin , @DRUG$ , disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ : Valdecoxib 10 mg BID did not show a significant effect on the plasma exposure or renal clearance of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Aspirin: Concomitant administration of low-dose @DRUG$ with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	DDI-false
OBJECTIVE : Our objective was to characterize the steady-state pharmacokinetics of @DRUG$ Cyclosporin and cyclosporin (INN, @DRUG$ ) when co-administered in de novo renal allograft recipients in the first year after transplantation.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Nifedipine: @DRUG$ 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of @DRUG$, a drug that is metabolized via CYP3A4.	DDI-false
When @DRUG$ is co-administered with @DRUG$, anticoagulation levels should be monitored frequently.	DDI-advise
Acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen and valproic acid/phenobarbital.	DDI-false
@DRUG$ ( eg , tubocurarine ) and other drugs , including ether , succinylcholine , @DRUG$ , decamethonium and sodium citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral .	DDI-false
No data are available for the coadministration of @DRUG$/ritonavir or @DRUG$/ritonavir and garlic capsules .	DDI-false
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with @DRUG$ for the following: sertraline and paroxetine.	DDI-false
Compounds in these categories result in a decreased efficacy of @DRUG$: phenothiazines, haloperidol, metoclopramide, @DRUG$.	DDI-effect
@DRUG$: In diabetic patients receiving diflunisal and @DRUG$, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	DDI-false
Coadministration of almotriptan and the potent CYP3A4 inhibitor @DRUG$ ( 400 mg q.d . for 3 days ) resulted in an approximately 60 % increase in the area under the plasma concentration-time curve and maximal plasma concentrations of @DRUG$.	DDI-false
Multivalent Cation-Containing products: Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, sucralfate, VIDEX chew/buffer tablets or child powder, or products containing calcium, iron or @DRUG$ The absorption of @DRUG$ , which leads to serum and urine levels significantly lower than desired.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , @DRUG$ , @DRUG$ ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
@DRUG$ Patients receiving @DRUG$ should not receive glutethimide treatment.	DDI-advise
@DRUG$ : @DRUG$ The analgesic effect of meperidine is enhanced.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
As with some other non-depolarizing neuromuscular blocking agents, the time of onset of the neuromuscular block is induced by @DRUG$ is lengthened and the duration of block is shortened in patients receiving phenytoin or @DRUG$.	DDI-effect
- When @DRUG$ or Bezalip retard is used concurrently with anion-exchange resins (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	DDI-advise
" Medicinal products not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, @DRUG$ Antimigraine : @DRUG$ Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
@DRUG$ , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of @DRUG$ , phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline, and metronidazole, delaying the elimination and increase in blood levels of these drugs.	DDI-mechanism
@DRUG$ (tricyclic), @DRUG$ or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Special care should be taken when administering @DRUG$ In cases of mixed medication overdose, since the toxic effects (such as cramps and cardiac arrhythmias) of other medicines taken during overdose (especially cyclic antidepressants) may occur with the reversal of the benzodiazepine effect by @DRUG$.	DDI-false
Vaccines: Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and @DRUG$ due to inhibition of antibody response.	DDI-effect
Plasma exposure (AUC) to valdecoxib was increased 62% when coadministered with @DRUG$ and 38% when coadministered with @DRUG$.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ ( such as loop or thiazide diuretics ) can be acutely worsened by @DRUG$ , especially when the recommended dose of the beta-agonist is exceeded .	DDI-effect
Magnesium/@DRUG$-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.	DDI-false
The in vitro interaction between nevirapine and the @DRUG$ @DRUG$ is complex.	DDI-false
(1968, 1970), the higher serum concentrations of penicillins and @DRUG$ reached after administration of @DRUG$ are due not only to slower renal elimination but also to an altered distribution in the body.	DDI-mechanism
Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, @DRUG$ , felodipine, digoxin, warfarin, isosorbide mononitrate, schnitztilol, ethanol or @DRUG$.	DDI-false
These data indicate that levetiracetam does not influence the plasma concentration of other @DRUG$ and that these AEDs do not influence the pharmacokinetics of @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
* Blood sampling for the pharmacokinetics of @DRUG$ and @DRUG$ was performed on day 1 , on weeks 1 , 2 , 3 , and 4 , and on months 2 , 3 , 6 , 9 , and 12 .	DDI-false
@DRUG$ and @DRUG$ similarly inhibit and stimulate EGF- or insulin-induced proliferation of prostatic epithelium .	DDI-false
@DRUG$ : Coadministration of single doses of @DRUG$ 3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction .	DDI-false
@DRUG$ : Because of the relationship of Accutane to vitamin A , patients should be advised against taking vitamin supplements containing @DRUG$ to avoid additive toxic effects	DDI-false
Acetaminophen, lidocaine, phenobarbital, @DRUG$, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
Microdosed minipill @DRUG$ preparations are not recommended for use with @DRUG$.	DDI-advise
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , @DRUG$ , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, antiemetics, @DRUG$, tranquilizers).	DDI-false
Drugs That Induce CYP3A4 @DRUG$: CYP3A4 is ordinarily a minor metabolizing enzyme of @DRUG$.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
Treatment with CYP3A4 inhibitors (e.g. @DRUG$ , intraconazole , @DRUG$ , indinavir , saquinavir , erythromycin , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
Protein Binding In vitro, @DRUG$ interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or @DRUG$.	DDI-mechanism
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Interaction of @DRUG$ with Other Drugs : Cimetidine : Co-administration of @DRUG$ 800 mg/ day) did not affect the pharmacokinetics of tiagabin in patients chronically receiving tiagabin.	DDI-false
Plasma valproate concentration should be monitored when @DRUG$ and @DRUG$ are co administered, and appropriate dosage adjustments of valproate should be made.	DDI-advise
Physiological oral @DRUG$ load constitutes the best tool for diagnosis of @DRUG$ deficiency and the first step of its treatment.	DDI-false
In clinical trials , @DRUG$ was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ The apparent values for oral clearance of furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13% and 15% respectively on the second day of therapy and were returned to baseline by day 87.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, sedatives, anesthetics) should be considered.	DDI-advise
@DRUG$ A drug interaction study of eplerenone with an NSAID has not been performed.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenously] @DRUG$ (e.g. tobramycin, gentamicin and amikacin), @DRUG$ , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-false
@DRUG$ ( but not @DRUG$ ): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies .	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetic agents, ACE inhibitors, @DRUG$ , fibrates , fluoxetine , @DRUG$ Propoxyphene, salicylates, somatostatin analogue (e.g. octreotide), sulphonamide antibiotics.	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients who are receptor blockers (e.g. propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate, and @DRUG$ , a @DRUG$ inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , @DRUG$ , digoxin , warfarin , @DRUG$ ==References====External links==	DDI-false
Co-administration of either intravenous or oral methylxanthines (e.g. aminophylline, @DRUG$ Patients who: @DRUG$ The evaluation has not yet been completed.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ Amphetamines may delay the intestinal absorption of @DRUG$.	DDI-false
@DRUG$ Elevates the enerohepatic elimination of @DRUG$ There may be a reduction in serum levels and t1/2.	DDI-false
Additional drugs that are not recommended for coadministration with @DRUG$ and @DRUG$ are included below.	DDI-false
Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, @DRUG$ for injection concentrate and @DRUG$ for injection concentrate) should not be treated with TAXOL.	DDI-false
The blood pressure effect of SULAR tended to be greater in patients on @DRUG$ than in patients on no other @DRUG$ therapy.	DDI-false
Because prostaglandins play an important role in hemostasis , and NSAIDs affect platelet function as well , concurrent therapy with all NSAIDs , including @DRUG$ , and @DRUG$ requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required .	DDI-advise
Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, @DRUG$, cimetidine, ketoconazole), though this has not been studied	DDI-mechanism
Thioridazine: co-administration of single doses of @DRUG$ 20 mg and @DRUG$ 50 mg resulted in additive effects on reduced alertness and impaired psychomotor performance 2 to 4 hours after administration.	DDI-effect
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	DDI-false
@DRUG$: Chloramphenicol, @DRUG$, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.	DDI-false
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of @DRUG$ with an @DRUG$ has not been conducted .	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ , other , especially diazoxide , or preanesthetic and anesthetic agents used in surgery or @DRUG$ , nondepolarizing , used in surgery	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , @DRUG$ , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , @DRUG$ , sympathomimetics (e.g. epinephrine, salbutamol, terbutaline), @DRUG$ , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$ ), magnesium salts, lithium, local anaesthetics, procainamide and @DRUG$.	DDI-false
Cholestyramine-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of @DRUG$).	DDI-false
@DRUG$: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : @DRUG$ , NSAIDs , corticosteroids , TNF blocking agents , @DRUG$ , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Resins : Since bile acid sequestrants can bind other medicines at the same time, patients should take @DRUG$ at least 1 hour before or 4 - 6 hours after a @DRUG$ To avoid hindering its absorption.	DDI-mechanism
@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
Potential differences in @DRUG$ Dosage and pharmacokinetics at different levels @DRUG$ exposure were assessed in the context of ANOVA .	DDI-false
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
Coadministration of @DRUG$ 30 mg and @DRUG$, a CYP2C19 substrate, resulted in a 45% decrease in clearance of diazepam.	DDI-mechanism
Co-administration of either intravenous or oral methylxanthines (e.g. @DRUG$ Theophylline) of patients who: @DRUG$ has not been completely evaluated .	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin , @DRUG$ , and barbiturates , and the antituberculosis drug rifampin .	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, @DRUG$, anesthetics) should be considered.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	DDI-false
- medicines associated with peripheral neuropathy include: @DRUG$ , chloramphenicol , cisplatin , @DRUG$ , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
In addition , @DRUG$ neither influenced the pharmacodynamics of warfarin , acetylsalicylic acid , piroxicam , and digoxin , nor the pharmacokinetics of @DRUG$ at steady state .	DDI-false
HIV protease inhibitors : @DRUG$ (800 mg t.i.d.) together with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-mechanism
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , @DRUG$ , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and @DRUG$.	DDI-false
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, @DRUG$, and nifedipine.	DDI-false
Antiacid, clarithromycin, didanosine, fluconazole, fluoxetine, indanavir, @DRUG$ , phenytoin, phenobarbitol, carbamazepine, rifabutin, rifampin, ritanovir, @DRUG$.	DDI-false
BACKGROUND : The effects of combined administration of @DRUG$ Hydrochloride and verapamil ( @DRUG$ A calcium channel blocker, the incidence of peritoneal metastasis of intestinal adenocarcinoma induced by azoxymethane (AOM) and the index of colorectal cancers were studied in male Wistar rats.	DDI-false
Another oral @DRUG$ ketoconazole inhibits metabolism @DRUG$ This results in increased plasma concentrations of astemizole and its active metabolite desmethylastermizole, which may prolong QT intervals.	DDI-false
Dose adjustment is not recommended . Levetiracetam had no effect on plasma concentrations of @DRUG$ , valproate , topiramate , or @DRUG$.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$ , @DRUG$ , Nefazodone, Nicardipine, Propofol, Protease inhibitors, quinidine, and verapamil.	DDI-false
May interact with the following: cholestyramine, colestipol (use with @DRUG$ may prevent the @DRUG$ from working properly;	DDI-false
Standard monitoring of methotrexate-related toxicity should be continued if @DRUG$ and @DRUG$ are administered concomitantly.	DDI-advise
@DRUG$ : Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of @DRUG$ , resulting in lower plasma concentrations , peak plasma levels , and AUC values .	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmia : amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines Midazolam, triazolam GI Motility agent: cisaprid	DDI-advise
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
In patients with mild to moderate hypertension , administration of 25 mg daily of VIOXX with the ACE inhibitor @DRUG$ , 10 to 40 mg for 4 weeks, with an average increase in mean arterial pressure of approximately 3 mm Hg compared to @DRUG$ alone .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
Hypotension : patients receiving diuretic therapy : patients below @DRUG$ In particular, patients who have recently started diuretic therapy may occasionally experience an excessive reduction in blood pressure after initiation of therapy. @DRUG$ or enalaprilat .	DDI-effect
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including @DRUG$ , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or @DRUG$ The absorption of ciprofloxacin can be significantly reduced, resulting in significantly lower serum and urine levels than desired.	DDI-mechanism
Medicines associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$ , gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$ , phenytoin, ribavirin and vincristine.	DDI-false
@DRUG$: @DRUG$ 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of nifedipine, a drug that is metabolized via CYP3A4.	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of @DRUG$ , increased Gleevec oral-dose clearance by 3.8-fold , which significantly ( p 0.05 ) decreased mean cmax and AUC(0 - 8) .	DDI-mechanism
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Medicines not to be administered with VIRACEPT @DRUG$ Amiodarone, quinidine antihistamines: astemizole, @DRUG$ Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., @DRUG$, carbamazepine, @DRUG$, ketoconazole), though this has not been studied	DDI-false
- Anabolic steroids ( nandrolone [ e.g. , Anabolin ] , oxandrolone [ e.g. , Anavar ] , oxymetholone [ e.g. , @DRUG$ ], stanozolol [e.g., @DRUG$ ] ) or	DDI-false
Aspirin : Simultaneous use of @DRUG$ and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of @DRUG$ This resulted in lower plasma concentrations, maximum plasma levels and AUC values.	DDI-false
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors , @DRUG$ The affinities for NMDA and Sigma-2 receptors, sodium channels and 5-HT transporters are significantly lower than ibogain.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , @DRUG$ , nefazodone , nicardipine , propofol , @DRUG$ , quinidine, and verapamil.	DDI-false
@DRUG$ ( Magnesium-Aluminum Hydroxide ): @DRUG$ Plasma concentrations were not affected by concomitant administration of antacids.	DDI-false
These results would seem to dictate against the clinical use of @DRUG$ with @DRUG$, or during the period following ELSPAR therapy when plasma asparagine levels are below normal.	DDI-advise
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	DDI-false
The extent to which @DRUG$-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved.	DDI-false
Aspirin , @DRUG$ , @DRUG$ , NSAIDs	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Patients taking @DRUG$ concomitantly with @DRUG$ More commonly reported both weight gain and weight loss, compared to patients taking either medication alone.	DDI-effect
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, antiemetics, sedatives, @DRUG$).	DDI-false
@DRUG$ : Amiodarone , @DRUG$ , flecainide , propafenone , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$ , ergotic derivatives, pimozide, @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-mechanism
@DRUG$ Â· may increase the effect of alcohol, @DRUG$ , and other CNS depressants .	DDI-effect
Studies to evaluate possible interactions between @DRUG$ and drugs other than @DRUG$ have not been performed.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and @DRUG$ when administered concomitantly with an intravenous opiate such as @DRUG$.	DDI-mechanism
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and H2 antagonists (such as @DRUG$ or ranitidine).	DDI-false
Bosentan is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as @DRUG$ and atorvastatin.	DDI-false
apomorphine - prior ingestion of diphenidol may decrease the @DRUG$ response to @DRUG$ in the treatment of poisoning .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
medicines that induce CYP3A4 ( @DRUG$ ) Racemic @DRUG$ Exposure was reduced by 80% by co-administration of rifampicin, a potent inducer of CYP3A4.	DDI-false
@DRUG$ serum levels should be monitored and appropriate dose adjustments considered for patients given both @DRUG$ and PEGASYS .	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, @DRUG$, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
CONCLUSIONS : Macrolide antibiotics inhibit the metabolism of @DRUG$ Metabolised by CYP3A4 (i.e. @DRUG$ , cerivastatin , lovastatin , simvastatin ) .	DDI-false
Intravenous @DRUG$ Adenosine was effectively administered in the presence of other cardiovascular drugs such as quinidine. @DRUG$ , calcium channel blocking agents , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile .	DDI-false
@DRUG$ (5 mg/kg), moclobemide (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (@DRUG$), erythromycin, azole antifungals.	DDI-false
In pigeons, naloxone did not change the effect of (-)-NANM systematically, @DRUG$ or @DRUG$.	DDI-false
@DRUG$ : @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium , including ACE inhibitors .	DDI-false
@DRUG$/Aluminium containing antacid products: Zalcitabine absorption is moderately reduced (approximately 25%) when co-administered with @DRUG$/Aluminium containing antacid products.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
The pharmacokinetics of @DRUG$ are unaltered in the presence of @DRUG$ and vice versa.	DDI-false
Oral Contraceptives: Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and @DRUG$ by approximately 30% and 20%.	DDI-false
Co-administration of other CYP3A4 inhibitors such as @DRUG$ Erythromycin with transdermal fentanyl may also lead to an increase in @DRUG$ Plasma concentrations that may increase or prolong adverse drug reactions and may cause severe respiratory depression.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Slow-channel calcium blockers, such as @DRUG$, @DRUG$ and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, sedatives, anesthetics) should be considered.	DDI-advise
Compounds tested in man include @DRUG$, theophylline, phenytoin, diazepam, @DRUG$ and antipyrine.	DDI-false
No data are available for the coadministration of INVIRASE/@DRUG$ or FORTOVASE/@DRUG$ and garlic capsules.	DDI-false
Catecholamine-depleting Agents: Patients taking both @DRUG$ and a drug that can deplete catecholamines (e.g., reserpine and @DRUG$) should be observed closely for signs of hypotension and/or severe bradycardia.	DDI-effect
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$ , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$: Co-administration of @DRUG$ with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone , suggesting that @DRUG$ The absorption of Fosinopril may be impaired.	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, @DRUG$ and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
acetaminophen/theophylline , @DRUG$/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/@DRUG$ , and valproic acid/phenobarbital .	DDI-false
There have been reports of QTc prolongation, with or without TdP, in patients taking amiodarone when @DRUG$, @DRUG$, or azoles were administered concomitantly.	DDI-false
It is recommended that concomitant use of @DRUG$ with aluminum hydroxide containing antacids for at least 4 hours following @DRUG$ administration .	DDI-false
however, it is considered to be unlikely that this decrease of phosphorylated lamivudine concentration is of clinical significance, as @DRUG$ is a more efficient substrate for deoxycytidine kinase than @DRUG$.	DDI-false
@DRUG$ : In diabetic patients receiving diflunisal and @DRUG$ No significant effects on tolbutamide plasma levels or fasting blood sugar were observed.	DDI-false
ACE inhibitors and angiotensin II receptor antagonists (congestive heart failure after myocardial infarction)- In EPHESUS, 3020 (91%) patients received @DRUG$ ACE inhibitors or angiotensin II receptor antagonists ( @DRUG$/ARB) were also administered 25 to 50 mg.	DDI-false
" Medicinal products not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, terfenadine antimigrain: ergot derivatives antimycobacterial agents: rifampine benzodiazepines midazolam, @DRUG$ GI motility agents : @DRUG$	DDI-false
Metformin: In healthy subjects given single 500 mg doses of @DRUG$ and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and @DRUG$ mean renal clearance decreased by 14%.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , antacids , H2-antagonists ( e.g. , @DRUG$ , ranitidine ) , and proton pump inhibitors ( e.g. , @DRUG$ , omeprazole ) .	DDI-false
The compounds that have been tested in humans include: @DRUG$ , @DRUG$ , propranolol , theophylline , and warfarin and no clinically meaningful interactions were found .	DDI-false
It is concluded that @DRUG$ and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy.	DDI-false
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate : @DRUG$ , haloperidol , @DRUG$ , pimozide .	DDI-false
While all the @DRUG$ ( SSRIs ) , e.g. , fluoxetine , @DRUG$ , paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
@DRUG$ and related drugs may decrease arterial responsiveness to @DRUG$.	DDI-effect
Other @DRUG$ (e.g. barbiturates, @DRUG$, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.	DDI-false
@DRUG$ : Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$ or hydrochlorothiazide .	DDI-false
Diphenhydramine hydrochloride has additive effects with @DRUG$ and other CNS depressants (hypnotics, @DRUG$, tranquilizers, etc).	DDI-false
@DRUG$ should be used cautiously in conjunction with @DRUG$ in hypoprothrombinemia.	DDI-advise
Medicines not administered with VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam , @DRUG$ GI motility agents : cisapride	DDI-false
Accordingly , when @DRUG$ is administered with oral @DRUG$ , the prothrombin time should be closely monitored during and for several days after concomitant drug administration .	DDI-advise
Quetiapine fumarate ('@DRUG$') is a newly introduced @DRUG$ with demonstrated efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system ( e.g. , phenytoin , carbamazepine , cimetidine , @DRUG$ ), although this has not yet been studied.	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Other @DRUG$ (e.g., @DRUG$) may also have this effect.	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including anti-arrhythmic agents such as quinidine and @DRUG$ , Herzglycosides and @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: orally @DRUG$ ACE inhibitors, disopyramide, @DRUG$ , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Using Angiotensin Converting Enzymes Inhibitors : The Use of @DRUG$ to control hypertension in patients on @DRUG$ It has been reported that severe leukopenia is induced.	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , @DRUG$ , clindamycin , @DRUG$ , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
@DRUG$ The administration of tiagabin in patients who had taken chronic valproate had no effect on @DRUG$ pharmacokinetics , but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8 % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$ FORADIL should be used with extreme caution in patients treated with monoamine oxidase inhibitors or tricyclic antidepressants, as the effect of @DRUG$ On the cardiovascular system can be potentiated by these active substances.	DDI-false
acetaminophen/@DRUG$ , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than ibogaine for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$ , @DRUG$ ( e.g. , in oral contraceptives ) .	DDI-false
Probenecid : @DRUG$ â€¢ Impairs renal tubular secretion of ciprofloxacin and leads to an increase in renal tubular secretion of ciprofloxacin. @DRUG$ in serum .	DDI-mechanism
Antiacid, clarithromycin, didanosine, fluconazole, @DRUG$ , indanavir, ketoconazole, phenytoin, phenobarbitol, @DRUG$ , rifabutin, rifampin, ritanovir, saquinavir.	DDI-false
Additional reductions in blood pressure may occur when @DRUG$ is administered with diuretics , @DRUG$ , or other vasodilators.	DDI-effect
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , @DRUG$ , disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g. octreotide), sulphonamide antibiotics.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, @DRUG$ , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , @DRUG$ , and quinidine .	DDI-false
@DRUG$ Lithium toxicity has been reported in patients receiving lithium concomitantly with medicines that cause sodium excretion, including @DRUG$.	DDI-false
Antiarrhythmics: @DRUG$, bepridil, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
In EM individuals treated with paroxetine or @DRUG$, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
however, no deleterious interactions were seen when ROMAZICON was administered after @DRUG$, inhalational anesthetics, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam ( @DRUG$ ) and @DRUG$ under acidic conditions similar to those found in vivo , resulting in a 3-ethoxylated product .	DDI-false
The extent to which @DRUG$-@DRUG$ interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved .	DDI-int
Interactions may occur between EPA supplements and aspirin and other @DRUG$ and herbs such as garlic ( Allium sativum ) and @DRUG$ ( Ginkgo biloba ) .	DDI-false
@DRUG$ may interact with alcohol , blood thinners , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , @DRUG$ , NSAIDs such as Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (FORTOVASE) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
- Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$ , cephalothine, erythromycin, and @DRUG$ In vitro does not affect the protein binding of diclofenac in human serum.	DDI-false
Antimycobacterial Agents: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of @DRUG$.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, carbamazepine, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	DDI-mechanism
In a similar study with tamsulosin in healthy volunteers, 1 of 24 subjects dosed with @DRUG$ 20 mg and @DRUG$ 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg.	DDI-effect
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ , alfentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
@DRUG$ Doxorubicin caused a decrease in @DRUG$ Phosphorylation (50 % inhibition of total phosphate formation) in U937/Molt 4 cells.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
On administration of oral @DRUG$, the need for @DRUG$ therapy should be reviewed and the dose reduced by approximately 50% or discontinued.	DDI-advise
Cimetidine: @DRUG$ concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with @DRUG$ (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).	DDI-mechanism
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
The management of the local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$ , tricyclic antidepressants or phenothiazines may produce severe , prolonged hypotension or hypertension .	DDI-false
Concomitant @DRUG$ , @DRUG$ , vincristine and prednisone chemotherapy plus highly active antiretroviral therapy in patients associated with human immunodeficiency virus, non-Hodgkin lymphoma.	DDI-false
Although neither dexamethasone nor retinyl acetate influenced the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and @DRUG$.	DDI-false
Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with phenytoin, warfarin, @DRUG$, clarithromycin or amoxicillin.	DDI-false
Valproat : The addition of tiagabin to patients who received valproate chronically had no effect on @DRUG$ pharmacokinetics , but valproate significantly decreased @DRUG$ In vitro binding from 96.3 to 94.8% resulted in an increase in free tiagabin concentration of about 40%.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (@DRUG$, saquinavir, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
- results of studies in patients with multiple sclerosis receiving TYSABRI and interferon beta-1a ( AVONEX 30 mcg IM once weekly), or @DRUG$ As regards the need for dose adjustment of @DRUG$ or glatiramer acetate .	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of @DRUG$ , phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$ , certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying the elimination and increase in blood levels of these drugs.	DDI-false
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Selective Serotonin Reuptake Inhibitors ( SSRIs ): @DRUG$ (e.g. fluoxetine, fluvoxamine, @DRUG$ , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5-HT1 agonists .	DDI-false
Caution should be exercised when: @DRUG$ It is used at the same time as @DRUG$ Because paranoid symptoms have been reported during therapy with this combination.	DDI-advise
In addition, results from regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance ( @DRUG$ , nevirapine , phenytoin , dexamethasone , or carbamazepine ) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations .	DDI-mechanism
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of @DRUG$.	DDI-mechanism
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
However, a crossover study in healthy subjects receiving either @DRUG$ 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (@DRUG$ , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	DDI-mechanism
MAO inhibitors: DURAGESIC is not recommended for use in patients who: @DRUG$ within 14 days because severe and unpredictable potentiation by @DRUG$ Opioid analgesics have been reported	DDI-false
@DRUG$: @DRUG$ IV/IM reduced the diuretic response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	DDI-false
@DRUG$ and @DRUG$: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-false
Although increased plasma concentrations ( AUC 0 - 24 hours ) @DRUG$ and/or @DRUG$ were observed following coadministration of loratadine with each of these drugs in normal volunteers ( n = 24 in each study ) , there were no clinically relevant changes in the safety profile of loratadine , as assessed by electrocardiographic parameters , clinical laboratory tests , vital signs , and adverse events .	DDI-false
- @DRUG$ or @DRUG$ (with hepatotoxic potential) must not be administered together with Bezalip or Bezalip retard.	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving @DRUG$ or tricyclic antidepressants may produce severe , prolonged hypertension .	DDI-effect
Acetaminophen , lidocaine , phenobarbital , @DRUG$ , @DRUG$ , and valproic acid were added to pooled human serum at therapeutic concentrations .	DDI-false
Investigations into the effect of @DRUG$ on the protein binding of anticoagulants of the coumarin type (@DRUG$) revealed no interaction.	DDI-false
This was expected because @DRUG$ â€¢ is mainly metabolised and renal excretion of unchanged @DRUG$ accounts for less than 1 % of the administered dose .	DDI-false
Co-administration of intravenous or oral administration @DRUG$ ( e.g. , @DRUG$ Theophylline) in patients receiving BROVANA has not been fully studied.	DDI-false
Acetaminophen : In normal volunteers , concomitant administration of diflunisal and @DRUG$ The result was an approximately 50% increase in @DRUG$ plasma levels.	DDI-false
@DRUG$, tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or @DRUG$;	DDI-false
Cardiovasculars: @DRUG$: In patients receiving @DRUG$ therapy, administration of oral amiodarone regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
DIGOXIN : Plasma @DRUG$ levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
conversely, diethylpropion may interfere with antihypertensive drugs (i.e., @DRUG$, @DRUG$).	DDI-false
@DRUG$ reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , @DRUG$ , estrogens , oral contraceptives , @DRUG$ , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Drug Interactions : @DRUG$ This may be associated with some medicines such as monoamine oxidase inhibitors ( @DRUG$ MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupentixol and ethanol cause additive CNS depression - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-int
The risk of myopathy during treatment with medicines in this class is associated with the use of @DRUG$ , fibric acid derivatives , niacin ( nicotinic acid ) , erythromycin , @DRUG$.	DDI-false
Digoxin, nimodipine and losartan: bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine , and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with lidocaine (@DRUG$ substrate) given for local @DRUG$.	DDI-false
@DRUG$ should be administered with caution to patients receiving @DRUG$ (disulfiram, Wyeth-Ayerst Laboratories).	DDI-advise
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , antacids , H2-antagonists ( e.g. , famotidine , @DRUG$ ), and proton pump inhibitors (e.g. @DRUG$ ,,,,,,,,,,,	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Injection : Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when with ethyl alcohol, phenothiazine, @DRUG$ , MAO inhibitors, and other antidepressants. When @DRUG$ It is administered concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations and irrational behaviour has been observed.	DDI-false
Cimetidine : @DRUG$ The concentrations in bile and cystic fluid were in patients with hydatidencysts who had @DRUG$ ( 10 mg/kg/day ) ( n=7 ) compared with albendazole ( 20 mg/kg/day ) alone ( n=12 ) .	DDI-mechanism
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: @DRUG$	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between VIRACEPT and dapsone , trimethoprim/sulfamethoxazole , clarithromycin , @DRUG$ Itraconazole or @DRUG$.	DDI-false
In vitro studies indicate that @DRUG$ does not inhibit P-glycoprotein-mediated transport of digoxin or @DRUG$ and that ertapenem is not a substrate for P-glycoprotein-mediated transport.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
It is recommended to avoid concurrent administration of @DRUG$ with @DRUG$ containing antacids for at least 4 hours following ethambutol administration.	DDI-advise
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Therefore, if hydroflumethiazide and @DRUG$ When co-administered, the patient should be closely monitored to determine whether the desired effect of the @DRUG$ ==References==	DDI-false
Antacids : Concomitant administration of @DRUG$ may reduce plasma levels of @DRUG$.	DDI-mechanism
Cyclosporine : Administration of nonsteroial anti-inflammatory drugs concomitantly with @DRUG$ has been associated with an increase in @DRUG$-induced toxicity , possibly due to decreased synthesis of renal prostacyclin .	DDI-false
Patients using CYP3A4 metabolized statins should have cholesterol levels monitored after @DRUG$ is initiated to see whether the @DRUG$ dose needs adjustment.	DDI-false
@DRUG$: Because @DRUG$ can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including TRICOR, there is a risk that an interaction will lead to deterioration.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , @DRUG$ , cisplatin, dapsone, disulfiram, ethionamide, @DRUG$ , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
@DRUG$ has been administered with tolazoline, dopamine, @DRUG$, steroids, surfactant, and high-frequency ventilation.	DDI-false
Medicines detected as CYP3A inhibitors of possible clinical significance based on clinical studies @DRUG$ The concomitant use of fluoxetine and @DRUG$ The maximum plasma concentration of alprazoleam increased by 46%, clearance by 21%, half-life by 17% and measured psychomotor performance.	DDI-false
Specific studies have confirmed these effects with sevoflurane, isoflurane, @DRUG$, @DRUG$, and midazolam.	DDI-false
The successive application of @DRUG$ (5 or 10 mg/kg egg weight (e.w.) and @DRUG$ (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone.	DDI-effect
- medicines associated with peripheral neuropathy include: @DRUG$ , @DRUG$ , cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Therefore , esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability ( eg , ketoconazole , @DRUG$ salts and @DRUG$ ) .	DDI-false
When other potent parental @DRUG$, such as @DRUG$, are used in combination with hydralazine, patients should be continuously observed for several hours for any excessive fall in blood pressure.	DDI-effect
Another oral azole antifungal, @DRUG$, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite @DRUG$ which may prolong QT intervals.	DDI-false
Hydrochlorothiazide : In normal volunteers , concomitant administration of @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, @DRUG$, dexamethasone, carbamazepine) may result in decreased plasma levels of saquinavir.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and @DRUG$.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-false
Influence of @DRUG$ on @DRUG$ Concentration (Mean change, 90% Confidence Interval)	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$: @DRUG$ enhance the adrenergic effect of norepinephrine.	DDI-false
Therapeutic concentrations of @DRUG$ , @DRUG$ , ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide do not alter ketorolac tromethamine protein binding.	DDI-false
Other CNS depressant drugs (e.g. barbiturates, @DRUG$, opioids and general anesthetics) have additive or potentiating effects with @DRUG$.	DDI-effect
Drug-Drug Interactions Between Keppra   And Other Antiepileptic Drugs ( AEDs ) @DRUG$ @DRUG$   ( 3000 mg daily ) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, @DRUG$ or some antihistamines.	DDI-false
@DRUG$ (e. g., @DRUG$, etc.) should be given concomitantly only with great caution.	DDI-false
The addition of @DRUG$ in a limited number of patients in three well-controlled studies caused no systematic changes in phenobarbital or @DRUG$ concentrations when compared to placebo.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Specific studies have confirmed these effects with sevoflurane, @DRUG$, @DRUG$, alfentanil, and midazolam.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
Similarly dialyzed were @DRUG$ , @DRUG$ Theophylline and theophylline, both in therapeutic concentrations in serum and with ethanol in three different concentrations in serum.	DDI-false
Coadministration of valdecoxib and Ortho-Novum 1/35   increased the exposure of @DRUG$ and @DRUG$ by 20 % and 34 % , respectively .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , @DRUG$ , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic antidepressants , @DRUG$ Theophylline, and metronidazole, delaying the elimination and increase in blood levels of these drugs.	DDI-false
As with other antipsychotics, it should be noted that: @DRUG$ may be capable of potentiating CNS depressants such as anesthetics , @DRUG$ And alcohol.	DDI-effect
Like ibogaine ( 40 mg/kg ) , 18-MC ( 40 mg/kg ) decreases the intravenous self-administration of @DRUG$ â€¢ Cocaine and oral self-administration of ethanol and @DRUG$ in rats ;	DDI-false
- @DRUG$: Indomethacin blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the @DRUG$-induced increase in plasma renin activity.	DDI-false
The average percentage increase in the @DRUG$ AUC after @DRUG$ The administration was 56.9% (range: 35 to 81 ).	DDI-mechanism
acetaminophen/@DRUG$, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
In addition , @DRUG$ The pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam and @DRUG$ , nor the pharmacokinetics of digoxin at steady state .	DDI-false
In separate studies with patients receiving maintenance doses of warfarin, @DRUG$ , or digoxin , irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin ( prothrombin time ) or pharmacokinetics of @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
In a Phase I trial using escalating doses of TAXOL ( 110 - 200 mg/m2 ) and @DRUG$ Myelosuppression was lower when TAXOL was given after cisplatin than with the alternative sequence (i.e., @DRUG$ before cisplatin ) .	DDI-false
Therapeutic concentrations of digoxin, @DRUG$, @DRUG$, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, @DRUG$ , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral @DRUG$ ) .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on cisapride absorption when it is coadministered with ranitidine.	DDI-false
â€¢ Interactions between EPO Supplements and @DRUG$ and other @DRUG$ and herbs such as garlic ( Allium sativum ) and ginkgo ( Ginkgo biloba ) .	DDI-false
The acute symptoms should be treated with short-acting, inhaled treatment. @DRUG$ such as @DRUG$ (The doctor should provide the patient with such medication and instruct the patient how to use it).	DDI-false
In addition, oxcarbazepine and @DRUG$ induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of @DRUG$ and oral contraceptives, resulting in a lower plasma concentration of these drugs.	DDI-false
Benzthiazide can interact with alcohol, blood thinners, @DRUG$ ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , norepinephrine , NSAIDs like @DRUG$ Or ibuprofen, and high blood pressure medications.	DDI-false
No significant drug-drug pharmacokinetic ( or pharmacodynamic ) interactions have been found in interaction studies with hydrochlorothiazide , @DRUG$ , warfarin , and @DRUG$.	DDI-false
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, @DRUG$, or @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Co-administration: Concomitant use of Argatroban with @DRUG$, @DRUG$, and other anticoagulants may increase the risk of bleeding.	DDI-false
Other medicinal products Interactions: No pharmacokinetic interactions between vardenafil and the following medicinal products have been observed: @DRUG$ , warfarin, digoxin, @DRUG$ ==References====External links==	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , @DRUG$ , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Therapeutic concentrations of @DRUG$ , warfarin , @DRUG$ Ketorolac Tromethamine Protein binding does not alter ketorolac tromethamine protein binding.	DDI-false
The interaction may be between: @DRUG$ - additions and aspirin and other non-steroidal anti-inflammatory medicines and herbs such as garlic (Allium sativum) and @DRUG$ ( Ginkgo biloba ).	DDI-int
It is suggested that in patients receiving @DRUG$ , alternatives to @DRUG$ should be used if anticonvulsant therapy is needed .	DDI-advise
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin, @DRUG$ , and amikacin ) , amphotericin B , foscarnet , intravenous pentamidine , @DRUG$ , and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
@DRUG$ : DURAGESIC   is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with opioid analgesics	DDI-false
@DRUG$ is a substrate for both CYP2D6 and @DRUG$.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and ciprofloxacin when administered concomitantly with an intravenous @DRUG$ such as morphine.	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenylbutazone , @DRUG$ , carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and @DRUG$ 72 .	DDI-false
Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but @DRUG$ significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-mechanism
Repeated doses of @DRUG$ given prior to a single dose of propranolol in human trials have been reported to decrease @DRUG$ absorption .	DDI-false
The hypoglycaemic effect of sulphonylureas may be caused by certain medicinal products, including: @DRUG$ and other drugs that are highly protein bound , @DRUG$ , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
In addition to the above mentioned interactions, chronic ( 2 weeks ) oral @DRUG$ The use affects the metabolism of @DRUG$ ==References====External links==* Official website	DDI-false
For example, if @DRUG$ are administered concomitantly with nilutamide , prothrombin time should be carefully monitored and if necessary , the dosage of @DRUG$ , should be reduced.	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , @DRUG$ , @DRUG$ , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , @DRUG$ , erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
Patients receiving other narcotic analgesics generally @DRUG$ , phenothiazines, sedatives, sedative hypnotic agents, tricyclic antidepressants or other CNS depressants (including alcohol) together with: @DRUG$ may exhibit an additive CNS depression .	DDI-effect
Benzylpenicillin , ampicillin , oxacillin , @DRUG$ , doxycycline, cephalothine, @DRUG$ In vitro sulfamethoxazole does not affect the protein binding of diclofenac in human serum.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, warfarin, digoxin, @DRUG$, and ranitidine.	DDI-false
It can interact with the following: cholestyramine, @DRUG$ ( use with @DRUG$ â€¢ can prevent the diuretic from working properly;	DDI-effect
Compounds tested in man include warfarin, theophylline, phenytoin, @DRUG$, aminopyrine and @DRUG$.	DDI-false
Drugs that may alter @DRUG$ Plasma concentrations Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when gleevec is administered with CYP3A4 inhibitors (e.g. ketoconazole, @DRUG$ , erythromycin , clarithromycin ) .	DDI-false
Possible drug interactions between Keppra and other AEDs (carbamazepine, @DRUG$ , @DRUG$ , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the @DRUG$ Indinavir for 48 weeks as initial therapy, with similar response observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).	DDI-false
Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, @DRUG$, @DRUG$, pimozide.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
The concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, @DRUG$ Myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g. methotrexate, asparaginase) effects with: @DRUG$ The toxicity in these organ systems can be increased.	DDI-effect
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$ , barbiturates , MAO inhibitors , and other antidepressants . When scopolamine is used concomitantly with injectable @DRUG$ An increased incidence of sedation, hallucinations, and irrational behaviour has been observed.	DDI-false
As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, opiates, and @DRUG$.	DDI-effect
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$ and glutethimide should not be administered to patients receiving @DRUG$.	DDI-advise
There have been case reports of increased steady-state levels of @DRUG$ , @DRUG$ , and phenytoin during concomitant therapy with amiodarone.	DDI-false
- @DRUG$ ==References====External links== @DRUG$ The use of sulfapyridin with these medicines may increase the likelihood of side effects affecting the blood.	DDI-false
â€¢ Drug interaction studies have shown that esomeprazole has no clinically significant interactions with phenytoin, @DRUG$ , quinidine , @DRUG$ or amoxicillin .	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with alprazolam): Coadministration of @DRUG$ with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-mechanism
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
@DRUG$ (but not @DRUG$): These drugs in combination with very high doses of quinolones have been shown to provoke convulsions in pre-clinical studies.	DDI-false
@DRUG$ : @DRUG$ ( CYP3A4 substrate ) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis .	DDI-false
Additional reductions in blood pressure may occur when @DRUG$ is administered with @DRUG$, antihypertensive agents, or other vasodilators.	DDI-effect
These drugs include the @DRUG$ And other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as @DRUG$, @DRUG$, carbamazepine, and phenobarbital.	DDI-false
Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , @DRUG$ , etc . ): in vitro and animal studies with the combination of amphotericin B and @DRUG$ Imidazole can cause fungal resistance to amphotericin B.	DDI-false
No pharmacokinetic interactions between dexmedetomidine and isoflurane , @DRUG$ , alfentanil , and @DRUG$ It's been detected.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/@DRUG$ , quinidine/lidocaine , theophylline/@DRUG$ , and valproic acid/phenobarbital .	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : @DRUG$ ( e.g. , @DRUG$ Amikacin, amphotericin B, cyclosporin, nonsteroidal anti-inflammatory drugs (e.g. ibuprofen), tacrolimus, vancomycin.	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ and rifampin should not beadministered concomitantly becausedecreases in @DRUG$ Plasma concentrations may reduce the efficacy of the medicinal product.	DDI-false
Digoxin, nimodipine and losartan: bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$ , and @DRUG$ has no significant effect on plasma levels of bosentan .	DDI-false
Antihistamines : @DRUG$ * , @DRUG$ * CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias .	DDI-false
In evaluating the potential for interactions among co-administered antiepilepsy drugs (@DRUG$), whether or not an @DRUG$ induces or does not induce metabolic enzymes is an important consideration.	DDI-false
These data indicate that levetiracetam does not influence the plasma concentration of other @DRUG$ and that these @DRUG$ do not influence the pharmacokinetics of levetiracetam.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine , @DRUG$ , niacin ( @DRUG$ Erythromycin, azole antifungals.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with @DRUG$.	DDI-effect
Hormonal Contraceptives , Including Oral , Injectable , Transdermal , and Implantable @DRUG$ : An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ The average decrease in estradiol levels of norethindron and ethinyl was 14% and 31% respectively.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$ : @DRUG$ , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .	DDI-false
Before using this medicine, tell your doctor or pharmacist about all prescription and non-prescription products that you can use, especially: aminoglycosides (e.g., @DRUG$ Amikacin ), amphotericin B, cyclosporin, @DRUG$ medicines (e.g. ibuprofen), tacrolimus, vancomycin.	DDI-false
The similarity of the @DRUG$ Study 1 (without concomitant use of AVONEX ) and Study 2 ( with concomitant use of AVONEX ) show that this change in clearance does not reduce the @DRUG$ Dose to maintain safety, general).	DDI-false
d-amphetamine with @DRUG$ or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
No significant difference was found between the mean values of the volume of distribution of @DRUG$ with and without @DRUG$ (13.0 and 12.6 liters, respectively).	DDI-false
Rifampin: Co-administration of VIOXX with @DRUG$ 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in @DRUG$ plasma concentrations.	DDI-false
The absorption of tetracycline, @DRUG$ , penicillin G , @DRUG$ , and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride ;	DDI-false
@DRUG$, ampicillin, oxacillin, @DRUG$, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
These results suggest that both @DRUG$ Retinyl acetate and possibly other glucocorticoids and @DRUG$ , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , @DRUG$ ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , @DRUG$ , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Flucytosine: while a synergistic relationship with @DRUG$ has been reported, concomitant use may increase the toxicity of @DRUG$ by possibly increasing its cellular uptake and/or impairing its renal excretion.	DDI-effect
@DRUG$ ) and many that are substrates for P450 2D6 ( many other antidepressants , phenothiazines , and the Type 1C antiarrhythmics @DRUG$ and flecainide ) .	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants , @DRUG$ , alcohol , barbiturates , monoamine oxidase inhibitors , narcotics , @DRUG$ , psychotropic medications , or other drugs that produce CNS depression .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and @DRUG$ with vincristine plus @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
@DRUG$ : Concomitant treatment with Accutane and tetracyclines should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri ( benign intracranial hypertension ) , some of which involved concomitant use of tetracyclines	DDI-false
Antiacid, clarithromycin, didanosine, fluconazole, fluoxetine, indanavir, ketoconazole, phenytoin, phenobarbitol, @DRUG$ , Rifabutin , Rifampin , Ritanovir , @DRUG$.	DDI-false
In the present study, the atypical antipsychotic @DRUG$ was tested in combination with an active dose of @DRUG$ in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, carbamazepine and possibly with griseofulvin, @DRUG$, and tetracyclines (72)	DDI-false
METHOD : This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg , 1 mg , or 2 mg twice daily with @DRUG$ and @DRUG$.	DDI-false
Compounds tested in man include warfarin , @DRUG$ , @DRUG$ , diazepam, aminopyrin and antipyrin.	DDI-false
Multivitamins or other products which: @DRUG$ Zinc, antacids or sucralfate should not be administered concomitantly with or within 2 hours after administration of @DRUG$ Because they may impair absorption, resulting in lower serum and urine levels of norfloxacin.	DDI-advise
* Possible interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ ritonavir, saquinavir, @DRUG$ , and nelfinavir ) , which are substrates and/or inhibitors of CYP3A4 , have not been evaluated in clinical trials .	DDI-false
The effects of ruthenium red (RR) on @DRUG$ (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
Therefore , @DRUG$ may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability ( eg , @DRUG$ , iron salts and digoxin ) .	DDI-mechanism
Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
- @DRUG$ (e.g., Mexate) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
Protein Binding In vitro , diclofenac interferes minimally or not at all with the protein binding of salicylic acid ( 20 % decrease in binding ) , @DRUG$ Prednisolone (10% reduction in binding) or @DRUG$.	DDI-false
In comparison of the digitalis tolerance in dogs stunned with @DRUG$ , @DRUG$ To cause ventricular tachycardia, or pentobarbital, the dosage of Ouabain required to cause ventricular tachycardia was significantly higher, such as the LD50 of Ouabain, with ketamine or innovar than with pentobarbital.	DDI-false
One single dose of liquid @DRUG$ did not affect the C max or AUC of @DRUG$ ;	DDI-false
@DRUG$: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of enalapril may result in a further deterioration of renal function.	DDI-false
@DRUG$ should not be administered concomitantly with other sympathomimetic drugs (such as @DRUG$) because of possible additive effects and increased toxicity.	DDI-advise
The expected changes in the laboratory estimates of PT and INR were based on: @DRUG$ However, these changes were not due to the concomitant use of @DRUG$ administration .	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Ergot Derivatives: Dihydroergotamine, ergonovine, ergotamine, @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when with ethyl alcohol, phenothiazine, barbiturates, MAO inhibitors and other @DRUG$. @DRUG$ is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-false
Although in clinical studies with IOPIDINE 0.5 % ophthalmic solution no specific drug interactions with topical glaucoma or systemic drugs have been identified, there is a possibility of additive or potentiating effects with CNS depressants ( @DRUG$ , barbiturates, opiates, @DRUG$ , anesthetics ) should be considered .	DDI-false
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral @DRUG$ norethindrone/ethinyl estradiol (1 mg /35 mcg combination, @DRUG$ 1/35 ).	DDI-false
Antiacid , clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , @DRUG$ , Phenobarbitol , @DRUG$ , Rifabutin , Rifampin , Ritanovir , Saquinavir .	DDI-false
Digoxin , Methotrexate , @DRUG$ : @DRUG$ , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs .	DDI-false
Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral @DRUG$ containing 0.03 mg ethinyl estradiol and 0.15 mg @DRUG$, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, @DRUG$, warfarin, @DRUG$ and phenobarbital.	DDI-false
Magnesium- and/or @DRUG$-containing antacids , products containing ferrous sulfate ( iron ) , multivitamin preparations containing zinc or other metal cations , or @DRUG$ Do not take chewable/buffered tablets or the pediatric powder for oral solution within 3 hours before or 2 hours after FACTIVE.	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$ , nifedipine , chlordiazepoxide , @DRUG$ , certain tricyclic antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-advise
These medicines include thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$ , estrogens , oral @DRUG$ , phenytoin , nicotinic acid , sympathomimet-ics , calcium channel blocking drugs , and isoniazid .	DDI-false
Although the magnitude of changes in @DRUG$ plasma exposure when coadministered with valdecoxib were not sufficient to warrant dosage adjustments , patients may experience enhanced sedative side effects caused by increased exposure of @DRUG$ Under these circumstances.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Drugs That Induce CYP3A4 ( Rifampicin ) Racemic @DRUG$ exposure was decreased 80 % by concomitant useof @DRUG$ , a potent inducer of CYP3A4 .	DDI-mechanism
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and @DRUG$).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac @DRUG$ , diuretics, H2 antagonists, @DRUG$ Prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , @DRUG$ chewable/buffered tablets or pediatric powder , or products containing @DRUG$ Iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-false
â€¢ Indinavir: concomitant use of @DRUG$ The use of VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and an 51% increase in nelfinavir plasma AUC. @DRUG$ plasma A.C.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, @DRUG$, diltiazem, @DRUG$, and some macrolide antibiotics.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
It is assumed that increased interaction between @DRUG$ and high affinity binding sites for apomorphine on dopamine2- and serotonin2-receptors underlies the antipsychotic action of @DRUG$ after their prolonged administration.	DDI-false
Concomitant use of agents in the @DRUG$ ( which includes @DRUG$ ) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug .	DDI-false
In addition , under the influence of sympatholytic medicinal products such as beta-blockers , clonidine , @DRUG$ , and @DRUG$ Signs of hypoglycaemia may be diminished or absent.	DDI-false
Effect of @DRUG$ on the Pharmacokinetics of Other Drugs : Clonazepam does not appear to alter the pharmacokinetics of @DRUG$ , carbamazepine , or phenobarbital .	DDI-false
It is recommended that serum lithium levels be monitored frequently if @DRUG$ is administered concomitantly with @DRUG$.	DDI-advise
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
- The action of @DRUG$ and @DRUG$ may be enhanced by Bezalip or Bezalip retard .	DDI-false
Potassium-sparing diuretics ( e.g. , @DRUG$ , triamterene , or amiloride ) , @DRUG$ supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$ , anticoagulants, oral vasodilators and additional oxygen. @DRUG$ or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , @DRUG$ Amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
It is recommended to avoid concurrent administration of @DRUG$ with aluminum hydroxide containing antacids for at least 4 hours following @DRUG$ administration.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa.	DDI-effect
Antiarrhythmia : Other antiarrhythmic drugs, such as @DRUG$ , procainamide , @DRUG$ , and phenytoin, were used at the same time as amiodarone.	DDI-false
Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-mechanism
Prednisone/@DRUG$: @DRUG$ did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.	DDI-false
@DRUG$: Inhibition of renal lithium clearance, leading to an increase in plasma @DRUG$ concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , @DRUG$ , nalbuphine, butorphanol, decicin and buprenorphine) should not be used in patients who have a history of treatment with a @DRUG$ such as Levo-Dromoran .	DDI-false
Physiological changes resulting from smoking cessation , with or without @DRUG$ The replacement may alter the pharmacokinetics of certain concomitant drugs, such as tricyclic antidepressants and @DRUG$.	DDI-false
Potential drug interactions between Keppra   and other AEDs ( carbamazepine , @DRUG$ , lamotrigine , @DRUG$ , phenytoin, primidone and valproate) were also evaluated by assessing levetiracetam serum concentrations and these AEDs in placebo-controlled clinical trials.	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain HMG-CoA reductase inhibitors, etc.).	DDI-mechanism
There are rare reports , however , from marketing experiences , of changes in effects of @DRUG$ Oral hypoglycaemic episodes in the presence of @DRUG$ The changes required in the doses of such agents.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Other Drug Interactions : No pharmacokinetic interactions were observed between vardenafil and the following drugs : glyburide , warfarin , digoxin , @DRUG$ , and @DRUG$.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodon, @DRUG$ , @DRUG$ , protease inhibitors, quinidine, and verapamil.	DDI-false
The pharmacokinetic or pharmacodynamic drug-effect interactions between: @DRUG$ and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1   g/kg/min . over 4 hours ) or acetaminophen ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of Argatroban 1.5   g/kg/min . over 18 hours ) .	DDI-false
Guardians of children who have been prescribed @DRUG$ should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of @DRUG$.	DDI-false
Bacteriostatic Antibiotics : Chloramphenicol , @DRUG$ The bactericidal effect of @DRUG$ may be impaired by sulfonamides, tetracyclines, or sulfonamides.	DDI-effect
Vaccines: Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and live or @DRUG$ due to inhibition of antibody response.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
Although no clinical studies have been conducted , it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers ( such as @DRUG$ , phenobarbital , @DRUG$ ) , CYP3A4 inhibitors ( azole antimycotics e.g. , ketoconazole ;	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
These drugs include the thiazides and other @DRUG$ , corticosteroids, phe-nothiazines, @DRUG$ , estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
Antacids : In a clinical pharmacology study, the concomitant use of antacids (aluminium hydroxide, @DRUG$ , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that @DRUG$ The absorption of Fosinopril may be impaired.	DDI-false
The co-administration of @DRUG$ â€¢ IV vasodilators such as nitroglycerin, nitroprusside, milrinone or IV-ACE inhibitors have not been studied (these medicinal products have not been co-administered with @DRUG$ in clinical trials ) .	DDI-false
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of @DRUG$.	DDI-effect
@DRUG$: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
While all the @DRUG$ (SSRIs), e.g., fluoxetine, sertraline, @DRUG$, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Cardiac effects of @DRUG$ Beta-adrenergic blocking agents, such as propranolol and @DRUG$, are directed against them.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, @DRUG$, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , @DRUG$ , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , @DRUG$ , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or @DRUG$, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-false
Ethopropazine may interact with @DRUG$ or other @DRUG$ , causing increased sedative effects .	DDI-false
Cytochrome P-450 inducers, such as phenytoin, carbamazepine and @DRUG$, induce @DRUG$ metabolism, causing an approximately 30% decrease in plasma clonazepam levels.	DDI-mechanism
Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral @DRUG$ , ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$ , propoxyphene , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers ( e.g. , @DRUG$ ), general anaesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$ , respiratory depression, hypotension, and deep sedation, or possibly lead to coma or death.	DDI-false
@DRUG$ The anorectic and stimulating effects of amphetamines can be inhibited by @DRUG$.	DDI-false
however , no deleterious interactions were seen when @DRUG$ was administered after narcotics , inhalational anesthetics , @DRUG$ Muscle relaxant antagonists used in combination with sedation or anaesthesia.	DDI-false
In vitro studies have shown that precipitation occurs when eye drops containing @DRUG$ are mixed with @DRUG$.	DDI-false
The use of local anesthetics containing epinephrine, or @DRUG$ to patients receiving monoamine oxidase inhibitors , @DRUG$ Or phenothiazines can cause severe, prolonged hypotension or hypertension.	DDI-effect
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine @DRUG$ : astemizole , terfenadine Antimigraine : @DRUG$ Antimycobacterial agents: rifampin benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
" Medicinal products not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, @DRUG$ Antimigraine: Ergot derivatives Antimycobacterial agents: rifampine benzodiazepine midazolam, triazolam GI motility agent: @DRUG$	DDI-false
@DRUG$ â€¢ patients receiving corticosteroid therapy may show a reduced response to toxoids and may be alive or @DRUG$ Because of the inhibition of the antibody response.	DDI-false
Cholestyramine and colestipol @DRUG$ : Absorption of @DRUG$ In the presence of anionic exchange resins the effect is impaired.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
- Antihypertensives : @DRUG$ The effect of various factors can be increased. @DRUG$ , necessitating a reduction in the dosage of these drugs .	DDI-effect
Coadministration of @DRUG$ ( 40 mg BID ( day 1 ) and 40 mg QD ( days 2 - 7 ) ) with glyburide ( 10 mg @DRUG$ The BID led to an increase in the AUC of glyburide by 21%-12 and an increase in Cmax of glyburide by 16%, resulting in a 16% decrease in the AUC of glucose.	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenyl-butazone , phenytoin sodium , carbamazepine and possibly with griseofulvin , @DRUG$ , and @DRUG$ ( 72 )	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , @DRUG$ , haloperidol, phenothiazine, @DRUG$ , tricyclic antidepressants or some antihistamines.	DDI-false
Nephrotoxicity following co-administration of cephalosporins with @DRUG$ Or potent diuretics like @DRUG$.	DDI-false
The effect of @DRUG$ on plasma lithium has not been studied, but cases of increased lithium plasma levels during @DRUG$ therapy have been reported.	DDI-false
- methotrexate (e.g. @DRUG$ The use of methotrexate with sulfapyridine may increase the likelihood of side effects affecting the liver and/or side effects of: @DRUG$	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral @DRUG$ , ACE inhibitors , disopyramide , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , @DRUG$ , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
@DRUG$ Treatment The urinary excretion of amphetamines is increased, and the efficacy is reduced by acidifying agents that are used in @DRUG$ therapy .	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing @DRUG$ (1 microgram/ml), @DRUG$ (10 ng/ml), and insulin (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
Dopamine antagonists : Da apomorphine is a @DRUG$ , it is possible that @DRUG$ , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
@DRUG$: Isoniazid is known to slow the metabolism of @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
Therefore , concurrent use of Trileptal with @DRUG$ may render these @DRUG$ less effective .	DDI-false
MAO Inhibitors: @DRUG$  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with @DRUG$	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ and @DRUG$.	DDI-effect
In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of @DRUG$ tolerance 30 min after @DRUG$ overload.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
Aspirin : Concomitant administration of low-dose aspirin with @DRUG$ This may lead to an increased rate of GI ulceration or other complications compared to the use of @DRUG$ alone .	DDI-false
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, salbutamol, terbutaline), @DRUG$ Phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g. oral) @DRUG$ ) .	DDI-false
Beta-blockers, clonidine, @DRUG$ salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
Patients receiving other @DRUG$s, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Hypotension   Patients on @DRUG$ Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.	DDI-false
- Carbamazepine : Isoniazid is known to slow down metabolism @DRUG$ Carbamazepine levels should be determined prior to co-administration with isooniazide, signs and symptoms of carbamazepine toxicity should be closely monitored and appropriate dose adjustment of the @DRUG$ It should be done.	DDI-false
Possible drug interactions of HUMORSOL with @DRUG$ or with other @DRUG$.	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
Potential drug interactions between Keppra   and other AEDs ( @DRUG$ , gabapentin , lamotrigine , @DRUG$ , phenytoin, primidone and valproate) were also evaluated by assessing levetiracetam serum concentrations and these AEDs in placebo-controlled clinical trials.	DDI-false
The hypoglycaemic effect of sulphonylureas may be caused by certain medicinal products, including: @DRUG$ and other drugs that are highly protein bound , salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and @DRUG$.	DDI-false
Therefore, patients under @DRUG$ therapy should be carefully monitored when concomitant @DRUG$ therapy is indicated.	DDI-advise
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors ( e.g. , cimetidine , @DRUG$ This effect can also be expected with CMI, and may be reduced by concomitant administration of liver enzyme inducers (e. g. barbiturates, phenytoin).	DDI-false
In patients with mild to moderate hypertension , administration of 25 mg daily of VIOXX with the @DRUG$ - benazepril, 10 to 40 mg over 4 weeks, was treated with an average increase in mean arterial pressure of approximately 3 mm Hg compared to @DRUG$ alone .	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or fluconazole.	DDI-false
Quinolones , including @DRUG$ , the effects of oral @DRUG$ , including warfarin or its derivatives or similar agents .	DDI-effect
@DRUG$ : Elevated @DRUG$ When SUPRAX is co-administered, levels have been reported during post-marketing use.	DDI-false
@DRUG$ : Concomitant treatment with Accutane and @DRUG$ The use of Accutane should be avoided as the use of Accutane has been associated with a number of cases of pseudotumour cerebri (benign intracranial hypertension), some of which involved the concomitant use of tetracyclines.	DDI-false
In clinical trials , FLOLAN was used with @DRUG$ , diuretics , anticoagulants , oral vasodilators , and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
It is recommended that if @DRUG$ is started in patients already receiving @DRUG$, prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary.	DDI-advise
- perhexiline hydrogen maleate or @DRUG$ ( with hepatotoxic potential ) must not be administered together with @DRUG$ or Bezalip retard .	DDI-advise
In clinical studies performed with Fondaparinux , the concomitant use of oral @DRUG$ ( warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ Piroxicam and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, @DRUG$ before cisplatin).	DDI-false
protein binding in vitro, @DRUG$ If the protein binding of salicylic acid ( 20 % decrease in binding ), tolbutamide does not affect minimally or at all the protein binding of salicylic acid ( 20 % decrease in binding ), @DRUG$ ( 10% decrease in binding ) or warfarin.	DDI-mechanism
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, @DRUG$, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with @DRUG$ , beta-blockers , felodipine , digoxin , @DRUG$ , isosorbide mononitrate, knitztilol, ethanol or itraconazole.	DDI-false
Moreover , additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels , and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data .	DDI-false
@DRUG$ in large amounts may counteract the antiepileptic effect of phenobarbital , @DRUG$ And increase the frequency of seizures in susceptible paediatric patients.	DDI-effect
@DRUG$: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and thiazide diuretics.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral @DRUG$).	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e.g. , cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , barbiturates , @DRUG$ ), and such an effect may be associated with: @DRUG$ as well .	DDI-mechanism
The coadministration of @DRUG$ decreases the biologic half-life of @DRUG$ because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine .	DDI-mechanism
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( phenytoin , valproate , oral contraceptive , @DRUG$ , @DRUG$ , probenecid) and by pharmacokinetic screening in placebo-controlled clinical trials in epilepsy patients.	DDI-false
Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Diphenhydramine hydrochloride has additive effects on alcohol and other @DRUG$ ( hypnotics , @DRUG$ , tranquilizers , etc ) .	DDI-false
@DRUG$ , clonidine, lithium salts and alcohol may either increase or weaken the blood sugar lowering effect of @DRUG$.	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ These include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$ Sodium colistimethate, magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-effect
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , @DRUG$ , @DRUG$ , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
* Cytochrome P-450 inducers, such as: @DRUG$ , carbamazepine and @DRUG$ , induce clonazepam metabolism , causing an approximately 30 % decrease in plasma clonazepam levels .	DDI-false
@DRUG$ : @DRUG$ Concentrations are increased by approximately 15% when digoxin and scremilol are co-administered.	DDI-false
@DRUG$, Methotrexate, Cyclosporine: Diclofenac, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
Monitoring for @DRUG$ - Toxicity and serial measurement of @DRUG$ Serum concentration should be considered during concomitant therapy with protease inhibitors.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , sulfonamides , chloramphenicol , probenecid , @DRUG$ , monoamine oxidase inhibitors , and @DRUG$.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, @DRUG$ , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , @DRUG$ ==References====External links==	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
CNS-active medicinal products ethanol : @DRUG$ 10 mg potentiated the CNS-impairing effects of @DRUG$ 0,75 g/kg for balance tests and response time for 1 hour after ethanol administration and on the number symbol substitution test ( DSST ), symbol copy test and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-effect
Digitalis glycosides: @DRUG$-induced hypokalemia may potentiate @DRUG$ toxicity.	DDI-effect
There have been isolated reports of patients experiencing increases in their prothrombin times when @DRUG$ was added to @DRUG$ therapy.	DDI-effect
Cohort 1 then received @DRUG$ plus @DRUG$ for 10 days, and cohort 2 received amprenavir plus rifampin for 4 days.	DDI-false
however, it adversely affected response duration suggesting that @DRUG$ should not be administered with HEXALEN and/or @DRUG$.1	DDI-advise
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Indinavir: Co-administration of indinavir and VIRACEPT resulted in an increase in @DRUG$ plasma AUC and a 51 % increase in @DRUG$ plasma A.C.	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Valproate : The addition of tiagabin to patients who received valproate chronically did not affect the pharmacokinetics of tiagabin, but @DRUG$ significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8 % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .	DDI-mechanism
Benzylpenicillin , @DRUG$ , oxacillin , @DRUG$ In vitro, doxycycline, cephalothine, erythromycin and sulfamethoxazole have no influence on the protein binding of diclofenac in human serum.	DDI-false
@DRUG$: Probenecid, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of @DRUG$ 1000 mg twice daily.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , @DRUG$ , disulfiram , @DRUG$ , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	DDI-false
In vitro data suggest that: @DRUG$ , when compared to ketoconazole , has a less pronounced effect on the biotransformation system responsible for the metabolism of @DRUG$.	DDI-mechanism
@DRUG$ gastrointestinal acidification agents ( @DRUG$ , reserpine , glutamic acid HCl , ascorbic acid , fruit juices , etc . ) lower absorption of amphetamines .	DDI-false
Antiepileptics : Possible interactions between @DRUG$ and other @DRUG$ were assessed in clinical studies .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Possible drug interactions between Keppra and other AEDs (carbamazepine, @DRUG$ , lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
Other medicines: In small groups of patients ( 7 - 10 / interaction study ), concomitant administration of azathioprin, gold, chloroquine, D-penicillamin, prednisolone, @DRUG$ , or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
@DRUG$ ( e. g. , ketoconazole , @DRUG$ In vitro and animal studies with the combination of amphotericin B and imidazoles indicate that imidazoles may cause fungal resistance to amphotericin B.	DDI-false
The initiation of @DRUG$ or @DRUG$ use may be precipitated by similar personality characteristics in the user, such as impulsivity and sensation seeking.	DDI-false
The effects of DCG-IV and L-CCG-1 upon @DRUG$ (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
Combination of @DRUG$ with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been used in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, @DRUG$ , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
Caution should also be taken in concurrent or serial use of other @DRUG$ and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate @DRUG$ Neuromuscular blocking effects.	DDI-false
This drug may interact with alcohol or other CNS depressants ( may potentiate the CNS depressant effects of either these medications or antihistamines ) , anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$ Concomitant use with antihistamines may have the anticholinergic and CNS depressive effects of @DRUG$ ) .	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : @DRUG$ Antimycobacterial agents: rifampin benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-advise
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , @DRUG$ , amikacin ) , @DRUG$ , cyclosporine , non-steroidal anti-inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin .	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , gentamicin , and amikacin ) , amphotericin B , @DRUG$ , intravenous pentamidine , @DRUG$ , and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Ethinyl Estradiol and @DRUG$ : Coadministration of VIRACEPT with OVCON-35 resulted in a 47 % decrease in ethinyl estradiol and an 18 % decrease in @DRUG$ plasma concentrations .	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , sulfonamides , @DRUG$ , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-effect
@DRUG$: In vitro data indicate that nefazodone inhibits the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, @DRUG$ , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	DDI-false
No important interactions to date @DRUG$ No clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$ Ethanol or itraconazole.	DDI-false
Magnesium- and/or @DRUG$-containing antacids , products containing ferrous sulfate ( iron ) , multivitamin preparations containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$ , beta-blockers, felodipine, digoxin, warfarin, @DRUG$ ==References====External links==	DDI-false
Imipramine ( 5 mg/kg ) , moclobemide ( 30 mg/kg ) , @DRUG$ Fluoxetine ( 20 mg/kg) @DRUG$ 30 mg/ kg) or vehicle.	DDI-false
It is recommended that if @DRUG$ is started in patients already receiving coumarin anticoagulants, prothrombin times should be closely monitored and adjustment of the @DRUG$ dose may be necessary.	DDI-advise
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, @DRUG$, and nifedipine.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$ FORADIL should be used with extreme caution in patients who are treated with: @DRUG$ Or tricyclic antidepressants, because the effect of formoterol on the cardiovascular system can be enhanced by these active substances.	DDI-false
@DRUG$ NSAIDs have an increase in plasma lithium levels and a decrease in renal @DRUG$ clearance .	DDI-false
- drug interactions between argatroban and co-administered aspirin ( 162.5 mg orally 26 and 2 hours before starting argatroban 1 g/kg/min for 4 hours), or @DRUG$ ( 1000 mg orally administered 12, 6 and 0 hours before, and 6 and 12 hours after, start of argatroban 1.5 g/kg/min. over 18 hours).	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, @DRUG$ , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and @DRUG$.	DDI-false
Aspirin : When @DRUG$ is administered with @DRUG$ His protein binding is reduced, although the clearance of free etodolac is not altered.	DDI-mechanism
When Anafranil is co-administered, close monitoring and careful dose adjustment are required. @DRUG$ or @DRUG$.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$ , azathioprin, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
Patients receiving @DRUG$, sulfonamides, or @DRUG$ should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.	DDI-false
Phenylbutazone: @DRUG$ causes increase (by about 80%) in the free fraction of @DRUG$.	DDI-mechanism
Beta-Blocking Agents   A pharmacokinetic study of felodipine in conjunction with @DRUG$ demonstrated no significant effects on the pharmacokinetics of @DRUG$.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
The effect of orally ingested @DRUG$ or @DRUG$ The breast milk on the infant was not evaluated.	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, @DRUG$ , thyroid products , estrogens , oral @DRUG$ , phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
The absorption of @DRUG$ , furosemide , penicillin G , hydrochlorothiazide , and @DRUG$ When co-administered with colestipol hydrochloride, the dose was significantly reduced;	DDI-false
@DRUG$, bepridil, sparfloxacin, and @DRUG$.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
As MHD, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., @DRUG$, @DRUG$).	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , @DRUG$ , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Can interact with the following: @DRUG$ , Colestipol (application with @DRUG$ â€¢ can prevent the diuretic from working properly;	DDI-effect
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, @DRUG$, @DRUG$, simvastatin).	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : @DRUG$ , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : @DRUG$	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, @DRUG$, reserpine.	DDI-effect
Olanzapine: Coadministration of @DRUG$ 3 mg and @DRUG$ 10 mg produced a decrease in DSST scores.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
@DRUG$ : @DRUG$ decreases lithium renal clearance and increases lithium plasma levels .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
In clinical studies, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators and additional oxygen. @DRUG$ or digoxin in whom therapy with @DRUG$ The apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13% and 15% respectively on the second day of therapy and were returned to baseline by day 87.	DDI-mechanism
Ethinyl Estradiol and Norethindrone: Coadministration of @DRUG$ with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-mechanism
This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or beta-adrenergic blocking agents , @DRUG$ Antihistamines or H1-blockers, tricyclic antidepressants and @DRUG$ ) could also contribute to an extension of the QTc interval.	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with 5HT3 antagonist class medications (including, for example, ondansetron, granisetron, @DRUG$ , palonosetron , and @DRUG$ ) is contraindicated .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
- Carbamazepine : Isoniazid is known to slow down metabolism @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of @DRUG$ toxicity should be monitored closely , and appropriate dosage adjustment of the anticonvulsant should be made .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as @DRUG$ ) , and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
MAO Inhibitors: @DRUG$  is not recommended for use in patients who have received @DRUG$ within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics	DDI-advise
The effects of mixing NovoLog with @DRUG$ - animal origin; or @DRUG$ preparations produced by other manufacturers have not been studied .	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e.g. , cimetidine , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , @DRUG$ , @DRUG$ ) , and such an effect may be anticipated with CMI as well .	DDI-false
Multivalent Cation-Containing Products : Simultaneous Application of a @DRUG$ , including ciprofloxacin, containing multivalent cational products such as magnesium or @DRUG$ Antacids, sucralfate, VIDEX chewable tablets or paediatric powders or products containing calcium, iron or zinc may significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-mechanism
This medication may interact with alcohol or other CNS depressants (may enhance the CNS depressive effect of either these drugs or antihistamines), anticholinergics or other anticholinergic drugs (anticholinergic effects may be intensified if these drugs are used simultaneously with antihistamines), and @DRUG$ ( concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$ ) .	DDI-false
Sedatives/@DRUG$ : triazolam , @DRUG$ CONTRAINDICATE because of the potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampine benzodiazepines midazolam, @DRUG$ GI motility agents : cisapride	DDI-false
- Anabolic steroids ( nandrolone [ e.g. , Anabolin ] , oxandrolone [ e.g. , Anavar ] , @DRUG$ [ e.g. , @DRUG$ ] , stanozolol [ e.g. , Winstrol ] ) or	DDI-false
The use of antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimid, @DRUG$ , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , @DRUG$ And vincristine.	DDI-false
@DRUG$ , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain @DRUG$ , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-mechanism
The concomitant use of @DRUG$ with @DRUG$ may result in an increased rate of GI ulceration or other complications , compared to use of CELEBREX alone .	DDI-effect
In clinical trials, @DRUG$ was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated , apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
@DRUG$ caused a statistically significant increase in plasma exposures of R-warfarin and @DRUG$ (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.	DDI-mechanism
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, @DRUG$, diltiazem, isoniazide, and some macrolide antibiotics.	DDI-mechanism
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Since amiodarone is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels.	DDI-false
Higher concentrations of dexamethasone (10(-8) - 10(-6) M) or @DRUG$ (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of @DRUG$.	DDI-effect
The absorption of the oral @DRUG$ Simultaneous administration of antacid containing aluminium and @DRUG$ is significantly reduced.	DDI-mechanism
Amprenavir significantly increased the area under the steady state curve ( AUC(sss ) @DRUG$ 2,93-fold and AUC(ss) of @DRUG$ by 13.3-fold .	DDI-false
Caution should be exercised when an HMG-CoA reductase inhibitor is administered concomitantly with medicinal products that may reduce the concentration or activity of endogenous steroid hormones, such as ketoconazole, @DRUG$ , and @DRUG$.	DDI-false
Drug interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-effect
In an emergency situation when opioid analgesia must be administered to a patient receiving @DRUG$, the amount of @DRUG$ required may be greater than usual, and the resulting respiratory depression may be deeper and more prolonged.	DDI-effect
Antiarrhythmics : Other @DRUG$ drugs , such as @DRUG$ , procainamide , disopyramide , and phenytoin , have been used concurrently with amiodarone .	DDI-false
ACE inhibitors: Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
Multivitamins, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
- Anabolic steroids ( @DRUG$ [ e.g. , Anabolin ] , @DRUG$ [ e.g. Anavar ], oxymetholone [ e.g. Anadrol ], Stanozolol [ e.g. Winstrol ] or	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
@DRUG$: Concomitant use of @DRUG$ may increase the risk of renal impairment, particularly in volume-depleted patients.	DDI-false
Although these results do not indicate a significant interaction between TORADOL and warfarin or @DRUG$, the administration of @DRUG$ to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	DDI-false
however, 150 mg of ranitidine q12h for 3 days increased the @DRUG$ C max by 23% and @DRUG$ AUC by 16%.	DDI-false
The gastrointestinal absorption of @DRUG$ When used concurrently with @DRUG$, ranitidine is accelerated.	DDI-mechanism
Loratadine ( 10 mg once daily ) has been coadministered with therapeutic doses of @DRUG$ , @DRUG$ , and ketoconazole in controlled clinical pharmacology studies in adult volunteers .	DDI-false
Coadministration of @DRUG$ and @DRUG$ 1/35  increased the exposure of norethindrone and ethinyl estradiol by 20% and 34%, respectively.	DDI-mechanism
Although glucocorticoids have shown to reduce @DRUG$-induced adverse reactions including fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, concomitant use of these active substances with @DRUG$ Beta-blockers and other antihypertensive agents may increase hypotension in PROLEUKIN.	DDI-false
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, clonidine, @DRUG$, and @DRUG$, the signs of hypoglycemia may be reduced or absent.	DDI-false
@DRUG$ should not be used in patients receiving @DRUG$..	DDI-advise
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Experience with co-administration of HMG-CoA reductase inhibitors and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of @DRUG$ in patients receiving @DRUG$.	DDI-advise
A two-way interaction between the @DRUG$ , @DRUG$ The coumarin anticoagulants were proposed.	DDI-int
- Lithium : @DRUG$ In general, diuretics (e.g. @DRUG$ ) because they reduce its renal clearance and add a high risk of lithium toxicity .	DDI-advise
Other potent inhibitors of CYP3A4 (e.g. itraconazole, clarithromycin, nefazodone, troleandomycin, @DRUG$ , @DRUG$ ) would be expected to behave similarly .	DDI-false
Selective Serotonin Reuptake Inhibitors ( SSRIs ): @DRUG$ (e.g. fluoxetine, fluvoxamine, paroxetine, @DRUG$ ) have been rarely reported to cause weakness, hyperreflection, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - @DRUG$ : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of @DRUG$ and @DRUG$.	DDI-advise
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and @DRUG$ ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and @DRUG$ with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Considerable caution should be exercised if PEGANONE is administered concurrently with @DRUG$ ( @DRUG$ As paranoid symptoms have been reported during therapy with this combination.	DDI-false
Rifampin : Co-administration of @DRUG$ rifampin 600 mg daily, a potent inducer of hepatic metabolism, caused @DRUG$ plasma concentrations .	DDI-false
The concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, @DRUG$ Myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g. methotrexate), @DRUG$ Effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
The co-administration of Natrecor with IV @DRUG$ Like nitroglycerin, nitroprusside, @DRUG$ ACE inhibitors have not been studied (these medicinal products have not been administered with Natrecor in clinical trials).	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , cefamandole , @DRUG$ or methylthiadiazole ( @DRUG$ ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Co-administration of @DRUG$ with Acamprosate produced a 25% increase in AUC and a 33% increase in the Cmax of @DRUG$.	DDI-false
@DRUG$ : Amphetamines may antagonize the hypotensive effects of @DRUG$.	DDI-false
The effect of valdecoxib on the anticoagulant effect of valdecoxib @DRUG$ ( 1 - 8 mg/day ) was studied in healthy subjects by coadministration of @DRUG$ 40 mg BID for 7 days .	DDI-false
In vitro studies have shown @DRUG$ can displace coumarin anticoagulants, such as @DRUG$, from their protein-binding sites.	DDI-mechanism
decreased levels of anti-factor Xa and @DRUG$, decreased @DRUG$ activity;	DDI-false
@DRUG$ showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude @DRUG$.	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , granisetron , dolasetron , @DRUG$ ==References====External links==	DDI-false
@DRUG$ : @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely , and appropriate dosage adjustment of the anticonvulsant should be made .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and nifedipine.	DDI-int
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and @DRUG$ Etodolac capsules and tablets lead to reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.	DDI-mechanism
@DRUG$ Interaction with other medicinal products metabolised by cytochrome P450 ( CYP): In vitro studies indicate that: @DRUG$ CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A were not inhibitory to the major cytochrome P450 isoforms.	DDI-false
Therefore, if digoxin is administered with @DRUG$, the clinician should be alert to the possibility of increases in @DRUG$ levels.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Caution is therefore advised when administering @DRUG$ to patients receiving @DRUG$.	DDI-advise
Anticholinesterases ( neostgmine , @DRUG$ ) , @DRUG$ , quinine , procainamide can enhance toxicity and cause cardio respiratory depression .	DDI-false
Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other @DRUG$ while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-false
Other interactions: @DRUG$ had no effect on the pharmacodynamics of glyburide (glucose and insulin concentrations) and @DRUG$ (prothrombin time or other pharmacodynamic parameters).	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
- anabolic steroids (Nandrolone [e.g. Anaboline ], @DRUG$ [ e.g. , @DRUG$ ], oxymethol [ e.g. Anadrol ], stanozole [ e.g. Winstrol ] or	DDI-false
The successive use of glycine ( 5 or 10 mg/kg egg weight (e.g.) and @DRUG$ 15 mg/kg E.w.) in a 10-minute interval, significantly the activation of spontaneous mobility of 17-day-old chick embryos compared to the effect of @DRUG$ alone .	DDI-false
@DRUG$ : In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and @DRUG$ were administered concomitantly for 6 days .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$ , imatinib , isoniazid , nefazodone , nicardipine , @DRUG$ , protease inhibitors, quinidine, and verapamil.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-advise
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Naproxen : The concomitant administration of @DRUG$ In normal subjects, naproxene and naproxene did not affect naproxene plasma levels, but significantly reduced the urinary excretion of naproxene. @DRUG$ and its glucuronide metabolite .	DDI-false
Concurrent administration of @DRUG$ and @DRUG$ may result in elevated serum levels of oxyphenbutazone.	DDI-mechanism
Concomitant administration of @DRUG$ , and other related compounds (e.g., @DRUG$ , quinidine and chloroquine ) may produce electrocardiographic abnormalities and increase the risk of convulsions .	DDI-effect
Acid-catalyzed ethanolysis of @DRUG$ in anhydrous and aqueous @DRUG$ solutions.	DDI-mechanism
Drug interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): @DRUG$ - Arecoline - Eproxindine - Ethanol : Flupentixol and ethanol cause additive CNS depression - Tricyclic antidepressants : Flupentixol increases the effect of @DRUG$	DDI-false
@DRUG$: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazides in some patients.	DDI-false
In patients receiving @DRUG$, the addition of @DRUG$ to therapy could prolong the prothrombin time.	DDI-effect
@DRUG$: In an interaction study of rheumatoid arthritis patients taking @DRUG$, CELEBREX did not have a significant effect on the pharmacokinetics of methotrexate.	DDI-false
Aspirin/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ ( 162.5 mg orally 26 and 2 hours before starting treatment with argatroban 1 g/kg/min for 4 hours) or @DRUG$ ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of Argatroban 1.5   g/kg/min . over 18 hours ) .	DDI-false
In separate studies of patients receiving maintenance doses of @DRUG$, @DRUG$, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
Therefore, the concomitant administration of @DRUG$ and glyburide is contraindicated, and alternative @DRUG$ should be considered.	DDI-false
@DRUG$ : @DRUG$ have been reported to cause a significant decrease in corticosteroid clearance .	DDI-false
Patients receiving high doses of @DRUG$ concomitantly with @DRUG$, as in rheumatic disease, may experience salicylate toxicity at lower doses because of competitive renal excretory sites.	DDI-effect
There have been reports of theophylline-related side effects in patients on concomitant therapy with @DRUG$ and @DRUG$.	DDI-effect
Insulin or oral hypoglycaemia: @DRUG$ may enhance the blood-sugar-reducing effect of @DRUG$ and oral hypoglycemics .	DDI-effect
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., @DRUG$, ritonavir, and erythromycin) has not been studied, increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications.	DDI-false
@DRUG$ The therapeutic effect of other @DRUG$ may be increased or increased.	DDI-effect
Compounds tested in humans include antipyrin, @DRUG$ , @DRUG$ Theophylline, warfarin and no clinically significant interactions were found.	DDI-false
Acetaminophen: In normal volunteers, concomitant administration of @DRUG$ and @DRUG$ resulted in an approximate 50% increase in plasma levels of acetaminophen.	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and procainamide, @DRUG$ and tricyclic anti-depressants.	DDI-false
Caution is therefore advised when administering @DRUG$ to patients receiving @DRUG$.	DDI-advise
@DRUG$ : Gastrointestinal acidifying agents ( guanethidine , @DRUG$ , glutamic acid HCl, ascorbic acid, fruit juices, etc. ) lower absorption of amphetamines.	DDI-false
@DRUG$ No significant differences in steady-state pharmacokinetics were observed. @DRUG$ When tiagabin is given as a single dose or S-warfarin.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Rhabdomyolysis has been observed in patients receiving @DRUG$ administered alone (at recommended dosages) or concomitantly with immunosuppressive drugs including @DRUG$.	DDI-effect
The administration of local @DRUG$ â€¢ Epinephrine or norepinephrine for patients who have monoamine oxidase inhibitors, tricyclic antidepressants, or @DRUG$ may produce severe , prolonged hypotension or hypertension .	DDI-effect
Magnesium/Aluminum-containing @DRUG$: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	DDI-false
In clinical trials with: @DRUG$ , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , @DRUG$ ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ Ciprofloxacin is co-administered with an intravenous opiate such as @DRUG$.	DDI-mechanism
@DRUG$: amphotericin B-induced hypokalemia may potentiate @DRUG$ toxicity.	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV were associated with beta-adrenergic blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$ , prazosin and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
Nifedipine: Vardenafil 20 mg, when co-administered with slow-release @DRUG$ 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of @DRUG$, a drug that is metabolized via CYP3A4.	DDI-false
Another oral @DRUG$, @DRUG$, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.	DDI-false
Simultaneous administration of mefloquine and other related compounds (e.g. quinine, @DRUG$ and @DRUG$ ) may produce electrocardiographic abnormalities and increase the risk of convulsions .	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ Eproxindine - ethanol : @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
However, concomitant administration of @DRUG$ with CELEBREX may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	DDI-false
Like ibogain ( 40 mg/kg), @DRUG$ ( 40 mg/kg ) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats ;	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$ Co-administration of apomorphine with medicinal products of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$ , palonosetron , and alosetron ) is contraindicated .	DDI-false
Therapeutic concentrations of digoxin, warfarin, @DRUG$, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
In comparison of the digitalis tolerance in dogs stunned with @DRUG$ , Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital .	DDI-effect
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: MTX, @DRUG$ , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , @DRUG$ , sulfasalazine , and anakinra .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in @DRUG$ metabolism, inhibitors of this enzyme system, notably oral @DRUG$, should be used cautiously in patients receiving clonazepam.	DDI-false
Use with Allopurinol: The principal pathway for detoxification of @DRUG$ is inhibited by @DRUG$.	DDI-mechanism
Patients receiving other @DRUG$s, general anaesthetics, phenothiazines, sedatives, sedative hypnotics, tricyclic antidepressants or others @DRUG$ ( including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression .	DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like dihydroergotamine or @DRUG$) and @DRUG$ within 24 hours of each other should be avoided.	DDI-advise
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and @DRUG$.	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$ , isosorbide mononitrate, schnitztilol, ethanol or @DRUG$.	DDI-false
Acidifying agents: @DRUG$ (@DRUG$, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Since animal studies indicated that the effect of @DRUG$ It can be an extension of treatment with @DRUG$ , barbiturates should be employed with caution .	DDI-effect
Hormonal Contraceptives , Including Oral , Injectable , Transdermal , and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ * Ortho-Novum caused average decreases in norethindron and @DRUG$ levels of 14 % and 31 % , respectively .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
While no in vivo drug-drug interaction studies were conducted between @DRUG$ and inducers of CYP3A , compounds that are potent CYP3A inducers ( such as carbamazepine , phenytoin , rifampin , and barbiturates ) would be expected to decrease @DRUG$ concentrations .	DDI-mechanism
@DRUG$ , such as @DRUG$ Diltiazem and nifedipine inhibit platelet activation in vitro and reduce intravascular adhesion of platelets.	DDI-false
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of azathioprine , @DRUG$ , chloroquine , D-penicillamine , prednisolone , @DRUG$ , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
@DRUG$ ( 10 mg once daily ) has been coadministered with therapeutic doses of erythromycin , @DRUG$ , and ketoconazole in controlled clinical pharmacology studies in adult volunteers.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , @DRUG$ , calcium channel blocking drugs , and @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$: In a single-dose interaction study in NIDDM subjects, decreases in @DRUG$ AUC and Cmax were observed, but were highly variable.	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$ , diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ And metronidazole, which delays the elimination and increase in blood levels of these drugs.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
- @DRUG$ ( nandrolone [ e.g. , Anabolin ] , oxandrolone [ e.g. , @DRUG$ ] , oxymetholone [ e.g. , Anadrol ] , stanozolol [ e.g. , Winstrol ] ) or	DDI-false
The effect of benzodiazepines can be enhanced by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$ , @DRUG$ , or other medicines that produce CNS depression.	DDI-false
Co-administration of HEXALEN with MAO inhibitor class antidepressants may lead to severe orthostatic hypotension.@DRUG$, an inhibitor of microsomal drug metabolism, increased the half-life of @DRUG$ and toxicity in a rat model.	DDI-mechanism
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-false
@DRUG$ Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazine, butyrophenone, thioxanthene) or @DRUG$ , may diminish the effectiveness of APOKYN .	DDI-false
Although no interaction between @DRUG$ Levo-dromoran and levo-dromoran have been observed, it is not recommended for use with @DRUG$.	DDI-false
@DRUG$ A iodine deficiency may increase the effect of @DRUG$.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$ , calcium channel blockers, cardiac nitrates, diuretics, @DRUG$ , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Antibiotics : In vitro and/or in vivo data show that @DRUG$ , @DRUG$ , and troleandomycin significantly inhibit the metabolism of cisapride, which may lead to an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Ketoconazole did not affect the conversion of @DRUG$ to the active metabolite after intravenous administration of @DRUG$ , and erythromycin had no clinically significant effect after oral administration .	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	DDI-false
@DRUG$ Diclofenac and other NSAIDs can inhibit the activity of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
- @DRUG$ Administration of methotrexate with sulfapyridine may increase the likelihood of side effects affecting the liver and/or side effects of methotrexate. @DRUG$	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ Phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.	DDI-false
Anticoagulants such as coumarin derivatives, indandion derivatives and platelet aggregation inhibitors such as non-steroidal anti-inflammatory drugs (NSAIDs) and @DRUG$ may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Although there is no documentation of such, a similar interaction between @DRUG$ and the @DRUG$ may occur .	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ with aminoglycoside antibiotics or potent diuretics such as @DRUG$.	DDI-effect
Lithium : @DRUG$ An increase in lithium plasma levels and a decrease in renal @DRUG$ clearance .	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-effect
Administration of @DRUG$ to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as @DRUG$ which sensitize the myocardium, may induce cardiac arrhythmia..	DDI-effect
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg @DRUG$ BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in @DRUG$ Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
Interaction of GABITRIL with Other Drugs : @DRUG$ : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on @DRUG$ pharmacokinetics.	DDI-false
Similarly dialyzed were phenobarbital, quinidine, and @DRUG$, both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum.	DDI-false
The effect of @DRUG$ on plasma lithium has not been studied , but cases of increased @DRUG$ plasma levels during TORADOL therapy have been reported .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Paroxetine: Coadministration of a single dose of @DRUG$ 20 mg and @DRUG$ 20 mg daily for 7 days did not produce any interaction on psychomotor performance.	DDI-false
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), @DRUG$ ( @DRUG$ NSAIDs (piroxicam) and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Other potent inhibitors of CYP3A4 (e.g. @DRUG$ , clarithromycin , @DRUG$ It is expected that troleandomycin, ritonavir, nelfinavir will behave similarly.	DDI-false
In single and multiple dose studies in healthy subjects receiving both @DRUG$ and @DRUG$ , prothrombin time ( measured as INR ) was increased by approximately 8 % to 11 % .	DDI-effect
@DRUG$ , and to a lesser extent, @DRUG$ , enhanced the translocating effect of oleate and increased its effectiveness in the transfer of phosphohydrolase from soluble to microsomal fraction.	DDI-false
@DRUG$ may interfere with the anti-glaucoma action of @DRUG$ or pilocarpine;	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
Injection : Lorazepam injection , like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl alcohol , @DRUG$ , @DRUG$ An increased incidence of sedation, hallucinations and irrational behaviour was observed with co-administration of scopolamine with injectable lorazepam.	DDI-false
@DRUG$ may decrease vascular response to pressor drugs such as @DRUG$.	DDI-effect
While all the @DRUG$ (SSRIs), e.g., fluoxetine, sertraline, paroxetine, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of @DRUG$ compared to etoposide alone.	DDI-false
Interactions may occur between EPA supplements and aspirin and other @DRUG$ and herbs such as garlic (Allium sativum) and ginkgo (@DRUG$).	DDI-false
Co-administration of valdecoxib ( 40 mg twice daily ( day 1 ) and 40 mg twice daily ( days 2 - 7 ) with glyburide ( 10 mg twice daily ) resulted in an increase in the @DRUG$ AUC0 - 12 and an increase of 16% @DRUG$ Cmax leading to a 16 % decrease in glucose AUC0 - 24 .	DDI-false
@DRUG$ did not affect the conversion of @DRUG$ to the active metabolite after intravenous administration of losartan , and erythromycin had no clinically significant effect after oral administration .	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein-bound, @DRUG$ , sulfonamides , chloramphenicol , @DRUG$ , Cumarine, monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-false
@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , @DRUG$ , acetaminophen , @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
@DRUG$ : @DRUG$ are inhibited by amphetamines .	DDI-false
Both efavirenz and @DRUG$ The treatment with PI indinavir was compared with triple therapy as early therapy for 48 weeks, with similar reactions observed with nevirapine therapies and superiority with @DRUG$.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens with sequentially high-dose PROLEUKIN and antineoplastic agents, especially dacarbazine. @DRUG$ , @DRUG$ and interferon-alfa .	DDI-false
@DRUG$ In a clinical pharmacology study, the concomitant use of antacids (aluminium hydroxide, @DRUG$ , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
Therapeutic concentrations of digoxin, @DRUG$ , @DRUG$ , naproxen , piroxicam , acetaminophen , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
Patients in a clinical study who were on established therapy with @DRUG$, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or sulfasalazine alone.	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-false
In EM patients treated with paroxetine, or @DRUG$ , the AUC of @DRUG$ The maximum is about 3- to 4-fold greater than atomoxetine alone.	DDI-mechanism
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Cyclopropane or @DRUG$ increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$, such as dopamine.	DDI-effect
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Effects of @DRUG$ on other Antiepilepsy Drugs (AEDs) : @DRUG$: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
It is recommended to avoid concurrent administration of ethambutol with @DRUG$ containing antacids for at least 4 hours following @DRUG$ administration.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
However, because some @DRUG$ have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients , the prothrombin time or other suitable coagulation test should be closely monitored if a @DRUG$ is administered concomitantly with warfarin or its derivatives .	DDI-false
Medicines not to be treated at the same time @DRUG$ Antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, terfenadine antimigrain: ergot derivatives antimycobacterial agents: rifampine benzodiazepine midazolam, triazolam GI motility agent: @DRUG$	DDI-advise
Multivitamins, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, @DRUG$, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$ ; Amiodaron, bepridil, @DRUG$ , propafenone , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
Patients receiving these drugs who are given @DRUG$ , or any other @DRUG$ The development of the specific toxicities of these drugs should be monitored, and especially patients with altered renal function.	DDI-false
There was no apparent pharmacokinetic interaction between @DRUG$ and @DRUG$ following single dose administration (10 mg and 600 mg, respectively) of each drug.	DDI-false
Therefore, EXTREME WARNING should be used when @DRUG$ to patients receiving @DRUG$ Hydrocarbon anaesthetics.	DDI-advise
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
In an emergency situation where opioid analgesia must be used in patients who: @DRUG$ , the amount of @DRUG$ required may be greater than usual , and the resulting respiratory depression may be deeper and more prolonged .	DDI-effect
because of this , the dosage of @DRUG$ ), should be adjusted if this @DRUG$ The medicine is given at the same time.	DDI-false
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: @DRUG$ , terfenadine Antimigraine : @DRUG$ Antimycobacterial agents: rifampin benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
acetaminophen/@DRUG$ , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/@DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Concomitant administration of Mefloquine and other related compounds ( eg , @DRUG$ , quinidine and @DRUG$ ) may cause electrocardiographic abnormalities and increase the risk of convulsions.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
The following examples are known to inhibit the metabolism of other related benzodiazepines, probably by inhibition of CYP3A: nefazodone, @DRUG$ , cimetidine , @DRUG$ Isoniazid, and some macrolide antibiotics.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of @DRUG$ , with @DRUG$ or Innovar than with pentobarbital .	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ Plasma concentrations : Caution recommended for use @DRUG$ With inhibitors of the CYP3A4 family (e.g. ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
No pharmacokinetic interactions between @DRUG$ and isoflurane, propofol, @DRUG$, and midazolam have been demonstrated.	DDI-false
The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, @DRUG$ before @DRUG$).	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, @DRUG$ , lincomycin , @DRUG$ , colistine, and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide, and quinidine.	DDI-false
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive everolimus tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with @DRUG$ and @DRUG$.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Although in clinical studies with IOPIDINE 0.5 % ophthalmic solution no specific drug interactions with topical glaucoma or systemic drugs have been identified, there is a possibility of additive or potentiating effects with: @DRUG$ - alcohol, barbiturates, @DRUG$ , sedatives, anaesthetics) should be considered.	DDI-false
Diphenhydramine hydrochloride has additive effects with @DRUG$ CNS depressants and other CNS depressants ( @DRUG$ , sedatives , tranquilizers , etc ) .	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
Hormonal @DRUG$ Co-administration of Trileptal with an oral @DRUG$ has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Coadministration of Itraconazole and @DRUG$, @DRUG$ or digoxin has led to increased plasma concentrations of the latter three drugs.	DDI-false
- Poor Metabolisers of Schuttoquin : Interactions of @DRUG$ Not studied with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine and propafenone), but these drugs are expected to increase blood levels of the R(+) enantiomer. @DRUG$ .	DDI-false
@DRUG$, and to a lesser extent, @DRUG$, enhanced the translocating action of oleate and increased its effectiveness in transferring the phosphohydrolase from the soluble to the microsomal fraction.	DDI-false
CONCLUSIONS : @DRUG$ Inhibition of metabolism of @DRUG$ Metabolised by CYP3A4 (i.e. atorvastatin, cerivastatin, lovastatin, simvastatin).	DDI-false
Potential pharmacokinetic interactions have been studied in clinical pharmacokinetic studies ( @DRUG$ , @DRUG$ , oral contraceptive , digoxin , warfarin , probenecid ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients .	DDI-false
@DRUG$ (NSAIDs)-A drug interaction study of eplerenone with an @DRUG$ has not been conducted.	DDI-false
Patients using CYP3A4 metabolised statins should maintain cholesterol levels after: @DRUG$ is initiated to see whether the @DRUG$ Dose adjustment.	DDI-false
When @DRUG$ was coadministered with phenytoin , rifampin , or H2antagonists , reduced plasma concentrations of @DRUG$ were reported .	DDI-false
These data indicate that @DRUG$ does not influence the plasma concentration of other AEDs and that these @DRUG$ Do not affect the pharmacokinetics of levetiracetam.	DDI-false
Digoxin : In controlled studies in healthy volunteers , @DRUG$ either had no effect ( one study ) or was associated with modest increases , about 30 % ( two studies ) in steady-state serum @DRUG$ concentrations .	DDI-mechanism
( 1968, 1970), the higher serum concentrations of @DRUG$ and @DRUG$ reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body .	DDI-false
@DRUG$ may enhance the effects of alcohol, @DRUG$, and other CNS depressants.	DDI-effect
Drugs That Inhibit @DRUG$ Metabolism Via Cytochrome P450 3A : The initial step in @DRUG$ The metabolism is catalysed by cytochrome P450 3A ( CYP 3A ).	DDI-false
â€¢ Drug interaction studies have shown that esomeprazole has no clinically significant interactions with phenytoin, @DRUG$ , quinidine, clarithromycin or @DRUG$.	DDI-false
The concomitant use of Natrecor with IV vasodilators such as nitroglycerin, @DRUG$ , @DRUG$ ACE inhibitors have not been studied (these medicinal products have not been administered with Natrecor in clinical trials).	DDI-false
While no in vivo drug-drug interaction studies have been conducted, drug-drug interaction studies have been conducted. @DRUG$ CYP3A inducers, compounds that are potent CYP3A inducers (such as carbamazepine, @DRUG$ It is expected that the concentration of estazolam, rifampin and barbiturates will decrease.	DDI-mechanism
Metoclopramide: Bioavailability is mildly reduced (approximately 10%) when @DRUG$ and @DRUG$ are coadministered.	DDI-mechanism
â™ª Drugs that can change â™ª @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations : Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , @DRUG$ ,,,,,,,,,,,	DDI-false
@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an @DRUG$ regimen reduces the plasma concentrations of saquinavir.	DDI-false
Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-effect
The risk of myopathy during treatment with medicines in this class is increased with concomitant administration of cyclosporin, fibric acid derivatives, niacin ( @DRUG$ ) , @DRUG$ , azole antifungals .	DDI-false
FLEXERIL may enhance the effects of @DRUG$, barbiturates, and other @DRUG$.	DDI-false
ACE Inhibitors and @DRUG$ 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ ( ACEI/ARB ).	DDI-false
Potential interactions between @DRUG$ , a substrate of CYP3A4 and protease inhibitors (ritonavir, saquinavir, indinavir and @DRUG$ ) , which are substrates and/or inhibitors of CYP3A4 , have not been evaluated in clinical trials .	DDI-false
Therefore, agents affecting sympathetic activity (e.g., @DRUG$ or @DRUG$) should be used with caution.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Cardiovasculars: Cardiac glycosides: In patients receiving digoxin therapy, administration of oral @DRUG$ regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
The extent to which @DRUG$-@DRUG$ interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.	DDI-int
Amantadine , @DRUG$ , and @DRUG$ may increase anticholinergic effect of clidinium .	DDI-false
Rifabutin: Coadministration of @DRUG$ and VIRACEPT resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
@DRUG$: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when @DRUG$ and allopurinol were administered concomitantly for 6 days.	DDI-false
Concomitant use of LEVSIN with other antimuscarinic agents, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors may lead to additive side effects due to cholinergic blockade, @DRUG$ or some @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , @DRUG$ , H2 antagonists , HMG-CoA reductase inhibitors , @DRUG$ ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
In addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , phenytoin , dexamethasone , or @DRUG$ ) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations .	DDI-mechanism
Example inhibitors include @DRUG$ , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , @DRUG$ , and verapamil .	DDI-false
@DRUG$ or @DRUG$ : The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers .	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
@DRUG$: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$ or hydrochlorothiazide.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
- Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$ , @DRUG$ In vitro, erythromycin and sulfamethoxazole have no influence on the protein binding of diclofenac in human serum.	DDI-false
- @DRUG$: @DRUG$ may potentiate the effect of various antihypertensive drugs, necessitating a reduction in the dosage of these drugs.	DDI-false
Aspirin/@DRUG$ : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1   g/kg/min . over 4 hours ) or acetaminophen ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of @DRUG$ 1.5 g/kg/min over 18 hours).	DDI-false
In clinical studies with @DRUG$ (@DRUG$, 1 mg) in men 18-41 years of age, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at Month 12.	DDI-false
Although the interaction between @DRUG$ Itraconazole, ritonavir and erythromycin) has not been studied, increased exposure to @DRUG$ may be expected when almotriptan is used concomitantly with these medications .	DDI-false
* This table is not all inclusive ** @DRUG$ may not be effective due to decreased @DRUG$ plasma concentrations in patients taking these agents concomitantly	DDI-false
There have been reports of QTc prolongation , with or without TdP , in patients taking @DRUG$ when @DRUG$ , macrolide antibiotics , or azoles were administered concomitantly .	DDI-false
For example, @DRUG$ (e.g., @DRUG$) may activate the renin-angiotensin-aldosterone system.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., @DRUG$), tacrolimus, vancomycin.	DDI-false
Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Coadministration of @DRUG$ did not influence the pharmacokinetics of @DRUG$.	DDI-false
Because changes in glucose concentrations with @DRUG$ coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for @DRUG$ (5 mg QD and 10 mg BID) with valdecoxib coadministration (up to 40 mg QD) is not indicated.	DDI-false
The management of the local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$ Or tricyclic antidepressants can cause severe, prolonged hypertension.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , @DRUG$ Beta blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$ , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Poor metabolizers have higher than expected plasma concentrations of @DRUG$ (@DRUG$) when given usual doses.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, TAXOL before @DRUG$).	DDI-false
Other interactions: @DRUG$ had no effect on the pharmacodynamics of @DRUG$ (glucose and insulin concentrations) and warfarin (prothrombin time or other pharmacodynamic parameters).	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: @DRUG$ , @DRUG$ , corticosteroids, TNF blockers, azathioprin, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine and anakinra.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
In a Phase I trial using escalating doses of TAXOL ( 110 - 200 mg/m2 ) and cisplatin ( 50 or 75 mg/m2 ) given as sequential infusions , myelosuppression was more profound when @DRUG$ The dose was given after cisplatin as with the alternative sequence (i.e. TAXOL before @DRUG$ ) .	DDI-false
@DRUG$: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in @DRUG$ plasma A.C.	DDI-false
@DRUG$ - Taking piperazine and a @DRUG$ together may increase the risk of convulsions (seizures).	DDI-false
Caution should be exercised when: @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as ketoconazole , @DRUG$ ==References====External links==	DDI-advise
@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.	DDI-false
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG$.	DDI-effect
The application of local anaesthetic solutions that @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ For this reason, severe, prolonged hypertension can arise.	DDI-effect
@DRUG$: @DRUG$ has no apparent pharmacokinetic interaction when administered with phenytoin.	DDI-false
Cardiac effects of @DRUG$ are antagonized by @DRUG$, such as propranolol and metoprolol.	DDI-effect
Magnesium and/or aluminium antacids, iron sulphate products, multivitamin preparations, @DRUG$ or other metal cations , or Videx ( @DRUG$ Do not take chewable tablets or the pediatric powder for oral solution within 3 hours before or 2 hours after FACTIVE.	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to @DRUG$.	DDI-effect
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
In monkeys, the effects of (-)-NANM, but not @DRUG$ or PCP , were antagonized by @DRUG$ ;	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , @DRUG$ , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as @DRUG$ ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
There was no significant difference ( p > 0.05 ) in AUC ( 48.59 + /- 8.52 vs. 49.9 + /- 9.93), Cmax ( 7.73 + /- 2.6 vs. 6.6 + /- 2.0 ) and tmax ( 1.1 + /- 0.6 vs. 1.6 + /- 1.1 ) for @DRUG$ versus @DRUG$/oxycodone regimens .	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
Urinary acidifying agents (@DRUG$, @DRUG$, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon , the concomitant use of @DRUG$ Salicylates and salicylates are not recommended.	DDI-false
@DRUG$ has been shown to have neuromuscular blocking properties that may enhance the action of other @DRUG$.	DDI-effect
When antizole is used concomitantly with medicinal products that increase or inhibit the cytochrome P450 system, reciprocal interactions may occur (e.g. phenytoin, carbamazepine, @DRUG$ , @DRUG$ ) , though this has not been studied	DDI-false
@DRUG$ taken concomitantly with @DRUG$ increases quinidine serum concentration by 33 % after two days .	DDI-false
Other Agents: @DRUG$ has been used concomitantly with @DRUG$ and/or digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazine, butyrophenone, @DRUG$ ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
Use with @DRUG$: The principal pathway for detoxification of @DRUG$ is inhibited by allopurinol.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , @DRUG$ , disulfiram , ethionamide , glutethimide , gold , @DRUG$ , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Antiarrhythmics : @DRUG$ , Bepridil, Flecainide, Propafenon, @DRUG$ CONTRAINDICATE because of the potential for serious and/or life-threatening reactions.	DDI-false
In addition, under the influence of sympatholytic medicinal products such as @DRUG$, clonidine, @DRUG$, and reserpine, the signs of hypoglycemia may be reduced or absent.	DDI-false
@DRUG$ Incorporating coumarin derivatives, indandion derivatives and @DRUG$ such as nonsteroidal anti-inflammatory drugs ( NSAIDs ) , and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin .	DDI-false
Therefore, EXTREME CAUTION should be exercised when administering @DRUG$ to patients receiving @DRUG$ or halogenated hydrocarbon anesthetics.	DDI-advise
Ethinyl Estradiol and @DRUG$: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
The similarity of the TYSABRI-associated adverse reaction profile between study 1 (without concomitant AVONEX) and study 2 (with concomitantly administered AVONEX) @DRUG$ ) points out that this change in clearance does not require a reduction in clearance. @DRUG$ Dose to maintain safety, general).	DDI-false
In clinical studies, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators and additional oxygen. @DRUG$ N = 23) or digoxin, in which FLOLAN therapy was initiated, apparent oral clearance values for furosemide ( n = 23) and @DRUG$ N = 30) had decreased by 13% and 15% respectively on the second day of therapy and had returned to baseline levels by day 87.	DDI-false
@DRUG$ : Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	DDI-false
CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of @DRUG$ 0.75 g/kg on balance testing and reaction time for 1 hour after @DRUG$ administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
"It is concluded that @DRUG$ and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral anticoagulant therapy .	DDI-false
There was no significant difference in the pharmacodynamic effect of @DRUG$ administered alone and warfarin administered with @DRUG$ as measured by prothrombin time.	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	DDI-mechanism
In pigeons, naloxone did not systematically alter the effects of (-)-NANM, @DRUG$ or @DRUG$.	DDI-false
@DRUG$: Coadministration of single doses of @DRUG$ 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and @DRUG$ Elevated plasma concentrations may occur when co-administered with other medicinal products. @DRUG$ ;	DDI-mechanism
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$ , lidocaine , @DRUG$ and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
ACE Inhibitors and @DRUG$ In clinical trials in patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors, and @DRUG$ increased mean serum potassium slightly ( about 0.09 - 0.13 mEq/L ) .	DDI-false
BACKGROUND : Effects of combined administration of bombsin and verapamil hydrochloride ( @DRUG$ ) , a @DRUG$ , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$ , ethionamide , glutethimide , gold , hydralazine , @DRUG$ , isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
BACKGROUND : The effects of the combined administration of bombsin and @DRUG$ ( verapamil ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( @DRUG$ ) and the index of colorectal cancers were studied in male Wistar rats.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , @DRUG$ , @DRUG$ or some antihistamines .	DDI-false
In addition to this pharmacological interaction , this report describes a novel chemical reaction between @DRUG$ ( a @DRUG$ ) and ethanol under acidic conditions similar to those found in vivo , resulting in a 3-ethoxylated product .	DDI-false
Drugs which inhibit CYP 3A4 ( e.g. , ketoconazole , @DRUG$ Erythromycin) have the potential to achieve increased plasma concentrations of @DRUG$.	DDI-mechanism
@DRUG$-Concomitant intake of @DRUG$ The absorption of vitamin K can be reduced.	DDI-false
@DRUG$ - inhibits the ERMBT and @DRUG$ and rifabutin are equipotent inducers of the ERMBT .	DDI-false
This time window is different than for other oral formulations of @DRUG$, which are usually administered 2 hours before or 6 hours after @DRUG$.	DDI-advise
Dosage adjustment may be warranted when @DRUG$ is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic @DRUG$ levels may rise resulting in toxicity.	DDI-false
Therefore, nitroglycerin or other @DRUG$ If possible, @DRUG$ should be discontinued (as for the management of angina) or other drugs with vasodilator activity.	DDI-advise
Digoxin , @DRUG$ and @DRUG$ : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan .	DDI-false
Pharmacokinetic or pharmacodynamic drug interactions between argatroban and co-administered aspirin (administered 162.5 mg orally 26 and 2 hours before starting treatment with aspirin/acetaminophen) have not been demonstrated. @DRUG$ 1 g/ kg/ min over 4 hours) or @DRUG$ ( 1000 mg orally administered 12, 6 and 0 hours before, and 6 and 12 hours after, start of argatroban 1.5 g/kg/min. over 18 hours).	DDI-false
Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with @DRUG$ (@DRUG$ substrate) given for local anesthesia.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and @DRUG$, and the @DRUG$ rifampin.	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
@DRUG$ As with some other quinolones, co-administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life .	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
@DRUG$: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Antihypertensives : @DRUG$ may antagonize the hypotensive effects of @DRUG$.	DDI-effect
The concurrent use of intravenously or orally administered @DRUG$ (e.g., aminophylline, theophylline) by patients receiving @DRUG$ has not been completely evaluated.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of fissteride doses have been co-administered in clinical trials with acetaminophen, @DRUG$ , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
- Lithium: @DRUG$ should generally not be given with diuretics (such as @DRUG$) because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-advise
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, @DRUG$ , @DRUG$ , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
Pyrantel ( e.g. , Antiminth ) - Taking @DRUG$ and @DRUG$ together may decrease the effects of piperazine .	DDI-effect
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
In Study 1, patients with colorectal cancer were given @DRUG$/@DRUG$/leucovorin (bolus-IFL) with or without AVASTIN.	DDI-false
@DRUG$: while a synergistic relationship with @DRUG$ has been reported, concomitant use may increase the toxicity of flucytosine by possibly increasing its cellular uptake and/or impairing its renal excretion.	DDI-false
Concomitant @DRUG$ , doxorubicin, vincristine and prednisone chemotherapy plus @DRUG$ Treatment in patients with human immunodeficiency virus-associated non-Hodgkin lymphoma.	DDI-false
In vitro studies have shown CASODEX can displace @DRUG$s, such as @DRUG$, from their protein-binding sites.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-mechanism
astemizole, @DRUG$, sparfloxacin, and @DRUG$.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, @DRUG$, anesthetics) should be considered.	DDI-false
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Other CNS depressants (e.g. @DRUG$ , sedatives, opioids and general @DRUG$ ) have additive or potentiating effects with INAPSINE .	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
ERYTHROMYCIN : In hypercholesterolemic patients , steady-state @DRUG$ AUC and Cmax increased after 10 days when co-administered with @DRUG$ A known inhibitor of cytochrome P450 3A4.	DDI-mechanism
Carbamazepine, @DRUG$, @DRUG$	DDI-false
@DRUG$ : Chloramphenicol , @DRUG$ , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins .	DDI-false
@DRUG$ ( e.g. , @DRUG$ , triamterene , or amiloride ) , potassium supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
Because of the increased risk of adverse reactions in patients who have regularly taken benzodiazepines, it is particularly important that physicians carefully monitor patients or their guardians. @DRUG$ , @DRUG$ The sedative use of ROMAZICON is intended to be part of the story before any process in which the use of ROMAZICON is planned.	DDI-false
@DRUG$ (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in @DRUG$ Cmax.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, @DRUG$, carbamazepine) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Antacids containing magnesium and/or aluminium, products which: @DRUG$ ( iron ) , multivitamin preparations containing @DRUG$ The pediatric powder for oral solution must not be taken within 3 hours before or 2 hours after FACTIV.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as @DRUG-DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and @DRUG$ ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, @DRUG$ , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, @DRUG$, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after @DRUG$ than with the alternate sequence (ie, TAXOL before cisplatin).	DDI-effect
Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, heart @DRUG$ , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , @DRUG$ ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , @DRUG$ , and sodium colistimethate ) , @DRUG$ salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Digoxin, @DRUG$ and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
The coadministration of @DRUG$ decreases the biologic half-life of @DRUG$ because of an increase in metabolic clearance that results in a greater amount of hydroxylated fenoprofen in the urine.	DDI-mechanism
In clinical trials , FLOLAN was used with digoxin , @DRUG$ , @DRUG$ In a pharmacokinetic sub-study in patients with congestive heart failure receiving furosemide or digoxin starting treatment with FLOLAN, visible values for oral clearance of furosemide (n = 23) and digoxin (n = 30) were reduced by 13 % and 15 % respectively on the second day of therapy and returned to baseline by day 87.	DDI-false
TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of Loratadine and @DRUG$ After 10 Days of Coadministration (@DRUG$ 10 mg) in Normal Volunteers	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : @DRUG$ , @DRUG$ , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
This appears to be the only clinically relevant interaction of this species with mefloquines, although theoretically the concomitant use of other drugs known to alter cardiac conduction (e.g. anti-arrhythmic or beta-adrenergic blockers, calcium channel blockers, antihistamines, or @DRUG$ , tricyclic antidepressants and @DRUG$ ) might also contribute to a prolongation of the QTc interval .	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and @DRUG$/phenobarbital.	DDI-false
The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Both @DRUG$ and 18-MC decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of @DRUG$ was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
In addition, certain drugs metabolised by this isoenzyme, including many antidepressants ( @DRUG$ , @DRUG$ , and others), can inhibit the activity of this isoenzyme, and so normal metab-olisers such as poor metabolisers in relation to concomitant therapy with other drugs metabolized by this enzyme system, resulting in drug interactions.	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenylbutazone , phenytoin sodium , carbamazepine , griseofulvin , @DRUG$ , and possibly with ampicillin and @DRUG$ 72 .	DDI-false
DOSTINEX should not be administered concomitantly with D2 antagonists such as phenothiazine, butyrophenone, @DRUG$ , or @DRUG$.	DDI-false
Population pharmacokinetic analyses revealed that @DRUG$, @DRUG$, corticosteroids, and TNF blocking agents did not influence abatacept clearance.	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$ , imatinib , isoniazid , nefazodone , @DRUG$ Propofol, protease inhibitors, quinidine and verapamil.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, @DRUG$, @DRUG$, and barbiturates) would be expected to decrease estazolam concentrations.	DDI-false
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of antipyrine elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown .	DDI-false
@DRUG$ should not be used with @DRUG$.	DDI-advise
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system ( e.g. , phenytoin , @DRUG$ , cimetidine , @DRUG$ ), although this has not yet been studied.	DDI-false
The absorption of tetracycline, furosemide, @DRUG$ , @DRUG$ Gemfibrozil was significantly reduced when co-administered with colestipol hydrochloride;	DDI-false
When the @DRUG$ was administered 30 minutes after the @DRUG$ nasal spray, the AUC of butorphanol increased 11% and Cmax decreased 18%.	DDI-mechanism
Possible pharmacokinetic interactions were observed in clinical pharmacokinetic studies (phenytoin, valproate, oral contraceptive, digoxin, @DRUG$ , @DRUG$ ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , @DRUG$ , @DRUG$ â€¢ (e.g. benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants and alcohol, may cause respiratory depression, hypotension and deep sedation, or may lead to coma or death.	DDI-false
In the case that you are taking @DRUG$ while taking aminosalicylic acid, higher doses of @DRUG$ may be needed.	DDI-false
Lithium: Valdecoxib 40 mg twice daily for 7 days resulted in a significant decrease in @DRUG$ serum clearance ( 25 % ) and renal clearance ( 30 % ) with a 34 % higher serum exposure compared to @DRUG$ alone .	DDI-false
A similar association , though less marked , has been suggested with @DRUG$ , phenylbutazone , @DRUG$ , carbamazepine, griseofulvin, topiramate, and possibly ampicillin and tetracycline 72.	DDI-false
@DRUG$ : @DRUG$ It does not appear to have a significant effect on the bioavailability of ciprofloxacin.	DDI-false
Cardiovasculars : @DRUG$ : In patients receiving @DRUG$ The oral administration of amiodarone regularly leads to an increase in serum digoxin concentration, which can reach toxic concentrations with resulting clinical toxicity.	DDI-false
- medicines associated with peripheral neuropathy include: @DRUG$ , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , @DRUG$ , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Plasma @DRUG$ concentration should be monitored when @DRUG$ Valproate and valproate should be administered concomitantly and appropriate dose adjustments of valproate should be made.	DDI-false
â€¢ Co-administration with compounds that are potent CYP3A4 inducers (e. g. @DRUG$ , phenytoin , dexamethasone , carbamazepine ) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving @DRUG$ and @DRUG$ concurrently.	DDI-effect
In patients taking CYP3A4 inducers such as rifampin, an alternative non-CYP3A4 substrate hypnotic agent may be considered. @DRUG$ , @DRUG$ And phenobarbital.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, @DRUG$, and isoniazid.	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral @DRUG$, methotrexate and @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous @DRUG$ ( e.g. , tobramycin , gentamicin , and amikacin ) , amphotericin B , @DRUG$ , intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
Erythromycin Co-administration of @DRUG$ Erythromycin ( PENDENDIL ) resulted in an approximately 2.5-fold increase in AUC and Cmax and approximately 2-fold increase in the half-life of @DRUG$.	DDI-false
It is concluded that chloral hydrate and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy .	DDI-false
@DRUG$: Altered serum levels of phenytoin (increased and decreased) have been reported in patients receiving concomitant @DRUG$.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, @DRUG$, itraconazole or fluconazole.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ The AUC0 - 12 of the blood decreased the AUC0 - 12 of the blood. @DRUG$ by approximately 20 % , peak blood concentration ( Cmax ) by 16 % , and 12-hour blood concentration ( C12hr ) by 26 % in healthy subjects when tacrolimus ( 2 doses of 0.1 mg/kg 12 hours apart ) was administered on the 10th day of CANCIDAS 70 mg daily , as compared to results from a control period in which tacrolimus was administered alone .	DDI-mechanism
Indinavir: Coadministration of @DRUG$ with VIRACEPT resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
Hormonal Contraceptives: It has not been established if there is a pharmacokinetic interaction between @DRUG$ and @DRUG$.	DDI-false
Cholestyramine and colestipol resins : Absorption of @DRUG$ is impaired in the presence of @DRUG$.	DDI-mechanism
Because a similar interaction is likely, @DRUG$ should also not be administered concurrently with @DRUG$.	DDI-advise
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , @DRUG$ , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and @DRUG$.	DDI-false
@DRUG$ may displace acidic drugs such as phenytoin or @DRUG$ from their binding sites.	DDI-mechanism
TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of @DRUG$ and Descarboethoxyloratadine After 10 Days of Coadministration (@DRUG$ 10 mg) in Normal Volunteers	DDI-false
Although the occurrence has not been reported with @DRUG$, nephrotoxicity has been reported following concomitant administration of other cephalosporins and @DRUG$.	DDI-false
Additionally, higher than expected @DRUG$ levels have been observed when they are begun in patients already taking @DRUG$.	DDI-mechanism
Saquinavir: The combination of @DRUG$, @DRUG$, and ZDV has been studied (as triple combination) in adults.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as @DRUG$ , intraconazole , ritonavir , indinavir , saquinavir , erythromycin , etc . ) is indicated , reduction of the @DRUG$ dose should be considered .	DDI-advise
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blockers, azathioprin, chloroquine, @DRUG$ , hydroxychloroquine , @DRUG$ , sulfasalazine , and anakinra .	DDI-false
A similar association , though less marked , has been suggested with barbiturates , @DRUG$ , phenytoin sodium , carbamazepine , griseofulvin , @DRUG$ , and possibly with ampicillin and tetracyclines 72 .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , @DRUG$ , disopyramide , fibrates , fluoxetine , @DRUG$ Propoxyphene, salicylates, somatostatin analogue (e.g. octreotide), sulphonamide antibiotics.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$ , beta blockers , @DRUG$ , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ Deficit and discrimination between magnesium deficiency due to insufficient magnesium intake, which requires only oral physiological supplement and @DRUG$ The depletion associated with a dysregulation of the control mechanisms of magnesium status, which requires more or less specific regulation of its causal dysregulation.	DDI-false
â€¢ Co-administration with compounds that are potent CYP3A4 inducers (e.g. phenobarbital, @DRUG$ , @DRUG$ Carbamazepine) may lead to decreased plasma levels of saquinavir.	DDI-false
â€¢ cimetidine) and many substrates for P450 2D6 ( many others) @DRUG$ , phenothiazines , and the @DRUG$ propafenone and flecainide ) .	DDI-false
@DRUG$ SHOULD BE USED WITH CAUTION IN THOSE PATIENTS REVEIVING @DRUG$ AND ITS CONGENERS.	DDI-advise
Potential drug interactions between Keppra   and other AEDs ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , @DRUG$ and @DRUG$ The serum concentrations of levetiracetam and these AEDs were also evaluated in placebo-controlled clinical trials.	DDI-false
@DRUG$ : Co-administration of VIOXX with rifampin 600 mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in @DRUG$ plasma concentrations .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$ does not alter @DRUG$ protein binding.	DDI-false
Can use thyroid drugs (e.g. levothyroxine), iodine-containing products, antacids, @DRUG$ ( e.g. , famotidine , ranitidine ) , and proton pump inhibitors ( e.g. , lansoprazole , @DRUG$ ) .	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of @DRUG$ Co-administration of nalfone and salicylates is not recommended.	DDI-mechanism
The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ ( such as loop or thiazide diuretics ) can be acutely worsened by beta-agonists , especially when the recommended dose of the @DRUG$ is exceeded .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Antidepressants (@DRUG$), @DRUG$ or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
plasma levels of several closely related @DRUG$ It has been reported that concomitant use of @DRUG$ Such an effect can also be expected with CMI.	DDI-mechanism
@DRUG$: Since bile acid sequestrants may bind other drugs given concurrently, patients should take @DRUG$ at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Potential interactions between TAXOL , a substrate of CYP3A4 , and @DRUG$ ( ritonavir , @DRUG$ In clinical trials, indinavir and nelfinavir) which are substrates and/ or inhibitors of CYP3A4 have not been studied.	DDI-false
@DRUG$ Incorporating oral, injectable, transdermal and implantable contraceptives: An interaction study showed that the concomitant use of bosentan and oral contraceptives in patients treated with other medicinal products has been reported. @DRUG$ Ortho-Novum caused average decreases in norethindron and ethinylestradiol levels by 14% and 31% respectively.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or @DRUG$) can be acutely worsened by @DRUG$, especially when the recommended dose of the beta-agonist is exceeded.	DDI-effect
Hormonal contraceptives Co-administration of Trileptal with an oral @DRUG$ has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and @DRUG$ (LNG).	DDI-false
@DRUG$ ( oral and @DRUG$ Dosage adjustment of antidiabetic medicinal products may be required.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
In monkeys , the effects of @DRUG$ , but not (+)-NANM or @DRUG$ , were antagonized by naloxone ;	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Other Drugs : Drugs such as quinidine , @DRUG$ Procainamide, phenothiazine, @DRUG$ , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$ reduced the blood AUC0 - 12 of tacrolimus by approximately 20 % , peak blood concentration ( Cmax ) by 16 % , and 12-hour blood concentration ( C12hr ) by 26 % in healthy subjects when tacrolimus ( 2 doses of 0.1 mg/kg 12 hours apart ) was administered on the 10th day of @DRUG$ 70 mg daily compared to results from a control period in which tacrolimus was administered alone.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Therefore, medications with a low therapeutic leeway, such as @DRUG$ , @DRUG$ Theophylline, and theophylline, could lead to delayed elimination and increase in serum half-life leading to toxic levels.	DDI-false
The pharmacokinetics of @DRUG$ The multiple input of @DRUG$ was not affected.	DDI-false
@DRUG$ : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , granisetron , @DRUG$ Palonosetron, and Alosetron) is contraindicated.	DDI-false
If @DRUG$ is administered with drugs that inhibit Pgp , increased concentrations of @DRUG$ It is likely, and caution is required.	DDI-false
@DRUG$ and Anticoagulants: Increased prothrombin time, with or without clinical bleeding, has been reported when @DRUG$ is administered concomitantly.	DDI-effect
Cohort 1 then received @DRUG$ plus rifabutin for 10 days , and cohort 2 received @DRUG$ plus rifampin for 4 days .	DDI-false
Concurrent administration of @DRUG$ and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension . Cimetidine , an inhibitor of microsomal drug metabolism , increased @DRUG$s half-life and toxicity in a rat model .	DDI-false
Compounds that have been tested in man include antipyrine, @DRUG$, propranolol, @DRUG$, and warfarin and no clinically meaningful interactions were found.	DDI-false
@DRUG$/@DRUG$ Rofecoxib had no clinically important effect on the pharmacokinetics of prednisolone or prednisone.	DDI-false
Since @DRUG$ There is the potential for the use of St. John's word in patients receiving amiodarone to reduce @DRUG$ levels .	DDI-false
The concomitant use of @DRUG$ or other @DRUG$ It can have an additive effect.	DDI-false
In Study 1, patients with colorectal cancer were administered. @DRUG$/5-FU/@DRUG$ (bolus-IFL ) with or without AVASTIN.	DDI-false
@DRUG$ and @DRUG$ are not.	DDI-false
Acetaminophen , @DRUG$ , phenobarbital , quinidine , theophylline , and @DRUG$ were added to pooled human serum at therapeutic concentrations .	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$ , Innovar Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with ketamine or Innovar than with @DRUG$.	DDI-false
INOmax has been administered with @DRUG$, @DRUG$, dobutamine, steroids, surfactant, and high-frequency ventilation.	DDI-false
Patients on @DRUG$ treatment should be closely monitored when @DRUG$ is introduced or withdrawn.	DDI-advise
Co-administration of other CYP3A4 inhibitors such as @DRUG$ and erythromycin with transdermal @DRUG$ This may also lead to an increase in fentanyl plasma concentrations, which may increase or prolong adverse drug reactions and cause severe respiratory depression.	DDI-mechanism
Since chronic dosing is required for therapeutic efficacy of @DRUG$ Future studies should focus on investigating the chronic dose effects of these drugs in combination with @DRUG$.	DDI-false
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including @DRUG$, and @DRUG$ requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	DDI-advise
Patients in a clinical trial who have established treatment with @DRUG$ , to which ENBREL was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or sulfasalazine alone .	DDI-false
With the morning dose of @DRUG$ On the 6th day, each volunteer received a single intravenous infusion of @DRUG$ ( 4 mg/ kg ).	DDI-false
Aspirin: When Lodine is administered with @DRUG$, its protein binding is reduced, although the clearance of free @DRUG$ is not altered.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$ Amantadine, haloperidol, phenothiazine, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
@DRUG$ in large amounts may counteract the antiepileptic effect of phenobarbital, @DRUG$ and primidone, and increase the frequency of seizures in susceptible pediatric patients.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , @DRUG$ ) , @DRUG$ , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$.	DDI-false
Binding to plasma protein is not significantly altered by @DRUG$ , @DRUG$ , or phenylbutazone.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
@DRUG$ : Indinavir ( 800 mg t.i.d . ) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC , a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life .	DDI-false
ACE inhibitors and angiotensin II receptor antagonists (hypertension)- In clinical trials in patients with hypertension, the addition of INSPRA 50 to 100 mg to @DRUG$ and @DRUG$ increased mean serum potassium slightly ( about 0.09 - 0.13 mEq/L ) .	DDI-false
The @DRUG$ are a family of @DRUG$ and hypnotic drugs .	DDI-false
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, @DRUG$, @DRUG$), though this has not been studied	DDI-false
The effectiveness of Progestin-Only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine and barbiturates, and the @DRUG$ @DRUG$.	DDI-false
@DRUG$: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
â€¢ Aspirin: Co-administration of a low dose @DRUG$ with @DRUG$ may result in an increased rate of GI ulceration or other complications , compared to use of VIOXX alone .	DDI-effect
Reported examples include the following: @DRUG$: @DRUG$ are known to inhibit CYP3A4 to varying degrees.	DDI-false
Lithium carbonate: The stimulatory effects of @DRUG$ may be inhibited by @DRUG$.	DDI-effect
Furosemide: Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Acidifying agents : Gastrointestinal acidifying agents ( guanethidine , @DRUG$ , glutamic acid HCl, @DRUG$ , fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	DDI-false
Dopamine antagonists : Da apomorphine is a @DRUG$ , it is possible that dopamine antagonists, such as the @DRUG$ - (Phenothiazine, butyrophenone, thioxanthene) or metoclopramide, may reduce the efficacy of APOKYN.	DDI-false
Agents Causing Renin Release : The antihypertensive effect of enalapril and @DRUG$ IV is augmented by @DRUG$ , which cause renin release (e.g., diuretics).	DDI-effect
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with @DRUG$ , methyldopa, nitrates, calcium blockers, hydralacin, @DRUG$ And digoxin without evidence of clinically significant adverse interactions.	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, phenytoin, carbamazepine, @DRUG$, phenobarbital or St.	DDI-false
In single and multiple dose studies in healthy subjects receiving both @DRUG$ and @DRUG$, prothrombin time (measured as INR) was increased by approximately 8% to 11%.	DDI-effect
The results of the ERMBT after 2 weeks of @DRUG$ and @DRUG$ therapy were increased 187 and 156%, respectively.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blockers, @DRUG$ , chloroquine , gold , hydroxychloroquine , leflunomide , @DRUG$ , and anakinra .	DDI-false
Antihypertensives : @DRUG$ should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a @DRUG$ Inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
The steady state plasma concentrations of @DRUG$ and @DRUG$ have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of alprazolam tablets in doses up to 4 mg/day.	DDI-false
In vitro studies show that ertapenem does not inhibit the P-glycoprotein-mediated transport of P-glycoprotein. @DRUG$ Vinblastin and the @DRUG$ is not a substrate for P-glycoprotein-mediated transport .	DDI-false
It is not known whether the effects of @DRUG$ are altered by concomitant medications that affect hepatic metabolism of drugs ( @DRUG$ , etc.), but doctors should ensure that a smaller starting dose and longer intervals between doses may be required.	DDI-advise
@DRUG$: Since @DRUG$ may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.	DDI-false
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, @DRUG$ , VIDEX chewable/buffer tablets or paediatric powders or products containing calcium, iron or zinc may cause absorption of @DRUG$ , resulting in serum and urine levels considerably lower than desired .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ In vitro studies in peripheral mononuclear blood cells, U937 and Molt-4 cells showed that: @DRUG$ significantly inhibited zalcitabine phosphorylation in a dose dependent manner .	DDI-false
- Perhexiline hydrogen maleate or @DRUG$ (with hepatotoxic potential) must not be administered together with @DRUG$ or Bezalip retard.	DDI-advise
Magnesium/Aluminum-containing @DRUG$ The absorption of zalcitabine is moderately reduced (approximately 25%) when co-administered with magnesium/@DRUG$-containing antacid products.	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, @DRUG$, phenytoin, dexamethasone, or @DRUG$) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
@DRUG$: In healthy subjects receiving the CYP3A4 inducer, carbamazepine, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to @DRUG$ was decreased approximately 72%.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$: Concomitant administration of diclofenac and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of @DRUG$, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitors (NNRTI) for @DRUG$ Therapeutic therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .	DDI-false
Antidepressants ( @DRUG$ Atropin or other anticholinergic agents or digitalisglycosides: co-administration with: @DRUG$ It may cause additive inotropic and/or chronotropic effects.	DDI-false
It can cause the excretion of @DRUG$ , lithium , and @DRUG$ It can also increase the toxicity of salicylates.	DDI-false
Monoamine Oxidase Inhibitors : Coadministration of @DRUG$ resulted in a 27 % decrease in @DRUG$ Clearance and an increase in Cmax of about 6%.	DDI-mechanism
Dose adjustment is not recommended . Levetiracetam had no effect on plasma concentrations of carbamazepine , @DRUG$ ##############################################################################################################################################################################################################################################################################################################################################################################################################################################################################################################################	DDI-false
When VIRACEPT is co-administered with @DRUG$ or @DRUG$.	DDI-false
Ethinyl Estradiol and @DRUG$: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , @DRUG$ , sulphonamides, chloramphenicol, probenecid, coumarine, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
@DRUG$ and @DRUG$ Concomitant use should not be performed as a decrease in nevirapine plasma concentrations may reduce the efficacy of the medicinal product.	DDI-advise
Insulin or Oral Hypoglycemics: @DRUG$ may enhance the blood-sugar-reducing effect of @DRUG$ and oral hypoglycemics.	DDI-effect
The pharmacokinetics of theophylline ( @DRUG$ 5.8 mg/ kg infused over 20 minutes) after a single oral dose of @DRUG$ ( 400 mg ) in 6 healthy subjects .	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
injection of @DRUG$ ( @DRUG$ ) were observed by measuring locomotor activity and stereotype behaviour.	DDI-false
@DRUG$ The concentrations of albendazolesulfoxide in bile and cystic fluid were increased in cimetidine ( 10 mg/kg/day) treated patients with hydatiden cysts ( approximately 2-fold) ( n=7 ) compared to @DRUG$ ( 20 mg/kg/day ) alone ( n=12 ) .	DDI-false
The results of the ERMBT after 2 weeks of @DRUG$ and @DRUG$ therapy were increased 187 and 156 % , respectively .	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	DDI-false
Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, @DRUG$, and other anticoagulants may increase the risk of bleeding.	DDI-effect
@DRUG$ Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, which may lead to increased plasma levels of @DRUG$.	DDI-false
The in vitro interaction between @DRUG$ and the @DRUG$ warfarin is complex .	DDI-false
Therefore, interactions following concomitant administration of psychotropic medicinal products (e.g. narcotics, @DRUG$ , antiemetics , sedatives , @DRUG$ ) .	DDI-false
Valproate : The addition of @DRUG$ to patients taking @DRUG$ Chronically, valproate had no effect on the pharmacokinetics of tiagabin, but valproate significantly reduced tiagabin binding in vitro from 96.3 to 94.8%, resulting in an increase in free tiagabin concentration of about 40%.	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$ , oral @DRUG$ , phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
@DRUG$ and verapamil use may be rarely associated with ventricular fibrillation when combined with @DRUG$.	DDI-effect
Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects ( such as convulsions and cardiac dysrhythmias ) of other drugs taken in overdose ( especially cyclic antidepressants ) may emerge with the reversal of the @DRUG$ effect by @DRUG$.	DDI-false
Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Potential drug interactions between @DRUG$   and other AEDs ( @DRUG$ , gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also evaluated by the evaluation of levetiracetam serum concentrations and these AEDs during placebo-controlled clinical trials.	DDI-false
Population pharmacokinetic studies showed higher concentrations of @DRUG$ among patients concurrently treated with @DRUG$ , an inhibitor of C.P.A ..	DDI-mechanism
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal.	DDI-false
@DRUG$: When Lodine is administered with aspirin, its protein binding is reduced, although the clearance of free @DRUG$ is not altered.	DDI-false
Hypotension patients receiving diuretic therapy: @DRUG$ and especially those in whom @DRUG$ The therapy has recently been initiated, as well as those who have severe dietary salt restriction or dialysis, may occasionally abruptly reduce blood pressure usually within the first hour after receiving the initial dose of captopril.	DDI-false
@DRUG$ (Phenytoin): steady-state plasma exposure (AUC) of @DRUG$ ( 40 mg BID for 12 days ) was decreased by 27 % when co-administered with multiple doses ( 300 mg QD for 12 days ) of phenytoin ( a CYP 3A4 inducer ) .	DDI-false
@DRUG$, tricyclic: Amphetamines may enhance the activity of tricyclic or @DRUG$;	DDI-false
Hypotension   Patients on Diuretic Therapy: Patients on diuretics and especially those in whom @DRUG$ therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of @DRUG$.	DDI-false
- Poor metabolisers of schuttoquine : interactions of schnitztilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and @DRUG$ ) were not studied, but these medications would be expected to increase blood levels of the R(+ ) enantiomer @DRUG$ .	DDI-effect
@DRUG$ As with some others @DRUG$ , concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life .	DDI-false
@DRUG$ : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other @DRUG$ , sedatives , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
Aspirin : In normal volunteers, a small decrease in @DRUG$ The concentrations were observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly .	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Most cases of serious or fatal adverse events involving @DRUG$ reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of @DRUG$ with other drugs affecting respiration.	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenyl-butazone , @DRUG$ , carbamazepine and possibly with @DRUG$ , ampicillin , and tetracyclines ( 72 )	DDI-false
Ethinyl Estradiol and Norethindrone : Coadministration of @DRUG$ This led to a decrease of 47% with OVCON-35. @DRUG$ The plasma concentrations of norethindron were reduced by 18%.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The binding to plasma protein is not significantly altered by: @DRUG$ , diphenylhydantoin or @DRUG$.	DDI-false
Coadministration with @DRUG$ increased exposure of @DRUG$ 46% (AUC).	DDI-mechanism
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$ and @DRUG$/Phenobarbital.	DDI-false
Selective Serotonin Reuptake Inhibitors ( SSRIs ): SSRIs ( e.g. , @DRUG$ , fluvoxamine , paroxetine , @DRUG$ ) have been rarely reported to cause weakness, hyperreflection, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
@DRUG$: Inhibition of renal @DRUG$ clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.	DDI-false
This interaction should be considered in patients who: @DRUG$ concomitantly with @DRUG$.	DDI-advise
There were no significant interactions between nisoldipine and @DRUG$ or @DRUG$.	DDI-false
@DRUG$: Coadministration of almotriptan and verapamil resulted in a 24% increase in plasma concentrations of @DRUG$.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/@DRUG$ , phenobarbital/@DRUG$ , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Both @DRUG$ - and 18-MC block @DRUG$-induced and nicotine-induced dopamine release in nucleus accumbens;	DDI-effect
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$ Co-administration of VIRACEPT and OVCON-35 resulted in a decrease in @DRUG$ and an 18 % decrease in norethindrone plasma concentrations .	DDI-false
@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
The effect of TORADOL on plasma @DRUG$ It has not been studied, but cases of increased @DRUG$ plasma levels during TORADOL therapy have been reported .	DDI-false
@DRUG$ (@DRUG$, propranolol) serum concentrations and pharmacologic effects may be increased.	DDI-false
Probenecid: @DRUG$ interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of ciprofloxacin in serum.	DDI-mechanism
However, if @DRUG$ is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
Hormonal @DRUG$ Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and @DRUG$ (LNG).	DDI-false
Concomitant administration of @DRUG$ (corresponding to 145 mg) @DRUG$ ) with pravastatin ( 40 mg ) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36 % ( range from 69 % decrease to 321 % increase ) and 28 % ( range from 54 % decrease to 128 % increase ) , respectively , and for 3 -hydroxy-iso-pravastatin by 55 % ( range from 32 % decrease to 314 % increase ) and 39 % ( range from 24 % decrease to 261 % increase ) , respectively in 23 healthy adults .	DDI-false
@DRUG$ (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in vardenafil Cmax.	DDI-false
Investigations into the effect of acitretin on the protein binding of @DRUG$ ( @DRUG$ ==References====External links==	DDI-false
@DRUG$ or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$ ;	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of @DRUG$ may be affected by the known CYP3A4 inducers (such as @DRUG$, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;	DDI-mechanism
Aspirin : Concomitant administration of low-dose @DRUG$ with VIOXX may result in an increased rate of GI ulceration or other complications , compared to use of @DRUG$ alone .	DDI-false
Patients receiving both @DRUG$ and furosemide should be observed closely to determine if the desired diuretic and/or antihypertensive effect of @DRUG$ is achieved .	DDI-false
@DRUG$     @DRUG$ antagonism	DDI-false
@DRUG$: The effect of celecoxib on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of @DRUG$.	DDI-false
The following examples are substances that can reduce the blood glucose lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g., @DRUG$ , salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$ , thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Aminoglutethimide: @DRUG$ may diminish adrenal suppression by @DRUG$.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , @DRUG$ , progestogens (e.g., orally) @DRUG$ ) .	DDI-false
Ritonavir: Coadministration of @DRUG$ with VIRACEPT resulted in a 152% increase in @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
@DRUG$ toxicity may be aggravated by the initial release of norepinephrine caused by @DRUG$ Injection .	DDI-effect
Before using this medicine, tell your doctor or pharmacist about all prescription and non-prescription products that you can use, in particular: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporin, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$ , @DRUG$.	DDI-false
@DRUG$: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, carbamazepine, and @DRUG$, and the antituberculosis drug rifampin.	DDI-false
In monkeys, the effects of @DRUG$, but not (+)-NANM or @DRUG$, were antagonized by naloxone;	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , sulfonamides , chloramphenicol , probenecid , @DRUG$ , monoamine oxidase inhibitors , and @DRUG$.	DDI-false
In vitro studies indicate that @DRUG$ does not inhibit P-glycoprotein-mediated transport of @DRUG$ or vinblastine and that ertapenem is not a substrate for P-glycoprotein-mediated transport.	DDI-false
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
Although these results do not indicate a significant interaction between @DRUG$ and @DRUG$ TORADOL should be used with extreme caution in patients taking anticoagulants and patients should be closely monitored.	DDI-false
Based on the chemical resemblance of @DRUG$ and ketoconazole, coadministration of astemizole with @DRUG$ is contraindicated.	DDI-false
" medicinal products identified as CYP3A inhibitors of potential clinical significance based on clinical trials involving alprazoleam (when co-administered with: @DRUG$ ): Coadministration of fluoxetine with @DRUG$ The maximum plasma concentration of alprazoleam increased by 46%, clearance by 21%, half-life by 17% and measured psychomotor performance.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, @DRUG$, @DRUG$, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
The hypoglycaemic effect of @DRUG$ It has been reported that the number of patients increases when @DRUG$ is given concurrently .	DDI-effect
The concomitant intake of alcohol and @DRUG$ â€¢ Does not affect the pharmacokinetics of @DRUG$ or acamprosate .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : @DRUG$ , niacin, danazol, diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$ , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
There have been greater than 2-fold increases in previously stable plasma levels of other @DRUG$ , including nortriptyline , when @DRUG$ has been administered in combination with these agents .	DDI-mechanism
@DRUG$ : ( oral agents and insulin ) - dosage adjustment of the @DRUG$ may be required .	DDI-false
@DRUG$ (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
@DRUG$/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , procainamide , @DRUG$ , and phenytoin , have been used concurrently with @DRUG$.	DDI-false
Haemodynamic effects of glucose and @DRUG$ were additive when @DRUG$ was co-administered but not under basal conditions.	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic clonidine . It is not known whether the concurrent use of these agents with @DRUG$ in humans can lead to resulting interference with the IOP lowering effect .	DDI-false
These increased exposures of @DRUG$ Estradiol and ethinylestradiol should be used when selecting an oral @DRUG$ For women taking valdecoxib.	DDI-false
Indinavir : Coadministration of @DRUG$ with @DRUG$ resulted in an 83 % increase in nelfinavir plasma AUC and a 51 % increase in indinavir plasma A.C.	DDI-mechanism
Erythromycin: In healthy individuals, plasma concentrations of @DRUG$ increased approximately 40% with coadministration of atorvastatin and @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-false
Anticonvulsants ( @DRUG$ ): Steady State Plasma Exposure (AUC) of @DRUG$ ( 40 mg BID for 12 days ) was decreased by 27 % when co-administered with multiple doses ( 300 mg QD for 12 days ) of phenytoin ( a CYP 3A4 inducer ) .	DDI-false
The pressor effects of catecholamines such as dopamine or @DRUG$ are enhanced by @DRUG$.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., @DRUG$, clarithromycin, @DRUG$, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.	DDI-false
The co-administration of @DRUG$ with IV vasodilators such as @DRUG$, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
Indinavir: Coadministration of @DRUG$ with @DRUG$ resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-mechanism
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, @DRUG$, and some macrolide antibiotics.	DDI-mechanism
Population pharmacokinetic analyses have shown that: @DRUG$ , NSAIDs , @DRUG$ TNF blockers do not affect abatacept clearance.	DDI-false
Concurrent administration of @DRUG$ (for the treatment of hypotension related to obstetric blocks) and @DRUG$ may cause severe, persistent hypertension or cerebrovascular accidents.	DDI-effect
â€¢ Interactions between EPO Supplements and @DRUG$ Other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ ( Ginkgo biloba ) .	DDI-false
In addition, certain drugs that are metabolized by this isoenzyme, including many @DRUG$ (tricyclic antidepressants, @DRUG$, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.	DDI-false
No pharmacokinetic interactions between: @DRUG$ and isoflurane , propofol , @DRUG$ , and midazolam have been demonstrated .	DDI-false
@DRUG$ @DRUG$	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of @DRUG$ toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , @DRUG$ , polymyxins, lincomycin, @DRUG$ , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
- medicines associated with peripheral neuropathy include: @DRUG$ , chloramphenicol , @DRUG$ , dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with @DRUG$ or Innovar than with pentobarbital.	DDI-false
While no in vivo drug interaction studies have been conducted between estazolam and CYP3A inducers, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, @DRUG$ , and barbiturates ) would be expected to decrease @DRUG$ concentrations .	DDI-false
Other reported interactions with @DRUG$ : Fentanyl ( @DRUG$ substrate ) in combination with amiodarone may cause hypotension , bradycardia , and decreased cardiac output .	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$ : @DRUG$ In patients treated with monoamine oxidase inhibitors or tricyclic antidepressants, the use should be carried out with extreme caution as the effect of formoterol on the cardiovascular system may be enhanced by these agents.	DDI-false
The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue D-Ala2-metenkephalinamide, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
- @DRUG$: @DRUG$ blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the bumetanide-induced increase in plasma renin activity.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , @DRUG$ , @DRUG$ , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
HIV Protease Inhibitors : Indinavir ( 800 mg t.i.d . ) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC , a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in @DRUG$ half-life .	DDI-false
Caution should also be taken in concurrent or serial use of other aminoglycosides and @DRUG$ because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate @DRUG$ neuromuscular blocking effects.	DDI-false
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$ , @DRUG$ Oestrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, valproate, @DRUG$, or @DRUG$.	DDI-false
@DRUG$ and @DRUG$: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
Potassium Supplements and Potassium-Sparing Diuretics : @DRUG$ The potassium loss can be mitigated by @DRUG$.	DDI-effect
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ , tricyclic Amphetamines may enhance the activity of tricyclic antidepressants or @DRUG$ ;	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: MTX, @DRUG$ , corticosteroids , @DRUG$ , azathioprin, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine and anakinra.	DDI-false
Therapeutic concentrations of digoxin , warfarin , ibuprofen , @DRUG$ , piroxicam , acetaminophen , phenytoin andtolbutamide did not alter @DRUG$ protein binding .	DDI-false
- @DRUG$ (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : @DRUG$ , Terfenadine Antimigraine : Ergo derivatives @DRUG$ rifampin benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Antagonism has been demonstrated between @DRUG$ and @DRUG$ in vitro.	DDI-effect
@DRUG$ ( e.g. , spironolactone , @DRUG$ Potassium supplements or salt substitutes containing potassium may lead to significant increases in serum potassium.	DDI-false
Based on these data, @DRUG$ should not be used in patients on @DRUG$ therapy.	DDI-advise
Although no studies have been performed, concomitant use of @DRUG$ and @DRUG$ The metabolism of phenytoin may change;	DDI-mechanism
The pharmacokinetics of a 1 mg dose of @DRUG$ administered as @DRUG$ were not affected by the coadministration of cimetidine ( 300 mg QID ) .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, opiates, sedatives, @DRUG$) should be considered.	DDI-advise
@DRUG$: Plasma concentrations of @DRUG$ decreased approximately 25% when colestipol and atorvastatin were coadministered.	DDI-false
Selective serotonin reuptake inhibitors (SSRIs): SSRIs (e.g. fluoxetine, @DRUG$ , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with @DRUG$.	DDI-effect
While no in vivo drug interaction studies have been conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (e.g. @DRUG$ , phenytoin , rifampin , and @DRUG$ Estazolam concentrations are expected to be reduced.	DDI-false
Concomitant administration of @DRUG$ (equivalent to 145mg @DRUG$) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	DDI-false
Therapeutic concentrations of digoxin , warfarin , ibuprofen , @DRUG$ , piroxicam , @DRUG$ , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
Cephalosporine-@DRUG$ containing side chains of N-methylthiotetrazole (Cefmenoxime, cefoperazone, cefotetan, cefamandol, latamoxef) or methylthiadiazol ( @DRUG$ ) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Standard monitoring of @DRUG$-related toxicity should be continued if @DRUG$ Methotrexate and methotrexate are administered at the same time.	DDI-false
These results suggest that both dexamethasone and retinyl acetate , and possibly other glucocorticoids and @DRUG$ , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF .	DDI-effect
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma ( HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide), @DRUG$ , teniposide, and prednisone with vincristine plus @DRUG$ ) without antiretroviral therapy.	DDI-false
d-amphetamine with desipramine or @DRUG$ and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
However , if @DRUG$ is to be initiated after cessation of @DRUG$ therapy , allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of Argatroban therapy .	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate , phenelzine sulfate , and pargyline HC1 : Concomitant use of @DRUG$ and non-selective @DRUG$ - May cause high blood pressure.	DDI-effect
Caution should be exercised if @DRUG$ and @DRUG$ are used together.	DDI-advise
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Other drug interactions Cimetidine, erythromycin and @DRUG$ had no effect on the pharmacokinetics of @DRUG$.	DDI-false
In addition, @DRUG$ alone can inhibit adrenal @DRUG$ synthesis and may cause adrenal insufficiency during corticosteroid withdrawal.	DDI-effect
Tolbutamide : In diabetic patients, the diflunisal and @DRUG$ , no significant effect on @DRUG$ plasma levels or fasting blood glucose .	DDI-false
CNS-Active Drugs Ethanol : Sonata 10 mg potentiated the CNS-impairing effects of @DRUG$ 0.75 g/kg on balance testing and reaction time for 1 hour after @DRUG$ Administration and on the digit symbol substitution test ( DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
- Anabolic steroids (@DRUG$ [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Other 5-HT1B/1D Agonists Concomitant use of other @DRUG$ within 24 hours of treatment with @DRUG$ is contraindicated .	DDI-advise
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, @DRUG$ , diuretics, sympathomimetics (e.g., epinephrine, salbutamol, @DRUG$ ), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Human pharmacokinetic data suggest that oral @DRUG$ â€¢ significantly inhibits the metabolism of @DRUG$ , resulting in a mean eight-fold increase in AUC of cisapride .	DDI-mechanism
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
Ketoconazole did not affect the conversion of @DRUG$ to the active metabolite after intravenous administration of @DRUG$, and erythromycin had no clinically significant effect after oral administration.	DDI-false
The hypoglycaemic effect of @DRUG$ â€¢ may be exacerbated by certain drugs, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, probenecid, @DRUG$ , monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-effect
@DRUG$, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
@DRUG$ can interact with chlorpromazine, increasing the metabolism of @DRUG$.	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an @DRUG$ containing aluminum and @DRUG$.	DDI-false
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., diuretics).	DDI-false
acetaminophen/@DRUG$, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
A study in eight healthy volunteers has shown a 50 % increase in mean peak nimodipine plasma concentrations and a 90 % increase in mean area under the curve , after a one week course of @DRUG$ 1,000 mg/day and @DRUG$ At 90 mg/day.	DDI-mechanism
Other cardiovascular agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , @DRUG$ Nitrates, calcium blockers, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors @DRUG$, @DRUG$ and nifedipine.	DDI-false
While all selective serotonin reuptake inhibitors ( @DRUG$ ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, @DRUG$ Escitalopram, fluoxetine, sertraline and paroxetine inhibit P450 2D6; they may vary to the extent of inhibition.	DDI-false
CYP2D6 inhibitors - @DRUG$ The metabolism is primarily via the CYP2D6 route to @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , @DRUG$ , @DRUG$ , diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazide, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, sedatives, anesthetics) should be considered.	DDI-advise
ACE-inhibitors : Reports suggest that @DRUG$ The antihypertensive effect of @DRUG$ can be reduced.	DDI-effect
@DRUG$ : Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
When other potent parental antihypertensive drugs, such as @DRUG$, are used in combination with @DRUG$, patients should be continuously observed for several hours for any excessive fall in blood pressure.	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of @DRUG$.	DDI-false
Lithium: In a study conducted in healthy subjects, mean steady-state @DRUG$ plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving @DRUG$ alone.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, carbamazepine and possibly with @DRUG$, ampicillin, and tetracyclines (72)	DDI-false
The additive CNS depression may occur if: @DRUG$ are administered concomitantly with other CNS depressants including barbiturates , @DRUG$ And alcohol.	DDI-effect
In both species , @DRUG$ , but not @DRUG$ , antagonizes the rate-reducing effects of morphine on FI and FR.	DDI-false
Magnesium- and/or aluminum-containing antacids , products containing ferrous sulfate ( @DRUG$ ) , multivitamin preparations containing zinc or other metal cations , or @DRUG$ Do not take chewable/buffered tablets or the pediatric powder for oral solution within 3 hours before or 2 hours after FACTIVE.	DDI-false
In vitro binding studies with human serum proteins indicate that: @DRUG$ binds differently than tolbutamide and does not interact with salicylate or @DRUG$.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$ , and @DRUG$.	DDI-false
Other interactions: Vardenafil had no effect on the pharmacodynamics of @DRUG$ (glucose and insulin concentrations) and @DRUG$ (prothrombin time or other pharmacodynamic parameters).	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
The concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, indomethacin), myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g., @DRUG$ , asparaginase ) effects with @DRUG$ may increase toxicity in these organ systems .	DDI-effect
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, @DRUG$, quinidine, and verapamil.	DDI-false
Clinical studies with @DRUG$ have identified potentially significant interactions with fluconazole and @DRUG$.	DDI-int
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Dopamine Antagonists : Since apomorphine is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , @DRUG$ Thioxanthene) or @DRUG$ , may diminish the effectiveness of APOKYN .	DDI-false
Other concomitant therapies : In clinical trials, the safety profile in patients with acamprosate concomitantly with @DRUG$ , hypnotics and @DRUG$ The use of placebo with these concomitant medications was similar to that of volunteers (including benzodiazepines), or non-opioid analgesics.	DDI-false
@DRUG$ may increase the ototoxic potential of @DRUG$ , especially in the presence of impaired renal function .	DDI-effect
@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).	DDI-false
Antiacid , @DRUG$ , Didanosine , @DRUG$ , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , Rifampin , Ritanovir , Saquinavir .	DDI-false
Carbamazepine : @DRUG$ There was no effect on steady-state plasma concentrations of @DRUG$ or its epoxide metabolite in patients with epilepsy .	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents , specifically , dacarbazine , cis-platinum , @DRUG$ and interferon-alfa .	DDI-effect
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blockers, @DRUG$ , chloroquine , @DRUG$ , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .	DDI-false
@DRUG$: The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of indomethacin.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e.g. , @DRUG$ , fluoxetine) and decreased by concomitant administration of liver enzyme inducers (e. g., barbiturates, phenytoin), and such an effect may be associated with: @DRUG$ as well .	DDI-mechanism
Ritonavir: Coadministration of @DRUG$ with VIRACEPT resulted in a 152% increase in nelfinavir plasma AUC and very little change in @DRUG$ plasma A.C.	DDI-false
Co-administration of ciprofloxacin with @DRUG$ @DRUG$ has , on rare occasions , resulted in severe hypoglycemia .	DDI-false
Coingestion of @DRUG$ with theophylline , @DRUG$ with acetaminophen , and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-false
Patients who have other narcotic analgesics, general anaesthetics, @DRUG$ , sedatives, sedative hypnotics, @DRUG$ or other CNS depressants ( including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression .	DDI-false
Antibiotics: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine: @DRUG$ inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for @DRUG$ metabolism.	DDI-mechanism
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: The effect of @DRUG$ on the anti-coagulant effect of warfarin was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.	DDI-false
Cyclopropane or @DRUG$ Elevates the autonomic irritability of the heart and can increase the myocardial function of certain intravenously administered @DRUG$ , such as dopamine .	DDI-effect
@DRUG$ : Gastrointestinal acidifying agents ( guanethidine , reserpine , @DRUG$ Ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, TAXOL before @DRUG$).	DDI-false
Concomitant use of @DRUG$ with other @DRUG$ It's not recommended.	DDI-advise
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, @DRUG$, @DRUG$) may result in decreased plasma levels of saquinavir.	DDI-false
There have been reports of @DRUG$-related side effects in patients on concomitant therapy with norfloxacin and @DRUG$.	DDI-false
cimetidine ) and many that are substrates for P450 2D6 ( many other @DRUG$ , @DRUG$ , and the Type 1C antiarrhythmics propafenone and flecainide ) .	DDI-false
In a 12-month controlled study, which included a 50 mg once daily @DRUG$ dose , 30 of the 528 BROVANA -treated subjects received concomitant @DRUG$ at study entry .	DDI-false
Other CNS depressant drugs (e.g. @DRUG$, tranquilizers, opioids and general @DRUG$) have additive or potentiating effects with INAPSINE.	DDI-false
@DRUG$ : @DRUG$ You have caused an increase in plasma lithium levels and a decrease in renal lithium clearance.	DDI-false
@DRUG$ is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as lovastatin and atorvastatin.	DDI-mechanism
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , @DRUG$ Antihistamines : astemizole, terfenadine antimigrain : ergot derivatives @DRUG$ rifampin benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
Plasma valproate concentration should be monitored when isoniazid and @DRUG$ are co administered, and appropriate dosage adjustments of @DRUG$ should be made.	DDI-false
An interaction study with @DRUG$ showed no clinically significant effect of anastrozole on @DRUG$ Pharmacokinetics or anticoagulant activity.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	DDI-false
Central Nervous System Depressants : The concomitant use of @DRUG$ (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$ , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, digoxin, @DRUG$, and @DRUG$.	DDI-false
@DRUG$ toxicity was usually reversible upon discontinuation of @DRUG$ and the ACE inhibitor.	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and @DRUG$ in rats;	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-false
@DRUG$ The risk of seizures may be reduced in patients who: @DRUG$	DDI-effect
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: @DRUG$, fluvoxamine, cimetidine, @DRUG$, isoniazide, and some macrolide antibiotics.	DDI-false
* Drug interactions : Flupentixol may interact with some drugs, such as @DRUG$ ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Imidazoles (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, @DRUG$ , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , @DRUG$ Propofol, protease inhibitors, quinidine and verapamil.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , @DRUG$ (e.g. epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$ , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	DDI-false
Protein Binding In vitro , @DRUG$ â€¢ Influences minimal or no protein binding of salicylic acid (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding) or @DRUG$.	DDI-mechanism
While all selective serotonin reuptake inhibitors ( @DRUG$ , e.g. fluoxetine, sertraline, paroxetine and @DRUG$ , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
(Concurrent use with @DRUG$ may enhance the possibility of @DRUG$ toxicity associated with hypokalemia.)	DDI-effect
Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (AEDs) Phenytoin @DRUG$  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir (@DRUG$) as the sole @DRUG$ due to the risk of decreased saquinavir plasma concentrations.	DDI-false
Digitalis glycosides : @DRUG$-induced hypokalemia may potentiate @DRUG$ toxicity .	DDI-effect
When @DRUG$ is co-administered with inducers of drug clearance , such as efavirenz , nevirapine , phenytoin , dexamethasone , or carbamazepine , use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
@DRUG$ ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between VIRACEPT and @DRUG$ , trimethoprim/@DRUG$ , clarithromycin , erythromycin , itraconazole or fluconazole .	DDI-false
Multivitamins , or other products containing iron or zinc , @DRUG$ Concomitant use of Sucralfate or Sucralfate should not occur with or within 2 hours of administration of Sucralfate or Sucralfate. @DRUG$ , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin .	DDI-advise
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
acetaminophen/theophylline , @DRUG$/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Therefore, @DRUG$ may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, @DRUG$, iron salts and digoxin).	DDI-mechanism
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Administration of @DRUG$ to patients receiving @DRUG$ Or halogenated hydrocarbon general anesthetics such as halothane, which sensitize the myocardial system, can cause cardiac arrhythmias.	DDI-effect
the doses of @DRUG$ required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of @DRUG$.	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local @DRUG$, procainamide, and quinidine.	DDI-false
Other reported interactions with amiodarone : @DRUG$ CYP3A4 substrate) in combination with @DRUG$ For this reason, hypotension, bradycardia, and reduced cardiac output may occur.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including nonsteroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, @DRUG$ , @DRUG$ , monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Potassium-sparing diuretics (e.g. spironolactone, @DRUG$ Potassium supplements or salt substitutes containing @DRUG$ may lead to significant increases in serum potassium.	DDI-false
Potassium-sparing diuretics (e.g. spironolactone, @DRUG$ , or @DRUG$ ) , potassium supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission ( e.g. , @DRUG$ Caution should be exercised as the effect of the toxin may be increased.	DDI-advise
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents , specifically , dacarbazine , @DRUG$ , Tamoxifene and @DRUG$.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of @DRUG$ is planned.	DDI-false
Interaction on the antinociceptive effect between neurotensin and @DRUG$ or @DRUG$.	DDI-false
The co-administration of @DRUG$ with IV vasodilators such as nitroglycerin, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs , e.g. , guanethidine , methyldopa , @DRUG$.	DDI-effect
@DRUG$ (NSAIDs)-A drug interaction study of @DRUG$ with an NSAID has not been conducted.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The administration of other @DRUG$ with @DRUG$ has been shown to reduce the antihypertensive effect in some patients and result in severe hyperkalemia in patients with impaired renal function.	DDI-effect
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmia: amiodarone, quinidine antihistamines: astemizole, @DRUG$ Antimigraine: Ergot derivatives Antimycobacterial agents: rifampine benzodiazepines midazolam, triazolam GI motility agent: cisapride	DDI-advise
@DRUG$ decreased the hyperuricemic effect of @DRUG$.	DDI-effect
medicines that inhibit both aldehyde oxidase and CYP3A4 @DRUG$ Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary or secondary enzymes used to treat @DRUG$ metabolism .	DDI-false
Therefore, when MIDAMOR and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.	DDI-false
@DRUG$ Based on reports of deep hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ The contraindicated medicines of the 5HT3 antagonist class (including, for example, Ondansetron, Granisetron, Dolasetron, Palonosetron, and Alosetron).	DDI-false
@DRUG$ The hydrocarbon anaesthetics increase the autonomic irritability of the heart and can sensitize the myocardium to the effect of certain intravenous catecholamines, such as @DRUG$.	DDI-effect
@DRUG$ , disopyramide , @DRUG$	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
@DRUG$ The concentrations of albendazolesulfoxide in bile and cystic fluid were observed in patients with hydatiden cysts who had had a @DRUG$ ( 10 mg/kg/day ) ( n=7 ) compared with albendazole ( 20 mg/kg/day ) alone ( n=12 ) .	DDI-false
In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of levobupivacaine to @DRUG$ and @DRUG$ , respectively .	DDI-false
Treatment with @DRUG$ can directly interfere with blood glucose levels or may interact with @DRUG$.	DDI-int
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ Such an effect can be expected with concomitant administration of hepatic enzyme inducers (e.g. barbiturates, phenytoin). @DRUG$ as well .	DDI-mechanism
The following examples are substances that can reduce the blood glucose lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, @DRUG$ , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , @DRUG$ Oestrogens, progestogens (e.g. in oral contraceptives).	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Hepatic enzyme inducers, inhibitors and substrates : drugs that induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity (e.g. barbiturates, @DRUG$ , carbamazepine , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased .	DDI-false
Medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$ , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , @DRUG$ Ribavirin and vincristine.	DDI-false
In the same study, it was shown that: @DRUG$ and stavudine had no significant effect on the intracellular phosphorylation of @DRUG$ in peripheral blood mononuclear cells .	DDI-false
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , antacids , @DRUG$ ( e.g. , famotidine , ranitidine ) , and @DRUG$ ( e.g. , lansoprazole , omeprazole ) .	DDI-false
@DRUG$ : The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Lithium: Inhibition of renal @DRUG$ clearance, leading to an increase in plasma @DRUG$ concentration, has been reported with some prostaglandin synthesis-inhibiting drugs.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and procainamide, cardiac glycosides and @DRUG$.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
Antiacid, clarithromycin, didanosine, @DRUG$ , fluoxetine, indanavir, ketoconazole, phenytoin, phenobarbitol, carbamazepine, @DRUG$ , rifampin, ritanovir, saquinavir.	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, @DRUG$, and @DRUG$.	DDI-false
Ritonavir (600 mg b.i.d.) co-administered with @DRUG$ 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in @DRUG$ Cmax.	DDI-false
Administration of repeated doses of FACTIV had no effect on the pharmacokinetics of theophylline, digoxin or an oral @DRUG$/ Levonorgestrol. @DRUG$ In healthy subjects.	DDI-false
- Poor metabolisers of schuttoquine : interactions of geschnitzilol with strong inhibitors of CYP2D6 (such as @DRUG$ , @DRUG$ , paroxetine, and propafenone) were not studied, but these medications would be expected to increase the blood levels of the R(+) enantiomer of scientilol.	DDI-false
Drugs that cause significant sustained elevation in gastric pH (@DRUG$ such as ranitidine or @DRUG$) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy.	DDI-false
Aspirin : Concurrent administration of @DRUG$ may lower @DRUG$ plasma levels , possibly by competing for protein-binding sites .	DDI-mechanism
No data from prospective clinical trials currently exist comparing the 3 approved agents ( @DRUG$ , @DRUG$ ==References==___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________	DDI-false
Other Drug Interactions : No pharmacokinetic interactions were observed between @DRUG$ And the following medications: glyburide, warfarin, digoxin, Maalox and @DRUG$.	DDI-false
Non-steroidal anti-inflammatory drugs ( but not @DRUG$ ): These drugs in combination with very high doses of @DRUG$ In preclinical studies, seizures have been shown to occur.	DDI-false
The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal @DRUG$ may also result in an increase in @DRUG$ Plasma concentrations that may increase or prolong adverse drug reactions and may cause severe respiratory depression.	DDI-false
No information is available about the interaction of @DRUG$ and @DRUG$ following multiple doses of either drug.	DDI-false
The use of @DRUG$ before @DRUG$ to attenuate some of the side effects of succinylcholine has not been studied.	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Administration of @DRUG$ The serum concentrations of amiodarone and @DRUG$ with oral amiodarone have been shown to decrease.	DDI-false
Consequently, drugs with a low therapeutic margin, such as vitamin K antagonists, @DRUG$, and @DRUG$, could have a delayed elimination and increases in their serum half-life leading to a toxic level.	DDI-false
The pharmacokinetics of @DRUG$ ( Cmax and AUC ) were not affected during multiple-dose @DRUG$ , suggesting no clinically significant pharmacokinetic interaction .	DDI-false
Interaction of @DRUG$ with Other Drugs : Cimetidine : Co-administration of @DRUG$ (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe , prolonged hypertension .	DDI-false
@DRUG$ : Plasma digoxin levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium .	DDI-false
- When Bezalip or Bezalip retard is used concurrently with @DRUG$ (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or @DRUG$ is impaired	DDI-false
@DRUG$ â€¢ and norethindron: concomitant use of VIRACEPT with @DRUG$ resulted in a 47 % decrease in ethinyl estradiol and an 18 % decrease in norethindrone plasma concentrations .	DDI-false
@DRUG$- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of @DRUG$ and salicylates is not recommended.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 Cimetidine : @DRUG$ inhibits both aldehyde oxidase ( in vitro ) and CYP3A4 ( in vitro and in vivo ) , the primary and secondary enzymes , respectively , responsible for @DRUG$ metabolism .	DDI-mechanism
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$    should be used with caution in patients receiving other local @DRUG$ or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive .	DDI-advise
Diuretics : patients on @DRUG$ , especially those with intravascular volume depletion , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$.	DDI-effect
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Thus agents likely to be concomitantly administered with @DRUG$ that are metabolized by this isoenzyme family may potentially interact with @DRUG$.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
@DRUG$ with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-mechanism
All subjects received amprenavir (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either @DRUG$ (300 mg once a day [QD]) (cohort 1) or @DRUG$ (600 mg QD) (cohort 2) for 14 days.	DDI-false
CONCLUSIONS : @DRUG$ inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 ( i.e. , atorvastatin , @DRUG$ , lovastatin , simvastatin ) .	DDI-mechanism
Methotrexate : Caution should be used if @DRUG$ It is given at the same time as @DRUG$.	DDI-advise
Like @DRUG$ ( 40 mg/kg ) , 18-MC ( 40 mg/kg ) decreases the intravenous self-administration of @DRUG$ â€¢ cocaine and oral self-administration of ethanol and nicotine in rats;	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or fluconazole.	DDI-false
Clonidine : Simultaneous use of @DRUG$ with @DRUG$ may potentiate blood-pressure- and heart-rate-lowering effects .	DDI-effect
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
@DRUG$ and @DRUG$ increased blood glucose at different times after the glucose overload.	DDI-false
Ingestion of diclofenac may increase serum concentrations of @DRUG$ and @DRUG$ and increase cyclosporine s nephrotoxicity.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , @DRUG$ , @DRUG$ , Sulfasalazine, and Anakinra.	DDI-false
In addition, several @DRUG$ The plasma concentrations of cytochrome P450 inducers, which are cytochrome P450 inducers, can be @DRUG$ and MHD .	DDI-mechanism
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), platelet inhibitors ( @DRUG$ ) , NSAIDs ( piroxicam ) , and @DRUG$ The pharmacokinetics/pharmacodynamics of fondaparinux sodium were not significantly affected.	DDI-false
@DRUG$: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on @DRUG$ absorption when it is coadministered with ranitidine.	DDI-false
- Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothine, @DRUG$ , and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ In human serum.	DDI-false
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, @DRUG$, @DRUG$, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, niacin (nicotinic acid), @DRUG$, azole antifungals.	DDI-false
however , 150 mg of @DRUG$ Q12h for 3 days increased the Ceftibuten C max by 23% and @DRUG$ AUC by 16 % .	DDI-mechanism
Aspirin : Concomitant administration of diclofenac and @DRUG$ It is not recommended that @DRUG$ is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations , peak plasma levels , and AUC values .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
@DRUG$ : @DRUG$ The diuretic response to furosemide was reduced by about 20% in normalovolemic healthy volunteers (mean sodium and urine production decreased by 17%).	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and procainamide, @DRUG$ and tricyclic anti-depressants.	DDI-false
Other medicinal products Interactions Oral contraceptives Keppra ( 500 mg twice daily ) did not affect the pharmacokinetics of an oral medicinal product. @DRUG$ containing 0.03 mg ethinyl estradiol and 0.15 mg @DRUG$ , or luteinising hormone and progesterone levels, suggesting that adverse effects on contraceptive efficacy are unlikely.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
Both @DRUG$ - and 18-MC blockmorphine-induced and @DRUG$-induced dopamine release in nucleus accumbens;	DDI-effect
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, @DRUG$, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Antidepressants, tricyclic: @DRUG$ may enhance the activity of tricyclic or @DRUG$;	DDI-effect
Possible drug interactions between Keppra and other AEDs (carbamazepine, @DRUG$ , lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also evaluated by the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies .	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or @DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the @DRUG$ is exceeded.	DDI-false
@DRUG$ ( eg , tubocurarine ) and other drugs , including ether , @DRUG$ , gallamine , decamethonium and sodium citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral .	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$ , e.g. , guanethidine , @DRUG$ , reserpine .	DDI-false
Medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$ , ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$ , phenytoin, ribavirin and vincristine.	DDI-false
Antacids : In a clinical pharmacology study, the concomitant use of antacids (aluminium hydroxide, @DRUG$ , and simethicone ) with @DRUG$ â€¢ decreased serum levels and urinary excretion of fosinoprilat compared to fosinopril alone, suggesting that antacids may impair the absorption of fosinopril.	DDI-mechanism
@DRUG$ : Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium , including ACE inhibitors .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Potential pharmacokinetic interactions have been studied in clinical pharmacokinetic studies ( @DRUG$ , valproate , oral @DRUG$ , digoxin , warfarin , probenecid ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients .	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Theophylline : The pharmacokinetics of @DRUG$ ( aminophylline 5.8 mg/kg infused over 20 minutes ) were unchanged following a single oral dose of @DRUG$ ( 400 mg ) in 6 healthy subjects .	DDI-false
In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose , 30 of the 528 @DRUG$ -treated subjects received concomitant @DRUG$ at study entry .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , @DRUG$ , and @DRUG$ CHOP chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$: Because of the relationship of Accutane to @DRUG$, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects	DDI-false
Based on the chemical resemblance of @DRUG$ Co-administration of ketoconazole and ketoconazole @DRUG$ with itraconazole is contraindicated .	DDI-false
- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	DDI-false
Antiacid , clarithromycin , @DRUG$ , fluconazole, fluoxetine, indanavir, ketoconazole, phenytoin, phenobarbitol, carbamazepine, rifabutin, rifampin, rinanovir, @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and @DRUG$.	DDI-false
@DRUG$s and Vasodilators : The following adverse events were experienced more commonly in patients receiving concomitant @DRUG$ Hypotension 10% vs. 4%, myocardial infarction 3% vs. 1%, severe pneumonia 5% vs. 3%, severe falls 9% vs. 3%, bone and joint injuries 6% vs. 2%.	DDI-false
Metformin : In healthy volunteers, the single doses of 500 mg cephalexin and @DRUG$ , plasma metformin mean cmax and AUC increased by an average of 34 % and 24 % , respectively , and @DRUG$ Mean renal clearance decreased by 14%.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 ( eg , phenobarbital , phenytoin , @DRUG$ , @DRUG$ ) may result in decreased plasma levels of saquinavir .	DDI-false
Other 5-HT1B/1D Agonists Concomitant use of other @DRUG$ within 24 hours of treatment with @DRUG$ is contraindicated.	DDI-advise
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with @DRUG$, ampicillin, and @DRUG$ (72)	DDI-false
Little or no change in the pharmacokinetics of either drug was observed when VIRACEPT was coadministered with @DRUG$ or @DRUG$.	DDI-false
Patients taking these medicines in combination with @DRUG$ should be monitored for signs of toxicity and the dose of @DRUG$ reduced if warranted .	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
FLEXERIL may enhance the effects of @DRUG$, @DRUG$, and other CNS depressants.	DDI-false
Micro-dosed @DRUG$ Preparations: Micro-dosed progesterone preparations (minipills that do not contain an @DRUG$) may be an inadequate method of contraception during Accutane therapy.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide , @DRUG$ , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$: No significant differences were observed in the steady-state pharmacokinetics of @DRUG$ or S-warfarin with the addition of tiagabine given as a single dose.	DDI-false
Therapeutic concentrations of @DRUG$, warfarin, @DRUG$, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Patients who have other narcotic analgesics, general anaesthetics, @DRUG$ , tranquilizers , sedative-hypnotics , tricyclic antidepressants or other CNS depressants ( including alcohol ) concomitantly with @DRUG$ may exhibit an additive CNS depression .	DDI-effect
Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with @DRUG$ (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-mechanism
The steady state plasma concentrations of imipramine and @DRUG$ It has been reported that concomitant use of @DRUG$ Tablets at doses up to 4 mg/ day.	DDI-mechanism
@DRUG$: Chloramphenicol, erythromycins, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of penicillins.	DDI-false
The effects of @DRUG$ Innovar anaesthesia @DRUG$ tolerance in dogs .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
It is believed that the toxicity may have resulted from a previously unrecognized interaction between @DRUG$ and @DRUG$ and a molecular basis for this interaction has been proposed.	DDI-effect
May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	DDI-false
Antagonism between @DRUG$ and @DRUG$ in vitro has been demonstrated.	DDI-effect
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or @DRUG$ @DRUG$ , Sucralfat, VIDEX chew/buffer tablets or children's powder, or products that contain calcium, iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-false
Based on the results of these studies, it is concluded that azithromycin can be safely administered with both. @DRUG$ and @DRUG$.	DDI-false
- Methotrexate ( e.g. , @DRUG$ ) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Multivalent Cation-Containing products: Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, sucralfate, VIDEX chew/buffer tablets or child powder, or products containing calcium, @DRUG$ Zinc, or zinc can significantly reduce the absorption of @DRUG$ , which leads to serum and urine levels significantly lower than desired.	DDI-false
The ECG changes and/ or hypokalaemia resulting from the use of @DRUG$ ( such as loop or @DRUG$ ) can be acutely worsened by beta-agonists , especially when the recommended dose of the beta-agonist is exceeded .	DDI-false
Diuretic agents reduce the renal clearance of @DRUG$ and add a high risk of @DRUG$ toxicity.	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, carbamazepine, @DRUG$, @DRUG$ or St.	DDI-false
A possible interaction between @DRUG$ and @DRUG$ , a fluoroquinolone antibiotic , has been reported , resulting in a potentiation of the hypoglycemic action of glyburide .	DDI-int
Prednisone/@DRUG$ : Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone .	DDI-false
Concurrent administration of @DRUG$ and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.@DRUG$ , an inhibitor of microsomal drug metabolism , increased altretamines half-life and toxicity in a rat model .	DDI-false
Interactions with mixed agonists/antagonists Opioid analgesics : agonists/antagonists analgesics (e.g. pentazocin, @DRUG$ , Butorphanol, Decocin and @DRUG$ (i) Do not administer to a patient who has received or is receiving therapy with a pure agonist opioid analgesics such as levo-dromorane.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , @DRUG$ Non-steroidal anti-inflammatory medicines (e.g. @DRUG$ ) , tacrolimus , vancomycin .	DDI-false
No information is available about the interaction of @DRUG$ and @DRUG$ After several doses of the two drugs.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Oral @DRUG$ Co-administration of atorvastatin and oral contraceptives increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30 % and 20 % .	DDI-false
Notably , systemic exposure ( AUC0 - 12 ) of dapsone hydroxylamine ( @DRUG$ ) was more than doubled in the presence of TMP/@DRUG$.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (etodolac capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free @DRUG$.	DDI-false
@DRUG$ , Methotrexate , Cyclosporine : Diclofenac , like other @DRUG$ , may affect renal prostaglandins and increase the toxicity of certain drugs .	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (@DRUG$, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
INOmax has been administered with @DRUG$, dopamine, dobutamine, @DRUG$, surfactant, and high-frequency ventilation.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , pentazocine , nalbuphine , @DRUG$ , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ Like Levo-Dromoran.	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Hepatic enzyme inducers, inhibitors and substrates : drugs that induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity (e.g., @DRUG$ , @DRUG$ Carbamazepine, rifampin) may improve the metabolism of corticosteroids and require that the dosage of corticosteroids be increased.	DDI-false
Because prostaglandins play an important role in hemostasis, and @DRUG$ â€¢ affects platelet function and concomitant therapy with all NSAIDs, including: @DRUG$ Warfarin requires close monitoring of patients to be sure that no change in their anticoagulant dosage is required.	DDI-false
@DRUG$ : Concomitant administration of @DRUG$ Co-administration of aspirin is not recommended as Diclofenac is displaced from its binding sites during concomitant administration of aspirin, resulting in lower plasma concentrations, maximum plasma levels, and AUC values.	DDI-false
@DRUG$ and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and @DRUG$ against HIV .	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$ , oral contraceptives, @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , @DRUG$ , nitrates , @DRUG$ , hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (@DRUG$, thiothixene, alprazolam).	DDI-false
In clinical trials , @DRUG$ was used with @DRUG$ In a pharmacokinetic sub-study in patients with heart failure receiving furosemide or digoxin starting treatment with FLOLAN, apparent values for oral clearance of furosemide (n = 23) and digoxin (n = 30) were reduced by 13 % and 15 % respectively on the second day of therapy and were returned to baseline at day 87.	DDI-false
Colestipol-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
(1968, 1970), the higher serum concentrations of @DRUG$ and @DRUG$ reached after administration of probenecid are due not only to slower renal elimination but also to an altered distribution in the body.	DDI-false
Pyrantel (e.g., @DRUG$) - Taking piperazine and @DRUG$ together may decrease the effects of piperazine.	DDI-false
Although these results do not indicate a significant interaction between @DRUG$ and warfarin or @DRUG$, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: MTX, NSAIDs, @DRUG$ TNF blockers, azathioprin, @DRUG$ , gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	DDI-false
Loratadine ( 10 mg once daily) was administered concomitantly with therapeutic doses of @DRUG$ , cimetidine, and @DRUG$ in controlled clinical pharmacology studies in adult volunteers .	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
INOmax has been administered with tolazoline, dopamine, @DRUG$, steroids, @DRUG$, and high-frequency ventilation.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Although no association between cause and effect has been established in clinical studies, physicians should be aware that variable effects of coagulation have been reported very rarely in patients receiving oral coagulation. @DRUG$ and @DRUG$.	DDI-effect
@DRUG$ ( e.g. , @DRUG$ The use of piperazin and pyrantel together may reduce the effects of piperazin.	DDI-false
Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, @DRUG$ salts and @DRUG$).	DDI-false
@DRUG$ therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by @DRUG$ used in methenamine therapy.	DDI-false
Antiarrhythmics : @DRUG$ , @DRUG$ , flecainide, propafenone, quinidine CONTRAINDICATES due to the potential for serious and/or life-threatening reactions.	DDI-false
The compounds tested in humans include warfarin, theophylline, @DRUG$ , @DRUG$ , aminopyrine and antipyrine .	DDI-false
Other drugs that inhibit the neuromuscular blocking effect of non-depolarizing substances such as e.g. @DRUG$ include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , @DRUG$ , colistine, and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide, and quinidine.	DDI-effect
@DRUG$ (e.g., spironolactone, triamterene, or @DRUG$), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Prednisone/@DRUG$ : @DRUG$ The pharmacokinetic effect of prednisolone or prednisone has not been clinically significantly affected.	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
Like ibogaine ( 40 mg/kg ) , 18-MC ( 40 mg/kg ) decreases the intravenous self-administration of @DRUG$ and @DRUG$ â€¢ oral self-administration of ethanol and nicotine in rats;	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-false
Single doses of either cholestyramine or colestipol @DRUG$ bind the @DRUG$ The absorption from the gastrointestinal tract is reduced by up to 85 and 43 percent respectively.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
These drugs include the thiazides and other diuretics , @DRUG$ , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , @DRUG$ , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$ In a pharmacokinetic sub-study in patients with heart failure receiving furosemide or digoxin starting treatment with FLOLAN, visible values for oral clearance of furosemide (n = 23) and digoxin (n = 30) were reduced by 13 % and 15 % respectively on the second day of therapy and were returned to baseline by day 87.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
In addition, @DRUG$ does not affect the in vitro glucuronidation of @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Digoxin and @DRUG$ use may be rarely associated with ventricular fibrillation when combined with @DRUG$.	DDI-effect
The pharmacokinetics of a 1 mg dose of butorphanol are administered as follows: @DRUG$ were not affected by the coadministration of @DRUG$ ( 300 mg QID ) .	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Simultaneous use of fenofibrate (equivalent to 145 mg) @DRUG$ ) with @DRUG$ ( 40 mg ) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36 % ( range from 69 % decrease to 321 % increase ) and 28 % ( range from 54 % decrease to 128 % increase ) , respectively , and for 3 -hydroxy-iso-pravastatin by 55 % ( range from 32 % decrease to 314 % increase ) and 39 % ( range from 24 % decrease to 261 % increase ) , respectively in 23 healthy adults .	DDI-mechanism
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, @DRUG$, carbamazepine) may result in decreased plasma levels of saquinavir.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral @DRUG$ @DRUG$/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium @DRUG$ , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or @DRUG$ The absorption of ciprofloxacin can be significantly reduced, resulting in significantly lower serum and urine levels than desired.	DDI-false
Because of the increased risk of adverse reactions in patients who: @DRUG$ on a regular basis , it is particularly important that physicians query patients or their guardians carefully about @DRUG$ , alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The risk of using @DRUG$ in combination with other drugs has not been systematically evaluated , but alcohol may potentiate the side effects of @DRUG$.	DDI-false
- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ for the following: sertraline and @DRUG$.	DDI-int
Treatment with CYP3A4 inhibitors (such as ketoconazole, @DRUG$ , @DRUG$ , indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of budesonide dose should be considered.	DDI-false
Other concomitant therapy Although no specific interaction studies have been performed, clinical trials with 1 mg or more of finasteride doses have been conducted at the same time. @DRUG$ Acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, heart nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as @DRUG$ ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Methenamine therapy: Urinary excretion of @DRUG$ is increased, and efficacy is reduced, by acidifying agents used in @DRUG$ therapy.	DDI-false
Benzthiazide may interact with @DRUG$, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	DDI-false
Other @DRUG$ (e.g. barbiturates, tranquilizers, @DRUG$ and general anesthetics) have additive or potentiating effects with INAPSINE.	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic @DRUG$.It is not known whether the concurrent use of these agents with ALPHAGAN P in humans can lead to resulting interference with the IOP lowering effect.	DDI-effect
@DRUG$: Caution should be used if diflunisal is administered concomitantly with @DRUG$.	DDI-false
Compounds tested in man include warfarin, @DRUG$, phenytoin, diazepam, @DRUG$ and antipyrine.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
It can interact with thyroid medications (e.g., @DRUG$ , iodine containing products, antacids, H2 antagonists (e.g. famotidine, ranitidine) and proton pump inhibitors (e.g. lansoprazole, @DRUG$ ) .	DDI-false
Oral @DRUG$: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, @DRUG$ 1/35 ).	DDI-false
Concurrent administration of @DRUG$ and androgens may result in elevated serum levels of @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$ , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipide, and prednisone with vincristine plus bleomycin) without treatment @DRUG$ therapy .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: In vitro and/or in vivo data show that clarithromycin, erythromycin, and @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
However, a crossover study in healthy subjects receiving either @DRUG$ 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of @DRUG$ (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	DDI-mechanism
This appears to be the only clinically relevant interaction of this species with mefloquines, although theoretically the concomitant use of other drugs known to alter cardiac conduction (e.g. anti-arrhythmic or beta-adrenergic blockers, calcium channel blockers, antihistamines, or @DRUG$ , @DRUG$ ) could also contribute to an extension of the QTc interval.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , @DRUG$ , danazol, diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), @DRUG$ , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Diuretics : @DRUG$ and other @DRUG$ can inhibit the activity of diuretics .	DDI-false
It has been reported that plasma levels of several closely related tricyclic antidepressants have been associated with the concomitant use of @DRUG$ Hepatic enzyme inhibitors (e.g. @DRUG$ , fluoxetine ) and decreased by the concomitant administration of hepatic enzyme inducers ( e.g. , barbiturates , phenytoin ) , and such an effect may be anticipated with CMI as well .	DDI-false
@DRUG$ The hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, has been reported, apparently due to an effect on certain microsomal enzyme systems, @DRUG$ Diazepam, certain tricyclic antidepressants, lidocaine, theophylline, and metronidazole, delaying the elimination and increase in blood levels of these drugs.	DDI-mechanism
@DRUG$ The steady-state plasma exposure ( AUC ) of valdecoxib ( 40 mg twice daily for 12 days ) was reduced by 27% when administered with multiple doses ( 300 mg once daily for 12 days ). @DRUG$ ( a CYP 3A4 inducer).	DDI-false
- if bezalip or @DRUG$ is used concurrently with @DRUG$ ( e.g. cholestryramine ) , an interval of at least 2 hours should be maintained between the two medicines , since the absorption of Bezalip or Bezalip retard is impaired	DDI-advise
High-dose @DRUG$ with @DRUG$ protection.	DDI-effect
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, @DRUG$ , @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ (@DRUG$, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives @DRUG$ : @DRUG$ benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (@DRUG$/ARB).	DDI-false
Anticoagulants : While studies have not shown @DRUG$ to interact with anticoagulants of the warfarin type , caution should be exercised , nonetheless , since interactions have been seen with other @DRUG$.	DDI-advise
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
@DRUG$: NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	DDI-false
The effects of @DRUG$ and L-CCG-1 upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Benzylpenicillin , @DRUG$ , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ In human serum.	DDI-false
@DRUG$ Eszopiclone 3 mg administered daily for 5 days had no effect on the pharmacokinetics of (R)- or @DRUG$ There were still changes in the pharmacodynamic profile (prothrombin time) after a single oral dose of 25 mg warfarin.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ (200 mg once daily) produced a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with @DRUG$ (5 mg) in healthy volunteers.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Because @DRUG$ It has not been shown that an additional effect over the @DRUG$ Co-administration of nalfon with salicylates is not recommended as as aspirin increases the rate of excretion of nalfon.	DDI-false
Other medicines: In small groups of patients ( 7 - 10 / interaction study ), the concomitant administration of azathioprin, gold, chloroquine, @DRUG$ , prednisolone , @DRUG$ The peak and AUC values of Diclofenac were not significantly affected by Diclofenac.	DDI-false
However , in the second study , administration of 12 g @DRUG$ 1 hour before dinner and 0.3 mg @DRUG$ About 4 hours after the same evening meal, cerivastatin AUC decreased by less than 8% and Cmax decreased by about 30% compared to the dose of cerivastatin sodium alone.	DDI-mechanism
In addition , Fondaparinux neither influenced the pharmacodynamics of warfarin , @DRUG$ , piroxicam, and @DRUG$ , nor the pharmacokinetics of digoxin at steady state .	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Diuretics: @DRUG$ and other @DRUG$ can inhibit the activity of diuretics.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , @DRUG$ , gold, hydroxychloroquine, leflunomide, sulfasalazine and @DRUG$.	DDI-false
Since @DRUG$ is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced amiodarone levels.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
These drugs include the thiazides and other diuretics , @DRUG$ , phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
@DRUG$ : Concomitant administration of diclofenac and aspirin is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations , peak plasma levels , and AUC values .	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs ( e.g. , triazolo-benzodiazepines , @DRUG$ , certain @DRUG$ ..............................................................................................................................................................................................................................................................................................................................................................................	DDI-false
@DRUG$ In a clinical pharmacology study, the concomitant use of antazide (aluminium hydroxide, magnesium hydroxide and simethicone) with: @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
Doxorubicin: @DRUG$ caused a decrease in @DRUG$ phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.	DDI-effect
@DRUG$: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with @DRUG$	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$ , ethanol or @DRUG$.	DDI-false
( In some patients , the steroidal anti-inflammatory agent can reduce the diuretic , natriuretic , and antihypertensive effects of @DRUG-DRUG$.	DDI-false
As Ibogain ( 40 mg/kg ), 18-MC ( 40 mg/kg ) reduces intravenous self-administration of morphine and @DRUG$ The oral self-administration of @DRUG$ and nicotine in rats ;	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-advise
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Drug-Drug Interactions Between @DRUG$ Phenytoin and other antiepileptics (AEDs) @DRUG$   ( 3000 mg daily ) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy .	DDI-false
Ritonavir and indinavir: When administered concomitantly with 5 mg @DRUG$ with 600 mg BID ritonavir , the Cmax and AUC of @DRUG$ were reduced by approximately 20 % .	DDI-false
* Cytochrome P-450 inducers, such as: @DRUG$ Inducing carbamazepine and phenobarbital @DRUG$ Metabolism, resulting in a decrease of approximately 30% in plasma clonazepam levels.	DDI-mechanism
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and ciprofloxacin when administered concomitantly with an intravenous opiate such as @DRUG$.	DDI-mechanism
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including nonsteroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, @DRUG$ , coumarins , @DRUG$ And beta-adrenergic blockers.	DDI-false
- Lithium : @DRUG$ should generally not be given with @DRUG$ Bumetanid) because they reduce renal clearance and increase a high risk of lithium toxicity.	DDI-advise
Interaction of @DRUG$ with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on @DRUG$ pharmacokinetics.	DDI-false
Magnesium- and/or aluminum-containing antacids , products containing ferrous sulfate ( @DRUG$ , multivitamin preparations containing zinc or other metal cations, or videx ( @DRUG$ Do not take chewable tablets or the pediatric powder for oral solution within 3 hours before or 2 hours after FACTIVE.	DDI-false
@DRUG$: In post-marketing experience, there have been reports of both increases and decreases in phenytoin levels with @DRUG$ co-administration, leading to alterations in seizure control.	DDI-false
Two groups (SH/DA; SH/FA) were treated daily with synthetic hydroalcoholic solutions which: @DRUG$ , methanol, higher @DRUG$ acetaldehyde and acetaldehyde in the same proportions as in the most common distilled and fermented alcoholic beverages;	DDI-false
@DRUG$: A single 10 mg dose of tiagabine did not affect the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Effect of AEDs in Pediatric Patients There was about a 22% increase of apparent total body clearance of @DRUG$ when it was co-administered with enzyme-inducing @DRUG$.	DDI-mechanism
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Antidepressants , @DRUG$ : Amphetamines may enhance the activity of tricyclic or @DRUG$ ;	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between VIRACEPT and dapsone , @DRUG$/sulfamethoxazole , clarithromycin , erythromycin , itraconazole or @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
- @DRUG$ (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
Aminosalicylic acid may decrease the amount of @DRUG$ ( @DRUG$ , Lanoxicaps ) that gets absorbed into your body .	DDI-false
Although these results do not indicate that there is a significant interaction between: @DRUG$ , and warfarin or heparin, the administration of @DRUG$ to patients taking anticoagulants should be done extremely cautiously , and patients should be closely monitored .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , @DRUG$ , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , @DRUG$ , leflunomide, sulfasalazine, and anakinra.	DDI-false
ACE-inhibitors Reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
Although there is little published information on concomitant administration of @DRUG$ and @DRUG$ , these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy .	DDI-false
Although the specific drug interaction was not studied in a clinical trial , there have been more than 50 episodes of concomitant use of antifibrinolytic therapies ( i.e. , tranexamic acid , @DRUG$ ) and @DRUG$.	DDI-false
The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with captopril ( captopril tablets , USP ) or initiating therapy with small doses ( 6.25 or 12.5 mg ) .	DDI-effect
Drug-drug interactions have not been observed between Argatroban and @DRUG$ or @DRUG$.	DDI-false
Potential pharmacokinetic interactions have been studied in clinical pharmacokinetic studies ( @DRUG$ , valproate, oral contraceptives, digoxin, @DRUG$ , probenecid ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients .	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , @DRUG$ chemotherapy), cardiotoxic (e. g., @DRUG$ Hepatotoxic (e.g. methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Although inhibition of CYP 3A4/5 by @DRUG$ and @DRUG$ did occur at high concentrations, it is not likely to be of clinical significance.	DDI-false
Concurrent administration of a TNF antagonist with @DRUG$ has been associated with an increased risk of serious infections and no significant additional efficacy over use of the @DRUG$ alone.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , gentamicin , and amikacin ) , @DRUG$ , @DRUG$ , intravenous pentamidine , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-false
and @DRUG$, such as @DRUG$.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-false
Nitrates : The simultaneous use of @DRUG$ with long- and short-acting @DRUG$ has been safely tolerated in patients with stable angina pectoris .	DDI-false
While no in vivo drug-drug interaction studies were conducted between @DRUG$ and inducers of CYP3A, compounds that are potent CYP3A inducers (such as @DRUG$, phenytoin, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.	DDI-mechanism
Other concomitant therapies : In clinical trials, the safety profile in patients with acamprosate concomitantly with @DRUG$ , hypnotics and sedatives ( including benzodiazepines ) , or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
Results demonstrate that @DRUG$ and its pharmacologically active 10-monohydroxy metabolite (@DRUG$) have little or no capacity to function as inhibitors for most of the human cytochrome P450 enzymes evaluated (CYP1A2, CYP2A6, CYP2C9, CYP2D6, CYP2E1, CYP4A9 and CYP4A11) with the exception of CYP2C19 and CYP3A4/5.	DDI-false
A direct causal relationship has not been established , but physicians should consider the possibility that @DRUG$ The response of a diabetic to @DRUG$ or oral hypoglycemic agents .	DDI-effect
@DRUG$: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-false
In addition, the mechanisms that can be similar to the development of dependency may be similar for @DRUG$ and @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Protein Binding In vitro, @DRUG$ interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), @DRUG$, prednisolone (10% decrease in binding), or warfarin.	DDI-mechanism
@DRUG$ Incorporating tranylcypromin sulfate, @DRUG$ , and pargyline HC1 : Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension .	DDI-false
Particular caution is recommended when administering Gleevec with CYP3A4 substrates that have a narrow therapeutic window (e.g., @DRUG$ or @DRUG$).	DDI-false
Erythromycin : In healthy individuals , plasma concentrations of atorvastatin increased approximately 40 % with coadministration of @DRUG$ and @DRUG$ A known inhibitor of cytochrome P450 3A4.	DDI-mechanism
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of @DRUG$ With medicines of the 5HT3 antagonist class (including, for example, Ondansetron, Granisetron, @DRUG$ , palonosetron , and alosetron ) is contraindicated .	DDI-advise
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$ , @DRUG$ , felodipine , digoxin , warfarin , isosorbide mononitrate , carvedilol , ethanol or itraconazole .	DDI-false
Cyclosporin, digoxin, methotrexate @DRUG$ As with other NSAIDs, due to effects on renal prostaglandins, changes in the elimination of these drugs may lead to increased serum levels of @DRUG$ , digoxin, methotrexate, and increased toxicity.	DDI-mechanism
In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	DDI-false
Medicines associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$ , gold, hydralazine, iodoquinol, isoniazid, @DRUG$ , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
In the present study , the @DRUG$ clozapine was tested in combination with an active dose of @DRUG$ in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates ( DRL ) procedures .	DDI-false
Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of @DRUG$ and @DRUG$ , including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroid inflammation, bullous pemphigoid, and Stevens-Johnson syndrome.	DDI-effect
Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
@DRUG$ has been shown to be antagonistic to beta-lactam antibiotics , including @DRUG$ , based on in vitro studies and time kill curves with enteric gram-negative bacilli .	DDI-effect
Concurrent administration of oxyphenbutazone and @DRUG$ may result in elevated serum levels of @DRUG$.	DDI-false
H2 Receptor Antagonists : @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of cisapride , there is no effect on @DRUG$ Absorption when co-administered with ranitidine.	DDI-false
Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown .	DDI-false
The clinical significance of this reduction is not known, hence zalcitabine is not recommended to be ingested simultaneously with @DRUG$/aluminum-containing @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Dopamine Antagonists : Since apomorphine is a dopamine agonist , it is possible that dopamine antagonists , such as the @DRUG$ (Phenothiazine, butyrophenone, thioxanthene) or @DRUG$ , may diminish the effectiveness of APOKYN .	DDI-false
Cardiovasculars: Cardiac glycosides: In patients receiving @DRUG$ therapy, administration of oral amiodarone regularly results in an increase in serum @DRUG$ concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), @DRUG$ (increased effect of corticosteroids).	DDI-false
Because of the possible side effects of the medicinal products in breast-feeding infants, it is necessary to decide whether breast-feeding should be discontinued or discontinued. @DRUG$ and @DRUG$ treatment .	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
Since the therapeutic range of @DRUG$ is narrow @DRUG$ serum levels should be monitored closely , and appropriate dosage adjustments of theophylline should be made .	DDI-false
however, it adversely affected response duration suggesting that @DRUG$ should not be administered with @DRUG$ and/or cisplatin.1	DDI-advise
@DRUG$, clonidine, lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., @DRUG$, @DRUG$) may increase their clearance, resulting in decreased plasma concentration.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
When CANCIDAS is co-administered with drug clearance inducers such as efavirenz, @DRUG$ , phenytoin , @DRUG$ Administration of a daily dose of 70 mg CANCIDAS or carbamazepine should be considered	DDI-false
Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , @DRUG$ , chlordiazepoxide , diazepam , certain tricyclic antidepressants , lidocaine , theophylline and @DRUG$ This delays elimination and increases blood levels of these drugs.	DDI-false
Ergot Derivatives : @DRUG$ , ergonovine , ergotamine , @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .	DDI-false
" Medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, @DRUG$ , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , @DRUG$ Ribavirin and vincristine.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with @DRUG$ ( alcohol , barbiturates , opiates , sedatives , anesthetics ) should be considered .	DDI-advise
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and @DRUG$, and the antituberculosis drug @DRUG$.	DDI-false
MAO inhibitors MAOI antidepressants, and a metabolite of @DRUG$ , slow @DRUG$ metabolism .	DDI-mechanism
In both species , @DRUG$ , but not (+)-NANM, antagonised the rate-reducing effects of @DRUG$ on FI and FR responding .	DDI-effect
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, @DRUG$ or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Antiarrhythmia : Other antiarrhythmic drugs, such as @DRUG$ , procainamide, disopyramide, and phenytoin were used at the same time as @DRUG$.	DDI-false
Pyrantel (e.g., @DRUG$) - Taking piperazine and pyrantel together may decrease the effects of @DRUG$.	DDI-false
Drugs That Inhibit @DRUG$ Metabolism Via Cytochrome P450 3A: The initial step in @DRUG$ metabolism is hydroxylation catalyzed by cytochrome P450 3A (CYP 3A).	DDI-false
In the presence of these @DRUG$ , larger doses of @DRUG$ may be required or adenosine may not be effective .	DDI-advise
Drug interactions between Keppra and other antiepileptic drugs ( @DRUG$ ) Phenytoin @DRUG$ In patients with refractory epilepsy, the administration of phenytoin (3,000 mg daily) had no effect on the pharmacokinetics of phenytoin.	DDI-false
@DRUG$: The stimulatory effects of @DRUG$ may be inhibited by lithium carbonate.	DDI-false
Tetracyclines: Concomitant treatment with @DRUG$ and tetracyclines should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	DDI-false
@DRUG$ , clonidine , @DRUG$ Salts and alcohol may either increase or weaken the hypoglycaemic effect of insulin.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-advise
Bacteriostatic Antibiotics : @DRUG$ , @DRUG$ The bactericidal effect of penicillins may be affected by sulfonamides or tetracyclines.	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	DDI-false
May interact @DRUG$ (changed hypoprothrombinemic activity), barbiturates, rifampin and other inducers of the hepatic microsomal enzyme oxidation system (reduced effect of diethylstilbestrol), @DRUG$ ( increased effect of corticosteroids ) .	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g., @DRUG$ , gentamicin , and amikacin ) , amphotericin B , foscarnet , intravenous @DRUG$ , vancomycin, and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., @DRUG$, carbamazepine, cimetidine, ketoconazole), though this has not been studied	DDI-mechanism
It is recommended not to exceed a single 5 mg dose of @DRUG$ in a 24-hour period when used in combination with @DRUG$.	DDI-advise
However , LDL-C reduction was greater when @DRUG$ and @DRUG$ They were given together as if each drug was given alone.	DDI-effect
@DRUG$ : @DRUG$ 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of digoxin after a single oral dose of 0.5 mg.	DDI-false
@DRUG$ ( 5 mg/kg ) , @DRUG$ ( 30 mg/kg ) , clonazepam ( 0.25 mg/kg ) , fluoxetine ( 20 mg/kg ) sertraline ( 30 mg/kg ) or vehicle was administered .	DDI-false
@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
In healthy volunteers, the pharmacokinetics of a 1 mg dose of @DRUG$ administered as @DRUG$ were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan .	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Chlorpromazine : @DRUG$ blocks dopamine and norepinephrine receptors , thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat amphetamine poisoning .	DDI-effect
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., @DRUG$, carbamazepine, cimetidine, @DRUG$), though this has not been studied	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Injection : Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system if with @DRUG$ , Phenothiazine, Barbiturates, MAO inhibitors, and other antidepressants. When @DRUG$ is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-false
Antiacid, clarithromycin, didanosine, @DRUG$ , fluoxetine, indanavir, ketoconazole, phenytoin, phenobarbitol, carbamazepine, rifabutin, rifampin, ritanovir, @DRUG$.	DDI-false
Interaction of @DRUG$ with Other Drugs : @DRUG$ : Co-administration of cimetidine ( 800 mg/day ) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics .	DDI-false
Antiarrhythmic agents, class I (such as flecainide, lidocaine, or @DRUG$): concurrent use with @DRUG$ may have a proarrhythmic effect.	DDI-false
@DRUG$ : @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R) or (S) warfarin, nor did there be changes in the pharmacodynamic profile (prothrombin time) after a single oral dose of 25 mg warfarin.	DDI-false
Other cardiovascular agents : enalapril and @DRUG$ n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n @DRUG$ , methyldopa , nitrates , calcium-blocking agents , hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
The compounds that have been tested in humans include: @DRUG$ , digoxin, propranolol, @DRUG$ No clinically significant interactions and warfarin were found.	DDI-false
- Anabolic steroids ( nandrolone [ e.g. , Anabolin ] , oxandrolone [ e.g. , Anavar ] , oxymetholone [ e.g. , Anadrol ] , @DRUG$ [ e.g. , @DRUG$ ] ) or	DDI-false
Although neither dexamethasone nor @DRUG$ Influenced the proliferation of prostate epithelium in RPMI1640 with transferrin alone, modifying the mitogenic effect of @DRUG$ and insulin .	DDI-effect
Primary and secondary @DRUG$ deficiencies constitute the sole indication of physiological oral @DRUG$ therapy .	DDI-false
The pharmacokinetics of a 1-mg dose of @DRUG$ administered as @DRUG$ were not affected by the coadministration of cimetidine (300 mg QID).	DDI-false
Therefore , interactions could occur following concomitant administration of @DRUG$ - narcotics, analgesics, @DRUG$ , sedatives , tranquilizers ) .	DDI-false
The following are known examples of drugs that inhibit the metabolism of other related benzodiazepines, probably by inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, @DRUG$ And some @DRUG$.	DDI-false
@DRUG$ : Coadministration of @DRUG$ The use of an experimental soft gelatine capsule formulation of saquinavir 1200 mg with VIRACEPT resulted in an 18 % increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma AC.	DDI-false
Saquinavir : The combination of HIVID, @DRUG$ , and @DRUG$ has been studied ( as triple combination ) in adults .	DDI-false
Additional reductions in blood pressure may occur when FLOLAN is administered with @DRUG$ , @DRUG$ , or other vasodilators.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX are certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine, and @DRUG$ ) , magnesium salts , lithium , local @DRUG$ , procainamide , and quinidine .	DDI-false
hypersensitivity reactions have been reported in patients receiving combination regimens with sequentially high-dose PROLEUKIN and @DRUG$ , in particular, dacarbazine, cis-platinum, @DRUG$ and interferon-alfa .	DDI-false
The effects of @DRUG$ ( RR ) on @DRUG$ ( InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry .	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral @DRUG$, @DRUG$ and 5-fluorouracil.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$: As with some other quinolones, concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
Drugs Interactions between Keppra and other antiepileptics (AEDs) Phenytoin @DRUG$   ( 3000 mg daily ) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy .	DDI-false
@DRUG$: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
Patients receiving both @DRUG$ and @DRUG$ should be observed closely to determine if the desired diuretic and/or antihypertensive effect of furosemide is achieved .	DDI-advise
Compounds in these categories result in a decreased efficacy of @DRUG$: @DRUG$, haloperidol, metoclopramide, pimozide.	DDI-effect
In a Phase I trial using escalating doses of TAXOL ( 110 - 200 mg/m2 ) and @DRUG$ Myelosuppression was lower when TAXOL was administered as sequential infusions ( 50 or 75 mg/ m2) than TAXOL. @DRUG$ , than with the alternative sequence (i.e., TAXOL before cisplatin).	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including @DRUG$ With multivalent cationic products such as magnesium or aluminium antacids, sucralfate, VIDEX chewable/buffer tablets or pediatric powders or products which: @DRUG$ Iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-mechanism
@DRUG$ , nimodipine and losartan: bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$ And losartan has no significant effect on bosentan plasma levels.	DDI-false
Hydrochlorothiazide : In normal volunteers , concomitant administration of @DRUG$ and @DRUG$ resulted in significantly increased plasma levels of hydrochlorothiazide .	DDI-mechanism
@DRUG$ Plasma concentrations of @DRUG$ decreased approximately 25 % when colestipol and atorvastatin were coadministered .	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other @DRUG$ while taking @DRUG$, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-effect
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral @DRUG$ This resulted in an 80% increase in etoposide exposure with a 38% decrease in total body clearance. @DRUG$ compared to etoposide alone .	DDI-false
Moreover, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Potential interactions between Keppra and other AEDs ( @DRUG$ , gabapentin , @DRUG$ , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
@DRUG$-Broad-spectrum antibiotics may sterilize the bowel and decrease the @DRUG$ contribution to the body by the intestinal microflora.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, @DRUG$ , amiodarone , quinidine , warfarin , tacrolimus , @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Azithromycin had no significant effect on Cmax and AUC of @DRUG$ However, although it significantly reduced the @DRUG$ tmax by 44 % and increased the intracellular exposure to phosphorylated zidovudine by 110 % .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with @DRUG$.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , @DRUG$ , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
The compounds tested in humans include warfarin, theophylline, @DRUG$ , diazepam , @DRUG$ and antipyrine .	DDI-false
@DRUG$ - Taking @DRUG$ and a phenothiazine together may increase the risk of convulsions (seizures).	DDI-false
Another oral azole antifungal, @DRUG$, inhibits the metabolism of @DRUG$, resulting in elevated plasma concentrations of astemizole and its active metabolite desmethylastermizole which may prolong QT intervals.	DDI-mechanism
In Study 1, patients with colorectal cancer received Irinotecan/@DRUG$/@DRUG$ (bolus-IFL) with or without AVASTIN.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ And other drugs that are highly protein bound, salicylates, sulphonamides, chloramphenicol, @DRUG$ , Cumarine, monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-false
Take special care with ROMAZICON in overdose with mixed medicinal products as the toxic effects (such as cramps and heart rhythm disorders) of other medicinal products taken with overdose (especially: @DRUG$ ) may emerge with the reversal of the benzodiazepine effect by @DRUG$.	DDI-false
Cephalosporine-@DRUG$ containing side chains of N-methylthiotetrazole (Cefmenoxime, Cefoperazone, Cefotetan), @DRUG$ , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
No pharmacokinetic interactions between dexmedetomidine and isoflurane, @DRUG$, @DRUG$, and midazolam have been demonstrated.	DDI-false
Benzthiazide can interact with alcohol, blood thinners, decongestant medications (allergic, cold, and sinus drugs), diabetes medications, lithium, norepinephrine, @DRUG$ like Aleve or @DRUG$ , and high blood pressure medications.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including nonsteroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, @DRUG$ , Cumarine, monoamine oxidase inhibitors and @DRUG$.	DDI-false
@DRUG$ did not alter the plasma levels of @DRUG$ when taken in combination.	DDI-false
In rats, co-administration of disulfiram and @DRUG$ in the diet for 78 weeks has been reported to cause tumors , and it has been suggested that disulfiram may react with @DRUG$ In the rat's stomach a nitrosamine is formed, which is tumorogenic.	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, CYP2D6, and @DRUG$.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Anticonvulsants (@DRUG$): Steady state plasma exposure (AUC) of @DRUG$ (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Strong inducers of cytochrome P450 enzymes ( i.e. @DRUG$ It has been shown that phenytoin and phenobarbital plasma levels of @DRUG$ ( 29 - 40% ).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir (@DRUG$) as the sole protease inhibitor due to the risk of decreased @DRUG$ plasma concentrations.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, @DRUG$, and quinidine.	DDI-false
â€¢ Rifampin: co-administration of VIOXX with @DRUG$ 600 mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in @DRUG$ plasma concentrations .	DDI-false
Since there is no data on the compatibility of @DRUG$ and crystalline @DRUG$ Preparations, NovoLog should not be mixed with these preparations.	DDI-false
@DRUG$ Co-administration of vardenafil 5 mg (600 mg b.i.d.) resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in vardenafil Cmax.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
In monkeys, @DRUG$ was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons @DRUG$ was about equipotent with (+)-NANM.	DDI-false
@DRUG$ and butyrophenones may reduce or reverse the pressor effect of @DRUG$.	DDI-effect
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : @DRUG$ ( eg , @DRUG$ , nalbuphine, butorphanol, decocin and buprenorphine) should not be administered to a patient who has received or is receiving therapy with a pure agonist opioid analgesics such as levo-dromorane.	DDI-false
Corticosteroids and @DRUG$ ( ACTH ): may potentiate @DRUG$- induced hypokalemia which may predispose the patient to cardiac dysfunction .	DDI-effect
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	DDI-false
Edema has been reported in patients concomitantly receiving @DRUG$ and @DRUG$.	DDI-effect
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other @DRUG$ , sedatives, hypnosis, sedatives (e.g. benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$ , respiratory depression, hypotension, and deep sedation, or possibly lead to coma or death.	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: @DRUG$ does not appear to alter the pharmacokinetics of @DRUG$, carbamazepine, or phenobarbital.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , @DRUG$ , leflunomide, sulfasalazine and @DRUG$.	DDI-false
In a clinical pharmacology study , indomethacin or @DRUG$ was administered to hypertensive patients receiving @DRUG$.	DDI-false
The concomitant use of @DRUG$ is not recommended since nitrofurantoin may antagonize the antibacterial effect of @DRUG$ in the urinary tract.	DDI-false
@DRUG$ reduced or eliminated the increases in FI responding produced by intermediate doses of either @DRUG$ or PCP in pigeons , but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM .	DDI-effect
There was no significant difference ( p > 0.05 ) in AUC ( 48.59 + /- 8.52 vs. 49.9 + /- 9.93), Cmax ( 7.73 + /- 2.6 vs. 6.6 + /- 2.0 ) and tmax ( 1.1 + /- 0.6 vs. 1.6 + /- 1.1 ) for levofloxacin compared to @DRUG$/@DRUG$ regimens .	DDI-false
@DRUG$-@DRUG$ may sterilize the bowel and decrease the vitamin K contribution to the body by the intestinal microflora.	DDI-false
â€¢ Dopamine antagonists: Since apomorphine is a dopamine agonist, dopamine antagonists such as the neuroleptics (phenothiazine, butyrophenone, @DRUG$ ) or @DRUG$ , can reduce the effectiveness of APOKYN.	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$ , antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$ , or other drugs that produce CNS depression .	DDI-false
In pigeons, naloxone did not systematically alter the effects of @DRUG$, (+)-NANM or @DRUG$.	DDI-false
There is a significant increase in exposure to @DRUG$ when Gleevec is coadministered with @DRUG$ (CYP3A4 inhibitor).	DDI-false
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ ed or digoxin, in which FLOLAN therapy was initiated, apparent oral clearance values for @DRUG$ ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Additional reductions in blood pressure may occur when FLOLAN is administered with @DRUG$, antihypertensive agents, or other @DRUG$.	DDI-false
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$ reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or @DRUG$ In pigeons, but not against the decreases in FI or FR react by high doses of PCP or either stereoisomer produced by NANM.	DDI-effect
- Indomethacin : @DRUG$ The increase in urine volume and sodium excretion observed during bumetanide treatment becomes blunt and inhibits @DRUG$-induced increase in plasma renin activity.	DDI-effect
This drug may interact with alcohol or other CNS depressants ( may potentiate the CNS depressant effects of either these medications or @DRUG$ ) , anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ) , and monoamine oxidase ( MAO ) inhibitors ( concurrent use with @DRUG$ The anticholinergic and CNS depressive effects of antihistamines may be prolonged and intensified.	DDI-false
@DRUG$ (600 mg b.i.d.) co-administered with @DRUG$ 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil Cmax.	DDI-mechanism
Therefore, when @DRUG$ and non-steroidal anti-inflammatory agents are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.	DDI-false
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , @DRUG$ Zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , @DRUG$ , dolasetron , @DRUG$ , and alosetron ) is contraindicated .	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	DDI-false
Patients with major psychotic disorders, treated with @DRUG$, should be treated with @DRUG$ only if the potential benefits outweigh the risks.	DDI-advise
Administration of @DRUG$ Co-administration of oral amiodarone resulted in a decrease in serum concentrations of @DRUG$ and desethylamiodarone .	DDI-false
@DRUG$ ) and many that are substrates for P450 2D6 ( many other @DRUG$ , phenothiazine, and type 1C antiarrhythmics propafenone and flecainide).	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ : Based on reports of deep hypotension and unconsciousness when apomorphin is associated with @DRUG$ , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated .	DDI-false
Antiarrhythmic agents, class I (such as @DRUG$, lidocaine, or @DRUG$): concurrent use with arbutamine may have a proarrhythmic effect.	DDI-false
@DRUG$ (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
@DRUG$ : Indinavir ( 800 mg t.i.d . ) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC , a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Therefore , when @DRUG$ and @DRUG$ When co-administered, the patient should be closely monitored to determine whether the desired effect of the diuretic is achieved.	DDI-advise
Potential interactions between @DRUG$ A substrate of CYP3A4 and @DRUG$ ( ritonavir , saquinavir , indinavir , and nelfinavir ) , which are substrates and/or inhibitors of CYP3A4 , have not been evaluated in clinical trials .	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, @DRUG$, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
Selective Serotonin Reuptake Inhibitors ( SSRIs ): SSRIs ( e.g. , fluoxetine , fluvoxamine , @DRUG$ Sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when co-administered with @DRUG$.	DDI-effect
Expected changes in laboratory assessments of PT and INR were observed after @DRUG$ administration, but these changes were not affected by concomitant @DRUG$ administration.	DDI-false
Cytochrome P-450 inducers , such as phenytoin , carbamazepine and @DRUG$ , induce @DRUG$ Metabolism, resulting in a decrease of approximately 30% in plasma clonazepam levels.	DDI-mechanism
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Other concomitant therapy Although no specific interaction studies have been performed, clinical trials with 1 mg or more of finasteride doses have been conducted at the same time. @DRUG$ , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
Potential drug interactions between: @DRUG$ The serum concentrations of levetiracetam and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) have also been studied. @DRUG$ â€¢ during placebo-controlled clinical trials.	DDI-false
The intensity , uniformity and time course of @DRUG$ interference by phenobarbital , secobarbital , glutethimide , @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	DDI-false
@DRUG$/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ Etodolac does not have an apparent pharmacokinetic interaction when given with @DRUG$.	DDI-false
Similarly dialyzed were @DRUG$, @DRUG$, and theophylline, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
@DRUG$ : Vardenafil ( 10 mg and 20 mg ) did not potentiate the increase in bleeding time caused by @DRUG$ ( two 81 mg tablets ) .	DDI-false
Astemizole, Bepridil, @DRUG$ , and @DRUG$.	DDI-false
Medicines not to be administered with VIRACEPT @DRUG$ Amiodarone, quinidine @DRUG$ Astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampine Benzodiazepines Midazolam, triazolam GI Motility agent: cisaprid	DDI-false
Antiacid , clarithromycin , Didanosine , Fluconazole , @DRUG$ , indanavir, ketoconazole, phenytoin, phenobarbitol, carbamazepine, rifabutin, @DRUG$ , Ritanovir , Saquinavir .	DDI-false
CONCLUSIONS: @DRUG$ inhibit the metabolism of @DRUG$ that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, simvastatin).	DDI-false
@DRUG$ had no effect on plasma levels of @DRUG$.	DDI-false
In addition, @DRUG$ and @DRUG$ induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.	DDI-false
@DRUG$ may suppress certain CYP450 enzymes , including CYP1A2 , CYP2C9 , CYP2D6 , and @DRUG$.	DDI-false
In clinical trials , FLOLAN was used with @DRUG$ , diuretics, anticoagulants, oral vasodilators and additional oxygen. @DRUG$ The apparent values for oral clearance of furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13% and 15% respectively on the second day of therapy and were returned to baseline by day 87.	DDI-false
@DRUG$ It has been shown that it is an antagonistic @DRUG$ , including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : @DRUG$ @DRUG$ : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
Antihypertensive medications, other, especially @DRUG$, or preanesthetic and anesthetic agents used in surgery or @DRUG$, nondepolarizing, used in surgery	DDI-false
Theophylline : As with some other @DRUG$ , concomitant use of @DRUG$ with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life .	DDI-false
d-amphetamine with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
The absorption of @DRUG$ Fororosemide, penicillin G, hydrochlorothiazide and gemfibrozil were co-administered with @DRUG$ ;	DDI-mechanism
CNS-Active Drugs @DRUG$ Sonata 10 mg increased the CNS-impairing effect of @DRUG$ 0,75 g/kg for balance tests and response time for 1 hour after ethanol administration and on the number symbol substitution test ( DSST ), symbol copy test and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
@DRUG$ , lidocaine, phenobarbital, quinidine, theophylline and @DRUG$ The pooled human serum was added at therapeutic concentrations.	DDI-false
- medicines associated with peripheral neuropathy include: @DRUG$ , chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$ , metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Amantadine, @DRUG$, and MAOIs may increase anticholinergic effect of @DRUG$.	DDI-effect
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of @DRUG$ , gold, chloroquine, D-penicillamine, @DRUG$ , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
Single doses of either @DRUG$ or colestipol @DRUG$ bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	DDI-false
Since the concomitant administration of @DRUG$ with amiodarone increases the prothrombin time by 100% after 3 to 4 days, the dose of the @DRUG$ should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	DDI-false
@DRUG$ FORADIL should be used with extreme caution in patients who are treated with: @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents .	DDI-false
Coadministration of @DRUG$ and the potent CYP3A4 inhibitor ketoconazole ( 400 mg q.d . for 3 days ) resulted in an approximately 60 % increase in the area under the plasma concentration-time curve and maximal plasma concentrations of @DRUG$.	DDI-false
Specific studies have these effects with: @DRUG$ , isoflurane , @DRUG$ , alfentanil , and midazolam .	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
Although this effect was noted even when @DRUG$ was given 4 hours prior to @DRUG$, this regimen did not result in diminished efficacy.	DDI-effect
Before using this medicine, tell your doctor or pharmacist about all prescription and non-prescription products you can use, in particular: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporin, @DRUG$ Drugs (e.g. @DRUG$ ==References====External links==	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, @DRUG$ Doses of 1 mg or more have been associated with acetaminophene, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and salicylates is not recommended.	DDI-mechanism
@DRUG$-A drug interaction study of @DRUG$ with lithium has not been conducted.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Moreover , additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels , and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ Relative to the control data.	DDI-false
Ingestion of @DRUG$ It may lead to an increase in serum concentrations of @DRUG$ and methotrexate and increase cyclosporine s nephrotoxicity .	DDI-mechanism
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , @DRUG$ , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , @DRUG$ , protease inhibitors , quinidine , and verapamil .	DDI-false
Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of @DRUG$ (800 mg/day) to patients taking tiagabine chronically had no effect on @DRUG$ pharmacokinetics.	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs ( e.g. , triazolo-@DRUG$ , @DRUG$ , certain HMG-CoA reductase inhibitors, etc.).	DDI-false
Ritonavir and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID @DRUG$, the Cmax and AUC of @DRUG$ were reduced by approximately 20%.	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Multivitamins, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG-DRUG$.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance , such as efavirenz , @DRUG$ , phenytoin , dexamethasone , or @DRUG$ , use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with griseofulvin, ampicillin, and @DRUG$ (72)	DDI-false
Can use thyroid drugs (e.g. levothyroxin), @DRUG$-containing products, antacids, H2 antagonists (e.g. famotidine, ranitidine) and proton pump inhibitors (e.g. lansoprazole, @DRUG$ ) .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/@DRUG$.	DDI-false
The effect of sulphonylureas and @DRUG$ Bezalip or @DRUG$ can complement this.	DDI-effect
Therefore, when Hydrochlorothiazide and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with medications of @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and @DRUG$ ) is contraindicated.	DDI-false
Population pharmacokinetic analyses showed that MTX, NSAIDs, corticosteroids, and @DRUG$ did not influence @DRUG$ clearance .	DDI-false
Population pharmacokinetic studies showed higher concentrations of @DRUG$ among patients concurrently treated with @DRUG$, an inhibitor of C.P.A..	DDI-mechanism
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and @DRUG$) would be expected to decrease @DRUG$ concentrations.	DDI-false
@DRUG$ : Concomitant administration of @DRUG$ ( 6 mg/kg once every 24 hours for 5 days ) and warfarin ( 25 mg single oral dose ) had no significant effect on the pharmacokinetics of either drug , and the INR was not significantly altered .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
@DRUG$, @DRUG$, Cyclosporine: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ (captopril tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	DDI-false
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Phenothiazines and @DRUG$ The print effect of @DRUG$ can be reduced or undone.	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Prednisone/prednisolone : @DRUG$ did not have any clinically important effect on the pharmacokinetics of prednisolone or @DRUG$.	DDI-false
Due to high inter-patient variability and limited sampling, the extent of the increase in SN38 levels in patients receiving concurrent @DRUG$ and @DRUG$ is uncertain.	DDI-false
Patients who begin taking @DRUG$ or who increase their diclofenac dose or any other NSAID while taking digoxin, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.	DDI-effect
@DRUG$ : Amphetamines inhibit the hypotensive effect of @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , @DRUG$ Magnesium salts, lithium, local anaesthetics, procainamide and @DRUG$.	DDI-false
The concomitant use of other CYP3A4 inhibitors such as diltiazem and @DRUG$ with transdermal @DRUG$ may also result in an increase in fentanyl plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	DDI-mechanism
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including @DRUG$ , with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffer tablets or child powder, or products that can significantly reduce calcium, iron or zinc absorption of @DRUG$ , which leads to serum and urine levels significantly lower than desired.	DDI-mechanism
Combinations of @DRUG$ and @DRUG$ : effects on drug discrimination and behavioral inhibition in rats .	DDI-false
- @DRUG$ (e.g., @DRUG$) Use of sulfapyridine with these medicines may increase the chance of side effects of these medicines	DDI-false
Administration of @DRUG$ to patients receiving cyclopropane or @DRUG$ Like halothanes, which sensitize myocardial infarction, can cause cardiac arrhythmias.	DDI-effect
When used in external subcutaneous infusion pumps for @DRUG$ , @DRUG$ should not be mixed with any other insulins or diluent .	DDI-false
Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes @DRUG$ undergoes extensive metabolism by CYP3A4 , and concomitant administration of strong inhibitors or inducers of CYP3A4 alter @DRUG$ concentrations significantly .	DDI-false
These drugs include the thiazides and other @DRUG$, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS, @DRUG$ treatment did not affect @DRUG$ distribution or clearance.	DDI-false
@DRUG$ and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).	DDI-false
Cytochrome P-450 inducers, such as @DRUG$, carbamazepine and @DRUG$, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.	DDI-false
@DRUG$: generally should not be given with @DRUG$.	DDI-advise
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Lithium : Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and @DRUG$ therapy .	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, @DRUG$ , benzodiazepines , @DRUG$ , calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , @DRUG$/@DRUG$ , phenobarbital/ valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, @DRUG$, and cimetidine.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or @DRUG$.	DDI-false
In the same study, it was shown that didanosine and @DRUG$ had no significant effect on the intracellular phosphorylation of @DRUG$ in peripheral blood mononuclear cells .	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, @DRUG$ , benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ ==See also==*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID==References==	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( phenytoin , @DRUG$ , oral contraceptives, digoxin, warfarin, @DRUG$ ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients .	DDI-false
Concomitant administration of fenofibrate ( equivalent to 145 mg TRICOR ) with @DRUG$ ( 20 mg ) once daily for 10 days resulted in approximately 17 % decrease ( range from 67 % decrease to 44 % increase ) in @DRUG$ AUC values in 22 healthy men.	DDI-false
@DRUG$: Vardenafil 20 mg, when co-administered with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of @DRUG$, a drug that is metabolized via CYP3A4.	DDI-false
Based on total @DRUG$ concentrations , @DRUG$ increased the AUC by 25 % and reduced the plasma and renal clearances by 20 % and 35 % , respectively .	DDI-mechanism
Investigations into the effect of @DRUG$ For protein binding of coumarin-type anticoagulants ( @DRUG$ ==References====External links==	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, @DRUG$, @DRUG$, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, @DRUG$, clarithromycin).	DDI-false
BACKGROUND : The effects of the combined administration of bombsin and @DRUG$ ( verapamil ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ The label index for colorectal cancer (AOM) was examined on male Wistar rats.	DDI-false
Estrogens , including oral @DRUG$ : @DRUG$ may decrease the hepatic metabolism of certain corticosteroids , thereby increasing their effect .	DDI-false
Magnesium/Aluminium containing antacid products: Zalcitabine absorption is moderately reduced (about 25%) when co-administered with @DRUG$/@DRUG$ containing antacid products.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
Doxorubicin : @DRUG$ caused a decrease in @DRUG$ phosphorylation ( 50 % inhibition of total phosphate formation ) in U937/Molt 4 cells .	DDI-effect
These drugs include the thiazides and other diuretics , corticosteroids , @DRUG$ , thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$ , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Dose adjustment is not recommended . Levetiracetam had no effect on plasma concentrations of @DRUG$ , valproate , @DRUG$ Or lamotrigine.	DDI-false
@DRUG$ The arterial responsiveness to @DRUG$ can be reduced.	DDI-effect
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , @DRUG$ , nifedipine , chlordiazepoxide , diazepam , certain tricyclic antidepressants , lidocaine , @DRUG$ and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
The extent to which SSRI@DRUG$ interactions can cause clinical problems depends on the degree of inhibition and pharmacokinetics of patients. @DRUG$ involved .	DDI-false
@DRUG$ , lidocaine, phenobarbital, quinidine, @DRUG$ , and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
If additional @DRUG$ are to be administered by any route , they should be used with caution because the pharmacologically predictable sympathetic effects of @DRUG$ may be potentiated .	DDI-advise
In clinical studies performed with Fondaparinux , the concomitant use of oral @DRUG$ ( @DRUG$ ), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam) and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and @DRUG$.	DDI-false
Cyclosporine : Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine , and because renal excretion is the primary elimination route of @DRUG$ including @DRUG$ There is a risk that an interaction will lead to a deterioration.	DDI-false
In addition, the results of regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or @DRUG$ CANCIDAS may become clinically meaningful @DRUG$ concentrations .	DDI-false
In monkeys , the effects of @DRUG$ , but not @DRUG$ or PCP , were antagonized by naloxone ;	DDI-false
These increased exposures of norethindrone and @DRUG$ should be taken into consideration when selecting an oral @DRUG$ for women taking valdecoxib .	DDI-false
Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
These results suggest that both dexamethasone and @DRUG$ , and possibly others @DRUG$ and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, @DRUG$, and alcohol.	DDI-effect
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Corticosteroids and @DRUG$ (ACTH): may potentiate @DRUG$- induced hypokalemia which may predispose the patient to cardiac dysfunction.	DDI-effect
However, neither @DRUG$ nor diazepam appears to affect @DRUG$ metabolism.	DDI-false
Drugs That Alter Renal Excretion @DRUG$: @DRUG$ is known to affect renal function and, consequently, alter the renal excretion of other drugs.	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, @DRUG$ , sympathomimetic agents ( e.g. , epinephrine , salbutamol , @DRUG$ ), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$: Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of ciprofloxacin in serum.	DDI-false
Intravenous @DRUG$ (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
@DRUG$: @DRUG$ is reported to be a weak inhibitor of aldehyde oxidase in rat liver, but its inhibitory effects in human liver are not known.	DDI-false
Special care is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window ( e.g. , cyclosporine or @DRUG$ ) .	DDI-advise
The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an @DRUG$ containing aluminum and @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
Lithium generally should not be given with diuretics because they reduce @DRUG$s renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
Can cause anticoagulants (modified hypoprothrombinemic activity), barbiturates, rifampin and other inducers of the hepatic microsomal enzyme oxidation system (reduced effect of @DRUG$ ) , @DRUG$ ( increased effect of corticosteroids ) .	DDI-false
Although other @DRUG$ are highly effective, there have been reports of pregnancy from women who have used @DRUG$, as well as topical/injectable/implantable/insertable hormonal birth control products.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
@DRUG$, @DRUG$, lidocaine	DDI-false
Tacrolimus   @DRUG$ may increase the blood concentration of @DRUG$.	DDI-false
Serious anticholinergic symptoms (i.e., severe dry mouth, urinary retention and blurred vision) have been associated with elevations in the serum levels of @DRUG$ when @DRUG$ therapy is initiated.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Saquinavir: The combination of HIVID, @DRUG$, and @DRUG$ has been studied (as triple combination) in adults.	DDI-false
Compounds that have been tested in man include antipyrine , digoxin , @DRUG$ , @DRUG$ No clinically significant interactions and warfarin were found.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , @DRUG$ or beta-adrenergic blocking agents , calcium channel blockers , antihistamines or @DRUG$ , tricyclic antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval .	DDI-false
There is therefore potential for interaction with other medicinal products metabolised by CYP 1A2 (e.g. @DRUG$ , @DRUG$ , and zileuton ) .	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients with receptor blockers (e.g. propranolol, @DRUG$ inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a @DRUG$ substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, @DRUG$ , benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
ANTACID ( @DRUG$ ): @DRUG$ plasma concentrations were not affected by co-administration of antacid .	DDI-false
Fulminant rhabdomyolysis has already been administered three weeks after initiation of a combined therapy with another @DRUG$ and @DRUG$ But can be seen after several months.	DDI-effect
In pigeons, @DRUG$ did not systematically alter the effects of (-)-NANM, @DRUG$ or PCP.	DDI-false
Oral doses of @DRUG$ - ( 10 - 20 mg/kg ), due to alcohol dehydrogenase inhibition, significantly reduces the rate of elimination of @DRUG$ The dose is administered to healthy volunteers at moderate doses (by about 40%).	DDI-mechanism
Other reported interactions with amiodarone: @DRUG$ ( @DRUG$ The substrate) in combination with amiodarone may cause hypotension, bradycardia, and reduced cardiac output.	DDI-false
Cefmenoxime, cefoperazone, @DRUG$ , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between @DRUG$ and @DRUG$.	DDI-false
- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving @DRUG$ therapy and concomitant @DRUG$.	DDI-effect
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been used in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, @DRUG$ , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , @DRUG$ ==See also==*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID==References==	DDI-false
Additional reductions in blood pressure may occur when @DRUG$ is administered with diuretics, antihypertensive agents, or other @DRUG$.	DDI-effect
@DRUG$/@DRUG$: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.	DDI-false
No data are available for the coadministration of @DRUG$/ritonavir or @DRUG$/ritonavir and garlic capsules.	DDI-false
@DRUG$ and @DRUG$ In clinical trials in patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists slightly increased the mean serum potassium (approximately 0.09 - 0.13 mEq/L).	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with @DRUG$ , steroids , or @DRUG$ may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with @DRUG$, @DRUG$, warfarin, and nifedipine.	DDI-false
Catecholamine-depleting Agents : Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines ( e.g. , @DRUG$ and @DRUG$ ) should be closely observed for signs of hypotension and/ or severe bradycardia.	DDI-false
@DRUG$ Administration of diflunisal to normal subjects receiving indomethacin decreased renal clearance and significantly increased @DRUG$ plasma levels.	DDI-false
Example inhibitors include azole antifungals , @DRUG$ , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , @DRUG$ ==References====External links==	DDI-false
Plasma levels of @DRUG$ may become subtherapeutic during @DRUG$ therapy.	DDI-mechanism
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drugs Which Require a Dose Reduction When Coadminstered With @DRUG$ @DRUG$: rifabutin	DDI-advise
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Notably , systemic exposure ( AUC0 - 12 ) of dapsone hydroxylamine ( @DRUG$ @DRUG$/SMX was more than doubled in the presence of @DRUG$/SMX.	DDI-false
astemizole , @DRUG$ , @DRUG$ ==References====External links==	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Antihistamines: @DRUG$*, @DRUG$* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral @DRUG$ , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ The apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13% and 15% respectively on the second day of therapy and were returned to baseline by day 87.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ has additive effects with @DRUG$ and other CNS depressants ( hypnotics , sedatives , tranquilizers , etc ) .	DDI-effect
As with some other @DRUG$ The time of onset of NUROMAX induced neuromuscular block is prolonged and the duration of the block is shortened in patients receiving phenytoin or @DRUG$.	DDI-effect
Patients receiving @DRUG$ , @DRUG$ , or sulphonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity of these drugs.	DDI-false
While all the selective serotonin reuptake inhibitors ( @DRUG$ ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,, @DRUG$ , sertraline , paroxetine , and fluvoxamine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
@DRUG$ has additive effects with alcohol and other CNS depressants ( hypnotics , sedatives , @DRUG$ ..............................................................................................................................................................................................................................................................................................................................................................................	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ As with other B-lactams, the renal excretion of cephalexin is inhibited by @DRUG$.	DDI-false
Although these results do not indicate a significant interaction between TORADOL and warfarin or heparin, @DRUG$ to patients taking @DRUG$ Patients should be closely monitored.	DDI-advise
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
@DRUG$ .Renal tube transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin , potentially leading to increased plasma levels of methotrexate .	DDI-false
Patients who begin taking @DRUG$ or who increase their @DRUG$ dose or any other NSAID while taking digoxin, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-false
Patients who begin taking diclofenac or who increase their @DRUG$ Dose or other NSAID while taking digoxin, @DRUG$ Cyclosporin can develop toxicity properties for these drugs.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
These results would seem to dictate against the clinical use of @DRUG$ â€¢ with ELSPAR, or during the following period @DRUG$ therapy when plasma asparagine levels are below normal .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), @DRUG$, vancomycin.	DDI-false
In rats, simultaneous ingestion of disulfiram and @DRUG$ in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with @DRUG$ in the rat stomach to form a nitrosamine, which is tumorigenic.	DDI-false
poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
Physiological oral @DRUG$ The supplementation ( 5 mg/kg/day ) is simple and can be done in the diet or with @DRUG$s, with practically only one contraindication: open kidney failure.	DDI-false
Antihistamines: @DRUG$ may counteract the sedative effect of @DRUG$.	DDI-effect
In EM-persons treated with @DRUG$ or fluoxetine, the AUC of @DRUG$ The maximum is about 3- to 4-fold greater than atomoxetine alone.	DDI-mechanism
The compounds in these categories lead to a reduced efficacy of bromocliptin mesylate: phenothiazine, @DRUG$ , @DRUG$ , pimozide .	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar Vet , or pentobarbital , the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with ketamine or Innovar than with @DRUG$.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , @DRUG$ , cyclosporine , non-steroidal anti-inflammatory drugs ( e.g. , @DRUG$ ==References====External links==	DDI-false
Coadministration of single, oral doses of @DRUG$ with @DRUG$ (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in zaleplons maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.	DDI-mechanism
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
@DRUG$ have been reported to blunt the hypotensive effect of systemic @DRUG$.	DDI-effect
Seizure , associated with increased @DRUG$ concentrations , has been reported with concomitant administration of intravenous @DRUG$.	DDI-false
WARFARIN: Co- administration of @DRUG$ and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Central nervous system depressants : Concomitant use of DURAGESIC (Fentanyl transdermal system ) with other central nervous system depressants, including but not limited to others @DRUG$ , sedatives, hypnotics, sedatives (e.g. benzodiazepines), generally @DRUG$ , phenothiazine, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and deep sedation, or possibly coma or death.	DDI-false
When @DRUG$ was coadministered with @DRUG$, rifampin, or H2antagonists, reduced plasma concentrations of itraconazole were reported.	DDI-mechanism
@DRUG$ Reports suggest that @DRUG$ may diminish the antihypertensive effect of ACE-inhibitors .	DDI-false
Other potent inhibitors of CYP3A4 (e.g. @DRUG$ , clarithromycin, nefazodon, @DRUG$ , ritonavir , nelfinavir ) would be expected to behave similarly .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : @DRUG$ , NSAIDs, corticosteroids, TNF blockers, azathioprin, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$ ==References====External links==	DDI-false
Selective Serotonin Reuptake Inhibitors ( @DRUG$ ): SSRIs ( e.g. , fluoxetine , fluvoxamine , @DRUG$ When co-administered with 5-HT1 agonists, weakness, hyperreflection, and incoordination have been rarely reported.	DDI-false
@DRUG$ : @DRUG$ and other NSAIDs can inhibit the activity of diuretics .	DDI-false
No data are available for the coadministration of INVIRASE/@DRUG$ or @DRUG$/ritonavir and garlic capsules.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
@DRUG$ ( SSRIs ): SSRIs (e.g. @DRUG$ Fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
@DRUG$: Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and live or inactivated vaccines due to inhibition of antibody response.	DDI-false
Lithium: @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	DDI-false
Oral @DRUG$: Multiple dose administration of @DRUG$ (8 mg/day monotherapy) did not alter the pharmacokinetics of oral contraceptives in healthy women of childbearing age.	DDI-false
@DRUG$ : Potentiation of warfarin-type ( CYP2C9 and @DRUG$ substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .	DDI-false
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , @DRUG$ , chloral hydrate and @DRUG$ The treatment was systematically studied in 16 patients receiving coumarin therapy.	DDI-false
Acidifying agents : Gastrointestinal acidifying agents ( @DRUG$ , reserpine , glutamic acid HCl , ascorbic acid , fruit juices , etc . ) lower absorption of @DRUG$.	DDI-mechanism
After multiple dosing, interferon beta-1a (@DRUG$  30 mcg IM once weekly) reduced @DRUG$  clearance by approximately 30%.	DDI-mechanism
The effects of adenosine are antagonized by @DRUG$ such as @DRUG$ and theophylline .	DDI-false
Although increased plasma concentrations ( AUC 0 - 24 hours) of loratadine and/ or @DRUG$ were observed following coadministration of loratadine with each of these drugs in normal volunteers ( n = 24 in each study ) , there were no clinically relevant changes in the safety profile of @DRUG$ , as assessed by electrocardiographic parameters , clinical laboratory tests , vital signs , and adverse events .	DDI-false
Because of the high inter-individual variability and limited sampling, the extent of the increase in @DRUG$ levels in patients receiving concurrent @DRUG$ and AVASTIN is uncertain .	DDI-false
This study shows that the concomitant use of @DRUG$ The dose and total exposure of @DRUG$ can be increased at least twice.	DDI-mechanism
Digoxin , Nimodipine and Losartan : @DRUG$ There are no significant pharmacokinetic interactions with @DRUG$ and nimodipine , and losartan has no significant effect on plasma levels of bosentan .	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , @DRUG$ , certain tricyclic antidepressants , lidocaine , theophylline and @DRUG$ This delays elimination and increases blood levels of these drugs.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
The use of antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isonazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$ , and @DRUG$.	DDI-false
Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, @DRUG$, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Other Agents : @DRUG$ has been used concomitantly with @DRUG$ Digoxin and/ or digoxin without evidence of clinically significant adverse interactions.	DDI-false
â€¢ Rifampin: concomitant use of @DRUG$ with @DRUG$ A potent inducer of hepatic metabolism, 600 mg daily, caused an approximate 50% decrease in rofecoxib plasma concentrations.	DDI-mechanism
Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : Phenytoin: @DRUG$ had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy.	DDI-false
- Vitamin K (e.g., @DRUG$, @DRUG$) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood	DDI-false
However, in another study in healthy volunteers, the pharmacokinetics of @DRUG$ were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of @DRUG$ nasal spray.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
A possible interaction between glyburide and @DRUG$ , a @DRUG$ , has been reported , resulting in a potentiation of the hypoglycemic action of glyburide .	DDI-false
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , antacids , H2-antagonists ( e.g. , @DRUG$ , ranitidine) and proton pump inhibitors (e.g. lansoprazole, @DRUG$ ) .	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., @DRUG$], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
Bacteriostatic Antibiotics: @DRUG$, erythromycins, sulfonamides, or @DRUG$ may interfere with the bactericidal effect of penicillins.	DDI-false
Other interactions : @DRUG$ â€¢ no effects on pharmacodynamics of @DRUG$ ( glucose and insulin concentrations ) and warfarin ( prothrombin time or other pharmacodynamic parameters ) .	DDI-false
Close supervision and careful adjustment of the dosage are required when @DRUG$ is used with other anticholinergic drugs or @DRUG$.	DDI-advise
A similar association, though less marked, has been suggested with barbiturates, @DRUG$, phenytoin sodium, carbamazepine, @DRUG$, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of @DRUG$ on the availability of digoxin and @DRUG$.	DDI-mechanism
@DRUG$: In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and @DRUG$.	DDI-false
CNS-Active Drugs Ethanol: @DRUG$ 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after @DRUG$ administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
@DRUG$ Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with medications of @DRUG$ It is contraindicated (including, for example, Ondansetron, Granisetron, Dolasetron, Palonosetron, and Alosetron).	DDI-false
@DRUG$ (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Studies in rats have shown that @DRUG$ administration attenuates certain types of adrenocortical steroid dependent hypertension, including @DRUG$ hypertension.	DDI-effect
Benzylpenicillin , ampicillin , oxacillin , @DRUG$ , doxycycline , cephalothin , erythromycin , and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum .	DDI-false
There was no significant difference between the mean volume of distribution of @DRUG$ with and without @DRUG$ ==References====External links==	DDI-false
Sulindac: The concomitant administration of @DRUG$ and @DRUG$ in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	DDI-mechanism
Antidepressants: In vitro data indicate that @DRUG$ inhibits the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
The monoamine oxidase inhibitory effects of @DRUG$ This should be taken into account if another medicine is prescribed after @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
In order to evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL ), the authors retrospectively compared a group of 24 patients with HIV-NHL who had been treated with the @DRUG$ , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
When LEVSIN is co-administered with others @DRUG$ , amantadine , @DRUG$ , phenothiazine, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Patients receiving high doses of salicylates concomitantly with @DRUG$ , as in rheumatic disease , may experience @DRUG$ toxicity at lower doses because of competitive renal excretory sites .	DDI-false
When co-administered with such medicines, the dose of @DRUG$ should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of @DRUG$.	DDI-false
Antihypertensive medications , other , especially @DRUG$ , or preanesthetic and anesthetic agents used in surgery or @DRUG$ , not depolarizing, used in surgery	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as @DRUG$ or ranitidine).	DDI-false
Data from in vitro studies of @DRUG$ Other than alprazolem, a possible interaction may be proposed for the following medicinal products: ergotamine, cyclosporin, amiodarone, @DRUG$ , and nifedipine .	DDI-int
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , @DRUG$ , amiodarone , @DRUG$ And nifedipine.	DDI-false
Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or @DRUG$ â€¢ antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, @DRUG$ inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
While @DRUG$ and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , betablockers , @DRUG$ , diuretics , and @DRUG$ ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$ , Methylxanthines and Diuretics : Concomitant treatment with xanthine derivatives , @DRUG$ , or diuretics may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
@DRUG$ : @DRUG$ The free share of Etodolac increases by about 80%.	DDI-false
@DRUG$ : Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs ( fluoxetine , thiothixene , alprazolam ) .	DDI-false
@DRUG$ : Ephedrine may enhance the metabolic clearance of corticosteroids , resulting in decreased blood levels and lessened physiologic activity , thus requiring an increase in @DRUG$ dosage .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other medicines: In small groups of patients ( 7 - 10 / interaction study ), the concomitant use of azathioprin, @DRUG$ , chloroquine , D-penicillamine , prednisolone , doxycycline , or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$ : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , @DRUG$ , sulfasalazine , and anakinra .	DDI-false
Although the pressor activity of @DRUG$ is very low compared to its antidiuretic activity, large doses of @DRUG$ Tablets should be used with other pressor agents only with careful patient monitoring.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
Cytochrome P-450 inducers, such as @DRUG$, @DRUG$ and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma clonazepam levels.	DDI-false
- medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine antimigrain: ergot derivatives antimycobacterial agents: rifampin benzodiazepine midazolam, triazolam GI motility agent: @DRUG$	DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or @DRUG$) and AXERT within 24 hours of each other should be avoided.	DDI-false
@DRUG$ Simultaneous use of Diclofenac and @DRUG$ It is not recommended as Diclofenac is displaced from its binding sites during concomitant administration of aspirin, resulting in lower plasma concentrations, maximum plasma levels, and AUC values.	DDI-false
Antidepressants (tricyclic), @DRUG$ or other anticholinergic agents, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	DDI-false
May interact with thyroid medication ( e.g. , @DRUG$ , iodine-containing products, @DRUG$ H2 antagonists (e.g. famotidine, ranitidine) and proton pump inhibitors (e.g. lansoprazole, omeprazole).	DDI-false
Effect of @DRUG$ on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of @DRUG$, carbamazepine, or phenobarbital.	DDI-false
These drugs include thiazides and other @DRUG$ , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$ , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Lithium toxicity was usually reversible upon discontinuation of @DRUG$ and the @DRUG$.	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
medicines that induce CYP3A4 ( @DRUG$ The Racemic zopiclone exposure was achieved by the simultaneous use of @DRUG$ , a potent inducer of CYP3A4 .	DDI-false
Both @DRUG$ The extracellular dopamine levels in the nucleus accumbens and 18-MC decrease, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens .	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of @DRUG$ that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, @DRUG$, simvastatin).	DDI-false
@DRUG$: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and @DRUG$ due to inhibition of antibody response.	DDI-false
Severe anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with increases in serum levels. @DRUG$ when @DRUG$ is added to the drug regimen .	DDI-effect
A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, @DRUG$, and tetracyclines (72)	DDI-false
In addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , @DRUG$ , phenytoin , dexamethasone , or @DRUG$ ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations .	DDI-false
@DRUG$ or @DRUG$ Elevates the autonomic irritability of the heart and can sensitize the myocardium to the effect of certain intravenous catecholamines, such as dopamine.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , @DRUG$ , glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$ , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole (Cefmenoxime, cefoperazone), @DRUG$ , @DRUG$ , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
In patients with mild to moderate hypertension, administration of 25 mg daily of @DRUG$ with the ACE inhibitor @DRUG$, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.	DDI-effect
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
â€¢ Dopamine antagonists : Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as neuroleptics ( @DRUG$ , @DRUG$ Thioxanthene or methoclopramide may reduce the efficacy of APOKYN.	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$ , diazepam , certain @DRUG$ , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING @DRUG$ TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE @DRUG$ SERUM LEVEL SHOULD BE OBTAINED.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Lithium: @DRUG$ decreases lithium renal clearance and increases @DRUG$ plasma levels.	DDI-mechanism
@DRUG$: In healthy subjects receiving the CYP3A4 inducer, @DRUG$, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to lapatinib was decreased approximately 72%.	DDI-false
Ritonavir and indinavir: Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID @DRUG$, the Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-mechanism
In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving @DRUG$ concurrently with @DRUG$.	DDI-effect
ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/ARB).	DDI-false
The peripheral vasoconstriction caused by high doses of @DRUG$ is antagonized by @DRUG$.	DDI-effect
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$ , @DRUG$ , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
HMG-CoA Reductase Inhibitors: Simvastatin (@DRUG$ substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
@DRUG$ The concomitant use of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$ , respiratory depression, hypotension, and deep sedation, or possibly lead to coma or death.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and @DRUG$ ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , @DRUG$ , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Moreover , additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels , and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ Relative to the control data.	DDI-false
Interaction with phenytoin, @DRUG$ and @DRUG$ It has also been reported that there are adverse clinical effects.	DDI-false
Dexamethasone: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg @DRUG$ was coadministered with each dose of @DRUG$ (15 mg/kg/day) in eight neurocysticercosis patients.	DDI-mechanism
Co-administration of MYOBLOC and @DRUG$ Neuromuscular transmissions (e.g. @DRUG$ Caution should be exercised as the effect of the toxin may be increased.	DDI-false
@DRUG$ ( 5 mg/kg ) , moclobemide ( 30 mg/kg ) , clonazepam ( 0.25 mg/kg ) , @DRUG$ ( 20 mg/kg ) sertraline ( 30 mg/kg ) or vehicle was administered .	DDI-false
@DRUG$ The effect of @DRUG$ on the anticoagulant effect of warfarin ( 1 - 8 mg/day ) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days .	DDI-false
Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window (e.g., cyclosporine or @DRUG$).	DDI-advise
Acetaminophen/@DRUG$, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Simultaneous use of @DRUG$ with @DRUG$ Thrombolytics and other anticoagulants may increase the risk of bleeding.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, @DRUG$ , @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
@DRUG$ Plasma digoxin levels and steady-state digoxin clearance were not affected by concomitant administration of 0.2 mg @DRUG$.	DDI-false
Omeprazole : The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ 2 hours after @DRUG$ At the dose that suppresses gastric acid secretion maximum.	DDI-false
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with captopril ( @DRUG$ tablets , USP ) or initiating therapy with small doses ( 6.25 or 12.5 mg ) .	DDI-false
@DRUG$ In an interaction study with patients with rheumatoid arthritis who: @DRUG$ CELEBREX had no significant effect on the pharmacokinetics of methotrexate.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: @DRUG$ , NSAIDs, corticosteroids, TNF blockers, azathioprin, chloroquine, gold, hydroxychloroquine, @DRUG$ , Sulfasalazine, and Anakinra.	DDI-false
@DRUG$ , @DRUG$ Lithium salts and alcohol may increase or weaken the hypoglycaemic effect of insulin.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , @DRUG$ , tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem, and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
This drug may interact with @DRUG$ Anticholinergic drugs or other anticholinergic drugs (anticholinergic effects can be intensified if these drugs are used concomitantly with antihistamines) and monoamine oxidase (MAO) inhibitors (simultaneous use with antihistamines can cause the anticholinergic and CNS depressive effects of @DRUG$ ) .	DDI-false
The absorption of @DRUG$, furosemide, penicillin G, hydrochlorothiazide, and @DRUG$ was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
The co-administration of @DRUG$ With IV-vasodilators such as nitroglycerin, @DRUG$ , milrinone , or IV ACE inhibitors has not been evaluated ( these drugs were not co-administered with Natrecor in clinical trials ) .	DDI-false
Although @DRUG$ It has been shown that PROLEUKIN-induced adverse reactions such as fever, renal insufficiency, hyperbilirubinaemia, confusion and dyspnoea are reduced, the concomitant administration of these active substances with PROLEUKIN can reduce the antitumour effectiveness of PROLEUKIN and should therefore be avoided. 12 beta-blockers and other antihypertensives may increase hypotension in @DRUG$.	DDI-false
omeprazole : The rate and extent of absorption of @DRUG$ was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion .	DDI-false
@DRUG$: Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	DDI-false
Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by @DRUG$ that cause renin release (e.g., diuretics).	DDI-effect
@DRUG$: Concomitant administration of diclofenac and @DRUG$ is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and @DRUG$/phenobarbital.	DDI-false
@DRUG$, including oral contraceptives: @DRUG$ may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of @DRUG$.	DDI-mechanism
The concomitant use of other CYP3A4 inhibitors such as @DRUG$ and @DRUG$ Transdermal fentanyl may also increase fentanyl plasma concentrations, which may increase or prolong adverse drug reactions and lead to severe respiratory depression.	DDI-false
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ ( captopril tablets , USP ) or initiating therapy with small doses ( 6.25 or 12.5 mg ) .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$ Patients receiving Antabuse should be used with caution ( @DRUG$ , Wyeth-Ayerst Laboratories ) .	DDI-advise
@DRUG$ : Because @DRUG$ If the pharmacokinetics of antipyrin are not affected, interactions with other medicinal products metabolised by the same cytochrome isozymes are not expected.	DDI-false
Warfarin : Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG$n , nor were there any changes in the pharmacodynamic profile ( prothrombin time ) following a single 25 mg oral dose of @DRUG$	DDI-false
There have been reports of theophylline-related side effects in patients on concomitant therapy with @DRUG$ and @DRUG$.	DDI-effect
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.	DDI-effect
@DRUG$: Amphetamines may antagonize the hypotensive effects of @DRUG$.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$ , protease inhibitors , @DRUG$ ==References====External links==	DDI-false
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
While all selective serotonin reuptake inhibitors ( SSRIs), e.g. fluoxetine, @DRUG$ , @DRUG$ , and fluvoxamine, inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant studies: @DRUG$ : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , @DRUG$ , and anakinra .	DDI-false
Physical changes resulting from the cessation of smoking, with or without @DRUG$ The pharmacokinetics of certain concomitant medicinal products, such as anticoagulants, may be replaced by the pharmacokinetics of certain concomitant medicinal products, such as anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, anticoagulants, and anticoagulants. @DRUG$ and theophylline .	DDI-false
Physicians needing to treatpatients co-infected with tuberculosis andusing a @DRUG$ containing regimen mayuse @DRUG$ instead.	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$ and valproic acid/phenobarbital.	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including anti-arrhythmic agents such as quinidine and @DRUG$ , @DRUG$ And tricyclic antidepressants.	DDI-false
Other Drug Interactions Oral Contraceptives @DRUG$ The pharmacokinetics of an oral contraceptive containing 0.03 mg ethinylestradiol and 0.15 mg ethinylestradiol were not affected. @DRUG$ , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .	DDI-false
The effects of DCG-IV and @DRUG$ upon phencyclidine (@DRUG$)-induced locomotion and behavioral changes in mice.	DDI-false
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
The effectiveness of Progestin-Only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$ , and barbiturates, and the antituberculosis drug @DRUG$.	DDI-false
Although there are no study data to evaluate the possibility , @DRUG$ , including sodium nitroprusside and nitroglycerin, may have an additive effect with @DRUG$ on the risk of developing methemoglobinemia .	DDI-effect
@DRUG$ The bioavailability is slightly reduced (about 10%) if: @DRUG$ and metoclopramide are coadministered .	DDI-false
Possible interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$ , primidone and @DRUG$ The serum concentrations of levetiracetam and these AEDs were also evaluated in placebo-controlled clinical trials.	DDI-false
Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of @DRUG$, valproate, topiramate, or lamotrigine.	DDI-false
The medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, @DRUG$ , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , @DRUG$ , phenytoin , ribavirin , and vincristine .	DDI-false
@DRUG$ may decrease the effect of @DRUG$, levodopa, and ketoconazole.	DDI-effect
Other CNS depressant drugs (e.g. barbiturates, @DRUG$, @DRUG$ and general anesthetics) have additive or potentiating effects with INAPSINE.	DDI-false
There have been greater than 2-fold increases in previously stable plasma levels of other antidepressants, including @DRUG$, when @DRUG$ has been administered in combination with these agents.	DDI-mechanism
@DRUG$: Concomitant administration of @DRUG$ and aspirin is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and @DRUG$ (such as @DRUG$ or ranitidine).	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
All subjects received @DRUG$ (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either rifabutin (300 mg once a day [QD]) (cohort 1) or @DRUG$ (600 mg QD) (cohort 2) for 14 days.	DDI-false
@DRUG$: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
In both cases, the pharmacokinetics of @DRUG$ affected by coadministration with @DRUG$.	DDI-false
Therophylline : A recent study has shown that the concomitant administration of isoniazid and @DRUG$ In some cases, increased plasma levels of theophylline and a slight decrease in elimination of @DRUG$ may occur.	DDI-false
@DRUG$ : Coadministration of ritonavir with VIRACEPT resulted in a 152 % increase in @DRUG$ Plasma AUC and very small change in ritonavir plasma A.C.	DDI-false
, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
@DRUG$: Administration of terfenadine with VIRACEPT resulted in the appearance of unchanged @DRUG$ in plasma;	DDI-false
There are case reports of patients who developed increased BUN , serum creatinine and serum potassium levels , and weight gain when @DRUG$ was used in conjunction with @DRUG$.	DDI-effect
- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar Vet , or pentobarbital , the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with @DRUG$ or Innovar than with pentobarbital .	DDI-false
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for @DRUG$ versus @DRUG$/oxycodone regimens.	DDI-false
@DRUG$ (10 mg once daily) has been coadministered with therapeutic doses of @DRUG$, cimetidine, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ : Chloramphenicol , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of @DRUG$.	DDI-false
In vitro studies show that ertapenem does not inhibit the P-glycoprotein-mediated transport of digoxin, or @DRUG$ and that @DRUG$ is not a substrate for P-glycoprotein-mediated transport .	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Administration of @DRUG$ The @DRUG$-induced neuromuscular block can be potentiated.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
In a median follow-up of 33 months, the combination of ARIMIDEX and @DRUG$ The benefit for effectiveness compared to @DRUG$ in all patients as well as in the hormone receptor-positive subpopulation .	DDI-false
Patients receiving azathioprine and @DRUG$ concomitantly should have a dose reduction of @DRUG$, to approximately 1/3 to 1/4 the usual dose.	DDI-false
Drug-drug interactions have not been observed between Argatroban and @DRUG$ or @DRUG$.	DDI-false
The effects of DCG-IV and @DRUG$ upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-effect
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, @DRUG$, paroxetine, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Urinary acidifying agents ( ammonium chloride , @DRUG$ , etc . ) increase the concentration of the ionized species of the @DRUG$ ==References====External links==* Official website	DDI-mechanism
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide , @DRUG$ , warfarin , @DRUG$ and phenobarbital .	DDI-false
OBJECTIVE : Our objective was to characterize the steady-state pharmacokinetics of @DRUG$ and @DRUG$ ( INN , ciclosporin ) when coadministered in de novo kidney allograft recipients during the first year after transplantation .	DDI-false
These drugs include the @DRUG$ and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , @DRUG$ , and isoniazid .	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-false
Urinary acidifying agents These agents ( @DRUG$ , @DRUG$ , etc . ) increase the concentration of the ionized species of the amphetamine molecule , thereby increasing urinary excretion .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Magnesium/Aluminum-containing @DRUG$ : Absorption of @DRUG$ When co-administered with magnesium/aluminium-containing antacids, the dose is slightly reduced (approximately 25%).	DDI-false
@DRUG$ orlistat can reduce the absorption of @DRUG$.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , @DRUG$ , Dapsone, Disulfiram, Ethionamide, Glutethimide, Gold, Hydralazine, Iodoquinol, @DRUG$ , metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: orally @DRUG$ , ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g. octreotide), sulphonamide antibiotics.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
â€¢ Dopamine antagonists : Since apomorphine is a dopamine agonist, it is possible that @DRUG$ , as e.g. the @DRUG$ ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
Antibiotics : In vitro and/or in vivo data show that clarithromycin, @DRUG$ , and troleandomycin significantly inhibit the metabolism of @DRUG$ , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-mechanism
Stavudine and @DRUG$ Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and zidovudine against HIV.	DDI-false
Loratadine (10 mg once daily) has been coadministered with therapeutic doses of @DRUG$, cimetidine, and @DRUG$ in controlled clinical pharmacology studies in adult volunteers.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-effect
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids , @DRUG$ VIDEX chewable/buffer tablets or paediatric powders or products containing calcium, iron or zinc may significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-false
Ephedrine: @DRUG$ may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in @DRUG$ dosage.	DDI-false
@DRUG$: In postmarketing experience there have been reports of a possible interaction between TORADOLIV/IM and @DRUG$ that resulted in apnea.	DDI-false
This effect is small with occasional doses of @DRUG$, but may be clinically significant when @DRUG$ are used on a continuous schedule.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	DDI-false
Compounds tested in man include @DRUG$, theophylline, @DRUG$, diazepam, aminopyrine and antipyrine.	DDI-false
, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$ and valproic acid/phenobarbital.	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$ , @DRUG$ Or phenothiazines can cause severe, prolonged hypotension or hypertension.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with @DRUG$ , beta-blockers , @DRUG$ , digoxin , warfarin , isosorbide mononitrate , carvedilol , ethanol or itraconazole .	DDI-false
Curariform muscle relaxants ( eg , tubocurarine ) and other drugs , including ether , @DRUG$ , gallamine , decamethonium and sodium citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral .	DDI-effect
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin, @DRUG$ , and amikacin), @DRUG$ , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-false
Potassium-sparing diuretics ( e.g. , @DRUG$ , Triamteren or @DRUG$ ) , potassium supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
- @DRUG$: Indomethacin blunts the increases in urine volume and sodium excretion seen during @DRUG$ treatment and inhibits the bumetanide-induced increase in plasma renin activity.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , @DRUG$ , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as @DRUG$ ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors , tricyclic antidepressants or phenothiazines may produce severe , prolonged hypotension or hypertension .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$ does not affect serum @DRUG$ levels .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
- When @DRUG$ Bezalip retard or bezalip retard is used at the same time as anion exchange resins (e.g. @DRUG$ ) , an interval of at least 2 hours should be maintained between the two medicines , since the absorption of Bezalip or Bezalip retard is impaired	DDI-advise
Clidinium may reduce the effect of phenothiazines, @DRUG$ , and @DRUG$.	DDI-false
- Lithium: Lithium should generally not be given with @DRUG$ (such as @DRUG$) because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-false
Bacteriostatic Antibiotics: @DRUG$, @DRUG$, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.	DDI-false
These drugs include thiazides and other diuretics, @DRUG$ , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , @DRUG$ , and isoniazid .	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, @DRUG$, @DRUG$, phenobarbital or St.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Experience with co-administration of @DRUG$ and Fentanyl in patients is limited , therefore , consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving @DRUG$.	DDI-false
Erythromycin Co-administration of felodipine (@DRUG$) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of @DRUG$.	DDI-false
In patients with chronic hepatitis C treated with @DRUG$ in combination with @DRUG$, PEGASYS treatment did not affect ribavirin distribution or clearance.	DDI-false
@DRUG$ as potent @DRUG$ "Excretion of the glucocorticoid-induced mouse mammary tumor virus gene.	DDI-false
Cyclopentolate may interfere with the anti-glaucoma action of @DRUG$ or @DRUG$ ;	DDI-false
To avoid the occurrence of severe hypersensitivity reactions, all TAXOL-treated patients with corticosteroids (such as dexamethasone), diphenhydramine and @DRUG$ ( such as cimetidine or @DRUG$ ) .	DDI-false
DOSTINEX should not be administered concurrently with D2-antagonists, such as @DRUG$, butyrophenones, @DRUG$, or metoclopramide.	DDI-false
The hypoglycaemic effect of @DRUG$ â€¢ may be exacerbated by certain medicines, including: @DRUG$ And other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, probenecid, coumarine, monoamine oxidase inhibitors and beta-adrenergic blockers.	DDI-effect
Cyclosporin, digoxin, methotrexate lodine, such as other NSAIDs, due to effects on renal prostaglandins, may cause changes in the elimination of these drugs to increase serum levels of cyclosporin, @DRUG$ , @DRUG$ , and increased toxicity .	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between @DRUG$ (a @DRUG$) and ethanol under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-false
@DRUG$ and @DRUG$ use may be rarely associated with ventricular fibrillation when combined with Adenocard.	DDI-false
Tetracyclines: Concomitant treatment with Accutane and @DRUG$ should be avoided because @DRUG$ use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	DDI-false
Hepatic enzyme inducers, inhibitors and substrates : drugs that induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity (e.g., @DRUG$ , phenytoin , carbamazepine , @DRUG$ ) can improve the metabolism of corticosteroids and require that the dosage of corticosteroids be increased.	DDI-false
Administration of @DRUG$ to patients receiving cyclopropane or @DRUG$ such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..	DDI-effect
Co-administration of intravenous or oral administration @DRUG$ (e.g. aminophylline, @DRUG$ ) by patients receiving BROVANA has not been completely evaluated .	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of the magnesium deficiency and to discriminate between magnesium deficiency due to insufficient @DRUG$ Ingestion that requires only oral physiological supplement and magnesium deficiency, which is accompanied by a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation .	DDI-false
In healthy volunteers, the pharmacokinetics of a 1 mg dose of butorphanol were administered as follows: @DRUG$ The concomitant administration of a single subcutaneous dose of 6 mg @DRUG$ was not affected.	DDI-false
@DRUG$: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on tolazamide (1 gm/day) 11 days after the addition of @DRUG$ (75 mg/day).	DDI-false
Anticholinesterases (neostgmine, @DRUG$), lignocaine, quinine, @DRUG$ can enhance toxicity and cause cardio respiratory depression.	DDI-false
Probenecid: As with other @DRUG$, the renal excretion of @DRUG$ is inhibited by probenecid.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or fluconazole.	DDI-false
â€¢ prostatic epithelial proliferate in a defined medium consisting of a basal medium RPMI1640 containing transferrin ( 1 micrograms/ ml), @DRUG$ ( 10 ng/ ml ) and @DRUG$ [ 3.7 micrograms/ ml or 0.1 IU/ ml].	DDI-false
The use of @DRUG$ before @DRUG$ to attenuate some of the side effects of succinylcholine has not been studied .	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Therefore, @DRUG$ should be taken at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption .	DDI-advise
Intravenous Adenocard ( @DRUG$ ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , beta-adrenergic blocking agents , @DRUG$ , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile .	DDI-false
Although glucocorticoids @DRUG$-induced side effects such as fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea have been shown to reduce, concomitant administration of these agents with PROLEUKIN may reduce the efficacy of antitumours. @DRUG$ and thus should be avoided . 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .	DDI-false
The effect of TORADOL on plasma @DRUG$ has not been studied , but cases of increased lithium plasma levels during @DRUG$ therapy have been reported .	DDI-false
Imidazoles (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Aspirin : Concomitant administration of @DRUG$ with @DRUG$ This may lead to an increased risk of GI ulcers and complications compared to valdecoxib alone.	DDI-effect
@DRUG$: Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (fluoxetine, thiothixene, alprazolam).	DDI-false
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral @DRUG$ , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ On the second day of therapy, apparent values for oral clearance of furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13 % and 15 % respectively and were returned to baseline by day 87.	DDI-false
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, salbutamol, @DRUG$ ) , isoniazid , phenothiazine derivatives , somatropin , @DRUG$ Oestrogens, progestogens (e.g. in oral contraceptives).	DDI-false
No clinically important pharmacokinetic interactions occurred when @DRUG$ was used concomitantly with propranolol or @DRUG$.	DDI-false
Although @DRUG$ used alone has little or no effect on pupil size , mydriasis resulting from concomitant therapy with BETAGAN and @DRUG$ may occur .	DDI-false
@DRUG$ caused a statistically significant increase in plasma exposures of R-warfarin and @DRUG$ ( 12 % and 15 % , respectively ) , and in the pharmacodynamic effects ( prothrombin time , measured as INR ) of warfarin .	DDI-mechanism
@DRUG$ Valdecoxib 40 mg twice daily for 7 days resulted in a significant decrease in @DRUG$ serum clearance ( 25 % ) and renal clearance ( 30 % ) with a 34 % higher serum exposure compared to lithium alone .	DDI-false
Clonidine: Concomitant administration of @DRUG$ with @DRUG$ may potentiate blood-pressure- and heart-rate-lowering effects.	DDI-effect
The zidovudine study dosed subjects with 1200 mg/day of @DRUG$ ( n = 7 ) ( later changed to 600 mg/day [ n = 5 ] ) for Days 8 to 21 of a 21-day course of 100 mg , five times/day of @DRUG$.	DDI-false
Coadministration of almotriptan and the potent CYP3A4 inhibitor @DRUG$ (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of @DRUG$.	DDI-false
The blood pressure effect of SULAR tended to be greater in patients on @DRUG$ than in patients on no other @DRUG$ therapy .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
; Naproxen : Simultaneous use of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$ , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite .	DDI-false
There are rare reports, however, from marketing experiences, of changes in effects of @DRUG$ or oral @DRUG$ in the presence of diclofenac that necessitated changes in the doses of such agents.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, @DRUG$, phenytoin, dexamethasone, or @DRUG$, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
A similar association, albeit less pronounced, was proposed with @DRUG$ phenylbutazone, phenytoin sodium, carbamazepine and possibly with @DRUG$ , ampicillin , and tetracyclines ( 72 )	DDI-false
Both ibogaine and @DRUG$ block morphine-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-effect
Potential interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also evaluated by evaluating serum concentrations of @DRUG$ and these @DRUG$ during placebo-controlled clinical studies .	DDI-false
DOSTINEX should not be co-administered with D2 antagonists such as @DRUG$ , butyrophenones , thioxanthines , or @DRUG$.	DDI-false
@DRUG$) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide).	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , @DRUG$ , cyclosporine , @DRUG$ , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Coingestion of @DRUG$ with theophylline, @DRUG$ with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Clidinium may decrease the effect of @DRUG$, levodopa, and @DRUG$.	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs , e.g. , guanethidine , @DRUG$ , @DRUG$.	DDI-false
CONCLUSIONS : Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 ( i.e. , @DRUG$ , cerivastatin , lovastatin , @DRUG$ ) .	DDI-false
This medicine can be used with @DRUG$ CNS depressants (may increase the CNS depressive effect of either these drugs or @DRUG$ Anticholinergic agents, anticholinergic agents or other medicines with anticholinergic activity (anticholinergic effects can be intensified if these drugs are used at the same time as antihistamines), and monoamine oxidase (MAO) inhibitors ( concomitant use with antihistamines can prolong and enhance the anticholinergic and CNS depressive effects of antihistamines.	DDI-false
@DRUG$ : May decrease renal tubular secretion of @DRUG$ This leads to increased blood levels and/ or ampicillin toxicity.	DDI-mechanism
@DRUG$ : Population pharmacokinetic analyses indicate that tiagabine clearance is 60 % greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs .	DDI-false
Methotrexate: @DRUG$ BID did not show a significant effect on the plasma exposure or renal clearance of @DRUG$.	DDI-false
@DRUG$ and @DRUG$ interact pharmacologically with orally administered anticoagulant agents, but the effect is not clinically significant.	DDI-false
@DRUG$: Cimetidine has been reported to produce clinically significant fluctuations in steady-state serum concentrations of various @DRUG$.	DDI-false
In addition to the above mentioned interactions, chronic ( 2 weeks ) oral @DRUG$ Administration affects the metabolism of phenytoin, dextromethorphan and @DRUG$.	DDI-false
To assess the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, @DRUG$ , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$ , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
However, because some quinolones have been reported to enhance the anticoagulant effects of @DRUG$ or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a @DRUG$ is administered concomitantly with warfarin or its derivatives.	DDI-false
However, neither @DRUG$ nor @DRUG$ appears to affect Dantrium metabolism.	DDI-false
Both the toxicity of filipin and the therapeutic value of @DRUG$ can be rationalized at the cellular and molecular level by the following observations: (i) these @DRUG$ showed differential effects on cells;	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, @DRUG$, and nifedipine.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
Intravenous adenocard (adenosine) has been effectively administered in the presence of other cardiovascular drugs such as quinidine, beta-adrenergic agents, @DRUG$ , and @DRUG$ , without any change in the adverse reaction profile .	DDI-false
@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/ARB).	DDI-false
Uricosuric drugs , such as probenecid and @DRUG$ , can inhibit renal tubular secretion of @DRUG$.	DDI-mechanism
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , haloperidol , @DRUG$ , monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .	DDI-false
A possible interaction between glyburide and ciprofloxacin, a @DRUG$, has been reported, resulting in a potentiation of the hypoglycemic action of @DRUG$.	DDI-false
The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of @DRUG$ with @DRUG$ resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of felodipine.	DDI-false
It was concluded that oral @DRUG$ and @DRUG$ can be administered concomitantly without a significant decrease in AUC, Cmax, or tmax.	DDI-false
Hormonal Contraceptives , Including Oral , Injectable , Transdermal , and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and @DRUG$ The rate is 14 % and 31 % respectively.	DDI-false
Although these results do not indicate a significant interaction between TORADOL and warfarin or @DRUG$, the administration of TORADOL to patients taking @DRUG$ should be done extremely cautiously, and patients should be closely monitored.	DDI-false
Consequently, the combination of @DRUG$ with @DRUG$ is also contraindicated.	DDI-advise
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Stavudine and Zidovudine @DRUG$ In vitro, the antiviral activity of @DRUG$ And zidovudine against HIV.	DDI-effect
Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge with the reversal of the benzodiazepine effect by flumazenil.	DDI-effect
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Other strong inhibitors of CYP3A4 ( e.g. , @DRUG$ , clarithromycin , nefazodone , troleandomycin , @DRUG$ , nelfinavir ) would be expected to behave similarly .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , @DRUG$ Somatropin, thyroid hormones, estrogens, progestogens (e.g. oral) @DRUG$ ) .	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
[Quantitative approach to treatment with incisive @DRUG$ by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with @DRUG$ are illustrated by six typical case reports.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , pentazocine , nalbuphine , butorphanol , dezocine and @DRUG$ Do NOT administer to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesics such as @DRUG$.	DDI-advise
Fluoxetine and @DRUG$ increased blood @DRUG$ at different times after the glucose overload.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, @DRUG$ , @DRUG$ , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, @DRUG$, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
Pharmacokinetic studies have demonstrated that @DRUG$ and erythromycin significantly increased the systemic exposure of @DRUG$ and/or its major metabolites.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as anesthetics, opiates, and @DRUG$.	DDI-false
High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of etoposide compared to etoposide alone.	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin is associated with @DRUG$ , the concomitant use of @DRUG$ The contraindicated medicines of the 5HT3 antagonist class (including, for example, Ondansetron, Granisetron, Dolasetron, Palonosetron, and Alosetron).	DDI-false
conversely, diethylpropion may interfere with @DRUG$ (i.e., @DRUG$, a-methyldopa).	DDI-false
Population pharmacokinetic analyses revealed that MTX, @DRUG$, corticosteroids, and @DRUG$ did not influence abatacept clearance.	DDI-false
Fluconazole: Concomitant administration of @DRUG$ at 200 mg QD resulted in a two-fold increase in @DRUG$ plasma concentration.	DDI-mechanism
- Poor metabolisers of schuttoquine : interactions of schnitztilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$ , @DRUG$ , and propafenone ) have not been studied , but these drugs would be expected to increase blood levels of the R(+ ) enantiomer of carvedilol .	DDI-false
@DRUG$ In vitro data show that nefazodone inhibits the metabolism of nefazodone. @DRUG$ This may lead to an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Other medicines: In small groups of patients ( 7 - 10 / interaction study ), concomitant administration of azathioprin, gold, chloroquine, D-penicillamin, prednisolone, doxycycline, or @DRUG$ The peak and AUC values of @DRUG$ were not significantly affected.	DDI-false
Cyclosporine : Because @DRUG$ Nephrotoxicity may occur with a decrease in creatinine clearance and an increase in serum creatinine, and as renal excretion of the primary elimination pathway of fibrat drugs including @DRUG$ There is a risk that an interaction will lead to a deterioration.	DDI-effect
Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat @DRUG$ poisoning.	DDI-false
Although no clinical studies have been conducted , it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers ( such as @DRUG$ , phenobarbital , rifampin ) , CYP3A4 inhibitors ( azole antimycotics e.g. , @DRUG$ ;	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , @DRUG$ , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , @DRUG$ , and vincristine .	DDI-false
Patients in a clinical study who were on established therapy with @DRUG$ , to which @DRUG$ A slight decrease in mean neutrophil count compared to groups treated with either ENBREL CI or sulfasalazine alone was observed.	DDI-effect
Antacids: Concomitant administration of @DRUG$ may reduce plasma levels of @DRUG$.	DDI-mechanism
Concomitant administration of Sonata (10 mg) and @DRUG$ (800 mg) produced an 85% increase in the mean Cmax and AUC of @DRUG$.	DDI-false
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of azathioprine , @DRUG$ , @DRUG$ , D-penicillamine , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, @DRUG$ , sympathomimetic agents ( e.g. , @DRUG$ , salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Certain endocrine and liver function tests may be affected by @DRUG$-containing oral @DRUG$.	DDI-false
Coingestion of acetaminophen with theophylline , phenobarbital with acetaminophen , and @DRUG$ with @DRUG$ at high to toxic concentrations decreases the binding of the target drug .	DDI-effect
Cardiac effects of dopamine are antagonized by beta-adrenergic blocking agents, such as @DRUG$ and @DRUG$.	DDI-false
As with other antipsychotic agents , it should be noted that HALDOL may be capable of potentiating @DRUG$ such as anesthetics , @DRUG$ , and alcohol .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics propafenone and @DRUG$).	DDI-false
Considerable caution should be exercised if @DRUG$ is administered concurrently with @DRUG$ (phenacemide) since paranoid symptoms have been reported during therapy with this combination.	DDI-advise
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$ Acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, @DRUG$ , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, @DRUG$).	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide , quinine , @DRUG$ , quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
It has been reported that plasma levels of several closely related tricyclic antidepressants have been increased by concomitant administration of methylphenidate or hepatic enzyme inhibitors (e. g. @DRUG$ , @DRUG$ This effect can also be expected with CMI, and may be reduced by concomitant administration of liver enzyme inducers (e. g. barbiturates, phenytoin).	DDI-false
In rats, co-administration of disulfiram and @DRUG$ in the diet for 78 weeks has been reported to cause tumors , and it has been suggested that @DRUG$ may react with nitrites in the rat stomach to form a nitrosamine , which is tumorigenic .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , @DRUG$ , A-blockers, analgesics, angiotensin converting enzyme ( ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, heart nitrates, @DRUG$ , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Compounds in these categories result in a decreased efficacy of @DRUG$ : @DRUG$ , haloperidol, methoclopramide, pimozide.	DDI-effect
@DRUG$ , @DRUG$ Abs and diuretics: Concomitant treatment with xanthine derivatives, steroids or diuretics may potentiate a potential hypocalemic effect of beta2-agonists.	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients receiving antihypertensive agents (e.g. @DRUG$ , a @DRUG$ Inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Coadministration of @DRUG$ Itraconazole has increased plasma concentrations of @DRUG$ In rare cases of life-threatening cardiac dysrrhythmias and a death.	DDI-false
@DRUG$/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and @DRUG$.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Antiarrhythmia : Other antiarrhythmic drugs, such as quinidine, @DRUG$ , disopyramide , and phenytoin , have been used concurrently with @DRUG$.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, @DRUG$, chloroquine, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
@DRUG$ TORADOL IV/IM reduced the diuretic response to @DRUG$ in normovolemic healthy subjects by approximately 20 % ( mean sodium and urinary output decreased 17 % ) .	DDI-false
Phenytoin: @DRUG$ has no apparent pharmacokinetic interaction when administered with @DRUG$.	DDI-false
Ethinyl Estradiol and Norethindrone : Coadministration of @DRUG$ with @DRUG$ This resulted in a 47% decrease in ethinylestradiol concentration and a 18% decrease in plasma concentrations of norethindron.	DDI-mechanism
This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or @DRUG$ - calcium channel blockers, antihistamines or H1-blockers, @DRUG$ ) could also contribute to an extension of the QTc interval.	DDI-false
increased levels of @DRUG$ and @DRUG$ activity ;	DDI-false
@DRUG$, such as verapamil, @DRUG$ and nifedipine, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
@DRUG$ The stimulating effects of amphetamines can be inhibited by @DRUG$.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$ , estrogens , oral @DRUG$ , phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
@DRUG$ , nifedipine , @DRUG$	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Methotrexate: Caution should be used if @DRUG$ is administered concomitantly with @DRUG$.	DDI-advise
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
Adequate monitoring of @DRUG$ plasma concentrations should be considered when therapy with @DRUG$ is initiated or changed in patients receiving theophylline.	DDI-false
@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
@DRUG$ (e.g., @DRUG$) - Taking piperazine and pyrantel together may decrease the effects of piperazine.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced adverse reactions such as fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, concomitant administration of these agents with PROLEUKIN may reduce the efficacy of antitumours. @DRUG$ 12 and should therefore be avoided. @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/@DRUG$, and valproic acid/phenobarbital.	DDI-false
@DRUG$: As with other b-lactam antibiotics, renal excretion of @DRUG$ is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 ( eg , phenobarbital , @DRUG$ , dexamethasone , @DRUG$ This may lead to decreased plasma levels of saquinavir.	DDI-false
The effects of concomitant @DRUG$ administration on the steady-state pharmacokinetics of @DRUG$.	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, @DRUG$).	DDI-advise
Selective serotonin reuptake inhibitors ( @DRUG$ ==References====External links== @DRUG$ , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5-HT1 agonists .	DDI-false
Antiacid , clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , @DRUG$ , Phenobarbitol , carbamazepine , Rifabutin , Rifampin , Ritanovir , @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Effect of @DRUG$ on the pharmacokinetics of @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of @DRUG$	DDI-effect
Cytochrome P-450 inducers, such as @DRUG$, carbamazepine and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma @DRUG$ levels.	DDI-false
Anticoagulants : potentiation of the warfarin type ( @DRUG$ and @DRUG$ substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Diclofenac may increase the serum concentration of digoxin and @DRUG$ and increase @DRUG$ s nephrotoxicity .	DDI-false
Phenytoin : Altered serum levels of @DRUG$ ( increased and decreased ) have been reported in patients receiving concomitant @DRUG$.	DDI-mechanism
In patients receiving Nalfon and a @DRUG$ concomitantly, any reduction in @DRUG$ dosage should be gradual in order to avoid the possible complications of sudden steroid withdrawal.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodon, @DRUG$ , propofol , protease inhibitors , @DRUG$ , and verapamil .	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Therefore, when @DRUG$ and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.	DDI-advise
@DRUG$ Angiotensin II receptor antagonists (hypertension)- In clinical trials in patients with hypertension who are also @DRUG$ 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists slightly increased the mean serum potassium (approximately 0.09 - 0.13 mEq/L).	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , @DRUG$ , propranolol , @DRUG$ , chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, which delays the elimination and increase in blood levels of these drugs.	DDI-false
There have been reports of QTc prolongation, with or without TdP, in patients taking @DRUG$ when @DRUG$, macrolide antibiotics, or azoles were administered concomitantly.	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, @DRUG$, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, @DRUG$ , diclofenac, doxycycline, @DRUG$ , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Chlorpromazine : @DRUG$ blocks dopamine and norepinephrine receptors , thus inhibiting the central stimulant effects of amphetamines and can be used to treat @DRUG$ poisoning .	DDI-false
Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$, such as @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$ , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as @DRUG$ ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Human pharmacokinetic data show that oral ketoconazole strongly inhibits the metabolism of ketoconazole. @DRUG$ resulting in an eight-fold increase in the mean AUC of @DRUG$.	DDI-false
Potential interactions between @DRUG$, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Moreover, additional interaction studies with @DRUG$ and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
@DRUG$: @DRUG$ are inhibited by amphetamines.	DDI-false
Interaction on the anticoagulant effect between @DRUG$ and enkephalins or @DRUG$.	DDI-effect
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, @DRUG$, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Magnesium/@DRUG$-containing antacid products : The absorption of zalcitabine is moderately reduced when co-administered with Magnesium/Aluminium-containing @DRUG$ (approx. 25%).	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced adverse reactions such as fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, co-administration of these active substances with PROLEUKIN may reduce the efficacy of PROLEUKIN against the tumour and should therefore be avoided. @DRUG$ may potentiate the hypotension seen with @DRUG$.	DDI-effect
Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge with the reversal of the benzodiazepine effect by @DRUG$.	DDI-false
It may be necessary to adjust the dosage of oral anticoagulants after initiation or discontinuation of @DRUG$. @DRUG$ may prolong prothrombin time .	DDI-false
@DRUG$ (@DRUG$) and BROVANA may interfere with the effect of each other when administered concurrently.	DDI-false
@DRUG$: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$.	DDI-false
Imidazoles (e.g. ketoconazole, @DRUG$ , clotrimazole , @DRUG$ In vitro and animal studies with the combination of amphotericin B and imidazoles indicate that imidazoles may cause fungal resistance to amphotericin B.	DDI-false
The hypoglycaemic effect of sulphonylureas may be due to certain medications, including: @DRUG$ And other medicines that are highly protein-bound, @DRUG$ , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Patients should be advised against the simultaneous use of other @DRUG$, and cautioned that the effect of @DRUG$ may be increased.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/ARB).	DDI-false
Additional reductions in blood pressure may occur when @DRUG$ is administered with diuretics, @DRUG$, or other vasodilators.	DDI-effect
Accordingly , careful patient monitoring and dose adjustment of @DRUG$ Co-administration of cephalexin and @DRUG$ is recommended in patients.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-advise
Because prostaglandins play an important role in haemostasis, and NSAIDs influence platelet function as well as concomitant therapy with all @DRUG$ , including Diclofenac, and warfarin requires close monitoring of patients to be sure that no change in their @DRUG$ dosage is required .	DDI-false
Therefore, the concomitant administration of @DRUG$ and @DRUG$ is contraindicated, and alternative hypoglycemic agents should be considered.	DDI-advise
@DRUG$ The AUC(s) of amprenavir decreased significantly by 82%, @DRUG$ The pharmacokinetics of rifampin had no effect.	DDI-false
Drug Interactions : @DRUG$ Maybe interact with some medications such as monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ Pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupentixol and ethanol lead to additive CNS depression - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$: TORADOLIV/IM has been administered concurrently with @DRUG$ in several clinical trials of postoperative pain without evidence of adverse interactions.	DDI-false
Drug/Laboratory Test Interaction @DRUG$ may cause a false low measurement of serum digoxin levels with the Digi- Tab  RIA Kit for @DRUG$.	DDI-false
apomorphine - prior ingestion of diphenidol may decrease the @DRUG$ response to @DRUG$ in the treatment of poisoning.	DDI-false
Concurrent administration of @DRUG$ (used to treat hypotension associated with birth blocks) and @DRUG$ may cause severe , persistent hypertension or cerebrovascular accidents .	DDI-effect
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, @DRUG$, cis-platinum, tamoxifen and interferon-alfa.	DDI-effect
@DRUG$ While a synergistic relationship with @DRUG$ Co-administration may increase the toxicity of flucytosine by potentially increasing cellular uptake and/ or impair renal excretion.	DDI-false
Injection : @DRUG$ injection , like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl alcohol , phenothiazines , barbiturates , MAO inhibitors , and other antidepressants . When @DRUG$ is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-false
@DRUG$ It has additive effects on alcohol and other CNS depressants ( @DRUG$ , sedatives, sedatives, etc.	DDI-effect
Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-false
â€¢ Drug interaction during pregnancy : @DRUG$ and @DRUG$ were studied following subcutaneous injections in pregnant mice .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , @DRUG$ , Nefazodon, Nicardipine, @DRUG$ , protease inhibitors , quinidine , and verapamil .	DDI-false
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, @DRUG$, @DRUG$, and phenobarbital.	DDI-false
Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, @DRUG$, @DRUG$ salts and digoxin).	DDI-false
ANTACID (@DRUG$): @DRUG$ plasma concentrations were not affected by co-administration of antacid.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramides, fibrates, @DRUG$ Monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$ , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The @DRUG$ are a family of @DRUG$ and hypnotic drugs.	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: @DRUG$ does not appear to alter the pharmacokinetics of phenytoin, @DRUG$, or phenobarbital.	DDI-false
Beta-adrenergic receptor antagonists ( @DRUG$ ) and @DRUG$ The effect of each other may be impaired when co-administered.	DDI-effect
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, decamethonium and @DRUG$, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , @DRUG$ , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as @DRUG$ In addition, quinolones anti-infections with no evidence of clinically significant adverse interactions.	DDI-false
While no in vivo drug interaction studies have been conducted between estazolam and CYP3A inducers, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and @DRUG$ ) would be expected to decrease @DRUG$ concentrations .	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, D-penicillamine, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , @DRUG$ Sodium colistimethate, magnesium salts, lithium, local anaesthetics, @DRUG$ , and quinidine .	DDI-false
Protein Binding In vitro , @DRUG$ interferes minimally or not at all with the protein binding of salicylic acid ( 20 % decrease in binding ) , @DRUG$ , prednisolone ( 10 % decrease in binding ) , or warfarin .	DDI-mechanism
A non-steroidal anti-inflammatory drug (@DRUG$)-A drug interaction study of eplerenone with a @DRUG$ It wasn't done.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, @DRUG$ (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
It is suggested that in patients receiving dopamine HCl , alternatives to @DRUG$ should be used if @DRUG$ therapy is needed .	DDI-false
The compounds tested in humans include warfarin, theophylline, @DRUG$ , diazepam , aminopyrine and @DRUG$.	DDI-false
The data from in vitro studies with benzodiazepines other than alprazolam indicate a possible interaction of the following medicinal products: @DRUG$ , cyclosporine , @DRUG$ , nicardipine , and nifedipine .	DDI-false
Adequate monitoring of @DRUG$ Plasma concentrations should be considered when initiating or changing VIOXX therapy in patients receiving @DRUG$.	DDI-false
Acetaminophen, lidocaine, @DRUG$, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
Because of the low effect on half-life, concomitant use with @DRUG$ The half-life of @DRUG$ is not recommended .	DDI-advise
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
The use of antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, and other medicines associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$ , iodoquinol, isoniazid, @DRUG$ , nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, @DRUG$, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , @DRUG$ , corticosteroids, TNF blockers, @DRUG$ , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine , fibric acid derivatives , niacin ( @DRUG$ ) , erythromycin , @DRUG$.	DDI-false
Antacids or @DRUG$ The effect of an increased pH on the bioavailability of @DRUG$ The study was conducted in 18 healthy adult volunteers.	DDI-false
To evaluate the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, @DRUG$ , vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipide, and @DRUG$ with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Patients using CYP3A4 metabolized @DRUG$ should have cholesterol levels monitored after TRACLEER is initiated to see whether the @DRUG$ dose needs adjustment .	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , hypnotics , @DRUG$ ( e.g. , benzodiazepines ) , general @DRUG$ , phenothiazine, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and deep sedation, or possibly coma or death.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and barbiturates, and the antituberculosis drug @DRUG$.	DDI-false
@DRUG$: Adrenergic blockers are inhibited by @DRUG$.	DDI-false
Coadministration of @DRUG$ and cyclosporine, @DRUG$ or digoxin has led to increased plasma concentrations of the latter three drugs.	DDI-mechanism
Benzthiazide may interact with alcohol , @DRUG$s , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , @DRUG$ , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications .	DDI-false
@DRUG$: When multiple doses of @DRUG$ and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	DDI-false
@DRUG$ and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and zidovudine against HIV.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
In the case that you are taking @DRUG$ while taking @DRUG$ , higher doses of digoxin may be needed .	DDI-advise
BACKGROUND: The effects of combined administration of @DRUG$ and @DRUG$ (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$ , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , @DRUG$ ==See also==*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID==References==	DDI-false
Substances that are potent inhibitors of CYP3A4 activity (eg, @DRUG$ and @DRUG$) decrease gefitinib metabolism and increase gefitinib plasma concentrations.	DDI-false
BACKGROUND : The effects of combined administration of @DRUG$ and verapamil hydrochloride ( verapamil ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( @DRUG$ ) and the index of colorectal cancers were studied in male Wistar rats.	DDI-false
Although increased plasma concentrations (AUC 0-24 hrs) of @DRUG$ and/or @DRUG$ were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$/theophylline , lidocaine/quinidine , phenobarbital/@DRUG$ , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Injection : Lorazepam injection , like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl alcohol , phenothiazines , barbiturates , MAO inhibitors , and other antidepressants . When @DRUG$ is used concomitantly with injectable @DRUG$ An increased incidence of sedation, hallucinations, and irrational behaviour has been observed.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Antiacid , clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , @DRUG$ , ritanovir, @DRUG$.	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of @DRUG$ that are metabolized by CYP3A4 (i.e., @DRUG$, cerivastatin, lovastatin, simvastatin).	DDI-false
Caution should be exercised when @DRUG$ It is specified in connection with @DRUG$.	DDI-advise
The medicinal products associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$ , @DRUG$ , nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
@DRUG$-@DRUG$ The absorption of vitamin K can be reduced.	DDI-false
In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the @DRUG$ @DRUG$, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
- When Bezalip or @DRUG$ ==References====External links==* Official website @DRUG$ (i) an interval of at least 2 hours between the two medicinal products should be maintained as the absorption of bezalip or bezalip retard is impaired.	DDI-advise
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , @DRUG$ , @DRUG$ , benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
(In some patients, the @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG$.	DDI-effect
Antiarrhythmics: @DRUG$, @DRUG$, flecainide, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Human pharmacokinetic data indicate that oral @DRUG$ Remarkably, cisaprid metabolism inhibits, resulting in an average eight-fold increase in @DRUG$ AUC.	DDI-false
Magnesium- and/or aluminum-containing antacids , products containing ferrous sulfate ( iron ) , @DRUG$ containing @DRUG$ or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
Coingestion of @DRUG$ With theophylline, phenobarbital with @DRUG$ , and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-false
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	DDI-false
â€¢ Saquinavir: concomitant use of @DRUG$ When using an experimental soft gelatine capsule formulation of saquinavir 1200 mg, VIRACEPT increased by 18%. @DRUG$ Plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Repeated doses of @DRUG$ given prior to a single dose of propranolol in human trials have been reported to decrease @DRUG$ absorption.	DDI-false
In a Phase I trial using escalating doses of TAXOL ( 110 - 200 mg/m2 ) and cisplatin ( 50 or 75 mg/m2 ) given as sequential infusions , myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence ( ie , @DRUG$ Before cisplatin).	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Medicines associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$ , @DRUG$ , hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Pyrantel (e.g., Antiminth) - Taking @DRUG$ and @DRUG$ together may decrease the effects of piperazine.	DDI-effect
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
Lithium: @DRUG$ decreases @DRUG$ renal clearance and increases lithium plasma levels.	DDI-mechanism
Aspirin : Simultaneous use of @DRUG$ Aspirin is not recommended as @DRUG$ is displaced from its binding sites during the concomitant administration of aspirin , resulting in lower plasma concentrations , peak plasma levels , and AUC values .	DDI-false
The concomitant use of nitrofurantoin is not recommended since @DRUG$ may antagonize the antibacterial effect of @DRUG$ in the urinary tract.	DDI-effect
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , @DRUG$ , @DRUG$ , erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, @DRUG$, and vincristine.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, calcium channel blocking agents, and @DRUG$, without any change in the adverse reaction profile.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
For treatment with CYP3A4 inhibitors (such as ketoconazole, intraconazole, ritonavir, @DRUG$ , saquinavir, erythromycin, etc.) is indicated, reduction of @DRUG$ The dose should be considered.	DDI-advise
These drugs include the thiazides and other @DRUG$ , corticosteroids, phe-nothiazines, thyroid products, @DRUG$ , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
@DRUG$- and/or aluminum-containing antacids , products containing @DRUG$ ( iron ) , multivitamin preparations containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , @DRUG$ , anticonvulsants , benzodiazepines , @DRUG$ , calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., @DRUG$, omeprazole).	DDI-false
Lithium toxicity was usually reversible upon discontinuation of @DRUG$ and the @DRUG$.	DDI-effect
@DRUG$ or Oral Hypoglycemics : @DRUG$ may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics .	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , @DRUG$ , sulphonamides, chloramphenicol, probenecid, @DRUG$ , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
The in vitro interaction between @DRUG$ and the @DRUG$ warfarin is complex.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
These drugs include the @DRUG$ and other diuretics , corticosteroids , phe-nothiazines , @DRUG$ , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimet-ics , calcium channel blocking drugs , and isoniazid .	DDI-false
Imipramine ( 5 mg/kg), moclobemid ( 30 mg/kg), clonazepam ( 0.25 mg/kg), @DRUG$ ( 20 mg/kg ) @DRUG$ 30 mg/ kg) or vehicle.	DDI-false
@DRUG$: In an interaction study of rheumatoid arthritis patients taking methotrexate, @DRUG$ did not have a significant effect on the pharmacokinetics of methotrexate.	DDI-false
Injection : Lorazepam injection , like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl alcohol , phenothiazines , @DRUG$ , MAO inhibitors and other antidepressants. If scopolamine is used concomitantly with injectable @DRUG$ An increased incidence of sedation, hallucinations, and irrational behaviour has been observed.	DDI-false
Lithium: @DRUG$ toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
However, the absolute number of @DRUG$-related deaths is far greater than the number of deaths in @DRUG$ or heroin users.	DDI-false
Furosemide : @DRUG$ IV/IM reduced the diuretic response rate to @DRUG$ In normalovolemic healthy subjects, approximately 20% (mean sodium and urine production decreased by 17%).	DDI-effect
Anticholinesterases (neostgmine, @DRUG$ ) , lignocaine , @DRUG$ Procainamide can increase toxicity and lead to heart respiratory depression.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and @DRUG$.	DDI-false
Hypotension    Patients on Diuretic Therapy : Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted , as well as those on severe dietary salt restriction or dialysis , may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of @DRUG$.	DDI-effect
In patients who have received @DRUG$ , doxapram may temporarily mask the residual effects of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
The use of antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimid, @DRUG$ , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and @DRUG$.	DDI-false
Oral @DRUG$ Valdecoxib ( 40 mg twice daily ) does not induce the metabolism of the combination of oral contraceptives Norethindron/@DRUG$ ( 1 mg/35 mcg combination, ortho-novum 1/35 ).	DDI-false
Accordingly, careful patient monitoring and dose adjustment of @DRUG$ is recommended in patients concomitantly taking @DRUG$ and metformin.	DDI-false
The pharmacokinetics of @DRUG$ were not significantly affected by @DRUG$	DDI-false
Compounds that have been tested in man include @DRUG$, @DRUG$, propranolol, theophylline, and warfarin and no clinically meaningful interactions were found.	DDI-false
Two per cent of patients who are at the same time treated with @DRUG$ and @DRUG$ developed neutropenia ( ANC   1 x 109/L ) .	DDI-effect
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with 5HT3 antagonist class medications (including, for example, ondansetron, granisetron, dolasetron, @DRUG$ , and @DRUG$ ) is contraindicated.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral @DRUG$ ( warfarin ) , @DRUG$ Acetylsalicylic acid, NSAIDs (piroxicam) and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$ with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-mechanism
- @DRUG$ (Nandrolone [e.g., @DRUG$ ] , oxandrolone [ e.g. , Anavar ] , oxymetholone [ e.g. , Anadrol ] , stanozolol [ e.g. , Winstrol ] ) or	DDI-false
- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
@DRUG$ The change from losartan to the active metabolite after intravenous administration of @DRUG$ , and erythromycin had no clinically significant effect after oral administration .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , @DRUG$ , polymyxins , @DRUG$ Clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
Vitamin A: Because of the relationship of Accutane to @DRUG$, patients should be advised against taking vitamin supplements containing @DRUG$ to avoid additive toxic effects	DDI-false
Other nephrotoxic medications : agents such as @DRUG$ , @DRUG$ , and pentamidine may enhance the potential for drug-induced renal toxicity , and should be used concomitantly only with great caution .	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
In a comparison of digitalis tolerance in dogs stunned with ketamine, Innovar Vet, or pentobarbital, the dosage of Ouabain was needed to cause ventricular tachycardia significantly higher, such as the LD50 of Ouabain, with @DRUG$ or @DRUG$ than with pentobarbital .	DDI-false
Patients who have other narcotic analgesics, general anaesthetics, @DRUG$ - sedatives, sedatives, sedative hypnotics, tricyclic antidepressants or other @DRUG$ In addition to DILAUDID, additive CNS depression may occur (including alcohol).	DDI-false
Cytochrome P-450 inducers, such as @DRUG$, carbamazepine and phenobarbital, induce @DRUG$ metabolism, causing an approximately 30% decrease in plasma clonazepam levels.	DDI-mechanism
These drugs include the @DRUG$ and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , @DRUG$ ==References====External links==	DDI-false
- @DRUG$ , oral ( diabetes medicine you take by mouth ) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral @DRUG$	DDI-false
The pharmacokinetics of @DRUG$ were not significantly affected by @DRUG$	DDI-false
Cimetidine (400 mg body weight ) had no effect on the bioavailability of vardenafil ( AUC) and the maximum concentration (Cmax) of @DRUG$ when co-administered with 20 mg @DRUG$ For healthy volunteers.	DDI-false
Since Nalfon has not been shown to have any additional effect over the @DRUG$ - alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ Salicylates and salicylates are not recommended.	DDI-false
Therapeutic concentrations of @DRUG$ , warfarin , ibuprofen , naproxen , @DRUG$ , acetaminophen , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
Warfarin : The effect of @DRUG$ The anticoagulant effects of warfarin have been studied in a group of healthy subjects who received 2-5 mg @DRUG$ daily.	DDI-false
Additionally , @DRUG$ The pharmacokinetics of @DRUG$ This reflects the absence of a role of CYP2D6 in zaleplon metabolism.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, @DRUG$ , fentanyl, alfentanyl, alprazolem, and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
Other concomitant therapy Although no specific interaction studies have been performed, clinical trials with 1 mg or more of finasteride doses have been conducted at the same time. @DRUG$ Acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, heart nitrates, diuretics, H2 antagonists, @DRUG$ , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
A study in eight healthy volunteers has shown a 50% increase in mean peak @DRUG$ plasma concentrations and a 90% increase in mean area under the curve, after a one week course of cimetidine at 1,000 mg/day and @DRUG$ at 90 mg/day.	DDI-false
@DRUG$/@DRUG$-containing antacid products: Zalcitabine absorption is moderately reduced (approximately 25%) when co-administered with magnesium/aluminium-containing antacid products.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, @DRUG$, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
In clinical trials , @DRUG$ - was treated with digoxin, diuretics, @DRUG$ In a pharmacokinetic sub-study in patients with congestive heart failure receiving furosemide or digoxin starting treatment with FLOLAN, visible values for oral clearance of furosemide (n = 23) and digoxin (n = 30) were reduced by 13 % and 15 % respectively on the second day of therapy and returned to baseline by day 87.	DDI-false
- @DRUG$ : Lithium should generally not be given with diuretics ( such as bumetanide ) because they reduce its renal clearance and add a high risk of @DRUG$ toxicity .	DDI-false
Ethosuximide : @DRUG$ The intestinal absorption of @DRUG$ can be delayed.	DDI-mechanism
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , @DRUG$ , salicylates , somatostatin analog ( e.g. , @DRUG$ ) , sulfonamide antibiotics .	DDI-false
The effect of @DRUG$ The pharmacokinetics of @DRUG$ administered orally has not been investigated .	DDI-false
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , @DRUG$ , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
The results of assays using red cells from healthy subjects to determine whether @DRUG$ would cause direct Coombs reactions in vitro showed no positive reaction at @DRUG$ concentrations as high as 40  g/mL.	DDI-false
Standard therapy includes @DRUG$ , such as @DRUG$ and gentamicin ;	DDI-false
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated , apparent oral clearance values for @DRUG$ ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ has been shown to be antagonistic to @DRUG$, including ceftazidime, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-effect
At steady state, @DRUG$ 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) @DRUG$, as assessed by ex vivo platelet aggregation and serum TXB2 generation in clotting blood.	DDI-false
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of @DRUG$, valproate, @DRUG$, or lamotrigine.	DDI-false
@DRUG$ : Clinical studies , as well as post-marketing observations , have shown that NSAIDs can reduce the natriuretic effect of furosemide and @DRUG$ in some patients .	DDI-false
@DRUG$ , @DRUG$ , heparin , NSAIDs	DDI-false
Digoxin: When multiple doses of @DRUG$ and @DRUG$ were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%.	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ Indinavir was observed for 48 weeks as initial therapy, with similar response rates. @DRUG$ regimens and superiority observed with efavirenz .	DDI-false
Pyrantel ( e.g. , Antiminth ) - Taking @DRUG$ and pyrantel together may decrease the effects of @DRUG$.	DDI-false
Lamivudine: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that @DRUG$ significantly inhibited @DRUG$ phosphorylation in a dose dependent manner.	DDI-effect
Physiological oral @DRUG$ Load provides the best tool for diagnosing @DRUG$ deficiency and the first step of its treatment .	DDI-false
@DRUG$: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving lithium alone.	DDI-false
This might be explained by a blockade by @DRUG$ of the elimination of @DRUG$ by the liver.	DDI-mechanism
Potassium Supplements and @DRUG$: @DRUG$ can attenuate potassium loss caused by thiazide diuretics.	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
Quinolones, including norfloxacin, may enhance the effects of oral @DRUG$, including @DRUG$ or its derivatives or similar agents.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Digoxin : @DRUG$ concentrations are increased by about 15 % when digoxin and @DRUG$ The medicine is given at the same time.	DDI-false
Concomitant cyclophosphamide, @DRUG$, vincristine, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Both @DRUG$ and @DRUG$ slow AV conduction.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ Because cyclosporin can cause nephrotoxicity with a decrease in creatinine clearance and increases in serum creatinine, and because renal excretion is the primary elimination route of @DRUG$ Including TRICOR, there is a risk that an interaction will lead to a deterioration.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
To determine whether @DRUG$ has a direct effect on the distribution of @DRUG$ , the elimination and distribution of cloxacillin was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of probenecid .	DDI-false
Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Withdrawal of @DRUG$ decreased the @DRUG$ requirement by 50 % .	DDI-mechanism
- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing @DRUG$.	DDI-false
@DRUG$ : Potential interactions between @DRUG$ and other AEDs were assessed in clinical studies .	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Imidazoles ( e. g. , @DRUG$ , miconazole , @DRUG$ In vitro and animal studies with the combination of amphotericin B and imidazoles indicate that imidazoles may cause fungal resistance to amphotericin B.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
Although no interaction between @DRUG$ and @DRUG$ has been observed, it is not recommended for use with MAO inhibitors.	DDI-false
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
In a 12-month controlled trial that included a 50 mcg once daily @DRUG$ dose, 30 of the 528 @DRUG$ -treated subjects received concomitant theophylline at study entry.	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, @DRUG$, and quinidine.	DDI-false
Prednisone/prednisolone: @DRUG$ did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral @DRUG$ , phenytoin , nicotinic acid , sympathomimetics , @DRUG$ ==References====External links==	DDI-false
â€¢ Methotrexate kidney tube transport of @DRUG$ Concomitant administration of ciprofloxacin may be inhibited, potentially leading to increased plasma levels of @DRUG$.	DDI-false
Hormonal Contraceptives , Including Oral , Injectable , Transdermal , and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ Average declines in @DRUG$ and ethinyl estradiol levels of 14 % and 31 % , respectively .	DDI-false
@DRUG$ could exaggerate the depression of AV nodal conduction observed with @DRUG$.	DDI-effect
@DRUG$ (e.g., spironolactone, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , @DRUG$ , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and @DRUG$.	DDI-false
Therefore , if @DRUG$ is administered with @DRUG$ The clinician should be aware of the possibility of increasing digoxin levels.	DDI-mechanism
In EM individuals treated with @DRUG$ or @DRUG$ The AUC of atomoxetine is about 6- to 8-fold and Css, max is about 3- to 4-fold greater than atomoxetine alone.	DDI-false
Injection : Lorazepam injection , like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl alcohol , @DRUG$ , barbiturates , @DRUG$ An increased incidence of sedation, hallucinations and irrational behaviour was observed with co-administration of scopolamine with injectable lorazepam.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, @DRUG$, clarithromycin).	DDI-false
Antihypertensive medications, other, especially @DRUG$, or pre@DRUG$ and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
Interactions may occur between @DRUG$ supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic ( Allium sativum ) and ginkgo ( Ginkgo biloba ) .	DDI-int
Interaction of @DRUG$ Cimetidine: Co-administration of cimetidine (800 mg/ day) in patients taking chronic tiagabin had no effect on @DRUG$ pharmacokinetics .	DDI-false
At a median follow-up of 33 months, the combination of @DRUG$ and @DRUG$ did not demonstrate any efficacy benefit when compared with tamoxifen in all patients as well as in the hormone receptor-positive subpopulation.	DDI-false
In an in vitro study of human liver microsomes, CYP2A6 inhibits hydroxylation of @DRUG$ by @DRUG$ ( 200 m m M i.e. , 350 mg/L ) was 17 - 28 % .	DDI-mechanism
Nevertheless, clinical studies, as well as postmarketing observations have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-effect
The extent to which @DRUG$-@DRUG$interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved.	DDI-int
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$ , somatropin, thyroid hormones, @DRUG$ , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including @DRUG$, tranquilizers, and alcohol.	DDI-effect
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ Antacids or aluminium antacids, sucralfate, VIDEX chewable/buffer tablets or pediatric powder or products containing calcium, iron or zinc may be used to absorb: @DRUG$ , resulting in serum and urine levels considerably lower than desired .	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, sertraline, @DRUG$, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Other @DRUG$ ( e.g. barbiturates , tranquilizers , opioids and general anesthetics ) have additive or potentiating effects with @DRUG$.	DDI-effect
Interactions with @DRUG$ : Agonist/antagonist analgesics ( eg , pentazocine , nalbuphine , butorphanol , @DRUG$ It should NOT be given to a patient who has received or received therapy with a pure agonist opioid analgesics such as levo-dromorane.	DDI-false
In some patients , the administration of a @DRUG$ The diuretic, natriuretic and antihypertensive effects of Loop, @DRUG$ can be reduced.	DDI-effect
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with @DRUG$ (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of @DRUG$.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: @DRUG$ , NSAIDs, corticosteroids, @DRUG$ , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, @DRUG$, prednisolone, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
( In some patients , the @DRUG$ The diuretic, natriuretic and antihypertensive effects of Loop, @DRUG$ can be reduced.	DDI-effect
Clinical interaction studies with @DRUG$ and @DRUG$ indicated that the coadministration of Femara with these drugs does not result in clinically- significant drug interactions.	DDI-false
These data indicate that levetiracetam does not influence the plasma concentration of other @DRUG$ and that these AEDs do not influence the pharmacokinetics of @DRUG$.	DDI-false
Catecholamine-depleting Agents: Patients taking both agents with b-blocking properties and a drug that can deplete catecholamines (e.g., @DRUG$ and @DRUG$) should be observed closely for signs of hypotension and/or severe bradycardia.	DDI-false
@DRUG$: The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
The following are examples of substances that can reduce the blood glucose-lowering effect: @DRUG$ , niacin, danazol, diuretics, sympathomimetics (e.g., @DRUG$ , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Other interactions Cimetidine, erythromycin and @DRUG$ The pharmacokinetics of @DRUG$ have not been affected.	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
Antiarrhythmics: Amiodarone, bepridil, flecainide, @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of AOM (7.4 mg/kg body weight) and subcutaneous injections of @DRUG$ (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of @DRUG$ (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Imidazole (e.g. @DRUG$ , miconazole, coagulation agent, @DRUG$ In vitro and animal studies with the combination of amphotericin B and imidazoles indicate that imidazoles may cause fungal resistance to amphotericin B.	DDI-false
These drugs include thiazides and other diuretics, @DRUG$ , @DRUG$ , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
@DRUG$ : Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs ( fluoxetine , thiothixene , @DRUG$ ) .	DDI-false
Concurrent administration of @DRUG$ and @DRUG$ may cause severe orthostatic hypotension . Cimetidine , an inhibitor of microsomal drug metabolism , increased altretamines half-life and toxicity in a rat model .	DDI-effect
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
certain @DRUG$ ( such as @DRUG$ ) ;	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, @DRUG$ , @DRUG$ , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, @DRUG$ , doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
In patients with CYP3A4 inducers such as @DRUG$ , phenytoin , @DRUG$ , and phenobarbital .	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should: @DRUG$ ( such as dexamethasone ) , diphen-hydramine and H2 antagonists ( such as cimetidine or @DRUG$ ) .	DDI-false
@DRUG$, warfarin, @DRUG$, NSAIDs	DDI-false
Also, phenobarbital, quinidine, and @DRUG$ , both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , @DRUG$ , terbutaline ) , isoniazid , @DRUG$ Somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Coadministration of single , oral doses of @DRUG$ A strong, selective CYP3A4 inhibitor with erythromycin ( 10 mg and 800 mg respectively) resulted in an increase in the maximum plasma concentrations of @DRUG$ and an increase in the area under the plasma concentration-time curve of 20%.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX are certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine, and @DRUG$ ) , magnesium salts , lithium , local anesthetics , @DRUG$ ==References====External links==	DDI-false
@DRUG$ also increased rate of dissolution , in a manner similar to @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , @DRUG$ , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$ , and isoniazid .	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
While 18-MC and @DRUG$ 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors , sodium channels , and the 5-HT transporter .	DDI-false
There have been case reports of increased steady-state levels of quinidine, @DRUG$, and phenytoin during concomitant therapy with @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , gentamicin , and amikacin ) , @DRUG$ , foscarnet , intravenous pentamidine , vancomycin , and @DRUG$ ] is contraindicated.	DDI-false
Potential interactions between @DRUG$ A substrate of CYP3A4 and protease inhibitors (ritonavir, saquinavir, @DRUG$ , and nelfinavir) which are substrates and/ or inhibitors of CYP3A4 have not been studied in clinical trials.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Hepatic enzyme inducers, inhibitors and substrates: medicines that induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, rifampin) may increase the metabolism of @DRUG$ , and require that the dosage of @DRUG$ be increased .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Imidazoles ( e. g. , ketoconazole , @DRUG$ In vitro and animal studies with the combination of amphotericin B and imidazoles indicate that imidazoles may cause fungal resistance to @DRUG$.	DDI-false
However, if @DRUG$ is to be initiated after cessation of heparin therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	DDI-false
The clinical significance of this reduction is unknown, therefore @DRUG$ is not recommended to be ingested simultaneously with magnesium/aluminum-containing @DRUG$.	DDI-advise
Conversely, diethylpropion can be used @DRUG$ ( i.e. , @DRUG$ ,,,,,,,,,,,	DDI-false
- When Bezalip or Bezalip retard is used concurrently with @DRUG$ (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	DDI-false
Aminoglutethimide : @DRUG$ may diminish adrenal suppression by @DRUG$.	DDI-effect
Antihypertensives : @DRUG$ The hypotensive effect of @DRUG$ can be antagonistic.	DDI-effect
Patients receiving other narcotic analgesics generally @DRUG$ , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic antidepressants or other @DRUG$ In addition to DILAUDID, additive CNS depression may occur (including alcohol).	DDI-false
Lithium : @DRUG$ Toxicity has been reported in patients receiving lithium concomitantly with medicinal products that cause sodium excretion, including @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Other medicines: medicines such as quinidine, disopyramide, procainamide, @DRUG$ , @DRUG$ , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Since animal studies suggest that the action of @DRUG$ Treatment with chlorpropamide may be prolonged, @DRUG$ should be employed with caution .	DDI-false
Dosage adjustment of @DRUG$ When co-administered with CYP2D6 inhibitors, it may be necessary, e.g. @DRUG$ , fluoxetine , and quinidine .	DDI-advise
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
Because prostaglandins play an important role in haemostasis, and NSAIDs influence platelet function as well as concomitant therapy with all @DRUG$ , including @DRUG$ Warfarin requires close monitoring of patients to be sure that no change in their anticoagulant dosage is required.	DDI-false
The absorption of @DRUG$, furosemide, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with @DRUG$;	DDI-mechanism
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and @DRUG$.	DDI-false
To assess the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, @DRUG$ , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$ , and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
These drugs include the thiazides and other diuretics , @DRUG$ , phenothiazines , @DRUG$ , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Injection : Lorazepam injection , like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl alcohol , phenothiazines , barbiturates , @DRUG$ , and other antidepressants . When @DRUG$ It is administered concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations and irrational behaviour has been observed.	DDI-false
@DRUG$/@DRUG$	DDI-false
Vitamin K (e.g. AquaMEPHYTON, @DRUG$ ) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the blood	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, @DRUG$, and quinidine.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
A 5-mg @DRUG$ dose should not be exceeded when used in combination with 200 mg once daily @DRUG$.	DDI-advise
- The action of @DRUG$ and @DRUG$ may be enhanced by Bezalip or Bezalip retard.	DDI-false
Acetaminophen : A report of severe @DRUG$ toxicity was reported in a patient receiving @DRUG$.	DDI-effect
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, sertraline, paroxetine, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Rifabutin: Coadministration of rifabutin and VIRACEPT resulted in a 32% decrease in @DRUG$ plasma AUC and a 207% increase in @DRUG$ plasma A.C.	DDI-false
Application with allopurinol: The main route to detoxification @DRUG$ This is inhibited by @DRUG$.	DDI-mechanism
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Effect of @DRUG$ on the Pharmacokinetics of Other Drugs : Clonazepam does not appear to alter the pharmacokinetics of phenytoin , @DRUG$ , or phenobarbital.	DDI-false
Human pharmacokinetic data suggest that oral @DRUG$ The metabolism of cisaprid is severely inhibited, resulting in an eight-fold increase in mean AUC of @DRUG$.	DDI-false
Urinary acidifying agents These agents (@DRUG$, @DRUG$, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, @DRUG$, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
poor metabolizers of @DRUG$ : interactions of geschnitzilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$ , and propafenone ) have not been studied , but these drugs would be expected to increase blood levels of the R(+ ) enantiomer of carvedilol .	DDI-false
Coadministration of valdecoxib ( 40 mg BID ( day 1 ) and 40 mg QD ( days 2 - 7 ) ) with @DRUG$ The pharmacokinetics (exposure) or pharmacodynamics (blood glucose and insulin levels) of @DRUG$ were not affected by QD 5 mg.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Multivitamins , or other products containing iron or @DRUG$ , antacids or @DRUG$ The use of norfloxacin should not be performed simultaneously with or within 2 hours after the administration of norfloxacin as it may impair absorption, resulting in lower serum and urine levels of norfloxacin.	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors , @DRUG$ or phenothiazines may produce severe , prolonged hypotension or hypertension .	DDI-effect
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, @DRUG$ , @DRUG$ , sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isonazide, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Other CNS depressant drugs ( e.g. barbiturates , @DRUG$ , opioids and general @DRUG$ ) have additive or potentiating effects with INAPSINE.	DDI-false
Glyburide : @DRUG$ No pharmacokinetic interaction is apparent when used with @DRUG$.	DDI-false
@DRUG$: Amphetamines inhibit the hypotensive effect of @DRUG$.	DDI-false
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when administering imatinib @DRUG$ with inhibitors of the CYP3A4 family ( e.g. , @DRUG$ , itraconazole , erythromycin , clarithromycin ) .	DDI-advise
@DRUG$ In vitro data show that: @DRUG$ This inhibits the metabolism of cisapride, which may lead to an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Oral Contraceptives: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	DDI-mechanism
The effects of @DRUG$ ( RR ) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Although there is little published information on concomitant administration of @DRUG$ and @DRUG$, these drugs are often administered concurrently without any evidence of interactions resulting in adverse effects or diminished efficacy.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with @DRUG$ , @DRUG$ Nitrates, calcium blockers, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
Chloral hydrate and @DRUG$ Interaction pharmacologically with orally administered @DRUG$ , but the effect is not clinically significant .	DDI-int
@DRUG$ The concentration of digoxin is increased by about 15 % when digoxin and @DRUG$ The medicine is given at the same time.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), @DRUG$, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
- medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, @DRUG$ Antihistamines : astemizole , @DRUG$ Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
- Poor metabolisers of schuttoquine : interactions of geschnitzilol with strong inhibitors of CYP2D6 (such as @DRUG$ , fluoxetine, paroxetine, and @DRUG$ These drugs are expected to increase the blood levels of the R(+) enantiomer of gelicilol.	DDI-false
Bacteriostatic Antibiotics: @DRUG$, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of @DRUG$.	DDI-effect
There are currently no data available from prospective clinical trials comparing the 3 approved active substances ( @DRUG$ , nevirapine or @DRUG$ ) .	DDI-false
@DRUG$ : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a @DRUG$ Inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, nefazodone, @DRUG$, ritonavir, nelfinavir) would be expected to behave similarly.	DDI-false
@DRUG$ or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$ ==References====External links==	DDI-effect
The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated, but @DRUG$ may potentiate the side effects of @DRUG$.	DDI-effect
Physiological changes resulting from smoking cessation, with or without @DRUG$ replacement, may alter the pharmacokinetics of certain concomitant medications, such as tricyclic antidepressants and @DRUG$.	DDI-false
In EM individuals treated with @DRUG$ or fluoxetine, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance , such as efavirenz , nevirapine , phenytoin , dexamethasone , or @DRUG$ Administration of a daily dose of 70 mg CANCIDAS should be considered.	DDI-advise
Probenecid: As with other b-lactam antibiotics, renal excretion of @DRUG$ is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for @DRUG$.	DDI-false
- @DRUG$: Interaction studies in humans have shown bumetanide to have no effect on @DRUG$ metabolism or on plasma prothrombin activity.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, @DRUG$, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , intraconazole , @DRUG$ , @DRUG$ , saquinavir , erythromycin , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of @DRUG$ on the availability of @DRUG$ and digitoxin.	DDI-mechanism
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
Acetaminophen/@DRUG$, @DRUG$/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as @DRUG$, phenytoin, rifampin, and @DRUG$) would be expected to decrease estazolam concentrations.	DDI-false
Probenecid: As with other b-lactam antibiotics, renal excretion of @DRUG$ is inhibited by @DRUG$ and resulted in an approximate 80% increase in the AUC for loracarbef.	DDI-mechanism
These results suggest that both @DRUG$ and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
Other CONCOMITANT THERAPY: Although no specific interaction studies have been conducted, cerivastatin sodium was co-administered with @DRUG$ , beta blockers, calcium channel blockers, diuretics and nonsteroidal anti-inflammatory drugs ( @DRUG$ ) without evidence of clinically significant adverse interactions.	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between VIRACEPT and @DRUG$ , trimethoprim/sulfamethoxazole , @DRUG$ , erythromycin , itraconazole or fluconazole .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-advise
@DRUG$ and @DRUG$ use may be rarely associated with ventricular fibrillation when combined with Adenocard .	DDI-false
@DRUG$ : Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium , including @DRUG$.	DDI-false
Tetracyclines: Concomitant treatment with Accutane and @DRUG$ should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$ , isoniazid , @DRUG$ , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
A clinical study in healthy male subjects ( n=24 ) showed that mixing NovoLog with NPH human insulin immediately prior to injection had a certain attenuation in peak concentrations of @DRUG$ However, the time to climax and the entire bioavailability of @DRUG$ were not significantly affected .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole (Cefmenoxime, cefoperazone), @DRUG$ , cefamandole , latamoxef ) or methylthiadiazole ( @DRUG$ ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
INOmax has been administered with tolazoline, dopamine, dobutamine, @DRUG$, @DRUG$, and high-frequency ventilation.	DDI-false
@DRUG$: @DRUG$ is primarily metabolized by CYP 2D6 and to a lesser extent by 3A4.	DDI-false
Mineral Oil-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as @DRUG$, phenytoin, @DRUG$, and phenobarbital.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, @DRUG$ , pimozide , carbamazepine , fentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
@DRUG$ : Quinolones have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives .	DDI-false
In neither case were the pharmacokinetics of @DRUG$ affected by coadministration with @DRUG$.	DDI-false
Corticosteroids , @DRUG$ â€¢ Aus- and diuretics: concomitant treatment with xanthine derivatives, @DRUG$ Diuretics may potentiate a possible hypocalemic effect of beta2-agonists.	DDI-false
Although BETAGAN used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with @DRUG$ and @DRUG$ may occur.	DDI-effect
Lymphocytopenia has been reported in patients receiving @DRUG$, and it is possible that the administration of @DRUG$ as antiemetic prophylaxis may have enhanced the likelihood of this effect.	DDI-effect
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
Antidepressants , @DRUG$ : @DRUG$ The activity of tricyclic or sympathomimetic agents can be increased;	DDI-false
@DRUG$ Rifampin CONTRAINDICATED since co-administration of this medicinal product with @DRUG$ In an antiretroviral regimen, this reduces the plasma concentrations of saquinavir.	DDI-false
Antiacid , clarithromycin , @DRUG$ , @DRUG$ , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , Rifampin , Ritanovir , Saquinavir .	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, methyldopa, reserpine.	DDI-effect
Example inhibitors include @DRUG$ , @DRUG$ , clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine and verapamil.	DDI-false
When CANCIDAS is co-administered with drug clearance inducers such as efavirenz, nevirapine, phenytoin, @DRUG$ Carbamazepine, use a daily dose of 70 mg @DRUG$ should be considered	DDI-false
Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes @DRUG$ undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter @DRUG$ concentrations significantly.	DDI-false
Human pharmacokinetic data indicate that oral @DRUG$ markedly inhibits the metabolism of @DRUG$, resulting in a mean eight-fold increase in AUC of cisapride.	DDI-mechanism
Then, the effects of the metabotropic glutamate receptor (mGluR ) agonists, @DRUG$ and L-CCG-1 , on the above behavioral changes induced by @DRUG$ were found .	DDI-false
These drugs include thiazides and other diuretics, @DRUG$ , phe-nothiazines , thyroid products , @DRUG$ , oral contraceptives , phenytoin , nicotinic acid , sympathomimet-ics , calcium channel blocking drugs , and isoniazid .	DDI-false
@DRUG$: Coadministration of moclobemide resulted in a 27% decrease in @DRUG$ clearance and an increase in Cmax of approximately 6%.	DDI-false
In vitro binding studies with human serum proteins indicate that @DRUG$ binds differently than tolbutamide and does not interact with @DRUG$ or dicumarol.	DDI-false
@DRUG$ : Amphetamines may delay intestinal absorption of @DRUG$ ;	DDI-false
Central nervous system depressants : the concomitant use of DURAGESIC (Fentanyl transdermal system ) with other central nervous system depressants, including but not limited to other opioids, @DRUG$ Hypnotics, sedatives (e.g. benzodiazepines), general @DRUG$ , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
In addition, several @DRUG$ s that are cytochrome P450 inducers can decrease plasma concentrations of @DRUG$ and MHD.	DDI-mechanism
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , @DRUG$ Salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO @DRUG$ INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE @DRUG$ SERUM LEVEL SHOULD BE OBTAINED.	DDI-false
The immediate release, but not the coat-core formulation of @DRUG$ increased plasma @DRUG$ concentrations by about 20%.	DDI-mechanism
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, @DRUG$, troleandomycin, ritonavir, @DRUG$) would be expected to behave similarly.	DDI-false
@DRUG$, including oral contraceptives: Estrogens may decrease the hepatic metabolism of certain @DRUG$, thereby increasing their effect.	DDI-false
The clinical significance of this reduction is not known, hence @DRUG$ is not recommended to be ingested simultaneously with magnesium/@DRUG$-containing antacids.	DDI-advise
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission ( e.g. , @DRUG$ ) should only be performed with caution as the effect of the toxin may be potentiated .	DDI-advise
Plasma levels of @DRUG$ It has been reported that the number of oral @DRUG$ ;	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , @DRUG$ - narcotics (e.g. benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$ , respiratory depression, hypotension, and deep sedation, or possibly lead to coma or death.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.	DDI-false
â€¢ Furosemide : TORADOL IV/IM reduced the @DRUG$ response to @DRUG$ In normalovolemic healthy subjects, approximately 20% (mean sodium and urine production decreased by 17%).	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , @DRUG$ , TNF blockers, azathioprin, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine and @DRUG$.	DDI-false
The pharmacokinetic properties of each medicinal product have been altered only slightly or not at all if: @DRUG$ was coadministered with lamivudine or @DRUG$.	DDI-false
Norepinephrine : @DRUG$ Elevate the adrenergic effect of @DRUG$.	DDI-effect
@DRUG$ may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
ACE Inhibitors and @DRUG$ ( Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS , 3020 ( 91 % ) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists ( ACEI/ARB ) .	DDI-false
@DRUG$ dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of @DRUG$ or the level of platelet aggregation in healthy adults.	DDI-false
Potassium-sparing diuretics (e.g. spironolactone, @DRUG$ , or amiloride ) , @DRUG$ supplements , or potassium-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$ , carbamazepine , and barbiturates , and the @DRUG$ rifampin .	DDI-false
@DRUG$ ( 10 mg once daily ) has been coadministered with therapeutic doses of erythromycin , cimetidine , and @DRUG$ in controlled clinical pharmacology studies in adult volunteers .	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and @DRUG$ (such as cimetidine or @DRUG$).	DDI-false
Simultaneous use of @DRUG$ with antiplatelet agents , @DRUG$ And other anticoagulants can increase the risk of bleeding.	DDI-effect
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and nifedipine.	DDI-int
Oral neomycin inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, @DRUG$ and @DRUG$.	DDI-false
(In some patients, the steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	DDI-false
Dose adjustment is not recommended . Levetiracetam had no effect on plasma concentrations of carbamazepine , valproate , @DRUG$ , or @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Dopamine Antagonists : Since apomorphine is a dopamine agonist , it is possible that dopamine antagonists , such as the @DRUG$ ( phenothiazines , @DRUG$ , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of @DRUG$ was 10% lower and the Cmax of @DRUG$ was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
@DRUG$ has been administered with tolazoline, dopamine, dobutamine, steroids, @DRUG$, and high-frequency ventilation.	DDI-false
@DRUG$: Administration of terfenadine with @DRUG$ resulted in the appearance of unchanged terfenadine in plasma;	DDI-false
The absorption of @DRUG$, @DRUG$, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
For information on the pharmacokinetics of @DRUG$ and @DRUG$ in combination, see Drug Interactions under CLINICAL PHARMACOLOGY section.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance , such as efavirenz , nevirapine , phenytoin , @DRUG$ Administration of a daily dose of 70 mg CANCIDAS or carbamazepine should be considered	DDI-advise
The risk of myopathy during treatment with medicines in this class is increased with concomitant administration of cyclosporin, fibric acid derivatives, @DRUG$ (nicotinic acid), @DRUG$ Azol Antimycotics.	DDI-false
These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these @DRUG$ do not influence the pharmacokinetics of @DRUG$.	DDI-false
Warfarin: The effect of @DRUG$ on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of @DRUG$ 40 mg BID for 7 days.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
The in vitro interaction between nevirapine and the @DRUG$ @DRUG$ is complex .	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (@DRUG$, reserpine, @DRUG$, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
The gastrointestinal absorption of cimetidine and @DRUG$ is accelerated when they are coadministered with @DRUG$.	DDI-mechanism
Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
apomorphine - prior ingestion of @DRUG$ may decrease the emetic response to @DRUG$ In the treatment of poisoning.	DDI-effect
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , @DRUG$ , azathioprin, chloroquine, @DRUG$ , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .	DDI-false
Then , the effects of metabotropic glutamate receptor ( mGluR ) agonists , @DRUG$ and @DRUG$ , on the above behavioral changes induced by PCP were found .	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or @DRUG$.	DDI-false
The following are examples of substances that can reduce the blood glucose-lowering effect: @DRUG$ , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , @DRUG$ Phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-false
Drug-drug interactions have not been observed between @DRUG$ and @DRUG$ or erythromycin.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, @DRUG$ and possibly with griseofulvin, ampicillin, and tetracyclines (72)	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
@DRUG$ Including tranylcypromin sulfate, phenelzinsulfate and pargylin HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension .	DDI-false
@DRUG$, including oral @DRUG$: Estrogens may decrease the hepatic metabolism of certain corticosteroids, thereby increasing their effect.	DDI-false
Population pharmacokinetic analyses revealed that @DRUG$ , NSAIDs , corticosteroids , and @DRUG$ did not influence abatacept clearance .	DDI-false
Careful observation is required when @DRUG$ is administered concurrently with @DRUG$.	DDI-advise
@DRUG$ The skeletal musculature has a tendency to antagonize the relaxing effect of @DRUG$ And can enhance the effect of succinylcholine.	DDI-effect
In comparison of the digitalis tolerance in dogs stunned with @DRUG$ , Innovar Vet, or Pentobarbital, the dosage of Ouabain needed to cause ventricular tachycardia was significantly higher, such as the LD50 of Ouabain, with ketamine or @DRUG$ than with pentobarbital .	DDI-false
The effects of GABITRIL on other antiepilepsia drugs ( @DRUG$ ) : Phenytoin : Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ In patients with epilepsy.	DDI-false
Hepatic enzyme inducers, inhibitors and substrates: drugs that induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity (e.g. barbiturates, phenytoin, carbamazepine, @DRUG$ ) may enhance the metabolism of @DRUG$ And demand that the corticosteroid dosage be increased.	DDI-mechanism
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/@DRUG$ (TMP/SMX).	DDI-false
@DRUG$ serum levels should be monitored and appropriate dose adjustments considered for patients given both @DRUG$ and PEGASYS.	DDI-false
In the same study it was shown that didanosine and @DRUG$ had no significant effect on the intracellular phosphorylation of @DRUG$ in peripheral blood mononuclear cells.	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral @DRUG$ administration impairs metabolism of phenytoin, dextromethorphan, and @DRUG$.	DDI-false
A two-way interaction between the @DRUG$, phenytoin, and the @DRUG$s has been suggested.	DDI-int
The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ Patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazine may experience severe, prolonged hypotension or hypertension.	DDI-false
- Anabolic steroids ( @DRUG$ [ e.g. Anaboline ], Oxandrolone [ e.g. Anavar ], Oxymetholone [ e.g. Anadrol ], @DRUG$ (e.g. Winstrol ]) or	DDI-false
Since the therapeutic range of theophylline is narrow @DRUG$ serum levels should be monitored closely , and appropriate dosage adjustments of @DRUG$ should be made .	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission ( e.g. , curare-like compounds ) should only be performed with caution as the effect of the @DRUG$ It can be potentiated.	DDI-false
Magnesium/Aluminum-containing Antacid Products : Absorption of @DRUG$ is moderately reduced ( approximately 25 % ) when coadministered with @DRUG$/aluminum-containing antacid products .	DDI-false
A interaction study with @DRUG$ There was no clinically significant effect of @DRUG$ The pharmacokinetics of warfarin or anticoagulant activity.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Zidovudine : There is no significant pharmacokinetic interaction between @DRUG$ and @DRUG$ , which has been clinically confirmed.	DDI-false
@DRUG$-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
@DRUG$ , nimodipine and losartan: bosentan has no significant pharmacokinetic interactions with @DRUG$ Nimodipine and losartan have no significant influence on bosentan plasma levels.	DDI-false
Coadministration of single, oral doses of zaleplon with @DRUG$ (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in @DRUG$s maximal plasma concentrations and a 20% increase in the area under the plasma concentration-time curve.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
Corresponding, careful patient monitoring and dose adjustment @DRUG$ is recommended in patients concomitantly taking @DRUG$ and metformin .	DDI-false
@DRUG$ : @DRUG$ may antagonize the hypotensive effects of antihypertensives .	DDI-false
Compounds that have been tested in man include @DRUG$, digoxin, @DRUG$, theophylline, and warfarin and no clinically meaningful interactions were found.	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., @DRUG$, fluoxetine, and quinidine.	DDI-advise
Severe anticholinergic symptoms (i.e. severe dry mouth, urinary retention and blurred vision) have been reported with increases in serum levels of @DRUG$ when @DRUG$ The therapy is initiated.	DDI-effect
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral @DRUG$ , and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
@DRUG$ (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
@DRUG$ or H 2 -receptor antagonists: The effect of increased gastric pH on the bioavailability of @DRUG$ was evaluated in 18 healthy adult volunteers.	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
- Anticoagulants: Interaction studies in humans have shown @DRUG$ to have no effect on @DRUG$ metabolism or on plasma prothrombin activity.	DDI-false
Antimycobacterial Agents : @DRUG$ Treated since co-administration of this medicine with saquinavir in a @DRUG$ The regimen reduces the plasma concentrations of saquinavir.	DDI-false
Although increased plasma concentrations (AUC 0-24 hrs) of @DRUG$ and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	DDI-false
It is not known if @DRUG$ When used with @DRUG$, their effectiveness varies.	DDI-false
Selective serotonin reuptake inhibitors (SSRIs): SSRIs (e.g. fluoxetine, fluvoxamine, @DRUG$ , @DRUG$ ) have been rarely reported to cause weakness, hyperreflection, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
Because of changes in glucose concentrations with @DRUG$ Co-administration was within normal variability and individual glucose concentrations were greater than or close to 70 mg/ dl, @DRUG$ ( 5 mg QD and 10 mg BID ) with valdecoxib coadministration ( up to 40 mg QD ) is not indicated .	DDI-false
Because @DRUG$ is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of @DRUG$.	DDI-false
By contrast, @DRUG$ (1 mM) and @DRUG$ (1 mM) had no significant effect on the translocation when added alone.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , @DRUG$ ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , @DRUG$ , progestogens (e.g. in oral contraceptives).	DDI-false
There was no evidence of any pharmacokinetic interactions between @DRUG$ and @DRUG$.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, @DRUG$, topiramate, and possibly with ampicillin and @DRUG$ 72.	DDI-false
- mineral oil compositional intake of mineral oil and @DRUG$ The absorption of @DRUG$ can be reduced.	DDI-false
@DRUG$ : @DRUG$ has no apparent pharmacokinetic interaction when administered with phenytoin .	DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or @DRUG$) and AXERT within 24 hours of each other should be avoided.	DDI-false
Other cardiovascular agents : enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents , @DRUG$ , nitrates , calcium-blocking agents , hydralazine , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
Coadministration of this oral @DRUG$ did not influence the pharmacokinetics of @DRUG$.	DDI-false
Potential drug interactions between Keppra   and other AEDs ( carbamazepine , gabapentin , @DRUG$ , phenobarbital, phenytoin, primidone and valproate) were also evaluated by the serum concentrations of @DRUG$ These AEDs during placebo-controlled clinical trials.	DDI-false
In both species, @DRUG$, but not @DRUG$, antagonized the rate-decreasing effects of morphine on FI and FR responding.	DDI-false
May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and @DRUG$ when administered concomitantly with an intravenous opiate such as morphine .	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Oral Contraceptives: Multiple dose administration of @DRUG$ (8 mg/day monotherapy) did not alter the pharmacokinetics of oral @DRUG$ in healthy women of childbearing age.	DDI-false
- The action of sulphonylureas and @DRUG$ may be enhanced by @DRUG$ or Bezalip retard .	DDI-effect
Administration of epinephrine to patients receiving @DRUG$ or @DRUG$ such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
hypersensitivity reactions : patients with a history of severe hypersensitivity reactions to products containing Cremophor EL (e.g. @DRUG$ For injection concentrate and tenipide for injection concentrate) should not be treated with @DRUG$.	DDI-advise
Antiacid, clarithromycin, didanosine, @DRUG$ , @DRUG$ , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , Rifampin , Ritanovir , Saquinavir .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$ : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and @DRUG$.	DDI-false
In Study 1 , patients with colorectal cancer were given irinotecan/5-FU/@DRUG$ ( bolus-IFL ) with or without @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the ACE inhibitor @DRUG$, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to @DRUG$ alone.	DDI-false
Urinary acidifying agents (@DRUG$, sodium acid phosphate, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	DDI-mechanism
The concomitant use of @DRUG$ is not recommended since @DRUG$ may antagonize the antibacterial effect of Norfloxacin in the urinary tract.	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Protein Binding In vitro, @DRUG$ interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), tolbutamide, prednisolone (10% decrease in binding), or warfarin.	DDI-mechanism
A potential interaction between oral @DRUG$ and oral @DRUG$ leading to severe hypoglycemia has been reported .	DDI-effect
Coingestion of acetaminophen with theophylline , phenobarbital with @DRUG$ , and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug .	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, phenothiazines, @DRUG$, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Indinavir: Coadministration of indinavir with @DRUG$ resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in @DRUG$ plasma A.C.	DDI-false
In patients with chronic hepatitis C treated with PEGASYS in combination with @DRUG$ , PEGASYS treatment does not affect @DRUG$ Distribution or release.	DDI-false
@DRUG$  has not been formally evaluated in combination with @DRUG$.	DDI-false
â€¢ Drug-drug interactions between Keppra and others @DRUG$ ( AEDs ) Phenytoin @DRUG$ In patients with refractory epilepsy, the administration of phenytoin (3,000 mg daily) had no effect on the pharmacokinetics of phenytoin.	DDI-false
Antiacid, clarithromycin, Didanosine, @DRUG$, @DRUG$, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
These increased exposures of norethindrone and @DRUG$ should be taken into consideration when selecting an oral contraceptive for women taking @DRUG$.	DDI-false
Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating @DRUG$ and @DRUG$, respectively.	DDI-false
An alternative non-CYP3A4 substrate @DRUG$ may be considered in patients taking CYP3A4 inducers such as rifampin, @DRUG$, carbamazepine, and phenobarbital.	DDI-false
Monitoring for amiodarone toxicity and serial measurement of @DRUG$ serum concentration during concomitant @DRUG$ therapy should be considered.	DDI-advise
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, @DRUG$, or carbamazepine, use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( @DRUG$ MAOI may theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and ethanol cause additive CNS depression - @DRUG$ Flupentixol increases the effect of tricyclic antidepressants	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically influence @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80 % increase in etoposide exposure with a 38 % decrease in total body clearance of @DRUG$ compared to @DRUG$ alone .	DDI-false
Antihypertensive Medications and @DRUG$: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or @DRUG$ (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.	DDI-false
@DRUG$: The combination of HIVID, saquinavir, and @DRUG$ has been studied (as triple combination) in adults.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Concomitantly given @DRUG$ did not interfere with the absorption of a tablet of @DRUG$.	DDI-false
- When Bezalip or @DRUG$ is used concurrently with @DRUG$ (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	DDI-advise
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, D-penicillamine, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , @DRUG$ Anaesthetics (e.g. benzodiazepines), general anaesthetics, phenothiazines, @DRUG$ And alcohol, can cause respiratory depression, hypotension, and deep sedation, or possibly lead to coma or death.	DDI-false
The monoamine oxidase inhibitory effects of @DRUG$ may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following @DRUG$.	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital.	DDI-false
At a median follow-up of 33 months, the combination of ARIMIDEX and @DRUG$ did not demonstrate any efficacy benefit when compared with @DRUG$ in all patients as well as in the hormone receptor-positive subpopulation.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
In approximately 30% of patients, the dose of @DRUG$ To maintain, had to be reduced @DRUG$ The concentrations within the therapeutic range, while no adjustment was required in the rest.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
In patients with mild to moderate hypertension, 25 mg daily @DRUG$ The ACE inhibitor benazepril, 10 to 40 mg for 4 weeks, was approximately 3 mm Hg higher than the mean arterial pressure. @DRUG$ alone .	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and procainamide, cardiac glycosides and @DRUG$.	DDI-false
Additional reductions in blood pressure may occur when FLOLAN is administered with diuretics, @DRUG$, or other @DRUG$.	DDI-false
@DRUG$ serum levels should be monitored and appropriate dose adjustments considered for patients given both theophylline and @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
No data are available for the coadministration of INVIRASE/ritonavir or @DRUG$/@DRUG$ and garlic capsules.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , @DRUG$ , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , @DRUG$ , nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Oral Contraceptives: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/@DRUG$ (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
â€¢ Furosemide : clinical trials, as well as post-marketing observations, have shown that: @DRUG$ The natriuretic effect of furosemide and @DRUG$ in some patients .	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., @DRUG$, analgesics, antiemetics, sedatives, tranquilizers).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Strong inducers of cytochrome P450 enzymes ( i.e. @DRUG$ , @DRUG$ The plasma levels of MHD ( 29 - 40% ) have been shown to decrease.	DDI-false
@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Nevertheless , clinical studies , as well as postmarketing observations have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ Some patients were diagnosed with thiazides and thiazides.	DDI-effect
Ethinyl Estradiol and @DRUG$ â€¢ Concomitant use of VIRACEPT with @DRUG$ resulted in a 47 % decrease in ethinyl estradiol and an 18 % decrease in norethindrone plasma concentrations .	DDI-false
However, patients on digoxin may show increases in digoxin concentrations after initiation of therapy with @DRUG$ , which may be clinically significant in patients prone to @DRUG$ toxicity .	DDI-false
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-mechanism
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Similarly dialyzed were phenobarbital , @DRUG$ , and theophylline , both alone at therapeutic concentrations in serum and with @DRUG$ at three different concentrations in serum .	DDI-false
In a study involving 12 adult volunteers, TORADOLORAL was coadministered with a single dose of 25 mg @DRUG$, causing no significant changes in pharmacokinetics or pharmacodynamics of @DRUG$.	DDI-false
HIV Protease Inhibitors : Indinavir ( 800 mg t.i.d . ) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-effect
Multivitamins, or other products containing iron or @DRUG$, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
5HT3 Antagonists : Based on reports of deep hypotension and loss of consciousness when @DRUG$ was administered with ondansetron , the concomitant use of @DRUG$ The contraindicated medicines of the 5HT3 antagonist class (including, for example, Ondansetron, Granisetron, Dolasetron, Palonosetron, and Alosetron).	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , @DRUG$ , Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
The concomitant use of @DRUG$s, vasoconstricting agents (such as @DRUG$) and some oxytocic drugs may result in severe hypertension.	DDI-false
only @DRUG$ enhances @DRUG$-induced increases in accumbal dopamine.	DDI-effect
Anticoagulants: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Caution should be exercised when: @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as ketoconazole , spironolactone , and @DRUG$.	DDI-advise
@DRUG$: Coadministration of @DRUG$ 3 mg and olanzapine 10 mg produced a decrease in DSST scores.	DDI-false
Serum lithium levels should be monitored frequently if @DRUG$ is administered concomitantly with @DRUG$.	DDI-advise
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , isosorbide mononitrate , @DRUG$ , @DRUG$ or itraconazole .	DDI-false
@DRUG$: The pharmacokinetics of theophylline (@DRUG$ 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.	DDI-false
A drug interaction study investigated the effect of the use of @DRUG$ Gel , 5 % , in combination with double strength ( 160 mg/800 mg ) @DRUG$/sulfamethoxazole ( TMP/SMX ) .	DDI-false
The effects of @DRUG$ were very strong and completely depressed the @DRUG$-induced hyperlocomotion .	DDI-effect
Hypotension   Patients on @DRUG$ Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of @DRUG$.	DDI-false
@DRUG$      @DRUG$ antagonism	DDI-false
As with some other nondepolarizing neuromuscular blocking agents , the time of onset of neuromuscular block induced by @DRUG$ The duration of the block is determined in patients who: @DRUG$ or carbamazepine .	DDI-effect
In a clinical pharmacology study , @DRUG$ Sulindac was given to hypertensive patients receiving @DRUG$.	DDI-false
As with other antipsychotic agents, it should be noted that @DRUG$ may be capable of potentiating CNS depressants such as @DRUG$, opiates, and alcohol.	DDI-effect
acetaminophen/theophylline , lidocaine/quinidine , @DRUG$/acetaminophen , @DRUG$/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
" Medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, @DRUG$ , cisplatin, dapson, disulfiram, ethionamide, glutethimide, @DRUG$ , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , @DRUG$ ( e.g. , octreotide ) , @DRUG$.	DDI-false
Adequate monitoring of @DRUG$ Plasma concentrations should be considered if treatment with: @DRUG$ is initiated or changed in patients receiving theophylline .	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as @DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the @DRUG$ is exceeded.	DDI-false
- may affect anticoagulants (modified hypoprothrombinemic activity), @DRUG$ , rifampin and other inducers of hepatic microsomal enzyme oxidation system ( decreased effect of @DRUG$ ) , corticosteroids ( increased effect of corticosteroids ) .	DDI-false
poor metabolizers of @DRUG$ : Interactions of @DRUG$ Not studied with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone), but these drugs would be expected to increase blood levels of the R(+) enantiomer of gelicilol.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 ( eg , phenobarbital , phenytoin , dexamethasone , @DRUG$ @DRUG$ may decrease plasma levels.	DDI-mechanism
Digoxin : When multiple doses of atorvastatin and @DRUG$ were coadministered , steady-state plasma @DRUG$ concentrations increased by approximately 20 % .	DDI-false
Drugs Interactions between Keppra and other antiepileptics ( AEDs ) @DRUG$ Keppra ( 3000 mg daily ) had no effect on the pharmacokinetics of @DRUG$ In patients with refractory epilepsy.	DDI-false
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system ( e.g. , @DRUG$ , carbamazepine , cimetidine , @DRUG$ ), although this has not yet been studied.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitors (NNRTI)-based antiretroviral therapy and concerns about @DRUG$ Metabolism disorders (@DRUG$) have led to significant shifts in treatment practices in HIV infection.	DDI-false
Other Drugs : Drugs such as @DRUG$ , disopyramide , procainamide , phenothiazines , antihistamines , and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
The data suggest that: @DRUG$ has a narrower spectrum of actions and will have a substantially greater therapeutic index than @DRUG$.	DDI-false
Numerous drug interactions are possible with some anticonvulsant agents, such as @DRUG$ and @DRUG$, which affect hepatic microsomal enzyme systems.	DDI-false
Central nervous system depressants: the concomitant use of DURAGESIC ( @DRUG$ Transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotic agents, sedatives (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$ , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-effect
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$ should not be taken within 2 hours of @DRUG$.	DDI-advise
The conversion of @DRUG$ to @DRUG$ The aldehyde oxidase is catalysed.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists ( Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS , 3020 ( 91 % ) patients receiving @DRUG$ 25 to 50 mg also received @DRUG$ Angiotensin II receptor antagonists ( ACEI/ ARB).	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
@DRUG$/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of penicillin V , oral @DRUG$ , methotrexate and @DRUG$.	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
Sine bradycardia was treated with oral @DRUG$ In combination with lidocaine ( CYP3A4 substrate ) for local @DRUG$.	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance , such as efavirenz , nevirapine , @DRUG$ Administration of a daily dose of 70 mg CANCIDAS should be considered	DDI-advise
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , @DRUG$ , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , @DRUG$ , progestogens (e.g. in oral contraceptives).	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., @DRUG$, omeprazole).	DDI-false
@DRUG$ , @DRUG$ In vitro,, oxacillin, chlortetracycline, doxycycline, cephalothine, erythromycin and sulfamethoxazole have no influence on the protein binding of diclofenac in human serum.	DDI-false
Drug-Drug Interactions Between Keppra   And Other Antiepileptic Drugs ( @DRUG$ ) @DRUG$ Keppra   ( 3000 mg daily ) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy .	DDI-false
@DRUG$: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or @DRUG$ with the addition of tiagabine given as a single dose.	DDI-false
Co-administration of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the @DRUG$ may be potentiated.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, @DRUG$, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
â€¢ amprenavir inhibits the ERMB, and @DRUG$ and @DRUG$ ERMBT's inductors are equipped.	DDI-false
Death due to fulminant pancreatitis possibly related to intravenous @DRUG$ and @DRUG$ has been reported .	DDI-effect
acetaminophen/@DRUG$ , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
The concomitant use of @DRUG$ tablets and other @DRUG$ is not recommended due to the increased possibility of gastrointestinal toxicity, with little or no increase in efficacy.	DDI-effect
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), platelet inhibitors ( @DRUG$ ) , @DRUG$ Piroxicam and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Antidepressants , @DRUG$ @DRUG$ may enhance the activity of tricyclic antidepressants or sympathomimetic agents ;	DDI-false
Diphenhydramine hydrochloride has additive effects on alcohol and other CNS depressants ( @DRUG$ , sedatives , @DRUG$ , etc ) .	DDI-false
@DRUG$ : @DRUG$ interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum .	DDI-false
Administration of @DRUG$ It has been reported that plasma levels of @DRUG$ , if given concomitantly .	DDI-mechanism
Medicines not to be treated at the same time @DRUG$ @DRUG$ : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-advise
@DRUG$ The anorectic and stimulating effects of @DRUG$ It can be inhibited by lithium carbonate.	DDI-false
@DRUG$ The concomitant use of Bepridil with long- and short-acting @DRUG$ It was safely tolerated in patients with stable angina pectoris.	DDI-false
Therefore , if digoxin is administered with @DRUG$ , the clinician should be alert to the possibility of increases in @DRUG$ levels .	DDI-false
@DRUG$ : Reports suggest that @DRUG$ The antihypertensive effect of angiotensin converting enzymes ( ACE) inhibitors may be reduced.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Benzthiazide may interact with alcohol , blood thinners , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , @DRUG$ , norepinephrine , @DRUG$ Such as Aleve or ibuprofen, and high blood pressure medications.	DDI-false
Antifungals: In vitro and/or in vivo data indicate that @DRUG$, itraconazole, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
Intravenous @DRUG$ ( @DRUG$ It was effectively administered in the presence of other cardiovascular drugs such as quinidine, beta-adrenergic blockers, calcium channel blockers, and angiotensin converting enzyme inhibitors without any change in the adverse reaction profile.	DDI-false
Both @DRUG$ and @DRUG$ slow AV conduction .	DDI-effect
@DRUG$ : Etodolac has no apparent pharmacokinetic interaction when administered with furosemide or @DRUG$.	DDI-false
Other medicinal products Interactions: no pharmacokinetic interactions between vardenafil and the following medicinal products have been observed: glyburide, @DRUG$ , digoxin, Maalox, and @DRUG$.	DDI-false
However, if Argatroban after termination of the @DRUG$ therapy , allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy .	DDI-false
The application of local anaesthetic solutions that @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors , tricyclic antidepressants or @DRUG$ For this reason, severe, prolonged hypotension or hypertension may occur.	DDI-effect
Oral Contraceptives: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	DDI-mechanism
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ These include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, @DRUG$ , local anesthetics, procainamide, and quinidine.	DDI-effect
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , @DRUG$ , propranolol , nifedipine , @DRUG$ , diazepam , certain tricyclic antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
Injection : Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system if with @DRUG$ , phenothiazine, barbiturates, MAO inhibitors and other antidepressants. If scopolamine is used simultaneously with injectable @DRUG$ , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-false
The effect of TORADOL on plasma lithium has not been studied, but cases of increased @DRUG$ plasma levels during @DRUG$ therapy have been reported.	DDI-mechanism
CONCLUSIONS/INTERPRETATION: @DRUG$ and @DRUG$ can exert additive vasodilator properties on renal and ocular circulation.	DDI-false
The medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$ , glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$ , phenytoin, ribavirin and vincristine.	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
These results suggest that both dexamethasone and dexamethasone @DRUG$ , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
Concurrent administration of @DRUG$ and of @DRUG$ may cause severe, persistent hypertension or cerebrovascular accidents.	DDI-false
@DRUG$ and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
@DRUG$: Clinical studies, as well as post marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazides in some patients.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , @DRUG$ , haloperidol , @DRUG$ , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some antihistamines .	DDI-false
The concurrent use of intravenously or orally administered methylxanthines (e.g., aminophylline, @DRUG$) by patients receiving @DRUG$ has not been completely evaluated.	DDI-false
BACKGROUND : The effects of the combined administration of bombsin and @DRUG$ (Verapamil ), @DRUG$ , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
It can interact with thyroid medications (e.g., @DRUG$ ) , iodine-containing products , antacids , H2-antagonists ( e.g. , famotidine , ranitidine ) , and proton pump inhibitors ( e.g. , @DRUG$ , omeprazole ) .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , @DRUG$ ), isoniazid, phenothiazine derivatives, @DRUG$ , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
In a 12-month controlled trial that included a 50 mcg once daily BROVANA dose, 30 of the 528 @DRUG$ -treated subjects received concomitant @DRUG$ at study entry.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
While all the @DRUG$ ( @DRUG$ ) , e.g. , citalopram , escitalopram , fluoxetine , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as @DRUG$ Beta-adrenerg blockers, calcium channel blockers and @DRUG$ , without changing the adverse reaction profile.	DDI-false
Although glucocorticoids have shown @DRUG$-induced adverse reactions including fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea to reduce, concomitant administration of these agents with PROLEUKIN may reduce the efficacy of PROLEUKIN against tumour and should therefore be avoided. @DRUG$ may potentiate the hypotension seen with PROLEUKIN .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	DDI-false
Warfarin : @DRUG$ It has been reported that the effects of oral @DRUG$ Warfarin or its derivatives.	DDI-false
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with @DRUG$ resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Magnesium- and/or aluminum-containing @DRUG$ , products containing @DRUG$ ( iron ) , multivitamin preparations containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
Take special care with ROMAZICON in overdose with mixed medicinal products as the toxic effects (such as cramps and heart rhythm disorders) of other medicinal products taken with overdose (especially: @DRUG$ ) may emerge with the reversal of the @DRUG$ Effect by flumazenil.	DDI-false
Amiodarone may suppress certain CYP450 enzymes , including CYP1A2 , @DRUG$ , CYP2D6 and @DRUG$.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
â€¢ Substances that are strong inhibitors of CYP3A4 activity (e.g. ketoconazole and itraconazole) decrease @DRUG$ metabolism and increase @DRUG$ plasma concentrations .	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, procainamide, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$ Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with 5HT3 antagonist class medications (including, for example, @DRUG$ Granisetron is contraindicated, and is contraindicated.	DDI-false
However , patients on @DRUG$ may show elevations of digoxin concentrations after initiation of therapy with FLOLAN , which may be clinically significant in patients prone to @DRUG$ toxicity .	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, @DRUG$, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (@DRUG$/@DRUG$).	DDI-false
Possible interactions between Keppra and other medicinal products @DRUG$ The evaluation of levetiracetam serum concentrations (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) was also performed. @DRUG$ during placebo-controlled clinical studies .	DDI-false
@DRUG$: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
Oral contraceptives: concomitant use of @DRUG$ N and oral contraceptives increased AUC values for norethindrone and @DRUG$ by approximately 30 % and 20 % .	DDI-mechanism
In both species, (-)-NANM, but not @DRUG$, antagonized the rate-decreasing effects of @DRUG$ on FI and FR responding.	DDI-false
Acidifying agents : @DRUG$ (Guanethidine, reserpine, glutamic acid HCl, @DRUG$ , fruit juices, etc.) lower absorption of amphetamines.	DDI-false
@DRUG$: Co- administration of @DRUG$ and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenyl-butazone , phenytoin sodium , @DRUG$ and possibly with griseofulvin , @DRUG$ , and tetracyclines ( 72 )	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, @DRUG$, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
These results suggest that both dexamethasone and retinyl acetate , and possibly other glucocorticoids and retinoids , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and @DRUG$.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
- @DRUG$, oral (diabetes medicine you take by mouth) Use of oral @DRUG$ with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral antidiabetics	DDI-false
Oral doses of @DRUG$ (10-20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of @DRUG$ (by approximately 40%) given to healthy volunteers in moderate doses.	DDI-mechanism
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, @DRUG$.	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/@DRUG$.	DDI-false
In vitro binding studies with human serum proteins indicate that glipizide binds differently than tolbutamide and does not interact with @DRUG$ or @DRUG$.	DDI-false
Coingestion of @DRUG$ with @DRUG$ , phenobarbital with acetaminophene, and valproic acid with phenobarbital at high to toxic concentrations reduces binding of the target drug.	DDI-effect
Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, @DRUG$ , bacitracin , polymyxins , lincomycin , @DRUG$ , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. @DRUG$ , tetracyclines , @DRUG$ , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Studies in rats have shown that @DRUG$ administration attenuates certain types of @DRUG$ dependent hypertension, including ACTH hypertension.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g., @DRUG$ , @DRUG$ Amphotericin B, foscarnet, intravenous pentamidine, vancomycin and nonsteroidal anti-inflammatory agents] is contraindicated.	DDI-false
Dexamethasone and retinyl acetate similarly inhibit and stimulate @DRUG$- or @DRUG$-induced proliferation of prostatic epithelium .	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or @DRUG$, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for @DRUG$ versus levofloxacin/@DRUG$ regimens.	DDI-false
@DRUG$ ( tricyclic ) , @DRUG$ Co-administration with arbutamine may lead to additive inotropic and/ or chronotropic effects.	DDI-false
The concurrent use of intravenously or orally administered methylxanthines (e.g., @DRUG$, @DRUG$) by patients receiving BROVANA has not been completely evaluated.	DDI-false
In addition, additional interaction studies with niacin and @DRUG$ They have no effect on @DRUG$ plasma levels , and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of digoxin relative to control data .	DDI-false
Elevated serum levels of @DRUG$ have been reported with concomitant use of @DRUG$ with norfloxacin.	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , @DRUG$ , disopyramide , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , somatostatin analog ( e.g. , @DRUG$ ) , sulfonamide antibiotics .	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines , presumably through inhibition of CYP3A : @DRUG$ , fluvoxamine, cimetidine, @DRUG$ Isoniazid, and some macrolide antibiotics.	DDI-false
â€¢ Co-administration with compounds that are potent CYP3A4 inducers (e. g. @DRUG$ , phenytoin , @DRUG$ , carbamazepine ) may result in decreased plasma levels of saquinavir .	DDI-false
It was concluded that oral @DRUG$ and @DRUG$ can be administered concomitantly without a significant decrease in AUC , Cmax , or tmax .	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists ( Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS , 3020 ( 91 % ) patients receiving INSPRA 25 to 50 mg also received @DRUG$ Angiotensin II receptor antagonists ( @DRUG$/ARB ).	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin, Gentamicin and amikacin), amphotericin B, @DRUG$ , intravenous pentamidine , vancomycin , and @DRUG$ ] is contraindicated.	DDI-false
These increased exposures of @DRUG$ and @DRUG$ should be taken into consideration when selecting an oral contraceptive for women taking valdecoxib.	DDI-false
@DRUG$ : In vitro and/or in vivo data indicate that fluconazole , itraconazole , and oral ketoconazole markedly inhibit the metabolism of @DRUG$ , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , @DRUG$ , calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$ , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Cholestyramine and @DRUG$ Resins : Absorption of @DRUG$ is impaired in the presence of anionic exchange resins .	DDI-false
@DRUG$ The increase in FI or FR response caused by intermediate doses of (+)-NANM or PCP in pigeons reduced or eliminated, but not the decrease in FI or FR response caused by high doses of PCP or either stereoisomer of @DRUG$.	DDI-false
Metformin : In healthy subjects given single 500 mg doses of @DRUG$ and metformin , plasma metformin mean cmax and AUC increased by an average of 34 % and 24 % , respectively , and @DRUG$ mean renal clearance decreased by 14 % .	DDI-false
Concomitant use of @DRUG$ with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug.	DDI-false
Interaction with @DRUG$, lidocaine and @DRUG$ has also been reported to produce adverse clinical effects.	DDI-false
@DRUG$ In an interaction study in rheumatoid arthritis patients taking methotrexate, @DRUG$ The pharmacokinetics of methotrexate were not significantly affected.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , @DRUG$ , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide and prednisone with vincristine plus). @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline ( an @DRUG$ The AUC of clonazepam was 10 % lower and the Cmax of clonazepam was 10 % lower. @DRUG$ The oral disintegrating tablet was 20% lower than propanthelin alone.	DDI-false
@DRUG$ Simultaneous use of low dose aspirin with @DRUG$ This may lead to an increased rate of GI ulceration or other complications compared to the use of VIOXX alone.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, @DRUG$, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Benzthiazide may interact with @DRUG$, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Antidepressants (@DRUG$), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	DDI-false
Antiacid , @DRUG$ , Didanosine , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , @DRUG$ , phenobarbitol, carbamazepine, rifabutin, rifampin, ritanovir, saquinavir.	DDI-false
â€¢ Concomitant administration of medicinal products that are nephrotoxic (e.g. aminoglycosides, indomethacin), myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g. @DRUG$ ) or hepatotoxic (e.g. @DRUG$ Asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$ , @DRUG$ , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Possible drug interactions of @DRUG$ with @DRUG$ or with other anticholinesterases.	DDI-int
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
Furosemide: Clinical studies, as well as post marketing observations, have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ and @DRUG$ in some patients.	DDI-false
Although the occurrence has not been reported with Cefizox, nephrotoxicity has been reported following concomitant administration of other @DRUG$ and @DRUG$.	DDI-effect
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$ , @DRUG$ ==References====External links==	DDI-false
Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications.	DDI-false
May interact @DRUG$ (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI   and concomitant interferon beta-1a ( @DRUG$ 30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate .	DDI-false
Clinical studies with @DRUG$ have identified potentially significant interactions with @DRUG$ and lithium.	DDI-int
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , @DRUG$ was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , betablockers , calcium-channel blockers , @DRUG$ , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
- @DRUG$: Interaction studies in humans have shown @DRUG$ to have no effect on warfarin metabolism or on plasma prothrombin activity.	DDI-false
@DRUG$ did not affect the conversion of losartan to the active metabolite after intravenous administration of @DRUG$, and erythromycin had no clinically significant effect after oral administration.	DDI-false
The inhibition of CYP-2C19 by @DRUG$ and @DRUG$ ==References====External links==	DDI-false
The compounds tested in humans include: @DRUG$ , theophylline , phenytoin , @DRUG$ , aminopyrine and antipyrine .	DDI-false
Psychoactive Drugs : Hallucinations have been reported if: @DRUG$ was used in patients taking psychoactive drugs ( fluoxetine , thiothixene , @DRUG$ ) .	DDI-effect
Concomitant administration of fenofibrate ( equivalent to 145 mg @DRUG$ ) with atorvastatin ( 20 mg ) once daily for 10 days resulted in approximately 17 % decrease ( range from 67 % decrease to 44 % increase ) in @DRUG$ AUC values in 22 healthy males .	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Digoxin: @DRUG$ concentrations are increased by about 15% when digoxin and @DRUG$ are administered concomitantly.	DDI-false
@DRUG$ : Dihydroergotamine , @DRUG$ , ergotamine, methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasms and ischaemia of extremities and other tissues.	DDI-false
Note : dissolution of aerosol particles of @DRUG$ in @DRUG$ A model of lung surfactant.	DDI-false
The benefits and risks of using @DRUG$ with @DRUG$ and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed	DDI-advise
The intensity, uniformity and time course of the anticoagulant interference by phenobarbital, secobarbital, @DRUG$ , chloral hydrate and methaqualone have been systematically studied in 16 patients who: @DRUG$ therapy .	DDI-false
Intravenous Adenocard ( @DRUG$ ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , beta-adrenergic blocking agents , calcium channel blocking agents , and @DRUG$ , without changing the adverse reaction profile.	DDI-false
Ketoconazole did not affect the conversion of @DRUG$ to the active metabolite after intravenous administration of losartan, and @DRUG$ had no clinically significant effect after oral administration.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , @DRUG$ , thyroid products, @DRUG$ , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
Although these results do not indicate a significant interaction between @DRUG$ and warfarin or @DRUG$ TORADOL should be used with extreme caution in patients taking anticoagulants and patients should be closely monitored.	DDI-false
It is recommended not to exceed a single dose of 5 mg. @DRUG$ in a 24-hour period when used in combination with @DRUG$.	DDI-advise
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a @DRUG$ substrate , and @DRUG$ , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
These data indicate that levetiracetam does not influence the plasma concentration of other AEDs and that these @DRUG$ do not influence the pharmacokinetics of @DRUG$.	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin , @DRUG$ Milrinone, or IV @DRUG$ has not been evaluated ( these drugs were not co-administered with Natrecor in clinical trials ) .	DDI-false
Drug interactions between Keppra and other antiepileptic drugs ( @DRUG$ Phenytoin Keppra ( 3000 mg daily ) had no effect on the pharmacokinetics of @DRUG$ In patients with refractory epilepsy.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , @DRUG$ , doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$ , quinidine, and verapamil.	DDI-false
Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , analgesics , antiemetics , @DRUG$ , @DRUG$ ) .	DDI-false
@DRUG$ did not alter the plasma levels of @DRUG$ when taken in combination .	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients with @DRUG$ Dexamethasone), diphen hydromine and H2 antagonists (such as: @DRUG$ ==References==	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Multivitamins or other products containing iron or zinc, antacids or @DRUG$ Co-administration with or within 2 hours after administration of @DRUG$ Because they may impair absorption, resulting in lower serum and urine levels of norfloxacin.	DDI-advise
When CANCIDAS is co-administered with inducers of drug clearance, such as @DRUG$, nevirapine, phenytoin, @DRUG$, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$, nondepolarizing (e.g., @DRUG$): possible increased responsiveness to the muscle relaxant.	DDI-false
- Antihypertensives: @DRUG$ may potentiate the effect of various @DRUG$, necessitating a reduction in the dosage of these drugs.	DDI-effect
@DRUG$ ==References====External links== @DRUG$ , etc . ) should be given concomitantly only with great caution .	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other @DRUG$ (hypnotics, @DRUG$, tranquilizers, etc).	DDI-false
Antiacid, clarithromycin, didanosine, fluconazole, fluoxetine, indanavir, @DRUG$ , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , @DRUG$ , ritanovir, saquinavir.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , @DRUG$ Angiotensin converting enzyme inhibitors ( ACE), @DRUG$ , benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
Clinical implications of @DRUG$ # Interactions with five @DRUG$.	DDI-int
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the cerivastatin AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
The use of antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$ , isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and @DRUG$.	DDI-false
The effect of @DRUG$ on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after rifampin withdrawal.	DDI-effect
@DRUG$ : Co-administration of VIOXX with @DRUG$ 600 mg daily , a potent inducer of hepatic metabolism , produced an approximate 50 % decrease in rofecoxib plasma concentrations .	DDI-false
@DRUG$ In post-marketing experience, both increases and decreases have been reported in @DRUG$ Concentrations with concomitant use of dexamethasone resulted in changes in seizure control.	DDI-false
@DRUG$: In diabetic patients receiving @DRUG$ and tolbutamide, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	DDI-false
Chloramphenicol has been shown to be antagonistic to @DRUG$, including @DRUG$, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including ciprofloxacin, containing multivalent cation products such as magnesium or aluminium antazida, @DRUG$ , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Warfarin: The effects of @DRUG$ and @DRUG$ on GI bleeding are synergistic, such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone.	DDI-effect
@DRUG$ , tricyclic @DRUG$ The effect of tricyclic antidepressants or sympathomimetics may be increased;	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , @DRUG$ , or @DRUG$ may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce hepatic metabolism @DRUG$ , phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$ , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in an approximate 50% increase in plasma levels of acetaminophen.	DDI-false
In patients with chronic hepatitis C treated with @DRUG$ in combination with COPEGUS, @DRUG$ treatment did not affect ribavirin distribution or clearance.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
May interact with thyroid medication ( e.g. , levothyroxine ) , @DRUG$-containing products , antacids , H2-antagonists ( e.g. , famotidine , ranitidine ) , and @DRUG$ ( e.g. , lansoprazole , omeprazole ) .	DDI-false
The benzodiazepines are a family of @DRUG$ and @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Digoxin  When given concomitantly with @DRUG$ the pharmacokinetics of @DRUG$ in patients with heart failure were not significantly altered.	DDI-false
There was no significant difference ( p > 0.05 ) in AUC ( 48.59 + /- 8.52 vs. 49.9 + /- 9.93), Cmax ( 7.73 + /- 2.6 vs. 6.6 + /- 2.0 ) and tmax ( 1.1 + /- 0.6 vs. 1.6 + /- 1.1 ) for @DRUG$ versus levofloxacin/@DRUG$ regimens .	DDI-false
Administration of @DRUG$ to patients receiving cyclopropane or halogenated hydrocarbon general anesthetics such as @DRUG$ which sensitize the myocardium , may induce cardiac arrhythmia ..	DDI-effect
In addition, Fondaparinux neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
@DRUG$ , Including Oral , Injectable , Transdermal , and Implantable Contraceptives : An interaction study demonstrated that co-administration of @DRUG$ The oral hormonal contraceptives Ortho-Novum and the oral hormonal contraceptives resulted in an average decrease in norethindrone and ethinylestradiol levels of 14% and 31% respectively.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
Administration of @DRUG$ to patients who are receiving sympathomimetic or @DRUG$ may result in an additive pressor effect .	DDI-effect
@DRUG$     @DRUG$ antagonism	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , @DRUG$ , @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , @DRUG$ , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , @DRUG$ ( e.g. , in oral @DRUG$ ) .	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine , fibric acid derivatives , @DRUG$ ( @DRUG$ ) , erythromycin , azole antifungals .	DDI-false
Agents Causing Renin Release: The antihypertensive effect of @DRUG$ and enalapril IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).	DDI-effect
MAO inhibitors : DURAGESIC is not recommended for use in patients who have received MAOI within 14 days because of severe and unpredictable potentiation due to: @DRUG$ It was about @DRUG$	DDI-advise
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$ , and @DRUG$.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , @DRUG$ , chloramphenicol, probenecid, coumarin, @DRUG$ , and beta adrenergic blocking agents .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , @DRUG$ , quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, @DRUG$ (e. g., fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
However, patients on @DRUG$ may show elevations of digoxin concentrations after initiation of therapy with @DRUG$, which may be clinically significant in patients prone to digoxin toxicity.	DDI-mechanism
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$ or @DRUG$ For this reason, severe, prolonged hypertension can arise.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	DDI-false
@DRUG$ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ @DRUG$ 20 mg and imipramine 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration .	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: @DRUG$, fluvoxamine, cimetidine, diltiazem, @DRUG$, and some macrolide antibiotics.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , @DRUG$ , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ â€¢ with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
@DRUG$ ( e. g. , ketoconazole , miconazole , @DRUG$ , fluconazole , etc . ): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , @DRUG$ , erythromycin, imatinib, @DRUG$ , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Both efavirenz and @DRUG$ It was compared to triple therapy with PI. @DRUG$ over 48 weeks as initial therapy , with similar responses being observed with nevirapine regimens and superiority observed with efavirenz .	DDI-false
With simultaneous dosing of @DRUG$ 20 mg and @DRUG$ 10 mg, 2 of 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.	DDI-effect
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including non-steroidal anti-inflammatory drugs and other drugs that are highly protein-bound, @DRUG$ , sulfonamides , chloramphenicol , probenecid , coumarins , @DRUG$ And beta-adrenergic blockers.	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Warfarin : Anticoagulant activity should be monitored, especially in the first few days after initiation or change @DRUG$ therapy in patients receiving @DRUG$ or similar agents , since these patients are at an increased risk of bleeding complications .	DDI-advise
In particular , convulsions have been reported when @DRUG$ is administered with @DRUG$ and special care should be taken when the treatment regimen includes both of these drugs .	DDI-effect
@DRUG$/Hypnotics: @DRUG$, midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
Antiarrhythmics: Amiodarone, @DRUG$, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Concomitant use of agents in the tricyclic antidepressant class (which includes @DRUG$) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the @DRUG$ or the other drug.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: orally @DRUG$ , ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylate, somatostatin analogue (e.g., @DRUG$ ) , sulfonamide antibiotics .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Both ibogaine and 18-MC block @DRUG$-induced and @DRUG$-induced dopamine release in the nucleus accumbens;	DDI-false
Clinical implications of @DRUG$ interactions with five @DRUG$.	DDI-int
Interactions may occur between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ (@DRUG$).	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: glyburide, warfarin, digoxin, Maalox, and @DRUG$.	DDI-false
Antiacid, clarithromycin, didanosine, fluconazole, @DRUG$ , Indanavir , @DRUG$ , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , Rifampin , Ritanovir , Saquinavir .	DDI-false
MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received @DRUG$ within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with opioid analgesics	DDI-false
@DRUG$ toxicity was usually reversible upon discontinuation of lithium and the @DRUG$.	DDI-false
@DRUG$ : The pharmacokinetics of @DRUG$ After a single oral dose of albendazole (400 mg), aminophylline 5.8 mg/kg infused over 20 minutes was unchanged in 6 healthy subjects.	DDI-false
Magnesium- and/or @DRUG$-containing antacids , products containing ferrous sulfate ( @DRUG$ Videx (didanosine) chewable tablets or the oral pediatric powder should not be taken within 3 hours before or 2 hours after FACTIV.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Probenecid : Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of @DRUG$ in serum .	DDI-false
CONCLUSIONS : Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 ( i.e. , atorvastatin , cerivastatin , @DRUG$ , @DRUG$ ) .	DDI-false
Antidepressants (tricyclic), @DRUG$ or other @DRUG$, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$ , ethionamide , glutethimide , @DRUG$ , hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
poor metabolizers of @DRUG$ : Interactions of geschnitzilol with potent inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine and @DRUG$ These drugs are expected to increase the blood levels of the R(+) enantiomer of gelicilol.	DDI-false
Therophylline: A recent study has shown that concomitan administration of isoniazid and theophylline may cause elevated plasma levels of @DRUG$, and in some instances a slight decrease in the elimination of @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Standard monitoring of methotrexate-related toxicity should be continued if @DRUG$ and @DRUG$ are administered concomitantly .	DDI-advise
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, @DRUG$, digoxin, Maalox, and @DRUG$.	DDI-false
Sulindac : The concomitant administration of @DRUG$ and @DRUG$ In normal subjects, this resulted in a reduction of about one third of the plasma levels of the active sulindac sulphide metabolite.	DDI-mechanism
@DRUG$ Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of methotrexate.	DDI-false
ACE inhibitors reports suggest that: @DRUG$ The antihypertensive effect of @DRUG$ can be reduced.	DDI-effect
@DRUG$ reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or @DRUG$ in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.	DDI-effect
@DRUG$ : The administration of diflunisal to normal volunteers receiving @DRUG$ Elevated renal clearance and significantly increased plasma levels of indomethacin.	DDI-false
Diltiazem , @DRUG$ , @DRUG$	DDI-false
Reports in the literature suggest that plasma levels of @DRUG$ (and its active metabolites) @DRUG$ It can be increased if paclitaxel and doxorubicin are used in combination.	DDI-false
@DRUG$ reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of @DRUG$ 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of Nalfon, the concomitant use of Nalfon and @DRUG$ is not recommended.	DDI-false
- When Bezalip or @DRUG$ is used concurrently with anion-exchange resins ( e.g. cholestryramine ) , an interval of at least 2 hours should be maintained between the two medicines , since the absorption of @DRUG$ or Bezalip retard is impaired	DDI-false
Coadministration of @DRUG$ ( 40 mg BID ( day 1 ) and 40 mg QD ( days 2 - 7 ) ) with @DRUG$ ( 10 mg glyburide BID ) resulted in 21 % increase in glyburide AUC0 - 12 and a 16 % increase in glyburide Cmax leading to a 16 % decrease in glucose AUC0 - 24 .	DDI-mechanism
@DRUG$, tricyclic antidepressants, and MAOIs may increase anticholinergic effect of @DRUG$.	DDI-effect
@DRUG$ reduce the renal clearance of @DRUG$ and add a high risk of lithium toxicity.	DDI-mechanism
The absorption of the oral @DRUG$ is significantly reduced by the concomitant administration of an antacid containing @DRUG$ and magnesium .	DDI-mechanism
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
The compounds tested in humans include: @DRUG$ , theophylline , @DRUG$ , diazepam , aminopyrine and antipyrine .	DDI-false
â€¢ Rifabutin: concomitant use of @DRUG$ â€¢ and VIRACEPT led to a decrease of 32% @DRUG$ Plasma AUC and an increase of 207% in rifabutin plasma A.C.	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, @DRUG$, @DRUG$).	DDI-false
@DRUG$ produced distinctive effects in each task: it substituted for the training dose in @DRUG$ discrimination and it increased the number of responses with short (<3 s) interresponse times as well as increasing overall response rates in the DRL schedule.	DDI-false
In a median follow-up of 33 months, the combination of @DRUG$ and @DRUG$ There was no benefit to efficacy in all patients and in the hormone receptor-positive subpopulation compared to tamoxifen.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar Vet , or pentobarbital , the dosage of @DRUG$ The need to cause ventricular tachycardia was significantly higher, as was the LD50 of Ouabain, with ketamine or @DRUG$ than with pentobarbital .	DDI-false
@DRUG$ : The stimulatory effects of @DRUG$ It can be inhibited by lithium carbonate.	DDI-false
Central nervous system depressants: the concomitant use of DURAGESIC ( @DRUG$ Transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$ , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-effect
In monkeys , @DRUG$ In the case of pigeons it was about 10 times stronger than (+)-NANM at decreasing response rates, while in the case of pigeons it was about 10 times stronger than (+)-NANM at decreasing response rates. @DRUG$ ==References====External links==	DDI-false
These results would seem to dictate against the clinical use of methotrexate with @DRUG$ , or during the following period @DRUG$ therapy when plasma asparagine levels are below normal .	DDI-false
Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or ergot-type medications (like @DRUG$ or methysergide) and AXERT within 24 hours of each other should be avoided.	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Terfenadine : Administration of terfenadine with @DRUG$ The result was the occurrence of unchanged @DRUG$ in plasma ;	DDI-false
@DRUG$: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with @DRUG$ (20 mg/kg/day) alone (n=12).	DDI-false
@DRUG$: @DRUG$ causes increase (by about 80%) in the free fraction of etodolac.	DDI-false
Since the therapeutic field of @DRUG$ Theophylline serum levels should be closely monitored and appropriate dose adjustments should be made. @DRUG$ It should be done.	DDI-false
However, because some @DRUG$ It has been reported that the anticoagulant effect of warfarin or its derivatives is increased in patients, prothrombin time or other appropriate coagulation tests should be closely monitored if a quinolone is antimicrobially co-administered with: @DRUG$ or its derivatives .	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : @DRUG$ - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
The medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$ , disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$ , and vincristine .	DDI-false
@DRUG$ : the concomitant use of DURAGESIC (Fentanyl transdermal system ) with other central nervous system depressants, including but not limited to other opioids, @DRUG$ , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like @DRUG$ ( MAOI ): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , gentamicin , and @DRUG$ ) , @DRUG$ , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-false
In a comparison of @DRUG$ Tolerance in dogs stunned with ketamine, Innovar Vet, or @DRUG$ The dosage of Ouabain needed to cause ventricular tachycardia was significantly higher, such as the LD50 of Ouabain, with ketamine or innovar than with pentobarbital.	DDI-false
Therefore , @DRUG$ should be discontinued at least two weeks prior to the cautious initiation of therapy with @DRUG$.	DDI-advise
Lithium: @DRUG$ 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to @DRUG$ alone.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , @DRUG$ , sulphonamides, chloramphenicol, probenecid, coumarine, @DRUG$ , and beta adrenergic blocking agents .	DDI-false
Bacteriostatic Antibiotics : Chloramphenicol , erythromycins , @DRUG$ , or tetracyclines may interfere with the bactericidal effect of @DRUG$.	DDI-effect
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , @DRUG$ , quinine , amiodarone , @DRUG$ , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
To determine whether probenecid has a direct effect on the distribution of @DRUG$ , the elimination and distribution of cloxacillin was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of @DRUG$.	DDI-false
Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that @DRUG$ It can lead to fungal resistance against amphotericin B.	DDI-false
Coingestion of @DRUG$ with theophylline , phenobarbital with acetaminophen , and @DRUG$ The binding of the target medication is reduced with phenobarbital at high to toxic concentrations.	DDI-false
Both @DRUG$ and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy , with similar responses being observed with nevirapine regimens and superiority observed with efavirenz .	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl, alfentanyl, @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
ANTACID (Magnesium-Aluminum Hydroxide): @DRUG$ plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
Acetaminophen/theophylline, @DRUG$/chinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
In a study in which patients with active RA were treated for up to 24 weeks with concurrent Kineret and @DRUG$ A 7% rate of severe infections was observed during treatment, which was higher than in @DRUG$ Alone ( 0% ).	DDI-false
Cardiac effects of dopamine are antagonized by @DRUG$, such as @DRUG$ and metoprolol.	DDI-false
@DRUG$ with desipramine or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
@DRUG$/@DRUG$ Pharmacokinetic or pharmacodynamic drug interactions have not been established between argatroban and co-administered aspirin ( 162.5 mg orally 26 and 2 hours before the start of argatroban 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally 12, 6 and 0 hours before and 6 and 12 hours after the start of argatroban 1.5 g/kg/min for 18 hours).	DDI-false
The following examples are substances that can reduce the blood glucose lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, @DRUG$ , @DRUG$ ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
As with some other @DRUG$ , the time of onset of the neuromuscular block is induced by NUROMAX and the duration of the block is shortened in patients @DRUG$ or carbamazepine .	DDI-effect
Ritonavir and @DRUG$: Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-false
Ethinyl Estradiol and @DRUG$ : Coadministration of @DRUG$ with OVCON-35 resulted in a 47 % decrease in ethinyl estradiol and an 18 % decrease in norethindrone plasma concentrations .	DDI-false
Anticholinesterases (neostgmine, @DRUG$), @DRUG$, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.	DDI-false
Monoamine oxidase inhibitors and tricyclic antidepressants: FORADIL should be used in patients treated with @DRUG$ or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents .	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ When co-administered with saquinavir, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
@DRUG$ administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of Betaseron on drug metabolism in MS patients is unknown .	DDI-mechanism
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$, warfarin, quinidine, clarithromycin or @DRUG$.	DDI-false
Lithium generally should not be given with @DRUG$ Because they reduce the renal clearance of lithium and a high risk for @DRUG$ toxicity .	DDI-false
Warfarin: The effect of @DRUG$ on the anti-coagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of 2-5 mg of warfarin.	DDI-false
Hormonal contraceptives Co-administration of @DRUG$ with an oral @DRUG$ has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).	DDI-mechanism
Imipramine (5 mg/kg), moclobemide (30 mg/kg), @DRUG$ (0.25 mg/kg), @DRUG$ (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
To assess the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine, and @DRUG$ ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , @DRUG$ , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramide, @DRUG$ , fluoxetine , monoamine oxidase ( MAO ) inhibitors , @DRUG$ , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing @DRUG$ or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , @DRUG$ , quinidine , warfarin , tacrolimus , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur when it contains its derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam.	DDI-false
Particular caution should be observed with @DRUG$ since there are conflicting results for the effect of colestipol hydrochloride on the availability of digoxin and @DRUG$.	DDI-false
Lithium : @DRUG$ decreases @DRUG$ renal clearance and increases lithium plasma levels .	DDI-mechanism
These drugs include the thiazides and other @DRUG$, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The concomitant use of vasopressors, vasoconstrictants (such as @DRUG$ ) and some @DRUG$ may result in severe hypertension .	DDI-effect
Concomitant cyclophosphamide , @DRUG$ , vincristine , and prednisone chemotherapy plus @DRUG$ Treatment in patients with human immunodeficiency virus-associated non-Hodgkin lymphoma.	DDI-false
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic @DRUG$.It is not known whether the concurrent use of these agents with @DRUG$ In humans, disturbances of the IOP-lowering effect may occur.	DDI-false
Patients treated with @DRUG$ may be resistant to the effects of @DRUG$.	DDI-effect
@DRUG$, @DRUG$, heparin, NSAIDs	DDI-false
Close supervision and careful adjustment of dosage are required when @DRUG$ is administered with @DRUG$ or sympathomimetic drugs .	DDI-advise
As with other antipsychotic agents , it should be noted that HALDOL may be capable of potentiating @DRUG$ such as @DRUG$ , opiates, and alcohol.	DDI-false
@DRUG$, or other products containing iron or @DRUG$, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal .	DDI-false
Other strong inhibitors of CYP3A4 (e.g., @DRUG$, @DRUG$, nefazodone, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
Alpha-blockers : When @DRUG$ 10 or 20 mg were administered to healthy subjects at the same time or 6 hours after a 10 mg dose. @DRUG$ , significant hypotension developed in a substantial number of subjects .	DDI-effect
@DRUG$ It has been reported that the blood pressure lowering effect of systemic @DRUG$ is dulled.It is not known whether concomitant use of these active substances with ALPHAGAN P in humans can result in a resulting interference with the IOP-lowering effect.	DDI-effect
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ (fluoxetine, @DRUG$, alprazolam).	DDI-false
@DRUG$: Diclofenac decreases lithium renal clearance and increases @DRUG$ plasma levels.	DDI-false
@DRUG$ (such as flecainide, lidocaine, or @DRUG$): concurrent use with arbutamine may have a proarrhythmic effect.	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin is associated with @DRUG$ , the concomitant use of apomorphine with drugs of the @DRUG$ ( including , for example , ondansetron , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated .	DDI-false
@DRUG$: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when @DRUG$ is co-administered with diltiazem.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , @DRUG$ When co-administered with angiotensin converting enzyme inhibitors ( ACE ), @DRUG$ Calcium channel blockers, diuretics and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Interactions with mixed agonists/antagonists Opioid analgesics : @DRUG$ (e.g. pentazocin, nalbuphin, butorphanol, decicin and @DRUG$ ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$ and @DRUG$ could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
In addition , @DRUG$ neither influenced the pharmacodynamics of warfarin , acetylsalicylic acid , @DRUG$ , and digoxin , nor the pharmacokinetics of digoxin at steady state .	DDI-false
Before using this medicine, tell your doctor or pharmacist about all prescription and non-prescription products you can use, especially: aminoglycosides (e.g., gentamicin, @DRUG$ ) , amphotericin B , @DRUG$ , non-steroidal anti-inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin .	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Furthermore it has been proposed that @DRUG$ resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested @DRUG$ being converted to the toxic metabolites.	DDI-mechanism
Cholestyramine and @DRUG$ Resins : The absorption of hydrochlorothiazide is impaired in the presence of @DRUG$.	DDI-false
In clinical studies, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators and additional oxygen. @DRUG$ â€¢ in whom treatment with @DRUG$ The apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13% and 15% respectively on the second day of therapy and were returned to baseline by day 87.	DDI-mechanism
- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( @DRUG$ , cefoperazone , cefotetan , @DRUG$ , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
The aim of this paper was to investigate the interaction between neurotensin and both. @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide , or @DRUG$ To the antinonciceptive effect of these peptides in mice after intracistern injection.	DDI-false
cimetidine ) and many that are substrates for P450 2D6 ( many other @DRUG$ , Phenothiazine, and the species 1C Antiarrhythmia @DRUG$ and flecainide ) .	DDI-false
@DRUG$: Ephedrine may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in @DRUG$ dosage.	DDI-false
@DRUG$ As with other B-lactam antibiotics, the renal excretion of Loracarbef is inhibited by probenecid and resulted in an approximately 80% increase in AUC for @DRUG$.	DDI-false
Although there are no study data to evaluate the possibility, @DRUG$, including sodium nitroprusside and @DRUG$, may have an additive effect with INOmax on the risk of developing methemoglobinemia.	DDI-false
@DRUG$: Amphetamines may antagonize the hypotensive effects of @DRUG$.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, @DRUG$, itraconazole or fluconazole.	DDI-false
Dopamine Antagonists : Since apomorphine is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( @DRUG$ , butyrophenones , @DRUG$ ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
magnesium and/or aluminium antacids, iron sulphate products, @DRUG$ Containing zinc or other metal cations; or @DRUG$ ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
@DRUG$: Digoxin concentrations are increased by about 15% when @DRUG$ and carvedilol are administered concomitantly.	DDI-false
Benzthiazide may interact with alcohol , blood thinners , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , norepinephrine , @DRUG$ like @DRUG$ Or ibuprofen, and high blood pressure medications.	DDI-false
@DRUG$ : Coadministration of @DRUG$ with VIRACEPT resulted in an 83 % increase in nelfinavir plasma AUC and a 51 % increase in indinavir plasma A.C.	DDI-false
Potential drug interactions between Keppra   and other @DRUG$ ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies .	DDI-false
Antiarrhythmic agents , class I ( such as flecainide , @DRUG$ , or @DRUG$ ): concurrent use with arbutamine may have a proarrhythmic effect .	DDI-false
Effects of @DRUG$ on Drug Metabolizing Enzymes and Drug Transport Systems @DRUG$ In vitro inhibits CYP3A4 and CYP2C8 at clinically relevant concentrations.	DDI-false
@DRUG$ : @DRUG$ , erythromycins , sulfonamides , or tetracyclines may interfere with the bactericidal effect of penicillins .	DDI-false
It differs structurally from the other HMGCoA reductase inhibitors currently available ( @DRUG$ , simvastatin and @DRUG$ This leads to unique biopharmaceutical properties compared to other active substances in this class.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
@DRUG$ In a clinical pharmacology study, the concomitant use of antacids (aluminium hydroxide, magnesium hydroxide, and @DRUG$ In combination with fosinopril reduced serum levels and urinary excretion of fosinoprilat given alone, suggesting that antacids may impair the absorption of fosinopril.	DDI-false
A drug interaction study investigated the effect of using ACZONE gel, 5%, in combination with double strength ( 160 mg/800 mg ) Trimethoprim/@DRUG$ ( TMP/@DRUG$ ).	DDI-false
@DRUG$ @DRUG$ are inhibited by amphetamines.	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs : Clonazepam does not appear to alter the pharmacokinetics of phenytoin , @DRUG$ , or @DRUG$.	DDI-false
Anticholinesterases ( neostgmine , @DRUG$ ), lignocaine, quinine, @DRUG$ can enhance toxicity and cause cardio respiratory depression .	DDI-false
The concomitant use of Natrecor with IV vasodilators such as @DRUG$ Nitroprusside, milrinone, or IV @DRUG$ These medicines were not administered with Natrecor in clinical trials.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , @DRUG$ , oral contraceptives , @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
@DRUG$: Dihydroergotamine, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$ , estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$ ==References====External links==	DDI-false
Warfarin : Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or @DRUG$ There were also no changes in the pharmacodynamic profile (prothrombin time) after a single oral dose of 25 mg. @DRUG$	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines , thyroid products , estrogens , oral @DRUG$ , phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and @DRUG$.	DDI-false
only @DRUG$ Elevated @DRUG$-induced increase in accumbal dopamine.	DDI-effect
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of @DRUG$ was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Intravenous @DRUG$ ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , beta-adrenergic blocking agents , @DRUG$ , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile .	DDI-false
Plasma concentrations (AUC 0-24 hrs) of @DRUG$ decreased 15% with coadministration of @DRUG$ relative to that observed with erythromycin alone.	DDI-mechanism
Coadministration of single , oral doses of @DRUG$ with @DRUG$ ( 10 mg and 800 mg , respectively ) , a strong , selective CYP3A4 inhibitor produced a 34 % increase in zaleplons maximal plasma concentrations and a 20 % increase in the area under the plasma concentration-time curve .	DDI-mechanism
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ , cyclosporin, ergo derivatives, @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
If antihistamines are used concomitantly with other CNS depressants, additive CNS depression may occur, including: @DRUG$ , @DRUG$ And alcohol.	DDI-false
Example inhibitors include azole antifungals , @DRUG$ , clarithromycin , @DRUG$ , doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , @DRUG$ (e. g., quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may increase plasma concentrations when co-administered with @DRUG$ ;	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. @DRUG$ , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine, and sodium colistimethate), @DRUG$ Salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
Other @DRUG$ (e.g. barbiturates, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with @DRUG$.	DDI-effect
@DRUG$ Including coumarin derivatives, indandion derivatives and platelet aggregation inhibitors such as non-steroidal anti-inflammatory drugs ( @DRUG$ ) , and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin .	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
No effects on plasma concentrations of @DRUG$ or @DRUG$ were observed.	DDI-false
- When @DRUG$ or Bezalip retard is used concurrently with @DRUG$ ( e.g. cholestryramine ) , an interval of at least 2 hours should be maintained between the two medicines , since the absorption of Bezalip or Bezalip retard is impaired	DDI-advise
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics ( such as loop or @DRUG$ ) can be acutely worsened by @DRUG$ , especially if the recommended dose of the beta agonist is exceeded.	DDI-effect
Imidazoles ( e. g. , @DRUG$ , miconazole , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of @DRUG$ Imidazole and imidazoles indicate that imidazoles can cause fungal resistance to amphotericin B.	DDI-false
@DRUG$: Because atorvastatin does not affect the pharmacokinetics of antipyrine, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, @DRUG$, and @DRUG$) would be expected to decrease estazolam concentrations.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis , it is particularly important that physicians query patients or their guardians carefully about benzodiazepine , @DRUG$ and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned .	DDI-false
It is recommended that if CASODEX is started in patients already receiving @DRUG$, prothrombin times should be closely monitored and adjustment of the @DRUG$ dose may be necessary.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : @DRUG$ , niacin , @DRUG$ , diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazide, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Cyclosporine: Administration of @DRUG$ concomitantly with @DRUG$ has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-mechanism
The concomitant use of Natrecor with IV vasodilators such as @DRUG$ , nitroprusside , @DRUG$ ACE inhibitors have not been studied (these medicinal products have not been administered with Natrecor in clinical trials).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or @DRUG$), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Conversely, the @DRUG$ have been reported to increase the serum levels and prolong the serum half-life of @DRUG$ by inhibiting its metabolism.	DDI-mechanism
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
@DRUG$ : rifampin CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of @DRUG$.	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as @DRUG$, @DRUG$, and alcohol.	DDI-false
Other Cardiovascular Agents : @DRUG$ Enalapril IV was co-administered with beta-adrenergic blockers, methyldopa, @DRUG$ , calcium blockers, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Antihypertensive medications , other , especially @DRUG$ , or pre@DRUG$ and anesthetic agents used in surgery or skeletal-muscle relaxants , nondepolarizing , used in surgery	DDI-false
This study showed that the potent cytochrome P450 enzyme inducer @DRUG$ did indeed have a marked effect on the metabolism of @DRUG$ , resulting in a 5-fold increase in clearance in patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder or bipolar disorder.	DDI-mechanism
Warfarin Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of @DRUG-DRUG$.	DDI-false
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), @DRUG$ Acetylsalicylic acid, NSAIDs ( @DRUG$ ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Co-administration of @DRUG$ with @DRUG$ It has been shown that the mean half-life and area under the concentration-time curve increase.	DDI-mechanism
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin , @DRUG$ , and @DRUG$ And the antituberculosis drug rifampin.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , @DRUG$ Cyclosporin, nonsteroidal anti-inflammatory medicines (e.g. ibuprofen), @DRUG$ , vancomycin .	DDI-false
Intravenous @DRUG$ Adenosine was effectively administered in the presence of other cardiovascular drugs such as quinidine, beta-adrenergic agents, calcium channel blockers, and @DRUG$ , without any change in the adverse reaction profile .	DDI-false
Central nervous system depressants : the concomitant use of DURAGESIC (Fentanyl transdermal system ) with other central nervous system depressants, including but not limited to other opioids, @DRUG$ , @DRUG$ , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
@DRUG$: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg @DRUG$ was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin, @DRUG$ , and amikacin ) , amphotericin B , foscarnet , intravenous pentamidine , vancomycin , and @DRUG$ ] is contraindicated.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, @DRUG$, @DRUG$, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
@DRUG$: The potential for pharmacokinetic drug-drug interactions between @DRUG$ and other agents has not been formally studied.	DDI-false
Oral @DRUG$ inhibits the gastrointestinal absorption of penicillin V , oral vitamin B-12 , methotrexate and @DRUG$.	DDI-mechanism
Another oral azole antifungal , ketoconazole , inhibits the metabolism of @DRUG$ , leading to increased plasma concentrations of @DRUG$ The active metabolite desmethylastermizole may prolong the QT interval.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , @DRUG$ , protease inhibitors, quinidine and @DRUG$.	DDI-false
The plasma exposure of diazepam ( 10 mg twice daily) was @DRUG$ The plasma exposure of valdecoxib ( 40 mg twice daily) was @DRUG$ 10 mg twice daily.	DDI-false
@DRUG$ : Haloperidol blocks dopamine and norepinephrine reuptake , thus inhibiting the central stimulant effects of @DRUG$.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
Drug/Laboratory Test Interaction @DRUG$ The Digi- Tab RIA Kit for @DRUG$ can result in incorrect, low measurement of serum digoxin levels.	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine , Innovar Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with ketamine or Innovar than with @DRUG$.	DDI-false
@DRUG$: @DRUG$ have been reported to cause a significant decrease in corticosteroid clearance.	DDI-false
@DRUG$ significantly decreased the AUC(ss) of amprenavir by 82%, but @DRUG$ had no effect on rifampin pharmacokinetics.	DDI-false
Cyclosporine, Digoxin, Methotrexate @DRUG$, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, @DRUG$, methotrexate, and increased toxicity.	DDI-mechanism
The pharmacokinetics of @DRUG$ were not affected by coadministration of @DRUG$ or hydrochlorothiazide	DDI-false
The following are known examples of drugs that inhibit the metabolism of other related benzodiazepines, probably by inhibition of CYP3A: @DRUG$ , fluvoxamine , @DRUG$ , diltiazem , isoniazide , and some macrolide antibiotics .	DDI-false
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive @DRUG$ level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for @DRUG$.	DDI-false
Ethosuximide : @DRUG$ may delay intestinal absorption of @DRUG$.	DDI-mechanism
â€¢ Furosemid : Clinical studies, as well as post-marketing observations, have shown that NSAIDs have the natriuretic effect of @DRUG$ and @DRUG$ in some patients .	DDI-false
The ECG changes and/or hypokalaemia resulting from the administration of non-potassium-sparing diuretics (such as loop or @DRUG$ ) can be acutely worsened by beta-agonists , especially when the recommended dose of the @DRUG$ is exceeded .	DDI-false
Antacids : In a clinical pharmacology study, concomitant administration of antacids (aluminium hydroxide, magnesium hydroxide and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat compared to fosinopril alone, suggesting that: @DRUG$ The recording of @DRUG$ may be affected.	DDI-mechanism
Rifampin significantly decreased the AUC(ss) of amprenavir by 82%, but @DRUG$ had no effect on @DRUG$ pharmacokinetics.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
May interact anticoagulants ( altered hypo-prothrombinemic effect ) , barbiturates , @DRUG$ â€¢ and other inducers of the hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$ ) .	DDI-false
@DRUG$ The effect of iodine or iodine excess can be the effect of @DRUG$ , and an iodine deficiency can increase the effect of Carbimazole .	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
Discontinuing @DRUG$ could pose a hazard to health if a potentially toxic drug that is significantly bound to the @DRUG$ has been titrated to a maintenance level while the patient was taking colestipol hydrochloride .	DDI-false
This could be explained by a blockage by @DRUG$ The elimination of @DRUG$ Through the liver.	DDI-mechanism
Antidepressants, tricyclic: @DRUG$ may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , @DRUG$ , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and @DRUG$.	DDI-false
Verapamil: Coadministration of almotriptan and @DRUG$ resulted in a 24% increase in plasma concentrations of @DRUG$.	DDI-false
Cyclosporine, Digoxin, Methotrexate Lodine, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$, digoxin, @DRUG$, and increased toxicity.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
Oral @DRUG$ inhibits the gastrointestinal absorption of @DRUG$ , oral vitamin B-12, methotrexate and 5-fluorouracil.	DDI-mechanism
In patients with mild to moderate hypertension, administration of 25 mg daily of VIOXX with the @DRUG$ benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to @DRUG$ alone.	DDI-false
The similarity of the TYSABRI -associated adverse event profile between Study 1 ( without co-administered @DRUG$ Study 2 (with concomitant use of AVONEX) shows that this change in clearance does not require a reduction in clearance. @DRUG$ Dose to maintain safety, general).	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, @DRUG$, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or @DRUG$, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
@DRUG$ (e.g. spironolactone, triamterene or amilorid), @DRUG$ Supplements or salt substitutes containing potassium may lead to significant increases in serum potassium.	DDI-false
- Benzylpenicillin, ampicillin, oxacillin, @DRUG$ , @DRUG$ , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ When co-administered with saquinavir, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , @DRUG$ , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Beta-blockers ( @DRUG$ , @DRUG$ ) serum concentrations and pharmacologic effects may be increased .	DDI-false
DOSTINEX should not be administered concurrently with D2-antagonists, such as @DRUG$, butyrophenones, thioxanthines, or @DRUG$.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, @DRUG$, antiemetics, sedatives, tranquilizers).	DDI-false
In patients with chronic hepatitis C treated with PEGASYS in combination with @DRUG$, PEGASYS treatment did not affect @DRUG$ distribution or clearance.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, @DRUG$, guanethidine, and @DRUG$, the signs of hypoglycemia may be reduced or absent.	DDI-false
@DRUG$ Other antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and @DRUG$ , have been used concurrently with amiodarone .	DDI-false
@DRUG$ may also decrease the absorption of @DRUG$, which can lead to a deficiency.	DDI-mechanism
@DRUG$ : There is no significant pharmacokinetic interaction between @DRUG$ and zalcitabine which has been confirmed clinically .	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Two of 16 subjects dosed simultaneously with @DRUG$ 10 mg and @DRUG$ 0.4 mg experienced a standing systolic blood pressure below 85 mm Hg.	DDI-effect
Potential interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ (ritonavir, @DRUG$, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of @DRUG$.	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , @DRUG$ , colistine, and sodium colistimethat), @DRUG$ salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
However, patients on @DRUG$ It may lead to increases in digoxin concentrations after initiation of therapy with @DRUG$ , which may be clinically significant in patients prone to digoxin toxicity .	DDI-mechanism
Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, CYP2C9, @DRUG$, and CYP3A4.	DDI-false
@DRUG$ Population pharmacokinetic analyses show that the clearance of tiagabin is 60% greater in patients taking phenytoin with or without other enzyme-inducing @DRUG$.	DDI-false
Since @DRUG$ is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels.	DDI-false
@DRUG$ It had no effect on the plasma levels of @DRUG$.	DDI-false
astemizole, bepridil, @DRUG$, and @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ prolong and intensify the anticholinergic ( drying ) effects of @DRUG$.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Strong inducers of cytochrome P450 enzymes ( i.e. carbamazepine , phenytoin and @DRUG$ It has been shown that plasma levels of @DRUG$ ( 29 - 40 % ) .	DDI-false
@DRUG$, such as verapamil, diltiazem and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
The co-administration of medicinal products which are nephrotoxic (e. g. @DRUG$ , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , @DRUG$ Hepatotoxic (e.g. methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Patients receiving @DRUG$ and @DRUG$ concomitantly should have a dose reduction of azathioprine, to approximately 1/3 to 1/4 the usual dose.	DDI-advise
The drug interaction studies with @DRUG$ were performed both with @DRUG$ and a rapidly hydrolyzed intravenous prodrug form.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
@DRUG$ : Simvastatin ( @DRUG$ The substrate) in combination with amiodarone has been associated with myopathy/rhabdomyolysis reports.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
Cardiac effects of @DRUG$ are antagonized by @DRUG$ , such as propranolol and metoprolol .	DDI-effect
Nursing Mothers It is not known whether @DRUG$ or @DRUG$ or its components are excreted in human milk.	DDI-false
Coadministration of valdecoxib (10 mg BID for 7 days) with @DRUG$ (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of @DRUG$.	DDI-false
The pharmacokinetics of naltrexone and its major metabolite @DRUG$ After co-administration with @DRUG$, treatment was unaffected.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac @DRUG$ , diuretics , @DRUG$ , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Oral Contraceptives : @DRUG$ â€¢ ( 40 mg twice daily ) does not induce the metabolism of the combination orally @DRUG$ Norethindron/ ethinylestradiol (combination 1 mg/35 mcg, ortho-novum 1/35 ).	DDI-false
Acetaminophen/theophylline, @DRUG$/chinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
@DRUG$ @DRUG$ 1000 mg twice daily) did not affect the pharmacokinetics of R and S warfarin.	DDI-false
Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of @DRUG$ and @DRUG$, including crescentic IgA glomerulonephritis, oculo-bulbar myasthenia gravis, inflammatory arthritis, thyroiditis, bullous pemphigoid, and Stevens-Johnson syndrome.	DDI-effect
@DRUG$: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for @DRUG$.	DDI-false
Concomitant administration of other @DRUG$ may potentiate the undesirable effects of @DRUG$.	DDI-effect
Aspirin : When @DRUG$ is administered with aspirin , its protein binding is reduced , although the clearance of free @DRUG$ is not altered .	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, @DRUG$ , diuretics , @DRUG$ E. g. epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e. g. in oral contraceptives).	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of theophylline (@DRUG$ , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state @DRUG$ peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	DDI-false
Studies in rats have shown that @DRUG$ administration attenuates certain types of @DRUG$ Conditional hypertension, including ACTH hypertension.	DDI-false
INOmax has been co-administered with tolazolen, @DRUG$ , dobutamine , @DRUG$ , surfactant , and high-frequency ventilation .	DDI-false
@DRUG$ reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which @DRUG$ was administered alone.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
An alternative non-CYP3A4 substrate @DRUG$ may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, @DRUG$, and phenobarbital.	DDI-false
Concomitant administration of @DRUG$ (equivalent to 145mg TRICOR) with @DRUG$ (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	DDI-mechanism
There have been reports of QTc prolongation, with or without TdP, in patients who: @DRUG$ when fluoroquinolones , @DRUG$ , or azoles were administered concomitantly .	DDI-false
@DRUG$ and Norethindrone: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
@DRUG$ In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased by approximately 17% in subjects receiving lithium 450 mg twice daily compared to subjects receiving 200 mg twice daily. @DRUG$ alone .	DDI-false
Multivalent Cation-Containing Products : Simultaneous Application of a @DRUG$ , including ciprofloxacin, containing multivalent cationic products such as magnesium or aluminium antacids, sucralfate, VIDEX chewable/buffer tablets or paediatric powders, or products containing calcium, iron or zinc may be used to absorb: @DRUG$ , which leads to serum and urine levels significantly lower than desired.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$ , sympathomimetics, calcium channel block drugs, and @DRUG$.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( phenytoin , @DRUG$ , oral contraceptive , @DRUG$ , warfarin, probenecid) and pharmacokinetic screening in placebo-controlled clinical trials in epilepsy patients.	DDI-false
Antidepressants (tricyclic), atropine or other @DRUG$, or @DRUG$: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Coadministration with @DRUG$ (40 mg BID for 7 days) resulted in a significant increase in dextromethorphan plasma levels suggesting that, at these doses, @DRUG$ is a weak inhibitor of 2D6.	DDI-false
@DRUG$ may decrease the amount of digoxin (@DRUG$, Lanoxicaps) that gets absorbed into your body.	DDI-mechanism
@DRUG$: Patients on @DRUG$, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with fosinopril sodium.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$ , nefazodone , @DRUG$ , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Coadministration of @DRUG$ (10 mg BID for 7 days) with glyburide (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of @DRUG$.	DDI-false
Lithium : Increased serum lithium levels and symptoms @DRUG$ Toxicity has been reported in patients who are at the same time: @DRUG$ Treatment and ACE inhibitors.	DDI-false
These increases should be considered when selecting an oral @DRUG$ for a woman taking @DRUG$.	DDI-advise
Carbamazepine : @DRUG$ It is known to slow the metabolism of carbamazepine and increase its serum levels. @DRUG$ Concentrations should be determined prior to co-administration with isoniazid, signs and symptoms of carbamazepine toxicity should be closely monitored and an appropriate dose adjustment of the anticonvulsant should be performed.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, @DRUG$ GI motility agents: cisapride	DDI-false
CNS-active medicinal products ethanol : @DRUG$ 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on the equilibrium test and the response time for 1 hour after @DRUG$ administration and on the digit symbol substitution test ( DSST ) , symbol copying test , and the variability component of the divided attention test for 2.5 hours after ethanol administration .	DDI-false
The possibility of hypotensive effects with @DRUG$ , can be minimized by either @DRUG$ or increasing the salt intake prior to initiation of treatment with PRINIVIL .	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants ( hypnotics , @DRUG$ , @DRUG$ , etc ) .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (AEDs) @DRUG$ Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
Benzthiazide may interact with alcohol, @DRUG$s, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Specific studies have these effects with: @DRUG$ , @DRUG$ , propofol, alfentanil, and midazolam.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Multivitamins , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with , or within 2 hours of , the administration of @DRUG$ , because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
Chronic administration of @DRUG$, a known enzyme inducer, may be associated with a decrease in the plasma half-life of @DRUG$.	DDI-mechanism
Other CNS depressants (e.g. @DRUG$ , tranquilizers , @DRUG$ and general anesthetics ) have additive or potentiating effects with INAPSINE .	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin , @DRUG$ , sympathomimet-ics , calcium channel blocking drugs , and isoniazid .	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
@DRUG$ It had no significant effect on the Cmax and AUC of zidovudine, although it significantly reduced Zidovudintmax by 44% and the intracellular exposure to phosphorylated @DRUG$ - 110%.	DDI-mechanism
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
@DRUG$ NSAIDs-A drug interaction study of eplerenone with a @DRUG$ has not been conducted .	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with CNS depressants ( alcohol , @DRUG$ , opiates , sedatives , @DRUG$ ) should be considered .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or ACTH treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving @DRUG$.	DDI-false
The possibility of hypotensive effects can be minimized by either discontinuing the @DRUG$ or increasing salt intake prior to initiation of treatment with @DRUG$.	DDI-effect
Although studies designed to examine drug interactions have not been done , it was noted that @DRUG$ or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients ( N=180 ) receiving Betaseron .	DDI-false
Therapeutic concentrations of @DRUG$ , warfarin, ibuprofen, @DRUG$ Ketorolac Tromethamine Protein binding does not alter ketorolac, piroxicam, acetaminophen, phenytoin and tolbutamide.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, @DRUG$, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Acetaminophen, lidocaine, phenobarbital, @DRUG$, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
Monitoring the amiodarone toxicity and serial measurement of @DRUG$ Serum concentration during concomitant administration @DRUG$ Treatment should be considered.	DDI-advise
At higher than recommended doses, @DRUG$ 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving @DRUG$ 7.5 to 15 mg/week for rheumatoid arthritis.	DDI-mechanism
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Drug interactions : Flupentixol may interact with some medications such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupentixol and ethanol cause additive CNS depression - @DRUG$ Flupenthixol increases the effect of @DRUG$	DDI-false
As with other antipsychotic agents , it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics , @DRUG$ , and @DRUG$.	DDI-false
Terfenadine: Administration of terfenadine with @DRUG$ resulted in the appearance of unchanged @DRUG$ in plasma;	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, @DRUG$, tamoxifen and @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Benzthiazide can interact with alcohol, blood thinners, decongestant medications (allergic, cold, and sinus drugs), diabetics, lithium, norepinephrine, NSAIDs such as @DRUG$ or @DRUG$ , and high blood pressure medications .	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenylbutazone , phenytoin sodium , @DRUG$ , griseofulvin , @DRUG$ , and possibly with ampicillin and tetracyclines 72 .	DDI-false
Hypotension    Patients on @DRUG$ Therapeutic therapy : patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted , as well as those on severe dietary salt restriction or dialysis , may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril .	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A , compounds that are potent CYP3A inducers ( such as carbamazepine , @DRUG$ , rifampin , and barbiturates ) would be expected to decrease @DRUG$ concentrations .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , @DRUG$ , warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ , pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Standard therapy includes antibiotics, such as @DRUG$ and @DRUG$;	DDI-false
A two-way interaction between the @DRUG$ , Phenytoin, and the @DRUG$s were proposed.	DDI-int
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or @DRUG$.	DDI-false
In patients receiving @DRUG$ A reduction in the steroid dose should be done step by step and at the same time with a steroid to avoid possible complications in case of sudden ingestion. @DRUG$ withdrawal .	DDI-false
BACKGROUND : The effects of combined administration of @DRUG$ and verapamil hydrochloride ( verapamil ) , a @DRUG$ The incidence of peritoneal metastasis of intestinal adenocarcinoma induced by azoxymethane (AOM) and the index of colorectal cancers were studied in male Wistar rats.	DDI-false
In separate studies in patients receiving maintenance doses of warfarin, hydrochlorothiazide or @DRUG$ Administration of irbesartan for 7 days had no effect on pharmacodynamics of @DRUG$ ( prothrombin time ) or pharmacokinetics of digoxin .	DDI-false
This antagonistic effect of @DRUG$ on @DRUG$ Natriuresis is not due to a direct effect on sodium excretion, but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanid.	DDI-mechanism
Reports in the literature suggest that plasma levels of @DRUG$ ( and its active metabolite doxorubicinol ) may be increased when @DRUG$ The doxorubicin and the doxorubicin are used in combination.	DDI-false
The effects of ruthenium red (@DRUG$) on @DRUG$ (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
@DRUG$: @DRUG$, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of penicillins.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ and @DRUG$ may reduce or reverse the pressor effect of epinephrine .	DDI-false
Multivitamins, or other products containing iron or @DRUG$, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
A crossover study in healthy subjects that either @DRUG$ 300 mg q.i.d . or 800 mg h.s . concomitantly with a 300 mg b.i.d . dosage of theophylline ( Theo-Dur , Key Pharmaceuticals , Inc. ) demonstrated less alteration in steady-state @DRUG$ Peak serum levels with the 800 mg h.s. regimen, especially in subjects aged 54 years and older.	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when @DRUG$ It was used with Ondansetron, the concomitant use of apomorphine with medicinal products of the 5HT3 antagonist class (including, for example, @DRUG$ Granisetron is contraindicated, and is contraindicated.	DDI-false
@DRUG$ Concomitant administration of diflunisal and naproxene in normal subjects had no effect on plasma concentrations of @DRUG$ , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite .	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other @DRUG$ (hypnotics, sedatives, @DRUG$, etc).	DDI-false
Potential drug interactions between Keppra   and other AEDs ( carbamazepine , gabapentin , @DRUG$ , phenobarbital , @DRUG$ , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
@DRUG$ : NSAIDs have produced an elevation of plasma @DRUG$ The concentrations and a reduction in renal lithium clearance.	DDI-false
CANCIDAS reduced AUC0 - 12 of blood from @DRUG$ 20 %, peak blood concentration (Cmax) by 16 % and 12-hour blood concentration (C12h) by 26 % in healthy volunteers if: @DRUG$ 2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily compared to results from a control period in which tacrolimus was administered alone.	DDI-false
Simultaneous use of fenofibrate (equivalent to 145 mg) @DRUG$ ) with @DRUG$ ( 20 mg ) once daily for 10 days resulted in approximately 17 % decrease ( range from 67 % decrease to 44 % increase ) in atorvastatin AUC values in 22 healthy males .	DDI-mechanism
@DRUG$, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/@DRUG$.	DDI-false
â€¢ Dopamine antagonists : Since apomorphine is a dopamine agonist, it is possible that @DRUG$ , such as neuroleptics (phenothiazines, @DRUG$ , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , @DRUG$ , polymyxins, lincomycin, clindamycin, @DRUG$ , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , @DRUG$ , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and @DRUG$.	DDI-false
Diazepam: @DRUG$ (@DRUG$) is a CYP 3A4 and CYP 2C19 substrate.	DDI-false
Theophylline: As with some other quinolones, concurrent administration of @DRUG$ with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-mechanism
Antacids : In a clinical pharmacology study, the concomitant use of antacids (aluminium hydroxide, @DRUG$ , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ Administration alone, suggesting that antacids may affect the absorption of fosinopril.	DDI-false
However , a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d . or 800 mg h.s . concomitantly with a 300 mg b.i.d . dosage of @DRUG$ ( @DRUG$ , Key Pharmaceuticals , Inc. ) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s . regimen , particularly in subjects aged 54 years and older .	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ : Diclofenac and others @DRUG$ The activity of diuretics can inhibit.	DDI-false
Oral @DRUG$ : Valdecoxib ( 40 mg BID ) did not induce the metabolism of the combination oral contraceptive @DRUG$/ethinyl estradiol ( 1 mg /35 mcg combination , Ortho-Novum 1/35 ) .	DDI-false
- Perhexiline hydrogen maleate or MAO-inhibitors ( with hepatotoxic potential ) must not be administered together with @DRUG$ or @DRUG$.	DDI-false
@DRUG$ : Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine , and because renal excretion is the primary elimination route of fibrate drugs including @DRUG$ There is a risk that an interaction will lead to a deterioration.	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenyl-butazone , @DRUG$ , @DRUG$ and possibly with griseofulvin, ampicillin, and tetracyclines (72)	DDI-false
It differs structurally from the other HMGCoA reductase inhibitors currently available ( lovastatin, @DRUG$ , and @DRUG$ ) , leading to unique biopharmaceutical properties relative to the other agents of this class .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$ , probably due to inhibition of CYP3A: @DRUG$ , fluvoxamine , cimetidine , diltiazem , isoniazide , and some macrolide antibiotics .	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
It is not known if @DRUG$ differ in their effectiveness when used with @DRUG$.	DDI-false
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with propranolol, @DRUG$, and @DRUG$.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , @DRUG$ , and simethicon) with fosinopril reduced serum levels and urinary excretion of fosinoprilat compared to fosinopril alone, suggesting that antacids may affect the absorption of @DRUG$.	DDI-false
Elevated serum levels of cyclosporine have been reported with concomitant use of @DRUG$ with @DRUG$.	DDI-mechanism
The following are examples of substances that can reduce the blood glucose-lowering effect: @DRUG$ , niacin , danazol , @DRUG$ , sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isonazide, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-effect
Coadministration of @DRUG$ ( 40 mg BID ( day 1 ) and 40 mg QD ( days 2 - 7 ) ) with glyburide ( 10 mg glyburide BID ) resulted in 21 % increase in @DRUG$ AUC0-12 and a 16% increase in glyburide Cmax lead to a 16% decrease in glucose AUC0-24.	DDI-false
Antidepressants : In vitro data show that nefazodone inhibits the metabolism of nefazodone. @DRUG$ , which can result in an increase in plasma @DRUG$ The concentrations and prolongation of the QT interval on the ECG.	DDI-false
@DRUG$ may decrease the hemodynamic effects of @DRUG$;	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Magnesium/@DRUG$-containing antacid products: absorption of @DRUG$ is moderately reduced ( approximately 25 % ) when coadministered with magnesium/aluminum-containing antacid products .	DDI-false
Ritonavir and @DRUG$ : Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID ritonavir , the Cmax and AUC of ritonavir were reduced by approximately 20 % .	DDI-false
Injection : Lorazepam injection , like other injectable @DRUG$ , produces depression of the central nervous system when administered with @DRUG$ , phenothiazines, barbiturates, MAO inhibitors, and other antidepressants. If scopolamine is associated with injectable lorazepam, an increased incidence of sedation, hallucinations and irrational behaviour has been observed.	DDI-effect
Other medicinal products Interactions Oral contraceptives Keppra ( 500 mg twice daily ) did not affect the pharmacokinetics of an oral medicinal product. @DRUG$ containing 0.03 mg @DRUG$ and 0.15 mg levonorgestrel , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .	DDI-false
It has been reported that plasma levels of several closely related tricyclic antidepressants have been increased by concomitant administration of methylphenidate or hepatic enzyme inhibitors (e. g. @DRUG$ Fluoxetine) and decreased by concomitant administration of liver enzyme inducers (e. g., barbiturates, @DRUG$ This effect can also be expected with CMI.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
The hypoglycaemic effect of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , @DRUG$ Chloramphenicol, probenecid, coumarine, monoamine oxidase inhibitors and beta-adrenergic blockers.	DDI-effect
@DRUG$: The stimulatory effects of amphetamines may be inhibited by @DRUG$.	DDI-false
Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of carbamazepine , valproate , topiramate , or @DRUG$.	DDI-false
Other medicinal products: In small groups of patients ( 7-10/interaction study ), the concomitant use of @DRUG$ , gold , chloroquine , D-penicillamine , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
It may increase excretion of @DRUG$, lithium, and ASA and may also increase the toxicity of @DRUG$.	DDI-false
@DRUG$: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
Iodine or iodine excess may decrease the effect of @DRUG$, and an @DRUG$ deficiency can increase the effect of Carbimazole.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives @DRUG$ : rifampin Benzodiazepines midazolam , @DRUG$ GI motility agents : cisapride	DDI-false
Although studies designed to examine drug interactions have not been done , it was noted that @DRUG$ or ACTH treatment of relapses for periods of up to 28 days has been administered to patients ( N=180 ) receiving @DRUG$.	DDI-false
No Important Interactions To Date @DRUG$ There are no clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$ or itraconazole .	DDI-false
Interaction with @DRUG$ other than @DRUG$ has not been specifically studied ;	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Acidifying agents : @DRUG$ (Guanethidine, Reserpin, @DRUG$ , ascorbic acid , fruit juices , etc . ) lower absorption of amphetamines .	DDI-false
Medicines not to be administered with VIRACEPT @DRUG$ Amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ Midazolam, triazolam GI Motility agent: cisapride	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , @DRUG$ , @DRUG$ , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
Monitoring for @DRUG$ toxicity and serial measurement of amiodarone serum concentration during concomitant @DRUG$ therapy should be considered .	DDI-false
- Anticoagulants : Interaction studies in humans have shown @DRUG$ to have no effect on @DRUG$ metabolism or on plasma prothrombin activity .	DDI-false
Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	DDI-false
@DRUG$ * Amphetamines increase the analgesic effect of @DRUG$.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, @DRUG$, cimetidine, diltiazem, isoniazide, and some @DRUG$.	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
To assess the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine, and @DRUG$ ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , @DRUG$ , teniposide, and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
@DRUG$ and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of stavudine and @DRUG$ against HIV.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Antacids : In a clinical pharmacology study, the concomitant use of a @DRUG$ (aluminium hydroxide, @DRUG$ In combination with fosinopril, serum concentrations and urinary excretion of fosinoprilat were reduced compared to fosinopril alone, suggesting that antacids may affect the absorption of fosinopril.	DDI-false
In clinical studies performed with @DRUG$ Co-administration of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs ( @DRUG$ Digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Patients who start taking Diclofenac or their dose of Diclofenac or any other @DRUG$ while taking @DRUG$ , methotrexate, or cyclosporin may develop toxicity properties for these drugs.	DDI-effect
Other Drug Interactions Oral @DRUG$ Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral @DRUG$ containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
There is a significant increase in exposure to @DRUG$ when @DRUG$ is coadministered with ketoconazole (CYP3A4 inhibitor).	DDI-false
@DRUG$: Simvastatin (CYP3A4 substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: @DRUG$, haloperidol, @DRUG$, pimozide.	DDI-false
Other reported interactions with amiodarone : Fentanyl ( @DRUG$ substrate ) in combination with @DRUG$ may cause hypotension , bradycardia , and decreased cardiac output .	DDI-false
As with other @DRUG$ , it should be noted that HALDOL may be able to potentiate CNS depressants such as anesthetics, @DRUG$ And alcohol.	DDI-effect
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
â€¢ Myocardial infarction, myocardial infarction, myocardial infarction, ventricular hypokinesia and severe rhabdomyolysis appear in patients who: @DRUG$ and @DRUG$ concurrently .	DDI-effect
Cytochrome P-450 inducers , such as phenytoin , carbamazepine and @DRUG$ Induce clonazepam metabolism, resulting in a decrease of approximately 30% in plasma. @DRUG$ levels .	DDI-false
As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving @DRUG$ or @DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Therapeutic concentrations of @DRUG$, @DRUG$, ibuprofen, naproxen, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Since higher doses of @DRUG$ (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of @DRUG$ should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily.	DDI-false
The effect of the blood pressure of @DRUG$ tended to be greater in patients on @DRUG$ As in patients who did not receive any other antihypertensive therapy.	DDI-effect
There have been reports of @DRUG$-related side effects in patients on concomitant therapy with norfloxacin and @DRUG$.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without @DRUG$ (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of @DRUG$ was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
@DRUG$ or Oral @DRUG$ : Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics .	DDI-false
The effects of @DRUG$ - antagonised by methylxanthines such as @DRUG$ and theophylline .	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ and @DRUG$ Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.	DDI-false
Compounds tested in man include @DRUG$, theophylline, phenytoin, @DRUG$, aminopyrine and antipyrine.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$ : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives @DRUG$ rifampin benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, dexamethasone, @DRUG$) may result in decreased plasma levels of saquinavir.	DDI-false
This time window is different than for other oral formulations of @DRUG$ Usually given 2 hours before or 6 hours after @DRUG$.	DDI-advise
Therapeutic concentrations of digoxin , warfarin , ibuprofen , naproxen , piroxicam , @DRUG$ , @DRUG$ The binding of ketorolac-tromethamine proteins was not altered by andtolbutamide.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramides, fibrates, @DRUG$ , @DRUG$ Propoxyphene, salicylates, somatostatin analogue (e.g. octreotide), sulphonamide antibiotics.	DDI-false
@DRUG$: Coadministration of a single dose of zaleplon and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of @DRUG$, but no change in the area under the plasma concentration-time curve.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with @DRUG$ Beta-blockers and other antihypertensive agents may increase hypotension at @DRUG$.	DDI-false
Insulin or Oral Hypoglycemics: @DRUG$ may enhance the blood-sugar-reducing effect of insulin and oral @DRUG$.	DDI-effect
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like @DRUG$ or @DRUG$, and high blood pressure medications.	DDI-false
The analysis of the Budesonide concentration after ultracentrifugation indicates that there is rapid equilibrium. @DRUG$ between the @DRUG$ Phase and aqueous phase.	DDI-false
Coadministration of Itraconazole and @DRUG$ , @DRUG$ or digoxin has led to increased plasma concentrations of the latter three drugs .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Aspirin, warfarin, @DRUG$, @DRUG$	DDI-false
Dopamine antagonists : since @DRUG$ is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or @DRUG$ , may diminish the effectiveness of APOKYN .	DDI-false
@DRUG$: Coadministration of single doses of @DRUG$ 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.	DDI-false
Therefore , when @DRUG$ The dose is given to a patient receiving warfarin. @DRUG$ To prevent excessive prolongation of prothrombin time, the dose should be reduced.	DDI-false
- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	DDI-false
BACKGROUND : The effects of combined administration of @DRUG$ and verapamil hydrochloride ( verapamil ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ The label index for colorectal cancer (AOM) was examined on male Wistar rats.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, @DRUG$ , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , @DRUG$ , local anesthetics , procainamide , and quinidine .	DDI-false
Lithium : NSAIDs have generated an increase in plasma @DRUG$ Concentrations and a reduction in kidneys @DRUG$ clearance .	DDI-false
- @DRUG$ (e.g. Mexat ) use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
@DRUG$, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Multivalent Cation-Containing products: Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, sucralfate, VIDEX chewable tablets or pediatric powder or products which: @DRUG$ , @DRUG$ Zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and @DRUG$) has not been studied, increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications.	DDI-false
These drugs include the thiazides and other @DRUG$ , corticosteroids , phe-nothiazines , thyroid products , estrogens , oral contraceptives , @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
@DRUG$ potentiates the muscle relaxant effect of all muscle relaxants, most notably @DRUG$, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.	DDI-effect
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with @DRUG$ (10 mg glyburide BID) resulted in 21% increase in @DRUG$ AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with @DRUG$ Beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$ Ethanol or itraconazole.	DDI-false
HMG-CoA Reductase Inhibitors : Simvastatin ( @DRUG$ substrate ) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis .	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
In vitro data suggest that itraconazole, when compared to @DRUG$, has a less pronounced effect on the biotransformation system responsible for the metabolism of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
The risk of myopathy during treatment with medicines in this class is associated with the use of @DRUG$ , @DRUG$ , niacin ( nicotinic acid ) , erythromycin , azole antifungals .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
Antidepressants : In vitro data suggest that @DRUG$ inhibits the metabolism of @DRUG$ , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-mechanism
Injection : Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system if with @DRUG$ If scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations and irrational behaviour has been observed.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and @DRUG$.	DDI-false
Adrenergic blockers @DRUG$ are inhibited by @DRUG$.	DDI-effect
â€¢ Dopamine antagonists: Since apomorphine is a dopamine agonist, dopamine antagonists such as the neuroleptics (phenothiazine, butyrophenone, @DRUG$ @DRUG$ may decrease the effectiveness of @DRUG$.	DDI-effect
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-mechanism
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , antacids , @DRUG$ ==References====External links== @DRUG$ ) , and proton pump inhibitors ( e.g. , lansoprazole , omeprazole ) .	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including @DRUG$ And other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, probenecid, coumarine, monoamine oxidase inhibitors and beta-adrenergic blockers.	DDI-effect
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: @DRUG$ , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , @DRUG$ GI motility agents : cisapride	DDI-false
Other concomitant therapies : In clinical trials, the safety profile in patients treated with acamprosate concomitantly with anxiolytics, @DRUG$ and sedatives ( including benzodiazepines ) , or @DRUG$ It was similar in patients taking placebo with these concomitant medications as in patients receiving placebo.	DDI-false
Indinavir: Coadministration of @DRUG$ with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in @DRUG$ plasma A.C.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
@DRUG$:Reports suggest that @DRUG$ may diminish the antihypertensive effect of ACE-inhibitors.	DDI-false
@DRUG$ The steady-state trough concentrations of albendazole sulphoxide were approximately 56% higher when dexamethasone 8 mg together with each dose of @DRUG$ ( 15 mg/kg/day ) in eight neurocysticercosis patients .	DDI-false
Antifungals: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral @DRUG$ markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO @DRUG$ INTOXICATION , PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON @DRUG$ THERAPY, A BASELINE PHENYTOIN SERUM SERUM LEVEL ANDIE.	DDI-false
Simultaneous cyclophosphamide, doxorubicin, @DRUG$ , and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related , non-Hodgkin lymphoma .	DDI-false
@DRUG$ , such as @DRUG$ and isoproterenol ;	DDI-false
@DRUG$ - prior ingestion of @DRUG$ may decrease the emetic response to apomorphine in the treatment of poisoning .	DDI-false
@DRUG$ (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
@DRUG$ The amount of digoxin (lanoxin, @DRUG$ ) that gets absorbed into your body .	DDI-false
Imidazoles (e. g., @DRUG$, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without propantheline (an @DRUG$ with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
@DRUG$ There is no significant pharmacokinetic interaction between ZDV and @DRUG$ , which has been clinically confirmed.	DDI-false
Corticosteroids , Methylxanthines and @DRUG$ Concomitant treatment with xanthine derivatives, steroids or diuretics may potentiate a possible hypokalemic effect @DRUG$	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-false
@DRUG$: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of @DRUG$ including TRICOR, there is a risk that an interaction will lead to deterioration.	DDI-false
Clidinium may decrease the effect of @DRUG$, @DRUG$, and ketoconazole.	DDI-false
@DRUG$, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Ergot Derivatives: Dihydroergotamine, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
@DRUG$ Caution should be exercised when using Diflunisal at the same time as @DRUG$.	DDI-false
Other CNS depressant drugs (e.g. @DRUG$, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with @DRUG$.	DDI-effect
Apomorphine - before taking @DRUG$ may decrease the @DRUG$ Reaction to apomorphine in the treatment of poisoning.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
Monoamine Oxidase Inhibitors and @DRUG$: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or beta-adrenergic blocking agents , @DRUG$ Antihistamines or H1-blockers, @DRUG$ and phenothiazines ) might also contribute to a prolongation of the QTc interval .	DDI-false
therefore, @DRUG$ should not be administered concurrently with @DRUG$ because of the potential for serious and/or life-threatening cardiac arrhythmias.	DDI-advise
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or @DRUG$ antagonists ( e.g. , verapamil , a @DRUG$ substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
@DRUG$: While studies have not shown @DRUG$ to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs.	DDI-false
Pretreatment of megakaryocytes with extracellular @DRUG$ (50 microM) also inhibited @DRUG$-induced responses.	DDI-effect
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Digoxin, nimodipine and losartan : @DRUG$ There are no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on @DRUG$ plasma levels.	DDI-false
Therefore, interactions may occur after concomitant administration of psychotropic medicinal products (e. g. @DRUG$ , analgesics , @DRUG$ , sedatives , tranquilizers ) .	DDI-false
A clinical study of healthy male volunteers ( n=24) showed that mixing @DRUG$ with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog , but that the time to peak and the total bioavailability of @DRUG$ were not significantly affected .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and @DRUG$.	DDI-false
Antiarrhythmic agents, class I (such as @DRUG$, @DRUG$, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, warfarin, @DRUG$, Maalox, and @DRUG$.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, @DRUG$ or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , @DRUG$ , tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
@DRUG$, an anionic-binding resin, has a considerable effect in lowering the rate and extent of @DRUG$ bioavailability.	DDI-mechanism
Lithium : In a study conducted in healthy subjects , mean steady-state lithium plasma levels increased approximately 17 % in subjects receiving @DRUG$ 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving @DRUG$ alone .	DDI-false
While all the @DRUG$ ( SSRIs), e.g. fluoxetine, sertraline, paroxetine, and @DRUG$ , inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Patients already stabilized on @DRUG$ should be closely monitored for loss of symptom control with @DRUG$ coadministration .	DDI-advise
Other nephrotoxic drugs : active ingredients such as @DRUG$ , cyclosporin, and @DRUG$ may enhance the potential for drug-induced renal toxicity , and should be used concomitantly only with great caution .	DDI-false
The effects of @DRUG$ are antagonized by methylxanthines such as @DRUG$ and theophylline.	DDI-effect
Refer to the package insert for @DRUG$ preparations before use of such preparations with @DRUG$.	DDI-advise
@DRUG$ : Because atorvastatin does not affect the pharmacokinetics of @DRUG$ Interactions with other medicines metabolised via the same cytochrome isozymes are not expected.	DDI-false
Ritonavir and @DRUG$: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID @DRUG$, the Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-false
Phenytoin: @DRUG$ may delay intestinal absorption of @DRUG$;	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, @DRUG$ , tacrolimus , @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, @DRUG$, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and @DRUG$ 72.	DDI-false
Glyburide: The concomitant administration of @DRUG$ with the @DRUG$ glyburide has, on rare occasions, resulted in severe hypoglycemia.	DDI-effect
Acidifying agents : Gastrointestinal acidifying agents ( @DRUG$ , @DRUG$ , glutamic acid HCl, ascorbic acid, fruit juices, etc. ) lower absorption of amphetamines.	DDI-false
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, @DRUG$, @DRUG$, or lamotrigine.	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$ , oral contraceptives , phenytoin , nicotinic acid , @DRUG$ , calcium channel block drugs, and isoniazid.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
Selective Serotonin Reuptake Inhibitors (@DRUG$): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with enalapril or @DRUG$.	DDI-effect
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of @DRUG$ , with ketamine or innovar as @DRUG$.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, @DRUG$, and beta adrenergic blocking agents.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
@DRUG$ should be administered with caution to patients taking @DRUG$, because of the possibility of conduction disturbances.	DDI-advise
The pressor effects of catecholamines such as @DRUG$ or @DRUG$ are enhanced by Bretylium Tosylate .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Injection : @DRUG$ Injection, like other injectable benzodiazepines, produces depression of the central nervous system when with ethyl alcohol, phenothiazine, barbiturates, @DRUG$ , and other antidepressants . When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-effect
Acidifying agents: @DRUG$ (guanethidine, reserpine, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
@DRUG$ , like verapamil, @DRUG$ and nifedipine , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .	DDI-false
Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
Administration of epinephrine to patients receiving @DRUG$ or halogenated hydrocarbon general anesthetics such as @DRUG$ which sensitize the myocardium, may induce cardiac arrhythmia..	DDI-false
No information is available about the use of @DRUG$ concurrently with @DRUG$.	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , @DRUG$ , granisetron , @DRUG$ , palonosetron , and alosetron ) is contraindicated .	DDI-false
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-false
Example inhibitors include azole antifungals , @DRUG$ , clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$ , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
There have been case reports of increased steady-state levels of @DRUG$, procainamide, and phenytoin during concomitant therapy with @DRUG$.	DDI-false
Coadministration of @DRUG$ and drugs that induce CYP3A may decrease @DRUG$ plasma concentrations and reduce its therapeutic effect.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG-DRUG$.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ , @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Presumably , @DRUG$ acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the @DRUG$ Elevated prothrombin-proconvertine concentrations.	DDI-mechanism
Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of @DRUG$ Digoxin or ethinyl estradiol/ levonorgestrol oral contraceptive product in healthy volunteers.	DDI-false
@DRUG$ The simultaneous use of @DRUG$ In normal subjects, this resulted in a reduction of about one third of the plasma levels of the active sulindac sulphide metabolite.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( @DRUG$ , cefoperazone , @DRUG$ , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing @DRUG$ ( 1 micrograms/ ml ), EGF ( 10 ng/ ml ) and @DRUG$ [ 3.7 micrograms/ ml or 0.1 IU/ ml].	DDI-false
@DRUG$ should not be taken within 2 hours of @DRUG$.	DDI-advise
The effects of @DRUG$ and of @DRUG$ anesthesia on digitalis tolerance in dogs.	DDI-false
Anticoagulants including coumarin derivatives , indandione derivatives , and @DRUG$ Like non-steroidal anti-inflammatory drugs (NSAIDs) and aspirin, the risk of bleeding can be increased when administered at the same time as @DRUG$.	DDI-effect
Hormonal contraceptives, including oral, injectable, transdermal and implantable contraceptives: An interaction study has shown that concomitant use of @DRUG$ The oral hormonal contraceptives Ortho-Novum resulted in an average decrease in norethindron and @DRUG$ levels of 14 % and 31 % , respectively .	DDI-false
@DRUG$ therapy Urinary excretion of @DRUG$ is increased , and efficacy is reduced by acidifying agents used in methenamine therapy .	DDI-false
In vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that @DRUG$ It can lead to fungal resistance against amphotericin B.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
It is recommended that serum @DRUG$ levels be monitored frequently if PRINIVIL is administered concomitantly with @DRUG$.	DDI-false
Studies in rats have shown that: @DRUG$ administration attenuates certain types of adrenocortical steroid dependent hypertension , including @DRUG$ hypertension .	DDI-effect
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Therefore, when using doses of @DRUG$ greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of @DRUG$ may be required.	DDI-advise
In monkeys, @DRUG$ was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with @DRUG$.	DDI-false
@DRUG$ has been shown to be antagonistic to beta-lactam antibiotics, including @DRUG$, based on in vitro studies and time kill curves with enteric gram-negative bacilli.	DDI-effect
Some @DRUG$/substances are known to accelerate metabolism @DRUG$ by stimulating the synthesis of CYP3A4 ( enzyme induction ) .	DDI-false
Specific interaction studies have shown: @DRUG$ : During the first day of concomitant administration , trough concentrations of @DRUG$ were increased by about 30-fold .	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	DDI-false
@DRUG$: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
In general, lithium should not be co-administered with @DRUG$ Because they reduce the renal clearance of @DRUG$ and increase a high risk of lithium toxicity.	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, @DRUG$, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-advise
In addition, additional interaction studies with niacin and @DRUG$ have not demonstrated any effect on fluvastatin plasma levels , and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ Relative to the control data.	DDI-false
Other @DRUG$ ( e.g. @DRUG$ , tranquilizers , opioids and general anesthetics ) have additive or potentiating effects with INAPSINE .	DDI-false
These results suggest that both dexamethasone and @DRUG$ , and possibly other glucocorticoids and @DRUG$ Prostate epithelium proliferation can be controlled by dose-dependent changes in insulin and EGF activity.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Other medicines: In small groups of patients ( 7 - 10 / interaction study ), the concomitant administration of azathioprin, gold, chloroquine, @DRUG$ , @DRUG$ , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
Theophylline : As with some others @DRUG$ , concurrent administration of ciprofloxacin with @DRUG$ may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life .	DDI-mechanism
Cholestyramine and colestipol @DRUG$ The absorption of hydrochlorothiazide is impaired in the presence of @DRUG$.	DDI-false
Since the therapeutic range of @DRUG$ is narrow @DRUG$ serum levels should be monitored closely, and appropriate dosage adjustments of theophylline should be made.	DDI-false
@DRUG$: A single 10 mg dose of @DRUG$ did not affect the pharmacokinetics of theophylline at steady state.	DDI-false
@DRUG$ : Coadministration of almotriptan and verapamil resulted in a 24 % increase in plasma concentrations of @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Although increased plasma concentrations ( AUC 0 - 24 hrs ) of @DRUG$ Co-administration of descarboethoxyloratadine and/ or descarboethoxyloratadine @DRUG$ with each of these drugs in normal volunteers ( n = 24 in each study ) , there were no clinically relevant changes in the safety profile of loratadine , as assessed by electrocardiographic parameters , clinical laboratory tests , vital signs , and adverse events .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , @DRUG$ , @DRUG$ , warfarin, isosorbide mononitrate, knitztilol, ethanol or itraconazole.	DDI-false
@DRUG$ should not be used with @DRUG$.	DDI-advise
A similar association , though less marked , has been suggested with barbiturates , phenylbutazone , @DRUG$ , carbamazepine , griseofulvin , topiramate , and possibly with @DRUG$ and tetracyclines 72 .	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to @DRUG$ may be expected when @DRUG$ is used concomitantly with these medications.	DDI-false
Folic acid in large amounts may counteract the antiepileptic effect of phenobarbital, @DRUG$ and @DRUG$, and increase the frequency of seizures in susceptible pediatric patients.	DDI-false
Theophylline: As with some other @DRUG$, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
This drug may interact with alcohol or other CNS depressants ( may potentiate the CNS depressant effects of either these medications or @DRUG$ Anticholinergic agents, anticholinergic agents or other anticholinergic agents (anticholinergic effects may be increased if these medicines are used concomitantly with anticholinergic agents. @DRUG$ ) , and monoamine oxidase ( MAO ) inhibitors ( concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ) .	DDI-false
@DRUG$ should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, @DRUG$, or metoclopramide.	DDI-advise
@DRUG$ may decrease the amount of digoxin (Lanoxin, @DRUG$) that gets absorbed into your body.	DDI-false
In addition , several AED s that are cytochrome P450 inducers can decrease plasma concentrations of @DRUG$ and @DRUG$.	DDI-false
Vardenafil (20 mg) did not potentiate the hypotensive effects of @DRUG$ during the 4-hour observation period in healthy volunteers when administered with @DRUG$ (0.5 g/kg body weight).	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$ , @DRUG$ , haloperidol , phenothiazines , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some antihistamines .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Drugs Which Require a Dose Reduction When Coadminstered With VIRACEPT @DRUG$: @DRUG$	DDI-false
Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well, concurrent therapy with all @DRUG$, including diclofenac, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	DDI-false
Since amiodarone is a substrate for CYP3A4 , there is the potential that the use of St. John s Wort in patients receiving @DRUG$ â€¢ could lead to a reduction in unemployment. @DRUG$ levels .	DDI-false
@DRUG$: Clinical studies, as well as post-marketing observations, have shown that NSAIDs can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-false
Drugs Interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect @DRUG$ pharmacodynamics - Arecolin - eproxindine - ethanol : flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
In the first therapy, efavirenz and nevirapine were compared with triple therapy with PI indinavir for 48 weeks. @DRUG$ regimens and superiority observed with @DRUG$.	DDI-false
cimetidine ) and many that are substrates for P450 2D6 ( many other antidepressants , @DRUG$ , and the @DRUG$ ==References====External links==	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$ , fibrous acid derivatives, @DRUG$ - (nicotinic acid), erythromycin, azole antifungals.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : @DRUG$ , @DRUG$ Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
@DRUG$ Reducing renal clearance of @DRUG$ And add a high risk of lithium toxicity.	DDI-mechanism
Specific studies have confirmed these effects with @DRUG$, isoflurane, @DRUG$, alfentanil, and midazolam.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, @DRUG$, sedatives, tranquilizers).	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	DDI-false
@DRUG$ (beta-blockers) and @DRUG$ may interfere with the effect of each other when administered concurrently.	DDI-effect
Acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen and valproic acid/phenobarbital.	DDI-false
International Normalized Ratio ( INR ) elevations and/or bleeding events have been reported in some patients taking @DRUG$ while on @DRUG$ therapy .	DDI-effect
Based on the results of these studies , it is concluded that @DRUG$ may be safely coadministered with both zidovudine and @DRUG$.	DDI-false
@DRUG$/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing antacid products.	DDI-false
As Ibogain ( 40 mg/kg ) reduces 18-MC ( 40 mg/kg ) intravenous self-administration of morphine and cocaine and oral self-administration of @DRUG$ and @DRUG$ in rats ;	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
If Bezalip or Bezalip retard is used simultaneously with anion exchange resins (e.g. @DRUG$ (i) an interval of at least 2 hours between the two medicinal products should be maintained as the absorption of @DRUG$ or Bezalip retard is impaired	DDI-false
Monitoring for @DRUG$ toxicity and serial measurement of @DRUG$ serum concentration during concomitant protease inhibitor therapy should be considered.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
In addition, additional interaction studies with niacin and propranolol have no effect on @DRUG$ Plasma levels and administration to a patient population that is chronically @DRUG$ The bioavailability of digoxin compared to control data was not different.	DDI-false
Discontinuing @DRUG$ could pose a hazard to health if a potentially toxic drug that is significantly bound to the resin has been titrated to a maintenance level while the patient was taking @DRUG$.	DDI-false
In addition to this pharmacological interaction, this report describes a novel chemical reaction between @DRUG$ (a benzodiazepine) and @DRUG$ under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-mechanism
An interaction study with warfarin showed no clinically significant effect of @DRUG$ on @DRUG$ Pharmacokinetics or anticoagulant activity.	DDI-false
@DRUG$ (400 mg b.i.d.) had no effect on @DRUG$ bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , @DRUG$ , estrogens , @DRUG$ (e.g. in oral contraceptives).	DDI-false
Among the @DRUG$, many, like @DRUG$, cannot be used clinically because they are toxic;	DDI-false
In addition, fondaparinux did not affect the pharmacodynamics of @DRUG$ , @DRUG$ , piroxicam , and digoxin , nor the pharmacokinetics of digoxin at steady state .	DDI-false
Other CNS depressant drugs (e.g. barbiturates, tranquilizers, opioids and general @DRUG$) have additive or potentiating effects with @DRUG$.	DDI-effect
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein-bound, @DRUG$ , sulphonamides, chloramphenicol, probenecid, coumarine, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Therefore, when @DRUG$ and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.	DDI-advise
However , the absolute number of @DRUG$-related deaths is far greater than the number of deaths in @DRUG$ or heroin users .	DDI-false
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , antacids , H2-antagonists ( e.g. , famotidine , ranitidine ) , and @DRUG$ ( e.g. , @DRUG$ ,,,,,,,,,,,	DDI-false
ACE Inhibitors and @DRUG$ In clinical trials in patients with hypertension, the addition of INSPRA 50 to 100 mg to @DRUG$ and angiotensin II receptor antagonists increased mean serum potassium slightly ( about 0.09 - 0.13 mEq/L ) .	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, @DRUG$ and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Naproxen : The concomitant administration of diflunisal and naproxen in normal volunteers had no effect on the plasma levels of @DRUG$ , but significantly decreased the urinary excretion of @DRUG$ And his glucuronide metabolite.	DDI-false
This medicine can be used with @DRUG$ or other CNS depressants (may enhance the CNS depressive effect of either these drugs or antihistamines), anticholinergics or other anticholinergic drugs (anticholinergic effects may be intensified if these drugs are used at the same time as antihistamines), and @DRUG$ ( concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ) .	DDI-false
@DRUG$-Vitamin K can antagonize the effect of @DRUG$	DDI-false
A potential interaction between oral @DRUG$ and oral @DRUG$ leading to severe hypoglycemia has been reported.	DDI-int
Antiarrhythmia: amiodarone, bepridil, @DRUG$ , propafenone , @DRUG$ CONTRAINDICATE because of the potential for serious and/or life-threatening reactions.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-int
Azithromycin had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-false
cimetidine ) and many that are substrates for P450 2D6 ( many other antidepressants , phenothiazines , and the @DRUG$ propafenone and @DRUG$ ) .	DDI-false
The intensity, uniformity and time course of the anticoagulant interference by phenobarbital, secobarbital, @DRUG$ , @DRUG$ In 16 patients receiving coumarin therapy, methaqualone and methaqualone were systematically studied.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
In vitro binding studies with human serum proteins indicate that: @DRUG$ It binds differently than tolbutamide and does not interact with @DRUG$ or dicumarol .	DDI-false
Following the administration of @DRUG$, the dose of other @DRUG$ should be reduced.	DDI-advise
Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and @DRUG$ is not recommended.	DDI-false
@DRUG$/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Drugs Interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : @DRUG$ Increases the effect of tricyclic antidepressants	DDI-false
Antihypertensives : @DRUG$ Caution should be exercised in patients receiving receptor-blocking agents (e. g. @DRUG$ , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Imipramine (5 mg/kg), @DRUG$ (30 mg/kg), clonazepam (0.25 mg/kg), @DRUG$ (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.	DDI-false
Antidepressants, tricyclic @DRUG$ may enhance the activity of tricyclic antidepressants or @DRUG$;	DDI-effect
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (nicotinic acid), @DRUG$, @DRUG$.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Cimetidine) and many substrates for P450 2D6 (many other antidepressants, @DRUG$ , and the type 1C antiarrhythmics propafenone and @DRUG$ ) .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Benzthiazide can interact with alcohol, @DRUG$s, @DRUG$ ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications .	DDI-false
Co-medications that induce CYP3A4 (e.g., @DRUG$, @DRUG$, carbamazepine, rifampin, phenobarbital or St.	DDI-false
@DRUG$: Valdecoxib 40 mg BID for 7 days produced significant decreases in @DRUG$ serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.	DDI-false
Slow-channel calcium blockers , such as @DRUG$ , diltiazem and @DRUG$ , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .	DDI-false
Chloral hydrate and @DRUG$ interact pharmacologically with orally administered @DRUG$, but the effect is not clinically significant.	DDI-int
@DRUG$/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.	DDI-false
Micro-dosed Progesterone Preparations: Micro-dosed progesterone preparations (minipills that do not contain an @DRUG$) may be an inadequate method of contraception during @DRUG$ therapy.	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine , Innovar Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with @DRUG$ Or Innovar as with Pentobarbital.	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and @DRUG$.	DDI-false
Additionally , @DRUG$ did not alter the pharmacokinetics of Sonata , reflecting the absence of a role of CYP2D6 in @DRUG$ s metabolism .	DDI-false
@DRUG$ , including norfloxacin , may enhance the effects of oral anticoagulants , including @DRUG$ or its derivatives or similar agents .	DDI-effect
Central nervous system depressants : Co-administration of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), generally @DRUG$ , @DRUG$ , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : @DRUG$ , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , @DRUG$ , terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
2 out of 16 subjects at the same time with @DRUG$ 10 mg and @DRUG$ 0.4 mg had standing systolic blood pressure below 85 mm Hg.	DDI-effect
If it is necessary to continue the @DRUG$ , initiate therapy with @DRUG$ At a dose of 5 mg daily, and ensure close medical monitoring after the initial dose until the blood pressure has stabilized.	DDI-advise
Influence of @DRUG$ On @DRUG$ Concentration (Mean change, 90% Confidence Interval)	DDI-false
Antiarrhythmic agents, class I (such as flecainide, lidocaine, or @DRUG$ ): co-administration with @DRUG$ may have a proarrhythmic effect .	DDI-false
Other Agents: PRINIVIL has been used concomitantly with @DRUG$ and/or @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetic agents, @DRUG$ , disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$ , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
@DRUG$: @DRUG$ decreases lithium renal clearance and increases lithium plasma levels.	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, @DRUG$ , erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$ , and verapamil .	DDI-false
@DRUG$: In vitro data indicate that @DRUG$ inhibits the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
@DRUG$: Because atorvastatin does not affect the pharmacokinetics of @DRUG$, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	DDI-false
However, the concomitant use of @DRUG$ and @DRUG$ (5-7.5 mg initial oral dose followed by 2.5-6 mg/day orally for 6-10 days) results in prolongation of the prothrombin time (PT) and International Normalized Ratio (INR).	DDI-effect
Anticoagulants : While studies have not shown @DRUG$ to interact with @DRUG$ However, caution should be exercised as interactions with other NSAIDs have been observed.	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat.	DDI-effect
Antipyrine: Because @DRUG$ does not affect the pharmacokinetics of antipyrine, interactions with other @DRUG$ metabolized via the same cytochrome isozymes are not expected.	DDI-false
@DRUG$ Not co-administered with D2 antagonists such as phenothiazines, butyrophenones, @DRUG$ , or methoclopramid.	DDI-advise
Based on known metabolic profiles, clinically significant drug interactions between VIRACEPT and Dapson are not expected. @DRUG$/@DRUG$ , clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
Consequently, @DRUG$ should be avoided in patients receiving ketoconazole and @DRUG$, which are very potent inhibitors of CYP3A.	DDI-advise
Erythromycin Co-administration of felodipine ( @DRUG$ ) with @DRUG$ The result was an approximately 2.5-fold increase in AUC and Cmax and an approximately 2-fold increase in the half-life of felodipine.	DDI-false
The ECG changes and/or hypokalaemia that may result from the administration of non-kalium-sparing diuretics (e.g. loop or thiazide diuretics) may be caused by: @DRUG$ , especially when the recommended dose of the @DRUG$ is exceeded .	DDI-false
" Medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, @DRUG$ , cisplatin, dapsone, disulfiram, @DRUG$ , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
acetaminophen/theophylline , lidocaine/@DRUG$ , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , @DRUG$/acetaminophen , and valproic acid/phenobarbital .	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: @DRUG$ , NSAIDs, corticosteroids, TNF blockers, azathioprin, chloroquine, @DRUG$ , hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
No pharmacokinetic interactions between dexmedetomidine and @DRUG$, propofol, @DRUG$, and midazolam have been demonstrated.	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, CYP2C9, @DRUG$, and CYP3A4.	DDI-false
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION , PRIOR TO ADMINISTERING @DRUG$ TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE @DRUG$ ....................................................................................................................................................................................................................................................................	DDI-false
The medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, @DRUG$ , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , @DRUG$ , isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Warfarin : @DRUG$ The effects of oral anticoagulant have been reported to be increased. @DRUG$ or its derivatives .	DDI-effect
@DRUG$ : Co- administration of @DRUG$ Compared to the concomitant use of warfarin and placebo, the administration of cerivastatin in healthy volunteers did not lead to changes in prothrombin time or coagulation factor VII.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ : Coadministration of saquinavir ( using an experimental soft-gelatin capsule formulation of saquinavir 1200 mg ) with VIRACEPT resulted in an 18 % increase in nelfinavir plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
Magnesium/@DRUG$-containing Antacid Products : Absorption of zalcitabine is moderately reduced ( approximately 25 % ) when coadministered with @DRUG$/aluminum-containing antacid products .	DDI-false
Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the @DRUG$ should be made.	DDI-false
Co-administration : Concomitant use of @DRUG$ Thrombolytics, thrombolytics and others @DRUG$ may increase the risk of bleeding .	DDI-effect
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ : Other antiarrhythmic drugs , such as quinidine , procainamide , disopyramide , and phenytoin , have been used concurrently with @DRUG$.	DDI-false
In addition, several AED s that are cytochrome P450 inducers can decrease plasma concentrations of @DRUG$ and @DRUG$.	DDI-false
While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , citalopram , @DRUG$ , fluoxetine , @DRUG$ , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
Drug Interactions : @DRUG$ MAOI could theoretically influence flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Concomitant cyclophosphamide, doxorubicin, vincristine, and @DRUG$ chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal .	DDI-false
Magnesium/@DRUG$-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ (such as loop or @DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , @DRUG$ , oral contraceptives , phenytoin , @DRUG$ , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Nonsteroidal Anti-Inflammatory Drugs: The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
These drugs include the thiazides and other diuretics , @DRUG$ , phenothiazines, thyroid products, @DRUG$ , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
@DRUG$ Other antiarrhythmic drugs, such as quinidine, @DRUG$ , disopyramide , and phenytoin , have been used concurrently with amiodarone .	DDI-false
This drug may interact with alcohol or other CNS depressants ( may potentiate the CNS depressant effects of either these medications or @DRUG$ Anticholinergic agents, anticholinergic agents or other medicines with anticholinergic activity (anticholinergic effects can be intensified if these drugs are used simultaneously with antihistamines), and @DRUG$ Concomitant use of antihistamines may prolong and increase the anticholinergic and CNS depressive effects of antihistamines.	DDI-false
acetaminophen/theophylline , lidocaine/@DRUG$ , phenobarbital/acetaminophen , phenobarbital/@DRUG$ , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
In two clinical studies, @DRUG$ (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of @DRUG$ by approximately 35%.	DDI-mechanism
Other Drug Interactions : No pharmacokinetic interactions were observed between @DRUG$ And the following medications: glyburide, warfarin, digoxin, @DRUG$ ==References====External links==	DDI-false
Although these results do not indicate a significant interaction between TORADOL and TORADOL. @DRUG$ ed or heparin, administration of TORADOL in patients who: @DRUG$ Patients should be closely monitored.	DDI-false
Oral @DRUG$: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive @DRUG$/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
Magnesium/Aluminium containing antacid products : The absorption of zalcitabine is moderately reduced (about 25%) when co-administered with Magnesium/@DRUG$ containing @DRUG$.	DDI-false
@DRUG$ containing magnesium trisilicate, when administered concomitantly with @DRUG$, reduce both the rate and extent of absorption.	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Digoxin : Digoxin concentrations are increased by about 15% if: @DRUG$ and @DRUG$ The medicine is given at the same time.	DDI-mechanism
These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines , @DRUG$ , estrogens , oral contraceptives , @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$ , doxorubicin , @DRUG$ , and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
@DRUG$: Quinolones have been reported to enhance the effects of the oral anticoagulant @DRUG$ or its derivatives.	DDI-false
@DRUG$- and/or aluminum-containing @DRUG$ , products containing ferrous sulfate ( iron ) , multivitamin preparations containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , @DRUG$ , @DRUG$ , phenothiazines , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some antihistamines .	DDI-false
Note: Dissolution of aerosol particles @DRUG$ in Survanta , a model @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
Other cardiovascular agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , calcium-blocking agents , hydralazine , prazosin and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Aspirin: Concomitant administration of aspirin with @DRUG$ may result in an increased risk of GI ulceration and complications compared to @DRUG$ alone.	DDI-false
The administration of local @DRUG$ containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive @DRUG$/@DRUG$ (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$ , beta-blockers , felodipine , @DRUG$ , warfarin , isosorbide mononitrate , carvedilol , ethanol or itraconazole .	DDI-false
Since @DRUG$ are potentiated by the @DRUG$ , they should be used cautiously in the treatment of convulsions .	DDI-advise
Since amiodarone is a substrate for CYP3A4, there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced @DRUG$ levels.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the antituberculosis drug @DRUG$.	DDI-effect
- @DRUG$ : Interaction studies in humans have shown bumetanide to have no effect on @DRUG$ Metabolism or plasma prothrombin activity.	DDI-false
Monoamine Oxidase Inhibitors: Coadministration of @DRUG$ resulted in a 27% decrease in @DRUG$ clearance and an increase in Cmax of approximately 6%.	DDI-mechanism
Other CNS depressants (e.g. barbiturates, @DRUG$ , opioids and general anesthetics ) have additive or potentiating effects with @DRUG$.	DDI-effect
- medicines associated with peripheral neuropathy include: @DRUG$ , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , @DRUG$ , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ , @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ decreased the hyperuricemic effect of @DRUG$.	DDI-effect
Antihypertensive agents: amiodarone should be used with caution in patients who are receptor blockers (e.g. propranolol, CYP3A4 inhibitor) or calcium channel antagonists (e.g. @DRUG$ , a CYP3A4 substrate , and diltiazem , a @DRUG$ Inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Other Drug Interactions Oral Contraceptives @DRUG$ 500 mg twice daily) affected the pharmacokinetics of an oral @DRUG$ Includes 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel or luteinising hormone and progesterone levels, indicating that impairment of antibetic efficacy is unlikely.	DDI-false
@DRUG$ may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, @DRUG$ , doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$ , protease inhibitors, quinidine, and verapamil.	DDI-false
Close observation of the patient is recommended when a @DRUG$ is administered to patients receiving catecholamine-depleting drugs such as @DRUG$, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may produce vertigo, syncope or postural hypotension.	DDI-advise
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Therefore, patients on @DRUG$ should be observed when @DRUG$ Tablets are either added or deleted from a therapeutic regimen.	DDI-advise
A drug-drug interaction study with @DRUG$ In healthy volunteers there was a decrease of 30% in @DRUG$ trough concentrations .	DDI-mechanism
- The action of @DRUG$ and insulin may be enhanced by Bezalip or @DRUG$.	DDI-effect
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , @DRUG$/@DRUG$ , and valproic acid/phenobarbital.	DDI-false
Hypotension : patients receiving diuretic therapy: patients on diuretics and especially those in which diuretic therapy has been recently initiated may occasionally experience an excessive reduction in blood pressure after initiation of therapy with @DRUG$ or @DRUG$.	DDI-false
Concomitant administration of @DRUG$ â€¢ ( corresponding to 145 mg TRICOR ) with atorvastatin ( 20 mg ) once daily for 10 days resulted in approximately 17% decrease (from 67% decline to 44% increase ) in @DRUG$ AUC values in 22 healthy men.	DDI-false
@DRUG$ : Vardenafil 20 mg , when co-administered with slow-release @DRUG$ 30 mg or 60 mg once daily , did not affect the relative bioavailability ( AUC ) or maximum concentration ( Cmax ) of nifedipine , a drug that is metabolized via CYP3A4 .	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
This appears to be the only clinically relevant interaction of this species with mefloquines, although theoretically, co-administration of other drugs known to alter the heart conduction (e.g., anti-arrhythmic or beta-adrenergic blockers, calcium channel blockers, @DRUG$ or H1-blocking agents , @DRUG$ ) could also contribute to an extension of the QTc interval.	DDI-false
The absorption of oral gemifloxacin is significantly reduced by the concomitant administration of an antacid containing @DRUG$ and @DRUG$.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - @DRUG$ : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , doxycycline , @DRUG$ , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , @DRUG$ ==References====External links==	DDI-false
Although these results do not indicate a significant interaction between TORADOL and TORADOL. @DRUG$ - or heparin, the administration of @DRUG$ In patients taking anticoagulants, caution should be exercised and patients should be closely monitored.	DDI-false
â€¢ Dopamine antagonists : Since apomorphine is a dopamine agonist, it is possible that @DRUG$ , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of @DRUG$.	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
There have been greater than 2-fold increases in previously stable plasma levels of other @DRUG$, including @DRUG$, when fluoxetine hydrochloride has been administered in combination with these agents.	DDI-false
Drugs Which Require a Dose Reduction When Coadminstered With @DRUG$ Antimycobacterial agents: @DRUG$	DDI-advise
Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 @DRUG$: @DRUG$ inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for zaleplon metabolism.	DDI-false
@DRUG$ : In healthy individuals , plasma concentrations of atorvastatin increased approximately 40 % with coadministration of @DRUG$ and erythromycin , a known inhibitor of cytochrome P450 3A4 .	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between VIRACEPT and dapsone , @DRUG$/sulfamethoxazole , clarithromycin , erythromycin , @DRUG$ or fluconazole .	DDI-false
Reciprocal interactions may occur with concomitant use of antizole and medicinal products that potentiate or inhibit the cytochrome P450 system (e.g. @DRUG$ , carbamazepine , @DRUG$ , ketoconazole ) , though this has not been studied	DDI-false
Even so @DRUG$ plasma concentrations in the presence of high doses of @DRUG$ were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary.	DDI-mechanism
In clinical trials , FLOLAN was used with digoxin , @DRUG$ In a pharmacokinetic sub-study in patients with congestive heart failure receiving furosemide or digoxin starting treatment with FLOLAN, apparent values for oral clearance of furosemide (n = 23) and @DRUG$ N = 30) had decreased by 13% and 15% respectively on the second day of therapy and had returned to baseline levels by day 87.	DDI-false
@DRUG$: The addition of tiagabine to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Phenothiazines - Taking @DRUG$ and a @DRUG$ together may increase the risk of convulsions ( seizures ) .	DDI-effect
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Drugs that have been associated with peripheral neuropathy include @DRUG$ , chloramphenicol , cisplatin , dapsone , disulfiram , @DRUG$ , glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: orally @DRUG$ , ACE inhibitors , @DRUG$ , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Colestipol : plasma concentrations of @DRUG$ About 25% declined if: @DRUG$ Atorvastatin and atorvastatin were co-administered.	DDI-false
Coadministration of @DRUG$ with 40 mg SULAR tablets in epileptic patients lowered the @DRUG$ plasma concentrations to undetectable levels.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ ( eg , tubocurarine ) and other drugs , including ether , succinylcholine , gallamine , decamethonium and sodium citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral .	DDI-effect
Suppression by @DRUG$ By @DRUG$-enhanced peritoneal metastases of intestinal adenocarcinoma induced by azoxymethane in Wistar rats.	DDI-effect
In the same study it was shown that @DRUG$ and stavudine had no significant effect on the intracellular phosphorylation of @DRUG$ in peripheral blood mononuclear cells.	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs ( e.g. , triazolo-@DRUG$ , dihydropyridine calcium channel blockers , certain @DRUG$ , etc . ) .	DDI-false
Imidazoles ( e. g. , ketoconazole , miconazole , @DRUG$ , @DRUG$ In vitro and animal studies with the combination of amphotericin B and imidazoles indicate that imidazoles may cause fungal resistance to amphotericin B.	DDI-false
magnesium and/or aluminium antacids, iron sulphate products, @DRUG$ Zinc or other metal cations, or Videx (didanosine) chewable tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
The availability of potent non-nucleoside reverse transcriptase inhibitors (@DRUG$)-based therapies for @DRUG$ Treatment and concerns about metabolic disorders associated with protease inhibitors (PI) have led to significant shifts in treatment practices in HIV infection.	DDI-false
Antifungals: In vitro and/or in vivo data indicate that @DRUG$, itraconazole, and oral @DRUG$ markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
The data from in vitro studies with benzodiazepines other than alprazolam indicate a possible interaction with the following medicinal products: ergotamine, @DRUG$ , @DRUG$ , nicardipine , and nifedipine .	DDI-false
@DRUG$ and Tricyclic Antidepressants : FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ On the cardiovascular system can be potentiated by these active substances.	DDI-false
Colestipol-Concomitant intake of @DRUG$ and @DRUG$ The absorption of vitamin K can be reduced.	DDI-mechanism
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING @DRUG$ TO A PATIENT ON @DRUG$ THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.	DDI-effect
@DRUG$ - ammonium chloride, @DRUG$ , etc . ) increase the concentration of the ionized species of the amphetamine molecule , thereby increasing urinary excretion .	DDI-false
The concomitant use of @DRUG$ or other @DRUG$ It can have an additive effect.	DDI-false
The effects of ruthenium red ( @DRUG$ ) on inositol 1,4,5-trisphosphate (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry .	DDI-false
@DRUG$ A small decrease in diflunisal levels was observed in normal subjects when multiple doses of @DRUG$ and aspirin were administered concomitantly .	DDI-false
As with other @DRUG$ "It should be pointed out that HALDOL will be able to potentiate @DRUG$ such as anesthetics , opiates , and alcohol .	DDI-effect
To avoid @DRUG$ Anaesthesia, corresponding adjustment of the @DRUG$ should be made .	DDI-false
@DRUG$ The plasma concentrations of cerivastatin were not affected by the concomitant use of @DRUG$.	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., amitriptyline, @DRUG$, and @DRUG$).	DDI-false
@DRUG$ and procainamide doses should be reduced by one-third when either is administered with @DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-effect
The management of the local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ For this reason, severe, prolonged hypertension can arise.	DDI-false
Lithium : @DRUG$ â€¢ have caused an increase in plasma @DRUG$ levels and a reduction in renal lithium clearance .	DDI-mechanism
Dose adjustment is not recommended. Levetiracetam had no effect on plasma concentrations of @DRUG$ , @DRUG$ , topiramate, or lamotrigine.	DDI-false
@DRUG$ Co-administration of rifabutin and VIRACEPT resulted in a 32% decrease in nelfinavir plasma AUC and a 20% increase. @DRUG$ plasma A.C.	DDI-false
Coingestion of acetaminophen with theophylline, phenobarbital with @DRUG$, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants , @DRUG$ , alcohol , barbiturates , monoamine oxidase inhibitors , @DRUG$ , Phenothiazine, psychotropic drugs, or other drugs that produce CNS depression.	DDI-false
Antiarrhythmics: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and @DRUG$, have been used concurrently with amiodarone.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , @DRUG$ , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving @DRUG$ therapy .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , @DRUG$ , tetracyclines, bacitracin, @DRUG$ , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, @DRUG$ , erythromycin, imatinib, isoniazid, @DRUG$ , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and @DRUG$ ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or @DRUG$) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations.	DDI-mechanism
astemizole, @DRUG$, @DRUG$, and terodiline.	DDI-false
Central nervous system depressants : Concomitant use of DURAGESIC (Fentanyl transdermal system ) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, sedatives (e.g., @DRUG$ ) , general @DRUG$ , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
HMG-CoA Reductase Inhibitors: @DRUG$ (CYP3A4 substrate) in combination with @DRUG$ has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
@DRUG$ : Atorvastatin plasma concentrations and LDL-C reduction were not altered by coadministration of @DRUG$.	DDI-false
However, @DRUG$ stimulated, but did not significantly inhibit, proliferation in the presence of @DRUG$.	DDI-effect
Acetaminophen, @DRUG$, @DRUG$, quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Other potent inhibitors of CYP3A4 (e.g. itraconazole, clarithromycin, @DRUG$ , troleandomycin , @DRUG$ , nelfinavir ) would be expected to behave similarly .	DDI-false
Concomitant @DRUG$ , doxorubicin, vincristine, and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related , non-Hodgkin lymphoma .	DDI-false
@DRUG$: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing @DRUG$ therapy in patients receiving warfarin or similar agents, since these patients are at an increased risk of bleeding complications.	DDI-false
@DRUG$ (@DRUG$), atropine or other anticholinergic agents, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Other CONCOMITANT THERAPY: Although specific interaction studies have not been performed, in clinical studies cerivastatin sodium was used together with angiotensin converting enzyme ( ACE) inhibitors, beta-blockers, @DRUG$ , @DRUG$ , and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ may also decrease the absorption of @DRUG$ That can lead to a deficiency.	DDI-mechanism
- Methotrexate ( e.g. , Mexate ) Use of @DRUG$ Sulfapyridine may increase the likelihood of side effects affecting the liver and/ or side effects of sulfapyridine. @DRUG$	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (@DRUG$, sedatives, @DRUG$, etc).	DDI-false
A inhibition of coagulation inhibition was observed during the use of @DRUG$ , secobarbital and @DRUG$ ;	DDI-false
Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of @DRUG$.	DDI-false
As the primary effect of @DRUG$ is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of @DRUG$.	DDI-effect
Clinical interaction studies with cimetidine and @DRUG$ indicated that the coadministration of @DRUG$ with these drugs does not result in clinically- significant drug interactions.	DDI-false
However, the pharmacodynamics of coadministration of @DRUG$ and @DRUG$ have not been evaluated.	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other @DRUG$ ( hypnotics , sedatives , @DRUG$ ..............................................................................................................................................................................................................................................................................................................................................................................	DDI-false
Additionally, @DRUG$ did not alter the pharmacokinetics of @DRUG$, reflecting the absence of a role of CYP2D6 in zaleplon s metabolism.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Before using this medication, tell your doctor or pharmacist about all prescription and non-prescription products you can use, especially from: @DRUG$ ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , non-steroidal anti-inflammatory drugs ( e.g. , @DRUG$ ==References====External links==	DDI-false
Other strong inhibitors of CYP3A4 ( e.g. , itraconazole , clarithromycin , nefazodone , @DRUG$ , ritonavir , @DRUG$ ) would be expected to behave similarly .	DDI-false
@DRUG$ : @DRUG$ is a CYP 2C9 substrate .	DDI-false
Potential interactions between @DRUG$, a substrate of CYP3A4, and protease inhibitors (@DRUG$, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Intravenous @DRUG$ : Treatment with @DRUG$ It should be interrupted if the use of a drug that has the potential to cause pancreatitis is required.	DDI-false
@DRUG$ and indinavir: Upon concomitant administration of 5 mg of @DRUG$ with 600 mg BID ritonavir, the Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as quinidine and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, valproate, oral @DRUG$, digoxin, @DRUG$, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Oral Contraceptives : @DRUG$ ( 40 mg BID ) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol ( 1 mg /35 mcg combination , @DRUG$ 1/35 ) .	DDI-false
Other nephrotoxic medications: agents such as aminoglycosides, @DRUG$, and @DRUG$ may enhance the potential for drug-induced renal toxicity, and should be used concomitantly only with great caution.	DDI-false
Warfarin : The effect of celecoxib on the anti-coagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of 2 - 5 mg of @DRUG$.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Nephrotoxic agents: Concomitant use of @DRUG$ [e.g. intravenous aminoglycosides (e.g. tobramycin, gentamicin and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin and @DRUG$ ] is contraindicated.	DDI-advise
Naproxen: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of @DRUG$, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
Other cardiovascular agents : enalapril and @DRUG$ IV were co-administered with beta-adrenergic blockers, methyldopa, nitrates, calcium blockers, @DRUG$ , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
Oral Anticoagulants : Pharmacokinetic Drug-Active Interactions between @DRUG$ and @DRUG$ 7.5 mg oral single dose) has not been established.	DDI-false
@DRUG$ should not be administered concurrently with D2-antagonists , such as phenothiazines , butyrophenones , thioxanthines , or @DRUG$.	DDI-advise
Bacteriostatic Antibiotics: @DRUG$, erythromycins, @DRUG$, or tetracyclines may interfere with the bactericidal effect of penicillins.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, @DRUG$, @DRUG$, sedatives, tranquilizers).	DDI-false
Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Beta-blockers, clonidine, lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
@DRUG$ and @DRUG$ should not beadministered concomitantly becausedecreases in nevirapine plasmaconcentrations may reduce the efficacy ofthe drug.	DDI-advise
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole (@DRUG$/SMX).	DDI-false
When other antiplatelet agents or @DRUG$ are used concomitantly, there is the potential for @DRUG$ to increase the risk of bleeding.	DDI-effect
Cimetidine (400 mg b.i.d.) did not affect @DRUG$ bioavailability ( AUC ) and maximum concentration ( Cmax ) of vardenafil when co-administered with 20 mg @DRUG$ For healthy volunteers.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, D-penicillamine, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
Concomitant cyclophosphamide , doxorubicin , @DRUG$ , and prednisone chemotherapy plus @DRUG$ Treatment in patients with human immunodeficiency virus-associated non-Hodgkin lymphoma.	DDI-false
Antiacid , clarithromycin , @DRUG$ , fluconazole, fluoxetine, indanavir, ketoconazole, phenytoin, phenobarbitol, @DRUG$ , rifabutin, rifampin, ritanovir, saquinavir.	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
@DRUG$ may interfere with the anti-glaucoma action of @DRUG$ or pilocarpine ;	DDI-effect
The concentrations of @DRUG$ , the active metabolite of irinotecan , were on average 33 % higher in patients receiving bolus-IFL in combination with @DRUG$ when compared with bolus-IFL alone .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Acetaminophen: Pharmacokinetic or pharmacodynamic drug-effect interactions between argatroban and concomitant use of argatroban have not been established. @DRUG$ ( 162.5 mg orally administered 26 and 2 hours before starting argatroban 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after starting argatroban). @DRUG$ 1.5   g/kg/min . over 18 hours ) .	DDI-false
We report the case of an adolescent with altered consciousness caused by @DRUG$ overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for @DRUG$.	DDI-false
The effects of mixing @DRUG$ with @DRUG$ of animal source or insulin preparations produced by other manufacturers have not been studied .	DDI-false
Other drug interactions Cimetidine, @DRUG$ and dextropropoxyphene had no effect on the pharmacokinetics of @DRUG$.	DDI-false
Diphenhydramine hydrochloride has additive effects with @DRUG$ and other CNS depressants ( hypnotics , sedatives , @DRUG$ , etc ) .	DDI-false
Drug Interactions : Flupentixol may interact with some medications such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupentixol and ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ â€¢ increases the effect of @DRUG$	DDI-effect
@DRUG$ In some patients with renal impairment, @DRUG$ , the co-administration of lisinopril may result in a further deterioration of renal function .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , @DRUG$ , and @DRUG$ Amphotericin B, foscarnet, intravenous pentamidine, vancomycin and nonsteroidal anti-inflammatory agents] is contraindicated.	DDI-false
The aim of this paper was to establish the interaction between @DRUG$ and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide , or tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Tricyclic antidepressants have been reported to blunt the hypotensive effect of systemic @DRUG$.It is not known whether the concurrent use of these agents with @DRUG$ in humans can lead to resulting interference with the IOP lowering effect.	DDI-false
@DRUG$ and its active metabolite , norfluoxe-tine , have long half-lives ( 4 to 16 days for @DRUG$ ) , that may affect strategies during conversion from one drug to the other .	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , @DRUG$ Amphotericin B, cyclosporin, nonsteroidal anti-inflammatory drugs (e.g. ibuprofen), tacrolimus, @DRUG$.	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Plasma @DRUG$ concentration should be monitored when isoniazid and @DRUG$ are co administered, and appropriate dosage adjustments of valproate should be made.	DDI-false
In pigeons, naloxone did not systematically change the effects of @DRUG$ , @DRUG$ or PCP .	DDI-false
The co-administration of Natrecor with IV @DRUG$ such as nitroglycerin, @DRUG$, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
INOmax has been administered with tolazoline , dopamine , dobutamine , @DRUG$ , @DRUG$ , and high-frequency ventilation .	DDI-false
The authors investigated the possibility of a similar interaction between @DRUG$ and @DRUG$.	DDI-false
@DRUG$ : Increased activity of both cyclosporine and @DRUG$ It may happen that the two are used at the same time.	DDI-false
Benzthiazide can be used with @DRUG$ , blood thinners , @DRUG$ "(allergic, cold, and sinus drugs), diabetics, lithium, norepinephrine, NSAIDs such as Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Therefore, it would be expected that a dosing schedule of @DRUG$ given at bedtime and cholestyramine given before the evening meal would not result in a significant decrease in the clinical effect of @DRUG$.	DDI-false
@DRUG$, @DRUG$, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
Multivitamins, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including sodium nitroprusside and @DRUG$, may have an additive effect with @DRUG$ on the risk of developing methemoglobinemia.	DDI-effect
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics, @DRUG$, and @DRUG$.	DDI-false
Therapeutic concentrations of @DRUG$ , warfarin , ibuprofen , naproxen , piroxicam , @DRUG$ , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
@DRUG$ : Coadministration of rifampin and @DRUG$ This resulted in an 82% decrease in nelfinavir plasma A.C.	DDI-false
It can be used with thyroid medications (e.g. levothyroxin), @DRUG$-containing products, antacids, H2 antagonists (e.g. famotidine, @DRUG$ , and proton pump inhibitors (e. g. lansoprazole, omeprazole).	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-false
In clinical studies with @DRUG$ ( @DRUG$ 1 mg) in men aged 18 to 41 years, the mean value of the prostata specific antigen in serum (PSA) decreased from 0.7 ng/ml at baseline to 0.5 ng/ml at month 12.	DDI-false
Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either @DRUG$ or @DRUG$ when the two agents were administered together.	DDI-false
This antagonistic effect of probenecid on @DRUG$ natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of @DRUG$.	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (@DRUG$, @DRUG$, tranquilizers, etc).	DDI-false
Valproate : The addition of @DRUG$ This did not affect the pharmacokinetics of tiagabin in patients taking valproate chronically, but valproate decreased significantly. @DRUG$ binding in vitro from 96.3 to 94.8 % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists ( Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS , 3020 ( 91 % ) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ ( @DRUG$/ARB ) .	DDI-false
Cardiac Glycosides: In a study of young healthy male subjects no evidence of a direct pharmacokinetic @DRUG$-@DRUG$ interaction could be found.	DDI-false
Diuretics: Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$ or @DRUG$.	DDI-false
In a study in which patients with active RA were treated with concomitant treatment for up to 24 weeks @DRUG$ and @DRUG$ therapy , a 7 % rate of serious infections was observed , which was higher than that observed with etanercept alone ( 0 % ) .	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
@DRUG$ with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain ;	DDI-mechanism
Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : @DRUG$: Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy.	DDI-false
Metformin: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma @DRUG$ mean cmax and AUC increased by an average of 34% and 24%, respectively, and @DRUG$ mean renal clearance decreased by 14%.	DDI-false
The co-administration of Natrecor with IV @DRUG$ Such as nitroglycerin, nitroprusside, milrinone or IV ACE inhibitors have not been studied (these medicinal products have not been co-administered with @DRUG$ From clinical trials).	DDI-false
Alkalinizing agents: Gastrointestinal alkalinizing agents (@DRUG$, etc.) increase absorption of @DRUG$.	DDI-mechanism
@DRUG$, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
Ingestion of @DRUG$ may increase serum concentrations of digoxin and @DRUG$ and increase cyclosporine s nephrotoxicity.	DDI-mechanism
Severe hypoglycemia has been reported in patients concomitantly receiving @DRUG$ and oral @DRUG$.	DDI-effect
In clinical trials with: @DRUG$ , the concomitant use of oral @DRUG$ The pharmacokinetics/pharmacodynamics of fondaparinux sodium are not significantly affected by warfarin, platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin.	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$ , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or @DRUG$ Also calcium channel blockers, antihistamines or H1-blockers, tricyclic antidepressants and phenothiazines could contribute to an extension of the QTc interval.	DDI-effect
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen and @DRUG$/Phenobarbital.	DDI-false
Injection : Lorazepam injection , like other injectable @DRUG$ , produces depression of the central nervous system when administered with ethyl alcohol, phenothiazine, barbiturates, MAO inhibitors and other @DRUG$.If scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations and irrational behaviour has been observed.	DDI-effect
@DRUG$: Haloperidol blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of @DRUG$.	DDI-false
â€¢ Use of epinephrine in patients who use cyclopropane or @DRUG$ such as @DRUG$ The myocardial sensitization can cause cardiac arrhythmias.	DDI-false
@DRUG$ , @DRUG$ , ethosuximide	DDI-false
Although neither @DRUG$ nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
Cardiovasculars : @DRUG$ : In patients receiving digoxin therapy , administration of oral @DRUG$ This regularly leads to an increase in digoxin serum concentration, which can reach toxic concentrations with resulting clinical toxicity.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or @DRUG$ , calcium channel blockers , antihistamines or @DRUG$ Also tricyclic antidepressants and phenothiazines could contribute to an extension of the QTc interval.	DDI-false
5HT3 Antagonists : Based on reports of deep hypotension and loss of consciousness when @DRUG$ was administered with @DRUG$ The concomitant use of apomorphine with medicines of the 5HT3 antagonist class (including, for example, Ondansetron, Granisetron, Dolasetron, Palonosetron, and Alosetron) is contraindicated.	DDI-effect
@DRUG$ - Taking piperazin and a @DRUG$ together may increase the risk of convulsions ( seizures ) .	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Intravenous Adenocard ( @DRUG$ It was effectively administered in the presence of other cardiovascular drugs, such as quinidine. @DRUG$ , calcium channel blockers, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
The addition of @DRUG$ in a limited number of patients in three well-controlled studies caused no systematic changes in @DRUG$ or primidone concentrations when compared to placebo.	DDI-false
Patients who have other narcotic analgesics, general anaesthetics, @DRUG$ , tranquilizers , sedative-hypnotics , tricyclic antidepressants or other CNS depressants ( including @DRUG$ DILAUDID can be combined with an additive CNS depression.	DDI-false
Folic acid in large amounts may counteract the antiepileptic effect of @DRUG$, @DRUG$ and primidone, and increase the frequency of seizures in susceptible pediatric patients.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
â€¢ Hormonal contraceptives Concomitant use of Trileptal with oral contraceptives @DRUG$ has been shown to influence the plasma concentrations of the two hormonal components , @DRUG$ ( EE ) and Levonorgestrel ( LNG ).	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , @DRUG$ , VIDEX chewable/buffered tablets or pediatric powder , or products containing @DRUG$ , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , @DRUG$ , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as @DRUG$ ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$ Because atorvastatin does not affect the pharmacokinetics of antipyrin, interactions with other @DRUG$ Metabolism via the same cytochrome isozymes is not expected.	DDI-false
@DRUG$ Tiagabin causes a slight decrease ( about 10% ) in steady state @DRUG$ concentrations .	DDI-false
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of @DRUG$, resulting in serum and urine levels considerably lower than desired.	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, @DRUG$, quinidine, clarithromycin or @DRUG$.	DDI-false
Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in @DRUG$ Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
- single doses of cholestyramine, or @DRUG$ @DRUG$ Bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent respectively.	DDI-false
Hepatic enzyme inducers, inhibitors and substrates : drugs that induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity (e.g. barbiturates, phenytoin, @DRUG$ , rifampin) can improve the metabolism of @DRUG$ And demand that the corticosteroid dosage be increased.	DDI-mechanism
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, @DRUG$, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, @DRUG$, ritonavir, @DRUG$) would be expected to behave similarly.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as @DRUG$, nevirapine, @DRUG$, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., @DRUG$, analgesics, antiemetics, @DRUG$, tranquilizers).	DDI-false
Other cardiovascular agents: @DRUG$ and @DRUG$ Co-administered with beta-adrenergic blockers, methyldopa, nitrates, calcium blockers, hydralacin, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
@DRUG$ : Potential interactions between Trileptal and other @DRUG$ were assessed in clinical studies .	DDI-false
Promethazine : Coadministration of a single dose of @DRUG$ and promethazine ( 10 and 25 mg , respectively ) resulted in a 15 % decrease in maximal plasma concentrations of @DRUG$ , but no change in the area under the plasma concentration-time curve .	DDI-false
The effects of @DRUG$ are antagonized by methylxanthines such as caffeine and @DRUG$.	DDI-effect
@DRUG$ , warfarin , heparin , @DRUG$	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , @DRUG$ , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ (e. g., fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
The co-administration of medicinal products which are nephrotoxic (e. g. @DRUG$ , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , @DRUG$ Effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
@DRUG$ (such as flecainide, @DRUG$, or quinidine): concurrent use with arbutamine may have a proarrhythmic effect.	DDI-false
@DRUG$ ; : Simultaneous application of @DRUG$ With active substances with b-blocking properties, blood pressure and heart rate lowering effects can be amplified.	DDI-false
It is believed that increased interactions between 3H-spiroperidol and high affinity binding points for @DRUG$ The antipsychotic effect of dopamine2 and serotonin2 receptors @DRUG$ after their prolonged administration .	DDI-false
@DRUG$ (e.g., Antiminth) - Taking piperazine and pyrantel together may decrease the effects of @DRUG$.	DDI-false
Ingestion of @DRUG$ may increase serum concentrations of digoxin and methotrexate and increase @DRUG$ s nephrotoxicity.	DDI-effect
ANTACID (@DRUG$): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-effect
These drugs include the thiazides and other diuretics , corticosteroids , @DRUG$ , thyroid products, estrogens, oral contraceptives, @DRUG$ , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving @DRUG$ and can result in serious or fatal bleeding.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ , pimozide , @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
In case you take @DRUG$ While taking aminosalicylic acid, higher doses of @DRUG$ It may be necessary.	DDI-false
In some patients, the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG-DRUG$.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, @DRUG$, isoniazide, and some macrolide antibiotics.	DDI-mechanism
HIV Protease Inhibitors : @DRUG$ ( 800 mg t.i.d . ) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC , a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life .	DDI-false
It is suggested that in patients receiving @DRUG$ , alternatives to phenytoin should be used if @DRUG$ Treatment is required.	DDI-false
@DRUG$ The effects of warfarin and @DRUG$ GI bleeding is synergistic, so users of both drugs together have a risk of severe GI bleeding higher than users of each drug alone.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Anticholinesterases : Concomitant use of @DRUG$ and @DRUG$ may produce severe weakness in patients with myasthenia gravis .	DDI-effect
Patients in a clinical trial based on established treatment with sulfasalazine for which: @DRUG$ It was found that a slight decrease in the mean neutrophil count compared to groups with either @DRUG$ CI or sulfasalazine alone.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Nephrotoxicity has been reported following concomitant administration of @DRUG$ - with aminoglycoside antibiotics or potent @DRUG$ For example, furosemide.	DDI-effect
An interaction study with warfarin showed no clinically significant effect of @DRUG$ on @DRUG$ pharmacokinetics or anticoagulant activity.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as @DRUG$ , Spironolacton, and @DRUG$.	DDI-false
Â· High dose cyclosporin A with concentrations above 2000 ng/ml administered with oral @DRUG$ has led to an 80 % increase in @DRUG$ exposure with a 38 % decrease in total body clearance of etoposide compared to etoposide alone .	DDI-false
@DRUG$ : Coadministration of indinavir with VIRACEPT resulted in an 83 % increase in nelfinavir plasma AUC and a 51 % increase in @DRUG$ plasma A.C.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , fibrates , fluoxetine , @DRUG$ , propoxyphene , salicylates , somatostatin analog ( e.g. , octreotide ) , @DRUG$.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, @DRUG$ , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and @DRUG$ ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Effect of Other Drugs on the Pharmacokinetics of @DRUG$ " : Literature reports suggest that @DRUG$ , an agent that decreases stomach acidity , does not greatly alter clonazepam pharmacokinetics .	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines , presumably through inhibition of CYP3A : @DRUG$ , @DRUG$ , cimetidine, diltiazem, isoniazid, and some macrolide antibiotics.	DDI-false
Reports in the literature suggest that plasma levels of doxorubicin ( and its active metabolite doxorubicinol ) may be increased when @DRUG$ and @DRUG$ ==References====External links==	DDI-mechanism
@DRUG$: @DRUG$ caused a decrease in zalcitabine phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	DDI-false
Aminosalicylic acid may decrease the amount of digoxin ( @DRUG$ , @DRUG$ ) that gets absorbed into your body .	DDI-false
The effects of adenosine are antagonized by @DRUG$ such as caffeine and @DRUG$.	DDI-false
Coadministration of @DRUG$ and cyclosporine, tacrolimus or @DRUG$ has led to increased plasma concentrations of the latter three drugs.	DDI-mechanism
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral @DRUG$ , phenytoin , @DRUG$ , sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Specific studies have confirmed these effects with sevoflurane, @DRUG$ , Propofol, Alfentanil, and @DRUG$.	DDI-false
@DRUG$, ampicillin, oxacillin, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Specific studies have confirmed these effects with @DRUG$, isoflurane, propofol, @DRUG$, and midazolam.	DDI-false
@DRUG$: Coadministration of @DRUG$ with VIRACEPT resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
Therophylline: A recent study has shown that concomitan administration of @DRUG$ and @DRUG$ may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of isoniazid.	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
If intravenous @DRUG$ is required to treat Pneumocystis carinii pneumonia , treatment with @DRUG$ should be interrupted .	DDI-advise
In vitro and/or in vivo data indicate that: @DRUG$ , @DRUG$ Cetoconazole and oral ketoconazole significantly inhibit the metabolism of cisapride, which may lead to an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
@DRUG$ : Chloramphenicol , erythromycins , sulfonamides , or @DRUG$ may interfere with the bactericidal effect of penicillins .	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either (+)-NANM or @DRUG$ in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of @DRUG$.	DDI-false
@DRUG$ , such as verapamil , diltiazem and @DRUG$ , inhibit platelet activation in vitro , and decrease platelet adhesion intravascularly .	DDI-false
@DRUG$ is metabolized to @DRUG$ by the cytochrome P450 (CYP450) enzyme group, specifically cytochromes P450 3A4 (CYP3A4) and CYP2C8.	DDI-false
Hypotension: Patients on Diuretic Therapy: Patients on diuretics and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$ or @DRUG$.	DDI-false
The hypoglycaemic effect of sulphonylureas may be due to certain medications, including: @DRUG$ And other medicines that are highly protein-bound, salicylates, sulphonamides, chloramphenicol, probenecid, coumarine, monoamine oxidase inhibitors and @DRUG$.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ When co-administered with saquinavir, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
The concomitant use of Natrecor with IV vasodilators such as nitroglycerin, nitroprusside, @DRUG$ , or IV @DRUG$ has not been evaluated ( these drugs were not co-administered with Natrecor in clinical trials ) .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
This drug may interact with alcohol or other CNS depressants ( may potentiate the CNS depressant effects of either these medications or antihistamines ) , anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ) , and @DRUG$ ( concurrent use with @DRUG$ The anticholinergic and CNS depressive effects of antihistamines may be prolonged and intensified.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine , amiodarone , quinidine , warfarin , @DRUG$ (e. g. cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including @DRUG$ and @DRUG$, may have an additive effect with INOmax on the risk of developing methemoglobinemia.	DDI-false
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other CNS depressants including barbiturates , tranquilizers , and @DRUG$.	DDI-effect
- magnesium and/or @DRUG$-containing antacids, iron sulphate-containing products, multivitamin preparations, @DRUG$ The pediatric powder for oral solution must not be taken within 3 hours before or 2 hours after FACTIV.	DDI-false
Effects of @DRUG$ on other Antiepilepsy Drugs (AEDs) : Phenytoin: @DRUG$ had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
Loratadine (10 mg once daily) has been coadministered with therapeutic doses of @DRUG$, @DRUG$, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.	DDI-false
In clinical trials with: @DRUG$ , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( @DRUG$ NSAIDs (piroxicam) and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Curariform muscle relaxants ( eg , @DRUG$ ) and other medicines, including ether, succinylcholine, gallamine, decamethonium and @DRUG$ Neuromuscular blocking should be intensified and administered with extreme caution to patients treated with Coly-Mycin M Parenteral.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, @DRUG$, opiates, sedatives, anesthetics) should be considered.	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., fluoxetine, sertraline, paroxetine, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and @DRUG$ (such as cimetidine or ranitidine).	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
A similar association , though less marked , has been suggested with @DRUG$ , phenylbutazone, phenytoin sodium, carbamazepine, @DRUG$ , topiramate , and possibly with ampicillin and tetracyclines 72 .	DDI-false
@DRUG$ : In healthy subjects receiving @DRUG$ Systemic exposure (AUC) to lapatinib was increased to approximately 3.6-fold control at 200 mg twice daily for 7 days and half-life increased to 1.7-fold control.	DDI-false
@DRUG$ SSRIs: SSRIs (e.g. fluoxetine, fluvoxamine, @DRUG$ , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5-HT1 agonists .	DDI-false
however, it is considered to be unlikely that this decrease of phosphorylated @DRUG$ concentration is of clinical significance, as lamivudine is a more efficient substrate for deoxycytidine kinase than @DRUG$.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients with @DRUG$ - dexamethasone), diphen hydromine and @DRUG$ (such as cimetidine or ranitidine).	DDI-false
This drug may interact with alcohol or other CNS depressants ( may potentiate the CNS depressant effects of either these medications or antihistamines ) , anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$ ) , and monoamine oxidase ( MAO ) inhibitors ( concurrent use with @DRUG$ The anticholinergic and CNS depressive effects of antihistamines may be prolonged and intensified.	DDI-false
Cyclosporine: Because @DRUG$ can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of @DRUG$ including TRICOR, there is a risk that an interaction will lead to deterioration.	DDI-effect
@DRUG$: The anorectic and stimulatory effects of @DRUG$ may be inhibited by lithium carbonate.	DDI-false
Oral Contraceptives : @DRUG$ ( 40 mg BID ) did not induce the metabolism of the combination oral contraceptive norethindrone/@DRUG$ ( 1 mg /35 mcg combination , Ortho-Novum 1/35 ) .	DDI-false
@DRUG$ Concomitant administration of daptomycin (6 mg/ kg once every 24 hours for 5 days) and @DRUG$ ( 25 mg single oral dose ) had no significant effect on the pharmacokinetics of either drug , and the INR was not significantly altered .	DDI-false
@DRUG$ has been reported to increase the @DRUG$ requirements in human subjects ingesting these agents simultaneously.	DDI-mechanism
In monkeys , the effects of (-)-NANM , but not @DRUG$ or @DRUG$ , were antagonistized by naloxone;	DDI-false
@DRUG$ As with other B-lactam antibiotics, renal excretion of @DRUG$ is inhibited by probenecid and resulted in an approximate 80 % increase in the AUC for loracarbef .	DDI-false
Patients receiving other narcotic analgesics , general anesthetics , phenothiazines , @DRUG$ , sedative-hypnotics , @DRUG$ Additional CNS depression may occur simultaneously with DILAUDID or other CNS depressions (including alcohol).	DDI-false
Patients receiving other narcotic analgesics , general @DRUG$ , @DRUG$ Anaesthetics, sedatives, sedative hypnotic drugs, tricyclic antidepressants or other CNS depressants (including alcohol) may exhibit additive CNS depression together with DILAUDID.	DDI-false
The hypoglycaemic effect of sulphonylureas may be caused by certain medicinal products, including: @DRUG$ And other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, probenecid, coumarin, @DRUG$ And beta-adrenergic blockers.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Consequently, @DRUG$ should be avoided in patients receiving @DRUG$ and itraconazole, which are very potent inhibitors of CYP3A.	DDI-advise
Serum @DRUG$ levels should be monitored frequently if INSPRA is administered concomitantly with @DRUG$.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, @DRUG$, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
In the second experiment , non-diabetic and streptozotocin-induced diabetic rats were fasted , and the same procedures were followed for estimation of @DRUG$ tolerance 30 min after @DRUG$ overload .	DDI-false
Concomitant use of @DRUG$ supplements and L-lysine may increase @DRUG$ absorption	DDI-false
Coadministration of terfenadine with @DRUG$ has led to elevated plasma concentrations of @DRUG$, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.	DDI-false
@DRUG$ : The concomitant use of Bepridil and @DRUG$ The treatment was well tolerated in patients with stable angina pectoris.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
METHODS : From the beginning of the experiment , rats were given 10 weekly subcutaneous injections of @DRUG$ 7.4 mg/ kg body weight) and subcutaneous injections @DRUG$ 40 Î¼g/kg body weight every other day and from week 16 intraperitoneal injections of verapamil ( 10 or 20 mg/kg body weight) every other day until the end of the experiment at week 45.	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$ , propranolol , nifedipine , chlordiazepoxide , @DRUG$ , certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying the elimination and increase in blood levels of these drugs.	DDI-false
â€¢ Corticosteroids, methylxanthine and diuretics: concomitant treatment with xanthine derivatives, @DRUG$ Diuretics may potentiate a possible hypokalemic effect @DRUG$	DDI-effect
Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and fluvastatin.	DDI-false
Oral Contraceptives : Valdecoxib ( 40 mg BID ) did not induce the metabolism of the combination oral contraceptive norethindrone/@DRUG$ ( 1 mg /35 mcg combination , @DRUG$ 1/35 ) .	DDI-false
Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of carbamazepine, valproate, topiramate, or @DRUG$.	DDI-false
@DRUG$ Adrenergic blockers are inhibited by @DRUG$.	DDI-false
Potential drug interactions between @DRUG$  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with acetaminophen, and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
In the first study, co-administration of 0.2 mg cerivastatin sodium and 12 g @DRUG$ resulted in decreases of more than 22 % for AUC and 40 % for Cmax when compared to dosing @DRUG$ alone .	DDI-false
Probenecid: As with other b-lactams, the renal excretion of @DRUG$ is inhibited by @DRUG$.	DDI-mechanism
Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with phenytoin, warfarin, quinidine, @DRUG$ or amoxicillin.	DDI-false
@DRUG$ reduced or eliminated the increases in FI responding produced by intermediate doses of either @DRUG$ or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.	DDI-effect
Drugs That Inhibit CYP3A4 (@DRUG$) CYP3A4 is a major metabolic pathway for elimination of @DRUG$.	DDI-false
Like ibogaine ( 40 mg/kg ) , @DRUG$ ( 40 mg/kg ) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats ;	DDI-false
In patients with mild to moderate hypertension, administration of 25 mg daily of @DRUG$ with the @DRUG$ benazepril, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
It may cause anticoagulants (modified hypoprothrombinemic activity), barbiturates, @DRUG$ N and other inducers of the hepatic microsomal enzyme oxidation system (reduced effect of @DRUG$ Corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids.	DDI-false
When co-administered with @DRUG$ 20 mg and @DRUG$ 10 mg, 2 in 9 subjects experienced a standing systolic blood pressure of less than 85 mm Hg.	DDI-effect
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( @DRUG$ ) , NSAIDs ( @DRUG$ Digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$ : @DRUG$ The intestinal absorption of ethosuximide may be delayed.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (@DRUG$, barbiturates, opiates, sedatives, anesthetics) should be considered.	DDI-false
@DRUG$ should be administered with caution to patients receiving @DRUG$ ( disulfiram , Wyeth-Ayerst Laboratories ) .	DDI-advise
Strong inducers of cytochrome P450 enzymes (i.e. @DRUG$, @DRUG$ and phenobarbital) have been shown to decrease the plasma levels of MHD (29-40%).	DDI-false
@DRUG$: Co-administration with @DRUG$ should be employed cautiously, as toxic epidermal necrolysis has been reported with concomitant use.	DDI-false
Concomitant administration of other @DRUG$ may potentiate the undesirable effects of @DRUG$.	DDI-effect
Although clinical studies have not been performed, based on the involvement of the cytochrome P-450 3A family in @DRUG$ metabolism, inhibitors of this enzyme system, notably oral antifungal agents, should be used cautiously in patients receiving @DRUG$.	DDI-false
These drugs include: @DRUG$ and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral @DRUG$ , phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
@DRUG$ and Zidovudine @DRUG$ can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.	DDI-false
Notably, systemic exposure (AUC0-12) of @DRUG$ (DHA) was more than doubled in the presence of TMP/@DRUG$.	DDI-false
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, @DRUG$ , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , @DRUG$ ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
@DRUG$ and @DRUG$ Patients receiving coumarin should not be taken.	DDI-false
- medicines associated with peripheral neuropathy include: @DRUG$ , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , @DRUG$ , phenytoin , ribavirin , and vincristine .	DDI-false
Administration of @DRUG$ to patients receiving @DRUG$ or halogenated hydrocarbon general anesthetics such as halothane which sensitize the myocardium, may induce cardiac arrhythmia..	DDI-effect
@DRUG$ With desipramine or protriptyline and possibly other tricycles, the concentration of @DRUG$ in the brain ;	DDI-false
May interact @DRUG$ ( altered hypo-prothrombinemic effect ) , barbiturates , rifampin and other inducers of hepatic microsomal enzyme oxidation system ( decreased effect of @DRUG$ Corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids, corticosteroids.	DDI-false
Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other NSAID while taking digoxin , methotrexate , or @DRUG$ It can develop toxicity characteristics for these drugs.	DDI-false
In the presence of these @DRUG$, larger doses of @DRUG$ may be required or adenosine may not be effective.	DDI-advise
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
However, patients on @DRUG$ - can increase of @DRUG$ concentrations after initiation of therapy with FLOLAN , which may be clinically significant in patients prone to digoxin toxicity .	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
@DRUG$ : Patients on @DRUG$ Treatment may show a reduced response to toxoids and live or inactivated vaccines due to inhibition of antibody response.	DDI-false
- may affect anticoagulants (modified hypoprothrombinemic activity), @DRUG$ , @DRUG$ â€¢ and other inducers of the liver microsomal enzyme oxidation system (reduced effect of diethylstilbestrol), corticosteroids (reinforced effect of corticosteroids).	DDI-false
In some patients , the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic , natriuretic , and antihypertensive effects of loop , @DRUG-DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Aerosol particles of @DRUG$ They were taken from a @DRUG$ Solution, dried, and collected by a cascade impactor for characterization or by a liquid impinger for resolution experiments.	DDI-false
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-effect
The effects of @DRUG$ (RR) on @DRUG$ (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
Tetracycline , a @DRUG$ , may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : @DRUG$ @DRUG$ Midazolam, triazolam GI Motility agent: cisapride	DDI-false
Although clinical studies have not been performed , based on the involvement of the cytochrome P-450 3A family in clonazepam metabolism , inhibitors of this enzyme system , notably oral @DRUG$ , should be used cautiously in patients receiving @DRUG$.	DDI-advise
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., fluoxetine, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Antiacid , @DRUG$ , didanosine, fluconazole, fluoxetine, indanavir, ketoconazole, phenytoin, phenobarbitol, carbamazepine, @DRUG$ , rifampin, ritanovir, saquinavir.	DDI-false
Antiarrhythmia: amiodarone, bepridil, @DRUG$ , @DRUG$ , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
The medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$ , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , @DRUG$ Ribavirin and vincristine.	DDI-false
For the concomitant use of active substances in the tricyclic antidepressant class (including @DRUG$ In addition, the use of medicines that may inhibit cytochrome P450 2D6 may be lower than normally used for either: @DRUG$ or the other drug .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
Probenecid : As with other b-lactams , the renal excretion of @DRUG$ This is inhibited by @DRUG$.	DDI-mechanism
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium antacids, @DRUG$ , @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Although there are no study data to evaluate the possibility, nitric oxide donor compounds, including @DRUG$ and nitroglycerin, may have an additive effect with @DRUG$ on the risk of developing methemoglobinemia.	DDI-effect
@DRUG$ It was combined with @DRUG$ , dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.	DDI-false
Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, cis-platinum, tamoxifen and @DRUG$.	DDI-effect
@DRUG$ 500 mg twice daily did not modify the rate or extent of @DRUG$ absorption or its plasma clearance or urinary excretion .	DDI-false
Strong inducers of cytochrome P450 enzymes ( i.e. @DRUG$ , phenytoin and @DRUG$ ) have been shown to decrease the plasma levels of MHD ( 29 - 40 % ) .	DDI-false
@DRUG$: @DRUG$ (CYP3A4 substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an @DRUG$ ( aluminum hydroxide , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenously] @DRUG$ ( e.g. , tobramycin , gentamicin , and amikacin ) , amphotericin B , foscarnet , intravenous pentamidine , @DRUG$ , and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
When the STADOL NS was administered 30 minutes after the @DRUG$ nasal spray , the AUC of @DRUG$ The Cmax decreased by 11% and the Cmax by 18%.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodon, @DRUG$ , propofol , @DRUG$ , quinidine , and verapamil .	DDI-false
In rats, co-administration of @DRUG$ It has been reported that tumours occur in the diet for 78 weeks, and it has been suggested that disulfiram with @DRUG$ in the rat stomach to form a nitrosamine , which is tumorigenic .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ did not affect the pharmacokinetics of @DRUG$.	DDI-false
The hypoglycaemic effect of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , sulfonamides , @DRUG$ , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-effect
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, @DRUG$, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Lack of an effect of @DRUG$ on the disposition of @DRUG$ and dideoxyinosine in HIV-infected patients.	DDI-false
Magnesium- and/or aluminum-containing @DRUG$ , products containing ferrous sulfate ( iron ) , @DRUG$ Zinc or other metal cations or Videx (didanosine) chewable tablets or the paediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIV.	DDI-false
Haloperidol: @DRUG$ blocks dopamine receptors, thus inhibiting the central stimulant effects of @DRUG$.	DDI-effect
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), @DRUG$ ( acetylsalicylic acid ) , @DRUG$ ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
During transfer to oral @DRUG$ , the dose levels of previously administered agents should be reduced by 30 to 50 % several days after the addition of oral @DRUG$.	DDI-false
@DRUG$ : When multiple doses of @DRUG$ and digoxin were coadministered , steady-state plasma digoxin concentrations increased by approximately 20 % .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine @DRUG$ Astemizole, terfenadine Antimigrain: ergot derivatives @DRUG$ : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
The hypoglycaemic effect of sulphonylureas may be caused by certain medicinal products, including: @DRUG$ And other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$ , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high @DRUG$ doses In vivo, the plasma levels of @DRUG$ increased by up to 40%, when Trileptal was given at doses above 1200 mg/day.	DDI-false
Rifampin: Co-administration of @DRUG$ with rifampin 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in @DRUG$ plasma concentrations.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ is the first @DRUG$ to be approved for clinical use, and has been studied extensively in humans since 1986.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , @DRUG$ , chlordiazepoxide , diazepam , certain tricyclic antidepressants , @DRUG$ , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
In interaction studies with hydrochlorothiazide, no significant pharmacokinetic (or pharmacodynamic) interactions were found. @DRUG$ , @DRUG$ , and nifedipine .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , @DRUG$ , @DRUG$ , disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , @DRUG$ Prostaglandin synthetase inhibitors (also known as prostaglandin synthetase inhibitors) @DRUG$ In addition, quinolones anti-infections with no evidence of clinically significant adverse interactions.	DDI-false
Dopamine Antagonists : Since apomorphine is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( @DRUG$ , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of @DRUG$.	DDI-effect
CYP3A4 inhibitors (e. g. @DRUG$ , @DRUG$ such as erythromycin ) have the potential to result in increased plasma concentrations of corticosteroids .	DDI-false
Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , @DRUG$ , disopyramide , and @DRUG$ , have been used concurrently with amiodarone .	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, antiemetics, sedatives, @DRUG$).	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: It is recommended that @DRUG$ be administered on an empty stomach;	DDI-false
@DRUG$ : Isolated cases of conduction disorder (frequently with hemodynamic compromise) were observed when COREG was co-administered with @DRUG$.	DDI-false
Therefore, when hydroflumethiazide and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained.)	DDI-false
Although @DRUG$ used alone has little or no effect on pupil size , mydriasis resulting from concomitant therapy with @DRUG$ It may occur that epinephrine and epinephrine occur.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Plasma exposure (AUC) to @DRUG$ was increased 62% when coadministered with fluconazole and 38% when coadministered with @DRUG$.	DDI-mechanism
Based on known metabolic profiles , clinically significant drug interactions are not expected between VIRACEPT and dapsone , trimethoprim/@DRUG$ , clarithromycin , erythromycin , @DRUG$ or fluconazole .	DDI-false
Cimetidine: @DRUG$ concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with @DRUG$ (20 mg/kg/day) alone (n=12).	DDI-false
We report the case of adolescent with altered consciousness caused by carbamazepine overdose with a positive tricyclic antidepressant to treat clinicians on the cross-reactivity of @DRUG$ With a toxicology screen for @DRUG$.	DDI-advise
The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-false
Administration of rifampin concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone.	DDI-false
@DRUG$, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
Coadministration of @DRUG$ with 40 mg @DRUG$ tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels.	DDI-mechanism
This appears to be the only clinically relevant interaction of this species with mefloquines, although theoretically the concomitant use of other medicinal products is known to alter the heart conduction (e.g. anti-arrhythmic or @DRUG$ , calcium channel blockers , @DRUG$ Tricyclic antidepressants and phenothiazines can also contribute to the prolongation of the QTc interval.	DDI-false
Drug interaction studies have shown that @DRUG$ No clinically significant interactions with phenytoin, warfarin, @DRUG$ , clarithromycin or amoxicillin.	DDI-false
Although neither dexamethasone nor @DRUG$ Influenced the proliferation of prostate epithelium in RPMI1640 with @DRUG$ alone , they modify the mitogenic effect of EGF and insulin .	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Interactions with mixed agonists/antagonists Opioid analgesics: agonists/antagonists analgesics (e.g. pentazocin, nalbuphin, butorphanol, @DRUG$ It should NOT be given to a patient who has received or received therapy with a pure agonist opioid analgesics such as @DRUG$.	DDI-advise
No significant interactions were found between @DRUG$ and warfarin or @DRUG$.	DDI-false
Conversely , the administration of STADOL NS ( 1 mg @DRUG$ QID ) did not alter the pharmacokinetics of a 300-mg dose of @DRUG$.	DDI-false
Methenamine therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by @DRUG$ used in @DRUG$ therapy.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
@DRUG$ should be used with caution in patients taking @DRUG$ Renal function should be carefully monitored.	DDI-advise
@DRUG$ Not simultaneously with D2 antagonists, e.g. @DRUG$ , butyrophenones , thioxanthines , or metoclopramide .	DDI-advise
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$, including norfloxacin, may enhance the effects of oral @DRUG$, including warfarin or its derivatives or similar agents.	DDI-effect
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Because prostaglandins play an important role in hemostasis, and @DRUG$ affect platelet function as well, concurrent therapy with all NSAIDs, including @DRUG$, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	DDI-false
Although increased plasma concentrations ( AUC 0 - 24 hrs ) of @DRUG$ and/or descarboethoxyloratadine were observed following coadministration of loratadine with each of these drugs in normal volunteers ( n = 24 in each study ) , there were no clinically relevant changes in the safety profile of @DRUG$ Rated by electrocardiographic parameters, clinical laboratory tests, vital signs and adverse events.	DDI-false
CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of @DRUG$ 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after @DRUG$ administration.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
@DRUG$: (oral agents and insulin) - dosage adjustment of the @DRUG$ may be required.	DDI-false
Compounds tested in man include warfarin, @DRUG$, phenytoin, diazepam, aminopyrine and @DRUG$.	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, @DRUG$, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
@DRUG$ Amiodarone should be used with caution in patients receiving receptor blockers (e.g. propranolol, CYP3A4 inhibitor), or @DRUG$ â€¢ antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
@DRUG$ including @DRUG$, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-effect
In clinical trials , FLOLAN was used with @DRUG$ , diuretics , anticoagulants , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated , apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
In addition, results from regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance ( @DRUG$ , @DRUG$ , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations .	DDI-false
Digoxin, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and @DRUG$, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Other drugs that inhibit the neuromuscular blocking effect of non-depolarizing substances such as e.g. @DRUG$ These include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$ Clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-effect
Coadministration of @DRUG$ and drugs primarily metabolized by CYP3A (e.g., @DRUG$) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects.	DDI-false
Close supervision and careful adjustment of the dosage are required when @DRUG$ is used with other @DRUG$ Sympathomimetics.	DDI-advise
Anti-arrhythmics and @DRUG$ could exaggerate the prolongation of the QT interval observed with @DRUG$.	DDI-effect
While no in vivo drug-drug interaction studies were conducted between @DRUG$ CYP3A inducers, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, @DRUG$ , and barbiturates ) would be expected to decrease estazolam concentrations .	DDI-mechanism
Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral @DRUG$ and @DRUG$.	DDI-effect
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Other reported interactions with @DRUG$: Fentanyl (CYP3A4 substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), @DRUG$ acetylsalicylic acid, NSAIDs (piroxicam) and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone , suggesting that antacids may impair absorption of @DRUG$.	DDI-false
Potential drug interactions between Keppra   and other AEDs ( carbamazepine , gabapentin , lamotrigine , @DRUG$ , @DRUG$ In placebo-controlled clinical trials, serum concentrations of levetiracetam and these AEDs have also been studied.	DDI-false
In monkeys, the effects of @DRUG$, but not @DRUG$ or PCP, were antagonized by naloxone;	DDI-false
Therefore , when @DRUG$ and nonsteroidal anti-inflammatory agents are used concomitantly , the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained . )	DDI-false
" Medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, @DRUG$ , cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$ , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
@DRUG$ A case of severe hypoglycaemia has been reported in a type II diabetic who continues to @DRUG$ ( 1 gm/day ) 11 days after the addition of doxepin ( 75 mg/day ) .	DDI-false
@DRUG$ and colestipol resins: Absorption of @DRUG$ is impaired in the presence of anionic exchange resins.	DDI-false
Valproate: The addition of tiagabine to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics, but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
@DRUG$ and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID @DRUG$, the Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-false
When other potent parents @DRUG$ , such as diazoxide , are used in combination with @DRUG$ Patients should be monitored continuously for several hours for an excessive decrease in blood pressure.	DDI-effect
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, @DRUG$, isoniazide, and some @DRUG$.	DDI-false
In the case that you are taking @DRUG$ while taking @DRUG$, higher doses of digoxin may be needed.	DDI-advise
@DRUG$ (but not aspirin): These drugs in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies.	DDI-false
CNS-Active Drugs @DRUG$: @DRUG$ 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Based on the chemical resemblance of @DRUG$ and @DRUG$, coadministration of astemizole with itraconazole is contraindicated.	DDI-false
The pharmacokinetics of naltrexone and its major metabolite @DRUG$ were unaffected following co-administration with @DRUG$.	DDI-false
plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-mechanism
- @DRUG$ (e.g., @DRUG$) or	DDI-false
@DRUG$ @DRUG$ are inhibited by amphetamines .	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (nicotinic acid), erythromycin, @DRUG$.	DDI-false
@DRUG$: Coadministration of single doses of @DRUG$ 3 mg and paroxetine 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.	DDI-false
@DRUG$ , @DRUG$ , Cyclosporin: Diclofenac, like other NSAIDs, can affect kidney prostaglandins and increase the toxicity of certain drugs.	DDI-false
The concomitant use of naltrexone with @DRUG$ The result was a 25% increase in AUC and a 33% increase in Cmax of @DRUG$.	DDI-false
@DRUG$ Since apomorphine is a dopamine agonist, dopamine antagonists such as the neuroleptics (phenothiazine, butyrophenone, thioxanthene) or metoclopramide may reduce the effectiveness of @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving @DRUG$ therapy.	DDI-false
Therefore, esomeprazole may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, @DRUG$, iron salts and @DRUG$).	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or fluconazole.	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$ , antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$ , psychotropic medications , or other drugs that produce CNS depression .	DDI-false
For treatment with CYP3A4 inhibitors (such as ketoconazole, intraconazole, ritonavir, @DRUG$ , saquinavir , @DRUG$ A reduction in the dose of budesonide should be considered.	DDI-false
Administration of epinephrine to patients receiving cyclopropane or @DRUG$ such as @DRUG$ which sensitize the myocardium, may induce cardiac arrhythmia..	DDI-false
@DRUG$ : The effects of @DRUG$ and NSAIDs on GI bleeding are synergistic , such that users of both drugs together have a risk of serious GI bleeding higher than that of users of either drug alone .	DDI-false
@DRUG$: @DRUG$ may enhance the metabolic clearance of corticosteroids, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.	DDI-false
@DRUG$ Inhibition of the kidneys @DRUG$ Clearance, leading to an increase in plasma lithium concentration, has been reported with some prostaglandin synthetic drugs.	DDI-false
OBJECTIVES: Report on a case of rhabdomyolysis resulting from the concomitant use of rhabdomyolysis. @DRUG$ and @DRUG$.	DDI-false
In healthy volunteers, the pharmacokinetics of a 1-mg dose of butorphanol administered as @DRUG$ were not affected by the coadministration of a single 6-mg subcutaneous dose of @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , @DRUG$ , cardiac nitrates, diuretics, H2 antagonists, @DRUG$ Prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, spironolactone, and @DRUG$.	DDI-advise
The co-administration of medicinal products which are nephrotoxic (e. g. @DRUG$ , indomethacin ) , myelotoxic ( e.g. , @DRUG$ Chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g. methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
@DRUG$ also should be used cautiously with other drugs (e.g., digitalis, @DRUG$) that sensitize the myocardium to the actions of sympathomimetic drugs.	DDI-advise
@DRUG$ overdose recognized by a @DRUG$ assay.	DDI-false
- slow channel calcium blockers, such as verapamil, @DRUG$ and @DRUG$ , inhibit platelet activation in vitro, and reduce platelet adhesion intravascularly.	DDI-false
Numerous drug interactions are possible with some @DRUG$, such as @DRUG$ and phenytoin, which affect hepatic microsomal enzyme systems.	DDI-false
@DRUG$ , @DRUG$ And MAOIs can increase anticholinergic effects of clidinium.	DDI-false
Medicines that cause the release of renin : The antihypertensive effect of @DRUG$ and @DRUG$ IV is augmented by antihypertensive agents that cause renin release ( e.g. , diuretics ) .	DDI-false
It is important that patients understand how to use @DRUG$  (@DRUG$) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
â€¢ Anticoagulants : potentiation of the @DRUG$ type ( @DRUG$ The anticoagulant response is almost always observed in patients receiving amiodarone and may lead to severe or fatal bleeding.	DDI-false
@DRUG$ A report of severe acetaminophen toxicity was reported in a patient receiving @DRUG$.	DDI-false
The effects of @DRUG$ are antagonized by @DRUG$ such as caffeine and theophylline .	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
There have been case reports of increased steady-state levels of quinidine, @DRUG$, and @DRUG$ during concomitant therapy with amiodarone.	DDI-false
@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when Proquin XR was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
Other medicines: In small groups of patients ( 7 - 10/interaction study ), concomitant administration of azathioprin, gold, chloroquine, D-penicillamin, @DRUG$ , @DRUG$ , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
These results suggest that the hepatoxicity of @DRUG$ In alcoholic beverages, interactions with its congeners and @DRUG$ ;	DDI-effect
Other Drugs:Drugs such as quinidine, @DRUG$, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Administering @DRUG$ together with @DRUG$ ( 100 - 500 microM ) inhibited InsP(3)-induced responses ( both Ca(2 + ) and current responses ) in a dose-dependent fashion .	DDI-effect
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( phenytoin , valproate , oral @DRUG$ , @DRUG$ , warfarin , probenecid ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients .	DDI-false
@DRUG$ ( @DRUG$ Atropin, or other anticholinergic agents or digitalisglycosides: Co-administration with arbutamine may cause additive inotropic and/or chronotropic effects.	DDI-false
@DRUG$ may interfere with the absorption of @DRUG$.	DDI-mechanism
Central nervous system depressants: Concomitant use of DURAGESIC (Fentanyl transdermal system) with others @DRUG$ , including but not limited to other opioids , sedatives , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , @DRUG$ , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Imipramine (5 mg/kg), @DRUG$ (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered.	DDI-false
Both ibogaine and @DRUG$ block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-effect
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Other drug interactions @DRUG$ , @DRUG$ and dextropropoxyphene had no effect on the pharmacokinetics of MHD .	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
d-amphetamine with @DRUG$ or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-false
Short-term pharmacokinetic studies have shown that concomitant use of warfarin and @DRUG$   ( etodolac capsules and tablets ) results in reduced protein binding of warfarin , but there was no change in the clearance of free @DRUG$.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
- When @DRUG$ or @DRUG$ When co-administered with anion exchange resins (e.g. cholestryramine), a distance of at least 2 hours between the two medicinal products should be maintained as the absorption of bezalip or bezalip retard is impaired.	DDI-false
However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of @DRUG$ (Theo-Dur , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state @DRUG$ peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	DDI-false
Therefore , the concomitant administration of @DRUG$ and glyburide is contraindicated , and alternative @DRUG$ It should be considered.	DDI-false
There are rare reports, however, from marketing experiences, from changes in the impact of @DRUG$ or oral @DRUG$ In the presence of Diclofenac, the changes required in the doses of such active substances.	DDI-false
Other concomitant therapy Although no specific interaction studies have been performed, clinical trials with 1 mg or more of finasteride doses have been conducted at the same time. @DRUG$ , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , @DRUG$ ==See also==*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID*NSAID==References==	DDI-false
Other nephrotoxic drugs: active ingredients such as aminoglycosides, @DRUG$ , and @DRUG$ The potential for drug-induced renal toxicity can be increased and should be used with great caution at the same time.	DDI-false
In addition, fondaparinux did not affect the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$ , and @DRUG$ The pharmacokinetics of digoxin in steady state.	DDI-false
d-amphetamine with desipramine or @DRUG$ and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain ;	DDI-false
The absorption of oral @DRUG$ is significantly reduced by the concomitant administration of an @DRUG$ containing aluminum and magnesium.	DDI-false
BACKGROUND : The effects of combined administration of bombesin and verapamil hydrochloride ( @DRUG$ ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane ( @DRUG$ ) and the index of colorectal cancers were studied in male Wistar rats.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
@DRUG$ (SSRIs): SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-false
Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
- Anabolic steroids (nandrolone [e.g., @DRUG$], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
The hypoglycaemic effect of sulphonylureas may be due to certain medications, including: @DRUG$ and other drugs that are highly protein bound , salicylates , sulfonamides , chloramphenicol , @DRUG$ , Cumarine, monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-false
Cyclosporin, digoxin, methotrexate lodine, like others @DRUG$ By effects on renal prostaglandins, changes in the elimination of these drugs can lead to increased serum levels of cyclosporin, digoxin, @DRUG$ , and increased toxicity .	DDI-mechanism
medicines that should not be combined with VIRACEPT antiarrhythmics: @DRUG$ , quinidine Antihistamines : astemizole , @DRUG$ Antimigraine: Ergot derivatives Antimycobacterial agents: rifampine benzodiazepines midazolam, triazolam GI motility agent: cisapride	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other @DRUG$ , amantadine , haloperidol , phenothiazines , monoamine oxidase ( MAO ) inhibitors , @DRUG$ Or some antihistamines.	DDI-false
The data suggest that @DRUG$ has a narrower spectrum of actions and will have a substantially greater therapeutic index than @DRUG$.	DDI-false
@DRUG$, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
To determine whether injection of @DRUG$ would permit larger doses of cisplatin to be administered , a fixed 9.9-g/m2 dose of @DRUG$ The intravenous administration was administered for three hours at the same time as cisplatin.	DDI-false
@DRUG$ in large amounts may counteract the antiepileptic effect of phenobarbital , phenytoin and @DRUG$ , and increase the frequency of seizures in susceptible paediatric patients.	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
Other medicines that can enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX are certain @DRUG$ - aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$ Sodium colistimethate, magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
In the first study, the co-administration of 0.2 mg @DRUG$ Cholestyramine decreased AUC by more than 22% and Cmax by 40% compared to dosing. @DRUG$ alone .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
â€¢ Hormonal contraceptives Concomitant use of @DRUG$ with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components , ethinylestradiol ( EE ) and @DRUG$ ( LNG ).	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( @DRUG$ In patients with renal failure (e. g., magnesium hydroxide and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ In comparison to Fosinopril alone, which suggests that antacids may affect the absorption of Fosinopril.	DDI-false
Although studies designed to examine drug interactions have not been done, it was noted that @DRUG$ or @DRUG$ treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving Betaseron.	DDI-false
CYP2D6 inhibitors - @DRUG$ is primarily metabolized by the CYP2D6 pathway to @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
However, severe reactions such as hypotension, treatment, dyspnoea require @DRUG$ Angioedema or generalised urticaria require immediate discontinuation @DRUG$ and aggressive symptomatic therapy .	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Other drug interactions @DRUG$, @DRUG$ and dextropropoxyphene had no effect on the pharmacokinetics of MHD.	DDI-false
Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	DDI-false
Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Administration of @DRUG$ concomitantly with oral amiodarone has been shown to result in decreases in serum concentrations of @DRUG$ and desethylamiodarone.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Interaction on the anticoagulant effect between @DRUG$ and @DRUG$ or tuftsin .	DDI-effect
- Lithium: @DRUG$ should generally not be given with @DRUG$ (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-advise
Other potent inhibitors of CYP3A4 (e.g. itraconazole, @DRUG$ , nefazodone , troleandomycin , ritonavir , @DRUG$ It would be expected that it would behave in a similar way.	DDI-false
@DRUG$ The most effective inhibition (66% inhibition at 10 microm) was significantly stronger than that of raw @DRUG$.	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants , @DRUG$ , alcohol , barbiturates , monoamine oxidase inhibitors , narcotics , phenothiazines , psychotropic medications , or other drugs that produce CNS depression .	DDI-effect
Cyclopropane or @DRUG$ Elevates the autonomic irritability of the heart and can sensitize the myocardium to the effect of certain intravenous catecholamines, such as @DRUG$.	DDI-effect
â€¢ Saquinavir: concomitant use of @DRUG$ ( using an experimental soft-gelatin capsule formulation of @DRUG$ VIRACEPT resulted in an 18 % increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma AC.	DDI-false
In the present study, the @DRUG$ @DRUG$ was tested in combination with an active dose of PCP in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , @DRUG$ , nalbuphine, butorphanol, @DRUG$ and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran .	DDI-false
A similar association , though less marked , has been suggested with barbiturates , @DRUG$ , phenytoin sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and @DRUG$ 72 .	DDI-false
A clinical study in healthy male volunteers (n=24) demonstrated that mixing @DRUG$ with NPH human insulin immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of @DRUG$ were not significantly affected.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and @DRUG$.	DDI-false
@DRUG$ : Plasma @DRUG$ The steady-state concentrations and digoxin clearance were not affected by concomitant administration of cerivastatin sodium 0.2 mg.	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and nifedipine.	DDI-int
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
In some patients , a @DRUG$-like reaction may be produced by the ingestion of @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : @DRUG$ Benzodiazepines midazolam , @DRUG$ GI motility agent: cisapride	DDI-false
Serial plasma and urine samples for measurement of @DRUG$, rifabutin, and @DRUG$ and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective @DRUG$ may cause hypertension.	DDI-effect
Metformin : In healthy volunteers, the single doses of 500 mg cephalexin and @DRUG$ , plasma @DRUG$ mean cmax and AUC increased by an average of 34 % and 24 % , respectively , and metformin mean renal clearance decreased by 14 % .	DDI-false
- Mephenytoin ( e.g. , @DRUG$ ) Use of @DRUG$ with these medicines may increase the chance of side effects of these medicines	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (@DRUG$), @DRUG$, azole antifungals.	DDI-false
High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of @DRUG$ compared to etoposide alone.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
The clinical significance of this reduction is not known , hence zalcitabine is not recommended to be ingested simultaneously with magnesium/@DRUG$-containing @DRUG$.	DDI-false
Ritonavir: Coadministration of ritonavir with @DRUG$ resulted in a 152% increase in @DRUG$ plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
@DRUG$ and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
The mean percentage increase in the @DRUG$ AUC after @DRUG$ administration was 56.9% (range: 35 to 81).	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg @DRUG$ in healthy volunteers.	DDI-false
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of @DRUG$, @DRUG$, topiramate, or lamotrigine.	DDI-false
@DRUG$ as potent @DRUG$ of glucocorticoid-induced mouse mammary tumor virus gene expression.	DDI-false
In addition, additional interaction studies with: @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels , and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data .	DDI-false
Therefore, it would be expected that a dosage regimen of @DRUG$ , given at the time of sleep and @DRUG$ given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium .	DDI-false
Reports in the literature suggest that plasma levels of doxorubicin ( and its active metabolite @DRUG$ ) may be increased when @DRUG$ and doxorubicin are used in combination .	DDI-false
@DRUG$-@DRUG$ can antagonize the effect of warfarin	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : @DRUG$ , niacin, danazol, diuretics, @DRUG$ E. g. epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e. g. in oral contraceptives).	DDI-false
] METHOD : This study was a multicentre randomized double-blind study in 101 patients randomly receiving 1:1:1. @DRUG$ tablets at doses of 0.5 mg , 1 mg , or 2 mg twice daily with @DRUG$ and prednisone .	DDI-false
Other Drug Interactions Oral @DRUG$ @DRUG$  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
In order to evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL ), the authors retrospectively compared a group of 24 patients with HIV-NHL who had been treated with the @DRUG$ , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with @DRUG$ plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including anti-arrhythmic agents such as @DRUG$ and @DRUG$ , cardiac glycosides and tricyclic anti-depressants .	DDI-false
Stavudine and Zidovudine @DRUG$ can antagonize the in vitro antiviral activity of stavudine and @DRUG$ against HIV .	DDI-effect
All subjects received @DRUG$ alone and following treatment with 100 mg of @DRUG$ as a single daily oral dose for seven days.	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenylbutazone , phenytoin sodium , @DRUG$ , @DRUG$ , topiramate, and possibly ampicillin and tetracycline 72.	DDI-false
Interaction on the antinociceptive effect between neurotensin and @DRUG$ or @DRUG$.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with @DRUG$ ( @DRUG$ , barbiturates , opiates , sedatives , anesthetics ) should be considered .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the @DRUG$ @DRUG$.	DDI-false
@DRUG$s and @DRUG$ : The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or vasodilators ( n = 94 ) compared to patients not receiving these concomitant drugs ( n = 456 ): hypotension 10 % vs 4 % , myocardial infarction 3 % vs 1 % , serious pneumonia 5 % vs 3 % , serious falls 9 % vs 3 % , and bone and joint injuries 6 % vs 2 % .	DDI-false
In order to evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL ), the authors retrospectively compared a group of 24 patients with HIV-NHL who had been treated with the @DRUG$ , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , @DRUG$ , and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
A dose increase of @DRUG$/@DRUG$ to 533/133 mg twice daily with food isrecommended in combination with nevirapine.	DDI-false
ACE inhibitors and angiotensin II receptor antagonists (hypertension)- In clinical trials in patients with hypertension, the addition of @DRUG$ 50 to 100 mg to ACE inhibitors and @DRUG$ Elevated mean serum potassium slightly (approximately 0.09 - 0.13 mEq/L).	DDI-effect
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, sedatives, @DRUG$) should be considered.	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide , digoxin , warfarin , @DRUG$ and @DRUG$.	DDI-false
Uricosuric drugs, such as @DRUG$ and sulfinpyrazone, can inhibit renal tubular secretion of @DRUG$.	DDI-mechanism
Although there is no study data to evaluate the possibility of nitric oxide donor compounds, including @DRUG$ ug and nitroglycerin, may have an additive effect with @DRUG$ on the risk of developing methemoglobinemia .	DDI-effect
@DRUG$ The administration of tiagabin in patients who: @DRUG$ Chronically, valproate had no effect on the pharmacokinetics of tiagabin, but valproate significantly reduced tiagabin binding in vitro from 96.3 to 94.8%, resulting in an increase in free tiagabin concentration of about 40%.	DDI-false
Oral Anticoagulants CAUTION SHOULD BE EXERCISED WHEN @DRUG$ ARE GIVEN IN CONJUNCTION WITH @DRUG$.	DDI-advise
Special care should be taken in the presence of digitalis preparations, as conflicting results for the effect of @DRUG$ As regards the availability of @DRUG$ and digitoxin .	DDI-mechanism
Cholestyramine and @DRUG$ @DRUG$: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.	DDI-false
Although no clinical studies have been conducted , it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers ( such as phenytoin , phenobarbital , @DRUG$ ) , CYP3A4 inhibitors ( azole antimycotics e.g. , @DRUG$ ;	DDI-false
@DRUG$ The toxicity was usually reversible after discontinuation of @DRUG$ and the ACE inhibitor .	DDI-false
Non-steroidal Anti-inflammatory Drugs : In some patients , the administration of a @DRUG$ can reduce the diuretic , natriuretic , and antihypertensive effects of @DRUG$.	DDI-effect
The action of the benzodiazepines may be potentiated by anticonvulsants , antihistamines , @DRUG$ , barbiturates, monoamine oxidase inhibitors, @DRUG$ , Phenothiazine, psychotropic drugs, or other drugs that produce CNS depression.	DDI-false
â€¢ Isoflurane potentiates the muscle relaxant effect of all @DRUG$ , most notably @DRUG$ MAC (minimum alveolar concentration) is reduced by the concomitant use of N 2O.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Although there are no formal interaction studies except for: @DRUG$ , based on these in vivo and in vitro studies , it is unlikely that co-administration of a 1 mg dose of @DRUG$ with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs .	DDI-false
Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system ( e.g. , phenytoin , carbamazepine , @DRUG$ , ketoconazole), although this has not been studied	DDI-mechanism
Coadministration of @DRUG$ and drugs that inhibit CYP3A may increase @DRUG$ plasma concentrations.	DDI-false
Human pharmacokinetics data indicate that oral @DRUG$ potently inhibits the metabolism of @DRUG$ resulting in an eight-fold increase in the mean AUC of cisapride.	DDI-mechanism
poor metabolizers of debrisoquin : Interactions of carvedilol with strong inhibitors of CYP2D6 ( such as @DRUG$ , fluoxetine , paroxetine , and propafenone ) have not been studied , but these drugs would be expected to increase blood levels of the R(+ ) enantiomer of @DRUG$ .	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ , carbamazepine , fentanyl , alfentanyl , alprazolam , and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, @DRUG$, lovastatin, @DRUG$).	DDI-false
Lithium : @DRUG$ Toxicity has been reported in patients receiving lithium concomitantly with medicinal products that cause sodium excretion, including @DRUG$.	DDI-false
The results of the studies in patients with multiple sclerosis who: @DRUG$ Interferon beta-1a ( @DRUG$   30 mcg IM once weekly ) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate .	DDI-false
Anticoagulants including coumarin derivatives , indandione derivatives , and platelet aggregation inhibitors such as @DRUG$ ( @DRUG$ Aspirin may increase the risk of bleeding when administered at the same time as ardeparin.	DDI-false
Monoamine Oxidase Inhibitors and @DRUG$: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (@DRUG$) was more than doubled in the presence of @DRUG$/SMX.	DDI-false
Strong inducers of cytochrome P450 enzymes ( i.e. carbamazepine , @DRUG$ and @DRUG$ The plasma level of MHD ( 29 - 40% ) has been shown to decrease.	DDI-false
@DRUG$ , Methotrexate , Cyclosporine : @DRUG$ Like other NSAIDs, kidney prostaglandins can also affect and increase the toxicity of certain drugs.	DDI-false
Stavudine and @DRUG$ Ribavirin can antagonize the in vitro antiviral activity of stavudine and @DRUG$ against HIV.	DDI-false
@DRUG$ has been shown to have neuromuscular blocking properties that may enhance the action of other @DRUG$.	DDI-effect
The physician is advised to monitor the plasma concentrations of @DRUG$ when any of these drugs is taken concurrently, and to increase the dose of @DRUG$ if necessary.	DDI-false
In vitro binding studies with human serum proteins indicate that @DRUG$ binds differently than @DRUG$ and does not interact with salicylate or dicumarol.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , @DRUG$ , dolasetron , palonosetron , and alosetron ) is contraindicated .	DDI-advise
In clinical studies, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators and additional oxygen. @DRUG$ in whom therapy with FLOLAN was initiated , apparent oral clearance values for @DRUG$ On the second day of therapy, digoxin (n=30) and n=23 were reduced by 13 % and 15 % respectively.	DDI-false
Sedatives/Hypnotics: @DRUG$, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
Antiarrhythmia : Other antiarrhythmic drugs, such as @DRUG$ - procainamide, disopyramide and @DRUG$ , were used simultaneously with amiodarone.	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , cefoperazone , cefotetan , @DRUG$ , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$ , the concomitant use of Nalfon and @DRUG$ is not recommended .	DDI-false
Administration of @DRUG$ has been reported to increase the plasma levels of @DRUG$, if given concomitantly.	DDI-mechanism
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$, the concomitant use of Nalfon and @DRUG$ is not recommended.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , @DRUG$ , hydroxychloroquine , leflunomide , @DRUG$ ==References====External links==	DDI-false
@DRUG$ (neostgmine, physostigmine), @DRUG$, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.	DDI-false
@DRUG$: In healthy subjects given single 500 mg doses of cephalexin and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and @DRUG$ mean renal clearance decreased by 14%.	DDI-false
This appears to be the only clinically relevant interaction of this species with mefloquines, although theoretically the concomitant use of other drugs known to alter the heart conduction (e.g. anti-arrhythmic or beta-adrenergic blockers, @DRUG$ , antihistamines or @DRUG$ Also tricyclic antidepressants and phenothiazines could contribute to an extension of the QTc interval.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, @DRUG$, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
Diphenhydramine hydrochloride has additive effects with @DRUG$ and other CNS depressants (@DRUG$, sedatives, tranquilizers, etc).	DDI-false
bacteriostatic antibiotics : chloramphenicol, @DRUG$ , @DRUG$ , or tetracyclines may interfere with the bactericidal effect of penicillins .	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing @DRUG$ 1 micrograms/ ml), @DRUG$ ( 10 ng/ml ) , and insulin ( 3.7 micrograms/ml or 0.1 IU/ml ) .	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
therefore, @DRUG$ or other @DRUG$ (as used for management of angina) or other drugs having vasodilator activity should, if possible, be discontinued before starting captopril.	DDI-false
Oral Contraceptives: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral contraceptive @DRUG$/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
- anabolic steroids (Nandrolone [e.g. Anaboline ], Oxandrolone [e.g., @DRUG$ ] , oxymetholone [ e.g. , @DRUG$ ], stanozolol [ e.g. Winstrol ] or	DDI-false
The use of acetaminophene with acetaminophene @DRUG$ , phenobarbital with acetaminophene and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug .	DDI-false
@DRUG$, barbiturates, or @DRUG$: potentiation of orthostatic hypotension may occur.	DDI-false
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission ( e.g. , curare-like compounds ) should only be performed with caution as the effect of the @DRUG$ It can be potentiated.	DDI-false
Lithium : In a study conducted in healthy subjects , mean steady-state lithium plasma levels increased approximately 17 % in subjects receiving lithium 450 mg BID with @DRUG$ - 200 mg twice daily compared to patients who: @DRUG$ alone .	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Insulin or Oral @DRUG$ The blood sugar-lowering effect of B-blocking agents can be: @DRUG$ and oral hypoglycaemic episodes.	DDI-false
Therefore you may need to take a @DRUG$ supplement while taking @DRUG$.	DDI-advise
Example inhibitors include azole antifungals , @DRUG$ , @DRUG$ , diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with xanthine derivatives , steroids , or @DRUG$ A possible hypocalemic effect of @DRUG$	DDI-effect
In some patients, the @DRUG$ can reduce the diuretic , natriuretic , and antihypertensive effects of @DRUG$.	DDI-effect
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, @DRUG$, barbiturates, @DRUG$, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Patients on @DRUG$ treatment should be closely monitored when @DRUG$ is introduced or withdrawn .	DDI-advise
CNS-Active Drugs Ethanol : Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after @DRUG$ Administration and on the Digit symbol substitution test ( DSST), symbol copy test, and the variability component of the shared attention test for 2.5 hours after @DRUG$ administration .	DDI-false
, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, valproic acid/@DRUG$.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g., @DRUG$ , gentamicin , and amikacin ) , amphotericin B , foscarnet , intravenous pentamidine , vancomycin , and @DRUG$ ] is contraindicated .	DDI-false
@DRUG$ : Administration of @DRUG$ concomitantly with cyclosporine has been associated with an increase in cyclosporine-induced toxicity , possibly due to decreased synthesis of renal prostacyclin .	DDI-false
- Lithium : @DRUG$ Bumetanid) as they reduce renal clearance and a high risk for the use of diuretics (e. g. @DRUG$ toxicity .	DDI-false
@DRUG$: The addition of tiagabine to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and @DRUG$ (iv) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$ , imatinib , isoniazid , @DRUG$ , nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
(@DRUG$ may increase the responsiveness to @DRUG$.)	DDI-effect
Patients who begin taking diclofenac or who increase their diclofenac dose or any other @DRUG$ while taking digoxin, methotrexate, or @DRUG$ may develop toxicity characteristics for these drugs.	DDI-effect
The possibility of hypotensive effects with @DRUG$ One week before starting treatment with captopril, salt intake can be minimized either by stopping the diuretic or by increasing the intake of salt ( @DRUG$ tablets , USP ) or initiating therapy with small doses ( 6.25 or 12.5 mg ) .	DDI-false
The concomitant intake of @DRUG$ and @DRUG$ does not affect the pharmacokinetics of either alcohol or acamprosate.	DDI-false
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , @DRUG$ and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy .	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications.	DDI-advise
CYP3A4 inhibitors (e. g. @DRUG$ , macrolide antibiotics such as @DRUG$ ) have the potential to result in increased plasma concentrations of corticosteroids .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Cefmenoxime, cefoperazone, cefotetan, cefamandol, @DRUG$ ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
The clinical significance of this reduction is not known, hence @DRUG$ is not recommended to be ingested simultaneously with @DRUG$/aluminum-containing antacids.	DDI-advise
Antacids containing @DRUG$ When co-administered with: @DRUG$ , reduce both the rate and extent of absorption .	DDI-mechanism
In chronic hepatitis C patients treated with @DRUG$ In combination with COPEGUS, PEGASYS treatment did not affect @DRUG$ distribution or clearance .	DDI-false
@DRUG$ A report of heavy @DRUG$ Toxicity has been reported in a patient receiving isoniazid.	DDI-false
In clinical studies performed with @DRUG$, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , @DRUG$ , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , @DRUG$ ( e.g. , in oral contraceptives ) .	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .	DDI-false
In these patients whose hypertension is associated with @DRUG$ , @DRUG$ 20 mg produced an additional reduction in blood pressure of 6/5 mm Hg supine systolic/ diastolic compared to placebo.	DDI-effect
A similar association, though less marked, has been suggested with barbiturates, @DRUG$, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and @DRUG$ 72.	DDI-false
@DRUG$ : @DRUG$ enhance the adrenergic effect of norepinephrine .	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Other medicinal products: In small groups of patients ( 7-10/interaction study ), the concomitant use of @DRUG$ , gold , chloroquine , D-penicillamine , prednisolone , @DRUG$ , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
Reports suggest that @DRUG$ may diminish the antihypertensive effect of ACE inhibitors, including @DRUG$.	DDI-effect
- @DRUG$ : @DRUG$ The effect of various antihypertensives can be increased, which requires a reduction in the dosage of these drugs.	DDI-false
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: @DRUG$, @DRUG$, metoclopramide, pimozide.	DDI-false
These drugs include: @DRUG$ and other @DRUG$ , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$ generally should not be given with diuretics because they reduce @DRUG$s renal clearance and add a high risk of lithium toxicity .	DDI-false
The concomitant use of other CYP3A4 inhibitors such as @DRUG$ and erythromycin with transdermal fentanyl may also result in an increase in @DRUG$ plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, phenytoin, @DRUG$, rifampin, @DRUG$ or St.	DDI-false
Experience with co-administration of @DRUG$ and Fentanyl in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving @DRUG$.	DDI-false
Other potent inhibitors of CYP3A4 (e.g. itraconazole, @DRUG$ , @DRUG$ , troleandomycin , ritonavir , nelfinavir ) would be expected to behave similarly .	DDI-false
Oral @DRUG$ Â· inhibits gastrointestinal absorption of penicillin V, orally @DRUG$ , methotrexate and 5-fluorouracil .	DDI-mechanism
Magnesium/aluminium-containing antacids : absorption of @DRUG$ When co-administered with magnesium/@DRUG$-containing antacids, the dose is slightly reduced (approximately 25%).	DDI-false
Rifabutin : Coadministration of @DRUG$ and @DRUG$ This resulted in a 32% decrease in nelfinavir plasma AUC and a 20% increase in rifabutin plasma AC.	DDI-mechanism
A similar association, though less marked, has been suggested with barbiturates, @DRUG$, phenytoin sodium, carbamazepine, griseofulvin, @DRUG$, and possibly with ampicillin and tetracyclines 72.	DDI-false
Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral @DRUG$ containing 0.03 mg @DRUG$ and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetic agents, @DRUG$ , disopyramide , @DRUG$ , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
Potential interactions between TAXOL , a substrate of CYP3A4 , and protease inhibitors ( ritonavir , @DRUG$ , indinavir and @DRUG$ ) , which are substrates and/or inhibitors of CYP3A4 , have not been evaluated in clinical trials .	DDI-false
Results of studies in multiple sclerosis patients taking @DRUG$ Co-administration of interferon beta-1a (AVONEX 30 mcg IM once weekly) or glatiramer acetate was not consistent with the need for dose adjustment of beta interferon or @DRUG$.	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of @DRUG$ and @DRUG$ when administered concomitantly with an intravenous opiate such as morphine.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, @DRUG$, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
@DRUG$/@DRUG$ Triazolam, midazolam CONTRAINDICATES due to the potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression.	DDI-false
The gastrointestinal absorption of @DRUG$ and @DRUG$ is accelerated when they are coadministered with cisapride.	DDI-false
Clinical studies of @DRUG$ alone or in combination with @DRUG$ did not include sufficient numbers of subjects aged 65 or over to determine whether they respond differently from younger subjects.	DDI-false
International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking @DRUG$ while on @DRUG$ therapy.	DDI-effect
Can use thyroid drugs (e.g. levothyroxin), @DRUG$-containing products, antacids, H2 antagonists (e.g. famotidine, ranitidine) and proton pump inhibitors (e.g., @DRUG$ ,,,,,,,,,,,	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , @DRUG$ , sympathomimetics , calcium channel blocking drugs , and @DRUG$.	DDI-false
Based on the chemical resemblance of @DRUG$ and ketoconazole, coadministration of @DRUG$ with itraconazole is contraindicated.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-false
@DRUG$: Amphetamines enhance the adrenergic effect of @DRUG$.	DDI-false
Carbamazepine : @DRUG$ It is known to slow down your metabolism @DRUG$ and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely , and appropriate dosage adjustment of the anticonvulsant should be made .	DDI-mechanism
The concomitant use of Natrecor with IV @DRUG$ such as @DRUG$ Nitroprusside, milrinone or IV ACE inhibitors have not been studied (these drugs were not administered with Natrecor in clinical trials).	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$ MTX, NSAIDs, corticosteroids, TNF blockers, azathioprin, chloroquine, gold, @DRUG$ , leflunomide , sulfasalazine , and anakinra .	DDI-false
@DRUG$ As with some other quinolones, concomitant administration of @DRUG$ with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
Coadministration of Itraconazole and cyclosporine, @DRUG$ or @DRUG$ has led to increased plasma concentrations of the latter three drugs.	DDI-false
@DRUG$ Supplements and @DRUG$: Fosinopril sodium can attenuate potassium loss caused by thiazide diuretics.	DDI-false
@DRUG$ inhibits the ERMBT, and rifampin and @DRUG$ are equipotent inducers of the ERMBT.	DDI-false
There have been greater than 2-fold increases in previously stable plasma levels of other @DRUG$, including nortriptyline, when @DRUG$ has been administered in combination with these agents.	DDI-mechanism
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
@DRUG$ : Concurrent administration of aspirin may lower @DRUG$ Plasma levels, possibly through competition for protein-binding sites.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
INOmax has been administered with tolazoline , @DRUG$ , @DRUG$ , steroids , surfactant , and high-frequency ventilation .	DDI-false
@DRUG$ (such as @DRUG$);	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
- Methotrexate (e.g., Mexate) Use of methotrexate with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	DDI-false
@DRUG$: while a synergistic relationship with amphotericin B has been reported, concomitant use may increase the toxicity of @DRUG$ by possibly increasing its cellular uptake and/or impairing its renal excretion.	DDI-false
Since there is a theoretical basis for these effects to be additive, the use of ergotamine containing or @DRUG$ ( like @DRUG$ or methysergide ) and AXERT within 24 hours of each other should be avoided .	DDI-false
Tacrolimus  @DRUG$ may increase the blood concentration of @DRUG$.	DDI-false
ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/ARB).	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramides, fibrates, fluoxetine, @DRUG$ , propoxyphene , @DRUG$ Somatostatin analogue (e.g. octreotide), sulphonamide antibiotics.	DDI-false
May interact with the following : cholestyramine , @DRUG$ The use of thiazide diuretics may prevent @DRUG$ - from proper work;	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Curariform muscle relaxants ( eg , tubocurarine ) and other drugs , including ether , @DRUG$ , gallamine , decamethonium and @DRUG$ Neuromuscular blocking should be intensified and administered with extreme caution to patients treated with Coly-Mycin M Parenteral.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ (such as @DRUG$) can be acutely worsened by beta-agonists, especially when the recommended dose of the beta-agonist is exceeded.	DDI-false
These drugs include: @DRUG$ and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and @DRUG$.	DDI-false
A drug interaction study investigated the effect of using ACZONE gel, 5%, in combination with double strength (160 mg/800 mg) trimethoprim/sulfamethoxazole ( @DRUG$/@DRUG$ ) .	DDI-false
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	DDI-false
@DRUG$ : Concomitant administration of antacids may reduce plasma levels of @DRUG$.	DDI-false
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for furosemide ( n = 23 ) and @DRUG$ ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
@DRUG$ SSRIs: SSRIs (e.g. fluoxetine, @DRUG$ , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5-HT1 agonists .	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , @DRUG$ , nicardipine , propofol , protease inhibitors , @DRUG$ , and verapamil .	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and barbiturates, and the @DRUG$ rifampin.	DDI-false
When CANCIDAS is co-administered with drug clearance inducers such as efavirenz, @DRUG$ , phenytoin, dexamethasone or carbamazepine, administration of a daily dose of 70 mg @DRUG$ should be considered	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Possible drug interactions of HUMORSOL with @DRUG$ or with other @DRUG$.	DDI-false
No pharmacokinetic interactions between @DRUG$ and isoflurane, propofol, alfentanil and @DRUG$ have been demonstrated .	DDI-false
Therefore, @DRUG$ may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, ketoconazole, @DRUG$ salts and digoxin).	DDI-mechanism
In the present study, the @DRUG$ clozapine was tested in combination with an active dose of @DRUG$ in two-lever drug discrimination and mixed signalled-unsignalled differential-reinforcement-of-low-rates (DRL) procedures.	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and @DRUG$, and the antituberculosis drug rifampin.	DDI-effect
After multiple dosing, @DRUG$ (@DRUG$  30 mcg IM once weekly) reduced TYSABRI  clearance by approximately 30%.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
It is recommended that the concomitant use of ethambutol with @DRUG$ containing @DRUG$ for at least 4 hours following ethambutol administration .	DDI-false
Therefore, EXTREME CAUTION should be exercised when administering dopamine HCl to patients receiving @DRUG$ or @DRUG$.	DDI-false
Drugs with a Narrow Therapeutic Index Digoxin : @DRUG$ ( 10 mg ) did not affect the pharmacokinetic or pharmacodynamic profile of @DRUG$ ( 0.375 mg q24h for 8 days ) .	DDI-false
@DRUG$ is metabolized to @DRUG$ by the cytochrome P450 ( CYP450 ) enzyme group , specifically cytochromes P450 3A4 ( CYP3A4 ) and CYP2C8 .	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	DDI-false
However, the concomitant use of @DRUG$ and @DRUG$ ( 5 - 7.5 mg initial oral dose followed by 2.5 - 6 mg/day orally for 6 - 10 days ) results in prolongation of the prothrombin time ( PT ) and International Normalized Ratio ( INR ) .	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
@DRUG$: Coadministration of @DRUG$ and verapamil resulted in a 24% increase in plasma concentrations of almotriptan.	DDI-false
Serial plasma and urine samples for the measurement of @DRUG$ , @DRUG$ , and rifampin and their 25-O-desacetyl metabolites , were measured by high-performance liquid chromatography .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : @DRUG$ , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives @DRUG$ rifampin benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
However, no harmful interactions have been observed when ROMAZICON is observed after @DRUG$ , inhalation anaesthetics, @DRUG$ Muscle relaxant antagonists used in combination with sedation or anaesthesia.	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating CNS depressants such as @DRUG$, opiates, and @DRUG$.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, @DRUG$ , diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ ( e.g. , in oral contraceptives ) .	DDI-false
The effect of benzodiazepines can be enhanced by anticonvulsants, antihistamines, alcohol, @DRUG$ , @DRUG$ Anaesthetics, phenothiazines, psychotropic drugs, or other drugs that produce CNS depression.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , @DRUG$ Doses of 1 mg or more have been associated with acetaminophene, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
Alcohol, @DRUG$, or @DRUG$: potentiation of orthostatic hypotension may occur.	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , @DRUG$ â€¢ hypnotism, sedatives (e.g. benzodiazepines), general anaesthesia, phenothiazine, @DRUG$ , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
- @DRUG$ ( @DRUG$ [ e.g. , Anabolin ] , oxandrolone [ e.g. , Anavar ] , oxymetholone [ e.g. , Anadrol ] , stanozolol [ e.g. , Winstrol ] ) or	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Another oral @DRUG$, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite desmethylastermizole which may prolong QT intervals.	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone , they modify the mitogenic effect of EGF and @DRUG$.	DDI-effect
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$ , @DRUG$ , nifedipine , chlordiazepoxide , diazepam , certain tricyclic antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
@DRUG$: As with other b-lactams, the renal excretion of @DRUG$ is inhibited by probenecid.	DDI-false
Concomitant cyclophosphamide, doxorubicin, @DRUG$, and prednisone chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Antidepressants, tricyclic @DRUG$ may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-effect
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Therefore, medications with a low therapeutic leeway, such as @DRUG$ , phenytoin , and @DRUG$ , delayed elimination and elevation of their serum half-life could lead to a toxic level.	DDI-false
@DRUG$: Amphetamines inhibit the hypotensive effect of @DRUG$.	DDI-false
Probenecid: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by @DRUG$ and resulted in an approximate 80% increase in the AUC for @DRUG$.	DDI-false
Additionally , higher than expected @DRUG$ The values were observed in patients already taking @DRUG$.	DDI-mechanism
Hepatic enzyme inducers, inhibitors and substrates : drugs that induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity (e.g. barbiturates, @DRUG$ , carbamazepine , @DRUG$ ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased .	DDI-false
Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
In a study in which patients with active RA were treated with concomitant treatment for up to 24 weeks @DRUG$   and anakinra therapy , a 7 % rate of serious infections was observed , which was higher than that observed with @DRUG$   alone ( 0 % ) .	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Oral @DRUG$: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral @DRUG$ norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
Antihypertensives: @DRUG$ may antagonize the hypotensive effects of @DRUG$.	DDI-effect
@DRUG$, a bacteriostatic antibiotic, may antagonize the bactericidal effect of @DRUG$ and concurrent use of these drugs should be avoided.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Notably, systemic exposure (AUC0-12) of dapsone hydroxylamine (DHA) was more than doubled in the presence of @DRUG$/@DRUG$.	DDI-false
Additionally , paroxetine did not alter the pharmacokinetics of @DRUG$ This is due to the lack of a role of CYP2D6 in @DRUG$ s metabolism .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
hypersensitivity reactions have been reported in patients receiving combination regimens with sequentially high-dose PROLEUKIN and @DRUG$ , specifically , @DRUG$ , cis-platinum , tamoxifen and interferon-alfa .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
@DRUG$-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of vitamin K.	DDI-false
In a study in which patients with active RA were treated for up to 24 weeks with concurrent ENBREL  and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$  alone (0%).	DDI-false
Other medicines: In small groups of patients ( 7 - 10/interaction study ), concomitant administration of azathioprin, gold, chloroquine, D-penicillamin, @DRUG$ Doxycycline, doxycycline or @DRUG$ The peak and AUC values of Diclofenac were not significantly affected.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, procainamide, @DRUG$, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, carbamazepine, @DRUG$, phenobarbital or St.	DDI-false
Other medicinal products: PRINIVIL was co-administered with @DRUG$ and/or @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
DOSTINEX should not be administered concurrently with D2-antagonists, such as @DRUG$, @DRUG$, thioxanthines, or metoclopramide.	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenyl-butazone , phenytoin sodium , carbamazepine and possibly with @DRUG$ , ampicillin, and @DRUG$ ( 72 )	DDI-false
conversely, @DRUG$ may interfere with antihypertensive drugs (i.e., @DRUG$, a-methyldopa).	DDI-int
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. @DRUG$), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or @DRUG$ is impaired	DDI-false
These drugs include the @DRUG$ and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : @DRUG$ ( e.g. gentamicin, amikacin), @DRUG$ , cyclosporine , non-steroidal anti-inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin .	DDI-false
Because there are no data on the compatibility of @DRUG$ and crystalline zinc insulin preparations, @DRUG$ should not be mixed with these preparations.	DDI-false
Benzylpenicillin , ampicillin , oxacillin , @DRUG$ In vitro, doxycycline, cephalothine, erythromycin and sulfamethoxazole have no effect on protein binding of @DRUG$ In human serum.	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Prior administration of @DRUG$ has no clinically important effect on the neuromuscular blocking action of @DRUG$.	DDI-false
@DRUG$ may antagonize the neuron blockade produced by @DRUG$ resulting in decreased antihypertensive effect and requiring increased dosage of the latter .	DDI-effect
These drugs include thiazides and other @DRUG$ , @DRUG$ , phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isoniazide.	DDI-false
Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and @DRUG$) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: orally @DRUG$ , @DRUG$ , disopyramide , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Elevated plasma levels of @DRUG$ have been reported with concomitant @DRUG$ use.	DDI-mechanism
Other CONCOMITANT THERAPY: Although no specific interaction studies have been conducted, cerivastatin sodium was used in clinical trials with angiotensin converting enzyme inhibitors (ACE), @DRUG$ , calcium-channel blockers , diuretics , and nonsteroidal anti-inflammatory drugs ( @DRUG$ ) without evidence of clinically significant adverse interactions.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , @DRUG$ , tacrolimus , cyclosporine , @DRUG$ , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
@DRUG$ may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, CYP2D6, and CYP3A4.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Warfarin : The effect of @DRUG$ The anticoagulant effect of warfarin ( 1 - 8 mg/ day ) was reported in healthy subjects when co-administered with @DRUG$ 40 mg twice daily for 7 days.	DDI-false
Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
( @DRUG$ The responsiveness to @DRUG$ can be increased. )	DDI-effect
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , @DRUG$ , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin , nitroprusside , @DRUG$ ACE inhibitors have not been studied (these medicinal products have not been co-administered with @DRUG$ in clinical trials ) .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
The hypoglycemic action of @DRUG$ â€¢ may be exacerbated by certain drugs, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, probenecid, @DRUG$ , monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , @DRUG$ , @DRUG$ And vincristine.	DDI-false
@DRUG$ and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , @DRUG$ , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and @DRUG$.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	DDI-false
â€¢ Furosemide: Clinical studies and post-marketing observations have shown that NSAIDs have the natriuretic effect of @DRUG$ and @DRUG$ in some patients .	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
In separate studies of patients receiving maintenance doses of @DRUG$, hydrochlorothiazide, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
@DRUG$ : The concomitant use of @DRUG$ with long- and short-acting nitrates has been safely tolerated in patients with stable angina pectoris .	DDI-false
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, @DRUG$, certain @DRUG$, etc.).	DDI-false
Inducers and Inhibitors of Hepatic Metabolism : @DRUG$ reduced plasma concentrations of @DRUG$ by about 70 % .	DDI-mechanism
These drugs include thiazides and other diuretics, @DRUG$ , phe-nothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimet-ics , calcium channel blocking drugs , and @DRUG$.	DDI-false
Protein Binding In vitro , diclofenac interferes minimally or not at all with the protein binding of @DRUG$ ( 20 % decrease in binding ) , @DRUG$ Prednisolone (10% reduction in binding) or warfarin.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
Warfarin: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing @DRUG$ therapy in patients receiving @DRUG$ or similar agents, since these patients are at an increased risk of bleeding complications.	DDI-advise
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of @DRUG$ on the cardiovascular system may be potentiated by these agents.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$ : MTX , NSAIDs , corticosteroids , TNF blocking agents , @DRUG$ , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .	DDI-false
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
@DRUG$ â€¢ Co-administration of a single dose of @DRUG$ 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance .	DDI-false
@DRUG$ In diabetic patients who: @DRUG$ No significant effects on tolbutamide plasma levels or fasting blood glucose were observed.	DDI-false
Dopamine-induced renal and mesenteric vasodilation is not antagonized by either @DRUG-DRUG$.	DDI-false
@DRUG$ : In some patients with compromised renal function who are being treated with nonsteroidal anti-inflammatory drugs , the co-administration of @DRUG$ For this reason, further deterioration of renal function may result.	DDI-false
When the @DRUG$ was administered 30 minutes after the @DRUG$ The AUC of butorphanol increased by 11% and the Cmax by 18%.	DDI-mechanism
Antiarrhythmic agents, class I (such as flecainide, @DRUG$, or @DRUG$): concurrent use with arbutamine may have a proarrhythmic effect.	DDI-false
- When @DRUG$ or @DRUG$ is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	DDI-false
@DRUG$ , Nimodipine and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and @DRUG$ It has no significant influence on bosentan plasma levels.	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
@DRUG$ : The effect of @DRUG$ The anticoagulant effects of warfarin have been studied in a group of healthy volunteers who received daily doses of 2-5 mg warfarin.	DDI-false
Other Chemotherapy Agents In a separate study , concomitant administration of @DRUG$ with capecitabine did not meaningfully alter the pharmacokinetics of either agent ( or the metabolites of @DRUG$ ) .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmia: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigrain: ergot derivatives @DRUG$ rifampin benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-advise
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ ==References====External links== @DRUG$ , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
Other reported interactions with @DRUG$ : @DRUG$ ( CYP3A4 substrate ) in combination with amiodarone may cause hypotension , bradycardia , and decreased cardiac output .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs (@DRUG$) : @DRUG$: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Co-administration of @DRUG$ and @DRUG$ did not alter the pharmacokinetics of cerivastatin sodium.	DDI-false
Combinations of @DRUG$ and @DRUG$: effects on drug discrimination and behavioral inhibition in rats.	DDI-false
Therapeutic concentrations of digoxin , @DRUG$ , ibuprofen , naproxen , @DRUG$ , acetaminophen , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Strong inducers of cytochrome P450 enzymes (i.e. @DRUG$, phenytoin and phenobarbital) have been shown to decrease the plasma levels of @DRUG$ (29-40%).	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Paroxetine : Coadministration of a single dose of @DRUG$ 20 mg and @DRUG$ 20 mg daily for 7 days did not produce any interaction on psychomotor performance .	DDI-false
@DRUG$ should not be administered concurrently with D2-antagonists, such as phenothiazines, @DRUG$, thioxanthines, or metoclopramide.	DDI-advise
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Anticoagulants: potentiation of the warfarin type ( CYP2C9 and @DRUG$ Anticoagulant response is almost always observed in patients who: @DRUG$ And can lead to severe or fatal bleeding.	DDI-false
@DRUG$ : Coadministration of ritonavir with @DRUG$ This resulted in an increase in nelfinavir plasma AUC of 152% and a very small change in ritonavir plasma AC.	DDI-false
@DRUG$ (ammonium chloride, sodium acid phosphate, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	DDI-mechanism
Acidifying agents: Gastrointestinal acidifying agents (guanethidine, @DRUG$, glutamic acid HCl, @DRUG$, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
Allopurinol : In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when @DRUG$ and @DRUG$ were administered concomitantly for 6 days .	DDI-false
Patients treated with @DRUG$ and @DRUG$ At the same time, an increase in INR and prothrombin time may need to be considered.	DDI-effect
Beta-Blocking Agents  A pharmacokinetic study of @DRUG$ in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of @DRUG$.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine @DRUG$ : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines @DRUG$ , triazolam GI motility agents : cisapride	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir ( FORTOVASE ) as the sole @DRUG$ Because of the risk of decline @DRUG$ plasma concentrations .	DDI-false
No significant pharmacokinetic interactions between medicinal products and medicinal products have been established in interaction studies with: @DRUG$ , digoxin , @DRUG$ , cimetidine and phenobarbital .	DDI-false
D-amphetamine with desipramine or protriptyline and possibly others @DRUG$ â€¢ Significant and sustained increases in the concentration of @DRUG$ in the brain ;	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Erythromycin Co-administration of @DRUG$ (PLENDIL) with @DRUG$ resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.	DDI-false
Non-steroidal Anti-inflammatory Agents: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of @DRUG$ may result in a further deterioration of renal function.	DDI-effect
This drug may interact with @DRUG$ or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
@DRUG$ (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, cimetidine, and @DRUG$ in controlled clinical pharmacology studies in adult volunteers.	DDI-false
Antibiotics : In vitro and/or in vivo data show that clarithromycin , @DRUG$ , and @DRUG$ Remarkably, inhibit the metabolism of cisaprid, which may lead to an increase in plasma cisaprid levels and prolongation of the QT interval on the ECG.	DDI-false
In patients who have received muscle relaxants , @DRUG$ The remaining effects of @DRUG$ can be temporarily obscured.	DDI-effect
Although there is no study data to evaluate the possibility of nitric oxide donor compounds, including @DRUG$ and @DRUG$ , may have an additive effect with INOmax on the risk of developing methaemoglobinaemia.	DDI-false
Histamine H2-receptor antagonists: @DRUG$ appear to have no significant effect on the bioavailability of @DRUG$.	DDI-false
@DRUG$ * Concomitant administration of single doses of Sonata 20 mg and @DRUG$ 50 mg resulted in additive effects on reduced alertness and impaired psychomotor performance 2 to 4 hours after administration.	DDI-false
@DRUG$ may decrease the effect of phenothiazines , @DRUG$ , and ketoconazole .	DDI-effect
No significant interactions were found between @DRUG$ and @DRUG$ or digoxin.	DDI-false
The compounds in these categories lead to a reduced efficacy of bromocliptin mesylate : @DRUG$ , @DRUG$ , methoclopramid, pimozide.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
In patients with chronic hepatitis C treated with PEGASYS in combination with COPEGUS , @DRUG$ The treatment did not affect @DRUG$ Distribution or release.	DDI-false
The effects of mixing @DRUG$ with insulins of animal source or @DRUG$ preparations produced by other manufacturers have not been studied .	DDI-false
â€¢ Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-effect interactions between argatroban and co-administered aspirin ( 162.5 mg orally 26 and 2 hours before starting argatroban 1 g/kg/min for 4 hours), or @DRUG$ ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of Argatroban 1.5   g/kg/min . over 18 hours ) .	DDI-false
These drugs include the @DRUG$ And other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and @DRUG$.	DDI-false
@DRUG$ : Phenylbutazone causes increase ( by about 80 % ) in the free fraction of @DRUG$.	DDI-false
The concomitant administration of @DRUG$ and other @DRUG$ have resulted in previous reports of rhabdomyolysis.	DDI-effect
Concomitant administration of @DRUG$ (equivalent to 145 mg @DRUG$) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, TAXOL before @DRUG$).	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, @DRUG$.	DDI-false
HIV Protease Inhibitors : Indinavir ( 800 mg t.i.d . ) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC , a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
Although there is no documentation of such, a similar interaction between @DRUG$ and the @DRUG$ may occur.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
It is recommended that CASODEX be used in patients who are already @DRUG$ Prothrombin times should be closely monitored and adjusted. @DRUG$ dose may be necessary .	DDI-false
@DRUG$: Administration of @DRUG$ with VIRACEPT resulted in the appearance of unchanged terfenadine in plasma;	DDI-false
Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of carbamazepine , @DRUG$ , topiramate, or lamotrigine.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Other Drug Interactions Oral @DRUG$ Keppra ( 500 mg twice daily ) affected the pharmacokinetics of an oral contraceptive with 0.03 mg ethinylestradiol and 0.15 mg @DRUG$ , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .	DDI-false
Cohort 1 then received amprenavir plus @DRUG$ for 10 days, and cohort 2 received @DRUG$ plus rifampin for 4 days.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, @DRUG$ or itraconazole.	DDI-false
FLEXERIL may enhance the effects of alcohol , @DRUG$ And others @DRUG$.	DDI-false
This medication may interact with alcohol or other CNS depressants (may potentiate the CNS depressive effect of either these drugs or antihistamines), @DRUG$ or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$ Inhibitors (co-administration with antihistamines may prolong and increase the anticholinergic and CNS depressive effects of antihistamines).	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.	DDI-effect
Patients receiving other narcotic analgesics, general anaesthetics, phenothiazine, sedatives, sedative hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) together with: @DRUG$ may exhibit an additive CNS depression .	DDI-effect
Patients receiving other narcotic analgesics generally @DRUG$ , phenothiazine, sedatives, @DRUG$ , tricyclic antidepressants or other CNS depressants (including alcohol) together with DILAUDID may exhibit additive CNS depression.	DDI-false
Lethargy and somnolence were observed after @DRUG$ and @DRUG$.	DDI-effect
It has been reported that phenobarbital toxicity in patients with chronic @DRUG$ treatment following the initiation of @DRUG$ therapy .	DDI-effect
Benzthiazide may interact with @DRUG$, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Patients receiving @DRUG$ along with either oral or intravenous @DRUG$ should be monitored for possible atrioventricular conduction disturbances, left ventricular failure and hypotension.	DDI-advise
Consequently , the combination of @DRUG$ with @DRUG$ is also contraindicated .	DDI-advise
@DRUG$, tricyclic antidepressants, and @DRUG$ may increase anticholinergic effect of clidinium.	DDI-false
It is recommended that concomitant use of @DRUG$ with @DRUG$ containing antacids for at least 4 hours following ethambutol administration .	DDI-advise
Antiarrhythmics: Amiodarone, bepridil, @DRUG$, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
For this reason, the dose of the @DRUG$ should be reduced by 30 - 50% at the start of treatment with @DRUG$ or Bezalip retard and then titrated according to the blood clotting parameters	DDI-advise
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$ , presumably through inhibition of CYP3A : nefazodone , @DRUG$ , cimetidine , diltiazem , isoniazide , and some macrolide antibiotics .	DDI-mechanism
Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. @DRUG$ , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine, and sodium colistimethate), magnesium salts, lithium, local @DRUG$ , procainamide , and quinidine .	DDI-false
Saquinavir: concomitant use of saquinavir (with an experimental soft gelatine capsule formulation of @DRUG$ 1200 mg) with @DRUG$ resulted in an 18 % increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Coingestion of @DRUG$ With theophylline, phenobarbital with acetaminophene and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug .	DDI-false
The bioavailability of the capsule formulation of @DRUG$ was not affected when administered 5 minutes following an @DRUG$.	DDI-false
@DRUG$ Supplements and @DRUG$ Fosinopril sodium may reduce potassium loss due to thiazide diuretics.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines , presumably through inhibition of CYP3A : @DRUG$ , fluvoxamine, cimetidine, diltiazem, isoniazid, and some @DRUG$.	DDI-false
Effect of @DRUG$ To the apparent volume of distribution and elimination of @DRUG$.	DDI-false
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of @DRUG$ was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
Drugs which inhibit CYP 3A4 (e.g., @DRUG$, @DRUG$ such as erythromycin) have the potential to result in increased plasma concentrations of corticosteroids.	DDI-false
HIV protease inhibitors: indinavir (800 mg t.i.d.) together with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC , a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life .	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been used in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, @DRUG$ Angiotensin converting enzymes (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium channel blockers, heart @DRUG$ , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients receiving antihypertensive agents (e.g. @DRUG$ , a CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, @DRUG$ inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
HIV Protease Inhibitors : Indinavir ( 800 mg t.i.d . ) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life .	DDI-false
@DRUG$ : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other @DRUG$ , including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and deep sedation, or possibly lead to coma or death.	DDI-false
Profound hypotensive episodes may occur when @DRUG$ infection and @DRUG$ It is used at the same time.	DDI-effect
@DRUG$ (@DRUG$)-A drug interaction study of eplerenone with an NSAID has not been conducted.	DDI-false
@DRUG$ : @DRUG$ *, terfenadine * CONTRAINDICATED due to the potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
The following are examples of substances that can reduce the blood glucose-lowering effect: @DRUG$ , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , @DRUG$ , thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
There have been case reports of increased steady-state levels of quinidine, @DRUG$ , and phenytoin during concomitant therapy with @DRUG$.	DDI-false
@DRUG$ : @DRUG$ ( 10 mg and 20 mg ) did not potentiate the increase in bleeding time caused by aspirin ( two 81 mg tablets ) .	DDI-false
Agents Causing Renin Release : The antihypertensive effect of @DRUG$ Ug and enalapril IV is supplemented by @DRUG$ that cause renin release ( e.g. , diuretics ) .	DDI-effect
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
It is suggested that in patients receiving @DRUG$, alternatives to @DRUG$ should be used if anticonvulsant therapy is needed.	DDI-advise
A possible interaction between @DRUG$ and @DRUG$, a fluoroquinolone antibiotic, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.	DDI-int
@DRUG$ : @DRUG$ It inhibits the blood pressure lowering effect of veratrum alkaloids.	DDI-false
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including @DRUG$, @DRUG$, and alcohol.	DDI-false
@DRUG$ , tricyclic: amphetamines can increase the activity of tricyclic or @DRUG$ ;	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, @DRUG$, griseofulvin, @DRUG$, and possibly with ampicillin and tetracyclines 72.	DDI-false
â€¢ WARFARIN: @DRUG$ and @DRUG$ No changes in prothrombin time or coagulation factor VII occurred in healthy volunteers compared to co-administration of warfarin and placebo.	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
These drugs include thiazides and other @DRUG$ , corticosteroids , phenothiazines , thyroid products , estrogens , oral @DRUG$ , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Interaction on the antinociceptive effect between @DRUG$ and @DRUG$ or tuftsin.	DDI-effect
Possible interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$ , primidone and valproate) were also evaluated by estimating the serum concentrations of levetiracetam and valproate. @DRUG$ â€¢ during placebo-controlled clinical trials.	DDI-false
The effects of GABITRIL on other antiepilepsia drugs ( AEDs ): @DRUG$ : @DRUG$ had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy .	DDI-false
Analysis of the concentration of @DRUG$ After ultracentrifugation, it was shown that there was a rapid equilibrium reaction of budesonide between the @DRUG$ and aqueous phase .	DDI-false
DIGOXIN : Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ â€¢ can cause acidic drugs such as: @DRUG$ or tolbutamide from their binding sites .	DDI-mechanism
The action of the @DRUG$ # Can be potentiated by: @DRUG$ , antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic drugs, or other drugs that produce CNS depression.	DDI-effect
These drugs include thiazides and other diuretics, @DRUG$ , phenothiazines , thyroid products , estrogens , oral @DRUG$ , phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
Co-administration of valdecoxib ( 40 mg twice daily ( day 1 ) and 40 mg twice daily ( days 2 - 7 ) with @DRUG$ 10 mg glyburide twice daily) resulted in an increase of 21% @DRUG$ AUC0-12 and a 16% increase in glyburide Cmax lead to a 16% decrease in glucose AUC0-24.	DDI-false
Concomitant administration of fenofibrate (equivalent to 145mg @DRUG$) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for @DRUG$ by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	DDI-false
@DRUG$ serum concentrations should be monitored closely when initiating or changing therapy with BEXTRA in patients receiving @DRUG$.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, @DRUG$ , bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$ , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Patients who start taking this medicine @DRUG$ or their dose of Diclofenac or any other dose of Diclofenac. @DRUG$ while taking digoxin , methotrexate , or cyclosporine may develop toxicity characteristics for these drugs .	DDI-false
Concomitant administration of @DRUG$ ( 10 mg ) and cimetidine ( 800 mg ) produced an 85 % increase in the mean Cmax and AUC of @DRUG$.	DDI-false
It is recommended not to exceed a single 2.5 mg @DRUG$ dose in a 24-hour period when used in combination with @DRUG$.	DDI-advise
@DRUG$: Quinolones have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives.	DDI-false
Hormonal Contraceptives , Including Oral , Injectable , Transdermal , and Implantable Contraceptives : An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive @DRUG$ The average decrease in estradiol levels of norethindron and ethinyl was 14% and 31% respectively.	DDI-mechanism
@DRUG$, other, especially @DRUG$, or preanesthetic and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery	DDI-false
Magnesium/@DRUG$-containing @DRUG$ The absorption of zalcitabine is moderately reduced (about 25%) when co-administered with magnesium/aluminium-containing antacids.	DDI-false
@DRUG$-@DRUG$ may decrease the absorption of vitamin K.	DDI-false
Garlic Capsules Garlic capsules should not be used while taking saquinavir ( @DRUG$ ==References====External links== @DRUG$ due to the risk of decreased saquinavir plasma concentrations .	DDI-false
OBJECTIVE : Our goal was to promote the steady-state pharmacokinetics of everolimus and @DRUG$ ( INN , @DRUG$ ) when coadministered in de novo kidney allograft recipients during the first year after transplantation .	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., @DRUG$, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Sine bradycardia has been reported with oral amiodarone in combination with lidocaine ( @DRUG$ substrate ) given for local @DRUG$.	DDI-false
A drug interaction study investigated the effect of using ACZONE gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/@DRUG$ ( TMP/SMX ).	DDI-false
Other potent inhibitors of CYP3A4 (e.g. itraconazole, @DRUG$ , nefazodone, troleandomycin, @DRUG$ nelfinavir is expected to behave similarly.	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Other medicines: In small groups of patients ( 7 - 10/interaction study ), concomitant administration of azathioprin, gold, chloroquine, D-penicillamin, @DRUG$ @DRUG$ peak and AUC values were not significantly affected by doxycycline, doxycycline or digitoxin.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , @DRUG$ , analgesics, antiemetics, @DRUG$ , tranquilizers ) .	DDI-false
In monkeys , @DRUG$ was about 10 times more potent than (+)-NANM in decreasing responding , whereas in pigeons (-)-NANM was about equipotent with @DRUG$.	DDI-false
Aspirin/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1   g/kg/min . over 4 hours ) or @DRUG$ ( 1000 mg orally administered 12, 6 and 0 hours before, and 6 and 12 hours after, beginning of the @DRUG$ 1.5 g/kg/min over 18 hours).	DDI-false
Antiacid, clarithromycin, @DRUG$ , fluconazole, fluoxetine, indanavir, ketoconazole, phenytoin, phenobarbitol, carbamazepine, @DRUG$ , Rifampin , Ritanovir , Saquinavir .	DDI-false
@DRUG$ : Amphetamines may antagonize the hypotensive effects of @DRUG$.	DDI-false
Therefore, esomeprazole may impair the absorption of medicines in which the pH of the stomach is an important determinant of bioavailability (e.g. @DRUG$ , iron salts and @DRUG$ ) .	DDI-false
Coingestion of acetaminophen with theophylline , @DRUG$ - with acetaminophene and @DRUG$ The binding of the target medication is reduced with phenobarbital at high to toxic concentrations.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Valdecoxib caused a statistically significant increase in plasma exposure of @DRUG$ pharmacodynamic effect (prothrombin time measured as INR) of @DRUG$.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
In patients taking diclofenac and @DRUG$ concomitantly , @DRUG$ toxicity may develop .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous @DRUG$ (e.g. tobramycin, gentamicin and @DRUG$ ) , amphotericin B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ Amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
ACE Inhibitors and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension , the addition of @DRUG$ 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly ( about 0.09 - 0.13 mEq/L ) .	DDI-false
DOSTINEX should not be administered concurrently with D2-antagonists , such as @DRUG$ , @DRUG$ Thioxanthine or methoclopramide.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: Coadministration of single doses of Sonata 20 mg and @DRUG$ 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, @DRUG$, @DRUG$, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of @DRUG$ and may potentiate the action of @DRUG$.	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ and salicylates is not recommended.	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., @DRUG$, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications.	DDI-advise
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, @DRUG$, ethanol or itraconazole.	DDI-false
Injection : Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system if with @DRUG$ , phenothiazines , @DRUG$ An increased incidence of sedation, hallucinations and irrational behaviour was observed with co-administration of scopolamine with injectable lorazepam.	DDI-false
Co-administration of naltrexone with @DRUG$ produced a 25% increase in AUC and a 33% increase in the Cmax of @DRUG$.	DDI-false
Coadministration of Itraconazole and @DRUG$, tacrolimus or @DRUG$ has led to increased plasma concentrations of the latter three drugs.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ : The combination of HIVID , @DRUG$ , and ZDV has been studied ( as triple combination ) in adults .	DDI-false
Other CNS depressant drugs ( e.g. @DRUG$ , @DRUG$ The effects of INAPSINE are additive or potentiating (e. g. opioids, and general anaesthetics).	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV were co-administered with beta-adrenergic blockers, methyldopa, @DRUG$ * Calcium blockers, hydralacin, @DRUG$ and digoxin without evidence of clinically significant adverse interactions .	DDI-false
There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable @DRUG$ therapy were treated concurrently with @DRUG$ (4 mg/kg once every 24 hours) for 14 days.	DDI-false
Both ibogaine and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only @DRUG$ increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
Both efavirenz and @DRUG$ have been compared to triple therapy with the PI indinavir over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with @DRUG$.	DDI-false
Promethazine: Coadministration of a single dose of @DRUG$ and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of @DRUG$, but no change in the area under the plasma concentration-time curve.	DDI-false
@DRUG$ with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of d-amphetamine in the brain;	DDI-mechanism
Similarly dialyzed were phenobarbital , @DRUG$ , and @DRUG$ , both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum .	DDI-false
â€¢ Medicines/Laboratory test interaction After treatment with @DRUG$ A false positive reaction to glucose in the urine can be observed in @DRUG$ tests ( Benedicts solution , Fehlings solution , or Clinitest tablets ) but not with enzyme based tests such as Clinistix and Glucose Enzymatic Test Strip USP .	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with @DRUG$ (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, carbamazepine, and barbiturates, and the @DRUG$ rifampin.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines , @DRUG$ , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimet-ics , @DRUG$ , and isoniazid .	DDI-false
There are 3 types of indications : specific ( for the treatment of some forms of @DRUG$ deficit i.e. acute ) , pharmacological ( i.e. without alterations of @DRUG$ status ) and mixed -- pharmacological and aetiopathogenic--(for example complications of chronic alcoholism ) .	DDI-false
It may increase excretion of barbiturates, @DRUG$, and ASA and may also increase the toxicity of @DRUG$.	DDI-false
Heart glycosides : In a study in young healthy male subjects no evidence of direct pharmacokinetics @DRUG$-@DRUG$ interaction could be found .	DDI-false
Lithium: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	DDI-false
The AUC of @DRUG$ was increased 2.2-fold by coadministration of @DRUG$ , a potent inhibitor of CYP3A4 , 400 mg daily for 5 days .	DDI-mechanism
@DRUG$ ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of amphotericin B and @DRUG$ Imidazole can cause fungal resistance to amphotericin B.	DDI-false
In a study in which the 2 mg @DRUG$ The oral disintegrating tablet was administered with and without propanthelin (an anticholinergic agent with multiple effects on the GI tract) to healthy subjects, the AUC of clonazepam was 10% lower and the Cmax of @DRUG$ was 20 % lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone .	DDI-false
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (@DRUG$), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
For this reason, the dose of @DRUG$ should be reduced by 30 - 50 % at the start of treatment with Bezalip or @DRUG$ retard and then titrated according to the blood clotting parameters	DDI-advise
@DRUG$ did not increase the plasma levels of @DRUG$.	DDI-false
Coadministration of @DRUG$ with Itraconazole has led to elevated plasma concentrations of @DRUG$, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.	DDI-false
@DRUG$ : @DRUG$ 40 mg twice daily resulted in a significant decrease in lithium serum clearance ( 25% ) and renal clearance ( 30% ) with 34% higher serum exposure compared to lithium alone.	DDI-false
Vitamin A : Because of the relationship between Accutane and @DRUG$ , patients should be advised against taking vitamin supplements containing @DRUG$ To avoid additive toxic effects	DDI-false
the doses of naloxone required to antagonize the effects of @DRUG$ were more than 100 times higher than those required to antagonize the effects of @DRUG$.	DDI-false
Coadministration of @DRUG$ with doses higher than 40 mg QD @DRUG$ It has not been studied.	DDI-false
@DRUG$ : Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60 % greater in patients taking phenytoin with or without other enzyme- inducing AEDs .	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , @DRUG$ ) , @DRUG$ , cyclosporine , non-steroidal anti-inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin .	DDI-false
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, @DRUG$, and cimetidine.	DDI-advise
Alcohol: @DRUG$ (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and @DRUG$ plasma levels were not altered when dosed simultaneously.	DDI-false
for adult-onset diabetics, dosage adjustment of @DRUG$ may be necessary during and after @DRUG$ therapy;	DDI-advise
In rats, simultaneous ingestion of @DRUG$ and @DRUG$ in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that disulfiram may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.	DDI-effect
Antiacid , clarithromycin , @DRUG$ , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , @DRUG$ , Ritanovir , Saquinavir .	DDI-false
A clinical study in healthy male volunteers ( n=24 ) demonstrated that mixing @DRUG$ with @DRUG$ Just before the injection, some attenuation in the peak concentration of NovoLog caused, but the time to the maximum and total bioavailability of NovoLog were not significantly affected.	DDI-false
Oral Contraceptives: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, @DRUG$ 1/35 ).	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
@DRUG$ or iodine excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of @DRUG$.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, @DRUG$, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-false
....................................................................................................................................................................................................................................................................................................................... @DRUG$ The absorption of vitamin K can be reduced.	DDI-false
@DRUG$ and @DRUG$ may have additive hypotensite effects due to the inhibition of each other s metabolism.	DDI-mechanism
Amiodarone taken concomitantly with @DRUG$ increases @DRUG$ serum concentration by 33% after two days.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including ciprofloxacin, containing multivalent cation products such as magnesium or aluminium antazida, sucralfat, VIDEX chewable tablets/buffer tablets or paediatric powders or products which: @DRUG$ Iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-mechanism
Patients should avoid concomitant use of other medicines. @DRUG$ , and warned that the effect of @DRUG$ The dose may be increased.	DDI-false
Because changes in glucose concentrations with @DRUG$ coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for glyburide (5 mg QD and 10 mg BID) with @DRUG$ coadministration (up to 40 mg QD) is not indicated.	DDI-false
Warfarin @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics of R and @DRUG$.	DDI-false
Non-selective MAO inhibitors including @DRUG$, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
It is assumed that increased interaction between @DRUG$ and high affinity binding sites for @DRUG$ on dopamine2- and serotonin2-receptors underlies the antipsychotic action of neuroleptics after their prolonged administration.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/@DRUG$ , @DRUG$/acetaminophen , and valproic acid/phenobarbital .	DDI-false
May interact @DRUG$ , barbiturates, rifampin and other inducers of the liver microsomal enzyme oxidation system (reduced effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$ ) .	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., @DRUG$]) or	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of @DRUG$, oral vitamin B-12, methotrexate and @DRUG$.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of fissteride doses have been co-administered in clinical trials with acetaminophen, @DRUG$ , A-blockers, analgesics, angiotensin converting enzyme ( ACE) inhibitors, @DRUG$ , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
The in vitro interaction between @DRUG$ and the antithrombotic agent @DRUG$ is complex.	DDI-int
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Furosemide: @DRUG$ IV/IM reduced the @DRUG$ response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	DDI-false
Lithium: NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal @DRUG$ clearance.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$ Calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs) and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., @DRUG$, cerivastatin, lovastatin, @DRUG$).	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Presumably, @DRUG$ acts as a stimulator of coumarin metabolism and has been reported to cause decreased serum levels of the @DRUG$ and increased prothrombin-proconvertin concentrations.	DDI-mechanism
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , @DRUG$ , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , @DRUG$ , and anakinra .	DDI-false
It can cause the excretion of @DRUG$ , @DRUG$ , and ASA and may also increase the toxicity of salicylates .	DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or @DRUG$ (like dihydroergotamine or methysergide) and @DRUG$ within 24 hours of each other should be avoided.	DDI-advise
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates , @DRUG$ , and @DRUG$.	DDI-false
Other CNS depressant drugs ( e.g. barbiturates , @DRUG$ , @DRUG$ ) have additive or potentiating effects with INAPSINE.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, @DRUG$, cimetidine, diltiazem, @DRUG$, and some macrolide antibiotics.	DDI-false
@DRUG$ is a substrate for both @DRUG$ and CYP3A4.	DDI-false
In vitro studies show that at therapeutic concentrations of @DRUG$ ( 300 m g/mL ) , the binding of @DRUG$ was reduced from approximately 99.2 % to 97.5 % , representing a potential twofold increase in unbound ketorolac plasma levels .	DDI-mechanism
Potassium-sparing diuretics (e.g., @DRUG$, triamterene, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Benzthiazide may interact with alcohol , @DRUG$s , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , norepinephrine , @DRUG$ Such as Aleve or ibuprofen, and high blood pressure medications.	DDI-false
However, patients may show increases in digoxin. @DRUG$ Concentrations following initiation of FLOLAN therapy, which may be clinically significant in patients who are susceptible to @DRUG$ toxicity .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Imidazoles (e. g., ketoconazole, @DRUG$, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
The medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$ , disulfiram , ethionamide , glutethimide , gold , hydralazine , @DRUG$ , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
When CANCIDAS is co-administered with drug clearance inducers such as efavirenz, nevirapine, @DRUG$ , dexamethasone , or @DRUG$ , use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
Vitamin A : Because of the relationship between Accutane and @DRUG$ , patients should be advised against taking @DRUG$ containing vitamin A to avoid additive toxic effects	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance , such as efavirenz , nevirapine , @DRUG$ , @DRUG$ Administration of a daily dose of 70 mg CANCIDAS or carbamazepine should be considered	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( @DRUG$ ), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam) and digoxin did not significantly affect @DRUG$ pharmacokinetics/pharmacodynamics.	DDI-false
Cyclosporine, Digoxin, Methotrexate @DRUG$, like other @DRUG$, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, methotrexate, and increased toxicity.	DDI-false
Other medicines that can improve neuromuscular blocking effects of non-depolarizing agents such as NUROMAX are certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local @DRUG$ , procainamide , and @DRUG$.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenously] @DRUG$ ( e.g. , tobramycin , gentamicin , and amikacin ) , amphotericin B , foscarnet , intravenous @DRUG$ , vancomycin, and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
While all the selective serotonin reuptake inhibitors ( @DRUG$ ), e.g., citalopram, escitalopram, @DRUG$ , sertraline, and paroxetine, inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
The use of antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$ , @DRUG$ , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing @DRUG$ , iron , or @DRUG$ may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Ethinyl Estradiol and Norethindrone: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in norethindrone plasma concentrations.	DDI-false
CNS-Active Drugs @DRUG$: Sonata 10 mg potentiated the CNS-impairing effects of @DRUG$ 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
Phenylbutazone : @DRUG$ causes increase ( by about 80 % ) in the free fraction of @DRUG$.	DDI-mechanism
Particular caution should be observed with digitalis preparations since there are conflicting results for the effect of colestipol hydrochloride on the availability of @DRUG$ and @DRUG$.	DDI-false
WARFARIN: Co- administration of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	DDI-false
Tolbutamide : In diabetic patients receiving @DRUG$ There were no significant effects on the @DRUG$ Plasma levels or fasting blood sugar.	DDI-false
May interact with the following: cholestyramine, @DRUG$ (use with @DRUG$ may prevent the diuretic from working properly;	DDI-effect
The availability of potent @DRUG$ (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .	DDI-false
Although these results do not indicate that there is a significant interaction between: @DRUG$ ed and warfarin or heparin, administration of TORADOL in patients who: @DRUG$ Patients should be closely monitored.	DDI-false
Plasma exposure of @DRUG$ (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of @DRUG$ (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.	DDI-false
@DRUG$ , Methylxanthines and @DRUG$ : Concomitant treatment with xanthine derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
- cholestyramine increase in cholestyramine and @DRUG$ The absorption of @DRUG$ can be reduced.	DDI-false
@DRUG$ AUC0-12 of tacrolimus in blood was reduced by approximately 20% in healthy subjects, the Cmax by 16% and the 12-hour blood concentration (C12h) by 26% if: @DRUG$ 2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily compared to results from a control period in which tacrolimus was administered alone.	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$ , nifedipine , chlordiazepoxide , diazepam , certain tricyclic antidepressants , lidocaine , theophylline and @DRUG$ This delays elimination and increases blood levels of these drugs.	DDI-false
Potassium Supplements and @DRUG$ : Fosinopril sodium can attenuate potassium loss caused by @DRUG$.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, @DRUG$ Amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with hydrochlorothiazide, digoxin, @DRUG$, and @DRUG$.	DDI-false
@DRUG$ : Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin , nor were there any changes in the pharmacodynamic profile ( prothrombin time ) following a single 25 mg oral dose of @DRUG$	DDI-false
The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as @DRUG$, triazolopyridazines and others, are also blocked by @DRUG$.	DDI-effect
No data are available for the coadministration of @DRUG$/ritonavir or FORTOVASE/@DRUG$ and garlic capsules.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$ , @DRUG$ , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
@DRUG$ and @DRUG$ ( ACTH ): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction .	DDI-false
No pharmacokinetic interactions between dexmedetomidine and @DRUG$ , @DRUG$ , alfentanil , and midazolam have been demonstrated .	DDI-false
Hormonal @DRUG$ Co-administration of @DRUG$ The plasma concentrations of the two hormone components ethinylestradiol (EE) and levonorgestrel (LNG) have been shown to be affected by oral contraceptives.	DDI-false
Co-administration: Concomitant use of @DRUG$ with @DRUG$, thrombolytics, and other anticoagulants may increase the risk of bleeding.	DDI-effect
Additionally, @DRUG$ did not alter the pharmacokinetics of Sonata, reflecting the absence of a role of CYP2D6 in @DRUG$ s metabolism.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been used in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, @DRUG$ , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac @DRUG$ , diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and quinolones anti-infections without evidence of clinically significant adverse interactions.	DDI-false
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with @DRUG$ ( @DRUG$ tablets , USP ) or initiating therapy with small doses ( 6.25 or 12.5 mg ) .	DDI-false
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, @DRUG$) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
These drugs include the @DRUG$ and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other drug interactions @DRUG$, erythromycin and dextropropoxyphene had no effect on the pharmacokinetics of @DRUG$.	DDI-false
Dopamine antagonists : Da apomorphine is a @DRUG$ , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of @DRUG$.	DDI-false
Although neither @DRUG$ The proliferation of the prostate epithelium in RPMI1640, which contains transferrin alone, was not influenced by retinyl acetate, they modify the mitogenic effect of @DRUG$ and insulin .	DDI-effect
Some @DRUG$/substances are known to accelerate the metabolism of @DRUG$ by stimulating the synthesis of CYP3A4 (enzyme induction).	DDI-false
Anticoagulants : Potentiation of warfarin-type ( CYP2C9 and CYP3A4 substrate ) @DRUG$ The response is almost always observed in patients who: @DRUG$ and can result in serious or fatal bleeding .	DDI-false
The effect of @DRUG$ on plasma @DRUG$ has not been studied , but cases of increased lithium plasma levels during TORADOL therapy have been reported .	DDI-false
@DRUG$ The plasma concentration of other CYP3A4 metabolised medicinal products is increased (e.g. triazolo-benzodiazepines, dihydropyridine-calcium channel blockers, certain @DRUG$ , etc . ) .	DDI-mechanism
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-mechanism
Tetracyclines: Concomitant treatment with @DRUG$ and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, @DRUG$, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Hormonal contraceptives: It has not been shown if there is a pharmacokinetic interaction between: @DRUG$ and @DRUG$.	DDI-false
Administration of @DRUG$ may potentiate @DRUG$-induced neuromuscular block.	DDI-effect
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$ toxicity has been reported to have occurred in a patient on chronic @DRUG$ treatment following the initiation of diclofenac therapy.	DDI-false
@DRUG$ Lithium toxicity has been reported in patients who: @DRUG$ concomitantly with drugs which cause elimination of sodium , including ACE inhibitors .	DDI-false
@DRUG$ potentiates the muscle relaxant effect of all muscle relaxants , most notably @DRUG$ MAC (minimum alveolar concentration) is reduced by the concomitant use of N 2O.	DDI-effect
Other medicinal products Interactions Oral contraceptives Keppra ( 500 mg twice daily ) did not affect the pharmacokinetics of an oral contraceptive with 0.03 mg @DRUG$ and 0.15 mg @DRUG$ , or of the luteinizing hormone and progesterone levels , indicating that impairment of contraceptive efficacy is unlikely .	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with CNS depressants ( alcohol , @DRUG$ , opiates , @DRUG$ , anesthetics ) should be considered .	DDI-false
@DRUG$ does not alter @DRUG$ protein binding .	DDI-false
@DRUG$: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on @DRUG$ (1 gm/day) 11 days after the addition of doxepin (75 mg/day).	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without @DRUG$ (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone.	DDI-false
@DRUG$: Reports suggest that @DRUG$ may diminish the antihypertensive effect of Angiotensin Converting Enzyme (ACE) inhibitors.	DDI-false
It may be necessary to adjust the dosage of oral @DRUG$ upon beginning or stopping disulfiram. since @DRUG$ may prolong prothrombin time.	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, @DRUG$, higher alcohols and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Serial plasma and urine samples for the measurement of @DRUG$ , rifabutin, and rifampin and their @DRUG$ , were measured by high-performance liquid chromatography.	DDI-false
Medicines associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$ , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , @DRUG$ , and vincristine .	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, @DRUG$, barbiturates, monoamine oxidase inhibitors, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Therophylline: A recent study has shown that concomitan administration of @DRUG$ and theophylline may cause elevated plasma levels of @DRUG$, and in some instances a slight decrease in the elimination of isoniazid.	DDI-false
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , secobarbital , glutethimide , @DRUG$ and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Although there are no study data to evaluate the possibility , @DRUG$ , including @DRUG$ Off and nitroglycerin, may have an additive effect with INOmax on the risk of developing methaemoglobinaemia.	DDI-false
In a study in which the oral disintegrating 2 mg clonazepam tablet with and without propanthelin ( @DRUG$ The AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the oral disintegrating tablet was given. @DRUG$ compared to when it was given alone .	DDI-false
@DRUG$ may interact with @DRUG$ or other CNS depressants, causing increased sedative effects.	DDI-effect
Population pharmacokinetic analyses revealed that MTX, @DRUG$, @DRUG$, and TNF blocking agents did not influence abatacept clearance.	DDI-false
In vitro and animal studies with the combination of amphotericin B and imidazoles suggest that: @DRUG$ may induce fungal resistance to @DRUG$.	DDI-effect
Although no studies have been conducted, concomitant administration of @DRUG$ and phenytoin may alter the metabolism of @DRUG$;	DDI-false
Flucytosine : while a synergistic relationship with @DRUG$ It has been reported that co-administration with @DRUG$ By possible increase in cellular uptake and/or impairment of renal excretion.	DDI-effect
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy , with similar responses being observed with nevirapine regimens and superiority observed with efavirenz .	DDI-false
It is assumed that the toxicity is caused by an unprecedented interaction between: @DRUG$ and @DRUG$ and a molecular basis for this interaction has been proposed .	DDI-effect
Dexamethasone : Steady-state trough concentrations of @DRUG$ were about 56 % higher when 8 mg dexamethasone was coadministered with each dose of @DRUG$ ( 15 mg/kg/day ) in eight neurocysticercosis patients .	DDI-false
1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high Trileptal doses In vivo, the plasma levels of @DRUG$ increased by up to 40%, when @DRUG$ was given at doses above 1200 mg/day.	DDI-mechanism
@DRUG$ In diabetic patients receiving diflunisal and tolbutamide, no significant effects on @DRUG$ Plasma levels or fasting blood sugar.	DDI-false
@DRUG$: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including @DRUG$, there is a risk that an interaction will lead to deterioration.	DDI-false
Thioridazine: Coadministration of single doses of @DRUG$ 20 mg and @DRUG$ 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.	DDI-effect
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
Digoxin , Nimodipine and @DRUG$ : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
@DRUG$ : Coadministration of @DRUG$ and VIRACEPT resulted in an 82 % decrease in nelfinavir plasma A.C.	DDI-false
The effect of benzodiazepines can be enhanced by anticonvulsants, antihistamines, alcohol, @DRUG$ - monoamine oxidase inhibitors, @DRUG$ , Phenothiazine, psychotropic drugs, or other drugs that produce CNS depression.	DDI-false
Multivitamins, or other products containing @DRUG$ or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
Other medicinal products Interactions: No pharmacokinetic interactions between vardenafil and the following medicinal products have been observed: @DRUG$ , warfarin , @DRUG$ , Maalox , and ranitidine .	DDI-false
The medicinal products associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$ , @DRUG$ , phenytoin , ribavirin , and vincristine .	DDI-false
Imidazoles (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
@DRUG$ or iodine excess may decrease the effect of @DRUG$, and an iodine deficiency can increase the effect of Carbimazole.	DDI-effect
Amantadine , @DRUG$ , and MAOIs may increase anticholinergic effect of @DRUG$.	DDI-effect
For example, when @DRUG$ are administered concomitantly with @DRUG$, prothrombin time should be carefully monitored and if necessary, the dosage of vitamin K antagonists should be reduced.	DDI-advise
@DRUG$: In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-@DRUG$ interaction could be found.	DDI-false
Pyrantel (e.g. Antiminth) - use of piperazin and @DRUG$ Together, the effect of @DRUG$ may decrease.	DDI-false
Coingestion of acetaminophen with theophylline, phenobarbital with acetaminophen, and @DRUG$ with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
@DRUG$ @DRUG$	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
therefore concomitant administration of @DRUG$ with @DRUG$ is contraindicated.	DDI-advise
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-advise
Digoxin , @DRUG$ ) and losartan: bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on @DRUG$ plasma levels.	DDI-false
- Methotrexate (e.g., Mexate) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	DDI-false
@DRUG$ : Coadministration of saquinavir ( using an experimental soft-gelatin capsule formulation of saquinavir 1200 mg ) with VIRACEPT resulted in an 18 % increase in @DRUG$ plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Study results in patients with multiple sclerosis, TYSABRI and concomitantly @DRUG$ ( @DRUG$   30 mcg IM once weekly ) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Little has been studied of the adverse effects of the exposure of the liver to the interaction of @DRUG$ with its congeners and @DRUG$, coexisting in the contents of alcoholic beverages.	DDI-false
Special care should be taken in the presence of digitalis preparations, as conflicting results for the effect of @DRUG$ on the availability of digoxin and @DRUG$.	DDI-mechanism
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Co-medications that induce CYP3A4 ( e.g. , @DRUG$ , phenytoin , @DRUG$ , rifampin , phenobarbital or St.	DDI-false
Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, naproxen, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Iodine or iodine excess may decrease the effect of Carbimazole, and an @DRUG$ deficiency can increase the effect of @DRUG$.	DDI-effect
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, @DRUG$, phenytoin, @DRUG$, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
To determine whether probenecid has a direct effect on the distribution of cloxacillin, the elimination and distribution of @DRUG$ was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of @DRUG$.	DDI-false
Coadministration with @DRUG$ (40 mg BID for 7 days) resulted in a significant increase in @DRUG$ plasma levels suggesting that, at these doses, valdecoxib is a weak inhibitor of 2D6.	DDI-mechanism
It may increase excretion of barbiturates , lithium , and @DRUG$ And can also increase the toxicity of @DRUG$.	DDI-false
Conversely, the administration of @DRUG$ (1 mg @DRUG$ QID) did not alter the pharmacokinetics of a 300-mg dose of cimetidine.	DDI-false
Digoxin, nimodipine and losartan: bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$ And losartan has no significant influence on @DRUG$ plasma levels.	DDI-false
@DRUG$ , clonazepam , @DRUG$	DDI-false
The concurrent use of intravenously or orally administered methylxanthines (e.g., @DRUG$, theophylline) by patients receiving @DRUG$ has not been completely evaluated.	DDI-false
@DRUG$ , or other products containing iron or zinc , antacids or @DRUG$ The use of norfloxacin should not be performed simultaneously with or within 2 hours after the administration of norfloxacin as it may impair absorption, resulting in lower serum and urine levels of norfloxacin.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
No data from prospective clinical trials currently exist comparing the 3 approved agents ( efavirenz , @DRUG$ or @DRUG$ ) .	DDI-false
When @DRUG$ is taken concurrently with oral @DRUG$ The attenuation of immunization cannot be excluded.	DDI-effect
Tinnitus and decreased hearing have been reported in patients concomitantly receiving @DRUG$ and @DRUG$.	DDI-effect
Hormonal contraceptives, including oral, injectable, transdermal and implantable contraceptives: An interaction study has shown that concomitant use of @DRUG$ and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14 % and 31 % , respectively .	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of @DRUG$ or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with CMI as well.	DDI-false
@DRUG$ is inhibited by @DRUG$.	DDI-mechanism
The clearance of @DRUG$ may be increased with concurrent use of @DRUG$.	DDI-mechanism
Other oral interactions @DRUG$ @DRUG$ The pharmacokinetics of an oral contraceptive containing 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel or luteinisation hormone and progesterone levels were not affected, suggesting that contraceptive efficacy is unlikely to be impaired.	DDI-false
Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of @DRUG$ and @DRUG$ Imidazole can cause fungal resistance to amphotericin B.	DDI-false
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of rifampin and extended a similar length of time after @DRUG$ withdrawal.	DDI-false
As with some other nondepolarizing neuromuscular blocking agents, the time of onset of neuromuscular block induced by @DRUG$ is lengthened and the duration of block is shortened in patients receiving @DRUG$ or carbamazepine.	DDI-effect
As @DRUG$ The predominant plasma substrate is only a weak inducer of UDP-glucuronyltransferase, it is unlikely that it will affect drugs that are mainly eliminated by conjugation by UDP-glucuronyltransferase (e.g. @DRUG$ , lamotrigine ) .	DDI-false
Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of @DRUG$ , and @DRUG$ had no clinically significant effect after oral administration .	DDI-false
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or S-warfarin with the addition of @DRUG$ given as a single dose.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Administration of @DRUG$ to patients who are receiving @DRUG$ or monoamine oxidase inhibiting drugs may result in an additive pressor effect .	DDI-effect
Interaction with @DRUG$ , @DRUG$ and theophylline has also been reported to produce adverse clinical effects .	DDI-false
Drug-drug interactions In vitro studies using human liver microsomes indicate that @DRUG$ and @DRUG$ are not inhibitors of cytochrome (CYP) P450 isoforms CYP3A4, CYP2D6, CYP2E1, or CYP1A2.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and @DRUG$ ) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-mechanism
Other reported interactions with amiodarone: Fentanyl (@DRUG$ substrate) in combination with @DRUG$ may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
Two groups ( SH/DA ; SH/FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$ , methanol, higher alcohols and @DRUG$ â€” in the same proportions as in the most frequently distilled and fermented alcoholic beverages;	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
These drugs include the thiazides and other @DRUG$, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$: In hypercholesterolemic patients, steady-state @DRUG$ AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of erythromycin, a known inhibitor of cytochrome P450 3A4.	DDI-false
acetaminophen/theophylline , @DRUG$/quinidine , phenobarbital/@DRUG$ , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Other Cardiovascular Agents: @DRUG$ and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : @DRUG$ , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , @DRUG$ , gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Norepinephrine: @DRUG$ enhance the adrenergic effect of @DRUG$.	DDI-effect
Antiepileptic drugs: Potential interactions between @DRUG$ and other @DRUG$ were assessed in clinical studies.	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, @DRUG$ before cisplatin).	DDI-false
However , high doses of @DRUG$ may reduce the efficacy of intrathecally administered @DRUG$.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and @DRUG$ ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving @DRUG$ therapy .	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , @DRUG$ , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and @DRUG$.	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
In an in vitro study in human liver microsomes, inhibition of CYP2A6 hydroxylation of @DRUG$ by @DRUG$ (200 m m M i.e., 350 mg/L) was 17-28%.	DDI-mechanism
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other @DRUG$ , sedatives , @DRUG$ Anaesthetics (e.g. benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants and alcohol can cause respiratory depression, hypotension and deep sedation, or possibly lead to coma or death.	DDI-false
In clinical trials, FLOLAN was treated with: @DRUG$ , diuretics , @DRUG$ , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Furosemide has a tendency to antagonize the skeletal muscle relaxing effect of @DRUG$ And can reinforce the action of @DRUG$.	DDI-false
Concomitant oral administration of @DRUG$ A known inhibitor of CYP3A4 activity in the liver and intestinal mucosa caused an eightfold increase in systemic exposure to oral @DRUG$.	DDI-mechanism
Lithium : @DRUG$ 40 mg BID for 7 days produced significant decreases in lithium serum clearance ( 25 % ) and renal clearance ( 30 % ) with a 34 % higher serum exposure compared to @DRUG$ alone .	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
- When @DRUG$ or Bezalip retard is used concurrently with anion-exchange resins ( e.g. cholestryramine ) , an interval of at least 2 hours should be maintained between the two medicines , since the absorption of @DRUG$ Bezalip retard is impaired	DDI-false
Glyburide : Concomitant use of @DRUG$ with the @DRUG$ Glyburide has, in rare cases, led to severe hypoglycaemia.	DDI-effect
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-effect
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
MAO inhibitors MAOI antidepressants, as well as a metabolite of @DRUG$, slow @DRUG$ metabolism.	DDI-mechanism
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
As with some other @DRUG$, the time of onset of neuromuscular block induced by NUROMAX is lengthened and the duration of block is shortened in patients receiving @DRUG$ or carbamazepine.	DDI-effect
@DRUG$ ( @DRUG$ ): Steady state plasma exposure ( AUC ) of valdecoxib ( 40 mg BID for 12 days ) was decreased by 27 % when co-administered with multiple doses ( 300 mg QD for 12 days ) of phenytoin ( a CYP 3A4 inducer ) .	DDI-false
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive @DRUG$/ethinyl estradiol (1 mg /35 mcg combination, @DRUG$ 1/35 ).	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, escitalopram, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ These include certain antibiotics (e.g. aminoglycosides, tetracyclines, @DRUG$ , polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-effect
In some patients , the administration of a @DRUG$ can reduce the diuretic , natriuretic , and antihypertensive effects of loop , potassium-sparing and @DRUG$.	DDI-effect
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
In vitro binding studies with human serum proteins show that glipizide binds differently than @DRUG$ â™ª And don't interact with me â™ª @DRUG$ or dicumarol .	DDI-false
Interactions with @DRUG$ Agonist/antagonist analgesics (e.g. pentazocin, nalbuphine, @DRUG$ , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran .	DDI-false
A clinical study in healthy male volunteers (n=24) demonstrated that mixing @DRUG$ with @DRUG$ immediately before injection produced some attenuation in the peak concentration of NovoLog, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.	DDI-false
@DRUG$ diminished the binding of @DRUG$ to human serum by a net change of 5.7% (percentage increase in free drug fraction [FDF], 11.0%) at 662 micromol/L and by a net change of 7.1% (percentage increase in FDF, 13.7%) at 1324 micromol/L.	DDI-mechanism
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as @DRUG$ , spironolactone , and cimetidine .	DDI-advise
The concomitant intake of @DRUG$ and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or acamprosate.	DDI-false
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors, @DRUG$ has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Effect of Other Drugs on the Pharmacokinetics of @DRUG$: Literature reports suggest that @DRUG$, an agent that decreases stomach acidity, does not greatly alter clonazepam pharmacokinetics.	DDI-false
@DRUG$ therapy: Urinary excretion of amphetamines is increased, and efficacy is reduced, by acidifying agents used in @DRUG$ therapy.	DDI-false
This change was not considered clinically significant and no dose adjustment is needed when @DRUG$ and @DRUG$ are coadministered.	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., @DRUG$]) or	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$, e.g., guanethidine, @DRUG$, reserpine.	DDI-false
@DRUG$ , a @DRUG$ , the bactericidal effect of penicillin can antagonize and concomitant use of these drugs should be avoided.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including non-steroidal anti-inflammatory drugs and other drugs that are highly protein bound, salicylates, @DRUG$ , chloramphenicol , probenecid , coumarins , @DRUG$ , and beta adrenergic blocking agents .	DDI-false
@DRUG$ : @DRUG$   is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics	DDI-false
In a comparison of digital tolerance in dogs stunned with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ The dose required to attract ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$ , with ketamine or Innovar than with pentobarbital .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , @DRUG$ , nifedipine , chlordiazepoxide , diazepam , certain tricyclic antidepressants , @DRUG$ Theophylline, and metronidazole, delaying the elimination and increase in blood levels of these drugs.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
@DRUG$ : @DRUG$ Caution should be exercised in patients receiving receptor blockers (e.g. propranolol, CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, CYP3A4 substrates and diltiazem, CYP3A4 inhibitor) due to the possible increase in bradycardia, sinus arrest and AV block.	DDI-false
Corticosteroids and Corticotropin ( @DRUG$ If you have a hypokalaemia that is induced by @DRUG$, you may be able to predispose the patient to cardiac dysfunction.	DDI-effect
@DRUG$ or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$;	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	DDI-false
Lithium: Lithium toxicity has been reported in patients who: @DRUG$ concomitantly with drugs which cause elimination of sodium , including @DRUG$.	DDI-effect
Based on known metabolic profiles , clinically significant drug interactions are not expected between @DRUG$ and dapsone , trimethoprim/sulfamethoxazole , clarithromycin , @DRUG$ , itraconazole or fluconazole .	DDI-false
@DRUG$ : In hypercholesterolemic patients , steady-state @DRUG$ AUC and Cmax increased approximately 50 % and 24 % respectively after 10 days with co-administration of erythromycin , a known inhibitor of cytochrome P450 3A4 .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , @DRUG$ , haloperidol, phenothiazine, monoamine oxidase (MAO) inhibitors, @DRUG$ Or some antihistamines.	DDI-false
Hydrochlorothiazide: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in significantly increased plasma levels of @DRUG$.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
Antiacid, @DRUG$, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, @DRUG$, phenytoin, dexamethasone, @DRUG$) may result in decreased plasma levels of saquinavir.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, @DRUG$ , tacrolimus, cyclosporin, ergot derivatives, pimozide, @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Valdecoxib caused a statistically significant increase in plasma exposures of @DRUG$ and @DRUG$ (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of warfarin.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ : Coadministration of saquinavir ( using an experimental soft-gelatin capsule formulation of @DRUG$ 1200 mg ) with VIRACEPT resulted in an 18 % increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
@DRUG$: Elevated carbamazepine levels have been reported in postmarketing experience when @DRUG$ is administered concomitantly.	DDI-false
Blood glucose concentrations should be carefully monitored when @DRUG$ and oral @DRUG$ are coadministered .	DDI-advise
Adrenergic blockers: @DRUG$ are inhibited by @DRUG$.	DDI-effect
@DRUG$ , Including Oral , Injectable , Transdermal , and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of norethindrone and ethinyl estradiol levels of 14 % and 31 % , respectively .	DDI-false
Cyclosporine: Because @DRUG$ can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of fibrate drugs including @DRUG$, there is a risk that an interaction will lead to deterioration.	DDI-effect
- @DRUG$ : Interaction studies in humans have shown @DRUG$ to have no effect on warfarin metabolism or on plasma prothrombin activity .	DDI-false
- @DRUG$ ( nandrolone [ e.g. , Anabolin ] , oxandrolone [ e.g. , Anavar ] , oxymetholone [ e.g. , Anadrol ] , @DRUG$ (e.g. Winstrol ]) or	DDI-false
@DRUG$ , @DRUG$ , lidocaine	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-effect
Close supervision and careful adjustment of dosage are required when @DRUG$ is administered with anticholinergic or @DRUG$.	DDI-advise
These drugs include thiazides and other @DRUG$ , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , @DRUG$ , calcium channel block drugs, and isoniazid.	DDI-false
@DRUG$: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of @DRUG$ and aspirin were administered concomitantly.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , @DRUG$ , warfarin , isosorbide mononitrate , carvedilol , @DRUG$ or itraconazole .	DDI-false
The concomitant use of @DRUG$ and other @DRUG$ Previous reports on rhabdomyolysis have led to this.	DDI-effect
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with @DRUG$, @DRUG$, and verapamil.	DDI-false
Compounds that have been tested in man include antipyrine, digoxin, propranolol, @DRUG$, and @DRUG$ and no clinically meaningful interactions were found.	DDI-false
Magnesium- and/or aluminum-containing antacids , products containing @DRUG$ ( iron ), @DRUG$ Zinc or other metal cations or Videx (didanosine) chewable tablets or the paediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIV.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of @DRUG$ 50 to 100 mg to @DRUG$ and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-effect
This study demonstrates that concurrent administration of @DRUG$ permits at least a twofold increase in dose and total exposure to @DRUG$.	DDI-mechanism
Particular caution is necessary when using ROMAZICON in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially @DRUG$) may emerge with the reversal of the @DRUG$ effect by flumazenil.	DDI-false
In addition, oxcarbazepine and @DRUG$ induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine calcium antagonists and oral @DRUG$, resulting in a lower plasma concentration of these drugs.	DDI-false
In clinical studies, FLOLAN was used with digoxin, diuretics, @DRUG$ In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin starting treatment with FLOLAN, visible values for oral clearance of furosemide (n = 23) and digoxin (n = 30) were reduced by 13 % and 15 % respectively on the second day of therapy and returned to baseline on day 87.	DDI-false
To determine whether @DRUG$ has a direct effect on the distribution of @DRUG$, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , @DRUG$ , glutethimide , gold , hydralazine , iodoquinol , @DRUG$ , metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Other binding proteins may be elevated in serum , i.e. , corticosteroid binding globulin ( CBG ) , sex hormone-binding globulin ( SHBG ) , leading to increased total circulating @DRUG$ and @DRUG$ , respectively .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
The effect of @DRUG$ on the @DRUG$ The need of our patient seemed to be a maximum of 5 to 7 days after the initiation of rifampin and extended a similar time after the withdrawal of rifampin.	DDI-effect
Anticoagulants including coumarin derivatives , indandione derivatives , and platelet aggregation inhibitors such as @DRUG$ ( NSAIDs ) , and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Possible interactions between Keppra and other medicinal products @DRUG$ (carbamazepine, gabapentin, lamotrigine, @DRUG$ , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
@DRUG$ and @DRUG$ : Increased prothrombin time , with or without clinical bleeding , has been reported when cefixime is administered concomitantly .	DDI-false
Other Drug Interactions Oral @DRUG$ Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg @DRUG$, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
@DRUG$: concurrent use may blunt the response to @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Anticoagulants including coumarin derivatives , indandione derivatives , and @DRUG$ such as nonsteroidal anti-inflammatory drugs ( NSAIDs ) , and @DRUG$ The risk of bleeding may be increased when co-administered with ardeparin.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, @DRUG$ and possibly with @DRUG$, ampicillin, and tetracyclines (72)	DDI-false
Although these results do not indicate a significant interaction between TORADOL and TORADOL. @DRUG$ or @DRUG$ TORADOL should be used with extreme caution in patients taking anticoagulants and patients should be closely monitored.	DDI-false
Cohort 1 then received amprenavir plus @DRUG$ For 10 days and cohort 2 received amprenavir plus @DRUG$ For 4 days.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$ , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , @DRUG$ ==References====External links==	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , @DRUG$ , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur when it contains its derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam.	DDI-false
However , in the second study , administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8 % and a decrease in Cmax of approximately 30 % compared to the dose @DRUG$ alone .	DDI-false
Another oral @DRUG$, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of astemizole and its active metabolite @DRUG$ which may prolong QT intervals.	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (@DRUG$, saquinavir, @DRUG$, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Potential interactions between Keppra and other AEDs ( @DRUG$ , @DRUG$ , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
@DRUG$: Plasma concentrations of atorvastatin decreased approximately 25% when @DRUG$ and atorvastatin were coadministered.	DDI-false
Study results in patients with multiple sclerosis, TYSABRI and interferon beta-1a ( @DRUG$   30 mcg IM once weekly ) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or @DRUG$.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or @DRUG$, calcium channel blockers, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/ARB).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$ , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , @DRUG$ , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$ is a neutralizing agent for @DRUG$ It protects against kidney damage.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , @DRUG$ , dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$ , ribavirin , and vincristine .	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
The concomitant administration of @DRUG$ and @DRUG$ is contraindicated.	DDI-advise
@DRUG$ : @DRUG$ may delay intestinal absorption of ethosuximide .	DDI-false
Lithium : @DRUG$ Toxicity has been reported in patients who: @DRUG$ concomitantly with drugs which cause elimination of sodium , including ACE inhibitors .	DDI-false
@DRUG$ Astemizole *, @DRUG$ * CONTRAINDICATED due to the potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
@DRUG$: Doxorubicin caused a decrease in @DRUG$ phosphorylation ( 50% inhibition of total phosphate formation) in U937/Molt 4 cells.	DDI-false
This medication may interact with alcohol or other CNS depressants (may potentiate the CNS depressive effect of either these drugs or antihistamines), @DRUG$ Anticholinergic effects may be increased if these drugs are used concomitantly with antihistamines and monoamine oxidase (MAO) inhibitors (co-administration with @DRUG$ The anticholinergic and CNS depressive effects of antihistamines may be prolonged and intensified.	DDI-false
Multivalent Cation-Containing Products : Simultaneous Application of a @DRUG$ , including ciprofloxacin, containing multivalent cation products such as magnesium or aluminium antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Nevertheless, clinical studies, as well as postmarketing observations have shown that @DRUG$ can reduce the natriuretic effect of furosemide and @DRUG$ in some patients.	DDI-effect
Patients receiving @DRUG$ along with either oral or intravenous @DRUG$ should be monitored for possible atrioventricular conduction disturbances , left ventricular failure and hypotension .	DDI-advise
DOSTINEX should not be administered concurrently with D2-antagonists , such as phenothiazines , @DRUG$ ##############################################################################################################################################################################################################################################################################################################################################################################################################################################################################################################################	DDI-false
Prednisone/@DRUG$: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or @DRUG$.	DDI-false
If cholinergic blockades occur, additive undesirable effects may occur if: @DRUG$ is administered concomitantly with other @DRUG$ , amantadine , haloperidol , phenothiazines , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some antihistamines .	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , @DRUG$ , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , @DRUG$ , teniposide, and prednisone with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
While all the @DRUG$ ( SSRIs ) , e.g. , @DRUG$ , sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
Other @DRUG$ (e.g. barbiturates, sedatives, @DRUG$ ) have additive or potentiating effects with INAPSINE.	DDI-false
Single doses of either cholestyramine or @DRUG$ @DRUG$ bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , @DRUG$ , dapsone , disopyramide , @DRUG$ Amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
Dopamine antagonists : since @DRUG$ It is possible that dopamine antagonists, such as neuroleptics ( @DRUG$ , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including anti-arrhythmic agents such as quinidine and procainamide , @DRUG$ and @DRUG$.	DDI-false
To determine whether the injection of thiosulfate would allow the administration of larger doses of cisplatin, a fixed dose of 9.9 g/m2 has been established. @DRUG$ was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
Antiarrhythmics : Other antiarrhythmic drugs , such as quinidine , procainamide , disopyramide , and @DRUG$ , have been used concurrently with @DRUG$.	DDI-false
Since @DRUG$ is primarily eliminated by the kidneys, coadministration of BARACLUDE with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either @DRUG$ or the coadministered drug.	DDI-false
There is a significant increase in exposure to imatinib when @DRUG$ is coadministered with @DRUG$ (CYP3A4 inhibitor).	DDI-mechanism
Lithium: In a study conducted in healthy subjects, mean steady-state @DRUG$ plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving lithium alone.	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, @DRUG$ , diuretics, sympathomimetics (e.g., epinephrine, @DRUG$ , terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system ( e.g. , phenytoin , @DRUG$ , cimetidine, ketoconazole), although this has not been studied	DDI-mechanism
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
We report the case of an adolescent with altered consciousness caused by carbamazepine overdose with a positive @DRUG$ level to alert clinicians to the cross-reactivity of @DRUG$ with a toxicology screen for tricyclic antidepressants.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-effect
Poor metabolisers have higher plasma concentrations than expected. @DRUG$ ( @DRUG$ - if the usual dose is given.	DDI-false
No pharmacokinetic interactions between dexmedetomidine and @DRUG$, propofol, alfentanil, and @DRUG$ have been demonstrated.	DDI-false
@DRUG$: When @DRUG$ 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of terazosin, significant hypotension developed in a substantial number of subjects.	DDI-false
Calcium Channel Blockers: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when @DRUG$ is co-administered with @DRUG$.	DDI-effect
A potential interaction between oral @DRUG$ and oral @DRUG$ leading to severe hypoglycemia has been reported.	DDI-effect
Possible interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors ( @DRUG$ , saquinavir , indinavir , and @DRUG$ In clinical trials, substrates and/or inhibitors of CYP3A4 have not been studied.	DDI-false
Other drugs that inhibit the neuromuscular blocking effect of non-depolarizing substances such as e.g. @DRUG$ These include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, @DRUG$ , lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Hormonal contraceptives, including oral, injectable, transdermal and implantable contraceptives: An interaction study has shown that concomitant use of @DRUG$ The oral hormonal contraceptives Ortho-Novum and the oral hormonal contraceptives caused average decreases in @DRUG$ and ethinyl estradiol levels of 14 % and 31 % , respectively .	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, @DRUG$, and some @DRUG$.	DDI-false
@DRUG$ * Including oral, injectable, transdermal and implantable contraceptives: An interaction study showed that the concomitant use of bosentan and oral hormonal contraceptives Ortho-Novum showed an average decrease in norethindrone and @DRUG$ The rate is 14 % and 31 % respectively.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, @DRUG$, @DRUG$, Maalox, and ranitidine.	DDI-false
Elevated serum levels of @DRUG$ have been reported with concomitant use of cyclosporine with @DRUG$.	DDI-false
Imidazoles (e. g., ketoconazole, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, @DRUG$ , probenecid , @DRUG$ , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with @DRUG$ , beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, knitztilol, @DRUG$ or itraconazole .	DDI-false
@DRUG$ - prior ingestion of diphenidol may decrease the emetic response to @DRUG$ in the treatment of poisoning.	DDI-false
@DRUG$, tricyclic: Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-false
Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Antihypertensive medications, other, especially diazoxide, or pre@DRUG$ and anesthetic agents used in surgery or @DRUG$, nondepolarizing, used in surgery	DDI-false
conversely, diethylpropion may interfere with @DRUG$ (i.e., guanethidine, @DRUG$).	DDI-false
In comparison of the digitalis tolerance in dogs stunned with @DRUG$ , Innovar Vet , or @DRUG$ , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with ketamine or Innovar than with pentobarbital .	DDI-false
@DRUG$ (5 mg/kg), moclobemide (30 mg/kg), @DRUG$ (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.	DDI-false
@DRUG$: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with ranitidine.	DDI-false
Concomitant administration of fenofibrate ( equivalent to 145 mg TRICOR ) with @DRUG$ ( 40 mg ) once daily for 10 days has been shown to increase the mean Cmax and AUC values for @DRUG$ by 36 % ( range from 69 % decrease to 321 % increase ) and 28 % ( range from 54 % decrease to 128 % increase ) , respectively , and for 3 -hydroxy-iso-pravastatin by 55 % ( range from 32 % decrease to 314 % increase ) and 39 % ( range from 24 % decrease to 261 % increase ) , respectively in 23 healthy adults .	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/@DRUG$).	DDI-false
- @DRUG$ (e.g., Mesantoin) Use of @DRUG$ with these medicines may increase the chance of side effects of these medicines	DDI-false
It is recommended that serum @DRUG$ levels be monitored frequently if @DRUG$ is administered concomitantly with lithium.	DDI-false
@DRUG$ Amphetamines may cause intestinal resorption of @DRUG$ ;	DDI-false
Although there have been no formal interaction studies other than with @DRUG$, based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of @DRUG$ with other drugs will result in clinically significant drug inhibition of cytochrome P450-mediated metabolism of the other drugs.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
Patients in a clinical study who were on established therapy with sulfasalazine, to which @DRUG$ was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or @DRUG$ alone.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Another oral azole antifungal, ketoconazole, inhibits the metabolism of astemizole, resulting in elevated plasma concentrations of @DRUG$ and its active metabolite @DRUG$ which may prolong QT intervals.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , @DRUG$ , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$ Co-administration of nalfone and salicylates is not recommended.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H1-blocking agents, @DRUG$ and @DRUG$) might also contribute to a prolongation of the QTc interval.	DDI-false
@DRUG$s and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant @DRUG$ or vasodilators (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.	DDI-false
Therefore, if MIDAMOR and @DRUG$ are used concomitantly , the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained .	DDI-false
Beta-blockers , @DRUG$ , @DRUG$ salts , and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin .	DDI-false
@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received @DRUG$ or angiotensin II receptor antagonists (ACEI/ARB).	DDI-false
Serial plasma and urine samples for measurement of amprenavir, @DRUG$, and @DRUG$ and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography.	DDI-false
@DRUG$ The renal tubular transport of methotrexate may be caused by concomitant use of @DRUG$ This may lead to increased plasma levels of methotrexate.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , @DRUG$ , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue @DRUG$ , or tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection .	DDI-false
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue @DRUG$ , or @DRUG$ , on the antinonciceptive effect of these peptides in mice after intracisternal injection .	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-false
However , a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d . or 800 mg h.s . concomitantly with a 300 mg b.i.d . dosage of theophylline ( @DRUG$ , Key Pharmaceuticals , Inc. ) demonstrated less alteration in steady-state @DRUG$ Peak serum levels with the 800 mg h.s. regimen, especially in subjects aged 54 years and older.	DDI-false
Drugs Interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect @DRUG$ pharmacodynamics - Arecolin - eproxindine - @DRUG$ Flupentixol and ethanol cause additive CNS depression - tricyclic antidepressants : flupentixol increases the effect of tricyclic antidepressants	DDI-false
Although in clinical studies with IOPIDINE 0.5 % ophthalmic solution no specific drug interactions with topical glaucoma or systemic drugs have been identified, there is a possibility of additive or potentiating effects with: @DRUG$ ( alcohol , barbiturates , opiates , sedatives , @DRUG$ ) should be considered.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, @DRUG$ The doses of 1 mg or more have been evaluated in clinical trials with: @DRUG$ Acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, heart nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
cimetidine ) and many that are substrates for P450 2D6 ( many other antidepressants , phenothiazines , and the Type 1C antiarrhythmics @DRUG$ and @DRUG$ ) .	DDI-false
Rifabutin : Coadministration of rifabutin and @DRUG$ resulted in a 32 % decrease in nelfinavir plasma AUC and a 207 % increase in @DRUG$ plasma A.C.	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Notably, systemic exposure (AUC0-12) of @DRUG$ (DHA) was more than doubled in the presence of @DRUG$/SMX.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Drugs that cause significant sustained elevation in gastric pH ( histamine H2-receptor antagonists such as @DRUG$ or @DRUG$ ) may reduce plasma concentrations of IRESSA and therefore potentially may reduce efficacy .	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, @DRUG$, @DRUG$, nelfinavir) would be expected to behave similarly.	DDI-false
Since Nalfon has not been shown to produce any additional effect over being obtained with aspirin alone and because aspirin increases the rate of excretion of @DRUG$ , the concomitant use of @DRUG$ Salicylates and salicylates are not recommended.	DDI-false
Curariform muscle relaxants (e.g. tubocurarin) and other medicines, including ethers, succinylcholine, gallamine, @DRUG$ and @DRUG$ Neuromuscular blocking should be intensified and administered with extreme caution to patients treated with Coly-Mycin M Parenteral.	DDI-false
@DRUG$ may interact with alcohol or other @DRUG$, causing increased sedative effects.	DDI-effect
The absorption of tetracycline, furosemide, penicillin G, @DRUG$, and @DRUG$ was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
Based on the chemical resemblance of @DRUG$ ed and ketoconazole, concomitant use of astemizole with @DRUG$ is contraindicated .	DDI-false
In a 12-month controlled study, which included a 50 mg once daily @DRUG$ - Dose, 30 out of 528 @DRUG$ -treated subjects received concomitant theophylline at study entry .	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : @DRUG$ - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
The interaction may be between: @DRUG$ supplements and aspirin and other @DRUG$ And herbs like garlic (Allium sativum) and ginkgo (Ginkgo biloba).	DDI-int
After multiple dosing, @DRUG$ (AVONEX  30 mcg IM once weekly) reduced @DRUG$  clearance by approximately 30%.	DDI-mechanism
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, @DRUG$, topiramate, and possibly with @DRUG$ and tetracyclines 72.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
@DRUG$ : Coadministration of rifabutin and @DRUG$ This resulted in a 32% decrease in nelfinavir plasma AUC and a 20% increase in rifabutin plasma AC.	DDI-false
Antiacid , clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , @DRUG$ , Rifampin , Ritanovir , @DRUG$.	DDI-false
@DRUG$ : In normal volunteers , concomitant administration of diflunisal and @DRUG$ This resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Anticoagulants : potentiation of the warfarin type ( @DRUG$ and CYP3A4 substrate ) @DRUG$ The response is almost always observed in patients receiving amiodarone and can lead to severe or fatal bleeding.	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
H2 Receptor Antagonists : @DRUG$ Co-administration results in an increased peak plasma concentration and AUC of cisaprid, there is no effect on cisaprid absorption when co-administered with @DRUG$.	DDI-false
The hypoglycemic effect of @DRUG$ has been reported to increase when @DRUG$ is given concurrently.	DDI-effect
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , pentazocine , nalbuphine , butorphanol , dezocine and @DRUG$ ) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ Like Levo-Dromoran.	DDI-false
@DRUG$: Amphetamines may counteract the sedative effect of @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Aspirin : @DRUG$ 10 mg and 20 mg) increased bleeding time caused by @DRUG$ Two 81 mg tablets).	DDI-false
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
Therefore , it would be expected that a dosing schedule of cerivastatin sodium given at bedtime and @DRUG$ Given before the Lord's Supper would not lead to a significant decrease in the clinical effect of @DRUG$.	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, spironolactone, and @DRUG$.	DDI-false
@DRUG$ : @DRUG$ You have caused an increase in plasma lithium levels and a decrease in renal lithium clearance.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as @DRUG$) can be acutely worsened by @DRUG$, especially when the recommended dose of the beta-agonist is exceeded.	DDI-effect
These data indicate that @DRUG$ "Does not affect the plasma concentration of other AEDs and that these AEDs do not affect the pharmacokinetics of @DRUG$.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, @DRUG$, nicardipine, and nifedipine.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, @DRUG$, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Cardiovasculars : Cardiac glycosides : In patients receiving digoxin therapy , administration of oral @DRUG$ regularly results in an increase in serum @DRUG$ Concentration that can achieve toxic values with resulting clinical toxicity.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, @DRUG$, oral @DRUG$, digoxin, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , @DRUG$ , nicardipine, and @DRUG$.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and @DRUG$) is contraindicated .	DDI-false
An interaction study with @DRUG$ showed no clinically significant effect of @DRUG$ on warfarin pharmacokinetics or anticoagulant activity.	DDI-false
The safety and efficacy of @DRUG$ in combination with any @DRUG$ have not been established.	DDI-false
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, analgesics, antiemetics, @DRUG$, tranquilizers).	DDI-false
The following are known examples of drugs that inhibit the metabolism of other related benzodiazepines, probably by inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, @DRUG$ , @DRUG$ And some macrolide antibiotics.	DDI-false
ACE Inhibitors and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension, the addition of @DRUG$ 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines , @DRUG$ , @DRUG$ , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Multivitamins, or other products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
In Study 1, patients with colorectal cancer were given irinotecan/5-FU/@DRUG$ (bolus-IFL) with or without @DRUG$.	DDI-false
Rifampin significantly decreased the AUC(ss) of @DRUG$ by 82%, but @DRUG$ had no effect on rifampin pharmacokinetics.	DDI-false
The similarity of the TYSABRI -associated adverse event profile between Study 1 ( without co-administered @DRUG$ ) and Study 2 ( with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI   dose to maintain safety , General ) .	DDI-false
Observations from drug interaction studies with @DRUG$ may not be predictive for @DRUG$.	DDI-false
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , antacids , @DRUG$ ( e.g. , @DRUG$ , ranitidine ) , and proton pump inhibitors ( e.g. , lansoprazole , omeprazole ) .	DDI-false
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., @DRUG$, sertraline, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with @DRUG$, digoxin, @DRUG$, and nifedipine.	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
Drug Interactions : Flupenthixol may interact with some drugs , like @DRUG$ ( MAOI ): @DRUG$ - Arecoline - Eproxindine - Ethanol : Flupentixol and ethanol cause additive CNS depression - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
Meperidine : @DRUG$ By increasing the analgesic effect of @DRUG$.	DDI-effect
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, phenobarbital, @DRUG$), CYP3A4 inhibitors (azole antimycotics e.g., @DRUG$;	DDI-false
@DRUG$ ( neostgmine , @DRUG$ Lignocaine, quinine, procainamide may increase toxicity and cause heart-respiratory depression.	DDI-false
Effect of Other Drugs on the Pharmacokinetics of Clonazepam: Literature reports suggest that @DRUG$, an agent that decreases stomach acidity, does not greatly alter @DRUG$ pharmacokinetics.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, cis-platinum, @DRUG$ and interferon-alfa.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an @DRUG$ with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of @DRUG$ was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
CONCLUSIONS : @DRUG$ inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 ( i.e. , atorvastatin , cerivastatin , lovastatin , @DRUG$ ) .	DDI-mechanism
Benzthiazide can interact with alcohol, blood thinners, decongestant medications (allergic, cold, and sinus drugs), diabetics, lithium, @DRUG$ , NSAIDs like @DRUG$ or Ibuprofen , and high blood pressure medications .	DDI-false
Patients treated within two to three weeks prior to administration of @DRUG$ should receive initial doses of @DRUG$ no greater than one-tenth ( 1/10 ) of the usual dose .	DDI-false
Hormonal contraceptives Co-administration of @DRUG$ with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and @DRUG$ (LNG).	DDI-false
It is possible that the cardiovascular action of other @DRUG$ could be enhanced by the addition of @DRUG$ .	DDI-effect
- Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothine, @DRUG$ , and @DRUG$ have no influence in vitro on the protein binding of diclofenac in human serum .	DDI-false
Hormonal contraceptives Co-administration of @DRUG$ with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components , @DRUG$ ( EE ) and Levonorgestrel ( LNG ).	DDI-false
Nifedipine : @DRUG$ 20 mg when administered concomitantly with slow release solution @DRUG$ 30 mg or 60 mg once daily did not affect the relative bioavailability (AUC) or the maximum concentration (Cmax) of nifedipine, a medicinal product metabolised by CYP3A4.	DDI-false
Further , no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of @DRUG$ and fluvastatin .	DDI-false
CNS-Active Drugs Ethanol: @DRUG$ 10 mg potentiated the CNS-impairing effects of @DRUG$ 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-effect
Erythromycin : In healthy people, plasma concentrations of @DRUG$ When co-administered with @DRUG$ and erythromycin , a known inhibitor of cytochrome P450 3A4 .	DDI-false
It may cause anticoagulants (modified hypoprothrombinemic activity), barbiturates, @DRUG$ â€¢ and other inducers of the hepatic microsomal enzyme oxidation system (reduced effect of diethylstilbestrol), @DRUG$ (Intensified effect of corticosteroids).	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( @DRUG$ , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
@DRUG$: The effect of valdecoxib on the anticoagulant effect of @DRUG$ (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
@DRUG$ Influence can be with alcohol, blood thinners, inflammatory medications (allergic, cold, and sinus drugs), diabetics, lithium, norepinephrine, NSAIDs such as Aleve or @DRUG$ , and high blood pressure medications .	DDI-int
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$ Although it significantly reduces zidovudine tmax by 44% and increased intracellular exposure to phosphorylated @DRUG$ - 110%.	DDI-false
Methenamine therapy Urinary excretion of @DRUG$ is increased, and efficacy is reduced by acidifying agents used in @DRUG$ therapy.	DDI-mechanism
These drugs include thiazides and other diuretics, @DRUG$ , phenothiazines, thyroid products, @DRUG$ , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
@DRUG$, @DRUG$, oxacillin, chlortetracycline, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, @DRUG$ and phenobarbital) have been shown to decrease the plasma levels of @DRUG$ (29-40%).	DDI-false
Dopamine-induced renal and mesenteric vasodilation is not antagonized by either @DRUG-DRUG$.	DDI-false
Compounds that have been tested in humans include antipyrin, digoxin, @DRUG$ , theophylline , and @DRUG$ and no clinically meaningful interactions were found .	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including ciprofloxacin, containing multivalent cation products such as magnesium or aluminium @DRUG$ , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Warfarin @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics of @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , @DRUG$ , @DRUG$ , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$: Coadministration of rifampin and VIRACEPT resulted in an 82% decrease in @DRUG$ plasma A.C.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
- Indomethacin : Indomethacin blunts the increases in urine volume and sodium excretion seen during @DRUG$ treatment and inhibits the @DRUG$-induced increase in plasma renin activity .	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ (ritonavir, saquinavir, indinavir, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
In vitro studies have shown @DRUG$ â€¢ can be coumarin anticoagulants, such as: @DRUG$ , from their protein-binding sites .	DDI-mechanism
Lithium: Lithium toxicity has been reported in patients who: @DRUG$ concomitantly with drugs which cause elimination of sodium , including @DRUG$.	DDI-effect
Cytochrome P-450 inducers , such as phenytoin , carbamazepine and phenobarbital , induce @DRUG$ Metabolism, resulting in a decrease in plasma by about 30% @DRUG$ levels .	DDI-false
In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors @DRUG$ , @DRUG$ and nifedipine .	DDI-false
Alcohol : @DRUG$ 0,5 g/kg body weight: approx. 40 ml absolute alcohol content at 70 kg persons) and @DRUG$ Plasma levels were not altered when co-administered.	DDI-false
Patients who have other narcotic analgesics, general anaesthetics, phenothiazine, sedatives, @DRUG$ , @DRUG$ Additional CNS depression may occur simultaneously with DILAUDID or other CNS depressions (including alcohol).	DDI-false
Metformin : In healthy subjects receiving single doses of 500 mg cephalexin and metformin, plasma @DRUG$ mean cmax and AUC increased by an average of 34 % and 24 % , respectively , and @DRUG$ Mean renal clearance decreased by 14%.	DDI-false
Beta-Blocking Agents A pharmacokinetic study with @DRUG$ in conjunction with metoprolol demonstrated no significant effects on the pharmacokinetics of @DRUG$.	DDI-false
@DRUG$: In vitro and/or in vivo data indicate that @DRUG$, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
- @DRUG$ Indomethacin blunts the increase in urine volume and sodium excretion during the @DRUG$ Treatment and inhibits bumetanide-induced increase in plasma renin activity.	DDI-false
Clinical interaction studies with cimetidine and @DRUG$ The concomitant use of @DRUG$ with these drugs does not result in clinically- significant drug interactions .	DDI-false
@DRUG$ : Amiodarone , bepridil , flecainide , @DRUG$ , Chinidine CONTRAINDICATES due to the potential for serious and/or life-threatening reactions.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other @DRUG$ , @DRUG$ , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
High-dose cyclosporin A resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in @DRUG$ exposure with a 38% decrease in total body clearance of etoposide compared to @DRUG$ alone.	DDI-false
@DRUG$ increases enterohepatic elimination of amiodarone and may reduce its serum levels and @DRUG$/2.	DDI-false
Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with @DRUG$, diltiazem, and @DRUG$.	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers ( e.g. , @DRUG$ ) , general anesthetics , @DRUG$ , skeletal muscle relaxants, and alcohol, may result in respiratory depression, hypotension, and deep sedation, or possibly in coma or death.	DDI-false
Death due to fulminant pancreatitis possibly related to intravenous @DRUG$ and @DRUG$ has been reported.	DDI-effect
The effects of DCG-IV and @DRUG$ After phencyclidine (@DRUG$)-induced movement and behavioural changes in mice.	DDI-false
In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulphenazole, @DRUG$ and @DRUG$.	DDI-false
No data are available for the coadministration of INVIRASE/ritonavir or @DRUG$/@DRUG$ And garlic capsules.	DDI-false
@DRUG$ (@DRUG$, sodium acid phosphate, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	DDI-false
Erythromycin Co-administration of felodipine ( @DRUG$ ) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax , and about 2- fold prolongation in the half- life of @DRUG$.	DDI-false
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as rifampin, phenytoin, @DRUG$, and @DRUG$.	DDI-false
Probenecid: Probenecid interferes with renal tubular secretion of @DRUG$ and produces an increase in the level of @DRUG$ in serum.	DDI-false
In another study , TORADOLIV/IM was given with two doses of 5000 U of @DRUG$ to 11 healthy volunteers , resulting in a mean template bleeding time of 6.4 minutes ( 3.2 to 11.4 min ) compared to a mean of 6.0 minutes ( 3.4 to 7.5 min ) for @DRUG$ alone and 5.1 minutes ( 3.5 to 8.5 min ) for placebo .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : @DRUG$ , quinidine @DRUG$ Astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampine Benzodiazepines Midazolam, triazolam GI Motility agent: cisaprid	DDI-false
Oral neomycin inhibits the gastrointestinal absorption of @DRUG$, oral @DRUG$, methotrexate and 5-fluorouracil.	DDI-false
- Indomethacin : @DRUG$ blunts the increases in urine volume and sodium excretion seen during @DRUG$ treatment and inhibits the bumetanide-induced increase in plasma renin activity .	DDI-mechanism
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin, gentamicin and @DRUG$ ) , amphotericin B , foscarnet , intravenous pentamidine , @DRUG$ , and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. @DRUG$ , @DRUG$ , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Drugs with a Narrow Therapeutic Index @DRUG$ : @DRUG$ ( 10 mg ) did not affect the pharmacokinetic or pharmacodynamic profile of digoxin ( 0.375 mg q24h for 8 days ) .	DDI-false
ACE Inhibitors and @DRUG$ ( Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS , 3020 ( 91 % ) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists ( ACEI/ARB ) .	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin, clarithromycin, diclofenac, @DRUG$ , erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Patients starting to take Diclofenac or @DRUG$ dose or any other NSAID while taking @DRUG$ , methotrexate, or cyclosporin may develop toxicity properties for these drugs.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance , such as @DRUG$ , nevirapine , @DRUG$ , dexamethasone , or carbamazepine , use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
Therefore, agents, the sympathetic activity (e.g., @DRUG$ or @DRUG$ ( ) should be used with caution.	DDI-false
In clinical studies conducted with fondaparinux, concomitant use of oral anticoagulants ( warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$, and @DRUG$) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Co-administration of other CYP3A4 inhibitors such as diltiazem and @DRUG$ With transdermal fentanyl it can also lead to an increase in @DRUG$ Plasma concentrations that may increase or prolong adverse drug reactions and may cause severe respiratory depression.	DDI-false
Potential interactions between @DRUG$ CYP3A4, a substrate of CYP3A4 and protease inhibitors ( @DRUG$ Clinical studies have not investigated saquinavir, indinavir and nelfinavir, which are substrates and/ or inhibitors of CYP3A4.	DDI-false
There have been case reports of increased steady-state levels of quinidine, @DRUG$ , and @DRUG$ â€¢ during concomitant therapy with amiodarone.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, @DRUG$ Doses of 1 mg or more were used concomitantly in clinical trials with acetaminophene, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, H2-antagonists, @DRUG$ Prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Both efavirenz and @DRUG$ Treatment with PI indinavir was compared with triple therapy for 48 weeks as an initial therapy, with similar response rates as in patients with PI indinavir. @DRUG$ regimens and superiority observed with efavirenz .	DDI-false
Micro-dosed @DRUG$ Preparations : Micro-dosed @DRUG$ preparations ( minipills that do not contain an estrogen ) may be an inadequate method of contraception during Accutane therapy .	DDI-false
- Methotrexate (e.g., Mexate) Use of @DRUG$ with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-effect
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, @DRUG$ or fluconazole.	DDI-false
Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including barbiturates, @DRUG$, and alcohol.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-int
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including non-steroidal anti-inflammatory drugs and other drugs that are highly protein bound, salicylates, @DRUG$ , chloramphenicol, probenecid, @DRUG$ , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
Example inhibitors include azole antifungals, @DRUG$, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Antibiotics : In vitro and/or in vivo data show that clarithromycin , erythromycin , and @DRUG$ The metabolism of @DRUG$ This may lead to an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
- Anabolic steroids ( nandrolone [ e.g. , @DRUG$ ], Oxandrolone [e.g., Anavar], Oxymetholone [e.g., Anadrol], @DRUG$ [ e.g. , Winstrol ] ) or	DDI-false
Fenfluramine may increase slightly the effect of antihypertensive drugs, e.g., @DRUG$, @DRUG$, reserpine.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, @DRUG$ , lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and @DRUG$.	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Carbamazepine: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-advise
@DRUG$: Concomitant administration of low-dose aspirin with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	DDI-false
Potential interactions between Keppra and other AEDs ( @DRUG$ , gabapentin , lamotrigine , phenobarbital , phenytoin , @DRUG$ and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide, digoxin, warfarin, @DRUG$ and @DRUG$.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , @DRUG$ , amikacin ) , amphotericin B , @DRUG$ , non-steroidal anti-inflammatory drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin .	DDI-false
Oral @DRUG$ : Pharmacokinetic drug-response interactions between @DRUG$ No evidence was provided for warfarin (7.5 mg single oral dose) and warfarin (7.5 mg single oral dose).	DDI-false
@DRUG$: The combination of HIVID, @DRUG$, and ZDV has been studied (as triple combination) in adults.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and @DRUG$ when administered concomitantly with an intravenous @DRUG$ such as morphine.	DDI-mechanism
Ketoconazole did not affect the conversion of losartan to the active metabolite after intravenous administration of @DRUG$, and @DRUG$ had no clinically significant effect after oral administration.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when @DRUG$ was used in conjunction with @DRUG$.	DDI-effect
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, @DRUG$ , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
@DRUG$: As with other @DRUG$, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for loracarbef.	DDI-false
The pharmacokinetics of @DRUG$ were not affected by coadministration of nifedipine or @DRUG$	DDI-false
conversely , diethylpropion may interfere with @DRUG$ ( i.e. , guanethidine , @DRUG$ ) .	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g. @DRUG$ , @DRUG$ , and erythromycin ) has not been studied , increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications .	DDI-false
Probenecid : As with other b-lactam antibiotics , renal excretion of loracarbef is inhibited by @DRUG$ and resulted in an approximate 80 % increase in the AUC for @DRUG$.	DDI-false
Therefore, medicinal products that are likely to be concomitant with @DRUG$ that are metabolized by this isoenzyme family may potentially interact with @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Injection: @DRUG$ injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Colestipol-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , @DRUG$ , and @DRUG$ In combination with fosinopril reduced serum levels and urinary excretion of fosinoprilat given alone, suggesting that antacids may impair the absorption of fosinopril.	DDI-false
Hepatic Enzyme Inducers , Inhibitors and Substrates : Drugs which induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity ( e.g. , @DRUG$ , phenytoin , @DRUG$ , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased .	DDI-false
Ethinyl Estradiol and @DRUG$: Coadministration of @DRUG$ with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g., @DRUG$ , gentamicin , and @DRUG$ ) , amphotericin B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Other strong inhibitors of CYP3A4 ( e.g. , itraconazole , clarithromycin , @DRUG$ , troleandomycin, ritonavir, @DRUG$ It would be expected that it would behave in a similar way.	DDI-false
INOmax has been administered with @DRUG$, dopamine, dobutamine, steroids, @DRUG$, and high-frequency ventilation.	DDI-false
Cardiac effects of @DRUG$ Beta-Adrenerg-Blocker, e.g. @DRUG$ and metoprolol .	DDI-effect
Nephrotoxicity has been reported following concomitant administration of cephalosporins with @DRUG$ or potent diuretics such as @DRUG$.	DDI-false
Although other @DRUG$ are highly effective , there have been reports of pregnancy from women who have used @DRUG$ , as well as topical/injectable/implantable/insertable hormonal birth control products .	DDI-false
In patients with mild to moderate hypertension , administration of 25 mg daily of VIOXX with the @DRUG$ @DRUG$ , 10 to 40 mg for 4 weeks , was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone .	DDI-false
Intermediate doses of @DRUG$ or @DRUG$ â€¢ a transient increase in FI response rates in monkeys and a sustained increase in FI response rates in pigeons;	DDI-false
Effect of @DRUG$ For the pharmacokinetic treatment of other medicinal products: @DRUG$ does not appear to alter the pharmacokinetics of phenytoin , carbamazepine , or phenobarbital .	DDI-false
While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , @DRUG$ , escitalopram, fluoxetine, @DRUG$ , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of @DRUG$ Although it significantly reduced zidovudine Tmax by 44% and increased intracellular exposure to phosphorylated zidovudine by 110%.	DDI-false
(In some patients, the @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.	DDI-effect
Repeated doses of @DRUG$ given prior to a single dose of @DRUG$ in human trials have been reported to decrease propranolol absorption.	DDI-mechanism
@DRUG$ (@DRUG$) produces psychotomimetic effects in humans that resemble schizophrenia symptoms.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , @DRUG$ , local anesthetics , procainamide , and @DRUG$.	DDI-false
There have been reports of QTc prolongation, with or without TdP, in patients taking @DRUG$ when fluoroquinolones, @DRUG$, or azoles were administered concomitantly.	DDI-false
Patients in a clinical study who were on established therapy with @DRUG$ It was found that ENBREL showed a slight decrease in the mean neutrophil count compared to groups treated either with ENBREL-KI or with ENBREL-KI. @DRUG$ alone .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Patients who begin taking @DRUG$ or who increase their diclofenac dose or any other NSAID while taking @DRUG$, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-effect
Drug/Laboratory Test Interactions @DRUG$, including @DRUG$, are known to occasionally induce a positive direct Coombs test.	DDI-false
The effects of ruthenium red ( RR ) on @DRUG$ (@DRUG$)-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry .	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an @DRUG$/levonorgestrol oral @DRUG$ in healthy subjects.	DDI-false
@DRUG$, @DRUG$, and azoles are known to cause QTc prolongation.	DDI-false
however, no deleterious interactions were seen when ROMAZICON was administered after narcotics, inhalational @DRUG$, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$, an inhibitor of P450 2C9, decreased active metabolite concentration and increased @DRUG$ concentration.	DDI-mechanism
An alternative non-CYP3A4 substrate hypnotic agent may be considered in patients taking CYP3A4 inducers such as @DRUG$, phenytoin, carbamazepine, and @DRUG$.	DDI-false
Adequate monitoring of theophylline plasma concentrations should be considered when therapy with @DRUG$ The treatment is initiated or modified in patients receiving @DRUG$.	DDI-advise
Other Drug Interactions Oral Contraceptives Keppra  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg @DRUG$ and 0.15 mg @DRUG$, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, @DRUG$, and phenytoin, have been used concurrently with amiodarone.	DDI-false
Valproate : The addition of @DRUG$ This did not affect the pharmacokinetics of tiagabin in patients chronically taking valproate. @DRUG$ Tiagabin binding in vitro decreased significantly from 96.3 to 94.8%, resulting in an increase in free tiagabin concentration of about 40%.	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, @DRUG$) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving @DRUG$ or @DRUG$ may produce severe, prolonged hypertension.	DDI-false
Antimycobacterial Agents: @DRUG$ CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
acetaminophen/theophylline , @DRUG$/@DRUG$ , phenobarbital/acetaminophen, phenobarbital/ valproic acid, quinidine/ lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Other Agents : @DRUG$ has been used concomitantly with nitrates and/or @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, @DRUG$ , danazol , diuretics , sympathomimetic agents ( e.g. , @DRUG$ , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , @DRUG$ , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , @DRUG$ , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , @DRUG$ , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and @DRUG$ Chemotherapy plus HAART with a group of 80 patients treated with CHOP chemotherapy or with a CHOP-like regimen (e.g. cyclophosphamide, doxorubicin, teniposide and prednisone) @DRUG$ plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Indinavir : Coadministration of @DRUG$ with VIRACEPT resulted in an 83 % increase in @DRUG$ plasma AUC and a 51 % increase in indinavir plasma A.C.	DDI-false
The aim of this paper was to study the interaction between neurotensin and both enkephalins or its synthetic analogue @DRUG$, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
In monkeys, (-)-NANM was about 10 times more potent than @DRUG$ in decreasing responding, whereas in pigeons @DRUG$ was about equipotent with (+)-NANM.	DDI-false
Although no interaction between MAO inhibitors and @DRUG$ has been observed, it is not recommended for use with @DRUG$.	DDI-advise
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ Flupentixol and ethanol cause additive CNS depression - @DRUG$ : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$: The concomitant use of Bepridil and @DRUG$ has been well tolerated in patients with stable angina.	DDI-false
â€¢ Dopamine antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of @DRUG$.	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients who block -@DRUG$ (e.g. propranolol, CYP3A4 inhibitor) or calcium channel antagonists (e.g. @DRUG$ , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, @DRUG$ , @DRUG$ , digoxin, warfarin, isosorbide mononitrate, schnitztilol, ethanol or itraconazole.	DDI-false
Patients receiving both indomethacin and @DRUG$ should be observed closely to determine if the desired diuretic and/or antihypertensive effect of @DRUG$ is achieved.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that @DRUG$, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
A clinical study in healthy male volunteers (n=24) demonstrated that mixing NovoLog with @DRUG$ immediately before injection produced some attenuation in the peak concentration of @DRUG$, but that the time to peak and the total bioavailability of NovoLog were not significantly affected.	DDI-false
@DRUG$ : Amiodarone , bepridil , flecainide , propafenone , @DRUG$ CONTRAINDICATE because of the potential for serious and/or life-threatening reactions.	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$ , nifedipine , @DRUG$ Diazepam, certain tricyclic antidepressants, lidocaine, theophylline, and metronidazole, delaying the elimination and increase in blood levels of these drugs.	DDI-false
Efavirenz and nevirapine were treated with @DRUG$ Indinavir was observed for 48 weeks as initial therapy, with similar response with nevirapine therapies and superiority with @DRUG$.	DDI-false
Potentiation occurs with @DRUG-DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , @DRUG$ , nitrofurantoin, phenytoin, @DRUG$ , and vincristine .	DDI-false
Micro-dosed @DRUG$ Preparations: Micro-dosed @DRUG$ preparations (minipills that do not contain an estrogen) may be an inadequate method of contraception during Accutane therapy.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Micro-dosed @DRUG$ Preparations : Micro-dosed progesterone preparations ( minipills that do not contain an estrogen ) may be an inadequate method of contraception during @DRUG$ therapy .	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramides, fibrates, @DRUG$ Monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
When LEVSIN is co-administered with other antimuscarinic agents, amantadine, haloperidol, phenothiazines, @DRUG$ , tricyclic antidepressants or some @DRUG$.	DDI-false
@DRUG$ : Vardenafil 20 mg , when co-administered with slow-release nifedipine 30 mg or 60 mg once daily , did not affect the relative bioavailability ( AUC ) or maximum concentration ( Cmax ) of @DRUG$ A drug that is metabolised by CYP3A4.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, @DRUG$ , @DRUG$ , polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
@DRUG$: Diazepam (@DRUG$) is a CYP 3A4 and CYP 2C19 substrate.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, @DRUG$ , polymyxins, lincomycin, clindamycin, colistine, and sodium colistimethate), @DRUG$ Salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , @DRUG$ , nicotinic acid, @DRUG$ , calcium channel block drugs, and isoniazid.	DDI-false
This indicates that @DRUG$ Do not lead to induction or inhibition of the liver microsome enzyme systems responsible for @DRUG$ metabolism.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , betablockers , calcium-channel blockers , @DRUG$ , and @DRUG$ NSAIDs without evidence of clinically significant adverse interactions.	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral @DRUG$ ) .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and @DRUG$), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
For example, inhibitors are azole antimycotics, @DRUG$ , clarithromycin , diclofenac , doxycycline , @DRUG$ , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Profound hypotensive episodes may occur when @DRUG$ infection and @DRUG$ are used concomitantly.	DDI-effect
@DRUG$ (e.g. flecainide, @DRUG$ Co-administration with arbutamine may have a proarrhythmic effect.	DDI-false
@DRUG$ , lidocaine, phenobarbital, @DRUG$ Theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Due to high inter-patient variability and limited sampling, the extent of the increase in @DRUG$ levels in patients receiving concurrent irinotecan and @DRUG$ is uncertain.	DDI-false
@DRUG$ caused a statistically significant increase in plasma exposures of R-warfarin and S-warfarin (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of @DRUG$.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
There is therefore an improvement effect of @DRUG$ upon the reaction of placental vessels to @DRUG$ in vitro .	DDI-effect
Drug interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): @DRUG$ - Arecolin - eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - @DRUG$ : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Since @DRUG$ is a substrate for CYP3A4 , there is the potential that the use of St. John s Wort in patients receiving @DRUG$ could result in reduced amiodarone levels .	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, @DRUG$ , felodipine , @DRUG$ , warfarin, isosorbide mononitrate, knitztilol, ethanol or itraconazole.	DDI-false
Cyclosporine, Digoxin, Methotrexate Lodine, like other @DRUG$, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$, digoxin, methotrexate, and increased toxicity.	DDI-mechanism
The intensity, uniformity and time course of the anticoagulant interference by @DRUG$ , @DRUG$ , glutethimide , chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
As @DRUG$, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., valproic acid, @DRUG$).	DDI-false
@DRUG$ Co-administration of rifabutin and VIRACEPT resulted in a decrease in @DRUG$ plasma AUC and a 207 % increase in rifabutin plasma A.C.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , @DRUG$ was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , betablockers , calcium-channel blockers , diuretics , and @DRUG$ ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and @DRUG$) decrease @DRUG$ metabolism and increase gefitinib plasma concentrations.	DDI-mechanism
May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, @DRUG$ , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , @DRUG$ , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
No data are available for the coadministration of @DRUG$/@DRUG$ FORTOVASE/ritonavir and garlic capsules.	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.	DDI-false
A potential interaction between oral @DRUG$ and oral @DRUG$ For this reason, severe hypoglycaemia has been reported.	DDI-effect
The effects of adenosine are antagonized by @DRUG$ Like caffeine and @DRUG$.	DDI-false
@DRUG$ : The combination of HIVID , saquinavir , and @DRUG$ It has been studied (as a triple combination) in adults.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , @DRUG$ , fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylate, somatostatin analogue (e.g., @DRUG$ ) , sulfonamide antibiotics .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , @DRUG$ , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , @DRUG$ H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Patients who have been treated with @DRUG$ within two to three weeks prior to the administration of @DRUG$ Initial doses of dopamine HCl should not exceed one tenth ( 1/10 ) of the usual dose.	DDI-advise
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ The oral clearance of furosemide (n = 23) and @DRUG$ ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Two percent of patients treated concurrently with @DRUG$  and @DRUG$ developed neutropenia (ANC   1 x 109/L).	DDI-effect
For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with @DRUG$ and a @DRUG$ do not outweigh the risks of severe myopathy, rhabdomyolysis, and acute renal failure.	DDI-effect
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
MAO Inhibitors: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with @DRUG$	DDI-advise
Concomitant cyclophosphamide, @DRUG$, @DRUG$, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including: @DRUG$ , CYP2C9 , @DRUG$ , and CYP3A4.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Diuretics : Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$ or @DRUG$.	DDI-false
@DRUG$ ( eg , tubocurarine ) and other drugs , including ether , succinylcholine , gallamine , @DRUG$ The neuromuscular blocking effect should be increased in patients treated with Coly-Mycin M Parenteral and sodium citrate should be administered with extreme caution.	DDI-false
@DRUG$, Nimodipine and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
These drugs include the @DRUG$ and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Antihypertensives: @DRUG$ may antagonize the hypotensive effects of @DRUG$.	DDI-effect
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, niacin (@DRUG$), erythromycin, @DRUG$.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Imipramine (5 mg/kg), @DRUG$ (30 mg/kg), @DRUG$ (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.	DDI-false
Digoxin , @DRUG$ and Losartan : Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine , and @DRUG$ It has no significant influence on bosentan plasma levels.	DDI-false
@DRUG$ : @DRUG$ may delay intestinal absorption of phenytoin ;	DDI-false
Probenecid: May decrease renal tubular secretion of @DRUG$ resulting in increased blood levels and/or @DRUG$ toxicity.	DDI-false
The use of antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimid, @DRUG$ , hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$ , phenytoin, ribavirin and vincristine.	DDI-false
The intensity , uniformity and time course of @DRUG$ - influence by phenobarbital, secobarbital, glutethimide, chloralhydrate and @DRUG$ The treatment was systematically studied in 16 patients receiving coumarin therapy.	DDI-false
Coadministration with valdecoxib (40 mg BID for 7 days) resulted in a significant increase in @DRUG$ plasma levels suggesting that, at these doses, @DRUG$ is a weak inhibitor of 2D6.	DDI-false
A potential interaction between oral @DRUG$ and oral @DRUG$ For this reason, severe hypoglycaemia has been reported.	DDI-int
In clinical trials, FLOLAN was used with @DRUG$, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ and @DRUG$ could exaggerate the prolongation of the QT interval observed with bepridil hydrochloride .	DDI-false
@DRUG$ - prior ingestion of @DRUG$ may decrease the emetic response to apomorphine in the treatment of poisoning.	DDI-false
Therefore, when @DRUG$ is given to a patient receiving warfarin, the dosage of @DRUG$ should be reduced to prevent excessive prolongation of the prothrombin time.	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g. itraconazole, @DRUG$ , and @DRUG$ In the absence of studies, increased exposure to almotriptan may be expected when Almotriptan is co-administered with these medicines.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, @DRUG$, griseofulvin, topiramate, and possibly with @DRUG$ and tetracyclines 72.	DDI-false
Two groups ( SH/DA ; SH/FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$ , @DRUG$ , higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages ;	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, alcohol and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	DDI-false
The effects of adenosine are antagonized by methylxanthines such as @DRUG$ and @DRUG$.	DDI-false
Antimycobacterial Agents : @DRUG$ CONTRAINDICATE since co-administration of this medicinal product with @DRUG$ In an antiretroviral regimen, this reduces the plasma concentrations of saquinavir.	DDI-false
@DRUG$/Aluminum-containing @DRUG$ : Absorption of zalcitabine is moderately reduced ( approximately 25 % ) when coadministered with magnesium/aluminum-containing antacid products .	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including @DRUG$ â™ª Like quinidine and @DRUG$ , cardiac glycosides and tricyclic anti-depressants .	DDI-false
The addition of @DRUG$ In a limited number of patients in three well-controlled studies, no systematic changes in phenobarbital or @DRUG$ Concentrations compared to placebo.	DDI-false
Isoflurane potentiates the muscle relaxant effect of all @DRUG$, most notably @DRUG$, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.	DDI-false
To determine whether @DRUG$ has a direct effect on the distribution of cloxacillin, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of @DRUG$.	DDI-false
Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , @DRUG$ , a CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and @DRUG$ , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Other CNS depressant drugs ( e.g. barbiturates , tranquilizers , opioids and general @DRUG$ ==References====External links==* http://www.statistics.sk/mosmis/eng/run.html* http://www.statistics.sk/mosmis/eng/run.html* http://www.statistics.sk/mosmis/eng/run.html	DDI-effect
This drug may interact with alcohol or other CNS depressants ( may potentiate the CNS depressant effects of either these medications or antihistamines ) , anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$ ) , and @DRUG$ ( concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ) .	DDI-false
@DRUG$ toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of @DRUG$ therapy .	DDI-false
MAO inhibitors @DRUG$, as well as a metabolite of @DRUG$, slow amphetamine metabolism.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, @DRUG$, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , @DRUG$ , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , @DRUG$ ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , intraconazole , ritonavir , indinavir , @DRUG$ , erythromycin, etc.) is indicated, reduction of @DRUG$ The dose should be considered.	DDI-advise
It is concluded that @DRUG$ and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy.	DDI-false
Multivitamins or other products containing iron @DRUG$ , antacids or sucralfate should not be administered concomitantly with , or within 2 hours of , the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
* Drug interactions : Flupentixol may interact with some drugs, such as @DRUG$ ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Anticoagulants including coumarin derivatives , indandione derivatives , and platelet aggregation inhibitors such as @DRUG$ ( NSAIDs ) and @DRUG$ The risk of bleeding may be increased when co-administered with ardeparin.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
@DRUG$ , tricyclic Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents ;	DDI-false
Benzthiazide may interact with alcohol , blood thinners , @DRUG$ (allergic, cold, and sinus medicines), diabetic, lithium, @DRUG$ , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications .	DDI-false
@DRUG$ Before performing an @DRUG$-mediated stress test, the stress test should be withdrawn for at least 48 hours.	DDI-advise
Although no clinical studies have been conducted, it is likely that the metabolism of @DRUG$ may be affected by the known CYP3A4 inducers ( such as phenytoin , @DRUG$ CYP3A4 inhibitors (e. g. azole antifungals, ketoconazole);	DDI-mechanism
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$ Amiodarone, quinidine antihistamines: astemizole, terfenadine antimigrain: ergot derivatives antimycobacterial agents: rifampine benzodiazepine midazolam, @DRUG$ GI motility agent: cisapride	DDI-false
Since @DRUG$ is an @DRUG$, it may have a strong affinity for anions other than the bile acids.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of @DRUG$ (such as loop or thiazide diuretics) can be acutely worsened by @DRUG$, especially when the recommended dose of the beta-agonist is exceeded.	DDI-effect
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , @DRUG$ , doxorubicin, teniposide, and @DRUG$ â€¢ with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: @DRUG$, @DRUG$, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-false
conversely, @DRUG$ may interfere with @DRUG$ (i.e., guanethidine, a-methyldopa).	DDI-int
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$ Amiodarone, quinidine antihistamines: @DRUG$ , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
In chronic hepatitis C patients treated with PEGASYS in combination with @DRUG$ , @DRUG$ treatment did not affect ribavirin distribution or clearance .	DDI-false
@DRUG$ â™ª As with others â™ª @DRUG$ The renal excretion of Loracarbef is inhibited by probenecid and led to an increase in AUC of about 80% in Loracarbef.	DDI-false
Drug interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Other medicines that can enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX are certain @DRUG$ ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , @DRUG$ , colistine, and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide, and quinidine.	DDI-false
In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$  and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$  alone (0%).	DDI-false
In contrast to the digital tolerance in dogs, Innovar Vet is anaesthetized with ketamine, or @DRUG$ The dose of Ouabain was needed to cause ventricular tachycardia significantly higher, such as the LD50 of Ouabain, with ketamine or Innovar than with @DRUG$.	DDI-false
" medicinal products identified as CYP3A inhibitors of potential clinical significance based on clinical trials involving alprazoleam (when co-administered with: @DRUG$ Co-administration of fluoxetine and alprazoleam increased the maximum plasma concentration of @DRUG$ The clearance decreased by 46%, the half-life decreased by 17% and the measured psychomotor performance decreased.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics , amantadine , haloperidol , phenothiazines , monoamine oxidase ( MAO ) inhibitors , @DRUG$ Or some antihistamines.	DDI-effect
The absorption of oral @DRUG$ is significantly reduced by the concomitant administration of an antacid containing aluminum and @DRUG$.	DDI-mechanism
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
Magnesium/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
In addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , @DRUG$ , phenytoin , @DRUG$ , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , @DRUG$ , estrogens, oral contraceptives, phenytoin, @DRUG$ , sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Digoxin, @DRUG$ and Losartan: @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : @DRUG$ Increases the effect of tricyclic antidepressants	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus @DRUG$ ) without receiving @DRUG$ therapy .	DDI-false
@DRUG$ : The combination of @DRUG$ , saquinavir , and ZDV has been studied ( as triple combination ) in adults .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Since Nalfon has not been shown to produce any additional effect over being given with aspirin alone and because aspirin increases the excretion rate of nalfon, concomitant use of @DRUG$ and @DRUG$ is not recommended .	DDI-advise
Dexamethasone and @DRUG$ similarly inhibit and stimulate EGF- or @DRUG$-induced proliferation of prostatic epithelium .	DDI-effect
HMG-CoA reductase inhibitors: @DRUG$ ( @DRUG$ The substrate) in combination with amiodarone has been associated with myopathy/rhabdomyolysis reports.	DDI-false
Fenfluramine may slightly increase the effect of antihypertensive agents, e.g. @DRUG$ , @DRUG$ , reserpine .	DDI-false
An additive hypotensive effect was associated with the combination of systemic @DRUG$ and @DRUG$ therapy .	DDI-effect
Therefore , @DRUG$ serum levels should be monitored and appropriate @DRUG$ Dose adjustments are made when these medicines are used at the same time.	DDI-false
Antidiabetic medicinal products : ( oral medicinal products and @DRUG$ - Dosage adjustment of the @DRUG$ may be required .	DDI-false
In pigeons, naloxone did not systematically alter the effects of @DRUG$, @DRUG$ or PCP.	DDI-false
Coadministration of terfenadine with @DRUG$ This resulted in increased plasma concentrations of @DRUG$ , resulting in rare instances of life- threatening cardiac dysrhythmias and one death .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, @DRUG$, sulfasalazine, and anakinra.	DDI-false
@DRUG$ In vitro data show that nefazodone inhibits the metabolism of cisapride, which may lead to an increase in plasma. @DRUG$ levels and prolongation of the QT interval on the ECG .	DDI-false
Antiarrhythmics : Other antiarrhythmic drugs , such as @DRUG$ , @DRUG$ , disopyramide , and phenytoin , have been used concurrently with amiodarone .	DDI-false
The compounds tested in humans include warfarin, @DRUG$ , phenytoin, diazepam, aminopyrin and @DRUG$.	DDI-false
Cholestyramine and @DRUG$ resins: Absorption of hydrochlorothiazide is impaired in the presence of @DRUG$.	DDI-false
Lithium : Increased serum @DRUG$ The concentrations and symptoms of lithium toxicity have been reported in patients with concomitant lithium and @DRUG$ therapy .	DDI-false
Coadministration of valdecoxib ( 10 mg BID for 7 days ) with @DRUG$ ( 5 mg QD or 10 mg BID ) did not affect the pharmacokinetics ( exposure ) of @DRUG$.	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , @DRUG$ , @DRUG$ Effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Interactions between medicinal products and medicinal products have not been observed. @DRUG$ and @DRUG$ or erythromycin .	DDI-false
Digoxin: When multiple doses of atorvastatin and @DRUG$ were coadministered, steady-state plasma @DRUG$ concentrations increased by approximately 20%.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-effect
medicines that should not be combined with VIRACEPT antiarrhythmics: @DRUG$ , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines @DRUG$ , triazolam GI motility agents : cisapride	DDI-false
Since higher doses of @DRUG$ ( 400 mg daily ) may result in higher increases in Cmax and AUC , a single 2.5 mg dose of @DRUG$ should not be exceeded in a 24-hour period when used in combination with ketoconazole 400 mg daily .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Before using this medicine, tell your doctor or pharmacist about all prescription and non-prescription products that you can use, especially: aminoglycosides (e.g., @DRUG$ , amikacin ) , amphotericin B , cyclosporine , non-steroidal anti-inflammatory drugs ( e.g. , @DRUG$ ) , tacrolimus , vancomycin .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , @DRUG$ , @DRUG$ , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Ethinyl Estradiol and Norethindrone: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in @DRUG$ and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
Oral @DRUG$: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/@DRUG$ (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
Cardiovasculars: @DRUG$: In patients receiving digoxin therapy, administration of oral @DRUG$ regularly results in an increase in serum digoxin concentration that may reach toxic levels with resultant clinical toxicity.	DDI-false
In the case that you are taking digoxin while taking @DRUG$, higher doses of @DRUG$ may be needed.	DDI-false
Other Drug Interactions : No pharmacokinetic interactions were observed between vardenafil and the following drugs : glyburide , @DRUG$ , digoxin , @DRUG$ , and ranitidine .	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with CNS depressants ( alcohol , barbiturates , @DRUG$ , @DRUG$ , anesthetics ) should be considered .	DDI-false
Furosemide : @DRUG$ IV/IM reduced the @DRUG$ The response to furosemide in normalovolemic healthy subjects was approximately 20% (mean sodium and urine production decreased by 17%).	DDI-false
In clinical studies performed with @DRUG$ , the concomitant use of oral anticoagulants ( warfarin ) , @DRUG$ ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( phenytoin , valproate , oral @DRUG$ , digoxin, warfarin, @DRUG$ ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients .	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, @DRUG$ , cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazoleam, and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Antipyrine : Because atorvastatin does not affect the pharmacokinetics of @DRUG$ Interactions with others @DRUG$ Metabolism via the same cytochrome isozymes is not expected.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Therefore, in patients taking @DRUG$ or oral @DRUG$, regular monitoring of blood glucose is recommended.	DDI-false
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Imidazole (e.g. @DRUG$ , @DRUG$ , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( @DRUG$ ): @DRUG$ - Arecoline - Eproxindine - Ethanol : Flupentixol and ethanol cause additive CNS depression - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
Study results in patients with multiple sclerosis, TYSABRI and interferon beta-1a ( @DRUG$ 30 mcg IM once weekly) or glatirameracetate were considered to be necessary for dose adjustment of @DRUG$ or glatiramer acetate .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Nonsteroidal Anti-Inflammatory Drugs (@DRUG$)-A drug interaction study of eplerenone with an @DRUG$ has not been conducted.	DDI-false
Mineral Oil-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
Anticoagulants: Potentiation of @DRUG$-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
The concomitant use of these oral @DRUG$ The pharmacokinetics of @DRUG$ have not been affected.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, @DRUG$ , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$ Nefazodone, fluvoxamine, cimetidine, @DRUG$ Isoniazid, and some macrolide antibiotics.	DDI-mechanism
@DRUG$-containing therapies should not be used with @DRUG$ Because they can reduce its pharmacological effect.	DDI-advise
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, @DRUG$, erythromycin, clarithromycin).	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
@DRUG$: @DRUG$ may delay intestinal absorption of phenytoin;	DDI-false
In patients with chronic hepatitis C treated with @DRUG$ in combination with COPEGUS, PEGASYS treatment did not affect @DRUG$ distribution or clearance.	DDI-false
@DRUG$ IV has been used concomitantly with @DRUG$ without evidence of clinically significant adverse reactions.	DDI-false
@DRUG$: @DRUG$, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
@DRUG$ reduced the blood AUC0-12 of @DRUG$ by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.	DDI-mechanism
Coingestion of acetaminophen with theophylline, phenobarbital with @DRUG$, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
@DRUG$: Co- administration of warfarin and cerivastatin to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of @DRUG$ and placebo.	DDI-false
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of @DRUG$ , gold, chloroquine, D-penicillamin, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
The plasma exposure of diazepam ( 10 mg twice daily ) was increased by 28% after administration of valdecoxib ( 40 mg twice daily ) for 12 days, while plasma exposure of @DRUG$ ( 40 mg BID ) was not substantially increased following administration of @DRUG$ ( 10 mg BID ) for 12 days .	DDI-false
Imidazoles ( e. g. , @DRUG$ , miconazole , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
Warfarin: Quinolones have been reported to enhance the effects of the oral @DRUG$ @DRUG$ or its derivatives.	DDI-false
HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-mechanism
Guardians of children who have been prescribed @DRUG$ The general concern about adherence to asthma therapy, in particular the neglect of anti-inflammatory therapy and the overuse of @DRUG$, should be alerted.	DDI-false
The intensity , uniformity and time course of anticoagulant interference by phenobarbital , @DRUG$ , @DRUG$ , chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
In separate studies of patients receiving maintenance doses of @DRUG$ , hydrochlorothiazide , or digoxin , @DRUG$ The 7-day administration did not affect the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.	DDI-false
In monkeys, the effects of (-)-NANM, but not @DRUG$ or PCP, were antagonized by @DRUG$;	DDI-false
@DRUG$: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or @DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, @DRUG$ , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
@DRUG$ Concomitant administration of low dose aspirin with VIOXX may lead to an increased rate of GI ulceration or other complications compared to the use of @DRUG$ alone .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
@DRUG$, clonazepam, @DRUG$	DDI-false
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, terfenadine antimigrain: ergot derivatives @DRUG$ : rifampin @DRUG$ Midazolam, triazolam GI Motility agent: cisapride	DDI-false
In monkeys, the effects of @DRUG$ , but not (+)-NANM or PCP, were antagonized by @DRUG$ ;	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , @DRUG$ , hydralazine , @DRUG$ , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, @DRUG$, and @DRUG$ (72)	DDI-false
@DRUG$: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat @DRUG$ poisoning.	DDI-false
These drugs include the @DRUG$ and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Acetaminophen , @DRUG$ , @DRUG$ , quinidine, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$: Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of @DRUG$	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Theophylline : A single 10 mg dose of @DRUG$ did not affect the pharmacokinetics of @DRUG$ at steady state .	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/@DRUG$ , @DRUG$/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ The simultaneous use of @DRUG$ Good tolerability was achieved in patients with stable angina pectoris and beta-blockers.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral contraceptive, @DRUG$, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Observations from drug interaction studies with @DRUG$ Maybe it's not predictable for @DRUG$.	DDI-false
Digoxin , @DRUG$ , @DRUG$ Diclofenac, like other NSAIDs, can affect the kidney prostaglandins and increase the toxicity of certain drugs.	DDI-false
( 1968 , 1970 ) , the higher serum concentrations of penicillins and @DRUG$ reached after administration of @DRUG$ are due not only to slower renal elimination but also to an altered distribution in the body .	DDI-mechanism
Sedatives/@DRUG$ : @DRUG$ , midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .	DDI-false
Drugs with a Narrow Therapeutic Index @DRUG$ Sonata ( 10 mg ) did not affect the pharmacokinetic or pharmacodynamic profile @DRUG$ ( 0.375 mg q24h for 8 days ) .	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving @DRUG$ or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-effect
Therapeutic concentrations of digoxin, @DRUG$ , ibuprofen , @DRUG$ , piroxicam , acetaminophen , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
Nifedipine : @DRUG$ 20 mg, when administered concomitantly with slow-release nifedipine 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or the maximum concentration (Cmax) of @DRUG$ , a drug that is metabolized via CYP3A4 .	DDI-false
Consequently, drugs with a low therapeutic margin, such as @DRUG$, @DRUG$, and theophylline, could have a delayed elimination and increases in their serum half-life leading to a toxic level.	DDI-false
In separate studies with patients who have maintenance doses @DRUG$ , @DRUG$ Administration of irbesartan for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or the pharmacokinetics of digoxin.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , @DRUG$ , @DRUG$ , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .	DDI-false
Other concomitant therapy Although no specific interaction studies have been performed, clinical trials with 1 mg or more of finasteride doses have been conducted at the same time. @DRUG$ , acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme ( ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, heart @DRUG$ , diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and quinolones anti-infections without evidence of clinically significant adverse interactions.	DDI-false
Acetaminophen: Pharmacokinetic or pharmacodynamic drug-effect interactions between argatroban and concomitant use of argatroban have not been established. @DRUG$ 162.5 mg orally administered 26 and 2 hours before the start of treatment. @DRUG$ 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after starting argatroban 1.5 g/kg/min for 18 hours).	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with @DRUG$ , methyldopa , nitrates , calcium-blocking agents , @DRUG$ , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some @DRUG$.	DDI-false
@DRUG$ , not depolarising (e.g., @DRUG$ ): possible increased responsiveness to the muscle relaxant .	DDI-false
The concomitant use of @DRUG$ is not recommended since nitrofurantoin may antagonize the antibacterial effect of @DRUG$ In the urinary tract.	DDI-false
There was not a significant difference (p > 0.05) in AUC (48.59 +/- 8.52 vs. 49.9 +/- 9.93), Cmax (7.73 +/- 2.6 vs. 6.6 +/- 2.0), and tmax (1.1 +/- 0.6 vs. 1.6 +/- 1.1) for levofloxacin versus @DRUG$/@DRUG$ regimens.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, @DRUG$, erythromycin, itraconazole or fluconazole.	DDI-false
The concentrations of SN38, the active metabolite of @DRUG$ In patients treated with bolus-IFL in combination with @DRUG$ when compared with bolus-IFL alone .	DDI-false
Concomitant administration of @DRUG$ The mean Cmax and AUC values for pravastatin ( 40 mg) once daily for 10 days ( corresponding to 145 mg TRICOR) were shown to be: @DRUG$ by 36 % ( range from 69 % decrease to 321 % increase ) and 28 % ( range from 54 % decrease to 128 % increase ) , respectively , and for 3 -hydroxy-iso-pravastatin by 55 % ( range from 32 % decrease to 314 % increase ) and 39 % ( range from 24 % decrease to 261 % increase ) , respectively in 23 healthy adults .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Antacids : In a clinical pharmacology study, the concomitant use of antacids (aluminium hydroxide, magnesium hydroxide, and @DRUG$ (iv) decreased serum levels and urinary excretion of fosinoprilat compared to fosinopril alone, suggesting that: @DRUG$ The absorption of Fosinopril may be impaired.	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs (AEDs) : @DRUG$: @DRUG$ had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
Cytochrome P-450 inducers , such as phenytoin , @DRUG$ and @DRUG$ Clonazepam induce metabolism, resulting in a 30% decrease in plasma clonazepam levels.	DDI-false
@DRUG$: @DRUG$ may diminish adrenal suppression by corticosteroids.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
While all the @DRUG$ (SSRIs), e.g., citalopram, escitalopram, fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
@DRUG$ : Coadministration of single doses of Sonata 20 mg and @DRUG$ 75 mg resulted in additive effects on decreased attention and impaired psychomotor performance 2 to 4 hours after administration.	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, @DRUG$ like @DRUG$ or Ibuprofen, and high blood pressure medications.	DDI-false
It is recommended that serum @DRUG$ levels be monitored frequently if PRINIVIL is administered concomitantly with @DRUG$.	DDI-false
Population pharmacokinetic analyses have shown that: @DRUG$ , NSAIDs, corticosteroids and TNF blockers did not affect @DRUG$ clearance .	DDI-false
Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine ( 800 mg/day ) to patients taking @DRUG$ chronically had no effect on @DRUG$ pharmacokinetics .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , @DRUG$ , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local @DRUG$ , procainamide , and quinidine .	DDI-false
@DRUG$ has been shown to have neuromuscular blocking properties that may enhance the action of other @DRUG$.	DDI-effect
Because @DRUG$ is metabolized by monoamine oxidase ( MAO ) , inhibition of this enzyme prolongs and potentiates the effect of @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Antiacid , clarithromycin , Didanosine , Fluconazole , @DRUG$ , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , @DRUG$ , rifampin, ritanovir, saquinavir.	DDI-false
Plasma levels of several closely related @DRUG$ have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors ( e.g. , cimetidine , @DRUG$ This effect can also be expected with CMI, and may be reduced by concomitant administration of liver enzyme inducers (e. g. barbiturates, phenytoin).	DDI-mechanism
The superiority of @DRUG$ over @DRUG$-based regimens has been observed in comparative data in a subset of patients with high viral loads .	DDI-false
Special care should be taken when administering @DRUG$ in cases of mixed drug overdosage since the toxic effects ( such as convulsions and cardiac dysrhythmias ) of other drugs taken in overdose ( especially cyclic antidepressants ) may emerge with the reversal of the @DRUG$ effect by flumazenil .	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Hormonal @DRUG$ Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, @DRUG$ (EE) and levonorgestrel (LNG).	DDI-false
Since @DRUG$ is a substrate for @DRUG$, there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced amiodarone levels.	DDI-false
@DRUG$: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
@DRUG$ The vascular response to pressure agents such as @DRUG$ can be reduced.	DDI-effect
A drug interaction study investigated the effect of using ACZONE gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (TMP/@DRUG$).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , @DRUG$ , A-blockers, analgesics, angiotensin converting enzyme ( ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, @DRUG$ , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, escitalopram, @DRUG$, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Potential interactions between TAXOL , a substrate of CYP3A4 , and protease inhibitors ( @DRUG$ , saquinavir , @DRUG$ , and nelfinavir ) , which are substrates and/or inhibitors of CYP3A4 , have not been evaluated in clinical trials .	DDI-false
The aim of this paper was to study the interaction between neurotensin and both @DRUG$ Of a thickness exceeding 2 mm @DRUG$ , or tuftsin , on the antinonciceptive effect of these peptides in mice after intracisternal injection .	DDI-false
Treatment with CYP3A4 inhibitors (such as ketoconazole, @DRUG$ ritonavir, indinavir, @DRUG$ , erythromycin, etc.) is indicated, reduction of budesonide dose should be considered.	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon , the concomitant use of Nalfon and @DRUG$ It's not recommended.	DDI-false
BACKGROUND : The effects of the combined administration of bombsin and verapamil hydrochloride (Verapamil ), a calcium channel blocker, on the incidence of peritoneal metastases of intestinal adenocarcinoma induced by @DRUG$ ( @DRUG$ ) and the index of colorectal cancers were studied in male Wistar rats.	DDI-false
@DRUG$ The co-administration of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), generally @DRUG$ , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
A similar association, albeit less pronounced, was proposed with barbiturates, phenylbutazone, phenytoin sodium, @DRUG$ and possibly with griseofulvin , ampicillin , and @DRUG$ ( 72 )	DDI-false
When the @DRUG$ was administered 30 minutes after the sumatriptan nasal spray , the AUC of @DRUG$ increased 11 % and Cmax decreased 18 % .	DDI-false
@DRUG$ : Coadministration of a single dose of zaleplon and @DRUG$ ( 10 and 25 mg , respectively ) resulted in a 15 % decrease in maximal plasma concentrations of zaleplon , but no change in the area under the plasma concentration-time curve .	DDI-false
Specific studies have confirmed these effects with sevoflurane, @DRUG$, propofol, alfentanil, and @DRUG$.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ , alprazolam , and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis , it is particularly important that physicians query patients or their guardians carefully about benzodiazepine , alcohol and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, niacin (nicotinic acid), erythromycin, @DRUG$.	DDI-false
@DRUG$ : Coadministration of eszopiclone 3 mg and @DRUG$ 10 mg produced a decrease in DSST scores .	DDI-false
The intensity, uniformity and time course of @DRUG$ interference by @DRUG$ , secobarbital, glutethimide, chloral hydrate and methaqualone have been systematically studied in 16 patients treated with coumarin.	DDI-false
This increase is due to the inhibition of @DRUG$ metabolism via P450 2C9 by @DRUG$ (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism).	DDI-mechanism
Acetaminophene: Pharmacokinetic or pharmacodynamic drug-effect interactions between @DRUG$ and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1   g/kg/min . over 4 hours ) or @DRUG$ ( 1000 mg orally administered 12, 6 and 0 hours before, and 6 and 12 hours after, start of argatroban 1.5 g/kg/min. over 18 hours).	DDI-false
Valproate @DRUG$  (1500 mg twice daily) did not alter the pharmacokinetics of @DRUG$ in healthy volunteers.	DDI-false
- @DRUG$ (e.g., AquaMEPHYTON, @DRUG$) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood	DDI-false
Ergot Derivatives: @DRUG$, @DRUG$, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Insulin or Oral Hypoglycemics : @DRUG$ The hypoglycaemic effect of insulin and oral @DRUG$ may be increased.	DDI-effect
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, nevirapine, phenytoin, dexamethasone, or carbamazepine) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations.	DDI-mechanism
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine , @DRUG$ , niacin ( nicotinic acid ) , @DRUG$ , azole antifungals .	DDI-false
Anticoagulants: While studies have not shown diclofenac to interact with @DRUG$, caution should be exercised, nonetheless, since interactions have been seen with other @DRUG$.	DDI-false
[ Quantitative approach to treatment with incisive @DRUG$ The problems encountered during the long-term treatment of psychotic patients with @DRUG$ are illustrated by six typical case reports .	DDI-false
Potential interactions between @DRUG$, a substrate of CYP3A4, and @DRUG$ (ritonavir, saquinavir, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ serum concentrations should be monitored closely when initiating or changing therapy with @DRUG$ in patients receiving lithium.	DDI-false
However, in another study in healthy volunteers, the pharmacokinetics of butorphanol were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of @DRUG$ was administered 1 minute after a 20-mg dose of @DRUG$ nasal spray.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Cholestyramine-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
magnesium and/or aluminium antacids, iron sulphate products, @DRUG$ containing zinc or other metal cations , or Videx ( @DRUG$ Do not take chewable tablets or the pediatric powder for oral solution within 3 hours before or 2 hours after FACTIVE.	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and barbiturates, and the antituberculosis drug rifampin.	DDI-effect
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, @DRUG$, quinidine, @DRUG$ or amoxicillin.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, @DRUG$, phenytoin, dexamethasone, or carbamazepine) with @DRUG$ may result in clinically meaningful reductions in caspofungin concentrations.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$/Hypnotics : triazolam , @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, @DRUG$ , doxycycline , erythromycin , imatinib , isoniazid , @DRUG$ , nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
- Carbamazepine : Isoniazid is known to slow down metabolism @DRUG$ Carbamazepine levels should be determined and increased prior to concomitant use of carbamazepine. @DRUG$ , signs and symptoms of carbamazepine toxicity should be monitored closely , and appropriate dosage adjustment of the anticonvulsant should be made .	DDI-false
In clinical studies performed with @DRUG$ Co-administration of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam) and digoxin did not significantly affect @DRUG$ pharmacokinetics/pharmacodynamics.	DDI-false
MAO inhibitors @DRUG$ , as well as a metabolite of @DRUG$ Slow amphetamine metabolism.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
@DRUG$ did not have a statistically significant effect on the pharmacokinetics of @DRUG$ (a CYP 2C9 and CYP 2C19 substrate).	DDI-false
@DRUG$ taken concomitantly with quinidine increases @DRUG$ serum concentration by 33% after two days.	DDI-false
Sine bradycardia was treated with oral @DRUG$ in combination with lidocaine ( @DRUG$ substrate ) given for local anesthesia .	DDI-false
Plasma levels of @DRUG$ have been reported to increase in the presence of oral @DRUG$;	DDI-false
Combinations in these categories result in reduced efficacy of @DRUG$ : phenothiazines , @DRUG$ , metoclopramide , pimozide .	DDI-effect
However, patients on digoxin may show elevations of digoxin concentrations after initiation of therapy with @DRUG$, which may be clinically significant in patients prone to @DRUG$ toxicity.	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter @DRUG$ protein binding.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
In addition to the above interactions, chronic (2 weeks) oral administration of Cordaron affects the metabolism of phenytoin, @DRUG$ , and @DRUG$.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , pentazocine , @DRUG$ , butorphanol , @DRUG$ and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$ is a substrate for both CYP2D6 and @DRUG$.	DDI-false
Other Chemotherapy Agents In a separate study, concomitant administration of lapatinib with @DRUG$ did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of @DRUG$).	DDI-false
However, reports suggest that NSAIDs have the antihypertensive effect of @DRUG$ , including @DRUG$.	DDI-false
@DRUG$ â€¢ Increases serum concentrations of @DRUG$.	DDI-mechanism
An additive hypotensive effect has been reported with the combination of systemic @DRUG$ and @DRUG$ therapy.	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
While all the @DRUG$ ( @DRUG$ Fluoxetine, sertraline, paroxetine and fluvoxamine, e.g., inhibit P450 2D6, they may vary to the extent of inhibition.	DDI-false
@DRUG$: Amphetamines enhance the adrenergic effect of @DRUG$.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, carbamazepine, and barbiturates, and the @DRUG$ rifampin.	DDI-false
It may be necessary to reduce the dosage of oral @DRUG$ After the start or stop of disulfiram. since @DRUG$ The prothrombin time may be prolonged.	DDI-false
@DRUG$ significantly increased the area under the curve at steady state (AUC(ss)) of rifabutin by 2.93-fold and the AUC(ss) of @DRUG$ by 13.3-fold.	DDI-mechanism
Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., @DRUG$, tacrine, and @DRUG$).	DDI-false
The successive application of glycine (5 or 10 mg/kg egg weight (e.w.) and @DRUG$ (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of @DRUG$ alone.	DDI-false
The effects of AEDs in paediatric patients There was approximately a 22% increase in apparent total body clearance. @DRUG$ when it was co-administered with enzyme-inducing @DRUG$.	DDI-mechanism
@DRUG$ : Since apomorphine is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , @DRUG$ , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
This was expected because @DRUG$ is primarily metabolized and renal excretion of unchanged @DRUG$ accounts for less than 1% of the administered dose.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/@DRUG$ , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/@DRUG$ , and valproic acid/phenobarbital .	DDI-false
Possible drug interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$ , phenytoin, primidone and @DRUG$ The serum concentrations of levetiracetam and these AEDs were also evaluated in placebo-controlled clinical trials.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
Saquinavir: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Longitudinal assessment of @DRUG$ in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on @DRUG$.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, @DRUG$, @DRUG$ and interferon-alfa.	DDI-false
Drug/LaboratoryTest Interactions @DRUG$ The bioassay methods for the determination of @DRUG$ levels .	DDI-false
Colestipol: Plasma concentrations of atorvastatin decreased approximately 25% when @DRUG$ and @DRUG$ were coadministered.	DDI-mechanism
In addition, under the influence of sympatholytics such as @DRUG$ , clonidine , @DRUG$ Reserpine, the signs of hypoglycaemia may be reduced or absent.	DDI-false
@DRUG$ (tricyclic), atropine or other @DRUG$, or digitalis glycosides: concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with CNS depressants ( alcohol , @DRUG$ , opiates , sedatives , anesthetics ) should be considered .	DDI-advise
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( @DRUG$ transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , @DRUG$ , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-effect
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
Curariform muscle relaxants ( eg , tubocurarine ) and other drugs , including ether , @DRUG$ , gallamine , @DRUG$ The neuromuscular blocking effect should be increased in patients treated with Coly-Mycin M Parenteral and sodium citrate should be administered with extreme caution.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-effect
Curariform muscle relaxants ( eg , @DRUG$ ) and other drugs , including ether , succinylcholine , gallamine , decamethonium and sodium citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral .	DDI-effect
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , @DRUG$ , certain tricyclic antidepressants, @DRUG$ Theophylline, and metronidazole, delaying the elimination and increase in blood levels of these drugs.	DDI-false
Antidepressants, @DRUG$: @DRUG$ may enhance the activity of tricyclic or sympathomimetic agents;	DDI-false
Potential interactions between TAXOL , a substrate of CYP3A4 , and protease inhibitors ( ritonavir , @DRUG$ , @DRUG$ , and nelfinavir) which are substrates and/ or inhibitors of CYP3A4 have not been studied in clinical trials.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , @DRUG$ , haloperidol, phenothiazine, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
Antiacid , @DRUG$ , @DRUG$ , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , Rifampin , Ritanovir , Saquinavir .	DDI-false
Cyclosporine: Because cyclosporine can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine, and because renal excretion is the primary elimination route of @DRUG$ including @DRUG$, there is a risk that an interaction will lead to deterioration.	DDI-false
The effect of orally ingested @DRUG$ or @DRUG$ from breast milk on the nursing infant has not been evaluated.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with @DRUG$ ( CYP3A4 substrate ) given for local @DRUG$.	DDI-false
@DRUG$: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, @DRUG$.	DDI-effect
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$ , chlordiazepoxide , @DRUG$ , certain tricyclic antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
@DRUG$ Administration of non-sterioal anti-inflammatory medicinal products together with cyclosporin has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacycline.	DDI-false
Since Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ Elevates the rate of excretion of Nalfon, concomitant use of @DRUG$ Salicylates and salicylates are not recommended.	DDI-false
Antiarrhythmic agents, class I (such as @DRUG$, lidocaine, or quinidine): concurrent use with @DRUG$ may have a proarrhythmic effect.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ , amiodarone , quinidine , @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Oral @DRUG$: Pharmacokinetic drug-drug interactions between Argatroban and @DRUG$ (7.5 mg single oral dose) have not been demonstrated.	DDI-false
@DRUG$ (10 mg once daily) has been coadministered with therapeutic doses of erythromycin, @DRUG$, and ketoconazole in controlled clinical pharmacology studies in adult volunteers.	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
All @DRUG$ should be used cautiously in patients taking @DRUG$.	DDI-advise
However, in another study in healthy volunteers, the pharmacokinetics of @DRUG$ 29% decrease in AUC and 38% decrease in Cmax) if a 1 mg dose of @DRUG$ One minute after a 20 mg dose of Sumatriptan nasal spray.	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as quinidine, @DRUG$, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
@DRUG$, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Antipyrine: Because @DRUG$ does not affect the pharmacokinetics of @DRUG$, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	DDI-false
Hypotension   Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of @DRUG$.	DDI-effect
@DRUG$: Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and @DRUG$ were coadministered.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , @DRUG$ , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , @DRUG$ , calcium channel block drugs, and isoniazid.	DDI-false
These drugs include the @DRUG$ Other diuretics, corticosteroids, phenothiazines, @DRUG$ , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , @DRUG$ , calcium channel blocking drugs , and @DRUG$.	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive @DRUG$ produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
In patients who induce CYP3A4 such as rifampin, phenytoin, @DRUG$ , and @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Theophylline : The pharmacokinetics of @DRUG$ ( @DRUG$ 5.8 mg/ kg over 20 minutes) were unchanged in 6 healthy subjects following a single oral dose of albendazole (400 mg).	DDI-false
@DRUG$ : Other @DRUG$ Medicines such as quinidine, procainamide, disopyramide and phenytoin have been used concomitantly with amiodarone.	DDI-false
Non-steroidal Anti-inflammatory Drugs : In some patients , the administration of a non-steroidal anti-inflammatory agent can reduce the diuretic , natriuretic , and antihypertensive effects of loop , @DRUG-DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In rats, co-administration of @DRUG$ and nitrite in the diet for 78 weeks has been reported to cause tumors , and it has been suggested that @DRUG$ From nitrites in the rat's stomach a nitrosamine, which is tumorous, can react.	DDI-false
Furosemide: Clinical studies, as well as post marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of @DRUG$ and thiazides in some patients.	DDI-effect
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as @DRUG$ or @DRUG$).	DDI-false
@DRUG$ and @DRUG$ : Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir , the Cmax and AUC of ritonavir were reduced by approximately 20 % .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
These drugs include: @DRUG$ and other diuretics, corticosteroids, @DRUG$ , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Although these results do not indicate a significant interaction between TORADOL and @DRUG$ or @DRUG$, the administration of TORADOL to patients taking anticoagulants should be done extremely cautiously, and patients should be closely monitored.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including nonsteroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, probenecid, @DRUG$ , @DRUG$ , and beta adrenergic blocking agents .	DDI-false
It may increase excretion of barbiturates, @DRUG$, and @DRUG$ and may also increase the toxicity of salicylates.	DDI-false
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
These drugs include thiazides and other diuretics, @DRUG$ , @DRUG$ , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
@DRUG$ and @DRUG$ FORADIL should be used with extreme caution in patients treated with monoamine oxidase inhibitors or tricyclic antidepressants, as the effect of formoterol on the cardiovascular system may be enhanced by these agents.	DDI-false
d-amphetamine with @DRUG$ or protriptyline and possibly other tricyclics cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
Tetracyclines : Since both @DRUG$ and @DRUG$ The combined application is contraindicated and can lead to increased intracranial pressure.	DDI-effect
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The @DRUG$ study dosed subjects with 1200 mg/day of @DRUG$ (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of zidovudine.	DDI-false
Betaseron administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of @DRUG$ elimination.14 The effect of alternate-day administration of 0.25 mg of @DRUG$ on drug metabolism in MS patients is unknown.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
All subjects received @DRUG$ monotherapy and after treatment with 100 mg @DRUG$ As a single daily oral dose for seven days.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
@DRUG$ The concomitant use of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$ And alcohol, can cause respiratory depression, hypotension, and deep sedation, or possibly lead to coma or death.	DDI-false
- The action of sulphonylureas and insulin may be enhanced by @DRUG$ or @DRUG$.	DDI-false
Both @DRUG$ and 18-MC block @DRUG$-induced and nicotine-induced dopamine release in the nucleus accumbens;	DDI-effect
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and @DRUG$.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including non-steroidal anti-inflammatory drugs and other drugs that are highly protein bound, salicylates, @DRUG$ , chloramphenicol, probenecid, coumarine, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
The effect of rifampin on the @DRUG$ requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal .	DDI-false
When other @DRUG$ or anticoagulants are used concomitantly, there is the potential for @DRUG$ to increase the risk of bleeding.	DDI-effect
Hepatic Enzyme Inducers , Inhibitors and Substrates : Drugs which induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity ( e.g. , barbiturates , phenytoin , @DRUG$ , rifampin ) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased .	DDI-false
Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system ( e.g. , @DRUG$ , carbamazepine, cimetidine, ketoconazole), although this has not been studied	DDI-mechanism
In addition, the results of regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone or carbamazepine) with @DRUG$ This may lead to a clinically significant reduction in @DRUG$ concentrations .	DDI-false
This seems to be the only clinically relevant interaction of this species with mefloquines, although theoretically, the concomitant use of other drugs is known to alter heart conduction (e.g., @DRUG$ Beta-Adrenerg-Blocker or Beta-Adrenerg-Blocker, @DRUG$ , antihistamines or H1-blocking agents , tricyclic antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , @DRUG$ - Nitrates, calcium blockers, @DRUG$ , prazosin and digoxin without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$, @DRUG$, verapamil	DDI-false
Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of cimetidine (800 mg/day) to patients taking @DRUG$ chronically had no effect on @DRUG$ pharmacokinetics.	DDI-false
In two combined 12-week placebo-controlled studies, the @DRUG$ doses of 15 mcg twice daily , 25 mcg twice daily , and 50 mcg once daily , 54 of 873 BROVANA -treated subjects received concomitant @DRUG$ at study entry .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Patients using CYP3A4 metabolized @DRUG$ should have cholesterol levels monitored after TRACLEER is initiated to see whether the @DRUG$ dose needs adjustment.	DDI-false
The coadministration of aspirin decreases the biologic half-life of @DRUG$ because of an increase in metabolic clearance that results in a greater amount of @DRUG$ in the urine.	DDI-false
@DRUG$ potentiates the muscle relaxant effect of all @DRUG$, most notably nondepolarizing muscle relaxants, and MAC (minimum alveolar concentration) is reduced by concomitant administration of N 2O.	DDI-effect
While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , @DRUG$ , sertraline , @DRUG$ , and fluvoxamine, inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
The steady state plasma concentrations of @DRUG$ and desipramine have been reported to be increased an average of 31% and 20%, respectively, by the concomitant administration of @DRUG$ tablets in doses up to 4 mg/day.	DDI-mechanism
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including @DRUG$ such as quinidine and @DRUG$, cardiac glycosides and tricyclic anti-depressants.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The action of the benzodiazepines may be potentiated by @DRUG$, antihistamines, alcohol, barbiturates, @DRUG$, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
@DRUG$ , nondepolarizing ( e.g. , tubocurarine ): possible increased responsiveness to the @DRUG$.	DDI-false
A drug-drug interaction study with @DRUG$ in healthy volunteers has shown a 30% decrease in @DRUG$ trough concentrations.	DDI-mechanism
â€¢ Dopamine antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ ( phenothiazines , butyrophenones , @DRUG$ ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., methotrexate, asparaginase) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
Hormonal contraceptives Co-administration of Trileptal with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, @DRUG$ (EE) and @DRUG$ (LNG).	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Non-steroidal anti-inflammatory drugs : In some patients, the administration of a non-steroidal anti-inflammatory agent may reduce the diuretic, natriuretic and antihypertensive effects of @DRUG-DRUG$.	DDI-false
The use of local anesthetics containing epinephrine, or @DRUG$ to patients receiving @DRUG$ , tricyclic antidepressants or phenothiazines may produce severe , prolonged hypotension or hypertension .	DDI-effect
Steady-state @DRUG$ plasma concentrations were 3- to 4-fold higher than in the absence of @DRUG$.	DDI-mechanism
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Because there is no data on the compatibility of NovoLog and crystalline @DRUG$ preparations , @DRUG$ should not be mixed with these preparations .	DDI-false
@DRUG$ : Since apomorphine is a dopamine agonist , it is possible that dopamine antagonists , such as the @DRUG$ - (Phenothiazine, butyrophenone, thioxanthene) or metoclopramide, may reduce the efficacy of APOKYN.	DDI-false
@DRUG$: Amphetamines potentiate the analgesic effect of @DRUG$.	DDI-false
Digoxin , @DRUG$ Bosentan has no significant pharmacokinetic interactions with @DRUG$ Nimodipine and losartan have no significant influence on bosentan plasma levels.	DDI-false
Phenytoin : Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60 % greater in patients taking phenytoin with or without other enzyme- inducing @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
Effect of @DRUG$ in Pediatric Patients There was about a 22% increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing @DRUG$.	DDI-false
These drugs include thiazides and other @DRUG$ , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$ , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ These include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and @DRUG$ , magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-effect
Lethargy and somnolence have been reported following doses of @DRUG$ and @DRUG$.	DDI-effect
Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and @DRUG$ against HIV.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ And other drugs that are highly protein-bound, salicylates, @DRUG$ Chloramphenicol, probenecid, coumarine, monoamine oxidase inhibitors and beta-adrenergic blockers.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, @DRUG$, dexamethasone, or @DRUG$) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, @DRUG$ or an @DRUG$/levonorgestrol oral contraceptive product in healthy subjects.	DDI-false
Coingestion of @DRUG$ with theophylline, phenobarbital with @DRUG$, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, @DRUG$, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
@DRUG$ ( @DRUG$ SSRIs (e.g. fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflection, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Studies in rats have shown that neomycin administration attenuates certain types of @DRUG$ dependent hypertension, including @DRUG$ hypertension.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, nevirapine, @DRUG$, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
Therophylline : A recent study has shown that concomitan administration of isoniazid and @DRUG$ Elevated plasma levels may occur. @DRUG$ , and in some instances a slight decrease in the elimination of isoniazid .	DDI-false
Oral Contraceptives : Coadministration of atorvastatin and an oral contraceptive increased AUC values for @DRUG$ and @DRUG$ by approximately 30 % and 20 % .	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between VIRACEPT and @DRUG$ , trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
C-cephalosporins containing side chains of N-methylthiotetrazole (Cefmenoxime), @DRUG$ , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or fluconazole.	DDI-false
The ECG changes and/ or hypokalaemia resulting from the use of @DRUG$ ( such as @DRUG$ ) can be acutely worsened by beta-agonists , especially when the recommended dose of the beta-agonist is exceeded .	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as @DRUG$, @DRUG$, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;	DDI-false
Magnesium- and/or aluminum-containing @DRUG$ , products containing ferrous sulfate ( iron ) , multivitamin preparations containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-false
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole ( @DRUG$ , cefoperazone , cefotetan , cefamandole , @DRUG$ ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
The possibility of hypotensive effects with @DRUG$ or enalaprilat can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
@DRUG$ : @DRUG$ ( 0.5 g/kg body weight : approximately 40 mL of absolute alcohol in a 70 kg person ) and vardenafil plasma levels were not altered when dosed simultaneously .	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , @DRUG$ In patients with anaemia (e. g., ritonavir and erythromycin), increased exposure to almotriptan may be expected if: @DRUG$ is used concomitantly with these medications .	DDI-advise
Barbiturates and @DRUG$ should not be administered to patients receiving @DRUG$.	DDI-advise
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, saquinavir, @DRUG$, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
@DRUG$ significantly increased the area under the curve at steady state (AUC(ss)) of @DRUG$ by 2.93-fold and the AUC(ss) of 25-O-desacetylrifabutin by 13.3-fold.	DDI-mechanism
Psychoactive Drugs : Hallucinations have been reported when @DRUG$ In patients who: @DRUG$ ( fluoxetine , thiothixene , alprazolam ) .	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Imidazoles (e. g., ketoconazole, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence (ie, @DRUG$ before cisplatin).	DDI-false
In addition, cases have been reported in which the concomitant use of @DRUG$ and @DRUG$ The heart enlargement and heart failure followed.	DDI-effect
Naproxen: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	DDI-effect
Theophylline: The pharmacokinetics of @DRUG$ (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of @DRUG$ (400 mg) in 6 healthy subjects.	DDI-false
Selective serotonin reuptake inhibitors ( @DRUG$ ): @DRUG$ Fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
Coadministration of @DRUG$ with doses higher than 40 mg QD @DRUG$ has not been studied.	DDI-false
Multivitamins , or other products containing iron or zinc , @DRUG$ or @DRUG$ should not be administered concomitantly with , or within 2 hours of , the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin .	DDI-false
Barbiturates and @DRUG$ Patients receiving @DRUG$ should not be taken.	DDI-advise
Other Drugs:Drugs such as @DRUG$, @DRUG$, procainamide, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$, @DRUG$, sparfloxacin, and terodiline.	DDI-false
Warfarin: The effect of celecoxib on the anti-coagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of 2-5 mg of @DRUG$.	DDI-false
Therefore , interactions could occur following concomitant administration of @DRUG$ ==References====External links== @DRUG$ , antiemetics, sedatives, sedatives).	DDI-false
Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of @DRUG$ 800 mg/ day) in patients chronically taking tiagabin had no effect on @DRUG$ pharmacokinetics .	DDI-false
Pretreatment of healthy volunteers with multiple doses of rifampin followed by a single dose of @DRUG$, increased @DRUG$ oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), @DRUG$.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Other Drugs : Drugs such as quinidine , disopyramide , procainamide , @DRUG$ , antihistamines , and @DRUG$ It may be associated with QT interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , @DRUG$ , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and @DRUG$.	DDI-false
Little or no change in the pharmacokinetics of either drug was observed when @DRUG$ was coadministered with @DRUG$ or stavudine.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
The concomitant use of @DRUG$ CELEBREX may lead to an increased rate of GI ulcers or other complications compared to the use of @DRUG$ alone .	DDI-false
Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing transferrin (1 microgram/ml), @DRUG$ (10 ng/ml), and @DRUG$ (3.7 micrograms/ml or 0.1 IU/ml).	DDI-false
â€¢ Dopamine antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as neuroleptics (phenothiazines, @DRUG$ , @DRUG$ ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
@DRUG$, other, especially diazoxide, or pre@DRUG$ and anesthetic agents used in surgery or skeletal-muscle relaxants, nondepolarizing, used in surgery	DDI-false
It may increase excretion of @DRUG$, @DRUG$, and ASA and may also increase the toxicity of salicylates.	DDI-false
Chronic administration of @DRUG$ , a known enzyme inducer , may be associated with a decrease in the plasma half-life of @DRUG$.	DDI-mechanism
To determine whether injection of @DRUG$ A fixed dose of 9.9 g/m2 thiosulfate was administered intravenously for three hours at an escalating dose of @DRUG$.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , @DRUG$ , diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodon, @DRUG$ , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Coingestion of acetaminophen with theophylline , @DRUG$ with acetaminophen , and valproic acid with @DRUG$ At high to toxic concentrations, binding of the target medication is reduced.	DDI-false
No significant pharmacokinetic (or pharmacodynamic) interactions have been observed in interaction studies with: @DRUG$ , digoxin , warfarin , and @DRUG$.	DDI-false
Edema has been reported in patients concomitantly receiving @DRUG$ and @DRUG$.	DDI-effect
Coadministration of @DRUG$ and @DRUG$ , tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs .	DDI-mechanism
Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., @DRUG$, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of @DRUG$), corticosteroids (increased effect of corticosteroids).	DDI-false
Concomitant use of @DRUG$ supplements and L-lysine may increase @DRUG$ absorption	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
The in vitro interaction between @DRUG$ and the antithrombotic agent @DRUG$ is complex .	DDI-int
@DRUG$ Dihydroergotamine, ergonovine, @DRUG$ , Methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischaemia of extremities and other tissues.	DDI-false
however , it adversely affected response duration suggesting that @DRUG$ It should not be combined with @DRUG$ and/or cisplatin.1	DDI-advise
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of azathioprine , @DRUG$ , chloroquine , @DRUG$ , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., @DRUG$) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
The inhibition of CYP-2C19 by @DRUG$ and @DRUG$, however, is clinically relevant.	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
The co-administration of Natrecor with IV @DRUG$ Such as nitroglycerin, nitroprusside, milrinone or IV @DRUG$ These medicines were not administered with Natrecor in clinical trials.	DDI-false
Methotrexate : @DRUG$ BID showed no significant effect on plasma exposure or renal clearance of @DRUG$.	DDI-false
Diphenhydramine hydrochloride has additive effects with @DRUG$ and other CNS depressants ( hypnotics , @DRUG$ , sedatives, etc.	DDI-false
Other medicines that can enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX are certain @DRUG$ - aminoglycosides, tetracyclines, bacitracin, @DRUG$ , lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
INOmax has been administered with @DRUG$ , dopamine , @DRUG$ , steroids, surfactant, and high-frequency ventilation.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , @DRUG$ , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and @DRUG$.	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$ , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and @DRUG$.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, @DRUG$ Doses of 1 mg or more were co-administered in clinical trials with acetaminophene, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$ , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Antacids : In a clinical pharmacology study, the concomitant use of antacids ( @DRUG$ , magnesium hydroxide , and @DRUG$ ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
For treatment with CYP3A4 inhibitors (such as ketoconazole, intraconazole, @DRUG$ , indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of @DRUG$ The dose should be considered.	DDI-advise
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, @DRUG$, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
The administration of local @DRUG$ containing @DRUG$ or norepinephrine to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-false
Close supervision and careful adjustment of the dosage are required when @DRUG$ is used with other anticholinergic drugs or @DRUG$.	DDI-advise
Poor metabolizers have higher than expected lasma concentrations of @DRUG$ ( @DRUG$ - if the usual dose is given.	DDI-false
Since @DRUG$ and potassium-sparing diuretics, including @DRUG$, may each be associated with increased serum potassium levels, the potential effects on potassium kinetics and renal function should be considered when these agents are administered concurrently.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or fluconazole.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, @DRUG$, @DRUG$, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Aspirin: Concomitant administration of diclofenac and @DRUG$ is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of @DRUG$, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$ Beta blockers, calcium channel blockers, cardiac nitrates, diuretics, @DRUG$ , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
bacteriostatic antibiotics: chloramphenicol, erythromycins, sulphonamides or @DRUG$ may interfere with the bactericidal effect of @DRUG$.	DDI-effect
- Anabolic steroids (@DRUG$ [e.g., Anabolin], oxandrolone [e.g., Anavar], @DRUG$ [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
and @DRUG$ , such as @DRUG$.	DDI-false
Psychoactive Drugs : Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs ( @DRUG$ , thiothixene , @DRUG$ ) .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
However, neither phenobarbital nor @DRUG$ appears to affect @DRUG$ metabolism .	DDI-false
Ibogain as well as 18-MC block @DRUG$-induced and @DRUG$-induced dopamine release in nucleus accumbens;	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , @DRUG$ ) , myelotoxic ( e.g. , @DRUG$ Chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g. methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Valproate: @DRUG$ causes a slight decrease (about 10%) in steady-state @DRUG$ concentrations.	DDI-mechanism
Magnesium/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.	DDI-false
We report on the case of a young person with a changed consciousness caused by: @DRUG$ overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for @DRUG$.	DDI-false
Injection: @DRUG$ injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Following the administration of @DRUG$ , the dose of other @DRUG$ should be reduced .	DDI-advise
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, @DRUG$, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	DDI-mechanism
Compounds tested in man include warfarin, theophylline, @DRUG$, @DRUG$, aminopyrine and antipyrine.	DDI-false
Population pharmacokinetic analyses revealed that MTX, @DRUG$, corticosteroids, and TNF blocking agents did not influence @DRUG$ clearance.	DDI-false
INOmax has been administered with tolazoline, dopamine, @DRUG$, @DRUG$, surfactant, and high-frequency ventilation.	DDI-false
@DRUG$ and @DRUG$ should not be coadministered .	DDI-advise
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , @DRUG$ - diuretics, sympathomimetics (e.g. epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$ Somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Dextromethorphan is a substrate for both @DRUG$ and @DRUG$.	DDI-false
However, 150 mg @DRUG$ q12h for 3 days increased the @DRUG$ C max by 23% and Ceftibutene AUC by 16%.	DDI-mechanism
The application of local anaesthetic solutions that @DRUG$ - Nonepinephrine in patients who: @DRUG$ , tricyclic antidepressants or phenothiazines may produce severe , prolonged hypotension or hypertension .	DDI-effect
Erythromycin Co-administration of felodipine (PLENDIL) with @DRUG$ resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$, such as dopamine and @DRUG$;	DDI-false
Experience with co-administration of @DRUG$ and @DRUG$ in patients is limited,therefore,consideration should be given to temporarily suspending use of HMG-CoA reductase inhibitors in patients receiving Fentanyl.	DDI-false
Interactions with @DRUG$ : Agonist/antagonist analgesics ( eg , pentazocine , @DRUG$ , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran .	DDI-false
Digoxin @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of @DRUG$ given as a 0.25 mg dose every day.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/@DRUG$ , phenobarbital/valproic acid , quinidine/@DRUG$ , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
"Ergot derivatives: dihydroergotamine, ergovine, @DRUG$ , @DRUG$ CONTRAINDICATE because of the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasms and ischaemia of extremities and other tissues.	DDI-false
The effect of TORADOL on plasma lithium has not been studied , but cases of increased @DRUG$ plasma levels during @DRUG$ therapy have been reported .	DDI-mechanism
@DRUG$: Increased activity of both cyclosporine and @DRUG$ may occur when the two are used concurrently.	DDI-false
Intravenous @DRUG$: Treatment with @DRUG$ should be interrupted when the use of a drug that has the potential to cause pancreatitis is required.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , @DRUG$ , amikacin ) , amphotericin B , cyclosporine , non-steroidal anti-inflammatory drugs ( e.g. , ibuprofen ) , @DRUG$ , vancomycin .	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, @DRUG$, and possibly with ampicillin and tetracyclines 72.	DDI-false
Cephalosporine-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefooperazone, cefotetan, cefamandol), @DRUG$ ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
It was shown that @DRUG$ antagonized evidently the antinociceptive effect of @DRUG$ and their analogue.	DDI-effect
Since there is a theoretical basis for these effects to be additive, the use of @DRUG$-containing or ergot-type drugs (such as @DRUG$ or methysergide ) and AXERT within 24 hours of each other should be avoided .	DDI-false
TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of @DRUG$ and @DRUG$ After 10 Days of Coadministration (Loratadine 10 mg) in Normal Volunteers	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and @DRUG$.	DDI-false
It is advisable to check coagulation time within the first few days after the start and discontinuation of @DRUG$ therapy, with an appropriate adjustment of the @DRUG$ dose, if necessary.	DDI-advise
Concomitant @DRUG$, @DRUG$, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma.	DDI-false
Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, phenytoin and @DRUG$) have been shown to decrease the plasma levels of @DRUG$ (29-40%).	DDI-false
@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
A dose increase of @DRUG$/@DRUG$ to 533/133 mg twice daily with food isrecommended in combination with nevirapine .	DDI-false
However, reports show that: @DRUG$ The antihypertensive effect of @DRUG$ can be reduced.	DDI-effect
@DRUG$ There was no statistically significant effect on the pharmacokinetics of @DRUG$ ( a CYP 2C9 and CYP 2C19 substrate ) .	DDI-false
Magnesium- and/or aluminum-containing @DRUG$ Products containing iron sulphate, multivitamin preparations, @DRUG$ or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg glyburide BID) resulted in 21% increase in @DRUG$ AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Insulin or Oral @DRUG$ The antihyperglycaemic effect of insulin and oral @DRUG$ may be enhanced by means of b-blocking properties.	DDI-false
- estrogens, including oral @DRUG$ : Estrogens may decrease the hepatic metabolism of certain @DRUG$ , which increases its effect.	DDI-false
"It is concluded that @DRUG$ and methaqualone may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy .	DDI-false
In addition, certain drugs that are metabolized by this isoenzyme, including many antidepressants (@DRUG$, @DRUG$, and others), may inhibit the activity of this isoenzyme, and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system, leading to drug interactions.	DDI-false
â€¢ Psychoactive Drugs : Hallucinations were reported when TORADOL was used in patients who had psychoactive drugs (fluoxetine, @DRUG$ , @DRUG$ ) .	DDI-false
@DRUG$: Concomitant administration of @DRUG$ at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration.	DDI-false
Coadministration of @DRUG$ CYP3A is the main metabolite of medicinal products (e. g. CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A, CYP3A @DRUG$ ) may result in increased plasma concentrations of the other drug that could increase or prolong both its therapeutic and adverse effects .	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs ( AEDs ) : @DRUG$ : Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy .	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with @DRUG$ Corticosteroids (e.g. @DRUG$ ) , diphen-hydramine and H2 antagonists ( such as cimetidine or ranitidine ) .	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin, gentamicin and amikacin), amphotericin B, foscarnet, intravenous @DRUG$ , @DRUG$ , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-false
@DRUG$ may also potentiate the replication of some organisms contained in @DRUG$.	DDI-effect
A clinical study in healthy male volunteers ( n=24 ) demonstrated that mixing NovoLog with @DRUG$ immediately before injection produced some attenuation in the peak concentration of NovoLog , but that the time to peak and the total bioavailability of @DRUG$ were not significantly affected .	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$ , digoxin, warfarin, isosorbide mononitrate, geschnitztilol, @DRUG$ or itraconazole .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
- When Bezalip or Bezalip retard is used concurrently with @DRUG$ (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or Bezalip retard is impaired	DDI-false
Anticoagulants including coumarin derivatives , indandione derivatives , and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs ( @DRUG$ ) , and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Little has been studied of the adverse effects of the exposure of the liver to the interaction of @DRUG$ with its congeners and @DRUG$ , coexisting in the contents of alcoholic beverages .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, @DRUG$), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
â€¢ Adverse reactions associated with @DRUG$s, such as CNS, heart and systemic (e.g. flu-like) effects may be more severe in elderly patients and may be more severe in the use of @DRUG$ in this population .	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$ , oral contraceptives , phenytoin , nicotinic acid , @DRUG$ , calcium channel blocking drugs , and isoniazid .	DDI-false
In patients who: @DRUG$ , @DRUG$ may temporarily mask the residual effects of muscle relaxant drugs .	DDI-false
@DRUG$ : May decrease renal tubular secretion of ampicillin resulting in increased blood levels and/or @DRUG$ toxicity .	DDI-false
Because @DRUG$ is metabolized by CYP2C9 and CYP3A4 , patients who require anticoagulation should receive low-molecular weight or standard @DRUG$.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, @DRUG$ or fluconazole.	DDI-false
ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/@DRUG$).	DDI-false
Patients who have been treated with MAO inhibitors within two to three weeks prior to the administration of @DRUG$ should receive initial doses of @DRUG$ no greater than one-tenth (1/10) of the usual dose.	DDI-false
Antidepressants , @DRUG$ : amphetamines can increase the activity of @DRUG$ or sympathomimetic agents ;	DDI-false
If @DRUG$ is mixed with NPH human insulin, @DRUG$ should be drawn into the syringe first.	DDI-false
Orlistat-@DRUG$ can reduce the absorption of @DRUG$.	DDI-mechanism
@DRUG$: As with some other quinolones, concurrent administration of ciprofloxacin with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
@DRUG$: Concomitant administration of aspirin with valdecoxib may result in an increased risk of GI ulceration and complications compared to @DRUG$ alone.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , @DRUG$ , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ (20 mg) did not potentiate the hypotensive effects of @DRUG$ during the 4-hour observation period in healthy volunteers when administered with alcohol (0.5 g/kg body weight).	DDI-false
In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of @DRUG$ to @DRUG$ and 3-hydroxy levobupivacaine , respectively .	DDI-false
@DRUG$ (e.g. spironolactone, triamterene or @DRUG$ Potassium supplements or salt substitutes containing potassium may lead to significant increases in serum potassium.	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients receiving antihypertensive agents (e.g. @DRUG$ , a CYP3A4 inhibitor) or calcium channel antagonists (e. g. @DRUG$ , a CYP3A4 substrate , and diltiazem , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
These increased exposures of norethindrone and @DRUG$ should be taken into consideration when selecting an oral @DRUG$ for women taking valdecoxib.	DDI-false
Discontinuing @DRUG$ could pose a hazard to health if a potentially toxic drug that is significantly bound to the @DRUG$ has been titrated to a maintenance level while the patient was taking colestipol hydrochloride.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	DDI-false
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, @DRUG$, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Antiacid , clarithromycin , Didanosine , Fluconazole , @DRUG$ , indanavir, ketoconazole, @DRUG$ , phenobarbitol, carbamazepine, rifabutin, rifampin, ritanovir, saquinavir.	DDI-false
Other CONCOMITANT THERAPY: Although no specific interaction studies have been conducted, cerivastatin sodium was co-administered with @DRUG$ , betablockers , calcium-channel blockers , diuretics , and @DRUG$ NSAIDs without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ taken concomitantly with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl procainamide by 55% and 33%, respectively.	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): @DRUG$ (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), @DRUG$, vancomycin.	DDI-false
"Ergot derivatives: dihydroergotamine, @DRUG$ , ergotamine , @DRUG$ CONTRAINDICATE because of the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasms and ischaemia of extremities and other tissues.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Valproate: The addition of @DRUG$ to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Coadministration of @DRUG$ Glyburide ( 40 mg twice daily ( day 1 ) and 40 mg twice daily ( days 2 - 7 ) with glyburide ( 10 mg twice daily ) increased the AUC of glyburide by 21% and increased the AUC by 16%. @DRUG$ Cmax leading to a 16 % decrease in glucose AUC0 - 24 .	DDI-false
Atromid-S may displace acidic drugs such as @DRUG$ or @DRUG$ From their binding sites.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
Other CNS depressant drugs (e.g. barbiturates, tranquilizers, @DRUG$ and general @DRUG$) have additive or potentiating effects with INAPSINE.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Digoxin, nimodipine and losartan : @DRUG$ has no significant pharmacokinetic interactions with digoxin and @DRUG$ , and losartan has no significant effect on plasma levels of bosentan .	DDI-false
Acetaminophen: In normal volunteers, concomitant administration of diflunisal and @DRUG$ resulted in an approximate 50% increase in plasma levels of @DRUG$.	DDI-false
Caution should be exercised if @DRUG$ and @DRUG$ are used together .	DDI-advise
Imipramine (5 mg/kg), moclobemide (30 mg/kg), @DRUG$ (0.25 mg/kg), fluoxetine (20 mg/kg) @DRUG$ (30 mg/kg) or vehicle was administered.	DDI-false
@DRUG$ , such as dopamine and @DRUG$ ;	DDI-false
The pharmacokinetics of @DRUG$ and its major metabolite 6-beta-naltrexol were unaffected following co-administration with @DRUG$.	DDI-false
The following are examples of substances that can reduce the blood glucose-lowering effect: @DRUG$ , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , @DRUG$ ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
- @DRUG$ or MAO-inhibitors ( with hepatotoxic potential ) must not be administered together with @DRUG$ or Bezalip retard .	DDI-advise
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION, PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON @DRUG$ THERAPY, A BASELINE @DRUG$ SERUM LEVEL SHOULD BE OBTAINED.	DDI-false
After multiple dosing , @DRUG$ ( AVONEX 30 mcg IM once weekly ) reduced @DRUG$   clearance by approximately 30 % .	DDI-mechanism
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
@DRUG$ generally should not be given with @DRUG$ because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-advise
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Vitamin K (e.g. @DRUG$ , Synkayvite) use of @DRUG$ These medicines may increase the likelihood of side effects affecting the blood.	DDI-false
ACE Inhibitors and @DRUG$ ( Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS , 3020 ( 91 % ) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists ( ACEI/@DRUG$ ) .	DDI-false
However, in the second study, administration of 12 g cholestyramine 1 hour before dinner and 0.3 mg @DRUG$ approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ The AUC of less than 8% and a decrease in Cmax of about 30% compared to the dose of cerivastatin sodium alone.	DDI-false
Other @DRUG$ Co-administration of other 5-HT1B/1D agonists within 24 hours of treatment with @DRUG$ is contraindicated .	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$ , @DRUG$ , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Drug/Laboratory Test Interaction Fosinopril may cause a false low measurement of serum @DRUG$ levels with the Digi- Tab  RIA Kit for @DRUG$.	DDI-false
1- nc means a mean change of less than 10% 2-pediatrics 3- mean increase in adults in high trileptal doses In vivo, plasma levels of @DRUG$ increased by up to 40 % , when @DRUG$ was given at doses above 1200 mg/day .	DDI-mechanism
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
@DRUG$ Because of the relationship between Accutane and @DRUG$ Patients should be prevented from taking vitamin A-containing supplements to avoid additive toxic effects.	DDI-false
Interactions with mixed agonists/antagonists Opioid Analgesics: Agonists/antagonists Analgesics (e.g. pentazocin, nalbuphin, butorphanol, decicin, and buprenorphine) should NOT be administered to a patient who has a history of therapy with a @DRUG$ such as @DRUG$.	DDI-advise
Digoxin , Methotrexate , @DRUG$ : Diclofenac , like other @DRUG$ , may affect renal prostaglandins and increase the toxicity of certain drugs .	DDI-false
Beta-blockers , @DRUG$ - lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin .	DDI-false
Selective Serotonin Reuptake Inhibitors ( SSRIs ): SSRIs ( e.g. , fluoxetine , @DRUG$ , @DRUG$ , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5-HT1 agonists .	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, D-penicillamine, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ - Altered serum levels of @DRUG$ Treatment (increased and decreased) has been reported in patients receiving ciprofloxacin concomitantly.	DDI-false
- Indomethacin: @DRUG$ blunts the increases in urine volume and sodium excretion seen during bumetanide treatment and inhibits the @DRUG$-induced increase in plasma renin activity.	DDI-effect
Cardiac effects of dopamine are antagonized by @DRUG$ For example, propranolol and @DRUG$.	DDI-false
@DRUG$ : Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .	DDI-false
Non-steroidal anti-inflammatory drugs : The administration of @DRUG$ to normal volunteers receiving indomethacin decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective @DRUG$ may cause hypertension.	DDI-false
Data from in vitro studies with benzodiazepines other than: @DRUG$ suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , @DRUG$ And nifedipine.	DDI-int
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : @DRUG$ Antimycobacterial agents : rifampin benzodiazepines @DRUG$ Triazolam GI motility agent: cisapride	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ Concomitant administration of fentanyl, alfentanyl, alprazolam and triazolam may result in increased plasma concentrations. @DRUG$ ;	DDI-mechanism
With the morning dose of @DRUG$ on day 6, each volunteer received a single intravenous infusion of @DRUG$ (4 mg/kg).	DDI-false
@DRUG$ also should be used cautiously with other drugs ( e.g. , digitalis , @DRUG$ ) that sensitize the myocardium to the actions of sympathomimetic drugs .	DDI-advise
Cimetidine (400 mg b.i.d.) had no effect on @DRUG$ bioavailability (AUC) and maximum concentration (Cmax) of vardenafil when co-administered with 20 mg @DRUG$ in healthy volunteers.	DDI-false
In evaluating the potential for interactions among co-administered antiepilepsy drugs ( @DRUG$ ), whether or not containing by weight: @DRUG$ One important consideration is to induce or not induce metabolic enzymes.	DDI-false
After multiple dosing, @DRUG$ ( @DRUG$ 30 mcg IM once weekly) reduced TYSABRI clearance by approximately 30%.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations : Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , @DRUG$ , erythromycin , clarithromycin ) .	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , @DRUG$ chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g. @DRUG$ Asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
@DRUG$ may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
however, 150 mg of @DRUG$ q12h for 3 days increased the @DRUG$ C max by 23% and ceftibuten AUC by 16%.	DDI-mechanism
Multivitamins, or other products containing @DRUG$ or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of @DRUG$, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-advise
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
Interactions may occur between @DRUG$ supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).	DDI-int
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of azathioprine , gold , @DRUG$ , D-penicillamine , prednisolone , @DRUG$ The peak and AUC values of Diclofenac were not significantly affected by Diclofenac.	DDI-false
Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, schnitztilol, @DRUG$ or @DRUG$.	DDI-false
@DRUG$: @DRUG$ (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, @DRUG$, and @DRUG$) is contraindicated .	DDI-false
Acetaminophene: Pharmacokinetic or pharmacodynamic drug-effect interactions between @DRUG$ 162.5 mg orally, 26 and 2 hours before the start of treatment. @DRUG$ 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after starting argatroban 1.5 g/kg/min for 18 hours).	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , @DRUG$ , isoniazid, nefazodon, nicardipine, propofol, @DRUG$ , quinidine, and verapamil.	DDI-false
* As Amiodarone is a substrate for @DRUG$ , there is the potential that the use of St. John s Wort in patients receiving amiodarone could result in reduced @DRUG$ levels .	DDI-false
Animal studies indicate that @DRUG$ may be ineffective if the patient has recently received a @DRUG$.	DDI-effect
These drugs include thiazides and other diuretics, @DRUG$ , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$ , calcium channel blocking drugs , and isoniazid .	DDI-false
Concomitant administration of @DRUG$ (equivalent to 145 mg TRICOR) with @DRUG$ (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.	DDI-mechanism
@DRUG$ The concomitant use of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including, but not limited to, other opioids, sedatives, hypnotic agents, sedatives (e.g., @DRUG$ Common anaesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may result in respiratory depression, hypotension and deep sedation, or possibly coma or death.	DDI-false
Dopamine Antagonists : Since @DRUG$ is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of @DRUG$.	DDI-false
Aspirin : A small decrease in diflunisal levels was observed in normal subjects when multiple doses of @DRUG$ and @DRUG$ They were administered at the same time.	DDI-mechanism
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Digoxin , Nimodipine and Losartan : @DRUG$ There are no significant pharmacokinetic interactions with digoxin and nimodipine and @DRUG$ has no significant effect on plasma levels of bosentan .	DDI-false
Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.	DDI-false
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , @DRUG$ , certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , @DRUG$ - Calcium channel blockers and @DRUG$ , without any change in the adverse reaction profile .	DDI-false
Some @DRUG$/substances are known to accelerate the metabolism of amiodarone by stimulating the synthesis of @DRUG$ (enzyme induction).	DDI-false
In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of digoxin or @DRUG$ and that @DRUG$ is not a substrate for P-glycoprotein-mediated transport.	DDI-false
A possible interaction between glyburide and ciprofloxacin , a @DRUG$ , has been reported leading to an amplification of the hypoglycaemic effect of @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Concurrent administration of HEXALEN and @DRUG$ may cause severe orthostatic hypotension . Cimetidine , an inhibitor of microsomal drug metabolism , increased @DRUG$s half-life and toxicity in a rat model .	DDI-false
Hormonal contraceptives Co-administration of Trileptal with an oral @DRUG$ It has been shown that plasma concentrations of the two hormonal components ethinylestradiol (EE) and @DRUG$ ( LNG ) .	DDI-false
Although there are no study data to evaluate the possibility , @DRUG$ , including sodium nitroprusside and @DRUG$ , may have an additive effect with INOmax on the risk of developing methemoglobinemia .	DDI-false
In clinical studies, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators and additional oxygen. @DRUG$ in whom therapy with FLOLAN was initiated , apparent oral clearance values for furosemide ( n = 23 ) and @DRUG$ ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , @DRUG$ , nicotinic acid, sympathomimetics, @DRUG$ , and isoniazid .	DDI-false
These increased exposures of norethindrone and ethinyl estradiol should be taken into consideration when selecting an oral @DRUG$ for women taking @DRUG$.	DDI-advise
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Aspirin/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin ( 162.5 mg orally given 26 and 2 hours prior to initiation of @DRUG$ 1   g/kg/min . over 4 hours ) or acetaminophen ( 1000 mg orally given 12 , 6 and 0 hours prior to , and 6 and 12 hours subsequent to , initiation of @DRUG$ 1.5   g/kg/min . over 18 hours ) .	DDI-false
Digoxin : @DRUG$ The concentrations are increased by about 15 % if: @DRUG$ ==References====External links==	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ and thus should be avoided. 12 Beta-blockers and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Concomitant use of @DRUG$ with other @DRUG$ is not recommended.	DDI-advise
Therefore, close monitoring of prothrombin time is recommended and adjustment of prothrombin time is recommended. @DRUG$ Dose may be necessary if: @DRUG$ is administered concomitantly .	DDI-advise
These drugs include thiazides and other diuretics, @DRUG$ , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and @DRUG$.	DDI-false
however, no deleterious interactions were seen when ROMAZICON was administered after @DRUG$, inhalational @DRUG$, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	DDI-false
@DRUG$: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , @DRUG$ , chloramphenicol , @DRUG$ , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: @DRUG$, fluvoxamine, cimetidine, diltiazem, isoniazide, and some @DRUG$.	DDI-false
Diphenhydramine hydrochloride has additive effects with @DRUG$ and other @DRUG$ (hypnotics, sedatives, tranquilizers, etc).	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar Vet , or @DRUG$ , the dosage of @DRUG$ The need to cause ventricular tachycardia was significantly higher than the LD50 of Ouabain, with ketamine or innovar than with pentobarbital.	DDI-effect
A similar association , though less marked , has been suggested with barbiturates , phenylbutazone , phenytoin sodium , carbamazepine , @DRUG$ , topiramate, and possibly with ampicillin and @DRUG$ 72 .	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
@DRUG$: In some patients with compromised renal function who are being treated with @DRUG$, the co-administration of lisinopril may result in a further deterioration of renal function.	DDI-false
@DRUG$ may decrease the effect of phenothiazines, @DRUG$, and ketoconazole.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Nephrotoxicity following co-administration of cephalosporins with @DRUG$ or potent @DRUG$ such as furosemide .	DDI-false
Lithium-A drug interaction study of @DRUG$ with @DRUG$ has not been conducted.	DDI-false
Caution should also be taken in concurrent or serial use of other @DRUG$ and polymyxins because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate @DRUG$ neuromuscular blocking effects.	DDI-false
An alternative non-CYP3A4 substrate @DRUG$ In patients with CYP3A4 inducers such as @DRUG$ , phenytoin , carbamazepine , and phenobarbital .	DDI-false
Both @DRUG$ and @DRUG$ enhance the locomotor and/or stereotypic effects of stimulants.	DDI-false
@DRUG$ : The concomitant use of @DRUG$   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
@DRUG$ therapy Urinary excretion of @DRUG$ is increased, and efficacy is reduced by acidifying agents used in methenamine therapy.	DDI-false
In separate studies with patients who have maintenance doses @DRUG$ , hydrochlorothiazide , or @DRUG$ , irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin ( prothrombin time ) or pharmacokinetics of digoxin .	DDI-false
@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$-A drug interaction study of eplerenone with @DRUG$ has not been conducted.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : @DRUG$ Chinidine Antihistamines: astemizole, terfenadine Antimigrain: @DRUG$ Antimycobacterial agents: rifampin benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
@DRUG$ The efficacy of the warfarin type ( CYP2C9 and CYP3A4 substrate) is almost always observed in patients who: @DRUG$ And can lead to severe or fatal bleeding.	DDI-false
Cyclosporine , Digoxin , Methotrexate @DRUG$ , like other NSAIDs , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine , digoxin , @DRUG$ , and increased toxicity.	DDI-mechanism
@DRUG$ : Plasma concentrations of atorvastatin decreased approximately 25 % when colestipol and @DRUG$ were coadministered .	DDI-false
In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$   and @DRUG$ therapy , a 7 % rate of serious infections was observed , which was higher than that observed with ENBREL   alone ( 0 % ) .	DDI-effect
In healthy volunteers, the pharmacokinetics of a 1 mg dose of @DRUG$ administered as STADOL NS were not affected by the coadministration of a single 6-mg subcutaneous dose of @DRUG$.	DDI-false
Chlorpromazine: Chlorpromazine blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat @DRUG$ poisoning.	DDI-false
@DRUG$: Coadministration of indinavir with @DRUG$ resulted in an 83% increase in nelfinavir plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
Medicines that may alter the plasma concentration of imatinib Drugs that may increase the plasma concentration of imatinib @DRUG$ Plasma concentrations : Caution should be exercised when gleevec is administered with inhibitors of the CYP3A4 family (e.g. @DRUG$ Itraconazole, erythromycin, clarithromycin).	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients receiving antihypertensive agents (e.g. @DRUG$ , a CYP3A4 inhibitor ) or @DRUG$ â€¢ antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Oral Contraceptives: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	DDI-false
@DRUG$ â€¢ may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$ , CYP2D6 , and CYP3A4 .	DDI-false
Other strong inhibitors of CYP3A4 (e.g., @DRUG$, clarithromycin, nefazodone, troleandomycin, @DRUG$, nelfinavir) would be expected to behave similarly.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac @DRUG$ , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Imidazoles (e. g., ketoconazole, @DRUG$, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
May interact with thyroid medication ( e.g. , @DRUG$ ) , @DRUG$-containing products , antacids , H2-antagonists ( e.g. , famotidine , ranitidine ) , and proton pump inhibitors ( e.g. , lansoprazole , omeprazole ) .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : @DRUG$ , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , @DRUG$ GI motility agents : cisapride	DDI-false
d-amphetamine with desipramine or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of @DRUG$ in the brain;	DDI-false
- Non-selective MAO inhibitors including tranylcypromin sulfate, @DRUG$ , and @DRUG$ HC1 : Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension .	DDI-false
Aspirin : Concomitant administration of @DRUG$ and @DRUG$ It is not recommended as Diclofenac is displaced from its binding sites during concomitant administration of aspirin, resulting in lower plasma concentrations, maximum plasma levels, and AUC values.	DDI-advise
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and @DRUG$.	DDI-false
- Haemodynamic effects of glucose and @DRUG$ were additive when @DRUG$ was co-administered but not under basal conditions .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , @DRUG$ , somatropin , thyroid hormones , estrogens , @DRUG$ ( e.g. , in oral contraceptives ) .	DDI-false
Therefore , when meclofenamate sodium is given to a patient receiving @DRUG$ , the dosage of @DRUG$ To prevent excessive prolongation of prothrombin time, the dose should be reduced.	DDI-false
Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as @DRUG$ or cimetidine) may reduce plasma concentrations of @DRUG$ and therefore potentially may reduce efficacy.	DDI-mechanism
Antiarrhythmic agents, class I (such as flecainide, @DRUG$, or quinidine): concurrent use with @DRUG$ may have a proarrhythmic effect.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (@DRUG$  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$ Amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$ , triazolam GI motility agents : cisapride	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, @DRUG$ , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
@DRUG$ : Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG$n , nor were there any changes in the pharmacodynamic profile ( prothrombin time ) following a single 25 mg oral dose of warfarin	DDI-false
Pregnancy : Category X : Use With @DRUG$ ( see CONTRAINDICATIONS ) Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to @DRUG$.	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, @DRUG$ , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , @DRUG$ , calcium channel block drugs, and isoniazid.	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class ( including , for example , @DRUG$ , granisetron , dolasetron , palonosetron , and alosetron ) is contraindicated .	DDI-advise
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, @DRUG$, amiodarone, nicardipine, and nifedipine.	DDI-int
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$ , imatinib, isoniazid, nefazodon, nicardipine, propofol, @DRUG$ , quinidine , and verapamil .	DDI-false
Lithium: NSAIDs have produced an elevation of plasma @DRUG$ levels and a reduction in renal @DRUG$ clearance.	DDI-false
It is possible that the cardiovascular effect of other @DRUG$ ), could be achieved by the addition of @DRUG$ .	DDI-effect
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum @DRUG$ , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing @DRUG$ Iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in significantly lower serum and urine levels than desired.	DDI-false
Resins : Since @DRUG$ TRICOR patients should be treated at least 1 hour before or 4 - 6 hours after @DRUG$ To avoid hindering its absorption.	DDI-false
- @DRUG$ ( nandrolone [ e.g. , Anabolin ] , oxandrolone [ e.g. , Anavar ] , @DRUG$ [ e.g. Anadrol ], stanozozole [ e.g. Winstrol ] or	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , @DRUG$ - Calcium blockers, @DRUG$ , prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: @DRUG$ potentiate the analgesic effect of meperidine.	DDI-false
The availability of potent @DRUG$ (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including @DRUG$ , sedatives, and alcohol.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , @DRUG$ , ergot derivatives , pimozide , carbamazepine , @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
How ibogain ( 40 mg/kg ) reduces intravenous self-injection of 18-MC ( 40 mg/kg ) @DRUG$ * Cocaine and oral self-administration of @DRUG$ nicotine in rats;	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
The action of the @DRUG$ It may be potentiated by anticonvulsants, antihistamines, @DRUG$ , barbiturates , monoamine oxidase inhibitors , narcotics , phenothiazines , psychotropic medications , or other drugs that produce CNS depression .	DDI-effect
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of phenytoin, @DRUG$, or @DRUG$.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , @DRUG$ , doxycycline , @DRUG$ Imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
therefore , @DRUG$ or other nitrates ( as used for management of angina ) or other drugs having vasodilator activity should , if possible , be discontinued before starting @DRUG$.	DDI-advise
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce hepatic metabolism @DRUG$ , phenytoin, propranolol, @DRUG$ , chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, which delays the elimination and increase in blood levels of these drugs.	DDI-false
Imidazoles (e. g., @DRUG$, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Therefore, the concomitant administration of TRACLEER and @DRUG$ is contraindicated, and alternative @DRUG$ should be considered.	DDI-false
This appears to be the only clinically relevant interaction of this species with @DRUG$ , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or beta-adrenergic blocking agents , calcium channel blockers , antihistamines or @DRUG$ , tricyclic antidepressants and phenothiazines ) might also contribute to a prolongation of the QTc interval .	DDI-effect
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, @DRUG$, rifampin, and @DRUG$) would be expected to decrease estazolam concentrations.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , @DRUG$ , salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$ , progestogens (e.g. in oral contraceptives).	DDI-false
@DRUG$ The pharmacokinetics of @DRUG$ have not been affected.	DDI-false
Potential drug interactions between @DRUG$ (Carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and other AED) @DRUG$ ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
May interact with the following : @DRUG$ , @DRUG$ (the use with thiazide diuretics can prevent the diuretic from working properly;	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : @DRUG$ , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and @DRUG$.	DDI-false
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel , 5 % , in combination with double strength ( 160 mg/800 mg ) trimethoprim/@DRUG$ ( TMP/SMX ) .	DDI-false
Isocarboxazid should be administered with caution to patients receiving @DRUG$ ( @DRUG$ , Wyeth-Ayerst Laboratories ) .	DDI-false
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ The apparent values for oral clearance of furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13% and 15% respectively on the second day of therapy and were returned to baseline by day 87.	DDI-false
Possible interactions between Keppra and other medicinal products @DRUG$ ( carbamazepine , gabapentin , @DRUG$ , phenobarbital, phenytoin, primidone and valproate) were also evaluated by the evaluation of levetiracetam serum concentrations and these AEDs in placebo-controlled clinical trials.	DDI-false
@DRUG$: @DRUG$ may antagonize the hypotensive effects of antihypertensives.	DDI-false
@DRUG$ : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , @DRUG$ , a CYP3A4 inhibitor ) or calcium channel antagonists (e.g. verapamil, a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Blood sampling for the pharmacokinetics of @DRUG$ and @DRUG$ was performed on day 1, on weeks 1, 2, 3, and 4, and on months 2, 3, 6, 9, and 12.	DDI-false
@DRUG$ may enhance the seizure risk in patients taking @DRUG$	DDI-effect
Oral neomycin inhibits the gastrointestinal absorption of penicillin V , oral @DRUG$ , @DRUG$ and 5-fluorouracil .	DDI-false
Experience with co-administration of HMG-CoA reductase inhibitors and @DRUG$ in patients is limited,therefore,consideration should be given to temporarily suspending use of @DRUG$ in patients receiving Fentanyl.	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Before using this medication, tell your doctor or pharmacist about all prescription and non-prescription products you can use, especially from: @DRUG$ # Amphotericin B, cyclosporin, amikacin, amphotericin B, cyclosporin, amikacin, amikacin, amikacin, amikacin, amikacin, amikacin @DRUG$ medicines (e.g. ibuprofen), tacrolimus, vancomycin.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline (an @DRUG$ with multiple effects on the GI tract) to healthy volunteers, the AUC of @DRUG$ was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone.	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to @DRUG$ , including antiarrhythmic agents such as quinidine and @DRUG$ , cardiac glycosides and tricyclic anti-depressants .	DDI-false
In clinical trials with: @DRUG$ , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and @DRUG$ The pharmacokinetics/pharmacodynamics of fondaparinux sodium were not significantly affected.	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including @DRUG$, @DRUG$, CYP2D6, and CYP3A4.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
DISCUSSION : @DRUG$ is a potent inhibitor of CYP3A4 , the major enzyme responsible for @DRUG$ metabolism .	DDI-mechanism
@DRUG$: Potentiation of warfarin-type (@DRUG$ and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
@DRUG$ : @DRUG$ concentrations in bile and cystic fluid were increased ( about 2-fold ) in hydatid cyst patients treated with cimetidine ( 10 mg/kg/day ) ( n=7 ) compared with albendazole ( 20 mg/kg/day ) alone ( n=12 ) .	DDI-false
Therefore, a slower onset can be anticipated if @DRUG$ is administered concomitantly with, or immediately following, a @DRUG$.	DDI-effect
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between @DRUG$ and @DRUG$.	DDI-false
Two per cent of patients who are at the same time treated with @DRUG$   and @DRUG$ Development of neutropenia (ANC 1 x 109/L).	DDI-effect
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$ , warfarin , @DRUG$ , clarithromycin or amoxicillin.	DDI-false
@DRUG$ should not be administered concurrently with D2-antagonists, such as @DRUG$, butyrophenones, thioxanthines, or metoclopramide.	DDI-advise
In a comparison of digitalis tolerance in dogs anesthetized with @DRUG$, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with pentobarbital.	DDI-false
- medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$ Triazolam GI motility agent: cisapride	DDI-false
@DRUG$ The pharmacokinetics of theophylline (aminophylline 5.8 mg/kg infused over 20 minutes) were following a single dose of @DRUG$ 400 mg) in 6 healthy subjects.	DDI-false
HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.	DDI-false
Administration of @DRUG$ concomitantly with oral @DRUG$ has been shown to result in decreases in serum concentrations of amiodarone and desethylamiodarone .	DDI-false
â€¢ Drug interaction studies have shown that esomeprazole does not interact clinically relevant with phenytoin, warfarin, quinidine, @DRUG$ or @DRUG$.	DDI-false
- Drugs with ototoxic potential : Especially in the presence of impaired renal function , the use of parenterally administered @DRUG$ In patients who: @DRUG$ are also being given should be avoided , except in life-threatening conditions .	DDI-advise
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80% increase in etoposide exposure with a 38% decrease in total body clearance of etoposide compared to @DRUG$ alone.	DDI-false
@DRUG$ The interaction with chlorpromazine may increase the metabolism of @DRUG$.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, @DRUG$ or fluconazole.	DDI-false
Probenecid : As with other b-lactam antibiotics , renal excretion of @DRUG$ is inhibited by @DRUG$ and resulted in an approximate 80 % increase in the AUC for loracarbef .	DDI-mechanism
Resins: Since bile acid sequestrants may bind other drugs given concurrently, patients should take @DRUG$ at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption.	DDI-mechanism
In the present study, the atypical antipsychotic @DRUG$ It was used in combination with an active dose of @DRUG$ In dual drug discrimination and mixed procedures, signals-unsigned differential enforcement of low rates (DRLs).	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing cerivastatin sodium alone.	DDI-false
Drugs That Inhibit CYP3A4 ( @DRUG$ CYP3A4 is an important metabolic pathway for elimination of @DRUG$.	DDI-false
@DRUG$ , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , @DRUG$ , certain tricyclic antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-mechanism
Therefore, interactions could occur following concomitant administration of @DRUG$ (e.g., narcotics, @DRUG$, antiemetics, sedatives, tranquilizers).	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with CMI as well.	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , analgesics , @DRUG$ , @DRUG$ , sedatives).	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , @DRUG$/valproic acid , quinidine/lidocaine , @DRUG$/acetaminophen , and valproic acid/phenobarbital .	DDI-false
medicines that should not be combined with VIRACEPT antiarrhythmics: @DRUG$ , quinidine Antihistamines : astemizole, terfenadine Antimigrain : ergot derivatives Antimycobacterial agents : rifampine Benzodiazepine midazolam, triazolam GI motility agent : @DRUG$	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin @DRUG$ Midazolam, triazolam GI motility agent : @DRUG$	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	DDI-false
Co-medicines that induce CYP3A4 (e.g. dexamethasone, @DRUG$ , carbamazepine, rifampin, @DRUG$ or St.	DDI-false
Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and @DRUG$ therapy.	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and @DRUG$/Phenobarbital.	DDI-false
Aspirin/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between @DRUG$ and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
However, it affected the duration of response, indicating that pyridoxin did not co-exist with @DRUG$ and/or @DRUG$.1	DDI-false
@DRUG$ ( 5 mg/kg ) , moclobemide ( 30 mg/kg ) , @DRUG$ Fluoxetine ( 20 mg/ kg ) sertraline ( 30 mg/ kg ) or vehicle was administered.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced adverse reactions including fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, concomitant use of these active substances with @DRUG$ The effectiveness of antitumours can be reduced. @DRUG$ and thus should be avoided . 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .	DDI-false
These drugs include: @DRUG$ And other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$ , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, barbiturates, @DRUG$, sedatives, @DRUG$) should be considered.	DDI-false
Co-administration: Concomitant use of @DRUG$ with antiplatelet agents, thrombolytics, and other @DRUG$ may increase the risk of bleeding.	DDI-effect
Human pharmacokinetics data indicate that oral @DRUG$ potently inhibits the metabolism of cisapride resulting in an eight-fold increase in the mean AUC of @DRUG$.	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
@DRUG$ and Norethindrone : Coadministration of @DRUG$ OVCON-35 reduced ethinyl estradiol by 47% and plasma concentrations of norethindron by 18%.	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
This may occur because @DRUG$ competitively displaces @DRUG$ from protein binding sites.	DDI-mechanism
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral @DRUG$ , ACE inhibitors , disopyramide , fibrates , @DRUG$ , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Strong inducers of cytochrome P450 enzymes (i.e. carbamazepine, @DRUG$ and @DRUG$) have been shown to decrease the plasma levels of MHD (29-40%).	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$ , probably due to inhibition of CYP3A: nefazodone, fluvoxamine, cimetidine, diltiazem, isoniazid and some @DRUG$.	DDI-mechanism
However, it is unlikely that this decrease in phosphorylated lamivudine concentration is of clinical importance since @DRUG$ is a more efficient substrate for deoxycytidine kinase than @DRUG$.	DDI-false
Magnesium- and/or @DRUG$-containing antacids , products containing @DRUG$ ( iron ) , multivitamin preparations containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
@DRUG$: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ Because of the relationship of @DRUG$ Patients should be advised not to take vitamin A-containing supplements to avoid additive toxic effects.	DDI-false
Another oral azole antifungal, @DRUG$ , inhibits the metabolism of astemizole , resulting in elevated plasma concentrations of @DRUG$ The active metabolite desmethylastermizole may prolong the QT interval.	DDI-false
@DRUG$: Coadministration of indinavir with VIRACEPT resulted in an 83% increase in @DRUG$ plasma AUC and a 51% increase in indinavir plasma A.C.	DDI-false
Warfarin: No significant differences were observed in the steady-state pharmacokinetics of @DRUG$ or @DRUG$ with the addition of tiagabine given as a single dose.	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics (such as loop or thiazide diuretics) can be acutely worsened by @DRUG$, especially when the recommended dose of the @DRUG$ is exceeded.	DDI-false
When @DRUG$ is co-administered with @DRUG$ , anticoagulation levels should be monitored frequently .	DDI-advise
Close supervision and careful adjustment of the dosage are required when nortriptyline hydrochloride is used with other @DRUG$ or @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , @DRUG$ salts , lithium , local @DRUG$ , procainamide, and quinidine.	DDI-false
Aminosalicylic acid may decrease the amount of @DRUG$ ( Lanoxin , @DRUG$ It is absorbed in your body.	DDI-false
Vaccines : Patients on @DRUG$ The treatment may show a reduced response to toxoids and may be alive or @DRUG$ due to inhibition of antibody response .	DDI-effect
The effects of mixing NovoLog with @DRUG$ of animal source or @DRUG$ preparations produced by other manufacturers have not been studied .	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, @DRUG$, antihistamines or H1-blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
For patients receiving both therapies, standard monitoring of @DRUG$ blood concentrations and appropriate @DRUG$ dosage adjustments are recommended.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
To assess the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine, and @DRUG$ CHOP chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or with a CHOP-like regimen (i.e. cyclophosphamide, doxorubicin, teniposide and prednisone with vincristine plus). @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
Other @DRUG$ ( e.g. , @DRUG$ ==References====External links==	DDI-false
Oral @DRUG$ .......................................................................................................................................................................................................................................................................................................................	DDI-false
Concurrent administration of @DRUG$ and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased @DRUG$s half-life and toxicity in a rat model.	DDI-false
@DRUG$ : In normal volunteers , a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and aspirin were administered concomitantly .	DDI-false
Drug interaction studies have shown that: @DRUG$ There are no clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In pigeons , @DRUG$ The impact of the @DRUG$ , (+)-NANM or PCP .	DDI-false
Treatment with @DRUG$ The once weekly 4 weeks in healthy subjects was associated with inhibition of P450 1A2 and an increase of 25%. @DRUG$ AUC .	DDI-mechanism
The hypoglycemic action of @DRUG$ â€¢ may be exacerbated by certain drugs, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, @DRUG$ , Cumarine, monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-effect
@DRUG$ , barbiturates , or @DRUG$ There may be an intensification of orthostatic hypotension.	DDI-false
A similar association , though less marked , has been suggested with barbiturates , phenylbutazone , phenytoin sodium , @DRUG$ , griseofulvin , topiramate , and possibly with @DRUG$ 72. and tetracyclines 72.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of @DRUG$, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, dacarbazine, cis-platinum, @DRUG$ and @DRUG$.	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, @DRUG$ , sympathomimetics (e.g. epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$ , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI   and concomitant interferon beta-1a ( AVONEX   30 mcg IM once weekly ) or @DRUG$ This was not conclusive in terms of the need for dose adjustment of the beta interferon or @DRUG$.	DDI-false
@DRUG$ , including oral contraceptives : @DRUG$ For this reason, the hepatic metabolism of certain corticosteroids can be reduced, increasing its effect.	DDI-false
In patients who have received @DRUG$, @DRUG$ may temporarily mask the residual effects of muscle relaxant drugs.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, @DRUG$, and barbiturates, and the @DRUG$ rifampin.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines , presumably through inhibition of CYP3A : nefazodone , fluvoxamine , @DRUG$ , diltiazem , @DRUG$ And some macrolide antibiotics.	DDI-false
@DRUG$ : @DRUG$ ( guanethidine , reserpine , glutamic acid HCl , ascorbic acid , fruit juices , etc . ) lower absorption of amphetamines .	DDI-false
Co-administration of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , @DRUG$ (e. g., quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolem and triazolam) may increase plasma concentrations when co-administered with @DRUG$ ;	DDI-mechanism
Phenytoin : Population pharmacokinetic analyses indicate that @DRUG$ Clearance is in patients who: @DRUG$ With or without other enzyme-inducing AEDs.	DDI-mechanism
@DRUG$ significantly decreased the AUC(ss) of @DRUG$ by 82%, but amprenavir had no effect on rifampin pharmacokinetics.	DDI-mechanism
For treatment with CYP3A4 inhibitors (such as ketoconazole, intraconazole, @DRUG$ , indinavir , @DRUG$ , erythromycin , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
@DRUG$ Supplements and Potassium-Sparing Diuretics: @DRUG$ can attenuate potassium loss caused by thiazide diuretics.	DDI-false
Agents Causing Renin Release : The antihypertensive effect of enalapril and enalapril IV is augmented by @DRUG$ that cause renin release ( e.g. , @DRUG$ ) .	DDI-false
Therophylline : A recent study has shown that @DRUG$ Theophylline may lead to increased plasma levels of theophylline and, in some cases, a slight decrease in elimination of @DRUG$.	DDI-false
@DRUG$: Concomitant administration of aspirin with @DRUG$ may result in an increased risk of GI ulceration and complications compared to valdecoxib alone.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral @DRUG$ ( warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs ( @DRUG$ Digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Aspirin: Concomitant use of diclofenac and aspirin is not recommended since @DRUG$ While co-administering @DRUG$ This resulted in lower plasma concentrations, maximum plasma levels and AUC values.	DDI-mechanism
The addition of @DRUG$ in a limited number of patients in three well-controlled studies caused no systematic changes in @DRUG$ or primidone concentrations when compared to placebo .	DDI-false
Patients who begin taking @DRUG$ or who increase their diclofenac dose or any other NSAID while taking digoxin, @DRUG$, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-effect
Results from existing clinical trials suggest no significant interactions between @DRUG$   and other therapies commonly used in MS patients , including the concurrent use of @DRUG$ For up to 28 days.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
Treatment with @DRUG$ can directly interfere with blood glucose levels or may interact with @DRUG$.	DDI-int
In clinical trials , FLOLAN was used with @DRUG$ In a pharmacokinetic sub-study in patients with heart failure receiving furosemide or digoxin starting treatment with FLOLAN, apparent oral clearance values for @DRUG$ On the second day of therapy, digoxin (n=30) and n=23 were reduced by 13 % and 15 % respectively.	DDI-false
@DRUG$ , an inhibitor of P450 2C9 , decreased active metabolite concentration and increased @DRUG$ concentration .	DDI-mechanism
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
injection of @DRUG$ (@DRUG$) were observed by measuring locomotor activity and stereotyped behavior.	DDI-false
FLEXERIL may enhance the effects of alcohol, @DRUG$, and other @DRUG$.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, fluvoxamine, @DRUG$, @DRUG$, isoniazide, and some macrolide antibiotics.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Single doses of either @DRUG$ or @DRUG$ resins bind the hydrochlorothiazide and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	DDI-false
Hormonal Contraceptives , Including Oral , Injectable , Transdermal , and Implantable @DRUG$ : An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14 % and 31 % , respectively .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , @DRUG$ , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
When @DRUG$ is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, dexamethasone, or @DRUG$, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-advise
Oral @DRUG$: Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and @DRUG$ by approximately 30% and 20%.	DDI-false
Although in clinical studies with IOPIDINE 0.5 % ophthalmic solution no specific drug interactions with topical glaucoma or systemic drugs have been identified, there is a possibility of additive or potentiating effects with CNS depressants (alcohol, @DRUG$ , @DRUG$ , sedatives , anesthetics ) should be considered .	DDI-false
The clearance of @DRUG$ may be increased with concurrent use of @DRUG$.	DDI-mechanism
@DRUG$ : @DRUG$ , ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasms and ischaemia of extremities and other tissues.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (@DRUG$/ARB).	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with aspirin alone and because @DRUG$ increases the rate of excretion of Nalfon, the concomitant use of @DRUG$ and salicylates is not recommended.	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$).	DDI-false
CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of @DRUG$ 70 mg daily, as compared to results from a control period in which @DRUG$ was administered alone.	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$ , oral @DRUG$ , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
In vitro studies show that: @DRUG$ - does not inhibit P-glycoprotein-mediated transport of digoxin or @DRUG$ And that ertapenem is not a substrate for P-glycoprotein-mediated transport.	DDI-false
There have been case reports of increased steady-state levels of quinidine, procainamide, and @DRUG$ during concomitant therapy with @DRUG$.	DDI-false
Lithium serum concentrations should be monitored closely when initiating or changing therapy with @DRUG$ in patients receiving @DRUG$.	DDI-advise
@DRUG$ and Angiotensin II Receptor Antagonists ( Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS , 3020 ( 91 % ) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists ( @DRUG$/ARB ) .	DDI-false
Patients receiving hydantoins , @DRUG$ , or @DRUG$ In case of increased activity of these drugs should be observed and therefore signs of toxicity by these drugs.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , gentamicin , and amikacin ) , amphotericin B , foscarnet , intravenous pentamidine , @DRUG$ , and @DRUG$ ] is contraindicated .	DDI-false
Ritonavir and indinavir: When vardenafil 5 mg is co-administered with 600 mg twice daily @DRUG$ Cmax and AUC of @DRUG$ were reduced by approximately 20 % .	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Psychoactive Drugs : Hallucinations have been reported when TORADOL was used in patients taking @DRUG$ ( @DRUG$ , thiothixene , alprazolam ) .	DDI-false
@DRUG$/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/@DRUG$ , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Hormonal contraceptives, including oral, injectable, transdermal, and implantable @DRUG$ An interaction study showed that the concomitant use of bosentan and oral hormonal contraceptives Ortho-Novum showed an average decrease in norethindron and @DRUG$ levels of 14 % and 31 % , respectively .	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$ , anticoagulants , oral @DRUG$ In a pharmacokinetic sub-study in patients with congestive heart failure receiving furosemide or digoxin starting treatment with FLOLAN, visible values for oral clearance of furosemide (n = 23) and digoxin (n = 30) were reduced by 13% and 15% respectively on the second day of therapy and returned to baseline by day 87.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Methotrexate : In an interaction study of rheumatoid arthritis patients taking @DRUG$ , @DRUG$ did not have a significant effect on the pharmacokinetics of methotrexate .	DDI-false
@DRUG$: @DRUG$ enhance the adrenergic effect of norepinephrine.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
However, because some @DRUG$ have been reported to enhance the anticoagulant effects of @DRUG$ or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a quinolone antimicrobial is administered concomitantly with warfarin or its derivatives.	DDI-effect
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., @DRUG$), tacrolimus, vancomycin.	DDI-false
Medicines detected as CYP3A inhibitors of possible clinical significance based on clinical studies @DRUG$ ( caution is recommended during coadministration with @DRUG$ Concomitant administration of fluoxetine and alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17% and decreased measured psychomotor performance.	DDI-false
Injection: Lorazepam injection, like other injectable @DRUG$, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, barbiturates, @DRUG$, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-effect
Veratrum alkaloids : @DRUG$ inhibit the hypotensive effect of @DRUG$.	DDI-effect
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including barbiturates, @DRUG$, and @DRUG$.	DDI-false
acetaminophen/theophylline , lidocaine/@DRUG$ , phenobarbital/@DRUG$ , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
The co-administration of @DRUG$ with IV vasodilators such as @DRUG$ , nitroprusside , milrinone , or IV ACE inhibitors has not been evaluated ( these drugs were not co-administered with Natrecor in clinical trials ) .	DDI-false
Other Drug Interactions Oral Contraceptives @DRUG$  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg @DRUG$ and 0.15 mg levonorgestrel, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , @DRUG$ , benzodiazepines , beta blockers , calcium-channel blockers , cardiac @DRUG$ , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-false
When the @DRUG$ was administered 30 minutes after the sumatriptan nasal spray, the AUC of @DRUG$ increased 11% and Cmax decreased 18%.	DDI-false
Concomitantly given @DRUG$ did not interfere with the absorption of a tablet of @DRUG$.	DDI-false
@DRUG$, clonidine, lithium salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
Several drug interaction studies have been completed with both @DRUG$ and @DRUG$.	DDI-false
- Anabolic steroids ( nandrolone [ e.g. , Anabolin ] , oxandrolone [ e.g. , Anavar ] , @DRUG$ [ e.g. Anadrol ], @DRUG$ [ e.g. , Winstrol ] ) or	DDI-false
@DRUG$ In some patients, the administration of a non-steroidal anti-inflammatory agent may reduce the diuretic, natriuretic and blood pressure lowering effect of Loop, @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Results of studies in multiple sclerosis patients taking @DRUG$  and concomitant @DRUG$ (AVONEX  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
In two combined 12-week placebo controlled trials that included BROVANA doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 @DRUG$ -treated subjects received concomitant @DRUG$ at study entry.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or beta-adrenergic blocking agents , calcium channel blockers , @DRUG$ Tricyclic antidepressants and H1 blocking agents @DRUG$ ) could also contribute to an extension of the QTc interval.	DDI-false
We report the case of an adolescent with altered consciousness caused by @DRUG$ overdose with a positive tricyclic antidepressant level to alert clinicians to the cross-reactivity of @DRUG$ with a toxicology screen for tricyclic antidepressants.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , pentazocine , @DRUG$ , @DRUG$ , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran .	DDI-false
Both @DRUG$ and nevirapine have been compared to triple therapy with the PI @DRUG$ over 48 weeks as initial therapy, with similar responses being observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
Based on total @DRUG$ concentrations, @DRUG$ increased the AUC by 25% and reduced the plasma and renal clearances by 20% and 35%, respectively.	DDI-mechanism
acetaminophen/@DRUG$ , lidocaine/@DRUG$ , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
In addition , @DRUG$ and @DRUG$ Induce a subset of the cytochrome P450 3A family ( CYP3A4 and CYP3A5) responsible for the metabolism of dihydropyridine-calcium antagonists and oral contraceptives, resulting in a lower plasma concentration of these drugs.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
Other Drug Interactions Oral Contraceptives @DRUG$  (500 mg twice daily) did not influence the pharmacokinetics of an oral contraceptive containing 0.03 mg ethinyl estradiol and 0.15 mg @DRUG$, or of the luteinizing hormone and progesterone levels, indicating that impairment of contraceptive efficacy is unlikely.	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$ , imatinib , @DRUG$ , Nefazodone, Nicardipine, Propofol, Protease inhibitors, quinidine, and verapamil.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , @DRUG$ , hydroxychloroquine, leflunomide, sulfasalazine and @DRUG$.	DDI-false
Ephedrine: @DRUG$ may enhance the metabolic clearance of @DRUG$, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.	DDI-mechanism
The additive CNS depression may occur if: @DRUG$ are administered concomitantly with other @DRUG$ Including barbiturates, tranquilizers and alcohol.	DDI-effect
@DRUG$ SSRIs: SSRIs (e.g. fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when co-administered with @DRUG$.	DDI-false
Concomitant administration of @DRUG$ doubled the AUC for @DRUG$.	DDI-mechanism
MAO Inhibitors : @DRUG$ The use in patients who received MAOI within 14 days is not recommended as severe and unpredictable potentiation due to: @DRUG$ has been reported with opioid analgesics	DDI-false
It is not known if other @DRUG$ , such as implants and injectables , are adequate methods of contraception during @DRUG$ therapy .	DDI-false
Preliminary studies indicate that the concomitant use of @DRUG$ and @DRUG$ results in a higher cardiac output and, usually, a lower pulmonary wedge pressure than when either drug is used alone.	DDI-effect
Concomitant administration of @DRUG$ and other related compounds ( eg , quinine , @DRUG$ Chloroquine) may cause electrocardiographic abnormalities and increase the risk of convulsions.	DDI-effect
Theophylline serum levels should be monitored and appropriate dose adjustments considered for patients given both @DRUG$ and @DRUG$.	DDI-advise
Oral neomycin inhibits the gastrointestinal absorption of @DRUG$ , oral @DRUG$ , methotrexate and 5-fluorouracil.	DDI-false
Patients in a clinical trial based on established treatment with sulfasalazine for which: @DRUG$ was added , were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either ENBREL CI or @DRUG$ alone .	DDI-false
Drugs with a tight therapeutic index @DRUG$ A single dose of eszopiclone 3 mg did not affect the pharmacokinetics of @DRUG$ measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days .	DDI-false
Potassium Supplements and @DRUG$: Fosinopril sodium can attenuate potassium loss caused by @DRUG$.	DDI-false
Like ibogain ( 40 mg/kg), @DRUG$ ( 40 mg/kg ) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ nicotine in rats;	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, @DRUG$, D-penicillamine, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
The effect of other medicinal products on the pharmacokinetics of @DRUG$ : Literature reports suggest that ranitidine , an agent that decreases stomach acidity , does not greatly alter @DRUG$ pharmacokinetics .	DDI-false
â€¢ CANCIDAS reduced AUC0 - 12 of tacrolimus in the blood by about 20%, maximum blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12h) by 26% in healthy subjects when tacrolimus (2 doses of 0.1 mg/kg 12 hours apart) was removed on 10 October. @DRUG$ 70 mg daily, compared to results from a control period in which @DRUG$ was administered alone .	DDI-false
aBased on reports of narcotic withdrawal syndrome in patients treated with @DRUG$ Simultaneously with methadone and signs of decreased plasma concentrations of @DRUG$.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
Therefore, concurrent use of @DRUG$ with @DRUG$ may render these contraceptives less effective.	DDI-effect
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-effect
Taking a @DRUG$ while you are taking or within 2 weeks of taking @DRUG$ may increase the risk of central nervous system depression or may cause a severe high blood pressure reaction.	DDI-effect
Tetracyclines: Concomitant treatment with @DRUG$ and @DRUG$ should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	DDI-advise
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , hypnotics , @DRUG$ (e.g. benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$ , respiratory depression, hypotension, and deep sedation, or possibly lead to coma or death.	DDI-false
Magnesium and/or aluminium antacids, iron sulphate products, multivitamin preparations containing zinc or other metal cations; or @DRUG$ ( @DRUG$ Do not take chewable tablets or the pediatric powder for oral solution within 3 hours before or 2 hours after FACTIVE.	DDI-false
@DRUG$ AUC(s) @DRUG$ by 82 % , but amprenavir had no effect on rifampin pharmacokinetics .	DDI-mechanism
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ Alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, @DRUG$, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to @DRUG$ was decreased approximately 72%.	DDI-mechanism
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, @DRUG$, and nifedipine.	DDI-int
The absorption of tetracycline , furosemide , @DRUG$ , hydrochlorothiazide , and @DRUG$ was significantly decreased when given simultaneously with colestipol hydrochloride ;	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines.	DDI-false
However, interactions can be expected, and @DRUG$ should NOT be used in combination with other @DRUG$.	DDI-advise
@DRUG$ may decrease the effect of phenothiazines, levodopa, and @DRUG$.	DDI-effect
In separate studies with patients who have maintenance doses @DRUG$ , hydrochlorothiazide , or digoxin , irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin ( prothrombin time ) or pharmacokinetics of @DRUG$.	DDI-false
Allopurinol: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when @DRUG$ and @DRUG$ were administered concomitantly for 6 days.	DDI-false
@DRUG$ (20 mg) did not potentiate the hypotensive effects of alcohol during the 4-hour observation period in healthy volunteers when administered with @DRUG$ (0.5 g/kg body weight).	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, @DRUG$ , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and @DRUG$.	DDI-false
This drug may interact with alcohol or other @DRUG$ (may increase the CNS depressive effect of either these drugs or antihistamines), anticholinergics or other drugs with anticholinergic activity (anticholinergic effects may be intensified if these drugs are concomitantly administered with @DRUG$ Inhibitors (co-administration with antihistamines may prolong and increase the anticholinergic and CNS depressive effects of antihistamines).	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), @DRUG$ (acetylsalicylic acid), NSAIDs (@DRUG$), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Tetracycline : Accompanying treatment with @DRUG$ and @DRUG$ should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri ( benign intracranial hypertension ) , some of which involved concomitant use of tetracyclines	DDI-advise
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, terfenadine antimigrain: @DRUG$ Antimycobacterial agents : rifampin Benzodiazepines midazolam , @DRUG$ GI motility agents : cisapride	DDI-false
The pressor effects of @DRUG$ Like dopamine or norepinephrine, @DRUG$ amplifies.	DDI-effect
Digoxin : @DRUG$ 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of @DRUG$ after a single 0.5 mg oral dose .	DDI-false
In a phase I study with escalating doses of TAXOL ( 110 - 200 mg/ m2) and cisplatin ( 50 or 75 mg/ m2) as sequential infusions, myelosuppression was more pronounced if: @DRUG$ was given after @DRUG$ than with the alternate sequence ( ie , TAXOL before cisplatin ) .	DDI-effect
Therefore, it would be expected that a dosing schedule of @DRUG$ given at bedtime and @DRUG$ given before the evening meal would not result in a significant decrease in the clinical effect of cerivastatin sodium.	DDI-false
Short-term pharmacokinetic studies have shown that concomitant administration of warfarin and lodine (Etodolac capsules and tablets) to reduce protein binding of @DRUG$ However, there was no change in the release of free @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Simultaneous absorption of mineral oil and vitamin K may reduce the absorption of @DRUG$.	DDI-false
Although no clinical studies have been performed, it is likely that the metabolism of levobupivacaine by the known CYP3A4 inducers (such as phenytoin, @DRUG$ , @DRUG$ CYP3A4 inhibitors (azole antifungals e.g. ketoconazole;	DDI-false
CONCLUSIONS: @DRUG$ inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, @DRUG$, simvastatin).	DDI-mechanism
@DRUG$ and @DRUG$ Co-administration of VIRACEPT and OVCON-35 resulted in a 47% decrease in ethinylestradiol and an 18% decrease in norethindron plasma concentrations.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to @DRUG$ and @DRUG$ increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
Although no interaction between MAO inhibitors and @DRUG$ has been observed , it is not recommended for use with @DRUG$.	DDI-advise
When Nortriptyline hydrochloride is used with other medicinal products, close monitoring and careful dose adjustment is required. @DRUG$ or @DRUG$.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, nevirapine, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in @DRUG$ concentrations.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, @DRUG$ , probenecid , coumarins , @DRUG$ And beta-adrenergic blockers.	DDI-false
@DRUG$: Interaction with Other Drugs that are Metabolized by Cytochrome P450 (CYP): At clinically relevant concentrations, in vitro studies indicate that @DRUG$ (0.6 M) was not inhibitory towards the major cytochrome P450 isoforms CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A.	DDI-false
Interactions with mixed agonists/antagonists Opioid analgesics : agonists/antagonists analgesics (e.g. @DRUG$ , nalbuphine , butorphanol , dezocine and @DRUG$ ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran .	DDI-false
However, in the second study, administration of 12 g cholestyramine 1 hour before the evening meal and 0.3 mg cerivastatin sodium approximately 4 hours after the same evening meal resulted in a decrease in the @DRUG$ AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing @DRUG$ alone.	DDI-false
Patients who have other narcotic analgesics, general anaesthetics, @DRUG$ , @DRUG$ , sedative hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) together with DILAUDID may exhibit additive CNS depression.	DDI-false
Uricosuric drugs, such as @DRUG$ and @DRUG$, can inhibit renal tubular secretion of nitrofurantoin.	DDI-false
Carbamazepine : Elevated @DRUG$ The post-marketing concentrations have been reported if: @DRUG$ is administered concomitantly .	DDI-mechanism
- benzylpenicillin, ampicillin, @DRUG$ Chlortetracycline, doxycycline, cephalothine, erythromycin and sulfamethoxazole have no in vitro effect on protein binding of @DRUG$ in human serum .	DDI-false
Imipramine: co-administration of single doses of @DRUG$ 20 mg and @DRUG$ 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration .	DDI-effect
@DRUG$: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, fibric acid derivatives, @DRUG$ (@DRUG$), erythromycin, azole antifungals.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, @DRUG$, @DRUG$, and possibly with ampicillin and tetracyclines 72.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, @DRUG$, nitrates, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenylbutazone, phenytoin sodium, carbamazepine, @DRUG$, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Standard therapy includes antibiotics , such as @DRUG$ and @DRUG$ ;	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( @DRUG$ Transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotic agents, sedatives (e.g., benzodiazepines), generally @DRUG$ , phenothiazine, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and deep sedation, or possibly coma or death.	DDI-effect
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, @DRUG$, clarithromycin or @DRUG$.	DDI-false
Fluconazole : Concomitant administration of @DRUG$ at 200 mg QD resulted in a two-fold increase in @DRUG$ plasma concentration .	DDI-mechanism
The effectiveness of Progestin-Only pills is caused by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin, carbamazepine, and @DRUG$ And the antituberculosis drug @DRUG$.	DDI-false
Rhabdomyolysis has been observed in patients receiving HMG-CoA reductase inhibitors administered alone (at recommended dosages) or concomitantly with @DRUG$ including @DRUG$.	DDI-false
In vitro and/or in vivo data indicate that fluconazole, @DRUG$ , and oral ketoconazole significantly inhibit the metabolism of @DRUG$ , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-mechanism
Coadministration with compounds that are potent inducers of CYP3A4 ( eg , @DRUG$ , phenytoin , dexamethasone , @DRUG$ ) may result in decreased plasma levels of saquinavir .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine  (@DRUG$ capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free @DRUG$.	DDI-false
Data from in vitro studies of @DRUG$ other than @DRUG$ suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and nifedipine.	DDI-false
Compounds tested in man include @DRUG$, theophylline, phenytoin, diazepam, aminopyrine and @DRUG$.	DDI-false
Ethopropazine can interact with @DRUG$ , increase the metabolism of @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
@DRUG$-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of @DRUG$.	DDI-false
However, LDL-C reduction was greater when @DRUG$ and @DRUG$ were coadministered than when either drug was given alone.	DDI-effect
Oral @DRUG$ inhibits the gastrointestinal absorption of penicillin V, oral vitamin B-12, @DRUG$ and 5-fluorouracil.	DDI-mechanism
Magnesium/Aluminum-containing @DRUG$: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/@DRUG$-containing antacid products.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).	DDI-false
The risk of using @DRUG$ in combination with other drugs has not been systematically evaluated, but @DRUG$ may potentiate the side effects of bromocriptine mesylate.	DDI-false
@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
The gastrointestinal absorption of cimetidine and @DRUG$ is accelerated when they are coadministered with @DRUG$.	DDI-mechanism
Pharmacokinetic studies have demonstrated that @DRUG$ Systemic exposure of erythromycin and erythromycin increased significantly. @DRUG$ Main metabolites and/or its main metabolites.	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The pressor effects of catecholamines such as dopamine or @DRUG$ are enhanced by @DRUG$.	DDI-effect
Use With @DRUG$ @DRUG$ is genotoxic and mutagenic .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-effect
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , @DRUG$ , erythromycin , @DRUG$ , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Pediatric Use The safety and effectiveness of @DRUG$, alone or in combination with @DRUG$ in patients below the age of 18 years have not been established.	DDI-false
While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , @DRUG$ , escitalopram, fluoxetine, sertraline, and @DRUG$ , inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
@DRUG$ : Patients on diuretics , especially those with intravascular volume depletion , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$.	DDI-false
@DRUG$: DURAGESIC  is not recommended for use in patients who have received @DRUG$ within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics	DDI-false
The effects of nonbenzodiazepine agonists at benzodiazepine receptors , such as @DRUG$ , triazolopyridazines and others , are also blocked by @DRUG$.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/@DRUG$).	DDI-false
Close supervision and careful adjustment of dosage are required when @DRUG$ is administered with anticholinergic or @DRUG$.	DDI-advise
Antiarrhythmics : Other @DRUG$ - medicinal products such as quinidine, procainamide, disopyramide and @DRUG$ , were used simultaneously with amiodarone.	DDI-false
Hydrochlorothiazide: In normal volunteers, concomitant administration of @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels of @DRUG$.	DDI-false
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
In the first study, concomitant administration of 0.2 mg cerivastatin sodium and 12 g @DRUG$ resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing @DRUG$ alone.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors , tricyclic antidepressants or @DRUG$ may produce severe , prolonged hypotension or hypertension .	DDI-effect
Based on known metabolic profiles , clinically significant drug interactions are not expected between @DRUG$ and dapsone , trimethoprim/sulfamethoxazole , clarithromycin , erythromycin , itraconazole or @DRUG$.	DDI-false
@DRUG$ , @DRUG$ â€¢ amphetamines may increase the activity of tricyclic antidepressants or sympathomimetics;	DDI-false
Acetaminophen, @DRUG$, phenobarbital, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The co-administration of Natrecor with IV @DRUG$ such as @DRUG$, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
@DRUG$: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
The urine of patients who: @DRUG$ can give a false-positive reaction for urinary bilirubin ( urobilin ) due to the presence of phenolic metabolites of @DRUG$.	DDI-false
Oral @DRUG$ : Multiple dose administration of @DRUG$ The pharmacokinetics of oral contraceptives in healthy women of childbearing potential have not changed ( 8 mg/ day monotherapy).	DDI-false
- anabolic steroids (Nandrolone [e.g. Anaboline ], Oxandrolone [e.g., @DRUG$ oxymethol [e.g. anadrol], @DRUG$ [ e.g. , Winstrol ] ) or	DDI-false
@DRUG$ , ampicillin , oxacillin , chlortetracycline , doxycycline , @DRUG$ , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum .	DDI-false
Lithium: Valdecoxib 40 mg BID for 7 days produced significant decreases in @DRUG$ serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to @DRUG$ alone.	DDI-false
@DRUG$ has additive effects with alcohol and other CNS depressants (hypnotics, @DRUG$, tranquilizers, etc).	DDI-effect
Cytochrome P-450 inducers , such as @DRUG$ , carbamazepine and phenobarbital, induce clonazepam metabolism, resulting in an approximately 30% decrease in plasma @DRUG$ levels .	DDI-false
Valproate : The addition of tiagabine to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics , but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8 % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .	DDI-false
HIV Protease Inhibitors : Indinavir ( 800 mg t.i.d . ) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC , a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life .	DDI-false
Amiodarone may suppress certain CYP450 enzymes , including @DRUG$ , CYP2C9, CYP2D6 and @DRUG$.	DDI-false
@DRUG$ â€¢ the amount of @DRUG$ Lanoxin (lanoxicaps) is absorbed into your body.	DDI-mechanism
The extent to which @DRUG$-TCA interactions can cause clinical problems depends on the degree of inhibition and pharmacokinetics of patients. @DRUG$ involved .	DDI-false
As the primary effect of @DRUG$ is to decrease conduction through the A-V node , higher degrees of heart block may be produced in the presence of @DRUG$.	DDI-effect
Lithium : @DRUG$ Toxicity has been reported in patients who: @DRUG$ Accompanied by medicines that cause the excretion of sodium, including ACE inhibitors.	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between @DRUG$ Trimethoprim/sulfamethoxazole and dapsone, @DRUG$ Erythromycin, itraconazole or fluconazole.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , pentazocine , @DRUG$ , butorphanol, decicin and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesics such as @DRUG$.	DDI-advise
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including @DRUG$ such as quinidine and procainamide, cardiac glycosides and tricyclic anti-depressants.	DDI-false
The concomitant use of Natrecor with IV vasodilators such as @DRUG$ , @DRUG$ , Milrinone or IV ACE inhibitors have not been studied (these drugs were not administered in clinical trials with Natrecor).	DDI-false
Methotrexate Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of @DRUG$ , potentially leading to increased plasma levels of methotrexate .	DDI-mechanism
Substances that are potent inhibitors of CYP3A4 activity (eg, @DRUG$ and itraconazole) decrease @DRUG$ metabolism and increase gefitinib plasma concentrations.	DDI-mechanism
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, TAXOL before cisplatin).	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blockers, azathioprin, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$ , and @DRUG$.	DDI-false
- Antidiabetics , oral ( diabetes medicine you take by mouth ) Use of oral @DRUG$ with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral @DRUG$	DDI-false
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, salbutamol, @DRUG$ ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , @DRUG$ , progestogens (e.g. in oral contraceptives).	DDI-false
Antidepressants ( @DRUG$ ) , atropine or other anticholinergic agents , or @DRUG$ : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects .	DDI-false
@DRUG$ : @DRUG$ Increases the effect of warfarin.	DDI-effect
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, escitalopram, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance , such as efavirenz , nevirapine , @DRUG$ , dexamethasone or carbamazepine, administration of a daily dose of 70 mg @DRUG$ should be considered	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , @DRUG$ , nifedipine, chlordiazepoxide, diazepam, certain @DRUG$ , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
Cholestyramine and colestipol @DRUG$: Absorption of hydrochlorothiazide is impaired in the presence of @DRUG$.	DDI-false
Reports in the literature suggest that plasma levels of doxorubicin (and its active metabolite @DRUG$) may be increased when paclitaxel and @DRUG$ are used in combination.	DDI-false
Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of theophylline, digoxin or an ethinylestradiol/levonorgestrol oral @DRUG$ in healthy subjects.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( phenytoin , @DRUG$ , oral @DRUG$ , digoxin , warfarin , probenecid ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients .	DDI-false
Co-medicines that induce CYP3A4 (e.g. @DRUG$ , @DRUG$ , carbamazepine , rifampin , phenobarbital or St.	DDI-false
Digoxin , Methotrexate , Cyclosporine : @DRUG$ , like other @DRUG$ , may affect renal prostaglandins and increase the toxicity of certain drugs .	DDI-false
No significant interactions were found between nisoldipine and @DRUG$ or @DRUG$.	DDI-false
In monkeys (-)-NANM was about 10 times stronger than @DRUG$ in decreasing responding , whereas in pigeons @DRUG$ was about equipotent with (+)-NANM .	DDI-false
Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with @DRUG$ , signs and symptoms of carbamazepine toxicity should be monitored closely , and appropriate dosage adjustment of the anticonvulsant should be made .	DDI-advise
Another oral azole antimycotics, ketoconazole, inhibits the metabolism of astemizole, resulting in increased plasma concentrations of @DRUG$ and its active metabolite @DRUG$ , which can prolong QT intervals.	DDI-false
In another study, TORADOLIV/IM was given with two doses of 5000 U of @DRUG$ to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for @DRUG$ alone and 5.1 minutes (3.5 to 8.5 min) for placebo.	DDI-false
@DRUG$: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	DDI-false
@DRUG$: As with other b-lactam antibiotics, renal excretion of loracarbef is inhibited by @DRUG$ and resulted in an approximate 80% increase in the AUC for loracarbef.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Magnesium- and/or aluminum-containing antacids , products containing ferrous sulfate ( iron ) , multivitamin preparations containing @DRUG$ or other metal cations , or @DRUG$ Do not take chewable/buffered tablets or the pediatric powder for oral solution within 3 hours before or 2 hours after FACTIVE.	DDI-false
Antibiotics : In vitro and/or in vivo data show that @DRUG$ , erythromycin, and troleandomycin significantly inhibit the metabolism of @DRUG$ This may lead to an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
ACE Inhibitors and @DRUG$ (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/ARB).	DDI-false
Patients in a clinical study who were on established therapy with sulfasalazine, to which ENBREL was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either @DRUG$ CI or @DRUG$ alone.	DDI-false
Human pharmacokinetic data indicate that oral ketoconazole markedly inhibits the metabolism of @DRUG$, resulting in a mean eight-fold increase in AUC of @DRUG$.	DDI-false
Magnesium- and/or aluminum-containing antacids , products containing @DRUG$ Iron, multivitamin preparations containing zinc or other metal cations, or Videx ( @DRUG$ ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and @DRUG$ (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
â€¢ Simultaneous use of calcium supplements and @DRUG$ may increase @DRUG$ absorption	DDI-false
The pharmacokinetics of @DRUG$ were not affected by coadministration of nifedipine or @DRUG$	DDI-false
@DRUG$ (tricyclic), atropine or other anticholinergic agents, or @DRUG$ Co-administration with arbutamine may lead to additive inotropic and/ or chronotropic effects.	DDI-false
Dopamine Antagonists : Since apomorphine is a dopamine agonist , it is possible that @DRUG$ , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or @DRUG$ , may diminish the effectiveness of APOKYN .	DDI-effect
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Digoxin, @DRUG$ and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , @DRUG$ Elevated plasma concentrations may occur when alprazom is co-administered with triazolam. @DRUG$ ;	DDI-mechanism
Standard monitoring of @DRUG$-related toxicity should be continued if @DRUG$ and methotrexate are administered concomitantly.	DDI-false
Plasma exposure of @DRUG$ (10 mg BID) was increased by 28% following administration of @DRUG$ (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of diazepam (10 mg BID) for 12 days.	DDI-mechanism
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Physiological changes resulting from smoking cessation, with or without nicotine replacement, may alter the pharmacokinetics of certain concomitant medications, such as @DRUG$ and @DRUG$.	DDI-false
Stavudine and @DRUG$ Ribavirin may antagonistise the antiviral activity of stavudine in vitro and @DRUG$ against HIV .	DDI-false
@DRUG$ In large quantities, the antiepileptic effect of @DRUG$ , phenytoin and primidone, and increase the frequency of seizures in susceptible paediatric patients.	DDI-effect
Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/@DRUG$-containing antacid products.	DDI-false
Digoxin, nimodipine and @DRUG$ : @DRUG$ has no significant pharmacokinetic interactions with digoxin and nimodipine , and losartan has no significant effect on plasma levels of bosentan .	DDI-false
To determine whether @DRUG$ has a direct effect on the distribution of cloxacillin, the elimination and distribution of @DRUG$ was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, @DRUG$, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Magnesium- and/or aluminum-containing antacids , products containing @DRUG$ ( @DRUG$ ) , multivitamin preparations containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin, warfarin, @DRUG$, @DRUG$ or amoxicillin.	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics , hypnotics and sedatives ( including @DRUG$ ) , or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
It may increase excretion of barbiturates , @DRUG$ , and ASA and may also increase the toxicity of @DRUG$.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Like ibogaine ( 40 mg/kg ) , 18-MC ( 40 mg/kg ) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and @DRUG$ in rats ;	DDI-false
HIV Protease Inhibitors: @DRUG$ (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase @DRUG$ plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants , @DRUG$ , @DRUG$ , barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic drugs, or other drugs that produce CNS depression.	DDI-false
@DRUG$: Coadministration of a single dose of @DRUG$ and promethazine (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
In clinical studies, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$ In a pharmacokinetic sub-study in patients with congestive heart failure receiving furosemide or digoxin starting treatment with FLOLAN, visible values for oral clearance of furosemide (n = 23) and @DRUG$ ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Since the concomitant administration of warfarin with @DRUG$ increases the prothrombin time by 100% after 3 to 4 days, the dose of the @DRUG$ should be reduced by one-third to one-half, and prothrombin times should be monitored closely.	DDI-false
Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including @DRUG$) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Other @DRUG$ Concomitant use of other @DRUG$ within 24 hours of treatment with AXERT is contraindicated.	DDI-false
@DRUG$ may add to or potentiate the therapeutic effect of other @DRUG$.	DDI-effect
The medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, @DRUG$ , Dapson, disulfiram, ethionamide, glutethimide, @DRUG$ , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Compounds that have been tested in man include antipyrine, @DRUG$, propranolol, theophylline, and @DRUG$ and no clinically meaningful interactions were found.	DDI-false
protein binding in vitro, @DRUG$ Influences minimally or not at all with the protein binding of @DRUG$ ( 20 % decrease in binding ) , tolbutamide , prednisolone ( 10 % decrease in binding ) , or warfarin .	DDI-mechanism
Therefore , concurrent use of @DRUG$ with @DRUG$ may render these contraceptives less effective .	DDI-effect
Other CONCOMITANT THERAPY: Although specific interaction studies have not been performed, in clinical studies cerivastatin sodium was used together with angiotensin converting enzyme ( ACE) inhibitors, beta-blockers, calcium channel blockers, @DRUG$ , and nonsteroidal anti-inflammatory drugs ( @DRUG$ ) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
- Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$ , @DRUG$ In vitro sulfamethoxazole does not affect the protein binding of diclofenac in human serum.	DDI-false
Drug/Laboratory Test Interaction @DRUG$ may cause a false low measurement of serum @DRUG$ levels with the Digi- Tab  RIA Kit for Digoxin.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, acetylsalicylic acid, @DRUG$, and digoxin, nor the pharmacokinetics of @DRUG$ at steady state.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
In a Phase I trial using escalating doses of @DRUG$ ( 110 - 200 mg/m2) and @DRUG$ ( 50 or 75 mg/m2 ) given as sequential infusions , myelosuppression was more profound when TAXOL was given after cisplatin than with the alternate sequence ( ie , TAXOL before cisplatin ) .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
Medicines not administered with VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ @DRUG$ Triazolam GI motility agent: cisapride	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines @DRUG$ Triazolam GI motility agent : @DRUG$	DDI-false
@DRUG$ caused a statistically significant increase in plasma exposures of @DRUG$ and S-warfarin ( 12 % and 15 % , respectively ) , and in the pharmacodynamic effects ( prothrombin time , measured as INR ) of warfarin .	DDI-mechanism
Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	DDI-false
Other cardiovascular agents: Enalapril and Enalapril IV were associated with beta-adrenergic blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$ , @DRUG$ And digoxin without evidence of clinically significant adverse interactions.	DDI-false
Coadministration of @DRUG$ and cyclosporine , @DRUG$ Digoxin has led to increased plasma concentrations of the last three drugs.	DDI-mechanism
Digoxin, nimodipine and losartan: bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine , and @DRUG$ It has no significant influence on bosentan plasma levels.	DDI-false
Coadministration of @DRUG$ with doses higher than 40 mg @DRUG$ (e.g., 40 mg BID) have not been studied.	DDI-false
Other Chemotherapy Agents In a separate study , concomitant administration of @DRUG$ with @DRUG$ The pharmacokinetics of an active substance (or metabolites of capecitabine) were not significantly altered.	DDI-false
While all selective serotonin reuptake inhibitors ( SSRIs), e.g. fluoxetine, @DRUG$ , paroxetine , and @DRUG$ , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
@DRUG$ , Methotrexate , @DRUG$ : Diclofenac , like other NSAIDs , may affect renal prostaglandins and increase the toxicity of certain drugs .	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and Lodine  (etodolac capsules and tablets) results in reduced protein binding of @DRUG$, but there was no change in the clearance of free warfarin.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein-bound, @DRUG$ , @DRUG$ Chloramphenicol, probenecid, coumarine, monoamine oxidase inhibitors and beta-adrenergic blockers.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , @DRUG$ , and Prednisone with @DRUG$ plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs ( AEDs ) : Phenytoin : @DRUG$ There was no effect on steady-state plasma concentrations of @DRUG$ In patients with epilepsy.	DDI-false
Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of @DRUG$ , potentially leading to increased plasma levels of @DRUG$.	DDI-false
Reports in the literature suggest that plasma levels of @DRUG$ (and its active metabolite @DRUG$) may be increased when paclitaxel and doxorubicin are used in combination.	DDI-false
Skeletal muscle relaxants, nondepolarizing (e.g., @DRUG$): possible increased responsiveness to the @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$ , clindamycin, colist, and @DRUG$ ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$ Acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, heart nitrates, @DRUG$ , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
The effect of benzodiazepines can be enhanced by anticonvulsants, antihistamines, alcohol, barbiturates, @DRUG$ , narcotics , @DRUG$ , psychotropic drugs, or other medicines that produce CNS depression.	DDI-false
The effects of mixing @DRUG$ with @DRUG$ Animal or insulin preparations from other manufacturers have not been studied.	DDI-false
Because Nalfon has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of Nalfon , the concomitant use of Nalfon and @DRUG$ is not recommended .	DDI-false
Erythromycin Co-administration of @DRUG$ (@DRUG$) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.	DDI-false
Drug-Drug Interactions Between @DRUG$  And Other Antiepileptic Drugs (@DRUG$) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
The data from in vitro studies with benzodiazepines other than alprazolam indicate a possible interaction of the following medicinal products: @DRUG$ , cyclosporine , amiodarone , nicardipine , and @DRUG$.	DDI-false
poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of @DRUG$ .	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, escitalopram, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Warfarin : Concomitant administration of @DRUG$ 6 mg/ kg once every 24 hours for 5 days) and @DRUG$ ( 25 mg single oral dose ) had no significant effect on the pharmacokinetics of either drug , and the INR was not significantly altered .	DDI-false
It has been reported that @DRUG$-related adverse reactions have been reported in patients on concomitant therapy with @DRUG$ and theophylline .	DDI-false
For this reason, the dose of the anticoagulant should be reduced by 30 - 50% at the start of treatment with @DRUG$ or @DRUG$ retard and then titrated according to the blood clotting parameters	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, triamterene, or amiloride), @DRUG$ supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Cholestyramine and colestipol resins: Absorption of @DRUG$ is impaired in the presence of @DRUG$.	DDI-mechanism
When @DRUG$, a potent inhibitor of CYP2D6, was co-administered with @DRUG$ at steady-state, exposure to either drug was not altered.	DDI-false
@DRUG$ Caution should also be exercised in other medicines (e.g. digitalis, glycoside) to sensitize myocardial disease to the effect of @DRUG$.	DDI-false
Concurrent administration of @DRUG$ Androgens and androgens may lead to increased serum levels of @DRUG$.	DDI-false
poor metabolizers of debrisoquin: Interactions of @DRUG$ with strong inhibitors of CYP2D6 (such as quinidine, @DRUG$, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
Although in clinical studies with IOPIDINE 0.5 % ophthalmic solution no specific drug interactions with topical glaucoma or systemic drugs have been identified, there is a possibility of additive or potentiating effects with CNS depressants ( @DRUG$ , barbiturates , @DRUG$ , sedatives , anesthetics ) should be considered .	DDI-false
Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving @DRUG$ 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving @DRUG$ alone.	DDI-false
Anticholinesterases ( neostgmine , physostigmine ) , lignocaine , @DRUG$ , @DRUG$ can enhance toxicity and cause cardio respiratory depression .	DDI-false
@DRUG$ Concomitant administration of warfarin and cerivastatin to healthy subjects resulted in concomitant administration of warfarin and cerivastatin to healthy subjects. @DRUG$ and placebo .	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or @DRUG$ The absorption of ciprofloxacin can be significantly reduced, resulting in significantly lower serum and urine levels than desired.	DDI-mechanism
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as @DRUG$, nevirapine, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of @DRUG$ should be considered	DDI-false
@DRUG$ may decrease the hemodynamic effects of @DRUG$ ;	DDI-effect
Ritonavir and @DRUG$: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of @DRUG$ were reduced by approximately 20%.	DDI-false
Drugs with a Narrow Therapeutic Index @DRUG$: Sonata (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of @DRUG$ (0.375 mg q24h for 8 days).	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, @DRUG$), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	DDI-false
Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)-A drug interaction study of @DRUG$ with an @DRUG$ has not been conducted.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between VIRACEPT and dapsone , trimethoprim/sulfamethoxazole , @DRUG$ , erythromycin , @DRUG$ or fluconazole .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO @DRUG$ INTOXICATION, PRIOR TO ADMINISTERING @DRUG$ TO A PATIENT ON PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL SHOULD BE OBTAINED.	DDI-false
@DRUG$: Concomitant administration of antacids may reduce plasma levels of @DRUG$.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , @DRUG$ , phenothiazines , monoamine oxidase ( MAO ) inhibitors , @DRUG$ Or some antihistamines.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Interaction of GABITRIL with Other Drugs : Cimetidine : Co-administration of @DRUG$ (800 mg/day) to patients taking @DRUG$ chronically had no effect on tiagabine pharmacokinetics.	DDI-false
@DRUG$: Concomitant administration of @DRUG$ with agents with b-blocking properties may potentiate blood-pressure- and heart-rate-lowering effects.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Patients receiving @DRUG$, @DRUG$, or sulfonylureas should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.	DDI-false
@DRUG$/prednisolone : @DRUG$ The pharmacokinetic effect of prednisolone or prednisone has not been clinically significantly affected.	DDI-false
@DRUG$ A change in serum levels of phenytoin (increased and decreased) has been reported in patients receiving @DRUG$ at the same time.	DDI-false
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (@DRUG$, thiothixene, @DRUG$).	DDI-false
Amiodarone taken concomitantly with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl @DRUG$ by 55% and 33%, respectively.	DDI-false
@DRUG$: The combination of @DRUG$, saquinavir, and ZDV has been studied (as triple combination) in adults.	DDI-false
@DRUG$-@DRUG$ can antagonize the effect of warfarin	DDI-false
- Anabolic steroids ( nandrolone [ e.g. , Anabolin ] , @DRUG$ [e.g. Anavar], oxymetholone [e.g., @DRUG$ ] , stanozolol [ e.g. , Winstrol ] ) or	DDI-false
@DRUG$ including tranylcypromine sulfate, @DRUG$, and pargyline HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-false
Omeprazole: The rate and extent of absorption of @DRUG$ was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/@DRUG$.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , @DRUG$/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and @DRUG$/phenobarbital .	DDI-false
@DRUG$: @DRUG$ concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with cimetidine (10 mg/kg/day) (n=7) compared with albendazole (20 mg/kg/day) alone (n=12).	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and cocaine and the oral self-administration of ethanol and nicotine in rats;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , @DRUG$ , doxorubicin , teniposide , and prednisone with vincristine plus @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
The interaction is a consequence of the hepatic-metabolism blocking of @DRUG$ by @DRUG$ , a highly potent CYP3A4 inhibitor , which also inhibits CYP2C9 .	DDI-mechanism
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of @DRUG$ with alprazolam increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
@DRUG$ and Tricyclic Antidepressants : FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ Because the effect of formoterol on the cardiovascular system can be enhanced by these active substances.	DDI-false
INOmax was co-administered with @DRUG$ , dopamine , dobutamine , @DRUG$ , surfactant , and high-frequency ventilation .	DDI-false
@DRUG$ : @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of cisapride , there is no effect on cisapride absorption when it is coadministered with ranitidine .	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , @DRUG$ , @DRUG$ Amphotericin B, cyclosporin, nonsteroidal anti-inflammatory drugs (e.g. ibuprofen), tacrolimus, vancomycin.	DDI-false
Anticholinesterases (neostgmine, physostigmine), @DRUG$, quinine, @DRUG$ can enhance toxicity and cause cardio respiratory depression.	DDI-false
Then, the effects of the metabotropic glutamate receptor ( mGluR ) agonists, DCG-IV and @DRUG$ To the above behavioral changes induced by @DRUG$ were found .	DDI-false
Beta-blocking Agents: The concomitant use of @DRUG$ and @DRUG$ has been well tolerated in patients with stable angina.	DDI-false
@DRUG$ : @DRUG$ Bepridil, flecainide, propafenone, quinidine CONTRAINDICATES due to the potential for serious and/or life-threatening reactions.	DDI-false
Caution should be exercised in patients receiving a high dose at the same time. @DRUG$ and @DRUG$ , as anorexia , tachypnea , lethargy and coma have been rarely reported due to a possible drug interaction .	DDI-advise
Other Drugs : Drugs such as @DRUG$ , disopyramide , procainamide , phenothiazines , @DRUG$ , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
ACE Inhibitors and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to @DRUG$ and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , @DRUG$ , @DRUG$ , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
@DRUG$ : @DRUG$ BID did not show a significant effect on the plasma exposure or renal clearance of methotrexate .	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
@DRUG$ and colestipol resins : Absorption of @DRUG$ In the presence of anionic exchange resins the effect is impaired.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
Close monitoring of the patient is recommended if: @DRUG$ Patients receiving catecholamine-degrading medicines, such as: @DRUG$ Because of the possible additive effects and the production of hypotension and/ or marks bradycardia, which can produce dizziness, syncope or postural hypotension.	DDI-advise
- @DRUG$ (e.g., @DRUG$, Synkayvite) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, 1 mg or more finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, heart nitrates, @DRUG$ H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs) and @DRUG$ Without evidence of clinically significant adverse interactions.	DDI-false
In patients taking @DRUG$ and lithium concomitantly, @DRUG$ toxicity may develop.	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and @DRUG$) is contraindicated .	DDI-false
Like ibogain ( 40 mg/kg), @DRUG$ ( 40 mg/kg ) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats ;	DDI-false
In addition, fondaparinux did not affect the pharmacodynamics of @DRUG$ , acetylsalicylic acid , @DRUG$ The pharmacokinetics of digoxin in steady state.	DDI-false
Effects of @DRUG$ on other Antiepilepsy Drugs (@DRUG$) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
â€¢ Drug interaction studies have shown that esomeprazole has no clinically significant interactions with phenytoin, @DRUG$ , @DRUG$ , clarithromycin or amoxicillin.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of @DRUG$ , phenytoin, propranolol, nifedipine, @DRUG$ Diazepam, certain tricyclic antidepressants, lidocaine, theophylline, and metronidazole, delaying the elimination and increase in blood levels of these drugs.	DDI-false
Potential drug interactions between Keppra  and other @DRUG$ (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
There was no significant difference in the pharmacodynamic effect of @DRUG$ administered alone and @DRUG$ administered with Lodine as measured by prothrombin time .	DDI-false
CNS-Active Drugs @DRUG$ : @DRUG$ 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance test and response time for 1 hour after ethanol administration and on the digit symbol substitution test ( DSST ), symbol copying test and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
Antiarrhythmics : Other @DRUG$ medicines such as quinidine, procainamide, @DRUG$ , and phenytoin , have been used concurrently with amiodarone .	DDI-false
The effect of benzodiazepines may be increased by anticonvulsants, @DRUG$ , alcohol , barbiturates , @DRUG$ Anaesthetics, phenothiazines, psychotropic drugs, or other drugs that produce CNS depression.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
Cimetidine) and many substrates for P450 2D6 (many other antidepressants, phenothiazines, and @DRUG$ @DRUG$ ==References====External links==	DDI-false
Concomitant administration of @DRUG$ doubled the AUC for @DRUG$.	DDI-mechanism
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, antiemetics, @DRUG$, @DRUG$).	DDI-false
The action of the @DRUG$ It may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$ , psychotropic medications , or other drugs that produce CNS depression .	DDI-effect
The effects of oral @DRUG$ on @DRUG$ induced hypertension were examined in conscious sheep.	DDI-false
@DRUG$-Concomitant intake of cholestyramine and vitamin K may reduce the absorption of @DRUG$.	DDI-false
( In some patients, the steroid may reduce the diuretic, natriuretic and blood pressure lowering effect of loop, @DRUG-DRUG$.	DDI-false
Insulin or Oral @DRUG$ : @DRUG$ may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics .	DDI-false
@DRUG$ : Atorvastatin had no clinically significant effect on prothrombin time when administered to patients receiving chronic @DRUG$ treatment .	DDI-false
Amprenavir significantly increased the area under the curve at steady state (AUC(ss)) of @DRUG$ by 2.93-fold and the AUC(ss) of @DRUG$ by 13.3-fold.	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
In addition , under the influence of sympatholytic medicinal products such as beta-blockers , @DRUG$ , guanethidine and @DRUG$ Signs of hypoglycaemia may be diminished or absent.	DDI-false
@DRUG$, tricyclic Amphetamines may enhance the activity of @DRUG$ or sympathomimetic agents;	DDI-false
The effects of ketamine and of @DRUG$ anesthesia on @DRUG$ tolerance in dogs.	DDI-false
Antiarrhythmics: Other @DRUG$ drugs, such as quinidine, procainamide, disopyramide, and phenytoin, have been used concurrently with @DRUG$.	DDI-false
Drug interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ - and ethanol cause additive CNS depression - @DRUG$ : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$/Acetaminophen: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or acetaminophen (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of @DRUG$ 1.5  g/kg/min. over 18 hours).	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with @DRUG$ plus bleomycin) without receiving antiretroviral therapy.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, @DRUG$), and such an effect may be anticipated with @DRUG$ as well.	DDI-mechanism
This seems to be the only clinically relevant interaction of this species with mefloquines, although theoretically, the concomitant use of other drugs is known to alter heart conduction (e.g., @DRUG$ - calcium channel blockers, antihistamines or H1-blockers, @DRUG$ and phenothiazines ) might also contribute to a prolongation of the QTc interval .	DDI-false
@DRUG$ including @DRUG$ , Phenelzinsulfate, and Pargylin HC1: Concurrent use of L-tyrosine and non-selective MAO inhibitors can cause high blood pressure.	DDI-false
Effect of Other Drugs on the Pharmacokinetics of @DRUG$: Literature reports suggest that ranitidine, an agent that decreases stomach acidity, does not greatly alter @DRUG$ pharmacokinetics.	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: @DRUG$ (e.g., gentamicin, amikacin), amphotericin B, cyclosporine, @DRUG$ drugs (e.g., ibuprofen), tacrolimus, vancomycin.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramide, @DRUG$ , fluoxetine , @DRUG$ Propoxyphene, salicylates, somatostatin analogue (e.g. octreotide), sulphonamide antibiotics.	DDI-false
- perhexiline hydrogen maleate or @DRUG$ Do not use with Bezalip or @DRUG$ (with hepatotoxic potential).	DDI-advise
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, @DRUG$, and quinidine.	DDI-advise
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as @DRUG$, phenobarbital, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., @DRUG$;	DDI-false
This appears to be the only clinically relevant interaction of this species with mefloquines, although theoretically the concomitant use of other medicinal products is known to alter the heart conduction (e.g. anti-arrhythmic or @DRUG$ , @DRUG$ Also antihistamines or H1-blockers, tricyclic antidepressants and phenothiazines could contribute to an extension of the QTc interval.	DDI-false
The effectiveness of Progestin-Only pills is reduced by hepatic enzyme-inducing drugs such as anticonvulsants @DRUG$ , carbamazepine , and barbiturates , and the antituberculosis drug @DRUG$.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, @DRUG$, leflunomide, sulfasalazine, and anakinra.	DDI-false
* Possible interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ ( @DRUG$ Clinical studies have not investigated saquinavir, indinavir and nelfinavir, which are substrates and/ or inhibitors of CYP3A4.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
aBased on reports of narcotic withdrawal syndrome in patients treated with nevirapine and @DRUG$ concurrently, and evidence of decreased plasma concentrations of @DRUG$.	DDI-false
It is important that patients understand how to @DRUG$   ( @DRUG$ ) capsules with the supplied AerolizerTM inhalation device and how it should be used in relation to other asthma or COPD medications they are taking .	DDI-false
Administering @DRUG$ together with @DRUG$ (100-500 microM) inhibited InsP(3)-induced responses (both Ca(2+) and current responses) in a dose-dependent fashion.	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (@DRUG$), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
A drug interaction study investigated the effect of the use of @DRUG$ 5 % gel in combination with double strength ( 160 mg/800 mg ) trimethoprim/sulfamethoxazole ( @DRUG$/SMX ).	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: @DRUG$ , NSAIDs , @DRUG$ TNF blockers, azathioprin, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine and anakinra.	DDI-false
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of @DRUG$ 1200mg) with @DRUG$ resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
If additional @DRUG$ are to be administered by any route, they should be used with caution because the pharmacologically predictable sympathetic effects of @DRUG$ may be potentiated.	DDI-advise
@DRUG$ (Phenytoin): Steady state plasma exposure (AUC) of @DRUG$ (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of phenytoin (a CYP 3A4 inducer).	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	DDI-false
Magnesium- and/or @DRUG$-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
While all the @DRUG$ (SSRIs), e.g., @DRUG$, escitalopram, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Concomitant cyclophosphamide , @DRUG$ , @DRUG$ , and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related , non-Hodgkin lymphoma .	DDI-false
Since animal studies suggest that the action of barbiturates may be prolonged by therapy with @DRUG$ , @DRUG$ , should be used with caution.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Because of its lack of platelet effects, @DRUG$ is not a substitute for @DRUG$ for cardiovascular prophylaxis.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving @DRUG$ (caution is recommended during coadministration with alprazolam): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of alprazolam by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Samplenecid : As with others @DRUG$ The renal excretion of Loracarbef is determined by: @DRUG$ and resulted in an approximate 80 % increase in the AUC for loracarbef .	DDI-mechanism
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , gentamicin , and @DRUG$ ) , amphotericin B , foscarnet , intravenous @DRUG$ , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-false
Benzthiazide may interact with alcohol , @DRUG$s , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , norepinephrine , NSAIDs like @DRUG$ or Ibuprofen , and high blood pressure medications .	DDI-false
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ Antacids or antacids of aluminium, sucralfat, VIDEX tablets, chewable/buffered tablets or pediatric powders or products which: @DRUG$ , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
These results would seem to dictate against the clinical use of methotrexate with @DRUG$, or during the period following @DRUG$ therapy when plasma asparagine levels are below normal.	DDI-false
@DRUG$ Diclofenac reduces renal clearance of lithium and increases clearance of Diclofenac. @DRUG$ plasma levels .	DDI-false
@DRUG$ (e. g., ketoconazole, miconazole, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
No significant drug-drug pharmacokinetic interactions have been found in interaction studies with hydrochlorothiazide , @DRUG$ , warfarin, cimetidine and @DRUG$.	DDI-false
Preliminary animal and human studies have shown that small quantities of systemically administered @DRUG$ enter the CSF primarily as 5-methyltetrahydro-folate and , in humans , remain 1 to 3 orders of magnitude lower than the usual @DRUG$ Concentrations after intrathecal administration.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines , thyroid products , estrogens , oral contraceptives , @DRUG$ , nicotinic acid , sympathomimet-ics , @DRUG$ , and isoniazid .	DDI-false
@DRUG$ The concomitant use of DURAGESIC ( @DRUG$ transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Other drug interactions cimetidine, @DRUG$ and @DRUG$ The pharmacokinetics of MHD have not been affected.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ (including @DRUG$), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$ , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , @DRUG$ , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the @DRUG$ propafenone and flecainide).	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, @DRUG$, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, opiates, @DRUG$, anesthetics) should be considered.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , @DRUG$ , cardiac @DRUG$ , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Acetaminophen/theophylline, @DRUG$/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/@DRUG$.	DDI-false
While all the @DRUG$ (SSRIs), e.g., citalopram, escitalopram, fluoxetine, @DRUG$, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, @DRUG$ , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , @DRUG$ Somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
In addition, results from regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance ( @DRUG$ Nevirapine, phenytoin, dexamethasone or @DRUG$ ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations .	DDI-false
@DRUG$ and @DRUG$	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$  and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with ENBREL  alone (0%).	DDI-effect
In clinical trials , FLOLAN was used with @DRUG$ In a pharmacokinetic sub-study in patients with heart failure receiving furosemide or digoxin starting treatment with FLOLAN, apparent values for oral clearance of furosemide (n = 23) and @DRUG$ ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
BACKGROUND : The effects of the combined administration of bombsin and verapamil hydrochloride (Verapamil ), a @DRUG$ , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ The label index for colorectal cancer (AOM) was examined on male Wistar rats.	DDI-false
Anticholinesterases (neostgmine, physostigmine), @DRUG$, @DRUG$, procainamide can enhance toxicity and cause cardio respiratory depression.	DDI-false
When @DRUG$ is taken concurrently with oral @DRUG$, attenuation of immunization cannot be excluded.	DDI-effect
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
- Mephenytoin (e.g., @DRUG$) Use of @DRUG$ with these medicines may increase the chance of side effects of these medicines	DDI-false
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-effect
Here we show that a combination of @DRUG$ or 3,7-dihydroxyflavone with @DRUG$ may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains .	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ generally should not be given with diuretics because they reduce @DRUG$s renal clearance and add a high risk of lithium toxicity.	DDI-false
The risk of myopathy during treatment with medicines in this class is increased with concomitant administration of cyclosporin, fibric acid derivatives, niacin (nicotinic acid), @DRUG$ , @DRUG$.	DDI-false
Potential differences in @DRUG$ dosing and pharmacokinetics at different levels of @DRUG$ exposure were assessed in the context of ANOVA.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( @DRUG$ , platelet inhibitors ( @DRUG$ NSAIDs (piroxicam) and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Cohort 1 then received amprenavir plus rifabutin for 10 days , and cohort 2 received @DRUG$ plus @DRUG$ For 4 days.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies ( @DRUG$ , valproate , oral contraceptive , @DRUG$ , warfarin , probenecid ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients .	DDI-false
@DRUG$ : As with other b-lactam antibiotics , renal excretion of loracarbef is inhibited by @DRUG$ and resulted in an approximate 80 % increase in the AUC for loracarbef .	DDI-false
CNS-Active Drugs @DRUG$: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after ethanol administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after @DRUG$ administration.	DDI-false
In the first study, concomitant administration of 0.2 mg @DRUG$ and 12 g cholestyramine resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing @DRUG$ alone.	DDI-false
These data suggest that levetiracetam is the plasma concentration of other @DRUG$ and that these @DRUG$ Do not affect the pharmacokinetics of levetiracetam.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
@DRUG$ and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to @DRUG$ and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
Although the specific drug interaction was not studied in a clinical trial, there were more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., @DRUG$ , @DRUG$ ) and NovoSeven .	DDI-false
Theophylline: As with some other @DRUG$, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
The effect of benzodiazepines can be enhanced by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$ , @DRUG$ , psychotropic medications , or other drugs that produce CNS depression .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
High-dose @DRUG$ resulting in concentrations above 2000 ng/mL administered with oral etoposide has led to an 80 % increase in @DRUG$ exposure with a 38 % decrease in total body clearance of etoposide compared to etoposide alone .	DDI-false
Potential pharmacokinetic interactions have been studied in clinical pharmacokinetic studies ( @DRUG$ , valproate , oral contraceptive , digoxin , warfarin , @DRUG$ ) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients .	DDI-false
Accordingly, careful patient monitoring and dose adjustment of @DRUG$ is recommended in patients concomitantly taking cephalexin and @DRUG$.	DDI-false
In addition, under the influence of sympatholytic medicinal products such as beta-blockers, @DRUG$, @DRUG$, and reserpine, the signs of hypoglycemia may be reduced or absent.	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and @DRUG$.	DDI-effect
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
@DRUG$ and indinavir : Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID @DRUG$ The Cmax and AUC of ritonavir were reduced by approximately 20%.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and antineoplastic agents, specifically, dacarbazine, @DRUG$, tamoxifen and interferon-alfa.	DDI-effect
Magnesium- and/or @DRUG$-containing @DRUG$ , products containing ferrous sulfate ( iron ) , multivitamin preparations containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for @DRUG$ (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
The effects of GABITRIL on other antiepilepsia drugs ( @DRUG$ Phenytoin : @DRUG$ This did not affect steady-state plasma concentrations of phenytoin in patients with epilepsy.	DDI-false
Valproate : The addition of tiagabine to patients taking @DRUG$ chronically had no effect on @DRUG$ The pharmacokinetics of valproate significantly reduced tiagabin binding in vitro from 96.3 to 94.8%, resulting in an increase of approximately 40% in free tiagabin concentrations.	DDI-false
Therapeutic concentrations of @DRUG$, warfarin, ibuprofen, @DRUG$, piroxicam, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
@DRUG$ : Diclofenac decreases @DRUG$ renal clearance and increases lithium plasma levels .	DDI-false
Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of @DRUG$ and @DRUG$.	DDI-false
Although no specific drug interactions with topical glaucoma or systemic drugs have been identified in clinical studies with IOPIDINE 0.5 % ophthalmic solution, there is a possibility of additive or potentiating effects with CNS depressants (alcohol, barbiturates, opiates, @DRUG$ , @DRUG$ ) should be considered.	DDI-false
Because there is a theoretical basis that these effects may be additive , use of @DRUG$-containing or ergot-type medications ( like dihydroergotamine or methysergide ) and @DRUG$ within 24 hours of each other should be avoided .	DDI-advise
poor metabolizers of debrisoquin: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, @DRUG$, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Amiodarone taken concomitantly with @DRUG$ for less than seven days increases plasma concentrations of procainamide and n-acetyl @DRUG$ by 55% and 33%, respectively.	DDI-false
Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
For example, inhibitors are azole antimycotics, @DRUG$ , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , @DRUG$ , protease inhibitors , quinidine , and verapamil .	DDI-false
@DRUG$ Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of R and @DRUG$.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , @DRUG$ , sulfonamides , @DRUG$ , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of felodipine with @DRUG$ resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of @DRUG$.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Ethinyl Estradiol and Norethindrone : Coadministration of @DRUG$ With OVCON-35, ethinylestradiol decreased by 47% and ethinylestradiol by 18%. @DRUG$ plasma concentrations .	DDI-false
@DRUG$ may interfere with the absorption of @DRUG$.	DDI-mechanism
There have been case reports of increased steady-state levels of quinidine, procainamide and @DRUG$ â€¢ during concomitant therapy with @DRUG$.	DDI-false
Repeated doses of colestipol hydrochloride given prior to a single dose of @DRUG$ in human trials have been reported to decrease @DRUG$ absorption .	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecolin - eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - @DRUG$ : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
d-amphetamine with @DRUG$ or protriptyline and possibly other @DRUG$ cause striking and sustained increases in the concentration of d-amphetamine in the brain ;	DDI-false
conversely , @DRUG$ Guanethidine may be antihypertensive medicines (i.e. guanethidine, @DRUG$ ) .	DDI-int
Vitamin A: Because of the relationship of Accutane to vitamin A, patients should be advised against taking @DRUG$ containing @DRUG$ to avoid additive toxic effects	DDI-false
The possibility of hypotensive effects with captopril can be minimized by either discontinuing the @DRUG$ or increasing the salt intake approximately one week prior to initiation of treatment with captopril (@DRUG$ tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	DDI-false
A direct causal relationship has not been established, but physicians should consider the possibility that @DRUG$ may alter a diabetic patient s response to insulin or oral @DRUG$.	DDI-effect
Lithium: Increased serum lithium levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant @DRUG$ and ACE inhibitor therapy.	DDI-false
When used concurrently with such drugs, the dose of @DRUG$ should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of @DRUG$.	DDI-false
Central nervous system depressants: Concomitant use of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$ , and @DRUG$ , respiratory depression, hypotension, and deep sedation, or possibly lead to coma or death.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , @DRUG$ , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine, and sodium colistimethate), magnesium salts, lithium, local anaesthetics, @DRUG$ ==References====External links==	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
Other concomitant therapy Although no specific interaction studies have been performed, clinical trials with 1 mg or more of finasteride doses have been conducted at the same time. @DRUG$ , acetylsalicylic acid , a-blockers , @DRUG$ Angiotensin converting enzymes (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also called NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ : In a study of young healthy male subjects no evidence of a direct pharmacokinetic captopril-@DRUG$ interaction could be found .	DDI-false
Because of changes in glucose concentrations with @DRUG$ Co-administration was within normal variability and individual glucose concentrations were above or close to 70 mg/ dl, dose adjustment for glyburide (5 mg QD and 10 mg twice daily) with: @DRUG$ Co-administration (up to 40 mg QD) is not indicated.	DDI-false
Nonsteroidal Anti-Inflammatory Drugs (@DRUG$)-A drug interaction study of @DRUG$ ==References====External links==	DDI-false
@DRUG$ : While studies have not shown diclofenac to interact with @DRUG$ , caution should be exercised , nonetheless , since interactions have been seen with other NSAIDs .	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
- @DRUG$: Lithium should generally not be given with @DRUG$ (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs Interactions : Flupentixol may interact with some drugs, such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - @DRUG$ Eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - tricyclic antidepressants : flupenthixol increases the effect of @DRUG$	DDI-false
It has been reported that inhibitors of endogenous prostaglandin synthesis are: @DRUG$ may reduce the antihypertensive effect of @DRUG$ , especially in cases of low renin hypertension.	DDI-effect
CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when @DRUG$ (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of @DRUG$ 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Example inhibitors include azole antifungals , @DRUG$ , clarithromycin , diclofenac , doxycycline , erythromycin , @DRUG$ , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Other CNS depressant drugs (e.g. barbiturates, @DRUG$, opioids and general @DRUG$) have additive or potentiating effects with INAPSINE.	DDI-false
In Europe , @DRUG$   was observed to occasionally intensify the effect of @DRUG$ - patients suffering from high blood pressure;	DDI-effect
@DRUG$ 500 mg twice daily did not modify the rate or extent of @DRUG$ absorption or its plasma clearance or urinary excretion.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain @DRUG$ , @DRUG$ Theophylline, and metronidazole, delaying the elimination and increase in blood levels of these drugs.	DDI-false
@DRUG$: Coadministration of ritonavir with @DRUG$ resulted in a 152% increase in nelfinavir plasma AUC and very little change in ritonavir plasma A.C.	DDI-false
The concomitant use of itraconazole with cyclosporin, @DRUG$ or @DRUG$ The plasma concentrations of the last three drugs have been increased.	DDI-false
H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of @DRUG$, there is no effect on @DRUG$ absorption when it is coadministered with ranitidine.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , @DRUG$ , nitrofurantoin, phenytoin, ribavirin and @DRUG$.	DDI-false
Lithium : Inhibition of the kidneys @DRUG$ Clearance resulting in an increase in plasma @DRUG$ concentration , has been reported with some prostaglandin synthesis-inhibiting drugs .	DDI-false
Before using this medicine, tell your doctor or pharmacist about all prescription and non-prescription products that you can use, especially: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$ , @DRUG$ Non-steroidal anti-inflammatory drugs (e.g. ibuprofen), tacrolimus, vancomycin.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for @DRUG$ therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-advise
- @DRUG$ : Lithium should generally not be given with @DRUG$ Bumetanid) because they reduce renal clearance and increase a high risk of lithium toxicity.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , gentamicin , and amikacin ) , amphotericin B , foscarnet , intravenous @DRUG$ , vancomycin, and @DRUG$ ] is contraindicated.	DDI-false
The absorption of tetracycline , @DRUG$ - penicillin G, hydrochlorothiazide and @DRUG$ When co-administered with colestipol hydrochloride, the dose was significantly reduced;	DDI-false
METHODS : From the beginning of the experiment , rats were given 10 weekly subcutaneous injections of AOM ( 7.4 mg/kg body weight ) and subcutaneous injections of @DRUG$ 40 Î¼g/kg body weight every other day and from week 16 intraperitoneal injections @DRUG$ 10 or 20 mg/kg body weight every other day until the end of the test at week 45.	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, @DRUG$, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: Because of the relationship of @DRUG$ to vitamin A, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-mechanism
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Phenytoin: In post-marketing experience, there have been reports of both increases and decreases in @DRUG$ levels with @DRUG$ co-administration, leading to alterations in seizure control.	DDI-mechanism
Drugs which inhibit CYP 3A4 ( e.g. , @DRUG$ Macrolide antibiotics such as erythromycin) have the potential to lead to increased plasma concentrations of @DRUG$.	DDI-mechanism
Cyclosporine, Digoxin, Methotrexate @DRUG$, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, digoxin, @DRUG$, and increased toxicity.	DDI-mechanism
These drugs include the @DRUG$ And other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$ , calcium channel block drugs, and isoniazid.	DDI-false
however , 150 mg of ranitidine q12h for 3 days increased the @DRUG$ C max by 23 % and @DRUG$ AUC by 16%.	DDI-false
These drugs include the @DRUG$ and other @DRUG$ , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
In interaction studies with hydrochlorothiazide, digoxin, no significant pharmacokinetic (or pharmacodynamic) interactions were found. @DRUG$ , and @DRUG$.	DDI-false
Psychoactive Drugs: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (@DRUG$, @DRUG$, alprazolam).	DDI-false
However, since there is an increased risk of bleeding with @DRUG$, caution should be employed when @DRUG$ is used with other drugs that affect hemostasis.	DDI-false
Rifampin significantly decreased the AUC(ss ) of @DRUG$ 82%, but @DRUG$ had no effect on rifampin pharmacokinetics .	DDI-false
@DRUG$ Simultaneous administration of a low dose @DRUG$ with VIOXX may result in an increased rate of GI ulceration or other complications , compared to use of VIOXX alone .	DDI-false
@DRUG$ (neostgmine, @DRUG$), lignocaine, quinine, procainamide can enhance toxicity and cause cardio respiratory depression.	DDI-false
@DRUG$ (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
In addition, results from regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance ( @DRUG$ , nevirapine , @DRUG$ CANCIDAS may lead to clinically significant reductions in caspofungin concentrations.	DDI-false
Bacteriostatic Antibiotics : @DRUG$ Erythromycins, sulphonamides, or @DRUG$ The bactericidal effect of penicillins may be impaired.	DDI-false
The conversion of @DRUG$ to @DRUG$ is catalyzed by aldehyde oxidase.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, @DRUG$ Doses of 1 mg or more have been associated with acetaminophene, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, @DRUG$ , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or fluconazole.	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with aspirin alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and @DRUG$ is not recommended.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
@DRUG$: Meclofenamate sodium enhances the effect of @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( @DRUG$ ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
No significant pharmacokinetic (or pharmacodynamic) interactions have been observed in interaction studies with: @DRUG$ , @DRUG$ , warfarin , and nifedipine .	DDI-false
Central nervous system depressants : Co-administration of @DRUG$   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other @DRUG$ Anaesthetics, hypnosis, tranquilizers (e.g. benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants and alcohol may cause respiratory depression, hypotension and deep sedation, or possibly lead to coma or death.	DDI-effect
@DRUG$ Congestive Heart Failure Post-myocardial infarction In EPHESUS, 3020 (91%) patients who: @DRUG$ ACE inhibitors or angiotensin II receptor antagonists (ACEI/ ARB) were also administered 25 to 50 mg.	DDI-false
- Poor metabolites of schuttoquine : interactions of schnitztilol with strong inhibitors of CYP2D6 (such as quinidine, fluoxetine, @DRUG$ , and @DRUG$ ) have not been studied , but these drugs would be expected to increase blood levels of the R(+ ) enantiomer of carvedilol .	DDI-false
The doctor is recommended to maintain plasma concentrations of @DRUG$ when any of these drugs is taken concurrently , and to increase the dose of @DRUG$ if necessary .	DDI-false
@DRUG$ : Since apomorphine is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( @DRUG$ , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, @DRUG$, troleandomycin, ritonavir, nelfinavir) would be expected to behave similarly.	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Benzthiazide may interact with @DRUG$ , blood thinners , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , norepinephrine , NSAIDs like @DRUG$ Or ibuprofen, and high blood pressure medications.	DDI-false
Anticoagulant inhibition was observed during the administration of @DRUG$, secobarbital and @DRUG$;	DDI-false
@DRUG$ : The potential for pharmacokinetic drug-drug interactions between @DRUG$ And other agents have not been formally investigated.	DDI-false
@DRUG$: Gastrointestinal acidifying agents (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
- antiacid, clarithromycin, didanosine, fluconazole, fluoxetine, indanavir, ketoconazole, @DRUG$ , Phenobarbitol , carbamazepine , Rifabutin , @DRUG$ , Ritanovir , Saquinavir .	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , @DRUG$ , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving @DRUG$ therapy .	DDI-false
The following eight target drug/added drug combinations were studied: @DRUG$/@DRUG$.	DDI-false
Although neither dexamethasone nor @DRUG$ Influenced the proliferation of prostate epithelium in RPMI1640 with transferrin alone, modifying the mitogenic effect of EGF and @DRUG$.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
Drug-Drug Interactions Between Keppra  And Other @DRUG$ (@DRUG$) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , @DRUG$ , calcium channel blockers, diuretics, and @DRUG$ ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and @DRUG$ ) , magnesium salts , @DRUG$ , local anesthetics, procainamide, and quinidine.	DDI-false
- Carbamazepine : Isoniazid is known to slow down metabolism @DRUG$ Increases and increases serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of carbamazepine toxicity should be monitored closely , and appropriate dosage adjustment of the anticonvulsant should be made .	DDI-false
Acetaminophen , @DRUG$ , phenobarbital , @DRUG$ , theophylline , and valproic acid were added to pooled human serum at therapeutic concentrations .	DDI-false
@DRUG$: Potential interactions between @DRUG$ and other AEDs were assessed in clinical studies.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other drug interactions @DRUG$, erythromycin and @DRUG$ had no effect on the pharmacokinetics of MHD.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$ , chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, @DRUG$ , ribavirin , and vincristine .	DDI-false
Intravenous Adenocard (@DRUG$) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, beta-adrenergic blocking agents, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Oral @DRUG$ CAUTION SHOULD BE EXERCISED WHEN COUMARIN ANTICOAGULANTS ARE GIVEN IN CONJUNCTION WITH @DRUG$.	DDI-false
Hepatic Enzyme Inducers , Inhibitors and Substrates : Drugs which induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity ( e.g. , @DRUG$ , phenytoin, carbamazepine, rifampin) may improve the metabolism of corticosteroids and require that the dosage of @DRUG$ be increased .	DDI-false
@DRUG$ "Powers the muscle relaxant effect of all @DRUG$ MAC (minimum alveolar concentration) is reduced by the concomitant use of N 2O.	DDI-effect
This drug may interact with @DRUG$ - or other CNS depressants (may increase the CNS depressive effect of these drugs or antihistamines), @DRUG$ â€¢ or other medicines with anticholinergic activity (anticholinergic effects can be intensified if these drugs are used simultaneously with antihistamines), and monoamine oxidase (MAO) inhibitors ( concomitant use with antihistamines can prolong and increase the anticholinergic and CNS depressive effects of antihistamines.	DDI-false
However, patients on digoxin may show elevations of @DRUG$ concentrations after initiation of therapy with FLOLAN, which may be clinically significant in patients prone to @DRUG$ toxicity.	DDI-false
Patients who begin taking diclofenac or who increase their @DRUG$ dose or any other NSAID while taking @DRUG$, methotrexate, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-false
Aspirin, warfarin, @DRUG$ , @DRUG$	DDI-false
When other @DRUG$ or @DRUG$ are used concomitantly , there is the potential for FLOLAN to increase the risk of bleeding .	DDI-false
The hypoglycaemic effect of sulphonylureas may be caused by certain medicinal products, including: @DRUG$ and other drugs that are highly protein bound , salicylates , sulfonamides , chloramphenicol , probenecid , @DRUG$ , monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-false
Because there are no data on the compatibility of @DRUG$ and crystalline @DRUG$ preparations, NovoLog should not be mixed with these preparations.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , @DRUG$ , @DRUG$ drugs ( e.g. , ibuprofen ) , tacrolimus , vancomycin .	DDI-false
Data from in vitro studies of @DRUG$ other than @DRUG$ Ergotamine, cyclosporin, amiodarone, nicardipine and nifedipine.	DDI-false
@DRUG$ : Increased activity of both @DRUG$ and corticosteroids may occur when the two are used concurrently .	DDI-false
@DRUG$ and Corticotropin (@DRUG$): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.	DDI-false
Serial plasma and urine samples for the measurement of amprenavir, rifabutin and @DRUG$ and their @DRUG$ , were measured by high-performance liquid chromatography .	DDI-false
Benzthiazide can be used with @DRUG$ - blood thinners, decongestant medications (allergic agents, colds, and sinus drugs), diabetes medications, @DRUG$ , norepinephrine, NSAIDs such as aleve or ibuprofen, and high blood pressure medications.	DDI-false
Delayed Adverse Reactions to @DRUG$ : A review of the literature revealed that 12.6 % ( range 11 - 28 % ) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered radiographic iodinated contrast media experienced acute , atypical adverse reactions .	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium @DRUG$ , @DRUG$ , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Antiacid , clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , @DRUG$ , Phenobarbitol , carbamazepine , @DRUG$ , rifampin, ritanovir, saquinavir.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with @DRUG$ or Innovar than with @DRUG$.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with @DRUG$ should be premedicated with corticosteroids (such as dexamethasone), diphen-hydramine and H2 antagonists (such as cimetidine or @DRUG$).	DDI-false
@DRUG$ : It has not been established if there is a pharmacokinetic interaction between acitretin and @DRUG$.	DDI-false
Magnesium- and/or aluminum-containing @DRUG$ Products containing iron sulphate ( @DRUG$ Videx (didanosine) chewable tablets or the oral pediatric powder should not be taken within 3 hours before or 2 hours after FACTIV.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and @DRUG$, cardiac glycosides and @DRUG$.	DDI-false
In vitro data suggest that itraconazole , when compared to @DRUG$ It has a less pronounced effect on the biotransformation system responsible for the metabolism of @DRUG$.	DDI-false
Cyclosporin, digoxin, methotrexate @DRUG$ , like other @DRUG$ By effects on renal prostaglandins, changes in the elimination of these drugs can lead to increased serum levels of cyclosporin, digoxin, methotrexate, and increased toxicity.	DDI-false
Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating @DRUG$ and @DRUG$, respectively.	DDI-false
Antiacid , clarithromycin , @DRUG$ , Fluconazole , Fluoxetine , Indanavir , @DRUG$ , phenytoin, phenobarbitol, carbamazepine, rifabutin, rifampin, ritanovir, saquinavir.	DDI-false
Short-term pharmacokinetic studies have shown that concomitant use of warfarin and lodine ( @DRUG$ capsules and tablets ) results in reduced protein binding of @DRUG$ However, there was no change in the release of free warfarin.	DDI-false
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, terfenadine antimigrain: ergot derivatives antimycobacterial agents: rifampin benzodiazepines @DRUG$ , @DRUG$ GI motility agents : cisapride	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and @DRUG$ such as @DRUG$ (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the @DRUG$ propafenone and flecainide).	DDI-false
Therefore, concurrent use of @DRUG$ with hormonal contraceptives may render these @DRUG$ less effective.	DDI-false
If you take digoxin while taking it @DRUG$ , higher doses of @DRUG$ It may be necessary.	DDI-false
@DRUG$ : Ephedrine may enhance the metabolic clearance of @DRUG$ The result was reduced blood levels and decreased physiological activity, resulting in an increase in corticosteroid dosage.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ It is administered concomitantly with other antimuscarinics, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-effect
@DRUG$ Amiodarone should be used with caution in patients who are receptor blockers (e.g. propranolol, CYP3A4 inhibitor) or calcium channel antagonists (e.g. @DRUG$ , a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and L-CCG-1, on the above behavioral changes induced by @DRUG$ were found.	DDI-false
Methotrexate : In an interaction study with rheumatoid arthritis patients @DRUG$ CELEBREX had no significant effect on the pharmacokinetics of @DRUG$.	DDI-false
Coadministration of valdecoxib and @DRUG$ 1/35  increased the exposure of @DRUG$ and ethinyl estradiol by 20% and 34%, respectively.	DDI-false
In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$ and @DRUG$ therapy, a 7% rate of serious infections was observed, which was higher than that observed with etanercept alone (0%).	DDI-effect
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Benzthiazide can interact with alcohol, @DRUG$s, decongestant medications (allergic, cold, and sinus drugs), diabetes medications, @DRUG$ , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications .	DDI-false
because of this, the dosage of @DRUG$ should be adjusted when these @DRUG$ are administered concomitantly.	DDI-false
Multivitamins, or other products containing @DRUG$ or zinc, @DRUG$ or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin.	DDI-false
- medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, @DRUG$ Antihistamines : astemizole , terfenadine Antimigraine : @DRUG$ Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients who are receptor blockers (e.g. propranolol, CYP3A4 inhibitor) or calcium channel antagonists (e.g. @DRUG$ , a CYP3A4 substrate and @DRUG$ , a CYP3A4 inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam ( caution is recommended during coadministration with alprazolam ): Coadministration of fluoxetine with @DRUG$ increased the maximum plasma concentration of @DRUG$ by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .	DDI-false
Veratrum alkaloids: @DRUG$ inhibit the hypotensive effect of @DRUG$.	DDI-effect
Ritonavir ( 600 mg b.i.d . ) co-administered with @DRUG$ 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in @DRUG$ Cmax .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , @DRUG$ , and @DRUG$ , magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, @DRUG$, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and @DRUG$.	DDI-false
@DRUG$ : Since bile acid sequestrants may bind other drugs given concurrently , patients should take @DRUG$ at least 1 hour before or 4 - 6 hours after a bile acid binding resin to avoid impeding its absorption .	DDI-false
@DRUG$: Ephedrine may enhance the metabolic clearance of @DRUG$, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in corticosteroid dosage.	DDI-false
@DRUG$ ( increases bioavailability by 50% ), @DRUG$ , and valproates .	DDI-false
@DRUG$ ( such as @DRUG$ ) ;	DDI-false
Cardiovascular diseases : Cardiovascular glycoside disorders : In patients who have @DRUG$ therapy , administration of oral @DRUG$ This regularly leads to an increase in digoxin serum concentration, which can reach toxic concentrations with resulting clinical toxicity.	DDI-false
However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of @DRUG$ (@DRUG$ , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state theophylline peak serum levels with the 800 mg h.s. regimen, particularly in subjects aged 54 years and older.	DDI-false
In patients taking diclofenac and @DRUG$ concomitantly, @DRUG$ toxicity may develop.	DDI-false
Therapeutic concentrations of digoxin, warfarin, @DRUG$, naproxen, piroxicam, @DRUG$, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of @DRUG$ needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$.	DDI-false
Since @DRUG$ is primarily eliminated by the kidneys, coadministration of @DRUG$ with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either entecavir or the coadministered drug.	DDI-false
@DRUG$ Hallucinations have been reported when TORADOL has been used in patients receiving psychoactive medicinal products ( @DRUG$ ==References====External links==	DDI-false
@DRUG$: The concomitant use of @DRUG$ and beta-blocking agents has been well tolerated in patients with stable angina.	DDI-false
In addition , Fondaparinux neither influenced the pharmacodynamics of @DRUG$ - acetylsalicylic acid, piroxicam and @DRUG$ The pharmacokinetics of digoxin in steady state.	DDI-false
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
@DRUG$ has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of @DRUG$.	DDI-effect
The superiority of @DRUG$ over @DRUG$-based regimens has been observed in comparative data in a subset of patients with high viral loads.	DDI-false
The results of the studies in patients with multiple sclerosis who: @DRUG$ Interferon beta-1a (AVONEX 30 mcg IM once weekly) or glatiramer acetate were not consistent with the need for dose adjustment. @DRUG$ or glatiramer acetate .	DDI-false
@DRUG$: Haloperidol blocks dopamine receptors, thus inhibiting the central stimulant effects of @DRUG$.	DDI-false
Acetaminophen: A report of severe @DRUG$ toxicity was reported in a patient receiving @DRUG$.	DDI-effect
It differs structurally from the other currently available @DRUG$ ( lovastatin , simvastatin , and @DRUG$ ) , leading to unique biopharmaceutical properties relative to the other agents of this class .	DDI-false
@DRUG$: Diclofenac and other @DRUG$ can inhibit the activity of diuretics.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (@DRUG$), @DRUG$ (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$ generally should not be given with diuretics because they reduce lithiums renal clearance and add a high risk of @DRUG$ toxicity .	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of zidovudine, although it significantly decreased the @DRUG$ tmax by 44% and increased the intracellular exposure to phosphorylated zidovudine by 110%.	DDI-mechanism
Dopamine antagonists : since @DRUG$ is a dopamine agonist , it is possible that dopamine antagonists , such as the @DRUG$ - (Phenothiazine, butyrophenone, thioxanthene) or metoclopramide, may reduce the efficacy of APOKYN.	DDI-false
â€¢ Dopamine antagonists : Since apomorphine is a dopamine agonist, it is possible that @DRUG$ , such as neuroleptics (phenothiazine, butyrophenone, @DRUG$ ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
Sine bradycardia was associated with oral amiodarone in combination with @DRUG$ ( @DRUG$ ==References====External links==	DDI-false
Cholestyramine-Concomitant intake of @DRUG$ and vitamin K may reduce the absorption of @DRUG$.	DDI-false
The @DRUG$ study dosed subjects with 1200 mg/day of azithromycin (n = 7) (later changed to 600 mg/day [n = 5]) for Days 8 to 21 of a 21-day course of 100 mg, five times/day of @DRUG$.	DDI-false
Vitamin A: Because of the relationship of @DRUG$ to @DRUG$, patients should be advised against taking vitamin supplements containing vitamin A to avoid additive toxic effects	DDI-effect
- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	DDI-false
Ethopropazine may interact with @DRUG$ or other @DRUG$, causing increased sedative effects.	DDI-false
@DRUG$ : When multiple doses of atorvastatin and @DRUG$ were coadministered , steady-state plasma digoxin concentrations increased by approximately 20 % .	DDI-false
Urinary acidifying agents ( @DRUG$ , @DRUG$ , etc . ) increase the concentration of the ionized species of the amphetamine molecule , thereby increasing urinary excretion .	DDI-false
Particular caution should be observed with @DRUG$ since there are conflicting results for the effect of @DRUG$ on the availability of digoxin and digitoxin.	DDI-effect
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, phenytoin, dexamethasone, or @DRUG$) with CANCIDAS may result in clinically meaningful reductions in @DRUG$ concentrations.	DDI-false
@DRUG$, Methotrexate, Cyclosporine: @DRUG$, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
It has been reported that results of studies in animals indicate that @DRUG$-induced ventricular arrhythmias during anesthesia can be reversed by @DRUG$.	DDI-effect
Binding to plasma protein is not significantly altered by diazepam , @DRUG$ , or @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
May interact with the following: @DRUG$, @DRUG$ (use with thiazide diuretics may prevent the diuretic from working properly;	DDI-false
Patients who have other narcotic analgesics, general anesthetics, phenothiazine, sedatives, sedative hypnotics, @DRUG$ or other CNS depressants ( including @DRUG$ DILAUDID can be combined with an additive CNS depression.	DDI-false
@DRUG$: The concomitant administration of @DRUG$ and sulindac in normal volunteers resulted in lowering of the plasma levels of the active sulindac sulfide metabolite by approximately one-third.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with @DRUG$;	DDI-mechanism
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, @DRUG$ , @DRUG$ Imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Insulin or Oral Hypoglycemics : Agents with b-blocking properties may enhance the blood-sugar-reducing effect of @DRUG$ and oral @DRUG$.	DDI-false
Benzylpenicillin, @DRUG$, oxacillin, chlortetracycline, doxycycline, cephalothin, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
CONCLUSIONS : @DRUG$ Inhibition of the metabolism of HMG-CoA reductase inhibitors metabolised by CYP3A4 (i.e. atorvastatin, cerivastatin, @DRUG$ ==References====External links==	DDI-mechanism
Drugs That Induce CYP3A4 (@DRUG$) Racemic @DRUG$ exposure was decreased 80% by concomitant useof rifampicin, a potent inducer of CYP3A4.	DDI-false
oral contraceptives: valdecoxib ( 40 mg twice daily) did not lead to metabolism of the oral combination @DRUG$ norethindrone/@DRUG$ ( 1 mg /35 mcg combination , Ortho-Novum 1/35 ) .	DDI-false
The risk of myopathy during treatment with medicines in this class is increased when cyclosporin is co-administered. @DRUG$ , niacin ( nicotinic acid ) , erythromycin , @DRUG$.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Additional reductions in blood pressure may occur when FLOLAN is administered with @DRUG$, @DRUG$, or other vasodilators.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$ is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4 , such as lovastatin and @DRUG$.	DDI-mechanism
Drug Interactions : Flupenthixol may interact with some drugs , like @DRUG$ ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : @DRUG$ - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
- When @DRUG$ Bezalip retard or bezalip retard is used concomitantly with anion exchange resins (e.g. cholestryramine), a distance of at least 2 hours should be maintained between the two medicinal products as the absorption of bezalip or @DRUG$ is impaired	DDI-false
Erythromycin: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of @DRUG$ and @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-mechanism
Antidepressants (tricyclic), atropine or other anticholinergic agents, or @DRUG$: concurrent use with @DRUG$ may produce additive inotropic and/or chronotropic effects.	DDI-false
The medicinal products associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$ , nitrofurantoin , @DRUG$ Ribavirin and vincristine.	DDI-false
Plasma valproate concentration should be monitored when @DRUG$ and @DRUG$ are co administered , and appropriate dosage adjustments of valproate should be made .	DDI-advise
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ deficiency due to an insufficient @DRUG$ The intake, which requires only oral physiological supplement and magnesium deficiency, related to a dysregulation of the control mechanisms of magnesium status, which requires more or less specific regulation of its causal dysregulation.	DDI-false
The absorption of @DRUG$ , furosemide , @DRUG$ â€¢ hydrochlorothiazide and gemfibrozil were significantly decreased when co-administered with colestipol hydrochloride;	DDI-false
@DRUG$ : In healthy individuals , plasma concentrations of atorvastatin increased approximately 40 % with coadministration of atorvastatin and @DRUG$ A known inhibitor of cytochrome P450 3A4.	DDI-false
@DRUG$ and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension , the addition of INSPRA 50 to 100 mg to @DRUG$ and angiotensin II receptor antagonists increased mean serum potassium slightly ( about 0.09 - 0.13 mEq/L ) .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Digoxin and @DRUG$ use may be rarely associated with ventricular fibrillation when combined with @DRUG$.	DDI-effect
@DRUG$ or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral @DRUG$.	DDI-false
Coingestion of @DRUG$ with @DRUG$, phenobarbital with acetaminophen, and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug.	DDI-effect
Oral @DRUG$ : Valdecoxib ( 40 mg BID ) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol ( 1 mg /35 mcg combination , @DRUG$ 1/35 ) .	DDI-false
Co-administration of @DRUG$ Acamprosate showed a 25% increase in AUC and a 33% increase in Cmax of @DRUG$.	DDI-false
In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated @DRUG$ plus VIOXX 25 mg daily, as compared to those taking @DRUG$ 2400 mg daily alone.	DDI-false
A direct causal relationship has not been established, but physicians should consider the possibility that @DRUG$ may alter a diabetic patient s response to @DRUG$ or oral hypoglycemic agents.	DDI-effect
@DRUG$ or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as @DRUG$.	DDI-effect
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
In view of the long and variable half-life of @DRUG$, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of @DRUG$.	DDI-false
In rats, simultaneous ingestion of disulfiram and @DRUG$ in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that @DRUG$ may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.	DDI-false
Tetracyclines : Concomitant treatment with @DRUG$ The use of Accutane has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which are associated with concomitant use of @DRUG$	DDI-false
@DRUG$ , Including Oral , Injectable , Transdermal , and Implantable @DRUG$ : An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and ethinyl estradiol levels of 14 % and 31 % , respectively .	DDI-false
The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	DDI-false
CONCLUSIONS: Macrolid antibiotics inhibit the metabolism of HMG-CoA reductase inhibitors metabolised by CYP3A4 (i.e. atorvastatin, @DRUG$ , @DRUG$ ==References====External links==	DDI-false
@DRUG$: Coadministration of a single dose of @DRUG$ 20 mg and paroxetine 20 mg daily for 7 days did not produce any interaction on psychomotor performance.	DDI-false
Although the occurrence of Cefizox has not been reported, nephrotoxicity has been reported after concomitant use with other medicinal products. @DRUG$ and @DRUG$.	DDI-effect
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (acetylsalicylic acid), @DRUG$ (piroxicam), and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
@DRUG$-induced renal and mesenteric vasodilation is not antagonized by either @DRUG$.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a @DRUG$ inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , @DRUG$ , hydralazine , iodoquinol , isoniazid , @DRUG$ , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Warfarin: The effect of @DRUG$ on the anticoagulant effect of @DRUG$ (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.	DDI-false
@DRUG$ : Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ or its epoxide metabolite in patients with epilepsy .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of @DRUG$, fibric acid derivatives, @DRUG$ (nicotinic acid), erythromycin, azole antifungals.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Carbamazepine : @DRUG$ It is known that the metabolism of carbamazepine is slowed and its serum levels increased Carbamazepine should be determined prior to co-administration with isoniazid, signs and symptoms of carbamazepine toxicity should be closely monitored and appropriate dose adjustment of the @DRUG$ It should be done.	DDI-false
Curariform muscle relaxants (e.g. tubocurarin) and other medicines, including ethers, @DRUG$ , @DRUG$ , decamethonium and sodium citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral .	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, @DRUG$, higher @DRUG$ and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , @DRUG$ , and @DRUG$.	DDI-false
Co-administration of valdecoxib ( 40 mg twice daily ( day 1 ) and 40 mg twice daily ( days 2 - 7 ) with glyburide ( 10 mg) @DRUG$ BID) resulted in a 21% increase in the AUC of glyburide and an 16% increase in AUC. @DRUG$ Cmax leading to a 16 % decrease in glucose AUC0 - 24 .	DDI-false
Strong inducers of cytochrome P450 enzymes (i.e. @DRUG$, phenytoin and @DRUG$) have been shown to decrease the plasma levels of MHD (29-40%).	DDI-false
The risk of use @DRUG$ in combination with other drugs has not been systematically evaluated , but @DRUG$ The side effects of bromocliptin mesylate may be increased.	DDI-false
CANCIDAS reduced the blood AUC0 - 12 of tacrolimus by approximately 20 % , peak blood concentration ( Cmax ) by 16 % , and 12-hour blood concentration ( C12hr ) by 26 % in healthy subjects when @DRUG$ ( 2 doses of 0.1 mg/kg 12 hours apart ) was administered on the 10th day of @DRUG$ 70 mg daily compared to results from a control period in which tacrolimus was administered alone.	DDI-false
Although @DRUG$ used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with @DRUG$ and epinephrine may occur.	DDI-false
In comparison of the digitalis tolerance in dogs stunned with @DRUG$ , Innovar Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with @DRUG$ or Innovar than with pentobarbital .	DDI-false
For these reasons , it is felt that , in most subjects who have had an unsatisfactory lipid response to either drug alone , the possible benefits of combined therapy with @DRUG$ and a @DRUG$ Not outweigh the risks of severe myopathy, rhabdomyolysis and acute renal failure.	DDI-effect
There have been case reports of increased steady-state levels of @DRUG$ , procainamide and phenytoin during concomitant therapy with @DRUG$.	DDI-false
Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 @DRUG$ : @DRUG$ In vitro, both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo) inhibits primary and secondary enzymes responsible for zaleplon metabolism.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants , antihistamines , alcohol , @DRUG$ , monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$ , or other medicines that produce CNS depression.	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$ Co-administration of apomorphine with medicinal products of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$ , dolasetron , palonosetron , and alosetron ) is contraindicated .	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$ , clindamycin , colistin , and sodium colistimethate ) , @DRUG$ salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing calcium, @DRUG$, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, @DRUG$ before cisplatin).	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$: In a study conducted in healthy subjects, mean steady-state @DRUG$ plasma levels increased approximately 17% in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving lithium alone.	DDI-false
The concomitant use of cholestyramine and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable @DRUG$ The treatment was co-administered with: @DRUG$ 4 mg/kg once every 24 hours for 14 days.	DDI-false
To determine whether probenecid has a direct effect on the distribution of @DRUG$, the elimination and distribution of @DRUG$ was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of probenecid.	DDI-false
Conversely, the administration of @DRUG$ (1 mg butorphanol QID) did not alter the pharmacokinetics of a 300-mg dose of @DRUG$.	DDI-false
@DRUG$ The effects are enhanced by @DRUG$.	DDI-effect
The administration of repeated doses of FACTIV did not affect the pharmacokinetics of the repeated dose of FACTIV. @DRUG$ , digoxin or an ethinylestradiol/levonorgestrol oral @DRUG$ In healthy subjects.	DDI-false
â€¢ Carbamazepine: In healthy subjects receiving the CYP3A4 inducer, @DRUG$ , at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days , systemic exposure ( AUC ) to @DRUG$ 72% decreased.	DDI-mechanism
In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence (ie, TAXOL before cisplatin).	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , pentazocine , nalbuphine , @DRUG$ , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
Although not observed in this study, adverse reactions may be due to the concomitant use of @DRUG$ and @DRUG$ by inhibition of tubular secretion via organic cationic transporter systems .	DDI-mechanism
- Perhexiline hydrogen maleate or @DRUG$ (with hepatotoxic potential) must not be administered together with Bezalip or @DRUG$.	DDI-advise
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive @DRUG$ tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with @DRUG$ and prednisone.	DDI-false
Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., @DRUG$, @DRUG$, and zileuton).	DDI-false
In addition , under the influence of sympatholytic medicinal products such as @DRUG$ , clonidine, guanethidine, and @DRUG$ , the signs of hypoglycemia may be reduced or absent .	DDI-false
When itraconazole is co-administered with @DRUG$ , rifampin, or H2 antagonists, reduced plasma concentrations of @DRUG$ were reported .	DDI-false
Acetaminophen , @DRUG$ , phenobarbital , quinidine , @DRUG$ , and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, @DRUG$, rifampin, and barbiturates) would be expected to decrease @DRUG$ concentrations.	DDI-false
@DRUG$ Angiotensin II receptor antagonists (Congestive Heart Failure Post-myocardial infarction)- In EPHESUS, 3020 (91%) patients also received INSPRA 25-50 mg. @DRUG$ or angiotensin II receptor antagonists ( ACEI/ARB ) .	DDI-false
@DRUG$ should not be administered concurrently with D2-antagonists, such as phenothiazines, butyrophenones, thioxanthines, or @DRUG$.	DDI-advise
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , @DRUG$ , gold, hydroxychloroquine, leflunomide, @DRUG$ , and anakinra .	DDI-false
Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of @DRUG$ , valproate, topiramate, or lamotrigine.	DDI-false
Serial plasma and urine samples for measurement of amprenavir, rifabutin, and @DRUG$ and their @DRUG$, were measured by high-performance liquid chromatography.	DDI-false
No formal clinical studies have been conducted to determine whether an interactive effect on bone loss between @DRUG$ and @DRUG$.	DDI-false
The co-administration of Natrecor with IV vasodilators such as @DRUG$, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
medicines that cause a significant sustained increase in the pH of the stomach ( @DRUG$ The plasma concentrations of ranitidine or cimetidine may be higher than the plasma concentrations of the active substance (e. g. ranitidine or cimetidine) and may be higher than the plasma concentrations of the active substance (e. g. ranitidine or cimetidine). @DRUG$ For this reason, effectiveness can be reduced.	DDI-mechanism
Terfenadine : Administration of @DRUG$ with @DRUG$ resulted in the appearance of unchanged terfenadine in plasma ;	DDI-false
Aspirin: When @DRUG$ is administered with @DRUG$, its protein binding is reduced, although the clearance of free etodolac is not altered.	DDI-mechanism
Diazepam : @DRUG$ ( @DRUG$ ==References====External links==	DDI-false
These results suggest that both dexamethasone and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
A 5-mg @DRUG$ dose should not be exceeded when used in combination with 200 mg once daily @DRUG$.	DDI-advise
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
Like ibogaine (40 mg/kg), @DRUG$ (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Administration of repeated doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of theophylline , @DRUG$ Ethinylestradiol/ Levonorgestrol oral contraceptive product in healthy volunteers.	DDI-false
When other potent parental @DRUG$, such as diazoxide, are used in combination with @DRUG$, patients should be continuously observed for several hours for any excessive fall in blood pressure.	DDI-effect
Multivitamins, or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without @DRUG$ ( an @DRUG$ with multiple effects on the GI tract ) to healthy volunteers , the AUC of clonazepam was 10 % lower and the Cmax of clonazepam was 20 % lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone .	DDI-false
These drugs include thiazides and other @DRUG$ , @DRUG$ , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isonazide.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
Other strong inhibitors of CYP3A4 ( e.g. , @DRUG$ , clarithromycin, nefazodon, troleandomycin, ritonavir, @DRUG$ It would be expected that it would behave in a similar way.	DDI-false
Lithium: @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , @DRUG$ , bacitracin, polymyxins, @DRUG$ , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ : generally should not be given with @DRUG$.	DDI-advise
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, orally @DRUG$ , @DRUG$ , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Imipramine: Coadministration of single doses of @DRUG$ 20 mg and @DRUG$ 75 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration.	DDI-effect
Saquinavir: Coadministration of saquinavir (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in @DRUG$ plasma AUC and a 4-fold increase in @DRUG$ plasma A.C.	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of corticosteroids).	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of @DRUG$ , phenytoin , propranolol , nifedipine , chlordiazepoxide , diazepam , certain tricyclic antidepressants , lidocaine , @DRUG$ And metronidazole, which delays the elimination and increase in blood levels of these drugs.	DDI-false
A drug interaction study investigated the effect of using ACZONE gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole ( @DRUG$/SMX ).	DDI-false
Cyclosporine , Digoxin , Methotrexate Lodine , like other @DRUG$ , through effects on renal prostaglandins , may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$ , digoxin , methotrexate , and increased toxicity .	DDI-mechanism
Other concomitant therapy Although specific interaction studies have not been performed, @DRUG$ Doses of 1 mg or more have been associated with acetaminophene, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, @DRUG$ , cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, @DRUG$ , doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, @DRUG$ , and verapamil .	DDI-false
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-effect
Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window ( e.g. , @DRUG$ or pimozide ) .	DDI-advise
The results increase the possibility that the ethanocyte reaction can occur in the stomach of people who consume @DRUG$ and @DRUG$ on a regular basis .	DDI-mechanism
The concomitant use of nitrofurantoin is not recommended since @DRUG$ The antibacterial effect of @DRUG$ in the urinary tract .	DDI-effect
In healthy volunteers, the pharmacokinetics of a 1-mg dose of @DRUG$ administered as @DRUG$ were not affected by the coadministration of a single 6-mg subcutaneous dose of sumatriptan.	DDI-false
Dexamethasone : Steady-state trough concentrations of albendazole sulfoxide were about 56 % higher when 8 mg @DRUG$ was coadministered with each dose of @DRUG$ 15 mg/ kg/ day) in eight neurocysticercosis patients.	DDI-mechanism
poor metabolizers of debrisoquin : Interactions of @DRUG$ with strong inhibitors of CYP2D6 ( such as quinidine , fluoxetine , @DRUG$ , and propafenone ) have not been studied , but these drugs would be expected to increase blood levels of the R(+ ) enantiomer of carvedilol .	DDI-false
@DRUG$: @DRUG$ appear to have no significant effect on the bioavailability of ciprofloxacin.	DDI-false
Serial plasma and urine samples for measurement of @DRUG$, @DRUG$, and rifampin and their 25-O-desacetyl metabolites, were measured by high-performance liquid chromatography.	DDI-false
Non-selective MAO inhibitors including @DRUG$, phenelzine sulfate, and @DRUG$ HC1: Concomitant use of L-tyrosine and non-selective MAO inhibitors may cause hypertension.	DDI-false
However, reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
@DRUG$: @DRUG$ has no apparent pharmacokinetic interaction when administered with glyburide.	DDI-false
Corticosteroids, @DRUG$ and @DRUG$: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ @DRUG$ For 48 weeks as initial therapy, with similar response rates observed with nevirapine therapies and superiority with efavirenz.	DDI-false
The reports suggest that NSAIDs can reduce the antihypertensive effect of @DRUG$.	DDI-false
Therophylline: A recent study has shown that concomitan administration of @DRUG$ and theophylline may cause elevated plasma levels of theophylline, and in some instances a slight decrease in the elimination of @DRUG$.	DDI-false
@DRUG$: DURAGESIC  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by @DRUG$ has been reported with opioid analgesics	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ It has been reported that tubular secretion of @DRUG$ And to increase its toxicity.	DDI-mechanism
Other medicines: In small groups of patients ( 7 - 10 / interaction study ), the concomitant administration of azathioprin, gold, chloroquine, @DRUG$ , prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac .	DDI-false
Interactions may occur between EPA supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and ginkgo (@DRUG$).	DDI-false
Lithium: In a study conducted in healthy subjects, mean steady-state lithium plasma levels increased approximately 17% in subjects receiving @DRUG$ 450 mg BID with @DRUG$ 200 mg BID as compared to subjects receiving lithium alone.	DDI-mechanism
The aim of this paper was to establish the interaction between @DRUG$ Enkephaline and its synthetic analogues D-Ala2-metenkephalinamide; or @DRUG$ , on the antinonciceptive effect of these peptides in mice after intracisternal injection .	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( @DRUG$ , magnesium hydroxide and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat compared to fosinopril alone, suggesting that antacids may affect the absorption of @DRUG$.	DDI-false
Concomitant administration of @DRUG$ 10 mg) and @DRUG$ ( 800 mg ) produced an 85 % increase in the mean Cmax and AUC of zaleplon .	DDI-mechanism
Selective Serotonin Reuptake Inhibitors (@DRUG$): @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: @DRUG$, haloperidol, metoclopramide, @DRUG$.	DDI-false
These drugs include the @DRUG$ And other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$ , calcium channel blocking drugs , and isoniazid .	DDI-false
When LEVSIN is co-administered with other antimuscarinic agents, amantadine, haloperidol, @DRUG$ - monoamine oxidase (MAO) inhibitors, @DRUG$ or some antihistamines .	DDI-false
Coadministration of single , oral doses of zaleplon with @DRUG$ ( 10 mg and 800 mg , respectively ) , a strong , selective CYP3A4 inhibitor produced a 34 % increase in @DRUG$s maximal plasma concentrations and a 20 % increase in the area under the plasma concentration-time curve .	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, @DRUG$, phenytoin sodium, carbamazepine, griseofulvin, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
In vitro studies indicate that ertapenem does not inhibit P-glycoprotein-mediated transport of @DRUG$ or @DRUG$ And that ertapenem is not a substrate for P-glycoprotein-mediated transport.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Oral Contraceptives : @DRUG$ ( 40 mg BID ) did not induce the metabolism of the combination oral contraceptive @DRUG$/ethinyl estradiol ( 1 mg /35 mcg combination , Ortho-Novum 1/35 ) .	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, @DRUG$, and erythromycin) has not been studied, increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications.	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and @DRUG$ suggest that @DRUG$ may induce fungal resistance to amphotericin B.	DDI-false
Concomitant use of @DRUG$ supplements and @DRUG$ may increase calcium absorption	DDI-mechanism
Agents Having Vasodilator Activity: Data on the effect of concomitant use of other @DRUG$ in patients receiving @DRUG$ for heart failure are not available;	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : @DRUG$ ( eg , pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran .	DDI-false
While all the @DRUG$ ( SSRIs ), e.g. @DRUG$ , escitalopram , fluoxetine , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
@DRUG$ and Norethindrone: Coadministration of VIRACEPT with @DRUG$ resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in norethindrone plasma concentrations.	DDI-false
ACE Inhibitors and @DRUG$ In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists ( @DRUG$/ARB).	DDI-false
Cytochrome P-450 inducers, such as phenytoin, carbamazepine and @DRUG$, induce clonazepam metabolism, causing an approximately 30% decrease in plasma @DRUG$ levels.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and procainamide, @DRUG$ and @DRUG$.	DDI-false
Olanzapine : Coadministration of @DRUG$ 3 mg and @DRUG$ 10 mg produced a decrease in DSST scores .	DDI-effect
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): @DRUG$ could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, @DRUG$, sedatives, anesthetics) should be considered.	DDI-false
Other medicines that can enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX are certain @DRUG$ ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , @DRUG$ , and quinidine .	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
@DRUG$ is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as @DRUG$ and atorvastatin.	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , @DRUG$ (e.g. epinephrine, salbutamol, @DRUG$ ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
These drugs include thiazides and other @DRUG$ , corticosteroids, phe-nothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin , nicotinic acid , sympathomimet-ics , calcium channel blocking drugs , and isoniazid .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including non-steroidal anti-inflammatory drugs and other drugs that are highly protein-bound, @DRUG$ , sulfonamides , chloramphenicol , probenecid , @DRUG$ , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
The aim of this paper was to study the interaction between neurotensin and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide, or @DRUG$, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, @DRUG$, and verapamil.	DDI-false
Severe hypoglycemia has been reported in patients concomitantly receiving @DRUG$ and oral @DRUG$.	DDI-effect
@DRUG$ In a clinical pharmacology study, concomitant administration of antazide (aluminium hydroxide, magnesium hydroxide and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat compared to fosinopril alone, suggesting that antacids may affect the absorption of @DRUG$.	DDI-false
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline, @DRUG$ or an ethinylestradiol/levonorgestrol oral @DRUG$ in healthy subjects.	DDI-false
Other Cardiovascular Agents : Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , @DRUG$ , calcium blockers, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
The possibility of hypotensive effects with PRINIVIL can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with @DRUG$.	DDI-effect
@DRUG$ including tranylcypromine sulfate , phenelzine sulfate , and @DRUG$ HC1 : Concurrent use of L-tyrosine and non-selective MAO inhibitors may lead to high blood pressure.	DDI-false
Central nervous system depressants: Concomitant use of DURAGESIC (Fentanyl transdermal system) with others @DRUG$ - including, but not limited to, other opioids, sedatives, @DRUG$ , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Phenothiazines - Taking @DRUG$ and a @DRUG$ together may increase the risk of convulsions (seizures).	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
In patients taking @DRUG$ and @DRUG$ concomitantly, lithium toxicity may develop.	DDI-effect
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , fibrates , @DRUG$ , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , somatostatin analog ( e.g. , @DRUG$ ==References====External links==	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
@DRUG$: In normal volunteers, concomitant administration of @DRUG$ and hydrochlorothiazide resulted in significantly increased plasma levels of hydrochlorothiazide.	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
In patients receiving Nalfon and a steroid concomitantly , any reduction in @DRUG$ Dosage should be done step by step to avoid possible complications in case of sudden @DRUG$ withdrawal .	DDI-false
The action of the @DRUG$ may be potentiated by @DRUG$, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
Anticholinesterases (neostgmine, @DRUG$), lignocaine, @DRUG$, procainamide can enhance toxicity and cause cardio respiratory depression.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , @DRUG$ , bacitracin, polymyxins, lincomycin, clindamycin, colistine, and sodium colistimethate), @DRUG$ salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, indinavir, @DRUG$, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Drug-Drug Interactions Between @DRUG$   And Other @DRUG$ Phenytoin Keppra ( 3000 mg daily ) did not affect the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
Other Cardiovascular Agents : Enalapril and enalapril IV have been used concomitantly with @DRUG$ , methyldopa , @DRUG$ , calcium blockers, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
These drugs include thiazides and other diuretics, @DRUG$ , phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$ , sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Iodine or @DRUG$ excess may decrease the effect of @DRUG$, and an iodine deficiency can increase the effect of Carbimazole.	DDI-false
Prednisone/prednisolone: @DRUG$ did not have any clinically important effect on the pharmacokinetics of prednisolone or @DRUG$.	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, @DRUG$ , felodipine, digoxin, @DRUG$ , isosorbide mononitrate, knitztilol, ethanol or itraconazole.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, phenytoin, @DRUG$, or @DRUG$, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
@DRUG$ reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when @DRUG$ (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which tacrolimus was administered alone.	DDI-false
poor metabolizers of @DRUG$ : Interactions of cemtilol with potent inhibitors of CYP2D6 (such as quinidine, fluoxetine, paroxetine and propafenone) have not been studied, but these drugs would be expected to increase blood levels of R(+) enantiomer @DRUG$ .	DDI-false
- @DRUG$ : @DRUG$ should generally not be given with diuretics ( such as bumetanide ) because they reduce its renal clearance and add a high risk of lithium toxicity .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral @DRUG$).	DDI-false
Warfarin: Concomitant administration of @DRUG$ (6 mg/kg once every 24 hours for 5 days) and @DRUG$ (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, @DRUG$, glutethimide, chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
While no in vivo drug interaction studies have been conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (e.g. @DRUG$ , phenytoin, rifampin, and barbiturates) would be expected to decrease @DRUG$ concentrations .	DDI-false
A similar association, albeit less pronounced, was proposed with barbiturates, phenylbutazone, phenytoin sodium, @DRUG$ and possibly with @DRUG$ Ampicillin and tetracycline (72)	DDI-false
aBased on reports of narcotic withdrawal syndrome in patients treated with @DRUG$ and methadone concurrently, and evidence of decreased plasma concentrations of @DRUG$.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , @DRUG$ , felodipine , digoxin , warfarin , isosorbide mononitrate , carvedilol , @DRUG$ or itraconazole .	DDI-false
@DRUG$ : @DRUG$ 20 mg, if concomitantly with slow-release nifedipine 30 mg or 60 mg once daily, does not affect the relative bioavailability ( AUC) or the maximum concentration ( Cmax) of nifedipine, a drug metabolised by CYP3A4.	DDI-false
These results would seem to dictate against the clinical use of @DRUG$ with ELSPAR, or during the period following @DRUG$ therapy when plasma asparagine levels are below normal.	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Dopamine antagonists : Da apomorphine is a @DRUG$ It is possible that dopamine antagonists, such as neuroleptics (phenothiazines, @DRUG$ , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
These results suggest that both @DRUG$ , and possibly other glucocorticoids and retinoids, prostatic epithelium proliferation may be caused by a dose-dependent change in activity of @DRUG$ and EGF .	DDI-effect
A drug-drug interaction study evaluated the effect of the use of @DRUG$ Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (TMP/SMX).	DDI-false
Although @DRUG$ administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by @DRUG$ Or in place, histological type, depth of involvement, labelling index, apoptotic index, or tumor vascularity of colon cancer, it significantly reduces the incidence of cancer metastases.	DDI-false
Â· Folic acid in large quantities can counteract the antiepileptic action of phenobarbital, @DRUG$ and @DRUG$ , and increase the frequency of seizures in susceptible pediatric patients .	DDI-false
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	DDI-false
Cardiac effects of @DRUG$ are antagonized by beta-adrenergic blocking agents, such as propranolol and @DRUG$.	DDI-effect
@DRUG$ and indinavir : Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir , the Cmax and AUC of @DRUG$ were reduced by approximately 20 % .	DDI-false
Concomitant administration of Mefloquine and other related compounds ( eg , @DRUG$ , @DRUG$ and chloroquine ) may produce electrocardiographic abnormalities and increase the risk of convulsions .	DDI-false
Rifampin: Coadministration of rifampin and @DRUG$ resulted in an 82% decrease in @DRUG$ plasma A.C.	DDI-false
Therefore , interactions could occur following concomitant administration of @DRUG$ ( e.g. , narcotics , analgesics , antiemetics , sedatives , @DRUG$ ) .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
@DRUG$ - Ingestion (e.g. Antiminth) @DRUG$ The effect of piperazin may decrease along with pyrantel.	DDI-false
Specific studies have confirmed these effects with @DRUG$, isoflurane, propofol, alfentanil, and @DRUG$.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: nefazodone, @DRUG$, cimetidine, @DRUG$, isoniazide, and some macrolide antibiotics.	DDI-false
Coingestion of acetaminophen with theophylline , phenobarbital with @DRUG$ , and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-false
Combination of amiodarone with others @DRUG$ therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$: @DRUG$  is not recommended for use in patients who have received MAOI within 14 days because severe and unpredictable potentiation by MAO inhibitors has been reported with opioid analgesics	DDI-false
Resins : Since @DRUG$ â€¢ to bind other medicinal products at the same time, patients should: @DRUG$ At least 1 hour before or 4 - 6 hours after a bile acid binding resin to prevent absorption.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing a high sequential dose. @DRUG$ and @DRUG$ , specifically , dacarbazine , cis-platinum , tamoxifen and interferon-alfa .	DDI-effect
- antidepressants ( tricyclic), @DRUG$ or other anticholinergic agents , or @DRUG$ : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects .	DDI-false
To determine whether injection of thiosulfate would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of cisplatin.	DDI-false
In clinical trials, FLOLAN was used with digoxin, @DRUG$, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
In patients with chronic hepatitis C treated with PEGASYS in combination with @DRUG$, @DRUG$ treatment did not affect ribavirin distribution or clearance.	DDI-false
There have been isolated reports of patients experiencing increases in their prothrombin times when @DRUG$ was added to @DRUG$ therapy .	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , @DRUG$ , ethionamide , @DRUG$ , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole (Cefmenoxime), @DRUG$ , @DRUG$ , cefamandole , latamoxef ) or methylthiadiazole ( cefazolin ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: MTX, NSAIDs, @DRUG$ , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , @DRUG$ , Sulfasalazine, and Anakinra.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , sulfonamides , chloramphenicol , probenecid , coumarins , @DRUG$ , and beta adrenergic blocking agents .	DDI-effect
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, @DRUG$, @DRUG$ and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
â€¢ Rifabutin: concomitant use of rifabutin and @DRUG$ This led to a decrease of 32%. @DRUG$ Plasma AUC and an increase of 207% in rifabutin plasma A.C.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a @DRUG$ substrate , and diltiazem , a @DRUG$ inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
The absorption of tetracycline , furosemide , @DRUG$ , hydrochlorothiazide , and gemfibrozil was significantly decreased when given simultaneously with @DRUG$ ;	DDI-mechanism
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, etc.).	DDI-mechanism
@DRUG$ Patients who: @DRUG$ Because of the possibility of conduction faults.	DDI-advise
@DRUG$/Aluminium containing antacid products: Zalcitabine absorption is moderately reduced (approximately 25%) when co-administered with magnesium/@DRUG$ containing antacid products.	DDI-false
Patients receiving high doses of @DRUG$ concomitantly with furosemide , as in rheumatic disease , may experience @DRUG$ toxicity at lower doses because of competitive renal excretory sites .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, @DRUG$) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	DDI-mechanism
acetaminophen/@DRUG$ , lidocaine/quinidine , phenobarbital/@DRUG$ , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
@DRUG$ : Steady-state trough concentrations of @DRUG$ were about 56 % higher when 8 mg dexamethasone was coadministered with each dose of albendazole ( 15 mg/kg/day ) in eight neurocysticercosis patients .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and @DRUG$.	DDI-false
In patients receiving Nalfon and a @DRUG$ At the same time, any reduction in steroid dosage should be gradual in order to avoid possible complications in case of sudden ingestion. @DRUG$ withdrawal .	DDI-false
Digoxin: In controlled studies in healthy volunteers, @DRUG$ either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum @DRUG$ concentrations.	DDI-mechanism
Concurrent administration of @DRUG$ and androgens may result in elevated serum levels of @DRUG$.	DDI-false
In the first study , concomitant administration of 0.2 mg @DRUG$ and 12 g @DRUG$ resulted in decreases of more than 22 % for AUC and 40 % for Cmax when compared to dosing cerivastatin sodium alone .	DDI-mechanism
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
the doses of @DRUG$ In order to reduce the impact of @DRUG$ They were more than 100 times higher than those required to antagonize the effects of morphine.	DDI-effect
Corticosteroids and @DRUG$ (@DRUG$): may potentiate amphotericin B- induced hypokalemia which may predispose the patient to cardiac dysfunction.	DDI-false
Acetaminophen/theophylline, @DRUG$/chinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
This antagonistic effect of @DRUG$ on bumetanide natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of @DRUG$.	DDI-false
Anticoagulants including coumarin derivatives , indandione derivatives , and @DRUG$ such as @DRUG$ NSAIDs and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
The hypoglycaemic effect of @DRUG$ â€¢ may be exacerbated by certain drugs, including nonsteroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, probenecid, coumarine, @DRUG$ And beta-adrenergic blockers.	DDI-effect
Reports suggest that @DRUG$ The antihypertensive effect of ACE inhibitors, including @DRUG$, may be reduced.	DDI-effect
These results suggest that both dexamethasone and retinyl acetate, and possibly other @DRUG$ and @DRUG$ , may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., @DRUG$, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The antihypertensive effect of enalapril and @DRUG$ IV is augmented by antihypertensive agents that cause renin release ( e.g. , @DRUG$ ) .	DDI-effect
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and @DRUG$ cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-effect
Antiacid, @DRUG$, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
In a study of 12 adult volunteers, TORADOLORAL was administered with a single dose of 25 mg. @DRUG$ , causing no significant changes in pharmacokinetics or pharmacodynamics of @DRUG$.	DDI-false
- Carbamazepine : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be used prior to concomitant administration with isoniazid, signs and symptoms of @DRUG$ The toxicity should be closely monitored and a corresponding dose adjustment of @DRUG$ should be made .	DDI-false
Promethazine: Coadministration of a single dose of zaleplon and @DRUG$ (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of @DRUG$, but no change in the area under the plasma concentration-time curve.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
Patients taking low-dose @DRUG$ plus @DRUG$ were not studied .	DDI-false
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole (Cefmenoxime), @DRUG$ , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( @DRUG$ ) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
- @DRUG$ , orally (diabetes medicine you take through your mouth) @DRUG$ Sulfapyridine may increase the likelihood of side effects affecting blood and/ or side effects or oral antidiabetic agents.	DDI-false
Although the magnitude of changes in diazepam plasma exposure when coadministered with @DRUG$ were not sufficient to warrant dosage adjustments , patients may experience enhanced sedative side effects caused by increased exposure of @DRUG$ Under these circumstances.	DDI-effect
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either @DRUG$ or @DRUG$ in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of NANM.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , @DRUG$ , dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$ , and vincristine .	DDI-false
Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
Antacids : In a clinical pharmacology study, concomitant administration of antacids (aluminium hydroxide, magnesium hydroxide and simethicone) with @DRUG$ - Decreased serum levels and urinary excretion of fosinoprilat compared to @DRUG$ administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
Tolbutamide: In diabetic patients receiving @DRUG$ and tolbutamide, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$ , propranolol , nifedipine , chlordiazepoxide , diazepam , certain @DRUG$ , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
@DRUG$: A report of severe @DRUG$ toxicity was reported in a patient receiving Isoniazid.	DDI-false
Primary and secondary @DRUG$ deficiencies constitute the sole indication of physiological oral @DRUG$ therapy.	DDI-false
Beta-Blocking Agents A pharmacokinetic study with @DRUG$ in conjunction with @DRUG$ There were no significant effects on the pharmacokinetics of felodipine.	DDI-false
If a @DRUG$ It is also used, it can increase the risk @DRUG$ toxicity .	DDI-effect
Interferon beta-1a ( @DRUG$   30 mcg IM once weekly ) reduced @DRUG$ Clearance is approximately 30%.	DDI-mechanism
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and @DRUG$] is contraindicated.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$ , beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, schnitztilol, ethanol or @DRUG$.	DDI-false
The medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$ , glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
Drug-Drug Interactions Between @DRUG$  And Other @DRUG$ (AEDs) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Slow-channel calcium blockers, such as @DRUG$, diltiazem and @DRUG$, inhibit platelet activation in vitro, and decrease platelet adhesion intravascularly.	DDI-false
In the same study it was shown that @DRUG$ and @DRUG$ had no significant effect on the intracellular phosphorylation of zalcitabine in peripheral blood mononuclear cells.	DDI-false
Urinary acidifying agents ( @DRUG$ , sodium phosphate, etc.) increase the concentration of ionized types of @DRUG$ molecule , thereby increasing urinary excretion .	DDI-mechanism
Other Agents: @DRUG$ has been used concomitantly with nitrates and/or @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, @DRUG$, phenytoin, dexamethasone, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in @DRUG$ concentrations.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), @DRUG$.	DDI-false
@DRUG$, nondepolarizing (e.g., tubocurarine): possible increased responsiveness to the @DRUG$.	DDI-false
The extent to which SSRI-@DRUG$interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the @DRUG$ involved.	DDI-false
Among the @DRUG$ , many , like @DRUG$ , can not be used clinically because they are toxic ;	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
BACKGROUND : The effects of combined administration of bombesin and @DRUG$ ( @DRUG$ A calcium channel blocker, the incidence of peritoneal metastasis of intestinal adenocarcinoma induced by azoxymethane (AOM) and the index of colorectal cancers were studied in male Wistar rats.	DDI-false
Nonsteroidal Anti-Inflammatory Drugs (@DRUG$)-A drug interaction study of @DRUG$ with an NSAID has not been conducted.	DDI-false
â€¢ Numerous drug interactions are possible in some patients. @DRUG$ , such as @DRUG$ and phenytoin , which affect hepatic microsomal enzyme systems .	DDI-false
In the same study it was shown that @DRUG$ and @DRUG$ The intracellular phosphorylation of zalcitabine in peripheral mononuclear blood cells had no significant influence.	DDI-false
Coadministration of @DRUG$ Medicines that induce CYP3A may lose weight @DRUG$ plasma concentrations and reduce its therapeutic effect .	DDI-false
@DRUG$ , @DRUG$ : Amphetamines may enhance the activity of tricyclic or sympathomimetic agents ;	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of carbamazepine, @DRUG$, topiramate, or @DRUG$.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Effects of GABITRIL on other Antiepilepsy Drugs (@DRUG$) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy.	DDI-false
When other @DRUG$ or @DRUG$ are used concomitantly, there is the potential for FLOLAN to increase the risk of bleeding.	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , @DRUG$ chemotherapy ) , cardiotoxic ( e.g. , doxorubicin ) or hepatotoxic ( e.g. , methotrexate , asparaginase ) effects with @DRUG$ The toxicity in these organ systems can be increased.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Five days of @DRUG$ treatment did not significantly affect steady-state pharmacokinetic variables of @DRUG$ compared with placebo;	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphenes, @DRUG$ , somatostatin analogue (e.g., @DRUG$ ==References====External links==	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
If Bezalip or Bezalip retard is used simultaneously with anion exchange resins (e.g. @DRUG$ ) , an interval of at least 2 hours should be maintained between the two medicines , since the absorption of Bezalip or @DRUG$ is impaired	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines @DRUG$, triazolam GI motility agents: cisapride	DDI-false
@DRUG$: A report of severe acetaminophen toxicity was reported in a patient receiving @DRUG$.	DDI-false
Data from in vitro studies of @DRUG$ A possible drug interaction with @DRUG$ for the following : sertraline and paroxetine .	DDI-false
Higher concentrations of @DRUG$ The mitogenic effects of @DRUG$ are enhanced by the use of 10(-8 ) - 10(-6 ) M or retinyl acetate ( 3 X 10(-8 ) - 10(-7 ) M.	DDI-effect
The effects of @DRUG$ are antagonized by @DRUG$ such as caffeine and theophylline.	DDI-effect
Antiarrhythmics: Amiodarone, @DRUG$, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$, digoxin, @DRUG$, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Warfarin: The effect of valdecoxib on the anticoagulant effect of @DRUG$ (1 - 8 mg/day) was studied in healthy subjects by coadministration of @DRUG$ 40 mg BID for 7 days.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , @DRUG$ Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines @DRUG$ , triazolam GI motility agents : cisapride	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$, @DRUG$, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Insulin or Oral @DRUG$: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of insulin and oral @DRUG$.	DDI-false
@DRUG$ , tricyclic: amphetamines can increase the activity of @DRUG$ sympathomimetics;	DDI-false
@DRUG$ plus @DRUG$ The therapy was poorly tolerated and 5 out of 11 subjects discontinued the therapy.	DDI-effect
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , @DRUG$ , propofol , protease inhibitors , quinidine , and @DRUG$.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
In clinical trials, @DRUG$ In a pharmacokinetic sub-study in patients with congestive heart failure receiving furosemide or digoxin starting treatment with FLOLAN, apparent values for oral clearance of furosemide (n = 23) and @DRUG$ ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Magnesium/Aluminum-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with @DRUG$/aluminum-containing @DRUG$.	DDI-false
Suppression by verapamil of @DRUG$-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ By Wistar rats.	DDI-false
@DRUG$ ( ' Seroquel ' ) is a newly introduced @DRUG$ With proven efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
Binding to plasma protein is not significantly altered by @DRUG$, diphenylhydantoin, or @DRUG$.	DDI-false
Warfarin and @DRUG$: Increased prothrombin time, with or without clinical bleeding, has been reported when @DRUG$ is administered concomitantly.	DDI-effect
@DRUG$ ; : Simultaneous application of @DRUG$ With valdecoxib, an increased risk of GI ulcers and complications may occur compared to valdecoxib alone.	DDI-false
In a study in which the oral decaying 2 mg clonazepam tablet with and without propanthelin (an anticholinergic agent with multiple effects on the GI tract) was administered to healthy subjects, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 10% lower. @DRUG$ 20 % lower if the orally disintegrating tablet is co-administered with @DRUG$ compared to when it was given alone .	DDI-mechanism
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/@DRUG$ , theophylline/@DRUG$ , and valproic acid/phenobarbital .	DDI-false
@DRUG$ (increases bioavailability by 50%), @DRUG$, and valproates.	DDI-false
Additive CNS depression may occur when antihistamines are administered concomitantly with other CNS depressants including @DRUG$ , tranquilizers , and @DRUG$.	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of @DRUG$, although it significantly decreased the zidovudine tmax by 44% and increased the intracellular exposure to phosphorylated @DRUG$ by 110%.	DDI-false
Caution should be exercised if an @DRUG$ is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as @DRUG$, spironolactone, and cimetidine.	DDI-advise
@DRUG$ , apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$ This delays elimination and increases blood levels of these drugs.	DDI-mechanism
Compounds in these categories result in a decreased efficacy of bromocriptine mesylate: phenothiazines, haloperidol, @DRUG$, @DRUG$.	DDI-false
@DRUG$s and vasodilators: The following side effects occurred more frequently in patients receiving concomitant antihypertensive medications or @DRUG$ Hypotension 10% vs. 4%, myocardial infarction 3% vs. 1%, severe pneumonia 5% vs. 3%, severe falls 9% vs. 3%, bone and joint injuries 6% vs. 2%.	DDI-false
@DRUG$: As with other @DRUG$, the renal excretion of cephalexin is inhibited by probenecid.	DDI-false
Both @DRUG$ The treatment with nevirapine was compared for 48 weeks with triple therapy with PI indinavir as initial therapy, with similar reactions observed with nevirapine therapies and superiority with @DRUG$.	DDI-false
A two-way interaction between the hydantoin antiepileptic, @DRUG$, and the @DRUG$s has been suggested.	DDI-false
@DRUG$, clonidine, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, heart @DRUG$ , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as @DRUG$ In addition, quinolones anti-infections with no evidence of clinically significant adverse interactions.	DDI-false
Plasma @DRUG$ concentration should be monitored when isoniazid and valproate are co administered , and appropriate dosage adjustments of @DRUG$ It should be done.	DDI-false
A inhibition of coagulation inhibition was observed during the use of @DRUG$ , @DRUG$ and glutethimide ;	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	DDI-mechanism
CNS-Active Drugs Ethanol: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after @DRUG$ administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after @DRUG$ administration.	DDI-false
@DRUG$: Concomitant administration of low-dose @DRUG$ with VIOXX may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminium @DRUG$ , Sucralfat, VIDEX chew/buffer tablets or paediatric powders, or products containing calcium, @DRUG$ , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Agents Causing Renin Release: The antihypertensive effect of enalapril and @DRUG$ IV is augmented by antihypertensive agents that cause renin release (e.g., @DRUG$).	DDI-effect
Patients who have other narcotic analgesics, general anaesthetics, @DRUG$ , tranquilizers , @DRUG$ , tricyclic antidepressants or other CNS depressants (including alcohol) together with DILAUDID may exhibit additive CNS depression.	DDI-false
Patients receiving other @DRUG$s , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic antidepressants or other CNS depressants ( including alcohol ) concomitantly with @DRUG$ It may have additive CNS depression.	DDI-effect
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
Coadministration of @DRUG$ (10 mg BID for 7 days) with @DRUG$ (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of glyburide.	DDI-false
Isocarboxazid should be administered with caution to patients receiving @DRUG$ (@DRUG$, Wyeth-Ayerst Laboratories).	DDI-false
If Bezalip or Bezalip retard is used concomitantly with @DRUG$ ( e.g. cholestryramine ) , an interval of at least 2 hours should be maintained between the two medicines , since the absorption of Bezalip or @DRUG$ is impaired	DDI-false
@DRUG$ When 5 mg is co-administered @DRUG$ with 600 mg BID ritonavir , the Cmax and AUC of ritonavir were reduced by approximately 20 % .	DDI-false
In clinical trials , FLOLAN was used with digoxin , diuretics , @DRUG$ , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ On the second day of therapy, apparent values for oral clearance of furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13 % and 15 % respectively and were returned to baseline by day 87.	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin , carbamazepine , and barbiturates , and the antituberculosis drug @DRUG$.	DDI-effect
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , @DRUG$ , oral @DRUG$ , phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of @DRUG$, digoxin or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.	DDI-false
Therefore , interactions could occur following concomitant administration of psychotropic drugs ( e.g. , narcotics , analgesics , @DRUG$ , sedatives , @DRUG$ ) .	DDI-false
@DRUG$ and @DRUG$ Resins : The absorption of hydrochlorothiazide is impaired in the presence of anionic resins.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a @DRUG$, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
A similar association, albeit less pronounced, was proposed with barbiturates, phenylbutazone, phenytoin sodium, carbamazepine, @DRUG$ , @DRUG$ Ampicillin and tetracycline 72.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
Valproate: The addition of @DRUG$ to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased @DRUG$ binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ , carbamazepine , fentanyl , @DRUG$ , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, @DRUG$, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin , clarithromycin , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , @DRUG$ , protease inhibitors , quinidine , and verapamil .	DDI-false
Pretreatment of healthy volunteers with multiple doses of @DRUG$ followed by a single dose of @DRUG$, increased Gleevec oral-dose clearance by 3.8-fold, which significantly (p 0.05) decreased mean cmax and AUC(0-8).	DDI-mechanism
Particular caution is recommended when administering @DRUG$ with CYP3A4 substrates that have a narrow therapeutic window (e.g., @DRUG$ or pimozide).	DDI-advise
The intensity , uniformity and time course of @DRUG$ interference by phenobarbital , secobarbital , glutethimide , chloral hydrate and methaqualone were systematically investigated in 16 patients receiving @DRUG$ therapy .	DDI-false
A drug-drug interaction study evaluated the effect of the use of ACZONE Gel, 5%, in combination with double strength (160 mg/800 mg) @DRUG$/sulfamethoxazole (TMP/@DRUG$).	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or @DRUG$.	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , @DRUG$ , or pentobarbital, the dose of Ouabain was needed to cause ventricular tachycardia significantly higher, such as the LD50 of @DRUG$ , with ketamine or Innovar than with pentobarbital .	DDI-false
"May interact with thyroid drugs (e.g. levothyroxine), products containing iodine, @DRUG$ H2 antagonists (e.g. famotidine, ranitidine) and proton pump inhibitors (e.g. @DRUG$ ,,,,,,,,,,,	DDI-false
Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ For the following: @DRUG$ and paroxetine .	DDI-int
Cyclopropane or @DRUG$ increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered catecholamines, such as @DRUG$.	DDI-effect
Central nervous system depressants : Concomitant use of DURAGESIC (Fentanyl transdermal system ) with other central nervous system depressants, including but not limited to others @DRUG$ , sedatives, hypnotics, sedatives (e.g. benzodiazepines), general anesthetics, phenothiazines, @DRUG$ And alcohol, can cause respiratory depression, hypotension, and deep sedation, or possibly lead to coma or death.	DDI-false
@DRUG$ To reduce the hepatic metabolism of warfarin-type anticoagulants, apparently due to an effect on certain microsomal enzyme systems, @DRUG$ , propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, delaying the elimination and increase in blood levels of these drugs.	DDI-mechanism
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , @DRUG$ Amphotericin B, Foscarnet, intravenous @DRUG$ , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, @DRUG$, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
No pharmacokinetic interactions between dexmedetomidine and isoflurane, @DRUG$, alfentanil, and @DRUG$ have been demonstrated.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, @DRUG$, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
@DRUG$ In a clinical pharmacology study, concomitant administration of antazide (aluminium hydroxide, magnesium hydroxide and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat compared to fosinopril alone, suggesting that: @DRUG$ The absorption of Fosinopril may be impaired.	DDI-false
Dopamine Antagonists: Since apomorphine is a @DRUG$, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, @DRUG$/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Other strong inhibitors of CYP3A4 ( e.g. , itraconazole , clarithromycin , @DRUG$ , @DRUG$ Ritonavir, nelfinavir, is expected to behave similarly.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Plasma @DRUG$ concentration should be monitored when @DRUG$ and valproate are co administered, and appropriate dosage adjustments of valproate should be made.	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and protease inhibitors (ritonavir, saquinavir, @DRUG$, and @DRUG$), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors , e.g. , paroxetine , @DRUG$ , and @DRUG$.	DDI-false
increased levels of @DRUG$ and @DRUG$ activity;	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or @DRUG$, may diminish the effectiveness of APOKYN.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ : Coadministration of @DRUG$ The use of VIRACEPT resulted in an increase in nelfinavir plasma AUC of 152% and a very small change in ritonavir plasma AC.	DDI-false
Central nervous system depressants: the concomitant use of DURAGESIC ( @DRUG$ transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , hypnotics , @DRUG$ â€¢ (e.g. benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants and alcohol, may cause respiratory depression, hypotension and deep sedation, or may lead to coma or death.	DDI-effect
Injection : @DRUG$ injection , like other injectable benzodiazepines , produces depression of the central nervous system when administered with @DRUG$ , phenothiazines , barbiturates , MAO inhibitors , and other antidepressants . When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-effect
Plasma valproate concentration should be monitored if isoniazide and @DRUG$ Dose adjustments will be made at the same time. @DRUG$ It should be done.	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics @DRUG$ and @DRUG$).	DDI-false
In EM individuals treated with paroxetine or fluoxetine, the AUC of @DRUG$ is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than @DRUG$ alone.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, @DRUG$, and @DRUG$] is contraindicated.	DDI-false
While no in vivo drug-drug interaction studies were conducted between @DRUG$ CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and @DRUG$ ) would be expected to decrease estazolam concentrations .	DDI-mechanism
Patients taking low-dose @DRUG$ plus @DRUG$ were not studied.	DDI-false
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (AEDs) @DRUG$ Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	DDI-false
A dose increase of @DRUG$/ritonavir to 533/133 mg twice daily with food isrecommended in combination with @DRUG$.	DDI-advise
Other cardiovascular agents : enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents , methyldopa , nitrates , @DRUG$ , hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of fissteride doses have been co-administered in clinical trials with acetaminophen, @DRUG$ , A-blockers, analgesics, angiotensin converting enzyme ( ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, @DRUG$ , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
"Animal studies show that: @DRUG$ may be ineffective if the patient has recently received a @DRUG$.	DDI-effect
Central nervous system depressants: the concomitant use of DURAGESIC ( @DRUG$ Transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$ Anaesthetics (e.g. benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants and alcohol can cause respiratory depression, hypotension and deep sedation, or possibly lead to coma or death.	DDI-effect
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, carbamazepine, rifampin, @DRUG$ or St.	DDI-false
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, terfenadine antimigrain: ergot derivatives @DRUG$ : rifampin Benzodiazepines midazolam , triazolam GI motility agents : @DRUG$	DDI-false
@DRUG$: Increased activity of both @DRUG$ and corticosteroids may occur when the two are used concurrently.	DDI-false
Tolbutamide: In diabetic patients receiving diflunisal and @DRUG$, no significant effects were seen on @DRUG$ plasma levels or fasting blood glucose.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , @DRUG$ Antimigraine : Ergot derivatives Antimycobacterial agents: rifampin @DRUG$ Midazolam, triazolam GI Motility agent: cisapride	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
Aspirin: Concomitant administration of @DRUG$ and aspirin is not recommended because @DRUG$ is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels, and AUC values.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, @DRUG$, and beta adrenergic blocking agents.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Patients receiving other narcotic analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic antidepressants or other @DRUG$ ( including @DRUG$ DILAUDID can be combined with an additive CNS depression.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Amiodarone taken with procainamide for less than seven days increases plasma concentrations of @DRUG$ and n-acetyl @DRUG$ by 55 % and 33 % , respectively .	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, @DRUG$ and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
5HT3 Antagonists : Based on reports of deep hypotension and loss of consciousness when @DRUG$ was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , @DRUG$ Dolasetron, palonosetron, and Alosetron) is contraindicated.	DDI-false
@DRUG$ : Concomitant treatment with Accutane and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri ( benign intracranial hypertension ) , some of which involved concomitant use of @DRUG$	DDI-false
@DRUG$ : @DRUG$ blocks dopamine receptors , thus inhibiting the central stimulant effects of amphetamines .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
Plasma @DRUG$ concentration should be monitored when isoniazid and valproate are co administered, and appropriate dosage adjustments of @DRUG$ should be made.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
The medicinal products associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$ , phenytoin , ribavirin , and @DRUG$.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( @DRUG$ Containing by weight not less than 10 % by weight of sucrose (excl. in immediate packings of a net content of >= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg but <= 1 kg and <= 1 kg) @DRUG$ â€¢ decreased serum levels and urinary excretion of fosinoprilat compared to fosinopril alone, suggesting that antacids may impair the absorption of fosinopril.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The concomitant use of other CYP3A4 inhibitors such as diltiazem and @DRUG$ with transdermal @DRUG$ This may also lead to an increase in fentanyl plasma concentrations, which may increase or prolong adverse drug reactions and cause severe respiratory depression.	DDI-mechanism
Inducers and Inhibitors of Hepatic Metabolism: @DRUG$ reduced plasma concentrations of @DRUG$ by about 70%.	DDI-mechanism
- @DRUG$ MAO inhibitors (with hepatotoxic potential) should not be administered with Bezalip or @DRUG$.	DDI-advise
@DRUG$: Valdecoxib 10 mg BID did not show a significant effect on the plasma exposure or renal clearance of @DRUG$.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , @DRUG$ , @DRUG$ , and anakinra .	DDI-false
@DRUG$ is the first @DRUG$ to be approved for clinical use , and has been studied extensively in humans since 1986 .	DDI-false
Remarkable is systemic exposure ( AUC0 - 12 ) @DRUG$ ( DHA ) was more than doubled in the presence of TMP/@DRUG$.	DDI-false
These drugs include thiazides and other diuretics, @DRUG$ , phenothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin , nicotinic acid , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Other reported interactions with @DRUG$ Fentanyl ( CYP3A4 substrate) in combination with @DRUG$ For this reason, hypotension, bradycardia, and reduced cardiac output may occur.	DDI-false
SINCE THE CONCOMPITANT MANAGEMENT OF THIS TWO THROUGH @DRUG$ INTOXICATION BEFORE DEVELOPMENT @DRUG$ To a patient on PHENYTOIN THERAPY, A BASELINE PHENYTOIN SERUM LEVEL, ANDIE.	DDI-false
* This table is not all included * * @DRUG$ may not be effective due to decreased @DRUG$ Plasma concentrations in patients taking these medicinal products at the same time	DDI-false
Coadministration of @DRUG$ with @DRUG$ has led to elevated plasma concentrations of terfenadine, resulting in rare instances of life- threatening cardiac dysrhythmias and one death.	DDI-mechanism
Hypersensitivity reactions have been reported in patients receiving combination regimens containing a high sequential dose. @DRUG$ and antineoplastic agents, in particular: @DRUG$ , cis-platinum, tamoxifen and interferon alpha.	DDI-effect
Furosemide: TORADOL IV/IM reduced the @DRUG$ response to @DRUG$ in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	DDI-false
Saquinavir: The combination of @DRUG$, saquinavir, and @DRUG$ has been studied (as triple combination) in adults.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Potential interactions between @DRUG$, a substrate of CYP3A4, and protease inhibitors (ritonavir, @DRUG$, indinavir, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
Ritonavir: Coadministration of ritonavir with VIRACEPT resulted in a 152% increase in @DRUG$ plasma AUC and very little change in @DRUG$ plasma A.C.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , @DRUG$ , phenothiazines , monoamine oxidase ( MAO ) inhibitors , tricyclic antidepressants or some @DRUG$.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an @DRUG$ ( aluminum hydroxide , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that antacids may impair absorption of @DRUG$.	DDI-false
Potential interactions between TAXOL, a substrate of CYP3A4, and @DRUG$ (ritonavir, saquinavir, @DRUG$, and nelfinavir), which are substrates and/or inhibitors of CYP3A4, have not been evaluated in clinical trials.	DDI-false
These drugs include thiazides and other @DRUG$ , corticosteroids , @DRUG$ , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
Other Drugs:Drugs such as quinidine, disopyramide, @DRUG$, @DRUG$, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, @DRUG$), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ Amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, @DRUG$ , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Multivalent Cation-Containing products: co-administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ Antacids, Sucralfat, @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Data suggest that coadministration of oral @DRUG$ and @DRUG$ can result in prolongation of the QT interval on the ECG.	DDI-effect
Ephedrine : @DRUG$ may enhance the metabolic clearance of @DRUG$ , resulting in decreased blood levels and lessened physiologic activity , thus requiring an increase in corticosteroid dosage .	DDI-mechanism
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, tranquilizers, @DRUG$, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
@DRUG$ The management of @DRUG$ In normal subjects receiving indomethacin, they decreased renal clearance and significantly increased plasma levels of indomethacin.	DDI-false
Drug Interactions : @DRUG$ may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): @DRUG$ - Arecoline - Eproxindine - Ethanol : Flupentixol and ethanol cause additive CNS depression - Tricyclic antidepressants : Flupentixol increases the effect of tricyclic antidepressants	DDI-false
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, @DRUG$, phenytoin, @DRUG$, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
Lamivudine : In vitro studies in peripheral mononuclear blood cells, U937 and Molt-4 cells showed that @DRUG$ significantly inhibited @DRUG$ phosphorylation in a dose dependent manner .	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine @DRUG$ : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , @DRUG$ GI motility agents : cisapride	DDI-false
The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered AVONEX ) and Study 2 (with co-administered @DRUG$ ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	DDI-false
Other @DRUG$ Concomitant use of other 5-HT1B/1D agonists within 24 hours of treatment with @DRUG$ is contraindicated.	DDI-false
The possibility of hypotensive effects with enalapril or enalaprilat can be minimized by either discontinuing the @DRUG$ or increasing the salt intake prior to initiation of treatment with enalapril or @DRUG$.	DDI-false
The possibility of hypotensive effects with @DRUG$ or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with enalapril or enalaprilat .	DDI-false
A study in eight healthy volunteers has shown a 50 % increase in mean peak @DRUG$ plasma concentrations and a 90 % increase in mean area under the curve , after a one week course of @DRUG$ 1 000 mg/ day and 90 mg/ day nimodipine.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , @DRUG$ , sulfonamides , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-effect
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Ethinyl Estradiol and @DRUG$: Coadministration of VIRACEPT with OVCON-35 resulted in a 47% decrease in ethinyl estradiol and an 18% decrease in @DRUG$ plasma concentrations.	DDI-false
However, it is unlikely that this decrease in phosphorylation will occur. @DRUG$ concentration is of clinical significance , as lamivudine is a more efficient substrate for deoxycytidine kinase than @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving @DRUG$ therapy.	DDI-false
Digoxin , @DRUG$ and Losartan : @DRUG$ There are no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on bosentan plasma levels.	DDI-false
Patients who have other narcotic analgesics, general anaesthetics, phenothiazine, sedatives, @DRUG$ , tricyclic antidepressants or other CNS depressants (including @DRUG$ DILAUDID can be combined with an additive CNS depression.	DDI-false
Oral @DRUG$: Pharmacokinetic drug-drug interactions between @DRUG$ and warfarin (7.5 mg single oral dose) have not been demonstrated.	DDI-false
Magnesium and/or aluminium antacids, iron sulphate products, multivitamin preparations containing zinc or other metal cations, or Videx ( @DRUG$ Do not take chewable tablets or the pediatric powder for oral solution within 3 hours before or 2 hours after @DRUG$.	DDI-advise
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , @DRUG$ , granisetron, dolasetron, palonosetron, and @DRUG$ ) is contraindicated .	DDI-false
@DRUG$: Concomitant use of @DRUG$ and corticosteroids may produce severe weakness in patients with myasthenia gravis.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Specific studies have confirmed these effects with sevoflurane , @DRUG$ , propofol , @DRUG$ , and midazolam .	DDI-false
At a median follow-up of 33 months , the combination of @DRUG$ and tamoxifen did not demonstrate any efficacy benefit when compared with @DRUG$ in all patients as well as in the hormone receptor-positive subpopulation .	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), @DRUG$, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), corticosteroids (increased effect of @DRUG$).	DDI-false
Glyburide : Concomitant use of @DRUG$ with the sulfonylurea @DRUG$ has , on rare occasions , resulted in severe hypoglycemia .	DDI-effect
@DRUG$ : TORADOLIV/IM has been administered concurrently with @DRUG$ In several clinical trials of postoperative pain without evidence of adverse interactions.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , @DRUG$ , isoniazid , metronidazole , @DRUG$ , phenytoin , ribavirin , and vincristine .	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, @DRUG$, nicardipine, and nifedipine.	DDI-false
Since the therapeutic range of theophylline is narrow @DRUG$ serum levels should be monitored closely, and appropriate dosage adjustments of @DRUG$ should be made.	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable @DRUG$: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Benzthiazide can interact with alcohol, blood thinners, decongestant medications (allergic, cold, and sinus drugs), diabetics, lithium, @DRUG$ , @DRUG$ like Aleve or Ibuprofen , and high blood pressure medications .	DDI-false
Because of its lack of platelet effects , @DRUG$ is not a substitute for @DRUG$ for cardiovascular prophylaxis .	DDI-false
@DRUG$: Diclofenac and other NSAIDs can inhibit the activity of @DRUG$.	DDI-false
Aspirin: Concurrent administration of @DRUG$ may lower @DRUG$ plasma levels, possibly by competing for protein-binding sites.	DDI-mechanism
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, @DRUG$ and sedatives (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
@DRUG$: Amiodarone, bepridil, @DRUG$, propafenone, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
@DRUG$ , bepridil , sparfloxacin , and @DRUG$.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , Innovar Vet , or pentobarbital , the dosage of ouabain needed to cause ventricular tachycardia was significantly higher , as was the LD50 of ouabain , with ketamine or @DRUG$ than with @DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , @DRUG$ , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , @DRUG$ , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$, other, especially diazoxide, or preanesthetic and anesthetic agents used in surgery or @DRUG$, nondepolarizing, used in surgery	DDI-false
Benzthiazide may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ may interact with alcohol , blood thinners , decongestant drugs ( allergy , cold , and sinus medicines ) , diabetic drugs , @DRUG$ , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications .	DDI-int
However, caution should be used when administering @DRUG$ with @DRUG$ since these patients are at increased risk of bleeding complications.	DDI-advise
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
Plasma concentrations of @DRUG$ are reduced when given concurrently with @DRUG$.	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
In clinical studies with fondaparinux, co-administration of @DRUG$ ( warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam) and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as @DRUG$ , intraconazole , ritonavir , indinavir , saquinavir , @DRUG$ , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
A similar association , though less marked , has been suggested with @DRUG$ , phenylbutazone , phenytoin sodium , carbamazepine , griseofulvin , topiramate , and possibly with @DRUG$ 72. and tetracyclines 72.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , @DRUG$ , @DRUG$ , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, @DRUG$, prednisolone, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .	DDI-false
Specific studies have confirmed these effects with @DRUG$, @DRUG$, propofol, alfentanil, and midazolam.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between: @DRUG$ and @DRUG$ , trimethoprim/sulfamethoxazole , clarithromycin , erythromycin , itraconazole or fluconazole .	DDI-false
iodine or iodine surplus may have the effect of @DRUG$ , and an iodine deficiency can increase the effect of @DRUG$.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ or aluminum antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Drug Interaction During Pregnancy: @DRUG$ and @DRUG$ were studied following subcutaneous injections in pregnant mice.	DDI-false
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral @DRUG$ norethindrone/@DRUG$ (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
Other reported interactions with amiodarone: @DRUG$ (@DRUG$ substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
Possible drug interactions between Keppra and other AEDs (carbamazepine, gabapentin, @DRUG$ , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies .	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines, presumably through inhibition of CYP3A: @DRUG$, fluvoxamine, @DRUG$, diltiazem, isoniazide, and some macrolide antibiotics.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate , @DRUG$ , and Pargylin HC1: Simultaneous use of @DRUG$ Non-selective MAO inhibitors can lead to hypertension.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound , salicylates , @DRUG$ , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, @DRUG$ (10% decrease in binding), or @DRUG$.	DDI-false
Although clinical studies have not been conducted based on the involvement of the cytochrome P-450 3A family in @DRUG$ metabolism , inhibitors of this enzyme system , notably oral @DRUG$ Clonazepam should be used with caution in patients receiving clonazepam.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without @DRUG$ The AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the oral disintegrating tablet was @DRUG$ compared to when it was given alone .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or @DRUG$ antacids, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
While 18-MC and ibogaine have similar affinities for kappa opioid and possibly nicotinic receptors , @DRUG$ It has much lower affinities than @DRUG$ For NMDA and Sigma-2 receptors, sodium channels and the 5-HT transporter.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Other Drug Interactions Oral @DRUG$ Keppra   ( 500 mg twice daily ) did not influence the pharmacokinetics of an oral @DRUG$ Includes 0.03 mg ethinylestradiol and 0.15 mg levonorgestrel or luteinising hormone and progesterone levels, indicating that impairment of antibetic efficacy is unlikely.	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Haloperidol reduced or eliminated the increases in FI responding produced by intermediate doses of either @DRUG$ or PCP in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of @DRUG$.	DDI-false
The results of the studies in patients with multiple sclerosis who: @DRUG$   and concomitant @DRUG$ ( AVONEX 30 mcg IM once weekly) or glatiramer acetate were not consistent with the need for dose adjustment of beta interferon or glatiramer acetate.	DDI-false
Reciprocal interactions may occur with concomitant use of Antizol and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, @DRUG$, @DRUG$, ketoconazole), though this has not been studied	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, @DRUG$, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
While no in vivo drug-drug interaction studies were conducted between @DRUG$ and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, @DRUG$, rifampin, and barbiturates) would be expected to decrease estazolam concentrations.	DDI-mechanism
These drugs include the @DRUG$ And other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
The concurrent use of @DRUG$ with @DRUG$ has not been formally studied .	DDI-false
Oral @DRUG$: @DRUG$ (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/ethinyl estradiol (1 mg /35 mcg combination, Ortho-Novum 1/35 ).	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, @DRUG$ , probenecid , @DRUG$ , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
@DRUG$: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and @DRUG$ therapy.	DDI-false
TABLE 1 Effects on Plasma Concentrations ( AUC 0 - 24 hrs ) of Loratadine and @DRUG$ After 10 days of co-administration ( @DRUG$ 10 mg ) in Normal Volunteers	DDI-false
Adequate monitoring of theophylline plasma concentrations should be considered when therapy with @DRUG$ is initiated or changed in patients receiving @DRUG$.	DDI-advise
BACKGROUND: The effects of combined administration of bombesin and @DRUG$ (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
CANCIDAS reduced the blood AUC0 - 12 of @DRUG$ 2 doses of 0.1 mg/kg at 12 hours intervals) on 10 October 2000 (see section 4.4). @DRUG$ 70 mg daily , as compared to results from a control period in which tacrolimus was administered alone .	DDI-false
In addition to the above mentioned interactions, chronic ( 2 weeks ) oral @DRUG$ Administration affects the metabolism of phenytoin, @DRUG$ , and methotrexate .	DDI-false
@DRUG$- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants , antihistamines , @DRUG$ , barbiturates , monoamine oxidase inhibitors , narcotics , @DRUG$ , psychotropic medications , or other drugs that produce CNS depression .	DDI-false
In comparison to the digital tolerance in dogs stunned with ketamine, @DRUG$ , or @DRUG$ The dosage of Ouabain needed to cause ventricular tachycardia was significantly higher, such as the LD50 of Ouabain, with ketamine or innovar than with pentobarbital.	DDI-false
Cimetidine : @DRUG$ It has been reported that there are clinically significant fluctuations in steady-state serum concentrations of different @DRUG$.	DDI-mechanism
However, if Argatroban is to be initiated after cessation of @DRUG$ therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of @DRUG$ therapy.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as @DRUG$ , intraconazole, ritonavir, @DRUG$ , saquinavir , erythromycin , etc . ) is indicated , reduction of the budesonide dose should be considered .	DDI-false
- @DRUG$ (e.g., Mexate) Use of methotrexate with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of @DRUG$	DDI-false
@DRUG$ in large amounts may counteract the antiepileptic effect of phenobarbital, phenytoin and @DRUG$, and increase the frequency of seizures in susceptible pediatric patients.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, @DRUG$, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Coadministration of @DRUG$ and Ortho-Novum 1/35  increased the exposure of @DRUG$ and ethinyl estradiol by 20% and 34%, respectively.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, @DRUG$, and verapamil.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$ , an anionic-binding resin, has a significant effect in reducing the rate and volume of @DRUG$ bioavailability .	DDI-mechanism
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
It may increase excretion of barbiturates, lithium, and @DRUG$ and may also increase the toxicity of @DRUG$.	DDI-false
Diphenhydramine hydrochloride has additive effects with alcohol and other CNS depressants (hypnotics, @DRUG$, @DRUG$, etc).	DDI-false
Coadministration of @DRUG$ The pharmacokinetics ( exposure ) or pharmacodynamics (blood glucose and insulin levels ) of @DRUG$ were not affected by glyburide ( 5 mg QD ) ( 40 mg twice daily ( day 1 ) and 40 mg QD ( days 2 - 7 ) ) with glyburide ( 5 mg QD ).	DDI-false
Dopamine antagonists : Da apomorphine is a @DRUG$ , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or @DRUG$ , may diminish the effectiveness of APOKYN .	DDI-false
In vitro studies have shown CASODEX can displace @DRUG$s , such as @DRUG$ , from their protein-binding sites .	DDI-false
gastrointestinal acidifying agents ( guanethidine, reserpine, @DRUG$ , @DRUG$ , fruit juices , etc . ) lower absorption of amphetamines .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$, doxorubicin, teniposide, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
therefore, @DRUG$ should be administered (with food) one hour after or more than two hours before @DRUG$.	DDI-advise
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur when it contains its derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam.	DDI-false
Intermediate doses of @DRUG$ or @DRUG$ produced transient increases in FI responding in monkeys and sustained increases in FI responding in pigeons;	DDI-false
@DRUG$: Concomitant use of anticholinesterase agents and @DRUG$ may produce severe weakness in patients with myasthenia gravis.	DDI-false
In monkeys, (-)-NANM was about 10 times more potent than @DRUG$ in decreasing responding, whereas in pigeons (-)-NANM was about equipotent with @DRUG$.	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, @DRUG$, or digoxin, irbesartan administration for 7 days had no effect on the pharmacodynamics of @DRUG$ (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
Protein Binding In vitro, @DRUG$ interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), tolbutamide, @DRUG$ (10% decrease in binding), or warfarin.	DDI-mechanism
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , @DRUG$ , tranquilizers ( e.g. , @DRUG$ ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Antibiotics : @DRUG$ have been reported to cause a significant decrease in @DRUG$ clearance .	DDI-mechanism
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or @DRUG$.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as @DRUG$, @DRUG$, phenytoin, dexamethasone, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
@DRUG$ can interact with @DRUG$ Elevation of the metabolism of chlorpromazine.	DDI-mechanism
WARFARIN : Co- administration of warfarin and @DRUG$ No changes in prothrombin time or coagulation factor VII occurred in healthy volunteers compared to concomitant use of @DRUG$ and placebo .	DDI-false
In addition , @DRUG$ The pharmacodynamics of @DRUG$ , acetylsalicylic acid , piroxicam , and digoxin , nor the pharmacokinetics of digoxin at steady state .	DDI-false
There are rare reports, however, from marketing experiences, of changes in effects of insulin or oral @DRUG$ in the presence of @DRUG$ that necessitated changes in the doses of such agents.	DDI-effect
Curariform muscle relaxants ( eg , tubocurarine ) and other drugs , including ether , succinylcholine , gallamine , @DRUG$ and sodium citrate , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral .	DDI-effect
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and @DRUG$), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
- Warfarin : The effect of @DRUG$ on the anti-coagulant effect of @DRUG$ was studied in a group of healthy subjects receiving daily doses of 2 - 5 mg of warfarin .	DDI-false
@DRUG$ : Amphetamines enhance the adrenergic effect of @DRUG$.	DDI-false
The pressor effects of @DRUG$ such as @DRUG$ or norepinephrine are enhanced by Bretylium Tosylate .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, @DRUG$, calcium-channel blockers, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
These drugs include the thiazides and other diuretics, @DRUG$, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Acidifying agents: Gastrointestinal acidifying agents (@DRUG$, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	DDI-mechanism
Haemodynamic effects of @DRUG$ and insulin were additive when @DRUG$ was co-administered but not under basal conditions.	DDI-false
The absorption of tetracycline, @DRUG$, @DRUG$, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramide, @DRUG$ , fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g. octreotide), sulphonamide antibiotics.	DDI-false
@DRUG$ : The concomitant administration of ciprofloxacin with the @DRUG$ Glyburide has, in rare cases, led to severe hypoglycaemia.	DDI-false
Antagonism between @DRUG$ and @DRUG$ in vitro has been demonstrated .	DDI-effect
@DRUG$/theophylline, lidocaine/quinidine, @DRUG$/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Reports in the literature suggest that plasma levels of @DRUG$ (and its active metabolite doxorubicinol) may be increased when paclitaxel and @DRUG$ are used in combination.	DDI-false
@DRUG$ or Oral Hypoglycemics: @DRUG$ may enhance the blood-sugar-reducing effect of insulin and oral hypoglycemics.	DDI-false
Patients receiving azathioprine and @DRUG$ concomitantly should have a dose reduction of @DRUG$ , to approximately 1/3 to 1/4 the usual dose .	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines @DRUG$ , triazolam GI motility agents : cisapride	DDI-advise
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., citalopram, @DRUG$, @DRUG$, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
acetaminophen/theophylline , lidocaine/@DRUG$ , phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , felodipine , digoxin , warfarin , @DRUG$ ==References====External links==	DDI-false
Selective Serotonin Reuptake Inhibitors ( SSRIs ): SSRIs ( e.g. , @DRUG$ , @DRUG$ Paoxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
@DRUG$: Coadministration of @DRUG$ (using an experimental soft-gelatin capsule formulation of saquinavir 1200mg) with VIRACEPT resulted in an 18% increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Hypotension - Patients on Diuretic Therapy : Patients on @DRUG$ , and especially those in whom diuretic therapy was recently instituted , may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$.	DDI-effect
Both @DRUG$ and @DRUG$ decrease extracellular levels of dopamine in the nucleus accumbens, but only ibogaine increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
May interact with thyroid medication ( e.g. , @DRUG$ ) , iodine-containing products , antacids , @DRUG$ ( e.g. , famotidine , ranitidine ) , and proton pump inhibitors ( e.g. , lansoprazole , omeprazole ) .	DDI-false
Injection : Lorazepam injection , like other injectable @DRUG$ , produces depression of the central nervous system when administered with ethyl alcohol , phenothiazines , barbiturates , MAO inhibitors , and other antidepressants . When scopolamine is used concomitantly with injectable @DRUG$ , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , @DRUG$ , @DRUG$ , oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Other interactions : Vardenafil had no effect on the pharmacodynamics of @DRUG$ ( glucose and insulin concentrations ) and @DRUG$ ( prothrombin time or other pharmacodynamic parameters ) .	DDI-false
@DRUG$ generally should not be given with @DRUG$ Because they reduce renal clearance of lithium and increase a high risk of lithium toxicity.	DDI-advise
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, @DRUG$, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$, or other drugs that produce CNS depression.	DDI-false
Imidazoles ( e. g. , ketoconazole , @DRUG$ , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$ , azathioprin, chloroquine, gold, @DRUG$ , leflunomide, sulfasalazine, and anakinra.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$ Meclofenamate sodium increases the effect of @DRUG$.	DDI-false
Metformin: In healthy subjects given single 500 mg doses of cephalexin and @DRUG$, plasma @DRUG$ mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis , it is particularly important that physicians query patients or their guardians carefully about benzodiazepine , alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of @DRUG$ is planned .	DDI-false
In addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , @DRUG$ , phenytoin , dexamethasone , or carbamazepine ) with CANCIDAS may result in clinically meaningful reductions in @DRUG$ concentrations .	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Non-steroidal anti-inflammatory drugs : In some patients, the administration of a non-steroidal anti-inflammatory agent may reduce the diuretic, natriuretic and antihypertensive effects of @DRUG-DRUG$.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
However, in the second study, administration of 12 g cholestyramine 1 hour before dinner and 0.3 mg @DRUG$ About 4 hours after the same evening meal, cerivastatin AUC decreased by less than 8% and Cmax decreased by about 30% compared to the dose. @DRUG$ alone .	DDI-false
Anticonvulsants (@DRUG$): Steady state plasma exposure (AUC) of valdecoxib (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of @DRUG$ (a CYP 3A4 inducer).	DDI-false
Furthermore, it was proposed that: @DRUG$ This resulted in induction of P-450IIE1 in patients with liver, which in turn resulted in a greater proportion of ingested @DRUG$ It is converted to toxic metabolites.	DDI-mechanism
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including @DRUG$ , with multivalent cation-containing products such as @DRUG$ Or aluminum antacids, sucralfat, VIDEX chew/buffer tablets or child powder, or products that contain calcium, iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-mechanism
@DRUG$ may displace acidic drugs such as @DRUG$ or tolbutamide from their binding sites.	DDI-mechanism
@DRUG$ The effect of alcohol, barbiturates and other @DRUG$ can be increased.	DDI-effect
Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as @DRUG$ , @DRUG$ , calcium channel blockers, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
@DRUG$ While a synergistic relationship with amphotericin B has been reported, concomitant administration may increase the toxicity of amphotericin B. @DRUG$ By possible increase in cellular uptake and/or impairment of renal excretion.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , @DRUG$ , and amikacin ) , amphotericin B , @DRUG$ , intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
Single doses of either cholestyramine or @DRUG$ resins bind the @DRUG$ and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	DDI-mechanism
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in @DRUG$ half-life.	DDI-false
Possible drug interactions of @DRUG$ with succinylcholine or with other @DRUG$.	DDI-int
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , citalopram , @DRUG$ , fluoxetine , sertraline , and @DRUG$ , inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
Since animal studies suggest that the action of barbiturates may be prolonged by therapy with @DRUG$, @DRUG$ should be employed with caution.	DDI-false
@DRUG$ Serum concentrations should be closely monitored if treatment with @DRUG$ in patients receiving lithium .	DDI-false
The concomitant intake of alcohol and Acamprosate does not affect the pharmacokinetics of either @DRUG$ or @DRUG$.	DDI-false
Potential drug interactions between Keppra   and other AEDs ( carbamazepine , gabapentin , @DRUG$ , phenobarbital, phenytoin, primidone and @DRUG$ ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
Since @DRUG$ is an @DRUG$ , it may have a strong affinity for anions other than the bile acids .	DDI-false
A similar association, albeit less pronounced, was proposed with barbiturates, @DRUG$ , @DRUG$ , carbamazepine, griseofulvin, topiramate, and possibly ampicillin and tetracycline 72.	DDI-false
therefore, close monitoring of prothrombin time is recommended, and adjustment of the @DRUG$ dose may be necessary when @DRUG$ is administered concomitantly.	DDI-advise
- anabolic steroids (Nandrolone [e.g. Anaboline ], Oxandrolone [e.g., @DRUG$ ] , @DRUG$ [ e.g. Anadrol ], stanozozole [ e.g. Winstrol ] or	DDI-false
- Anabolic steroids ( @DRUG$ [ e.g. Anaboline ], Oxandrolone [ e.g. Anavar ], Oxymetholone [ e.g., @DRUG$ ] , stanozolol [ e.g. , Winstrol ] ) or	DDI-false
@DRUG$: The concomitant use of Bepridil with long- and short-acting @DRUG$ has been safely tolerated in patients with stable angina pectoris.	DDI-false
- Vitamin K (e.g., @DRUG$, Synkayvite) Use of @DRUG$ with these medicines may increase the chance of side effects affecting the blood	DDI-false
Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or @DRUG$ were observed following coadministration of loratadine with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of @DRUG$, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	DDI-false
Cyclosporine, Digoxin, Methotrexate @DRUG$, like other NSAIDs, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of @DRUG$, digoxin, methotrexate, and increased toxicity.	DDI-mechanism
Diuretics: Patients on @DRUG$, especially those with intravascular volume depletion, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$.	DDI-effect
Patients receiving other narcotic analgesics, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Physicians needing to treatpatients co-infected with tuberculosis andusing a @DRUG$ containing regimen mayuse @DRUG$ instead .	DDI-false
Vardenafil ( 20 mg ) did not potentiate the hypotensive effects of @DRUG$ during the 4-hour observation period in healthy volunteers when administered with @DRUG$ ( 0.5 g/kg body weight ) .	DDI-false
@DRUG$, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	DDI-false
Drug/Laboratory Test Interaction @DRUG$ â™ª Can cause a false, low measurement of the serum â™ª @DRUG$ Levels with the Digi Tab RIA kit for digoxin.	DDI-false
- Anabolic steroids ( nandrolone [ e.g. , @DRUG$ ] , oxandrolone [ e.g. , Anavar ] , oxymetholone [ e.g. , @DRUG$ ], stanozolol [ e.g. Winstrol ] or	DDI-false
Although the specific drug interaction was not studied in a clinical trial, there have been more than 50 episodes of concomitant use of antifibrinolytic therapies (i.e., @DRUG$, aminocaproic acid) and @DRUG$.	DDI-false
All subjects received @DRUG$ ( 1,200 mg twice a day ) for 4 days , followed by a 7-day washout period , followed by either rifabutin ( 300 mg once a day [ QD ] ) ( cohort 1 ) or @DRUG$ ( 600 mg QD ) ( cohort 2 ) for 14 days .	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, @DRUG$, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine , @DRUG$ , or pentobarbital, the dosage of Ouabain needed to cause ventricular tachycardia was significantly higher, such as the LD50 of Ouabain, with @DRUG$ Or Innovar as with Pentobarbital.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , @DRUG$ Amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Cyclopropane or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$ , such as @DRUG$.	DDI-false
Injection : @DRUG$ Injection, like other injectable benzodiazepines, produces depression of the central nervous system when with ethyl alcohol, phenothiazine, @DRUG$ , MAO inhibitors , and other antidepressants . When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-effect
Cyclosporin : Management of @DRUG$ concomitantly with @DRUG$ The effect of cyclosporin has been associated with an increase in the toxicity caused by cyclosporin, possibly due to decreased synthesis of renal prostacycline.	DDI-mechanism
Co-administration of @DRUG$ and aminoglycosides or other agents interfering with neuromuscular transmission (e.g., @DRUG$) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-advise
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	DDI-false
@DRUG$ â€¢ the concomitant use of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$ , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and @DRUG$ in rats;	DDI-false
@DRUG$: Coadministration of single doses of eszopiclone 3 mg and @DRUG$ 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.	DDI-false
@DRUG$ In vitro and/or in vivo data show that fluconazole, itraconazole and oral ketoconazole significantly inhibit the metabolism of cisapride, which may lead to an increase in plasma. @DRUG$ The concentrations and prolongation of the QT interval on the ECG.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ : Digoxin concentrations are increased by about 15 % when @DRUG$ ==References====External links==	DDI-false
In separate studies in patients receiving maintenance doses of warfarin, hydrochlorothiazide or @DRUG$ , irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin ( prothrombin time ) or pharmacokinetics of @DRUG$.	DDI-false
@DRUG$, @DRUG$, or narcotics: potentiation of orthostatic hypotension may occur.	DDI-false
Ketoconazole ( 200 mg once daily ) produced a 10-fold increase in @DRUG$ AUC and a 4-fold increase in Cmax when co-administered with @DRUG$ 5 mg) in healthy volunteers.	DDI-false
Central nervous system depressants : Co-administration of @DRUG$ Fentanyl transdermal system (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotic agents, sedatives (e.g., @DRUG$ ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-effect
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and itraconazole) decrease @DRUG$ metabolism and increase @DRUG$ plasma concentrations.	DDI-false
Ritonavir (600 mg b.i.d.) co-administered with @DRUG$ 5 mg resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in vardenafil Cmax.	DDI-false
@DRUG$: @DRUG$ (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and vardenafil plasma levels were not altered when dosed simultaneously.	DDI-false
Warfarin-@DRUG$ can antagonize the effect of @DRUG$	DDI-effect
@DRUG$ @DRUG$ , as well as a metabolite of furazolidone , slow amphetamine metabolism .	DDI-false
@DRUG$: Co- administration of warfarin and @DRUG$ to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of warfarin and placebo.	DDI-false
@DRUG$ , Including Oral , Injectable , Transdermal , and Implantable Contraceptives : An interaction study demonstrated that co-administration of bosentan and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14 % and 31 % , respectively .	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and simethicone ) with @DRUG$ reduced serum levels and urinary excretion of @DRUG$ In comparison to Fosinopril alone, which suggests that antacids may affect the absorption of Fosinopril.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , @DRUG$ , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , @DRUG$ , salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., oral) @DRUG$ ) .	DDI-false
Central Nervous System Depressants: The concomitant use of @DRUG$  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including @DRUG$ and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma ( HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide), @DRUG$ , teniposide , and prednisone with @DRUG$ Bleomycin) without antiretroviral therapy.	DDI-false
This effect can be mediated by the ability to @DRUG$ It is used to induce microsomal enzymes and thus the catabolism of @DRUG$.	DDI-mechanism
Coadministration of @DRUG$ with @DRUG$ For this reason, terfenadine resulted in increased plasma concentrations, which in rare cases resulted in life-threatening cardiac dysrrhythmias and death.	DDI-mechanism
- @DRUG$, oral (diabetes medicine you take by mouth) Use of oral antidiabetics with sulfapyridine may increase the chance of side effects affecting the blood and/or the side effects or oral @DRUG$	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$, @DRUG$, and barbiturates, and the antituberculosis drug rifampin.	DDI-false
Coadministration of @DRUG$ with 40 mg SULAR tablets in epileptic patients lowered the @DRUG$ Plasma concentrations up to undetectable concentrations.	DDI-false
Ethinyl estradiol and norethindron: concomitant use of VIRACEPT with @DRUG$ resulted in a 47 % decrease in ethinyl estradiol and an 18 % decrease in @DRUG$ plasma concentrations .	DDI-false
Non-steroidal anti-inflammatory drugs : In some patients, the administration of a @DRUG$ The diuretic, natriuretic and antihypertensive effects of Loop, @DRUG$ can be reduced.	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , @DRUG$ , local anesthetics , procainamide , and quinidine .	DDI-false
If Bezalip or Bezalip retard is used concomitantly with @DRUG$ A minimum interval of 2 hours between the two medicinal products should be maintained (e.g. cholestryramine), since the absorption of @DRUG$ Bezalip retard is impaired	DDI-false
@DRUG$ : Coadministration of a single dose of @DRUG$ Promethazine and promethazine (10 and 25 mg respectively) resulted in a 15% decrease in the maximum plasma concentrations of zaleplon, but no change in the area under the plasma concentration-time curve.	DDI-false
@DRUG$-Concomitant intake of colestipol and vitamin K may reduce the absorption of @DRUG$.	DDI-false
@DRUG$ (SSRIs): @DRUG$ (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants : @DRUG$ In patients treated with @DRUG$ Or tricyclic antidepressants, because the effect of formoterol on the cardiovascular system can be enhanced by these active substances.	DDI-advise
Patients receiving @DRUG$ and allopurinol concomitantly should have a dose reduction of @DRUG$, to approximately 1/3 to 1/4 the usual dose.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum antacids, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
These drugs include the @DRUG$ and other diuretics, @DRUG$, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or @DRUG$ to patients receiving monoamine oxidase inhibitors or tricyclic antidepressants may produce severe, prolonged hypertension.	DDI-false
The safety and efficacy of concomitant use of @DRUG$ and @DRUG$ is unknown , and the concomitant use of two potentially hepatotoxic medications is not ordinarily recommended unless the probable benefits outweigh the known risks .	DDI-effect
Concomitant administration of fenofibrate (equivalent to 145mg TRICOR) with @DRUG$ (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for @DRUG$ by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$: In normal volunteers, concomitant administration of diflunisal and acetaminophen resulted in an approximate 50% increase in plasma levels of @DRUG$.	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
The effect of benzodiazepines may be increased by: @DRUG$ , @DRUG$ â€¢ alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazine, psychotropic drugs, or other drugs that produce CNS depression.	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , @DRUG$/@DRUG$ , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
@DRUG$ Keppra  (1000 mg twice daily) did not influence the pharmacokinetics of @DRUG$.	DDI-false
@DRUG$-containing therapies should not be used with @DRUG$ as they may diminish its pharmacologic action.	DDI-advise
Haloperidol : @DRUG$ â€¢ Impairs dopamine receptors and thus inhibits the central stimulating effects of @DRUG$.	DDI-effect
For example, when vitamin K antagonists are administered concomitantly with @DRUG$, prothrombin time should be carefully monitored and if necessary, the dosage of @DRUG$ should be reduced.	DDI-false
- Oral @DRUG$ Containing (pills for birth control) @DRUG$ or	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , @DRUG$ , ritonavir , and erythromycin ) has not been studied , increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications .	DDI-false
Other CNS depressant drugs (e.g. @DRUG$, @DRUG$, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and @DRUG$/@DRUG$.	DDI-false
Corticosteroids, @DRUG$ and Diuretics: Concomitant treatment with xanthine derivatives, steroids, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-false
@DRUG$:Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	DDI-false
Effect of Other Drugs on the Pharmacokinetics of Clonazepam : Literature reports suggest that @DRUG$ , an agent that decreases stomach acidity , does not greatly alter @DRUG$ pharmacokinetics .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : @DRUG$ Antimycobacterial agents : @DRUG$ benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
It would be expected that @DRUG$ use during therapy with @DRUG$ would worsen the incidence or severity of diarrhea , but this has not been studied .	DDI-effect
It is therefore necessary to be familiar with the clinical and paraclinical pattern @DRUG$ deficit and to discriminate between magnesium deficiency due to an insufficient @DRUG$ The intake, which requires only oral physiological supplement and magnesium deficiency, related to a dysregulation of the control mechanisms of magnesium status, which requires more or less specific regulation of its causal dysregulation.	DDI-false
As with other @DRUG$ , it should be noted that HALDOL may be capable of potentiating CNS depressants such as anesthetics , opiates , and @DRUG$.	DDI-effect
In patients with mild to moderate hypertension, 25 mg daily @DRUG$ with the @DRUG$ benazepril , 10 to 40 mg for 4 weeks , was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to ACE inhibitor alone .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including nonsteroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, @DRUG$ , @DRUG$ , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
In a pharmacokinetic interaction study with @DRUG$ , bioavailability parameters , the degree of protein binding , and the anticoagulant effect ( measured by prothrombin time ) of @DRUG$ were not significantly changed .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
@DRUG$ has a tendency to antagonize the skeletal muscle relaxing effect of tubocurarine and may potentiate the action of @DRUG$.	DDI-effect
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, @DRUG$, amiodarone, nicardipine, and nifedipine.	DDI-false
- Anabolic steroids ( nandrolone [ e.g. , Anabolin ] , @DRUG$ [ e.g. , Anavar ] , @DRUG$ [ e.g. Anadrol ], stanozozole [ e.g. Winstrol ] or	DDI-false
â€¢ Hormonal contraceptives, including oral, injectable, transdermal and implantable contraceptives: An interaction study showed that co-administration of bosentan and oral contraceptives with other medicinal products (e. g. @DRUG$ â€¢ Ortho-Novum caused average decreases in @DRUG$ Ethinyl estradiol levels are 14% and 31% respectively.	DDI-false
@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when @DRUG$ was given alone or when Proquin XR was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
The effects of @DRUG$ (@DRUG$) on inositol 1,4,5-trisphosphate (InsP(3))-induced responses were studied in rat bone marrow megakaryocytes with the patch-clamp whole-cell recording technique in combination with fura-2 microfluorometry.	DDI-false
A possible interaction between glyburide and @DRUG$, a @DRUG$, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.	DDI-false
@DRUG$ In vitro and/or in vivo data indicate that: @DRUG$ , itraconazole , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-false
Data from in vitro studies of benzodiazepines other than @DRUG$ suggest a possible drug interaction for the following : @DRUG$ , cyclosporin, amiodarone, nicardipine, and nifedipine.	DDI-int
Indinavir : Coadministration of indinavir with @DRUG$ resulted in an 83 % increase in @DRUG$ Plasma AUC and indinavir plasma A.C. increased by 51%.	DDI-false
These drugs include the @DRUG$ And other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazide.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., @DRUG$, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, @DRUG$, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Specific interaction studies have demonstrated the following: @DRUG$: During the first day of concomitant administration, trough concentrations of @DRUG$ were increased by about 30-fold.	DDI-false
@DRUG$ : In vitro and/or in vivo data indicate that fluconazole , @DRUG$ , and oral ketoconazole markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-false
@DRUG$ : Concomitant administration of @DRUG$ at 200 mg QD resulted in a two-fold increase in celecoxib plasma concentration .	DDI-false
The following are examples of substances that can reduce the blood glucose-lowering effect: @DRUG$ , niacin, danazol, diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazide, phenothiazine derivatives, somatropin, @DRUG$ Oestrogens, progestogens (e.g. in oral contraceptives).	DDI-false
A similar association, albeit less pronounced, was proposed with @DRUG$ , phenylbutazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin and @DRUG$ ( 72 )	DDI-false
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without propantheline (an anticholinergic agent with multiple effects on the GI tract) to healthy volunteers, the AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone.	DDI-false
Other medicines: In small groups of patients ( 7 - 10/interaction study ), the concomitant administration of azathioprin, gold, @DRUG$ , D-penicillamine , prednisolone , doxycycline , or digitoxin did not significantly affect the peak levels and AUC values of @DRUG$.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with @DRUG$ may increase toxicity in these organ systems.	DDI-effect
In patients receiving Nalfon and a @DRUG$ concomitantly, any reduction in steroid dosage should be gradual in order to avoid the possible complications of sudden @DRUG$ withdrawal.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and @DRUG$ Concomitant use with saquinavir may result in increased plasma concentrations.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-false
@DRUG$ ( Neostgmin, Physostigmin), @DRUG$ , quinine, procainamide may increase toxicity and cause heart respiratory depression.	DDI-false
â€¢ Amiodarone together with @DRUG$ increases @DRUG$ serum concentration by 33 % after two days .	DDI-false
Methotrexate Renal tubular transport of @DRUG$ may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of methotrexate.	DDI-mechanism
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , @DRUG$ , hypnotics , tranquilizers ( e.g. , benzodiazepines ) , general anesthetics , @DRUG$ , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
Uricosuric drugs , such as @DRUG$ and sulfinpyrazone , can inhibit renal tubular secretion of @DRUG$.	DDI-mechanism
Diclofenac may cause serum concentrations of @DRUG$ Methotrexate and increase @DRUG$ s nephrotoxicity .	DDI-false
Colestipol : Plasma concentrations of atorvastatin decreased approximately 25 % when @DRUG$ and @DRUG$ were coadministered .	DDI-mechanism
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Concomitant administration of Mefloquine and other related compounds (eg, quinine, @DRUG$ and @DRUG$) may produce electrocardiographic abnormalities and increase the risk of convulsions.	DDI-false
For example, inhibitors are azole antimycotics, @DRUG$ , clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodon, nicardipine, propofol, @DRUG$ , quinidine, and verapamil.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Concurrent administration of drugs possessing nephrotoxic ( e.g. , aminoglycosides , indomethacin ) , myelotoxic ( e.g. , cytotoxic chemotherapy ) , cardiotoxic ( e.g. , @DRUG$ ) or hepatotoxic ( e.g. , methotrexate , @DRUG$ Effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
May interact with the following : @DRUG$ , colestipol ( use with thiazide diuretics may prevent the @DRUG$ from working properly ;	DDI-false
@DRUG$ , ampicillin , @DRUG$ , chlortetracycline , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum .	DDI-false
To determine if the injection of thiosulfate is larger doses of thiosulfate @DRUG$ to be administered , a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of cisplatin .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , @DRUG$ , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , @DRUG$ ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Potential drug interactions between Keppra  and other AEDs (@DRUG$, gabapentin, @DRUG$, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
( In some patients @DRUG$ The diuretic, natriuretic and blood pressure lowering effects of loop, potassium saving and @DRUG$ can be reduced.	DDI-effect
These results suggest that both dexamethasone and retinyl acetate , and possibly other glucocorticoids and @DRUG$ Prostate epithelium proliferation can be regulated by dose-dependent changes in insulin and @DRUG$ activity.	DDI-effect
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
These drugs include: @DRUG$ And other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and @DRUG$.	DDI-false
We report the case of a young person with altered consciousness caused by a carbamazepine overdose with a positive @DRUG$ level to alert clinicians to the cross-reactivity of @DRUG$ with a toxicology screen for tricyclic antidepressants .	DDI-false
As with other @DRUG$ It should be noted that HALDOL may be able to treat CNS depressants such as CNS depressants. @DRUG$ , opiates, and alcohol.	DDI-effect
@DRUG$ Keppra ( 1000 mg twice daily ) did not affect the pharmacokinetics of R and @DRUG$.	DDI-false
The intensity, uniformity and time course of the anticoagulant interference by phenobarbital, @DRUG$ , glutethimide , chloral hydrate and @DRUG$ The treatment was systematically studied in 16 patients receiving coumarin therapy.	DDI-false
Warfarin : @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG$n or there were changes in the pharmacodynamic profile (prothrombin time) after a single oral dose of 25 mg warfarin.	DDI-false
Estrogens, including oral contraceptives: @DRUG$ may decrease the hepatic metabolism of certain @DRUG$ , which increases its effect.	DDI-mechanism
Patients who have been treated with @DRUG$ within two to three weeks prior to the administration of dopamine HCl should receive initial doses of @DRUG$ no greater than one-tenth (1/10) of the usual dose.	DDI-false
@DRUG$ may increase the ototoxic potential of @DRUG$, especially in the presence of impaired renal function.	DDI-effect
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and @DRUG$ when administered concomitantly with an intravenous opiate such as @DRUG$.	DDI-mechanism
Gleevec will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-@DRUG$, dihydropyridine calcium channel blockers, certain @DRUG$, etc.).	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, nefazodone, troleandomycin, @DRUG$, nelfinavir) would be expected to behave similarly.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with pentobarbital.	DDI-false
Selective serotonin reuptake inhibitors ( @DRUG$ SSRIs (e.g. fluoxetine, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when co-administered with @DRUG$.	DDI-false
Lithium: Increased serum @DRUG$ levels and symptoms of lithium toxicity have been reported in patients receiving concomitant lithium and @DRUG$ therapy.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , NSAIDs , @DRUG$ , @DRUG$ , azathioprin, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine and anakinra.	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : @DRUG$ ( e.g. , gentamicin , @DRUG$ Amphotericin B, cyclosporin, nonsteroidal anti-inflammatory drugs (e.g. ibuprofen), tacrolimus, vancomycin.	DDI-false
Paroxetine: Coadministration of single doses of @DRUG$ 3 mg and @DRUG$ 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., aminoglycosides, @DRUG$), myelotoxic (e.g., @DRUG$ chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
â€¢ Hormonal contraceptives Concomitant use of Trileptal with an oral contraceptive has shown that it affects the plasma concentrations of the two hormonal components, @DRUG$ (EE ) and @DRUG$ ( LNG ) .	DDI-false
@DRUG$-@DRUG$ The intestine can sterilize and reduce the vitamin K contribution to the body through the intestinal microflora.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with TAXOL should be premedicated with corticosteroids ( such as @DRUG$ , diphenhydramine and H2 antagonists (such as cimetidine or @DRUG$ ) .	DDI-false
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of @DRUG$ (20% decrease in binding), tolbutamide, @DRUG$ (10% decrease in binding), or warfarin.	DDI-false
We report the case of an adolescent with altered consciousness caused by @DRUG$ overdose with a positive @DRUG$ level to alert clinicians to the cross-reactivity of carbamazepine with a toxicology screen for tricyclic antidepressants.	DDI-effect
Similarly , @DRUG$ decreased the rate of elimination of @DRUG$ ( about 50% ) by the same mechanism.	DDI-mechanism
While all the selective serotonin reuptake inhibitors (@DRUG$), e.g., citalopram, escitalopram, fluoxetine, sertraline, and @DRUG$, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
In clinical studies performed with Fondaparinux, the concomitant use of oral anticoagulants (warfarin), platelet inhibitors (@DRUG$), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
Concomitant administration of @DRUG$ (equivalent to 145 mg TRICOR) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in @DRUG$ AUC values in 22 healthy males.	DDI-false
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, terfenadine antimigrain: ergot derivatives antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agent : @DRUG$	DDI-false
Therefore , @DRUG$ may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability ( eg , ketoconazole , iron salts and @DRUG$ ) .	DDI-mechanism
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors , e.g. , paroxetine , fluoxetine , and @DRUG$.	DDI-advise
Presumably, @DRUG$ acts as a stimulator of @DRUG$ metabolism and has been reported to cause decreased serum levels of the coumarin anticoagulants and increased prothrombin-proconvertin concentrations.	DDI-mechanism
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones, such as ketoconazole, @DRUG$, and @DRUG$.	DDI-false
Anticoagulants: Potentiation of @DRUG$-type (CYP2C9 and @DRUG$ substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
@DRUG$: Concomitant administration of @DRUG$ (6 mg/kg once every 24 hours for 5 days) and warfarin (25 mg single oral dose) had no significant effect on the pharmacokinetics of either drug, and the INR was not significantly altered.	DDI-false
- When @DRUG$ or Bezalip retard is used concurrently with @DRUG$ (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or Bezalip retard is impaired	DDI-advise
Although glucocorticoids have been shown to reduce PROLEUKIN-induced adverse reactions such as fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, co-administration of these active substances with PROLEUKIN may reduce the efficacy of PROLEUKIN against the tumour and should therefore be avoided. 12 @DRUG$ @DRUG$ may increase hypotension and other antihypertensive agents.	DDI-effect
CANCIDAS reduced the blood AUC0-12 of tacrolimus by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when @DRUG$ (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of CANCIDAS 70 mg daily, as compared to results from a control period in which @DRUG$ was administered alone.	DDI-false
@DRUG$ , such as probenecid and @DRUG$ , can inhibit renal tubular secretion of nitrofurantoin .	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, @DRUG$, and barbiturates) would be expected to decrease @DRUG$ concentrations.	DDI-false
A similar association, albeit less pronounced, was proposed with @DRUG$ phenylbutazone, phenytoin sodium, @DRUG$ and possibly with griseofulvin, ampicillin, and tetracyclines (72)	DDI-false
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., @DRUG$, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with @DRUG$ as well.	DDI-mechanism
Psychoactive Drugs: Hallucinations have been reported when @DRUG$ was used in patients taking psychoactive drugs (fluoxetine, thiothixene, @DRUG$).	DDI-effect
This change was not considered clinically significant and no dose adjustment is required if: @DRUG$ and @DRUG$ are coadministered .	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
Other strong inhibitors of CYP3A4 (e.g., @DRUG$, clarithromycin, nefazodone, @DRUG$, ritonavir, nelfinavir) would be expected to behave similarly.	DDI-false
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever , renal insufficiency , hyperbilirubinemia , confusion , and dyspnea , concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of @DRUG$ Beta-blockers and other antihypertensive agents may increase the hypotension observed with PROLEUKIN.	DDI-false
Conversely , the @DRUG$ It has been reported that serum levels have been increased and the serum half-life of @DRUG$ by inhibiting its metabolism .	DDI-mechanism
While all selective serotonin reuptake inhibitors ( @DRUG$ ) , e.g. , fluoxetine , @DRUG$ , paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
Oral @DRUG$ CAUTION SHOULD BE EXERCISED WHEN @DRUG$ ARE GIVEN IN CONJUNCTION WITH TRICOR.	DDI-false
Patients receiving @DRUG$ and allopurinol concomitantly should have a dose reduction of @DRUG$ , to approximately 1/3 to 1/4 the usual dose .	DDI-false
The possibility of hypotensive effects with enalapril or @DRUG$ The treatment can be either by stopping the diuretic or by increasing the intake of salt before starting treatment with @DRUG$ or enalaprilat .	DDI-false
Administration of doxapram to patients who are receiving @DRUG$ or @DRUG$ may result in an additive pressor effect .	DDI-false
Digoxin, nimodipine and @DRUG$ : Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$ And losartan has no significant effect on bosentan plasma levels.	DDI-false
iodine or iodine surplus may have the effect of @DRUG$ , and an @DRUG$ Deficiency can increase the effect of carbimazole.	DDI-false
The concomitant use of @DRUG$ or other @DRUG$ may have an additive effect.	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without propantheline ( an anticholinergic agent with multiple effects on the GI tract ) to healthy volunteers , the AUC of @DRUG$ was 10 % lower and the Cmax of @DRUG$ was 20 % lower when the orally disintegrating tablet was given with propantheline compared to when it was given alone .	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, phenothiazines, antihistamines, and @DRUG$ may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
The absorption of tetracycline, @DRUG$, penicillin G, hydrochlorothiazide, and @DRUG$ was significantly decreased when given simultaneously with colestipol hydrochloride;	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone , suggesting that @DRUG$ may impair absorption of fosinopril .	DDI-false
@DRUG$ Co-administration of indinavir and VIRACEPT resulted in an increase in @DRUG$ plasma AUC and a 51 % increase in indinavir plasma A.C.	DDI-false
In addition, the results of regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance (efavirenz, nevirapine, @DRUG$ CANCIDAS may cause clinically significant reductions in @DRUG$ concentrations .	DDI-false
The co-administration of Natrecor with IV @DRUG$ such as nitroglycerin, nitroprusside, milrinone, or IV @DRUG$ has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
@DRUG$: The concomitant administration of ciprofloxacin with the sulfonylurea @DRUG$ has, on rare occasions, resulted in severe hypoglycemia.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, @DRUG$, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
Treatment with CYP3A4 inhibitors (such as ketoconazole, @DRUG$ , ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, @DRUG$ The dose should be considered.	DDI-advise
The pharmacokinetics of @DRUG$ and its major metabolite 6-beta-naltrexol were unaffected following co-administration with @DRUG$.	DDI-false
No data are available for the concomitant use of INVIRASE/@DRUG$ or @DRUG$/ritonavir with garlic capsules.	DDI-false
Digoxin @DRUG$   ( 1000 mg twice daily ) did not influence the pharmacokinetics and pharmacodynamics ( ECG ) of @DRUG$ given as a 0.25 mg dose every day .	DDI-false
â€¢ Drug interactions: Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors ( @DRUG$ ): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ Eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - tricyclic antidepressants : flupenthixol increases the effect of tricyclic antidepressants	DDI-false
Phenytoin: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.	DDI-mechanism
No Important Interactions To Date @DRUG$ does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, @DRUG$ , felodipine , digoxin , warfarin , @DRUG$ , carvedilol , ethanol or itraconazole .	DDI-false
Cohort 1 then received amprenavir plus @DRUG$ for 10 days, and cohort 2 received amprenavir plus @DRUG$ for 4 days.	DDI-false
Terfenadine: Administration of @DRUG$ with @DRUG$ resulted in the appearance of unchanged terfenadine in plasma;	DDI-false
In separate studies of patients receiving maintenance doses of @DRUG$, hydrochlorothiazide, or digoxin, @DRUG$ administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of digoxin.	DDI-false
@DRUG$ : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , granisetron , dolasetron , palonosetron , and @DRUG$ ) is contraindicated.	DDI-false
Similarly dialyzed were @DRUG$ , quinidine , and @DRUG$ , both at therapeutic concentrations in serum and with ethanol in three different concentrations in serum.	DDI-false
Remarkably, the systemic exposure ( AUC0 - 12 ) of dapsonhydroxylamin ( DHA) in the presence of @DRUG$/@DRUG$ was more than doubled.	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
The aim of this paper was to study the interaction between @DRUG$ and both enkephalins or its synthetic analogue @DRUG$, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as phenytoin, @DRUG$, @DRUG$), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , @DRUG$ , VIDEX chewable/buffer tablets or pediatric powder, or products containing calcium, @DRUG$ Zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the @DRUG$ (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Interaction between @DRUG$ and @DRUG$ In the development of spontaneous motility in chick embryos.	DDI-effect
@DRUG$ , ampicillin , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum .	DDI-false
Antifungals : In vitro and/or in vivo data indicate that fluconazole , itraconazole , and oral @DRUG$ The metabolism of @DRUG$ , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
Pre-treatment of megakaryocytes with extracellular @DRUG$ * ( 50 microM ) also inhibited @DRUG$-induced reactions.	DDI-effect
the doses of @DRUG$ required to antagonize the effects of (-)-NANM were more than 100 times higher than those required to antagonize the effects of @DRUG$.	DDI-effect
The administration of repeated doses of FACTIV did not affect the pharmacokinetics of the repeated dose of FACTIV. @DRUG$ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, @DRUG$, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
This appears to be the only clinically relevant interaction of this species with @DRUG$ Although theoretically, the concomitant use of other drugs is known to alter the heart conduction (e.g., anti-arrhythmic or beta-adrenergic blockers, calcium channel blockers, @DRUG$ Tricyclic antidepressants and phenothiazines can also contribute to the prolongation of the QTc interval.	DDI-effect
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, @DRUG$, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Coadministration of @DRUG$ decreased the maximum plasma concentration of @DRUG$ by 6%, decreased clearance by 38%, and increased half-life by 58%.	DDI-mechanism
These drugs include the @DRUG$ And other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$ , sympathomimetics , calcium channel blocking drugs , and isoniazid .	DDI-false
Antidepressants: In vitro data indicate that nefazodone inhibits the metabolism of @DRUG$, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
@DRUG$ : Clinical studies, as well as post-marketing observations, have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazides in some patients .	DDI-false
Antimycobacterial Agents : @DRUG$ The plasma concentrations of @DRUG$ are reduced due to the concomitant use of this medicine with saquinavir in an antiretroviral regimen.	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, @DRUG$, monoamine oxidase inhibitors, @DRUG$, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, @DRUG$, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, @DRUG$/acetaminophen and valproic acid/@DRUG$.	DDI-false
Micro-dosed Progesterone Preparations : Micro-dosed progesterone preparations ( minipills that do not contain an @DRUG$ ) may be an inadequate method of contraception during @DRUG$ therapy .	DDI-false
CNS-Active Drugs @DRUG$: Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after @DRUG$ administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after ethanol administration.	DDI-false
These effects were not observed when @DRUG$ 20 mg was taken 24 hours before the @DRUG$.	DDI-false
@DRUG$ MAOI antidepressants, as well as a metabolite of @DRUG$ , slow amphetamine metabolism .	DDI-false
In vitro data suggest that: @DRUG$ When compared to @DRUG$ , has a less pronounced influence on the biotransformation system responsible for the metabolism of astemizole.	DDI-false
In contrast to the digital tolerance in dogs, Innovar Vet is anaesthetized with ketamine, or @DRUG$ The dosage of Ouabain needed to cause ventricular tachycardia was significantly higher, such as the LD50 of Ouabain, with ketamine or @DRUG$ As with Pentobarbital.	DDI-false
This medication can be used with alcohol or other CNS depressants (may potentiate the CNS depressive effect of either these medications or @DRUG$ ) , @DRUG$ or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ) , and monoamine oxidase ( MAO ) inhibitors ( concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ) .	DDI-false
A similar association, albeit less pronounced, was proposed with barbiturates, phenyl-butazone, @DRUG$ , carbamazepine and possibly with griseofulvin, @DRUG$ â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€” â€”	DDI-false
Erythromycin Co-administration of @DRUG$ ( @DRUG$ ) with erythromycin resulted in approximately 2.5- fold increase in the AUC and Cmax , and about 2- fold prolongation in the half- life of felodipine .	DDI-false
Therefore , the combined use of @DRUG$ with @DRUG$ should generally be avoided .	DDI-advise
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma ( HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e. cyclophosphamide), @DRUG$ , teniposide , and @DRUG$ â€¢ with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
For example , when vitamin K antagonists are administered concomitantly with @DRUG$ The prothrombin time should be carefully monitored and, if necessary, the dose of @DRUG$ should be reduced .	DDI-false
Reciprocal interactions may occur with concomitant use of @DRUG$ and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, @DRUG$), though this has not been studied	DDI-mechanism
@DRUG$: In vitro and/or in vivo data show that clarithromycin, erythromycin, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , @DRUG$ , disulfiram, ethionamide, @DRUG$ , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Close supervision and careful adjustment of dosage are required when @DRUG$ is administered with @DRUG$ or sympathomimetic drugs.	DDI-advise
The action of the benzodiazepines may be potentiated by anticonvulsants , antihistamines , @DRUG$ , @DRUG$ , monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic drugs, or other drugs that produce CNS depression.	DDI-false
, Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors ( e.g. , itraconazole , ritonavir , and @DRUG$ ) has not been studied , increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Particular caution is necessary when using @DRUG$ in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially cyclic antidepressants) may emerge with the reversal of the benzodiazepine effect by @DRUG$.	DDI-false
Broad-Spectrum Antibiotics-@DRUG$ may sterilize the bowel and decrease the @DRUG$ contribution to the body by the intestinal microflora.	DDI-false
In a phase I study with escalating doses of @DRUG$ ( 110 - 200 mg/m2 ) and cisplatin ( 50 or 75 mg/m2 ) given as sequential infusions , myelosuppression was more profound when @DRUG$ The dose was given after cisplatin as with the alternative sequence (i.e., TAXOL before cisplatin).	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , @DRUG$ , lincomycin, clindamycin, colist, and @DRUG$ ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
This antagonistic effect of @DRUG$ on @DRUG$ natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of bumetanide.	DDI-mechanism
The possibility of hypotensive effects with enalapril or @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake prior to initiation of treatment with @DRUG$ or enalaprilat.	DDI-false
There was no evidence of any pharmacokinetic interactions between @DRUG$ and @DRUG$.	DDI-false
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients concomitantly @DRUG$ and @DRUG$ therapy .	DDI-effect
Coadministration of phenytoin with 40 mg @DRUG$ Tablets in epileptic patients decreased the @DRUG$ Plasma concentrations up to undetectable concentrations.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ (i) increased plasma concentrations (e. g., disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may be associated with increased plasma concentrations with: @DRUG$ ;	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Patients who have been treated with @DRUG$ within two to three weeks prior to the administration of @DRUG$ should receive initial doses of dopamine HCl no greater than one-tenth (1/10) of the usual dose.	DDI-advise
In addition to this pharmacological interaction, this report describes a novel chemical reaction between temazepam (a @DRUG$) and @DRUG$ under acidic conditions similar to those found in vivo, resulting in a 3-ethoxylated product.	DDI-false
Antihypertensive Medications and @DRUG$ The following adverse reactions occurred more frequently in patients receiving concomitant antihypertensive medicinal products or @DRUG$ Hypotension 10% vs. 4%, myocardial infarction 3% vs. 1%, severe pneumonia 5% vs. 3%, severe falls 9% vs. 3%, bone and joint injuries 6% vs. 2%.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, @DRUG$, carbamazepine and possibly with griseofulvin, ampicillin, and @DRUG$ (72)	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , @DRUG$ , sympathomimet-ics , calcium channel blocking drugs , and @DRUG$.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Concomitant administration of fenofibrate (equivalent to 145 mg TRICOR) with @DRUG$ (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in @DRUG$ AUC values in 22 healthy males.	DDI-false
Lithium generally should not be given with @DRUG$ because they reduce @DRUG$s renal clearance and add a high risk of lithium toxicity.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as @DRUG$, intraconazole, @DRUG$, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Oral @DRUG$ : Multiple dose administration of tiagabine ( 8 mg/day monotherapy ) did not alter the pharmacokinetics of oral @DRUG$ in healthy women of childbearing age .	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose @DRUG$ and @DRUG$, specifically, dacarbazine, cis-platinum, tamoxifen and interferon-alfa.	DDI-effect
If a @DRUG$ is also used, it may increase the risk of @DRUG$ toxicity.	DDI-effect
Aspirin , @DRUG$ , heparin , @DRUG$	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
The absorption of tetracycline, @DRUG$, penicillin G, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with @DRUG$;	DDI-mechanism
Diuretics : @DRUG$ And other NSAIDs can inhibit the activity of @DRUG$.	DDI-effect
plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., @DRUG$, @DRUG$), and such an effect may be anticipated with CMI as well.	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, @DRUG$, and @DRUG$.	DDI-false
As with other @DRUG$, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as anesthetics, opiates, and alcohol.	DDI-effect
Concurrent use with @DRUG$ or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of @DRUG$.	DDI-mechanism
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ @DRUG$, triazolam GI motility agents: cisapride	DDI-false
Withdrawal of @DRUG$ decreased the @DRUG$ requirement by 50%.	DDI-mechanism
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, @DRUG$, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
@DRUG$ ( e. g. , ketoconazole , miconazole , clotrimazole , @DRUG$ , etc . ): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Urinary acidifying agents (ammonium chloride, @DRUG$, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	DDI-mechanism
Possible interactions between Keppra and other medicinal products @DRUG$ (Carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$ The serum concentrations of levetiracetam and these AEDs were also evaluated in placebo-controlled clinical trials.	DDI-false
Ritonavir ( 600 mg b.i.d . ) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in @DRUG$ Cmax .	DDI-false
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of @DRUG$, @DRUG$ or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.	DDI-false
The effect of @DRUG$   on @DRUG$ ==References====External links==	DDI-false
ACE Inhibitors and @DRUG$ (Hypertension)- In clinical studies of patients with hypertension, the addition of INSPRA 50 to 100 mg to ACE inhibitors and @DRUG$ increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
These drugs include thiazides and other diuretics, @DRUG$ , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and @DRUG$.	DDI-false
â€¢ Carbamazepine : Isoniazid is known to slow down the metabolism of carbamazepine and increase serum levels @DRUG$ Concentrations should be determined prior to co-administration with isooniazide, signs and symptoms of carbamazepine toxicity should be closely monitored and appropriate dose adjustment of the @DRUG$ should be made .	DDI-false
Because of his lack of platelet effect @DRUG$ is not a substitute for @DRUG$ For cardiovascular prophylaxis.	DDI-false
To determine whether probenecid has a direct influence on the distribution of @DRUG$ , the elimination and distribution of @DRUG$ was studied in six patients , five lacking kidney function and one with a partially impaired renal function , in the presence or absence of probenecid .	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between VIRACEPT and dapsone , trimethoprim/@DRUG$ , @DRUG$ Erythromycin, itraconazole or fluconazole.	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ Amiodarone should be used with caution in patients who are receptor blockers (e.g. propranolol, CYP3A4 inhibitor) or calcium channel antagonists (e.g. verapamil, @DRUG$ Substrate, and diltiazem, an inhibitor of CYP3A4) due to the potential for bradycardia, sinus arrest, and AV block;	DDI-false
The co-administration of medicinal products which are nephrotoxic (e. g. @DRUG$ , @DRUG$ Myelotoxic (e.g. cytotoxic chemotherapy), cardiotoxic (e.g. doxorubicin) or hepatotoxic (e.g. methotrexate, asparaginase) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, @DRUG$, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Concomitant administration of @DRUG$ (corresponding to 145 mg) @DRUG$ ) with atorvastatin ( 20 mg ) once daily for 10 days resulted in approximately 17 % decrease ( range from 67 % decrease to 44 % increase ) in atorvastatin AUC values in 22 healthy males .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, digoxin, warfarin, @DRUG$, carvedilol, @DRUG$ or itraconazole.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as @DRUG$ or aluminum @DRUG$ , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
Standard monitoring of @DRUG$-related toxicity should be continued if VIOXX and @DRUG$ are administered concomitantly.	DDI-false
@DRUG$ In general, should not be combined with @DRUG$ Because they reduce renal clearance and add a high risk of lithium toxicity.	DDI-advise
Lithium: @DRUG$ have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	DDI-mechanism
@DRUG$: Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
Nephrotoxicity has been reported following concomitant administration of cephalosporins with aminoglycoside antibiotics or potent @DRUG$ such as @DRUG$.	DDI-false
Cefmenoxime, cefoperazone, cefotetan, cefamandol, latamoxef) or methylthiadiazole ( @DRUG$ ) can cause vitamin K deficiency and hypoprothrombinemia .	DDI-false
Data from in vitro studies of @DRUG$ In addition to alprazolem, a possible interaction may be proposed for the following medicinal products: ergotamine, @DRUG$ , amiodarone, nicardipine, and nifedipine.	DDI-int
@DRUG$ ( metoprolol , @DRUG$ Serum concentrations and pharmacological effects may be increased.	DDI-false
Notably , systemic exposure ( AUC0 - 12 ) of @DRUG$ ( @DRUG$ ) was more than doubled in the presence of TMP/SMX .	DDI-false
Antibiotics: In vitro and/or in vivo data show that @DRUG$, erythromycin, and troleandomycin markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
@DRUG$ : Clinical studies, as well as post-marketing observations, have shown that NSAIDs have the natriuretic effect of @DRUG$ and thiazides in some patients .	DDI-false
Concurrent use with @DRUG$ or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of @DRUG$.	DDI-mechanism
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
acetaminophen/@DRUG$, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, @DRUG$, carbamazepine, @DRUG$, topiramate, and possibly with ampicillin and tetracyclines 72.	DDI-false
Omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after @DRUG$ at the dose that maximally suppresses gastric acid secretion.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Cyclosporine , Digoxin , Methotrexate @DRUG$ As with other NSAIDs, due to effects on renal prostaglandins, changes in the elimination of these drugs can lead to increased serum levels of cyclosporin, @DRUG$ , methotrexate , and increased toxicity .	DDI-mechanism
@DRUG$ Since apomorphine is a dopamine agonist, it is possible that @DRUG$ , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Antiacid , clarithromycin , @DRUG$ Fluconazole, fluoxetine, indanavir, ketoconazole, @DRUG$ , phenobarbitol, carbamazepine, rifabutin, rifampin, ritanovir, saquinavir.	DDI-false
@DRUG$ (@DRUG$): Cerivastatin plasma concentrations were not affected by co-administration of antacid.	DDI-false
Consequently , @DRUG$ In patients who have ketoconazole and @DRUG$ These are very potent inhibitors of CYP3A.	DDI-advise
Since @DRUG$ Not significantly inhibit CYP2A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4 in vitro, @DRUG$ It is not expected that by inhibiting the metabolism mediated by these isozymes, they will significantly interact with other medicinal products in vivo.	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-advise
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , @DRUG$ Calcium channel blockers, cardiac nitrates, @DRUG$ H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ In patients receiving @DRUG$, serum concentrations should be closely monitored when starting or changing BEXTRA therapy.	DDI-false
Methenamin therapy : Urine excretion of @DRUG$ The effectiveness is determined by acidifying agents which are used in @DRUG$ therapy .	DDI-false
Dopamine Antagonists : Since apomorphine is a dopamine agonist , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or @DRUG$ , may reduce the effectiveness of @DRUG$.	DDI-effect
The following examples are known to inhibit the metabolism of other related benzodiazepines, probably by inhibition of CYP3A: nefazodone, @DRUG$ , @DRUG$ Diltiazem, isoniazid, and some macrolide antibiotics.	DDI-false
@DRUG$ As with some other quinolones, co-administration of ciprofloxacin with theophylline may lead to increased serum concentrations. @DRUG$ and prolongation of its elimination half-life .	DDI-false
Compounds in these categories result in a decreased efficacy of @DRUG$: phenothiazines, haloperidol, @DRUG$, pimozide.	DDI-effect
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, @DRUG$ , colistine, and sodium colistimethat, magnesium salts, lithium, local @DRUG$ , procainamide, and quinidine.	DDI-false
Hypersensitivity reactions have been reported in patients receiving combination regimens with sequentially high-dose PROLEUKIN and antineoplastic agents, especially dacarbazine, cis-platinum. @DRUG$ and @DRUG$.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam ( caution is recommended during coadministration with alprazolam ): Coadministration of @DRUG$ with @DRUG$ increased the maximum plasma concentration of alprazolam by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Mineral Oil-Concomitant intake of @DRUG$ and @DRUG$ may reduce the absorption of vitamin K.	DDI-mechanism
The pharmacokinetics of @DRUG$ (Cmax and AUC) were not affected during multiple-dose @DRUG$, suggesting no clinically significant pharmacokinetic interaction.	DDI-false
@DRUG$ Hallucinations have been reported when TORADOL has been used in patients receiving psychoactive medications (fluoxetine, @DRUG$ ==References====External links==	DDI-false
This medication may be used with alcohol or other CNS depressants (may increase CNS depressive effects either of these drugs or antihistamines), anticholinergics or other anticholinergic drugs (anticholinergic effects may be intensified if these drugs are used concomitantly with antihistamines), and monoamine oxidase (MAO) inhibitors ( concomitant use with anticholinergic agents). @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$ ) .	DDI-false
@DRUG$ : @DRUG$ may counteract the sedative effect of antihistamines .	DDI-false
@DRUG$ and retinyl acetate similarly inhibit and stimulate EGF- or @DRUG$-induced proliferation of prostatic epithelium .	DDI-effect
Erythromycin concomitant use of Felodipine (PLENDIL) with @DRUG$ The result was an approximately 2.5-fold increase in AUC and Cmax and an approximately 2-fold increase in the half-life of @DRUG$.	DDI-false
Iodine or @DRUG$ Surplus may reduce the effect of carbimazole, and a @DRUG$ Deficiency can increase the effect of carbimazole.	DDI-false
@DRUG$: @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal lithium clearance.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with TAXOL should be premedicated with corticosteroids ( such as dexamethasone ) , diphen-hydramine and @DRUG$ ( such as @DRUG$ or ranitidine ) .	DDI-false
@DRUG$ does not affect the pharmacokinetics of @DRUG$.	DDI-false
In patients receiving @DRUG$ and a @DRUG$ At the same time, any reduction in steroid dose should be done gradually to avoid possible complications of sudden steroid withdrawal.	DDI-advise
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , @DRUG$ , anticonvulsants , benzodiazepines , beta blockers , @DRUG$ , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Imidazoles ( e. g. , ketoconazole , @DRUG$ , @DRUG$ , fluconazole , etc . ): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Ethinyl Estradiol and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47 % decrease in @DRUG$ - and a decrease of 18% @DRUG$ plasma concentrations .	DDI-false
This effect is small with occasional doses of @DRUG$ However, it may be clinically significant if: @DRUG$ ==References====External links==	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or Innovar than with pentobarbital.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$, @DRUG$, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine, @DRUG$, @DRUG$ (nicotinic acid), erythromycin, azole antifungals.	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, @DRUG$ like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
medicines that require dose reduction when co-administered with VIRACEPT @DRUG$ : @DRUG$	DDI-false
In a study in which the 2 mg clonazepam orally disintegrating tablet was administered with and without @DRUG$ ( an anticholinergic agent with multiple effects on the GI tract ) to healthy volunteers , the AUC of @DRUG$ The Cmax of clonazepam was 10% lower when the oral disintegrating tablet was administered with propanthelin compared to the single dose.	DDI-false
The absorption of tetracycline, furosemide, penicillin G, hydrochlorothiazide and @DRUG$ was significantly decreased when given simultaneously with @DRUG$ ;	DDI-mechanism
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, diuretics, @DRUG$ (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Hormonal @DRUG$ Co-administration of @DRUG$ with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, ethinylestradiol (EE) and levonorgestrel (LNG).	DDI-false
When used in external subcutaneous infusion pumps for @DRUG$, NovoLog should not be mixed with any other @DRUG$ or diluent.	DDI-false
Therefore , patients on @DRUG$ should be observed when @DRUG$ The tablets are either added or removed from a therapeutic treatment regimen.	DDI-advise
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , @DRUG$ , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of @DRUG$ (7.4 mg/kg body weight) and subcutaneous injections of bombesin (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of @DRUG$ (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.	DDI-false
In rats, simultaneous ingestion of @DRUG$ and nitrite in the diet for 78 weeks has been reported to cause tumors, and it has been suggested that @DRUG$ may react with nitrites in the rat stomach to form a nitrosamine, which is tumorigenic.	DDI-false
Even so @DRUG$ Plasma concentrations at high doses of @DRUG$ were almost 5-fold lower than those seen in CYP 2D6 poor metabolizers suggesting that dose adjustment is not necessary .	DDI-mechanism
While no in vivo drug-drug interaction studies were conducted between @DRUG$ and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and barbiturates) would be expected to decrease @DRUG$ concentrations.	DDI-mechanism
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , Dapson, disopyramide, quinine, amiodarone, quinidine, @DRUG$ , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of @DRUG$	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, @DRUG$, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., @DRUG$, @DRUG$).	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
This increase is due to the inhibition of @DRUG$ metabolism via P450 2C9 by @DRUG$ (see CLINICAL PHARMACOLOGY - Pharmacokinetics: Metabolism )	DDI-mechanism
In general, these drugs have one or more pharmacological activities, similar to bepridil hydrochloride, including @DRUG$ Like quinidine and procainamide, heart glycoside and @DRUG$.	DDI-false
Because there are no data on the compatibility of @DRUG$ and crystalline zinc insulin preparations , @DRUG$ Don't mix with these preparations.	DDI-false
While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , @DRUG$ , @DRUG$ , paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics , amantadine , @DRUG$ , phenothiazines , @DRUG$ , tricyclic antidepressants or some antihistamines .	DDI-false
- Mineral oil compositional intake of @DRUG$ The intake of @DRUG$ can be reduced by vitamin K.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
The effectiveness of @DRUG$-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin , @DRUG$ , and barbiturates , and the antituberculosis drug rifampin .	DDI-effect
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and @DRUG$.	DDI-false
The co-administration of Natrecor with IV vasodilators such as @DRUG$, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with @DRUG$ in clinical trials).	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	DDI-false
Lithium serum concentrations should be closely monitored when treatment with @DRUG$ in patients receiving @DRUG$.	DDI-advise
The compounds in these categories lead to a reduced efficacy of bromocliptin mesylate: phenothiazine, @DRUG$ , methoclopramid, @DRUG$.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, @DRUG$, carbamazepine, @DRUG$) may enhance the metabolism of corticosteroids and require that the dosage of the corticosteroid be increased.	DDI-false
Cytochrome P-450 inducers, such as phenytoin, @DRUG$ and phenobarbital, induce @DRUG$ metabolism, causing an approximately 30% decrease in plasma clonazepam levels.	DDI-mechanism
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and antineoplastic agents, specifically, @DRUG$, @DRUG$, tamoxifen and interferon-alfa.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
Anticoagulants: While studies have not shown @DRUG$ to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other @DRUG$.	DDI-advise
Nonsteroidal Anti-Inflammatory Drugs: The administration of diflunisal to normal volunteers receiving @DRUG$ decreased the renal clearance and significantly increased the plasma levels of @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , quinidine @DRUG$ : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : @DRUG$ benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
Anticonvulsants (phenytoin): steady-state plasma exposure (AUC) of @DRUG$ ( 40 mg BID for 12 days ) was decreased by 27 % when co-administered with multiple doses ( 300 mg QD for 12 days ) of @DRUG$ ( a CYP 3A4 inducer).	DDI-mechanism
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, @DRUG$, @DRUG$, ritonavir, nelfinavir) would be expected to behave similarly.	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, methanol, higher @DRUG$ and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, @DRUG$, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Before using this medicine, tell your doctor or pharmacist about all prescription and non-prescription products that you can use, especially: aminoglycosides (e.g., gentamicin, amikacin), @DRUG$ , cyclosporin, non-steroidal anti-inflammatory drugs (e.g. ibuprofen), tacrolimus, @DRUG$.	DDI-false
Epinephrine should not be co-administered with other @DRUG$ ( such as @DRUG$ ) because of possible additive effects and increased toxicity .	DDI-false
Because there is a theoretical basis that these effects may be additive, use of ergotamine-containing or ergot-type medications (like @DRUG$ or methysergide) and @DRUG$ within 24 hours of each other should be avoided.	DDI-advise
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, @DRUG$, and anakinra.	DDI-false
Although not observed in this study, adverse effects could potentially arise from co-administration of @DRUG$ and @DRUG$ by inhibition of tubular secretion via organic cationic transporter systems.	DDI-mechanism
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
- @DRUG$ or MAO-inhibitors (with hepatotoxic potential) must not be administered together with Bezalip or @DRUG$.	DDI-advise
Haemodynamic effects of @DRUG$ and insulin were additive when @DRUG$ The administration was performed simultaneously, but not under basal conditions.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, @DRUG$, calcium-blocking agents, hydralazine, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, @DRUG$ Amiodarone, quinidine, warfarin, @DRUG$ (e. g. cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including @DRUG$ , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
The pressor effects of @DRUG$ such as dopamine or norepinephrine are enhanced by @DRUG$.	DDI-effect
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, @DRUG$, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Since animal studies suggest that the action of @DRUG$ may be prolonged by therapy with chlorpropamide, @DRUG$ should be employed with caution.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, @DRUG$, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
In clinical trials, FLOLAN was treated with: @DRUG$ , @DRUG$ In a pharmacokinetic sub-study in patients with congestive heart failure receiving furosemide or digoxin starting treatment with FLOLAN, visible values for oral clearance of furosemide (n = 23) and digoxin (n = 30) were reduced by 13% and 15% respectively on the second day of therapy and were returned to baseline by day 87.	DDI-false
The intensity , uniformity and time course of anticoagulant interference by @DRUG$ , secobarbital , @DRUG$ , chloral hydrate and methaqualone were systematically investigated in 16 patients receiving coumarin therapy .	DDI-false
Folic acid in large amounts may counteract the antiepileptic effect of @DRUG$ , @DRUG$ and primidone , and increase the frequency of seizures in susceptible pediatric patients .	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, clotrimazole, fluconazole, etc.): in vitro and animal studies with the combination of @DRUG$ and @DRUG$ suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, @DRUG$, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
Although @DRUG$ have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Carbamazepine , @DRUG$ , @DRUG$	DDI-false
poor metabolizers of @DRUG$: Interactions of carvedilol with strong inhibitors of CYP2D6 (such as @DRUG$, fluoxetine, paroxetine, and propafenone) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of carvedilol .	DDI-false
The risk of using bromocriptine mesylate in combination with other drugs has not been systematically evaluated , but @DRUG$ The side effects of @DRUG$ can be increased.	DDI-effect
Although neither @DRUG$ nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of EGF and insulin.	DDI-false
Hypotension   Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom @DRUG$ therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, @DRUG$, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
If NovoLog is mixed with @DRUG$, @DRUG$ should be drawn into the syringe first.	DDI-false
- benzylpenicillin, ampicillin, @DRUG$ , chlortetracycline , doxycycline , cephalothin , erythromycin , and @DRUG$ In vitro does not affect the protein binding of diclofenac in human serum.	DDI-false
Theophylline: As with some other quinolones, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of @DRUG$ and prolongation of its elimination half-life.	DDI-false
Oral Contraceptives : Coadministration of @DRUG$ and an oral contraceptive increased AUC values for @DRUG$ Ethinylestradiol by about 30% and 20%.	DDI-mechanism
Antiarrhythmia : Other antiarrhythmic drugs, such as quinidine, @DRUG$ , @DRUG$ , and phenytoin, were used at the same time as amiodarone.	DDI-false
Patients receiving other @DRUG$s, general anesthetics, phenothiazines, tranquilizers, @DRUG$, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Urinary alkalinizing agents (@DRUG$, some thiazides) increase the concentration of the non-ionized species of the @DRUG$ molecule, thereby decreasing urinary excretion.	DDI-mechanism
@DRUG$ , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with , or within 2 hours of , the administration of @DRUG$ , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin .	DDI-advise
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$ , @DRUG$ , calcium channel block drugs, and isoniazid.	DDI-false
Since there is a theoretical basis for these effects to be additive, the use of ergotamine containing or @DRUG$ (such as dihydroergotamine or methysergide) and @DRUG$ Within 24 hours of each other should be avoided.	DDI-advise
Cimetidine (400 mg b.i.d.) had no effect on vardenafil bioavailability (AUC) and maximum concentration (Cmax) of @DRUG$ when co-administered with 20 mg @DRUG$ in healthy volunteers.	DDI-false
Plasma exposure of @DRUG$ 10 mg twice daily) by 28%. @DRUG$ ( 40 mg BID ) for 12 days , while plasma exposure of valdecoxib ( 40 mg BID ) was not substantially increased following administration of diazepam ( 10 mg BID ) for 12 days .	DDI-mechanism
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , @DRUG$ Amphotericin B, Foscarnet, intravenous pentamidine, @DRUG$ , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-false
A possible interaction between @DRUG$ and ciprofloxacin, a @DRUG$, has been reported, resulting in a potentiation of the hypoglycemic action of glyburide.	DDI-false
@DRUG$ may interact with alcohol, @DRUG$s, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, lithium, norepinephrine, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-int
Carbamazepine: @DRUG$ had no effect on the steady-state plasma concentrations of @DRUG$ or its epoxide metabolite in patients with epilepsy.	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., ketoconazole, @DRUG$, erythromycin, clarithromycin).	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Anti-arrhythmic agents, class I (such as @DRUG$ , lidocaine or quinidine): concomitant use with @DRUG$ - May have a proarrhythmic effect.	DDI-false
Antihypertensives: @DRUG$ should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , @DRUG$ ) , isoniazid , @DRUG$ , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
@DRUG$ and Zidovudine @DRUG$ In vitro, the antiviral activity of stavudine and zidovudine against HIV can be antagonistic.	DDI-false
â€¢ CANCIDAS reduced blood AUC0-12 of tacrolimus by about 20%, maximum blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12h) by 26% in healthy subjects if: @DRUG$ 2 doses of 0.1 mg/ kg at 12 hours intervals) was administered on the 10th day of CANCIDAS 70 mg daily compared to results from a control period in which: @DRUG$ was administered alone .	DDI-false
@DRUG$: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of amphetamines and can be used to treat amphetamine poisoning.	DDI-false
@DRUG$ Co-administration of cimetidine results in increased plasma concentration and AUC of cisapride, there is no effect on the absorption of cisapride when co-administered with @DRUG$.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., @DRUG$, a CYP3A4 substrate, and @DRUG$, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or prednisone.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., @DRUG$, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, @DRUG$, and quinidine.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral @DRUG$, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Warfarin: No significant differences were observed in the steady-state pharmacokinetics of R-warfarin or @DRUG$ with the addition of @DRUG$ given as a single dose.	DDI-false
@DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing @DRUG$.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of the magnesium deficiency and to distinguish between magnesium deficiency due to insufficient magnesium uptake, which requires only an oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation .	DDI-false
Both ibogaine and @DRUG$ â€¢ Block @DRUG$-induced and nicotine-induced dopamine release in the core accumbens;	DDI-effect
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., gentamicin, amikacin), amphotericin B, @DRUG$, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), @DRUG$, vancomycin.	DDI-false
Substances that are potent inhibitors of CYP3A4 activity (eg, ketoconazole and @DRUG$) decrease gefitinib metabolism and increase @DRUG$ plasma concentrations.	DDI-mechanism
Other CNS depressants (e.g. barbiturates, sedatives, @DRUG$ and general @DRUG$ ) have additive or potentiating effects with INAPSINE.	DDI-false
Anticoagulants : While studies have not shown diclofenac to interact with @DRUG$ However, caution should be exercised since interactions with other @DRUG$ have been seen.	DDI-false
Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of @DRUG$ and @DRUG$.	DDI-false
Although increased plasma concentrations ( AUC 0 - 24 hours ) of loratadine and/ or descarboethoxyloratadine after concomitant administration of @DRUG$ with each of these drugs in normal volunteers ( n = 24 in each study ) , there were no clinically relevant changes in the safety profile of @DRUG$ Rated by electrocardiographic parameters, clinical laboratory tests, vital signs and adverse events.	DDI-false
conversely , @DRUG$ may interfere with antihypertensive drugs ( i.e. , @DRUG$ , a-methyldopa ) .	DDI-int
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, @DRUG$, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ has additive effects with alcohol and other CNS depressants (@DRUG$, sedatives, tranquilizers, etc).	DDI-effect
Concomitant administration of @DRUG$ and other related compounds (eg, @DRUG$, quinidine and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.	DDI-effect
@DRUG$ : Because of the relationship of Accutane to vitamin A , patients should be advised against taking @DRUG$ containing vitamin A to avoid additive toxic effects	DDI-false
Dexamethasone and @DRUG$ similarly inhibit and stimulate EGF- or @DRUG$-induced proliferation of prostatic epithelium.	DDI-effect
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about @DRUG$, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	DDI-false
@DRUG$ : When @DRUG$ is administered with aspirin , its protein binding is reduced , although the clearance of free etodolac is not altered .	DDI-false
These drugs include the thiazides and other diuretics , @DRUG$ , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$ , and isoniazid .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
However, because some @DRUG$ have been reported to enhance the anticoagulant effects of warfarin or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a @DRUG$ is administered concomitantly with warfarin or its derivatives.	DDI-false
Digoxin : If multiple doses @DRUG$ and @DRUG$ Plasma digoxin concentrations at steady-state increased by about 20%.	DDI-mechanism
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ deficit and to discriminate between @DRUG$ deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and magnesium depletion related to a dysregulation of the control mechanisms of magnesium status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Limited clinical data in angina patients receiving concomitant @DRUG$ and @DRUG$ therapy indicate no discernible changes in serum digoxin levels.	DDI-false
* Drug interactions : Flupentixol may interact with some drugs, such as @DRUG$ ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - @DRUG$ Flupentixol increases the effect of tricyclic antidepressants	DDI-false
@DRUG$: Other antiarrhythmic drugs, such as @DRUG$, procainamide, disopyramide, and phenytoin, have been used concurrently with amiodarone.	DDI-false
@DRUG$ in large amounts may counteract the antiepileptic effect of @DRUG$, phenytoin and primidone, and increase the frequency of seizures in susceptible pediatric patients.	DDI-effect
Ritonavir and indinavir : Upon concomitant administration of 5 mg of @DRUG$ â€¢ 600 mg twice daily @DRUG$ , the Cmax and AUC of ritonavir were reduced by approximately 20 % .	DDI-mechanism
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$, presumably through inhibition of CYP3A: nefazodone, @DRUG$, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.	DDI-mechanism
@DRUG$ does not affect the pharmacokinetics of @DRUG$.	DDI-false
Drug/Laboratory Test Interactions The urine of patients who take @DRUG$ can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of @DRUG$.	DDI-false
Therapeutic concentrations of digoxin, @DRUG$ , ibuprofen , naproxen , piroxicam , @DRUG$ , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
@DRUG$ or @DRUG$ excess may decrease the effect of Carbimazole, and an iodine deficiency can increase the effect of Carbimazole.	DDI-false
ANTACID ( @DRUG$ ): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
A direct causal relationship was not established, but doctors should have the possibility that @DRUG$ may alter a diabetic patient s response to insulin or oral @DRUG$.	DDI-effect
In vitro, Diclofenac interfers minimally or not at all with the protein binding of @DRUG$ ( 20 % decrease in binding), tolbutamide, @DRUG$ ( 10% decrease in binding ) or warfarin.	DDI-false
Ketoconazole : In healthy subjects receiving @DRUG$ One CYP3A4 inhibitor, with 200 mg twice daily for 7 days, systemic exposure ( AUC) @DRUG$ The half-life increased to 1.7 times the control.	DDI-mechanism
The pharmacokinetics of a 1-mg dose of @DRUG$ administered as STADOL NS were not affected by the coadministration of @DRUG$ (300 mg QID).	DDI-false
Rifampin: Co-administration of @DRUG$ with @DRUG$ 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in rofecoxib plasma concentrations.	DDI-mechanism
* Bosentan is also expected to decrease plasma concentrations of other statins that have significant metabolism by CYP3A4, such as CYP3A4 and CYP3A4. @DRUG$ and @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with medications of @DRUG$ ( including , for example , ondansetron , @DRUG$ Dolasetron, palonosetron, and Alosetron) is contraindicated.	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other @DRUG$ while taking digoxin , @DRUG$ Cyclosporin can develop toxicity properties for these drugs.	DDI-effect
- Anabolic steroids (nandrolone [e.g., Anabolin], @DRUG$ [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	DDI-false
Oral @DRUG$ inhibits the gastrointestinal absorption of penicillin V, oral @DRUG$, methotrexate and 5-fluorouracil.	DDI-mechanism
Limited comparative data in patients with high viral loads treated with @DRUG$- or @DRUG$-based regimens currently exist .	DDI-false
- @DRUG$: @DRUG$ should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of lithium toxicity.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, @DRUG$, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Therefore, patients with @DRUG$ Treatment should be carefully monitored if: @DRUG$ therapy is indicated .	DDI-advise
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, @DRUG$, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Coadministration of @DRUG$ and Ortho-Novum 1/35  increased the exposure of norethindrone and @DRUG$ by 20% and 34%, respectively.	DDI-false
@DRUG$: @DRUG$ 40 mg BID for 7 days produced significant decreases in lithium serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to lithium alone.	DDI-false
Drugs that cause significant sustained elevation in gastric pH (histamine H2-receptor antagonists such as ranitidine or @DRUG$) may reduce plasma concentrations of @DRUG$ and therefore potentially may reduce efficacy.	DDI-mechanism
@DRUG$ , lidocaine , @DRUG$ , quinidine , theophylline , and valproic acid were added to pooled human serum at therapeutic concentrations .	DDI-false
The absorption of tetracycline, furosemide, @DRUG$, hydrochlorothiazide, and gemfibrozil was significantly decreased when given simultaneously with @DRUG$;	DDI-mechanism
Drugs that have been associated with peripheral neuropathy include @DRUG$, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Sine bradycardia was treated with oral @DRUG$ in combination with @DRUG$ ( CYP3A4 substrate ) given for local anesthesia .	DDI-false
@DRUG$ : @DRUG$ Co-administration of vardenafil 10 mg (800 mg t.i.d.) resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in the half-life of vardenafil.	DDI-false
The pharmacokinetics of @DRUG$ and its major metabolite @DRUG$ were unaffected following co-administration with Acamprosate .	DDI-false
@DRUG$: Concomitant treatment with @DRUG$ and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of tetracyclines	DDI-false
@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with @DRUG$ and nimodipine, and losartan has no significant effect on plasma levels of bosentan.	DDI-false
CONCLUSIONS : Macrolide antibiotics inhibit the metabolism of @DRUG$ Metabolised by CYP3A4 (i.e. atorvastatin, @DRUG$ ==References====External links==	DDI-false
@DRUG$ may increase sensitivity to the @DRUG$.	DDI-effect
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral @DRUG$, @DRUG$, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Anticholinesterases: Concomitant use of @DRUG$ and @DRUG$ may produce severe weakness in patients with myasthenia gravis.	DDI-effect
Multivalent Cation-Containing Products : Simultaneous Application of a @DRUG$ , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , @DRUG$ , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-mechanism
Although there are no study data to evaluate the possibility, @DRUG$, including sodium nitroprusside and nitroglycerin, may have an additive effect with @DRUG$ on the risk of developing methemoglobinemia.	DDI-effect
@DRUG$, @DRUG$, and MAOIs may increase anticholinergic effect of clidinium.	DDI-false
Because prostaglandins play an important role in hemostasis , and NSAIDs affect platelet function as well , concurrent therapy with all @DRUG$ , including Diclofenac, and @DRUG$ requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required .	DDI-advise
Pyrantel ( e.g. , @DRUG$ ) - Taking @DRUG$ and pyrantel together may decrease the effects of piperazine .	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, carbamazepine, rifampin) may enhance the metabolism of corticosteroids and require that the dosage of the @DRUG$ be increased.	DDI-false
DIGOXIN: Plasma @DRUG$ levels and @DRUG$ clearance at steady-state were not affected by co-administration of 0.2 mg cerivastatin sodium.	DDI-false
Antidepressants: In vitro data indicate that @DRUG$ inhibits the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, @DRUG$, ethanol or itraconazole.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , platelet inhibitors ( acetylsalicylic acid ) , @DRUG$ ( @DRUG$ Digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Azithromycin had no significant impact on the Cmax and AUC of zidovudine , although it significantly decreased the @DRUG$ tmax by 44 % and increased the intracellular exposure to phosphorylated @DRUG$ - 110%.	DDI-false
Potassium-sparing diuretics (e.g., @DRUG$, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Curariform muscle relaxants (eg, tubocurarine) and other drugs, including ether, succinylcholine, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with @DRUG$ Parenteral.	DDI-effect
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine @DRUG$ : astemizole , @DRUG$ Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
@DRUG$ toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of @DRUG$ therapy.	DDI-false
@DRUG$ â™ª As with others â™ª @DRUG$ , the renal excretion of cephalexin is inhibited by probenecid .	DDI-false
Investigations into the effect of @DRUG$ As regards the protein binding of @DRUG$ There was no interaction with warfarin.	DDI-false
@DRUG$) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and @DRUG$).	DDI-false
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral @DRUG$ In a pharmacokinetic substudy in patients with congestive heart failure: @DRUG$ or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for furosemide ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Although no specific studies have been performed, co-administration with medicinal products primarily metabolised by CYP3A4 (e. g. @DRUG$ , Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, @DRUG$, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, @DRUG$, and prednisone with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
Multivitamins , or other products containing @DRUG$ or zinc , antacids or @DRUG$ should not be administered concomitantly with , or within 2 hours of , the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin .	DDI-false
Cohort 1 then received amprenavir plus rifabutin for 10 days, and cohort 2 received @DRUG$ plus @DRUG$ for 4 days.	DDI-false
Fenfluramine may increase slightly the effect of @DRUG$ , e.g. , @DRUG$ , methyldopa, reserpine.	DDI-false
@DRUG$ , ampicillin , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and @DRUG$ In vitro does not affect the protein binding of diclofenac in human serum.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Concomitant use of LEVSIN with other antimuscarinic agents, amantadine, may lead to additive side effects due to cholinergic blockade. @DRUG$ , @DRUG$ , monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-false
Antiacid , @DRUG$ , didanosine, fluconazole, @DRUG$ , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , Rifampin , Ritanovir , Saquinavir .	DDI-false
Antiacid, clarithromycin, didanosine, @DRUG$ , fluoxetine, indanavir, @DRUG$ , Phenytoin , Phenobarbitol , carbamazepine , Rifabutin , Rifampin , Ritanovir , Saquinavir .	DDI-false
Since entecavir is primarily eliminated by the kidneys , coadministration of @DRUG$ with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either @DRUG$ - or the co-administered drug.	DDI-false
â€¢ Drug-drug interactions between Keppra and others @DRUG$ ( @DRUG$ Phenytoin Keppra (3,000 mg daily) did not affect the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
Patients receiving @DRUG$ , sulfonamides , or @DRUG$ should be observed for increased activity of these drugs and , therefore , signs of toxicity from these drugs .	DDI-false
@DRUG$-A Study on the Interaction of Eplerenone with @DRUG$ has not been conducted .	DDI-false
Consequently , @DRUG$ should be avoided in patients receiving @DRUG$ And itraconazole, which are very potent inhibitors of CYP3A.	DDI-advise
@DRUG$ Keppra  (1500 mg twice daily) did not alter the pharmacokinetics of @DRUG$ in healthy volunteers.	DDI-false
Again, @DRUG$ neutralized the increase in glycemia after @DRUG$ overload both in diabetic and non-diabetic rats.	DDI-false
Vaccines : Patients on @DRUG$ therapy may exhibit a diminished response to toxoids and @DRUG$ Because of the inhibition of the antibody response.	DDI-effect
@DRUG$: TORADOL IV/IM reduced the @DRUG$ response to furosemide in normovolemic healthy subjects by approximately 20% (mean sodium and urinary output decreased 17%).	DDI-false
It has been reported that plasma levels of several closely related tricyclic antidepressants are associated with the co-administration of methylphenidate or hepatic enzyme inhibitors (e.g. cimetidine, @DRUG$ ed) and decreased by concomitant administration of liver enzyme inducers (e. g. barbiturates, phenytoin), and such an effect may be associated with: @DRUG$ as well .	DDI-mechanism
Other potent inhibitors of CYP3A4 (e.g. @DRUG$ , @DRUG$ , nefazodone , troleandomycin , ritonavir , nelfinavir ) would be expected to behave similarly .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The pharmacokinetics of @DRUG$ The concomitant use of @DRUG$ ( 400 mg).	DDI-false
Specific studies have these effects with: @DRUG$ , isoflurane , propofol , @DRUG$ , and midazolam .	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, intraconazole, ritonavir, @DRUG$, saquinavir, @DRUG$, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
@DRUG$ produced distinctive effects in each task : it substituted for the training dose in @DRUG$ - Discrimination and increased the number of responses with short ( < 3 s ) interresponse times and increased overall response rates in the DRL scheme.	DDI-false
Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on plasma levels of @DRUG$.	DDI-false
Numerous drug interactions are possible with some @DRUG$ , like phenobarbitone and @DRUG$ , which affect hepatic microsomal enzyme systems .	DDI-false
Acidifying agents : Gastrointestinal acidifying agents ( guanethidine , reserpine , glutamic acid HCl , @DRUG$ , fruit juices, etc.) lower absorption of @DRUG$.	DDI-mechanism
Substances that are potent inhibitors of CYP3A4 activity (e.g. @DRUG$ and @DRUG$ ) decrease gefitinib metabolism and increase gefitinib plasma concentrations .	DDI-false
No Important Interactions To Date @DRUG$ There are no clinically important pharmacokinetic interactions with captopril, beta-blockers, @DRUG$ , digoxin , warfarin , isosorbide mononitrate , carvedilol , ethanol or itraconazole .	DDI-false
Patients receiving other narcotic analgesics, general @DRUG$, @DRUG$, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
This medicine can be used with alcohol or other forms of interaction. @DRUG$ (may increase the CNS depressive effect of these drugs or antihistamines), @DRUG$ or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ) , and monoamine oxidase ( MAO ) inhibitors ( concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines ) .	DDI-false
The bioavailability of the capsule formulation of @DRUG$ The effect was not affected by administration of 5 minutes after @DRUG$.	DDI-false
Therefore, interactions after concomitant use of @DRUG$ - narcotics, analgesics, antiemetics, @DRUG$ , tranquilizers ) .	DDI-false
Aspirin: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of @DRUG$ and aspirin were administered concomitantly.	DDI-false
Other concomitant therapies : In clinical studies, the safety profile in patients with acamprosate concomitantly with anxiolytics, hypnotics and @DRUG$ ( including benzodiazepines ) , or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications .	DDI-false
Interactions may occur between EPA supplements and aspirin and other @DRUG$ and herbs such as garlic (Allium sativum) and @DRUG$ (Ginkgo biloba).	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , @DRUG$ , thyroid hormones, @DRUG$ , progestogens (e.g. in oral contraceptives).	DDI-false
Patients on @DRUG$ should receive 70 mg of @DRUG$ daily.	DDI-advise
In addition, we have shown that @DRUG$ is a useful pharmacological tool with which to examine the @DRUG$-mediated responses of megakaryocytes.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, @DRUG$, Ritanovir, Saquinavir.	DDI-false
@DRUG$: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that @DRUG$ significantly inhibited zalcitabine phosphorylation in a dose dependent manner.	DDI-false
In the @DRUG$ study, @DRUG$ had no effect on the prothrombin time or other pharmacodynamic parameters.	DDI-false
@DRUG$ It has not been shown if there is a pharmacokinetic interaction between: @DRUG$ and combined oral contraceptives .	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride , including @DRUG$ such as @DRUG$ And procainamide, cardiac glycosides and tricyclic antidepressants.	DDI-false
â€¢ Drug interaction studies have shown that esomeprazole does not interact clinically significantly with @DRUG$ , warfarin , quinidine , clarithromycin or @DRUG$.	DDI-false
Additive CNS depression may occur when @DRUG$ are administered concomitantly with other @DRUG$ including barbiturates, tranquilizers, and alcohol.	DDI-effect
Ingestion of diclofenac may increase serum concentrations of digoxin and @DRUG$ and increase @DRUG$ s nephrotoxicity.	DDI-false
A similar association, albeit less pronounced, was proposed with @DRUG$ , phenyl-butazone , @DRUG$ , carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines ( 72 )	DDI-false
In addition, fondaparinux did not affect the pharmacodynamics of @DRUG$ Acetylsalicylic acid, piroxicam and digoxin, nor the pharmacokinetics of @DRUG$ at steady state .	DDI-false
Hormonal contraceptives Co-administration of @DRUG$ with an oral contraceptive has been shown to influence the plasma concentrations of the two hormonal components, @DRUG$ (EE) and levonorgestrel (LNG).	DDI-false
Coadministration of @DRUG$ 30 mg and @DRUG$ The CYP2C19 substrate resulted in a 45% decrease in diazepam clearance.	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, @DRUG$, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramides, fibrates, fluoxetine, @DRUG$ , propoxyphene, salicylates, @DRUG$ ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
@DRUG$: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
Benzylpenicillin , ampicillin , oxacillin , chlortetracycline , doxycycline , cephalothin , erythromycin , and @DRUG$ have no influence in vitro on the protein binding of @DRUG$ In human serum.	DDI-false
- Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$ , cephalothin , @DRUG$ In vitro sulfamethoxazole does not affect the protein binding of diclofenac in human serum.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (@DRUG$): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ : Coadministration of @DRUG$ resulted in a 27 % decrease in almotriptan clearance and an increase in Cmax of approximately 6 % .	DDI-false
The administration of local @DRUG$ containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe, prolonged hypertension.	DDI-false
Aminosalicylic acid may decrease the amount of @DRUG$ (@DRUG$, Lanoxicaps) that gets absorbed into your body.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , @DRUG$ , Calcium channel blocker, heart @DRUG$ , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
@DRUG$ In healthy subjects receiving the CYP3A4 inducer, carbamazepine, with 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) of @DRUG$ 72% decreased.	DDI-false
medicines that should not be combined with VIRACEPT antiarrhythmics: @DRUG$ , quinidine Antihistamines : astemizole, terfenadine Antimigrain : ergot derivatives Antimycobacterial agents : @DRUG$ benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when @DRUG$ is administered concomitantly with other @DRUG$, amantadine, haloperidol, phenothiazines, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some antihistamines.	DDI-effect
@DRUG$ had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable @DRUG$ therapy .	DDI-false
@DRUG$ : It is recommended that @DRUG$ be administered on an empty stomach ;	DDI-false
Multivitamins or other products containing iron or zinc, antacids or @DRUG$ should not be administered concomitantly with , or within 2 hours of , the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
The availability of potent @DRUG$ (NNRTI)-based regimens for antiretroviral therapy and concerns regarding @DRUG$ (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, @DRUG$.	DDI-false
@DRUG$ and Angiotensin II Receptor Antagonists (Hypertension)- In clinical studies of patients with hypertension, the addition of @DRUG$ 50 to 100 mg to ACE inhibitors and angiotensin II receptor antagonists increased mean serum potassium slightly (about 0.09-0.13 mEq/L).	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Antacids : In a clinical pharmacology study, the concomitant use of antacids (aluminium hydroxide, @DRUG$ -, and simethicone) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
However, diethylpropion may interfere with antihypertensive medicinal products (i.e. @DRUG$ , @DRUG$ ) .	DDI-false
Intravenous Adenocard ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as quinidine , @DRUG$ , @DRUG$ , and angiotensin converting enzyme inhibitors, without any change in the adverse event profile.	DDI-false
Coingestion of acetaminophen with @DRUG$ , phenobarbital with acetaminophene and @DRUG$ with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , @DRUG$ , sulfonamides , chloramphenicol , @DRUG$ , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
Aspirin, @DRUG$, heparin, @DRUG$	DDI-false
Administration of repeat doses of @DRUG$ had no effect on the repeat dose pharmacokinetics of theophylline, @DRUG$ or an ethinylestradiol/levonorgestrol oral contraceptive product in healthy subjects.	DDI-false
In addition, fondaparinux did not affect the pharmacodynamics of warfarin, @DRUG$ , piroxicam, and digoxin, nor the pharmacokinetics of @DRUG$ At Steady State.	DDI-false
Anticholinesterases ( neostgmine , physostigmine ) , @DRUG$ , quinine , @DRUG$ can enhance toxicity and cause cardio respiratory depression .	DDI-false
Another oral @DRUG$ Ketoconazole inhibits the metabolism of astemizole, resulting in increased plasma concentrations of astemizole and its active metabolite. @DRUG$ , which can prolong QT intervals.	DDI-false
Central nervous system depressants: Concomitant use of DURAGESIC (Fentanyl transdermal system) with others @DRUG$ , including but not limited to other opioids, sedatives, hypnotic, sedatives (e.g. benzodiazepines), general anesthetics, @DRUG$ , skeletal muscle relaxants, and alcohol, may result in respiratory depression, hypotension, and deep sedation, or possibly in coma or death.	DDI-false
BACKGROUND: The effects of combined administration of bombesin and verapamil hydrochloride (verapamil), a @DRUG$, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by azoxymethane (@DRUG$) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for @DRUG$ ( n = 23 ) and @DRUG$ ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Intravenous @DRUG$ (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as @DRUG$, beta-adrenergic blocking agents, calcium channel blocking agents, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, @DRUG$ , lincomycin , clindamycin , @DRUG$ Sodium colistimethate, magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, @DRUG$, erythromycin, etc.) is indicated, reduction of the budesonide dose should be considered.	DDI-false
Magnesium- and/or aluminum-containing @DRUG$, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
@DRUG$ : Etodolac has no apparent pharmacokinetic interaction when administered with @DRUG$.	DDI-false
The drug interaction studies with @DRUG$ were performed both with @DRUG$ and a rapidly hydrolyzed intravenous prodrug form .	DDI-false
Cytochrome P-450 inducers, such as phenytoin, carbamazepine and phenobarbital, induce @DRUG$ metabolism, causing an approximately 30% decrease in plasma @DRUG$ levels.	DDI-false
In Study 1, patients with colorectal cancer received irinotecan/@DRUG$/leucovorin (bolus-IFL) with or without @DRUG$.	DDI-false
@DRUG$ : @DRUG$-induced hypokalemia may potentiate digitalis toxicity .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$ or Oral Hypoglycemics : Agents with b-blocking properties may enhance the blood-sugar-reducing effect of @DRUG$ and oral hypoglycemics .	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, @DRUG$, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Digoxin, Methotrexate, @DRUG$: @DRUG$, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
@DRUG$ Reports suggest that @DRUG$ may diminish the antihypertensive effect of ACE-inhibitors.	DDI-false
Efavirenz and nevirapine were compared with triple therapy with PI. @DRUG$ over 48 weeks as initial therapy , with similar responses being observed with @DRUG$ Regimes and superiority observed with efavirenz.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, @DRUG$ or fluconazole.	DDI-false
@DRUG$: Altered serum levels of @DRUG$ (increased and decreased) have been reported in patients receiving concomitant ciprofloxacin.	DDI-false
@DRUG$ : Since bile acid sequestrants may bind other drugs given concurrently , patients should take TRICOR at least 1 hour before or 4 - 6 hours after a @DRUG$ to avoid impeding its absorption .	DDI-false
The medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$ , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , @DRUG$ , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Dosage adjustment of STRATTERA may be necessary when coadministered with CYP2D6 inhibitors , e.g. , @DRUG$ , @DRUG$ , and quinidine .	DDI-false
@DRUG$ may interact with @DRUG$ * Blood thinners, decongestant medications (allergic agents, colds, and sinus drugs), diabetics, lithium, norepinephrine, NSAIDs such as aleve or ibuprofen, and high blood pressure medications.	DDI-int
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac @DRUG$ , diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs) and @DRUG$ without evidence of clinically significant adverse interactions .	DDI-false
for adult-onset diabetics , dosage adjustment of @DRUG$ may be necessary during and after @DRUG$ therapy ;	DDI-advise
The action of the @DRUG$ may be potentiated by anticonvulsants , antihistamines , alcohol , barbiturates , monoamine oxidase inhibitors , narcotics , phenothiazines , @DRUG$ , or other drugs that produce CNS depression .	DDI-effect
H2 Receptor Antagonists: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on cisapride absorption when it is coadministered with @DRUG$.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: @DRUG$ (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Oral Contraceptives : Valdecoxib ( 40 mg BID ) did not induce the metabolism of the combination oral contraceptive @DRUG$/ethinyl estradiol ( 1 mg /35 mcg combination , @DRUG$ 1/35 ) .	DDI-false
@DRUG$ : Clinical studies , as well as post marketing observations , have shown that NSAIDs can reduce the natriuretic effect of @DRUG$ Some patients were diagnosed with thiazides and thiazides.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, amantadine, haloperidol, @DRUG$, monoamine oxidase (MAO) inhibitors, tricyclic antidepressants or some @DRUG$.	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/@DRUG$, phenobarbital/ valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
@DRUG$: Potential interactions between Trileptal and other @DRUG$ were assessed in clinical studies.	DDI-false
Specific studies have confirmed these effects with sevoflurane, isoflurane, propofol, @DRUG$, and @DRUG$.	DDI-false
Oral @DRUG$: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	DDI-false
@DRUG$ (neostgmine, physostigmine), lignocaine, @DRUG$, procainamide can enhance toxicity and cause cardio respiratory depression.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , @DRUG$ When co-administered with saquinavir, increased plasma concentrations may occur;	DDI-false
Patients who have other narcotic analgesics, general anaesthetics, phenothiazine, sedatives, @DRUG$ Tricyclic antidepressants or other @DRUG$ In addition to DILAUDID, additive CNS depression may occur (including alcohol).	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
@DRUG$ Indinavir (800 mg t.i.d.) together with vardenafil 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in vardenafil Cmax and a 2-fold increase in vardenafil Cmax. @DRUG$ half-life .	DDI-false
Lithium: Increased serum @DRUG$ levels and symptoms of @DRUG$ toxicity have been reported in patients receiving concomitant lithium and ACE inhibitor therapy.	DDI-false
@DRUG$: Since both @DRUG$ and tetracyclines can cause increased intracranial pressure, their combined use is contraindicated.	DDI-false
@DRUG$, such as probenecid and sulfinpyrazone, can inhibit renal tubular secretion of @DRUG$.	DDI-mechanism
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, butorphanol, dezocine and @DRUG$) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ such as Levo-Dromoran.	DDI-false
METHODS : From the beginning of the experiment , rats were given 10 weekly subcutaneous injections of @DRUG$ 7.4 mg/kg body weight) and subcutaneous injections of bombsin ( 40 Î¼g/kg body weight ) every other day and from week 16 intraperitoneal injections of @DRUG$ 10 or 20 mg/kg body weight every other day until the end of the test at week 45.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$: Gastrointestinal acidifying agents (guanethidine, @DRUG$, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of amphetamines.	DDI-false
@DRUG$ 400 mg B.i.d.) had no effect on @DRUG$ bioavailability ( AUC ) and maximum concentration ( Cmax ) of vardenafil when co-administered with 20 mg Vardenafil in healthy volunteers .	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , @DRUG$ Anaesthetics (e.g. benzodiazepines), general @DRUG$ , phenothiazine, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and deep sedation, or possibly coma or death.	DDI-false
Other @DRUG$ (e.g. @DRUG$, tranquilizers, opioids and general anesthetics) have additive or potentiating effects with INAPSINE.	DDI-false
Aspirin : If Lodine together with @DRUG$ , its protein binding is reduced , although the clearance of free @DRUG$ is not altered .	DDI-false
Medicines detected as CYP3A inhibitors of a possible clinical significance based on clinical trials involving alprazoleam ( Caution is recommended when co-administered with alprazoleam): @DRUG$ with alprazolam increased the maximum plasma concentration of @DRUG$ by 46 % , decreased clearance by 21 % , increased half-life by 17 % , and decreased measured psychomotor performance .	DDI-false
Compounds tested in man include warfarin , theophylline , phenytoin , @DRUG$ , aminopyrin and @DRUG$.	DDI-false
Aspirin: In normal volunteers, a small decrease in @DRUG$ levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly.	DDI-false
A similar association , though less marked , has been suggested with @DRUG$ , phenylbutazone , phenytoin sodium , @DRUG$ , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72 .	DDI-false
In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of @DRUG$ to @DRUG$ and 3-hydroxy levobupivacaine, respectively.	DDI-false
Injection : Lorazepam injection , like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl alcohol , phenothiazines , @DRUG$ , @DRUG$ An increased incidence of sedation, hallucinations and irrational behaviour was observed with co-administration of scopolamine with injectable lorazepam.	DDI-false
However, a crossover study in healthy subjects receiving either Tagamet 300 mg q.i.d. or 800 mg h.s. simultaneously with a 300 mg b.i.d. dose. @DRUG$ ( Theo-Dur , Key Pharmaceuticals , Inc. ) demonstrated less alteration in steady-state @DRUG$ Peak serum levels with the 800 mg h.s. regimen, especially in subjects aged 54 years and older.	DDI-false
unlike @DRUG$ , @DRUG$ does not affect responding for a nondrug reinforcer ( water ) .	DDI-false
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering @DRUG$ with inhibitors of the CYP3A4 family (e.g., ketoconazole, itraconazole, @DRUG$, clarithromycin).	DDI-advise
Although neither dexamethasone nor retinyl acetate affected the proliferation of prostatic epithelium in RPMI1640 containing @DRUG$ alone, they modify the mitogenic effect of @DRUG$ and insulin.	DDI-false
@DRUG$ had no significant effect on the anticoagulant effect of @DRUG$ in healthy subjects on stable warfarin therapy.	DDI-false
@DRUG$ (such as flecainide, lidocaine, or quinidine): concurrent use with @DRUG$ may have a proarrhythmic effect.	DDI-false
Fenfluramine may have the effect of @DRUG$ ==References====External links==* Official website	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$ or halogenated hydrocarbon anesthetics increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered @DRUG$, such as dopamine.	DDI-effect
- monoamine oxidase inhibitors, and @DRUG$ FORADIL should be used in patients with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents .	DDI-false
@DRUG$ In a clinical pharmacology study, concomitant use of @DRUG$ Administration of aluminium hydroxide, magnesium hydroxide and simethicone with fosinopril reduced serum levels and urinary excretion of fosinoprilat compared to fosinopril alone, suggesting that antacids may affect the absorption of fosinopril.	DDI-false
Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of @DRUG$ (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of @DRUG$ (10 mg BID) for 12 days.	DDI-false
In vitro studies indicate that @DRUG$ does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that @DRUG$ It is not a substrate for P-glycoprotein-mediated transport.	DDI-false
SINCE THE CONCOMITANT ADMINISTRATION OF THESE TWO DRUGS CAN LEAD TO PHENYTOIN INTOXICATION , PRIOR TO ADMINISTERING DISULFIRAM TO A PATIENT ON @DRUG$ THERAPY , A BASELINE @DRUG$ SERUM LEVEL SHOULD BE OBTAINED .	DDI-false
Analysis of the concentration of @DRUG$ After ultracentrifugation, it was shown that there was a rapid equilibrium reaction of @DRUG$ Between the Survanta and the aqueous phase.	DDI-false
Antiarrhythmics: @DRUG$, bepridil, flecainide, @DRUG$, quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including barbiturates, tranquilizers, and @DRUG$.	DDI-false
In addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , @DRUG$ (including dexamethasone or carbamazepine) @DRUG$ This may lead to clinically significant reductions in caspofungin concentrations.	DDI-mechanism
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
The intensity, uniformity and time course of the anticoagulant interference by @DRUG$ , secobarbital, glutethimide, chloral hydrate and methaqualone have been systematically studied in 16 patients who: @DRUG$ therapy .	DDI-false
@DRUG$ " should be taken as being judged, and @DRUG$ should be taken with a main meal of the day , preferably the evening meal ..	DDI-false
@DRUG$: Concurrent administration of aspirin may lower @DRUG$ plasma levels, possibly by competing for protein-binding sites.	DDI-false
A similar association, albeit less pronounced, was proposed with @DRUG$ , phenylbutazone, phenytoin sodium, carbamazepine, griseofulvin, @DRUG$ Ampicillin and tetracycline 72.	DDI-false
Since amiodarone is a substrate for @DRUG$ , there is the potential that the use of St. John's word in patients who @DRUG$ This could lead to reduced amiodarone levels.	DDI-false
Patients already stabilized on @DRUG$ should be closely monitored for loss of symptom control with @DRUG$ coadministration.	DDI-advise
Injection : Lorazepam injection , like other injectable @DRUG$ , produces depression of the central nervous system when with ethyl alcohol, phenothiazine, barbiturates, @DRUG$ , and other antidepressants . When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-effect
@DRUG$ may increase slightly the effect of @DRUG$, e.g., guanethidine, methyldopa, reserpine.	DDI-effect
It is structurally distinct from the other currently available @DRUG$ (lovastatin, @DRUG$, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , disopyramide , quinine , amiodarone , quinidine , warfarin , @DRUG$ (e. g. cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may exhibit increased plasma concentrations when co-administered with saquinavir;	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors ( e.g. , itraconazole , ritonavir , and @DRUG$ ) has not been studied , increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications .	DDI-false
To determine whether injection of thiosulfate would permit larger doses of @DRUG$ to be administered, a fixed 9.9-g/m2 dose of thiosulfate was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
@DRUG$ : In healthy individuals , plasma concentrations of @DRUG$ Co-administration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4, increased by approximately 40%.	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$ , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or beta-adrenergic blocking agents , calcium channel blockers , antihistamines or H1-blocking agents , tricyclic antidepressants and @DRUG$ ) might also contribute to a prolongation of the QTc interval .	DDI-effect
@DRUG$ : Gastrointestinal acidifying agents ( guanethidine , reserpine , glutamic acid HCl , @DRUG$ , fruit juices , etc . ) lower absorption of amphetamines .	DDI-false
Potassium-sparing diuretics (e.g., spironolactone, @DRUG$, or amiloride), @DRUG$ supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Antihypertensives : Amiodarone should be used with caution in patients receiving   -receptor blocking agents ( e.g. , propranolol , a @DRUG$ inhibitor ) or calcium channel antagonists ( e.g. , @DRUG$ , a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an @DRUG$ (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Non-steroidal anti-inflammatory drugs : The administration of @DRUG$ To normal volunteers who @DRUG$ Elevated renal clearance and significantly increased plasma levels of indomethacin.	DDI-mechanism
@DRUG$ had no significant effect on the anticoagulant effect of @DRUG$ In healthy volunteers for stable warfarin therapy.	DDI-false
Based on known metabolic profiles , clinically significant drug interactions are not expected between VIRACEPT and dapsone , trimethoprim/sulfamethoxazole , @DRUG$ , erythromycin, itraconazole or @DRUG$.	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron , the concomitant use of apomorphine with drugs of the 5HT3 antagonist class ( including , for example , ondansetron , granisetron , @DRUG$ , palonosetron , and alosetron ) is contraindicated .	DDI-false
@DRUG$/Hypnotics : @DRUG$ , midazolam CONTRAINDICATED due to potential for serious and/or life-threatening reactions such as prolonged or increased sedation or respiratory depression .	DDI-false
Both @DRUG$ And his chief metabolites, @DRUG$ , are inhibitors of the cytochrome P450 3A4 enzyme system .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (@DRUG$) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ , Methylxanthines and Diuretics : Concomitant treatment with @DRUG$ Steroids, or diuretics may potentiate a potential hypocalemic effect of beta2-agonists.	DDI-false
@DRUG$ diminished the binding of @DRUG$ to human serum by a net change of 5.7 % ( percentage increase in free drug fraction [ FDF ] , 11.0 % ) at 662 micromol/L and by a net change of 7.1 % ( percentage increase in FDF , 13.7 % ) at 1324 micromol/L.	DDI-mechanism
Selective serotonin reuptake inhibitors (SSRIs): @DRUG$ ( e.g. , @DRUG$ Fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when co-administered with 5-HT1 agonists.	DDI-false
The extent to which SSRI@DRUG$ interactions may cause clinical problems depends on the degree of inhibition and pharmacokinetics of patients. @DRUG$ involved .	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with @DRUG$ Bleomycin) without reception @DRUG$ therapy .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as @DRUG$), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, @DRUG$, prednisolone, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
@DRUG$: Administration of nonsteroial anti-inflammatory drugs concomitantly with cyclosporine has been associated with an increase in @DRUG$-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, @DRUG$, paroxetine, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Oral contraceptives : multiple doses @DRUG$ The pharmacokinetics of oral ( 8 mg/ day monotherapy) @DRUG$ in healthy women of childbearing age .	DDI-false
The intensity, uniformity and time course of anticoagulant interference by phenobarbital, secobarbital, glutethimide, chloral hydrate and @DRUG$ were systematically investigated in 16 patients receiving @DRUG$ therapy.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Antacids : In a clinical pharmacology study, the concomitant use of a @DRUG$ ( aluminum hydroxide , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
@DRUG$ Renal tubular transport of methotrexate may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of methotrexate.	DDI-false
@DRUG$ The concomitant use of aspirin with valdecoxib may be @DRUG$ alone .	DDI-false
@DRUG$ and retinyl acetate similarly inhibit and stimulate @DRUG$- or insulin-induced proliferation of prostatic epithelium.	DDI-effect
The effects of @DRUG$ are antagonized by methylxanthines such as caffeine and @DRUG$.	DDI-effect
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Reports in the literature suggest that the plasma levels of doxorubicin (and its active metabolite) @DRUG$ ) may be increased when paclitaxel and @DRUG$ ==References====External links==	DDI-false
This study demonstrated that the potent cytochrome P450 enzyme-inducer @DRUG$ did indeed have a marked effect on the metabolism of @DRUG$, resulting in a 5-fold increase in clearance when administered concomitantly to patients with DSM-IV-diagnosed schizophrenia, schizoaffective disorder, or bipolar disorder.	DDI-mechanism
In Study 1 , patients with colorectal cancer were given @DRUG$/5-FU/leucovorin ( bolus-IFL ) with or without @DRUG$.	DDI-false
The pharmacokinetics of @DRUG$ , are unchanged in the presence of @DRUG$ and vice versa .	DDI-false
To evaluate the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., @DRUG$ , doxorubicin, teniposide, and prednisone with @DRUG$ plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
@DRUG$ increases enterohepatic elimination of @DRUG$ and may reduce its serum levels and t1/2.	DDI-false
Coadministration of @DRUG$ and Ortho-Novum 1/35   increased the exposure of @DRUG$ and ethinyl estradiol by 20 % and 34 % , respectively .	DDI-false
Benzthiazide may interact with alcohol, blood thinners, decongestant drugs (allergy, cold, and sinus medicines), diabetic drugs, @DRUG$, norepinephrine, NSAIDs like Aleve or @DRUG$, and high blood pressure medications.	DDI-false
Acetaminophen: In normal volunteers, concomitant administration of @DRUG$ and acetaminophen resulted in an approximate 50% increase in plasma levels of @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$-Concomitant intake of cholestyramine and @DRUG$ may reduce the absorption of vitamin K.	DDI-false
Pharmacokinetic Interaction between @DRUG$ and rifabutin or @DRUG$ In healthy men.	DDI-false
@DRUG$ Treatment: urinary excretion of amphetamines is increased, and efficacy is reduced by @DRUG$ used in methenamine therapy .	DDI-false
Epinephrine also should be used cautiously with other drugs (e.g., @DRUG$, @DRUG$) that sensitize the myocardium to the actions of sympathomimetic drugs.	DDI-false
To determine whether injection of thiosulfate would permit larger doses of cisplatin to be administered, a fixed 9.9-g/m2 dose of @DRUG$ was given intravenously over three hours concurrently with escalating doses of @DRUG$.	DDI-false
@DRUG$ The hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocain, @DRUG$ And metronidazole, which delays the elimination and increase in blood levels of these drugs.	DDI-mechanism
In order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with @DRUG$ Dexamethasone, diphen hydromine and H2 antagonists (such as cimetidine or @DRUG$ ) .	DDI-false
@DRUG$ The co-administration of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ â€¢ (e.g. benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants and alcohol, may cause respiratory depression, hypotension and deep sedation, or may lead to coma or death.	DDI-false
Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 @DRUG$: Cimetidine inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for @DRUG$ metabolism.	DDI-false
Anticoagulant inhibition was observed during the administration of phenobarbital, @DRUG$ and @DRUG$;	DDI-false
Lithium: @DRUG$ have produced an elevation of plasma @DRUG$ levels and a reduction in renal lithium clearance.	DDI-mechanism
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
@DRUG$ The addition of tiagabin in patients who received valproate chronically did not affect the pharmacokinetics of tiagabin, but @DRUG$ Tiagabin binding in vitro decreased significantly from 96.3 to 94.8%, resulting in an increase in free tiagabin concentration of about 40%.	DDI-false
@DRUG$: @DRUG$ (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by aspirin (two 81 mg tablets).	DDI-false
@DRUG$ should not be used as a substitute for oral or inhaled @DRUG$.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, @DRUG$, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and @DRUG$.	DDI-false
Further, no effects on either @DRUG$ levels or prothrombin times were observed in a study involving concomitant administration of warfarin and @DRUG$.	DDI-false
Corticosteroids , Methylxanthines and @DRUG$ : Accompanying treatment with @DRUG$ , steroids , or diuretics may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with @DRUG$ may exhibit an additive CNS depression.	DDI-effect
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , @DRUG$/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/@DRUG$.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blockers, azathioprin, @DRUG$ , gold , @DRUG$ , leflunomide , sulfasalazine , and anakinra .	DDI-false
It is recommended to avoid concurrent administration of ethambutol with @DRUG$ Containing antacids for at least 4 hours after @DRUG$ administration .	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as quinidine and @DRUG$, @DRUG$ and tricyclic anti-depressants.	DDI-false
Beta-Blocking Agents  A pharmacokinetic study of felodipine in conjunction with @DRUG$ demonstrated no significant effects on the pharmacokinetics of @DRUG$.	DDI-false
Theophylline: As with some other quinolones, concomitant use of @DRUG$ with @DRUG$ It may lead to increased serum concentrations of theophylline and an extension of the elimination half-life.	DDI-mechanism
Therefore , a slower onset can be anticipated if @DRUG$ The application is made at the same time as an @DRUG$ or directly on it.	DDI-effect
Cyclosporine : Because @DRUG$ can produce nephrotoxicity with decreases in creatinine clearance and rises in serum creatinine , and because renal excretion is the primary elimination route of @DRUG$ including TRICOR , there is a risk that an interaction will lead to deterioration .	DDI-effect
Although glucocorticoids have been shown to reduce PROLEUKIN-induced adverse reactions such as fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, co-administration of these active substances with PROLEUKIN may reduce the efficacy of PROLEUKIN against the tumour and should therefore be avoided. 12 @DRUG$ and other @DRUG$ may potentiate the hypotension seen with PROLEUKIN .	DDI-false
Acetaminophen, @DRUG$, phenobarbital, quinidine, @DRUG$, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with @DRUG$ â€¢ Accompanied by anxiolytics, hypnotic agents and @DRUG$ The use of placebo with these concomitant medications was similar to that of volunteers (including benzodiazepines), or non-opioid analgesics.	DDI-false
@DRUG$ The effect of carbimazole and a iodine excess may reduce the effect of carbimazole. @DRUG$ Deficiency can increase the effect of carbimazole.	DDI-false
Cytochrome P-450 inducers, such as phenytoin, @DRUG$ and phenobarbital, induce clonazepam metabolism, causing an approximately 30% decrease in plasma @DRUG$ levels.	DDI-false
Warfarin: @DRUG$ have been reported to enhance the effects of the oral @DRUG$ warfarin or its derivatives.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and @DRUG$   ( @DRUG$ capsules and tablets ) results in reduced protein binding of warfarin , but there was no change in the clearance of free warfarin .	DDI-false
@DRUG$: In healthy subjects given single 500 mg doses of @DRUG$ and metformin, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	DDI-false
@DRUG$: The effect of valdecoxib on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of @DRUG$ 40 mg BID for 7 days.	DDI-false
Cephalosporins-@DRUG$ containing side chains of N-methylthiotetrazole (cefmenoxime, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (@DRUG$) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, trimethoprim/sulfamethoxazole, @DRUG$, erythromycin, itraconazole or @DRUG$.	DDI-false
May interact with thyroid medication (e.g., levothyroxine), @DRUG$-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Patients who have other narcotic analgesics, general anaesthetics, phenothiazine, @DRUG$ , sedative hypnotics, tricyclic antidepressants or other @DRUG$ In addition to DILAUDID, additive CNS depression may occur (including alcohol).	DDI-false
Both @DRUG$ Indinavir was compared with PI for 48 weeks as initial therapy, with similar response rates observed in chronic renal failure patients. @DRUG$ regimens and superiority observed with efavirenz .	DDI-false
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (@DRUG$) Phenytoin Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy.	DDI-false
These drugs include the thiazides and other @DRUG$ , corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel block drugs, and @DRUG$.	DDI-false
Ingestion of @DRUG$ may increase serum concentrations of @DRUG$ and methotrexate and increase cyclosporine s nephrotoxicity.	DDI-mechanism
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
An encephalopathic syndrome ( characterized by weakness , lethargy , fever , tremulousness and confusion , extrapyramidal symptoms , leukocytosis , elevated serum enzymes , BUN , and FBS ) followed by irreversible brain damage has occurred in a few patients treated with @DRUG$ plus @DRUG$.	DDI-effect
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and @DRUG$.	DDI-false
To avoid the occurrence of severe hypersensitivity reactions, all TAXOL-treated patients with corticosteroids (e. g. @DRUG$ ) , diphen-hydramine and H2 antagonists ( such as @DRUG$ ==References==	DDI-false
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, terfenadine antimigrain: ergot derivatives @DRUG$ : rifampin Benzodiazepines @DRUG$ Triazolam GI motility agent: cisapride	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Again , @DRUG$ Neutralizes the increase in glycaemia after @DRUG$ overload both in diabetic and non-diabetic rats .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Antiarrhythmics : @DRUG$ , bepridil , @DRUG$ , propafenone , quinidine CONTRAINDICATED due to potential for serious and/or life-threatening reactions .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , @DRUG$ , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, @DRUG$, alcohol, @DRUG$, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Benzylpenicillin, ampicillin, @DRUG$, chlortetracycline, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
Therefore, concomitant use of @DRUG$ with hormonal contraceptives may render these @DRUG$ less effective .	DDI-false
Although neither dexamethasone nor @DRUG$ affected the proliferation of prostatic epithelium in RPMI1640 containing transferrin alone, they modify the mitogenic effect of EGF and @DRUG$.	DDI-effect
@DRUG$ Inhibitors Felodipine is metabolized by @DRUG$.	DDI-false
@DRUG$: In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and @DRUG$, a known inhibitor of cytochrome P450 3A4.	DDI-false
These results suggest that both @DRUG$ and retinyl acetate, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
"May interact with thyroid drugs (e.g. levothyroxine), products containing iodine, @DRUG$ , @DRUG$ ( e.g. , famotidine , ranitidine ) , and proton pump inhibitors ( e.g. , lansoprazole , omeprazole ) .	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, @DRUG$ or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
The toxicity of Filipin as well as the therapeutic value of @DRUG$ (i) these factors can be rationalised at both cellular and molecular level by the following observations: @DRUG$ Â· showed differential effects on the cells ;	DDI-false
@DRUG$, tricyclic @DRUG$ may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following: @DRUG$, cyclosporine, amiodarone, nicardipine, and @DRUG$.	DDI-false
Lithium carbonate: The anorectic and stimulatory effects of @DRUG$ may be inhibited by @DRUG$.	DDI-effect
Based on known metabolic profiles , clinically significant drug interactions are not expected between @DRUG$ and dapsone , @DRUG$/sulfamethoxazole , clarithromycin , erythromycin , itraconazole or fluconazole .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Since the concomitant administration of @DRUG$ with @DRUG$ The prothrombin time should be increased by 100% after 3 to 4 days, the dose of the anticoagulant should be reduced by one third to one half and the prothrombin time closely monitored.	DDI-false
Tetracyclines: Since both @DRUG$ and @DRUG$ can cause increased intracranial pressure, their combined use is contraindicated.	DDI-effect
Probenecid: As with other @DRUG$, renal excretion of loracarbef is inhibited by probenecid and resulted in an approximate 80% increase in the AUC for @DRUG$.	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, @DRUG$, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
In general , these are drugs that have one or more pharmacologic activities similar to @DRUG$ , including anti-arrhythmic agents such as @DRUG$ and procainamide , cardiac glycosides and tricyclic anti-depressants .	DDI-false
Compounds that have been tested in man include @DRUG$ , digoxin, propranolol, theophylline, and @DRUG$ No clinically significant interactions were found.	DDI-false
Other CONCOMITANT THERAPY: Although no specific interaction studies have been conducted, cerivastatin sodium was co-administered with @DRUG$ , betablockers , calcium-channel blockers , @DRUG$ , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
Suppression by @DRUG$ of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ By Wistar rats.	DDI-false
The effects of adenosine are antagonized by methylxanthines such as @DRUG$ and @DRUG$.	DDI-false
Dose adjustment is not recommended.Levetiracetam had no effect on plasma concentrations of @DRUG$, valproate, topiramate, or @DRUG$.	DDI-false
@DRUG$ have been reported to decrease the tubular secretion of @DRUG$ and to potentiate its toxicity.	DDI-mechanism
OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of everolimus and @DRUG$ (INN, @DRUG$) when coadministered in de novo kidney allograft recipients during the first year after transplantation.	DDI-false
Coingestion of acetaminophen with theophylline , @DRUG$ with @DRUG$ Valproic acid with phenobarbital in high to toxic concentrations decreases the binding of the target drug.	DDI-effect
In view of the long and variable half-life of @DRUG$ The potential for drug interactions is not only with concomitant medication, but also with medications given after discontinuation of @DRUG$.	DDI-false
Antiacid, clarithromycin, Didanosine, Fluconazole, @DRUG$, Indanavir, Ketoconazole, @DRUG$, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Coadministration of @DRUG$ â€¢ ( 10 mg twice daily for 7 days) with @DRUG$ The pharmacokinetics (exposure) of glyburide was not affected by QD 5 mg or 10 mg twice daily.	DDI-false
There is a significant increase in exposure to @DRUG$ when @DRUG$ is coadministered with ketoconazole ( CYP3A4 inhibitor ) .	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists ( Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS , 3020 ( 91 % ) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or @DRUG$ ( ACEI/@DRUG$ ).	DDI-false
When Itraconazole was coadministered with phenytoin, @DRUG$, or H2antagonists, reduced plasma concentrations of @DRUG$ were reported.	DDI-false
To evaluate the effect of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or CHOP-like regimen (i.e., cyclophosphamide, doxorubicin), @DRUG$ , and prednisone with vincristine plus bleomycin) without reception @DRUG$ therapy .	DDI-false
vasopressors, such as @DRUG$ and @DRUG$;	DDI-false
however, no deleterious interactions were seen when @DRUG$ was administered after narcotics, inhalational anesthetics, @DRUG$ and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other @DRUG$ while taking digoxin , methotrexate , or @DRUG$ It can develop toxicity characteristics for these drugs.	DDI-effect
In clinical studies performed with Fondaparinux , the concomitant use of oral @DRUG$ ( Warfarin), platelet inhibitors ( @DRUG$ NSAIDs (piroxicam) and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Delayed Adverse Reactions to @DRUG$: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various interleukin-2 containing regimens who were subsequently administered @DRUG$ experienced acute, atypical adverse reactions.	DDI-false
There is thus an enhancement effect of @DRUG$ upon the reaction of placental vessels to @DRUG$ in vitro.	DDI-effect
@DRUG$ It was also used at the same time as @DRUG$ without evidence of clinically significant adverse reactions .	DDI-false
- benzylpenicillin, ampicillin, @DRUG$ , @DRUG$ , doxycycline , cephalothin , erythromycin , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum .	DDI-false
H2 Receptor Antagonists : Cimetidine coadministration leads to an increased peak plasma concentration and AUC of @DRUG$ There is no effect on cisapride absorption when combined with @DRUG$.	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the @DRUG$ (phenothiazines, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
@DRUG$ The effect of valdecoxib on the anticoagulant effect of valdecoxib @DRUG$ Co-administration of BEXTRA 40 mg twice daily for 7 days has been studied in healthy subjects (1-8 mg/ day).	DDI-false
However, the absolute number of alcohol-related deaths is far greater than the number of deaths in @DRUG$ or @DRUG$ users.	DDI-false
Plasma exposure of diazepam (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of @DRUG$ (40 mg BID) was not substantially increased following administration of @DRUG$ (10 mg BID) for 12 days.	DDI-false
Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with @DRUG$ , steroids , or diuretics may potentiate a possible hypokalemic effect of   @DRUG$	DDI-effect
@DRUG$: Administration of nonsteroial anti-inflammatory drugs concomitantly with @DRUG$ has been associated with an increase in cyclosporine-induced toxicity, possibly due to decreased synthesis of renal prostacyclin.	DDI-false
In clinical trials, FLOLAN was used with @DRUG$, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ should be withdrawn at least 48 hours before conducting an @DRUG$-mediated stress test.	DDI-advise
Nephrotoxic agents : Concomitant administration of @DRUG$ and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), @DRUG$, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-advise
No pharmacokinetic interactions between @DRUG$ and @DRUG$ , propofol , alfentanil , and midazolam have been demonstrated .	DDI-false
Nephrotoxic agents: Concomitant use of @DRUG$ and agents with nephrotoxic potential [ e.g. , intravenous aminoglycosides ( e.g. , tobramycin , gentamicin , and amikacin ) , amphotericin B , @DRUG$ , intravenous pentamidine , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-advise
Patients receiving both indomethacin and @DRUG$ should be observed closely to determine if the desired diuretic and/or antihypertensive effect of @DRUG$ is achieved .	DDI-false
However, concomitant administration of aspirin with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of @DRUG$ alone.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, @DRUG$ or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
CONCLUSIONS: @DRUG$ inhibit the metabolism of HMG-CoA reductase inhibitors that are metabolized by CYP3A4 (i.e., atorvastatin, cerivastatin, lovastatin, @DRUG$).	DDI-mechanism
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (@DRUG$, nevirapine, phenytoin, @DRUG$, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
Ketoconazole: In healthy subjects receiving @DRUG$, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to @DRUG$ was increased to approximately 3.6-fold of control and half-life increased to 1.7-fold of control.	DDI-mechanism
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between magnesium deficiency due to an insufficient magnesium intake which only requires oral physiological supplementation and @DRUG$ depletion related to a dysregulation of the control mechanisms of @DRUG$ status which requires more or less specific regulation of its causal dysregulation.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$, and vincristine.	DDI-false
* Drug interactions : Flupentixol may interact with some drugs, such as @DRUG$ ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Concomitant administration of fenofibrate (equivalent to 145 mg @DRUG$) with @DRUG$ (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in atorvastatin AUC values in 22 healthy males.	DDI-mechanism
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol, methanol, higher @DRUG$ and @DRUG$ in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
CNS-Active Drugs @DRUG$ : Sonata 10 mg potentiated the CNS-impairing effects of ethanol 0.75 g/kg on balance testing and reaction time for 1 hour after @DRUG$ administration and on the digit symbol substitution test ( DSST ) , symbol copying test , and the variability component of the divided attention test for 2.5 hours after ethanol administration .	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (phenytoin, @DRUG$, oral contraceptive, @DRUG$, warfarin, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
Other reported interactions with @DRUG$: @DRUG$ (CYP3A4 substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
Oral @DRUG$ CAUTION SHOULD BE EXERCISED WHEN @DRUG$ ARE GIVEN IN CONJUNCTION WITH TRICOR .	DDI-false
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Ingestion of diclofenac may increase serum concentrations of @DRUG$ and methotrexate and increase @DRUG$ s nephrotoxicity.	DDI-false
â€¢ Corticosteroids, methylxanthine and diuretics: concomitant treatment with xanthine derivatives, @DRUG$ , or @DRUG$ may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
For this reason, drugs with a low therapeutic margin, such as vitamin K antagonists, @DRUG$ , and @DRUG$ , could have a delayed elimination and increases in their serum half-life leading to a toxic level .	DDI-false
Simultaneous use of active substances in the @DRUG$ ( which includes Anafranil ) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the @DRUG$ Or the other drug.	DDI-false
The medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$ , disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$ , phenytoin , ribavirin , and vincristine .	DDI-false
Warfarin : @DRUG$ In patients receiving chronic prothrombin, this did not have a clinically significant effect on the prothrombin time. @DRUG$ treatment .	DDI-false
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, @DRUG$, sulfonamides, chloramphenicol, @DRUG$, coumarins, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
Antacids or @DRUG$: The effect of increased gastric pH on the bioavailability of @DRUG$ was evaluated in 18 healthy adult volunteers.	DDI-false
- Non-selective MAO inhibitors including tranylcypromin sulfate, phenylzinsulfate and @DRUG$ HC1 : Simultaneous application of @DRUG$ Non-selective MAO inhibitors can lead to hypertension.	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: cisapride	DDI-advise
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, danazol, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and @DRUG$.	DDI-false
Other CNS depressant drugs (e.g. barbiturates, tranquilizers, @DRUG$ and general anesthetics) have additive or potentiating effects with @DRUG$.	DDI-effect
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine , Innovar Vet , or pentobarbital , the dosage of @DRUG$ The need to cause ventricular tachycardia was significantly higher than the LD50 of Ouabain, with ketamine or innovar than with pentobarbital.	DDI-false
Therefore, the concomitant use of @DRUG$ with @DRUG$ is contraindicated .	DDI-advise
Aspirin/@DRUG$: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered aspirin (162.5 mg orally given 26 and 2 hours prior to initiation of Argatroban 1  g/kg/min. over 4 hours) or @DRUG$ (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of Argatroban 1.5  g/kg/min. over 18 hours).	DDI-false
In vitro studies show significant inhibition of the formation of oxidised irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors sulfenazol, @DRUG$ and @DRUG$.	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin, clarithromycin, @DRUG$ , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
Concurrent administration of a @DRUG$ with ORENCIA has been associated with an increased risk of serious infections and no significant additional efficacy over use of the @DRUG$ alone.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, @DRUG$, troleandomycin, @DRUG$, nelfinavir) would be expected to behave similarly.	DDI-false
Both the toxicity of @DRUG$ and the therapeutic value of @DRUG$ can be rationalized at the cellular and molecular level by the following observations : ( i ) these polyene antibiotics showed differential effects on cells ;	DDI-false
@DRUG$: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when COREG is co-administered with @DRUG$.	DDI-false
It has been shown that @DRUG$ The anticoagulant effect of @DRUG$ and their analogue .	DDI-effect
Magnesium/aluminium-containing antacids : absorption of @DRUG$ When co-administered with @DRUG$ containing magnesium/aluminium, the dose is moderately reduced (about 25%).	DDI-false
Inhibitors Of Endogenous Prostaglandin Synthesis It has been reported that @DRUG$ may reduce the antihypertensive effect of @DRUG$, especially in cases of low renin hypertension.	DDI-effect
Although the interaction between @DRUG$ and other potent CYP3A4 inhibitors (e.g., itraconazole, ritonavir, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications.	DDI-false
Antidepressants ( @DRUG$ ) , @DRUG$ or other anticholinergic agents , or digitalis glycosides : concurrent use with arbutamine may produce additive inotropic and/or chronotropic effects .	DDI-false
Anticoagulants: Potentiation of warfarin-type (CYP2C9 and @DRUG$ substrate) @DRUG$ response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Drug interactions : Flupentixol may interact with some medications such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupentixol and ethanol cause additive CNS depression - @DRUG$ : @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
The concomitant use of Natrecor with IV @DRUG$ - Like nitroglycerin, @DRUG$ , Milrinone or IV ACE inhibitors have not been studied (these drugs were not administered in clinical trials with Natrecor).	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, @DRUG$, calcium channel blocking drugs, and isoniazid.	DDI-false
- Anabolic steroids (nandrolone [e.g., @DRUG$], @DRUG$ [e.g., Anavar], oxymetholone [e.g., Anadrol], stanozolol [e.g., Winstrol]) or	DDI-false
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], @DRUG$ [e.g., Winstrol]) or	DDI-false
@DRUG$ may interact with any of the following: - @DRUG$ (e.g., Tylenol) (with long-term, high-dose use) or	DDI-int
A possible interaction between @DRUG$ It has been reported that ciprofloxacin, a fluoroquinolone antibiotic, increased the hypoglycaemic effect of @DRUG$.	DDI-false
To avoid @DRUG$ intoxication, appropriate adjustment of the @DRUG$ should be made.	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phe-nothiazines , thyroid products , estrogens , oral contraceptives , @DRUG$ , nicotinic acid , sympathomimet-ics , calcium channel blocking drugs , and @DRUG$.	DDI-false
In clinical trials, @DRUG$ was used with digoxin, diuretics, anticoagulants, oral @DRUG$, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
@DRUG$ (Magnesium-Aluminum Hydroxide): Cerivastatin plasma concentrations were not affected by co-administration of @DRUG$.	DDI-false
@DRUG$ and Norethindrone : Coadministration of VIRACEPT with OVCON-35 resulted in a 47 % decrease in ethinyl estradiol and an 18 % decrease in @DRUG$ plasma concentrations .	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$ , warfarin , isosorbide mononitrate , @DRUG$ Ethanol or itraconazole.	DDI-false
Because @DRUG$ It has not been shown that an additional effect over that with aspirin alone and because @DRUG$ increases the rate of excretion of Nalfon , the concomitant use of Nalfon and salicylates is not recommended .	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, @DRUG$ , polymyxins, lincomycin, clindamycin, colistine, and sodium colistimethate), magnesium salts, lithium, local @DRUG$ , procainamide , and quinidine .	DDI-false
Aspirin, @DRUG$, @DRUG$, NSAIDs	DDI-false
@DRUG$ did not alter the pharmacokinetics of @DRUG$.	DDI-false
The use of local anesthetics containing epinephrine, or @DRUG$ to patients receiving monoamine oxidase inhibitors or @DRUG$ may produce severe , prolonged hypertension .	DDI-effect
Concurrent administration of low-dose @DRUG$ and @DRUG$ may produce an additive or potentiating effect on urine flow .	DDI-effect
Serum lithium levels should be monitored frequently if @DRUG$ It is given at the same time as @DRUG$.	DDI-advise
Patients receiving other @DRUG$s, general @DRUG$, phenothiazines, tranquilizers, sedative-hypnotics, tricyclic antidepressants or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
The blood pressure effect of @DRUG$ tended to be greater in patients on @DRUG$ than in patients on no other antihypertensive therapy.	DDI-effect
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (@DRUG$, cefoperazone, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Other medicinal products Interactions: No pharmacokinetic interactions between vardenafil and the following medicinal products have been observed: @DRUG$ , @DRUG$ ==References====External links==	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, e.g. @DRUG$ , @DRUG$ , phenytoin, dexamethasone or carbamazepine, administration of a daily dose of 70 mg CANCIDAS should be considered	DDI-false
Conversely , the administration of @DRUG$ ( 1 mg @DRUG$ QID ) did not alter the pharmacokinetics of a 300-mg dose of cimetidine .	DDI-false
The absorption of @DRUG$ , @DRUG$ , penicillin G , hydrochlorothiazide , and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride ;	DDI-false
Valproate: The addition of tiagabine to patients taking @DRUG$ chronically had no effect on @DRUG$ pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , @DRUG$ , @DRUG$ , sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
INOmax has been administered with tolazoline, @DRUG$, @DRUG$, steroids, surfactant, and high-frequency ventilation.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazide, @DRUG$ , nicardipine , @DRUG$ , protease inhibitors , quinidine , and verapamil .	DDI-false
@DRUG$ (e.g., spironolactone, @DRUG$, or amiloride), potassium supplements, or potassium-containing salt substitutes may lead to significant increases in serum potassium.	DDI-false
Therefore , if @DRUG$ The treatment with VAPRISOL is carried out, the clinician should focus on the possibility of increasing the @DRUG$ levels .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, @DRUG$, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
The effects of ketamine and of @DRUG$ anesthesia on @DRUG$ Tolerance in dogs.	DDI-false
The effect of benzodiazepines may be increased by anticonvulsants, antihistamines, @DRUG$ , barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, @DRUG$ , or other drugs that produce CNS depression .	DDI-false
A drug-drug interaction study evaluated the effect of the use of @DRUG$ 5 % gel in combination with double strength ( 160 mg/800 mg ) trimethoprim/sulfamethoxazole ( TMP/@DRUG$ ).	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenylbutazone, phenytoin sodium, @DRUG$, griseofulvin, topiramate, and possibly with ampicillin and @DRUG$ 72.	DDI-false
Based on the chemical similarity of itraconazole and @DRUG$ , coadministration of astemizole with @DRUG$ is contraindicated .	DDI-false
In bioavailability studies with normal subjects , the concurrent administration of @DRUG$ at therapeutic levels did not significantly influence the bioavailability of @DRUG$ tablets .	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ Midazolam, triazolam GI Motility agent: cisapride	DDI-advise
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, salbutamol, terbutaline), isoniazid, @DRUG$ , somatropin , @DRUG$ Oestrogens, progestogens (e.g. in oral contraceptives).	DDI-false
@DRUG$, lidocaine, phenobarbital, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
The action of the @DRUG$ It may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, @DRUG$ , Phenothiazine, psychotropic drugs, or other drugs that produce CNS depression.	DDI-effect
Antihypertensives : Amiodarone should be used with caution in patients receiving   -@DRUG$ blocking agents ( e.g. , propranolol , a CYP3A4 inhibitor ) or calcium channel antagonists ( e.g. , verapamil , a CYP3A4 substrate , and diltiazem , a @DRUG$ inhibitor ) because of the possible potentiation of bradycardia , sinus arrest , and AV block ;	DDI-false
Norepinephrine: @DRUG$ enhance the adrenergic effect of @DRUG$.	DDI-effect
@DRUG$ , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , phenytoin , propranolol , @DRUG$ , chlordiazepoxide , diazepam , certain tricyclic antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-mechanism
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with @DRUG$ (such as @DRUG$), diphen-hydramine and H2 antagonists (such as cimetidine or ranitidine).	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, @DRUG$ or other CNS depressants (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, @DRUG$ ( e.g. , @DRUG$ , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Other medicines: In small groups of patients ( 7 - 10/interaction study ), the concomitant administration of azathioprin, gold, @DRUG$ , @DRUG$ Prednisolone, doxycycline or digitoxin did not significantly affect the peak and AUC values of diclofenac.	DDI-false
No Important Interactions To Date @DRUG$ There are no clinically relevant pharmacokinetic interactions with @DRUG$ , beta-blockers, felodipine, digoxin, warfarin, isosorbide mononitrate, scotilol, ethanol or itraconazole.	DDI-false
@DRUG$ : Da apomorphine is a @DRUG$ , it is possible that dopamine antagonists , such as the neuroleptics ( phenothiazines , butyrophenones , thioxanthenes ) or metoclopramide , may diminish the effectiveness of APOKYN .	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, @DRUG$, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$: The rate and extent of absorption of ciprofloxacin was bioequivalent when Proquin XR was given alone or when @DRUG$ was given 2 hours after omeprazole at the dose that maximally suppresses gastric acid secretion.	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, @DRUG$, and the Type 1C antiarrhythmics @DRUG$ and flecainide).	DDI-false
@DRUG$ : Adrenergic blockers are inhibited by @DRUG$.	DDI-false
The pharmacokinetics of @DRUG$ were not affected by multiple-dose administration of @DRUG$.	DDI-false
â€¢ Co-administration of a single dose of 25 mg @DRUG$ The pharmacokinetics of @DRUG$ have not been affected.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
@DRUG$ When vardenafil 10 or 20 mg was given to healthy subjects either simultaneously or 6 hours after a 10 mg dose @DRUG$ Significant hypotension develops in a significant number of subjects.	DDI-false
Probenecid: @DRUG$, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of @DRUG$ 1000 mg twice daily.	DDI-false
A study of eight healthy volunteers showed a 50% increase in average peak levels. @DRUG$ - plasma concentrations and an increase in the mean area below the curve by 90%, after a one-week cimetidine cycle at 1,000 mg/ day and @DRUG$ at 90 mg/day .	DDI-false
For example , @DRUG$ ( e.g. , @DRUG$ ==See also====References====External links==	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Amiodarone may suppress certain CYP450 enzymes , including @DRUG$ , @DRUG$ , CYP2D6 , and CYP3A4 .	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain medications, including non-steroidal anti-inflammatory drugs and other medicines that are highly protein-bound, @DRUG$ , sulfonamides , @DRUG$ , probenecid, coumarine, monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-false
Like @DRUG$ (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of morphine and cocaine and the oral self-administration of @DRUG$ and nicotine in rats;	DDI-false
@DRUG$ , including oral contraceptives: estrogens may cause hepatic metabolism of certain @DRUG$ , which increases its effect.	DDI-false
For patients receiving both therapies , standard monitoring of @DRUG$ blood concentrations and appropriate @DRUG$ Dose adjustment is recommended.	DDI-false
The interaction of GABITRIL with other drugs : @DRUG$ Co-administration of cimetidine (800 mg/ day) in patients taking chronic tiagabin had no effect on @DRUG$ pharmacokinetics .	DDI-false
These drugs include thiazides and other diuretics, @DRUG$ , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , @DRUG$ , sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Additive adverse effects resulting from cholinergic blockade may occur when LEVSIN is administered concomitantly with other antimuscarinics, @DRUG$, haloperidol, phenothiazines, @DRUG$, tricyclic antidepressants or some antihistamines.	DDI-false
@DRUG$ : Amphetamines may counteract the sedative effect of @DRUG$.	DDI-false
Lithium : In a study conducted in healthy subjects , mean steady-state lithium plasma levels increased approximately 17 % in subjects receiving @DRUG$ 450 mg twice daily with @DRUG$ 200 mg twice daily compared to people who only receive lithium.	DDI-mechanism
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , sulfonamides , @DRUG$ , probenecid , coumarins , monoamine oxidase inhibitors , and @DRUG$.	DDI-false
These drugs include: @DRUG$ And other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$ , sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as @DRUG$.	DDI-advise
In clinical studies performed with Fondaparinux, the concomitant use of oral @DRUG$ (@DRUG$), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Benzylpenicillin, ampicillin, oxacillin, @DRUG$, @DRUG$, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated @DRUG$ plus @DRUG$ 25 mg daily, as compared to those taking ibuprofen 2400 mg daily alone.	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with @DRUG$, methyldopa, nitrates, calcium-blocking agents, hydralazine, prazosin and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
- medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, @DRUG$ Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : @DRUG$ benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-false
@DRUG$ @DRUG$ The pharmacokinetics of valproate in healthy volunteers have not been altered (500 mg twice daily).	DDI-false
Concomitant cyclophosphamide , @DRUG$ , vincristine , and @DRUG$ chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-associated non-Hodgkin lymphoma.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, @DRUG$, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Central Nervous System Depressants : The concomitant use of @DRUG$   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , sedatives , hypnotics , @DRUG$ â€¢ (e.g. benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants and alcohol, may cause respiratory depression, hypotension and deep sedation, or may lead to coma or death.	DDI-effect
Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose PROLEUKIN and @DRUG$, specifically, dacarbazine, @DRUG$, tamoxifen and interferon-alfa.	DDI-false
- Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, @DRUG$ In vitro, cephalothine, erythromycin and sulfamethoxazole have no effect on protein binding of @DRUG$ In human serum.	DDI-false
@DRUG$ It was used with tolazolin, dopamine, dobutamine, @DRUG$ , surfactant , and high-frequency ventilation .	DDI-false
Before using this medication , tell your doctor or pharmacist of all prescription and nonprescription products you may use , especially of : aminoglycosides ( e.g. , gentamicin , amikacin ) , amphotericin B , cyclosporine , @DRUG$ Drugs (e.g. ibuprofen), tacrolimus, @DRUG$.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Therefore, if @DRUG$ is administered with @DRUG$, the clinician should be alert to the possibility of increases in digoxin levels.	DDI-mechanism
Hypotension: Patients on Diuretic Therapy: Patients on @DRUG$ and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with @DRUG$ or enalaprilat.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, @DRUG$, ribavirin, and vincristine.	DDI-false
@DRUG$ * : potentiation of the warfarin type ( @DRUG$ and CYP3A4 substrate ) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Other reported interactions with @DRUG$: Fentanyl (@DRUG$ substrate) in combination with amiodarone may cause hypotension, bradycardia, and decreased cardiac output.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , @DRUG$ , ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, @DRUG$ And vincristine.	DDI-false
The administration of local anesthetic solutions containing epinephrine or @DRUG$ to patients receiving @DRUG$, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-effect
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, @DRUG$, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Probenecid: @DRUG$ interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of @DRUG$ in serum.	DDI-mechanism
Sinus bradycardia has been reported with oral @DRUG$ in combination with @DRUG$ (CYP3A4 substrate) given for local anesthesia.	DDI-false
Medicines associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$ , gold , hydralazine , @DRUG$ , isoniazid , metronidazole , nitrofurantoin , phenytoin , ribavirin , and vincristine .	DDI-false
Therefore, interactions may occur after concomitant administration of psychotropic medicinal products (e. g. @DRUG$ , analgesics , antiemetics , sedatives , @DRUG$ ) .	DDI-false
METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive @DRUG$ tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with cyclosporine and @DRUG$.	DDI-false
Compounds that have been tested in man include @DRUG$, digoxin, propranolol, theophylline, and @DRUG$ and no clinically meaningful interactions were found.	DDI-false
Non-steroidal anti-inflammatory drugs : In some patients, the administration of a @DRUG$ can reduce the diuretic , natriuretic , and antihypertensive effects of loop , potassium-sparing and @DRUG$.	DDI-effect
Tetracycline : Accompanying treatment with Accutane and @DRUG$ It should be avoided because: @DRUG$ use has been associated with a number of cases of pseudotumor cerebri ( benign intracranial hypertension ) , some of which involved concomitant use of tetracyclines	DDI-false
Potential drug interactions between: @DRUG$   and other AEDs ( carbamazepine , gabapentin , @DRUG$ , phenobarbital, phenytoin, primidone and valproate) were also evaluated by the evaluation of levetiracetam serum concentrations and these AEDs in placebo-controlled clinical trials.	DDI-false
Co-medications that induce CYP3A4 (e.g., dexamethasone, @DRUG$, @DRUG$, rifampin, phenobarbital or St.	DDI-false
Metformin : In healthy subjects given single 500 mg doses of @DRUG$ and @DRUG$ Mean plasma petformin clearance of cmax and AUC increased by an average of 34% and 24%, respectively, and mean renal clearance of metformin by 14%.	DDI-mechanism
As with some other @DRUG$, the time of onset of neuromuscular block induced by @DRUG$ is lengthened and the duration of block is shortened in patients receiving phenytoin or carbamazepine.	DDI-false
@DRUG$ : In post-marketing experience , there have been reports of both increases and decreases in phenytoin levels with @DRUG$ co-administration , leading to alterations in seizure control .	DDI-false
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when administering imatinib @DRUG$ with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , itraconazole , @DRUG$ ,,,,,,,,,,,	DDI-advise
@DRUG$ : Alcohol ( 0.5 g/kg body weight : approximately 40 mL of absolute alcohol in a 70 kg person ) and @DRUG$ Plasma levels were not altered when co-administered.	DDI-false
Possible drug interactions between Keppra and other AEDs (carbamazepine, @DRUG$ , lamotrigine , phenobarbital , @DRUG$ In placebo-controlled clinical trials, serum concentrations of levetiracetam and these AEDs have also been studied.	DDI-false
Although clinical studies have not been conducted based on the involvement of the cytochrome P-450 3A family in @DRUG$ metabolism , inhibitors of this enzyme system , notably oral antifungal agents , should be used cautiously in patients receiving @DRUG$.	DDI-false
INOmax has been administered with tolazoline, @DRUG$, dobutamine, @DRUG$, surfactant, and high-frequency ventilation.	DDI-false
The immediate release, but not the Coat Core formulation of @DRUG$ increased plasma @DRUG$ concentrations by about 20 % .	DDI-mechanism
All @DRUG$ should be used cautiously in patients taking @DRUG$.	DDI-advise
The following eight target drug/added drug combinations were studied : @DRUG$/@DRUG$.	DDI-false
These data indicate that @DRUG$ does not influence the plasma concentration of other AEDs and that these @DRUG$ do not influence the pharmacokinetics of levetiracetam.	DDI-false
â€¢ Saquinavir : The combination of @DRUG$ , @DRUG$ ZDV has been studied (as a triple combination) in adults.	DDI-false
It may be necessary to adjust the dosage of oral @DRUG$ upon beginning or stopping @DRUG$. since disulfiram may prolong prothrombin time.	DDI-advise
Medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$ , ethionamide, glutethimide, gold, hydralazine, iodoquinol, @DRUG$ , metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, @DRUG$, and isoniazid.	DDI-false
@DRUG$, a @DRUG$, may antagonize the bactericidal effect of penicillin and concurrent use of these drugs should be avoided.	DDI-false
@DRUG$ , tricyclic : @DRUG$ The activity of tricyclic or sympathomimetic agents can be increased;	DDI-false
Due to high inter-patient variability and limited sampling , the extent of the increase in @DRUG$ levels in patients receiving concurrent irinotecan and @DRUG$ is uncertain .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , @DRUG$ , corticosteroids, TNF blockers, azathioprin, chloroquine, @DRUG$ , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .	DDI-false
Dopamine Antagonists: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, @DRUG$) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , @DRUG$ , cefotetan , cefamandole , @DRUG$ Methylthiadiazole (Cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
CONCLUSIONS : @DRUG$ Inhibition of the metabolism of HMG-CoA reductase inhibitors metabolised by CYP3A4 (i.e. @DRUG$ , cerivastatin , lovastatin , simvastatin ) .	DDI-mechanism
In monkeys, the effects of (-)-NANM, but not (+)-NANM or @DRUG$, were antagonized by @DRUG$;	DDI-false
The aim of this paper was to study the interaction between @DRUG$ and both @DRUG$ or its synthetic analogue D-Ala2-metenkephalinamide, or tuftsin, on the antinonciceptive effect of these peptides in mice after intracisternal injection.	DDI-false
@DRUG$ 150 mg twice daily did not interact significantly with @DRUG$ (AUC was decreased by 15-20 %).	DDI-false
@DRUG$ Nimodipine and losartan: @DRUG$ There are no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on bosentan plasma levels.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, @DRUG$, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
@DRUG$ may increase slightly the effect of antihypertensive drugs, e.g., guanethidine, methyldopa, @DRUG$.	DDI-effect
Cephalosporins-Cephalosporins containing side chains of N-methylthiotetrazole ( cefmenoxime , @DRUG$ , cefotetan , @DRUG$ Methylthiadiazole (cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
While all the selective serotonin reuptake inhibitors (SSRIs), e.g., @DRUG$, sertraline, @DRUG$, and fluvoxamine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
Like @DRUG$ 40 mg/kg and 18-MC ( 40 mg/kg) reduce intravenous self-administration of morphine and @DRUG$ and the oral self-administration of ethanol and nicotine in rats ;	DDI-false
Digoxin: @DRUG$ 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of @DRUG$ after a single 0.5 mg oral dose.	DDI-false
Meperidine: @DRUG$ potentiate the analgesic effect of @DRUG$.	DDI-effect
The management of the local @DRUG$ containing @DRUG$ Patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazine may experience severe, prolonged hypotension or hypertension.	DDI-false
Delayed Adverse Reactions to Iodinated Contrast Media: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various @DRUG$ containing regimens who were subsequently administered @DRUG$ experienced acute, atypical adverse reactions.	DDI-effect
Other CNS depressant drugs ( e.g. @DRUG$ , tranquilizers , opioids and general anesthetics ) have additive or potentiating effects with @DRUG$.	DDI-effect
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and @DRUG$.	DDI-false
Vaccines: Patients on corticosteroid therapy may exhibit a diminished response to toxoids and @DRUG-DRUG$ due to inhibition of antibody response.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and @DRUG$  (@DRUG$ capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free warfarin.	DDI-false
==References====External links== @DRUG$ , @DRUG$ In vitro inhibition of platelet activation and decrease of platelet adhesion intravascular.	DDI-false
Physiological changes resulting from smoking cessation, with or without @DRUG$ replacement, may alter the pharmacokinetics of certain concomitant medications, such as @DRUG$ and theophylline.	DDI-false
In a Phase I trial using escalating doses of TAXOL ( 110 - 200 mg/m2 ) and @DRUG$ Myelosuppression was lower when TAXOL was given after cisplatin than with the alternative sequence (i.e., TAXOL prior to @DRUG$ ) .	DDI-false
The risk of a potential interaction between @DRUG$ and @DRUG$ concentrates has not been adequately evaluated in preclinical or clinical studies.	DDI-false
Magnesium- and/or @DRUG$-containing antacids, products containing ferrous sulfate (iron), @DRUG$ containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Drug/Laboratory Test Interaction Because @DRUG$ may affect the APTT assay , @DRUG$ present in plasma samples may interfere with one-stage coagulation assays based on the APTT ( such as factor VIII , IX , and XI assays ) .	DDI-false
Other drug interactions Cimetidine , @DRUG$ and dextropropoxyphene had no effect on the pharmacokinetics of @DRUG$.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, @DRUG$, sulfasalazine, and anakinra.	DDI-false
It can be used with thyroid medications (e.g. levothyroxin), iodine-containing products, antacids, H2 antagonists (e.g., @DRUG$ , @DRUG$ , and proton pump inhibitors (e. g. lansoprazole, omeprazole).	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, @DRUG$, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
@DRUG$: rifampin CONTRAINDICATED since the coadministration of this product with @DRUG$ in an antiretroviral regimen reduces the plasma concentrations of saquinavir.	DDI-false
This appears to be the only clinically relevant interaction of this species with @DRUG$ , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or beta-adrenergic blocking agents , @DRUG$ Also antihistamines or H1-blockers, tricyclic antidepressants and phenothiazines could contribute to an extension of the QTc interval.	DDI-effect
In vitro studies show that CYP3A4 isoform and CYP1A2 isoform are the metabolism of @DRUG$ To Desbutyl levobupivacain and @DRUG$ , respectively .	DDI-false
acetaminophen/@DRUG$ , lidocaine/quinidine , phenobarbital/acetaminophen , @DRUG$/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
@DRUG$ These medicines in combination with very high doses of @DRUG$ have been shown to provoke convulsions in pre-clinical studies .	DDI-false
@DRUG$ : @DRUG$ It is known that they cause osteoporosis.	DDI-false
@DRUG$: Serious side effects and even death have been reported following the concomitant use of certain drugs with @DRUG$.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
Saturation agents : gastrointestinal saturation agents ( @DRUG$ , reserpine, glutamic acid HCl, @DRUG$ , fruit juices , etc . ) lower absorption of amphetamines .	DDI-false
Another oral azole antifungal, @DRUG$ , inhibits the metabolism of astemizole, resulting in increased plasma concentrations of astemizole and its active metabolite @DRUG$ which may prolong QT intervals .	DDI-false
hypersensitivity reactions : patients with a history of severe hypersensitivity reactions to products containing Cremophor EL (e.g. cyclosporin for injection concentrate and @DRUG$ The medicine must not be treated with @DRUG$.	DDI-advise
Lithium : In a study conducted in healthy subjects , mean steady-state @DRUG$ plasma levels increased approximately 17 % in subjects receiving lithium 450 mg BID with CELEBREX 200 mg BID as compared to subjects receiving @DRUG$ alone .	DDI-false
Use with @DRUG$ The main route to detoxification of azathioprin is inhibited by @DRUG$.	DDI-false
Single doses of either @DRUG$ or colestipol resins bind the @DRUG$ and reduce its absorption from the gastrointestinal tract by up to 85 and 43 percent, respectively.	DDI-mechanism
In a Phase I trial using escalating doses of @DRUG$ (110-200 mg/m2) and cisplatin (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).	DDI-false
Substances that are potent inhibitors of CYP3A4 activity (e.g. ketoconazole and @DRUG$ ) decrease @DRUG$ metabolism and increase gefitinib plasma concentrations .	DDI-mechanism
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
Concurrent administration of @DRUG$ and @DRUG$ may cause severe orthostatic hypotension.Cimetidine, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.	DDI-effect
Drug-drug interactions In vitro studies using human liver microsomes indicate that @DRUG$ and @DRUG$ are not inhibitors of cytochrome ( CYP ) P450 isoforms CYP3A4 , CYP2D6 , CYP2E1 , or CYP1A2 .	DDI-false
@DRUG$: astemizole*, @DRUG$* CONTRAINDICATED due to potential for serious and/or life-threatening cardiac arrhythmias.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$ also should be used cautiously with other drugs ( e.g. , @DRUG$ , glycosides ) that sensitize the myocardium to the actions of sympathomimetic drugs .	DDI-advise
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib : Caution should be exercised when gleevec is administered with CYP3A4 inhibitors (e.g. ketoconazole, @DRUG$ , @DRUG$ , clarithromycin ) .	DDI-false
Antifungals: In vitro and/or in vivo data indicate that @DRUG$, @DRUG$, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with @DRUG$ 10 mg resulted in a 16-fold increase in vardenafil AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
No pharmacokinetic interactions between @DRUG$ and isoflurane, @DRUG$, alfentanil, and midazolam have been demonstrated.	DDI-false
Molecular basis for the selective toxicity of @DRUG$ for yeast and @DRUG$ For animal cells.	DDI-false
Antiacid , @DRUG$ , Didanosine , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , @DRUG$ , rifabutin, rifampin, ritanovir, saquinavir.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$ , ergotic derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, @DRUG$ , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Insulin or Oral @DRUG$: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of @DRUG$ and oral hypoglycemics.	DDI-false
Other CONCOMITANT THERAPY: Although no specific interaction studies have been conducted, cerivastatin sodium was co-administered with @DRUG$ , @DRUG$ , calcium-channel blockers , diuretics , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
Drugs With A Narrow Therapeutic Index @DRUG$ A single dose of @DRUG$ 3 mg did not affect the pharmacokinetics of digoxin measured at steady state following dosing of 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.	DDI-false
DOSTINEX should not be administered concurrently with D2-antagonists, such as phenothiazines, @DRUG$, thioxanthines, or @DRUG$.	DDI-false
Multivalent Cation-Containing Products : Concomitant administration of a quinolone, including @DRUG$ With multivalent cation-containing products such as magnesium or aluminium @DRUG$ , Sucralfat, VIDEX chew/buffer tablets or children's powder, or products that contain calcium, iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-mechanism
No significant pharmacokinetic interactions were found in interaction studies with hydrochlorothiazide, digoxin. @DRUG$ , @DRUG$ and phenobarbital .	DDI-false
Imipramin ( 5 mg/ kg ), @DRUG$ Fluoxetine ( 20 mg/kg) @DRUG$ ( 30 mg/kg ) or vehicle was administered .	DDI-false
@DRUG$ has been administered with @DRUG$, dopamine, dobutamine, steroids, surfactant, and high-frequency ventilation.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$, barbiturates, MAO inhibitors, and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Amiodarone may suppress certain CYP450 enzymes, including CYP1A2, @DRUG$, @DRUG$, and CYP3A4.	DDI-false
Interactions between EPA supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ ( @DRUG$ ) .	DDI-false
gastrointestinal acidifying agents ( guanethidine, @DRUG$ , @DRUG$ , ascorbic acid , fruit juices , etc . ) lower absorption of amphetamines .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, @DRUG$, ethionamide, glutethimide, gold, @DRUG$, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or @DRUG$), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Antihypertensive Medications and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant @DRUG$ or @DRUG$ (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , @DRUG$ , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , @DRUG$ , thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and @DRUG$ In combination with fosinopril, reduced serum levels and urinary excretion of fosinoprilat are administered alone, suggesting that antacids may affect the absorption of @DRUG$.	DDI-false
Probenecid : @DRUG$ , a renal tubular secretion blocking agent , administered at a dose of 500 mg four times a day , did not change the pharmacokinetics of @DRUG$ 1000 mg twice daily.	DDI-false
Plasma exposure of @DRUG$ (10 mg BID) was increased by 28% following administration of valdecoxib (40 mg BID) for 12 days, while plasma exposure of valdecoxib (40 mg BID) was not substantially increased following administration of @DRUG$ (10 mg BID) for 12 days.	DDI-false
Since the therapeutic range of @DRUG$ is narrow theophylline serum levels should be monitored closely, and appropriate dosage adjustments of @DRUG$ should be made.	DDI-false
Corticosteroids , @DRUG$ And diuretics: concomitant treatment with xanthine derivatives, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, @DRUG$, and vincristine.	DDI-false
@DRUG$ It was used with tolazolin, dopamine, dobutamine, steroids, @DRUG$ , and high-frequency ventilation .	DDI-false
@DRUG$: @DRUG$ inhibit the hypotensive effect of veratrum alkaloids.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , @DRUG$ , tacrolimus, cyclosporin, ergot derivatives, @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
@DRUG$ - prior ingestion of diphenidol may decrease the emetic response to @DRUG$ In the treatment of poisoning.	DDI-false
@DRUG$ and indinavir: Upon concomitant administration of 5 mg of Vardenafil with 600 mg BID ritonavir, the Cmax and AUC of @DRUG$ were reduced by approximately 20%.	DDI-false
Consequently , estazolam should be avoided in patients receiving @DRUG$ and @DRUG$ , which are very potent inhibitors of CYP3A .	DDI-false
@DRUG$ : Diazepam ( @DRUG$ ==References====External links==	DDI-false
@DRUG$: In a study of healthy male volunteers no significant pharmacokinetic interaction occurred when captopril and @DRUG$ were administered concomitantly for 6 days.	DDI-false
Therefore, if @DRUG$ is administered with VAPRISOL, the clinician should be alert to the possibility of increases in @DRUG$ levels.	DDI-false
ACE inhibitors: reports suggest that @DRUG$ may diminish the antihypertensive effect of @DRUG$.	DDI-effect
Other concomitant therapies : In clinical trials , the safety profile in subjects treated with Acamprosate concomitantly with anxiolytics , hypnotics and sedatives ( including @DRUG$ ) , or @DRUG$ It was similar in patients taking placebo with these concomitant medications as in patients receiving placebo.	DDI-false
@DRUG$ , or other products containing iron or zinc , antacids or sucralfate should not be administered concomitantly with , or within 2 hours of , the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
Numerous drug interactions are possible with some anticonvulsant agents , such as @DRUG$ and @DRUG$ , which affect liver microsomal enzyme systems.	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
- Warfarin-@DRUG$ may have the effect of @DRUG$	DDI-effect
Curariform muscle relaxants (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, @DRUG$ and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Antiarrhythmics: @DRUG$, bepridil, flecainide, propafenone, @DRUG$ CONTRAINDICATED due to potential for serious and/or life-threatening reactions.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: @DRUG$, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$ Co-administration of diflunisal and naproxene in normal subjects had no effect on the plasma levels of naproxene, but significantly reduced urinary excretion of naproxene. @DRUG$ and its glucuronide metabolite .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , @DRUG$ ), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ ( e.g. , in oral contraceptives ) .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , @DRUG$ , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
Nephrotoxicity following concomitant administration of @DRUG$ with @DRUG$ or potent diuretics such as furosemide .	DDI-effect
Other concomitant therapies : In clinical trials, the safety profile in patients with @DRUG$ concomitantly with anxiolytics , @DRUG$ The occurrence of sedatives (including benzodiazepines) or non-opioid analgesics was similar to those in patients receiving placebo with these concomitant drugs.	DDI-false
@DRUG$: As with some other quinolones, concurrent administration of @DRUG$ with theophylline may lead to elevated serum concentrations of theophylline and prolongation of its elimination half-life.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions , all patients treated with @DRUG$ ed should be pre-treated with: @DRUG$ * (such as dexamethasone), diphenhydramine and H2 antagonists (such as cimetidine or ranitidine).	DDI-false
Therefore , when @DRUG$ The patient should be closely monitored to determine whether the desired effect of the @DRUG$ is obtained .	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between @DRUG$ and dapsone, trimethoprim/@DRUG$, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
Use with @DRUG$: The principal pathway for detoxification of azathioprine is inhibited by @DRUG$.	DDI-false
Administration of epinephrine to patients receiving @DRUG$ or halogenated hydrocarbon general anesthetics such as @DRUG$ The myocardial sensitization can cause cardiac arrhythmias.	DDI-false
Stavudine and Zidovudine Ribavirin can antagonize the in vitro antiviral activity of @DRUG$ and @DRUG$ against HIV .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
@DRUG$ * ( 200 mg once daily ) to a 10-fold increase in vardenafil AUC and a 4-fold increase in Cmax when co-administered with @DRUG$ 5 mg) in healthy volunteers.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants phenytoin , carbamazepine , and @DRUG$ , and the @DRUG$ rifampin .	DDI-false
- strong inducers of cytochrome P450 enzymes (e.g. carbamazepine, @DRUG$ It has been shown that plasma levels of phenobarbital and phenobarbital @DRUG$ ( 29 - 40 % ) .	DDI-false
In vitro studies indicate that , at therapeutic concentrations of @DRUG$ ( 300 m g/mL ) , the binding of ketorolac was reduced from approximately 99.2 % to 97.5 % , representing a potential twofold increase in unbound @DRUG$ plasma levels .	DDI-false
Digoxin : If multiple doses @DRUG$ Digoxin and digoxin were co-administered, steady-state plasma @DRUG$ Concentrations increased by about 20%.	DDI-false
@DRUG$ including tranylcypromine sulfate, phenelzine sulfate, and pargyline HC1: Concomitant use of @DRUG$ and non-selective MAO inhibitors may cause hypertension.	DDI-false
Although these results do not indicate a significant interaction between TORADOL and warfarin, or @DRUG$ , the administration of TORADOL to patients taking @DRUG$ should be done extremely cautiously , and patients should be closely monitored .	DDI-false
In a Phase I trial using escalating doses of TAXOL (110-200 mg/m2) and @DRUG$ (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence (ie, TAXOL before cisplatin).	DDI-false
Antipyrine : Because @DRUG$ â€¢ Does not affect the pharmacokinetics of @DRUG$ , interactions with other drugs metabolized via the same cytochrome isozymes are not expected .	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ and @DRUG$) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies.	DDI-false
acetaminophen/@DRUG$, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Population pharmacokinetic analyses revealed that @DRUG$, NSAIDs, corticosteroids, and @DRUG$ did not influence abatacept clearance.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
For this reason, the dose of @DRUG$ At the start of treatment, the dose should be reduced by 30-50%. @DRUG$ Delay bezalip and then titrate according to blood clotting parameters	DDI-advise
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with @DRUG$ , @DRUG$ , quinidine, clarithromycin or amoxicillin.	DDI-false
Although no specific drug interactions with topical glaucoma or systemic medications have been identified in clinical studies, there has been an increase in the incidence of adverse drug reactions. @DRUG$ - 0.5 % ophthalmic solution, the possibility of additive or potentiating effects with CNS depressants (alcohol, barbiturates, @DRUG$ , sedatives , anesthetics ) should be considered .	DDI-advise
Antacids : In a clinical pharmacology study, the concomitant use of a @DRUG$ Aluminium hydroxide, magnesium hydroxide and @DRUG$ ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
Acetaminophen/theophylline, @DRUG$/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and @DRUG$/Phenobarbital.	DDI-false
Both the toxicity of @DRUG$ The therapeutic value of amphotericin B can be rationalised at both cellular and molecular level by the following observations: (i ) these @DRUG$ showed differential effects on cells ;	DDI-false
Patients receiving hydantoins, @DRUG$, or @DRUG$ should be observed for increased activity of these drugs and, therefore, signs of toxicity from these drugs.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , @DRUG$ , Phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ ( e.g. , in oral contraceptives ) .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with @DRUG$: MTX, @DRUG$, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like @DRUG$ (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ Quinolone has been reported to enhance the effects of oral anticoagulant. @DRUG$ ==References==<br>	DDI-false
In a similar study with @DRUG$ in healthy volunteers , 1 of 24 subjects dosed with Vardenafil 20 mg and @DRUG$ 0.4 mg separated by 6 hours experienced a standing systolic blood pressure below 85 mm Hg .	DDI-false
This medicine can be used with @DRUG$ or other @DRUG$ (may increase CNS depressive effects of either these drugs or antihistamines), anticholinergics or other medicines with anticholinergic activity (anticholinergic effects may be increased if these drugs are used concomitantly with antihistamines) and monoamine oxidase (MAO) inhibitors (simultaneous use with antihistamines may prolong and increase anticholinergic and CNS depressive effects of antihistamines).	DDI-false
Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with @DRUG$, warfarin, quinidine, clarithromycin or amoxicillin.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a @DRUG$ , including ciprofloxacin, containing multivalent cation products such as: @DRUG$ Or aluminum antacids, sucralfat, VIDEX chew/buffer tablets or child powder, or products that contain calcium, iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-mechanism
@DRUG$ : @DRUG$ inhibit the hypotensive effect of veratrum alkaloids .	DDI-false
METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of @DRUG$ (7.4 mg/kg body weight) and subcutaneous injections of @DRUG$ (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of verapamil (10 or 20 mg/kg body weight) every other day until the end fo the experiment in week 45.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , @DRUG$ , doxorubicin , @DRUG$ , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Dosage adjustment may be warranted when @DRUG$ is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic @DRUG$ levels may rise resulting in toxicity .	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
When used in external subcutaneous infusion pumps for insulin, @DRUG$ Should not be mixed with others @DRUG$ or diluent .	DDI-false
It can be used with thyroid drugs (e.g. levothyroxin), iodine-containing products, antacids, H2 antagonists (e.g. famotidine, ranitidine) and proton pump inhibitors (e.g. @DRUG$ , @DRUG$ ) .	DDI-false
The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when @DRUG$ was administered on the same day as @DRUG$ than when these drugs were given on separate days (1.3%, 1/80 patients).	DDI-effect
Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$, including @DRUG$.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, @DRUG$, antihistamines or H1-blocking agents, @DRUG$ and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
This increased exposure of norethindron and ethinylestradiol should be considered in the selection of oral @DRUG$ for women taking @DRUG$.	DDI-advise
All subjects received @DRUG$ (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either @DRUG$ (300 mg once a day [QD]) (cohort 1) or rifampin (600 mg QD) (cohort 2) for 14 days.	DDI-false
@DRUG$: Dihydroergotamine, ergonovine, ergotamine, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
Anti-arrhythmics and @DRUG$ The extension of the QT interval observed with @DRUG$ could exaggerate.	DDI-effect
These drugs include thiazides and other diuretics, corticosteroids, @DRUG$ , thyroid products, estrogens, oral contraceptives, @DRUG$ , nicotinic acid, sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
It is not known if the effects of @DRUG$ are altered by concomitant medications that affect hepatic metabolism of drugs (@DRUG$, etc.), but physicians should be alert to the possibility that a smaller initial dose and longer intervals between doses may be needed.	DDI-advise
The administration of local anesthetic solutions containing epinephrine or norepinephrine to patients receiving monoamine oxidase inhibitors, @DRUG$ or @DRUG$ may produce severe, prolonged hypotension or hypertension.	DDI-false
Lithium: Lithium toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-effect
Antihypertensive Medications and Vasodilators : The following adverse events were experienced more commonly in patients receiving concomitant @DRUG$ or @DRUG$ ( n = 94 ) compared to patients not receiving these concomitant drugs ( n = 456 ): hypotension 10 % vs 4 % , myocardial infarction 3 % vs 1 % , serious pneumonia 5 % vs 3 % , serious falls 9 % vs 3 % , and bone and joint injuries 6 % vs 2 % .	DDI-effect
Colestipol-Concomitant intake of colestipol and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other @DRUG$, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Injection : @DRUG$ Injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$ , barbiturates , MAO inhibitors , and other antidepressants . When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-effect
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril , beta-blockers , @DRUG$ , digoxin , @DRUG$ , isosorbide mononitrate, knitztilol, ethanol or itraconazole.	DDI-false
However , patients on digoxin may show elevations of @DRUG$ concentrations after initiation of therapy with @DRUG$ , which may be clinically significant in patients prone to digoxin toxicity .	DDI-false
In patients with CYP3A4 inducers such as @DRUG$ , phenytoin, carbamazepine, and @DRUG$.	DDI-false
- @DRUG$ or MAO-inhibitors (with hepatotoxic potential) must not be administered together with @DRUG$ or Bezalip retard.	DDI-advise
@DRUG$ and @DRUG$ Ribavirin can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , @DRUG$ , danazol , @DRUG$ , sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isonazide, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of levobupivacaine may be affected by the known CYP3A4 inducers (such as @DRUG$, phenobarbital, @DRUG$), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$ , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and @DRUG$.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of warfarin and Lodine   ( @DRUG$ capsules and tablets ) results in reduced protein binding of warfarin , but there was no change in the clearance of free @DRUG$.	DDI-false
therefore , @DRUG$ - ug should not be co-administered with @DRUG$ because of the potential for serious and/or life-threatening cardiac arrhythmias .	DDI-advise
In vitro studies indicate that, at therapeutic concentrations of @DRUG$ (300 m g/mL), the binding of @DRUG$ was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound ketorolac plasma levels.	DDI-mechanism
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ with desipramine or @DRUG$ The concentration of D-amphetamine in the brain is significantly and sustainably increased by the tricycles and possibly by other tricycles;	DDI-mechanism
Antacids : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of @DRUG$ as compared with @DRUG$ Administration alone, suggesting that antacids may affect the absorption of fosinopril.	DDI-false
@DRUG$ had no significant effect on the anticoagulant effect of warfarin in healthy subjects on stable @DRUG$ therapy.	DDI-false
Therefore when @DRUG$ are administered concomitantly with @DRUG$ their dosage should be reduced .	DDI-advise
Presumably, phenytoin acts as a stimulator of @DRUG$ metabolism and has been reported to cause decreased serum levels of the @DRUG$ and increased prothrombin-proconvertin concentrations.	DDI-false
An additional reduction in blood pressure may occur if FLOLAN is co-administered with: @DRUG$ , antihypertensive or other @DRUG$.	DDI-false
Warfarin : The effects of @DRUG$ and @DRUG$ GI bleeding is synergistic, so users of both drugs together have a risk of severe GI bleeding higher than users of each drug alone.	DDI-effect
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of theophylline , @DRUG$ In healthy volunteers oral contraceptives or @DRUG$/ levonorgestrol.	DDI-false
@DRUG$: Because @DRUG$ does not affect the pharmacokinetics of antipyrine, interactions with other drugs metabolized via the same cytochrome isozymes are not expected.	DDI-false
Although in clinical studies with IOPIDINE 0.5 % ophthalmic solution no specific drug interactions with topical glaucoma or systemic drugs have been identified, there is a possibility of additive or potentiating effects with: @DRUG$ ( alcohol , @DRUG$ , opiates , sedatives , anesthetics ) should be considered .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , @DRUG$ , iodoquinol , isoniazid , metronidazole , nitrofurantoin , @DRUG$ Ribavirin and vincristine.	DDI-false
In vitro, diclofenac interfers minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), @DRUG$ , @DRUG$ ( 10 % decrease in binding ) , or warfarin .	DDI-false
Digoxin, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and @DRUG$, and @DRUG$ has no significant effect on plasma levels of bosentan.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazide, @DRUG$ , nicardipine, propofol, protease inhibitors, quinidine and @DRUG$.	DDI-false
Veratrum alkaloids: @DRUG$ inhibit the hypotensive effect of @DRUG$.	DDI-effect
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, @DRUG$, nicardipine, and nifedipine.	DDI-int
- Anabolic steroids (nandrolone [e.g., Anabolin], oxandrolone [e.g., @DRUG$], oxymetholone [e.g., Anadrol], @DRUG$ [e.g., Winstrol]) or	DDI-false
Effect of @DRUG$ in Pediatric Patients There was about a 22 % increase of apparent total body clearance of levetiracetam when it was co-administered with enzyme-inducing @DRUG$.	DDI-false
@DRUG$-@DRUG$ Adequate side chains of N-methylthiotetrazole (Cefmenoxime, cefooperazone, cefotetan, cefamandol, latamoxef) or methylthiadiazole (Cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
@DRUG$ may augment the activity of other @DRUG$.	DDI-effect
The co-administration of @DRUG$ with IV @DRUG$ such as nitroglycerin, nitroprusside, milrinone, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g. itraconazole, @DRUG$ , and erythromycin ) has not been studied , increased exposures to @DRUG$ may be expected when almotriptan is used concomitantly with these medications .	DDI-false
Interaction of @DRUG$ In vitro data showed that: @DRUG$ is 96 % bound to human plasma protein and therefore has the potential to interact with other highly protein bound compounds .	DDI-false
@DRUG$: In vitro and/or in vivo data indicate that fluconazole, itraconazole, and oral ketoconazole markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
It is structurally distinct from the other currently available @DRUG$ (@DRUG$, simvastatin, and pravastatin), leading to unique biopharmaceutical properties relative to the other agents of this class.	DDI-false
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, phenytoin, dexamethasone, @DRUG$) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , @DRUG$ , cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$ , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Conversely, the administration of STADOL NS (1 mg @DRUG$ QID) did not alter the pharmacokinetics of a 300-mg dose of @DRUG$.	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of norethindrone and @DRUG$ levels of 14% and 31%, respectively.	DDI-false
Drug interactions : Flupentixol may interact with some medicines such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect flupentixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: @DRUG$ and @DRUG$ cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-effect
Elevated plasma levels of @DRUG$ It was over a simultaneous @DRUG$ use .	DDI-mechanism
The following examples are substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, diuretics, sympathomimetics (e.g. epinephrine, salbutamol, terbutaline), @DRUG$ , phenothiazine derivatives , somatropin , thyroid hormones , @DRUG$ , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
There is therefore potential for interaction with other medicinal products metabolised by CYP 1A2 (e.g. @DRUG$ Takrin, and @DRUG$ ) .	DDI-false
Warfarin : The effect of @DRUG$ on the anticoagulant effect of @DRUG$ Co-administration of BEXTRA 40 mg twice daily for 7 days has been studied in healthy subjects (1-8 mg/ day).	DDI-false
@DRUG$ In normal subjects, co-administration of diflunisal and acetaminophen resulted in an increase in plasma levels of approximately 50% of @DRUG$.	DDI-false
@DRUG$: The concomitant administration of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite.	DDI-false
@DRUG$ will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain @DRUG$, etc.).	DDI-mechanism
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : @DRUG$ The use of pentazocin, nalbuphin, butorphanol, decocin, and buprenorphine should not be administered to a patient who has received or received treatment with a pure agonist opioid analgesics such as @DRUG$.	DDI-advise
Oral Contraceptives: Coadministration of atorvastatin and an oral @DRUG$ increased AUC values for @DRUG$ and ethinyl estradiol by approximately 30% and 20%.	DDI-false
Ingestion of diclofenac may increase serum concentrations of @DRUG$ and @DRUG$ and increase cyclosporine s nephrotoxicity .	DDI-false
Other medicines that can improve neuromuscular blocking effects of non-depolarizing agents such as NUROMAX are certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, @DRUG$ , local @DRUG$ , procainamide, and quinidine.	DDI-false
Quinolones, including @DRUG$, may enhance the effects of oral @DRUG$, including warfarin or its derivatives or similar agents.	DDI-effect
- Methotrexate (e.g., @DRUG$) Use of @DRUG$ with sulfapyridine may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
There is a significant increase in exposure to imatinib if: @DRUG$ is coadministered with @DRUG$ CYP3A4 inhibitor).	DDI-mechanism
Both efavirenz and nevirapine have been compared to triple therapy with the @DRUG$ indinavir over 48 weeks as initial therapy, with similar responses being observed with @DRUG$ regimens and superiority observed with efavirenz.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , @DRUG$ , @DRUG$ , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
The interaction may be between: @DRUG$ Food supplements and aspirin and other non-steroidal anti-inflammatory medicines and herbs such as garlic (Allium sativum) and ginkgo ( @DRUG$ ) .	DDI-int
These drugs include the thiazides and other diuretics, corticosteroids, phe-nothiazines, @DRUG$, estrogens, oral @DRUG$, phenytoin, nicotinic acid, sympathomimet-ics, calcium channel blocking drugs, and isoniazid.	DDI-false
Sinus bradycardia has been reported with oral amiodarone in combination with @DRUG$ (CYP3A4 substrate) given for local @DRUG$.	DDI-false
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole ( @DRUG$ , cefoperazone , cefotetan , cefamandole , latamoxef ) or methylthiadiazole ( @DRUG$ ) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Concurrent administration of oxyphenbutazone and @DRUG$ may result in elevated serum levels of @DRUG$.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, @DRUG$, dapsone, disulfiram, ethionamide, @DRUG$, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Simultaneous absorption of colestipol and vitamin K may reduce the absorption of @DRUG$.	DDI-false
@DRUG$: Amphetamines may delay intestinal absorption of @DRUG$;	DDI-false
Therefore, when @DRUG$ and @DRUG$ are used concomitantly, the patient should be observed closely to determine if the desired effect of the diuretic is obtained.)	DDI-advise
Warfarin: Eszopiclone 3 mg administered daily for 5 days did not affect the pharmacokinetics of@DRUG-DRUG$, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of warfarin	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: @DRUG$ increases the effect of Tricyclic antidepressants	DDI-false
Patients who begin taking diclofenac or who increase their diclofenac dose or any other NSAID while taking @DRUG$, @DRUG$, or cyclosporine may develop toxicity characteristics for these drugs.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), @DRUG$, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
No significant pharmacokinetic interactions between medicinal products and medicinal products have been established in interaction studies with: @DRUG$ , digoxin, warfarin, @DRUG$ and phenobarbital .	DDI-false
Selective Serotonin Reuptake Inhibitors ( @DRUG$ ==References====External links== @DRUG$ , fluvoxamine , paroxetine , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5-HT1 agonists .	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , @DRUG$ , corticosteroids, TNF blockers, azathioprin, @DRUG$ , gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, @DRUG$, @DRUG$, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Potential drug interactions between Keppra  and other AEDs (carbamazepine, gabapentin, lamotrigine, @DRUG$, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of @DRUG$ and these AEDs during placebo-controlled clinical studies.	DDI-false
Acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/@DRUG$ and valproic acid/phenobarbital.	DDI-false
The following examples are known to inhibit the metabolism of other related benzodiazepines, probably by inhibition of CYP3A: nefazodone, @DRUG$ , cimetidine, diltiazem, isoniazide, and some @DRUG$.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitors (NNRTI) for @DRUG$ therapy and concerns regarding protease inhibitor (@DRUG$)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection .	DDI-false
Benzylpenicillin, ampicillin, oxacillin, @DRUG$, doxycycline, cephalothin, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
Furthermore, there was no pharmacodynamic interaction due to the concomitant use of @DRUG$ and @DRUG$ ER .	DDI-false
No formal clinical studies have been conducted to determine whether an interactive effect on bone loss between @DRUG$ and @DRUG$.	DDI-false
Interactions may occur between EPA supplements and @DRUG$ and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ (Ginkgo biloba).	DDI-false
Co-administration of @DRUG$ and @DRUG$ or other agents interfering with neuromuscular transmission (e.g., curare-like compounds) should only be performed with caution as the effect of the toxin may be potentiated.	DDI-advise
The pressor effects of @DRUG$ For example, dopamine or @DRUG$ The Bretylium tosylate is reinforced by the Bretylium tosylate.	DDI-false
@DRUG$ , Methylxanthines and Diuretics : Concomitant treatment with xanthine derivatives , steroids , or diuretics may potentiate a possible hypokalemic effect of   @DRUG$	DDI-false
Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (@DRUG$, valproate, oral contraceptive, digoxin, @DRUG$, probenecid) and through pharmacokinetic screening in the placebo-controlled clinical studies in epilepsy patients.	DDI-false
In a pharmacokinetic interaction study with @DRUG$, bioavailability parameters, the degree of protein binding, and the anticoagulant effect (measured by prothrombin time) of @DRUG$ were not significantly changed.	DDI-false
Digoxin, Methotrexate, @DRUG$: Diclofenac, like other @DRUG$, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
Interactions with Mixed Agonist/Antagonist Opioid Analgesics : Agonist/antagonist analgesics ( eg , pentazocine , nalbuphine , @DRUG$ , dezocine and @DRUG$ (i) Do not administer to a patient who has received or is receiving therapy with a pure agonist opioid analgesics such as levo-dromorane.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and @DRUG$ (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$ , @DRUG$ , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, @DRUG$, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
The pharmacokinetics of @DRUG$ and its major metabolite @DRUG$ were unaffected following co-administration with Acamprosate.	DDI-false
@DRUG$ Maybe interact with alcohol, blood thinners, @DRUG$ ( allergy , cold , and sinus medicines ) , diabetic drugs , lithium , norepinephrine , NSAIDs like Aleve or Ibuprofen , and high blood pressure medications .	DDI-int
A similar association, albeit less pronounced, was proposed with @DRUG$ , @DRUG$ , phenytoin sodium , carbamazepine , griseofulvin , topiramate , and possibly with ampicillin and tetracyclines 72 .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, @DRUG$, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Psychoactive Drugs : Hallucinations were reported when TORADOL was used in patients receiving psychoactive drugs ( @DRUG$ , @DRUG$ ==References====External links==	DDI-false
omeprazole: The rate and extent of absorption of ciprofloxacin was bioequivalent if @DRUG$ was given alone or when @DRUG$ 2 hours after administration of omeprazole at the dose that suppresses gastric acid secretion maximum.	DDI-false
Injection : @DRUG$ injection , like other injectable @DRUG$ , produces depression of the central nervous system when administered with ethyl alcohol, phenothiazine, barbiturates, MAO inhibitors and other antidepressants. When scopolamine is simultaneously observed with injectable lorazepam, an increased incidence of sedation, hallucinations and irrational behaviour.	DDI-false
Antibiotics: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and troleandomycin markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
H2 receptor antagonists: @DRUG$ coadministration leads to an increased peak plasma concentration and AUC of @DRUG$ , there is no effect on cisapride absorption when it is coadministered with ranitidine .	DDI-mechanism
Other @DRUG$ (e.g. barbiturates, tranquilizers, opioids and general @DRUG$ ) have additive or potentiating effects with INAPSINE.	DDI-false
In addition, Fondaparinux neither influenced the pharmacodynamics of warfarin, @DRUG$, piroxicam, and @DRUG$, nor the pharmacokinetics of digoxin at steady state.	DDI-false
@DRUG$ or @DRUG$ excess may decrease the effect of Carbimazole , and an iodine deficiency can increase the effect of Carbimazole .	DDI-false
However, severe reactions, such as hypotension requiring treatment, dyspnea requiring @DRUG$, angioedema, or generalized urticaria require immediate discontinuation of @DRUG$ and aggressive symptomatic therapy.	DDI-false
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	DDI-false
Ergot Derivatives: Dihydroergotamine, @DRUG$, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
The intensity, uniformity and time course of anticoagulant interference by @DRUG$, secobarbital, glutethimide, @DRUG$ and methaqualone were systematically investigated in 16 patients receiving coumarin therapy.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , @DRUG$ , phenytoin , @DRUG$ , and vincristine .	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of @DRUG$ 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (@DRUG$, barbiturates, opiates, sedatives, anesthetics) should be considered.	DDI-advise
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , @DRUG$ , chloramphenicol, probenecid, @DRUG$ , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-false
Multivitamins or other products which: @DRUG$ or zinc , antacids or sucralfate should not be administered concomitantly with , or within 2 hours of , the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
In monkeys, (-)-NANM was about 10 times more potent than (+)-NANM in decreasing responding, whereas in pigeons @DRUG$ was about equipotent with @DRUG$.	DDI-false
Medicines not to be administered with VIRACEPT @DRUG$ : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : @DRUG$ Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
Other Cardiovascular Agents: Enalapril and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, @DRUG$, hydralazine, @DRUG$ and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Caution should also be exercised when using other aminoglycosides concomitantly or serially. @DRUG$ because they may enhance neomycin s nephrotoxicity and/or ototoxicity and potentiate @DRUG$ neuromuscular blocking effects .	DDI-false
Levosimendan has no clinically important pharmacokinetic interactions with captopril, beta-blockers, felodipine, @DRUG$ , @DRUG$ , isosorbide mononitrate , carvedilol , ethanol or itraconazole .	DDI-false
Studies in humans show that the absorption of @DRUG$ as reflected in urinary excretion is markedly decreased even when administered one hour before @DRUG$.	DDI-mechanism
Drugs that may alter imatinib plasma concentrations Drugs that may increase imatinib plasma concentrations : Caution is recommended when administering @DRUG$ ketoconazole, itraconazole, erythromycin, @DRUG$ ) .	DDI-advise
Intravenous Adenocard (adenosine) has been effectively administered in the presence of other cardioactive drugs, such as quinidine, @DRUG$, @DRUG$, and angiotensin converting enzyme inhibitors, without any change in the adverse reaction profile.	DDI-false
Clinical studies with celecoxib have identified potentially significant interactions with @DRUG$ and @DRUG$.	DDI-false
Moreover, additional interaction studies with niacin and propranolol have not demonstrated any effect on @DRUG$ plasma levels, and administration to a patient population chronically receiving digoxin resulted in no difference in the extent of bioavailability of @DRUG$ relative to control data.	DDI-false
" Medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, @DRUG$ , cisplatin, dapson, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and @DRUG$.	DDI-false
In these subjects, @DRUG$ did not alter the anticoagulant effect of @DRUG$ as determined by prothrombin time.	DDI-false
Drug/LaboratoryTest Interactions @DRUG$ may interfere with bioassay procedures for the determination of @DRUG$ levels.	DDI-false
@DRUG$: Lithium toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
Therefore, interactions could occur following concomitant administration of psychotropic drugs (e.g., narcotics, analgesics, @DRUG$, sedatives, @DRUG$).	DDI-false
In addition , Fondaparinux neither influenced the pharmacodynamics of warfarin , acetylsalicylic acid , piroxicam , and @DRUG$ , nor the pharmacokinetics of @DRUG$ at steady state .	DDI-false
Although @DRUG$ It has been shown that PROLEUKIN-induced side effects such as fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, concomitant use of these agents with @DRUG$ may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided . 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with PROLEUKIN .	DDI-false
May interact anticoagulants (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of @DRUG$).	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
Antibiotics : In vitro and/or in vivo data show that clarithromycin , erythromycin , and @DRUG$ markedly inhibit the metabolism of cisapride , which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG .	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, @DRUG$, intravenous @DRUG$, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other @DRUG$ and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and @DRUG$/phenobarbital.	DDI-false
- @DRUG$ Using methotrexate with @DRUG$ may increase the chance of side effects affecting the liver and/or the side effects of methotrexate	DDI-false
If Bezalip or Bezalip retard is used concomitantly with @DRUG$ ( e.g. @DRUG$ (i) an interval of at least 2 hours between the two medicinal products should be maintained as the absorption of bezalip or bezalip retard is impaired.	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Since animal studies suggest that the action of @DRUG$ may be prolonged by therapy with @DRUG$, barbiturates should be employed with caution.	DDI-effect
Other Drugs : In small groups of patients ( 7 - 10/interaction study ) , the concomitant administration of @DRUG$ , gold , @DRUG$ D-penicillamine, prednisolone, doxycycline or digitoxin did not significantly affect the peak and AUC values of diclofenac.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related benzodiazepines , presumably through inhibition of CYP3A : nefazodone , fluvoxamine , cimetidine , @DRUG$ Isoniazide, and some @DRUG$.	DDI-false
A single dose of liquid @DRUG$ did not affect the C max or AUC of @DRUG$;	DDI-false
Population pharmacokinetic analyses showed that MTX, @DRUG$ , corticosteroids, and @DRUG$ did not influence abatacept clearance .	DDI-false
@DRUG$/Prednisolone : Rofecoxib had no clinically important effect on the pharmacokinetics of prednisolone or @DRUG$.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA : MTX , @DRUG$ , corticosteroids , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and @DRUG$.	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with medications of @DRUG$ (including, for example, ondansetron, granisetron, @DRUG$ , palonosetron , and alosetron ) is contraindicated .	DDI-false
- Anabolic steroids ( nandrolone [ e.g. , Anabolin ] , oxandrolone [ e.g. , @DRUG$ ], oxymetholone [e.g. Anadrol ], stanozool [e.g., @DRUG$ ] ) or	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/@DRUG$, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Remarkable is systemic exposure ( AUC0 - 12 ) @DRUG$ @DRUG$/SMX has more than doubled (DHA ) in the presence of @DRUG$/SMX.	DDI-false
In separate studies in patients receiving a maintenance dose of warfarin, hydrochlorothiazide or digoxin, administration of irbesartan for 7 days had no effect on pharmacodynamics of @DRUG$ ( prothrombin time ) or pharmacokinetics of @DRUG$.	DDI-false
DOSTINEX should not be co-administered with D2 antagonists such as @DRUG$ , butyrophenones , @DRUG$ , or metoclopramide .	DDI-false
The use of NUROMAX before @DRUG$ To attenuate some of the side effects of @DRUG$ has not been studied .	DDI-false
Imidazoles ( e. g. , @DRUG$ , miconazole , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of amphotericin B and @DRUG$ Imidazole can cause fungal resistance to amphotericin B.	DDI-false
@DRUG$ , Methylxanthines and Diuretics : Concomitant treatment with xanthine derivatives , steroids , or @DRUG$ may potentiate a possible hypokalemic effect of   beta2-agonists .	DDI-false
- When Bezalip or @DRUG$ is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or Bezalip retard is impaired	DDI-false
Oral Contraceptives: Valdecoxib (40 mg BID) did not induce the metabolism of the combination oral contraceptive norethindrone/@DRUG$ (1 mg /35 mcg combination, @DRUG$ 1/35 ).	DDI-false
The medicines associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$ , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , @DRUG$ Ribavirin and vincristine.	DDI-false
The use of acetaminophene with acetaminophene @DRUG$ , phenobarbital with @DRUG$ , and valproic acid with phenobarbital at high to toxic concentrations decreases the binding of the target drug .	DDI-false
â™ª Drugs that can change â™ª @DRUG$ Plasma concentrations Drugs that may increase @DRUG$ Plasma concentrations: Caution should be exercised when gleevec is administered with inhibitors of the CYP3A4 family (e.g. ketoconazole, itraconazole, erythromycin, clarithromycin).	DDI-false
Because there is a theoretical basis that these effects may be additive , use of @DRUG$-containing or ergot-type medications ( like dihydroergotamine or @DRUG$ AXERT and AXERT should be avoided within 24 hours of each other.	DDI-false
FACTIV had no significant influence on the anticoagulant effect of @DRUG$ in healthy subjects on stable @DRUG$ therapy .	DDI-false
Interactions with @DRUG$ : Agonist/antagonist analgesics ( eg , pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a @DRUG$ Like Levo-Dromoran.	DDI-false
Coadministration of esomeprazole 30 mg and @DRUG$ The CYP2C19 substrate resulted in a 45% decrease in clearance of @DRUG$.	DDI-false
Multivalent Cation-Containing products: Concomitant administration of quinolone, including ciprofloxacin, with multivalent cation-containing products such as @DRUG$ Antacids or antacids of aluminium, sucralfate, @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or zinc may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, @DRUG$).	DDI-false
@DRUG$: Coadministration of rifampin and @DRUG$ resulted in an 82% decrease in nelfinavir plasma A.C.	DDI-false
The possibility of hypotensive effects with @DRUG$ Treatment with Enalapril or @DRUG$ can be minimized by stopping the diuretic or increasing salt intake before starting treatment.	DDI-false
Plasma @DRUG$ The concentration should be monitored if isoniazid and @DRUG$ When co-administered, appropriate dose adjustments of valproate should be made.	DDI-false
@DRUG$ ; : Simultaneous application of @DRUG$ The plasma levels of diflunisal can be reduced.	DDI-false
Compounds tested in man include warfarin, theophylline, @DRUG$, diazepam, aminopyrine and @DRUG$.	DDI-false
The co-administration of @DRUG$ with IV @DRUG$ such as nitroglycerin , nitroprusside , milrinone , or IV ACE inhibitors has not been evaluated ( these drugs were not co-administered with Natrecor in clinical trials ) .	DDI-false
The initiation of @DRUG$ or @DRUG$ use may be precipitated by similar personality characteristics in the user , such as impulsivity and sensation seeking .	DDI-false
Acetaminophene, lidocaine, phenobarbital, @DRUG$ , theophylline, and @DRUG$ The pooled human serum was added at therapeutic concentrations.	DDI-false
Antihypertensive agents: amiodarone should be used with caution in patients receiving receptor blockers (e.g. propranolol, CYP3A4 inhibitor), or @DRUG$ antagonists ( e.g. , @DRUG$ , a CYP3A4 substrate and diltiazem, a CYP3A4 inhibitor ) because of the potential for bradycardia, sinus arrest and AV block;	DDI-false
In Study 1, patients with colorectal cancer were given irinotecan/@DRUG$/leucovorin (bolus-IFL) with or without @DRUG$.	DDI-false
Lithium : @DRUG$ 40 mg BID for 7 days produced significant decreases in @DRUG$ serum clearance ( 25 % ) and renal clearance ( 30 % ) with a 34 % higher serum exposure compared to lithium alone .	DDI-mechanism
Potassium-sparing diuretics ( e.g. , spironolactone , triamterene , or @DRUG$ ) , potassium supplements , or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, @DRUG$, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
@DRUG$: Population pharmacokinetic analyses indicate that @DRUG$ clearance is 60% greater in patients taking phenytoin with or without other enzyme- inducing AEDs.	DDI-false
Concurrent administration of drugs possessing nephrotoxic (e.g., @DRUG$, indomethacin), myelotoxic (e.g., cytotoxic chemotherapy), cardiotoxic (e.g., doxorubicin) or hepatotoxic (e.g., methotrexate, @DRUG$) effects with PROLEUKIN may increase toxicity in these organ systems.	DDI-false
Therefore , @DRUG$ may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability ( eg , ketoconazole , @DRUG$ Salts and digoxin).	DDI-mechanism
Colestipol: Plasma concentrations of @DRUG$ decreased approximately 25% when @DRUG$ and atorvastatin were coadministered.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine @DRUG$ : @DRUG$ , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
Other medicines that can enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX are certain antibiotics (e.g. aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), @DRUG$ Salts, lithium, local anaesthetics, procainamide and @DRUG$.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$ , doxorubicin , vincristine , and @DRUG$ ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , teniposide , and prednisone with vincristine plus bleomycin ) without receiving antiretroviral therapy .	DDI-false
Beta-blockers, clonidine, @DRUG$ salts, and alcohol may either potentiate or weaken the blood-glucose-lowering effect of @DRUG$.	DDI-effect
Cyclosporine, Digoxin, Methotrexate Lodine, like other @DRUG$, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of cyclosporine, @DRUG$, methotrexate, and increased toxicity.	DDI-mechanism
@DRUG$ â€¢ no significant impact on the @DRUG$ pharmacokinetics .	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with @DRUG$.	DDI-effect
Aspirin: Concomitant administration of low-dose @DRUG$ with @DRUG$ may result in an increased rate of GI ulceration or other complications, compared to use of VIOXX alone.	DDI-effect
Possible interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, @DRUG$ Serum concentrations of levetiracetam and valproate have also been studied by @DRUG$ â€¢ during placebo-controlled clinical trials.	DDI-false
@DRUG$ After market introduction, reports on potential interactions between TORDOLIV/IM and TORDOLIV/IM have been published. @DRUG$ that resulted in apnea .	DDI-false
Concomitant use of agents in the @DRUG$ (which includes @DRUG$) with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant agent or the other drug.	DDI-false
Additional reductions in blood pressure may occur when @DRUG$ Use with diuretics, antihypertensives or other @DRUG$.	DDI-effect
Central nervous system depressants : Co-administration of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ (e.g. benzodiazepines), general anesthetics, phenothiazines, @DRUG$ , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
â€¢ lorazepam: concomitant use of single doses of @DRUG$ 3 mg and @DRUG$ 2 mg had no clinically relevant effects on pharmacodynamics or the pharmacokinetics of either medicinal product.	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron , the concomitant use of @DRUG$ With drugs of the @DRUG$ It is contraindicated (including, for example, Ondansetron, Granisetron, Dolasetron, Palonosetron, and Alosetron).	DDI-advise
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, opiates, sedatives, @DRUG$) should be considered.	DDI-false
Although glucocorticoids have been shown to reduce @DRUG$-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with PROLEUKIN.	DDI-false
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, pentazocine, nalbuphine, @DRUG$, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
Intravenous Adenocard ( @DRUG$ ) has been effectively administered in the presence of other cardioactive drugs , such as @DRUG$ , beta-adrenergic blocking agents , calcium channel blocking agents , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , @DRUG$ , metronidazole, nitrofurantoin, phenytoin, ribavirin and @DRUG$.	DDI-false
@DRUG$ ( ' @DRUG$ ) is a newly introduced atypical antipsychotic with proven efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with griseofulvin, ampicillin, and @DRUG$ (72)	DDI-false
- Urine alkalinisation agents ( @DRUG$ , some thiazides) increase the concentration of non-ionized species of @DRUG$ molecule , thereby decreasing urinary excretion .	DDI-mechanism
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Concomitant administration of @DRUG$ and other related compounds (eg, quinine, @DRUG$ and chloroquine) may produce electrocardiographic abnormalities and increase the risk of convulsions.	DDI-effect
Resins: Since @DRUG$ may bind other drugs given concurrently, patients should take @DRUG$ at least 1 hour before or 4-6 hours after a bile acid binding resin to avoid impeding its absorption.	DDI-false
@DRUG$: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of @DRUG$ with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without propantheline ( an anticholinergic agent with multiple effects on the GI tract ) to healthy volunteers , the AUC of clonazepam was 10 % lower and the Cmax of clonazepam was 20 % lower when the orally disintegrating tablet was given with @DRUG$ compared to when it was given alone .	DDI-false
Tolazamide: A case of severe hypoglycemia has been reported in a type II diabetic patient maintained on @DRUG$ (1 gm/day) 11 days after the addition of @DRUG$ (75 mg/day).	DDI-effect
@DRUG$ , including oral @DRUG$ : Estrogens may decrease the hepatic metabolism of certain corticosteroids , thereby increasing their effect .	DDI-false
Other concomitant therapies : In clinical trials, the safety profile in patients with acamprosate concomitantly with @DRUG$ , @DRUG$ The occurrence of sedatives (including benzodiazepines) or non-opioid analgesics was similar to those in patients receiving placebo with these concomitant drugs.	DDI-false
A similar association, though less marked, has been suggested with @DRUG$, phenyl-butazone, @DRUG$, carbamazepine and possibly with griseofulvin, ampicillin, and tetracyclines (72)	DDI-false
Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing @DRUG$, @DRUG$, higher alcohols and acetaldehyde in the same proportions as those found in most common distilled and fermented alcoholic beverages;	DDI-false
Carbamazepine: @DRUG$ is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$, signs and symptoms of carbamazepine toxicity should be monitored closely, and appropriate dosage adjustment of the anticonvulsant should be made.	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.	DDI-false
When @DRUG$ A potent inhibitor of CYP2D6 was co-administered with: @DRUG$ at steady-state , exposure to either drug was not altered .	DDI-false
Therefore , when @DRUG$ is given to a patient receiving @DRUG$ The dose of warfarin should be reduced to prevent excessive prolongation of prothrombin time.	DDI-advise
Before using this medicine, tell your doctor or pharmacist about all prescription and non-prescription products you can use, especially: aminoglycosides (e.g., gentamicin, @DRUG$ ) , amphotericin B , cyclosporine , non-steroidal anti-inflammatory drugs ( e.g. , @DRUG$ ) , tacrolimus , vancomycin .	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following : @DRUG$ , cyclosporine , amiodarone , nicardipine , and nifedipine .	DDI-int
Antacids, products containing iron, multivitamin preparations, @DRUG$ or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including ciprofloxacin, with multivalent cation-containing products such as magnesium or aluminum @DRUG$, sucralfate, VIDEX chewable/buffered tablets or pediatric powder, or products containing @DRUG$, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-false
Patients using other @DRUG$s, general anaesthetics, phenothiazines, @DRUG$ , sedative-hypnotics , tricyclic antidepressants or other CNS depressants ( including alcohol ) concomitantly with DILAUDID may exhibit an additive CNS depression .	DDI-false
Longitudinal assessment of @DRUG$ For de novo kidney transplant recipients in the first year after transplantation: pharmacokinetics, exposure-effect relationships and influence on @DRUG$.	DDI-false
- anabolic steroids (Nandrolone [e.g., @DRUG$ ] , oxandrolone [ e.g. , Anavar ] , @DRUG$ [ e.g. Anadrol ], stanozozole [ e.g. Winstrol ] or	DDI-false
Therapeutic concentrations of digoxin, warfarin, @DRUG$ , naproxen , piroxicam , acetaminophen , phenytoin andtolbutamide did not alter @DRUG$ protein binding .	DDI-false
Other drugs : Drugs like @DRUG$ , disopyramide, procainamide, @DRUG$ , antihistamines , and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia .	DDI-false
@DRUG$ (neostgmine, physostigmine), lignocaine, quinine, @DRUG$ can enhance toxicity and cause cardio respiratory depression.	DDI-false
@DRUG$ could exaggerate the depression of AV nodal conduction observed with @DRUG$.	DDI-effect
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, @DRUG$, doxycycline, or @DRUG$ did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants, antihistamines, alcohol, @DRUG$, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-effect
@DRUG$: Since @DRUG$ is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (phenothiazines, butyrophenones, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
@DRUG$-cephalosporins containing side chains of N-methylthiotetrazole ( @DRUG$ Cefoperazone, cefotetan, cefamandol, latamoxef) or methylthiadiazole (cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , @DRUG$ , @DRUG$ , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, @DRUG$, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, @DRUG$, local anesthetics, procainamide, and quinidine.	DDI-false
Other medicines not recommended for concomitant use @DRUG$ and @DRUG$ ==References====External links==	DDI-false
Drugs that may alter @DRUG$ plasma concentrations Drugs that may increase imatinib plasma concentrations: Caution is recommended when administering Gleevec with inhibitors of the CYP3A4 family (e.g., @DRUG$, itraconazole, erythromycin, clarithromycin).	DDI-false
Although studies designed to examine drug interactions have not been done , it was noted that corticosteroid or @DRUG$ The treatment of relapses for up to 28 days was administered to patients ( N=180 ) at @DRUG$.	DDI-false
Antibiotics : In vitro and/or in vivo data show that clarithromycin , erythromycin , and troleandomycin markedly inhibit the metabolism of @DRUG$ What can lead to an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, @DRUG$, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Administration to outpatients The effects of @DRUG$ â€¢ may be attenuated before a @DRUG$ is completely cleared from the body .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , @DRUG$ salts , lithium , local anesthetics , @DRUG$ ==References====External links==	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Benzylpenicillin, ampicillin, oxacillin, @DRUG$, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum.	DDI-false
@DRUG$, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of @DRUG$.	DDI-false
metformin : In healthy subjects with a single dose of 500 mg metformin @DRUG$ and metformin , plasma @DRUG$ Mean cmax and AUC increased by an average of 34% and 24%, respectively, and mean renal clearance of metformin by 14%.	DDI-false
Coadministration of valdecoxib and @DRUG$ 1/35   increased the exposure of norethindrone and @DRUG$ by 20 % and 34 % , respectively .	DDI-false
Chlorpromazine: @DRUG$ blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of @DRUG$ and can be used to treat amphetamine poisoning.	DDI-effect
Medicines not to be combined with VIRACEPT antiarrhythmics: amiodarone, quinidine antihistamines: astemizole, terfenadine antimigrain: ergot derivatives antimycobacterial agents: @DRUG$ Benzodiazepines @DRUG$ Triazolam GI motility agent: cisapride	DDI-false
- When Bezalip or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of @DRUG$ or @DRUG$ is impaired	DDI-false
Injection : Lorazepam injection , like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl alcohol , phenothiazines , barbiturates , MAO inhibitors , and other @DRUG$.When scopolamine is used concomitantly with injectable @DRUG$ An increased incidence of sedation, hallucinations, and irrational behaviour has been observed.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and @DRUG$), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
Phenytoin : @DRUG$ Intestinal absorption may be delayed @DRUG$ ;	DDI-mechanism
This medication may interact with alcohol or other CNS depressants (may potentiate the CNS depressive effect of either these drugs or antihistamines), @DRUG$ Anticholinergic effects may be increased if these drugs are used concomitantly with antihistamines, and monoamine oxidase (MAO) inhibitors ( concomitant use with antihistamines may cause the anticholinergic and CNS depressive effects of @DRUG$ ) .	DDI-false
Compounds that have been tested in man include antipyrine, @DRUG$, @DRUG$, theophylline, and warfarin and no clinically meaningful interactions were found.	DDI-false
Curariform muscle relaxants (e.g. tubocurarin) and other medicines, including ethers, succinylcholine, @DRUG$ , decamethonium and @DRUG$ , potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral .	DDI-false
Pharmacokinetic Interaction between @DRUG$ and @DRUG$ or rifampin in healthy males.	DDI-false
In addition, @DRUG$ neither influenced the pharmacodynamics of @DRUG$, acetylsalicylic acid, piroxicam, and digoxin, nor the pharmacokinetics of digoxin at steady state.	DDI-false
Example inhibitors include @DRUG$, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
@DRUG$ : In healthy subjects receiving the CYP3A4 inducer , @DRUG$ , at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days , systemic exposure ( AUC ) to lapatinib was decreased approximately 72 % .	DDI-false
Because there is a theoretical basis that these effects may be additive, use of @DRUG$-containing or @DRUG$ (like dihydroergotamine or methysergide) and AXERT within 24 hours of each other should be avoided.	DDI-false
Magnesium- and/or @DRUG$-containing antacids , products containing ferrous sulfate ( iron ) , multivitamin preparations containing zinc or other metal cations , or Videx ( @DRUG$ Do not take chewable tablets or the pediatric powder for oral solution within 3 hours before or 2 hours after FACTIVE.	DDI-false
Data from in vitro studies @DRUG$ other than alprazolam suggest a possible drug interaction for the following : ergotamine , cyclosporine , amiodarone , nicardipine , and @DRUG$.	DDI-int
Although glucocorticoids have been shown to reduce PROLEUKIN-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with PROLEUKIN may reduce the antitumor effectiveness of PROLEUKIN and thus should be avoided. 12 @DRUG$ and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-effect
Curariform muscle relaxants (e.g. tubocurarin) and other medicines, including ethers, succinylcholine, @DRUG$ , decamethonium and sodium citrate, increase neuromuscular blocking and should be used with extreme caution in patients with @DRUG$ Parenteral .	DDI-effect
@DRUG$ : In a clinical pharmacology study , coadministration of an antacid ( @DRUG$ , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that antacids may impair absorption of fosinopril .	DDI-false
@DRUG$ : Accompanying treatment with @DRUG$ and tetracyclines should be avoided because Accutane use has been associated with a number of cases of pseudotumor cerebri ( benign intracranial hypertension ) , some of which involved concomitant use of tetracyclines	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , @DRUG$ Angiotensin converter enzyme inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Antifungals: In vitro and/or in vivo data indicate that fluconazole, @DRUG$, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , @DRUG$ , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , thyroid hormones , estrogens , @DRUG$ ( e.g. , in oral contraceptives ) .	DDI-false
Drug Interactions: Flupenthixol may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - @DRUG$: Flupenthixol increases the effect of @DRUG$	DDI-false
Effect of @DRUG$ in Pediatric Patients There was about a 22% increase of apparent total body clearance of @DRUG$ when it was co-administered with enzyme-inducing AEDs.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Compounds tested in man include warfarin, theophylline, phenytoin, @DRUG$, @DRUG$ and antipyrine.	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with @DRUG$ concomitantly with anxiolytics, hypnotics and @DRUG$ (including benzodiazepines), or non-opioid analgesics was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with @DRUG$, beta-blockers, @DRUG$, digoxin, warfarin, isosorbide mononitrate, carvedilol, ethanol or itraconazole.	DDI-false
Naproxen: The concomitant administration of diflunisal and @DRUG$ in normal volunteers had no effect on the plasma levels of naproxen, but significantly decreased the urinary excretion of @DRUG$ and its glucuronide metabolite.	DDI-false
@DRUG$ may decrease the amount of @DRUG$ (Lanoxin, Lanoxicaps) that gets absorbed into your body.	DDI-mechanism
The clinical significance of this reduction is unknown, therefore it is recommended not to take zalcitabine concomitantly with @DRUG$/@DRUG$-containing antacids.	DDI-false
In clinical trials , FLOLAN was used with @DRUG$ â€¢ Diuretics, anticoagulants, oral vasodilators and additional oxygen. @DRUG$ On the second day of therapy, apparent values for oral clearance of furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13 % and 15 % respectively and were returned to baseline by day 87.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and @DRUG$.	DDI-false
@DRUG$, Methotrexate, @DRUG$: Diclofenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs.	DDI-false
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when administering imatinib @DRUG$ with inhibitors of the CYP3A4 family ( e.g. , ketoconazole , @DRUG$ Erythromycin, clarithromycin, erythromycin, erythromycin, erythromycin.	DDI-advise
Nevirapine and @DRUG$ Concomitant use should not occur as the decrease in @DRUG$ Plasma concentrations may reduce the efficacy of the medicinal product.	DDI-false
@DRUG$ MAOI antidepressants , as well as a metabolite of furazolidone , slow @DRUG$ metabolism .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT @DRUG$: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (@DRUG$, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing @DRUG$ or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Other interactions : @DRUG$ had no effect on the pharmacodynamics of glyburide ( glucose and insulin concentrations ) and @DRUG$ ( prothrombin time or other pharmacodynamic parameters ) .	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , @DRUG$ , danazol, diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazide, phenothiazine derivatives, somatropin, @DRUG$ Oestrogens, progestogens (e.g. in oral contraceptives).	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Digoxin, Nimodipine and @DRUG$: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	DDI-false
Multivalent Cation-Containing Products: Concurrent administration of a quinolone, including @DRUG$, with multivalent cation-containing products such as magnesium or aluminum antacids, @DRUG$, VIDEX chewable/buffered tablets or pediatric powder, or products containing calcium, iron, or zinc may substantially decrease the absorption of ciprofloxacin, resulting in serum and urine levels considerably lower than desired.	DDI-mechanism
Compounds that have been tested in man include antipyrine , digoxin , propranolol , @DRUG$ , and @DRUG$ No clinically significant interactions were found.	DDI-false
The application of local anaesthetic solutions that @DRUG$ Patients receiving monoamine oxidase inhibitors, @DRUG$ or phenothiazines may produce severe , prolonged hypotension or hypertension .	DDI-effect
Compounds tested in man include warfarin, theophylline, @DRUG$, diazepam, @DRUG$ and antipyrine.	DDI-false
In addition, certain drugs that are metabolised by this isoenzyme, including many @DRUG$ ( @DRUG$ , selective serotonin reuptake inhibitors , and others ) , may inhibit the activity of this isoenzyme , and thus may make normal metab-olizers resemble poor metabolizers with regard to concomitant therapy with other drugs metabolized by this enzyme system , leading to drug interactions .	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with @DRUG$, betablockers, @DRUG$, diuretics, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$- and/or aluminum-containing antacids , products containing ferrous sulfate ( iron ) , multivitamin preparations containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
Therefore, the concomitant use of TRACLEER and @DRUG$ is contraindicated , and alternative @DRUG$ It should be considered.	DDI-false
If treatment with inhibitors of CYP3A4 activity (such as ketoconazole, @DRUG$, ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated, reduction of the @DRUG$ dose should be considered.	DDI-advise
Elevated serum levels of cyclosporin have been reported with concomitant administration of @DRUG$ with @DRUG$.	DDI-mechanism
@DRUG$: The effect of @DRUG$ on the anticoagulant effect of warfarin (1 - 8 mg/day) was studied in healthy subjects by coadministration of BEXTRA 40 mg BID for 7 days.	DDI-false
Other Drug Interactions : No pharmacokinetic interactions were observed between @DRUG$ And the following medications: @DRUG$ , warfarin , digoxin , Maalox , and ranitidine .	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The effect of @DRUG$  on @DRUG$ was not studied.	DDI-false
@DRUG$ : Serious side effects and even death have been reported following the concomitant use of certain drugs with @DRUG$.	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs : Clonazepam does not appear to alter the pharmacokinetics of @DRUG$ , @DRUG$ , or phenobarbital.	DDI-false
@DRUG$ : Probenecid interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of @DRUG$ in serum .	DDI-false
Potential drug interactions between @DRUG$   and other @DRUG$ ( carbamazepine , gabapentin , lamotrigine , phenobarbital , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of levetiracetam and these AEDs during placebo-controlled clinical studies .	DDI-false
Selective Serotonin Reuptake Inhibitors (SSRIs): SSRIs (e.g., @DRUG$, fluvoxamine, @DRUG$, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with @DRUG$, phenothiazines, barbiturates, MAO inhibitors, and other antidepressants.When scopolamine is used concomitantly with injectable @DRUG$, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or @DRUG$ than with @DRUG$.	DDI-false
The pharmacokinetics of @DRUG$ were unchanged following coadministration with @DRUG$ (400 mg).	DDI-false
Coadministration of @DRUG$ did not influence the pharmacokinetics of @DRUG$.	DDI-false
It may increase excretion of @DRUG$ , lithium and ASA and may also increase the toxicity of @DRUG$.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
In separate studies with patients who have maintenance doses @DRUG$ Administration of irbesartan for 7 days had no effect on the pharmacodynamics of hydrochlorothiazide or digoxin. @DRUG$ ( prothrombin time ) or pharmacokinetics of digoxin .	DDI-false
@DRUG$ and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists (ACEI/@DRUG$).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with @DRUG$, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ Co-administration of vardenafil 5 mg resulted in a 49-fold increase in vardenafil AUC and a 13-fold increase in vardenafil AUC. @DRUG$ Cmax .	DDI-false
@DRUG$ or Oral Hypoglycemics: Agents with b-blocking properties may enhance the blood-sugar-reducing effect of @DRUG$ and oral hypoglycemics.	DDI-false
Specific studies have confirmed these effects with sevoflurane, @DRUG$, propofol, @DRUG$, and midazolam.	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to bepridil hydrochloride, including anti-arrhythmic agents such as @DRUG$ and procainamide, cardiac glycosides and @DRUG$.	DDI-false
Antidepressants , tricyclic @DRUG$ â€¢ the activity of @DRUG$ or sympathomimetic agents ;	DDI-effect
Results from existing clinical trials suggest no significant interactions between @DRUG$  and other therapies commonly used in MS patients, including the concurrent use of @DRUG$ for up to 28 days.	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, Dapson, disopyramide, quinine, amiodarone, @DRUG$ , warfarin , tacrolimus , @DRUG$ , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
Antibiotics: In vitro and/or in vivo data show that clarithromycin, @DRUG$, and troleandomycin markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
Antidepressants, tricyclic: @DRUG$ â€¢ the activity of @DRUG$ sympathomimetics;	DDI-effect
- @DRUG$ : Bumatanide may have the effect of various @DRUG$ , necessitating a reduction in the dosage of these drugs .	DDI-false
Coadministration of valdecoxib (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg @DRUG$ BID) resulted in 21% increase in @DRUG$ AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of @DRUG$, phenytoin, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Carbamazepine: Elevated @DRUG$ levels have been reported in postmarketing experience when @DRUG$ is administered concomitantly.	DDI-mechanism
Interactions may occur between @DRUG$ supplements and aspirin and other non-steroidal anti-inflammatory drugs and herbs such as garlic (Allium sativum) and @DRUG$ (Ginkgo biloba).	DDI-int
Medicines not to be treated at the same time @DRUG$ Antiarrhythmics : amiodarone , quinidine Antihistamines : @DRUG$ , terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampine benzodiazepine midazolam, triazolam GI motility agent: cisapride	DDI-advise
However , if @DRUG$ Treatment with heparin should be initiated after discontinuation of heparin therapy, so that sufficient time is given for the effect of heparin on the aPTT to decrease before starting treatment. @DRUG$ therapy .	DDI-false
Indinavir : Coadministration of indinavir with @DRUG$ resulted in an 83 % increase in nelfinavir plasma AUC and a 51 % increase in @DRUG$ plasma A.C.	DDI-false
Higher concentrations of @DRUG$ (10(-8) - 10(-6) M) or retinyl acetate (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of @DRUG$.	DDI-effect
Central nervous system depressants : Co-administration of @DRUG$   ( fentanyl transdermal system ) with other central nervous system depressants , including but not limited to other opioids , @DRUG$ Hypnosis, sedatives (e.g., benzodiazepines), general anaesthetics, phenothiazines, skeletal muscle relaxants and alcohol, can cause respiratory depression, hypotension and deep sedation, or possibly lead to coma or death.	DDI-effect
@DRUG$ and tricyclic antidepressants : @DRUG$ In patients treated with monoamine oxidase inhibitors or tricyclic antidepressants, the use should be carried out with extreme caution as the effect of formoterol on the cardiovascular system may be enhanced by these agents.	DDI-false
@DRUG$ : Coadministration of saquinavir ( using an experimental soft-gelatin capsule formulation of saquinavir 1200 mg ) with @DRUG$ resulted in an 18 % increase in nelfinavir plasma AUC and a 4-fold increase in saquinavir plasma A.C.	DDI-false
Concomitant administration of fenofibrate (equivalent to 145 mg @DRUG$) with atorvastatin (20 mg) once daily for 10 days resulted in approximately 17% decrease (range from 67% decrease to 44% increase) in @DRUG$ AUC values in 22 healthy males.	DDI-false
Therapeutic concentrations of digoxin, warfarin, @DRUG$ , naproxen, piroxicam, @DRUG$ , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
Here we show that a combination of @DRUG$ or 3,7-dihydroxyflavone with @DRUG$ may be used to sensitize resistant strains of Enterococcus faecalis and Enterococcus faecium to the level of vancomycin-sensitive strains.	DDI-false
Ergot Derivatives : @DRUG$ , @DRUG$ , ergotamine, methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasms and ischaemia of extremities and other tissues.	DDI-false
Potential interactions between TAXOL , a substrate of CYP3A4 , and protease inhibitors ( @DRUG$ , @DRUG$ , indinavir , and nelfinavir ) , which are substrates and/or inhibitors of CYP3A4 , have not been evaluated in clinical trials .	DDI-false
@DRUG$: Since both acitretin and @DRUG$ can cause increased intracranial pressure, their combined use is contraindicated.	DDI-false
Nevertheless, the effects of @DRUG$ on travelers receiving comedication, particularly diabetics or patients using @DRUG$, should be checked before departure.	DDI-advise
@DRUG$s and Vasodilators: The following adverse events were experienced more commonly in patients receiving concomitant antihypertensive medications or @DRUG$ (n = 94) compared to patients not receiving these concomitant drugs (n = 456): hypotension 10% vs 4%, myocardial infarction 3% vs 1%, serious pneumonia 5% vs 3%, serious falls 9% vs 3%, and bone and joint injuries 6% vs 2%.	DDI-false
@DRUG$: Coadministration of almotriptan and @DRUG$ resulted in a 24% increase in plasma concentrations of almotriptan.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations, or Videx (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
The intensity, uniformity and time course of the anticoagulant interference by @DRUG$ , secobarbital , glutethimide , @DRUG$ In 16 patients receiving coumarin therapy, methaqualone and methaqualone were systematically studied.	DDI-false
Ritonavir: Coadministration of ritonavir with @DRUG$ resulted in a 152% increase in nelfinavir plasma AUC and very little change in @DRUG$ plasma A.C.	DDI-false
Pharmacokinetic studies have demonstrated that @DRUG$ and @DRUG$ significantly increased the systemic exposure of cilostazol and/or its major metabolites.	DDI-false
In a Phase I trial using escalating doses of @DRUG$ ( 110 - 200 mg/m2 ) and cisplatin ( 50 or 75 mg/m2 ) given as sequential infusions , myelosuppression was more profound when TAXOL was given after @DRUG$ than with the alternate sequence ( ie , TAXOL before cisplatin ) .	DDI-false
Thus, concomitant therapy with @DRUG$ and @DRUG$ should not require dosage adjustment of either drug.	DDI-false
Data suggest that coadministration of oral @DRUG$ and @DRUG$ can result in prolongation of the QT interval on the ECG .	DDI-effect
The medicinal products associated with peripheral neuropathy are antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$ , glutethimide , gold , @DRUG$ , iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ The use of certain antibiotics (e.g. @DRUG$ , tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, lithium, local anaesthetics, procainamide and quinidine.	DDI-effect
Phenytoin : Population pharmacokinetic analyses indicate that tiagabine clearance is 60 % greater in patients taking @DRUG$ With or without other enzyme-inducing @DRUG$.	DDI-false
@DRUG$ : @DRUG$ may diminish adrenal suppression by corticosteroids .	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$ , @DRUG$ , chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine and anakinra.	DDI-false
@DRUG$: Plasma digoxin levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
There was no significant difference in the pharmacodynamic effect of @DRUG$ administered alone and @DRUG$ administered with Lodine as measured by prothrombin time.	DDI-false
â€¢ Co-administration with compounds that are potent CYP3A4 inducers (e. g. @DRUG$ , @DRUG$ , dexamethasone , carbamazepine ) may result in decreased plasma levels of saquinavir .	DDI-false
- ketoconazole, miconazole, coagulation agents, @DRUG$ , etc . ): in vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
@DRUG$: @DRUG$ is a CYP 3A4 substrate and CYP 2C19 substrate and inhibitor.	DDI-false
Other medicinal products Interactions: no pharmacokinetic interactions between vardenafil and the following medicinal products have been observed: glyburide, @DRUG$ , @DRUG$ ==References====External links==	DDI-false
This drug may interact with alcohol or other CNS depressants ( may potentiate the CNS depressant effects of either these medications or @DRUG$ ) , anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ) , and monoamine oxidase ( MAO ) inhibitors ( concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$ ) .	DDI-false
Warfarin: @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or (S)-warfarin, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of @DRUG$	DDI-false
INOmax has been administered with tolazoline , dopamine , @DRUG$ , @DRUG$ , surfactant , and high-frequency ventilation .	DDI-false
@DRUG$: Because of the relationship of Accutane to vitamin A, patients should be advised against taking vitamin supplements containing @DRUG$ to avoid additive toxic effects	DDI-false
Suppression by @DRUG$ of bombesin-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ in wistar rats.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Rifabutin: Coadministration of @DRUG$ and @DRUG$ resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-mechanism
In monkeys, the effects of (-)-NANM, but not @DRUG$ or @DRUG$, were antagonized by naloxone;	DDI-false
Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: aminoglycosides (e.g., @DRUG$, amikacin), amphotericin B, cyclosporine, non-steroidal anti-inflammatory drugs (e.g., ibuprofen), tacrolimus, @DRUG$.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of fissteride doses have been co-administered in clinical trials with acetaminophen, @DRUG$ , a-blockers , @DRUG$ Angiotensin converting enzymes (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also called NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
The administration of local @DRUG$ containing epinephrine or @DRUG$ to patients receiving monoamine oxidase inhibitors, tricyclic antidepressants or phenothiazines may produce severe, prolonged hypotension or hypertension.	DDI-false
Although the occurrence has not been reported with @DRUG$, nephrotoxicity has been reported following concomitant administration of other @DRUG$ and aminoglycosides.	DDI-false
The pressor effects of @DRUG$ such as @DRUG$ or norepinephrine are enhanced by Bretylium Tosylate.	DDI-false
Acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, @DRUG$/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound , salicylates , @DRUG$ , chloramphenicol , probenecid , coumarins , monoamine oxidase inhibitors , and beta adrenergic blocking agents .	DDI-effect
In addition , @DRUG$ and MHD induce a subgroup of the cytochrome P450 3A family ( CYP3A4 and CYP3A5 ) responsible for the metabolism of @DRUG$ This leads to a lower plasma concentration of these drugs.	DDI-false
The administration of local anesthetic solutions containing @DRUG$ or norepinephrine to patients receiving @DRUG$ or tricyclic antidepressants may produce severe , prolonged hypertension .	DDI-effect
Medicines associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, @DRUG$ , gold , hydralazine , iodoquinol , @DRUG$ , metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Multivitamins , or other products containing iron or @DRUG$ , @DRUG$ or sucralfate should not be administered concomitantly with , or within 2 hours of , the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin .	DDI-false
@DRUG$ The blood pressure lowering effect of 20 mg @DRUG$ during the 4-hour observation period in healthy volunteers when administered with alcohol ( 0.5 g/kg body weight ) .	DDI-false
May interact @DRUG$ ( altered hypo-prothrombinemic effect ) , barbiturates , @DRUG$ and other inducers of hepatic microsomal enzyme oxidation system ( decreased effect of diethylstilbestrol ) , corticosteroids ( increased effect of corticosteroids ) .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, @DRUG$, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
When LEVSIN is co-administered with other antimuscarinic agents, amantadine, haloperidol, @DRUG$ , @DRUG$ , tricyclic antidepressants or some antihistamines .	DDI-false
In general, these are drugs that have one or more pharmacologic activities similar to @DRUG$, including anti-arrhythmic agents such as @DRUG$ and procainamide, cardiac glycosides and tricyclic anti-depressants.	DDI-false
Imidazoles ( e. g. , ketoconazole , miconazole , clotrimazole , @DRUG$ In vitro and animal studies with the combination of amphotericin B and imidazoles indicate that imidazoles may cause fungal resistance to @DRUG$.	DDI-false
In clinical studies performed with Fondaparinux , the concomitant use of oral anticoagulants ( warfarin ) , @DRUG$ ( acetylsalicylic acid ) , NSAIDs ( piroxicam ) , and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of @DRUG$.	DDI-false
The addition of tiagabine in a limited number of patients in three well-controlled studies caused no systematic changes in @DRUG$ or @DRUG$ concentrations when compared to placebo.	DDI-false
In a study in which the 2 mg @DRUG$ orally disintegrating tablet was administered with and without propantheline ( an @DRUG$ The AUC of clonazepam was 10% lower and the Cmax of clonazepam was 20% lower when the oral disintegrating tablet was administered with propanthelin compared to the single dose.	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine , although theoretically , coadministration of other drugs known to alter cardiac conduction ( eg , anti-arrhythmic or @DRUG$ , calcium channel blockers , antihistamines or H1-blocking agents , tricyclic antidepressants and @DRUG$ ) could also contribute to an extension of the QTc interval.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenously] @DRUG$ ( e.g. , tobramycin , gentamicin , and amikacin ) , amphotericin B , foscarnet , intravenous pentamidine , vancomycin , and @DRUG$ ] is contraindicated .	DDI-false
Co-administration of colestipol and @DRUG$ The absorption of vitamin K can be reduced.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, @DRUG$, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should: @DRUG$ ( such as @DRUG$ ) , diphen-hydramine and H2 antagonists ( such as cimetidine or ranitidine ) .	DDI-false
Examples of inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, @DRUG$ , doxycycline , erythromycin , @DRUG$ , isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Other Cardiovascular Agents: Enalapril and @DRUG$ IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
Injection : Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when with ethyl alcohol, phenothiazine, barbiturates, @DRUG$ , and other @DRUG$.When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-false
DIGOXIN: Plasma @DRUG$ levels and digoxin clearance at steady-state were not affected by co-administration of 0.2 mg @DRUG$.	DDI-false
There are 3 types of indications: specific (for the treatment of some forms of @DRUG$ deficit i.e. acute), pharmacological (i.e. without alterations of @DRUG$ status) and mixed--pharmacological and aetiopathogenic--(for example complications of chronic alcoholism).	DDI-false
Although glucocorticoids have been shown to reduce PROLEUKIN-induced adverse reactions such as fever, renal failure, hyperbilirubinaemia, confusion and dyspnoea, concomitant administration of these agents with PROLEUKIN may reduce the efficacy of antitumours. @DRUG$ and thus should be avoided . 12 Beta-blockers and other antihypertensives may potentiate the hypotension seen with @DRUG$.	DDI-false
The @DRUG$ are a family of anxiolytic and @DRUG$.	DDI-false
Resins: Since @DRUG$ may bind other drugs given concurrently, patients should take TRICOR at least 1 hour before or 4-6 hours after a @DRUG$ to avoid impeding its absorption.	DDI-false
@DRUG$ reduce the renal clearance of lithium and add a high risk of @DRUG$ toxicity.	DDI-effect
BACKGROUND: The effects of combined administration of @DRUG$ and verapamil hydrochloride (verapamil), a calcium channel blocker, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ (AOM) and the labeling index of intestinal cancers were investigated in male Wistar rats.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , @DRUG$ , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , pimozide , carbamazepine , fentanyl , alfentanyl , alprazolam , and @DRUG$ ) may have elevated plasma concentrations when coadministered with saquinavir ;	DDI-false
â€¢ Drug-drug interactions between Keppra and others @DRUG$ ( AEDs ) @DRUG$ Keppra   ( 3000 mg daily ) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy .	DDI-false
@DRUG$ (5 mg/kg), @DRUG$ (30 mg/kg), clonazepam (0.25 mg/kg), fluoxetine (20 mg/kg) sertraline (30 mg/kg) or vehicle was administered.	DDI-false
@DRUG$, Nimodipine and Losartan: Bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and @DRUG$ has no significant effect on plasma levels of bosentan.	DDI-false
@DRUG$: @DRUG$ have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives.	DDI-false
Other Drugs:Drugs such as @DRUG$, disopyramide, @DRUG$, phenothiazines, antihistamines, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
To determine if the injection of thiosulfate is larger doses of thiosulfate @DRUG$ A fixed dose of 9.9 g/m2 thiosulfate was administered for three hours concomitantly with an escalating dose of @DRUG$.	DDI-false
Co-administration of @DRUG$ with @DRUG$ produced a 25% increase in AUC and a 33% increase in the Cmax of acamprosate.	DDI-mechanism
The following precautions should be kept in mind in the treatment of anticholinesterase poisoning although they do not bear directly on the use of @DRUG$ and @DRUG$.	DDI-advise
Central nervous system depressants : Co-administration of @DRUG$   ( @DRUG$ Transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotic agents, sedatives (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants and alcohol, may result in respiratory depression, hypotension and deep sedation, or possibly in coma or death.	DDI-false
Similarly dialyzed were phenobarbital, @DRUG$, and @DRUG$, both alone at therapeutic concentrations in serum and with ethanol at three different concentrations in serum.	DDI-false
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. @DRUG$ , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , @DRUG$ , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between @DRUG$ and the following drugs: @DRUG$, warfarin, digoxin, Maalox, and ranitidine.	DDI-false
Other Drug Interactions: No pharmacokinetic interactions were observed between vardenafil and the following drugs: glyburide, @DRUG$, digoxin, @DRUG$, and ranitidine.	DDI-false
In addition , higher-than expected steady-state serum concentrations of @DRUG$ At the start of therapy, therapy was observed in patients already taking @DRUG$.	DDI-mechanism
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, antacids, H2-antagonists (e.g., @DRUG$, ranitidine), and proton pump inhibitors (e.g., lansoprazole, @DRUG$).	DDI-false
- When @DRUG$ or Bezalip retard is used concurrently with anion-exchange resins (e.g. cholestryramine), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of Bezalip or @DRUG$ is impaired	DDI-false
Stavudine and @DRUG$ @DRUG$ can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of @DRUG$, with ketamine or Innovar than with @DRUG$.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions between VIRACEPT and @DRUG$ , @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or fluconazole.	DDI-false
@DRUG$ Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with 5HT3 antagonist class drugs (including, for example, ondansetron, granisetron, dolasetron, @DRUG$ ==References====External links==	DDI-false
@DRUG$ (ammonium chloride, @DRUG$, etc.) increase the concentration of the ionized species of the amphetamine molecule, thereby increasing urinary excretion.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
Amiodarone taken concomitantly with @DRUG$ Elevates plasma concentrations of procainamide and N-acetyl for less than seven days @DRUG$ by 55 % and 33 % , respectively .	DDI-false
Because of the increased risk of adverse reactions in patients who have been taking benzodiazepines on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, @DRUG$ and sedative use as part of the history prior to any procedure in which the use of @DRUG$ is planned.	DDI-false
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Dose adjustment is not recommended.@DRUG$ had no effect on plasma concentrations of carbamazepine , valproate , @DRUG$ Or lamotrigine.	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetics, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analogue (e.g., @DRUG$ ) , @DRUG$.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, @DRUG$, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
- @DRUG$ ( e.g. , @DRUG$ ) or	DDI-false
Other @DRUG$ (e.g. barbiturates, tranquilizers, opioids and general @DRUG$) have additive or potentiating effects with INAPSINE.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , sucralfate , @DRUG$ chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or @DRUG$ The absorption of ciprofloxacin can be significantly reduced, resulting in significantly lower serum and urine levels than desired.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: @DRUG$, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
@DRUG$ MAOI antidepressants, as well as a metabolite of furazolidone, slow @DRUG$ metabolism.	DDI-false
Therapeutic concentrations of digoxin , warfarin , @DRUG$ , naproxen , @DRUG$ Acetaminophen, phenytoin andtolbutamide did not alter the binding of ketorolac tromethamine proteins.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the @DRUG$ phenytoin, @DRUG$, and barbiturates, and the antituberculosis drug rifampin.	DDI-false
To avoid the occurrence of severe hypersensitivity reactions, all TAXOL-treated patients with corticosteroids (e. g. @DRUG$ , diphenhydramine and @DRUG$ (such as cimetidine or ranitidine).	DDI-false
â€¢ Hormonal contraceptives, including oral, injectable, transdermal and implantable contraceptives: An interaction study showed that the concomitant use of bosentan and oral hormonal contraceptives Ortho-Novum showed an average decrease in @DRUG$ and @DRUG$ The rate is 14 % and 31 % respectively.	DDI-false
Other drug interactions @DRUG$ , erythromycin and @DRUG$ had no effect on the pharmacokinetics of MHD .	DDI-false
While all the @DRUG$ ( SSRIs ) , e.g. , citalopram , escitalopram , fluoxetine , sertraline , and @DRUG$ , inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
These increased exposures of @DRUG$ and @DRUG$ The choice of an oral contraceptive for women taking valdecoxib should be considered.	DDI-false
Because changes in glucose concentrations when valdecoxib was co-administered were within normal variability and individual glucose concentrations were greater than or close to 70 mg/ dl, a dose adjustment for valdecoxib was observed. @DRUG$ ( 5 mg QD and 10 mg BID ) with @DRUG$ Co-administration (up to 40 mg QD) is not indicated.	DDI-advise
In some patients, a @DRUG$-like reaction may be produced by the ingestion of @DRUG$.	DDI-false
@DRUG$: In normal volunteers, a small decrease in diflunisal levels was observed when multiple doses of diflunisal and @DRUG$ were administered concomitantly.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (iron), multivitamin preparations containing zinc or other metal cations, or @DRUG$ (@DRUG$) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with @DRUG$, steroids, or @DRUG$ may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Plasma exposure of @DRUG$ ( 10 mg BID ) was increased by 28 % following administration of valdecoxib ( 40 mg BID ) for 12 days , while plasma exposure of valdecoxib ( 40 mg BID ) was not substantially increased following administration of @DRUG$ 10 mg twice daily.	DDI-false
Two groups ( SH/DA ; SH/FA ) were submitted to daily treatment with synthetic hydroalcoholic solutions containing ethanol , @DRUG$ , higher alcohols and @DRUG$ â€” in the same proportions as in the most frequently distilled and fermented alcoholic beverages;	DDI-false
Coadministration of @DRUG$ Cyclosporin, tacrolimus or @DRUG$ has led to increased plasma concentrations of the latter three drugs .	DDI-mechanism
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , propoxyphene , salicylates , @DRUG$ ( e.g. , @DRUG$ ==References====External links==	DDI-false
â€¢ Aspirin: Concomitant use of diclofenac and @DRUG$ is not recommended because diclofenac is displaced from its binding sites during the concomitant administration of @DRUG$ , resulting in lower plasma concentrations , peak plasma levels , and AUC values .	DDI-false
@DRUG$, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, @DRUG$, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, thereby delaying elimination and increasing blood levels of these drugs.	DDI-mechanism
Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including barbiturates , @DRUG$ And alcohol.	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant @DRUG$ (@DRUG$  30 mcg IM once weekly) or glatiramer acetate were inconclusive with regard to the need for dose adjustment of the beta-interferon or glatiramer acetate.	DDI-false
H2 receptor antagonists: co-administration of cimetidine results in increased peak plasma concentration and AUC of cisapride, there is no effect on @DRUG$ absorption when it is coadministered with @DRUG$.	DDI-false
In a study in which patients with active RA were treated for up to 24 weeks with concurrent @DRUG$ and etanercept therapy, a 7% rate of serious infections was observed, which was higher than that observed with @DRUG$ alone (0%).	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine @DRUG$: @DRUG$, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
@DRUG$/prednisolone: @DRUG$ did not have any clinically important effect on the pharmacokinetics of prednisolone or prednisone.	DDI-false
Lithium: @DRUG$ toxicity has been reported in patients receiving @DRUG$ concomitantly with drugs which cause elimination of sodium, including ACE inhibitors.	DDI-false
@DRUG$: The pharmacokinetics of @DRUG$ (aminophylline 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of albendazole (400 mg) in 6 healthy subjects.	DDI-false
Injection : Lorazepam injection , like other injectable @DRUG$ , produces depression of the central nervous system when administered with ethyl alcohol , phenothiazines , @DRUG$ , MAO inhibitors , and other antidepressants . When scopolamine is used concomitantly with injectable lorazepam , an increased incidence of sedation , hallucinations , and irrational behavior has been observed .	DDI-effect
Simultaneous use of oxyphenbutazone and @DRUG$ There may be increased serum levels of @DRUG$.	DDI-false
Medicines that may alter the plasma concentration of imatinib Medicines that may increase the plasma concentration of imatinib: Caution should be exercised when gleevec is administered with inhibitors of the CYP3A4 family (e.g. ketoconazole, itraconazole, @DRUG$ , @DRUG$ ) .	DDI-false
Serum @DRUG$ levels should be monitored frequently if INSPRA is administered concomitantly with @DRUG$.	DDI-false
Ephedrine: Ephedrine may enhance the metabolic clearance of @DRUG$, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in @DRUG$ dosage.	DDI-false
This seems to be the only clinically relevant interaction of this species with mefloquines, although theoretically, the concomitant use of other drugs is known to alter heart conduction (e.g., @DRUG$ or beta-adrenergic blocking agents , calcium channel blockers , antihistamines or H1-blocking agents , tricyclic antidepressants and @DRUG$ ) might also contribute to a prolongation of the QTc interval .	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, @DRUG$, piroxicam, acetaminophen, @DRUG$ andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-effect
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , fibrates , fluoxetine , monoamine oxidase ( MAO ) inhibitors , @DRUG$ , salicylates , @DRUG$ (e.g. octreotide), sulphonamide antibiotics.	DDI-false
@DRUG$: Tiagabine causes a slight decrease (about 10%) in steady-state @DRUG$ concentrations.	DDI-false
Ethinyl Estradiol and Norethindrone : Coadministration of VIRACEPT with @DRUG$ resulted in a 47 % decrease in @DRUG$ and an 18 % decrease in norethindrone plasma concentrations .	DDI-false
HMG-CoA Reductase Inhibitors: @DRUG$ (@DRUG$ substrate) in combination with amiodarone has been associated with reports of myopathy/rhabdomyolysis.	DDI-false
Antiacid, clarithromycin, @DRUG$, Fluconazole, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, @DRUG$, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Imidazoles (e.g. ketoconazole, @DRUG$ , clotrimazole , fluconazole , etc . ): in vitro and animal studies with the combination of amphotericin B and @DRUG$ Imidazole can cause fungal resistance to amphotericin B.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, @DRUG$, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, @DRUG$, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , @DRUG$ , @DRUG$ , terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
In rats, concomitant use of disulfiram and nitrite in the diet for 78 weeks has been reported to cause tumours, and it has been suggested that: @DRUG$ may react with @DRUG$ In the rat's stomach a nitrosamine is formed, which is tumorogenic.	DDI-effect
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (NSAIDs), and @DRUG$ may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
As higher doses of @DRUG$ A single dose of 2.5 mg vardenafil should not be exceeded in a 24-hour period when used in combination with @DRUG$ 400 mg daily.	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or @DRUG$ antagonists (e.g., verapamil, a CYP3A4 substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - @DRUG$ : Flupenthixol and @DRUG$ Cause additive CNS depression - Tricyclic antidepressants : flupenthixol increases the effect of tricyclic antidepressants	DDI-false
Benzthiazide may interact with alcohol , blood thinners , @DRUG$ ( allergy , cold , and sinus medicines ) , diabetic drugs , @DRUG$ , norepinephrine, NSAIDs such as aleve or ibuprofen, and high blood pressure medications.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : @DRUG$ , niacin, danazol, diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazide, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., oral) @DRUG$ ) .	DDI-false
Plasma exposure ( AUC ) to valdecoxib was increased 62 % when coadministered with @DRUG$ and 38 % when coadministered with @DRUG$.	DDI-false
Additive CNS depression may occur when antihistamines are administered concomitantly with other @DRUG$ including @DRUG$, tranquilizers, and alcohol.	DDI-false
Toxicological and toxicokinetic studies in rats showed no changes in clearance or toxicological profile @DRUG$ or @DRUG$ When the two agents were administered together.	DDI-false
Cimetidine: Albendazole sulfoxide concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with @DRUG$ (10 mg/kg/day) (n=7) compared with @DRUG$ (20 mg/kg/day) alone (n=12).	DDI-false
Antibiotics : In vitro and/or in vivo data show that @DRUG$ , erythromycin , and troleandomycin markedly inhibit the metabolism of cisapride , which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG .	DDI-false
In vitro studies indicate that @DRUG$ does not inhibit P-glycoprotein-mediated transport of digoxin or vinblastine and that @DRUG$ is not a substrate for P-glycoprotein-mediated transport.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of fissteride doses have been co-administered in clinical trials with acetaminophen, @DRUG$ , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , @DRUG$ , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , @DRUG$ , anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, @DRUG$ , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Imipramine ( 5 mg/kg ) , @DRUG$ 30 mg/kg, clonazepam ( 0.25 mg/kg), @DRUG$ ( 20 mg/kg ) sertraline ( 30 mg/kg ) or vehicle was administered .	DDI-false
@DRUG$ or @DRUG$: The effect of increased gastric pH on the bioavailability of ceftibuten was evaluated in 18 healthy adult volunteers.	DDI-false
Coadministration of @DRUG$ and @DRUG$, tacrolimus or digoxin has led to increased plasma concentrations of the latter three drugs.	DDI-mechanism
Antiacid , clarithromycin , Didanosine , Fluconazole , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , @DRUG$ , @DRUG$ , rifampin, ritanovir, saquinavir.	DDI-false
@DRUG$ : @DRUG$ There is no apparent pharmacokinetic interaction with glyburide.	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics : amiodarone , quinidine Antihistamines : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : @DRUG$ benzodiazepines midazolam, triazolam GI motility agent: cisaprid	DDI-advise
Note: dissolution of aerosol particles of budesonide in @DRUG$, a model @DRUG$.	DDI-false
- @DRUG$ Interaction studies in humans have no effect on @DRUG$ blood levels .	DDI-false
Interaction of @DRUG$ with Other Drugs : @DRUG$ : Co-administration of cimetidine (800 mg/day) to patients taking tiagabine chronically had no effect on tiagabine pharmacokinetics.	DDI-false
- @DRUG$ (e.g., @DRUG$) or	DDI-false
Example inhibitors include azole antifungals , ciprofloxacin , clarithromycin , @DRUG$ , doxycycline, erythromycin, imatinib, @DRUG$ , Nefazodone, Nicardipine, Propofol, Protease inhibitors, quinidine, and verapamil.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, @DRUG$, alprazolam, and @DRUG$) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: @DRUG$	DDI-false
@DRUG$ : @DRUG$ Metabolism is primarily done by CYP 2D6 and to a lesser extent by 3A4.	DDI-false
Non-selective MAO inhibitors including tranylcypromine sulfate , phenelzine sulfate , and @DRUG$ HC1 : Concomitant use of L-tyrosine and non-selective @DRUG$ - May cause high blood pressure.	DDI-false
Anticoagulants : Potentiation of warfarin-type ( @DRUG$ Anticoagulant response is almost always observed in patients who: @DRUG$ and can result in serious or fatal bleeding .	DDI-false
The effect of @DRUG$ on the warfarin requirement of our patient appeared to be maximal 5 to 7 days after the initiation of @DRUG$ and extended a similar length of time after rifampin withdrawal .	DDI-false
Drug interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): @DRUG$ - Arecolin - Eproxindine - Ethanol : @DRUG$ and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Data from in vitro studies of alprazolam suggest a possible drug interaction with @DRUG$ for the following: @DRUG$ and paroxetine.	DDI-int
â€¢ Furosemid : Clinical studies, as well as post-marketing observations, have shown that @DRUG$ The natriuretic effect of furosemide and @DRUG$ In some patients.	DDI-effect
â€¢ Carbamazepine : Isoniazid is known to slow down the metabolism of carbamazepine and increase serum levels @DRUG$ levels should be determined prior to concurrent administration with isoniazid , signs and symptoms of @DRUG$ toxicity should be monitored closely , and appropriate dosage adjustment of the anticonvulsant should be made .	DDI-false
@DRUG$ has also been shown to inhibit P450 1A2, an isoform also involved in @DRUG$metabolism.	DDI-mechanism
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives @DRUG$: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
It may be necessary to adjust the dosage of oral @DRUG$ After starting or stopping @DRUG$. as disulfiram can prolong the prothrombin time.	DDI-advise
In two combined 12-week placebo-controlled studies, the @DRUG$ Doses of 15 mcg twice daily, 25 mcg twice daily, and 50 mcg once daily, 54 of 873 @DRUG$ At baseline, the patients treated with theophylline received theophylline at the same time.	DDI-false
Ethinyl Estradiol and @DRUG$ Co-administration of VIRACEPT and OVCON-35 resulted in a decrease in @DRUG$ The plasma concentrations of norethindron were reduced by 18%.	DDI-false
For example, inhibitors are azole antimycotics, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, @DRUG$ , isoniazid , nefazodone , nicardipine , @DRUG$ , protease inhibitors, quinidine, and verapamil.	DDI-false
Repeated doses of colestipol hydrochloride given prior to a single dose of @DRUG$ in human trials have been reported to decrease @DRUG$ absorption.	DDI-false
Therefore, smaller doses of @DRUG$ may be effective in the presence of @DRUG$.	DDI-effect
Another oral @DRUG$ ketoconazole inhibits the metabolism of astemizole, resulting in increased plasma concentrations of @DRUG$ The active metabolite desmethylastermizole may prolong the QT interval.	DDI-false
@DRUG$ and tricyclic anti-depressants could exaggerate the prolongation of the QT interval observed with @DRUG$.	DDI-effect
Epinephrine should also be cautious with other medicines (e.g. digitalis, @DRUG$ ) that sensitize the myocardium to the actions of @DRUG$.	DDI-false
Acidifying agents : @DRUG$ ( @DRUG$ , reserpine , glutamic acid HCl , ascorbic acid , fruit juices , etc . ) lower absorption of amphetamines .	DDI-false
Coingestion of acetaminophen with @DRUG$, phenobarbital with acetaminophen, and valproic acid with @DRUG$ at high to toxic concentrations decreases the binding of the target drug.	DDI-false
This seems to be the only clinically relevant interaction of this species with mefloquines, although theoretically, the concomitant use of other drugs is known to alter heart conduction (e.g., @DRUG$ or @DRUG$ Also calcium channel blockers, antihistamines or H1-blockers, tricyclic antidepressants and phenothiazines could contribute to an extension of the QTc interval.	DDI-false
This interaction should be given consideration in patients taking @DRUG$ concomitantly with @DRUG$.	DDI-advise
Curariform muscle relaxants (e.g. tubocurarin) and other medicines, including ether, succinylcholine, gallamine, decamethonium and @DRUG$ , enhance neuromuscular blocking effect and should be used with extreme caution in patients with @DRUG$ Parenteral .	DDI-effect
@DRUG$: @DRUG$ may counteract the sedative effect of antihistamines.	DDI-false
In the post-marketing experience, bleeding has been reported, mainly in elderly patients, associated with an increase in prothrombin time in patients who: @DRUG$ concurrently with @DRUG$.	DDI-effect
If @DRUG$ is mixed with @DRUG$, NovoLog should be drawn into the syringe first.	DDI-false
However, in the second study, administration of 12 g @DRUG$ 1 hour before the evening meal and 0.3 mg cerivastatin sodium about 4 hours after the same evening meal led to a decrease in the @DRUG$ The AUC of less than 8% and a decrease in Cmax of about 30% compared to the dose of cerivastatin sodium alone.	DDI-false
Other Drugs : Drugs such as quinidine , disopyramide , @DRUG$ , @DRUG$ , antihistamines and tricyclic antidepressants may be associated with QT interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
@DRUG$ : Concurrent administration of @DRUG$ may lower meclofenamate sodium plasma levels , possibly by competing for protein-binding sites .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , @DRUG$ , hydralazine , iodoquinol , isoniazid , metronidazole , nitrofurantoin , @DRUG$ Ribavirin and vincristine.	DDI-false
@DRUG$ had no significant impact on the Cmax and AUC of zidovudine , although it significantly decreased the @DRUG$ Tmax increased by 44% and intracellular exposure to phosphorylated zidovudine by 110%.	DDI-mechanism
acetaminophen/theophylline, @DRUG$/quinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, @DRUG$/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), @DRUG$.	DDI-false
Other Cardiovascular Agents: @DRUG$ and enalapril IV have been used concomitantly with beta adrenergic-blocking agents, methyldopa, nitrates, calcium-blocking agents, @DRUG$, prazosin and digoxin without evidence of clinically significant adverse interactions.	DDI-false
To determine whether probenecid has a direct effect on the distribution of @DRUG$, the elimination and distribution of cloxacillin was studied in six patients, five lacking kidney function and one with a partially impaired renal function, in the presence or absence of @DRUG$.	DDI-false
A similar association, though less marked, has been suggested with barbiturates, phenyl-butazone, phenytoin sodium, carbamazepine and possibly with @DRUG$, @DRUG$, and tetracyclines (72)	DDI-false
In addition to the interactions noted above, chronic (  2 weeks) oral Cordarone administration impairs metabolism of phenytoin, @DRUG$, and @DRUG$.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, clarithromycin, nefazodone, troleandomycin, @DRUG$, @DRUG$) would be expected to behave similarly.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., @DRUG$, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous @DRUG$ (e.g., @DRUG$, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous pentamidine, vancomycin, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
These drugs include thiazides and other diuretics, corticosteroids, @DRUG$ , thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$ ==References====External links==	DDI-false
The following are examples of substances that may increase the hypoglycaemic effect and susceptibility to hypoglycaemia: oral antidiabetic agents, @DRUG$ , disopyramide , fibrates , @DRUG$ Monoamine oxidase (MAO) inhibitors, propoxyphene, salicylate, somatostatin analogue (e.g. octreotide), sulphonamide antibiotics.	DDI-false
Coadministration of @DRUG$ (40 mg BID (day 1) and 40 mg QD (days 2-7)) with glyburide (10 mg @DRUG$ BID) resulted in 21% increase in glyburide AUC0-12 and a 16% increase in glyburide Cmax leading to a 16% decrease in glucose AUC0-24.	DDI-false
Digoxin , @DRUG$ , Cyclosporine : Diclofenac , like other @DRUG$ , can affect the kidney prostaglandins and increase the toxicity of certain medications.	DDI-false
Drug-Drug Interactions Between Keppra  And Other Antiepileptic Drugs (@DRUG$) @DRUG$ Keppra  (3000 mg daily) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy.	DDI-false
@DRUG$ ( neostgmine , physostigmine ) , lignocaine , quinine , @DRUG$ can enhance toxicity and cause cardio respiratory depression .	DDI-false
May interact with thyroid medication (e.g., levothyroxine), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and @DRUG$ (e.g., lansoprazole, omeprazole).	DDI-false
@DRUG$/@DRUG$-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing antacid products.	DDI-false
- The action of @DRUG$ Insulin may be caused by: @DRUG$ Or delay Bezalip.	DDI-effect
Antibiotics : In vitro and/or in vivo data show that clarithromycin, @DRUG$ , and troleandomycin significantly inhibit the metabolism of cisapride, which may lead to an increase in plasma @DRUG$ The concentrations and prolongation of the QT interval on the ECG.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as @DRUG$ or aluminum antacids , sucralfate , VIDEX chewable/buffered tablets or pediatric powder , or products containing calcium , iron , or @DRUG$ The absorption of ciprofloxacin can be significantly reduced, resulting in significantly lower serum and urine levels than desired.	DDI-false
Phenytoin : In post-marketing experience, there have been reports of both increases and decreases in @DRUG$ levels with @DRUG$ co-administration , leading to alterations in seizure control .	DDI-mechanism
Oral Contraceptives : Valdecoxib ( 40 mg BID ) did not induce the metabolism of the combination oral contraceptive @DRUG$/@DRUG$ 1 mg/35 mg combination, ortho-novum 1/35).	DDI-false
@DRUG$ @DRUG$ The pharmacokinetics and pharmacodynamics (ECG) of digoxin administered daily as 0.25 mg did not affect ( 1000 mg twice daily ) the pharmacokinetics and pharmacodynamics (ECG) of digoxin.	DDI-false
iodine or iodine excess may affect the effect of carbimazole and a @DRUG$ Deficiency can increase the effect of @DRUG$.	DDI-effect
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : amiodarone , @DRUG$ @DRUG$ : astemizole , terfenadine Antimigraine : ergot derivatives Antimycobacterial agents : rifampin Benzodiazepines midazolam , triazolam GI motility agents : cisapride	DDI-false
@DRUG$ has been administered with tolazoline, dopamine, dobutamine, @DRUG$, surfactant, and high-frequency ventilation.	DDI-false
Lithium : @DRUG$ have produced an elevation of plasma lithium levels and a reduction in renal @DRUG$ clearance .	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - @DRUG$ - Eproxindine - ethanol : flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
@DRUG$ : Clinical studies , as well as post-marketing observations , have shown that @DRUG$ can reduce the natriuretic effect of furosemide and thiazides in some patients .	DDI-false
In a comparison of @DRUG$ tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$.	DDI-false
@DRUG$ NSAIDs-A drug interaction study with: @DRUG$ ==References====External links==	DDI-false
These drugs include the thiazides and other diuretics , corticosteroids , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , @DRUG$ , sympathomimetics , @DRUG$ ==References====External links==	DDI-false
@DRUG$ including coumarin derivatives, indandione derivatives, and @DRUG$ such as nonsteroidal anti-inflammatory drugs (NSAIDs), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Mineral Oil-Concomitant intake of mineral oil and @DRUG$ may reduce the absorption of @DRUG$.	DDI-false
@DRUG$, lidocaine, phenobarbital, quinidine, theophylline, and @DRUG$ were added to pooled human serum at therapeutic concentrations.	DDI-false
Bosentan is also expected to reduce plasma concentrations of other @DRUG$ that have significant metabolism by CYP3A4, such as lovastatin and @DRUG$.	DDI-false
Hepatic Enzyme Inducers , Inhibitors and Substrates : Drugs which induce cytochrome P450 3A4 ( CYP 3A4 ) enzyme activity ( e.g. , @DRUG$ , phenytoin, carbamazepine, rifampin) may increase the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased .	DDI-mechanism
Metformin: In healthy subjects given single 500 mg doses of cephalexin and @DRUG$, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and @DRUG$ mean renal clearance decreased by 14%.	DDI-false
It is recommended that if: @DRUG$ It is started in patients who already have @DRUG$ , prothrombin times should be closely monitored and adjustment of the anticoagulant dose may be necessary .	DDI-advise
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, @DRUG$, corticosteroids, @DRUG$, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Because prostaglandins play an important role in hemostasis, and NSAIDs affect platelet function as well, concurrent therapy with all @DRUG$, including @DRUG$, and warfarin requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.	DDI-false
@DRUG$ : In hypercholesterolemic patients , steady-state cerivastatin AUC and Cmax increased approximately 50 % and 24 % respectively after 10 days with co-administration of @DRUG$ , a known inhibitor of cytochrome P450 3A4 .	DDI-false
Data from in vitro studies of @DRUG$ other than alprazolam suggest a possible drug interaction for the following: ergotamine, cyclosporine, amiodarone, nicardipine, and @DRUG$.	DDI-int
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: MTX, NSAIDs, @DRUG$ TNF blockers, azathioprin, chloroquine, @DRUG$ , hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
Patients with high doses of @DRUG$ concomitantly with @DRUG$ As with rheumatic diseases, salicylate toxicity may occur at lower doses due to competing renal excretion sites.	DDI-effect
Drugs Interactions : Flupentixol may interact with some medicines, such as monoamine oxidase inhibitors (MAOI): MAOI may theoretically affect @DRUG$ pharmacodynamics - Arecolin - eproxindine - ethanol : flupenthixol and ethanol cause additive CNS depression - tricyclic antidepressants : @DRUG$ Increases the effect of tricyclic antidepressants	DDI-false
Valproate : The addition of tiagabine to patients taking valproate chronically had no effect on @DRUG$ pharmacokinetics , but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8 % , which resulted in an increase of approximately 40 % in the free tiagabine concentration .	DDI-false
@DRUG$ Other antiarrhythmic drugs, such as @DRUG$ Procainamide, disopyramide and phenytoin were used concomitantly with amiodarone.	DDI-false
Effect of Clonazepam on the Pharmacokinetics of Other Drugs: Clonazepam does not appear to alter the pharmacokinetics of @DRUG$, @DRUG$, or phenobarbital.	DDI-false
Aspirin : Simultaneous use of @DRUG$ with valdecoxib may result in an increased risk of GI ulceration and complications compared to @DRUG$ alone .	DDI-false
@DRUG$ For normal volunteers, simultaneous use of diflunisal and @DRUG$ resulted in an approximate 50 % increase in plasma levels of acetaminophen .	DDI-false
Results of studies in multiple sclerosis patients taking TYSABRI  and concomitant interferon beta-1a (AVONEX  30 mcg IM once weekly) or @DRUG$ were inconclusive with regard to the need for dose adjustment of the @DRUG$ or glatiramer acetate.	DDI-false
Administration of repeated doses of FACTIV had no effect on the pharmacokinetics of theophylline, @DRUG$ or an ethinylestradiol/levonorgestrol oral @DRUG$ in healthy subjects .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac @DRUG$, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
Other strong inhibitors of CYP3A4 (e.g., itraconazole, @DRUG$, nefazodone, troleandomycin, ritonavir, @DRUG$) would be expected to behave similarly.	DDI-false
Compounds tested in man include @DRUG$ , @DRUG$ , phenytoin, diazepam, aminopyrin and antipyrin.	DDI-false
Other concomitant therapy Although specific interaction studies have not been performed, 1 mg or more finasteride doses have been reported in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, heart nitrates, @DRUG$ , H2 antagonists , @DRUG$ Prostaglandin synthetase inhibitors (also known as NSAIDs) and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ and Anticoagulants : Increased prothrombin time , with or without clinical bleeding , has been reported when @DRUG$ is administered concomitantly .	DDI-effect
Other medicines that may enhance the neuromuscular blocking effect of non-depolarizing substances such as NUROMAX include certain antibiotics (e.g. aminoglycosides, tetracyclines, @DRUG$ , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , @DRUG$ , local anesthetics , procainamide , and quinidine .	DDI-false
Study results in patients with multiple sclerosis, TYSABRI and concomitantly @DRUG$ ( AVONEX 30 mcg IM once weekly ) or @DRUG$ This was not conclusive in terms of the need for dose adjustment of beta interferon or glatiramer acetate.	DDI-false
@DRUG$ has additive effects with alcohol and other CNS depressants ( hypnotics , @DRUG$ , sedatives, etc.	DDI-effect
These data indicate that @DRUG$ does not influence the plasma concentration of other @DRUG$ and that these AEDs do not influence the pharmacokinetics of levetiracetam.	DDI-false
Therapeutic concentrations of digoxin, @DRUG$, ibuprofen, naproxen, @DRUG$, acetaminophen, phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
In patients taking @DRUG$ and @DRUG$ concomitantly , lithium toxicity may develop .	DDI-effect
In clinical studies performed with @DRUG$, the concomitant use of oral @DRUG$ (warfarin), platelet inhibitors (acetylsalicylic acid), NSAIDs (piroxicam), and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Corticosteroids, Methylxanthines and @DRUG$: Concomitant treatment with @DRUG$, steroids, or diuretics may potentiate a possible hypokalemic effect of  beta2-agonists.	DDI-false
Selective serotonin reuptake inhibitors (SSRIs): SSRIs (e.g. fluoxetine, fluvoxamine, paroxetine, @DRUG$ ) have been rarely reported to cause weakness, hyperreflexia, and incoordination when co-administered with @DRUG$.	DDI-effect
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/@DRUG$.	DDI-false
However, the pharmacodynamics of concomitant use of @DRUG$ and @DRUG$ ==References====External links==	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of magnesium deficit and to discriminate between @DRUG$ Deficiency due to insufficient absorption of magnesium, which requires only an oral physiological supplement and @DRUG$ The depletion associated with a dysregulation of the control mechanisms of magnesium status, which requires more or less specific regulation of its causal dysregulation.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, @DRUG$, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and prednisone with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, @DRUG$, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, @DRUG$, @DRUG$, or other drugs that produce CNS depression.	DDI-false
Tagamet, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain @DRUG$, lidocaine, theophylline and @DRUG$, thereby delaying elimination and increasing blood levels of these drugs.	DDI-false
Lithium: @DRUG$ toxicity has been reported in patients receiving lithium concomitantly with drugs which cause elimination of sodium, including @DRUG$.	DDI-false
@DRUG$ ( e.g. , spironolactone , triamterene , or amiloride ) , potassium supplements , or @DRUG$-containing salt substitutes may lead to significant increases in serum potassium .	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including non-steroidal anti-inflammatory drugs and other drugs that are highly protein bound, salicylates, @DRUG$ , @DRUG$ , probenecid, coumarine, monoamine oxidase inhibitors, and beta-adrenergic blockers.	DDI-false
Lorazepam: Coadministration of single doses of @DRUG$ 3 mg and @DRUG$ 2 mg did not have clinically relevant effects on the pharmacodynamics or pharmacokinetics of either drug.	DDI-false
@DRUG$ : @DRUG$ CONTRAINDICATED since the coadministration of this product with saquinavir in an antiretroviral regimen reduces the plasma concentrations of saquinavir .	DDI-false
These increased exposures of @DRUG$ When selecting an oral contraceptive for women under @DRUG$, ethinylestradiol and ethinylestradiol should be considered.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and @DRUG$ without evidence of clinically significant adverse interactions.	DDI-false
H2 Receptor Antagonists: Cimetidine coadministration leads to an increased peak plasma concentration and AUC of cisapride, there is no effect on @DRUG$ absorption when it is coadministered with @DRUG$.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenously] @DRUG$ ( e.g. , @DRUG$ , gentamicin , and amikacin ) , amphotericin B , foscarnet , intravenous pentamidine , vancomycin , and non-steroidal anti-inflammatory agents ] is contraindicated .	DDI-false
@DRUG$ and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
Other substances: Grapefruit juice given to healthy volunteers increased @DRUG$ AUC by 50% and Cmax by 84%, resulting in increased plasma levels of @DRUG$.	DDI-false
- @DRUG$ (nandrolone [e.g., Anabolin], oxandrolone [e.g., Anavar], oxymetholone [e.g., @DRUG$], stanozolol [e.g., Winstrol]) or	DDI-false
Other concomitant therapies: In clinical trials, the safety profile in subjects treated with Acamprosate concomitantly with @DRUG$, hypnotics and sedatives (including benzodiazepines), or @DRUG$ was similar to that of subjects taking placebo with these concomitant medications.	DDI-false
Because @DRUG$ has not been shown to produce any additional effect beyond that obtained with @DRUG$ alone and because aspirin increases the rate of excretion of Nalfon, the concomitant use of Nalfon and salicylates is not recommended.	DDI-false
Although no studies have been conducted , concomitant administration of @DRUG$ The metabolism of phenytoin and phenytoin may change. @DRUG$ ;	DDI-false
The effects of @DRUG$ and @DRUG$ After phencyclidine (PCP)-induced movement and behavioural changes in mice.	DDI-false
- @DRUG$ or @DRUG$ ( with hepatotoxic potential ) must not be administered together with Bezalip or Bezalip retard .	DDI-false
This appears to be the only clinically relevant interaction of this kind with Mefloquine, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or @DRUG$, calcium channel blockers, antihistamines or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-false
Antacids containing iron sulphate ( @DRUG$ ) , multivitamin preparations containing zinc or other metal cations , or Videx ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
These drugs include the thiazides and other @DRUG$, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimet-ics, @DRUG$, and isoniazid.	DDI-false
Antidepressants, tricyclic: Amphetamines may enhance the activity of @DRUG$ or @DRUG$;	DDI-false
Intravenous @DRUG$ ( adenosine ) has been effectively administered in the presence of other cardioactive drugs , such as @DRUG$ , beta-adrenergic blocking agents , calcium channel blocking agents , and angiotensin converting enzyme inhibitors , without any change in the adverse reaction profile .	DDI-false
Example inhibitors include azole antifungals , @DRUG$ , clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, nefazodon, @DRUG$ Propofol, protease inhibitors, quinidine and verapamil.	DDI-false
Other medicines that can improve neuromuscular blocking effects of non-depolarizing agents such as NUROMAX are certain antibiotics (e.g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistine and sodium colistimethate), magnesium salts, @DRUG$ , local anaesthetics, @DRUG$ ==References====External links==	DDI-false
Other drugs that inhibit the neuromuscular blocking effect of non-depolarizing substances such as e.g. @DRUG$ include certain @DRUG$ ( e. g. , aminoglycosides , tetracyclines , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-effect
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, @DRUG$, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
@DRUG$: Population pharmacokinetic analyses indicate that tiagabine clearance is 60% greater in patients taking @DRUG$ with or without other enzyme- inducing AEDs.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, @DRUG$, and alosetron) is contraindicated .	DDI-false
Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with @DRUG$ , warfarin, quinidine, clarithromycin or amoxicillin.	DDI-false
@DRUG$ In healthy subjects receiving single doses of 500 mg cephalexin and metformin, mean cmax and AUC values in metformin plasma increased by an average of 34% and 24%, respectively. @DRUG$ mean renal clearance decreased by 14 % .	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
The concomitant use of BOTOX and @DRUG$ or other agents interfering with neuromuscular transmission ( e.g. , @DRUG$ Caution should be exercised as the effect of the toxin may be increased.	DDI-false
@DRUG$ (SSRIs): SSRIs (e.g., fluoxetine, @DRUG$, paroxetine, sertraline) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with 5-HT1 agonists.	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or @DRUG$, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval.	DDI-effect
Coadministration of @DRUG$ with 40 mg @DRUG$ tablets in epileptic patients lowered the nisoldipine plasma concentrations to undetectable levels .	DDI-mechanism
In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (efavirenz, nevirapine, @DRUG$, @DRUG$, or carbamazepine) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations.	DDI-false
Short-term pharmacokinetic studies have demonstrated that concomitant administration of @DRUG$ and Lodine  (etodolac capsules and tablets) results in reduced protein binding of warfarin, but there was no change in the clearance of free @DRUG$.	DDI-false
@DRUG$ , @DRUG$ And losartan: bosentan has no significant pharmacokinetic interactions with digoxin and nimodipine, and losartan has no significant effect on bosentan plasma levels.	DDI-false
@DRUG$ (e.g., Antiminth) - Taking piperazine and @DRUG$ together may decrease the effects of piperazine.	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , @DRUG$ , @DRUG$ , quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam) may have increased plasma concentrations when co-administered with saquinavir;	DDI-false
Bosentan is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as @DRUG$ and @DRUG$.	DDI-false
Other cardiovascular agents : enalapril and @DRUG$ IV were co-administered with beta-adrenerg blockers, methyldopa, nitrates, calcium blockers, hydralazine, @DRUG$ And digoxin without evidence of clinically significant adverse interactions.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum @DRUG$ , sucralfate , @DRUG$ The chewable/buffered tablets or paediatric powders, or products that contain calcium, iron or zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-false
@DRUG$: While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other @DRUG$.	DDI-false
@DRUG$ : @DRUG$ have been reported to enhance the effects of the oral anticoagulant warfarin or its derivatives .	DDI-false
Can use thyroid drugs (e.g. levothyroxine), iodine-containing products, antacids, @DRUG$ For example, famotidine, ranitidine and proton pump inhibitors (e.g. @DRUG$ , omeprazole ) .	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the @DRUG$ , doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ â€¢ with vincristine plus bleomycin) without antiretroviral therapy.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, @DRUG$, @DRUG$, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
@DRUG$ did not affect the conversion of losartan to the active metabolite after intravenous administration of losartan , and @DRUG$ After oral administration, treatment had no clinically significant effect.	DDI-false
@DRUG$ and moclobemide increased blood @DRUG$ at different times after the glucose overload.	DDI-false
Additive CNS depression may occur when @DRUG$ It is used concomitantly with other CNS depressants, including @DRUG$ , tranquilizers , and alcohol .	DDI-effect
Steady-state @DRUG$ plasma concentrations were 3- to 4-fold higher than in the absence of @DRUG$.	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, @DRUG$, estrogens, progestogens (e.g., in oral contraceptives).	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce hepatic metabolism @DRUG$ , phenytoin , @DRUG$ , nifedipine , chlordiazepoxide , diazepam , certain tricyclic antidepressants , lidocaine , theophylline and metronidazole , thereby delaying elimination and increasing blood levels of these drugs .	DDI-false
Theophylline: The pharmacokinetics of theophylline (@DRUG$ 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of @DRUG$ (400 mg) in 6 healthy subjects.	DDI-false
@DRUG$ products containing iron or zinc, @DRUG$ or sucralfate should not be administered concomitantly with , or within 2 hours of , the administration of norfloxacin , because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin .	DDI-false
Although BETAGAN alone has little or no effect on pupil size, mydriasis from concomitant therapy with @DRUG$ and @DRUG$ may occur .	DDI-effect
CONCLUSIONS: Macrolide antibiotics inhibit the metabolism of @DRUG$ that are metabolized by CYP3A4 (i.e., atorvastatin, @DRUG$, lovastatin, simvastatin).	DDI-false
Therefore, if hydrochlorothiazide and @DRUG$ are used concomitantly , the patient should be observed closely to determine if the desired effect of the @DRUG$ is obtained .	DDI-false
The following are examples of substances that can reduce the hypoglycaemic effect: corticosteroids, niacin, danazol, @DRUG$ , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , @DRUG$ , estrogens , progestogens ( e.g. , in oral contraceptives ) .	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, @DRUG$, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-false
The possibility of hypotensive effects with @DRUG$ can be minimized by either discontinuing the diuretic or increasing the salt intake approximately one week prior to initiation of treatment with captopril (@DRUG$ tablets, USP) or initiating therapy with small doses (6.25 or 12.5 mg).	DDI-false
@DRUG$ ) and many that are substrates for P450 2D6 ( many other antidepressants , phenothiazines , and the @DRUG$ propafenone and flecainide ) .	DDI-false
Antidepressants , tricyclic @DRUG$ The effect of tricyclic antidepressants may be increased or @DRUG$ ;	DDI-effect
@DRUG$ : @DRUG$ causes a slight decrease ( about 10 % ) in steady-state valproate concentrations .	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of @DRUG$ may be affected by the known CYP3A4 inducers (such as phenytoin, @DRUG$, rifampin), CYP3A4 inhibitors (azole antimycotics e.g., ketoconazole;	DDI-mechanism
Injection : Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when with ethyl alcohol, phenothiazine, @DRUG$ An increased incidence of sedation, hallucinations and irrational behaviour was observed with co-administration of scopolamine with injectable lorazepam.	DDI-false
Compounds that have been tested in man include antipyrine , @DRUG$ , propranolol , @DRUG$ No clinically significant interactions and warfarin were found.	DDI-false
The co-administration of Natrecor with IV vasodilators such as nitroglycerin, @DRUG$, @DRUG$, or IV ACE inhibitors has not been evaluated (these drugs were not co-administered with Natrecor in clinical trials).	DDI-false
@DRUG$: @DRUG$ may delay intestinal absorption of phenytoin;	DDI-false
Drugs With A Narrow Therapeutic Index @DRUG$ A single dose of @DRUG$ 3 mg did not affect the pharmacokinetics of digoxin measured in steady state after 0.5 mg twice daily for one day and 0.25 mg daily for the next 6 days.	DDI-false
Protein Binding In vitro, diclofenac interferes minimally or not at all with the protein binding of salicylic acid (20% decrease in binding), @DRUG$, @DRUG$ (10% decrease in binding), or warfarin.	DDI-false
Acidifying agents: @DRUG$ (guanethidine, reserpine, glutamic acid HCl, ascorbic acid, fruit juices, etc.) lower absorption of @DRUG$.	DDI-mechanism
@DRUG$ Co-administered with quinidine elevations @DRUG$ The serum concentration by 33% after two days.	DDI-false
A potential interaction between oral @DRUG$ and oral @DRUG$ leading to severe hypoglycemia has been reported.	DDI-effect
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, @DRUG$, protease inhibitors, quinidine, and verapamil.	DDI-false
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral @DRUG$ , and supplemental oxygen . In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or digoxin in whom therapy with FLOLAN was initiated , apparent oral clearance values for @DRUG$ ( n = 23 ) and digoxin ( n = 30 ) were decreased by 13 % and 15 % , respectively , on the second day of therapy and had returned to baseline values by day 87 .	DDI-false
Estrogens, including oral @DRUG$: Estrogens may decrease the hepatic metabolism of certain @DRUG$, thereby increasing their effect.	DDI-false
Other strong inhibitors of CYP3A4 ( e.g. , itraconazole , clarithromycin , nefazodone , @DRUG$ , @DRUG$ , nelfinavir ) would be expected to behave similarly .	DDI-false
Although specific studies have not been performed , coadministration with drugs that are mainly metabolized by CYP3A4 ( eg , calcium channel blockers , dapsone , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , @DRUG$ Elevated plasma concentrations may occur when pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam are co-administered. @DRUG$ ;	DDI-mechanism
apomorphine - prior ingestion of @DRUG$ may decrease the emetic response to @DRUG$ in the treatment of poisoning.	DDI-effect
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, @DRUG$, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with CNS depressants (alcohol, @DRUG$, @DRUG$, sedatives, anesthetics) should be considered.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
@DRUG$ decreased the hyperuricemic effect of @DRUG$.	DDI-effect
Selective Serotonin Reuptake Inhibitors ( SSRIs ): SSRIs ( e.g. , @DRUG$ , fluvoxamine , @DRUG$ , sertraline ) have been rarely reported to cause weakness , hyperreflexia , and incoordination when coadministered with 5-HT1 agonists .	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, @DRUG$ , barbiturates, MAO inhibitors, and other antidepressants. When @DRUG$ It is administered concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations and irrational behaviour has been observed.	DDI-false
Antacids : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and simethicone ) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone , suggesting that antacids may impair absorption of @DRUG$.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, @DRUG$, tranquilizers (e.g., @DRUG$), general anesthetics, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
Ethosuximide: @DRUG$ may delay intestinal absorption of @DRUG$.	DDI-mechanism
@DRUG$ and rifampin should not beadministered concomitantly becausedecreases in @DRUG$ plasmaconcentrations may reduce the efficacy ofthe drug.	DDI-false
Corticosteroids , Methylxanthines and Diuretics : Concomitant treatment with @DRUG$ , @DRUG$ Diuretics may potentiate a possible hypocalemic effect of beta2-agonists.	DDI-false
Injection: Lorazepam injection, like other injectable benzodiazepines, produces depression of the central nervous system when administered with ethyl alcohol, phenothiazines, @DRUG$, MAO inhibitors, and other antidepressants.When @DRUG$ is used concomitantly with injectable lorazepam, an increased incidence of sedation, hallucinations, and irrational behavior has been observed.	DDI-false
Antidiabetics: Because @DRUG$ may increase blood glucose concentrations, dosage adjustments of @DRUG$ may be required.	DDI-effect
@DRUG$ Co-administration of ritonavir and VIRACEPT resulted in an increase in nelfinavir plasma AUC of 152% and very small changes in @DRUG$ plasma A.C.	DDI-false
Magnesium- and/or aluminum-containing antacids, products containing ferrous sulfate (@DRUG$), multivitamin preparations containing zinc or other metal cations, or Videx (didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after @DRUG$.	DDI-advise
- Vitamin K ( e.g. , @DRUG$ , @DRUG$ ) Use of sulfapyridine with these medicines may increase the chance of side effects affecting the blood	DDI-false
Nephrotoxic agents : Concomitant administration of VISTIDE and agents with nephrotoxic potential [e.g., intravenous aminoglycosides (e.g., tobramycin, gentamicin, and amikacin), amphotericin B, foscarnet, intravenous @DRUG$, @DRUG$, and non-steroidal anti-inflammatory agents] is contraindicated.	DDI-false
@DRUG$: May decrease renal tubular secretion of @DRUG$ resulting in increased blood levels and/or ampicillin toxicity.	DDI-mechanism
The compounds in these categories lead to a reduced efficacy of bromocliptin mesylate : @DRUG$ , haloperidol , metoclopramide , @DRUG$.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$ , and @DRUG$.	DDI-false
The effects of DCG-IV and @DRUG$ upon @DRUG$ (PCP)-induced locomotion and behavioral changes in mice .	DDI-false
@DRUG$ : Isoniazid is known to slow the metabolism of carbamazepine and increase its serum levels Carbamazepine levels should be determined prior to concurrent administration with @DRUG$ , signs and symptoms of carbamazepine toxicity should be monitored closely , and appropriate dosage adjustment of the anticonvulsant should be made .	DDI-false
Magnesium- and/or aluminum-containing antacids , products containing @DRUG$ (iron), multivitamin preparations containing zinc or other metal cations; or @DRUG$ ( didanosine ) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after FACTIVE .	DDI-false
however, no deleterious interactions were seen when @DRUG$ was administered after @DRUG$, inhalational anesthetics, muscle relaxants and muscle relaxant antagonists administered in conjunction with sedation or anesthesia.	DDI-false
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, @DRUG$, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or @DRUG$ Antacids, sucralfate, VIDEX chewing/buffering tablets or paediatric powders, or products containing calcium, @DRUG$ Zinc can significantly reduce the absorption of ciprofloxacin, resulting in serum and urine levels significantly lower than desired.	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, ethionamide, glutethimide, gold, hydralazine, @DRUG$, @DRUG$, metronidazole, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
Acetazolamide, some @DRUG$ ) increase the concentration of the non-ionized species of the @DRUG$ molecule , thereby decreasing urinary excretion .	DDI-mechanism
@DRUG$ In a study conducted in healthy volunteers, mean steady-state lithium plasma levels increased by approximately 17% in patients receiving lithium 450 mg twice daily. @DRUG$ 200 mg BID as compared to subjects receiving lithium alone .	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of bosentan and the oral @DRUG$ Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
@DRUG$ , ampicillin, oxacillin, chlortetracycline, doxycycline, cephalothine, @DRUG$ , and sulfamethoxazole have no influence in vitro on the protein binding of diclofenac in human serum .	DDI-false
Caution should be exercised if an HMG-CoA reductase inhibitor is administered concomitantly with drugs that may decrease the levels or activity of endogenous steroid hormones , such as @DRUG$ , @DRUG$ ==References====External links==	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, @DRUG$, propoxyphene, salicylates, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
However, interactions may be expected, and @DRUG$ should NOT be used in combination with other @DRUG$.	DDI-advise
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain @DRUG$ (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), @DRUG$ salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, @DRUG$ GI motility agents: cisapride	DDI-false
Therefore, EXTREME CAUTION should be exercised when administering @DRUG$ to patients receiving cyclopropane or @DRUG$.	DDI-advise
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants : FORADIL should be administered with extreme caution in patients being treated with @DRUG$ or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents .	DDI-false
This drug may interact with alcohol or other @DRUG$ (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
@DRUG$: @DRUG$, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of levetiracetam 1000 mg twice daily.	DDI-false
@DRUG$: @DRUG$ interferes with renal tubular secretion of ciprofloxacin and produces an increase in the level of ciprofloxacin in serum.	DDI-false
Analysis of the concentration of @DRUG$ following ultracentrifugation indicated that there is rapid equilibration of budesonide between the @DRUG$ and aqueous phase.	DDI-false
May interact @DRUG$ (altered hypo-prothrombinemic effect), barbiturates, rifampin and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of diethylstilbestrol), @DRUG$ (increased effect of corticosteroids).	DDI-false
@DRUG$ and @DRUG$ Elevated blood sugar at different times after glucose overload.	DDI-false
@DRUG$: Coadministration of rifabutin and @DRUG$ resulted in a 32% decrease in nelfinavir plasma AUC and a 207% increase in rifabutin plasma A.C.	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, amiodarone, @DRUG$, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, @DRUG$, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with TAXOL should be premedicated with corticosteroids (such as @DRUG$), diphen-hydramine and H2 antagonists (such as cimetidine or @DRUG$).	DDI-false
Erythromycin Co-administration of felodipine (@DRUG$) with @DRUG$ resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of felodipine.	DDI-false
@DRUG$: Elevated @DRUG$ levels have been reported in postmarketing experience when SUPRAX is administered concomitantly.	DDI-false
Therapeutic concentrations of digoxin, warfarin, ibuprofen, naproxen, @DRUG$ , acetaminophen , phenytoin andtolbutamide did not alter @DRUG$ protein binding .	DDI-false
Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, @DRUG$, Phenytoin, Phenobarbitol, carbamazepine, Rifabutin, Rifampin, Ritanovir, Saquinavir.	DDI-false
Hypotension   Patients on @DRUG$ Therapy: Patients on diuretics and especially those in whom @DRUG$ therapy was recently instituted, as well as those on severe dietary salt restriction or dialysis, may occasionally experience a precipitous reduction of blood pressure usually within the first hour after receiving the initial dose of captopril.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, Innovar Vet, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with @DRUG$ or @DRUG$ than with pentobarbital.	DDI-false
Ritonavir (600 mg b.i.d.) co-administered with Vardenafil 5 mg resulted in a 49-fold increase in @DRUG$ AUC and a 13-fold increase in @DRUG$ Cmax.	DDI-false
- The action of sulphonylureas and insulin may be enhanced by @DRUG$ or @DRUG$.	DDI-false
Antifungals: In vitro and/or in vivo data indicate that @DRUG$, itraconazole, and oral ketoconazole markedly inhibit the metabolism of cisapride, which can result in an increase in plasma @DRUG$ levels and prolongation of the QT interval on the ECG.	DDI-false
acetaminophen/theophylline, @DRUG$/@DRUG$, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
Steady-state serum concentrations of @DRUG$ are reported to fluctuate significantly when @DRUG$ The medication is either added or removed from the medication regimen.	DDI-mechanism
Although these results do not indicate a significant interaction between TORADOL and warfarin or @DRUG$ , the management of @DRUG$ to patients taking anticoagulants should be done extremely cautiously , and patients should be closely monitored .	DDI-false
Prednisone/prednisolone : Rofecoxib did not have any clinically important effect on the pharmacokinetics of @DRUG$ or @DRUG$.	DDI-false
Lithium: Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving concomitant @DRUG$ and @DRUG$ therapy.	DDI-effect
In contrast, the management of @DRUG$ The pharmacokinetics of a 300 mg dose of @DRUG$ have not been altered (butorphanol QID 1 mg).	DDI-false
Magnesium/Aluminum-containing Antacid Products: Absorption of @DRUG$ is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.	DDI-false
Potential drug interactions between @DRUG$  and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and valproate) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies.	DDI-false
Plasma concentrations (AUC 0-24 hrs) of erythromycin decreased 15% with coadministration of @DRUG$ relative to that observed with @DRUG$ alone.	DDI-false
@DRUG$ Reports suggest that NSAIDs may diminish the antihypertensive effect of @DRUG$.	DDI-false
@DRUG$ : Coadministration of @DRUG$ This resulted in an increase of 24% in plasma concentrations of almotriptan.	DDI-false
The effect of clonazepam on the pharmacokinetics of other medicinal products : clonazepam does not appear to alter the pharmacokinetics of clonazepam @DRUG$ , carbamazepine, or @DRUG$.	DDI-false
@DRUG$/Acetaminophen : Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between Argatroban and concomitantly administered @DRUG$ ( 162.5 mg orally administered 26 and 2 hours before the start of argatroban 1 g/kg/min for 4 hours) or acetaminophen ( 1000 mg orally administered 12, 6 and 0 hours before and 6 and 12 hours after the start of argatroban 1.5 g/kg/min for 18 hours).	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, @DRUG$, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$: @DRUG$ are known to cause osteoporosis.	DDI-false
In addition , results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance ( efavirenz , nevirapine , @DRUG$ , @DRUG$ CANCIDAS may lead to clinically significant reductions in caspofungin concentrations.	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and retinoids, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of @DRUG$ and EGF.	DDI-effect
Molecular basis for the selective toxicity of @DRUG$ for yeast and @DRUG$ for animal cells.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , @DRUG$ ), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., orally) @DRUG$ ) .	DDI-false
Potential drug interactions between Keppra   and other AEDs ( carbamazepine , gabapentin , lamotrigine , @DRUG$ , phenytoin , primidone and valproate ) were also assessed by evaluating the serum concentrations of @DRUG$ These AEDs during placebo-controlled clinical trials.	DDI-false
Other medicinal products Interactions: No pharmacokinetic interactions between vardenafil and the following medicines have been observed: glyburide, warfarin, @DRUG$ , @DRUG$ , and ranitidine .	DDI-false
While no in vivo drug-drug interaction studies were conducted between @DRUG$ and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, @DRUG$, and barbiturates) would be expected to decrease estazolam concentrations.	DDI-mechanism
Concomitant administration of fenofibrate (equivalent to 145mg @DRUG$) with @DRUG$ (40 mg) once daily for 10 days has been shown to increase the mean Cmax and AUC values for pravastatin by 36% (range from 69% decrease to 321% increase) and 28% (range from 54% decrease to 128% increase), respectively, and for 3 -hydroxy-iso-pravastatin by 55% (range from 32% decrease to 314% increase) and 39% (range from 24% decrease to 261% increase), respectively in 23 healthy adults.	DDI-mechanism
@DRUG$: (oral agents and @DRUG$) - dosage adjustment of the antidiabetic drug may be required.	DDI-false
@DRUG$: In an interaction study of rheumatoid arthritis patients taking methotrexate, CELEBREX did not have a significant effect on the pharmacokinetics of @DRUG$.	DDI-false
Imidazoles (e. g., ketoconazole, miconazole, @DRUG$, fluconazole, etc.): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
The similarity of the @DRUG$ -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the TYSABRI  dose to maintain safety, General).	DDI-false
- Anabolic steroids ( nandrolone [ e.g. , Anabolin ] , oxandrolone [ e.g. , Anavar ] , oxymetholone [ e.g. , @DRUG$ ] , @DRUG$ (e.g. Winstrol ]) or	DDI-false
Compounds that have been tested in man include @DRUG$, digoxin, propranolol, @DRUG$, and warfarin and no clinically meaningful interactions were found.	DDI-false
Lithium-A study on the interaction of @DRUG$ with @DRUG$ has not been conducted .	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., barbiturates, phenytoin, carbamazepine, @DRUG$) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	DDI-mechanism
While all selective serotonin reuptake inhibitors ( SSRIs), e.g., citalopram, escitalopram, @DRUG$ , @DRUG$ , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
@DRUG$ and Tricyclic Antidepressants: FORADIL should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-false
however, 150 mg of @DRUG$ q12h for 3 days increased the ceftibuten C max by 23% and @DRUG$ AUC by 16%.	DDI-mechanism
Anticonvulsants (Phenytoin): Steady state plasma exposure (AUC) of @DRUG$ (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of @DRUG$ (a CYP 3A4 inducer).	DDI-mechanism
In clinical studies with fondaparinux, concomitant use of oral anticoagulants ( warfarin), platelet inhibitors (acetylsalicylic acid) and NSAIDs ( @DRUG$ ) , and @DRUG$ did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium .	DDI-false
Garlic Capsules Garlic capsules should not be used while taking @DRUG$ (@DRUG$) as the sole protease inhibitor due to the risk of decreased saquinavir plasma concentrations.	DDI-false
No dose adjustment of @DRUG$ It is necessary, but increased effects of @DRUG$ should be considered .	DDI-false
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, @DRUG$ Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as @DRUG$ (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with ardeparin.	DDI-false
Central nervous system depressants : Co-administration of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, @DRUG$ ( e.g. , @DRUG$ ) , general anesthetics , phenothiazines , skeletal muscle relaxants , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
@DRUG$: Coadministration of single doses of eszopiclone 3 mg and @DRUG$ 20 mg daily for 7 days produced no pharmacokinetic or pharmacodynamic interaction.	DDI-false
Magnesium/@DRUG$-containing Antacid Products: Absorption of zalcitabine is moderately reduced (approximately 25%) when coadministered with magnesium/aluminum-containing @DRUG$.	DDI-false
@DRUG$ : In a single-dose interaction study in NIDDM subjects , decreases in @DRUG$ AUC and Cmax were observed but were very variable.	DDI-false
Moreover, additional interaction studies with @DRUG$ and propranolol have not demonstrated any effect on fluvastatin plasma levels, and administration to a patient population chronically receiving @DRUG$ resulted in no difference in the extent of bioavailability of digoxin relative to control data.	DDI-false
Therefore when @DRUG$ are administered concomitantly with @DRUG$ their dosage should be reduced.	DDI-advise
Then, the effects of metabotropic glutamate receptor (mGluR) agonists, @DRUG$ and @DRUG$, on the above behavioral changes induced by PCP were found.	DDI-false
As with other antipsychotic agents, it should be noted that HALDOL may be capable of potentiating @DRUG$ such as anesthetics, @DRUG$, and alcohol.	DDI-false
May interact with thyroid medication (e.g., @DRUG$), iodine-containing products, @DRUG$, H2-antagonists (e.g., famotidine, ranitidine), and proton pump inhibitors (e.g., lansoprazole, omeprazole).	DDI-false
Urinary acidifying agents These agents (ammonium chloride, @DRUG$, etc.) increase the concentration of the ionized species of the @DRUG$ molecule, thereby increasing urinary excretion.	DDI-mechanism
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect flupenthixol pharmacodynamics - Arecoline - Eproxindine - Ethanol : Flupenthixol and @DRUG$ cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of @DRUG$	DDI-false
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with alprazolam for the following : @DRUG$ and paroxetine .	DDI-false
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, @DRUG$ , diazepam , certain tricyclic antidepressants , lidocaine , theophylline and @DRUG$ This delays elimination and increases blood levels of these drugs.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, @DRUG$), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, progestogens (e.g., in oral contraceptives).	DDI-false
Stavudine and Zidovudine @DRUG$ can antagonize the in vitro antiviral activity of @DRUG$ and zidovudine against HIV.	DDI-effect
Probenecid : May decrease renal tubular secretion of @DRUG$ resulting in increased blood levels and/or @DRUG$ toxicity .	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists ( Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS , 3020 ( 91 % ) patients receiving INSPRA 25 to 50 mg also received ACE inhibitors or angiotensin II receptor antagonists ( @DRUG$/@DRUG$ ) .	DDI-false
Population pharmacokinetic analyses revealed that MTX, NSAIDs, @DRUG$, and @DRUG$ did not influence abatacept clearance.	DDI-false
It differs structurally from the other currently available @DRUG$ ( @DRUG$ , simvastatin, and pravastatin), resulting in unique biopharmaceutical properties compared to the other active substances in this class.	DDI-false
The availability of potent non-nucleoside reverse transcriptase inhibitor (@DRUG$)-based regimens for @DRUG$ therapy and concerns regarding protease inhibitor (PI)-related metabolic disturbances have led to significant shifts in treatment practices in HIV infection.	DDI-false
Drug interaction studies have shown that esomeprazole does not have any clinically significant interactions with phenytoin , warfarin , @DRUG$ , @DRUG$ or amoxicillin .	DDI-false
@DRUG$ Inhibitors Felodipine is metabolized by @DRUG$.	DDI-false
While all the selective serotonin reuptake inhibitors ( SSRIs ) , e.g. , fluoxetine , sertraline , @DRUG$ , and @DRUG$ , inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
These increased exposures of @DRUG$ and ethinyl estradiol should be taken into consideration when selecting an oral @DRUG$ for women taking valdecoxib.	DDI-false
In a clinical pharmacology study, @DRUG$ or sulindac was administered to hypertensive patients receiving @DRUG$.	DDI-false
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with @DRUG$ (alcohol, barbiturates, @DRUG$, sedatives, anesthetics) should be considered.	DDI-false
Both @DRUG$ Nevirapine was treated with triple therapy with: @DRUG$ Indinavir for 48 weeks as initial therapy, with similar response observed with nevirapine regimens and superiority observed with efavirenz.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, @DRUG$ , azathioprine , @DRUG$ , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, @DRUG$, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
These drugs include the @DRUG$ and other diuretics , @DRUG$ , phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isonazide.	DDI-false
The majority of patients in RA clinical trials received one or more of the following concomitant studies: @DRUG$ : MTX , NSAIDs , corticosteroids , TNF blocking agents , azathioprine , chloroquine , @DRUG$ , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .	DDI-false
Oral @DRUG$: Coadministration of @DRUG$ and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%.	DDI-false
@DRUG$/prednisolone: Rofecoxib did not have any clinically important effect on the pharmacokinetics of prednisolone or @DRUG$.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$, presumably through inhibition of CYP3A: @DRUG$, fluvoxamine, cimetidine, diltiazem, isoniazide, and some macrolide antibiotics.	DDI-mechanism
Based on these data, @DRUG$ should not be used in patients on @DRUG$ therapy .	DDI-advise
The following are examples of substances that may reduce the blood-glucose-lowering effect : @DRUG$ , niacin, danazol, diuretics, sympathomimetics (e.g., epinephrine, salbutamol, terbutaline), isoniazide, @DRUG$ Somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -@DRUG$ blocking agents (e.g., propranolol, a CYP3A4 inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
In addition, the results of regression analyses of the patient's pharmacokinetic data suggest that the concomitant use of other inducers of drug clearance (efavirenz, nevirapine, @DRUG$ , dexamethasone , or @DRUG$ ) with CANCIDAS may result in clinically meaningful reductions in caspofungin concentrations .	DDI-false
Substances that are potent inhibitors of CYP3A4 activity (e.g. ketoconazole and @DRUG$ ) Reduction of gefitinib metabolism and increase @DRUG$ plasma concentrations .	DDI-mechanism
Methotrexate Renal tubular transport of methotrexate may be inhibited by concomitant administration of @DRUG$, potentially leading to increased plasma levels of @DRUG$.	DDI-false
In clinical trials , FLOLAN was used with digoxin , diuretics , anticoagulants , oral vasodilators , and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ On the second day of therapy, apparent values for oral clearance of furosemide ( n = 23 ) and digoxin ( n = 30 ) were reduced by 13 % and 15 % respectively and were returned to baseline by day 87.	DDI-false
Pyrantel (e.g., Antiminth) - Taking piperazine and @DRUG$ together may decrease the effects of @DRUG$.	DDI-false
Quinolones, including @DRUG$, may enhance the effects of oral anticoagulants, including @DRUG$ or its derivatives or similar agents.	DDI-effect
These drugs include the thiazides and other diuretics , @DRUG$ , phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, @DRUG$ ==References====External links==	DDI-false
Potential interactions between @DRUG$ , a substrate of CYP3A4 and protease inhibitors (ritonavir, @DRUG$ , indinavir , and nelfinavir ) , which are substrates and/or inhibitors of CYP3A4 , have not been evaluated in clinical trials .	DDI-false
@DRUG$/theophylline, lidocaine/quinidine, phenobarbital/@DRUG$, phenobarbital/valproic acid, quinidine/lidocaine, theophylline/acetaminophen, and valproic acid/phenobarbital.	DDI-false
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, cerivastatin sodium was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, @DRUG$, @DRUG$, and nonsteroidal anti-inflammatory drugs (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Co-medicines that induce CYP3A4 (e.g. dexamethasone, phenytoin, @DRUG$ , @DRUG$ , phenobarbital or St.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, @DRUG$, and anakinra.	DDI-false
â€¢ Drug/laboratory test interaction Fosinopril may cause false low serum measurement @DRUG$ levels with the Digi- Tab   RIA Kit for @DRUG$.	DDI-false
@DRUG$ : In a study conducted in healthy subjects, mean steady-state @DRUG$ 17% of patients receiving lithium 450 mg twice daily increased with CELEBREX 200 mg twice daily compared to patients receiving lithium alone.	DDI-false
These drugs include: @DRUG$ and other @DRUG$ , corticosteroids , phe-nothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , sympathomimet-ics , calcium channel blocking drugs , and isoniazid .	DDI-false
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, disopyramide, quinine, @DRUG$, quinidine, @DRUG$, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, @DRUG$, @DRUG$, somatostatin analog (e.g., octreotide), sulfonamide antibiotics.	DDI-false
@DRUG$: Chloramphenicol, erythromycins, sulfonamides, or tetracyclines may interfere with the bactericidal effect of @DRUG$.	DDI-false
ACE Inhibitors and Angiotensin II Receptor Antagonists (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving @DRUG$ 25 to 50 mg also received ACE inhibitors or @DRUG$ (ACEI/ARB).	DDI-false
@DRUG$ taken concomitantly with @DRUG$ The plasma concentrations of procainamide and n-acetylprocainamide are increased by 55% and 33% respectively for less than seven days.	DDI-false
@DRUG$ (eg, @DRUG$) and other drugs, including ether, succinylcholine, gallamine, decamethonium and sodium citrate, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with Coly-Mycin M Parenteral.	DDI-false
Corticosteroids, Methylxanthines and Diuretics: Concomitant treatment with xanthine derivatives, @DRUG$, or diuretics may potentiate a possible hypokalemic effect of  @DRUG$	DDI-effect
Non-steroidal Anti-inflammatory Drugs: In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of loop, potassium-sparing and @DRUG$.	DDI-effect
Elevated serum levels of @DRUG$ It was used via a concomitant use of @DRUG$ with norfloxacin .	DDI-false
The hypoglycaemic effect of sulphonylureas can be enhanced by certain drugs, including nonsteroidal anti-inflammatory drugs and other medicines that are highly protein bound, salicylates, sulphonamides, chloramphenicol, @DRUG$ , coumarins , monoamine oxidase inhibitors , and @DRUG$.	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, @DRUG$, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
Central Nervous System Depressants : The concomitant use of DURAGESIC   ( fentanyl transdermal system ) with other @DRUG$ , including but not limited to other opioids, sedatives, hypnotic agents, sedatives (e.g. benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$ , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
Antihypertensives: Amiodarone should be used with caution in patients receiving  -receptor blocking agents (e.g., propranolol, a @DRUG$ inhibitor) or calcium channel antagonists (e.g., verapamil, a @DRUG$ substrate, and diltiazem, a CYP3A4 inhibitor) because of the possible potentiation of bradycardia, sinus arrest, and AV block;	DDI-false
Central nervous system depressants: Concomitant use of DURAGESIC (Fentanyl transdermal system) with others @DRUG$ , including but not limited to other opioids , sedatives , hypnotics , @DRUG$ â€¢ (e.g. benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants and alcohol, may cause respiratory depression, hypotension and deep sedation, or may lead to coma or death.	DDI-false
This drug may interact with alcohol or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), @DRUG$ or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines), and monoamine oxidase (MAO) inhibitors (concurrent use with @DRUG$ may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
- @DRUG$ ( e.g. , @DRUG$ The use of sulfapyridin with these medicines may increase the likelihood of side effects of these medicines.	DDI-false
@DRUG$ While studies have not shown diclofenac to interact with anticoagulants of the warfarin type, caution should be exercised, however, since interactions with other @DRUG$ have been seen.	DDI-false
Patients receiving other narcotic analgesics, general anesthetics, phenothiazines, @DRUG$, sedative-hypnotics, tricyclic antidepressants or other @DRUG$ (including alcohol) concomitantly with DILAUDID may exhibit an additive CNS depression.	DDI-false
Folic acid in large amounts may counteract the antiepileptic effect of @DRUG$ , phenytoin and @DRUG$ , and increase the frequency of seizures in susceptible pediatric patients .	DDI-false
Multiple-dose administration of the potent CYP3A4 inducer @DRUG$ (600 mg every 24 hours, q24h, for 14 days), however, reduced @DRUG$ Cmax and AUC by approximately 80%.	DDI-mechanism
The risk of myopathy during treatment with drugs of this class is increased with concurrent administration of cyclosporine , fibric acid derivatives , @DRUG$ ( nicotinic acid ) , erythromycin , @DRUG$.	DDI-false
Patients receiving other narcotic analgesics , general anesthetics , phenothiazines , tranquilizers , sedative-hypnotics , tricyclic antidepressants or other CNS depressants ( including @DRUG$ ) concomitantly with @DRUG$ It may have additive CNS depression.	DDI-effect
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, @DRUG$, disulfiram, ethionamide, glutethimide, gold, hydralazine, iodoquinol, isoniazid, metronidazole, @DRUG$, phenytoin, ribavirin, and vincristine.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and @DRUG$) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of fosinopril.	DDI-false
Epinephrine should not be administered concomitantly with other @DRUG$ (such as @DRUG$) because of possible additive effects and increased toxicity.	DDI-false
In clinical studies with fondaparinux, the concomitant use of oral anticoagulants ( @DRUG$ ) , platelet inhibitors ( acetylsalicylic acid ) , @DRUG$ Piroxicam and digoxin did not significantly affect the pharmacokinetics/pharmacodynamics of fondaparinux sodium.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, @DRUG$, @DRUG$, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and quinidine.	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, magnesium hydroxide, and simethicone) with @DRUG$ reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that @DRUG$ may impair absorption of fosinopril.	DDI-false
When CANCIDAS is co-administered with inducers of drug clearance, such as efavirenz, nevirapine, @DRUG$, @DRUG$, or carbamazepine, use of a daily dose of 70 mg of CANCIDAS should be considered	DDI-false
This appears to be the only clinically relevant interaction of this kind with @DRUG$ Although theoretically, the concomitant use of other drugs is known to alter the heart conduction (e.g., anti-arrhythmic or beta-adrenergic blockers, calcium channel blockers, antihistamines or H1 blockers, @DRUG$ ) could also contribute to an extension of the QTc interval.	DDI-effect
May interact with thyroid medication ( e.g. , levothyroxine ) , iodine-containing products , @DRUG$ H2 antagonists (e.g. @DRUG$ , ranitidine) and proton pump inhibitors (e. g. lansoprazole, omeprazole).	DDI-false
Acetaminophen, @DRUG$, phenobarbital, @DRUG$, theophylline, and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus @DRUG$) without receiving antiretroviral therapy.	DDI-false
Nevertheless, caution is indicated in the co-administration of @DRUG$ with any of the @DRUG$ and also in switching from one class to the other.	DDI-advise
In the presence of this @DRUG$ , larger doses of adenosine may be required or @DRUG$ may not be effective .	DDI-advise
Antihypertensive Medications and @DRUG$ : The following adverse events were experienced more commonly in patients receiving concomitant @DRUG$ Hypotension 10% vs. 4%, myocardial infarction 3% vs. 1%, severe pneumonia 5% vs. 3%, severe falls 9% vs. 3%, bone and joint injuries 6% vs. 2%.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (fentanyl transdermal system) with other @DRUG$, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general anesthetics, phenothiazines, skeletal muscle relaxants, and @DRUG$, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related , systemic , non-Hodgkin lymphoma ( HIV-NHL ) , the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide , doxorubicin , vincristine , and prednisone ( CHOP ) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen ( i.e. , cyclophosphamide , doxorubicin , @DRUG$ , and prednisone with vincristine plus @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
Dopamine Antagonists: Since apomorphine is a dopamine agonist, it is possible that dopamine antagonists, such as the neuroleptics (@DRUG$, @DRUG$, thioxanthenes) or metoclopramide, may diminish the effectiveness of APOKYN.	DDI-false
The similarity of the TYSABRI -associated adverse event profile between Study 1 (without co-administered @DRUG$ ) and Study 2 (with co-administered AVONEX ) indicates that this alteration in clearance does not necessitate reduction of the @DRUG$  dose to maintain safety, General).	DDI-false
These results suggest that both dexamethasone and dexamethasone @DRUG$ , and possibly other glucocorticoids and retinoids, the proliferation of prostate epithelium can be regulated by a dose-dependent change in activity of @DRUG$ and EGF .	DDI-effect
Special care should be taken when: @DRUG$ Because there are contradictory results for the effect of colestipolhydrochloride on the availability of @DRUG$ and digitoxin .	DDI-false
@DRUG$ ( @DRUG$ Serum concentrations and pharmacological effects may be increased.	DDI-false
The following are examples of drugs known to inhibit the metabolism of other related @DRUG$ , presumably through inhibition of CYP3A : nefazodone , fluvoxamine , @DRUG$ Diltiazem, isoniazid, and some macrolide antibiotics.	DDI-mechanism
The absorption of tetracycline, furosemide, penicillin G, @DRUG$, and gemfibrozil was significantly decreased when given simultaneously with @DRUG$;	DDI-mechanism
Drug interaction studies have shown that @DRUG$ does not have any clinically significant interactions with phenytoin, warfarin, quinidine, clarithromycin or @DRUG$.	DDI-false
@DRUG$ The activity of other @DRUG$ can be increased.	DDI-effect
@DRUG$ â€¢ Concomitant use of indinavir with @DRUG$ This resulted in an 83% increase in nelfinavir plasma AUC and an 51% increase in indinavir plasma AC.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, @DRUG$, diclofenac, doxycycline, @DRUG$, imatinib, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , @DRUG$ , anticonvulsants , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as @DRUG$ In addition, quinolones anti-infections with no evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ toxicity has been reported to have occurred in a patient on chronic @DRUG$ treatment following the initiation of diclofenac therapy .	DDI-false
@DRUG$ Co-administration of moclobemid resulted in a decrease in @DRUG$ clearance and an increase in Cmax of approximately 6 % .	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been used in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, @DRUG$ , anticonvulsants , @DRUG$ , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Data from in vitro studies of benzodiazepines other than alprazolam suggest a possible drug interaction for the following : @DRUG$ , @DRUG$ , amiodarone, nicardipine, and nifedipine.	DDI-false
- antidiabetic medicines, orally (diabetes medicines you take through your mouth) use of oral antidiabetic medicines with @DRUG$ The likelihood of side effects affecting the blood and/or side effects or oral @DRUG$	DDI-false
In vitro and/or in vivo data indicate that fluconazole, @DRUG$ , and oral ketoconazole significantly inhibits the metabolism of cisapride, which may lead to an increase in plasma @DRUG$ The concentrations and prolongation of the QT interval on the ECG.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as ketoconazole , @DRUG$ , ritonavir , @DRUG$ , saquinavir, erythromycin, etc.) is indicated, reduction of budesonide dose should be considered.	DDI-false
Use with @DRUG$ : The use of @DRUG$ To control hypertension in patients with azathioprine, severe leukopenia has been reported.	DDI-false
Antacids : In a clinical pharmacology study, the concomitant use of a @DRUG$ - (aluminium hydroxide, magnesium hydroxide and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat given as compared to fosinopril alone, suggesting that: @DRUG$ may impair absorption of fosinopril .	DDI-false
The action of the @DRUG$ may be potentiated by anticonvulsants , antihistamines , alcohol , barbiturates , @DRUG$ , narcotics , phenothiazines , psychotropic medications , or other drugs that produce CNS depression .	DDI-effect
Drugs That Should Not Be Coadministered With @DRUG$ Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: @DRUG$ Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-advise
Warfarin : @DRUG$ 3 mg administered daily for 5 days did not affect the pharmacokinetics of (R)- or @DRUG$ , nor were there any changes in the pharmacodynamic profile ( prothrombin time ) following a single 25 mg oral dose of warfarin	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, @DRUG$, thyroid products, estrogens, oral contraceptives, @DRUG$, nicotinic acid, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high-dose PROLEUKIN and antineoplastic agents, in particular: @DRUG$ , cis-platinum , tamoxifen and @DRUG$.	DDI-false
Digoxin: Digoxin concentrations are increased by about 15% when @DRUG$ and @DRUG$ are administered concomitantly.	DDI-mechanism
@DRUG$, such as probenecid and @DRUG$, can inhibit renal tubular secretion of nitrofurantoin.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: @DRUG$, NSAIDs, @DRUG$, TNF blocking agents, azathioprine, chloroquine, gold, hydroxychloroquine, leflunomide, sulfasalazine, and anakinra.	DDI-false
@DRUG$- and/or aluminum-containing antacids , products containing ferrous sulfate ( iron ) , multivitamin preparations containing zinc or other metal cations , or @DRUG$ Do not take chewable/buffered tablets or the pediatric powder for oral solution within 3 hours before or 2 hours after FACTIVE.	DDI-false
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin is associated with @DRUG$ Co-administration of apomorphine with medicinal products of the 5HT3 antagonist class (including, for example, @DRUG$ Granisetron is contraindicated, and is contraindicated.	DDI-false
Antibiotics: In vitro and/or in vivo data show that clarithromycin, erythromycin, and @DRUG$ markedly inhibit the metabolism of @DRUG$, which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-mechanism
Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, calcium channel blockers, dapsone, @DRUG$, @DRUG$, amiodarone, quinidine, warfarin, tacrolimus, cyclosporine, ergot derivatives, pimozide, carbamazepine, fentanyl, alfentanyl, alprazolam, and triazolam) may have elevated plasma concentrations when coadministered with saquinavir;	DDI-false
- Anabolic steroids ( nandrolone [ e.g. , Anabolin ] , @DRUG$ [ e.g. , Anavar ] , oxymetholone [ e.g. , Anadrol ] , stanozolol [ e.g. , @DRUG$ ] ) or	DDI-false
- @DRUG$: Bumetanide may potentiate the effect of various @DRUG$, necessitating a reduction in the dosage of these drugs.	DDI-false
Nephrotoxic agents: Concomitant administration of VISTIDE and substances with nephrotoxic potential [e.g. intravenous aminoglycosides (e.g. tobramycin, gentamicin and amikacin), @DRUG$ , Foscarnet, intravenous pentamidine, @DRUG$ , and non-steroidal anti-inflammatory agents ] is contraindicated.	DDI-false
The majority of patients in RA clinical studies received one or more of the following concomitant medications with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blocking agents, azathioprine, chloroquine, gold, @DRUG$, leflunomide, @DRUG$, and anakinra.	DDI-false
May interact with thyroid medication ( e.g. , levothyroxine ) , @DRUG$-containing products , antacids , H2-antagonists ( e.g. , @DRUG$ , ranitidine ) , and proton pump inhibitors ( e.g. , lansoprazole , omeprazole ) .	DDI-false
5HT3 Antagonists : Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with @DRUG$ Co-administration of apomorphine with medicinal products of the 5HT3 antagonist class (including, for example, ondansetron, granisetron, dolasetron, palonosetron, and @DRUG$ ) is contraindicated.	DDI-false
@DRUG$: Steady-state trough concentrations of @DRUG$ were about 56% higher when 8 mg dexamethasone was coadministered with each dose of albendazole (15 mg/kg/day) in eight neurocysticercosis patients.	DDI-false
Benzylpenicillin , @DRUG$ , oxacillin, chlortetracycline, doxycycline, @DRUG$ In vitro, erythromycin and sulfamethoxazole have no influence on the protein binding of diclofenac in human serum.	DDI-false
These drugs include thiazides and other @DRUG$ , corticosteroids, phe-nothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$ , sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , @DRUG$ , benzodiazepines , beta blockers , calcium-channel blockers , cardiac nitrates , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as @DRUG$ In addition, quinolones anti-infections with no evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ diminished binding of @DRUG$ by a net change of 9.9% (percentage increase in FDF, 21.2%) at 1732 micromol/L.	DDI-mechanism
5HT3 antagonists : Based on reports of deep hypotension and loss of consciousness when apomorphin was administered with ondansetron, the concomitant use of apomorphin with 5HT3 antagonist class medications (including, for example, ondansetron, @DRUG$ , @DRUG$ , palonosetron , and alosetron ) is contraindicated .	DDI-false
@DRUG$ is also expected to reduce plasma concentrations of other statins that have significant metabolism by CYP3A4, such as lovastatin and @DRUG$.	DDI-mechanism
Benzylpenicillin, ampicillin, oxacillin, chlortetracycline, doxycycline, @DRUG$, erythromycin, and sulfamethoxazole have no influence in vitro on the protein binding of @DRUG$ in human serum.	DDI-false
Drug-Drug Interactions Between @DRUG$   And Other Antiepileptic Drugs ( AEDs ) Phenytoin Keppra   ( 3000 mg daily ) had no effect on the pharmacokinetic disposition of @DRUG$ in patients with refractory epilepsy .	DDI-false
@DRUG$ : As with other b-lactams , the renal excretion of @DRUG$ The treatment is inhibited by probenecid.	DDI-false
Drugs that have been associated with peripheral neuropathy include @DRUG$ , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , @DRUG$ , gold, hydralazine, iodoquinol, isoniazid, metronidazole, nitrofurantoin, phenytoin, ribavirin and vincristine.	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., @DRUG$, @DRUG$, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when almotriptan is used concomitantly with these medications.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental @DRUG$.In a pharmacokinetic substudy in patients with congestive heart failure receiving furosemide or @DRUG$ in whom therapy with FLOLAN was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-false
Data from in vitro studies of @DRUG$ suggest a possible drug interaction with alprazolam for the following: sertraline and @DRUG$.	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when apomorphine was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, ondansetron, @DRUG$, @DRUG$, palonosetron, and alosetron) is contraindicated .	DDI-false
Beta-blockers, @DRUG$, lithium salts, and @DRUG$ may either potentiate or weaken the blood-glucose-lowering effect of insulin.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, @DRUG$, nefazodone, nicardipine, propofol, @DRUG$, quinidine, and verapamil.	DDI-false
acetaminophen/@DRUG$ , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/@DRUG$ , and valproic acid/phenobarbital .	DDI-false
@DRUG$ @DRUG$, as well as a metabolite of furazolidone, slow amphetamine metabolism.	DDI-false
Antiacid , clarithromycin , Didanosine , @DRUG$ , Fluoxetine , Indanavir , Ketoconazole , Phenytoin , Phenobarbitol , @DRUG$ , Rifabutin , Rifampin , Ritanovir , Saquinavir .	DDI-false
Serial plasma and urine samples for measurement of amprenavir , @DRUG$ , and @DRUG$ and their 25-O-desacetyl metabolites , were measured by high-performance liquid chromatography .	DDI-false
No Important Interactions To Date Levosimendan does not have clinically important pharmacokinetic interactions with captopril, @DRUG$, felodipine, digoxin, warfarin, @DRUG$, carvedilol, ethanol or itraconazole.	DDI-false
Acetaminophen/theophylline, lidocaine/@DRUG$, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
cimetidine) and many that are substrates for P450 2D6 (many other @DRUG$, @DRUG$, and the Type 1C antiarrhythmics propafenone and flecainide).	DDI-false
Plasma exposure of diazepam ( 10 mg BID ) was increased by 28 % following administration of @DRUG$ - ug ( 40 mg twice daily) for 12 days, while plasma exposure of @DRUG$ After administration of diazepam ( 10 mg twice daily ) for 12 days, the dose ( 40 mg twice daily ) was not significantly increased.	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of fissteride doses have been co-administered in clinical trials with acetaminophen, @DRUG$ , A-blockers, analgesics, angiotensin converting enzyme ( ACE) inhibitors, anticonvulsants, benzodiazepines, beta-blockers, calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, @DRUG$ ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
OTHER CONCOMITANT THERAPY : Although specific interaction studies were not performed , in clinical studies , cerivastatin sodium was used concomitantly with angiotensin- converting enzyme ( ACE ) inhibitors , @DRUG$ , @DRUG$ , diuretics , and nonsteroidal anti-inflammatory drugs ( NSAIDs ) without evidence of clinically significant adverse interactions .	DDI-false
The pharmacokinetics of irbesartan were not affected by coadministration of @DRUG$ or @DRUG$	DDI-false
While @DRUG$ and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors , 18-MC has much lower affinities than ibogaine for NMDA and sigma-2 receptors , sodium channels , and the 5-HT transporter .	DDI-false
@DRUG$ In vitro and/or in vivo data show that: @DRUG$ Erythromycin, and troleandomycin significantly inhibit the metabolism of cisapride, which may lead to an increase in plasma cisapride levels and prolongation of the QT interval on the ECG.	DDI-false
@DRUG$ : @DRUG$ had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment .	DDI-false
Stavudine and @DRUG$ @DRUG$ can antagonize the in vitro antiviral activity of stavudine and zidovudine against HIV .	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants, @DRUG$, alcohol, barbiturates, @DRUG$, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression.	DDI-false
Quetiapin fumarate ( " @DRUG$ ==References====External links== @DRUG$ With proven efficacy in the treatment of positive and negative symptoms of schizophrenia.	DDI-false
@DRUG$ : In a clinical pharmacology study , coadministration of an antacid ( aluminum hydroxide , magnesium hydroxide , and simethicone ) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with @DRUG$ Administration alone, suggesting that antacids may affect the absorption of fosinopril.	DDI-false
@DRUG$ â€¢ has additive effects on alcohol and other @DRUG$ ( hypnotics , sedatives , tranquilizers , etc ) .	DDI-effect
Both @DRUG$ and @DRUG$ Take extracellular levels of dopamine in the nucleus accumbens, but only ibogain increases extracellular levels of serotonin in the nucleus accumbens.	DDI-false
It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of @DRUG$ Deficit and to discriminate between magnesium deficiency due to insufficient magnesium uptake, which requires only oral physiological supplement and magnesium degradation, which with a dysregulation of the control mechanisms of @DRUG$ Status that requires more or less specific regulation of its causal dysregulation.	DDI-false
Oral @DRUG$ gastrointestinal absorption of penicillin V, oral vitamin B-12, @DRUG$ and 5-fluorouracil .	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, @DRUG$, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, @DRUG$ (e.g., in oral contraceptives).	DDI-false
acetaminophen/theophylline, lidocaine/quinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/lidocaine, theophylline/@DRUG$, and valproic acid/phenobarbital.	DDI-false
Other chemotherapeutic agents In a separate study, concomitant use of lapatinib with @DRUG$ The pharmacokinetics of an active substance (or metabolites of @DRUG$ ) .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues , chloramphenicol , cisplatin , dapsone , disulfiram , ethionamide , glutethimide , gold , hydralazine , iodoquinol , isoniazid , metronidazole , @DRUG$ , @DRUG$ Ribavirin and vincristine.	DDI-false
Although the interaction between almotriptan and other potent CYP3A4 inhibitors (e.g., itraconazole, @DRUG$, and erythromycin) has not been studied, increased exposures to almotriptan may be expected when @DRUG$ is used concomitantly with these medications.	DDI-advise
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia : oral antidiabetic products , ACE inhibitors , disopyramide , fibrates , @DRUG$ - monoamine oxidase (MAO) inhibitors, @DRUG$ , salicylates , somatostatin analog ( e.g. , octreotide ) , sulfonamide antibiotics .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, calcium-channel blockers, cardiac nitrates, diuretics, @DRUG$, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
While all the @DRUG$ (SSRIs), e.g., citalopram, @DRUG$, fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition.	DDI-false
In clinical trials, FLOLAN was used with digoxin, diuretics, anticoagulants, oral vasodilators, and supplemental oxygen.In a pharmacokinetic substudy in patients with congestive heart failure receiving @DRUG$ or digoxin in whom therapy with @DRUG$ was initiated, apparent oral clearance values for furosemide (n = 23) and digoxin (n = 30) were decreased by 13% and 15%, respectively, on the second day of therapy and had returned to baseline values by day 87.	DDI-mechanism
While all the @DRUG$ ( SSRIs), e.g. citalopram, escitalopram, @DRUG$ , sertraline , and paroxetine , inhibit P450 2D6 , they may vary in the extent of inhibition .	DDI-false
These drugs include the thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, @DRUG$, @DRUG$, and isoniazid.	DDI-false
Injection : @DRUG$ injection , like other injectable benzodiazepines , produces depression of the central nervous system when administered with ethyl alcohol , phenothiazines , barbiturates , MAO inhibitors , and other antidepressants . When scopolamine is used concomitantly with injectable @DRUG$ An increased incidence of sedation, hallucinations, and irrational behaviour has been observed.	DDI-false
@DRUG$ Chlorpromazine blocks dopamine and norepinephrine receptors, which inhibits the central stimulant effect of amphetamines and is used to treat @DRUG$ poisoning .	DDI-false
Although the magnitude of changes in @DRUG$ plasma exposure when coadministered with @DRUG$ were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of diazepam under this circumstance.	DDI-false
Like ibogaine (40 mg/kg), 18-MC (40 mg/kg) decreases the intravenous self-administration of @DRUG$ and @DRUG$ and the oral self-administration of ethanol and nicotine in rats;	DDI-false
Anticoagulants including coumarin derivatives, indandione derivatives, and platelet aggregation inhibitors such as nonsteroidal anti-inflammatory drugs (@DRUG$), and aspirin may increase the risk of bleeding when administered concomitantly with @DRUG$.	DDI-effect
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, dexamethasone, carbamazepine) may result in decreased plasma levels of @DRUG$.	DDI-mechanism
No pharmacokinetic interactions between @DRUG$ and @DRUG$, propofol, alfentanil, and midazolam have been demonstrated.	DDI-false
- @DRUG$: Lithium should generally not be given with diuretics (such as bumetanide) because they reduce its renal clearance and add a high risk of @DRUG$ toxicity.	DDI-false
Veratrum alkaloids : @DRUG$ inhibit the hypotensive effect of @DRUG$.	DDI-effect
Therefore, in patients who: @DRUG$ or oral @DRUG$ , regular monitoring of blood glucose is recommended .	DDI-false
Antacids: In a clinical pharmacology study, coadministration of an antacid (aluminum hydroxide, @DRUG$, and simethicone) with fosinopril reduced serum levels and urinary excretion of fosinoprilat as compared with fosinopril administered alone, suggesting that antacids may impair absorption of @DRUG$.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and dapsone, @DRUG$/sulfamethoxazole, clarithromycin, erythromycin, itraconazole or @DRUG$.	DDI-false
@DRUG$ @DRUG$  (1500 mg twice daily) did not alter the pharmacokinetics of valproate in healthy volunteers.	DDI-false
Interactions with @DRUG$ : @DRUG$ ( eg , pentazocine , nalbuphine , butorphanol , dezocine and buprenorphine ) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran .	DDI-false
Co-administration of valdecoxib (40 mg twice daily for 7 days) resulted in a significant increase in @DRUG$ plasma levels suggesting that , at these doses , @DRUG$ is a weak inhibitor of 2D6 .	DDI-false
@DRUG$/@DRUG$ , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , quinidine/lidocaine , theophylline/acetaminophen , and valproic acid/phenobarbital .	DDI-false
Interactions may occur between @DRUG$ supplements and aspirin and other @DRUG$ and herbs such as garlic (Allium sativum) and ginkgo (Ginkgo biloba).	DDI-int
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with CNS depressants ( @DRUG$ , barbiturates , opiates , sedatives , @DRUG$ ) should be considered.	DDI-false
Patients who have other narcotic analgesics, general anesthetics, phenothiazine, sedatives, sedative hypnotics, @DRUG$ or other @DRUG$ In addition to DILAUDID, additive CNS depression may occur (including alcohol).	DDI-false
d-amphetamine with desipramine or @DRUG$ and possibly other @DRUG$ â€¢ significantly and sustainably increase the concentration of D-amphetamine in the brain;	DDI-false
Drug Interactions : Flupenthixol may interact with some drugs , like Monoamine oxidase inhibitors ( MAOI ): MAOI could theoretically affect @DRUG$ pharmacodynamics - @DRUG$ - Eproxindine - Ethanol : Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants : Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
Imidazoles ( e. g. , ketoconazole , miconazole , @DRUG$ In vitro and animal studies with the combination of @DRUG$ and imidazoles suggest that imidazoles may induce fungal resistance to amphotericin B.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, @DRUG$ GI motility agents: @DRUG$	DDI-false
@DRUG$ Influence may include alcohol, @DRUG$s, decongestant medications (allergic, cold, and sinus drugs), diabetes medications, lithium, norepinephrine, NSAIDs such as aleve or ibuprofen, and high-pressure medications.	DDI-int
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, colistin, and sodium colistimethate), magnesium salts, lithium, local anesthetics, procainamide, and @DRUG$.	DDI-effect
In some patients, the administration of a @DRUG$ can reduce the diuretic, natriuretic, and antihypertensive effects of @DRUG$.	DDI-effect
Therefore, the combined use of @DRUG$ with @DRUG$ should generally be avoided.	DDI-advise
The majority of patients in RA clinical trials received one or more of the following concomitant drugs with ORENCIA: MTX, NSAIDs, corticosteroids, TNF blockers, azathioprin, chloroquine, gold, @DRUG$ , leflunomide , @DRUG$ ==References====External links==	DDI-false
Uricosuric drugs, such as probenecid and @DRUG$, can inhibit renal tubular secretion of @DRUG$.	DDI-mechanism
Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of IOPIDINE 0.5 % Ophthalmic Solution , the possibility of an additive or potentiating effect with CNS depressants ( alcohol , barbiturates , @DRUG$ , sedatives , @DRUG$ ) should be considered .	DDI-false
5HT3 Antagonists: Based on reports of profound hypotension and loss of consciousness when @DRUG$ was administered with ondansetron, the concomitant use of apomorphine with drugs of the 5HT3 antagonist class (including, for example, @DRUG$, granisetron, dolasetron, palonosetron, and alosetron) is contraindicated .	DDI-false
Drugs that have been associated with peripheral neuropathy include antiretroviral nucleoside analogues, chloramphenicol, cisplatin, dapsone, disulfiram, @DRUG$, glutethimide, gold, hydralazine, iodoquinol, isoniazid, @DRUG$, nitrofurantoin, phenytoin, ribavirin, and vincristine.	DDI-false
INOmax was co-administered with @DRUG$ , @DRUG$ , dobutamine , steroids , surfactant , and high-frequency ventilation .	DDI-false
TABLE 1 Effects on Plasma Concentrations ( AUC 0 - 24 hrs ) of @DRUG$ and @DRUG$ After 10 days of co-administration ( loratadine 10 mg ) in normal volunteers	DDI-false
Vitamin A : Because of the relationship of @DRUG$ to @DRUG$ Patients should be prevented from taking vitamin A-containing supplements to avoid additive toxic effects.	DDI-effect
Possible interactions between Keppra and other AEDs (carbamazepine, gabapentin, lamotrigine, phenobarbital, phenytoin, primidone and @DRUG$ ) were also assessed by evaluating the serum concentrations of levetiracetam and these @DRUG$ during placebo-controlled clinical studies .	DDI-false
This medicine can be used with alcohol or other forms of interaction. @DRUG$ ( may potentiate the CNS depressant effects of either these medications or antihistamines ) , anticholinergics or other medications with anticholinergic activity ( anticholinergic effects may be potentiated when these medications are used concurrently with antihistamines ) , and monoamine oxidase ( MAO ) inhibitors ( concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of @DRUG$ ) .	DDI-false
@DRUG$ Co-administration of rifampin and VIRACEPT resulted in a decrease in @DRUG$ plasma A.C.	DDI-false
The hypoglycemic action of @DRUG$ may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, probenecid, @DRUG$, monoamine oxidase inhibitors, and beta adrenergic blocking agents.	DDI-effect
Diuretics: Diclofenac and other @DRUG$ can inhibit the activity of @DRUG$.	DDI-effect
Ergot Derivatives : @DRUG$ , ergonovine , @DRUG$ , Methylergonovine CONTRAINDICATED due to the potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischaemia of extremities and other tissues.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as @DRUG$ include certain antibiotics ( e. g. , aminoglycosides , @DRUG$ , bacitracin , polymyxins , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , lithium , local anesthetics , procainamide , and quinidine .	DDI-effect
It is also expected that bosentan will increase plasma concentrations of other @DRUG$ , which have a significant metabolism by CYP3A4, such as lovastatin and @DRUG$.	DDI-false
As with other antipsychotics, it should be noted that: @DRUG$ may be capable of potentiating CNS depressants such as @DRUG$ , opiates , and alcohol .	DDI-effect
Potassium Supplements and @DRUG$ : @DRUG$ can attenuate potassium loss caused by thiazide diuretics .	DDI-false
acetaminophen/theophylline , lidocaine/quinidine , phenobarbital/acetaminophen , phenobarbital/valproic acid , @DRUG$/lidocaine , theophylline/acetaminophen , and valproic acid/@DRUG$.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or @DRUG$, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with pentobarbital.	DDI-false
Antimycotics: In vitro and/or in vivo data show that fluconazole, itraconazole and oral @DRUG$ Remarkably inhibit the metabolism of cisaprid, which may lead to an increase in plasma. @DRUG$ The concentrations and prolongation of the QT interval on the ECG.	DDI-false
Drugs Demonstrated to be CYP 3A Inhibitors of Possible Clinical Significance on the Basis of Clinical Studies Involving Alprazolam (caution is recommended during coadministration with @DRUG$): Coadministration of fluoxetine with alprazolam increased the maximum plasma concentration of @DRUG$ by 46%, decreased clearance by 21%, increased half-life by 17%, and decreased measured psychomotor performance.	DDI-false
Theophylline: A single 10 mg dose of @DRUG$ did not affect the pharmacokinetics of @DRUG$ at steady state.	DDI-false
The successive application of @DRUG$ ( 5 or 10 mg/kg egg weight ( e.w . ) and @DRUG$ ( 15 mg/kg e.w . ) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of glutamate alone .	DDI-effect
OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, @DRUG$ was used concomitantly with angiotensin- converting enzyme (ACE) inhibitors, betablockers, calcium-channel blockers, diuretics, and @DRUG$ (NSAIDs) without evidence of clinically significant adverse interactions.	DDI-false
Cimetidine : Albendazole sulfoxide concentrations in bile and cystic fluid were increased ( about 2-fold ) in hydatid cyst patients treated with @DRUG$ ( 10 mg/kg/day ) ( n=7 ) compared with @DRUG$ Alone ( 20 mg/kg/day ) ( n=12 ).	DDI-false
There are no data for concomitant use of @DRUG$/ritonavir or FORTOVASE/@DRUG$ and garlic capsules.	DDI-false
@DRUG$   should be used with caution in patients receiving other local @DRUG$ or agents structurally related to amide-type local anesthetics since the toxic effects of these drugs could be additive.	DDI-advise
DIGOXIN: plasma digoxin levels and @DRUG$ The steady-state clearance was not affected by concomitant administration of 0.2 mg @DRUG$.	DDI-false
These medicines include thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, orally @DRUG$ , phenytoin , @DRUG$ , sympathomimetics, calcium channel block drugs, and isoniazid.	DDI-false
@DRUG$ and @DRUG$ may have additive hypotensite effects due to the inhibition of each other s metabolism .	DDI-mechanism
Administration of repeat doses of FACTIVE had no effect on the repeat dose pharmacokinetics of @DRUG$ , @DRUG$ Ethinylestradiol/ Levonorgestrol oral contraceptive product in healthy volunteers.	DDI-false
Epinephrine also should be used cautiously with other drugs (e.g., @DRUG$, glycosides) that sensitize the myocardium to the actions of @DRUG$.	DDI-false
@DRUG$ : When @DRUG$ 10 or 20 mg were given to healthy subjects either simultaneously or 6 hours after a 10 mg dose of terazosin, and significant hypotension developed in a significant number of subjects.	DDI-false
Influence of @DRUG$ on @DRUG$ Concentration (average change, 90% confidence ratio )	DDI-false
The action of the benzodiazepines may be potentiated by anticonvulsants , antihistamines , alcohol , @DRUG$ , monoamine oxidase inhibitors , narcotics , @DRUG$ , psychotropic medications , or other drugs that produce CNS depression .	DDI-false
No effect on plasma concentrations of @DRUG$ or @DRUG$ were observed .	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, finasteride doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, angiotensin-converting enzyme (ACE) inhibitors, anticonvulsants, benzodiazepines, @DRUG$, @DRUG$, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
@DRUG$ In some patients, the administration of a non-steroidal anti-inflammatory agent may reduce the diuretic, natriuretic and blood pressure lowering effect of loop, potassium sparing and @DRUG$.	DDI-false
In a comparison of digitalis tolerance in dogs anesthetized with ketamine, @DRUG$, or pentobarbital, the dosage of ouabain needed to cause ventricular tachycardia was significantly higher, as was the LD50 of ouabain, with ketamine or Innovar than with @DRUG$.	DDI-false
The hypoglycemic action of sulfonylureas may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, @DRUG$, probenecid, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
While all selective serotonin reuptake inhibitors ( @DRUG$ , e.g. fluoxetine, sertraline, @DRUG$ , and fluvoxamine, inhibit P450 2D6, they may vary in extent of inhibition.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics : @DRUG$ Chinidine Antihistamines: @DRUG$ , terfenadine Antimigrain: ergot derivatives Antimycobacterial agents: rifampine benzodiazepine midazolam, triazolam GI motility agent: cisapride	DDI-false
@DRUG$ The simultaneous use of @DRUG$ and naproxen in normal volunteers had no effect on the plasma levels of naproxen , but significantly decreased the urinary excretion of naproxen and its glucuronide metabolite .	DDI-false
This drug may interact with @DRUG$ or other CNS depressants (may potentiate the CNS depressant effects of either these medications or antihistamines), anticholinergics or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with @DRUG$), and monoamine oxidase (MAO) inhibitors (concurrent use with antihistamines may prolong and intensify the anticholinergic and CNS depressant effects of antihistamines).	DDI-false
Previous studies have demonstrated a significant reduction in the oral bioavailability of trovafloxacin and ciprofloxacin when administered concomitantly with an intravenous @DRUG$ such as @DRUG$.	DDI-false
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, @DRUG$, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, somatostatin analog (e.g., @DRUG$), sulfonamide antibiotics.	DDI-false
@DRUG$: Macrolide antibiotics have been reported to cause a significant decrease in @DRUG$ clearance.	DDI-false
Therefore, the use of @DRUG$ Not required is an adjustment in @DRUG$ dose to maintain therapeutic digoxin levels .	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , @DRUG$ ( e.g. , epinephrine , salbutamol , terbutaline ) , @DRUG$ Phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g. in oral contraceptives).	DDI-false
@DRUG$: Potentiation of @DRUG$-type (CYP2C9 and CYP3A4 substrate) anticoagulant response is almost always seen in patients receiving amiodarone and can result in serious or fatal bleeding.	DDI-false
Benzthiazide may interact with alcohol, blood thinners, @DRUG$ (allergy, cold, and sinus medicines), diabetic drugs, lithium, @DRUG$, NSAIDs like Aleve or Ibuprofen, and high blood pressure medications.	DDI-false
Multivitamins , or other products containing iron or @DRUG$ , antacids or sucralfate should not be administered concomitantly with , or within 2 hours of , the administration of @DRUG$ Because they may impair absorption, resulting in lower serum and urine levels of norfloxacin.	DDI-advise
The safety and effectiveness of @DRUG$ In combination with any @DRUG$ have not been established .	DDI-false
@DRUG$ @DRUG$  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of digoxin given as a 0.25 mg dose every day.	DDI-false
Interactions with @DRUG$: Agonist/antagonist analgesics (eg, @DRUG$, nalbuphine, butorphanol, dezocine and buprenorphine) should NOT be administered to a patient who has received or is receiving a course of therapy with a pure agonist opioid analgesic such as Levo-Dromoran.	DDI-false
When other @DRUG$ or anticoagulants are used concomitantly , there is the potential for @DRUG$ to increase the risk of bleeding .	DDI-effect
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, @DRUG$, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, estrogens, progestogens (e.g., in oral @DRUG$).	DDI-false
The following are examples of substances that may reduce the blood-glucose-lowering effect : corticosteroids , niacin , danazol , diuretics , sympathomimetic agents ( e.g. , epinephrine , salbutamol , terbutaline ) , isoniazid , phenothiazine derivatives , somatropin , @DRUG$ , estrogens, progestogens (e.g., orally) @DRUG$ ) .	DDI-false
Central nervous system depressants : Co-administration of DURAGESIC (Fentanyl transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), generally @DRUG$ , phenothiazines , @DRUG$ , and alcohol , may cause respiratory depression , hypotension , and profound sedation , or potentially result in coma or death .	DDI-false
@DRUG$ should not be used in patients receiving @DRUG$ ..	DDI-advise
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants, phenytoin, propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, @DRUG$ , theophylline and @DRUG$ This delays elimination and increases blood levels of these drugs.	DDI-false
Multivalent Cation-Containing Products : Concurrent administration of a quinolone , including ciprofloxacin , with multivalent cation-containing products such as magnesium or aluminum antacids , @DRUG$ , VIDEX chewable/buffer tablets or pediatric powder, or products containing calcium, iron, or @DRUG$ may substantially decrease the absorption of ciprofloxacin , resulting in serum and urine levels considerably lower than desired .	DDI-false
The increase of @DRUG$ level, however, is small (15%) when given with @DRUG$.	DDI-mechanism
@DRUG$: In post-marketing experience, there have been reports of both increases and decreases in @DRUG$ levels with dexamethasone co-administration, leading to alterations in seizure control.	DDI-false
The absorption of tetracycline, @DRUG$ , @DRUG$ , hydrochlorothiazide , and gemfibrozil was significantly decreased when given simultaneously with colestipol hydrochloride ;	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, dapsones, disopyramide, quinine, amiodarone, quinidine, warfarin, tacrolimus, cyclosporin, ergot derivatives, pimozide, carbamazepine, @DRUG$ , alfentanyl , alprazolam , and triazolam ) may have elevated plasma concentrations when coadministered with @DRUG$ ;	DDI-mechanism
Tagamet, apparently due to an effect on certain microsomal enzyme systems, has been reported to reduce hepatic metabolism @DRUG$ , @DRUG$ , propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, theophylline and metronidazole, delaying the elimination and increase in blood levels of these drugs.	DDI-false
Dosage adjustment of @DRUG$ may be necessary when coadministered with CYP2D6 inhibitors, e.g., paroxetine, fluoxetine, and @DRUG$.	DDI-advise
When Itraconazole was coadministered with @DRUG$, rifampin, or H2antagonists, reduced plasma concentrations of @DRUG$ were reported.	DDI-false
The majority of cases of serious or fatal adverse events @DRUG$ reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients , or the simultaneous administration of @DRUG$ With other medicines that affect breathing.	DDI-false
When @DRUG$ is added to or withdrawn from treatment, dosage adjustment of @DRUG$ may be required.	DDI-advise
Concurrent administration of @DRUG$ and antidepressants of the MAO inhibitor class may cause severe orthostatic hypotension.@DRUG$, an inhibitor of microsomal drug metabolism, increased altretamines half-life and toxicity in a rat model.	DDI-false
Metformin: In healthy subjects given single 500 mg doses of @DRUG$ and @DRUG$, plasma metformin mean cmax and AUC increased by an average of 34% and 24%, respectively, and metformin mean renal clearance decreased by 14%.	DDI-mechanism
It is concluded that chloral hydrate and @DRUG$ may be administered safely without additional caution in prothrombin test monitoring during oral @DRUG$ therapy.	DDI-false
Monoamine Oxidase Inhibitors and Tricyclic Antidepressants: @DRUG$ should be administered with extreme caution in patients being treated with monoamine oxidase inhibitors or @DRUG$ because the action of formoterol on the cardiovascular system may be potentiated by these agents.	DDI-advise
@DRUG$: The addition of @DRUG$ to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but valproate significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
@DRUG$ Renal tubular transport of methotrexate may be inhibited by concomitant administration of ciprofloxacin, potentially leading to increased plasma levels of @DRUG$.	DDI-false
@DRUG$-A @DRUG$ With lithium was not performed.	DDI-false
Example inhibitors include azole antifungals, ciprofloxacin, clarithromycin, diclofenac, @DRUG$, erythromycin, @DRUG$, isoniazid, nefazodone, nicardipine, propofol, protease inhibitors, quinidine, and verapamil.	DDI-false
Concomitant administration of Mefloquine and other related compounds (eg, @DRUG$, quinidine and @DRUG$) may produce electrocardiographic abnormalities and increase the risk of convulsions.	DDI-false
@DRUG$ : Anticoagulant activity should be monitored , particularly in the first few days after initiating or changing @DRUG$ Treatment in patients receiving warfarin or similar active substances as these patients have an increased risk of bleeding complications.	DDI-false
Acetaminophen , lidocaine , @DRUG$ , quinidine , @DRUG$ , and valproic acid were added to pooled human serum at therapeutic concentrations.	DDI-false
@DRUG$: Digoxin concentrations are increased by about 15% when digoxin and @DRUG$ are administered concomitantly.	DDI-false
@DRUG$: Concomitant administration of fluconazole at 200 mg QD resulted in a two-fold increase in @DRUG$ plasma concentration.	DDI-false
Imidazoles ( e. g. , ketoconazole , miconazole , @DRUG$ , fluconazole , etc . ): in vitro and animal studies with the combination of amphotericin B and imidazoles suggest that imidazoles may induce fungal resistance to @DRUG$.	DDI-false
In a Phase I trial using escalating doses of TAXOL ( 110 - 200 mg/m2 ) and @DRUG$ ( 50 or 75 mg/m2 ) given as sequential infusions , myelosuppression was more profound when @DRUG$ was given after cisplatin than with the alternate sequence ( ie , TAXOL before cisplatin ) .	DDI-false
These results suggest that both @DRUG$ Acetate and retinyl acetate, and possibly other @DRUG$ Prostate epithelium proliferation can be regulated by dose-dependent changes in insulin and EGF activity.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, @DRUG$ Antihistamines: astemizole, terfenadine Antimigraine: @DRUG$ Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Compounds in these categories result in a decreased efficacy of @DRUG$: phenothiazines, @DRUG$, metoclopramide, pimozide.	DDI-effect
The majority of patients in RA clinical trials received one or more of the following concomitant medicines with ORENCIA: MTX, @DRUG$ , @DRUG$ , TNF blocking agents , azathioprine , chloroquine , gold , hydroxychloroquine , leflunomide , sulfasalazine , and anakinra .	DDI-false
Example inhibitors include @DRUG$ , ciprofloxacin , @DRUG$ , diclofenac , doxycycline , erythromycin , imatinib , isoniazid , nefazodone , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
@DRUG$ and @DRUG$ resins: Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.	DDI-false
@DRUG$ and methaqualone interact pharmacologically with orally administered @DRUG$, but the effect is not clinically significant.	DDI-int
Antidepressants, @DRUG$ @DRUG$ may enhance the activity of tricyclic antidepressants or sympathomimetic agents;	DDI-false
The ECG changes and/or hypokalemia that may result from the administration of non-potassium sparing diuretics ( such as @DRUG-DRUG$ ) can be acutely worsened by beta-agonists , especially when the recommended dose of the beta-agonist is exceeded .	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: @DRUG$, quinidine @DRUG$: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin Benzodiazepines midazolam, triazolam GI motility agents: cisapride	DDI-false
Although no specific studies have been performed, concomitant use with medicinal products primarily metabolised by CYP3A4 (e.g. calcium channel blockers, @DRUG$ , disopyramide , quinine , amiodarone , quinidine , warfarin , tacrolimus , cyclosporine , ergot derivatives , @DRUG$ When co-administered with saquinavir, carbamazepine, fentanyl, alfentanyl, alprazolam and triazolam may exhibit increased plasma concentrations;	DDI-false
To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the cyclophosphamide, doxorubicin, vincristine, and @DRUG$ (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, teniposide, and @DRUG$ with vincristine plus bleomycin) without receiving antiretroviral therapy.	DDI-false
@DRUG$, but not @DRUG$, decreases heart rate at high doses.	DDI-false
@DRUG$ diminished binding of @DRUG$ Net change of 9.9 % ( percentage increase for FDF, 21.2% ) at 1732 micromol/L.	DDI-mechanism
However, because some quinolones have been reported to improve the anticoagulant effect of @DRUG$ The prothrombin time or any other appropriate coagulation test should be closely monitored in patients or their derivatives if: @DRUG$ It is administered concomitantly with warfarin or its derivatives.	DDI-false
Ergot Derivatives : Dihydroergotamine , @DRUG$ , ergotamine , methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute @DRUG$ Toxicity characterized by peripheral vasospasm and ischemia of extremities and other tissues.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions are not expected between VIRACEPT and @DRUG$, trimethoprim/sulfamethoxazole, clarithromycin, @DRUG$, itraconazole or fluconazole.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics ( e. g. , aminoglycosides , tetracyclines , bacitracin , @DRUG$ , lincomycin , clindamycin , colistin , and sodium colistimethate ) , magnesium salts , @DRUG$ , local anesthetics, procainamide, and quinidine.	DDI-false
Particular caution is necessary when using @DRUG$ In the case of overdosing of mixed medicinal products, as the toxic effects (such as seizures and cardiac arrhythmias) of other medicinal products taken with overdose (especially: @DRUG$ The inverse effect of benzodiazepine by flumazenil may occur.	DDI-effect
@DRUG$ does not affect serum @DRUG$ levels.	DDI-false
Based on known metabolic profiles, clinically significant drug interactions between VIRACEPT and dapsone, trimethoprim/@DRUG$, clarithromycin, @DRUG$ Itraconazole or fluconazole.	DDI-false
@DRUG$ : Steady-state trough concentrations of albendazole sulfoxide were about 56 % higher when 8 mg @DRUG$ was coadministered with each dose of albendazole ( 15 mg/kg/day ) in eight neurocysticercosis patients .	DDI-false
HIV Protease Inhibitors: Indinavir (800 mg t.i.d.) co-administered with Vardenafil 10 mg resulted in a 16-fold increase in @DRUG$ AUC, a 7-fold increase in @DRUG$ Cmax and a 2-fold increase in vardenafil half-life.	DDI-false
To assess the effects of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin's lymphoma (HIV-NHL), the authors retrospectively compared a group of 24 patients with HIV-NHL treated with the cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy regimen plus HAART with a group of 80 patients treated with CHOP chemotherapy or a CHOP-like regimen (i.e., cyclophosphamide, doxorubicin, tenipide and prednisone). @DRUG$ plus @DRUG$ ) without receiving antiretroviral therapy .	DDI-false
@DRUG$ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ â€¢ @DRUG$ 20 mg and thioridazine 50 mg produced additive effects on decreased alertness and impaired psychomotor performance for 2 to 4 hours after administration .	DDI-false
Effects of @DRUG$ on other Antiepilepsy Drugs (AEDs) : Phenytoin: Tiagabine had no effect on the steady-state plasma concentrations of @DRUG$ in patients with epilepsy.	DDI-false
The effectiveness of progestin-only pills is reduced by hepatic enzyme-inducing drugs such as the anticonvulsants @DRUG$ , carbamazepine, and @DRUG$ And the antituberculosis drug rifampin.	DDI-false
Therefore, prothrombin time should be carefully monitored in patients receiving @DRUG$ and @DRUG$-like drugs simultaneously.	DDI-advise
These drugs include the @DRUG$ and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, @DRUG$, sympathomimetics, calcium channel blocking drugs, and isoniazid.	DDI-false
Other concomitant therapy Although specific interaction studies were not performed, @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen, acetylsalicylic acid, a-blockers, analgesics, @DRUG$, anticonvulsants, benzodiazepines, beta blockers, calcium-channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also referred to as NSAIDs), and quinolone anti-infectives without evidence of clinically significant adverse interactions.	DDI-false
While no in vivo drug-drug interaction studies were conducted between estazolam and inducers of CYP3A , compounds that are potent CYP3A inducers ( such as carbamazepine , @DRUG$ , rifampin, and @DRUG$ Estazolam concentrations are expected to be reduced.	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, phenobarbital/@DRUG$, quinidine/lidocaine, theophylline/acetaminophen and @DRUG$/Phenobarbital.	DDI-false
However , in another study in healthy volunteers , the pharmacokinetics of @DRUG$ were significantly altered ( 29 % decrease in AUC and 38 % decrease in Cmax ) when a 1-mg dose of STADOL NS was administered 1 minute after a 20-mg dose of @DRUG$ nasal spray .	DDI-false
â€¢ Diuretics reduce renal clearance of @DRUG$ " and a high risk for @DRUG$ toxicity .	DDI-false
@DRUG$: Coadministration of @DRUG$ and VIRACEPT resulted in an 82% decrease in nelfinavir plasma A.C.	DDI-false
Interaction with @DRUG$ other than @DRUG$ has not been specifically studied;	DDI-false
@DRUG$: Hallucinations have been reported when TORADOL was used in patients taking psychoactive drugs (fluoxetine, thiothixene, @DRUG$).	DDI-false
@DRUG$: Steady-state trough concentrations of albendazole sulfoxide were about 56% higher when 8 mg dexamethasone was coadministered with each dose of @DRUG$ (15 mg/kg/day) in eight neurocysticercosis patients.	DDI-false
It is assumed that increased interaction between @DRUG$ and high affinity binding sites for @DRUG$ Dopamine2 and serotonin2 receptors are based on the antipsychotic activity of neuroleptics after prolonged administration.	DDI-false
Drug Interactions: @DRUG$ may interact with some drugs, like Monoamine oxidase inhibitors (MAOI): MAOI could theoretically affect @DRUG$ pharmacodynamics - Arecoline - Eproxindine - Ethanol: Flupenthixol and Ethanol cause additive CNS depression - Tricyclic antidepressants: Flupenthixol increases the effect of Tricyclic antidepressants	DDI-false
These results suggest that both dexamethasone and @DRUG$, and possibly other glucocorticoids and @DRUG$, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of insulin and EGF.	DDI-false
ACE inhibitors and angiotensin II receptor antagonists (congestive heart failure after myocardial infarction)- In EPHESUS, 3020 (91%) patients also received INSPRA 25-50 mg. @DRUG$ or @DRUG$ ( ACEI/ARB ).	DDI-false
These drugs include thiazides and other diuretics, @DRUG$ , phenothiazines , thyroid products , estrogens , oral contraceptives , phenytoin , nicotinic acid , @DRUG$ , calcium channel blocking drugs , and isoniazid .	DDI-false
Investigations into the effect of acitretin on the protein binding of @DRUG$ (@DRUG$) revealed no interaction.	DDI-false
Central Nervous System Depressants: The concomitant use of DURAGESIC  (@DRUG$ transdermal system) with other central nervous system depressants, including but not limited to other opioids, sedatives, hypnotics, tranquilizers (e.g., benzodiazepines), general @DRUG$, phenothiazines, skeletal muscle relaxants, and alcohol, may cause respiratory depression, hypotension, and profound sedation, or potentially result in coma or death.	DDI-effect
Oral Contraceptives : Valdecoxib ( 40 mg BID ) did not induce the metabolism of the combination oral @DRUG$ @DRUG$/ethinyl estradiol ( 1 mg /35 mcg combination , Ortho-Novum 1/35 ) .	DDI-false
For example, inhibitors are azole antimycotics, @DRUG$ , clarithromycin, diclofenac, doxycycline, erythromycin, imatinib, isoniazid, @DRUG$ , nicardipine , propofol , protease inhibitors , quinidine , and verapamil .	DDI-false
While no in vivo drug-drug interaction studies were conducted between @DRUG$ and inducers of CYP3A, compounds that are potent CYP3A inducers (such as carbamazepine, phenytoin, rifampin, and @DRUG$) would be expected to decrease estazolam concentrations.	DDI-mechanism
No data are available for the coadministration of INVIRASE/@DRUG$ or FORTOVASE/@DRUG$ and garlic capsules .	DDI-false
Drug/Laboratory Test Interactions @DRUG$ , including @DRUG$ , are known to occasionally induce a positive direct Coombs test .	DDI-false
In EM individuals treated with @DRUG$ or @DRUG$, the AUC of atomoxetine is approximately 6- to 8-fold and Css,max is about 3- to 4-fold greater than atomoxetine alone.	DDI-false
Ethosuximide: @DRUG$ may delay intestinal absorption of @DRUG$.	DDI-mechanism
This effect may be mediated by the ability of @DRUG$ to induce microsomal enzymes and, thus, the catabolism of @DRUG$.	DDI-mechanism
Valproate: The addition of @DRUG$ to patients taking valproate chronically had no effect on tiagabine pharmacokinetics, but @DRUG$ significantly decreased tiagabine binding in vitro from 96.3 to 94.8%, which resulted in an increase of approximately 40% in the free tiagabine concentration.	DDI-false
Use with Angiotensln Converting Enzyme Inhibitors: The use of @DRUG$ to control hypertension in patients on @DRUG$ has been reported to induce severe leukopenia.	DDI-effect
Concomitant cyclophosphamide , doxorubicin , vincristine , and @DRUG$ chemotherapy plus @DRUG$ therapy in patients with human immunodeficiency virus-related , non-Hodgkin lymphoma .	DDI-false
@DRUG$ The use of piperazin and pyrantel together may reduce the effects of @DRUG$.	DDI-false
Drugs That Should Not Be Coadministered With VIRACEPT Antiarrhythmics: amiodarone, quinidine Antihistamines: astemizole, terfenadine Antimigraine: ergot derivatives Antimycobacterial agents: rifampin @DRUG$ midazolam, triazolam GI motility agents: @DRUG$	DDI-false
The concomitant use of other CYP3A4 inhibitors such as diltiazem and erythromycin with transdermal @DRUG$ may also result in an increase in @DRUG$ plasma concentrations, which could increase or prolong adverse drug effects and may cause serious respiratory depression.	DDI-false
Bacteriostatic Antibiotics: Chloramphenicol, erythromycins, @DRUG$, or @DRUG$ may interfere with the bactericidal effect of penicillins.	DDI-false
Tolbutamide: In diabetic patients receiving @DRUG$ and @DRUG$, no significant effects were seen on tolbutamide plasma levels or fasting blood glucose.	DDI-false
Nevertheless, clinical trials and post-marketing observations have shown that: @DRUG$ The natriuretic effect of furosemide and @DRUG$ In some patients.	DDI-effect
@DRUG$ : In vitro and/or in vivo data show that clarithromycin , erythromycin , and @DRUG$ markedly inhibit the metabolism of cisapride , which can result in an increase in plasma cisapride levels and prolongation of the QT interval on the ECG .	DDI-false
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, @DRUG$, chloroquine, D-penicillamine, @DRUG$, doxycycline, or digitoxin did not significantly affect the peak levels and AUC values of diclofenac.	DDI-false
The gastrointestinal absorption of @DRUG$ and ranitidine is accelerated when they are coadministered with @DRUG$.	DDI-mechanism
@DRUG$: Dihydroergotamine, ergonovine, @DRUG$, methylergonovine CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues.	DDI-false
@DRUG$ also increased rate of dissolution, in a manner similar to @DRUG$.	DDI-false
Serial plasma and urine samples for measurement of @DRUG$, rifabutin, and rifampin and their @DRUG$, were measured by high-performance liquid chromatography.	DDI-false
Vitamin A: Because of the relationship of Accutane to @DRUG$, patients should be advised against taking @DRUG$ containing vitamin A to avoid additive toxic effects	DDI-false
Other concomitant therapy Although specific interaction studies were not performed , @DRUG$ doses of 1 mg or more were concomitantly used in clinical studies with acetaminophen , acetylsalicylic acid , a-blockers , analgesics , angiotensin-converting enzyme ( ACE ) inhibitors , anticonvulsants , benzodiazepines , @DRUG$ , calcium channel blockers, cardiac nitrates, diuretics, H2 antagonists, HMG-CoA reductase inhibitors, prostaglandin synthetase inhibitors (also known as NSAIDs), and quinolone anti-infections without evidence of clinically significant adverse interactions.	DDI-false
BACKGROUND : The effects of combined administration of bombesin and verapamil hydrochloride ( @DRUG$ ) , a calcium channel blocker , on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by @DRUG$ ( AOM ) and the labeling index of intestinal cancers were investigated in male Wistar rats .	DDI-false
An alternative non-CYP3A4 substrate @DRUG$ may be considered in patients taking CYP3A4 inducers such as rifampin , @DRUG$ , carbamazepine , and phenobarbital .	DDI-false
Interaction between @DRUG$ and @DRUG$ in the development of spontaneous motility in chick embryos.	DDI-effect
Coadministration with compounds that are potent inducers of CYP3A4 (eg, phenobarbital, @DRUG$, @DRUG$, carbamazepine) may result in decreased plasma levels of saquinavir.	DDI-false
While 18-MC and @DRUG$ have similar affinities for kappa opioid and possibly nicotinic receptors, 18-MC has much lower affinities than @DRUG$ for NMDA and sigma-2 receptors, sodium channels, and the 5-HT transporter.	DDI-false
Therapeutic concentrations of digoxin , warfarin , @DRUG$ , @DRUG$ , piroxicam , acetaminophen , phenytoin andtolbutamide did not alter ketorolac tromethamine protein binding .	DDI-false
In separate studies of patients receiving maintenance doses of warfarin, hydrochlorothiazide, or @DRUG$, irbesartan administration for 7 days had no effect on the pharmacodynamics of warfarin (prothrombin time) or pharmacokinetics of @DRUG$.	DDI-false
Human pharmacokinetic data indicate that oral @DRUG$ markedly inhibits the metabolism of cisapride, resulting in a mean eight-fold increase in AUC of @DRUG$.	DDI-false
@DRUG$ : Dihydroergotamine , ergonovine , ergotamine , @DRUG$ CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues .	DDI-false
Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., @DRUG$, phenytoin, carbamazepine, rifampin) may enhance the metabolism of @DRUG$ and require that the dosage of the corticosteroid be increased.	DDI-mechanism
The following are examples of substances that may reduce the blood-glucose-lowering effect: corticosteroids, niacin, danazol, diuretics, sympathomimetic agents (e.g., epinephrine, salbutamol, terbutaline), isoniazid, phenothiazine derivatives, somatropin, thyroid hormones, @DRUG$, @DRUG$ (e.g., in oral contraceptives).	DDI-false
When itraconazole is co-administered with phenytoin @DRUG$ , or H2antagonists , reduced plasma concentrations of @DRUG$ were reported .	DDI-false
Antiacid, clarithromycin, Didanosine, @DRUG$, Fluoxetine, Indanavir, Ketoconazole, Phenytoin, Phenobarbitol, carbamazepine, @DRUG$, Rifampin, Ritanovir, Saquinavir.	DDI-false
Drug-Drug Interactions Between @DRUG$   And Other Antiepileptic Drugs ( @DRUG$ ) Phenytoin Keppra   ( 3000 mg daily ) had no effect on the pharmacokinetic disposition of phenytoin in patients with refractory epilepsy .	DDI-false
Other concomitant therapy Although no specific interaction studies have been conducted, 1 mg or more of finasteride doses have been co-administered in clinical trials with acetaminophen, acetylsalicylic acid, A-blockers, analgesics, angiotensin converting enzyme (ACE) inhibitors, anticonvulsants, @DRUG$ , beta blocker, calcium channel blocker, heart @DRUG$ , diuretics , H2 antagonists , HMG-CoA reductase inhibitors , prostaglandin synthetase inhibitors ( also referred to as NSAIDs ) , and quinolone anti-infectives without evidence of clinically significant adverse interactions .	DDI-false
Cholestyramine and @DRUG$ resins: Absorption of @DRUG$ is impaired in the presence of anionic exchange resins.	DDI-false
Amantadine , tricyclic antidepressants , and @DRUG$ may increase anticholinergic effect of @DRUG$.	DDI-effect
Because of the increased risk of adverse reactions in patients who have been taking @DRUG$ on a regular basis, it is particularly important that physicians query patients or their guardians carefully about benzodiazepine, alcohol and @DRUG$ use as part of the history prior to any procedure in which the use of ROMAZICON is planned.	DDI-false
@DRUG$ : Since @DRUG$ It is possible that dopamine antagonists, such as neuroleptics (phenothiazines, butyrophenone, thioxanthene) or metoclopramide, may reduce the efficacy of APOKYN.	DDI-false
Patients who have other narcotic analgesics, general anaesthetics, phenothiazine, @DRUG$ , sedative hypnotic agents, tricyclic antidepressants or other CNS depressants (including alcohol) together with @DRUG$ may exhibit an additive CNS depression .	DDI-effect
The following are examples of substances that may increase the blood-glucose-lowering effect and susceptibility to hypoglycemia: oral antidiabetic products, ACE inhibitors, @DRUG$, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, propoxyphene, salicylates, @DRUG$ (e.g., octreotide), sulfonamide antibiotics.	DDI-false
Cephalosporine cephalosporine containing side chains of N-methylthiotetrazole (Cefmenoxime, cefoperazone), @DRUG$ , cefamandole , @DRUG$ Methylthiadiazole (Cefazolin) may cause vitamin K deficiency and hypoprothrombinaemia.	DDI-false
Acetaminophen/theophylline, @DRUG$/chinidine, phenobarbital/acetaminophen, phenobarbital/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Although increased plasma concentrations (AUC 0-24 hrs) of loratadine and/or @DRUG$ were observed following coadministration of @DRUG$ with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of loratadine, as assessed by electrocardiographic parameters, clinical laboratory tests, vital signs, and adverse events.	DDI-false
In order to determine whether the injection of @DRUG$ ), would increase doses of @DRUG$ A fixed dose of 9.9 g/m2 thiosulfate was administered intravenously for three hours at the same time as an escalating dose of cisplatin.	DDI-false
All subjects received @DRUG$ ( 1,200 mg twice a day ) for 4 days , followed by a 7-day washout period , followed by either @DRUG$ ( 300 mg once daily [ QD ] ) ( cohort 1 ) or rifampin ( 600 mg QD ) ( cohort 2 ) for 14 days.	DDI-false
Hormonal Contraceptives, Including Oral, Injectable, Transdermal, and Implantable Contraceptives: An interaction study demonstrated that co-administration of @DRUG$ and the oral hormonal contraceptive Ortho-Novum produced average decreases of @DRUG$ and ethinyl estradiol levels of 14% and 31%, respectively.	DDI-false
Other Drugs:Drugs such as quinidine, @DRUG$, procainamide, phenothiazines, @DRUG$, and tricyclic antidepressants may be associated with QT-interval prolongation and an increased risk of ventricular arrhythmia.	DDI-false
Although no clinical studies have been conducted, it is likely that the metabolism of @DRUG$ The known inducers of CYP3A4 (e. g. @DRUG$ , phenobarbital, rifampin), CYP3A4 inhibitors (azole antifungals, e.g. ketoconazole;	DDI-mechanism
@DRUG$-Cephalosporins containing side chains of N-methylthiotetrazole (cefmenoxime, @DRUG$, cefotetan, cefamandole, latamoxef) or methylthiadiazole (cefazolin) can cause vitamin K deficiency and hypoprothrombinemia.	DDI-false
Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as NUROMAX include certain antibiotics (e. g., aminoglycosides, tetracyclines, bacitracin, polymyxins, lincomycin, clindamycin, @DRUG$, and sodium colistimethate), magnesium salts, lithium, local @DRUG$, procainamide, and quinidine.	DDI-false
@DRUG$ Because corticosteroids may increase blood sugar levels, dose adjustments of @DRUG$ It may be necessary.	DDI-false
Coadministration of @DRUG$ and the potent CYP3A4 inhibitor ketoconazole (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of @DRUG$.	DDI-false
Tagamet , apparently through an effect on certain microsomal enzyme systems , has been reported to reduce the hepatic metabolism of warfarin-type anticoagulants , @DRUG$ , propranolol, nifedipine, chlordiazepoxide, diazepam, certain tricyclic antidepressants, lidocaine, @DRUG$ And metronidazole, which delays the elimination and increase in blood levels of these drugs.	DDI-false
If treatment with inhibitors of CYP3A4 activity ( such as @DRUG$ , @DRUG$ , ritonavir, indinavir, saquinavir, erythromycin, etc.) is indicated and Budesonide dose reduction should be considered.	DDI-false
Although no interaction between @DRUG$ and Levo-Dromoran has been observed, it is not recommended for use with @DRUG$.	DDI-false
Combination of @DRUG$ with other antiarrhythmic therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to @DRUG$.	DDI-false
Pharmacokinetic Interaction between amprenavir and @DRUG$ or @DRUG$ in healthy males .	DDI-false
therefore , @DRUG$ or other @DRUG$ If possible, treatment of angina or other medications with vasodilator activity should be discontinued before the start of captopril.	DDI-false
- The action of sulphonylureas and @DRUG$ may be enhanced by Bezalip or @DRUG$.	DDI-effect
The hypoglycemic action of sulfonylurea may be potentiated by certain drugs including nonsteroidal anti-inflammatory agents and other drugs that are highly protein bound, salicylates, sulfonamides, chloramphenicol, @DRUG$, coumarins, @DRUG$, and beta adrenergic blocking agents.	DDI-false
- antihypertensive medicines, other, especially diazoxide, or pre@DRUG$ and anesthetics in surgery or @DRUG$ , nondepolarizing , used in surgery	DDI-false
Acetaminophen/theophylline, lidocaine/chinidine, phenobarbital/acetaminophen, @DRUG$/valproic acid, quinidine/@DRUG$, theophylline/acetaminophen and valproic acid/phenobarbital.	DDI-false
Epinephrine should also be used cautiously with other medicines (e.g. @DRUG$ , glycosides ) that sensitize the myocardium to the actions of @DRUG$.	DDI-false
